Sp1 S-protein S-protein 0.8152327537536621
. O O 0.9997182488441467
Costimulation O O 0.9917176961898804
of O O 0.9997764229774475
human B-cell_line B-cell_type 0.4569096863269806
CD4+ I-cell_line I-cell_type 0.6610429286956787
T I-cell_line I-cell_type 0.779459536075592
cells E-cell_line E-cell_type 0.7704538106918335
with O O 0.9987105131149292
LFA-3 S-protein S-protein 0.9168621301651001
and O O 0.9902903437614441
B7 S-protein S-protein 0.5669687986373901
induce O O 0.9922609925270081
distinct O O 0.9803358912467957
effects O O 0.998762845993042
on O O 0.9999791383743286
AP-1 O S-protein 0.9003621339797974
and O O 0.9841317534446716
NF-kappa B-protein B-protein 0.47363942861557007
B E-protein E-protein 0.9874855875968933
transcription B-protein B-protein 0.6197747588157654
factors E-protein E-protein 0.9915953278541565
. O O 0.9996461868286133
We O O 0.9999831914901733
have O O 0.9999964237213135
earlier O O 0.9999620914459229
shown O O 0.9999758005142212
that O O 0.9999926090240479
stimulation O O 0.9964338541030884
of O O 0.999885082244873
human B-cell_line B-cell_type 0.4756391942501068
CD4+ I-cell_line I-cell_type 0.6699929237365723
T I-cell_line I-cell_type 0.8113915324211121
cells E-cell_line E-cell_type 0.8398357033729553
with O O 0.9992045760154724
SEA O O 0.5171507000923157
presented O O 0.9988905787467957
on O O 0.9999600648880005
Chinese B-cell_line O 0.8210937976837158
hamster I-cell_line O 0.7112914323806763
ovary I-cell_line O 0.6420958638191223
( I-cell_line O 0.9779238104820251
CHO I-cell_line O 0.5983225107192993
) I-cell_line O 0.96368408203125

downstream O O 0.6263473033905029
of O O 0.9990456700325012
the O O 0.9999676942825317
transcription B-DNA B-DNA 0.49998921155929565
start I-DNA I-DNA 0.39234915375709534
site E-DNA E-DNA 0.9729415774345398
. O O 0.9997778534889221
We O O 0.9997977614402771
have O O 0.9999914169311523
previously O O 0.9995471835136414
identified O O 0.9999393224716187
new O O 0.9784500002861023
binding O B-DNA 0.5899977087974548
sites O E-DNA 0.9359081983566284
for O O 0.9980873465538025
transcription B-protein B-protein 0.45563048124313354
factors E-protein E-protein 0.9841548204421997
downstream O O 0.9689031839370728
of O O 0.9998950958251953
the O O 0.9998109936714172
transcription B-DNA B-DNA 0.5240979790687561
start I-DNA I-DNA 0.5991131663322449
site E-DNA E-DNA 0.9897962212562561
( O O 0.9986191987991333
nt B-DNA B-DNA 0.5778591632843018
465 I-DNA I-DNA 0.4366740882396698
to I-DNA I-DNA 0.550715982913971
720 E-DNA E-DNA 0.5348640084266663

highly O O 0.9171432852745056
effective O O 0.9978750944137573
in O O 0.9999456405639648
recruiting O O 0.9993234872817993
the O O 0.9998847246170044
signaling O O 0.97081458568573
pathways O O 0.9975480437278748
of O O 0.9999798536300659
IL-6-type B-protein B-protein 0.3810567855834961
cytokine I-protein I-protein 0.7234225273132324
receptors E-protein E-protein 0.9914407730102539
. O O 0.9998682737350464
Induction O O 0.9979228377342224
of O O 0.9998737573623657
CIITA S-protein S-protein 0.9071154594421387
and O O 0.9969649910926819
modification O O 0.9911878108978271
of O O 0.9990848302841187

apoptosis O O 0.9334172606468201
in O O 0.9999129772186279
a O O 0.9999233484268188
manner O O 0.9994543194770813
similar O O 0.9999804496765137
to O O 0.9999902248382568
that O O 0.9999884366989136
of O O 0.999913215637207
glucocorticoids O O 0.7456383109092712
. O O 0.9994811415672302
In O O 0.9999905824661255
the O O 0.9999923706054688
absence O O 0.999839186668396
of O O 0.9999712705612183
TCR S-protein S-protein 0.9882849454879761
-mediated O O 0.9876244068145752
activation O O 0.9975785613059998
, O O 0.9999804496765137
Vpr S-protein S-protein 0.952099621295929
induces O O 0.999528169631958
apoptosis O O 0.9879515767097473
whereas O O 0.9999920129776001
in O O 0.9999516010284424
its O O 0.9997715353965759
presence O O 0.9955794215202332
, O O 0.9999736547470093

In O O 0.9996347427368164
contrast O O 0.9997653365135193
, O O 0.9999903440475464
in O O 0.9999157190322876
normal O O 0.9820014834403992
- O O 0.9994434714317322
salt O O 0.7697542905807495
rats O O 0.9975237250328064
creatinine B-Chemical B-Chemical 0.9277124404907227
clearance O O 0.9694427847862244
was O O 0.9999353885650635
decreased O O 0.9971104860305786
but O O 0.9997780919075012
to O O 0.9998207688331604
a O O 0.9999111890792847
lesser O O 0.9993429780006409
extent O O 0.9993242025375366
at O O 0.9999984502792358
week O O 0.9999585151672363
2 O O 0.9997009038925171
and O O 0.9998668432235718
3 O O 0.9966444969177246
, O O 0.9999369382858276
and O O 0.9999747276306152
in O O 0.9998596906661987
salt O O 0.5068914890289307
- O O 0.9980047345161438
loaded O O 0.9977536797523499
rats O O 0.9947073459625244
creatinine B-Chemical B-Chemical 0.9280475378036499
clearance O O 0.9672663807868958
did O O 0.9999821186065674
not O O 0.9999271631240845
change O O 0.9990547299385071
for O O 0.9999823570251465
2 O O 0.9992306232452393
weeks O O 0.999961256980896
and O O 0.9999904632568359
was O O 0.9999792575836182
decreased O O 0.9989657402038574
by O O 0.9999791383743286
43 O O 0.9999382495880127
% O O 0.9999878406524658
at O O 0.999998927116394
week O O 0.9999563694000244
3 O O 0.9990346431732178
. O O 0.9999984502792358

CONCLUSIONS O O 0.9989437460899353
: O O 0.9999959468841553
The O O 0.9999895095825195
data O O 0.9978864789009094
on O O 0.9999598264694214
TR O O 0.40683770179748535
( O O 0.8971171379089355
- O O 0.9231486320495605
) O O 0.9717463254928589
rats O O 0.997627317905426
indicate O O 0.9999948740005493
that O O 0.999994158744812
Pgp O O 0.3379599153995514
plays O O 0.9979637861251831
an O O 0.99998939037323
important O O 0.9996949434280396
role O O 0.999799907207489
in O O 0.999987006187439
the O O 0.9999619722366333
compensation O O 0.9976075887680054
of O O 0.9999396800994873
MRP2 O O 0.6396405100822449
deficiency O O 0.7045544385910034
in O O 0.9901543855667114
the O O 0.9992259740829468
BBB O O 0.615655243396759
. O O 0.999451220035553

Treatment O O 0.9964367151260376
- O O 0.9998818635940552
related O O 0.9989268183708191
adverse O O 0.7514216899871826
events O O 0.6278663873672485
( O O 0.9968343377113342
AEs O O 0.8414275050163269
) O O 0.9527164101600647
occurred O O 0.9994213581085205
in O O 0.9999954700469971
44 O O 0.9997478127479553
% O O 0.9999489784240723
and O O 0.9999743700027466
52 O O 0.9998173117637634
% O O 0.9999679327011108
, O O 0.999980092048645
57 O O 0.999904990196228
% O O 0.9999685287475586
, O O 0.9999558925628662
and O O 0.9999697208404541
41 O O 0.9998101592063904
% O O 0.9999741315841675
of O O 0.9999537467956543
the O O 0.9997485280036926
asenapine B-Chemical B-Chemical 0.93600994348526
at O O 0.9986550807952881
5 O O 0.9779436588287354
and O O 0.9995170831680298
10 O O 0.9997150301933289
mg O O 0.9996641874313354
BID O O 0.6586809754371643
, O O 0.9889840483665466
haloperidol B-Chemical B-Chemical 0.9272921085357666
, O O 0.9835039377212524
and O O 0.9996436834335327
placebo O O 0.6996661424636841
groups O O 0.9694826006889343
, O O 0.9999823570251465
respectively O O 0.9999948740005493
. O O 0.9999984502792358

The O O 0.999451220035553
side O O 0.9967020153999329
effect O O 0.9992353916168213
profiles O O 0.9997995495796204
of O O 0.9999785423278809
the O O 0.999984622001648
atypical O O 0.8887674808502197
antipsychotics O O 0.7589311003684998
are O O 0.9999450445175171
more O O 0.9998446702957153
advantageous O O 0.9912170171737671
than O O 0.9999680519104004
those O O 0.9999778270721436
of O O 0.999962329864502
the O O 0.9998706579208374
conventional O O 0.9178041815757751
neuroleptics O O 0.6307703852653503
. O O 0.9999090433120728

active O O 0.8995377421379089
on O O 0.9986957907676697
PKC O S-protein 0.7410914301872253
, O O 0.9972690939903259
but O O 0.9999010562896729
more O O 0.9996153116226196
active O O 0.991018533706665
on O O 0.9996334314346313
cyclic O B-protein 0.6108863949775696
nucleotide-dependent O I-protein 0.3834232687950134
kinases O E-protein 0.966381847858429
. O O 0.9998148083686829
Con O B-protein 0.7807480692863464
A O E-protein 0.9259091019630432
stimulation O O 0.9940345883369446
was O O 0.9999933242797852
found O O 0.9999772310256958
to O O 0.9999868869781494
increase O O 0.9999134540557861
both O O 0.9999254941940308
binding O O 0.9853002429008484
of O O 0.9990800619125366
AP-1 O S-protein 0.9179502725601196
to O O 0.991456925868988

correspondence O O 0.9779649972915649
with O O 0.9999873638153076
common B-DNA O 0.9042439460754395
allelic I-DNA O 0.6837010979652405
variants E-DNA O 0.4532531499862671
. O O 0.9999288320541382
It O O 0.9999096393585205
has O O 0.9999896287918091
been O O 0.999957799911499
recently O O 0.999868631362915
claimed O O 0.9999849796295166
that O O 0.9999827146530151
polymorphism O O 0.9602916836738586
for O O 0.9998985528945923
the O O 0.9999440908432007
vitamin B-protein B-protein 0.39590272307395935
D I-protein I-protein 0.8273530602455139
receptor E-protein E-protein 0.8045888543128967

The O O 0.999669075012207
results O O 0.9999617338180542
of O O 0.9999901056289673
serum O O 0.9796044826507568
liver O O 0.8907589316368103
function O O 0.8682710528373718
tests O O 0.9957060217857361
suggested O O 0.9999560117721558
hepatocellular O B-Disease 0.5338988900184631
injury O I-Disease 0.9786298871040344
in O O 0.9658705592155457
10 O O 0.9961547255516052
( O O 0.9998000264167786
63 O O 0.9998812675476074
% O O 0.9999082088470459
) O O 0.9996082186698914
; O O 0.99997878074646
the O O 0.9999634027481079
rest O O 0.9986106157302856
showed O O 0.9999815225601196
a O O 0.9999610185623169
mixed O O 0.9861754775047302
pattern O O 0.9742461442947388
. O O 0.9999943971633911

Abstract O O 0.8991479277610779
Serum O O 0.8618854880332947
aminotransferase O O 0.7387627959251404
elevations O O 0.7220773696899414
are O O 0.9999431371688843
a O O 0.999994158744812
commonly O O 0.9898064732551575
known O O 0.9994600415229797
adverse O O 0.9621143937110901
effect O O 0.996971607208252
of O O 0.9998631477355957
3 O B-Chemical 0.7752697467803955
- O I-Chemical 0.9885038733482361
hydroxy O I-Chemical 0.9547021389007568
- O I-Chemical 0.9833247661590576
3 O I-Chemical 0.9645763635635376
- O I-Chemical 0.99433833360672
methylglutaryl O I-Chemical 0.942672073841095
coenzyme O I-Chemical 0.9301813840866089
A O I-Chemical 0.940041720867157
reductase O I-Chemical 0.9412152171134949
inhibitor O I-Chemical 0.9381901621818542
( O O 0.5852348208427429
statin B-Chemical B-Chemical 0.7962232232093811
) O O 0.6010775566101074
therapy O O 0.9866004586219788
. O O 0.9999986886978149

Because O O 0.9997945427894592
of O O 0.9999749660491943
the O O 0.99997878074646
rapid O O 0.9928021430969238
systemic O O 0.9840123653411865
clearance O O 0.9947303533554077
of O O 0.9993300437927246
BCNU B-Chemical B-Chemical 0.9409583806991577
( O O 0.8858870267868042
1 B-Chemical B-Chemical 0.7910641431808472
, I-Chemical I-Chemical 0.9760105013847351
3 I-Chemical I-Chemical 0.9792560338973999
- I-Chemical I-Chemical 0.9905626773834229
bis I-Chemical I-Chemical 0.9691653847694397
- I-Chemical I-Chemical 0.9922782182693481
( I-Chemical I-Chemical 0.9901973009109497
2 I-Chemical I-Chemical 0.9852922558784485
- I-Chemical I-Chemical 0.9956445693969727
chloroethyl I-Chemical I-Chemical 0.9567540287971497
) I-Chemical I-Chemical 0.9706013798713684
- I-Chemical I-Chemical 0.9934195876121521
1 I-Chemical I-Chemical 0.9741259813308716
- I-Chemical I-Chemical 0.9952561259269714
nitrosourea I-Chemical I-Chemical 0.9293705224990845
) O O 0.768722653388977
, O O 0.9807299375534058
intra O O 0.4264683127403259
- O O 0.7061895728111267
arterial O O 0.7941015958786011
administration O O 0.929290235042572
should O O 0.9999629259109497
provide O O 0.9999957084655762
a O O 0.9999734163284302
substantial O O 0.9994144439697266
advantage O O 0.998838484287262
over O O 0.9999874830245972
intravenous O O 0.8357661366462708
administration O O 0.8725646734237671
for O O 0.9998067021369934
the O O 0.9998998641967773
treatment O O 0.9998250603675842
of O O 0.9999920129776001
malignant B-Disease O 0.6717824339866638
gliomas I-Disease O 0.7213699221611023
. O O 0.999076247215271

nuclear B-protein B-protein 0.7451310157775879
factors E-protein E-protein 0.9645504951477051
binding O O 0.9940167665481567
to O O 0.9999600648880005
the O O 0.9999063014984131
PRE-I B-DNA B-DNA 0.5930677056312561
site E-DNA E-DNA 0.9654254913330078
and O O 0.9951243996620178
compared O O 0.9999138116836548
the O O 0.9999840259552002
binding O O 0.9022390246391296
activities O O 0.9958459734916687
of O O 0.9999847412109375
these O O 0.9999716281890869
factors O O 0.9714382290840149
to O O 0.9998262524604797
the O O 0.9997562766075134
IL-4 S-protein B-DNA 0.5281606912612915
promoter O E-DNA 0.9872794151306152
of O O 0.9896592497825623
Th1 B-cell_type B-cell_line 0.684017539024353
and I-cell_type I-cell_line 0.662219226360321
Th2 I-cell_type I-cell_line 0.29959461092948914
cells E-cell_type E-cell_line 0.7545295357704163
. O O 0.9999123811721802
We O O 0.9977387189865112

Although O O 0.998576283454895
CD40 S-protein S-protein 0.9523023962974548
lacks O O 0.9998345375061035
intrinsic O O 0.9550256133079529
tyrosine O B-protein 0.7189481854438782
kinase O E-protein 0.9277398586273193
activity O O 0.9951560497283936
, O O 0.9999960660934448
its O O 0.999970555305481
ligation O O 0.9930926561355591
induces O O 0.9999593496322632
protein O O 0.8645994067192078
tyrosine O O 0.7718471884727478
phosphorylation O O 0.9619725942611694
, O O 0.9997709393501282
which O O 0.9999786615371704
is O O 0.9999878406524658
necessary O O 0.9999703168869019
for O O 0.9999923706054688
several O O 0.9993413090705872
CD40 S-protein S-protein 0.9812721610069275
-mediated O O 0.9839162230491638
events O O 0.9964084029197693
. O O 0.9999970197677612
We O O 0.9999827146530151
show O O 0.9999971389770508
that O O 0.9999982118606567
engagement O O 0.9968841671943665
of O O 0.999920129776001
CD40 S-protein S-protein 0.9611493945121765
induces O O 0.9998327493667603
tyrosine O O 0.7887254953384399
phosphorylation O O 0.9479697346687317
and O O 0.9987323880195618
activation O O 0.9882680773735046

up-regulation O O 0.9882209897041321
of O O 0.9998596906661987
HB-EGF B-RNA B-RNA 0.9025880098342896
mRNA E-RNA E-RNA 0.9961811304092407
and O O 0.9988353848457336
kappa O B-protein 0.7746853828430176
B O E-protein 0.9129708409309387
binding O O 0.8400976061820984
activity O O 0.9899729490280151
induced O O 0.9999724626541138
by O O 0.9999836683273315
PAF S-protein S-protein 0.9530348777770996
. O O 0.9999127388000488
The O O 0.999984622001648
antagonists O O 0.9477065205574036
, O O 0.999286949634552
however O O 0.999936580657959
, O O 0.9999744892120361
had O O 0.9999817609786987
no O O 0.9996902942657471

Therefore O O 0.9991067051887512
, O O 0.9999655485153198
in O O 0.9999252557754517
adult O O 0.8225989937782288
patients O O 0.986951470375061
affected O O 0.9990837574005127
by O O 0.9999899864196777
HUS O O 0.8019211888313293
, O O 0.9881685376167297
dialysis O O 0.5815748572349548
should O O 0.9957315325737
not O O 0.9998409748077393
be O O 0.9999715089797974
discontinued O O 0.9890633225440979
prematurely O O 0.9994788765907288
; O O 0.9999908208847046
moreover O O 0.9997418522834778
, O O 0.9999804496765137
bilateral O O 0.9593651294708252
nephrectomy O O 0.8117712736129761
, O O 0.995780348777771
for O O 0.9998573064804077
treatment O O 0.9994640946388245
of O O 0.9999748468399048
severe O O 0.9669340252876282
hypertension O B-Disease 0.9585175514221191
and O O 0.9555432200431824
microangiopathic O B-Disease 0.7001898288726807
hemolytic O I-Disease 0.5072600841522217
anemia O I-Disease 0.9481793642044067
, O O 0.9687645435333252
should O O 0.9999079704284668
be O O 0.9999849796295166
performed O O 0.9999698400497437
with O O 0.9999916553497314
caution O O 0.9797832369804382
. O O 0.9999982118606567

effect O O 0.9946296215057373
on O O 0.99997878074646
the O O 0.999860405921936
reporter O B-cell_line 0.5577270984649658
cells O E-cell_line 0.49615225195884705
could O O 0.9997689127922058
be O O 0.999994158744812
measured O O 0.9996968507766724
, O O 0.999983549118042
neither O O 0.9999914169311523
by O O 0.9999867677688599
cocultivation O O 0.9890676140785217
of O O 0.9996328353881836
activator B-cell_line B-cell_type 0.5877497792243958
cells E-cell_line E-cell_type 0.9406386613845825
nor O O 0.9976832866668701
by O O 0.9999873638153076
coincubation O O 0.9825166463851929
of O O 0.9996094107627869
BZLF B-protein B-protein 0.35070186853408813
1 E-protein E-protein 0.9671885371208191
-containing O O 0.9889188408851624
cell O O 0.9541305303573608
lysates O O 0.9343222975730896
. O O 0.9999769926071167
Latency O O 0.8379604816436768

of O O 0.9966112971305847
the O O 0.9999674558639526
transcriptional B-protein B-protein 0.7320989370346069
factor E-protein E-protein 0.9362084269523621
( O O 0.9669608473777771
FcRFgamma S-protein S-protein 0.9280426502227783
) O O 0.9608083367347717
bound O O 0.9995294809341431
to O O 0.9999812841415405
the O O 0.9999057054519653
gamma B-DNA B-DNA 0.34086474776268005
response I-DNA I-DNA 0.4926418662071228
region E-DNA E-DNA 0.8016046285629272
were O O 0.9996724128723145
similarly O O 0.9996271133422852
or O O 0.9997305274009705
less O O 0.9993405938148499
abundantly O O 0.9549791216850281
induced O O 0.9995530247688293
by O O 0.9999923706054688
IFNgamma S-protein S-protein 0.8234608173370361
treatment O O 0.9907213449478149
in O O 0.999929666519165
PMA O O 0.3754611313343048
-or O O 0.9352445602416992
RA-differentiated O B-cell_line 0.5874711275100708
U937 B-cell_line I-cell_line 0.6901040077209473
cells E-cell_line E-cell_line 0.9973917007446289
, O O 0.9986716508865356
indicating O O 0.9999983310699463
that O O 0.9999988079071045
increased O O 0.9907329082489014
IP-10 B-RNA B-RNA 0.7339578866958618
mRNA E-RNA E-RNA 0.9943566918373108
induction O O 0.9972020387649536
was O O 0.9999908208847046
not O O 0.9999574422836304
due O O 0.9999935626983643
to O O 0.9999904632568359
the O O 0.9999392032623291
augmented O O 0.9849268198013306
ability O O 0.9995137453079224
of O O 0.9999464750289917
the O O 0.9997560381889343
cells O O 0.9722002148628235
to O O 0.9998797178268433
respond O O 0.9999414682388306

; O O 0.9306372404098511

Renal O O 0.6473841667175293
tissue O O 0.7699217200279236
was O O 0.9960383176803589
obtained O O 0.9999793767929077
for O O 0.9999957084655762
determination O O 0.9958081245422363
of O O 0.9998124241828918
glomerular O O 0.6530687212944031
size O O 0.5476781725883484
and O O 0.9755673408508301
sclerosis O O 0.5207997560501099
. O O 0.9998799562454224

and O O 0.9737144112586975
0.0023 O O 0.8280641436576843
, O O 0.9993854761123657
respectively O O 0.9999498128890991
) O O 0.999779999256134
. O O 0.9999946355819702
In O O 0.9999673366546631
addition O O 0.9997751116752625
, O O 0.999993085861206
Northern O O 0.9714632034301758
blot O O 0.9319563508033752

Allopregnanolone B-Chemical B-Chemical 0.9365126490592957
( O O 0.9658067226409912
3alpha B-Chemical B-Chemical 0.9547421336174011
- I-Chemical I-Chemical 0.9946600794792175
hydroxy I-Chemical I-Chemical 0.9592291116714478
- I-Chemical I-Chemical 0.9673599600791931
5alpha I-Chemical I-Chemical 0.9634265303611755
- I-Chemical I-Chemical 0.9948835968971252
pregnan I-Chemical I-Chemical 0.971006453037262
- I-Chemical I-Chemical 0.9921344518661499
20 I-Chemical I-Chemical 0.9711222052574158
- I-Chemical I-Chemical 0.9919907450675964
one I-Chemical I-Chemical 0.9364491105079651
) O O 0.9108034372329712
, O O 0.769262969493866
pregnanolone B-Chemical B-Chemical 0.9381730556488037
( O O 0.961793839931488
3alpha B-Chemical B-Chemical 0.9504362344741821
- I-Chemical I-Chemical 0.9948470592498779
hydroxy I-Chemical I-Chemical 0.955286979675293
- I-Chemical I-Chemical 0.9834158420562744
5beta I-Chemical I-Chemical 0.9702127575874329
- I-Chemical I-Chemical 0.9959593415260315
pregnan I-Chemical I-Chemical 0.9674074053764343
- I-Chemical I-Chemical 0.9921171069145203
20 I-Chemical I-Chemical 0.9688063263893127
- I-Chemical I-Chemical 0.9916955828666687
one I-Chemical I-Chemical 0.9279136061668396
) O O 0.8920223712921143
and O O 0.805199921131134
ganaxolone B-Chemical B-Chemical 0.9283098578453064
( O O 0.9950575828552246
a O O 0.9997015595436096
synthetic O O 0.8772303462028503
derivative O O 0.8316285610198975
of O O 0.9937410950660706
allopregnanolone B-Chemical B-Chemical 0.9438515305519104
3alpha B-Chemical I-Chemical 0.9024823904037476
- I-Chemical I-Chemical 0.9790983200073242
hydroxy I-Chemical I-Chemical 0.9582611918449402
- I-Chemical I-Chemical 0.9753115773200989
3beta I-Chemical I-Chemical 0.9679227471351624
- I-Chemical I-Chemical 0.9950302839279175
methyl I-Chemical I-Chemical 0.9673448801040649
- I-Chemical I-Chemical 0.9869055151939392
5alpha I-Chemical I-Chemical 0.959243893623352
- I-Chemical I-Chemical 0.9941437840461731
pregnan I-Chemical I-Chemical 0.9670023322105408
- I-Chemical I-Chemical 0.9912475943565369
20 I-Chemical I-Chemical 0.9677445292472839
- I-Chemical I-Chemical 0.9880317449569702
one I-Chemical I-Chemical 0.9289624691009521
) O O 0.6197665929794312
were O O 0.9997226595878601
tested O O 0.9999867677688599
for O O 0.9999945163726807
their O O 0.9999144077301025
ability O O 0.9995552897453308
to O O 0.9999853372573853
suppress O O 0.9996981620788574
the O O 0.9988321661949158
expression O O 0.9616938233375549
( O O 0.9997890591621399
anticonvulsant O O 0.7632157802581787
effect O O 0.9295095205307007
) O O 0.9991753697395325
and O O 0.9999433755874634
development O O 0.9766604900360107
( O O 0.9997885823249817
antiepileptogenic O O 0.6533910036087036
effect O O 0.8253042697906494
) O O 0.9984245300292969
of O O 0.999338686466217
cocaine B-Chemical B-Chemical 0.9189701080322266
- O O 0.9815232157707214
kindled O O 0.9922985434532166
seizures B-Disease B-Disease 0.9600419998168945
in O O 0.9828643798828125
male O O 0.9724732637405396
, O O 0.9996050000190735
Swiss O O 0.9713289737701416
- O O 0.9917872548103333
Webster O O 0.8959718346595764
mice O O 0.99395751953125
. O O 0.9999994039535522

Treatment O O 0.9964367151260376
- O O 0.9998818635940552
related O O 0.9989268183708191
adverse O O 0.7514216899871826
events O O 0.6278663873672485
( O O 0.9968343377113342
AEs O O 0.8414275050163269
) O O 0.9527164101600647
occurred O O 0.9994213581085205
in O O 0.9999954700469971
44 O O 0.9997478127479553
% O O 0.9999489784240723
and O O 0.9999743700027466
52 O O 0.9998173117637634
% O O 0.9999679327011108
, O O 0.999980092048645
57 O O 0.999904990196228
% O O 0.9999685287475586
, O O 0.9999558925628662
and O O 0.9999697208404541
41 O O 0.9998101592063904
% O O 0.9999741315841675
of O O 0.9999537467956543
the O O 0.9997485280036926
asenapine S-Chemical B-Chemical 0.93600994348526
at O O 0.9986550807952881
5 O O 0.9779436588287354
and O O 0.9995170831680298
10 O O 0.9997150301933289
mg O O 0.9996641874313354
BID O O 0.6586809754371643
, O O 0.9889840483665466
haloperidol S-Chemical B-Chemical 0.9272921085357666
, O O 0.9835039377212524
and O O 0.9996436834335327
placebo O O 0.6996661424636841
groups O O 0.9694826006889343
, O O 0.9999823570251465
respectively O O 0.9999948740005493
. O O 0.9999984502792358

In O O 0.9977662563323975
controls O O 0.9918397665023804
, O O 0.9999953508377075
no O O 0.9999194145202637
predictive O O 0.9854187965393066
values O O 0.9848548769950867
for O O 0.9999641180038452
renal O O 0.8840711116790771
parameters O O 0.6476084589958191
were O O 0.9997000694274902
observed O O 0.9999419450759888
. O O 0.9999992847442627

factor O E-protein 0.7829859852790833
expression O O 0.9457452297210693
of O O 0.9993139505386353
human B-cell_type B-cell_type 0.5654427409172058
monocytes E-cell_type E-cell_type 0.9837157130241394
is O O 0.9991662502288818
suppressed O O 0.9988345503807068
by O O 0.9999887943267822
lysophosphatidylcholine O O 0.6788676381111145
. O O 0.9998999834060669
The O O 0.9999949932098389
expression O O 0.9966758489608765
of O O 0.9997323155403137
tissue B-protein B-protein 0.5606683492660522
factor E-protein I-protein 0.8255822062492371
( O I-protein 0.7757852673530579
TF S-protein I-protein 0.618415355682373

the O O 0.9982705116271973
interleukin B-DNA B-DNA 0.3215215504169464
( I-DNA I-DNA 0.38502243161201477
IL I-DNA I-DNA 0.6566340923309326
) I-DNA I-DNA 0.7139954566955566
-2 I-DNA I-DNA 0.7704030871391296
homology I-DNA I-DNA 0.3525463938713074
NFAT-1 I-DNA I-DNA 0.3011709451675415
region E-DNA E-DNA 0.7620505690574646
was O O 0.9994545578956604
mutated O O 0.9977224469184875
resulted O O 0.999974250793457
in O O 0.9999772310256958
almost O O 0.9991536140441895
complete O O 0.9964955449104309
elimination O O 0.9985727071762085
of O O 0.9998670816421509
suppression O O 0.983253002166748
by O O 0.9998916387557983
CD8+ B-cell_type B-cell_type 0.8368651270866394
T I-cell_type I-cell_type 0.9334926009178162
cells E-cell_type E-cell_type 0.9383955597877502

resting O B-cell_type 0.4411141276359558
cells O E-cell_type 0.9031974673271179
. O O 0.9996949434280396
Following O O 0.9998164772987366
neutrophil O O 0.5920063257217407
stimulation O O 0.9813172221183777
with O O 0.9999558925628662
proinflammatory O O 0.6768994331359863
agonists O O 0.40958133339881897
( O O 0.995058536529541
such O O 0.9995535016059875

immobilized O O 0.8581632971763611
anti-CD3 B-protein B-protein 0.5239889621734619
monoclonal I-protein I-protein 0.8318607807159424
antibody E-protein E-protein 0.993363618850708
( O O 0.9780362248420715
mAb S-protein S-protein 0.9701001048088074
) O O 0.9424294829368591
in O O 0.9998685121536255
the O O 0.9999390840530396
presence O O 0.9967994689941406
or O O 0.9999340772628784
absence O O 0.999556839466095
of O O 0.999980092048645
an O O 0.9999432563781738
additional O O 0.9903470873832703
costimulatory O O 0.6665099263191223
signal O O 0.6045077443122864
delivered O O 0.9991506338119507
by O O 0.9999831914901733
anti-CD28 B-protein S-protein 0.45571690797805786

by O O 0.9991600513458252
a O O 0.9999048709869385
downstream B-DNA O 0.8819534182548523
T I-DNA B-DNA 0.6478143334388733
lymphocyte-specific I-DNA I-DNA 0.5409667491912842
enhancer I-DNA I-DNA 0.4212186336517334
element E-DNA E-DNA 0.9894136190414429
. O O 0.9997846484184265
We O O 0.9999802112579346
report O O 0.9999961853027344
the O O 0.9999953508377075
identification O O 0.9992056488990784
of O O 0.9999768733978271
a O O 0.9997370839118958
T B-protein B-protein 0.46127617359161377
cell-specific I-protein I-protein 0.6163827776908875
transcription I-protein I-protein 0.8171918988227844
factor E-protein E-protein 0.9831250905990601
, O O 0.9887396693229675
TCF-1 S-protein S-protein 0.9707996845245361
, O O 0.9917131662368774
binding O O 0.8456383943557739
to O O 0.9462247490882874

was O O 0.9939444661140442
greatly O O 0.9984062314033508
impaired O O 0.9996312856674194
in O O 0.9999915361404419
its O O 0.9999538660049438
ability O O 0.9992548823356628
to O O 0.9999767541885376
abrogate O O 0.9965794682502747
binding O O 0.990952730178833
of O O 0.9998016953468323
the O O 0.9998677968978882
basic O B-protein 0.569359540939331
helix-loop-helix B-protein I-protein 0.7647987008094788
protein E-protein E-protein 0.9825426340103149
, O O 0.985162079334259
E47 S-protein S-protein 0.9406859278678894
, O O 0.9935550093650818
to O O 0.9999017715454102
an O O 0.9998970031738281
E B-DNA B-DNA 0.398430734872818
box I-DNA I-DNA 0.38024744391441345
recognition I-DNA I-DNA 0.4842013418674469
sequence E-DNA E-DNA 0.9090126752853394
. O O 0.9997846484184265
Tyloxapol O O 0.922821581363678
inhibits O O 0.9995930790901184
NF-kappa B-protein B-protein 0.6809776425361633
B E-protein E-protein 0.9692848920822144
and O O 0.9921596646308899
cytokine S-protein S-protein 0.7858100533485413
release O O 0.915432333946228

T O O 0.3392256200313568
cell O O 0.45749738812446594
functions O O 0.9813490509986877
by O O 0.9999890327453613
activation O O 0.9956513047218323
of O O 0.9997602105140686
signal B-protein B-protein 0.49026164412498474
transducers I-protein I-protein 0.4865339398384094
and I-protein I-protein 0.740406334400177
activators I-protein I-protein 0.64288330078125
of I-protein I-protein 0.910633385181427
transcription I-protein I-protein 0.5796968936920166
( I-protein I-protein 0.8190925717353821
STAT I-protein I-protein 0.9399424195289612
) I-protein I-protein 0.5364172458648682
proteins E-protein E-protein 0.9956607222557068
. O O 0.9998748302459717
We O O 0.9999845027923584
examined O O 0.9999872446060181
the O O 0.9999680519104004

gene E-DNA E-DNA 0.9667595028877258
. O O 0.9997791647911072
The O O 0.9998972415924072
P B-DNA B-DNA 0.5955261588096619
sequence E-DNA E-DNA 0.9944949746131897
was O O 0.9983224272727966
located O O 0.9999247789382935
between O O 0.9945411086082458
positions O O 0.876907467842102
-79 O B-DNA 0.5379817485809326
and O I-DNA 0.8218822479248047
-69 O E-DNA 0.683516800403595
relative O O 0.935289740562439
to O O 0.9995428323745728
the O O 0.9998607635498047
transcription B-DNA B-DNA 0.5218754410743713
start I-DNA I-DNA 0.3964233994483948
site E-DNA E-DNA 0.9423858523368835
of O O 0.9960810542106628
the O O 0.9998281002044678
human B-DNA B-DNA 0.680885374546051
IL-4 I-DNA I-DNA 0.7738794088363647
gene E-DNA E-DNA 0.9858517050743103
, O O 0.9804016947746277
and O O 0.999930739402771
this O O 0.9999266862869263
location O O 0.9747353792190552

specificity O O 0.9406782984733582
for O O 0.9995729327201843
c-Maf S-protein S-protein 0.9808855652809143
in O O 0.999750554561615
IL-4 S-protein S-protein 0.9755184650421143
expression O O 0.9975813627243042
during O O 0.9999767541885376
T O O 0.859424352645874
cell O O 0.7833684682846069
development O O 0.9954001307487488
and O O 0.999841570854187
directs O O 0.9977198243141174
thereby O O 0.9999707937240601
Th2 O O 0.3450653553009033
differentiation O O 0.9648908972740173
. O O 0.9999723434448242
Human B-protein O 0.8261549472808838
T-cell I-protein O 0.7716509103775024
leukemia I-protein O 0.830780565738678
virus I-protein O 0.9247194528579712
type I-protein O 0.9511988162994385

the O O 0.9974300265312195
other O O 0.9985753297805786
BRCA1 B-DNA B-DNA 0.7197778224945068
allele E-DNA E-DNA 0.970987856388092
. O O 0.9992972612380981
Using O O 0.9999700784683228
the O O 0.9999752044677734
technique O O 0.9981396198272705
of O O 0.9999481439590454
reverse O O 0.8058282136917114
transcription-polymerase O O 0.6315527558326721
chain O O 0.7239824533462524
reaction O O 0.9516251683235168
( O O 0.9994317889213562
PCR O O 0.9189566969871521
) O O 0.9991656541824341
with O O 0.9999641180038452
RNA O O 0.5976119637489319
isolated O O 0.9772871732711792
from O O 0.9998437166213989
lymphoid B-cell_line B-cell_line 0.3387281596660614
cell I-cell_line I-cell_line 0.46409380435943604
lines E-cell_line E-cell_line 0.9904937148094177
of O O 0.9993677735328674
the O O 0.9999676942825317
patient O O 0.9905293583869934
and O O 0.9996566772460938
of O O 0.9999314546585083
controls O O 0.9957093000411987
, O O 0.9999969005584717
no O O 0.9999560117721558
evidence O O 0.9998539686203003

The O O 0.9995348453521729
role O O 0.9987965822219849
of O O 0.9999097585678101
the O O 0.9999353885650635
renin O O 0.8762179017066956
- O O 0.9915962815284729
- O O 0.9975425004959106
angiotensin S-Chemical B-Chemical 0.9262602925300598
system O O 0.7720931768417358
in O O 0.9999750852584839
the O O 0.999797523021698
maintenance O O 0.9878348708152771
of O O 0.9993207454681396
blood O O 0.9157373309135437
pressure O O 0.7547846436500549
during O O 0.9999430179595947
halothane S-Chemical B-Chemical 0.9219837188720703
anesthesia O O 0.3694140315055847
and O O 0.9988487958908081
sodium B-Chemical B-Chemical 0.9418489933013916
nitroprusside E-Chemical I-Chemical 0.9553579092025757
( O O 0.7608253359794617
SNP S-Chemical B-Chemical 0.9106176495552063
) O O 0.6304531693458557
- O O 0.9939470291137695
induced O O 0.997846245765686
hypotension O B-Disease 0.9881864190101624
was O O 0.9900733232498169
evaluated O O 0.9999644756317139
. O O 0.9999992847442627

sites O O 0.5576175451278687
of O O 0.9995216131210327
vascular O O 0.8856272101402283
inflammation O O 0.8987175226211548
by O O 0.9999228715896606
resident O B-cell_type 0.6636819243431091
and O I-cell_type 0.8932607173919678
nonresident O I-cell_type 0.7289144992828369
vascular B-cell_type I-cell_type 0.48754438757896423
wall I-cell_type I-cell_type 0.642417848110199
cells E-cell_type E-cell_type 0.8157748579978943
, O O 0.9965367317199707
but O O 0.9999125003814697

the O O 0.9975518584251404
level O O 0.999866247177124
of O O 0.9999780654907227
a O O 0.9998956918716431
number O O 0.999612033367157
of O O 0.9999876022338867
specific B-protein O 0.9554551839828491
binding I-protein B-protein 0.6714022755622864
complexes E-protein E-protein 0.9785799980163574
relative O O 0.9985342025756836
to O O 0.999976396560669
the O O 0.9997174143791199
resting B-cell_type B-cell_type 0.5447443127632141
cells E-cell_type E-cell_type 0.944198489189148
. O O 0.9997912049293518
The O O 0.9999922513961792
regulatory O O 0.8124719262123108
mechanisms O O 0.9658553004264832
of O O 0.9998562335968018
the O O 0.9999552965164185
human B-DNA B-DNA 0.5195273160934448
and I-DNA I-DNA 0.4728282690048218
murine I-DNA I-DNA 0.7549066543579102
TNF I-DNA I-DNA 0.8893561959266663
genes E-DNA E-DNA 0.9962961077690125
are O O 0.9993916749954224
discussed O O 0.9999786615371704
. O O 0.9999990463256836
Enhancement O O 0.9990941286087036
of O O 0.9999814033508301
human O O 0.7611478567123413
immunodeficiency O O 0.7499814629554749
virus O O 0.8296452760696411
1 O O 0.9198792576789856

Small O O 0.9786801338195801
- O O 0.9968312382698059
and O O 0.9995183944702148
medium O O 0.9962669014930725
- O O 0.9994638562202454
sized O O 0.9963100552558899
hepatic O O 0.6096010804176331
veins O O 0.7022657990455627
were O O 0.9990584254264832
blocked O O 0.9994145631790161
by O O 0.999981164932251
thrombosis O B-Disease 0.9702001810073853
. O O 0.9992314577102661

Combining O O 0.9991470575332642
the O O 0.9999806880950928
two O O 0.9995973706245422
fentanyl B-Chemical B-Chemical 0.8995323777198792
groups O O 0.8923627734184265
revealed O O 0.9999678134918213
further O O 0.9987595081329346
significant O O 0.998581051826477
benefits O O 0.9905514717102051
from O O 0.9999467134475708
the O O 0.9996726512908936
avoidance O O 0.9806020259857178
of O O 0.9988411068916321
opioids O O 0.5716260075569153
, O O 0.9956762194633484
reducing O O 0.9984967708587646
postoperative B-Disease O 0.8967283964157104
nausea I-Disease O 0.5190147757530212
and I-Disease O 0.9483473896980286
vomiting I-Disease O 0.8477319478988647
and O O 0.9297935962677002
nausea B-Disease B-Disease 0.9081506133079529
prior O O 0.8749545812606812
to O O 0.9978785514831543
discharge O O 0.5863926410675049
from O O 0.9995144605636597
35 O O 0.999351441860199
% O O 0.9999527931213379
and O O 0.9999710321426392
33 O O 0.9998003840446472
% O O 0.9999607801437378
to O O 0.9999592304229736
22 O O 0.9998893737792969
% O O 0.9999639987945557
and O O 0.9999678134918213
19 O O 0.9999350309371948
% O O 0.9999818801879883
( O O 0.9999842643737793
P O O 0.9993570446968079
= O O 0.9999812841415405
0 O O 0.9999228715896606
. O O 0.9999818801879883
049 O O 0.9983553290367126
and O O 0.9999731779098511
P O O 0.9952398538589478
= O O 0.9999420642852783
0 O O 0.9998912811279297
. O O 0.9999088048934937
035 O O 0.9962102174758911
) O O 0.999616265296936
, O O 0.9999954700469971
respectively O O 0.9999953508377075
, O O 0.9999908208847046
while O O 0.9999935626983643
nausea B-Disease O 0.9420279264450073
in O O 0.9900851249694824
the O O 0.9995436072349548
first O O 0.9990866184234619
24 O O 0.999579131603241
h O O 0.9776833057403564
was O O 0.999971866607666
decreased O O 0.9989356398582458
from O O 0.9999798536300659
42 O O 0.9998971223831177
% O O 0.999980092048645
to O O 0.9999802112579346
27 O O 0.9999401569366455
% O O 0.9999822378158569
( O O 0.9999887943267822
P O O 0.9997103810310364
= O O 0.9999825954437256
0 O O 0.9998879432678223
. O O 0.9999244213104248
034 O O 0.981478214263916
) O O 0.9997126460075378
. O O 0.9999953508377075

Of O O 0.9998853206634521
the O O 0.9999897480010986
82 O O 0.9991890788078308
evaluable O O 0.9785966873168945
patients O O 0.9994145631790161
, O O 0.9999890327453613
50 O O 0.9971764087677002
did O O 0.9999620914459229
not O O 0.9999186992645264
show O O 0.9999834299087524
any O O 0.9998291730880737
recurrence O O 0.6250802874565125
after O O 0.9996172189712524
1 O O 0.9995342493057251
year O O 0.9999593496322632
( O O 0.9999920129776001
61 O O 0.999955415725708
% O O 0.999954342842102
) O O 0.999790608882904
, O O 0.9999815225601196
while O O 0.9999887943267822
32 O O 0.9946176409721375
presented O O 0.9999269247055054
with O O 0.9999723434448242
one O O 0.9952670335769653
or O O 0.9996737241744995
more O O 0.9996790885925293
recurrences O O 0.4999154806137085
( O O 0.9990755319595337
39 O O 0.9998548030853271
% O O 0.9999145269393921
) O O 0.9997445940971375
. O O 0.9999970197677612

, O O 0.9503923654556274

Administration O O 0.9971567392349243
of O O 0.9993796348571777
[ B-Chemical B-Chemical 0.9122043251991272
3H I-Chemical I-Chemical 0.9760129451751709
] I-Chemical I-Chemical 0.9873560667037964
- I-Chemical I-Chemical 0.9914180040359497
5 I-Chemical I-Chemical 0.9573488235473633
- I-Chemical I-Chemical 0.9931083917617798
azadeoxycytidine E-Chemical I-Chemical 0.92774897813797
during O O 0.999591052532196
the O O 0.9999711513519287
repair O O 0.8334095478057861
synthesis O O 0.5388987064361572
induced O O 0.9987187385559082
by O O 0.9999409914016724
1 B-Chemical B-Chemical 0.6618934869766235
, I-Chemical I-Chemical 0.7632676959037781
2 I-Chemical I-Chemical 0.9209349751472473
- I-Chemical I-Chemical 0.9924982190132141
DMH E-Chemical I-Chemical 0.955993115901947
further O O 0.9888178110122681
showed O O 0.9999947547912598
that O O 0.9999977350234985
0 O O 0.9926785230636597
. O O 0.9999080896377563
019 O O 0.9994264841079712
mol O O 0.999323844909668
% O O 0.9999028444290161
of O O 0.9995761513710022
cytosine S-Chemical B-Chemical 0.9261835217475891
residues O O 0.7390756011009216
in O O 0.9989452958106995
DNA O O 0.9187772274017334
were O O 0.9999459981918335
substituted O O 0.9999527931213379
by O O 0.9999964237213135
the O O 0.9998965263366699
analogue O O 0.9375474452972412
, O O 0.9997279047966003
indicating O O 0.9999891519546509
that O O 0.9999912977218628
incorporation O O 0.9971599578857422
of O O 0.9998027682304382
5 B-Chemical B-Chemical 0.5178176164627075
- I-Chemical I-Chemical 0.970011293888092
AzC E-Chemical I-Chemical 0.947507381439209
occurs O O 0.9826425313949585
during O O 0.9999240636825562
repair O O 0.9046855568885803
synthesis O O 0.5387807488441467
. O O 0.9999755620956421

discuss O O 0.9991331696510315
recent O O 0.9994213581085205
advances O O 0.9992813467979431
in O O 0.9999771118164062
transcriptional O O 0.9433834552764893
regulation O O 0.9955542683601379
during O O 0.9999783039093018
myelopoiesis O O 0.9031289219856262
. O O 0.9999755620956421
Activation O O 0.995594322681427
of O O 0.9996633529663086
transcription O B-protein 0.481519490480423
factor O I-protein 0.7703090906143188
NF-kappa B-protein I-protein 0.6454133987426758
B E-protein E-protein 0.9975416660308838
by O O 0.999840259552002
phagocytic O O 0.7583900690078735
stimuli O O 0.5456539392471313
in O O 0.9987623691558838
human O B-cell_type 0.7441002726554871
neutrophils O E-cell_type 0.9783088564872742
. O O 0.9996985197067261
Phagocytosis O O 0.8600277900695801
represents O O 0.9999260902404785
an O O 0.9999909400939941
important O O 0.9973539113998413
physiological O O 0.9621066451072693
trigger O O 0.9249232411384583
for O O 0.9998393058776855
the O O 0.9999493360519409

for O O 0.9959573149681091
both O O 0.9997885823249817
c-Myb S-protein S-protein 0.7877281308174133
and O O 0.9582380056381226
Ets S-protein S-protein 0.8891064524650574
for O O 0.9935890436172485
transcriptional O O 0.9239229559898376
activity O O 0.9920807480812073
, O O 0.9999936819076538
providing O O 0.9999920129776001
one O O 0.9999561309814453
explanation O O 0.9999463558197021
for O O 0.999996542930603
why O O 0.9999911785125732
synergy O O 0.962644100189209
between O O 0.9989861845970154

the O O 0.998828113079071
synergistic O O 0.9680373668670654
function O O 0.9971752166748047
of O O 0.9999234676361084
activation O B-protein 0.5931273698806763
domains O E-protein 0.9788763523101807
in O O 0.9995923638343811
Oct-1 S-protein S-protein 0.9770094752311707
and O O 0.9958525896072388
OCA-B S-protein S-protein 0.8486309051513672
( O O 0.9843252897262573
mediated O O 0.9002829790115356
by O O 0.9975075721740723
the O O 0.999625563621521
combined O O 0.9803171157836914

cell O O 0.3860135078430176
proliferation O O 0.9745801687240601
. O O 0.9999970197677612
Further O O 0.9998582601547241
Northern O O 0.9965376853942871
analyses O O 0.9996510744094849
indicated O O 0.9999926090240479
that O O 0.9999955892562866
there O O 0.9999822378158569
was O O 0.9999955892562866
no O O 0.9999884366989136
significant O O 0.999240517616272
change O O 0.9994971752166748
in O O 0.9999454021453857
17beta-HSD B-protein O 0.6067809462547302
IV E-protein O 0.5591326951980591
or O O 0.9940488338470459
DNA-PK B-RNA O 0.23721319437026978
( I-RNA O 0.6846305131912231

directly O O 0.9212164282798767

cytosol O O 0.4422979950904846
of O O 0.9795224666595459
monocytes S-cell_type S-cell_type 0.9893733859062195
and O O 0.9896289706230164
macrophages S-cell_type S-cell_type 0.9852946996688843
as O O 0.9997441172599792
a O O 0.9999656677246094
DNA-binding B-protein B-protein 0.3365102708339691

mobility O O 0.9153976440429688
shift O O 0.9881781935691833
assays O O 0.9994171857833862
, O O 0.999993085861206
we O O 0.999987006187439
found O O 0.9999897480010986
that O O 0.9999991655349731
in O O 0.9999350309371948
the O O 0.9999483823776245
presence O O 0.9994038343429565
of O O 0.9999895095825195
rabbit O O 0.6054063439369202
reticulocyte O O 0.5970959663391113
lysate O O 0.7655300498008728
, O O 0.9998317956924438
human B-protein B-protein 0.5155131220817566
ER E-protein E-protein 0.865744411945343
reduced O O 0.9982485771179199
the O O 0.9998999834060669
binding O O 0.979546844959259
activities O O 0.9983550906181335
of O O 0.9999853372573853
chicken B-protein B-protein 0.3631488084793091
immature I-protein I-protein 0.4871463179588318
erythrocyte I-protein I-protein 0.39816418290138245
nuclear I-protein I-protein 0.7431527972221375
extracted I-protein I-protein 0.8541048765182495
proteins E-protein E-protein 0.987406313419342
to O O 0.9979827404022217
GATA B-DNA S-protein 0.4965275824069977
and I-DNA O 0.9365457892417908

mutations O O 0.849456250667572
in O O 0.9999740123748779
the O O 0.9999043941497803
AP-1 B-DNA B-DNA 0.3389201760292053
( I-DNA I-DNA 0.5123388767242432
III I-DNA I-DNA 0.7810865044593811
) E-DNA I-DNA 0.5416213274002075
, O I-DNA 0.5307521224021912
AP3-L S-DNA I-DNA 0.44367942214012146
, O I-DNA 0.5199951529502869
and O I-DNA 0.5670078992843628
DBF B-DNA I-DNA 0.7194008231163025
sites E-DNA E-DNA 0.9932805895805359
and O O 0.9958009123802185
in O O 0.9998109936714172
the O O 0.99972003698349
AP3-L S-DNA B-DNA 0.3457479774951935
and O I-DNA 0.3204762041568756
DBF-sites S-DNA E-DNA 0.3205171227455139
, O O 0.9267880320549011
whereas O O 0.9998169541358948
viruses O O 0.928234338760376
mutated O O 0.9961112141609192

can O O 0.9903541803359985
still O O 0.9999425411224365
be O O 0.9999743700027466
reprogrammed O O 0.9919765591621399
to O O 0.9998817443847656
express O O 0.9999083280563354
their O O 0.9992597699165344
globin B-DNA B-DNA 0.4390324652194977
genes E-DNA E-DNA 0.9442477226257324
in O O 0.9990185499191284
erythroid B-cell_type B-cell_type 0.6569056510925293
heterokaryons E-cell_type E-cell_type 0.8930463194847107
, O O 0.9893659353256226
indicating O O 0.9999862909317017
that O O 0.9999974966049194
de O O 0.9660469889640808
novo O O 0.9660360813140869
induction O O 0.9991480112075806
of O O 0.9999690055847168
GATA-1 S-protein S-protein 0.9187217950820923
is O O 0.9992656111717224
not O O 0.9998607635498047
required O O 0.9999071359634399
for O O 0.9999829530715942
globin B-DNA B-DNA 0.3070216178894043
gene E-DNA E-DNA 0.9163571000099182
activation O O 0.9442899227142334
following O O 0.9990267753601074
cell O O 0.960576593875885
fusion O O 0.9539917707443237
. O O 0.9999539852142334
Role O O 0.9806964993476868
of O O 0.9992101192474365
HIV-1 B-protein O 0.4859147071838379
Nef E-protein S-protein 0.4986242353916168
expression O O 0.9906120896339417
in O O 0.9999351501464844
activation O O 0.8696250915527344

cell I-cell_line I-cell_line 0.44141456484794617
lines E-cell_line E-cell_line 0.9964884519577026
lacking O O 0.9996227025985718
JAK3 S-protein S-protein 0.8011516332626343
. O O 0.9998100399971008
Although O O 0.9998857975006104
IL-2 S-protein S-protein 0.9985445737838745
-induced O O 0.996508777141571
phosphorylation O O 0.9915105700492859
of O O 0.9997997879981995
IL-2R B-protein B-protein 0.5256181359291077
beta E-protein E-protein 0.974131166934967
, O O 0.9891436696052551
JAK1 S-protein S-protein 0.982368528842926
, O O 0.9955488443374634
and O O 0.99931800365448
STAT5 S-protein S-protein 0.982111930847168
all O O 0.9993853569030762
required O O 0.9999595880508423
the O O 0.9999899864196777
presence O O 0.9997139573097229
of O O 0.999971866607666
JAK3 S-protein S-protein 0.9818560481071472
, O O 0.997589111328125
IL-4 S-protein S-protein 0.9979957342147827
-mediated O O 0.9926618337631226
phosphorylation O O 0.9860479831695557
of O O 0.9996563196182251
JAK1 S-protein S-protein 0.9214190244674683

The O O 0.9996405839920044
development O O 0.9973575472831726
of O O 0.9998626708984375
psychosis O B-Disease 0.9771215319633484
related O O 0.9811798334121704
to O O 0.9998468160629272
antiepileptic O O 0.7184197306632996
drug O O 0.6391439437866211
treatment O O 0.9094327092170715
is O O 0.999933123588562
usually O O 0.9999376535415649
attributed O O 0.9999713897705078
to O O 0.9999895095825195
the O O 0.9997926354408264
interaction O O 0.9984889030456543
between O O 0.9999665021896362
the O O 0.9994940757751465
epileptic O O 0.4966726303100586
brain O O 0.585870623588562
substratum O O 0.8049352169036865
and O O 0.996227502822876
the O O 0.9994031190872192
antiepileptic O O 0.5375458002090454
drugs O O 0.840021014213562
. O O 0.9999889135360718

, O O 0.9907517433166504
we O O 0.9999736547470093
have O O 0.9999966621398926
studied O O 0.9999167919158936
their O O 0.9999682903289795
pattern O O 0.9986306428909302
of O O 0.9998244643211365
expression O O 0.9968515038490295
in O O 0.9999871253967285
mouse O O 0.660197377204895
hematopoietic O O 0.5042191743850708
tissues O O 0.8050201535224915
in O O 0.999891996383667
the O O 0.9999275207519531
adult O O 0.9152851700782776
and O O 0.9897286891937256
during O O 0.9996320009231567
ontogeny O O 0.5930589437484741
using O O 0.9992006421089172
an O O 0.999907374382019
anti-runt O B-protein 0.6168480515480042
box O I-protein 0.44257569313049316
antiserum O E-protein 0.707436203956604
. O O 0.9969237446784973
In O O 0.9999841451644897
the O O 0.999967098236084
adult O O 0.9035677313804626
bone O O 0.8818303942680359
marrow O O 0.9093730449676514
, O O 0.9995638728141785
we O O 0.9999691247940063
found O O 0.9998610019683838
expression O O 0.9988897442817688
of O O 0.9998244643211365

Close O O 0.9733759164810181
observation O O 0.9987296462059021
of O O 0.9999616146087646
the O O 0.9999173879623413
response O O 0.9854006171226501
status O O 0.9984789490699768
both O O 0.9999983310699463
clinically O O 0.9961326122283936
and O O 0.999670147895813
with O O 0.9999697208404541
beta O O 0.5634922385215759
- O O 0.9744815230369568
hCG O O 0.8944967985153198
values O O 0.9981467723846436
may O O 0.9999983310699463
indicate O O 0.999998927116394
whether O O 0.9999977350234985
and O O 0.9998612403869629
when O O 0.9999954700469971
more O O 0.9992930889129639
agressive O O 0.9583182334899902
combination O O 0.9788692593574524
chemotherapy O O 0.9910311698913574
should O O 0.999996542930603
be O O 0.9999853372573853
started O O 0.9998586177825928
. O O 0.9999974966049194
( O O 0.9988555908203125
ABSTRACT O O 0.9833347201347351
TRUNCATED O O 0.9995400905609131
AT O O 0.9999933242797852
250 O O 0.9896537661552429
WORDS O O 0.9987764954566956
) O O 0.9998828172683716

IL-1beta S-protein B-protein 0.7170170545578003
receptor O I-protein 0.4450961947441101
type O I-protein 0.673321008682251
1 O E-protein 0.8746407628059387
, O O 0.9592550992965698
which O O 0.9995354413986206
transduces O O 0.9984437823295593
IL-1beta S-protein S-protein 0.9456914067268372
signal O O 0.9047525525093079
. O O 0.9999215602874756
Our O O 0.9999966621398926
findings O O 0.9998856782913208
reveal O O 0.9999972581863403
that O O 0.9999803304672241
monocyte-derived B-protein O 0.6240073442459106
IL-1beta E-protein S-protein 0.4260687530040741

Side O O 0.8869554996490479
- O O 0.9954857230186462
effects O O 0.9980952143669128
tended O O 0.9999496936798096
to O O 0.9997215867042542
diminish O O 0.9787812829017639
during O O 0.9992341995239258
treatment O O 0.9959356784820557
but O O 0.999976634979248
remained O O 0.9992074370384216
significant O O 0.9992144107818604
at O O 0.999998927116394
week O O 0.9999488592147827
8 O O 0.999594509601593
. O O 0.9999984502792358

of O O 0.9955116510391235
the O O 0.9999067783355713
cells O O 0.9611977338790894
to O O 0.9997612833976746
plastic O O 0.8288891911506653
surfaces O O 0.814197838306427
and O O 0.9980939030647278
repression O O 0.9806588888168335
of O O 0.9997178912162781
the O O 0.9995385408401489
myeloperoxidase B-DNA B-DNA 0.3283296823501587
and I-DNA I-DNA 0.46399667859077454
CD34 I-DNA I-DNA 0.6781271696090698
genes E-DNA E-DNA 0.9958802461624146
. O O 0.9997954964637756
Moreover O O 0.9998538494110107
, O O 0.9999457597732544
DEM O O 0.45502352714538574

or O O 0.944656491279602

Swiss O O 0.9600409269332886
albino O O 0.5695847272872925
mice O O 0.68865567445755
prepared O O 0.9994052648544312
with O O 0.9999924898147583
intrajugular O O 0.876975953578949
catheters O O 0.693398654460907
were O O 0.9999220371246338
tested O O 0.9999898672103882
in O O 0.9999901056289673
photocell O O 0.9440776109695435
cages O O 0.9778237342834473
after O O 0.9999959468841553
administration O O 0.9993662238121033
of O O 0.9999496936798096
93 O O 0.9894223809242249
mg O O 0.9994823932647705
/ O O 0.9999303817749023
kg O O 0.9986373782157898
( O O 0.9999160766601562
LD50 O O 0.9063317775726318
) O O 0.9978300929069519
of O O 0.9997087121009827
cocaine S-Chemical B-Chemical 0.9150816798210144
and O O 0.9853460788726807
GNC92H2 S-Chemical B-Chemical 0.9212474822998047
infusions O O 0.7897130250930786
ranging O O 0.999984622001648
from O O 0.9999681711196899
30 O O 0.999055802822113
to O O 0.9998745918273926
190 O O 0.99972003698349
mg O O 0.9995648264884949
/ O O 0.9999837875366211
kg O O 0.9996405839920044
. O O 0.9999984502792358

expression O O 0.9795595407485962
through O O 0.999982476234436
an O O 0.999970555305481
effect O O 0.9996557235717773
mediated O O 0.9999574422836304
by O O 0.9999936819076538
estrogen B-protein B-protein 0.5457243919372559
receptor I-protein I-protein 0.5093133449554443
beta E-protein E-protein 0.9637484550476074
( O O 0.9784911870956421
ERbeta S-protein S-protein 0.9314771890640259
) O O 0.9813293218612671
. O O 0.99997878074646
We O O 0.9999915361404419
also O O 0.9999934434890747
report O O 0.9999964237213135
that O O 0.9999946355819702
in O O 0.9995761513710022
RAW B-cell_line B-cell_line 0.7664409279823303
264.7 I-cell_line I-cell_line 0.6028931140899658
cells E-cell_line E-cell_line 0.9977061748504639
, O O 0.9996249675750732
an O O 0.9999749660491943
E O O 0.6186783313751221

Using O O 0.9986127614974976
macaque O O 0.45627883076667786
monkeys O O 0.6350891590118408
with O O 0.9998704195022583
different O O 0.9989829659461975
types O O 0.9994049072265625
of O O 0.9998924732208252
MPTP S-Chemical B-Chemical 0.9101995229721069
- O O 0.9693139791488647
induced O O 0.996278703212738
parkinsonism O B-Disease 0.9870380163192749
, O O 0.9919756054878235
the O O 0.9999258518218994
current O O 0.9949772953987122
study O O 0.9997678399085999
evaluated O O 0.9999712705612183
the O O 0.9999836683273315
degree O O 0.999714195728302
to O O 0.9999961853027344
which O O 0.9999983310699463
rate O O 0.9992913007736206
of O O 0.999750554561615
symptom O O 0.5683751702308655
progression O O 0.5588634610176086
, O O 0.9989175796508789
symptom O O 0.6628148555755615
severity O O 0.534356951713562
, O O 0.9990033507347107
and O O 0.9998002648353577
response O O 0.9894481897354126
to O O 0.9998170733451843
and O O 0.9998557567596436
duration O O 0.9923580288887024
of O O 0.999915361404419
levodopa S-Chemical B-Chemical 0.9238747358322144
therapy O O 0.9603862762451172
may O O 0.9999957084655762
be O O 0.9999934434890747
involved O O 0.9999721050262451
in O O 0.9999912977218628
the O O 0.9999510049819946
development O O 0.998735249042511
of O O 0.999964714050293
LIDs O B-Disease 0.9500990509986877
. O O 0.9990360736846924

. O O 0.9958838820457458
Increased O O 0.9994720816612244
levels O O 0.9997690320014954
of O O 0.9999547004699707
membrane-associated O O 0.8115690350532532
PKC S-protein S-protein 0.8775027990341187
activity O O 0.9991076588630676
persisted O O 0.9999855756759644
until O O 0.9999984502792358
17-29 O O 0.9972901344299316
days O O 0.9998354911804199
. O O 0.9999986886978149
However O O 0.9999731779098511
, O O 0.9999725818634033
longer O O 0.9985190033912659
periods O O 0.9999732971191406
of O O 0.9999721050262451
incubation O O 0.9773043394088745

GDSP O O 0.37842363119125366

However O O 0.9988365769386292
, O O 0.9999809265136719
the O O 0.999927282333374
increase O O 0.9732768535614014
in O O 0.9960575103759766
release O O 0.9791247248649597
of O O 0.9979380965232849
ACh S-Chemical B-Chemical 0.9318301677703857
produced O O 0.9938285946846008
by O O 0.9999963045120239
the O O 0.9999561309814453
first O O 0.995840847492218
application O O 0.999526858329773
of O O 0.9998365640640259
KCl S-Chemical B-Chemical 0.9197297692298889
was O O 0.9963122010231018
2 O O 0.9978331923484802
- O O 0.9984927177429199
fold O O 0.9977684020996094
higher O O 0.999896764755249
in O O 0.9999796152114868
WSP O O 0.5234563946723938
versus O O 0.998349666595459
WSR O O 0.48045164346694946
mice O O 0.957460343837738
. O O 0.9999985694885254

strong O O 0.9633435606956482
inhibition O O 0.9944592714309692
seen O O 0.9999854564666748
with O O 0.9999730587005615
IL-4 S-protein S-protein 0.9885989427566528
in O O 0.9996567964553833
NK B-cell_type B-cell_type 0.8767803311347961
cells E-cell_type E-cell_type 0.972625732421875
. O O 0.9998007416725159
Additionally O O 0.999981164932251
, O O 0.9999730587005615
IL-13 S-protein S-protein 0.9777226448059082
suppresses O O 0.9996691942214966
IL-2-induced O O 0.6040107011795044
NK O O 0.3571157455444336
cytolytic O O 0.6881511807441711
and O O 0.9664493203163147
proliferative O O 0.960786759853363
activities O O 0.9967999458312988
although O O 0.9999938011169434
less O O 0.9996253252029419
efficiently O O 0.9993448853492737
than O O 0.9999570846557617
IL-4 S-protein S-protein 0.9563467502593994
. O O 0.9996156692504883
In O O 0.9991363883018494
T B-cell_type B-cell_type 0.8111938238143921
cells E-cell_type E-cell_type 0.9552223682403564

element E-DNA E-DNA 0.8281519412994385

I B-protein B-protein 0.33943480253219604
kappaB I-protein I-protein 0.461830198764801
alpha E-protein E-protein 0.9720930457115173
nor O O 0.9962891340255737
a O O 0.9998705387115479
mutation O O 0.9856847524642944
in O O 0.9999023675918579
p50 S-protein S-protein 0.8621213436126709
or O O 0.9874093532562256
relA S-protein S-protein 0.5798370242118835
, O O 0.9970436692237854
the O O 0.9999842643737793
two O O 0.9989112615585327
major O O 0.9319655299186707
subunits O O 0.7013903856277466
of O O 0.9930204749107361
NF-kappaB S-protein S-protein 0.985569417476654
in O O 0.9998492002487183
this O O 0.9998018145561218
cell O O 0.9003913998603821
line O O 0.5596235394477844
, O O 0.99603670835495
accounts O O 0.9999502897262573
for O O 0.9999912977218628
this O O 0.9997020363807678
phosphorylation O O 0.8413445949554443
defect O O 0.8641952276229858
. O O 0.9999215602874756
As O O 0.9997290968894958
well O O 0.9988147020339966
as O O 0.9999769926071167
culminating O O 0.9997491240501404
in O O 0.9999798536300659
the O O 0.9999665021896362
inducible O O 0.9327391386032104
phosphorylation O O 0.9610670208930969
of O O 0.9996556043624878
I B-protein B-protein 0.7559429407119751
kappaB E-protein I-protein 0.6831189393997192
alpha O E-protein 0.9434292912483215
on O O 0.9957072138786316
serines O O 0.8294340372085571
32 O O 0.9238220453262329
and O O 0.988860547542572
36 O O 0.8585858941078186
, O O 0.9999034404754639
all O O 0.9999940395355225
the O O 0.9999836683273315
stimuli O O 0.972785234451294
that O O 0.9999487400054932

The O O 0.9995018243789673
anti O O 0.9508174657821655
- O O 0.9799051284790039
dementia B-Disease O 0.6681901812553406
effects O O 0.9754155874252319
of O O 0.9997597336769104
s B-Chemical B-Chemical 0.8843932747840881
- I-Chemical I-Chemical 0.9939351677894592
limonene I-Chemical E-Chemical 0.9254848957061768
and O O 0.8993062973022461
s B-Chemical B-Chemical 0.8584222793579102
- I-Chemical I-Chemical 0.9913724660873413
perillyl I-Chemical I-Chemical 0.95259028673172
alcohol I-Chemical I-Chemical 0.9376800060272217
were O O 0.9957582354545593
observed O O 0.9998660087585449
using O O 0.999995231628418
the O O 0.9999274015426636
passive O O 0.9340031147003174
avoidance O O 0.785551905632019
test O O 0.9744219779968262
( O O 0.9999716281890869
PA O O 0.6132067441940308
) O O 0.9975589513778687
and O O 0.9999901056289673
the O O 0.9999886751174927
open O O 0.9182845950126648
field O O 0.9521356225013733
habituation O O 0.9081366658210754
test O O 0.9965769648551941
( O O 0.999987006187439
OFH O O 0.7999375462532043
) O O 0.9982931017875671
. O O 0.9999949932098389

Regulation O O 0.988018274307251
of O O 0.9995697140693665
transcription O O 0.8767481446266174
of O O 0.9977051615715027
the O O 0.9998034834861755
human B-DNA B-DNA 0.503970205783844
erythropoietin I-DNA I-DNA 0.6257688403129578
receptor I-DNA I-DNA 0.6485871076583862
gene E-DNA E-DNA 0.9913427829742432
by O O 0.9993948936462402
proteins O O 0.9115613698959351
binding O O 0.9942014813423157
to O O 0.9997522234916687
GATA-1 B-DNA B-DNA 0.7036601305007935
and I-DNA I-DNA 0.9181116223335266
Sp1 I-DNA I-DNA 0.4792013168334961
motifs E-DNA E-DNA 0.9441968202590942
. O O 0.9995070695877075
Erythropoietin S-protein S-protein 0.682246744632721
( O O 0.9013643860816956

cells E-cell_type E-cell_type 0.6165163516998291

Mitochondrial O O 0.8156497478485107
radiocalcium S-Chemical B-Chemical 0.9193984270095825
uptakes O O 0.8668233752250671
were O O 0.9999631643295288
significantly O O 0.9999511241912842
decreased O O 0.9988839030265808
in O O 0.9999521970748901
animals O O 0.9580369591712952
pretreated O O 0.9996583461761475
with O O 0.9999829530715942
acetylsalicylic B-Chemical B-Chemical 0.9102290272712708
acid E-Chemical I-Chemical 0.952551543712616
or O O 0.8853659629821777
dipyridamole S-Chemical B-Chemical 0.9344425797462463
or O O 0.9744876623153687
when O O 0.9997020363807678
hydrocortisone S-Chemical B-Chemical 0.9341594576835632
was O O 0.995367169380188
added O O 0.9999188184738159
to O O 0.999981164932251
the O O 0.998863935470581
epinephrine S-Chemical B-Chemical 0.9240482449531555
infusion O O 0.9001529216766357
( O O 0.9993364214897156
2 O O 0.9995777010917664
, O O 0.9997734427452087
682 O O 0.9978658556938171
, O O 0.9999107122421265
2 O O 0.9995013475418091
, O O 0.9998061060905457
803 O O 0.9962062835693359
, O O 0.9998699426651001
and O O 0.9998784065246582
3 O O 0.9992769360542297
, O O 0.9999103546142578
424 O O 0.9993366599082947
counts O O 0.9997748732566833
per O O 0.9999802112579346
minute O O 0.9997857213020325
per O O 0.9999483823776245
gram O O 0.9993466734886169
of O O 0.9998878240585327
dried O O 0.6479159593582153
fraction O O 0.465665340423584
, O O 0.9961488246917725
respectively O O 0.9999603033065796
) O O 0.9999123811721802
. O O 0.9999958276748657

lymphomas O O 0.6143883466720581
exhibiting O O 0.9940675497055054
plasmacytoid O O 0.6618783473968506
differentiation O O 0.9832430481910706
. O O 0.9999912977218628
The O O 0.9999843835830688
translocated B-DNA O 0.6193732023239136
PAX-5 I-DNA B-DNA 0.46750351786613464
gene E-DNA E-DNA 0.9747524857521057
is O O 0.9973949193954468
deregulated O O 0.9994627833366394
by O O 0.9999959468841553
the O O 0.9999479055404663
insertion O O 0.9654422402381897
of O O 0.9988094568252563
IgH B-DNA B-DNA 0.5281458497047424
regulatory I-DNA I-DNA 0.7228716015815735
elements E-DNA E-DNA 0.985081672668457
into O O 0.9994812607765198
its O O 0.9996445178985596
5 B-DNA B-DNA 0.4845082461833954
' I-DNA I-DNA 0.7215628623962402
region E-DNA E-DNA 0.9696460962295532
, O O 0.9949252605438232
which O O 0.9999487400054932
may O O 0.9999934434890747
contribute O O 0.9999978542327881
to O O 0.9999834299087524
tumorigenesis O O 0.8837080001831055

NF-kappaB S-protein S-protein 0.9610446691513062
translocation O O 0.9902594685554504
induced O O 0.999972939491272
by O O 0.999984860420227
HIV-1 O O 0.8548281192779541
replication O O 0.9617903828620911
itself O O 0.999708354473114
in O O 0.9999363422393799
chronically B-cell_line O 0.5315512418746948
infected I-cell_line O 0.5842326879501343
U937 I-cell_line B-cell_line 0.6557500958442688
cells E-cell_line E-cell_line 0.9954713582992554
, O O 0.9983168840408325

Organophosphate S-Chemical B-Chemical 0.9255813956260681
- O O 0.934230625629425
induced O O 0.9977748990058899
convulsions O B-Disease 0.9662967920303345
and O O 0.9637954831123352
prevention O O 0.9606953263282776
of O O 0.9988534450531006
neuropathological O O 0.713647723197937
damages O O 0.916958212852478
. O O 0.9993763566017151

silent B-DNA O 0.7259228825569153
DRA I-DNA B-DNA 0.34710559248924255
reporter I-DNA I-DNA 0.5615242123603821
construct E-DNA E-DNA 0.9982553124427795
. O O 0.999736487865448
Moreover O O 0.9996750354766846
, O O 0.9999681711196899
replacement O O 0.9935711622238159
of O O 0.9997989535331726
the O O 0.9998483657836914
DQB B-DNA B-DNA 0.50626540184021
X2-box E-DNA E-DNA 0.9465402364730835
with O O 0.9982618689537048
the O O 0.9998688697814941
DRA B-DNA B-DNA 0.6938461661338806
X2-box E-DNA E-DNA 0.9475813508033752
markedly O O 0.9841354489326477
diminished O O 0.9996384382247925
the O O 0.9999867677688599
activity O O 0.9994063377380371
of O O 0.999984860420227
the O O 0.9998679161071777
DQB B-DNA B-DNA 0.7523663640022278
promoter E-DNA E-DNA 0.9901559352874756
in O O 0.9990518689155579
the O O 0.9999597072601318
mutant B-cell_line O 0.5065964460372925
cell E-cell_line O 0.5188931226730347
. O O 0.9989118576049805
None O O 0.999626874923706
of O O 0.9999922513961792
the O O 0.9999668598175049
hybrid B-DNA O 0.4139310419559479

is O O 0.9910163879394531
transactivated O O 0.9961258769035339
by O O 0.999984622001648
TNF-alpha S-protein S-protein 0.9887962341308594
upon O O 0.9977560639381409
transfection O O 0.9834266901016235
in O O 0.9999668598175049
293 B-cell_line B-cell_line 0.6074829697608948
cells E-cell_line E-cell_line 0.967888593673706
. O O 0.9998948574066162
We O O 0.9999923706054688
propose O O 0.9999979734420776
that O O 0.9999955892562866
direct O O 0.9853034019470215
interaction O O 0.9968891739845276

Elevated O O 0.894588828086853
plus O O 0.9662095308303833
maze O O 0.820205569267273
and O O 0.9991496801376343
passive O O 0.8771827220916748
avoidance O O 0.7159674167633057
apparatus O O 0.7807132601737976
served O O 0.9997534155845642
as O O 0.9999966621398926
the O O 0.9999721050262451
exteroceptive O O 0.6459864974021912
behavioral O O 0.8124391436576843
models O O 0.9892569184303284
for O O 0.9999586343765259
testing O O 0.9811770915985107
memory O O 0.7338719964027405
. O O 0.9995917677879333

p50 B-protein B-protein 0.64117032289505
homodimers E-protein E-protein 0.9590122699737549
or O O 0.9947380423545837
closely O O 0.7764660716056824
related O O 0.894059419631958
species O O 0.826478898525238
, O O 0.9991018772125244
rather O O 0.9999450445175171
than O O 0.9999865293502808
the O O 0.9998542070388794
p50-p56 B-protein B-protein 0.4637741148471832
heterodimer E-protein E-protein 0.9371495842933655
of O O 0.9828920364379883
NF-kappa B-protein B-protein 0.8776285648345947
B E-protein E-protein 0.9895558953285217
that O O 0.9985533356666565
is O O 0.9999879598617554
the O O 0.9999796152114868
predominant O O 0.8694533705711365
NF-kappa B-protein B-protein 0.5941188335418701
B E-protein I-protein 0.4772651493549347
species O E-protein 0.8423147201538086
in O O 0.9982036352157593

Finally O O 0.9949102997779846
, O O 0.9999748468399048
6 O O 0.9991262555122375
weeks O O 0.9999713897705078
later O O 0.9999384880065918
, O O 0.9999521970748901
diffuse O O 0.9623980522155762
chorioretinal B-Disease O 0.48654693365097046
atrophy I-Disease O 0.8635515570640564
with O O 0.990812361240387
optic B-Disease B-Disease 0.6630163788795471
atrophy I-Disease I-Disease 0.8841444849967957
occurred O O 0.8460001349449158
and O O 0.9993069171905518
the O O 0.9999268054962158
vision O O 0.8012909293174744
in O O 0.9975894689559937
his O O 0.9987108707427979
left O O 0.9456139802932739
eye O O 0.5411335825920105
was O O 0.9989116191864014
lost O O 0.9754085540771484
. O O 0.9999910593032837

of O O 0.9956274032592773
NF-kappaB-responsive B-DNA B-DNA 0.5786105394363403
reporter I-DNA I-DNA 0.5933226346969604
gene E-DNA E-DNA 0.9887209534645081
was O O 0.9975415468215942
not O O 0.9998785257339478
inhibited O O 0.9997726082801819
by O O 0.9999932050704956
IL-1 S-protein B-protein 0.8023792505264282
receptor O I-protein 0.550248920917511
antagonist O E-protein 0.9005759358406067
. O O 0.9909828305244446
TLR2 S-protein S-protein 0.7134767174720764
and O O 0.9761881232261658
TLR4 S-protein S-protein 0.8252736330032349
were O O 0.9994663596153259
expressed O O 0.9998576641082764
on O O 0.9999035596847534
the O O 0.9998674392700195
cell O O 0.8948869109153748
surface O O 0.9183626174926758
of O O 0.9978581070899963
HDMEC S-cell_type S-cell_line 0.7335677742958069
and O O 0.8861591815948486
THP-1 B-cell_line B-cell_line 0.6726545691490173
cells E-cell_line E-cell_line 0.9509782791137695
. O O 0.999891996383667
These O O 0.9999955892562866
findings O O 0.9993618130683899

turnover O O 0.9520784616470337
demonstrated O O 0.9999649524688721
an O O 0.9999954700469971
increased O O 0.9988014698028564
degradation O O 0.9962402582168579
of O O 0.9999681711196899
IkappaBalpha S-protein S-protein 0.994724690914154
in O O 0.9997825026512146
HIV-1-infected B-cell_line B-cell_line 0.424304723739624
cells E-cell_line E-cell_line 0.544279158115387
that O O 0.9985541701316833
may O O 0.9999932050704956
account O O 0.9999978542327881
for O O 0.9999951124191284
the O O 0.999981164932251
constitutive B-DNA O 0.9596448540687561
DNA E-DNA O 0.9329971075057983
binding O O 0.9696690440177917
activity O O 0.9981784820556641
. O O 0.9999982118606567
A O O 0.9999786615371704
dramatic O O 0.9934705495834351
increase O O 0.9985527396202087
in O O 0.9998354911804199
the O O 0.9996894598007202
intracellular O O 0.9320992231369019
levels O O 0.9925353527069092
of O O 0.9998974800109863
NF-kappaB S-protein B-protein 0.9307940006256104
subunits O E-protein 0.8072761297225952
c-Rel S-protein S-protein 0.9674938321113586
and O O 0.9952497482299805
NF-kappaB2 B-protein S-protein 0.8965435028076172

with O O 0.9967935681343079
those O O 0.9999697208404541
of O O 0.999990701675415
a O O 0.9999380111694336
variety O O 0.994426965713501
of O O 0.9999028444290161
proteins O O 0.8814657330513
involved O O 0.9996658563613892
in O O 0.9999634027481079
transcription O O 0.9604353904724121
, O O 0.999868631362915
suggesting O O 0.9999949932098389
that O O 0.9999986886978149
the O O 0.9998911619186401
G0S24 B-protein B-protein 0.317155659198761
product E-protein E-protein 0.8347928524017334
has O O 0.9996639490127563
a O O 0.9999648332595825
similar O O 0.9994950294494629
role O O 0.999083399772644
. O O 0.9999945163726807
Regulation O O 0.993970513343811

, O O 0.9503923654556274

OBJECTIVES O O 0.9723161458969116
: O O 0.9999613761901855
To O O 0.9999862909317017
study O O 0.9999676942825317
the O O 0.9999637603759766
long O O 0.9808552861213684
- O O 0.9972666501998901
term O O 0.9991113543510437
effects O O 0.9994118213653564
of O O 0.9999493360519409
androgen O B-Chemical 0.9342102408409119
treatment O O 0.9793072938919067
on O O 0.9999798536300659
atherosclerosis O B-Disease 0.9726883172988892
in O O 0.9911077618598938
postmenopausal O O 0.7171759605407715
women O O 0.7354367971420288
. O O 0.9999856948852539

its O O 0.9973594546318054
neglect O O 0.9798396229743958
in O O 0.9999054670333862
naive B-cell_type B-cell_type 0.7830181121826172
T I-cell_type I-cell_type 0.905768871307373
cells E-cell_type E-cell_type 0.9681013822555542
. O O 0.9997895359992981
These O O 0.9999991655349731
alternative O O 0.966813862323761
polyadenylation O O 0.8132115602493286
events O O 0.9756278395652771

hMR S-protein S-protein 0.47155001759529114
) O O 0.9463849067687988
, O O 0.9999195337295532
we O O 0.9999831914901733
developed O O 0.9999569654464722
a O O 0.9999853372573853
new O O 0.9721227884292603
monoclonal B-protein B-protein 0.7211310863494873
antibody E-protein E-protein 0.9788532853126526
( O O 0.9801130294799805
mAb S-protein S-protein 0.9637665748596191
) O O 0.9363608956336975
raised O O 0.9997902512550354
against O O 0.9999781847000122
the O O 0.9998296499252319
hormone-binding B-protein B-protein 0.5720605850219727
domain E-protein E-protein 0.9647844433784485
( O O 0.986761212348938
HBD S-protein S-protein 0.9871845841407776
) O O 0.9938826560974121
. O O 0.9999855756759644
For O O 0.9999833106994629
this O O 0.9999876022338867

Tax S-protein S-protein 0.9213228821754456
. O O 0.9995803236961365
IL-2 S-protein S-protein 0.9831036329269409
induced O O 0.9996528625488281
the O O 0.9999192953109741
DNA O O 0.939559280872345
binding O O 0.8923344612121582
activity O O 0.991148829460144
of O O 0.9997749924659729
STAT3 S-protein S-protein 0.9768060445785522
and O O 0.9928239583969116
STAT5 S-protein S-protein 0.9621782898902893
of O O 0.9700868725776672

. O O 0.9957497119903564
In O O 0.9994900226593018
vitro O O 0.9897899031639099
inhibition O O 0.9961168766021729
of O O 0.9999591112136841
NF-kappa B-protein B-protein 0.7141705751419067
B E-protein E-protein 0.9966163039207458
expression O O 0.9984826445579529
by O O 0.9999920129776001
antisense O O 0.7641255259513855
oligodeoxynucleotides O O 0.38994133472442627
( O O 0.9771511554718018
ODNs O S-protein 0.47304052114486694
) O O 0.9544569849967957
inhibited O O 0.993669331073761
growth O O 0.9844992756843567
of O O 0.999830961227417
these O O 0.9997943043708801
culture-adapted B-cell_line B-cell_line 0.4265546202659607
Tax-transformed I-cell_line I-cell_line 0.573762834072113
fibroblasts E-cell_line E-cell_line 0.937929093837738
as O O 0.999136745929718
well O O 0.9995120763778687
as O O 0.9999876022338867
an O O 0.9998575448989868
HTLV-I-transformed B-cell_line B-cell_line 0.5614254474639893
human I-cell_line I-cell_line 0.798123836517334
lymphocyte I-cell_line I-cell_line 0.9154926538467407
line E-cell_line E-cell_line 0.9775951504707336
. O O 0.9996458292007446
In O O 0.9991713762283325

the O O 0.9969770908355713
GATA-binding B-protein B-protein 0.5718635320663452
proteins E-protein E-protein 0.9947946667671204
, O O 0.998913049697876
we O O 0.9999922513961792
hope O O 0.9999935626983643
to O O 0.9999954700469971
learn O O 0.9999889135360718
what O O 0.9999920129776001
proteins O O 0.8592791557312012
GATA-1 S-protein S-protein 0.7383687496185303
binds O O 0.9965856075286865
to O O 0.9999653100967407
in O O 0.9997033476829529
the O O 0.9997498393058777
basic O O 0.8868786096572876
transcription O O 0.7340161204338074
machinery O O 0.6650069355964661
or O O 0.9995167255401611

do O O 0.9876876473426819

the O O 0.9975766539573669
human B-DNA B-DNA 0.49834001064300537
androgen I-DNA I-DNA 0.5464485287666321
receptor I-DNA I-DNA 0.530431866645813
gene E-DNA E-DNA 0.9919609427452087
. O O 0.9996993541717529
This O O 0.9999836683273315
finding O O 0.9995949864387512
supports O O 0.9999890327453613
a O O 0.9999853372573853
polyclonal O O 0.8706276416778564
reactive O O 0.7699369192123413
process O O 0.9294798970222473
as O O 0.9999951124191284
the O O 0.9999918937683105
underlying O O 0.9707109332084656
etiology O O 0.9805245399475098
for O O 0.9999526739120483
palmar O O 0.6685770153999329
fibromatosis O O 0.7125017046928406

Both O O 0.9979990124702454
GATA-1 S-protein S-protein 0.9570070505142212
and O O 0.9743020534515381
CACCC-binding B-protein B-protein 0.3636185824871063
proteins E-protein E-protein 0.9916648268699646
are O O 0.9998854398727417
critical O O 0.999203622341156
for O O 0.9999872446060181
the O O 0.999941349029541
developmentally O O 0.9626832604408264
regulated O O 0.9817700982093811
expression O O 0.9973887801170349
of O O 0.999956488609314
erythroid-specific B-DNA B-DNA 0.4864100217819214
genes E-DNA E-DNA 0.9876232147216797
. O O 0.9998724460601807
We O O 0.999984622001648
hypothesize O O 0.9998900890350342
that O O 0.9999911785125732
interference O O 0.9924185276031494
in O O 0.9999030828475952
DNA-binding O O 0.8347888588905334
activities O O 0.989059329032898
of O O 0.9998612403869629
GATA-1 S-protein S-protein 0.9193483591079712
and O O 0.9925137162208557
CACCC-binding B-protein B-protein 0.3561495542526245

We O O 0.9990471005439758
suspect O O 0.9999966621398926
that O O 0.9999992847442627
the O O 0.9999207258224487
C/EBP B-DNA B-protein 0.26709356904029846
epsilon I-DNA I-protein 0.33785027265548706
promoter/enhancer E-DNA E-protein 0.7382875084877014
contains O O 0.9979594945907593
a O O 0.9999822378158569
retinoic B-DNA B-DNA 0.7581793665885925
acid-response I-DNA I-DNA 0.4408785104751587
element E-DNA E-DNA 0.813194215297699
that O O 0.9952492713928223
is O O 0.9999290704727173
directly O O 0.9940472841262817
stimulated O O 0.9987467527389526
by O O 0.9999858140945435
retinoids O O 0.5980063080787659
. O O 0.99983811378479
Dual O O 0.96262526512146
effects O O 0.9993731379508972
of O O 0.9999784231185913
LPS B-protein B-protein 0.8946863412857056
antibodies E-protein E-protein 0.7655547857284546

The O O 0.9993993043899536
effects O O 0.9997283816337585
of O O 0.9999786615371704
the O O 0.9999312162399292
adjunctive O O 0.9151715636253357
bupropion S-Chemical B-Chemical 0.8968209028244019
on O O 0.9975461363792419
male O O 0.877165675163269
sexual O O 0.6952825784683228
dysfunction O O 0.9655796885490417
induced O O 0.9696717262268066
by O O 0.9999114274978638
a O O 0.9998723268508911
selective B-Chemical O 0.9163016676902771
serotonin I-Chemical B-Chemical 0.922501802444458
reuptake I-Chemical O 0.8890988230705261
inhibitor E-Chemical O 0.9277734160423279
: O O 0.9559008479118347
a O O 0.999924898147583
double O O 0.976838231086731
- O O 0.9962955117225647
blind O O 0.9537534713745117
placebo O O 0.8747893571853638
- O O 0.9932592511177063
controlled O O 0.9848508834838867
and O O 0.999681830406189
randomized O O 0.9926294088363647
study O O 0.9997474551200867
. O O 0.999997615814209

dependently O O 0.9882833957672119

Raloxifene B-Chemical B-Chemical 0.9171232581138611
did O O 0.9994082450866699
not O O 0.9998074173927307
increase O O 0.9975361824035645
risk O O 0.9847226738929749
for O O 0.9995934367179871
cataracts B-Disease B-Disease 0.9449468851089478
( O O 0.9751983880996704
RR O O 0.39668431878089905
0 O O 0.757434606552124
. O O 0.9989311099052429
9 O O 0.9984470009803772
; O O 0.999931812286377
95 O O 0.9996366500854492
% O O 0.9999613761901855
CI O O 0.8437893986701965
0 O O 0.9920377731323242
. O O 0.9999728202819824
8 O O 0.9998008608818054
- O O 0.9985978007316589
1 O O 0.9994458556175232
. O O 0.999875545501709
1 O O 0.9979100823402405
) O O 0.9965716600418091
, O O 0.9999333620071411
gallbladder B-Disease B-Disease 0.6851247549057007
disease I-Disease I-Disease 0.9895979166030884
( O O 0.9741844534873962
RR O O 0.49754199385643005
1 O O 0.8528883457183838
. O O 0.9994955062866211
0 O O 0.9991900324821472
; O O 0.9999366998672485
95 O O 0.999607503414154
% O O 0.9999650716781616
CI O O 0.82257080078125
0 O O 0.9927873015403748
. O O 0.9999754428863525
7 O O 0.9997157454490662
- O O 0.9986132383346558
1 O O 0.9995715022087097
. O O 0.9999065399169922
3 O O 0.9981446266174316
) O O 0.9952432513237
, O O 0.9999425411224365
endometrial B-Disease B-Disease 0.7048401236534119
hyperplasia I-Disease I-Disease 0.8844159245491028
( O O 0.9603536128997803
RR O O 0.5431143641471863
1 O O 0.8138649463653564
. O O 0.9992614388465881
3 O O 0.9985187649726868
; O O 0.999920129776001
95 O O 0.9995781779289246
% O O 0.9999632835388184
CI O O 0.7910699844360352
0 O O 0.9910983443260193
. O O 0.9999760389328003
4 O O 0.9997205138206482
- O O 0.9983962178230286
5 O O 0.9995679259300232
. O O 0.9998736381530762
1 O O 0.9982433319091797
) O O 0.9952933192253113
, O O 0.9998952150344849
or O O 0.9996046423912048
endometrial B-Disease B-Disease 0.6877443194389343
cancer I-Disease I-Disease 0.9596958160400391
( O O 0.9605382084846497
RR O O 0.5170043706893921
0 O O 0.9146678447723389
. O O 0.9997418522834778
9 O O 0.9991647005081177
; O O 0.9999332427978516
95 O O 0.9997168183326721
% O O 0.9999707937240601
CI O O 0.8626500964164734
0 O O 0.9941902160644531
. O O 0.9999818801879883
3 O O 0.999713122844696
- O O 0.9994845390319824
2 O O 0.9998231530189514
. O O 0.9999157190322876
7 O O 0.9993705153465271
) O O 0.9990026354789734
. O O 0.9999903440475464

known O O 0.989590585231781

Gamma B-Chemical B-Chemical 0.9383410811424255
- I-Chemical I-Chemical 0.9846974611282349
hexachlorocyclohexane E-Chemical I-Chemical 0.9502882957458496
( O O 0.9457303881645203
gamma B-Chemical B-Chemical 0.9034820795059204
- I-Chemical I-Chemical 0.9909278750419617
HCH E-Chemical I-Chemical 0.9627661108970642
) O O 0.680020809173584
, O O 0.9997499585151672
the O O 0.999988317489624
active O O 0.9952360987663269
ingredient O O 0.992660403251648
of O O 0.9984449744224548
the O O 0.9994750618934631
insecticide O O 0.5941131114959717
lindane S-Chemical B-Chemical 0.7383105158805847
, O O 0.9924833178520203
has O O 0.9999865293502808
been O O 0.9999419450759888
shown O O 0.9999940395355225
to O O 0.999962329864502
decrease O O 0.9907869696617126
seizure O B-Disease 0.9643361568450928
threshold O O 0.5183189511299133
to O O 0.9973127245903015
pentylenetrazol O B-Chemical 0.9319291114807129
( O O 0.786552906036377
PTZ S-Chemical B-Chemical 0.7773144841194153
) O O 0.4867720603942871
3 O O 0.8199636936187744
h O O 0.9279876947402954
after O O 0.9998255372047424
exposure O O 0.9547663927078247
to O O 0.9995067119598389
gamma B-Chemical B-Chemical 0.8858696222305298
- I-Chemical I-Chemical 0.9920392036437988
HCH E-Chemical I-Chemical 0.9591911435127258
and O O 0.9944128394126892
conversely O O 0.9969441294670105
increase O O 0.9858134388923645
threshold O O 0.9898423552513123
to O O 0.9998905658721924
PTZ S-Chemical B-Chemical 0.9223257303237915
- O O 0.9485474228858948
induced O O 0.9976707100868225
seizures O B-Disease 0.9920592308044434
24 O O 0.8122703433036804
h O O 0.9343467354774475
after O O 0.9997889399528503
exposure O O 0.9290459752082825
to O O 0.9992905855178833
gamma B-Chemical B-Chemical 0.900419294834137
- I-Chemical I-Chemical 0.993935763835907
HCH E-Chemical I-Chemical 0.9662556052207947
( O O 0.9828715324401855
Vohland O O 0.8104618191719055
et O O 0.8903865814208984
al O O 0.9805067777633667
. O O 0.9999017715454102
1981 O O 0.9811202883720398
) O O 0.9999281167984009
. O O 0.9999980926513672

No O O 0.9926242232322693
ototoxic B-Disease O 0.5005031228065491
factor O O 0.5013030767440796
, O O 0.9942215085029602
other O O 0.9999241828918457
than O O 0.9999558925628662
DFO B-Chemical B-Chemical 0.8933122754096985
, O O 0.9939237236976624
was O O 0.9998966455459595
present O O 0.9999592304229736
in O O 0.9999924898147583
any O O 0.9999595880508423
of O O 0.9999663829803467
the O O 0.9999592304229736
patients O O 0.9997535347938538
. O O 0.9999991655349731

to O O 0.9948240518569946
activate O O 0.9983154535293579
Tcf-dependent O O 0.5838690400123596
transcription O O 0.6438723802566528
in O O 0.996753990650177
T B-cell_type B-cell_type 0.7752919793128967
lymphocytes E-cell_type E-cell_type 0.991996705532074
. O O 0.9993391633033752
In O O 0.9999679327011108
contrast O O 0.9985674619674683
, O O 0.9999572038650513
in O O 0.9994578957557678
C57MG B-cell_line B-cell_line 0.6290745139122009
fibroblast I-cell_line I-cell_line 0.6734634637832642
cells E-cell_line E-cell_line 0.8773865103721619
, O O 0.9997127652168274
lithium O O 0.7242759466171265
inactivates O O 0.9987103939056396
GSK-3beta S-protein S-protein 0.939432680606842
and O O 0.9897123575210571
induces O O 0.9996500015258789
Tcf-controlled O O 0.7681325674057007
transcription O O 0.8045843243598938
. O O 0.9990772008895874
This O O 0.9999792575836182
is O O 0.9999872446060181
the O O 0.9999970197677612
first O O 0.9993053674697876
demonstration O O 0.9990910291671753
that O O 0.9999926090240479
lithium O O 0.8614081740379333
can O O 0.9977624416351318
alter O O 0.9977526068687439
gene O O 0.975985050201416
expression O O 0.9978815913200378
of O O 0.9999567270278931
Tcf-responsive B-DNA B-DNA 0.47695720195770264
genes E-DNA E-DNA 0.9850245714187622
, O O 0.9959439635276794
and O O 0.9999282360076904
points O O 0.9998168349266052
to O O 0.9999892711639404
a O O 0.999955415725708
difference O O 0.999620795249939
in O O 0.99993896484375
regulation O O 0.9990329742431641
of O O 0.9999562501907349
Wnt O S-protein 0.5222009420394897
signaling O O 0.7786924242973328
between O O 0.9886210560798645
fibroblasts S-cell_type S-cell_type 0.8935379981994629
and O O 0.9964271187782288

kb O E-protein 0.726418673992157
from O O 0.9829322099685669
SOX9 S-DNA S-DNA 0.5068597197532654
. O O 0.999542236328125
Likewise O O 0.9999423027038574
, O O 0.9999737739562988
the O O 0.9999456405639648
breakpoints O O 0.8652974367141724
in O O 0.9997509121894836
two O O 0.9997221827507019
of O O 0.9999479055404663
the O O 0.9999803304672241
previously O O 0.9923680424690247
described O O 0.999051034450531
cases O O 0.9808820486068726
also O O 0.9999591112136841
map O O 0.9750622510910034
more O O 0.9983001351356506
than O O 0.9998212456703186
130 O O 0.8617432117462158
kb O O 0.49064335227012634
and O O 0.9374870657920837
, O O 0.983643114566803

Locomotor O O 0.7938999533653259
activity O O 0.7356697916984558
was O O 0.9994427561759949
measured O O 0.9999738931655884
again O O 0.9999892711639404
for O O 0.9999972581863403
30 O O 0.9995124340057373
min O O 0.9991680383682251
at O O 0.9999969005584717
the O O 0.9999890327453613
beginning O O 0.9999178647994995
of O O 0.9999881982803345
days O O 0.9998231530189514
1 O O 0.9992815852165222
and O O 0.9997996687889099
21 O O 0.9980460405349731
of O O 0.9999129772186279
sugar O O 0.6783693432807922
access O O 0.9556753039360046
. O O 0.9999971389770508

M. O O 0.9437927007675171
, O O 0.9993649125099182
Donnelley O O 0.998002827167511
, O O 0.9999749660491943
T. O O 0.9975893497467041
, O O 0.9999845027923584
Bucala O O 0.9982191920280457
, O O 0.9999794960021973
R. O O 0.9995905756950378
, O O 0.9999841451644897
Sherry O O 0.9986679553985596
, O O 0.9999723434448242
B. O O 0.9996451139450073
, O O 0.9999794960021973
Manogue O O 0.9958475828170776
, O O 0.9999819993972778
K.R. O O 0.9993519186973572
, O O 0.9999831914901733
Tortolani O O 0.9948782920837402
, O O 0.9999706745147705
A.J. O O 0.9989020824432373
, O O 0.9999812841415405
Cerami O O 0.998316764831543
, O O 0.9999912977218628
A. O O 0.9998970031738281
& O O 0.9999728202819824
Tracey O O 0.9990841150283813
, O O 0.9999948740005493
K.J. O O 0.9975826740264893
( O O 0.9999037981033325
1995 O O 0.9989104270935059
) O O 0.9997150301933289
Mol.Med.1 O O 0.9970858693122864
, O O 0.9999799728393555
254-266 O O 0.9904788732528687

These O O 0.9998304843902588
findings O O 0.9999531507492065
suggest O O 0.9999979734420776
that O O 0.9999927282333374
the O O 0.9997922778129578
effects O O 0.9996716976165771
of O O 0.9997536540031433
estradiol S-Chemical B-Chemical 0.9384323954582214
on O O 0.9937061667442322
seizure O B-Disease 0.9609736204147339
threshold O O 0.6746202111244202
and O O 0.9975152015686035
damage O O 0.500476062297821
may O O 0.9988119602203369
be O O 0.999903678894043
altered O O 0.9986118078231812
by O O 0.9999902248382568
sex O O 0.5064830183982849
- O O 0.9966217279434204
related O O 0.9987963438034058
differences O O 0.9330271482467651
in O O 0.9987810254096985
the O O 0.9992665648460388
hormonal O O 0.8555520176887512
environment O O 0.8222798705101013
. O O 0.9999904632568359

putative O B-protein 0.7316997051239014
transcription B-protein I-protein 0.49445483088493347
factor E-protein E-protein 0.9675300121307373
with O O 0.9981074333190918
a O O 0.9999475479125977
basic B-protein B-protein 0.7809622287750244
helix-loop-helix I-protein I-protein 0.561963677406311
domain E-protein E-protein 0.9345160722732544
and O O 0.9764309525489807
is O O 0.9998236298561096
known O O 0.9999432563781738
to O O 0.999958872795105
be O O 0.9999618530273438
predominantly O O 0.9866672158241272
expressed O O 0.9987712502479553
in O O 0.9997352957725525
hematopoietic B-cell_type B-cell_type 0.7430474162101746
cells E-cell_type E-cell_type 0.9635751843452454
. O O 0.9998493194580078
We O O 0.9958718419075012

in O O 0.9984691739082336
three O O 0.9998496770858765
patients O O 0.9998867511749268
. O O 0.9999986886978149
In O O 0.999991774559021
the O O 0.9999793767929077
second O O 0.9977926015853882
male O O 0.993518054485321
patient O O 0.9997405409812927
, O O 0.999994158744812
no O O 0.9993671774864197
abnormalities O O 0.9862927198410034
were O O 0.9999833106994629
found O O 0.9999736547470093
. O O 0.9999920129776001
As O O 0.9934509992599487

gp41 S-protein S-protein 0.8808490037918091
-induced O O 0.9962389469146729
IL-10 S-protein S-protein 0.9691362380981445
up-regulation O O 0.9912294149398804
is O O 0.9999469518661499
mediated O O 0.9998471736907959
by O O 0.9999947547912598
the O O 0.9999769926071167
previously O O 0.9967324733734131
described O O 0.9995291233062744
synergistic O O 0.9393772482872009
activation O O 0.9874601364135742
of O O 0.9997087121009827
cAMP O O 0.41647112369537354
and O O 0.9326818585395813
NF-kappaB S-protein S-protein 0.884196937084198
pathways O O 0.9857358336448669
. O O 0.9999747276306152
gp41 S-protein S-protein 0.8012231588363647
induced O O 0.9936624765396118
cAMP O O 0.5026361346244812
accumulation O O 0.9827969074249268
in O O 0.9997624754905701
monocytes S-cell_type S-cell_type 0.977908194065094
in O O 0.9995379447937012
a O O 0.9999085664749146
time- O O 0.957290768623352
and O O 0.9914223551750183
concentration-dependent O O 0.9717475771903992
manner O O 0.9895222783088684
and O O 0.9999841451644897
the O O 0.9999780654907227
adenylate B-protein O 0.7913897037506104
cyclase E-protein O 0.7105172276496887
inhibitor O O 0.7458791732788086
SQ O O 0.6840548515319824
22536 O O 0.39280715584754944
suppressed O O 0.9119431972503662
gp41 S-protein S-protein 0.7758455276489258
-induced O O 0.9947983026504517
IL-10 S-protein S-protein 0.9542001485824585
production O O 0.9935732483863831
in O O 0.9998131394386292
monocytes S-cell_type S-cell_type 0.9752030372619629
. O O 0.9994280934333801
In O O 0.9999077320098877
contrast O O 0.9981411695480347
, O O 0.9999603033065796

An O O 0.9992727637290955
objective O O 0.9744662642478943
response O O 0.9957795143127441
was O O 0.9999676942825317
observed O O 0.9999223947525024
in O O 0.999988317489624
73 O O 0.9967331886291504
. O O 0.9999932050704956
5 O O 0.9998981952667236
% O O 0.9999725818634033
of O O 0.9999761581420898
the O O 0.9999562501907349
patients O O 0.9997405409812927
( O O 0.9999946355819702
95 O O 0.9993395209312439
% O O 0.9999639987945557
confidence O O 0.8487687110900879
interval O O 0.9562486410140991
[ O O 0.9944222569465637
CI O O 0.48814985156059265
] O O 0.9897053837776184
, O O 0.9999526739120483
55 O O 0.9994989633560181
. O O 0.9999858140945435
6 O O 0.9998817443847656
- O O 0.9992777705192566
87 O O 0.99906986951828
. O O 0.9999860525131226
1 O O 0.9998884201049805
% O O 0.9999040365219116
) O O 0.9995032548904419
, O O 0.9999923706054688
including O O 0.9999942779541016
4 O O 0.9990739822387695
complete O O 0.9944085478782654
responses O O 0.996845006942749
( O O 0.9999866485595703
11 O O 0.999887228012085
. O O 0.9999542236328125
7 O O 0.9999228715896606
% O O 0.9999070167541504
) O O 0.9995784163475037
. O O 0.9999951124191284

CONCLUSION O O 0.9986465573310852
: O O 0.999981164932251
Complications O O 0.6956555247306824
associated O O 0.9938114285469055
with O O 0.9999514818191528
epidural O O 0.8248474597930908
steroid S-Chemical B-Chemical 0.9245375990867615
injections O O 0.9373480677604675
are O O 0.999985933303833
rare O O 0.9959497451782227
. O O 0.9999985694885254

The O O 0.9996201992034912
most O O 0.9982948899269104
frequently O O 0.9982209801673889
observed O O 0.9894932508468628
side O O 0.9870858788490295
effect O O 0.9971750974655151
was O O 0.9999711513519287
fecal B-Disease O 0.8596124649047852
occult I-Disease O 0.767984926700592
blood I-Disease O 0.6746451258659363
( O O 0.9990962743759155
25 O O 0.9999364614486694
% O O 0.9999691247940063
of O O 0.9999375343322754
patients O O 0.9995608925819397
) O O 0.9998956918716431
; O O 0.9999744892120361
however O O 0.9999613761901855
, O O 0.9999876022338867
there O O 0.9999784231185913
was O O 0.9999853372573853
no O O 0.9999804496765137
other O O 0.9999674558639526
evidence O O 0.9997428059577942
of O O 0.9999828338623047
gastrointestinal B-Disease O 0.8069666624069214
( I-Disease O 0.9450243711471558
GI I-Disease O 0.5342322587966919
) I-Disease O 0.9610828757286072
bleeding I-Disease O 0.8957703709602356
in O O 0.9939330220222473
these O O 0.9991699457168579
patients O O 0.9995892643928528
. O O 0.9999994039535522

it O O 0.9930496215820312

It O O 0.9970065951347351
occurs O O 0.9993368983268738
especially O O 0.9994831085205078
in O O 0.9999747276306152
older O O 0.9755561351776123
patients O O 0.9997172951698303
and O O 0.9999972581863403
during O O 0.9999840259552002
the O O 0.9999929666519165
first O O 0.9999712705612183
two O O 0.9999924898147583
weeks O O 0.99998939037323
of O O 0.9999728202819824
treatment O O 0.9994683861732483
. O O 0.9999995231628418

The O O 0.9992671608924866
plasma O O 0.8162838816642761
level O O 0.9890674948692322
of O O 0.9996547698974609
ANP O B-Chemical 0.9069939851760864
did O O 0.9992485642433167
not O O 0.9999409914016724
always O O 0.9997612833976746
increase O O 0.9767706394195557
in O O 0.9991136193275452
all O O 0.9999042749404907
the O O 0.999893069267273
patients O O 0.9990384578704834
with O O 0.9999791383743286
clinical O O 0.8373037576675415
and O O 0.9185600280761719
subclinical O O 0.8988777995109558
heart O O 0.5676468014717102
failure O O 0.9568151831626892
. O O 0.9989131689071655

After O O 0.9995260238647461
withdrawal O O 0.8971558213233948
of O O 0.9944853186607361
octreotide S-Chemical B-Chemical 0.9333654642105103
in O O 0.9975124597549438
10 O O 0.9987213015556335
patients O O 0.999279797077179
without O O 0.9999197721481323
gallstones O O 0.9478598237037659
, O O 0.9915838241577148
8 O O 0.9957824945449829
patients O O 0.9992061257362366
assessed O O 0.9999366998672485
had O O 0.9998829364776611
return O O 0.9873233437538147
of O O 0.9979669451713562
normal O O 0.9479004144668579
gallbladder O O 0.7238532304763794
contractility O O 0.49629509449005127
within O O 0.9997935891151428
1 O O 0.9996150732040405
month O O 0.999974250793457
. O O 0.9999991655349731

. O O 0.9884327054023743
LMP1 S-protein S-protein 0.9489431381225586
contains O O 0.9994421601295471
two O O 0.9961955547332764
domains O O 0.8805289268493652
that O O 0.9996919631958008
activate O O 0.999747097492218
the O O 0.9998805522918701
transcription B-protein B-protein 0.559736967086792
factor E-protein E-protein 0.909576952457428
NF-kappaB S-protein S-protein 0.7734907269477844
, O O 0.9977476000785828
one O O 0.9995774626731873
through O O 0.9998911619186401
interactions O O 0.9943906664848328
with O O 0.9999434947967529

the O O 0.9984685778617859
higher-order O B-protein 0.8423133492469788
protein O I-protein 0.36923491954803467
complex O E-protein 0.9900134801864624
formed O O 0.9996002316474915
on O O 0.9999641180038452
DNA O O 0.8904046416282654
by O O 0.9998469352722168
RFX S-protein S-protein 0.7584978342056274
, O O 0.9610570073127747
X2BP S-protein S-protein 0.6314325928688049
and O O 0.9388821721076965
NF-Y S-protein S-protein 0.88866126537323
. O O 0.9994326233863831
This O O 0.999966025352478
suggests O O 0.9999861717224121
other O O 0.9999114274978638

Dual O O 0.5079784393310547

This O O 0.9992142915725708
observation O O 0.9976093769073486
, O O 0.9999876022338867
along O O 0.9999849796295166
with O O 0.9999967813491821
the O O 0.999954104423523
rapid O O 0.9886178374290466
rate O O 0.9995878338813782
of O O 0.9998903274536133
decline O O 0.6517698168754578
in O O 0.9724606275558472
red O O 0.6153539419174194
cell O O 0.7647451162338257
mass O O 0.9621719121932983
parameters O O 0.9776067733764648
of O O 0.999864935874939
affected O O 0.8893245458602905
dogs O O 0.9717445373535156
, O O 0.9999831914901733
suggests O O 0.9999908208847046
that O O 0.9999923706054688
a O O 0.9997472167015076
hemolytic B-Disease O 0.5998232364654541
component O O 0.7767689228057861
complicated O O 0.998200535774231
the O O 0.9998119473457336
red O O 0.7668847441673279
cell O O 0.7311931848526001
production O O 0.8892269730567932
problem O O 0.8657505512237549
and O O 0.9999449253082275
that O O 0.9999963045120239
multiple O O 0.9860411286354065
toxicologic O O 0.6355942487716675
mechanisms O O 0.8017748594284058
contributed O O 0.9998564720153809
to O O 0.9999780654907227
the O O 0.999783456325531
cytopenia B-Disease B-Disease 0.9563094973564148
. O O 0.9988922476768494

Sulfonamides S-Chemical O 0.48855167627334595
were O O 0.9852778315544128
associated O O 0.9997381567955017
with O O 0.9999561309814453
anencephaly O B-Chemical 0.9034186601638794
( O O 0.9470910429954529
adjusted O O 0.9800644516944885
OR O O 0.9300280213356018
[ O O 0.9836079478263855
AOR O O 0.694267213344574
] O O 0.9395918846130371
= O O 0.999849796295166
3 O O 0.9996127486228943
. O O 0.9999178647994995
4 O O 0.9975113868713379
; O O 0.9999666213989258
95 O O 0.9990953207015991
% O O 0.9999493360519409
confidence O O 0.8170663714408875
interval O O 0.8589332699775696
[ O O 0.990227460861206
CI O O 0.490063339471817
] O O 0.9851195216178894
, O O 0.9999532699584961
1 O O 0.9998569488525391
. O O 0.9999649524688721
3 O O 0.9997625946998596
- O O 0.9982888102531433
8 O O 0.999243974685669
. O O 0.999841570854187
8 O O 0.9970397353172302
) O O 0.9953964352607727
, O O 0.9999121427536011
hypoplastic O B-Disease 0.8854308128356934
left O I-Disease 0.8759588599205017
heart O I-Disease 0.9652466177940369
syndrome O I-Disease 0.9991794228553772
( O O 0.9834725856781006
AOR O O 0.532096266746521
= O O 0.9908162355422974
3 O O 0.9991230368614197
. O O 0.9999556541442871
2 O O 0.9995095729827881
; O O 0.9999501705169678
95 O O 0.9994480013847351
% O O 0.9999544620513916
CI O O 0.552994430065155
, O O 0.9981690645217896
1 O O 0.9997572302818298
. O O 0.9999558925628662
3 O O 0.9998251795768738
- O O 0.9989319443702698
7 O O 0.9995864033699036
. O O 0.9999363422393799
6 O O 0.9993496537208557
) O O 0.9970472455024719
, O O 0.9999686479568481
coarctation O O 0.668433666229248
of O O 0.9376521110534668
the O O 0.9884054660797119
aorta O O 0.6825854778289795
( O O 0.9987359642982483
AOR O O 0.8804357647895813
= O O 0.9990456700325012
2 O O 0.999731719493866
. O O 0.9999611377716064
7 O O 0.9993033409118652
; O O 0.9999517202377319
95 O O 0.9993896484375
% O O 0.9999567270278931
CI O O 0.6007587909698486
, O O 0.9985561966896057
1 O O 0.9997602105140686
. O O 0.9999608993530273
3 O O 0.9998223185539246
- O O 0.9988911747932434
5 O O 0.9996076226234436
. O O 0.9999183416366577
6 O O 0.9990146160125732
) O O 0.9966555833816528
, O O 0.999976396560669
choanal O O 0.42516714334487915
atresia O O 0.6476658582687378
( O O 0.981671154499054
AOR O O 0.6224464774131775
= O O 0.9964930415153503
8 O O 0.9996545314788818
. O O 0.9999699592590332
0 O O 0.9997020363807678
; O O 0.9999622106552124
95 O O 0.9996874332427979
% O O 0.9999561309814453
CI O O 0.6442663073539734
, O O 0.9988800883293152
2 O O 0.9998160004615784
. O O 0.9999517202377319
7 O O 0.999817430973053
- O O 0.9984115362167358
23 O O 0.998812198638916
. O O 0.9999634027481079
5 O O 0.999193012714386
) O O 0.9978356957435608
, O O 0.9999816417694092
transverse O O 0.5440521836280823
limb O O 0.49722880125045776
deficiency O O 0.7579013705253601
( O O 0.9962722063064575
AOR O O 0.7296164035797119
= O O 0.9980713725090027
2 O O 0.9997190833091736
. O O 0.9999634027481079
5 O O 0.9993281364440918
; O O 0.9999450445175171
95 O O 0.999552309513092
% O O 0.9999575614929199
CI O O 0.5081281065940857
, O O 0.9980077147483826
1 O O 0.9997636675834656
. O O 0.9999558925628662
0 O O 0.9998809099197388
- O O 0.9990960359573364
5 O O 0.9996722936630249
. O O 0.9999102354049683
9 O O 0.9987486600875854
) O O 0.9960302710533142
, O O 0.9999433755874634
and O O 0.9998693466186523
diaphragmatic O O 0.7168505787849426
hernia O O 0.915221095085144
( O O 0.9804209470748901
AOR O O 0.7219071984291077
= O O 0.9958125948905945
2 O O 0.999575674533844
. O O 0.9999693632125854
4 O O 0.9995540976524353
; O O 0.9999586343765259
95 O O 0.99972003698349
% O O 0.9999701976776123
CI O O 0.6926813125610352
, O O 0.9988889098167419
1 O O 0.999855637550354
. O O 0.999972939491272
1 O O 0.9998944997787476
- O O 0.9994478821754456
5 O O 0.9997604489326477
. O O 0.9999250173568726
4 O O 0.9992119073867798
) O O 0.9988604784011841
. O O 0.9999915361404419

TCR S-protein S-protein 0.39917489886283875

, O O 0.9655971527099609
originally O O 0.9964714050292969
isolated O O 0.9988716244697571
as O O 0.9999959468841553
a O O 0.9998369216918945
myeloid O B-DNA 0.3771023154258728
differentiation O I-DNA 0.48723703622817993
primary B-DNA I-DNA 0.6410197019577026
response I-DNA I-DNA 0.9058027863502502
gene E-DNA E-DNA 0.9856547713279724
, O O 0.9973387122154236
is O O 0.9999594688415527
shown O O 0.9999818801879883
to O O 0.9999923706054688
act O O 0.9998525381088257
as O O 0.9999955892562866
an O O 0.9999397993087769
adaptor O O 0.7539991736412048

individuals O O 0.8929888606071472
. O O 0.9999891519546509
The O O 0.999991774559021
allele-specific O O 0.5539089441299438
expression O O 0.9265214204788208

induction O O 0.9802556037902832
of O O 0.99983811378479
NF-kappa B-protein B-protein 0.7632160186767578
B E-protein E-protein 0.9941956400871277
DNA-binding O O 0.8837533593177795
activity O O 0.9971500039100647
by O O 0.9999923706054688
T- B-protein B-protein 0.7432173490524292
cell I-protein I-protein 0.5833629965782166
mitogens E-protein E-protein 0.9410675168037415
. O O 0.9996541738510132
However O O 0.9999450445175171
, O O 0.9999470710754395
Nef S-protein S-protein 0.998308539390564
does O O 0.9996929168701172
not O O 0.9999053478240967
affect O O 0.9996496438980103

The O O 0.9995487332344055
median O O 0.9974823594093323
age O O 0.9999738931655884
of O O 0.9999911785125732
those O O 0.9999758005142212
patients O O 0.9971331357955933
developing O O 0.9986215829849243
Grade O O 0.9784452319145203
3 O O 0.9726722836494446
- O O 0.9802749752998352
4 O O 0.9449911713600159
neutropenia B-Disease B-Disease 0.9575824737548828
was O O 0.9879032969474792
significantly O O 0.9998155236244202
higher O O 0.9997288584709167
than O O 0.9999885559082031
that O O 0.9999806880950928
of O O 0.9999502897262573
the O O 0.9999333620071411
remaining O O 0.9989715814590454
patients O O 0.9998214840888977
( O O 0.9999923706054688
75 O O 0.9997580647468567
years O O 0.9999395608901978
vs O O 0.9997168183326721
. O O 0.9999864101409912
72 O O 0.9999105930328369
years O O 0.9999741315841675
; O O 0.9999942779541016
P O O 0.9988840222358704
= O O 0.9999829530715942
0 O O 0.9998902082443237
. O O 0.9998658895492554
047 O O 0.9843810796737671
) O O 0.9996936321258545
. O O 0.9999942779541016

it O O 0.996722400188446
mediates O O 0.9999347925186157
some O O 0.9999935626983643
of O O 0.9999922513961792
the O O 0.9999598264694214
Ca O O 0.3802779018878937
( O O 0.8336310386657715
2+ O O 0.7118175029754639
) O O 0.6830721497535706
-dependent O O 0.974857747554779
transcriptional O O 0.9517310857772827
events O O 0.9903370141983032
that O O 0.999992847442627
follow O O 0.9998594522476196
TCR S-protein S-protein 0.8701491951942444
engagement O O 0.9913451671600342
. O O 0.9999953508377075
Here O O 0.9999802112579346
we O O 0.9999924898147583
show O O 0.9999934434890747
that O O 0.9999970197677612
CaMKIV/Gr S-protein S-protein 0.8511349558830261
induces O O 0.9997966885566711
the O O 0.9999634027481079
transcription B-protein B-protein 0.5584883093833923
factor I-protein I-protein 0.8791853189468384
activation I-protein I-protein 0.4921901226043701
protein I-protein I-protein 0.587684154510498
1 E-protein E-protein 0.9897581338882446
( O O 0.9802139401435852
AP-1 S-protein S-protein 0.9903783798217773
) O O 0.9715150594711304
alone O O 0.9956835508346558
or O O 0.9999014139175415
in O O 0.9995601773262024
synergy O O 0.7817403674125671
with O O 0.998474657535553
T B-protein B-protein 0.696071445941925
cell I-protein I-protein 0.541910707950592
mitogens E-protein E-protein 0.9580500721931458
and O O 0.9975232481956482
with O O 0.9999639987945557
the O O 0.9999178647994995
p21ras B-protein B-protein 0.6791716814041138
oncoprotein E-protein E-protein 0.9649839997291565
. O O 0.9994786381721497
CaMKIV/ B-protein O 0.5695844888687134
Gr E-protein S-protein 0.5422934889793396
signaling O O 0.9190630316734314
is O O 0.9997184872627258
associated O O 0.9999523162841797
with O O 0.9999949932098389
transcriptional O O 0.9357089400291443
activation O O 0.9835912585258484
of O O 0.9995027780532837
c-fos S-DNA S-DNA 0.8739660978317261
but O O 0.9783581495285034
is O O 0.9997264742851257
independent O O 0.9988483190536499
of O O 0.9997345805168152
p21ras S-DNA S-protein 0.7715297341346741
or O O 0.9852635860443115
calcineurin S-protein S-protein 0.8918861150741577

Permeability O O 0.8644701242446899
, O O 0.9560989737510681
ultrastructural O O 0.8688333034515381
changes O O 0.7892858982086182
, O O 0.9982866644859314
and O O 0.9998992681503296
distribution O O 0.9869962930679321
of O O 0.9995098114013672
novel O O 0.8665566444396973
proteins O O 0.7338875532150269
in O O 0.9998947381973267
the O O 0.9999085664749146
glomerular O O 0.8322234153747559
barrier O O 0.9590135812759399
in O O 0.9999575614929199
early O O 0.9231844544410706
puromycin B-Chemical B-Chemical 0.8873870372772217
aminonucleoside E-Chemical I-Chemical 0.9133221507072449
nephrosis O B-Disease 0.9753440022468567
. O O 0.9992386102676392

In O O 0.9995567202568054
mice O O 0.9977433681488037
, O O 0.9999821186065674
apomorphine S-Chemical B-Chemical 0.9271401166915894
produced O O 0.9981586337089539
qualitatively O O 0.9939979314804077
different O O 0.9991486072540283
responses O O 0.996202290058136
under O O 0.9999909400939941
novel O O 0.8359906077384949
conditions O O 0.48263707756996155
when O O 0.999723494052887
compared O O 0.999958872795105
to O O 0.9999909400939941
those O O 0.9998515844345093
behaviors O O 0.9447222948074341
elicited O O 0.9996778964996338
in O O 0.9999914169311523
the O O 0.9999415874481201
home O O 0.984169602394104
test O O 0.9947614073753357
cage O O 0.9932743310928345
. O O 0.9999992847442627

age O O 0.936120867729187
, O O 0.9998214840888977
in O O 0.9999628067016602
relation O O 0.9981160163879395
also O O 0.9999642372131348
to O O 0.9999716281890869
plasma O O 0.8710545301437378
testosterone O O 0.8366159796714783
and O O 0.9971925616264343
cortisol O O 0.9685118794441223
. O O 0.9999831914901733
The O O 0.9999977350234985
same O O 0.9998869895935059
parameters O O 0.9802844524383545
have O O 0.9999914169311523
been O O 0.9999715089797974
examined O O 0.9999834299087524
in O O 0.9999923706054688
a O O 0.9999843835830688
group O O 0.9957848191261292
of O O 0.999858021736145
soccer O O 0.7547552585601807
players O O 0.8607802391052246

IL-1beta S-protein S-protein 0.891836404800415
) O O 0.9833806753158569
is O O 0.9999256134033203
expressed O O 0.9999057054519653
in O O 0.9999523162841797
LCLs S-cell_line O 0.6911477446556091
and O O 0.9743919968605042
investigate O O 0.9993802309036255
the O O 0.9999719858169556
influence O O 0.9994102716445923
of O O 0.9999809265136719
the O O 0.9999569654464722
individual O O 0.9313352108001709
latent B-protein B-protein 0.7015904188156128
proteins E-protein E-protein 0.959542989730835
on O O 0.9994446635246277
the O O 0.9998899698257446
expression O O 0.9957879185676575
of O O 0.9996978044509888
IL-1beta S-protein S-protein 0.9783807396888733
. O O 0.9993777275085449
Using O O 0.9997188448905945
RT-PCR O O 0.31009921431541443
, O O 0.9651938676834106

Twenty O O 0.9901671409606934
- O O 0.9994459748268127
three O O 0.9999725818634033
of O O 0.9999874830245972
the O O 0.9999704360961914
patients O O 0.9996274709701538
had O O 0.9999792575836182
previously O O 0.9996923208236694
taken O O 0.9999209642410278
appetite B-Chemical B-Chemical 0.9356415271759033
suppressants I-Chemical I-Chemical 0.9313449263572693
, O O 0.9895893931388855
mainly O O 0.9992058873176575
fenfluramines B-Chemical B-Chemical 0.8971965909004211
, O O 0.9922296404838562
as O O 0.9999748468399048
compared O O 0.9999856948852539
with O O 0.9999966621398926
only O O 0.9998941421508789
5 O O 0.9997513890266418
of O O 0.9998188614845276
the O O 0.9999490976333618
controls O O 0.9972394704818726
( O O 0.9999884366989136
66 O O 0.998779833316803
versus O O 0.9999750852584839
6 O O 0.9998482465744019
% O O 0.9999525547027588
, O O 0.9999760389328003
p O O 0.9985975623130798
< O O 0.9997426867485046
0 O O 0.9996912479400635
. O O 0.9998836517333984
0001 O O 0.9746374487876892
) O O 0.9993368983268738
. O O 0.9999971389770508

trifluoromethylketone O O 0.47777271270751953

The O O 0.9994994401931763
effect O O 0.9997240900993347
of O O 0.9997368454933167
amiloride B-Chemical B-Chemical 0.9330089688301086
on O O 0.9747645258903503
lithium B-Chemical B-Chemical 0.9244133830070496
- O O 0.9209734201431274
induced O O 0.9976031184196472
polydipsia B-Disease B-Disease 0.963479220867157
and O O 0.9112598299980164
polyuria B-Disease B-Disease 0.9420874118804932
and O O 0.9868085384368896
on O O 0.9995375871658325
the O O 0.9998051524162292
lithium B-Chemical B-Chemical 0.9222835898399353
concentration O O 0.8827875256538391
in O O 0.9998289346694946
the O O 0.9994964599609375
plasma O O 0.82782381772995
, O O 0.9960950016975403
brain O O 0.7673215866088867
, O O 0.992428719997406
kidney O O 0.7491151094436646
, O O 0.979856550693512
thyroid O O 0.5666883587837219
and O O 0.9705420136451721
red O O 0.8532075881958008
blood O O 0.8072513937950134
cells O O 0.7253783345222473
was O O 0.9999274015426636
investigated O O 0.9999735355377197
in O O 0.9999901056289673
rats O O 0.9950218200683594
, O O 0.9999687671661377
chronically O O 0.8588677644729614
treated O O 0.9788680076599121
with O O 0.9998856782913208
LiCl B-Chemical B-Chemical 0.9081300497055054
. O O 0.9993667006492615

The O O 0.999573290348053
mean O O 0.9931695461273193
age O O 0.9997432827949524
of O O 0.9999692440032959
patients O O 0.9945918917655945
in O O 0.9999909400939941
the O O 0.9999395608901978
16 O O 0.998424768447876
probable O O 0.937383234500885
cases O O 0.9825208783149719
was O O 0.9999926090240479
57 O O 0.9995529055595398
. O O 0.9999862909317017
9 O O 0.9973368048667908
, O O 0.9998799562454224
with O O 0.9999520778656006
hepatotoxicity O B-Disease 0.9792006015777588
being O O 0.9595425724983215
more O O 0.9928765892982483
common O O 0.9969391822814941
in O O 0.9999619722366333
women O O 0.999613344669342
. O O 0.9999986886978149

, O O 0.9785283207893372
C. O O 0.9654847979545593
, O O 0.9991336464881897
and O O 0.9999068975448608
Rothman O O 0.9865662455558777
, O O 0.99991774559021
P. O O 0.9957146048545837
, O O 0.9999752044677734
Science O O 0.9988623857498169
1995. O O 0.9999890327453613
269 O O 0.9992334842681885
: O O 0.9999598264694214
245 O O 0.993507981300354
) O O 0.9998830556869507
. O O 0.9999970197677612
Absence O O 0.999872088432312
of O O 0.9999586343765259
T-cell- B-protein B-protein 0.6074607372283936
and I-protein I-protein 0.7774108052253723
B-cell-specific I-protein I-protein 0.47980988025665283
transcription I-protein I-protein 0.7070693373680115
factors E-protein E-protein 0.9956181049346924
TCF-1 S-protein S-protein 0.9473644495010376

site E-DNA E-DNA 0.8427494764328003
, O O 0.9954344630241394
and O O 0.999962329864502
a O O 0.9999473094940186
novel O O 0.9226611256599426
palindromic B-DNA B-DNA 0.5195252895355225
octamer I-DNA I-DNA 0.3948589861392975
sequence E-DNA E-DNA 0.9665761590003967
( O O 0.9962953925132751
POS S-DNA S-DNA 0.9246814250946045
) O O 0.9820191860198975
. O O 0.9999833106994629
The O O 0.9999713897705078
tandem O O 0.6047922968864441

of O O 0.9929621815681458
Ig B-DNA B-DNA 0.5038365721702576
genes E-DNA E-DNA 0.9953765869140625
. O O 0.9998007416725159
Although O O 0.9999731779098511
mutation O O 0.9945321083068848
occurs O O 0.9999300241470337
specifically O O 0.9999246597290039
in O O 0.9995597004890442
B B-cell_type B-cell_type 0.9011298418045044
cells E-cell_type E-cell_type 0.9861029386520386
during O O 0.9993568062782288

a O O 0.9976831674575806
down-regulation O O 0.9941433072090149
of O O 0.999771773815155
AR S-protein S-protein 0.7424630522727966
and O O 0.9823982119560242
PSA S-protein O 0.507935643196106
levels O O 0.9993194341659546
. O O 0.9999982118606567
The O O 0.9999982118606567
effects O O 0.9999414682388306
of O O 0.9999892711639404
MCM O S-protein 0.7294595837593079
on O O 0.9994507431983948
cellular O O 0.9401938319206238
proliferation O O 0.9857143759727478
, O O 0.9997861981391907
AR B-protein B-protein 0.4609353244304657
protein E-protein E-protein 0.918978214263916
and O O 0.9911509156227112
PSA S-protein O 0.5384821891784668

in O O 0.9957731366157532
differentiating B-cell_line O 0.5046412944793701
THP-1 I-cell_line B-cell_line 0.5604559183120728
cells E-cell_line E-cell_line 0.9596889019012451
. O O 0.9998410940170288
Monocyte-macrophage O O 0.8667038083076477
differentiation O O 0.9920139908790588
was O O 0.9999774694442749
used O O 0.9999880790710449
as O O 0.9999969005584717
a O O 0.9999833106994629
model O O 0.9832225441932678
system O O 0.9882780909538269
for O O 0.9999697208404541
studying O O 0.9995960593223572

METHODS O O 0.9807424545288086
: O O 0.9999363422393799
Using O O 0.9999682903289795
the O O 0.9999878406524658
General O O 0.9697549343109131
Practice O O 0.9894790053367615
Research O O 0.9979450106620789
Database O O 0.9971864819526672
we O O 0.9999984502792358
conducted O O 0.9999934434890747
a O O 0.9999972581863403
cohort O O 0.9663500189781189
analysis O O 0.9969835877418518
and O O 0.9999796152114868
case O O 0.9936880469322205
- O O 0.9995929598808289
control O O 0.9957327246665955
study O O 0.9979198575019836
nested O O 0.9999163150787354
within O O 0.9999148845672607
a O O 0.9999350309371948
population O O 0.9752033948898315
of O O 0.9989976286888123
women O O 0.9979935884475708
aged O O 0.9999585151672363
between O O 0.9999432563781738
15 O O 0.999578058719635
and O O 0.9999403953552246
39 O O 0.9998899698257446
years O O 0.9999775886535645
with O O 0.9999880790710449
acne O B-Disease 0.9687576293945312
, O O 0.8924619555473328
hirsutism O B-Disease 0.9413684010505676
or O O 0.9756701588630676
PCOS O O 0.7977600693702698
to O O 0.9929706454277039
estimate O O 0.9999294281005859
the O O 0.9999294281005859
risk O O 0.9996366500854492
of O O 0.9999765157699585
VTE O B-Disease 0.9528180360794067
associated O O 0.7282536625862122
with O O 0.9977245926856995
CPA S-Chemical B-Chemical 0.9256556630134583
/ O O 0.9782097935676575
EE S-Chemical B-Chemical 0.9332841634750366
. O O 0.9993688464164734

the O O 0.9987261891365051
test O O 0.9984873533248901
was O O 0.9999897480010986
lower O O 0.9999504089355469
in O O 0.999955415725708
elderly O O 0.8857992887496948
subjects O O 0.9775556921958923
than O O 0.9999229907989502
in O O 0.9998249411582947
adults O O 0.9981390237808228
. O O 0.9999979734420776
In O O 0.9999878406524658
the O O 0.9999806880950928
control O O 0.9644362926483154
group O O 0.9833751320838928
, O O 0.9999867677688599
dexamethasone O O 0.9097901582717896
produced O O 0.9999043941497803
a O O 0.9999765157699585
significant O O 0.9987327456474304
depression O O 0.9600374102592468
of O O 0.9995712637901306
Type B-protein B-protein 0.4729865789413452
I I-protein I-protein 0.8528527021408081
receptors E-protein E-protein 0.9912664294242859
( O O 0.9981605410575867
from O O 0.9999585151672363
267 O O 0.8926562070846558
+/- O O 0.9923838973045349
72 O O 0.9822830557823181
to O O 0.9995425939559937
169 O O 0.9769588112831116
+/- O O 0.9971479773521423
71 O O 0.9756102561950684
receptors O O 0.5006387829780579
per O O 0.9994390606880188
cell O O 0.9623547792434692

Sirolimus S-Chemical B-Chemical 0.9080234169960022
represents O O 0.9981252551078796
a O O 0.999987006187439
major O O 0.9969227910041809
therapeutic O O 0.9878492951393127
advance O O 0.9899892807006836
in O O 0.999958872795105
the O O 0.99982750415802
prevention O O 0.9946764707565308
of O O 0.9999556541442871
acute O O 0.838331401348114
renal O O 0.7183853983879089
allograft O O 0.6489224433898926
rejection O O 0.8934754729270935
and O O 0.9870778322219849
chronic O O 0.7966551184654236
allograft O O 0.34998852014541626
nephropathy O O 0.7310238480567932
. O O 0.9989610910415649

METHODS O O 0.9874985814094543
: O O 0.9999784231185913
In O O 0.9999905824661255
the O O 0.9999556541442871
population O O 0.9536595940589905
based O O 0.9982779026031494
, O O 0.9999638795852661
nationwide O O 0.9900868535041809
Swedish O O 0.8458379507064819
Inpatient O O 0.526283860206604
Register O O 0.9267634749412537
a O O 0.9998074173927307
cohort O O 0.9887368083000183
of O O 0.999756395816803
1065 O O 0.9851961135864258
patients O O 0.9997206330299377
with O O 0.99997878074646
Wegener B-Disease O 0.5775589942932129
' I-Disease O 0.6145220398902893
s I-Disease O 0.560809314250946
granulomatosis I-Disease O 0.6581382155418396
, O O 0.9868578910827637
1969 O O 0.9920706152915955
- O O 0.9981465339660645
95 O O 0.8972139954566956
, O O 0.9999058246612549
was O O 0.9999508857727051
identified O O 0.9999858140945435
. O O 0.999998927116394

The O O 0.9965360164642334
MTCP1 B-DNA B-DNA 0.3847303092479706
gene E-DNA E-DNA 0.9761585593223572
is O O 0.9975161552429199
involved O O 0.9999899864196777
in O O 0.9999923706054688
the O O 0.9999566078186035
t B-DNA B-DNA 0.4546946585178375
( I-DNA I-DNA 0.7301260828971863
X I-DNA I-DNA 0.683313250541687
; I-DNA I-DNA 0.8459525108337402
14 I-DNA I-DNA 0.9253836274147034
) I-DNA I-DNA 0.5609488487243652
( I-DNA I-DNA 0.560149610042572
q28 I-DNA I-DNA 0.8980900049209595
; I-DNA I-DNA 0.9747002124786377
q11 I-DNA I-DNA 0.8411706686019897
) I-DNA E-DNA 0.5383120775222778
translocation E-DNA O 0.5655844211578369
associated O O 0.9915948510169983
with O O 0.9999798536300659
these O O 0.9998869895935059
T-cell O O 0.5515255928039551
proliferations O O 0.5415645241737366
. O O 0.9999842643737793
Alternative O O 0.9930936098098755
splicing O O 0.9695423245429993
generates O O 0.9995805621147156
type B-RNA O 0.817439079284668
A I-RNA O 0.48101526498794556
and I-RNA O 0.8353074193000793
B I-RNA O 0.30110427737236023

as O O 0.9923316240310669
well O O 0.9983029365539551
as O O 0.9999902248382568
Ca2+-induced O O 0.869164764881134
activation O O 0.978752851486206
of O O 0.9989660978317261
Rap1 S-protein S-protein 0.9918655753135681
. O O 0.999786913394928
From O O 0.9999947547912598
our O O 0.9999197721481323
results O O 0.9997863173484802
, O O 0.9999974966049194
we O O 0.9999971389770508
conclude O O 0.999998927116394
that O O 0.9999953508377075
Rap1 S-protein S-protein 0.9850283861160278
activation O O 0.9979390501976013

by O O 0.9975776076316833
calcineurin S-protein S-protein 0.9073247313499451
is O O 0.9997870326042175
opposed O O 0.9998605251312256
by O O 0.9999970197677612
the O O 0.9999661445617676
JNK S-protein S-protein 0.8860175609588623
signal O O 0.9092192053794861
transduction O O 0.934333860874176
pathway O O 0.9974722266197205
. O O 0.999996542930603
Thiol O O 0.8078981041908264
modulation O O 0.9868292212486267
inhibits O O 0.9999607801437378
the O O 0.9999085664749146
interleukin B-protein B-protein 0.4763798415660858
( I-protein I-protein 0.4816003441810608
IL I-protein I-protein 0.8675292730331421
) I-protein I-protein 0.8326754570007324
-1 E-protein E-protein 0.9878366589546204
-mediated O O 0.9687984585762024
activation O O 0.9808805584907532

Simultaneously O O 0.9968650937080383
, O O 0.9999603033065796
we O O 0.999930739402771
found O O 0.9999825954437256
that O O 0.9999926090240479
these O O 0.999983549118042
two O O 0.9994609951972961
lemon O O 0.6986566185951233
essential O O 0.9075713753700256
oil O O 0.8897523880004883
components O O 0.9753800630569458
could O O 0.9999964237213135
inhibit O O 0.9998012185096741
acetylcholinesterase O O 0.390522837638855
activity O O 0.8092861771583557
in O O 0.9998323917388916
vitro O O 0.9715632200241089
using O O 0.9997672438621521
the O O 0.9999336004257202
Ellman O O 0.7845386862754822
method O O 0.964809238910675
. O O 0.9999878406524658

provide O O 0.9991276860237122
initial O O 0.9982908368110657
evidence O O 0.9999305009841919
linking O O 0.9999624490737915
abnormal O O 0.9441561102867126
behavior O O 0.9844814538955688
of O O 0.9998767375946045
STAT S-protein S-protein 0.6675661206245422
pathways O O 0.9759944677352905
for O O 0.9999483823776245
cytokine S-protein S-protein 0.966915488243103
signaling O O 0.9890600442886353
to O O 0.9999516010284424
the O O 0.9998866319656372
development O O 0.9979908466339111
of O O 0.9999836683273315
an O O 0.999871015548706
inflammatory O O 0.91868656873703
disease O O 0.8760125041007996
. O O 0.999993085861206
In O O 0.9999905824661255
that O O 0.999993085861206
context O O 0.9998571872711182
, O O 0.9999985694885254
the O O 0.999994158744812
results O O 0.9999618530273438
also O O 0.999998927116394
change O O 0.9999943971633911
the O O 0.9999849796295166
current O O 0.9892202019691467
scheme O O 0.9983916878700256
for O O 0.9999892711639404
asthma O O 0.8546919822692871
pathogenesis O O 0.939930260181427
to O O 0.9999300241470337
one O O 0.9997418522834778
that O O 0.9999443292617798
must O O 0.9999774694442749
include O O 0.9999920129776001
a O O 0.9995633959770203
localized O O 0.8561450839042664

between O O 0.9930264949798584
nucleotide O O 0.7591341733932495
-180 O O 0.38911134004592896
and O O 0.905516505241394
-210 O O 0.3586724102497101
that O O 0.9975130558013916
leads O O 0.9999374151229858
to O O 0.9999864101409912
increased O O 0.9943959712982178
expression O O 0.9967748522758484
in O O 0.9999316930770874
T B-cell_type B-cell_type 0.9023042321205139
cells E-cell_type E-cell_type 0.9915905594825745
. O O 0.9997379183769226
Together O O 0.9999895095825195
these O O 0.9999902248382568
results O O 0.9999614953994751
demonstrate O O 0.9999949932098389
that O O 0.9999817609786987
T O O 0.6245489716529846

signals O O 0.8227530121803284
, O O 0.999747097492218
such O O 0.9999903440475464
as O O 0.9999910593032837
activation O O 0.994584858417511
of O O 0.9998394250869751
the O O 0.9998449087142944
CD28 B-protein B-protein 0.41183018684387207
cell I-protein I-protein 0.7609317302703857
surface I-protein I-protein 0.8901423215866089
molecule E-protein E-protein 0.9807873964309692
on O O 0.9977533221244812
T B-cell_type B-cell_type 0.8884504437446594
cells E-cell_type E-cell_type 0.9895285964012146
, O O 0.9971227049827576
lead O O 0.999941349029541
to O O 0.999966025352478
activation O O 0.9965265393257141
through O O 0.9999842643737793
a O O 0.9998862743377686
distinct O O 0.9849593043327332
region O O 0.9324434399604797

Study O O 0.9992895126342773
of O O 0.9999595880508423
the O O 0.9999669790267944
role O O 0.9997754693031311
of O O 0.9999675750732422
vitamin B-Chemical B-Chemical 0.9520692825317383
B12 E-Chemical I-Chemical 0.9433491826057434
and O O 0.9217778444290161
folinic B-Chemical B-Chemical 0.9201850295066833
acid E-Chemical I-Chemical 0.9456238150596619
supplementation O O 0.5894458293914795
in O O 0.9997674822807312
preventing O O 0.9981740713119507
hematologic O O 0.6564315557479858
toxicity O O 0.5710676312446594
of O O 0.929344654083252
zidovudine S-Chemical B-Chemical 0.9233132004737854
. O O 0.999419093132019

likely O O 0.978488564491272
to O O 0.9999364614486694
be O O 0.9999895095825195
the O O 0.999985933303833
result O O 0.999982476234436
of O O 0.9999954700469971
aberrant O O 0.9306309819221497
splicing O O 0.9823847413063049
. O O 0.999994158744812
While O O 0.9999936819076538
we O O 0.9998900890350342
can O O 0.9999953508377075
not O O 0.9999852180480957
exclude O O 0.9999827146530151
that O O 0.9999110698699951
alterations O O 0.9955339431762695
in O O 0.9998947381973267
TSG101 S-DNA S-DNA 0.5172253251075745
and O O 0.926240861415863

lies O O 0.8537608981132507
upstream O O 0.9871242046356201
of O O 0.9999430179595947
the O O 0.9999752044677734
major B-DNA B-DNA 0.6197282671928406
I I-DNA I-DNA 0.4072503447532654
gamma I-DNA I-DNA 0.5041532516479492
3 I-DNA I-DNA 0.569939911365509
transcription I-DNA I-DNA 0.49551475048065186
initiation I-DNA I-DNA 0.450173556804657
site E-DNA E-DNA 0.8778364062309265
and O O 0.9949213862419128
displays O O 0.9995136260986328
more O O 0.9934279322624207
than O O 0.9997346997261047
90 O O 0.8955685496330261
% O O 0.9869670271873474
identity O O 0.9686912894248962
with O O 0.9998589754104614
the O O 0.9999204874038696
corresponding O O 0.9548979997634888

HBV O O 0.7744477391242981
viral O O 0.7576141953468323
load O O 0.6747486591339111
was O O 0.9925946593284607
performed O O 0.9999895095825195
with O O 0.9999972581863403
Amplicor O O 0.7430702447891235
HBV O O 0.7989280819892883
Monitor O O 0.9396845102310181
test O O 0.9952620267868042
v2 O O 0.9505996108055115
. O O 0.9999431371688843
0 O O 0.9762711524963379
( O O 0.9998599290847778
Roche O O 0.9778958559036255
Diagnostics O O 0.9277364611625671
, O O 0.9999357461929321
Penzberg O O 0.865928053855896
, O O 0.9994588494300842
Germany O O 0.910634458065033
) O O 0.9985055923461914
. O O 0.9999969005584717

indicated O O 0.9933847784996033
that O O 0.9999940395355225
inhibiting O O 0.9965213537216187
nuclear O O 0.9485313296318054
translocation O O 0.9751188158988953
of O O 0.9993067979812622
c-Rel/p65 B-protein B-protein 0.45454996824264526
heterodimers E-protein E-protein 0.9782468676567078
prevented O O 0.9993765950202942
LPS O O 0.9403275847434998
induction O O 0.9980000853538513
of O O 0.9999654293060303
TF S-protein B-DNA 0.4871922731399536
gene O E-DNA 0.8636444807052612
transcription O O 0.8118570446968079
in O O 0.9989657402038574
monocytic B-cell_type B-cell_type 0.6412699222564697
cells E-cell_type E-cell_type 0.927836537361145
. O O 0.9994927644729614

cultures E-cell_line E-cell_line 0.8478329181671143
. O O 0.9998701810836792
( O O 0.9994937181472778
ABSTRACT O O 0.8819555044174194
TRUNCATED O O 0.9905305504798889
AT O O 0.9998743534088135
250 O O 0.9929894208908081
WORDS O O 0.995707094669342
) O O 0.9998775720596313
Occurrence O O 0.9993440508842468
of O O 0.9999721050262451
a O O 0.9998522996902466
silencer S-DNA O 0.7408542037010193
of O O 0.9865976572036743
the O O 0.9997031092643738
interleukin-2 B-DNA B-DNA 0.4715205430984497
gene E-DNA E-DNA 0.9758312106132507
in O O 0.9985169768333435
naive O O 0.5171122550964355
but O O 0.7844038605690002
not O O 0.8792412877082825
in O O 0.989646852016449
memory B-cell_type B-cell_type 0.6473516225814819
resting I-cell_type I-cell_type 0.6258259415626526
T I-cell_type I-cell_type 0.7972495555877686
helper I-cell_type I-cell_type 0.945026159286499
lymphocytes E-cell_type E-cell_type 0.9773185849189758

. O O 0.9930792450904846
We O O 0.9999812841415405
compared O O 0.9999803304672241
the O O 0.9999755620956421
pattern O O 0.997288703918457
using O O 0.9999278783798218
nuclear O O 0.880385160446167
extracts O O 0.9644102454185486
from O O 0.9999376535415649
human O B-cell_type 0.4938809275627136
brain O I-cell_type 0.7457332015037537
and O I-cell_type 0.5984086990356445
lymphocytes S-cell_type E-cell_type 0.8233342170715332
. O O 0.9995953440666199
Interestingly O O 0.9935861229896545

can O O 0.9954743981361389
cause O O 0.9999568462371826
substantial O O 0.9906820058822632
T O O 0.7843636870384216
cell O O 0.46740514039993286
proliferation O O 0.9938912391662598
in O O 0.9999955892562866
the O O 0.9999561309814453
absence O O 0.9994953870773315
of O O 0.9999610185623169
IL-2 S-protein S-protein 0.9688859581947327
, O O 0.9959632158279419
which O O 0.9999315738677979
is O O 0.9999696016311646
driven O O 0.9991768002510071
by O O 0.9999175071716309

Histology O O 0.9145352840423584
was O O 0.9899271726608276
performed O O 0.9999761581420898
in O O 0.9999864101409912
DOX B-Chemical S-Chemical 0.8994773030281067
- O O 0.923194408416748
rats O O 0.9971802234649658
at O O 0.9999972581863403
6 O O 0.9987046718597412
and O O 0.9999485015869141
9 O O 0.9998325109481812
weeks O O 0.9999932050704956
after O O 0.9999990463256836
the O O 0.9999923706054688
last O O 0.9996558427810669
DOX B-Chemical B-Chemical 0.9171208143234253
dose O O 0.9469908475875854
and O O 0.9999561309814453
in O O 0.9999849796295166
all O O 0.9995118379592896
controls O O 0.9983186721801758
. O O 0.9999991655349731

In O O 0.9996680021286011
particular O O 0.9999794960021973
it O O 0.9999895095825195
illustrates O O 0.9999524354934692
the O O 0.9999245405197144
derangements O O 0.961818516254425
of O O 0.9970026612281799
thyroid O O 0.5123035311698914
function O O 0.6944317817687988
seen O O 0.9854068756103516
in O O 0.9998524188995361
pregnant O O 0.6792295575141907
women O O 0.9751308560371399
with O O 0.9999514818191528
eating B-Disease O 0.6590636372566223
disorders I-Disease O 0.9737115502357483
and O O 0.9679875373840332
reminds O O 0.9966501593589783
us O O 0.9999345541000366
that O O 0.9999977350234985
when O O 0.9999676942825317
a O O 0.9999123811721802
cause O O 0.9954049587249756
for O O 0.9997591376304626
thyrotoxicosis B-Disease B-Disease 0.9764763712882996
remains O O 0.9757181406021118
obscure O O 0.8107303977012634
, O O 0.9998058676719666
thyroxine B-Chemical B-Chemical 0.9085926413536072
abuse O O 0.4690350890159607
should O O 0.999294638633728
be O O 0.9999823570251465
considered O O 0.9999692440032959
and O O 0.9999676942825317
explored O O 0.9996695518493652
. O O 0.9999972581863403

a O O 0.9961124062538147
patient O O 0.9991258978843689
with O O 0.9999861717224121
systemic O O 0.9867594838142395
glucocorticoid O O 0.9541521668434143
resistance O O 0.9893038272857666
and O O 0.9999595880508423
chronic O O 0.9493260979652405
lymphocytic O O 0.9396549463272095
leukemia O O 0.9176321625709534
. O O 0.9999933242797852
The O O 0.9999796152114868
human B-protein B-protein 0.5587069392204285
glucocorticoid I-protein I-protein 0.492667019367218
receptor E-protein E-protein 0.9771576523780823
( O O 0.9782702922821045
GR S-protein S-protein 0.9869642853736877
) O O 0.9926310777664185
is O O 0.9999513626098633
expressed O O 0.9999645948410034
as O O 0.9999964237213135
two O O 0.9984034895896912
alternatively O O 0.885363757610321
spliced O O 0.835462212562561
isoforms O O 0.7274919152259827
, O O 0.9931825995445251
GRalpha S-protein S-protein 0.9374306797981262
and O O 0.9857965111732483
GRbeta S-protein S-protein 0.9128097295761108

of O O 0.9972535967826843
human O O 0.5331175327301025
erythrocyte O O 0.31639963388442993
ghost O O 0.3989179730415344
membrane O O 0.24131149053573608
by O O 0.9949842691421509
glucocorticoids O O 0.8707026839256287
and O O 0.9987510442733765
the O O 0.9999727010726929
influence O O 0.998279333114624
of O O 0.9999587535858154
the O O 0.999828577041626
glucocorticoid O B-protein 0.6281819343566895
receptor O I-protein 0.6458758115768433
antagonist O E-protein 0.6439173817634583

or O O 0.9687821269035339
p56 B-protein B-protein 0.6332291960716248
( I-protein I-protein 0.5052362680435181
lck I-protein I-protein 0.9661170840263367
) E-protein E-protein 0.9882534742355347
levels O O 0.996802806854248
with O O 0.9999895095825195
response O O 0.945861279964447
or O O 0.9973207116127014
disease O O 0.9618973731994629
variables O O 0.9838119149208069
, O O 0.9999948740005493
except O O 0.9999916553497314
for O O 0.9999814033508301
lower O O 0.9917700290679932
TCRzeta S-protein S-protein 0.6846316456794739
levels O O 0.9957269430160522
( O O 0.9999895095825195
P O O 0.9989057779312134
< O O 0.9998595714569092
0.001 O O 0.9994363188743591
) O O 0.999769389629364
in O O 0.9999867677688599
the O O 0.9999648332595825
presence O O 0.9983797073364258
of O O 0.9999700784683228
bone O O 0.8203343152999878
metastases O O 0.7117142081260681
, O O 0.9990701079368591
were O O 0.9999849796295166
not O O 0.9999091625213623
found O O 0.9999520778656006
. O O 0.9999961853027344
Abnormal O O 0.9157416224479675
NFkappaB S-protein S-protein 0.968275785446167
activation O O 0.9979717135429382
after O O 0.9999762773513794
stimulation O O 0.9975296854972839
with O O 0.9999897480010986
phorbol O O 0.8910359740257263
myristate O O 0.9194465279579163

Omeprazole S-Chemical B-Chemical 0.9098941683769226
is O O 0.9993307590484619
the O O 0.9999939203262329
first O O 0.9979895353317261
drug O O 0.9950118064880371
designed O O 0.9998687505722046
to O O 0.9999384880065918
block O O 0.9997500777244568
the O O 0.9999195337295532
final O O 0.9979598522186279
step O O 0.999656081199646
in O O 0.9999927282333374
the O O 0.9998452663421631
acid O O 0.4067460596561432
secretory O O 0.8946219682693481
process O O 0.997601330280304
within O O 0.9999934434890747
the O O 0.9999053478240967
parietal O O 0.8144292831420898
cell O O 0.4630914032459259
. O O 0.9997941851615906

Myasthenia O B-Disease 0.8028580546379089
gravis O I-Disease 0.9595252275466919
presenting O O 0.6974246501922607
as O O 0.9952096343040466
weakness O O 0.6434016823768616
after O O 0.9977623224258423
magnesium S-Chemical B-Chemical 0.9218060970306396
administration O O 0.9878822565078735
. O O 0.9999963045120239

T I-cell_type B-cell_type 0.5202776789665222

While O O 0.9993839263916016
contractions O O 0.694497287273407
to O O 0.9877349734306335
carbachol B-Chemical B-Chemical 0.9293063879013062
and O O 0.9446852803230286
ATP B-Chemical B-Chemical 0.9323368072509766
were O O 0.9995798468589783
the O O 0.9999903440475464
same O O 0.9999750852584839
in O O 0.9999717473983765
inflamed O O 0.755793571472168
and O O 0.9670321345329285
in O O 0.9960278272628784
control O O 0.9752604365348816
strips O O 0.9831953644752502
when O O 0.9999954700469971
related O O 0.9993639588356018
to O O 0.9999669790267944
a O O 0.9997666478157043
reference O O 0.9844755530357361
potassium B-Chemical B-Chemical 0.9129499793052673
response O O 0.9540013074874878
, O O 0.9999288320541382
isoprenaline B-Chemical B-Chemical 0.9264630675315857
- O O 0.9618393778800964
induced O O 0.995732843875885
relaxations O O 0.84030681848526
were O O 0.997963547706604
smaller O O 0.9989563226699829
in O O 0.9999668598175049
inflamed O O 0.7556285262107849
strips O O 0.7358096837997437
. O O 0.99998939037323

effect O O 0.99757319688797
on O O 0.9999914169311523
phorbol O O 0.8447996377944946
ester-induced O O 0.9798070192337036
up-regulation O O 0.9980624318122864
of O O 0.999891996383667
HB-EGF B-RNA B-RNA 0.8738656640052795
mRNA E-RNA E-RNA 0.9930332899093628
and O O 0.9983808994293213
kappa O B-protein 0.7249177694320679
B O E-protein 0.8618946671485901
binding O O 0.6465331315994263
activity O O 0.9719679355621338
. O O 0.9999850988388062
Pretreatment O O 0.9929084777832031
of O O 0.9990420937538147
monocytes S-cell_type S-cell_type 0.9645097851753235
with O O 0.9988735318183899

effect O O 0.991006076335907
. O O 0.9999933242797852
Induction O O 0.9966568946838379
of O O 0.9998824596405029
monocytic O O 0.655146598815918
differentiation O O 0.9033870100975037
and O O 0.9963997602462769
NF-kappa B-protein B-protein 0.5698770880699158
B E-protein E-protein 0.9954557418823242
-like O O 0.9870663285255432
activities O O 0.9981340765953064
by O O 0.9999971389770508
human O O 0.8372936248779297
immunodeficiency O O 0.8593443036079407
virus O O 0.8890232443809509
1 O O 0.9482120275497437
infection O O 0.9797422289848328
of O O 0.9997385144233704
myelomonoblastic B-cell_type B-cell_type 0.6493535041809082
cells E-cell_type E-cell_type 0.9607845544815063
. O O 0.9997913241386414
The O O 0.9999980926513672
effects O O 0.9999598264694214
of O O 0.9999933242797852
human O O 0.8919188976287842
immunodeficiency O O 0.8980294466018677
virus O O 0.9398637413978577
1 O O 0.9568284749984741
( O O 0.9984235763549805
HIV-1 O O 0.9259373545646667
) O O 0.9969069361686707

lymphoproliferative O O 0.7362315058708191
diseases O O 0.8065742254257202
were O O 0.9999285936355591
studied O O 0.9999871253967285
for O O 0.999995231628418
expression O O 0.9974703788757324
of O O 0.9998871088027954
c-Jun S-protein S-protein 0.8559772372245789
( O O 0.9928773045539856
a O O 0.9979057312011719
component O O 0.9874852299690247
of O O 0.998994767665863
the O O 0.9996480941772461
transcription B-protein B-protein 0.48079752922058105
factor E-protein E-protein 0.8641816973686218
AP-1 S-protein S-protein 0.5576791763305664
) O O 0.9225631952285767
and O O 0.9989016056060791
glutathione-S-transferase B-protein B-protein 0.4108348786830902
pi E-protein E-protein 0.9495017528533936
( O O 0.9831293225288391
GST-pi S-protein S-protein 0.9113093614578247
) O O 0.9659160375595093
using O O 0.9995031356811523
immunocytochemical O O 0.8587087988853455
methods O O 0.954807698726654

in O O 0.9992738366127014
this O O 0.9999947547912598
report O O 0.9997922778129578
, O O 0.99998939037323
we O O 0.9999486207962036
have O O 0.9999957084655762
identified O O 0.9999819993972778
two O O 0.9990519881248474
potential O O 0.9460117816925049
Ets B-DNA B-DNA 0.5477678179740906
binding I-DNA I-DNA 0.6907697319984436
sites E-DNA E-DNA 0.9184934496879578
, O O 0.9929764866828918
EBS1 O S-DNA 0.9869458079338074
and O O 0.9885309934616089
EBS2 S-DNA S-DNA 0.9575704336166382
, O O 0.9901860952377319
which O O 0.9996069073677063
are O O 0.9999107122421265
conserved O O 0.9975295662879944
in O O 0.9999263286590576
both O O 0.9996059536933899
the O O 0.9973498582839966
human B-DNA B-DNA 0.5482568144798279
and I-DNA I-DNA 0.5932599306106567
murine I-DNA I-DNA 0.8047657012939453

IkappaB B-protein B-protein 0.4576142430305481
alpha E-protein E-protein 0.9757381081581116
. O O 0.999133288860321
The O O 0.9999876022338867
thymic O O 0.7517427802085876
cellularity O O 0.7500610947608948
of O O 0.99834144115448
these O O 0.9999570846557617
mice O O 0.9626743793487549
was O O 0.9999586343765259
significantly O O 0.9998182654380798
decreased O O 0.9995835423469543
. O O 0.9999967813491821
The O O 0.9999922513961792
proportion O O 0.9997047781944275
of O O 0.9999659061431885
mature O B-cell_type 0.6270809173583984
, O I-cell_type 0.7887909412384033
TCRhigh B-cell_type I-cell_type 0.32499662041664124
thymocytes E-cell_type E-cell_type 0.7856837511062622

% O O 0.7687984108924866
) O O 0.9495406746864319
reduction O O 0.9967567324638367
in O O 0.9997223019599915
TNF B-DNA B-DNA 0.8534988760948181
promoter E-DNA E-DNA 0.8657479882240295
activity O O 0.982067883014679
was O O 0.9999780654907227
observed O O 0.9999833106994629
with O O 0.9999970197677612
the O O 0.9999791383743286
AP-2 B-DNA B-DNA 0.5759073495864868
site I-DNA E-DNA 0.8665881752967834
mutation E-DNA O 0.6492974758148193
. O O 0.9999692440032959
However O O 0.9998694658279419
, O O 0.9999556541442871
mutation O O 0.9946310520172119
of O O 0.9997836947441101

CD36 S-protein S-protein 0.753330409526825
is O O 0.9993311166763306
involved O O 0.9999885559082031
in O O 0.9999585151672363
phagocytosis O O 0.7999176979064941
of O O 0.9982470273971558
apoptotic B-cell_type B-cell_type 0.6265909075737
cells E-cell_type E-cell_type 0.9566201567649841
, O O 0.9960668683052063
and O O 0.9997846484184265
foam O O 0.748043954372406
cell O O 0.5897173881530762
formation O O 0.9855227470397949
by O O 0.999991774559021
uptake O O 0.9939051270484924
of O O 0.9998733997344971
oxidized B-protein O 0.865574836730957
low I-protein O 0.9268854260444641
density I-protein O 0.9280892610549927
lipoprotein E-protein O 0.758379340171814
. O O 0.9996819496154785
To O O 0.9999945163726807
study O O 0.9999688863754272
the O O 0.9999361038208008
molecular O O 0.9491369128227234
mechanisms O O 0.9929981231689453
that O O 0.9999948740005493
control O O 0.9999369382858276
the O O 0.9999226331710815
transcription O O 0.9583346843719482
of O O 0.9978061318397522

Its O O 0.9991270899772644
prolonged O O 0.8154153823852539
use O O 0.8969852924346924
or O O 0.9983457326889038
overuse O O 0.9344591498374939
has O O 0.9509773254394531
been O O 0.9957526922225952
associated O O 0.9997959733009338
with O O 0.9999101161956787
seizures B-Disease B-Disease 0.9794301986694336
, O O 0.9887810945510864
intracerebral B-Disease B-Disease 0.5291781425476074
hemorrhage I-Disease I-Disease 0.9485281109809875
, O O 0.9495348930358887
neuropsychiatric B-Disease O 0.508579432964325
symptoms I-Disease O 0.9562618136405945
, O O 0.9715822339057922
and O O 0.9986735582351685
nonhemorrhagic O O 0.7021351456642151
cerebral B-Disease O 0.5603017210960388
infarction I-Disease O 0.945152759552002
. O O 0.9988020658493042

tool O O 0.45638981461524963
for O O 0.9858223795890808
predicting O O 0.9997420907020569
the O O 0.9999896287918091
occurrence O O 0.9997760653495789
of O O 0.9999935626983643
such O O 0.9989163875579834
proliferations O O 0.9976457953453064
. O O 0.9999980926513672
Effects O O 0.9999489784240723
of O O 0.9999772310256958
prostaglandin B-protein O 0.643567681312561
E2 E-protein O 0.5532887578010559
on O O 0.9988019466400146
Th0-type B-cell_line B-cell_line 0.5444638729095459
human I-cell_line I-cell_line 0.7430693507194519
T I-cell_line I-cell_line 0.8609821796417236
cell I-cell_line I-cell_line 0.9023732542991638
clones E-cell_line E-cell_line 0.998150646686554
: O O 0.9976244568824768
modulation O O 0.9854764342308044

Peroxisome B-protein B-protein 0.45358845591545105
proliferator-activated I-protein I-protein 0.5344952940940857
receptor E-protein E-protein 0.943099319934845
. O O 0.9921420812606812
Retinoid-like B-protein B-protein 0.4729008674621582
receptors E-protein E-protein 0.989441990852356
play O O 0.9995545744895935
a O O 0.9999934434890747
central O O 0.9889371395111084

required O O 0.9908960461616516
for O O 0.9999275207519531
ZAP-70 S-protein S-protein 0.9226424694061279
signaling O O 0.9860497117042542
function O O 0.9989141225814819
leading O O 0.9997990727424622
to O O 0.9999358654022217
cellular O O 0.953624963760376
responses O O 0.991784930229187
. O O 0.9999934434890747
Differential O O 0.9926987290382385
induction O O 0.9989808201789856
of O O 0.9999639987945557
DNA-binding B-protein O 0.523697018623352
activities E-protein O 0.9080731272697449
following O O 0.9998716115951538
CD19 S-protein S-protein 0.948564887046814
cross-linking O O 0.9657988548278809
in O O 0.9996721744537354
human B-cell_type B-cell_type 0.5458388328552246
B I-cell_type I-cell_type 0.6861095428466797
lineage I-cell_type I-cell_type 0.701481282711029
cells E-cell_type E-cell_type 0.8307034373283386
. O O 0.9998181462287903
The O O 0.999991774559021
B B-protein B-protein 0.7352033853530884
cell-specific I-protein I-protein 0.6270495653152466
cell I-protein I-protein 0.4720477759838104
surface I-protein I-protein 0.6093853116035461
molecule E-protein E-protein 0.9652745127677917
CD19 S-protein S-protein 0.6586923599243164
is O O 0.9992663264274597
expressed O O 0.999824583530426
at O O 0.9999960660934448
all O O 0.999947190284729
stages O O 0.9997813105583191
of O O 0.9999688863754272
B O O 0.742042064666748
cell O O 0.6144353151321411
development O O 0.9892058372497559
, O O 0.9999276399612427
including O O 0.9999613761901855
normal O B-cell_type 0.6056787967681885
plasma O I-cell_type 0.6341381669044495
cells O E-cell_type 0.9795621633529663
, O O 0.9959859251976013
and O O 0.9998694658279419
mediates O O 0.9782150983810425
signal O O 0.9612541198730469

( O O 0.7351237535476685

On O O 0.9992062449455261
the O O 0.9999889135360718
next O O 0.9999043941497803
day O O 0.9999727010726929
he O O 0.9999467134475708
died O O 0.9780408143997192
, O O 0.9998886585235596
probably O O 0.9983357787132263
as O O 0.999923825263977
a O O 0.9999663829803467
result O O 0.9999560117721558
of O O 0.9999816417694092
heart B-Disease O 0.6616379022598267
failure I-Disease O 0.9595308303833008
. O O 0.996959924697876

prolonged O O 0.862238883972168
immunosuppression O O 0.9872072339057922
. O O 0.9999909400939941
Although O O 0.9999915361404419
it O O 0.9998329877853394
can O O 0.9999773502349854
be O O 0.9999692440032959
incorporated O O 0.9997308850288391
into O O 0.9999691247940063
the O O 0.9997038245201111
DNA O O 0.9382376074790955
of O O 0.9981410503387451
dividing O B-cell_type 0.7885392904281616
cells O E-cell_type 0.9661195278167725
, O O 0.9991720914840698
fludarabine O O 0.849902331829071
is O O 0.9998655319213867
also O O 0.9999881982803345
a O O 0.9999909400939941
potent O O 0.9870648384094238
inhibitor O O 0.9641537070274353
of O O 0.9994514584541321
cells O O 0.9568836092948914
with O O 0.9999806880950928
a O O 0.9999039173126221
low O O 0.9757888317108154
growth O O 0.9156507253646851
fraction O O 0.8936777710914612
, O O 0.9999277591705322
thus O O 0.9999949932098389
it O O 0.9999797344207764
must O O 0.9999912977218628
have O O 0.9999960660934448
other O O 0.9999079704284668
mechanisms O O 0.9985858201980591
of O O 0.9999305009841919
action O O 0.9956220984458923

. O O 0.9928353428840637
Cortivazol O O 0.8100628852844238
is O O 0.9998617172241211
a O O 0.9999724626541138
phenylpyrazolo O O 0.7022029161453247
glucocorticoid O O 0.6458874940872192
of O O 0.9868936538696289
high O O 0.9433386921882629
potency O O 0.9558690190315247
and O O 0.9982023239135742
unusual O O 0.9054467082023621
structure O O 0.9404396414756775
. O O 0.9999693632125854
In O O 0.999907374382019
both O O 0.9984709620475769
wild-type S-cell_line B-cell_line 0.3247971832752228
and O I-cell_line 0.49222132563591003
highly O I-cell_line 0.4341617226600647
dexamethasone B-cell_line I-cell_line 0.668458878993988
( I-cell_line I-cell_line 0.7141155004501343
dex I-cell_line I-cell_line 0.8891388177871704
) I-cell_line I-cell_line 0.8913689255714417
-resistant I-cell_line I-cell_line 0.9590280652046204
clones E-cell_line E-cell_line 0.9966337084770203
of O O 0.998671293258667
the O O 0.9997690320014954
human B-cell_line B-cell_line 0.4293767511844635
leukemic I-cell_line I-cell_line 0.6836397051811218
cell I-cell_line I-cell_line 0.9159848093986511
line I-cell_line I-cell_line 0.5657045245170593
CEM E-cell_line E-cell_line 0.8822106122970581
, O O 0.9951847195625305
exposure O O 0.9871658682823181

Subjects O O 0.9943663477897644
supplied O O 0.9999006986618042
information O O 0.9997664093971252
on O O 0.9999902248382568
oral B-Chemical B-Chemical 0.6466890573501587
- I-Chemical I-Chemical 0.8037356734275818
contraceptive E-Chemical I-Chemical 0.9386868476867676
use O O 0.8277192711830139
and O O 0.9995798468589783
major O O 0.9785832166671753
cardiovascular O O 0.8458171486854553
risk O O 0.7611402869224548
factors O O 0.8133839964866638
. O O 0.9999866485595703

, O O 0.9439334273338318
ie O O 0.9784579873085022
, O O 0.9991918206214905
nonresponsive O B-cell_type 0.5673832297325134
hematopoietic B-cell_type I-cell_type 0.5654259324073792
progenitors E-cell_type E-cell_type 0.9397850632667542
with O O 0.9996013045310974
no O O 0.9997407793998718
erythropoietic O O 0.8298070430755615
potential O O 0.9685416221618652
are O O 0.9999449253082275
forced O O 0.9972249269485474
into O O 0.9999037981033325
apoptosis O O 0.9847436547279358
; O O 0.9999566078186035
( O O 0.9998793601989746
4 O O 0.9994910955429077
) O O 0.9996352195739746
the O O 0.9999709129333496
system O O 0.9954774975776672
is O O 0.9999417066574097
cell O O 0.9092473387718201
division O O 0.834631085395813
controlled O O 0.9847255349159241

The O O 0.9990653395652771
animals O O 0.9595867991447449
that O O 0.9998435974121094
had O O 0.9995206594467163
experienced O O 0.9989446997642517
cyclic O O 0.4861699640750885
sucrose S-Chemical O 0.39226004481315613
and O O 0.9532938003540039
chow O O 0.46921804547309875
were O O 0.9985865354537964
hyperactive O O 0.8954557776451111
in O O 0.9832653999328613
response O O 0.9940826296806335
to O O 0.9999375343322754
amphetamine S-Chemical B-Chemical 0.9319083094596863
compared O O 0.9982314705848694
with O O 0.9999934434890747
four O O 0.9991241097450256
control O O 0.9287750720977783
groups O O 0.9887120723724365
( O O 0.9999856948852539
ad O O 0.9622077345848083
libitum O O 0.4647360146045685
10 O O 0.9471496343612671
% O O 0.9983932375907898
sucrose S-Chemical B-Chemical 0.9070566892623901
and O O 0.9729592204093933
chow O O 0.905785083770752
followed O O 0.9999393224716187
by O O 0.9999747276306152
amphetamine S-Chemical B-Chemical 0.9379311800003052
injection O O 0.6775344610214233
, O O 0.99905925989151
cyclic O O 0.7845867872238159
chow O O 0.6833435893058777
followed O O 0.9998860359191895
by O O 0.9999840259552002
amphetamine S-Chemical B-Chemical 0.9338530898094177
injection O O 0.7546878457069397
, O O 0.9997560381889343
ad O O 0.9417538046836853
libitum O O 0.6288768649101257
chow O O 0.9115306735038757
with O O 0.9999346733093262
amphetamine S-Chemical B-Chemical 0.9366946220397949
, O O 0.9191680550575256
or O O 0.9997851252555847
cyclic O O 0.5404439568519592
10 O O 0.8922361731529236
% O O 0.9980922341346741
sucrose S-Chemical B-Chemical 0.8934829831123352
and O O 0.9533815383911133
chow O O 0.9063363671302795
with O O 0.9999363422393799
a O O 0.9996932744979858
saline O O 0.5585204362869263
injection O O 0.7474518418312073
) O O 0.995897650718689
. O O 0.9999961853027344

hormone.2+o O O 0.42325693368911743
Regulation O O 0.9875756502151489
of O O 0.9997760653495789
M-CSF S-protein S-protein 0.9465848207473755
expression O O 0.9982523322105408
by O O 0.9999895095825195
M-CSF S-protein S-protein 0.9149287939071655
: O O 0.9901666641235352
role O O 0.9924949407577515
of O O 0.9994291663169861
protein B-protein B-protein 0.5139753222465515
kinase I-protein I-protein 0.6724867224693298
C E-protein E-protein 0.9897693395614624
and O O 0.9866243600845337
transcription B-protein B-protein 0.536410927772522
factor I-protein I-protein 0.828552782535553
NF I-protein I-protein 0.44885337352752686
kappa I-protein I-protein 0.9204661250114441
B E-protein E-protein 0.9861750602722168
. O O 0.9990606904029846
Macrophage-colony-stimulating B-protein B-protein 0.5305361747741699
factor E-protein E-protein 0.9349258542060852
( O O 0.9283739924430847
M-CSF S-protein S-protein 0.9853639006614685
) O O 0.9597567319869995
, O O 0.9993870258331299
also O O 0.9999139308929443
referred O O 0.999983549118042
to O O 0.999953031539917
as O O 0.9998980760574341
CSF-1 S-protein S-protein 0.8476853966712952
, O O 0.9895477294921875
regulates O O 0.9999313354492188
the O O 0.9998852014541626
survival O O 0.9939714074134827
, O O 0.999072790145874
growth O O 0.9887851476669312
, O O 0.9988056421279907
differentiation O O 0.9939502477645874
and O O 0.9994779229164124
functional O O 0.9777651429176331
activity O O 0.997300922870636
of O O 0.9999203681945801
monocytes S-cell_type S-cell_type 0.904391348361969

low O O 0.961517333984375
cytoplasmic O O 0.9427458047866821
levels O O 0.9979245662689209
of O O 0.999954104423523
I B-RNA B-RNA 0.7563821077346802
kappa I-RNA I-RNA 0.9707509875297546
B I-RNA I-RNA 0.9819060564041138
alpha/MAD-3 I-RNA I-RNA 0.9893758296966553
mRNA E-RNA E-RNA 0.9944400787353516
are O O 0.9996286630630493
maintained O O 0.9999605417251587
by O O 0.9999988079071045
a O O 0.9999771118164062
translation-dependent O O 0.8480734825134277
degradation O O 0.7983364462852478
mechanism O O 0.9656239748001099
. O O 0.9999897480010986
Distinct O O 0.9909811615943909
roles O O 0.9953559637069702
of O O 0.9999301433563232
the O O 0.9999169111251831
molecular O B-protein 0.7385459542274475
chaperone B-protein I-protein 0.44201138615608215
hsp90 E-protein E-protein 0.6987952589988708
in O O 0.9952066540718079
modulating O O 0.9889281988143921
dioxin O B-protein 0.5857697129249573
receptor O E-protein 0.8128788471221924
function O O 0.9668226838111877
via O O 0.999871015548706
the O O 0.9998971223831177
basic O B-protein 0.6894780397415161
helix-loop-helix S-protein I-protein 0.39020970463752747
and O I-protein 0.4715394079685211
PAS B-protein I-protein 0.7790114283561707
domains E-protein E-protein 0.9534568786621094
. O O 0.9998156428337097
The O O 0.999993085861206
intracellular B-protein B-protein 0.7862216830253601
dioxin I-protein I-protein 0.4998331069946289
receptor E-protein E-protein 0.8889371156692505
mediates O O 0.4755103886127472
signal O O 0.995220959186554

the O O 0.9962015748023987

. O O 0.9905299544334412
In O O 0.9999426603317261
conclusion O O 0.9998838901519775
, O O 0.9999988079071045
this O O 0.9999892711639404
case O O 0.9950826168060303
report O O 0.9998262524604797
emphasizes O O 0.9999779462814331
1 O O 0.9910815954208374
) O O 0.9996219873428345
the O O 0.9999901056289673
possibility O O 0.9998966455459595
of O O 0.9999921321868896
a O O 0.9998922348022461
syndrome O O 0.9764087796211243
of O O 0.9994353652000427
acquired O O 0.708339512348175

CONCLUSIONS O O 0.9979481101036072
: O O 0.9999951124191284
The O O 0.9999634027481079
administration O O 0.9986636638641357
of O O 0.9989922642707825
methylprednisolone S-Chemical B-Chemical 0.9229768514633179
and O O 0.9632353782653809
gentamicin S-Chemical B-Chemical 0.9292482137680054
in O O 0.9969690442085266
the O O 0.9999426603317261
posterior O O 0.93157958984375
sub O O 0.9951921701431274
- O O 0.9996790885925293
Tenon O O 0.9617523550987244
' O O 0.9862740635871887
s O O 0.9684180021286011
space O O 0.9842154383659363
was O O 0.9999661445617676
related O O 0.9999804496765137
to O O 0.9999860525131226
a O O 0.9997952580451965
high O O 0.9922040700912476
incidence O O 0.9913841485977173
of O O 0.9996752738952637
side O O 0.8845380544662476
effects O O 0.8813403248786926
including O O 0.9988400340080261
nausea O O 0.9438762664794922
, O O 0.9272016286849976
vomiting O B-Disease 0.9135521650314331
, O O 0.9085962176322937
and O O 0.9912609457969666
headache O B-Disease 0.9766606688499451
. O O 0.9989193677902222

. O O 0.9938471913337708
Only O O 0.9999278783798218
those O O 0.9999716281890869
TCC S-cell_line O 0.31329572200775146
with O O 0.998563826084137
low O O 0.9874818325042725
IFN-gamma S-protein S-protein 0.9613248109817505
levels O O 0.9976505637168884
in O O 0.9999948740005493
the O O 0.9999750852584839
absence O O 0.999365508556366
of O O 0.9999735355377197
IL-12 S-protein S-protein 0.9444839358329773
responded O O 0.9996480941772461
to O O 0.9999538660049438
IL-12 S-protein S-protein 0.985295295715332
by O O 0.9998782873153687
additional O O 0.9966094493865967
enhancement O O 0.9945578575134277
of O O 0.9998045563697815
IFN-gamma S-protein S-protein 0.9709991216659546
production O O 0.9981786012649536
. O O 0.9999985694885254
The O O 0.9999814033508301
IL-12 S-protein S-protein 0.7953587174415588
nonresponsiveness O O 0.8125615119934082
of O O 0.9988067150115967
the O O 0.9996416568756104
Th2 B-cell_line B-cell_line 0.5114631652832031
clones E-cell_line E-cell_line 0.9883092641830444
was O O 0.9997922778129578
further O O 0.9999258518218994
evident O O 0.9999741315841675
by O O 0.9999982118606567
the O O 0.9999877214431763
total O O 0.9854478240013123
lack O O 0.997832715511322
of O O 0.999901294708252

CONCLUSION O O 0.9975798726081848
: O O 0.9999648332595825
TEE O O 0.33868059515953064
with O O 0.9968673586845398
sedation O O 0.7894110083580017
presents O O 0.999606192111969
a O O 0.9999704360961914
low O O 0.9924611449241638
rate O O 0.9996979236602783
of O O 0.9998237490653992
events O O 0.9623346924781799
. O O 0.9999866485595703

There O O 0.9996328353881836
was O O 0.999985933303833
no O O 0.9999872446060181
correlation O O 0.9951605200767517
between O O 0.9997735619544983
SBP O O 0.35601431131362915
change O O 0.9475735425949097
and O O 0.9997434020042419
outcome O O 0.9919771552085876
. O O 0.9999973773956299

Thus O O 0.9982396364212036
, O O 0.9999802112579346
while O O 0.9999914169311523
whole O O 0.976738691329956
body O O 0.9608307480812073
hyperthermia B-Disease O 0.9122502207756042
enhances O O 0.9619540572166443
Adriamycin B-Chemical B-Chemical 0.9277566075325012
- O O 0.929495632648468
mediated O O 0.9966384172439575
antitumor O O 0.6846747994422913
effect O O 0.9707449674606323
, O O 0.9999827146530151
normal O O 0.9625741839408875
tissue O O 0.7356643676757812
toxicity B-Disease O 0.7407404780387878
is O O 0.9871394038200378
also O O 0.9995905756950378
increased O O 0.9965113997459412
, O O 0.9998966455459595
and O O 0.9999802112579346
the O O 0.9999643564224243
potential O O 0.9986913800239563
therapeutic O O 0.9750210046768188
gain O O 0.8667252659797668
of O O 0.9972935318946838
the O O 0.9997678399085999
combined O O 0.9798619747161865
modality O O 0.8365165591239929
treatment O O 0.9970977306365967
is O O 0.9999895095825195
eroded O O 0.9995236396789551
. O O 0.999998927116394

cells E-cell_type E-cell_type 0.6906149387359619
and O O 0.9959765076637268
similar O O 0.9982907176017761
to O O 0.9998685121536255
IFN-alpha S-protein S-protein 0.9462987184524536
( O O 0.9859700798988342
STAT1 S-protein S-protein 0.9718573093414307
and O O 0.9909509420394897
STAT3 S-protein S-protein 0.9880632758140564
) O O 0.988396942615509
and O O 0.9996100068092346
IFN-gamma S-protein B-protein 0.9326488971710205
( O I-protein 0.9568992257118225
STAT1 S-protein I-protein 0.8908087611198425
) O I-protein 0.734359622001648
receptor O E-protein 0.8507530689239502
activation O O 0.9710100293159485
in O O 0.9997753500938416
CLL S-cell_line S-cell_line 0.6398447751998901
. O O 0.9919105172157288
Further O O 0.9998015761375427
, O O 0.9999814033508301
in O O 0.999931812286377
consecutive O O 0.9957045912742615
samples O O 0.9962798953056335
of O O 0.9999758005142212
fresh O O 0.7657737731933594
blood O O 0.6535459160804749
obtained O O 0.9816784262657166
from O O 0.9999182224273682
patients O O 0.9991337656974792
with O O 0.9999579191207886
B-CLL B-cell_line B-cell_line 0.4157683849334717
cells E-cell_line E-cell_line 0.5276157259941101
, O O 0.9997236132621765
the O O 0.999996542930603
addition O O 0.9999210834503174
of O O 0.9999712705612183
IL-10 S-protein S-protein 0.9172945022583008
inhibited O O 0.9935374855995178
B-CLL S-cell_line O 0.3602452278137207
proliferation O O 0.9687886238098145
, O O 0.9997989535331726
enhanced O O 0.991424024105072
B-CLL S-cell_line O 0.2357407659292221
differentiation O O 0.9539530277252197
, O O 0.9990872144699097
but O O 0.9997344613075256

and O O 0.9936639070510864
an O O 0.9999891519546509
increase O O 0.9984925985336304
of O O 0.9998942613601685
NF B-protein B-protein 0.360080361366272
kappa I-protein I-protein 0.7957946062088013
B I-protein I-protein 0.8813954591751099
binding I-protein I-protein 0.6041406989097595
complexes E-protein E-protein 0.9832940101623535
containing O O 0.9965900182723999
c-rel S-protein S-protein 0.8629171252250671
and O O 0.9426287412643433
p50 S-protein S-protein 0.910406231880188
. O O 0.996831476688385
This O O 0.9999734163284302
treatment O O 0.9998337030410767
also O O 0.9999867677688599
caused O O 0.9999396800994873
increased O O 0.9965644478797913
tyrosine O O 0.8849760293960571
phosphorylation O O 0.9684314131736755
of O O 0.999518871307373
specific O B-protein 0.8817757964134216
protein O I-protein 0.527882993221283
substrates O E-protein 0.8934864401817322
. O O 0.9970366954803467
R24 S-protein S-protein 0.9397174715995789
-stimulated O O 0.9875364899635315
increases O O 0.991701066493988
in O O 0.9988508224487305
proliferation O O 0.9943410158157349
, O O 0.9999184608459473
cytotoxicity O O 0.8423639535903931
, O O 0.9995697140693665

just O O 0.990607738494873

IL-2 S-protein S-protein 0.8613023161888123
and O O 0.9943892359733582
IFN-gamma S-protein S-protein 0.9588159918785095
, O O 0.9970799088478088
whereas O O 0.999946117401123
Th2 B-cell_line B-cell_line 0.3891308903694153
cells E-cell_line E-cell_line 0.5369123816490173
produce O O 0.9990430474281311
IL-4 S-protein S-protein 0.9764750599861145
, O O 0.9943835735321045
IL-5 S-protein S-protein 0.990803599357605
, O O 0.9951883554458618
IL-6 S-protein S-protein 0.9938684105873108
, O O 0.9953977465629578
IL-10 S-protein S-protein 0.9921718835830688
, O O 0.9898264408111572
and O O 0.9974865913391113
IL-13 S-protein S-protein 0.9944895505905151
. O O 0.9998513460159302
In O O 0.9999819993972778
many O O 0.9986806511878967
pathological O O 0.9615179896354675
situations O O 0.9957542419433594
, O O 0.9999969005584717
the O O 0.9999817609786987
balance O O 0.9985249638557434
between O O 0.9998462200164795
Th1 O O 0.30995187163352966
and O O 0.9622116088867188
Th2 O O 0.6410652995109558
immune O O 0.9051921963691711
responses O O 0.9921254515647888
determines O O 0.9999760389328003

IL-4 S-protein S-protein 0.8652611374855042
, O O 0.9951044321060181
and O O 0.9991126656532288
IL-5 S-protein S-protein 0.8499574065208435
independently O O 0.9325070977210999
up-regulated O O 0.9840371608734131
TGF-beta1 B-RNA B-RNA 0.7859889268875122
mRNA E-RNA E-RNA 0.9893681406974792
and O O 0.9970548152923584
product O O 0.9103962779045105
expression O O 0.9969950914382935
by O O 0.9999771118164062
eosinophils S-cell_type S-cell_type 0.9705463647842407
in O O 0.9996610879898071
all O O 0.9996734857559204
donors O O 0.993698239326477
. O O 0.9999971389770508
Interestingly O O 0.9995483756065369
, O O 0.9999679327011108
TGF-alpha S-protein S-protein 0.9907517433166504
production O O 0.9983320832252502
by O O 0.9999699592590332
eosinophils S-cell_type S-cell_type 0.9833036661148071
was O O 0.9997983574867249
up-regulated O O 0.9997476935386658
by O O 0.999987006187439
IL-3 S-protein S-protein 0.7896354794502258

previously O O 0.9893285632133484
been O O 0.99982088804245
shown O O 0.9998581409454346
to O O 0.9999641180038452
be O O 0.9999219179153442
nuclear O O 0.8279712200164795
matrix O O 0.37135884165763855
associated O O 0.8750603199005127
. O O 0.9995884299278259
Subnuclear O O 0.8948333263397217
fractionation O O 0.9731072783470154
reveals O O 0.9999486207962036
that O O 0.9999961853027344
there O O 0.9999831914901733
are O O 0.9999961853027344
two O O 0.9985194802284241
ATF1 B-protein B-protein 0.27150872349739075
isoforms E-protein E-protein 0.77983158826828
which O O 0.9994248151779175
appear O O 0.9999617338180542
to O O 0.9999709129333496
differ O O 0.9999587535858154

However O O 0.9987906813621521
, O O 0.9999368190765381
pretreatment O O 0.9745873808860779
with O O 0.9998704195022583
RAMH S-Chemical B-Chemical 0.924968957901001
significantly O O 0.9977326393127441
reversed O O 0.9968262910842896
such O O 0.9996838569641113
an O O 0.9999191761016846
effect O O 0.9991432428359985
of O O 0.9998043179512024
THP S-Chemical B-Chemical 0.9289120435714722
( O O 0.9908261895179749
15 O O 0.9992269277572632
mg O O 0.999607264995575
/ O O 0.999985933303833
kg O O 0.9997984766960144
i O O 0.9998414516448975
. O O 0.9999107122421265
p O O 0.9994483590126038
. O O 0.9998772144317627
) O O 0.9995766282081604
. O O 0.9999911785125732

The O O 0.9986679553985596
symptoms O O 0.5657602548599243
occurred O O 0.9983252882957458
around O O 0.9999839067459106
2 O O 0.9999521970748901
weeks O O 0.9999822378158569
after O O 0.9999945163726807
starting O O 0.9925543665885925
clozapine B-Chemical B-Chemical 0.924389660358429
in O O 0.9995706677436829
an O O 0.9999667406082153
inpatient O O 0.9225552082061768
setting O O 0.9937105178833008
. O O 0.9999995231628418

cells E-cell_line E-cell_type 0.6880854368209839
, O O 0.996875524520874
consistent O O 0.9998900890350342
with O O 0.9999918937683105
the O O 0.9999353885650635
activated O O 0.8943234086036682
phenotype O O 0.7132366299629211
of O O 0.9947916269302368
these O O 0.9995242357254028
cells O O 0.9422761797904968
. O O 0.9999527931213379
Upon O O 0.9977501034736633
stimulation O O 0.9977770447731018
with O O 0.9999724626541138
mitogens O S-protein 0.9067119359970093
, O O 0.9990444779396057
formation O O 0.9936938881874084
of O O 0.9996235370635986
the O O 0.999717652797699
transactivating O B-protein 0.452265202999115
complex O E-protein 0.8251450657844543
, O O 0.9214096069335938
nuclear B-protein B-protein 0.6004091501235962
factor I-protein I-protein 0.5180049538612366
of I-protein I-protein 0.9266452193260193
activated I-protein I-protein 0.9711360335350037
T I-protein I-protein 0.974743664264679
cells E-protein E-protein 0.9529111981391907
( O O 0.9712398052215576
NF-AT S-protein S-protein 0.9548743963241577

Heavy O O 0.7976475954055786
proteinuria O B-Disease 0.9016740322113037
was O O 0.9817107319831848
common O O 0.9989410042762756
after O O 0.999995231628418
the O O 0.9999610185623169
use O O 0.9999619722366333
of O O 0.9998890161514282
SRL S-Chemical B-Chemical 0.9307398796081543
as O O 0.9984205961227417
rescue O O 0.8816986680030823
therapy O O 0.9983792304992676
for O O 0.9999915361404419
renal O O 0.8820768594741821
transplantation O O 0.5608033537864685
. O O 0.9999642372131348

Severe O O 0.9865790009498596
side O O 0.9450179934501648
effects O O 0.9688877463340759
in O O 0.9998862743377686
terms O O 0.9996546506881714
of O O 0.9998917579650879
mental O O 0.929985523223877
confusion B-Disease O 0.488781213760376
and O O 0.9863860607147217
progressive O O 0.7563806176185608
hyperbilirubinemia B-Disease B-Disease 0.9078378677368164
, O O 0.9237868189811707
however O O 0.9992074370384216
, O O 0.9999730587005615
point O O 0.9997631907463074
to O O 0.9999908208847046
an O O 0.9998922348022461
enhancement O O 0.9870426654815674
not O O 0.9998551607131958
only O O 0.9999830722808838
of O O 0.9998615980148315
antineoplastic O O 0.5357882380485535
effects O O 0.7856997847557068
but O O 0.9995595812797546
also O O 0.9999736547470093
of O O 0.9997493624687195
toxicity B-Disease B-Disease 0.965777575969696
in O O 0.9775672554969788
normal O O 0.8796589374542236
tissues O O 0.8227776885032654
. O O 0.9999896287918091

is O O 0.9958623647689819
not O O 0.9997685551643372
sufficient O O 0.9999032020568848
to O O 0.9999793767929077
induce O O 0.9999443292617798
apoptosis O O 0.9689609408378601
of O O 0.9992454051971436
the O O 0.9996008276939392
cells O O 0.9647375345230103
. O O 0.9999942779541016
Interestingly O O 0.9995415210723877
, O O 0.9999715089797974

The O O 0.9991948008537292
area O O 0.9987993240356445
under O O 0.9999697208404541
the O O 0.9999300241470337
curve O O 0.9926747679710388
was O O 0.9999942779541016
537 O O 0.9980347752571106
+ O O 0.9999562501907349
/ O O 0.9999955892562866
- O O 0.9999754428863525
149 O O 0.9997770190238953
ng O O 0.9995693564414978
/ O O 0.9999905824661255
ml O O 0.999891996383667
x O O 0.9962456822395325
hours O O 0.999687671661377
, O O 0.9999934434890747
volume O O 0.9972565770149231
of O O 0.9997448325157166
distribution O O 0.9809995889663696
( O O 0.9996999502182007
Vd O O 0.9627357125282288
) O O 0.9977019429206848
3504 O O 0.9982110261917114
+ O O 0.9999569654464722
/ O O 0.9999948740005493
- O O 0.9999657869338989
644 O O 0.9996576309204102
l O O 0.9999005794525146
/ O O 0.999971866607666
m2 O O 0.9997009038925171
, O O 0.9999829530715942
and O O 0.9999855756759644
total O O 0.9968510270118713
clearance O O 0.9968265891075134
( O O 0.9999735355377197
ClT O O 0.9112769961357117
) O O 0.9969821572303772
was O O 0.9999927282333374
204 O O 0.9982300400733948
+ O O 0.9999420642852783
39 O O 0.999860405921936
. O O 0.9999901056289673
3 O O 0.9999140501022339
l O O 0.9999291896820068
/ O O 0.9999860525131226
hour O O 0.9999254941940308
/ O O 0.9999805688858032
m2 O O 0.9979581832885742
. O O 0.999990701675415

protein O O 0.4051291346549988
components O O 0.48457881808280945
of O O 0.9981662631034851
this O O 0.9999241828918457
complex O O 0.7916384339332581
are O O 0.9989266991615295
specifically O O 0.9996726512908936
competed O O 0.9998290538787842
by O O 0.9999970197677612
an O O 0.99989914894104
AP1 B-DNA B-DNA 0.36900249123573303
consensus I-DNA I-DNA 0.7964314222335815
motif E-DNA E-DNA 0.9309977293014526
and O O 0.9974229335784912
were O O 0.9999817609786987
shown O O 0.9999943971633911
by O O 0.9999920129776001
supershift O O 0.7591862678527832
to O O 0.9771816730499268

that O O 0.9934725761413574
proerythroblasts S-cell_type S-cell_type 0.6101235747337341
and O O 0.9229047298431396
mature B-cell_type B-cell_type 0.567421555519104
erythroid I-cell_type I-cell_type 0.7467955350875854
cells E-cell_type E-cell_type 0.9484273195266724
contain O O 0.9996030926704407
a O O 0.9999585151672363
diffusible O O 0.9262723922729492
activity O O 0.9745181202888489
( O O 0.999552309513092
TAG O O 0.8322609066963196
) O O 0.9993333220481873
capable O O 0.9999312162399292
of O O 0.9999746084213257
transcriptional O O 0.9130634665489197
activation O O 0.9791009426116943
of O O 0.9991931319236755
GATA-1 S-protein S-protein 0.8965907692909241
and O O 0.9879332184791565

Her O O 0.993992030620575
vocal O O 0.7552870512008667
change O O 0.616282045841217
and O O 0.9954110980033875
weakness O O 0.7476980090141296
began O O 0.9905455112457275
to O O 0.9977099895477295
improve O O 0.9985600113868713
spontaneously O O 0.9961861968040466
about O O 0.9999704360961914
3 O O 0.9991303086280823
weeks O O 0.9999748468399048
after O O 0.9999850988388062
transfer O O 0.9822849035263062
. O O 0.9999945163726807

BACKGROUND O O 0.9907955527305603
: O O 0.9999889135360718
The O O 0.9999935626983643
possible O O 0.9991288781166077
role O O 0.99958735704422
of O O 0.999921441078186
alcohol S-Chemical B-Chemical 0.9267767071723938
in O O 0.9987831711769104
the O O 0.9998157620429993
development O O 0.9921994805335999
of O O 0.999754011631012
hepatotoxicity O B-Disease 0.9911003708839417
associated O O 0.9343075156211853
with O O 0.9997108578681946
therapeutic O O 0.7149156928062439
doses O O 0.9828293919563293
of O O 0.9995813965797424
paracetamol S-Chemical B-Chemical 0.9411437511444092
( O O 0.818841814994812
acetaminophen S-Chemical B-Chemical 0.932540774345398
) O O 0.8917351961135864
is O O 0.9999691247940063
currently O O 0.9999876022338867
debated O O 0.9999936819076538
. O O 0.9999990463256836

no O O 0.99399334192276
apparent O O 0.9981818199157715
association O O 0.9987789988517761
of O O 0.9999500513076782
HLA-DR3 S-protein S-protein 0.6065236330032349
with O O 0.99639892578125
SSB S-protein S-protein 0.9011695384979248
reactivity O O 0.9691922664642334
in O O 0.9998084902763367
controls O O 0.9887950420379639
. O O 0.9999840259552002
CONCLUSION O O 0.9977729916572571
. O O 0.9999760389328003
Anti-La B-cell_line B-cell_line 0.40201711654663086
( I-cell_line I-cell_line 0.5695552229881287
SSB I-cell_line I-cell_line 0.6187794804573059
) I-cell_line I-cell_line 0.729633092880249
specific I-cell_line I-cell_line 0.681126594543457
T I-cell_line I-cell_line 0.7743339538574219
cells E-cell_line E-cell_line 0.7707991600036621
occur O O 0.9995019435882568
in O O 0.9999604225158691

the O O 0.9982238411903381
DNA-binding B-protein B-protein 0.4561518132686615
domain E-protein E-protein 0.9319821000099182
of O O 0.990246057510376
the O O 0.9996968507766724
transcription B-protein B-protein 0.5287483930587769
factor E-protein E-protein 0.907803475856781
AML1 S-protein S-protein 0.7279383540153503
fused O O 0.9921318888664246
in-frame O O 0.8428181409835815
to O O 0.9977414608001709
the O O 0.9998109936714172
entire O O 0.983544647693634
MDS1/EVI1 S-DNA S-DNA 0.6650841236114502
with O O 0.9951589703559875
the O O 0.999933123588562
exclusion O O 0.999308705329895
of O O 0.9999738931655884
its O O 0.9999386072158813
first O O 0.9573580026626587
12 O O 0.9285147190093994
amino O O 0.6887862086296082
acids O O 0.482489675283432
. O O 0.9986242055892944
In O O 0.9999547004699707
this O O 0.999946117401123

therapy O O 0.9619925618171692
, O O 0.9996964931488037
and O O 0.999972939491272
development O O 0.9989830851554871
of O O 0.9999668598175049
pharmaceutical O O 0.8749487400054932
products O O 0.7028478980064392
. O O 0.9998027682304382
Cytokines S-protein S-protein 0.8759163618087769
control O O 0.9903708100318909
growth O O 0.9878478050231934
, O O 0.9996113181114197
differentiation O O 0.9951110482215881
, O O 0.9994140863418579
death O O 0.9567868709564209
, O O 0.998013973236084
and O O 0.9996285438537598
function O O 0.9963812232017517
of O O 0.9998401403427124
cells O O 0.9443273544311523
of O O 0.9994010925292969
lymphocytic B-cell_type O 0.5619738698005676
, I-cell_type O 0.8665437698364258
hemopoietic I-cell_type O 0.4476293623447418
systems E-cell_type O 0.6095218062400818
, O O 0.9864400029182434
and O O 0.9991326928138733
together O O 0.9996067881584167
with O O 0.9998960494995117
nerve B-cell_type B-cell_type 0.5484983325004578
cells E-cell_type E-cell_type 0.9466572403907776

The O O 0.973973274230957
Li S-Chemical B-Chemical 0.909532368183136
- O O 0.8110085129737854
treated O O 0.9973835349082947
rats O O 0.9940541386604309
produced O O 0.9999569654464722
a O O 0.9999572038650513
large O O 0.9984849095344543
volume O O 0.9955542683601379
of O O 0.9998782873153687
hypotonic O O 0.8069693446159363
urine O O 0.4035074710845947
with O O 0.9994494318962097
low O O 0.9729273915290833
ionic O O 0.5607147216796875
concentrations O O 0.5703046321868896
. O O 0.9999706745147705

cellular B-protein B-protein 0.7355090379714966
factor E-protein E-protein 0.8671824336051941
induced O O 0.9821509122848511
by O O 0.9997546076774597
IFN-gamma S-protein S-protein 0.9964565634727478
in O O 0.9994326233863831
promonocytic B-cell_type B-cell_type 0.5988464951515198
cells E-cell_type E-cell_type 0.9380598664283752
. O O 0.9997097849845886
Substitution O O 0.9774464964866638
mutations O O 0.9857220649719238
in O O 0.9999949932098389
this O O 0.9999467134475708
consensus B-DNA B-DNA 0.5397098660469055
sequence E-DNA E-DNA 0.8571712374687195
eliminate O O 0.9977532029151917
binding O O 0.9868908524513245
of O O 0.9995920062065125
the O O 0.999884843826294
inducible B-protein O 0.7691468596458435
factor E-protein O 0.6309996843338013
. O O 0.9881558418273926
The O O 0.9999287128448486
GAS B-DNA S-DNA 0.5016568899154663

IC50s O O 0.3202801048755646
) O O 0.9703865051269531
for O O 0.9999477863311768
the O O 0.9999799728393555
steroid-sensitive O O 0.7036819458007812
group O O 0.6143304109573364
ranged O O 0.9998809099197388
from O O 0.9999784231185913
2 O O 0.9673417806625366
x O O 0.9965993762016296
10 O O 0.9976949095726013
( O O 0.9998014569282532
-10 O O 0.9982569813728333
) O O 0.9983198046684265
mol/L O O 0.9792613387107849
for O O 0.999940037727356
budesonide O O 0.4636906385421753
to O O 0.9964871406555176
7 O O 0.9658568501472473
x O O 0.992478609085083
10 O O 0.9872708916664124
( O O 0.999534010887146
-8 O O 0.9908469319343567

Patients O O 0.9932209253311157
had O O 0.9999785423278809
received O O 0.9998711347579956
a O O 0.9999574422836304
median O O 0.9994831085205078
of O O 0.9998286962509155
2 O O 0.9968301653862
( O O 0.9998517036437988
range O O 0.9990741014480591
, O O 0.9999362230300903
1 O O 0.9995868802070618
- O O 0.9982511401176453
4 O O 0.9979200959205627
) O O 0.9993138313293457
prior O O 0.9990630745887756
regimens O O 0.9963506460189819
. O O 0.9999988079071045

Of O O 0.9995983242988586
our O O 0.9996259212493896
control O O 0.9208918213844299
group O O 0.9797226786613464
( O O 0.9999698400497437
n O O 0.9967936873435974
= O O 0.999854326248169
50 O O 0.9979806542396545
) O O 0.9999090433120728
, O O 0.9999955892562866
21 O O 0.9940411448478699
patients O O 0.9996329545974731
( O O 0.9999954700469971
42 O O 0.9999599456787109
% O O 0.9999604225158691
) O O 0.9998960494995117
were O O 0.9999942779541016
established O O 0.9902334213256836
hepatitis O B-Disease 0.958405613899231
. O O 0.9979134202003479

25-dihydroxyvitamin I-protein O 0.7240368723869324
D3 I-protein O 0.8647507429122925
[ I-protein O 0.9945428371429443
1 I-protein O 0.9905558228492737
, I-protein O 0.9970353841781616
25 I-protein O 0.9727357029914856
( I-protein O 0.999519944190979
OH I-protein O 0.9799348711967468

Both O O 0.9987574815750122
obstructive O O 0.7671236395835876
( O O 0.7833970189094543
P O O 0.5477322936058044
less O O 0.5126765966415405
than O O 0.9293601512908936
0 O O 0.9809051752090454
. O O 0.9909738898277283
05 O O 0.9629587531089783
) O O 0.9945823550224304
and O O 0.9999189376831055
central O O 0.8909386396408081
apnoea O B-Disease 0.6036721467971802
( O O 0.8829975128173828
P O O 0.5976170301437378
less O O 0.8760652542114258
than O O 0.9940118193626404
0 O O 0.998832643032074
. O O 0.9991527795791626
05 O O 0.98842453956604
) O O 0.9989116191864014
occurred O O 0.9999167919158936
more O O 0.9999603033065796
frequently O O 0.9995269775390625
in O O 0.9999746084213257
patients O O 0.999842643737793
who O O 0.9999871253967285
had O O 0.9999707937240601
a O O 0.9999043941497803
morphine S-Chemical B-Chemical 0.9182537794113159
infusion O O 0.9101664423942566
. O O 0.9999841451644897

a O O 0.9962673783302307
kappa B-DNA B-DNA 0.5978274345397949
B-like I-DNA I-DNA 0.9167962670326233
site E-DNA E-DNA 0.990119218826294
in O O 0.999314546585083
the O O 0.9999189376831055
TF B-DNA B-DNA 0.6777536273002625
promoter E-DNA E-DNA 0.9945161938667297
. O O 0.9994311928749084
Nuclear O O 0.975967526435852
translocation O O 0.989959180355072
of O O 0.9998006224632263
cytosolic B-protein B-protein 0.6316152811050415
c-Rel/p65 I-protein I-protein 0.5008960366249084
heterodimers E-protein E-protein 0.9779144525527954
and O O 0.996292233467102
other O O 0.9983842372894287
members O O 0.9611365795135498
of O O 0.9994126558303833
the O O 0.9999159574508667
NF-kappa B-protein B-protein 0.747699499130249
B/Rel I-protein I-protein 0.8478015661239624
family E-protein E-protein 0.9806430339813232
requires O O 0.999175488948822
dissociation O O 0.9783928394317627
and O O 0.9990947246551514
proteolytic O O 0.94566410779953
degradation O O 0.9916605353355408
of O O 0.9999299049377441
the O O 0.9998512268066406
inhibitor B-protein O 0.8878024220466614
protein E-protein O 0.7212571501731873
, O O 0.9937214851379395
I B-protein B-protein 0.9129847288131714
kappa I-protein I-protein 0.9812884330749512
B I-protein E-protein 0.6921919584274292

block O O 0.6072145700454712
in O O 0.9959512948989868
granulocyte O O 0.624284029006958
maturation O O 0.9182201623916626
observed O O 0.9991124272346497
in O O 0.9999300241470337
C/EBPalpha-deficient B-cell_type B-cell_line 0.6154548525810242
hematopoietic I-cell_type I-cell_line 0.6269903779029846
cells E-cell_type E-cell_line 0.6717004776000977
. O O 0.9998390674591064
The O O 0.9999990463256836
results O O 0.9999804496765137
of O O 0.9999940395355225
these O O 0.9999872446060181
and O O 0.9995893836021423
other O O 0.9998763799667358
studies O O 0.9998111128807068
suggest O O 0.9999970197677612
that O O 0.9999958276748657
additional O O 0.9817834496498108
C/EBPalpha B-DNA B-DNA 0.8107836842536926
target I-DNA I-DNA 0.7228360176086426
genes E-DNA E-DNA 0.9692879915237427
, O O 0.9987909197807312
possibly O O 0.9999064207077026
other O O 0.9996482133865356

Focal O O 0.8393294811248779
injury O O 0.6046500205993652
in O O 0.9385344982147217
the O O 0.9782468676567078
cortex O O 0.7395254969596863
was O O 0.9993389248847961
produced O O 0.999976634979248
by O O 0.9999880790710449
infusion O O 0.9745450615882874
of O O 0.9968568086624146
lactate S-Chemical B-Chemical 0.9339096546173096
at O O 0.9832168817520142
acid O O 0.8693280816078186
pH O O 0.7063294649124146
or O O 0.9996682405471802
by O O 0.9999065399169922
stab O O 0.43928757309913635
caused O O 0.9869274497032166
by O O 0.9998844861984253
needle O O 0.8528432250022888
insertion O O 0.6707265377044678
. O O 0.9999783039093018

markedly O O 0.9901543855667114
inhibited O O 0.9897415637969971
LPS-stimulated O O 0.8124529719352722
accumulation O O 0.9945472478866577
of O O 0.9998935461044312
mRNA O S-RNA 0.961163341999054
for O O 0.9959410429000854
ELAM-1 S-protein S-protein 0.8514919281005859
and O O 0.9950365424156189
expression O O 0.9937064051628113
of O O 0.9996122717857361
ELAM-1 S-protein S-protein 0.8229410648345947
and O O 0.9812907576560974
ICAM-1 S-protein S-protein 0.8754519820213318
( O O 0.9839233756065369
IC50 O S-protein 0.6799492239952087
< O O 0.9404213428497314
10 O O 0.9635748267173767
nM O O 0.9471756219863892
, O O 0.9995545744895935
both O O 0.9999572038650513
P O O 0.8970429301261902
< O O 0.9954458475112915
0.001 O O 0.9888385534286499
, O O 0.9999182224273682
n O O 0.994792640209198
= O O 0.9995285272598267
4-9 O O 0.9948904514312744
) O O 0.9997475743293762
; O O 0.9999663829803467
inhibition O O 0.987653911113739
of O O 0.9987515211105347
expression O O 0.9949052333831787
by O O 0.9999803304672241
dexamethasone O O 0.7979317903518677
was O O 0.9992732405662537
reversed O O 0.9999324083328247
by O O 0.999995231628418
RU-486 O O 0.4993461072444916
( O O 0.9469460844993591
both O O 0.9985864162445068

Mature O O 0.8139411211013794
male O O 0.8662364482879639
and O O 0.9867162704467773
female O O 0.9814797043800354
mice O O 0.9979279041290283
from O O 0.9999916553497314
six O O 0.9991651773452759
inbred O O 0.9043406844139099
stains O O 0.5640254020690918
were O O 0.9997678399085999
tested O O 0.999982476234436
for O O 0.9999704360961914
susceptibility O O 0.8408743739128113
to O O 0.9984607696533203
behavioral O O 0.7941575646400452
seizures O O 0.6418272852897644
induced O O 0.9375654458999634
by O O 0.9996497631072998
a O O 0.9999527931213379
single O O 0.9995105266571045
injection O O 0.9901407361030579
of O O 0.9996343851089478
cocaine S-Chemical B-Chemical 0.9213137030601501
. O O 0.9996836185455322

The O O 0.9916406869888306

and O O 0.9882386922836304
the O O 0.9999630451202393
effects O O 0.9999434947967529
of O O 0.999987006187439
CyA O O 0.5730388760566711
upon O O 0.9993329644203186
it O O 0.9985517859458923
. O O 0.9999927282333374
Antisense O O 0.9540695548057556
oligonucleotides O O 0.819635808467865
to O O 0.9996247291564941
the O O 0.9998785257339478
p65 B-protein B-protein 0.47944942116737366
subunit E-protein E-protein 0.9486900568008423
of O O 0.9909341335296631
NF-kappa B-protein B-protein 0.8009257316589355
B E-protein E-protein 0.9708695411682129
block O O 0.9090737700462341
CD11b S-protein S-protein 0.9035947918891907
expression O O 0.9896043539047241
and O O 0.9997007846832275
alter O O 0.9680813550949097
adhesion O O 0.8313902616500854
properties O O 0.9500359296798706
of O O 0.9998998641967773
differentiated O O 0.688173234462738
HL-60 B-cell_line B-cell_line 0.36995837092399597
granulocytes E-cell_line E-cell_line 0.709460437297821
. O O 0.9996775388717651

monoclonal I-protein I-protein 0.507172167301178
antibody E-protein E-protein 0.9706444144248962
( O O 0.9482441544532776
mAb S-protein S-protein 0.8124529123306274
) O O 0.5700682997703552
activated O O 0.8955875635147095
phosphatidylinositol B-protein B-protein 0.540036141872406
3-kinase E-protein E-protein 0.9832767248153687
and O O 0.9950132966041565
subsequently O O 0.9855775237083435
induced O O 0.9954972267150879
nuclear O O 0.9216451644897461
expression O O 0.977247416973114
of O O 0.9992629885673523
NF-kappa B-protein B-protein 0.9037177562713623
B E-protein E-protein 0.9917114973068237
, O O 0.9912749528884888
which O O 0.9999352693557739
was O O 0.9999299049377441
identified O O 0.9999656677246094
by O O 0.9999865293502808
electrophoretic O O 0.9068319201469421
mobility O O 0.9420902729034424
shift O O 0.9765313267707825
assays O O 0.9958462119102478
. O O 0.9999752044677734
n-Acetyl-L-cysteine O O 0.7032421231269836
( O O 0.9851310849189758
NAC O O 0.6990195512771606

factor E-protein E-protein 0.9453975558280945
, O O 0.9659883379936218
PEBP2 S-protein S-protein 0.7576212882995605
. O O 0.9998643398284912
The O O 0.9999819993972778
granulocyte-macrophage B-DNA B-DNA 0.44633573293685913
colony-stimulating I-DNA I-DNA 0.6005684733390808
factor I-DNA I-DNA 0.7984169721603394
( I-DNA I-DNA 0.41140666604042053
GM-CSF I-DNA I-DNA 0.5761737823486328
) I-DNA I-DNA 0.6616829633712769
gene I-DNA I-DNA 0.722362220287323
promoter E-DNA E-DNA 0.9822573065757751
contains O O 0.9995554089546204
a O O 0.9999260902404785
consensus O B-DNA 0.5094276070594788
sequence O E-DNA 0.8219149112701416

is O O 0.9914636015892029
regulated O O 0.9988945126533508
in O O 0.9999885559082031
a O O 0.999963641166687
complex O O 0.9340198636054993
fashion O O 0.9618031978607178
and O O 0.9997841715812683
may O O 0.9999589920043945
play O O 0.9999829530715942
a O O 0.9999940395355225
role O O 0.9998898506164551
in O O 0.999994158744812
the O O 0.9999814033508301
regulation O O 0.999500036239624
of O O 0.9999512434005737
genes O O 0.545966386795044
involved O O 0.9998723268508911
in O O 0.9999643564224243
myeloid O O 0.6929535269737244
differentiation O O 0.9713917374610901
. O O 0.9999804496765137
Effects O O 0.9998031258583069
of O O 0.9999047517776489

elements O E-DNA 0.9554026126861572
as O O 0.9986550807952881
well O O 0.9994096755981445
as O O 0.9999921321868896
its O O 0.99992835521698
cytoplasmic O O 0.5704989433288574
or O O 0.9034446477890015
nuclear O O 0.8283809423446655
location O O 0.8454005718231201
: O O 0.9959864020347595
in O O 0.9998632669448853
resting B-cell_type B-cell_type 0.4731862545013428
memory I-cell_type I-cell_type 0.7547572255134583
T I-cell_type I-cell_type 0.9490659832954407
cells E-cell_type E-cell_type 0.9687181711196899
the O O 0.998532772064209
activator S-DNA O 0.6696705222129822
is O O 0.9977554678916931
located O O 0.9999254941940308
in O O 0.999987006187439
the O O 0.9998008608818054
cytoplasm O O 0.6860029697418213
and O O 0.978371262550354

the O O 0.9989823698997498
preferential O O 0.9853945970535278
suppression O O 0.9975802898406982
of O O 0.999963641166687
Stat1 S-protein S-protein 0.9870550632476807
activity O O 0.9987467527389526
. O O 0.9999951124191284
cAMP O O 0.8796144723892212
inhibited O O 0.9997344613075256
the O O 0.9999778270721436
induction O O 0.9987585544586182
of O O 0.9999146461486816
expression O O 0.9909652471542358
of O O 0.999679684638977
IL-2 B-protein B-protein 0.5806366205215454
receptor I-protein I-protein 0.5231011509895325
components E-protein E-protein 0.9446028470993042
, O O 0.9980351328849792
but O O 0.9999620914459229
did O O 0.9999717473983765
not O O 0.9999634027481079
inhibit O O 0.9991551637649536
IL-4 B-protein S-protein 0.7298213839530945
receptor I-protein O 0.5829110741615295
alpha-chain E-protein O 0.5435144901275635
and O O 0.9276900887489319
CD69 S-protein S-protein 0.9028054475784302
expression O O 0.9981037378311157
or O O 0.9999514818191528
the O O 0.9999291896820068

constructs E-DNA E-DNA 0.8191915154457092

BACKGROUND O O 0.9895027875900269
: O O 0.9999809265136719
A O O 0.9999874830245972
previous O O 0.9997560381889343
randomized O O 0.9694185853004456
controlled O O 0.9844496846199036
trial O O 0.9878355860710144
evaluating O O 0.9999808073043823
the O O 0.999870777130127
use O O 0.9998477697372437
of O O 0.9999321699142456
spironolactone B-Chemical B-Chemical 0.9242901802062988
in O O 0.9990615248680115
heart B-Disease O 0.6064096689224243
failure I-Disease O 0.9561721086502075
patients O O 0.8197701573371887
reported O O 0.9999476671218872
a O O 0.9998786449432373
low O O 0.9901339411735535
risk O O 0.9957849383354187
of O O 0.9996719360351562
hyperkalemia B-Disease B-Disease 0.9890118837356567
( O O 0.9560388326644897
2 O O 0.9974082112312317
% O O 0.9987788796424866
) O O 0.9959408044815063
and O O 0.9996659755706787
renal B-Disease B-Disease 0.6368054151535034
insufficiency I-Disease I-Disease 0.9906576871871948
( O O 0.9604110717773438
0 O O 0.9989228844642639
% O O 0.999819815158844
) O O 0.9996026158332825
. O O 0.9999959468841553

disclose O O 0.9962322115898132
a O O 0.9999611377716064
common O O 0.9460725784301758
element O O 0.5358949899673462
within O O 0.999771773815155
their O O 0.9997264742851257
promoters S-DNA S-DNA 0.965225100517273
, O O 0.998190701007843
defined O O 0.9786070585250854
Interferon B-DNA B-DNA 0.4737057685852051
Stimulated I-DNA I-DNA 0.539027214050293
Response I-DNA I-DNA 0.527039110660553
Element E-DNA E-DNA 0.8930385708808899
( O O 0.9770988821983337
ISRE S-DNA S-DNA 0.9770032167434692
) O O 0.9748268127441406
, O O 0.9994016885757446
which O O 0.9999487400054932
binds O O 0.9998863935470581
a O O 0.9998262524604797
nuclear B-protein B-protein 0.4718225598335266
factor E-protein E-protein 0.7276884317398071
( O O 0.6345266103744507
s O O 0.5566918253898621
) O O 0.4650462865829468
translocated O O 0.8958619832992554
from O O 0.9996258020401001
the O O 0.9995867609977722
cytoplasm O O 0.7461494207382202
to O O 0.9944672584533691
the O O 0.9990532994270325

, O O 0.9734826683998108
including O O 0.9997305274009705
hematological O O 0.9106944799423218
malignancies O O 0.90870600938797
. O O 0.9999945163726807
The O O 0.9999839067459106
human B-DNA B-DNA 0.4803831875324249
androgen I-DNA I-DNA 0.5675172209739685
receptor I-DNA I-DNA 0.6707248091697693
gene E-DNA E-DNA 0.9640364050865173
( O O 0.9809119701385498
HUMARA S-DNA S-DNA 0.9530229568481445
) O O 0.9782537221908569
assay O O 0.9982653260231018
is O O 0.999998927116394
the O O 0.9999942779541016
newest O O 0.9971768856048584
of O O 0.9999316930770874
such O O 0.9991869330406189
methods O O 0.9973803162574768
, O O 0.9999866485595703
and O O 0.9999872446060181
the O O 0.9999836683273315
majority O O 0.9638899564743042

By O O 0.9998145699501038
November O O 0.9999858140945435
1984 O O 0.9999916553497314
the O O 0.9999970197677612
Committee O O 0.9997755885124207
on O O 0.9998914003372192
Safety O O 0.9665094614028931
of O O 0.9958630800247192
Medicines O O 0.8253737092018127
had O O 0.9998784065246582
received O O 0.9999933242797852
82 O O 0.9996005892753601
reports O O 0.9996745586395264
of O O 0.999984860420227
possible O O 0.9922339916229248
hepatotoxicity B-Disease B-Disease 0.9779517650604248
associated O O 0.9059677124023438
with O O 0.9992984533309937
the O O 0.9992449283599854
drug O O 0.9564737677574158
, O O 0.9996067881584167
including O O 0.9999608993530273
five O O 0.9980005621910095
deaths B-Disease O 0.9208714962005615
. O O 0.9994993209838867

of O O 0.9947097301483154
IL-2 B-DNA B-DNA 0.7467153072357178
promoter E-DNA E-DNA 0.9857776761054993
-driven O O 0.968408465385437
transcription O O 0.9614248871803284
and O O 0.9988138675689697
blocked O O 0.9968476891517639
the O O 0.9998968839645386
ability O O 0.9996205568313599
of O O 0.9999570846557617
constitutively O O 0.7315620183944702
active O O 0.6973733901977539
Ras S-protein S-protein 0.7433568835258484
and O O 0.9833828806877136
Raf-1 S-protein S-protein 0.9948974251747131
to O O 0.998819887638092
costimulate O O 0.9947239756584167
NF-AT S-protein S-protein 0.9898127913475037
activity O O 0.9986415505409241

presence O O 0.971365749835968
of O O 0.9998089671134949
IL-4 S-protein S-protein 0.97382652759552
and O O 0.990972638130188
CD40 S-protein S-protein 0.9769721031188965
signaling O O 0.9933865666389465
. O O 0.9999921321868896
Finally O O 0.9999324083328247
, O O 0.9999169111251831
CD27 S-protein S-protein 0.961794376373291
cross-linking O O 0.9898501634597778
resulted O O 0.9999481439590454
in O O 0.9999862909317017
the O O 0.999975323677063
up-regulation O O 0.9976760745048523
of O O 0.9998776912689209
positive B-protein B-protein 0.8319938778877258
regulatory I-protein I-protein 0.5101694464683533
domain I-protein I-protein 0.6885967254638672
I-binding I-protein I-protein 0.7005144357681274
factor-1 E-protein E-protein 0.9752859473228455
. O O 0.9961798191070557
Taken O O 0.9999252557754517
together O O 0.9999756813049316
, O O 0.9999961853027344
our O O 0.9999847412109375
findings O O 0.9986326098442078

whereas O O 0.9953799247741699
E2F1 B-protein B-protein 0.889828085899353
and I-protein I-protein 0.9409570693969727
-3 E-protein E-protein 0.6675126552581787
are O O 0.996616780757904
first O O 0.9946141839027405
detected O O 0.9997692704200745
in O O 0.9998961687088013
late O O 0.9528740644454956
G1 O O 0.5710796117782593
, O O 0.997494101524353
and O O 0.9999780654907227
their O O 0.999906063079834
expression O O 0.9803061485290527
levels O O 0.999721348285675
increase O O 0.9996621608734131
towards O O 0.9999300241470337
S O O 0.8086360692977905
phase O O 0.8869054317474365
. O O 0.999907374382019
Intriguingly O O 0.9992421865463257
, O O 0.9999951124191284
the O O 0.9999793767929077
major B-protein O 0.8478390574455261
E2F I-protein B-protein 0.7488512992858887
complex E-protein E-protein 0.9786569476127625
that O O 0.9991576671600342
we O O 0.9996148347854614
detected O O 0.9996750354766846
in O O 0.9998501539230347
quiescent B-cell_type B-cell_type 0.5801906585693359
human I-cell_type I-cell_type 0.3410393297672272
B-lymphocytes E-cell_type E-cell_type 0.5821477770805359
is O O 0.998457670211792
consisted O O 0.9999513626098633

human B-cell_line B-cell_line 0.31738242506980896
T-cell I-cell_line I-cell_line 0.5222470760345459
lines E-cell_line E-cell_line 0.9979687333106995
. O O 0.9999072551727295
The O O 0.9999831914901733
HTLV-I B-protein B-protein 0.34971410036087036
transcriptional I-protein I-protein 0.45758917927742004
activator I-protein I-protein 0.704086184501648
tax E-protein E-protein 0.9251753091812134
was O O 0.9985645413398743
used O O 0.9999587535858154
to O O 0.9999796152114868
gain O O 0.9998637437820435
insight O O 0.999414324760437
into O O 0.9999936819076538
the O O 0.9999521970748901
mechanism O O 0.9987892508506775
of O O 0.9999672174453735
lymphotoxin B-DNA B-DNA 0.39404603838920593
( I-DNA I-DNA 0.8591093420982361
LT I-DNA I-DNA 0.27951207756996155
; I-DNA I-DNA 0.5446540713310242
TNF-beta I-DNA I-DNA 0.5511382222175598
) I-DNA I-DNA 0.6325756907463074
gene E-DNA E-DNA 0.9777211546897888
induction O O 0.9917606115341187
. O O 0.9999911785125732
Tax-expressing B-cell_line B-cell_line 0.46952569484710693
cell I-cell_line I-cell_line 0.5172913074493408
lines E-cell_line E-cell_line 0.995911717414856
produce O O 0.9997287392616272
LT S-protein O 0.299252450466156
biologic O O 0.6622903347015381
activity O O 0.985564649105072
. O O 0.9999915361404419
An O O 0.9941225647926331

detail O O 0.9511914849281311
, O O 0.9999631643295288
there O O 0.9999977350234985
is O O 0.9999984502792358
very O O 0.999895453453064
little O O 0.9998869895935059
information O O 0.9999349117279053
about O O 0.9999982118606567
the O O 0.999990701675415
regulation O O 0.9997414946556091
of O O 0.9999834299087524
CTCF S-protein S-protein 0.9712715148925781
activity O O 0.9985440969467163
. O O 0.9999977350234985
Therefore O O 0.9999955892562866
we O O 0.9999948740005493
investigated O O 0.9998916387557983
CTCF S-protein S-protein 0.9226212501525879
expression O O 0.9954594969749451
and O O 0.9998148083686829
phosphorylation O O 0.9629939198493958
during O O 0.9999488592147827
induced O O 0.984002411365509
differentiation O O 0.9916744828224182
of O O 0.9998693466186523

Mouse O O 0.8661622405052185
strain O O 0.7074741125106812
- O O 0.9788590669631958
dependent O O 0.9792490601539612
effect O O 0.9964258074760437
of O O 0.999483585357666
amantadine B-Chemical B-Chemical 0.9310385584831238
on O O 0.9952859282493591
motility O O 0.5634893774986267
and O O 0.9973965883255005
brain O O 0.8830757141113281
biogenic O O 0.6982648372650146
amines B-Chemical B-Chemical 0.8155977725982666
. O O 0.9995561242103577

in O O 0.995355486869812
T-cell B-cell_line B-cell_type 0.3265116214752197
populations E-cell_line E-cell_type 0.4966747462749481
enriched O O 0.9488006234169006
for O O 0.9991887211799622
cells O O 0.9539019465446472
that O O 0.999932050704956
had O O 0.9999610185623169
previously O O 0.999678373336792
been O O 0.9998917579650879
primed O O 0.9985583424568176
in O O 0.9999274015426636
vivo O O 0.9721176028251648
or O O 0.9987209439277649
in O O 0.9988829493522644
vitro O O 0.9903297424316406
, O O 0.999843955039978
indicating O O 0.9999697208404541
that O O 0.9999760389328003
priming O O 0.864565908908844
increases O O 0.9995366334915161
the O O 0.9998350143432617
expression O O 0.9993207454681396
of O O 0.9999634027481079
the O O 0.9993906021118164
IL-13 B-DNA B-DNA 0.6566444635391235
and I-DNA I-DNA 0.6259899735450745
IL-4 I-DNA I-DNA 0.4444499611854553
genes E-DNA E-DNA 0.99205482006073
in O O 0.9995911717414856
a O O 0.9999531507492065
coordinate O O 0.9806749224662781
manner O O 0.9977346658706665
. O O 0.9999984502792358
Because O O 0.9999964237213135
the O O 0.9999446868896484
primed B-cell_line O 0.7386783957481384
T I-cell_line O 0.31059956550598145

We O O 0.9980576634407043
postulate O O 0.9998835325241089
that O O 0.9999878406524658
by O O 0.9999442100524902
virtue O O 0.9964358806610107
of O O 0.9999593496322632
its O O 0.9999752044677734
direct O O 0.992174506187439
blocking O O 0.955161988735199
action O O 0.9639716744422913
on O O 0.9999288320541382
IKr O O 0.3924823999404907
, O O 0.994540274143219
ketoconazole S-Chemical B-Chemical 0.9148494005203247
alone O O 0.9544729590415955
may O O 0.9999947547912598
prolong O O 0.9996743202209473
QT O O 0.7414507865905762
interval O O 0.753705620765686
and O O 0.9987506866455078
induce O O 0.9996225833892822
TdP O O 0.8571374416351318
. O O 0.9974355101585388

very O O 0.9890599250793457
early O O 0.9991635084152222
during O O 0.9999984502792358
the O O 0.9999929666519165
monocyte O O 0.7698202133178711
differentiation O O 0.9582295417785645
process O O 0.9984580278396606
. O O 0.999998927116394
Here O O 0.9999277591705322
we O O 0.9999929666519165
demonstrate O O 0.9999908208847046
that O O 0.999994158744812
the O O 0.9996981620788574
human B-DNA B-DNA 0.49886587262153625

Smmhc S-protein S-protein 0.32950595021247864
) O O 0.8470357060432434
. O O 0.9998514652252197
To O O 0.9999955892562866
examine O O 0.9999855756759644
the O O 0.9999696016311646
effect O O 0.9999055862426758
of O O 0.9999845027923584
the O O 0.9998910427093506
inv B-DNA B-DNA 0.6394281387329102
( I-DNA I-DNA 0.848950982093811
16 I-DNA I-DNA 0.5811831951141357
) I-DNA I-DNA 0.5161738395690918
( I-DNA I-DNA 0.9125063419342041
p13 I-DNA I-DNA 0.45187947154045105
; I-DNA I-DNA 0.7221725583076477
q22 I-DNA I-DNA 0.8991559743881226
) E-DNA E-DNA 0.72794508934021
on O O 0.9856632351875305
myelopoiesis O O 0.8423604965209961
, O O 0.999721109867096
we O O 0.9999752044677734
used O O 0.9999841451644897
the O O 0.9999213218688965
hMRP8 B-DNA B-DNA 0.6535097360610962
promoter I-DNA E-DNA 0.9607963562011719

a O O 0.9971712231636047
proline-rich B-protein B-DNA 0.6957845687866211
sequence E-protein E-DNA 0.8514294028282166
in O O 0.9996415376663208
the O O 0.9999746084213257
membrane-proximal B-protein B-DNA 0.7120522856712341
region E-protein E-DNA 0.5172358155250549
of O O 0.9863998889923096
CD40 S-protein S-protein 0.6082134246826172
. O O 0.9997463822364807
Deletion O O 0.9929773211479187
of O O 0.999675989151001
this O O 0.9998061060905457
sequence O O 0.9596610069274902
abolishes O O 0.9997965693473816
the O O 0.9999809265136719
capacity O O 0.9983819723129272
of O O 0.9998769760131836
CD40 S-protein S-protein 0.8562703132629395

the O O 0.9977915287017822
AP-1 O B-DNA 0.41603612899780273
consensus O I-DNA 0.8204138875007629
sequence O E-DNA 0.9851898550987244
, O O 0.993309497833252
TRE O S-DNA 0.9852244853973389
, O O 0.9856488704681396
and O O 0.9980290532112122
AP-1 O B-DNA 0.4134247899055481
enhancer O E-DNA 0.9578178524971008
activity O O 0.9498991966247559
, O O 0.9999167919158936
in O O 0.9997701048851013
Jurkat B-cell_line B-cell_line 0.8596407175064087
cells E-cell_line E-cell_line 0.9937211275100708
. O O 0.9999074935913086
PMA O O 0.9403761029243469
was O O 0.9999308586120605
also O O 0.9999874830245972
found O O 0.999977707862854
to O O 0.9999849796295166
increase O O 0.9999649524688721
the O O 0.9998691082000732
AP-1 O B-DNA 0.4745675027370453
enhancer O E-DNA 0.9841647744178772
activity O O 0.9769167304039001
, O O 0.999948263168335

protection O O 0.9775444269180298
to O O 0.9997751116752625
T B-cell_line B-cell_line 0.4251534640789032
cell I-cell_line I-cell_line 0.3616075813770294
lines E-cell_line E-cell_line 0.9929229021072388
from O O 0.9998636245727539
TCR S-protein S-protein 0.8860432505607605
-mediated O O 0.9934661984443665
apoptosis O O 0.9795399904251099
. O O 0.9999979734420776
These O O 0.999993085861206
data O O 0.9993946552276611
demonstrate O O 0.9999974966049194
a O O 0.9999908208847046
new O O 0.9948276877403259
antiapoptotic O O 0.9189828634262085
role O O 0.9688748717308044
for O O 0.9990430474281311
Notch-1 S-protein S-protein 0.9545062780380249
, O O 0.9982810020446777
providing O O 0.9999724626541138
evidence O O 0.9999603033065796
that O O 0.9999964237213135
, O O 0.9992389678955078
in O O 0.9999449253082275
addition O O 0.9991081357002258
to O O 0.9996993541717529

death O O 0.6426429152488708
, O O 0.9987310767173767
is O O 0.9999723434448242
perhaps O O 0.9999611377716064
the O O 0.9999834299087524
best O O 0.9998637437820435
understood O O 0.9997674822807312
of O O 0.9999685287475586
the O O 0.9999439716339111
programmed O B-DNA 0.7809278964996338
cell O I-DNA 0.6550807952880859
death O I-DNA 0.42730769515037537
associated O I-DNA 0.5746419429779053
genes O E-DNA 0.9803693890571594
. O O 0.9998937845230103
Here O O 0.9999052286148071
, O O 0.9999939203262329
Stanley O O 0.9891479015350342
Korsmeyer O O 0.9442468881607056
provides O O 0.9999504089355469
a O O 0.9999936819076538
brief O O 0.9939601421356201
overview O O 0.9993519186973572
of O O 0.9999226331710815
bcl-2 S-protein S-protein 0.5499774813652039
, O O 0.9920119643211365
concentrating O O 0.9960240125656128
on O O 0.9999067783355713
its O O 0.9997571110725403

which O O 0.9955868721008301
otherwise O O 0.9999655485153198
do O O 0.9999898672103882
not O O 0.9998449087142944
express O O 0.9997871518135071
ICSAT S-protein S-protein 0.9334889650344849
. O O 0.9998959302902222
When O O 0.9999984502792358
the O O 0.9999649524688721
binding O O 0.981952965259552
of O O 0.9992929697036743
ICSAT S-protein S-protein 0.5820878148078918
to O O 0.9908527731895447
four O O 0.9956117272377014
different O O 0.9974961876869202
ICSs S-DNA S-DNA 0.687134861946106
was O O 0.9960442781448364
tested O O 0.9999644756317139
, O O 0.9999986886978149
the O O 0.999983549118042
relative O O 0.9952892065048218
differences O O 0.9992175102233887
in O O 0.9999535083770752
binding O O 0.9447767734527588
affinities O O 0.9862171411514282
for O O 0.9999815225601196
those O O 0.9999669790267944
ICSs S-DNA O 0.3624632656574249
were O O 0.9997010827064514
determined O O 0.9999915361404419
. O O 0.9999980926513672
To O O 0.9999945163726807
study O O 0.9999845027923584
the O O 0.9999642372131348
functional O O 0.9798091650009155
role O O 0.9961751699447632

of O O 0.998034656047821
the O O 0.9999843835830688
vitamin B-protein B-protein 0.5620313882827759
D I-protein I-protein 0.6954407691955566
receptor E-protein E-protein 0.9892956614494324
( O O 0.984655499458313
VDR O S-protein 0.9904659986495972
) O O 0.9900369644165039
in O O 0.9998249411582947
parathyroid O O 0.5628102421760559
glands O O 0.5369691848754883
of O O 0.9976917505264282
uremic O O 0.7216125726699829
animals O O 0.7307567000389099
and O O 0.9972794651985168
humans O O 0.8557603359222412
has O O 0.9998281002044678
been O O 0.9999591112136841
observed O O 0.9999550580978394
. O O 0.9999991655349731
Similar O O 0.9998432397842407
results O O 0.9998648166656494
have O O 0.9999954700469971
been O O 0.9999309778213501
obtained O O 0.9999617338180542
by O O 0.9999901056289673
our O O 0.9997225403785706
own O O 0.987557053565979
group O O 0.9838130474090576
in O O 0.9999216794967651
peripheral B-cell_type B-cell_type 0.7698222398757935
blood I-cell_type I-cell_type 0.9528051614761353

We O O 0.9992669224739075
postulate O O 0.999931812286377
that O O 0.999996542930603
the O O 0.9999676942825317
mechanism O O 0.9997079968452454
of O O 0.9999231100082397
the O O 0.9997801184654236
simvastatinezetimibe S-Chemical B-Chemical 0.9300060272216797
- O O 0.9109170436859131
induced O O 0.9968478083610535
hepatotoxicity O B-Disease 0.984264075756073
is O O 0.9971062541007996
the O O 0.9999771118164062
increased O O 0.9977430105209351
simvastatin S-Chemical B-Chemical 0.8798147439956665
exposure O O 0.9295125603675842
by O O 0.9999409914016724
ezetimibe S-Chemical B-Chemical 0.9283978343009949
inhibition O O 0.8872721195220947
of O O 0.9996013045310974
UGT O O 0.41493695974349976
enzymes O O 0.7832870483398438
. O O 0.9999958276748657

and O O 0.9672564268112183
inhibits O O 0.9995400905609131
tumor O O 0.680452287197113
cell O O 0.4779700040817261
apoptosis O O 0.9685317873954773
. O O 0.9999831914901733
Abnormalities O O 0.9936984777450562
of O O 0.9998332262039185
retinoblastoma B-protein B-protein 0.5398347973823547
protein E-protein E-protein 0.964579701423645
( O O 0.9398382306098938
pRB S-protein S-protein 0.9690789580345154
) O O 0.9734008312225342
and O O 0.998807430267334
mutations O O 0.9157440066337585
of O O 0.999016284942627
RB O B-DNA 0.5022326111793518
gene O E-DNA 0.9693728089332581
have O O 0.9986224174499512
been O O 0.9999271631240845
reported O O 0.9999706745147705
in O O 0.9999755620956421
up O O 0.9992278814315796
to O O 0.9998960494995117
70 O O 0.9996309280395508
% O O 0.9999140501022339
of O O 0.9999603033065796
MM O O 0.6517383456230164
patients O O 0.9508310556411743
and O O 0.9998757839202881
80 O O 0.9981485605239868
% O O 0.9998492002487183
of O O 0.9999662637710571
MM-derived B-cell_line B-cell_line 0.7310032844543457
cell I-cell_line I-cell_line 0.7572564482688904
lines E-cell_line E-cell_line 0.9986850619316101
. O O 0.9998854398727417
Because O O 0.9999796152114868
dephosphorylated B-protein O 0.33391517400741577
( I-protein O 0.667268693447113
activated I-protein O 0.37974900007247925

The O O 0.99918133020401
novel O O 0.6625296473503113
immunosuppressive O O 0.3106587827205658
( O O 0.9703629016876221
IS O O 0.7387807369232178
) O O 0.9889363646507263
drug O O 0.9845102429389954
sirolmus B-Chemical B-Chemical 0.9220900535583496
( O O 0.9647205471992493
Srl B-Chemical B-Chemical 0.9149101376533508
) O O 0.6816222667694092
lacks O O 0.9996286630630493
nephrotoxic B-Disease O 0.7394489049911499
effects O O 0.5107594728469849
; O O 0.9992955923080444
however O O 0.9999721050262451
, O O 0.9999740123748779
proteinuria B-Disease B-Disease 0.9635137319564819
associated O O 0.9521954655647278
with O O 0.9994741082191467
Srl B-Chemical B-Chemical 0.9140254259109497
has O O 0.9978392720222473
been O O 0.9996397495269775
reported O O 0.9999629259109497
following O O 0.999982476234436
renal O O 0.9459850788116455
transplantation O O 0.8335764408111572
. O O 0.9999929666519165

transactivation O O 0.8826678991317749
activity O O 0.9953597187995911
of O O 0.9999319314956665
GATA-1 S-protein S-protein 0.9274500012397766
for O O 0.9993568062782288
the O O 0.9999406337738037
MBP B-DNA B-DNA 0.44258567690849304
promoter E-DNA E-DNA 0.9900962114334106
in O O 0.9988879561424255
a O O 0.9998905658721924
dose-dependent O O 0.9673773646354675
manner O O 0.9974159002304077
. O O 0.9999986886978149
Our O O 0.9999967813491821
results O O 0.9999686479568481
provide O O 0.9999985694885254
the O O 0.9999954700469971
first O O 0.9973434805870056
evidence O O 0.9999371767044067
that O O 0.9999948740005493
both O O 0.9996793270111084
GATA-1 S-protein S-protein 0.840984046459198
and O O 0.9751273393630981

a O O 0.9989249110221863
2-day O O 0.8791150450706482
incubation O O 0.9239599108695984
in O O 0.9993712306022644
LDL S-protein S-cell_line 0.8265167474746704
, O O 0.9977971315383911
the O O 0.9999771118164062
binding O O 0.9664276838302612
of O O 0.9979894161224365
NF-kappa B-protein B-protein 0.8857905268669128
B E-protein E-protein 0.9780599474906921
, O O 0.9913353323936462
which O O 0.9999217987060547
is O O 0.9999464750289917
believed O O 0.9999656677246094
to O O 0.9999572038650513
be O O 0.9998931884765625
a O O 0.9992972612380981

Secondary O O 0.9908011555671692
outcomes O O 0.9985753297805786
were O O 0.9999974966049194
a O O 0.9999911785125732
postdose O O 0.9205608367919922
SCr O O 0.6426066756248474
increase O O 0.9840502142906189
> O O 0.9997302889823914
or O O 0.9999514818191528
= O O 0.9999414682388306
25 O O 0.9999010562896729
% O O 0.999975323677063
, O O 0.9999945163726807
a O O 0.9999715089797974
postdose O O 0.9668270349502563
estimated O O 0.9937834739685059
glomerular O O 0.752268373966217
filtration O O 0.8131395578384399
rate O O 0.9905023574829102
decrease O O 0.9867070913314819
of O O 0.9974892139434814
> O O 0.9992311000823975
or O O 0.9999268054962158
= O O 0.9999086856842041
25 O O 0.9997662901878357
% O O 0.9999419450759888
, O O 0.9999790191650391
and O O 0.9999864101409912
the O O 0.9999749660491943
mean O O 0.9991369843482971
peak O O 0.9697063565254211
change O O 0.9865068197250366
in O O 0.9998071789741516
SCr O O 0.4259253442287445
. O O 0.9991766810417175

present O O 0.9943128824234009
an O O 0.9999805688858032
obstacle O O 0.9971829652786255
to O O 0.9999488592147827
gene O O 0.9521517157554626
therapy O O 0.9988610744476318
in O O 0.9999957084655762
an O O 0.9999144077301025
MHC S-protein S-protein 0.4922819137573242
-diverse O O 0.8729753494262695
human O O 0.6111780405044556
population O O 0.6024575233459473
. O O 0.9998577833175659
Characterization O O 0.9990167617797852
of O O 0.9999786615371704
the O O 0.9998892545700073
human B-DNA B-DNA 0.4212426245212555
platelet/endothelial I-DNA I-DNA 0.5280882120132446
cell I-DNA I-DNA 0.6539614796638489
adhesion I-DNA I-DNA 0.77922523021698
molecule-1 I-DNA I-DNA 0.8192514181137085
promoter E-DNA E-DNA 0.98653644323349
: O O 0.9876047372817993

CONCLUSIONS O O 0.9968149065971375
: O O 0.9999850988388062
Topical O O 0.9689470529556274
papaverine S-Chemical B-Chemical 0.9143643379211426
for O O 0.9929543137550354
the O O 0.999932050704956
treatment O O 0.9997133612632751
of O O 0.9999500513076782
vasospasm O B-Disease 0.9595593810081482
was O O 0.9752827882766724
associated O O 0.9998323917388916
with O O 0.9999934434890747
the O O 0.999944806098938
onset O O 0.9941530823707581
of O O 0.9998835325241089
a O O 0.9997989535331726
transient O O 0.7292603254318237
disturbance O O 0.4495115280151367
in O O 0.981519341468811
neurophysiological O O 0.885787308216095
function O O 0.7293633222579956
of O O 0.9877043962478638
the O O 0.9981226325035095
ascending O O 0.8643450736999512
auditory O O 0.9034035801887512
brainstem O O 0.5991532206535339
pathway O O 0.9560652375221252
. O O 0.9999986886978149

NF-kappa B-protein B-protein 0.6827276349067688
B E-protein E-protein 0.993208110332489
nuclear O O 0.9754053354263306
translocation O O 0.9950029253959656
. O O 0.9999920129776001
This O O 0.9999761581420898
results O O 0.9999639987945557
in O O 0.9999924898147583
increased O O 0.9986503720283508
transcription O O 0.9821615219116211
of O O 0.999512791633606
NF-kappa B-DNA B-protein 0.7920393943786621
B-dependent-genes E-DNA E-protein 0.9552341103553772
, O O 0.9939743876457214
including O O 0.9999550580978394
those O O 0.9999579191207886
encoding O O 0.9957389831542969
p105 S-protein S-protein 0.8049941062927246
and O O 0.9481968283653259
I B-protein B-protein 0.8110148310661316
kappa I-protein I-protein 0.8917571306228638
B I-protein I-protein 0.7187246084213257
alpha E-protein E-protein 0.9742598533630371
( O O 0.9805444478988647
MAD3 S-DNA S-protein 0.9334772229194641
) O O 0.9615879654884338
. O O 0.9999716281890869
These O O 0.9999632835388184

is O O 0.9977339506149292
known O O 0.9999868869781494
about O O 0.999996542930603
negative O O 0.961334764957428
regulation O O 0.9963191747665405
of O O 0.9999550580978394
IL-1beta S-protein S-protein 0.9690630435943604
expression O O 0.9983342289924622
at O O 0.9999991655349731
the O O 0.9999951124191284
transcriptional O O 0.9165073037147522
level O O 0.9980103373527527
, O O 0.9999886751174927
which O O 0.9999856948852539
may O O 0.9999920129776001
play O O 0.9999891519546509
an O O 0.9999954700469971
important O O 0.9993069171905518
role O O 0.9995699524879456
in O O 0.9999802112579346

of O O 0.9977091550827026
mitogen-activated B-protein B-protein 0.5006569027900696
protein I-protein I-protein 0.38752853870391846
kinase E-protein E-protein 0.8994405269622803
pathways O O 0.9459410309791565
in O O 0.9999611377716064
interleukin-8 S-protein S-protein 0.9396284222602844
production O O 0.9965202808380127
by O O 0.9999514818191528
human B-cell_type B-cell_type 0.7180388569831848
monocytes E-cell_type E-cell_type 0.9873470067977905
and O O 0.9947604537010193
polymorphonuclear B-cell_type B-cell_type 0.7110863924026489

be O O 0.9967560172080994
specifically O O 0.9995624423027039
induced O O 0.9999485015869141
by O O 0.999994158744812
ligands O O 0.9517444372177124
of O O 0.9995427131652832
the O O 0.9999452829360962
CDR2-loop S-protein S-protein 0.6027435660362244
in O O 0.9661022424697876
domain B-protein O 0.8090603351593018
1 E-protein O 0.7981825470924377
( O O 0.9824381470680237
D1 S-protein O 0.5426874160766602
) O O 0.883649468421936
of O O 0.9974750876426697
CD4 S-protein S-protein 0.7963957190513611
( O O 0.964042067527771
virus B-protein O 0.6404189467430115
envelope I-protein O 0.39634737372398376
and I-protein O 0.8607742786407471
anti-CD4 I-protein B-protein 0.20338888466358185

In O O 0.9997338652610779
isolated O O 0.9089861512184143
perfused O O 0.8687424063682556
heart O O 0.6857423186302185
preparations O O 0.752659261226654
from O O 0.9997878670692444
isoproterenol B-Chemical B-Chemical 0.9253979325294495
- O O 0.8579773306846619
pretreated O O 0.98748779296875
rats O O 0.9938740134239197
, O O 0.9999932050704956
the O O 0.9998817443847656
isoproterenol B-Chemical B-Chemical 0.9303309321403503
- O O 0.8274701237678528
induced O O 0.9982567429542542
maximal O O 0.9285121560096741
increase O O 0.6607718467712402
in O O 0.8677434921264648
left O O 0.8719038367271423
ventricular O O 0.8476858735084534
systolic O O 0.8339378833770752
pressure O O 0.6640146374702454
was O O 0.9995999932289124
significantly O O 0.9999440908432007
reduced O O 0.9971207976341248
, O O 0.9999258518218994
compared O O 0.9999822378158569
with O O 0.999987006187439
saline O O 0.5588076710700989
- O O 0.9912033081054688
pretreated O O 0.9954873919487
rats O O 0.9956889748573303
( O O 0.9999924898147583
the O O 0.999947190284729
EC50 O O 0.6444458365440369
of O O 0.9814852476119995
the O O 0.9993649125099182
isoproterenol B-Chemical B-Chemical 0.9374943971633911
- O O 0.6961166262626648
induced O O 0.9898999333381653
increase O O 0.7591150999069214
in O O 0.9550086855888367
left O O 0.938877522945404
ventricular O O 0.9005388617515564
systolic O O 0.860226035118103
pressure O O 0.5660548806190491
was O O 0.999671459197998
enhanced O O 0.9982301592826843
approximately O O 0.9996165037155151
22 O O 0.9993066787719727
- O O 0.9994893074035645
fold O O 0.9985185265541077
) O O 0.9999194145202637
. O O 0.9999964237213135

, O O 0.9785400629043579
inhibits O O 0.9990052580833435
granzyme B-RNA B-RNA 0.8224394917488098
B I-RNA I-RNA 0.9718135595321655
mRNA I-RNA I-RNA 0.7722688317298889
transcript E-RNA E-RNA 0.992331862449646
in O O 0.9990841150283813
phytohemagglutinin-activated B-cell_type B-cell_type 0.42606228590011597
peripheral I-cell_type I-cell_type 0.52464759349823
blood I-cell_type I-cell_type 0.5143074989318848
mononuclear I-cell_type I-cell_type 0.5405787229537964
cells E-cell_type E-cell_type 0.594930112361908
. O O 0.9997615218162537
Transfection O O 0.989378035068512
of O O 0.9997872710227966
a O O 0.9993746876716614
reporter O B-DNA 0.7509443759918213
construct O E-DNA 0.9127276539802551
containing O O 0.9967567324638367
the O O 0.9992893934249878
-148 B-DNA B-DNA 0.7262957096099854
to I-DNA I-DNA 0.5390986204147339
+60 I-DNA I-DNA 0.40473034977912903
region E-DNA E-DNA 0.9463097453117371
of O O 0.9962537288665771
the O O 0.9996646642684937
human O B-DNA 0.48154133558273315
granzyme B-DNA I-DNA 0.6864191889762878
B I-DNA I-DNA 0.8052026033401489
promoter E-DNA E-DNA 0.9792947173118591
demonstrated O O 0.9988100528717041
that O O 0.9999955892562866
this O O 0.9998444318771362
region O O 0.9833264946937561
was O O 0.9999833106994629
the O O 0.9999858140945435
target O O 0.9968587160110474
for O O 0.9999476671218872
dexamethasone O O 0.8702815175056458
repression O O 0.9680382609367371

Immunohistochemical O O 0.8459632396697998
studies O O 0.9980966448783875
showed O O 0.9999977350234985
that O O 0.9999878406524658
administration O O 0.9972731471061707
of O O 0.9997242093086243
terbutaline S-Chemical B-Chemical 0.9294947385787964
on O O 0.9990308284759521
PN O O 0.6832748651504517
2 O O 0.9441235661506653
to O O 0.9982787370681763
5 O O 0.89333176612854
produced O O 0.9998364448547363
a O O 0.9998877048492432
robust O O 0.9868274927139282
increase O O 0.8672444820404053
in O O 0.9822806715965271
microglial O O 0.7538495063781738
activation O O 0.823447048664093
on O O 0.9997746348381042
PN O O 0.6021080613136292
30 O O 0.4800024926662445
in O O 0.9996556043624878
the O O 0.9998606443405151
cerebral O O 0.7357104420661926
cortex O O 0.8024365305900574
, O O 0.9919589757919312
as O O 0.9999629259109497
well O O 0.9998430013656616
as O O 0.9999874830245972
in O O 0.9998072981834412
cerebellar O O 0.3989001512527466
and O O 0.9787130355834961
cerebrocortical O O 0.7903103828430176
white O O 0.817618727684021
matter O O 0.5428026914596558
. O O 0.9999098777770996

prospectively O O 0.9947294592857361
in O O 0.9999921321868896
90 O O 0.9978016018867493
patients O O 0.9999380111694336
with O O 0.9999880790710449
stage O O 0.9333321452140808
I-III O O 0.9129585027694702
breast O O 0.971710205078125
cancer O O 0.9725965261459351
. O O 0.9999991655349731
Whereas O O 0.9999825954437256
PHA S-protein S-protein 0.9808885455131531
-induced O O 0.9964821338653564
proliferation O O 0.998724639415741
of O O 0.9999490976333618
PBMCs S-cell_type S-cell_type 0.9532408118247986
derived O O 0.9989418387413025
from O O 0.9999420642852783
patients O O 0.9997226595878601
with O O 0.9999754428863525
breast O O 0.7742683291435242

the O O 0.9966566562652588
MBC O S-cell_type 0.824908971786499
over O O 0.9956684112548828
baseline O O 0.9834655523300171
and O O 0.9998980760574341
a O O 0.9999485015869141
fivefold O O 0.9905331134796143
increase O O 0.9954442977905273
over O O 0.9999188184738159
placebo-treated O O 0.8495211601257324
subjects O O 0.9268239736557007
. O O 0.9999966621398926
The O O 0.9999769926071167
T3 O S-DNA 0.615206241607666
-group O O 0.4910370707511902
showed O O 0.999889612197876
no O O 0.9999823570251465
change O O 0.9998615980148315
in O O 0.9999650716781616
MBC O S-cell_type 0.8543063998222351
over O O 0.9991790652275085
the O O 0.9999850988388062
study O O 0.9994962215423584

which O O 0.9819728136062622

Acetaminophen B-Chemical B-Chemical 0.9323345422744751
( O O 0.9958840012550354
up O O 0.9995819926261902
to O O 0.9998588562011719
150 O O 0.9996662139892578
micrograms O O 0.9989998936653137
/ O O 0.9999761581420898
mL O O 0.9967030882835388
) O O 0.9994562268257141
did O O 0.9999958276748657
not O O 0.9999679327011108
retard O O 0.999653697013855
the O O 0.9997407793998718
incorporation O O 0.9888607859611511
of O O 0.9997991919517517
radioactive O O 0.783818781375885
adenosine B-Chemical B-Chemical 0.8859483599662781
into O O 0.9895336031913757
ATP B-Chemical B-Chemical 0.8578779101371765
in O O 0.9978920817375183
slices O O 0.9880148768424988
of O O 0.9997385144233704
rat O O 0.9128344655036926
cerebral O O 0.8832416534423828
cortex O O 0.6180633902549744
. O O 0.9999310970306396

Endothelial O O 0.690947949886322
function O O 0.5462821125984192
was O O 0.9980807304382324
assessed O O 0.9999418258666992
by O O 0.9999825954437256
acetylcholine B-Chemical B-Chemical 0.9304680824279785
- O O 0.9361737370491028
induced O O 0.9975797533988953
vasorelaxation O O 0.8984436988830566
and O O 0.9685484766960144
phenylephrine B-Chemical B-Chemical 0.9261088967323303
- O O 0.9325276017189026
induced O O 0.998474657535553
vasoconstriction O O 0.8284496665000916
in O O 0.991117000579834
aortic O O 0.6274484992027283
segments O O 0.716601550579071
. O O 0.9999771118164062

Pergolide S-Chemical B-Chemical 0.8885098695755005
was O O 0.9952313303947449
discontinued O O 0.9990861415863037
in O O 0.9999821186065674
10 O O 0.9990168809890747
patients O O 0.999795138835907
with O O 0.9999474287033081
valvular O B-Disease 0.6527440547943115
heart O I-Disease 0.4902079403400421
disease O I-Disease 0.9874477982521057
, O O 0.9773702025413513
resulting O O 0.9996034502983093
in O O 0.9999176263809204
a O O 0.999771773815155
lower O O 0.9933104515075684
regurgitation O O 0.6035284996032715
grade O O 0.860457181930542
( O O 0.9995995163917542
p O O 0.9996139407157898
= O O 0.999953031539917
0 O O 0.9998109936714172
. O O 0.9998724460601807
01 O O 0.9982450008392334
) O O 0.9995182752609253
at O O 0.9999977350234985
the O O 0.999980092048645
second O O 0.9961240887641907
transthoracic O O 0.5143039226531982
echocardiography O O 0.7192074656486511
and O O 0.9961134195327759
the O O 0.9999324083328247
two O O 0.9997871518135071
patients O O 0.9992176294326782
with O O 0.9999645948410034
heart O B-Disease 0.5438246130943298
failure O I-Disease 0.981975257396698
returned O O 0.9712384939193726
to O O 0.9995738863945007
nearly O O 0.9992734789848328
normal O O 0.9898492097854614
clinical O O 0.9927608966827393
examination O O 0.997811496257782
. O O 0.9999992847442627

transduction O O 0.9336528182029724
and O O 0.9981162548065186
antigen-stimulated O O 0.9512800574302673
B-cell-mediated O O 0.9272118210792542
immune O O 0.9772735238075256
responses O O 0.9974291920661926
is O O 0.9999921321868896
discussed O O 0.9999822378158569
. O O 0.9999991655349731
Involvement O O 0.9999066591262817
of O O 0.9999884366989136
intracellular O O 0.7249087691307068
Ca2+ O O 0.39824894070625305
in O O 0.9960208535194397
oxidant-induced O O 0.4817516803741455

expression O O 0.9712949395179749
of O O 0.9995819926261902
genes S-DNA O 0.5638099312782288
encoding O O 0.968123733997345
transcription B-protein B-protein 0.5192914605140686
factors E-protein E-protein 0.9932112097740173
: O O 0.9927145838737488
c-fos S-DNA S-DNA 0.6875994205474854
and O O 0.8920558094978333
c-jun S-DNA S-DNA 0.7877764105796814
and O O 0.9857250452041626
formation O O 0.9828375577926636
of O O 0.9992817044258118
AP1 B-protein B-protein 0.8314562439918518
transcriptional I-protein I-protein 0.4358309507369995
complex E-protein E-protein 0.9908396601676941
in O O 0.9993559718132019
human B-cell_type B-cell_type 0.649983286857605
monocytes E-cell_type E-cell_type 0.9598633646965027
was O O 0.9987092018127441
investigated O O 0.9999345541000366
. O O 0.999997615814209
It O O 0.999950647354126
was O O 0.9999723434448242
found O O 0.9999890327453613
that O O 0.9999939203262329
lipopolysaccharide O O 0.9264482259750366
induced O O 0.9993519186973572
strongly O O 0.9907047152519226
both O O 0.9997490048408508
c-fos S-DNA S-DNA 0.7972732186317444
and O O 0.9474818110466003
c-jun S-DNA S-DNA 0.9345575571060181
expression O O 0.9958996176719666
as O O 0.9999865293502808
well O O 0.9968174695968628

Irreversible O O 0.8826659321784973
damage O O 0.6006938815116882
to O O 0.9829311966896057
the O O 0.9917086958885193
medullary O O 0.6973156929016113
interstitium O O 0.2683519721031189
in O O 0.9983056783676147
experimental O O 0.9070138931274414
analgesic O O 0.4893166720867157
nephropathy B-Disease O 0.810383141040802
in O O 0.989841878414154
F344 O O 0.5015993118286133
rats O O 0.9896775484085083
. O O 0.9999985694885254

from O O 0.996609091758728

site E-DNA E-DNA 0.6920265555381775
for O O 0.9885100722312927
protein O O 0.5600125789642334
( O O 0.9238882660865784
s O O 0.6912931203842163
) O O 0.6361714005470276
whose O O 0.9974344372749329
binding O O 0.9690589904785156
is O O 0.9995902180671692
inducible O O 0.9990711212158203
by O O 0.999993085861206
PMA O O 0.9564608931541443
. O O 0.999974250793457
One O O 0.9991506338119507
protein O O 0.8768236637115479
, O O 0.9912028312683105
NF-GM2 S-protein S-protein 0.9640534520149231
is O O 0.9994507431983948
similar O O 0.9999557733535767
to O O 0.9999861717224121
the O O 0.9999356269836426
transcription B-protein B-protein 0.48755449056625366
factor E-protein E-protein 0.9281375408172607
NF-kB S-protein S-protein 0.5199815630912781
. O O 0.9991126656532288
GC-box S-DNA S-DNA 0.9493555426597595
is O O 0.9997419714927673
a O O 0.9999662637710571
binding B-DNA O 0.630695641040802
site E-DNA O 0.750005304813385
for O O 0.9918497800827026
constitutively B-protein O 0.92542964220047
bound I-protein O 0.9729500412940979

cells E-cell_type E-cell_type 0.7315892577171326
. O O 0.9997828602790833
Here O O 0.9999878406524658
we O O 0.9999984502792358
summarize O O 0.9999772310256958
studies O O 0.9996888637542725
which O O 0.999997615814209
investigate O O 0.9999921321868896
the O O 0.999981164932251
mechanism O O 0.9983624815940857
by O O 0.9999942779541016
which O O 0.9999972581863403
these O O 0.9999109506607056
cytokines S-protein S-protein 0.9875156879425049
selectively O O 0.9991903901100159
reprogramme O O 0.9156721234321594
gene O O 0.7420210242271423
expression O O 0.9912866950035095
in O O 0.9999148845672607
T-lymphocytes S-cell_type S-cell_type 0.9695022106170654
. O O 0.9998024106025696
Cytokine S-protein O 0.6032363176345825
stimulation O O 0.9901060461997986
leads O O 0.9999679327011108
to O O 0.999994158744812
the O O 0.9999433755874634
phosphorylation O O 0.9813457131385803
of O O 0.9997907280921936
specific O O 0.929768443107605
tyrosine O O 0.516930341720581
residues O O 0.6880869269371033
within O O 0.9995737671852112
the O O 0.9999635219573975
intracellular B-protein B-protein 0.5990921258926392
domain E-protein E-protein 0.9197772741317749
of O O 0.9847787022590637
the O O 0.9993399977684021
corresponding O O 0.9008558988571167
cytokine B-protein B-protein 0.5902776122093201
receptor E-protein E-protein 0.7411090731620789

METHODS O O 0.9735255837440491
: O O 0.9999631643295288
Retrospective O O 0.9974148273468018
review O O 0.9994148015975952
of O O 0.9999864101409912
medical O O 0.9932505488395691
records O O 0.9934613704681396
of O O 0.9999505281448364
236 O O 0.9964259266853333
patients O O 0.9995749592781067
with O O 0.9999610185623169
hyperthyroidism B-Disease B-Disease 0.9695917367935181
admitted O O 0.9824783205986023
in O O 0.9998729228973389
our O O 0.9997796416282654
department O O 0.9955413937568665
( O O 0.9999762773513794
in O O 0.9999375343322754
- O O 0.9991005659103394
or O O 0.9997180104255676
out O O 0.9997575879096985
- O O 0.9995784163475037
patients O O 0.999394416809082
) O O 0.9999617338180542
from O O 0.9999945163726807
1986 O O 0.9994999170303345
to O O 0.9999456405639648
1992 O O 0.9998258948326111
. O O 0.9999992847442627

By O O 0.9994912147521973
contrast O O 0.9998894929885864
, O O 0.9999955892562866
we O O 0.999894380569458
were O O 0.9999953508377075
unable O O 0.9999164342880249
to O O 0.9999574422836304
substantiate O O 0.9999204874038696
an O O 0.9998856782913208
increased O O 0.9895087480545044
risk O O 0.9965697526931763
from O O 0.9999909400939941
paracetamol B-Chemical B-Chemical 0.9254670143127441
consumption O O 0.9510366320610046
for O O 0.9999769926071167
renal B-Disease O 0.850002646446228
papillary I-Disease O 0.532375693321228
necrosis I-Disease O 0.9105671644210815
or O O 0.9518685340881348
any O O 0.9974767565727234
of O O 0.9998190999031067
these O O 0.999677300453186
cancers B-Disease O 0.8806436657905579
although O O 0.9985396862030029
there O O 0.9999955892562866
was O O 0.999990701675415
a O O 0.999984860420227
suggestion O O 0.999982476234436
of O O 0.9999738931655884
an O O 0.999528169631958
association O O 0.9712489247322083
with O O 0.9998724460601807
cancer B-Disease B-Disease 0.9612806439399719
of I-Disease O 0.6350796222686768
the I-Disease O 0.5502424836158752
ureter I-Disease O 0.8482444286346436
. O O 0.999298095703125

combination E-protein O 0.6917293667793274
. O O 0.9998797178268433
Synergistic O O 0.9755270481109619
transactivation O O 0.9926079511642456
of O O 0.9999676942825317
the O O 0.9998623132705688
BMRF1 B-DNA B-DNA 0.6119959950447083
promoter E-DNA E-DNA 0.9909923076629639
by O O 0.9997137188911438
the O O 0.9999279975891113
Z/c-myb B-protein S-protein 0.3716196119785309
combination E-protein O 0.40727025270462036
appears O O 0.9988152980804443
to O O 0.9999951124191284
involve O O 0.9999980926513672
direct O O 0.9944542050361633
binding O O 0.9929038882255554
by O O 0.9999693632125854
the O O 0.9997062087059021
Z B-protein B-DNA 0.37447190284729004

and O O 0.9397093653678894
cytochemistry O O 0.8914167881011963
of O O 0.9987232089042664
bone B-cell_type B-cell_type 0.6766095757484436
marrow I-cell_type I-cell_type 0.48917028307914734
progenitors E-cell_type E-cell_type 0.9584120512008667
. O O 0.9995278120040894
X O B-DNA 0.5259769558906555
chromosome O E-DNA 0.9621116518974304
inactivation O O 0.9641643762588501
and O O 0.9996644258499146
polymorphism O O 0.9226685166358948
of O O 0.9987780451774597
the O O 0.9998077750205994
human B-DNA B-protein 0.4777994155883789
androgen I-DNA I-protein 0.42598503828048706
receptor I-DNA E-protein 0.6983937621116638
( I-DNA O 0.5817253589630127
HUMARA I-DNA S-protein 0.45223182439804077
) I-DNA O 0.4503777027130127

( O O 0.921034574508667
1996 O O 0.9366592764854431
) O O 0.974100649356842
J.Exp.Med. O O 0.9506148099899292
, O O 0.9990822076797485
in O O 0.9999583959579468
press O O 0.9855386018753052
] O O 0.9983717799186707
. O O 0.9999926090240479
We O O 0.9999377727508545
have O O 0.9999921321868896
now O O 0.9999805688858032
elucidated O O 0.9986514449119568

lost O O 0.9283719062805176
CD5 S-protein S-protein 0.9109172821044922
surface O O 0.9425086379051208
expression O O 0.9983360171318054
over O O 0.9999945163726807
a O O 0.9999891519546509
period O O 0.9999762773513794
of O O 0.9999721050262451
time O O 0.9997175335884094
in O O 0.9999569654464722
culture O O 0.9476941823959351
. O O 0.9999867677688599
Analysis O O 0.9998039603233337
at O O 0.9999947547912598
the O O 0.9999803304672241
phenotype O O 0.8069684505462646
and O O 0.9747151136398315
genetic O O 0.9637718796730042
level O O 0.9991495609283447
showed O O 0.9999973773956299
that O O 0.9999953508377075
lack O O 0.9982306361198425
of O O 0.9998486042022705
CD5 S-protein S-protein 0.9643969535827637
expression O O 0.9979782700538635
was O O 0.9999959468841553
due O O 0.9999945163726807
neither O O 0.9999631643295288
to O O 0.9999741315841675
segregation O O 0.9913431406021118
of O O 0.9999363422393799
human B-DNA B-protein 0.4905959665775299
autosome I-DNA I-protein 0.33547377586364746
11 E-DNA E-protein 0.6321319937705994
, O O 0.9415566921234131
on O O 0.9995984435081482
which O O 0.9999945163726807
the O O 0.9997450709342957
CD5 B-DNA B-DNA 0.5816778540611267
gene E-DNA E-DNA 0.9559502601623535
has O O 0.9985284805297852
been O O 0.9998641014099121
mapped O O 0.9988118410110474
, O O 0.9998733997344971
nor O O 0.9969596862792969

Hippocampal O O 0.5473508238792419
ACh B-Chemical B-Chemical 0.8378660082817078
also O O 0.9948062300682068
was O O 0.9999699592590332
measured O O 0.9999285936355591
during O O 0.9999929666519165
testing O O 0.9991353154182434
for O O 0.9999830722808838
handling O O 0.9198707938194275
- O O 0.996772825717926
induced O O 0.9932749271392822
convulsions B-Disease B-Disease 0.9658107161521912
. O O 0.9986043572425842

in O O 0.998128354549408
a O O 0.9998995065689087
highly O O 0.9701927900314331
synergistic O O 0.967780351638794
manner O O 0.9979696869850159
. O O 0.9999979734420776
We O O 0.9999874830245972
suggest O O 0.999998927116394
that O O 0.9999995231628418
the O O 0.9999605417251587
T O O 0.7201023101806641
cell-specific O O 0.7248268127441406
expression O O 0.9826574921607971
of O O 0.9998598098754883
the O O 0.9998218417167664
IL-3 B-DNA B-DNA 0.5799871683120728
gene E-DNA E-DNA 0.9754447340965271
is O O 0.9969910383224487
partly O O 0.9989284873008728
controlled O O 0.9994507431983948
through O O 0.999993085861206
the O O 0.9996969699859619
enhancer O S-DNA 0.8523304462432861
by O O 0.9993582367897034
cooperation O O 0.9992675185203552
between O O 0.9998965263366699
Oct B-protein S-protein 0.5309591293334961
and I-protein O 0.9423633813858032
NFAT I-protein B-protein 0.5955673456192017
family I-protein I-protein 0.6120581030845642
proteins E-protein E-protein 0.9967647790908813
. O O 0.9997434020042419
Adenovirus B-protein B-protein 0.7689377069473267
E1B I-protein I-protein 0.2999650239944458
19K I-protein I-protein 0.6968148946762085
protein E-protein E-protein 0.9831558465957642
is O O 0.9992915391921997
required O O 0.9999616146087646

These O O 0.9995703101158142
effects O O 0.9989914298057556
gave O O 0.9999840259552002
rise O O 0.9940173625946045
to O O 0.9998823404312134
an O O 0.9999061822891235
increase O O 0.9772491455078125
in O O 0.9943336248397827
the O O 0.9983049631118774
right O O 0.9962165951728821
atrial O O 0.8563662171363831
pressure O O 0.5536841154098511
and O O 0.9992390871047974
a O O 0.9998325109481812
decrease O O 0.9752184748649597
in O O 0.9944420456886292
the O O 0.9967460632324219
left O O 0.9853640198707581
one O O 0.9986554384231567
with O O 0.9999969005584717
a O O 0.9999251365661621
consequent O O 0.9983002543449402
stretching O O 0.6960787177085876
of O O 0.9693228602409363
the O O 0.9931923747062683
foramen O O 0.9066810607910156
ovale O O 0.8114921450614929
and O O 0.9999253749847412
the O O 0.9999667406082153
creation O O 0.9938388466835022
of O O 0.9998995065689087
massive O O 0.9478335976600647
right O O 0.9868707656860352
- O O 0.9978017210960388
to O O 0.9997740387916565
- O O 0.9994569420814514
left O O 0.9990037083625793
shunting O O 0.9863573312759399
. O O 0.9999915361404419

are O O 0.9982070922851562
required O O 0.9998469352722168
for O O 0.9999837875366211
optimal O O 0.977592408657074
augmentation O O 0.9965583682060242
of O O 0.9999450445175171
NFAT B-DNA B-DNA 0.7240711450576782
promoter E-DNA E-DNA 0.9256429672241211
activity O O 0.979170560836792
. O O 0.9999678134918213
SLP-76 S-protein S-protein 0.843794047832489
( O O 0.9291199445724487
SH2 B-protein B-protein 0.4851832091808319
domain I-protein I-protein 0.428570032119751
leukocyte I-protein I-protein 0.8455295562744141
protein E-protein E-protein 0.9749218821525574
of O O 0.9759676456451416
76 O B-protein 0.7979263067245483
kDa O E-protein 0.9120546579360962
) O O 0.8948591351509094
is O O 0.9999796152114868
a O O 0.9999914169311523
recently O O 0.963935911655426
identified O O 0.9871922731399536
substrate O O 0.953410267829895
of O O 0.9978421926498413

with O O 0.9971883893013

to O O 0.9979769587516785
the O O 0.9998939037322998
paucity O O 0.9826272130012512
of O O 0.9998024106025696
metabolic O O 0.7718057632446289
substrates O O 0.7396496534347534
. O O 0.9998478889465332
Different O O 0.9967879056930542
sequence O O 0.9708448052406311
requirements O O 0.9946987628936768
for O O 0.9999732971191406
expression O O 0.9961754083633423
in O O 0.9998412132263184
erythroid B-cell_type B-cell_type 0.7729782462120056
and I-cell_type I-cell_type 0.8497726321220398
megakaryocytic I-cell_type I-cell_type 0.9333979487419128
cells E-cell_type E-cell_type 0.9400748014450073
within O O 0.9994051456451416

. O O 0.9967674016952515
These O O 0.9999972581863403
data O O 0.9999064207077026
suggest O O 0.9999982118606567
that O O 0.999996542930603
L. O O 0.8966319561004639
pneumophila O O 0.7206937074661255
possesses O O 0.9998311996459961
a O O 0.9999511241912842
growth O O 0.881388783454895
phase-dependent O O 0.8915328979492188
resistance O O 0.9887928366661072
to O O 0.9999332427978516
stress O O 0.9629343152046204
that O O 0.9999403953552246
is O O 0.9999910593032837
independent O O 0.9996875524520874
of O O 0.999902606010437
RpoS S-protein S-protein 0.8957420587539673
control O O 0.9859106540679932

Frequency O O 0.9737286567687988
of O O 0.999434769153595
generalized O O 0.9647417664527893
tonic O O 0.4819340705871582
- O O 0.8754432797431946
clonic O O 0.4784850776195526
seizures O O 0.48992547392845154
increased O O 0.9822778701782227
from O O 0.9998584985733032
one O O 0.9999089241027832
per O O 0.999881386756897
6 O O 0.9997518658638
months O O 0.9999678134918213
to O O 0.9999603033065796
two O O 0.9999781847000122
per O O 0.9997802376747131
month O O 0.9999569654464722
. O O 0.9999991655349731

The O O 0.9997201561927795
possible O O 0.9976015686988831
beneficial O O 0.9742966890335083
effect O O 0.9989686012268066
of O O 0.9999099969863892
ribavirin B-Chemical B-Chemical 0.9245632886886597
during O O 0.9998512268066406
the O O 0.9999737739562988
initial O O 0.996179461479187
days O O 0.9999561309814453
of O O 0.9999635219573975
AHF B-Disease O 0.8070778250694275
is O O 0.9950965046882629
discussed O O 0.9999616146087646
. O O 0.9999992847442627

IL-1ra O S-protein 0.9340135455131531
production O O 0.9968587160110474
. O O 0.9999942779541016
Thus O O 0.9996777772903442
, O O 0.9999911785125732
the O O 0.9999892711639404
balance O O 0.9992684721946716
between O O 0.9999350309371948
an O O 0.9998735189437866
endogenously B-protein O 0.673611044883728
produced I-protein O 0.872902512550354
viral I-protein B-DNA 0.46418026089668274
inducer E-protein E-DNA 0.5148306488990784
( O O 0.984743595123291
IL-1 B-protein B-protein 0.38087281584739685
beta E-protein E-protein 0.8840809464454651
) O O 0.8919047117233276
and O O 0.9998358488082886
an O O 0.9996417760848999
inhibitor O O 0.9492361545562744
( O O 0.9987240433692932
IL-1ra S-protein S-protein 0.711521327495575
) O O 0.9747674465179443
may O O 0.9999731779098511
represent O O 0.9999955892562866
an O O 0.9999940395355225
important O O 0.9981734752655029
pathway O O 0.9982082843780518
leading O O 0.9999181032180786
to O O 0.9999749660491943
modulation O O 0.995036780834198
of O O 0.9999411106109619
HIV O O 0.7337469458580017
expression O O 0.9821661114692688
from O O 0.999927282333374
monocytic B-cell_type B-cell_type 0.7491998672485352
cells E-cell_type E-cell_type 0.9759150743484497
. O O 0.9996310472488403
Herpesvirus B-cell_line B-cell_line 0.6027207970619202
saimiri I-cell_line I-cell_line 0.46176227927207947
immortalized I-cell_line I-cell_line 0.8513799905776978
gamma I-cell_line I-cell_line 0.3223854601383209
delta I-cell_line I-cell_line 0.6563828587532043
T I-cell_line I-cell_line 0.6249140501022339
cell I-cell_line I-cell_line 0.862021267414093
line E-cell_line E-cell_line 0.9867992997169495
activated O O 0.9792567491531372
by O O 0.9999349117279053
IL-12 S-protein S-protein 0.9765571355819702
. O O 0.9997250437736511
IL-12 S-protein S-protein 0.9867120981216431
is O O 0.9998960494995117
a O O 0.9999840259552002
novel O O 0.9303799271583557
heterodimeric B-protein B-protein 0.5844072699546814
cytokine E-protein E-protein 0.9258766174316406
important O O 0.9880528450012207
for O O 0.9999339580535889
the O O 0.9999686479568481
regulation O O 0.9915376901626587

The O O 0.9995562434196472
maximum O O 0.9950460195541382
levels O O 0.9998778104782104
of O O 0.9999698400497437
these O O 0.9999276399612427
markers O O 0.9299678206443787
induced O O 0.9999068975448608
by O O 0.9999390840530396
ML-9 O S-protein 0.5782356262207031
were O O 0.9991818070411682
comparable O O 0.9998986721038818
to O O 0.9999841451644897
those O O 0.9999610185623169
induced O O 0.9997879862785339
by O O 0.9999736547470093
VD3 O S-protein 0.6521681547164917
, O O 0.9908332228660583
but O O 0.9999388456344604
after O O 0.9999908208847046
removal O O 0.9989050626754761
of O O 0.9999145269393921
ML-9 O S-protein 0.44464826583862305
from O O 0.9937993884086609

Two O O 0.9942230582237244
patients O O 0.9992710947990417
attained O O 0.9998924732208252
a O O 0.999854326248169
complete O O 0.988447368144989
response O O 0.9932864308357239
( O O 0.999968409538269
4 O O 0.9999175071716309
% O O 0.9998924732208252
) O O 0.9996919631958008
and O O 0.9999661445617676
11 O O 0.9970396161079407
patients O O 0.9988549947738647
( O O 0.9999902248382568
22 O O 0.9999425411224365
% O O 0.9999531507492065
) O O 0.9998177886009216
achieved O O 0.9998371601104736
a O O 0.9999651908874512
partial O O 0.9901924133300781
response O O 0.9940849542617798
. O O 0.9999961853027344

The O O 0.973973274230957
Li B-Chemical B-Chemical 0.909532368183136
- O O 0.8110091090202332
treated O O 0.9973835349082947
rats O O 0.9940541386604309
produced O O 0.9999569654464722
a O O 0.9999572038650513
large O O 0.9984849095344543
volume O O 0.9955542683601379
of O O 0.9998782873153687
hypotonic O O 0.8069693446159363
urine O O 0.4035074710845947
with O O 0.9994494318962097
low O O 0.9729273915290833
ionic O O 0.5607146620750427
concentrations O O 0.5703046321868896
. O O 0.9999706745147705

site E-DNA E-DNA 0.8390921950340271
, O O 0.9976619482040405
denoted O O 0.9967944025993347
the O O 0.9996415376663208
C-site S-DNA S-DNA 0.6807308197021484
, O O 0.9032721519470215
was O O 0.9997366070747375
shown O O 0.9999926090240479
by O O 0.9999951124191284
several O O 0.9996435642242432
criteria O O 0.9894044399261475
, O O 0.9999071359634399
including O O 0.999954342842102
cell O O 0.9397892951965332
distribution O O 0.9566832184791565
studies O O 0.9966803789138794
, O O 0.9999581575393677
stimulation O O 0.9716665148735046
experiments O O 0.9919602274894714
, O O 0.9999649524688721
supershift O O 0.8449245691299438
assays O O 0.9544293880462646
, O O 0.9994900226593018
and O O 0.9997300505638123
cross-competition O O 0.8736122846603394
electrophoretic O O 0.8803319334983826
mobility O O 0.9604607224464417
shift O O 0.9824320673942566
assays O O 0.9953299760818481
to O O 0.999980092048645
bind O O 0.9996021389961243
the O O 0.999832034111023
transcription B-protein B-protein 0.521547794342041
factor I-protein E-protein 0.8938712477684021
AP-1 E-protein S-protein 0.4778619110584259
. O O 0.9991419315338135

Three O O 0.9993228912353516
time O O 0.9995555281639099
domain O O 0.9828541278839111
indexes O O 0.9950668811798096
of O O 0.9998230338096619
hemodynamic O O 0.7465134859085083
variability O O 0.615985095500946
were O O 0.9998424053192139
employed O O 0.9999669790267944
: O O 0.9999951124191284
the O O 0.9999814033508301
standard O O 0.9955515265464783
deviation O O 0.9899398684501648
of O O 0.9996055960655212
mean O O 0.9963717460632324
arterial O O 0.9840467572212219
pressure O O 0.8755737543106079
as O O 0.9999812841415405
a O O 0.9999924898147583
measure O O 0.9999300241470337
of O O 0.999924898147583
blood O O 0.9406956434249878
pressure O O 0.851499080657959
variability O O 0.9208999276161194
and O O 0.9999537467956543
the O O 0.9999840259552002
standard O O 0.99456787109375
deviation O O 0.969681978225708
of O O 0.9987395405769348
beat O O 0.7093312740325928
- O O 0.9792313575744629
to O O 0.999669075012207
- O O 0.998965859413147
beat O O 0.983984112739563
intervals O O 0.994644045829773
( O O 0.9999902248382568
SDRR O O 0.7094420194625854
) O O 0.9970417618751526
and O O 0.9999868869781494
the O O 0.9999610185623169
root O O 0.9259814023971558
mean O O 0.994076132774353
square O O 0.9842139482498169
of O O 0.9994878768920898
successive O O 0.9965528249740601
differences O O 0.9853814244270325
in O O 0.9998536109924316
R O O 0.9375543594360352
- O O 0.980891764163971
wave O O 0.9786750078201294
- O O 0.9992309808731079
to O O 0.9999372959136963
- O O 0.9970893263816833
R O O 0.9689610600471497
- O O 0.9985722303390503
wave O O 0.996274471282959
intervals O O 0.9997549653053284
as O O 0.9999994039535522
measures O O 0.9999591112136841
of O O 0.9999308586120605
heart O O 0.8299819827079773
rate O O 0.7870281338691711
variability O O 0.6447635889053345
. O O 0.9999881982803345

In O O 0.9996545314788818
the O O 0.9999457597732544
remaining O O 0.9996551275253296
three O O 0.999594509601593
patients O O 0.9992758631706238
, O O 0.9999715089797974
procainamide S-Chemical B-Chemical 0.9336596727371216
was O O 0.9949938654899597
administered O O 0.999871015548706
orally O O 0.9988129138946533
for O O 0.9999916553497314
treatment O O 0.9995538592338562
of O O 0.9999724626541138
chronic O O 0.7641763687133789
premature O O 0.7859605550765991
ventricular O O 0.6558351516723633
contractions O O 0.9216902256011963
or O O 0.9750394821166992
atrial O B-Disease 0.628822922706604
flutter O I-Disease 0.9747442603111267
. O O 0.9972142577171326

The O O 0.9994795918464661
historical O O 0.9643890261650085
controls O O 0.9548795223236084
consisted O O 0.9999886751174927
of O O 0.9999915361404419
50 O O 0.998611330986023
consecutive O O 0.9991623163223267
patients O O 0.9992115497589111
who O O 0.9999781847000122
underwent O O 0.999883770942688
CT O O 0.4374956488609314
without O O 0.9971147775650024
prophylactic O O 0.8528409004211426
lamivudine B-Chemical B-Chemical 0.922289252281189
. O O 0.9997826218605042

We O O 0.9989107847213745
wanted O O 0.9999723434448242
to O O 0.9999635219573975
study O O 0.9999816417694092
whether O O 0.9999898672103882
tAMCA S-Chemical B-Chemical 0.9084460139274597
retains O O 0.9943426847457886
its O O 0.9998914003372192
convulsive O O 0.6461123824119568
action O O 0.5278596878051758
if O O 0.9991657733917236
incorporated O O 0.9997084736824036
into O O 0.999991774559021
a O O 0.9999175071716309
FS O O 0.4773325026035309
. O O 0.9990932941436768

Minimal O O 0.6531019806861877
cholestasis B-Disease B-Disease 0.5723599195480347
was O O 0.9776195287704468
seen O O 0.9998921155929565
in O O 0.9999924898147583
two O O 0.9998736381530762
cases O O 0.9989286065101624
and O O 0.9999790191650391
portal O O 0.7454509735107422
fibrosis B-Disease O 0.6768004894256592
of O O 0.8053045868873596
a O O 0.9842029809951782
reversible O O 0.9628981351852417
degree O O 0.973081648349762
in O O 0.999901533126831
eight O O 0.9985623955726624
. O O 0.9999880790710449

) E-protein O 0.7734521627426147

in O O 0.9978204965591431
IL-1 S-protein S-protein 0.9782249927520752
signal O O 0.9839805960655212
transduction O O 0.9965225458145142
. O O 0.9999951124191284
We O O 0.9997053742408752
generated O O 0.9984715580940247
permanent O B-cell_line 0.7618082165718079
clones O E-cell_line 0.8290351629257202
of O O 0.9982660412788391
the O O 0.9999091625213623
murine B-cell_line B-cell_line 0.39799055457115173
T I-cell_line I-cell_line 0.565878689289093
cell I-cell_line I-cell_line 0.8521203994750977
line I-cell_line I-cell_line 0.8170515894889832
EL4 I-cell_line I-cell_line 0.48305830359458923
6.1 E-cell_line E-cell_line 0.9831576943397522
overexpressing O O 0.9777104258537292
human B-protein B-protein 0.4405626058578491
( I-protein I-protein 0.6330125331878662
h I-protein I-protein 0.4841422438621521
) I-protein I-protein 0.4224855303764343
IRAK E-protein E-protein 0.42731913924217224
to O O 0.9588097333908081
evaluate O O 0.9999046325683594
the O O 0.9999667406082153
role O O 0.9975454211235046

. O O 0.9939895868301392
All O O 0.9999923706054688
of O O 0.9999957084655762
the O O 0.9999951124191284
parameters O O 0.9748101830482483
were O O 0.9999340772628784
also O O 0.9999438524246216
tested O O 0.9998817443847656
for O O 0.9999604225158691
correlation O O 0.991177499294281
, O O 0.9999598264694214
and O O 0.9999825954437256
a O O 0.9999823570251465
significant O O 0.9976871013641357
inverse O O 0.9767677187919617
correlation O O 0.9940137267112732
was O O 0.9999839067459106
found O O 0.9999750852584839
between O O 0.9993475079536438
age O O 0.9963935017585754
and O O 0.9996829032897949
type B-protein B-protein 0.9488991498947144
I E-protein I-protein 0.6579710245132446
and O I-protein 0.9262984395027161
type B-protein I-protein 0.555444598197937
II I-protein I-protein 0.8826692700386047
receptors E-protein E-protein 0.9930132031440735
when O O 0.9999566078186035
all O O 0.9999568462371826
subjects O O 0.9981021285057068
were O O 0.9999840259552002
plotted O O 0.9911989569664001
and O O 0.9998050332069397
between O O 0.9981827735900879
aged O O 0.9960395097732544
and O O 0.9993509650230408
CD4 S-cell_type O 0.6464552283287048
and O O 0.9927076697349548
age O O 0.9947054982185364
and O O 0.9997878670692444
CD4/CD8 S-cell_type O 0.43241220712661743
in O O 0.9994348883628845
the O O 0.9999428987503052
aged O O 0.9876349568367004
group O O 0.9980387091636658
. O O 0.999998927116394
These O O 0.999996542930603
data O O 0.9998290538787842
show O O 0.9999977350234985
that O O 0.9999967813491821
aged O O 0.990035891532898
subjects O O 0.9978680610656738
have O O 0.9999946355819702
reductions O O 0.9958270192146301

hr O O 0.4982875883579254
. O O 0.9978995323181152
Our O O 0.9999926090240479
data O O 0.9994182586669922
demonstrate O O 0.9999948740005493
that O O 0.9999969005584717
hydrocortisone O O 0.9395910501480103
induces O O 0.9995481371879578
IkappaB S-protein S-protein 0.9889172315597534
and O O 0.9971591234207153
suppresses O O 0.9989826083183289
NF-kappaB S-protein S-protein 0.9927461743354797
expression O O 0.9990353584289551
in O O 0.9999561309814453
MNC S-cell_type S-cell_type 0.8260869979858398
in O O 0.9993463158607483
parallel O O 0.9779444336891174
. O O 0.9999542236328125
IkappaB S-protein S-protein 0.990788996219635
further O O 0.9996281862258911
reduces O O 0.9999253749847412
the O O 0.999893307685852
translocation O O 0.9920772910118103
of O O 0.9996988773345947
NF-kappaB S-protein S-protein 0.9804964661598206
into O O 0.9995244741439819
the O O 0.9993048906326294

these O O 0.9992769360542297
findings O O 0.9999632835388184
indicate O O 0.9999988079071045
that O O 0.9999957084655762
A/R O S-protein 0.7165852189064026
elicits O O 0.9994238615036011
a O O 0.9999864101409912
two-phase O O 0.8573523759841919
neutrophil-endothelial O O 0.7840211987495422
cell O O 0.8052621483802795
adhesion O O 0.8237629532814026
response O O 0.9634163975715637
that O O 0.9999481439590454
involves O O 0.9999898672103882
transcription-independent O O 0.7803861498832703

Together O O 0.9996988773345947
these O O 0.999995231628418
findings O O 0.9999721050262451
show O O 0.9999977350234985
that O O 0.9999980926513672
the O O 0.9998524188995361
GlyT1 O O 0.8737512826919556
inhibitor O O 0.7430165410041809
, O O 0.9991565942764282
SSR103800 S-Chemical B-Chemical 0.915022611618042
, O O 0.9817131161689758
produces O O 0.9998624324798584
antipsychotic O O 0.8220289945602417
- O O 0.9207317233085632
like O O 0.9482128620147705
effects O O 0.9856382012367249
, O O 0.9999140501022339
which O O 0.9999536275863647
differ O O 0.9999573230743408
from O O 0.9999691247940063
those O O 0.9999315738677979
observed O O 0.9997712969779968
with O O 0.9999885559082031
compounds O O 0.9475727677345276
primarily O O 0.9990376234054565
targeting O O 0.9999016523361206
the O O 0.9997512698173523
dopaminergic O O 0.5577787160873413
system O O 0.7531130313873291
, O O 0.9995566010475159
and O O 0.9999570846557617
has O O 0.9999700784683228
a O O 0.999961256980896
reduced O O 0.9864215850830078
side O O 0.9790982007980347
- O O 0.996825098991394
effect O O 0.9973053932189941
potential O O 0.9989368319511414
as O O 0.9999886751174927
compared O O 0.9999585151672363
with O O 0.9999979734420776
these O O 0.999901533126831
latter O O 0.9927672147750854
drugs O O 0.9968256950378418
. O O 0.9999983310699463

METHODS O O 0.9771806001663208
: O O 0.9998698234558105
We O O 0.9999203681945801
used O O 0.9999871253967285
computerized O O 0.9805923700332642
pharmacy O O 0.9766221642494202
records O O 0.993159294128418
to O O 0.9999955892562866
identify O O 0.9999501705169678
all O O 0.9999427795410156
adult O O 0.8622997403144836
psychiatric O O 0.6302880048751831
inpatients O O 0.5105400085449219
treated O O 0.9968400001525879
with O O 0.9999701976776123
clozapine S-Chemical B-Chemical 0.9308440089225769
( O O 0.9914275407791138
1995 O O 0.9881924986839294
- O O 0.9411523938179016
96 O O 0.8289079070091248
) O O 0.9333889484405518
, O O 0.9999912977218628
reviewed O O 0.9998937845230103
their O O 0.9999579191207886
medical O O 0.9900133609771729
records O O 0.9876912832260132
to O O 0.9999899864196777
score O O 0.999562680721283
incidence O O 0.9436857104301453
and O O 0.9993890523910522
severity O O 0.8854405283927917
of O O 0.9932065010070801
delirium O O 0.9276653528213501
, O O 0.9637678265571594
and O O 0.9994168281555176
tested O O 0.9973589777946472
associations O O 0.9962180256843567
with O O 0.9999964237213135
potential O O 0.9959751963615417
risk O O 0.9880070686340332
factors O O 0.9091175198554993
. O O 0.9999921321868896

chemical O O 0.728050708770752
agents O O 0.8361459970474243
which O O 0.999909520149231
induce O O 0.9999771118164062
the O O 0.9995152950286865
leukaemic B-cell_type B-cell_type 0.4522130489349365
cells E-cell_type E-cell_type 0.9744008183479309
to O O 0.9985309839248657
overcome O O 0.9998472929000854
their O O 0.9998874664306641
block O O 0.9862090945243835
in O O 0.9998356103897095
differentiation O O 0.9945318698883057
. O O 0.9999946355819702
In O O 0.9999661445617676
order O O 0.9999221563339233
to O O 0.999994158744812
understand O O 0.9999783039093018
this O O 0.9999754428863525
block O O 0.9993738532066345
the O O 0.9999793767929077
cascade O O 0.9862240552902222
of O O 0.999738872051239
molecular O O 0.8509478569030762
events O O 0.9738352298736572

of O O 0.99875807762146
the O O 0.999987006187439
growth B-protein B-protein 0.8293318748474121
factors E-protein E-protein 0.9670476913452148
that O O 0.9995916485786438
controls O O 0.9998914003372192
the O O 0.999842643737793
proliferation O O 0.9944242835044861
and O O 0.9994969367980957
differentiation O O 0.9964307546615601
of O O 0.9999403953552246
hematopoietic B-cell_type B-cell_type 0.7807971835136414
cells E-cell_type E-cell_type 0.9793435335159302
and O O 0.995257556438446
SCL S-protein S-cell_type 0.636807918548584
, O O 0.985170304775238
also O O 0.9995684027671814
known O O 0.9999587535858154
as O O 0.9997866749763489
Tcl-5 S-protein S-protein 0.6653114557266235
or O O 0.9702994227409363

in O O 0.9967610239982605

The O O 0.9994226694107056
development O O 0.9965850114822388
of O O 0.9999531507492065
severe O O 0.9824684262275696
CAB O O 0.7013745307922363
- O O 0.8564725518226624
induced O O 0.9861556887626648
anemia O B-Disease 0.9751279950141907
in O O 0.9700974225997925
prostate O B-Disease 0.6309452056884766
cancer O I-Disease 0.9702219367027283
patients O O 0.6694574952125549
did O O 0.9997240900993347
not O O 0.9999191761016846
correlate O O 0.9998894929885864
with O O 0.9999712705612183
T O O 0.8964789509773254
baseline O O 0.9169387817382812
values O O 0.987703800201416
( O O 0.9999878406524658
T O O 0.9785891175270081
< O O 0.999531626701355
3 O O 0.9998626708984375
ng O O 0.9992095232009888
/ O O 0.999990701675415
ml O O 0.9995427131652832
versus O O 0.9992548823356628
T O O 0.9537030458450317
> O O 0.9976407289505005
or O O 0.9999793767929077
= O O 0.9999812841415405
3 O O 0.9999476671218872
ng O O 0.9995641112327576
/ O O 0.9999854564666748
ml O O 0.9996893405914307
) O O 0.9995785355567932
, O O 0.999992847442627
with O O 0.9999934434890747
age O O 0.9971972703933716
( O O 0.9999829530715942
< O O 0.9998283386230469
76 O O 0.9997554421424866
yrs O O 0.9995953440666199
versus O O 0.9998407363891602
> O O 0.9999004602432251
or O O 0.9999451637268066
= O O 0.9999728202819824
76 O O 0.9998114705085754
yrs O O 0.9991046786308289
) O O 0.9996230602264404
, O O 0.9999896287918091
and O O 0.9999809265136719
clinical O O 0.9841287136077881
stage O O 0.9767802357673645
( O O 0.9999115467071533
stage O O 0.9933472871780396
C O O 0.9385906457901001
versus O O 0.9998252987861633
stage O O 0.9727104306221008
D1 O O 0.9145917296409607
) O O 0.9994463324546814
. O O 0.9999971389770508

in B-DNA O 0.998234748840332
vivo I-DNA O 0.9551491737365723
footprinted I-DNA B-DNA 0.8924244046211243
DNA I-DNA I-DNA 0.6866141557693481
motifs E-DNA E-DNA 0.9528419375419617
within O O 0.9996156692504883
an O O 0.9999229907989502
alpha-globin B-DNA B-DNA 0.6429465413093567
enhancer E-DNA E-DNA 0.9954406023025513
. O O 0.9995067119598389
Erythroid O O 0.6816902160644531
lineage O O 0.506541907787323
and O O 0.9912042021751404
developmental O O 0.9673430919647217
stage O O 0.9638487696647644
specificities O O 0.9912290573120117
. O O 0.9999977350234985
Transcriptional O O 0.9324927926063538
regulation O O 0.9959702491760254
of O O 0.9999496936798096
the O O 0.9997010827064514
human B-DNA B-DNA 0.5550844669342041
alpha-like I-DNA I-DNA 0.7630138397216797
globin I-DNA I-DNA 0.7578304409980774
genes E-DNA E-DNA 0.9973594546318054
, O O 0.9983810186386108
embryonic B-DNA B-protein 0.43791720271110535
zeta I-DNA I-protein 0.38443461060523987
2 E-DNA E-protein 0.7189707159996033
and O O 0.8975756168365479
adult B-DNA B-protein 0.5839895606040955
alpha E-DNA E-protein 0.7045484781265259
, O O 0.928447961807251
during O O 0.9994328618049622

phosphorylation O O 0.8578698039054871
. O O 0.9993582367897034
IL-12 S-protein S-protein 0.9683651924133301
and O O 0.9898356795310974
IL-2 S-protein S-protein 0.9882088899612427
can O O 0.999799907207489
stimulate O O 0.9997615218162537
mitogen- B-cell_type O 0.470548540353775
or I-cell_type O 0.7805743217468262

T-cell O O 0.3289395272731781
proliferative O O 0.8827664256095886
activity O O 0.9902817010879517
is O O 0.9999496936798096
IL2 S-protein S-protein 0.8390862345695496
and O O 0.9871788024902344
not O O 0.9924927353858948
IL15 S-protein S-protein 0.7877558469772339
. O O 0.999652624130249
The O O 0.9999594688415527
gene O O 0.9336978793144226
encoding O O 0.9383611679077148
a O O 0.9944220185279846

myogenic B-protein B-protein 0.7334246039390564
factors E-protein E-protein 0.9700098037719727
remain O O 0.9992992877960205
unaltered O O 0.9992085099220276
in O O 0.9999538660049438
rhabdomyosarcomas O O 0.46405166387557983
. O O 0.9996292591094971
Selection O O 0.9971684813499451
against O O 0.9999399185180664
such O O 0.9985094666481018
mutations O O 0.9928398132324219
may O O 0.999996542930603
be O O 0.9999967813491821
the O O 0.9999879598617554
result O O 0.999971866607666
of O O 0.9999920129776001
functional O O 0.9863134622573853
redundancy O O 0.9957310557365417
of O O 0.9999675750732422
these O O 0.9999672174453735
myogenic B-protein B-protein 0.595026433467865
transcription I-protein I-protein 0.5814307332038879
factors E-protein E-protein 0.9948834776878357
. O O 0.9996654987335205
Function O O 0.9971543550491333
and O O 0.9995530247688293
activation O O 0.998205304145813
of O O 0.9998804330825806
NF-kappa B-protein B-protein 0.8692715764045715
B E-protein E-protein 0.9772909283638
in O O 0.9987611770629883

rhesus O O 0.7033174633979797
macaques O O 0.3271753489971161
have O O 0.9995033740997314
, O O 0.9999741315841675
on O O 0.9999847412109375
the O O 0.9999573230743408
average O O 0.9961431622505188
, O O 0.9998062252998352
significantly O O 0.996198832988739
decreased O O 0.9931021928787231
plasma O O 0.8357601165771484
cyst O O 0.6766455173492432
( O O 0.9755777716636658
e O O 0.9444771409034729
) O O 0.9607763886451721
ine O O 0.9428791403770447
and O O 0.9989417195320129
intracellular O O 0.9099768400192261
GSH O O 0.7381008267402649
levels O O 0.9981054067611694
, O O 0.9999946355819702
we O O 0.9999934434890747
also O O 0.9999910593032837
hypothesize O O 0.9998759031295776
that O O 0.9999955892562866
AIDS O O 0.8556320667266846

Prolactin O O 0.7150827646255493
exceeded O O 0.9730931520462036
20 O O 0.9917689561843872
ng O O 0.9969698786735535
. O O 0.9999955892562866
/ O O 0.9999797344207764
ml O O 0.9979931116104126
. O O 0.9998238682746887
in O O 0.9999550580978394
5 O O 0.9970347881317139
men O O 0.9986397624015808
and O O 0.9999384880065918
was O O 0.9999673366546631
normal O O 0.9604101181030273
in O O 0.9997125267982483
2 O O 0.9649956822395325
at O O 0.9997593760490417
repeat O O 0.9408935308456421
determination O O 0.9363380074501038
. O O 0.9999951124191284

act O O 0.9727315306663513
as O O 0.9999570846557617
signalling O O 0.9844396114349365
agents O O 0.9907564520835876
in O O 0.9999911785125732
the O O 0.999962568283081
regulation O O 0.9991382360458374
of O O 0.9999871253967285
certain O O 0.9984629154205322
cellular O O 0.8844061493873596
processes O O 0.8420989513397217
, O O 0.9998855590820312
for O O 0.9999908208847046
example O O 0.997620165348053
, O O 0.9999333620071411
during O O 0.9999293088912964
cell O O 0.9633410573005676
cycle O O 0.9737867712974548
entry O O 0.9972195625305176
. O O 0.9999977350234985
To O O 0.9999918937683105
test O O 0.9999555349349976
this O O 0.9999374151229858
hypothesis O O 0.982075035572052
, O O 0.9999836683273315
we O O 0.9999827146530151
have O O 0.9999927282333374
been O O 0.9999773502349854
interested O O 0.9999539852142334
to O O 0.9999904632568359
determine O O 0.9999910593032837
which O O 0.9999361038208008
, O O 0.9998311996459961
if O O 0.999954342842102
any O O 0.9997904896736145
, O O 0.9999556541442871
cell O O 0.9240685105323792
cycle O O 0.9131988286972046
entry O O 0.9689239263534546
events O O 0.9916989803314209
are O O 0.9999905824661255
affected O O 0.9997588992118835
by O O 0.9999926090240479
oxidative O O 0.9210262894630432
signalling O O 0.9437056183815002
. O O 0.9999898672103882

demonstrated O O 0.9969592094421387
that O O 0.9999983310699463
the O O 0.9998890161514282
mouse B-DNA B-DNA 0.44763121008872986
CPO I-DNA I-DNA 0.6524401307106018
gene E-DNA E-DNA 0.9935531616210938
spans O O 0.9973059892654419
approximately O O 0.9935990571975708
11 O O 0.9454332590103149
kb O O 0.772517204284668
and O O 0.993569016456604
consists O O 0.9999454021453857
of O O 0.9998607635498047
seven B-DNA O 0.9598891735076904
exons E-DNA S-DNA 0.9498257040977478
, O O 0.9861798882484436
just O O 0.9979717135429382
like O O 0.9998146891593933
its O O 0.999826967716217
human O O 0.5669721961021423
counterpart O O 0.2655560076236725
. O O 0.9988441467285156
Functional O O 0.9936932325363159
analysis O O 0.999580442905426
of O O 0.9999861717224121
the O O 0.9995618462562561
promoter O S-DNA 0.5722976326942444

E2F B-protein S-protein 0.854805588722229
components E-protein O 0.560535728931427
, O O 0.9981671571731567
DP1 S-protein S-protein 0.8252497315406799
and O O 0.9946904182434082
E2F4 S-protein S-protein 0.8852505683898926
, O O 0.9983699917793274
as O O 0.9999793767929077
B-lymphocytes S-cell_type S-cell_type 0.8620736598968506
progressed O O 0.999195396900177
from O O 0.9999626874923706
G0 O O 0.4488980770111084
into O O 0.9970771074295044
early O O 0.7150291204452515
G1 O O 0.3830386996269226
. O O 0.9990692734718323
This O O 0.9999880790710449
increase O O 0.9976651668548584
in O O 0.99899822473526
mobility O O 0.9907804131507874
was O O 0.9999892711639404
attributable O O 0.9999698400497437
to O O 0.9999889135360718
dephosphorylation O O 0.9871029257774353
, O O 0.9999886751174927
as O O 0.9999949932098389
lambda O O 0.8834763765335083
phosphatase O O 0.42388013005256653
treatment O O 0.9984045624732971
could O O 0.9999992847442627
convert O O 0.9999537467956543
the O O 0.9998779296875

Migraine O B-Chemical 0.5653176307678223
( O O 0.9525863528251648
20 O O 0.9979495406150818
% O O 0.9997004270553589
) O O 0.9992824196815491
was O O 0.9999816417694092
not O O 0.9999492168426514
an O O 0.999984860420227
uncommon O O 0.981803297996521
cause O O 0.9964154958724976
of O O 0.9998630285263062
cranial O B-Disease 0.6756590604782104
neuropathy O I-Disease 0.9025327563285828
although O O 0.987286388874054
malignancies O O 0.8006042242050171
arising O O 0.968880295753479
from O O 0.9996508359909058
the O O 0.9997146725654602
reticuloendothelial O O 0.4982142150402069
system O O 0.5318109393119812
or O O 0.9960732460021973
related O O 0.9497952461242676
structures O O 0.8192940354347229
of O O 0.9871835708618164
the O O 0.9943557977676392
head O O 0.9266602993011475
and O O 0.9988051652908325
neck O O 0.9586181640625
were O O 0.9999295473098755
more O O 0.9995280504226685
frequent O O 0.9945499300956726
( O O 0.9999725818634033
26 O O 0.9999185800552368
% O O 0.9999039173126221
) O O 0.9997947812080383
. O O 0.9999972581863403

would O O 0.9981447458267212
be O O 0.9999860525131226
mediated O O 0.9997585415840149
through O O 0.9999971389770508
the O O 0.9999842643737793
retention O O 0.9982571005821228
of O O 0.9999589920043945
Rel/NF-kappaB B-protein B-protein 0.8493465185165405
proteins E-protein E-protein 0.9782299995422363
in O O 0.9999063014984131
the O O 0.9999357461929321
cytosol S-cell_type O 0.747247576713562
. O O 0.9992325305938721
However O O 0.9996684789657593
, O O 0.9999444484710693

several O O 0.9933896064758301
lymphoid B-cell_line B-cell_line 0.39581671357154846
leukemia I-cell_line I-cell_line 0.6643603444099426
cell I-cell_line I-cell_line 0.8265172839164734
lines E-cell_line E-cell_line 0.9982525706291199
which O O 0.9987391829490662
are O O 0.9999750852584839
known O O 0.999943733215332
to O O 0.9999758005142212
harbor O O 0.9969069361686707
SCL B-DNA B-DNA 0.33148300647735596
gene I-DNA E-DNA 0.8774572610855103
rearrangements E-DNA O 0.7081191539764404
. O O 0.9999080896377563
In O O 0.9999667406082153
most O O 0.9989696741104126
cell O O 0.9317211508750916
lines O O 0.7211791276931763
, O O 0.9997665286064148
proteins O O 0.9661325216293335

agammaglobulinemia O O 0.7005086541175842
( O O 0.993513286113739
XLA O O 0.80772465467453
) O O 0.9956152439117432
. O O 0.9999871253967285
The O O 0.9999802112579346
gene O O 0.9395163655281067
is O O 0.9994338154792786
expressed O O 0.9998939037322998
in O O 0.9999102354049683
all O O 0.9994089603424072
hematopoietic B-cell_type B-cell_type 0.8048575520515442
cells E-cell_type E-cell_type 0.9398641586303711
with O O 0.9990148544311523

In O O 0.9997581839561462
7 O O 0.9994489550590515
of O O 0.9999648332595825
the O O 0.9999732971191406
18 O O 0.9986637830734253
rats O O 0.9624921679496765
, O O 0.9993632435798645
degeneration O O 0.7967924475669861
and O O 0.9981265664100647
myocyte O O 0.6168844699859619
vacuolisation O O 0.5883249044418335
were O O 0.9994708895683289
found O O 0.9999903440475464
. O O 0.9999988079071045

was O O 0.9919300079345703
further O O 0.9996446371078491
shown O O 0.9999862909317017
by O O 0.9999918937683105
co-transfection O O 0.9608882069587708
of O O 0.9995675683021545
a O O 0.9997550845146179
CAT B-DNA B-DNA 0.6412304639816284
reporter I-DNA I-DNA 0.5947859287261963
construct E-DNA E-DNA 0.9918745160102844
with O O 0.999552309513092
the O O 0.9995131492614746
ICAM-I B-DNA B-DNA 0.7294474244117737
promoter E-DNA E-DNA 0.9914407730102539
and O O 0.9947285056114197
a O O 0.9998119473457336
plasmid S-DNA S-DNA 0.9274681210517883
expressing O O 0.8844508528709412
TaxI S-protein S-protein 0.5872732400894165
. O O 0.9994581341743469
The O O 0.9999967813491821
mechanism O O 0.999170184135437
of O O 0.9999350309371948
down-regulation O O 0.9934040904045105
of O O 0.9998272061347961
ICAM-I S-protein O 0.24936771392822266
or O O 0.8114516735076904
LFA-I S-protein S-protein 0.2697943150997162
in O O 0.9889051914215088
4 B-cell_line O 0.9681293964385986
ATL I-cell_line B-cell_line 0.44707390666007996
cell I-cell_line I-cell_line 0.5832735896110535
lines E-cell_line E-cell_line 0.9986283779144287
was O O 0.9998397827148438
next O O 0.9998595714569092

region E-DNA E-DNA 0.6005468964576721
of O O 0.9968649744987488
the O O 0.9999135732650757
beta-globin B-DNA B-DNA 0.3860577940940857
cluster E-DNA E-DNA 0.9117501378059387
contains O O 0.9994823932647705
five O O 0.995029628276825
DNase B-DNA B-DNA 0.479218453168869
I I-DNA I-DNA 0.35036009550094604
hypersensitive I-DNA I-DNA 0.6782826781272888
sites E-DNA E-DNA 0.960184633731842
( O O 0.9938901662826538
5'HS1-5 S-DNA S-DNA 0.98259037733078
) O O 0.9784648418426514
required O O 0.9996819496154785
for O O 0.9999743700027466
locus O O 0.40811687707901
activation O O 0.9589298367500305
. O O 0.9999076128005981
5'HS3 S-DNA S-DNA 0.9544700384140015
contains O O 0.9992534518241882
six O O 0.980791449546814
G-rich O B-DNA 0.3486403822898865
motifs O E-DNA 0.6566690802574158
that O O 0.9984022974967957
are O O 0.9999892711639404
essential O O 0.9996769428253174
for O O 0.9999908208847046
its O O 0.9999504089355469
activity O O 0.9992638230323792
. O O 0.9999960660934448
Members O O 0.975847065448761

Urgent O O 0.9195007681846619
fasciotomies O O 0.6236543655395508
were O O 0.9984263181686401
performed O O 0.9999802112579346
and O O 0.9999895095825195
the O O 0.9999457597732544
patient O O 0.9979320764541626
made O O 0.9999681711196899
an O O 0.9999110698699951
uneventful O O 0.9847383499145508
recovery O O 0.9575697779655457
with O O 0.9999887943267822
the O O 0.999950647354126
withdrawal O O 0.986339807510376
of O O 0.9997242093086243
simvastatin B-Chemical B-Chemical 0.9278233647346497
. O O 0.9991779923439026

the O O 0.99774169921875
human B-DNA B-protein 0.6095513701438904
class I-DNA I-protein 0.5904985666275024
II I-DNA I-protein 0.6613864302635193
isotypes E-DNA E-protein 0.9889812469482422
. O O 0.9998593330383301
Restoration O O 0.9975994229316711
of O O 0.9999485015869141
the O O 0.9999370574951172
Epstein-Barr B-protein B-protein 0.37338876724243164
virus I-protein I-protein 0.6858863234519958
ZEBRA I-protein I-protein 0.7365514039993286
protein E-protein E-protein 0.9242159128189087
's O O 0.9536651968955994
capacity O O 0.9970675110816956
to O O 0.9999481439590454
disrupt O O 0.9996898174285889
latency O O 0.9950383305549622
by O O 0.9999983310699463
the O O 0.9999855756759644
addition O O 0.9998962879180908
of O O 0.9999816417694092
heterologous B-protein O 0.7645530700683594
activation I-protein O 0.9574314951896667

Almost O O 0.9994083642959595
half O O 0.9999748468399048
of O O 0.9999927282333374
the O O 0.9999597072601318
cases O O 0.9985169768333435
was O O 0.9999829530715942
related O O 0.9999771118164062
to O O 0.9999834299087524
a O O 0.9995317459106445
warfarin B-Chemical B-Chemical 0.9258595705032349
- O O 0.7850870490074158
drug O O 0.9162548184394836
interaction O O 0.8969621658325195
. O O 0.9999942779541016

, I-protein O 0.9645614624023438
Src I-protein B-protein 0.48473697900772095
homology I-protein I-protein 0.5039734840393066
3 I-protein E-protein 0.7308076620101929
, I-protein O 0.889600396156311
and I-protein O 0.9792583584785461
pleckstrin I-protein B-protein 0.45794108510017395
homology I-protein I-protein 0.4462309777736664
domains E-protein E-protein 0.9257423877716064
and O O 0.9992309808731079
a O O 0.9999493360519409
putative B-protein B-protein 0.8008774518966675
guanine I-protein I-protein 0.33730533719062805
nucleotide I-protein I-protein 0.6801538467407227
exchange I-protein I-protein 0.7531235814094543
domain E-protein E-protein 0.9699617028236389
. O O 0.9997530579566956
The O O 0.9999961853027344
role O O 0.9988407492637634
of O O 0.9998884201049805
p95vav S-protein S-protein 0.9155887961387634
in O O 0.9970069527626038
TCR S-protein S-protein 0.9779767394065857
-mediated O O 0.9909143447875977
signaling O O 0.9732245802879333
processes O O 0.9983962178230286
is O O 0.9999939203262329
unclear O O 0.99776291847229
. O O 0.9999988079071045

Animal O O 0.8610295653343201
studies O O 0.9856756329536438
and O O 0.9999022483825684
mechanistic O O 0.9488757252693176
studies O O 0.9972864389419556
indicate O O 0.9999948740005493
that O O 0.999984622001648
nicotine B-Chemical B-Chemical 0.9233140349388123
could O O 0.9993185997009277
play O O 0.9999048709869385
a O O 0.999976634979248
role O O 0.9986094236373901
in O O 0.9999433755874634
accelerating O O 0.9856552481651306
atherosclerosis B-Disease O 0.9314836263656616
, O O 0.9797350168228149
but O O 0.9998856782913208
evidence O O 0.9991820454597473
among O O 0.9999879598617554
humans O O 0.7679949998855591
is O O 0.9997556805610657
too O O 0.9994101524353027
inadequate O O 0.9968212842941284
to O O 0.9999704360961914
be O O 0.9999455213546753
definitive O O 0.9994680285453796
about O O 0.9999957084655762
such O O 0.9999569654464722
an O O 0.9999271631240845
effect O O 0.9998617172241211
. O O 0.9999991655349731

these O O 0.9983300566673279
patients O O 0.9993614554405212
received O O 0.9999511241912842
ketoconazole O O 0.7230212688446045
, O O 0.9992185831069946
in O O 0.9999927282333374
spite O O 0.9998856782913208
of O O 0.9999911785125732
a O O 0.9999184608459473
marked O O 0.9942814111709595
reduction O O 0.9939168095588684
in O O 0.9993172883987427
morning O O 0.9299033880233765
plasma O O 0.9046840667724609
cortisol O O 0.7173476219177246
and O O 0.9994004964828491
urinary O O 0.7221820950508118

4.0 O O 0.9843528866767883
+/- O O 0.9998891353607178
0.31 O O 0.9998112320899963
and O O 0.9999723434448242
4.1 O O 0.9992074370384216
+/- O O 0.9999662637710571
0.34 O O 0.9999208450317383
vs. O O 0.9999887943267822
2.9 O O 0.9995330572128296
+/- O O 0.9999681711196899
0.29 O O 0.999927282333374
nmol/L O O 0.9941903352737427
, O O 0.9999852180480957
p O O 0.9981281161308289
< O O 0.9995952248573303
.001 O O 0.9982207417488098
) O O 0.9994996786117554
and O O 0.999955415725708
inversely O O 0.9967801570892334
correlated O O 0.9993948936462402
with O O 0.9999905824661255
the O O 0.9999312162399292
levels O O 0.9998495578765869

kinase E-protein E-protein 0.7001314759254456

Effects O O 0.9985173344612122
of O O 0.9998501539230347
calcium S-Chemical B-Chemical 0.9343957304954529
channel O O 0.6380447149276733
blockers O O 0.7009371519088745
on O O 0.9997137188911438
bupivacaine S-Chemical B-Chemical 0.9241224527359009
- O O 0.9317869544029236
induced O O 0.9960567951202393
toxicity O B-Disease 0.9907208681106567
. O O 0.9983955025672913

Studies O O 0.9990788698196411
in O O 0.9999880790710449
DBA O O 0.7855858206748962
/ O O 0.9985795021057129
2J O O 0.9807618260383606
mice O O 0.9991583824157715
showed O O 0.9999984502792358
that O O 0.9999936819076538
: O O 0.999406099319458
1 O O 0.9985324144363403
) O O 0.9980583786964417
pretreatment O O 0.9659170508384705
with O O 0.9999401569366455
acetaminophen S-Chemical B-Chemical 0.9404747486114502
( O O 0.9891736507415771
100 O O 0.9985252022743225
mg O O 0.9993909597396851
/ O O 0.9999617338180542
kg O O 0.9989345669746399
) O O 0.9998824596405029
increased O O 0.9993273019790649
the O O 0.9997819066047668
interval O O 0.9803158640861511
between O O 0.9988364577293396
the O O 0.9997945427894592
administration O O 0.995855987071991
of O O 0.9997698664665222
caffeine S-Chemical B-Chemical 0.9245453476905823
( O O 0.9931687116622925
300 O O 0.9980849027633667
to O O 0.9999107122421265
450 O O 0.9993891716003418
mg O O 0.9995220899581909
/ O O 0.9999485015869141
kg O O 0.9993816614151001
IP O O 0.4863378405570984
) O O 0.9859431982040405
and O O 0.9999371767044067
the O O 0.9999319314956665
onset O O 0.9889011383056641
of O O 0.9995884299278259
fatal O O 0.781423032283783
convulsions O B-Disease 0.8378680944442749
by O O 0.9928128123283386
a O O 0.9998077750205994
factor O O 0.9902500510215759
of O O 0.9994274377822876
about O O 0.999882698059082
two O O 0.9996116757392883
; O O 0.9998353719711304
and O O 0.999792754650116
2 O O 0.9986780285835266
) O O 0.9967131614685059
pretreatment O O 0.9447193145751953
with O O 0.9999291896820068
acetaminophen S-Chemical B-Chemical 0.9408618807792664
( O O 0.9866212606430054
75 O O 0.9987541437149048
mg O O 0.999581515789032
/ O O 0.9999676942825317
kg O O 0.9992465972900391
) O O 0.999832034111023
reduced O O 0.9996851682662964
the O O 0.9999052286148071
incidence O O 0.9961835741996765
of O O 0.9998682737350464
audiogenic O O 0.6129153966903687
seizures O O 0.5317164063453674
produced O O 0.9875029921531677
in O O 0.9999300241470337
the O O 0.999890923500061
presence O O 0.9976874589920044
of O O 0.9997699856758118
caffeine S-Chemical B-Chemical 0.9309107661247253
( O O 0.9796441793441772
12 O O 0.9977231621742249
. O O 0.9999265670776367
5 O O 0.9998691082000732
to O O 0.9998842477798462
75 O O 0.9995762705802917
mg O O 0.9997667670249939
/ O O 0.999969482421875
kg O O 0.9996575117111206
IP O O 0.6048182249069214
) O O 0.9968569278717041
. O O 0.9999970197677612

pregnancy O O 0.9785088896751404
can O O 0.999990701675415
induce O O 0.9999701976776123
anomalies O O 0.9467180967330933
in O O 0.9999598264694214
HPA O O 0.8107066750526428
axis O O 0.8861421346664429
function O O 0.9993914365768433
in O O 0.9999812841415405
adulthood O O 0.9783706665039062
. O O 0.9999860525131226
Clinically O O 0.9951205849647522
, O O 0.9999628067016602
it O O 0.9999663829803467
may O O 0.9999923706054688
be O O 0.9999879598617554
postulated O O 0.9963055849075317
that O O 0.9999715089797974
disturbed O O 0.9208002090454102
fetal O O 0.8337770700454712
brain O O 0.8777855038642883
development O O 0.99250727891922

age-related O O 0.9581706523895264
decline O O 0.9883469939231873
in O O 0.999749481678009
induction O O 0.9947299957275391
of O O 0.9999022483825684
NF B-protein B-protein 0.4455188810825348
kappa I-protein I-protein 0.8358609080314636
B E-protein E-protein 0.9775775074958801
could O O 0.9997485280036926
not O O 0.999981164932251
be O O 0.9999892711639404
attributed O O 0.99997878074646
to O O 0.9999915361404419
alteration O O 0.9950290322303772
in O O 0.9999281167984009
the O O 0.9998524188995361
composition O O 0.9948391318321228
of O O 0.9998842477798462
subunits O O 0.5611824989318848
, O O 0.9495350122451782
p50 S-protein S-protein 0.9463169574737549
and O O 0.9486896395683289
p65 S-protein S-protein 0.9101942777633667
were O O 0.9932401180267334

. O O 0.9959237575531006
The O O 0.9999526739120483
class B-protein B-protein 0.5111652612686157
II I-protein I-protein 0.42138394713401794
transactivator E-protein E-protein 0.808663547039032
CIITA S-protein S-protein 0.5560339093208313
is O O 0.9994105100631714
required O O 0.9999402761459351
for O O 0.999977707862854
transcriptional O O 0.9280216693878174
activation O O 0.9858275651931763
of O O 0.9998196959495544
the O O 0.9999380111694336
major B-DNA B-DNA 0.5721033811569214
histocompatibility I-DNA I-DNA 0.5712548494338989
complex I-DNA I-DNA 0.6389699578285217
( I-DNA I-DNA 0.6571454405784607
MHC I-DNA I-DNA 0.8982006907463074
) I-DNA I-DNA 0.9312834143638611
class I-DNA I-DNA 0.9501798748970032
II I-DNA I-DNA 0.8657543063163757
genes E-DNA E-DNA 0.9977241158485413
. O O 0.9998304843902588
Aside O O 0.9994412064552307
from O O 0.9999933242797852
an O O 0.9997935891151428
N-terminal B-DNA B-protein 0.4535556435585022
acidic I-DNA I-protein 0.7591468095779419
transcriptional I-DNA I-protein 0.8691256642341614
activation I-DNA I-protein 0.9317607879638672
domain E-DNA E-protein 0.9917227625846863
, O O 0.9995806813240051
little O O 0.9994972944259644
is O O 0.9999822378158569
known O O 0.9999920129776001
about O O 0.9999949932098389
how O O 0.9999933242797852
this O O 0.9997310042381287
factor O O 0.9622467160224915
functions O O 0.9987714886665344
. O O 0.9999973773956299
Extensive O O 0.983465313911438
mutagenesis O O 0.9731068015098572
of O O 0.999518871307373
CIITA S-protein S-protein 0.7851880788803101
was O O 0.9997426867485046

critical O O 0.9739413857460022
role O O 0.9992225170135498
in O O 0.999977707862854
B O O 0.6192136406898499
cell O O 0.45418351888656616
development O O 0.9930237531661987
in O O 0.9999920129776001
the O O 0.9999473094940186
bursa O O 0.899310290813446
. O O 0.9997959733009338
Granulocyte B-protein O 0.8013367652893066

-transformed I-cell_line O 0.885778546333313
CD8+ I-cell_line B-cell_line 0.41957443952560425
T I-cell_line I-cell_line 0.5616023540496826
cell I-cell_line I-cell_line 0.36805784702301025
clone E-cell_line E-cell_line 0.984062671661377
from O O 0.9998626708984375
an O O 0.9999253749847412
HIV-infected O O 0.6379052400588989
individual O O 0.8280004262924194
and O O 0.9822612404823303
supernatants O O 0.3235514760017395
from O O 0.9986655712127686
CD8+ B-cell_type B-cell_type 0.8135703206062317
T I-cell_type I-cell_type 0.9061181545257568
cells E-cell_type E-cell_type 0.9378299117088318
of O O 0.9980783462524414
HIV-1-infected O O 0.6033450365066528
asymptomatic O O 0.48556777834892273
subjects O O 0.7900689244270325

c-jun S-DNA S-DNA 0.7810204029083252
and O O 0.9899858236312866
AP1 S-protein S-protein 0.8728353977203369
. O O 0.9998998641967773
The O O 0.999996542930603
data O O 0.9996753931045532
suggest O O 0.9999977350234985
that O O 0.9999970197677612
differences O O 0.997333288192749
in O O 0.9997349381446838
functional O O 0.9692826271057129
responses O O 0.9914306998252869
elicited O O 0.999931812286377
in O O 0.9997678399085999
monocytes S-cell_type S-cell_type 0.9879502058029175
by O O 0.9998786449432373
all O O 0.9998356103897095
three O O 0.9956440925598145
factors S-protein O 0.8288465738296509
may O O 0.999988317489624
be O O 0.9999922513961792
dependent O O 0.9999030828475952
on O O 0.9999758005142212
different O O 0.998904824256897
routes O O 0.9955507516860962
on O O 0.9999604225158691
nuclear O O 0.8205090761184692
signalling O O 0.8463007807731628
employed O O 0.9978315234184265
by O O 0.9999915361404419
the O O 0.999962568283081
factors S-protein O 0.9809789657592773
. O O 0.9999525547027588
Regulation O O 0.9991716146469116
of O O 0.9998624324798584

Neonatal O O 0.8252959847450256
pyridoxine S-Chemical S-Chemical 0.9018996357917786
responsive O O 0.8177465796470642
convulsions O O 0.6377019882202148
due O O 0.9989221096038818
to O O 0.9999605417251587
isoniazid S-Chemical B-Chemical 0.9262192249298096
therapy O O 0.9841394424438477
. O O 0.9999983310699463

induces O O 0.9954337477684021
nuclear O B-protein 0.6657393574714661
factors O E-protein 0.9700810313224792
that O O 0.9976426959037781
form O O 0.998314380645752
complexes O O 0.9063420295715332
with O O 0.9999518394470215
cyclic B-protein B-protein 0.7365288138389587
AMP I-protein I-protein 0.6251441836357117
response I-protein I-protein 0.7635776996612549
element-binding I-protein I-protein 0.909766435623169
protein E-protein E-protein 0.9861968159675598
( O O 0.9771016240119934
CREB S-protein S-protein 0.9912707805633545
) O O 0.9922212958335876
. O O 0.9999867677688599
Four O O 0.9948505759239197
complexes O O 0.7711554765701294
are O O 0.999927282333374
identified O O 0.999974250793457
by O O 0.9999935626983643
the O O 0.9998718500137329

NIN B-Disease O 0.7456372976303101
correlated O O 0.9929017424583435
with O O 0.9999496936798096
blood O O 0.9294843077659607
oxygen B-Chemical B-Chemical 0.9287731051445007
level O O 0.9883413910865784
- O O 0.9995595812797546
dependent O O 0.9989759922027588
( O O 0.999956488609314
BOLD O O 0.8431914448738098
) O O 0.9924329519271851
activity O O 0.9712168574333191
levels O O 0.999679684638977
in O O 0.9999971389770508
a O O 0.9999709129333496
midpontine O O 0.6064549684524536
site O O 0.7897286415100098
in O O 0.9999500513076782
the O O 0.9999287128448486
posterior O O 0.8678330779075623
basis O O 0.9828385710716248
pontis O O 0.7567150592803955
. O O 0.9999731779098511

elucidate O O 0.9725074172019958
differences O O 0.99853515625
between O O 0.9999357461929321
TCR S-protein S-protein 0.9027857184410095
and O O 0.9681599140167236
CD2 S-protein S-protein 0.9269370436668396
signaling O O 0.9829937219619751
pathways O O 0.9979795813560486
in O O 0.999991774559021
the O O 0.9999161958694458
same O O 0.9993401169776917
T B-cell_type B-cell_type 0.7641840577125549
cells E-cell_type E-cell_type 0.9845559597015381
. O O 0.9995877146720886
Activation O O 0.9968390464782715
of O O 0.9995325803756714

promoters E-DNA E-DNA 0.7409006357192993
of O O 0.9983355402946472
certain O O 0.9952475428581238
growth- B-DNA B-DNA 0.5825076103210449
and I-DNA I-DNA 0.8072819709777832
cell I-DNA I-DNA 0.6656718254089355
cycle-controlling I-DNA I-DNA 0.407009482383728
genes E-DNA E-DNA 0.9733049869537354
and O O 0.9907370209693909
forms O O 0.9983256459236145
distinct O O 0.9956170320510864
heteromeric B-protein B-protein 0.6361329555511475
complexes E-protein E-protein 0.9639428853988647
with O O 0.9997778534889221
other O O 0.9981805086135864
nuclear B-protein B-protein 0.657358705997467
proteins E-protein E-protein 0.9819003343582153
. O O 0.9995038509368896
It O O 0.9999258518218994
has O O 0.999970555305481
therefore O O 0.9999614953994751
been O O 0.9999754428863525
proposed O O 0.9999856948852539
that O O 0.9999924898147583
E2F S-protein S-protein 0.9856323003768921
is O O 0.9990758895874023
involved O O 0.9999871253967285
in O O 0.9999810457229614
cellular O O 0.9638312458992004
proliferation O O 0.9876391291618347
control O O 0.9992664456367493
. O O 0.9999954700469971
Human O O 0.5508136749267578
T-cell O O 0.29037413001060486

while O O 0.9993317723274231
a O O 0.9999911785125732
second O O 0.9859733581542969
group O O 0.9809159636497498
replicated O O 0.9995381832122803
with O O 0.9999442100524902
delayed O O 0.814395546913147
or O O 0.9786477088928223
slightly O O 0.9667105674743652
delayed O O 0.908059298992157
kinetics O O 0.5627154111862183
in O O 0.9997009038925171
CEMxl74 B-cell_line B-cell_line 0.7978591918945312
cells E-cell_line E-cell_line 0.9892905354499817
( O O 0.9987610578536987
SIVmac239 O O 0.8281760811805725
> O O 0.9447309374809265
substSp34 S-protein S-protein 0.5449305772781372
> O O 0.9946773052215576
deltaNFkappaBdeltaSpl234 S-protein S-protein 0.5430959463119507
approximately O O 0.9882700443267822
deltaNFkappaBdeltaSp1 S-protein S-protein 0.7211941480636597
> O O 0.9916853904724121
substSpl234 S-protein S-protein 0.6458017230033875
) O O 0.9788876175880432
. O O 0.9999849796295166
Reversions O O 0.9889228343963623
or O O 0.9997381567955017
additional O O 0.9834513664245605
mutations O O 0.9656121730804443
were O O 0.9999839067459106
not O O 0.999913215637207
detected O O 0.9998689889907837
in O O 0.9997825026512146

in O O 0.9972904920578003
Hungary O O 0.8471677303314209
. O O 0.9998888969421387
T-cell O O 0.7457588315010071
expression O O 0.9762845635414124
of O O 0.9997833371162415
the O O 0.9999513626098633
human B-DNA B-DNA 0.6077445149421692
GATA-3 I-DNA I-DNA 0.7087291479110718
gene E-DNA E-DNA 0.9898802042007446
is O O 0.9984834790229797
regulated O O 0.9999274015426636
by O O 0.9999970197677612
a O O 0.9998806715011597
non-lineage-specific B-DNA O 0.6738805174827576
silencer E-DNA O 0.49556785821914673

Cauda O B-Disease 0.5193896293640137
equina O I-Disease 0.8623940944671631
syndrome O I-Disease 0.9951321482658386
is O O 0.9914119243621826
a O O 0.9999009370803833
rare O O 0.9828916788101196
complication O O 0.9367488026618958
of O O 0.9991625547409058
epidural O O 0.5565223097801208
anesthesia O O 0.8722714781761169
. O O 0.9994673132896423

RESULTS O O 0.9985478520393372
: O O 0.9999901056289673
The O O 0.9999818801879883
median O O 0.9943786263465881
cumulative O O 0.9891244173049927
doses O O 0.9993667006492615
of O O 0.9998030066490173
cyclophosphamide S-Chemical B-Chemical 0.9283156991004944
among O O 0.9961801767349243
cases O O 0.9952947497367859
( O O 0.9999924898147583
n O O 0.9991714954376221
= O O 0.9999231100082397
11 O O 0.997444748878479
) O O 0.9994034767150879
and O O 0.9999573230743408
controls O O 0.950352668762207
( O O 0.9999563694000244
n O O 0.9986138343811035
= O O 0.9999158382415771
25 O O 0.997334897518158
) O O 0.9997408986091614
were O O 0.9999909400939941
113 O O 0.9982826709747314
g O O 0.99819415807724
and O O 0.9998852014541626
25 O O 0.999622106552124
g O O 0.9993143081665039
, O O 0.9999160766601562
respectively O O 0.9999889135360718
. O O 0.9999977350234985

thyroglobulin B-protein B-protein 0.24428223073482513
receptors E-protein E-protein 0.9881489872932434
and O O 0.9971007704734802
T O O 0.7523902654647827
cell O O 0.5219842195510864
proliferation O O 0.9727879166603088
in O O 0.9999243021011353
Hashimoto O O 0.5997254252433777
's O O 0.9513935446739197
thyroiditis O O 0.8115613460540771
. O O 0.9999058246612549
Immunoglobulin B-protein B-protein 0.3911559581756592
molecules E-protein E-protein 0.9729042649269104
on O O 0.9990425705909729
the O O 0.9997861981391907
surface O O 0.9967283010482788
of O O 0.9997668862342834
a O O 0.9975525736808777
B B-cell_type B-cell_type 0.6546823382377625
lymphocyte E-cell_type E-cell_type 0.9403305649757385
are O O 0.9993094205856323
the O O 0.9999834299087524
endogenous O O 0.8049929141998291
`` O O 0.6299583911895752

protein E-protein E-protein 0.9420639872550964
, O O 0.9953533411026001
indicating O O 0.9999805688858032
that O O 0.9999955892562866
it O O 0.9994656443595886
is O O 0.9999415874481201
not O O 0.9996241331100464
associated O O 0.9998824596405029
with O O 0.9999943971633911
an O O 0.999636173248291
inhibitor O O 0.9768428802490234
( O O 0.9995566010475159
IKB O S-protein 0.7975110411643982
) O O 0.9956474900245667
. O O 0.9999933242797852
This O O 0.9998818635940552
factor O O 0.9728279709815979
remained O O 0.9995760321617126
clustered O O 0.9971666932106018
in O O 0.999826967716217

binds O O 0.8026853799819946
Fos B-protein S-protein 0.8296531438827515
and I-protein O 0.9810075163841248
Jun I-protein B-protein 0.4771484136581421
heterodimers E-protein E-protein 0.9614388942718506
) O O 0.9713738560676575
. O O 0.999975323677063
Western O O 0.9831211566925049
blot O O 0.97918301820755
analysis O O 0.9996432065963745
of O O 0.9999865293502808
nuclear O O 0.88839191198349
extracts O O 0.9748513102531433
showed O O 0.9999822378158569
that O O 0.9999979734420776
the O O 0.9999397993087769
impaired O O 0.9627884030342102
DNA-protein O O 0.4334428608417511
interactions O O 0.891055703163147
in O O 0.9998025298118591

nuclear B-protein B-protein 0.7792367339134216
factor I-protein I-protein 0.4329942464828491
of I-protein I-protein 0.49709615111351013
mitogenic-activated I-protein I-protein 0.6773556470870972
T I-protein I-protein 0.863122284412384
cells E-protein E-protein 0.8508443236351013
( O O 0.974679708480835
NF-MATp35 S-protein S-protein 0.64865642786026
) O O 0.9729210734367371
that O O 0.9999270439147949
is O O 0.9999611377716064
clearly O O 0.9995985627174377
different O O 0.9998906850814819
from O O 0.9999946355819702
the O O 0.9999250173568726
known O O 0.9925158619880676
NF- B-protein B-protein 0.501708447933197
kappaB/Rel I-protein I-protein 0.7412388920783997
family I-protein I-protein 0.5103079080581665
members E-protein E-protein 0.9915719032287598
. O O 0.9997901320457458
Induction O O 0.9950894713401794
of O O 0.9996911287307739
NF-MATp35 S-protein S-protein 0.9614376425743103
was O O 0.9995098114013672
shown O O 0.9999845027923584
to O O 0.9999933242797852
depend O O 0.9999877214431763
on O O 0.9996967315673828
de O O 0.804028332233429

can O O 0.994159460067749
result O O 0.999967098236084
in O O 0.9999933242797852
the O O 0.9999797344207764
production O O 0.9995321035385132
of O O 0.99998939037323
major B-protein B-protein 0.7087731957435608
proinflammatory I-protein I-protein 0.4251616597175598
cytokines E-protein E-protein 0.9855208992958069
, O O 0.9991325736045837
which O O 0.9999803304672241
may O O 0.999990701675415
play O O 0.9999861717224121
an O O 0.9999927282333374
important O O 0.999636173248291
role O O 0.9998413324356079
in O O 0.9999910593032837
the O O 0.9999493360519409
pathophysiology O O 0.9885813593864441
of O O 0.9999065399169922

Low O O 0.9298751354217529
- O O 0.9894223809242249
dose O O 0.9972952008247375
haloperidol S-Chemical B-Chemical 0.9245978593826294
did O O 0.9987536668777466
not O O 0.9998779296875
differ O O 0.9999762773513794
from O O 0.9999850988388062
placebo O O 0.9702456593513489
on O O 0.9999381303787231
any O O 0.9999840259552002
measure O O 0.9998607635498047
of O O 0.9999089241027832
efficacy O O 0.5610747933387756
or O O 0.9921992421150208
side O O 0.921595573425293
effects O O 0.9408884048461914
. O O 0.9999936819076538

baT O E-protein 0.6030082106590271
. O O 0.9927612543106079
None O O 0.9999583959579468
of O O 0.9999964237213135
these O O 0.9999843835830688
polymorphisms S-DNA O 0.64629727602005
change O O 0.9993866682052612
the O O 0.9999386072158813
translated B-protein B-protein 0.7673619985580444
protein E-protein E-protein 0.9470927715301514
. O O 0.9981499910354614
Since O O 0.9999467134475708
sequence B-DNA O 0.9644237756729126
variations E-DNA O 0.9889647960662842
in O O 0.9999885559082031
the O O 0.999729335308075
3 B-DNA B-DNA 0.592803418636322
' I-DNA I-DNA 0.5456685423851013
UTR E-DNA E-DNA 0.8374003767967224
of O O 0.9507575631141663
VDR S-protein S-protein 0.42910802364349365
have O O 0.9988705515861511
been O O 0.9998784065246582
linked O O 0.9999721050262451
to O O 0.9999940395355225
the O O 0.9999229907989502
different O O 0.9991838335990906

164 O O 0.9523900747299194
patients O O 0.9996256828308105
( O O 0.9999970197677612
mean O O 0.9999326467514038
age O O 0.9990992546081543
+ O O 0.9999805688858032
/ O O 0.9999945163726807
- O O 0.9999116659164429
standard O O 0.9974108338356018
deviation O O 0.9719167947769165
[ O O 0.9986822009086609
SD O O 0.47888317704200745
] O O 0.9608577489852905
81 O O 0.9924924969673157
. O O 0.9999949932098389
6 O O 0.9999054670333862
+ O O 0.9999874830245972
/ O O 0.9999984502792358
- O O 0.999961256980896
6 O O 0.9999479055404663
. O O 0.9999876022338867
8 O O 0.9999308586120605
years O O 0.999967098236084
) O O 0.9999483823776245
were O O 0.9999924898147583
admitted O O 0.9998908042907715
. O O 0.9999990463256836

Spironolactone B-Chemical B-Chemical 0.9222486019134521
- O O 0.9737306833267212
induced O O 0.9994057416915894
renal B-Disease B-Disease 0.6228618621826172
insufficiency I-Disease I-Disease 0.9817975759506226
and O O 0.8482504487037659
hyperkalemia B-Disease B-Disease 0.966539740562439
in O O 0.983913242816925
patients O O 0.999550998210907
with O O 0.9999598264694214
heart B-Disease O 0.6233193278312683
failure I-Disease O 0.9687156677246094
. O O 0.9979325532913208

Apomorphine S-Chemical B-Chemical 0.9266831278800964
, O O 0.9904314875602722
a O O 0.9998557567596436
nonselective O O 0.7562193274497986
dopamine B-Chemical B-Chemical 0.8985673785209656
agonist E-Chemical O 0.5849652886390686
, O O 0.9984900951385498
was O O 0.9998868703842163
selected O O 0.9999891519546509
due O O 0.9999990463256836
to O O 0.9999853372573853
its O O 0.9999208450317383
biphasic O O 0.7312509417533875
behavioral O O 0.6756906509399414
effects O O 0.8546359539031982
, O O 0.9998424053192139
its O O 0.9999547004699707
ability O O 0.998941957950592
to O O 0.9999619722366333
induce O O 0.9995337724685669
hypothermia O B-Disease 0.9827996492385864
, O O 0.9712162017822266
and O O 0.9996386766433716
to O O 0.9999325275421143
produce O O 0.9999178647994995
distinct O O 0.989234209060669
changes O O 0.9663146138191223
to O O 0.9997792840003967
dopamine S-Chemical B-Chemical 0.9233241677284241
turnover O O 0.6212682723999023
in O O 0.995862603187561
the O O 0.9986869692802429
rodent O O 0.9467476010322571
brain O O 0.8495737314224243
. O O 0.9999908208847046

mononuclear B-cell_type B-cell_type 0.2476729303598404
leukocytes E-cell_type E-cell_type 0.9792689681053162
in O O 0.9996362924575806
polycystic O O 0.8519555330276489
ovary O O 0.7932549715042114
syndrome O O 0.9352232217788696
. O O 0.9999573230743408
OBJECTIVE O O 0.9326024651527405
: O O 0.9990115165710449
Many O O 0.9998562335968018
studies O O 0.9999352693557739
have O O 0.9999980926513672
suggested O O 0.9999961853027344
that O O 0.9999954700469971
there O O 0.9999912977218628
is O O 0.9999973773956299
a O O 0.9999940395355225
possible O O 0.9987471103668213
hormonal O O 0.9723171591758728
dysregulation O O 0.9824182391166687
of O O 0.9998887777328491
hypothalamic-pituitary-adrenal O O 0.8091804385185242
( O O 0.9784261584281921
HPA O O 0.8946946859359741
) O O 0.9766573905944824
axis O O 0.9541854858398438
and O O 0.9999662637710571
an O O 0.9999918937683105
increased O O 0.9964504241943359
cortisol O O 0.9114453196525574
clearance O O 0.9963564872741699
in O O 0.9999858140945435
patients O O 0.9998776912689209
with O O 0.9999905824661255

NFAT B-protein B-protein 0.6052783131599426
family E-protein E-protein 0.960300624370575
of O O 0.9815266728401184
transcription B-protein B-protein 0.5026322603225708
factors E-protein E-protein 0.996048629283905
has O O 0.9996423721313477
facilitated O O 0.9999120235443115
rapid O O 0.9957744479179382
progress O O 0.9995599389076233
in O O 0.9999843835830688
the O O 0.9999321699142456
understanding O O 0.9997534155845642
of O O 0.999987006187439
the O O 0.9999518394470215
signalling O O 0.9279748797416687
mechanisms O O 0.9837337136268616
that O O 0.999976634979248
control O O 0.9997672438621521
the O O 0.9998639822006226
activity O O 0.9993042945861816
of O O 0.9999674558639526
NFAT S-protein S-protein 0.9894184470176697
. O O 0.9999040365219116
Differential O O 0.9591415524482727
RNA O O 0.4535466432571411
display O O 0.5853999853134155
identifies O O 0.9988241791725159
novel B-DNA B-DNA 0.8697924613952637
genes E-DNA E-DNA 0.7799031734466553
associated O O 0.9979934692382812
with O O 0.999993085861206
decreased O O 0.9896473288536072
vitamin B-protein B-protein 0.6344281435012817
D I-protein I-protein 0.4499702453613281
receptor E-protein E-protein 0.9492241740226746
expression O O 0.9929190278053284
. O O 0.9999922513961792
To O O 0.9999706745147705
characterize O O 0.9996410608291626
further O O 0.999761164188385
the O O 0.9999717473983765
function O O 0.9998219609260559
of O O 0.9999878406524658
the O O 0.9998629093170166
intracellular B-protein O 0.7436432838439941
vitamin I-protein O 0.4601694345474243

primary O O 0.4201066792011261
isolates O O 0.7761080265045166
in O O 0.9998202919960022
vitro O O 0.9930124878883362
. O O 0.9999904632568359
In O O 0.9999877214431763
addition O O 0.9999042749404907
, O O 0.9999897480010986
BMT O O 0.38228610157966614
exhibited O O 0.9976639747619629
antiviral O O 0.9585094451904297
activity O O 0.9957796335220337
against O O 0.9999651908874512
SIVmac251 O S-protein 0.6460164189338684

This O O 0.9988056421279907
calls O O 0.9997120499610901
for O O 0.9999645948410034
attention O O 0.9935577511787415
when O O 0.9999744892120361
ketoconazole B-Chemical B-Chemical 0.9206506609916687
is O O 0.9915868043899536
administered O O 0.9997401833534241
to O O 0.9999388456344604
patients O O 0.9998124241828918
with O O 0.9999955892562866
risk O O 0.9677259922027588
factors O O 0.9536083936691284
for O O 0.9998038411140442
acquired O O 0.9585293531417847
long B-Disease O 0.9235843420028687
QT I-Disease O 0.4916776120662689
syndrome I-Disease O 0.9552924036979675
. O O 0.9994885921478271

when O O 0.9989866614341736
considering O O 0.9999891519546509
both O O 0.9999898672103882
groups O O 0.9993395209312439
of O O 0.9999767541885376
patients O O 0.9994070529937744
together O O 0.9999899864196777
or O O 0.9999744892120361
separately O O 0.9998325109481812
. O O 0.9999979734420776
Conversely O O 0.9998506307601929
, O O 0.9999892711639404
a O O 0.9999825954437256
significant O O 0.9961636066436768
negative O O 0.9659888744354248
correlation O O 0.9910750389099121
was O O 0.9999804496765137
found O O 0.9999778270721436
between O O 0.9985027313232422
VDR S-protein S-protein 0.4371224045753479
and O O 0.9721973538398743
serum O O 0.782567024230957

transcription B-protein B-protein 0.38897350430488586
factor I-protein E-protein 0.9559744596481323
Oct-2A E-protein S-protein 0.6556810736656189
and O O 0.9978540539741516
the O O 0.9999186992645264
high B-protein B-protein 0.9119563102722168
mobility I-protein I-protein 0.7086545825004578
group I-protein I-protein 0.35166388750076294
protein E-protein I-protein 0.8864465951919556
I/Y S-protein E-protein 0.7637007236480713
in O O 0.9989491105079651
HLA-DRA B-DNA B-DNA 0.444703608751297
gene E-DNA E-DNA 0.8914621472358704
expression O O 0.9691984057426453
. O O 0.9999858140945435
The O O 0.9999743700027466
class B-DNA B-DNA 0.394252747297287
II I-DNA I-DNA 0.4509355425834656
major I-DNA I-DNA 0.6650206446647644
histocompatibility I-DNA I-DNA 0.8149544596672058
complex I-DNA I-DNA 0.5538626909255981
gene E-DNA E-DNA 0.942889392375946
HLA-DRA S-DNA S-DNA 0.7905429005622864
is O O 0.9982421398162842
expressed O O 0.999394416809082
in O O 0.999332845211029
B B-cell_type B-cell_type 0.9109079837799072
cells E-cell_type E-cell_type 0.9811553955078125
, O O 0.9943482279777527
activated O O 0.6004881262779236

reticulocyte O O 0.5122851133346558
lysate O O 0.7718324065208435
. O O 0.9997983574867249
This O O 0.9999074935913086
lysate O O 0.8919931054115295
was O O 0.9992333650588989
also O O 0.9999784231185913
necessary O O 0.9999644756317139
for O O 0.9999731779098511

resting O O 0.8347681164741516
G0/G1 O O 0.4740976393222809
state O O 0.4958738684654236
. O O 0.9998759031295776
We O O 0.9999916553497314
now O O 0.9999988079071045
report O O 0.999997615814209
that O O 0.9999939203262329
interferon-beta O S-protein 0.9140918254852295
is O O 0.9997780919075012
the O O 0.9999945163726807
principal O O 0.9853376746177673
mediator O O 0.9837141633033752
of O O 0.9999446868896484
stromal O O 0.8608002066612244
cell-mediated O O 0.9114611148834229
Tcell O O 0.8392364978790283
rescue O O 0.9956417083740234
from O O 0.9999932050704956
apoptosis O O 0.9112999439239502

be O O 0.996776282787323
present O O 0.9999054670333862
at O O 0.9999971389770508
low O O 0.9881479144096375
levels O O 0.9994743466377258
in O O 0.9999734163284302
mature B-cell_line B-cell_line 0.6821570992469788
B-cell I-cell_line I-cell_line 0.3523937165737152
lines E-cell_line E-cell_line 0.9823827743530273
and O O 0.9993126392364502
, O O 0.9998680353164673
unexpectedly O O 0.9981729984283447
, O O 0.9999630451202393
in O O 0.9998835325241089
one O O 0.9997089505195618
plasma O O 0.5112501382827759
cell O O 0.3684145212173462

MCP-1 S-protein S-protein 0.8452147841453552
. O O 0.9997844099998474
These O O 0.9999934434890747
activities O O 0.9993728995323181
may O O 0.9999971389770508
contribute O O 0.9999979734420776
to O O 0.999993085861206
the O O 0.9999291896820068
immunomodulatory O O 0.9377737045288086
properties O O 0.9636664986610413
of O O 0.9999579191207886
heparin O O 0.616955578327179
. O O 0.9995205402374268
[ O O 0.9987862706184387
Molecular-biologic O O 0.9711542725563049
aspects O O 0.997548520565033
of O O 0.9999016523361206
interaction O O 0.9814127683639526
between O O 0.9992930889129639

The O O 0.996809184551239
[ O O 0.9755658507347107
verapamil S-Chemical B-Chemical 0.8746825456619263
] O O 0.58701491355896
o O O 0.787714958190918
that O O 0.9959115982055664
arrested O O 0.9840412139892578
atrial O O 0.6728775501251221
beating O O 0.7801904678344727
( O O 0.9920511841773987
AC O O 0.5851156711578369
) O O 0.9487545490264893
was O O 0.9999539852142334
also O O 0.999991774559021
potentiated O O 0.9999583959579468
with O O 0.9999963045120239
the O O 0.9999644756317139
order O O 0.9774869084358215
LNa O O 0.7557485699653625
= O O 0.985819935798645
LNa O B-Chemical 0.8989062905311584
+ O O 0.9367737174034119
LCa O O 0.8216151595115662
= O O 0.9649702310562134
LNa O O 0.8726341724395752
+ O O 0.9624857306480408
HCa O O 0.8727996945381165
= O O 0.9501467347145081
LCa O O 0.800813615322113
> O O 0.9892252087593079
HCa O O 0.7481622099876404
= O O 0.9967600703239441
N O O 0.7125235795974731
. O O 0.9999228715896606

type O I-protein 0.45214006304740906
I O E-protein 0.5907430052757263
, O O 0.8964404463768005
showing O O 0.9989699125289917
that O O 0.9999876022338867
NF-kappa B-protein B-protein 0.7675648331642151
B E-protein E-protein 0.9895574450492859
activity O O 0.997300922870636
can O O 0.9999946355819702
be O O 0.9999872446060181
modulated O O 0.9996820688247681
even O O 0.9999738931655884
in O O 0.9999439716339111
a O O 0.9992108345031738
B-cell B-cell_line B-cell_line 0.8290691375732422
line E-cell_line E-cell_line 0.9820429682731628
that O O 0.991569459438324
constitutively O O 0.9995201826095581
expresses O O 0.9999126195907593
this O O 0.9998592138290405
factor O O 0.9669756889343262

NWP S-cell_line S-protein 0.7761359214782715
by O O 0.9995065927505493
disruption O O 0.9964721202850342
of O O 0.9998836517333984
the O O 0.9999309778213501
receptor O O 0.7333768010139465
dimerization O O 0.4041513502597809
process O O 0.45485472679138184
and/or O O 0.4450622797012329
by O O 0.9985540509223938
interference O O 0.9881746768951416
of O O 0.9985754489898682
receptor B-protein B-protein 0.7374628782272339
complex E-protein E-protein 0.9111167192459106
binding O O 0.8964357972145081
to O O 0.9988422989845276
the O O 0.9998621940612793
consensus B-DNA B-DNA 0.5114978551864624
response I-DNA I-DNA 0.772598922252655
elements E-DNA E-DNA 0.983111560344696
present O O 0.9969061017036438
in O O 0.9999725818634033
the O O 0.9999457597732544
enhancer B-DNA B-DNA 0.542738676071167
regions E-DNA E-DNA 0.9259388446807861
of O O 0.996508777141571
steroid-responsive B-DNA B-DNA 0.45893415808677673
genes E-DNA E-DNA 0.9880339503288269
. O O 0.9998605251312256
We O O 0.9999185800552368
employed O O 0.9994575381278992
electromobility O O 0.8850193619728088
shift O O 0.9489560127258301
assay O O 0.9925649166107178
( O O 0.9998695850372314
EMSA O O 0.9564850330352783
) O O 0.9994161128997803
to O O 0.9999815225601196
screen O O 0.9920559525489807
for O O 0.9999568462371826
the O O 0.9999243021011353

In O O 0.9996609687805176
24 O O 0.9996334314346313
of O O 0.9999772310256958
these O O 0.9998130202293396
patients O O 0.9933682084083557
chemical O O 0.6336615681648254
cystitis B-Disease B-Disease 0.6260274052619934
was O O 0.9905707836151123
severe O O 0.9912322163581848
enough O O 0.9993512034416199
for O O 0.9999933242797852
them O O 0.9996857643127441
to O O 0.999976634979248
drop O O 0.9992871880531311
out O O 0.999964714050293
of O O 0.9999843835830688
the O O 0.9999603033065796
study O O 0.9998548030853271
. O O 0.9999992847442627

functions O O 0.9812629818916321
of O O 0.9998307228088379
infiltrating B-cell_type O 0.8204654455184937
CD4-bearing I-cell_type B-cell_type 0.40865832567214966
T I-cell_type I-cell_type 0.6994553208351135
cells E-cell_type E-cell_type 0.6780693531036377
may O O 0.9995946288108826
include O O 0.9999958276748657
cytotoxicity O O 0.9431759715080261
, O O 0.9998372793197632
inhibition O O 0.983918309211731
of O O 0.9991626739501953
viral O O 0.6210118532180786

effect O O 0.9949344992637634
, O O 0.9999954700469971
the O O 0.9999912977218628
mineralocorticoid B-protein B-protein 0.6296675205230713
receptor E-protein E-protein 0.9609574675559998
is O O 0.9957079887390137
involved O O 0.9999899864196777
in O O 0.9999932050704956
the O O 0.9999761581420898
inhibition O O 0.9959020018577576
of O O 0.9999288320541382
monocyte O O 0.6102417707443237
IL-1ra S-protein S-protein 0.5399718880653381
secretion O O 0.9152752757072449
by O O 0.9997765421867371
cortisol O O 0.9299488067626953
. O O 0.9998229146003723
Target O O 0.8232790231704712
structures O O 0.636880099773407
of O O 0.9993970394134521
the O O 0.9998834133148193
CD8 O S-protein 0.552950382232666
( O O 0.5729991793632507
+ O O 0.40801694989204407
) O O 0.39150935411453247
-T-cell O O 0.4004840850830078
response O O 0.6089298129081726
to O O 0.9812621474266052

leukocyte O O 0.30865663290023804

serum O O 0.537132978439331
, O O 0.9884875416755676
which O O 0.9999186992645264
indicated O O 0.9998252987861633
NF-kappa B-protein B-protein 0.6731694340705872
B E-protein E-protein 0.9945204854011536
activation O O 0.9967316389083862
in O O 0.9999843835830688
this O O 0.9999570846557617
setting O O 0.9939066767692566
. O O 0.9999923706054688
At O O 0.9999735355377197
variance O O 0.9968900084495544
, O O 0.9999845027923584
in O O 0.9996969699859619
PAEC S-cell_line S-cell_line 0.8861075043678284
incubated O O 0.9517505764961243
with O O 0.9999034404754639
the O O 0.9999644756317139
homologous O O 0.7541079521179199
serum O O 0.6611309051513672
, O O 0.9974193572998047
NF-kappa B-protein B-protein 0.7293519973754883
B E-protein E-protein 0.9852079153060913
was O O 0.9995660185813904
strictly O O 0.9992407560348511
localized O O 0.9972165822982788
in O O 0.9999794960021973
the O O 0.9998012185096741
cell O O 0.9625844955444336
cytoplasm O O 0.8842719793319702
. O O 0.9999657869338989
Treatment O O 0.9993858337402344
of O O 0.9998086094856262

A O O 0.9986584186553955
slow O O 0.960985004901886
bolus O O 0.6601355075836182
of O O 0.9953078627586365
subhypnotic O O 0.5259553790092468
doses O O 0.9550148844718933
of O O 0.9977165460586548
ketamine B-Chemical B-Chemical 0.932528555393219
( O O 0.9876498579978943
0 O O 0.9895939826965332
. O O 0.9992163181304932
25 O O 0.9997590184211731
mg O O 0.9998103976249695
/ O O 0.9999765157699585
kg O O 0.999207079410553
or O O 0.9999916553497314
0 O O 0.9998917579650879
. O O 0.9999803304672241
50 O O 0.999916672706604
mg O O 0.9998642206192017
/ O O 0.9999798536300659
kg O O 0.9993226528167725
) O O 0.999880313873291
was O O 0.9999964237213135
given O O 0.9999963045120239
to O O 0.9999552965164185
10 O O 0.9990480542182922
cancer B-Disease O 0.8695737719535828
patients O O 0.9088719487190247
whose O O 0.9993294477462769
pain B-Disease B-Disease 0.9663670063018799
was O O 0.9938703775405884
unrelieved O O 0.9963085055351257
by O O 0.9999891519546509
morphine B-Chemical B-Chemical 0.9368385672569275
in O O 0.9994495511054993
a O O 0.9999508857727051
randomized O O 0.8607047200202942
, O O 0.9942800998687744
double O O 0.9928574562072754
- O O 0.9988559484481812
blind O O 0.9526590704917908
, O O 0.9982663989067078
crossover O O 0.9064650535583496
, O O 0.9981821775436401
double O O 0.9854773879051208
- O O 0.9981721639633179
dose O O 0.9996827840805054
study O O 0.9999347925186157
. O O 0.9999992847442627

of O O 0.9963521957397461
granulocytes S-cell_type S-cell_type 0.9528985619544983
by O O 0.999775230884552
4 O O 0.9784654974937439
beta-phorbol O O 0.9794865846633911
12-myristate O O 0.9919078350067139
13-acetate O O 0.9921637773513794
( O O 0.99996018409729
PMA O O 0.9867783784866333
) O O 0.9998784065246582
, O O 0.9999943971633911
the O O 0.9999821186065674
levels O O 0.9999382495880127

( O O 0.735123872756958

Initial O O 0.9956578016281128
testing O O 0.9990517497062683
in O O 0.9999982118606567
a O O 0.9999845027923584
time O O 0.9991629123687744
- O O 0.9998559951782227
dependent O O 0.9955399632453918
forgetting O O 0.9552677273750305
task O O 0.9504573345184326
employing O O 0.9999549388885498
a O O 0.9999120235443115
24 O O 0.9249245524406433
- O O 0.9923040270805359
h O O 0.950264573097229
delay O O 0.9165970087051392
between O O 0.9991855025291443
training O O 0.9983402490615845
and O O 0.9999880790710449
testing O O 0.9992431402206421
showed O O 0.9999980926513672
that O O 0.9999523162841797
metrifonate B-Chemical B-Chemical 0.9117703437805176
improved O O 0.9786054491996765
object O O 0.8911496996879578
recognition O O 0.9134917259216309
( O O 0.9998552799224854
at O O 0.9999916553497314
10 O O 0.9977801442146301
and O O 0.9998643398284912
30 O O 0.9997054934501648
mg O O 0.999854564666748
/ O O 0.9999884366989136
kg O O 0.9997828602790833
, O O 0.9999938011169434
p O O 0.9997758269309998
. O O 0.9999651908874512
o O O 0.999908447265625
. O O 0.9995575547218323
) O O 0.9995483756065369
, O O 0.9999784231185913
whereas O O 0.9999908208847046
Ro4368554 B-Chemical B-Chemical 0.9055541157722473
was O O 0.9972121119499207
inactive O O 0.9826443791389465
. O O 0.999996542930603

Pneumonitis O B-Disease 0.978135883808136
, O O 0.9758613705635071
bilateral O O 0.9210835099220276
pleural O O 0.8094232678413391
effusions O O 0.6017603278160095
, O O 0.999265730381012
echocardiographic O O 0.8258253335952759
evidence O O 0.9642949104309082
of O O 0.9997848868370056
cardiac O O 0.8592537045478821
tamponade O O 0.691359281539917
, O O 0.9889211654663086
and O O 0.9997476935386658
positive O O 0.9338930249214172
autoantibodies O O 0.35684019327163696
developed O O 0.9985264539718628
in O O 0.9999871253967285
a O O 0.9999721050262451
43 O O 0.9977914094924927
- O O 0.9998424053192139
year O O 0.9999192953109741
- O O 0.999911904335022
old O O 0.999100923538208
man O O 0.996274471282959
, O O 0.9999873638153076
who O O 0.999840497970581
was O O 0.9999556541442871
receiving O O 0.9999828338623047
long O O 0.9752023816108704
- O O 0.9980979561805725
term O O 0.9930620789527893
sulfasalazine S-Chemical B-Chemical 0.9329617619514465
therapy O O 0.9883260130882263
for O O 0.9999831914901733
chronic O O 0.7666034698486328
ulcerative O O 0.4924030601978302
colitis O O 0.94245445728302
. O O 0.9988364577293396

phosphonate-containing O B-protein 0.614725649356842
liposomes O E-protein 0.7930299639701843
. O O 0.9992864727973938
Neutrophil O O 0.4773482084274292
accumulation O O 0.9799066185951233
and O O 0.9996867179870605
development O O 0.9979193806648254
of O O 0.9999648332595825
lung O O 0.8207921981811523
injury O O 0.6375043988227844
were O O 0.9996501207351685
also O O 0.9999606609344482
substantially O O 0.9994598031044006
diminished O O 0.9996067881584167
. O O 0.999997615814209
Lung O O 0.8436216711997986
instillation O O 0.9472952485084534
of O O 0.999000608921051
TNF-alpha S-protein S-protein 0.981942355632782
in O O 0.9997205138206482
alveolar O O 0.557216227054596
macrophage-depleted O O 0.5173272490501404
rats O O 0.7234455943107605
restored O O 0.999414324760437
the O O 0.9999449253082275
NF-kappaB S-protein S-protein 0.9716463685035706
activation O O 0.9769318699836731
response O O 0.9936047196388245
in O O 0.9999428987503052
whole O O 0.9631884694099426
lung O O 0.8663306832313538
. O O 0.9997311234474182
These O O 0.9999953508377075
data O O 0.9996864795684814
suggest O O 0.9999963045120239
that O O 0.9999970197677612
, O O 0.9997506737709045
in O O 0.9999778270721436
this O O 0.99989914894104
inflammatory O O 0.746100127696991
model O O 0.8557689189910889
, O O 0.9999200105667114
initial O O 0.993593156337738
activation O O 0.9980230331420898
of O O 0.9998525381088257
NF-kappaB S-protein S-protein 0.9909233450889587
occurs O O 0.99962317943573
in O O 0.9996832609176636

cells O E-cell_type 0.7240491509437561
. O O 0.9997683167457581
These O O 0.9999977350234985
results O O 0.999947190284729
indicate O O 0.999998927116394
a O O 0.9999935626983643
differential O O 0.9977105855941772
role O O 0.9996320009231567
of O O 0.9999644756317139
Spi-1 S-DNA S-protein 0.9815172553062439
on O O 0.9990906715393066
the O O 0.9999181032180786
differentiation O O 0.9900017976760864
of O O 0.9999309778213501
human B-cell_line B-cell_type 0.447238951921463
myeloid I-cell_line I-cell_type 0.688826858997345
leukemia I-cell_line I-cell_type 0.7757943868637085
cells E-cell_line E-cell_type 0.8705633878707886
. O O 0.9998857975006104
Copyright O O 0.970851480960846
1998 O O 0.9696236848831177
Academic O O 0.9933277368545532
Press O O 0.9701341986656189
. O O 0.9999799728393555
In O O 0.9998875856399536
vivo O O 0.9865520596504211
function O O 0.9975082874298096
of O O 0.9999570846557617
an O O 0.999954342842102
interleukin B-protein B-protein 0.35197585821151733
2 I-protein I-protein 0.4344449043273926
receptor I-protein I-protein 0.5036041736602783
beta I-protein I-protein 0.47895312309265137
chain E-protein E-protein 0.9909172654151917
( B-protein O 0.9834789037704468

T B-cell_type B-cell_type 0.3587602972984314
cells E-cell_type E-cell_type 0.894340991973877
. O O 0.9994826316833496
We O O 0.9999879598617554
show O O 0.9999966621398926
that O O 0.9999977350234985
PNU156804 O O 0.532669186592102
does O O 0.9997851252555847
not O O 0.9999595880508423
inhibit O O 0.9994714856147766
c-myc O B-RNA 0.6521062850952148
and O I-RNA 0.5411453247070312
bcl-2 O I-RNA 0.6605049967765808
mRNA O E-RNA 0.9657608866691589
induction O O 0.9928205609321594
. O O 0.9999957084655762
On O O 0.9999942779541016
the O O 0.9999892711639404
other O O 0.9999446868896484
hand O O 0.999874472618103
, O O 0.999991774559021
PNU156804 O O 0.656168520450592
efficiently O O 0.9989280104637146
inhibits O O 0.9999862909317017
the O O 0.9999316930770874
activation O O 0.9990261793136597
of O O 0.9999717473983765
the O O 0.9997557997703552
NF-kappa B-protein B-protein 0.7286357283592224
B E-protein E-protein 0.930381715297699
and O O 0.909935712814331
AP-1 S-protein S-protein 0.9087157845497131
transcription O B-protein 0.5522292256355286
factors O E-protein 0.9910964965820312
. O O 0.9995978474617004
PNU156804 O O 0.38466715812683105
inhibition O O 0.9827533960342407
of O O 0.9996964931488037
NF-kappa B-protein B-protein 0.7828181982040405
B E-protein E-protein 0.9943233728408813
activation O O 0.9967213273048401
is O O 0.9999890327453613
due O O 0.9999970197677612
to O O 0.9999947547912598
the O O 0.9999737739562988
inhibition O O 0.9933918118476868
of O O 0.9997792840003967

phagocyte/neutrophil I-cell_type I-protein 0.20156246423721313
series E-cell_type E-protein 0.6354812979698181
. O O 0.9986793398857117
For O O 0.9999641180038452
example O O 0.9907755255699158
dendritic B-cell_type B-cell_type 0.5116736888885498
cells E-cell_type E-cell_type 0.9415230751037598
( O O 0.9805278778076172
DC S-cell_type S-cell_type 0.9363101720809937
) O O 0.9927268028259277
can O O 0.999929666519165
be O O 0.9999842643737793
found O O 0.9999535083770752
in O O 0.9998836517333984
colonies O O 0.8129841089248657
of O O 0.9982927441596985
GM-CSF-responsive B-cell_type B-cell_line 0.4372202754020691
bone I-cell_type I-cell_line 0.5001091361045837
marrow I-cell_type I-cell_line 0.5945100784301758
cells E-cell_type E-cell_line 0.5426071882247925
, O O 0.9945770502090454
and O O 0.9999682903289795
under O O 0.9999644756317139
experimental O O 0.9598458409309387
conditions O O 0.9952638149261475
are O O 0.9999936819076538
routinely O O 0.9989866614341736
expanded O O 0.9997795224189758
as O O 0.9999935626983643
a O O 0.9999557733535767
population O O 0.9626800417900085
in O O 0.9997443556785583

proteins E-protein E-protein 0.911236584186554
have O O 0.9997466206550598
suggested O O 0.9999970197677612
that O O 0.9999988079071045
significant O O 0.9979156851768494
E2A B-protein S-protein 0.8545601963996887
protein E-protein O 0.5644224286079407
expression O O 0.9907388687133789
is O O 0.9999723434448242
restricted O O 0.9996053576469421
to O O 0.9999594688415527
B-lymphocytes S-cell_type S-cell_type 0.9273645877838135
. O O 0.9997938275337219
We O O 0.9999701976776123
have O O 0.9999908208847046
developed O O 0.9999475479125977
a O O 0.9999616146087646
monoclonal B-protein B-protein 0.7810607552528381
antibody E-protein E-protein 0.9052194356918335
, O O 0.9948764443397522
Yae S-protein S-protein 0.9808852076530457
, O O 0.9901573657989502
which O O 0.9999150037765503
is O O 0.999984622001648
specific O O 0.9993826150894165
for O O 0.9999500513076782

not O O 0.9198371767997742

Twenty O O 0.9921108484268188
patients O O 0.9996352195739746
were O O 0.9999977350234985
asked O O 0.9999818801879883
to O O 0.9999804496765137
quantify O O 0.9999582767486572
the O O 0.9997557997703552
severity O O 0.9113945960998535
of O O 0.9929337501525879
pain B-Disease B-Disease 0.9659076929092407
after O O 0.9957269430160522
receiving O O 0.9998847246170044
standard O O 0.9828799366950989
lidocaine B-Chemical B-Chemical 0.9159275889396667
in O O 0.9998583793640137
one O O 0.9999725818634033
femoral O O 0.9225203990936279
area O O 0.9936328530311584
and O O 0.9999958276748657
buffered O O 0.9979442954063416
lidocaine B-Chemical B-Chemical 0.9168427586555481
in O O 0.9996582269668579
the O O 0.9999308586120605
opposite O O 0.9905228018760681
femoral O O 0.9092925786972046
area O O 0.9901956915855408
. O O 0.9999994039535522

3-kinase O O 0.529927134513855
activation O O 0.9646928310394287
. O O 0.9999352693557739
These O O 0.9999953508377075
results O O 0.9998753070831299
indicate O O 0.9999974966049194
that O O 0.9999963045120239
the O O 0.9999120235443115
mechanism O O 0.9990898370742798
by O O 0.9999927282333374
which O O 0.999994158744812
YM268 O O 0.47623422741889954
increased O O 0.9965097308158875
glucose O O 0.8469973802566528
uptake O O 0.9915953278541565
, O O 0.9999804496765137
may O O 0.9999890327453613
be O O 0.9999936819076538
accounted O O 0.9999918937683105
for O O 0.9999880790710449
in O O 0.9999958276748657
part O O 0.9998036026954651
by O O 0.9999957084655762
the O O 0.999975323677063
enhancement O O 0.9900792837142944

based O O 0.9971345663070679
on O O 0.9999926090240479
reports O O 0.9999098777770996
that O O 0.9999977350234985
antioxidants O O 0.898558497428894
which O O 0.9996181726455688
eliminate O O 0.9994753003120422
ROS O O 0.40952450037002563
should O O 0.9994114637374878
block O O 0.9998910427093506
the O O 0.9999206066131592
activation O O 0.9980995059013367
of O O 0.9999411106109619
NF-kappa B-protein B-protein 0.8284426927566528
B E-protein E-protein 0.9909528493881226
and O O 0.9964206218719482
subsequently O O 0.9984993934631348
HIV O O 0.8113759160041809
transcription O O 0.8621616959571838
, O O 0.9989308714866638
and O O 0.9998924732208252
thus O O 0.999863862991333
antioxidants O O 0.696729838848114
can O O 0.9997100234031677
be O O 0.9999849796295166
used O O 0.9999823570251465
as O O 0.999995231628418
therapeutic O O 0.9466254115104675
agents O O 0.969940185546875
for O O 0.9999688863754272
AIDS O O 0.909278392791748
. O O 0.9999896287918091
Incubation O O 0.9876009225845337
of O O 0.9997168183326721
Jurkat B-cell_line B-cell_line 0.7633572220802307
T I-cell_line I-cell_line 0.8778430819511414
cells E-cell_line E-cell_line 0.9830349683761597
( O O 0.998740017414093
1 O O 0.9931199550628662
x O O 0.9944925308227539
10 O O 0.9967363476753235

Fifteen O O 0.9966098666191101
female O O 0.9463338255882263
migraineurs B-Disease O 0.7237454652786255
( I-Disease O 0.9990743398666382
without I-Disease O 0.9989641904830933
aura I-Disease O 0.7136016488075256
) I-Disease O 0.9717867374420166
and O O 0.999790370464325
eight O O 0.9955838322639465
controls O O 0.9951891899108887
participated O O 0.9999091625213623
in O O 0.9999940395355225
the O O 0.9999926090240479
study O O 0.9999321699142456
. O O 0.9999992847442627

Compression B-Disease O 0.548597514629364
neuropathy I-Disease O 0.6756795048713684
of I-Disease O 0.8324870467185974
the I-Disease O 0.967818558216095
radial I-Disease O 0.8815818428993225
nerve I-Disease O 0.5070711970329285
due O O 0.9981014132499695
to O O 0.9998549222946167
pentazocine B-Chemical B-Chemical 0.9343032240867615
- O O 0.9419209957122803
induced O O 0.9994075298309326
fibrous B-Disease B-Disease 0.6644089221954346
myopathy I-Disease I-Disease 0.8743593692779541
. O O 0.9984582662582397

Macrophage O O 0.666061282157898
- O O 0.9211365580558777
migration O O 0.8803863525390625
inhibition O O 0.7918853759765625
( O O 0.9992200136184692
MIF O O 0.6860498189926147
) O O 0.9840753674507141
test O O 0.9973915815353394
with O O 0.9999948740005493
ampicillin S-Chemical B-Chemical 0.9298756122589111
was O O 0.9982784986495972
positive O O 0.9877641797065735
. O O 0.9999963045120239

mapping O O 0.831183671951294
and O O 0.9779541492462158
hybrid B-DNA B-DNA 0.6453412175178528
promoter I-DNA I-DNA 0.637682318687439
constructs E-DNA E-DNA 0.9873024225234985
demonstrate O O 0.9997411370277405
that O O 0.9999991655349731
the O O 0.9999395608901978
newly O O 0.9487372636795044
identified O O 0.986338198184967
Tat-responsive B-DNA B-DNA 0.49325984716415405
element E-DNA E-DNA 0.9928411245346069
corresponds O O 0.9988191723823547
to O O 0.999988317489624
a O O 0.999526858329773
sequence O O 0.9406445622444153
within O O 0.9999039173126221
the O O 0.9999619722366333
viral B-DNA B-DNA 0.4576178193092346
long I-DNA I-DNA 0.772226870059967
terminal I-DNA I-DNA 0.9230448007583618
repeat E-DNA E-DNA 0.991196870803833
( O O 0.9833701848983765
LTR S-DNA S-DNA 0.999369204044342
) O O 0.9759842157363892
previously O O 0.9990609288215637
identified O O 0.9999784231185913
as O O 0.9999969005584717
the O O 0.999910831451416
HIV-1 B-DNA B-DNA 0.5611311197280884
enhancer E-DNA E-DNA 0.8993477821350098

This O O 0.9995496869087219
shunt O O 0.9816972613334656
of O O 0.9986138343811035
blood O O 0.5921214818954468
via O O 0.9951590895652771
a O O 0.9995513558387756
patent B-Disease O 0.981296718120575
foramen I-Disease O 0.8964374661445618
ovale I-Disease O 0.6660062074661255
occurred O O 0.9992836117744446
in O O 0.999976634979248
the O O 0.9998942613601685
presence O O 0.9967468976974487
of O O 0.999886155128479
a O O 0.9995179176330566
normal O O 0.9531697630882263
pulmonary O O 0.8274388313293457
artery O O 0.5331038236618042
pressure O O 0.7069577574729919
, O O 0.9975124597549438
and O O 0.9997867941856384
was O O 0.9995678067207336
probably O O 0.9998401403427124
precipitated O O 0.998365581035614
by O O 0.9999730587005615
a O O 0.9993522763252258
propafenone B-Chemical B-Chemical 0.9052416086196899
overdose B-Disease B-Disease 0.9382559657096863
. O O 0.9994423985481262

lymphocytic B-protein I-protein 0.6083868741989136
aldosterone I-protein I-protein 0.49416542053222656
receptors E-protein E-protein 0.9887750148773193
. O O 0.9998342990875244
Results O O 0.9998922348022461
in O O 0.9999849796295166
two O O 0.9996927976608276
affected O O 0.942050039768219
infants O O 0.9383577704429626
. O O 0.9999723434448242
We O O 0.9999855756759644
report O O 0.9999963045120239
two O O 0.9999700784683228
patients O O 0.9998339414596558
with O O 0.9999912977218628
transient O O 0.9255309700965881
pseudohypoaldosteronism O O 0.9319563508033752
due O O 0.9999802112579346
to O O 0.9999785423278809
obstructive O O 0.9593834280967712
renal O O 0.9375976324081421
disease O O 0.7490255832672119
. O O 0.99998939037323
Both O O 0.9999886751174927
patients O O 0.9996285438537598
presented O O 0.9999908208847046
with O O 0.9999902248382568
a O O 0.9997947812080383
salt-losing O O 0.582836925983429
episode O O 0.5175577998161316

second O O 0.9810907244682312
week O O 0.9997757077217102
of O O 0.9999412298202515
treatment O O 0.9994792342185974
and O O 0.9999908208847046
at O O 0.9999924898147583
the O O 0.9999876022338867
end O O 0.9997934699058533
of O O 0.9999945163726807
the O O 0.9999910593032837
6-week O O 0.953781008720398
washout O O 0.5607650876045227
period O O 0.9982333183288574
with O O 0.9999988079071045
no O O 0.9998965263366699
statistically O O 0.9855791330337524
significant O O 0.998960018157959
change O O 0.9970545768737793
in O O 0.9998557567596436
cortisol O B-Chemical 0.8661290407180786
response O O 0.9551357626914978
. O O 0.9999864101409912

on O O 0.9964697360992432
activation O O 0.997097373008728
of O O 0.9999524354934692
a O O 0.9998236298561096
phorbol B-protein B-protein 0.6226162314414978
ester-responsive I-protein I-protein 0.46524086594581604
protein I-protein I-protein 0.4876788556575775
kinase I-protein I-protein 0.48113787174224854
C E-protein E-protein 0.9790031313896179
or O O 0.9932063817977905
elevation O O 0.9804689288139343
of O O 0.9995883107185364
cytosolic O O 0.8382545709609985
calcium O O 0.8910526037216187
. O O 0.9999039173126221
Furthermore O O 0.9999771118164062
, O O 0.9998841285705566
CD28 S-protein S-protein 0.9831059575080872
-dependent O O 0.9948220252990723

Patients O O 0.9947237968444824
with O O 0.9999675750732422
large O O 0.9453620910644531
pelvic B-Disease O 0.5151799917221069
tumor I-Disease O 0.582619309425354
loads O O 0.7801036834716797
are O O 0.9993712306022644
, O O 0.9999707937240601
according O O 0.9999980926513672
to O O 0.9999872446060181
existing O O 0.9970340728759766
classifications O O 0.9987037181854248
, O O 0.999993085861206
at O O 0.999983549118042
high O O 0.9898202419281006
risk O O 0.9968975782394409
to O O 0.9999703168869019
die O O 0.9739388227462769
and O O 0.9998154044151306
to O O 0.9998801946640015
develop O O 0.9992929697036743
drug O O 0.7298747897148132
resistance O O 0.9188427329063416
. O O 0.9994295239448547

in O O 0.9948347806930542
T B-cell_type B-cell_type 0.8711032271385193
cells E-cell_type E-cell_type 0.9928076267242432
. O O 0.9994876384735107
Accumulating O O 0.9991905093193054
data O O 0.998759388923645
from O O 0.9999970197677612
a O O 0.9999746084213257
number O O 0.9994090795516968
of O O 0.9999730587005615
laboratories O O 0.9571828842163086
have O O 0.9999579191207886
recently O O 0.999975323677063
indicated O O 0.9999957084655762
that O O 0.9999958276748657
the O O 0.9999169111251831
response O O 0.9975641965866089
of O O 0.9998806715011597
transcription B-protein B-protein 0.469370573759079
factor E-protein E-protein 0.910079836845398
NF-kappaB S-protein S-protein 0.6318094730377197
to O O 0.9990980625152588
alterations O O 0.9844041466712952
in O O 0.9999351501464844
the O O 0.9997031092643738

AP-1 S-protein S-protein 0.636927604675293

markedly O O 0.9940102100372314
increased O O 0.9976850748062134
IL-2 S-protein S-protein 0.9838932752609253
production O O 0.9980559349060059
in O O 0.9999635219573975
both O O 0.9995267391204834
cell O O 0.93939208984375
types O O 0.7088683247566223
, O O 0.9998534917831421
but O O 0.999896764755249
levels O O 0.9998003840446472
of O O 0.9999703168869019
IL-2 S-protein S-protein 0.9803826808929443
in O O 0.9995759129524231
neonatal B-cell_type B-cell_type 0.6791805624961853
T I-cell_type I-cell_type 0.8774852156639099
cells E-cell_type E-cell_type 0.9747418761253357
remained O O 0.9989547729492188
clearly O O 0.9998044371604919
lower O O 0.9999104738235474
than O O 0.9999755620956421
those O O 0.9999661445617676
of O O 0.9999558925628662
adult B-cell_type B-cell_type 0.575079083442688
T I-cell_type I-cell_type 0.6580162048339844
cells E-cell_type E-cell_type 0.9697644710540771
( O O 0.99699866771698
respective O O 0.9986388087272644
mean O O 0.9986385703086853
values O O 0.9978631138801575
: O O 0.9999909400939941
385 O O 0.996095597743988
+/- O O 0.9998956918716431

A O O 0.9983758926391602
Phase O O 0.9965435862541199
II O O 0.955208957195282
trial O O 0.9952906370162964
of O O 0.999737560749054
cisplatin B-Chemical B-Chemical 0.9334779381752014
plus O O 0.789229691028595
WR B-Chemical B-Chemical 0.9443446397781372
- I-Chemical I-Chemical 0.9912142753601074
2721 I-Chemical E-Chemical 0.9121699929237366
( O O 0.9504406452178955
amifostine B-Chemical B-Chemical 0.92781662940979
) O O 0.7640045285224915
for O O 0.9998502731323242
metastatic O O 0.8134476542472839
breast B-Disease O 0.6922363638877869
carcinoma I-Disease O 0.9168555736541748
: O O 0.9853155612945557
an O O 0.9999353885650635
Eastern O O 0.9777975082397461
Cooperative O O 0.9456592202186584
Oncology O O 0.7750800251960754
Group O O 0.9702969193458557
Study O O 0.9986003041267395
( O O 0.9999580383300781
E8188 O O 0.883945107460022
) O O 0.999284565448761
. O O 0.999994158744812

agent O O 0.7868162393569946
. O O 0.9999552965164185
The O O 0.9999970197677612
present O O 0.9969432950019836
study O O 0.9999629259109497
examined O O 0.9999935626983643
the O O 0.9999899864196777
effect O O 0.9999760389328003
of O O 0.9999903440475464
ADT O O 0.5610775947570801
pretreatment O O 0.9967340230941772
on O O 0.9999724626541138
NF-kappa B-protein B-protein 0.6110672950744629
B E-protein E-protein 0.9906486868858337
activation O O 0.9959819316864014
in O O 0.9999494552612305
response O O 0.9276330471038818
to O O 0.9938919544219971

to O O 0.9420586228370667
6 O O 0.8607698678970337
) O O 0.9820209741592407
of O O 0.9999719858169556
the O O 0.9999804496765137
membrane-bound B-protein B-protein 0.6010907888412476
enzyme E-protein E-protein 0.8560281991958618
followed O O 0.9997816681861877
by O O 0.9999977350234985
a O O 0.9999667406082153
later O O 0.9681578874588013
activation O O 0.9702082872390747
( O O 0.9990195035934448
hour O O 0.9785269498825073
48 O O 0.9321768283843994
) O O 0.9926488995552063
of O O 0.9999310970306396
the O O 0.999950647354126
total O O 0.8319219350814819
, O O 0.9382435083389282
membrane-bound B-protein O 0.525000810623169
and I-protein O 0.9438091516494751
cytosolic I-protein O 0.7433934807777405
enzyme E-protein O 0.7075363993644714
. O O 0.9990198612213135
By O O 0.9903035759925842

also O O 0.9754917025566101
induces O O 0.9997979998588562
an O O 0.999931812286377
array O O 0.9957258701324463
of O O 0.999927282333374
cellular B-DNA B-DNA 0.670120358467102
genes E-DNA E-DNA 0.9548338651657104
. O O 0.9996095299720764
Tax S-protein S-protein 0.9984982013702393
-mediated O O 0.9961177110671997
transformation O O 0.9986068606376648
of O O 0.9999122619628906
T B-cell_type B-cell_type 0.8999233841896057
cells E-cell_type E-cell_type 0.9870922565460205
likely O O 0.9986555576324463
involves O O 0.9999977350234985
the O O 0.99998939037323
deregulated O O 0.9309643507003784
expression O O 0.9934359788894653
of O O 0.9999488592147827
various O O 0.974177360534668
cellular B-DNA B-DNA 0.5919521450996399
genes E-DNA E-DNA 0.9148364067077637
that O O 0.998080849647522
normally O O 0.9999226331710815
regulate O O 0.9995089769363403
lymphocyte S-cell_type O 0.45244577527046204
growth O O 0.6824778318405151
produced O O 0.9798629879951477

promoter I-DNA I-DNA 0.6626741886138916
serum I-DNA I-DNA 0.851230263710022
response I-DNA I-DNA 0.6611358523368835
element E-DNA E-DNA 0.9578799605369568
, O O 0.9944682121276855
together O O 0.9999829530715942
with O O 0.9999910593032837
differences O O 0.9947210550308228
in O O 0.9999027252197266
the O O 0.9998528957366943
spacing O O 0.9584888219833374
between O O 0.9987573623657227
the O O 0.9997856020927429
SRF B-DNA B-DNA 0.35838860273361206
and I-DNA I-DNA 0.47846585512161255
ETS I-DNA I-DNA 0.7687219977378845
motifs E-DNA E-DNA 0.9790654182434082
, O O 0.9986360669136047
appear O O 0.9999837875366211
to O O 0.9999938011169434
account O O 0.9999983310699463
for O O 0.9999969005584717
the O O 0.9999891519546509
inability O O 0.9996750354766846
of O O 0.9999839067459106
the O O 0.9999594688415527
SCMV B-DNA B-DNA 0.4356270432472229
SNEs E-DNA E-DNA 0.5182898044586182
to O O 0.9936261177062988
respond O O 0.9999674558639526
to O O 0.9999817609786987
serum O O 0.9508156180381775
induction O O 0.9948327541351318
. O O 0.9999812841415405
T-cell S-cell_type O 0.3081125319004059
-directed O O 0.8624281883239746

A O O 0.999411940574646
search O O 0.9995262622833252
of O O 0.9999725818634033
the O O 0.9999574422836304
literature O O 0.9746119379997253
on O O 0.9999443292617798
the O O 0.9998314380645752
thromboembolic B-Disease O 0.7357173562049866
complications O O 0.816410481929779
of O O 0.9479722380638123
CC B-Chemical B-Chemical 0.9227893352508545
does O O 0.9985414743423462
not O O 0.999936580657959
include O O 0.9999922513961792
this O O 0.9997531771659851
severe O O 0.9867114424705505
ophthalmic O O 0.6564481258392334
complication O O 0.937886118888855
, O O 0.9911003708839417
although O O 0.9999179840087891
mild O O 0.986093282699585
visual B-Disease O 0.8097109794616699
disturbance I-Disease O 0.892029881477356
after O O 0.9873380661010742
CC B-Chemical B-Chemical 0.925400972366333
intake O O 0.8879519104957581
is O O 0.9999774694442749
not O O 0.9999343156814575
uncommon O O 0.9991808533668518
. O O 0.9999982118606567

indeed O O 0.9900659322738647
function O O 0.9996193647384644
as O O 0.9999977350234985
a O O 0.999970555305481
transcriptional O B-protein 0.7710368037223816
activator O E-protein 0.892198383808136
in O O 0.9988172650337219
S49 B-cell_line B-cell_line 0.8543967008590698
cells E-cell_line E-cell_line 0.9921940565109253
and O O 0.9989461302757263
, O O 0.9999725818634033
moreover O O 0.9995232820510864
, O O 0.9999617338180542
that O O 0.9999921321868896
GIG18 S-DNA S-protein 0.5605221390724182
induction O O 0.9965192079544067
may O O 0.9999960660934448
be O O 0.9999985694885254
a O O 0.9999897480010986
marker O O 0.9956182241439819
of O O 0.9999350309371948
early O O 0.9209854602813721
apoptotic O O 0.8750952482223511
events O O 0.9838191866874695
in O O 0.9999594688415527
steroid-treated O B-cell_type 0.38937175273895264
cells O E-cell_type 0.5989685654640198
. O O 0.9997991919517517
Taken O O 0.9999516010284424
together O O 0.9999032020568848

PMA O O 0.7080279588699341
and O O 0.9976939558982849
okadaic O O 0.8938712477684021
acid O O 0.8984636068344116
in O O 0.9994149208068848
inducing O O 0.9956921935081482
c-jun S-DNA S-DNA 0.957631528377533
transcription O O 0.9617951512336731
. O O 0.9999768733978271
The O O 0.9999933242797852
induction O O 0.9978006482124329
of O O 0.9999141693115234
AP1 S-protein S-protein 0.9039031267166138
by O O 0.9997145533561707
okadaic O O 0.9136418104171753
acid O O 0.9298295378684998
suggests O O 0.9999046325683594
that O O 0.9999983310699463
protein B-protein B-protein 0.7843437194824219
phosphatases I-protein I-protein 0.3319648504257202
1 I-protein I-protein 0.8716520071029663
and I-protein I-protein 0.8419482111930847
2A E-protein E-protein 0.8442943692207336
( O O 0.9705542325973511
PP1 S-protein S-protein 0.9281710982322693
and O O 0.9889260530471802
PP2A S-protein S-protein 0.8961424231529236
) O O 0.9929459691047668
may O O 0.9999921321868896
be O O 0.9999948740005493
involved O O 0.9999548196792603
in O O 0.9999321699142456
T O O 0.6860567331314087
cell O O 0.4850728213787079
activation O O 0.9904987215995789
as O O 0.9999843835830688
important O O 0.9934518337249756
negative O O 0.8530329465866089

METHODS O O 0.9856935739517212
: O O 0.999954342842102
Patients O O 0.9993953704833984
with O O 0.9999877214431763
a O O 0.9997543692588806
clinical O O 0.9662569761276245
diagnosis O O 0.9469547271728516
of O O 0.999660849571228
ischemic B-Disease B-Disease 0.5593591928482056
stroke I-Disease I-Disease 0.9094675779342651
( O O 0.9701971411705017
within O O 0.9992959499359131
24 O O 0.999809205532074
hours O O 0.9998626708984375
) O O 0.9999767541885376
were O O 0.9999973773956299
consecutively O O 0.9998478889465332
allocated O O 0.9999923706054688
to O O 0.9999935626983643
receive O O 0.9999349117279053
placebo O O 0.9045504331588745
( O O 0.9994804263114929
n O O 0.9810441136360168
= O O 0.9995092153549194
100 O O 0.9966250658035278
) O O 0.9998086094856262
, O O 0.9999938011169434
1 O O 0.9996494054794312
mg O O 0.9997543692588806
/ O O 0.9999796152114868
h O O 0.999257504940033
( O O 0.9999604225158691
low O O 0.9994250535964966
- O O 0.9992665648460388
dose O O 0.9978255033493042
) O O 0.9984831213951111
nimodipine B-Chemical B-Chemical 0.9420120716094971
( O O 0.991295337677002
n O O 0.8022274971008301
= O O 0.9917621612548828
101 O O 0.9389134645462036
) O O 0.9983874559402466
, O O 0.9999867677688599
or O O 0.9999582767486572
2 O O 0.999663233757019
mg O O 0.9997005462646484
/ O O 0.9999806880950928
h O O 0.9985062479972839
( O O 0.9999649524688721
high O O 0.9987755417823792
- O O 0.9991661310195923
dose O O 0.9980316758155823
) O O 0.9986675977706909
nimodipine B-Chemical B-Chemical 0.939231812953949
( O O 0.9937354922294617
n O O 0.8344346284866333
= O O 0.9948019981384277
94 O O 0.979550838470459
) O O 0.9995900988578796
. O O 0.9999974966049194

members E-protein O 0.46636998653411865

an O O 0.9976366758346558
october B-protein B-DNA 0.4654099643230438
sequence E-protein E-DNA 0.9907196760177612
( O O 0.9938437938690186
Oct-1 S-protein S-DNA 0.9048128128051758
) O O 0.9769655466079712
. O O 0.9999865293502808
This O O 0.999923586845398
Oct-1 S-protein S-protein 0.9223207831382751
-binding O O 0.9625389575958252
phenotype O O 0.9349498748779297
remained O O 0.9999396800994873
stable O O 0.9992296695709229
in O O 0.9999788999557495
culture O O 0.944157063961029
for O O 0.9999545812606812
up O O 0.9997612833976746
to O O 0.999859094619751
3 O O 0.9985394477844238
days O O 0.9998441934585571

Tumor B-protein B-protein 0.5168787240982056
necrosis I-protein I-protein 0.756138265132904
factor E-protein E-protein 0.9225131869316101
( O O 0.9394059777259827
TNF S-protein S-protein 0.8786128759384155
) O O 0.9019309282302856
mediates O O 0.997119665145874
a O O 0.9998886585235596
wide O O 0.9859539866447449
variety O O 0.995907187461853
of O O 0.9999709129333496
disease O O 0.9005303978919983
states O O 0.9828795790672302
including O O 0.9999911785125732
septic O O 0.8542300462722778
shock O O 0.7470792531967163
, O O 0.9983460903167725
acute O O 0.92878258228302
and O O 0.9917536973953247
chronic O O 0.9787712693214417
inflammation O O 0.9395023584365845
, O O 0.9999295473098755
and O O 0.9998670816421509
cachexia O O 0.8065369129180908

, O O 0.9218838214874268
Ci-I S-cell_line B-cell_line 0.5438681244850159
, O I-cell_line 0.7430214881896973
Sc-I S-cell_line I-cell_line 0.4348282814025879
, O I-cell_line 0.7648138403892517
and O I-cell_line 0.5071868896484375
Raji B-cell_line I-cell_line 0.7588796615600586
cells E-cell_line E-cell_line 0.9964219331741333
induced O O 0.9998428821563721
by O O 0.9999860525131226
mAb B-protein B-protein 0.500092625617981
L243 E-protein E-protein 0.8504155874252319
, O O 0.9725399017333984
and O O 0.9994603991508484
it O O 0.9998884201049805

mice O O 0.9068770408630371
, O O 0.9996852874755859
as O O 0.9999822378158569
compared O O 0.99981290102005
with O O 0.9999639987945557
controls O O 0.9769358038902283
, O O 0.9998394250869751
more O O 0.9958323836326599
rapidly O O 0.8739119172096252
depressed O O 0.8686829209327698
peripheral O B-cell_type 0.6816151142120361
white O I-cell_type 0.6645176410675049
blood O I-cell_type 0.5376924872398376
cell O E-cell_type 0.8907111287117004
and O O 0.9559968113899231
granulocyte O O 0.49315935373306274
counts O O 0.6922533512115479
. O O 0.9999760389328003
As O O 0.9995959401130676
expected O O 0.9988908171653748
, O O 0.9999778270721436
nearly O O 0.9984785914421082
all O O 0.9995765089988708
control O O 0.9606685638427734
mice O O 0.9743427634239197
( O O 0.9998396635055542
94.4 O O 0.9910336136817932
% O O 0.9984638690948486
) O O 0.9995173215866089

No O O 0.9962475895881653
differences O O 0.9942710399627686
were O O 0.9999732971191406
observed O O 0.9998799562454224
with O O 0.9999915361404419
respect O O 0.9998242259025574
to O O 0.9999908208847046
side O O 0.950307309627533
effects O O 0.9843724966049194
and O O 0.9999120235443115
general O O 0.9454469680786133
tolerability O O 0.599411129951477
. O O 0.9999790191650391

HTLV-1-transformed O B-cell_line 0.6871081590652466
cell O I-cell_line 0.8589680194854736
line O E-cell_line 0.99116450548172
and O O 0.9932212829589844
then O O 0.9990447163581848
stimulated O O 0.997788667678833
its O O 0.9998476505279541
proliferation O O 0.9968794584274292
. O O 0.9999957084655762
In O O 0.9999785423278809
contrast O O 0.9997050166130066
, O O 0.9999712705612183
IL-2 S-protein S-protein 0.9873642325401306
did O O 0.9996306896209717
neither O O 0.9999773502349854
in O O 0.9999266862869263
a O O 0.9992555975914001
cell O B-cell_line 0.6944318413734436
line O E-cell_line 0.6731806993484497

Veno B-Disease O 0.4759877920150757
- I-Disease O 0.815574586391449
occlusive I-Disease O 0.9102051258087158
liver I-Disease O 0.6154248714447021
disease I-Disease O 0.9617143273353577
after O O 0.9854958653450012
dacarbazine B-Chemical B-Chemical 0.9249959588050842
therapy O O 0.9073293209075928
( O O 0.9999635219573975
DTIC B-Chemical O 0.7115054726600647
) O O 0.9646899104118347
for O O 0.9997729659080505
melanoma B-Disease B-Disease 0.9662128686904907
. O O 0.9988546371459961

blood O O 0.694166898727417
. O O 0.9990829229354858
GR6 S-DNA S-DNA 0.7126532793045044
is O O 0.996759831905365
activated O O 0.9970701932907104
in O O 0.9999481439590454
the O O 0.999778687953949
UCSD-AML1 B-cell_line B-cell_line 0.7187899947166443
cell I-cell_line I-cell_line 0.860438346862793
line E-cell_line E-cell_line 0.9774428606033325
and O O 0.9949122071266174
in O O 0.9986043572425842

the O O 0.9919141530990601
B B-protein B-protein 0.39133548736572266
subunit E-protein E-protein 0.951162576675415
. O O 0.9986667633056641
Furthermore O O 0.9999759197235107
, O O 0.9999923706054688
the O O 0.9999901056289673
sharply O O 0.9801886081695557
reduced O O 0.9933909177780151
NF-AT S-protein S-protein 0.9870928525924683
activity O O 0.9970184564590454
produced O O 0.9999773502349854
by O O 0.9999856948852539
co-transfecting B-DNA O 0.9373220801353455
BKO E-DNA S-protein 0.5184009075164795

signal O O 0.899562656879425
integration O O 0.9947720170021057
during O O 0.9999713897705078
costimulation O O 0.9867160320281982
of O O 0.9997480511665344
T B-cell_type B-cell_type 0.7618373036384583
lymphocytes E-cell_type E-cell_type 0.9962816834449768
. O O 0.9996219873428345
T B-cell_type B-cell_type 0.6196760535240173
lymphocyte E-cell_type E-cell_type 0.8841562867164612
activation O O 0.9567906260490417
and O O 0.998335063457489
interleukin-2 S-protein S-protein 0.9017034769058228
( O O 0.9287899732589722
IL-2 S-protein S-protein 0.9755138158798218
) O O 0.9677032232284546

human I-protein B-protein 0.4797578454017639
p65 I-protein I-protein 0.670304000377655
NF-kappa I-protein I-protein 0.4347181022167206
B I-protein I-protein 0.8888534903526306
subunit E-protein E-protein 0.8426098227500916
and O O 0.9919286966323853
binding O O 0.9334818720817566
was O O 0.9994183778762817
inhibited O O 0.9998725652694702
by O O 0.9999920129776001
I B-protein B-protein 0.6202554106712341
kappa I-protein I-protein 0.8971463441848755
B-alpha E-protein E-protein 0.9689224362373352
and O O 0.9684765934944153
-beta O B-protein 0.43567025661468506
proteins O E-protein 0.9750651121139526
. O O 0.9995275735855103
In O O 0.9999648332595825
addition O O 0.9992815852165222
, O O 0.9999849796295166
the O O 0.9999479055404663
65-kD B-protein B-protein 0.4280736744403839
protein E-protein E-protein 0.9769749641418457
associated O O 0.9980483055114746
with O O 0.99998939037323
the O O 0.999816358089447
p50 B-protein B-protein 0.6526470184326172
subunit E-protein E-protein 0.9552884101867676
of O O 0.9942734837532043
NF-kappa B-protein B-protein 0.8034403920173645
B E-protein E-protein 0.9850220084190369
and O O 0.9964674711227417
the O O 0.9997228980064392
kappa B-DNA B-DNA 0.5065292119979858
B I-DNA I-DNA 0.5524228811264038
probe E-DNA E-DNA 0.8795182108879089
to O O 0.9912522435188293
form O O 0.9930404424667358
a O O 0.9990426898002625

induced O O 0.9866465330123901
by O O 0.9998263716697693
IL-4 S-protein S-protein 0.9941951632499695
were O O 0.9997209906578064
not O O 0.9997733235359192
affected O O 0.9996215105056763
in O O 0.9999653100967407
p47phox-deficient O O 0.42840203642845154
patients O O 0.8138821721076965
, O O 0.999847412109375
which O O 0.99998939037323
raises O O 0.9999849796295166
the O O 0.9999527931213379
possibility O O 0.9999489784240723
that O O 0.9999954700469971
p47phox O S-protein 0.6309421062469482
may O O 0.9987302422523499
be O O 0.9999947547912598
important O O 0.9998918771743774
in O O 0.9999845027923584
other O O 0.9997829794883728
signaling O O 0.9454957842826843
activities O O 0.9982584118843079
as O O 0.9999966621398926
well O O 0.9977846741676331

either O O 0.9992374181747437
endogenous B-protein O 0.8431059122085571
TNF-alpha E-protein S-protein 0.6097047328948975
or O O 0.9924386143684387
IL-10 S-protein S-protein 0.9856148958206177
was O O 0.9995521903038025
not O O 0.9999254941940308
involved O O 0.9999772310256958
in O O 0.9999946355819702
the O O 0.9999831914901733
cooperativity O O 0.9952687621116638
, O O 0.9999690055847168

transcription O O 0.7784171104431152
and O O 0.9961826205253601
their O O 0.9999408721923828
interactions O O 0.9986987113952637
with O O 0.9999746084213257
PKC S-protein S-protein 0.995810866355896
-dependent O O 0.9949256181716919
signaling O O 0.9745713472366333
systems O O 0.9779154062271118
. O O 0.9999833106994629
gamma B-protein B-protein 0.4195108711719513
B*CaM-K E-protein E-protein 0.9282121658325195
and O O 0.972783625125885
delta B-protein B-protein 0.3525169789791107
CaM-AI E-protein E-protein 0.8522186279296875
, O O 0.9425931572914124

: O O 0.9278370141983032
2430 O O 0.8759499192237854
] O O 0.9774295091629028
OCA-B S-protein S-protein 0.7285528182983398
is O O 0.9999055862426758
a O O 0.9999812841415405
B-cell-specific B-protein B-protein 0.423147588968277
coregulator E-protein E-protein 0.8192241787910461
of O O 0.9702183604240417
the O O 0.9995070695877075
broadly O O 0.8773355484008789
expressed O O 0.9564005136489868
POU B-protein B-protein 0.3651731312274933
domain I-protein I-protein 0.6564375162124634
transcription I-protein I-protein 0.7896248698234558
factor E-protein E-protein 0.9586278200149536
Oct-1 S-protein S-protein 0.8278858661651611
. O O 0.9997925162315369
OCA-B S-protein S-protein 0.9444518089294434
associates O O 0.8095808029174805
with O O 0.9999580383300781
the O O 0.9999504089355469
Oct-1 B-protein B-protein 0.39401695132255554
POU I-protein I-protein 0.7189171314239502
domain E-protein E-protein 0.9347889423370361
, O O 0.9979910850524902
a O O 0.9999315738677979
bipartite O B-protein 0.7124199271202087
DNA-binding O I-protein 0.5650670528411865
structure O E-protein 0.7470765709877014
containing O O 0.9962937235832214
a O O 0.999800980091095
POU-specific B-protein B-protein 0.31512340903282166
( I-protein I-protein 0.42106893658638
POU I-protein I-protein 0.5797102451324463
[ I-protein I-protein 0.6324387192726135
S I-protein I-protein 0.7713052034378052
] I-protein I-protein 0.7122662663459778

might O O 0.998184859752655
constitute O O 0.9999973773956299
one O O 0.9999767541885376
of O O 0.9999939203262329
the O O 0.9999890327453613
mechanisms O O 0.999055802822113
underlying O O 0.9999839067459106
the O O 0.9999853372573853
inducible O O 0.9716519117355347
expression O O 0.9965601563453674
of O O 0.9999406337738037
kappa B-DNA B-DNA 0.5363277196884155
B-dependent I-DNA I-DNA 0.7568978667259216
genes E-DNA E-DNA 0.9918779134750366
in O O 0.9993380904197693
microglia S-cell_type S-cell_type 0.7053592801094055
stimulated O O 0.9005184173583984
by O O 0.9996970891952515
A O O 0.9303645491600037
beta O O 0.44613927602767944

Crossover O O 0.8451315760612488
studies O O 0.9949483871459961
were O O 0.9999973773956299
performed O O 0.9999923706054688
2 O O 0.9989380240440369
weeks O O 0.9999728202819824
apart O O 0.9998435974121094
. O O 0.9999994039535522

subunits O E-protein 0.7841435670852661
during O O 0.9996652603149414
differentiation O O 0.9960325360298157
of O O 0.9999393224716187
both O O 0.9994383454322815
native B-cell_type B-cell_type 0.5108070969581604
monocytes E-cell_type E-cell_type 0.8343930244445801
and O O 0.9973828196525574
the O O 0.9988947510719299
cell B-cell_line B-cell_line 0.7531429529190063
line E-cell_line I-cell_line 0.35895633697509766
THP-1 S-cell_line E-cell_line 0.6704849600791931
, O O 0.9436289072036743
and O O 0.9997197985649109
found O O 0.9996914863586426
that O O 0.9998464584350586
transcriptional O O 0.49577099084854126
and O O 0.7780595421791077

for O O 0.9938720464706421

also O O 0.9846569895744324
impaired O O 0.9992576241493225
by O O 0.9999921321868896
expression O O 0.9980857372283936
of O O 0.999937891960144
the O O 0.9997308850288391
Itk B-protein B-protein 0.47453388571739197
mutant E-protein E-protein 0.9224798083305359
. O O 0.9979082345962524
These O O 0.9999970197677612
results O O 0.9999432563781738
demonstrate O O 0.9999969005584717
that O O 0.9999878406524658
Itk S-protein S-protein 0.9932934045791626
plays O O 0.9979044198989868

( O O 0.9640381932258606
C/EBP B-DNA O 0.40488892793655396
epsilon E-DNA O 0.44976893067359924
) O O 0.6860145330429077
. O O 0.9997755885124207
Human O B-protein 0.7872329354286194
C/EBP B-DNA I-protein 0.23641613125801086
epsilon E-DNA E-protein 0.730712354183197
is O O 0.999529242515564
a O O 0.9999901056289673
newly O O 0.9429726004600525
cloned O O 0.9229062795639038
gene O O 0.7227668166160583
coding O O 0.958650529384613
for O O 0.999687910079956
a O O 0.9997934699058533
CCAAT/enhancer B-protein B-DNA 0.313182532787323

Minimal O O 0.6531020998954773
cholestasis O B-Disease 0.5723594427108765
was O O 0.9776195287704468
seen O O 0.9998921155929565
in O O 0.9999924898147583
two O O 0.9998736381530762
cases O O 0.9989286065101624
and O O 0.9999790191650391
portal O O 0.7454509735107422
fibrosis O O 0.6768004894256592
of O O 0.8053021430969238
a O O 0.9842027425765991
reversible O O 0.9628981351852417
degree O O 0.973081648349762
in O O 0.999901533126831
eight O O 0.9985623955726624
. O O 0.9999880790710449

Postural O O 0.5904099345207214
tremor B-Disease O 0.7148138880729675
showed O O 0.9928401708602905
no O O 0.9996309280395508
significant O O 0.9993442893028259
difference O O 0.9941767454147339
between O O 0.9999239444732666
the O O 0.9999444484710693
first O O 0.9993764758110046
and O O 0.9998493194580078
third O O 0.9996641874313354
session O O 0.9998644590377808
( O O 0.999995231628418
P O O 0.9994290471076965
= O O 0.9999781847000122
0 O O 0.9998816251754761
. O O 0.999942421913147
07 O O 0.9981868863105774
) O O 0.9994877576828003
. O O 0.9999966621398926

Finally O O 0.9952319264411926
, O O 0.9999582767486572
15 O O 0.9991251826286316
patients O O 0.9997827410697937
were O O 0.9999967813491821
excluded O O 0.9998795986175537
from O O 0.9999897480010986
the O O 0.9998908042907715
study O O 0.9994444251060486
( O O 0.9999885559082031
noncompliance O O 0.8272578716278076
14 O O 0.9339715242385864
, O O 0.9995735287666321
death O O 0.9275733828544617
1 O O 0.6653451919555664
) O O 0.9037424325942993
; O O 0.9990828037261963
thus O O 0.9997910857200623
, O O 0.9999523162841797
60 O O 0.9979554414749146
patients O O 0.9994519352912903
( O O 0.9999887943267822
31 O O 0.9994316697120667
in O O 0.999957799911499
group O O 0.9963082671165466
I O O 0.9851500391960144
and O O 0.9999165534973145
29 O O 0.9990919828414917
in O O 0.9999523162841797
group O O 0.9882269501686096
II O O 0.7373398542404175
) O O 0.9986520409584045
were O O 0.999995231628418
eligible O O 0.9999401569366455
for O O 0.9999933242797852
analysis O O 0.998376727104187
. O O 0.9999992847442627

Their O O 0.9986851811408997
use O O 0.9998358488082886
in O O 0.9999717473983765
orthotopic O O 0.7979276180267334
liver O O 0.7983258366584778
transplantation O O 0.6035686135292053
( O O 0.9996708631515503
OLTX O O 0.5426769256591797
) O O 0.9930805563926697
has O O 0.9998944997787476
dramatically O O 0.9976434111595154
improved O O 0.9917471408843994
success O O 0.9873777031898499
rates O O 0.9995488524436951
. O O 0.9999994039535522

Allopurinol S-Chemical B-Chemical 0.9189952611923218
decreased O O 0.8900418281555176
serum O O 0.9245092868804932
urate S-Chemical B-Chemical 0.9312541484832764
from O O 0.9924754500389099
76 O O 0.9990788698196411
+ O O 0.9999778270721436
/ O O 0.9999979734420776
- O O 0.9999793767929077
5 O O 0.9999630451202393
to O O 0.9999827146530151
30 O O 0.999911904335022
+ O O 0.9999833106994629
/ O O 0.9999967813491821
- O O 0.9999532699584961
3 O O 0.9998629093170166
micromol O O 0.8848122954368591
/ O O 0.9989890456199646
L O O 0.9335460662841797
( O O 0.9998608827590942
P O O 0.9933383464813232
< O O 0.9997873902320862
0 O O 0.9996827840805054
. O O 0.9997264742851257
001 O O 0.9746788740158081
) O O 0.9981607794761658
in O O 0.9999814033508301
saline O O 0.6813750863075256
and O O 0.9987467527389526
from O O 0.9999762773513794
84 O O 0.9973387122154236
+ O O 0.9999492168426514
/ O O 0.9999963045120239
- O O 0.9999526739120483
13 O O 0.9998120665550232
to O O 0.9999778270721436
28 O O 0.9997667670249939
+ O O 0.9999599456787109
/ O O 0.9999945163726807
- O O 0.9999054670333862
2 O O 0.9996576309204102
micromol O O 0.743870198726654
/ O O 0.9962252378463745
L O O 0.8365103006362915
in O O 0.997588038444519
dex S-Chemical B-Chemical 0.9344444870948792
- O O 0.9187507629394531
treated O O 0.9971619844436646
( O O 0.9999611377716064
P O O 0.9700381755828857
< O O 0.9984821677207947
0 O O 0.9995222091674805
. O O 0.9996042847633362
01 O O 0.9941900968551636
) O O 0.9987223744392395
groups O O 0.9997875094413757
. O O 0.9999990463256836

the O O 0.9989668130874634
range O O 0.99737548828125
of O O 0.9999104738235474
precursor O O 0.7901404500007629
frequencies O O 0.9468296766281128
for O O 0.9999207258224487
T-lymphocytes S-cell_type S-cell_type 0.8875364065170288
that O O 0.9996274709701538
recognized O O 0.997658371925354
VZV B-protein B-protein 0.4969395399093628
gE E-protein E-protein 0.8365556597709656
or O O 0.9925752878189087
VZV B-protein B-protein 0.5629566311836243
IE62 E-protein E-protein 0.8731262683868408
was O O 0.999546468257904
similar O O 0.9999808073043823
whether O O 0.9999984502792358
these O O 0.9999322891235352
proteins O O 0.9008546471595764
were O O 0.999858021736145
expressed O O 0.9998918771743774
by O O 0.9999918937683105
HSV-1 O O 0.543448269367218
or O O 0.9976367950439453
a O O 0.9995307922363281
vaccinia O O 0.734896719455719
vector O O 0.505687952041626
. O O 0.9999068975448608
These O O 0.9999674558639526

Twenty O O 0.9957939386367798
children O O 0.9970192909240723
with O O 0.9999270439147949
acute B-Disease O 0.7486703991889954
lymphoblastic I-Disease O 0.5150331854820251
leukemia I-Disease O 0.8307110071182251
who O O 0.9251525402069092
developed O O 0.9972959160804749
meningeal B-Disease B-Disease 0.4832225441932678
disease I-Disease I-Disease 0.9863951206207275
were O O 0.9959375858306885
treated O O 0.9999556541442871
with O O 0.9999924898147583
a O O 0.9999160766601562
high O O 0.9959302544593811
- O O 0.9989542961120605
dose O O 0.9991555213928223
intravenous O O 0.8341917395591736
methotrexate B-Chemical B-Chemical 0.9185953140258789
regimen O O 0.7272261381149292
that O O 0.9990897178649902
was O O 0.9999383687973022
designed O O 0.9999871253967285
to O O 0.9999897480010986
achieve O O 0.9995538592338562
and O O 0.9998674392700195
maintain O O 0.999685525894165
CSF O O 0.6934899687767029
methotrexate B-Chemical B-Chemical 0.9085662961006165
concentrations O O 0.9545567035675049
of O O 0.9998687505722046
10 O O 0.9861838221549988
( O O 0.9998024106025696
- O O 0.998023509979248
5 O O 0.996630847454071
) O O 0.9986238479614258
mol O O 0.9694194793701172
/ O O 0.99945467710495
L O O 0.8708457350730896
without O O 0.9999253749847412
the O O 0.9999707937240601
need O O 0.9996380805969238
for O O 0.9999912977218628
concomitant O O 0.9562933444976807
intrathecal O O 0.6910459995269775
dosing O O 0.5470824837684631
. O O 0.9999531507492065

transcription B-protein O 0.5658543705940247

Patients O O 0.9867624640464783
received O O 0.9998542070388794
amifostine B-Chemical B-Chemical 0.9326163530349731
, O O 0.983178436756134
910 O O 0.9967777132987976
mg O O 0.9995926022529602
/ O O 0.9999575614929199
m2 O O 0.9993335604667664
intravenously O O 0.989306628704071
over O O 0.9999709129333496
15 O O 0.9999097585678101
minutes O O 0.9999439716339111
. O O 0.9999992847442627

with O O 0.9961929321289062
LMP1 S-protein S-protein 0.9928816556930542
in O O 0.9991727471351624
EBV-transformed B-cell_line B-cell_line 0.7532539963722229
cells E-cell_line E-cell_line 0.9085606932640076
. O O 0.9997488856315613
In O O 0.9999397993087769
transfection O O 0.9437643885612488
assays O O 0.9848566651344299
, O O 0.9999057054519653
TRADD S-protein S-protein 0.609764814376831
and O O 0.9679640531539917
TES2 S-protein S-protein 0.7276973724365234
synergistically O O 0.9253877997398376
mediated O O 0.9922599196434021
high-level O O 0.9637365937232971
NF-kappaB S-protein S-protein 0.9795753359794617
activation O O 0.9978819489479065
. O O 0.9999949932098389
These O O 0.9999934434890747
results O O 0.999932050704956
indicate O O 0.9999970197677612
that O O 0.9999946355819702
LMP1 S-protein S-protein 0.9591296315193176
appropriates O O 0.9967457056045532
TRADD S-protein S-protein 0.7523220777511597
to O O 0.9985522627830505
enable O O 0.9998449087142944
efficient O O 0.9766984581947327
long-term O O 0.9147464036941528
lymphoblastoid O O 0.7286481261253357
cell O O 0.594026505947113
outgrowth O O 0.6874864101409912
. O O 0.9999489784240723

As O O 0.9998136162757874
the O O 0.9999580383300781
most O O 0.9994613528251648
potent O O 0.9809772372245789
dose O O 0.9894089698791504
( O O 0.9998964071273804
1 O O 0.9999023675918579
mg O O 0.9997838139533997
/ O O 0.9999737739562988
kg O O 0.9995173215866089
) O O 0.9999312162399292
of O O 0.9998243451118469
lipopolysaccharide B-Chemical B-Chemical 0.9361160397529602
was O O 0.9932780861854553
administered O O 0.9998615980148315
two O O 0.9999898672103882
weeks O O 0.999988317489624
, O O 0.9999972581863403
one O O 0.9999936819076538
day O O 0.9999793767929077
before O O 0.9999978542327881
or O O 0.9999785423278809
after O O 0.9999898672103882
the O O 0.9999173879623413
methamphetamine B-Chemical B-Chemical 0.9244449138641357
dosing O O 0.8770483732223511
regimen O O 0.895722508430481
, O O 0.9998418092727661
methamphetamine B-Chemical B-Chemical 0.9274390935897827
- O O 0.760924756526947
induced O O 0.99750816822052
striatal O O 0.7568517923355103
dopamine B-Chemical B-Chemical 0.9287756681442261
and O O 0.9859043955802917
3 B-Chemical B-Chemical 0.8483943939208984
, I-Chemical I-Chemical 0.9869208335876465
4 I-Chemical I-Chemical 0.9758854508399963
- I-Chemical I-Chemical 0.9938390851020813
dihydroxyphenylacetic I-Chemical I-Chemical 0.923425018787384
acid I-Chemical I-Chemical 0.935340940952301
depletions O O 0.5249397158622742
remained O O 0.9997029900550842
unaltered O O 0.9922491312026978
. O O 0.9999992847442627

Calcineurin O B-Chemical 0.8961348533630371
- O O 0.6175980567932129
inhibitor O O 0.584198534488678
induced O O 0.992584228515625
pain O B-Disease 0.9255483746528625
syndrome O I-Disease 0.9856284856796265
( O O 0.9718025922775269
CIPS O B-Disease 0.9505016803741455
) O O 0.8227061629295349
: O O 0.9995099306106567
a O O 0.9995731711387634
severe O O 0.9751811623573303
disabling O O 0.5788026452064514
complication O O 0.8266571164131165
after O O 0.9972676038742065
organ O O 0.936133623123169
transplantation O O 0.8834500312805176
. O O 0.999996542930603

by O O 0.9961590766906738
protein O O 0.8719699382781982
from O O 0.9993488192558289
12-O-tetradecanoyl B-cell_line B-cell_line 0.4087387025356293
12-phorbol I-cell_line I-cell_line 0.5538713335990906
13-acetate-stimulated I-cell_line I-cell_line 0.5684707760810852
T I-cell_line I-cell_line 0.7948471903800964
cells E-cell_line E-cell_line 0.9469864964485168
. O O 0.9998683929443359
The O O 0.9999967813491821
shorter O O 0.9769402742385864
C-terminal O O 0.6451521515846252
peptide O O 0.4053783714771271
of O O 0.9574413299560547
isoform O O 0.4637156128883362
NF-ATc/B S-protein S-protein 0.6216707229614258
exerts O O 0.9991372227668762
a O O 0.9999583959579468
suppressive O O 0.9286945462226868
transcriptional O O 0.8858155012130737
effect O O 0.9972745776176453
. O O 0.9999966621398926
These O O 0.9999936819076538
properties O O 0.9951450228691101
of O O 0.9998600482940674
NF-ATc/B B-protein B-protein 0.9285241961479187
and I-protein I-protein 0.9039469957351685
-C E-protein E-protein 0.6340286135673523
might O O 0.9948806762695312
be O O 0.9999839067459106
of O O 0.9999232292175293
importance O O 0.9989688396453857
for O O 0.9999861717224121
gene O O 0.9587315917015076
regulation O O 0.9965597987174988
in O O 0.9999756813049316
naive B-cell_type B-cell_type 0.666034460067749
T I-cell_type I-cell_type 0.8344006538391113
lymphocytes E-cell_type E-cell_type 0.9770301580429077
in O O 0.9989331364631653
which O O 0.9999717473983765
NF-ATc/B B-protein B-protein 0.7366189956665039
and I-protein I-protein 0.784539520740509
-C E-protein E-protein 0.6163823008537292
are O O 0.9879712462425232
predominantly O O 0.9896939396858215
synthesized O O 0.9966448545455933
. O O 0.9999971389770508
Selection O O 0.9946548938751221
and O O 0.9993853569030762
long-term O O 0.9844666719436646
persistence O O 0.9973862767219543
of O O 0.9999548196792603
reactive O O 0.7273622155189514
CTL B-cell_line O 0.22065900266170502

express O B-protein 0.9024223685264587
factors O E-protein 0.899655282497406
that O O 0.9993420243263245
preferentially O O 0.9990991353988647
enhance O O 0.9976598024368286
expression O O 0.9976589679718018
from O O 0.9999912977218628
REV O B-DNA 0.22867977619171143
or O I-DNA 0.9233565926551819
avian B-DNA I-DNA 0.7543367147445679
sarcoma/leukemia I-DNA I-DNA 0.7785768508911133
virus I-DNA I-DNA 0.7368776202201843
LTRs E-DNA E-DNA 0.6616977453231812
. O O 0.9994387030601501
REV B-DNA B-DNA 0.33593830466270447
LTRs E-DNA E-DNA 0.9626997113227844
work O O 0.9978845715522766
efficiently O O 0.9998257756233215
in O O 0.9999526739120483
human B-cell_type B-cell_type 0.7866689562797546

of O O 0.9926290512084961

expression O O 0.9708282947540283
of O O 0.9998321533203125
this O O 0.9995796084403992
gene O O 0.9097162485122681
in O O 0.9989796280860901
blood B-cell_type B-cell_type 0.7494751811027527
cells E-cell_type E-cell_type 0.9876041412353516
was O O 0.9991694688796997
first O O 0.999866247177124
investigated O O 0.999972939491272
in O O 0.9999411106109619
fractions O O 0.9745152592658997
of O O 0.9994335770606995
nucleated B-cell_type B-cell_type 0.5029449462890625
cells E-cell_type E-cell_type 0.8395377993583679
, O O 0.9977726340293884

. O O 0.993518054485321
We O O 0.9999736547470093
sought O O 0.9999717473983765
to O O 0.9999879598617554
determine O O 0.9999966621398926
the O O 0.9999755620956421
activities O O 0.9997808337211609
of O O 0.9999898672103882
various O O 0.9900162816047668
environmental O O 0.9186847805976868
estrogens O O 0.49766698479652405
on O O 0.9996986389160156
the O O 0.9997674822807312

a O O 0.9971076846122742
complex O O 0.9589676856994629
group O O 0.9658626317977905
of O O 0.999934196472168
transient O O 0.8305275440216064
and O O 0.9821696877479553
sustained O O 0.982941210269928
responses O O 0.9960313439369202
to O O 0.9999716281890869
cell O O 0.9690528512001038
activation O O 0.9974748492240906
. O O 0.999997615814209
Finally O O 0.9999014139175415
, O O 0.9999912977218628
the O O 0.9999594688415527
activation-induced O O 0.9519009590148926
changes O O 0.9952545166015625
in O O 0.999942421913147
one O O 0.9991857409477234
set O O 0.9970279335975647
of O O 0.9998898506164551
phosphoproteins S-protein S-protein 0.8261132836341858
were O O 0.9997814297676086
dramatically O O 0.9993243217468262
inhibited O O 0.9999309778213501
by O O 0.999995231628418
cyclosporin O O 0.9515423774719238
A O O 0.8919063210487366
. O O 0.9999077320098877
We O O 0.999951958656311
suggest O O 0.9999957084655762

) I-protein I-protein 0.6343919038772583
2 I-protein I-protein 0.46373534202575684
domain-containing I-protein I-protein 0.621837317943573
intracellular I-protein I-protein 0.6287264823913574
molecules E-protein E-protein 0.9608529806137085
to O O 0.999197781085968
the O O 0.9996780157089233
cell O O 0.9010652303695679
membrane O O 0.7736406326293945
via O O 0.9950064420700073
tyrosine-based O B-DNA 0.7433003187179565
signaling O I-DNA 0.5068840384483337
motifs O E-DNA 0.50177001953125
. O O 0.9996111989021301
We O O 0.9999896287918091
describe O O 0.9999924898147583
here O O 0.9999741315841675
a O O 0.9999939203262329
novel O O 0.944319486618042
molecule O O 0.5255224108695984
of O O 0.9960312247276306
this O O 0.999823272228241
group O O 0.9289975166320801
termed O O 0.9975706934928894
SIT S-protein S-protein 0.5524053573608398
( O O 0.973969578742981
SHP2 B-protein B-protein 0.5758844614028931
interacting I-protein I-protein 0.4904221296310425
transmembrane I-protein I-protein 0.710045576095581
adaptor I-protein I-protein 0.5641357898712158
protein E-protein E-protein 0.9867767691612244
) O O 0.937576949596405
. O O 0.9998953342437744
SIT S-protein S-protein 0.9439509510993958
is O O 0.9998766183853149
a O O 0.9999794960021973
disulfide-linked B-protein B-protein 0.4797894060611725
homodimeric I-protein I-protein 0.6749097108840942
glycoprotein E-protein E-protein 0.8747742176055908
that O O 0.9967395663261414

Ikaros S-protein S-protein 0.5706911683082581
and O O 0.9774534106254578
Aiolos S-protein O 0.46913543343544006
is O O 0.9995902180671692
mediated O O 0.9999316930770874
through O O 0.9999691247940063
histone B-protein B-protein 0.6373648643493652
deacetylase I-protein I-protein 0.4146728515625
complexes E-protein E-protein 0.994951605796814
. O O 0.9999315738677979
Here O O 0.9998860359191895
we O O 0.999951958656311

) O O 0.6013631820678711
and O O 0.973892331123352
progesterone O B-protein 0.42595478892326355
receptor O E-protein 0.9787850975990295
. O O 0.9991938471794128
To O O 0.9999901056289673
investigate O O 0.9999858140945435
the O O 0.9999885559082031
effect O O 0.999967098236084
of O O 0.9999876022338867
treatment O O 0.9996011853218079
with O O 0.9999963045120239
a O O 0.9997767806053162
pan O B-protein 0.6237977147102356
anti B-protein I-protein 0.6368572115898132
gamma/delta I-protein I-protein 0.40885600447654724
antibody E-protein E-protein 0.9678531885147095
, O O 0.9988572597503662
lymphocytes S-cell_type S-cell_type 0.9653841257095337
were O O 0.9998241066932678
incubated O O 0.99981290102005
for O O 0.9999924898147583
3 O O 0.9865698218345642
hr O O 0.9883047342300415
with O O 0.9999809265136719
the O O 0.9998860359191895

killer I-cell_type I-cell_type 0.44260239601135254
cells E-cell_type E-cell_type 0.9038986563682556
. O O 0.9997684359550476
The O O 0.9999982118606567
role O O 0.9989867806434631
of O O 0.9999493360519409
cellular O O 0.8619617819786072
redox O O 0.6661800742149353
status O O 0.968010425567627
in O O 0.9999616146087646
both O O 0.999629020690918
cytotoxic O O 0.7762346267700195
activity O O 0.9776907563209534
and O O 0.999713122844696
NF-kappa B-protein B-protein 0.6218432188034058
B E-protein E-protein 0.9899808764457703
activation O O 0.9937025308609009
in O O 0.9997645020484924
natural B-cell_type B-cell_type 0.9434086680412292

The O O 0.9996401071548462
average O O 0.9945476055145264
hearing O O 0.5319945812225342
loss O O 0.8322422504425049
for O O 0.9418565034866333
speech O O 0.4450569450855255
frequencies O O 0.5171409249305725
was O O 0.9993371367454529
about O O 0.9999706745147705
10 O O 0.999763548374176
dB O O 0.9867085218429565
after O O 0.9999600648880005
prilocaine S-Chemical B-Chemical 0.9281061887741089
and O O 0.9838391542434692
15 O O 0.9760265946388245
dB O O 0.8337750434875488
after O O 0.9999356269836426
bupivacaine S-Chemical B-Chemical 0.9204400181770325
. O O 0.9997362494468689

, O O 0.8902024030685425
and O O 0.9821626543998718
cysteine B-protein B-protein 0.5866886973381042
proteases E-protein E-protein 0.9286018013954163
, O O 0.9974465370178223
termed B-protein O 0.9872626662254333
caspases E-protein S-protein 0.7337198853492737
, O O 0.998143196105957
are O O 0.9999796152114868
involved O O 0.9999737739562988
in O O 0.9999861717224121
the O O 0.9999266862869263
apoptotic O O 0.8282812237739563
cascade O O 0.8496991991996765
leading O O 0.999314546585083
to O O 0.9999618530273438
proteolysis O O 0.9045916795730591
of O O 0.9991053938865662
specific O O 0.9285041689872742
substrates O O 0.5621798634529114
and O O 0.9991034865379333
to O O 0.9999616146087646
morphological O O 0.9602047801017761
changes O O 0.992708146572113
associated O O 0.9999587535858154
with O O 0.9999885559082031
programmed O O 0.8727670907974243
cell O O 0.8526338934898376
death O O 0.9599476456642151
. O O 0.9999945163726807
Although O O 0.9999912977218628
common O O 0.9816480875015259
members O O 0.9697586297988892
of O O 0.9998764991760254
the O O 0.9998651742935181
apoptotic O O 0.6139773726463318
cascade O O 0.4663276672363281

Our O O 0.9990049004554749
experience O O 0.9988715052604675
supports O O 0.9999831914901733
the O O 0.9999880790710449
safety O O 0.9989160299301147
of O O 0.9999632835388184
giving O O 0.9953397512435913
AraG S-Chemical B-Chemical 0.9358772039413452
as O O 0.9900168776512146
salvage O O 0.5093781352043152
therapy O O 0.9929613471031189
in O O 0.9999912977218628
synchrony O O 0.5178307294845581
with O O 0.9979040622711182
etoposide S-Chemical B-Chemical 0.9233921766281128
and O O 0.9600297212600708
cyclophosphamide S-Chemical B-Chemical 0.9260329008102417
, O O 0.9964973330497742
although O O 0.9999758005142212
neurological O O 0.8016110062599182
toxicity O O 0.5597925782203674
must O O 0.9880236387252808
be O O 0.9998506307601929
closely O O 0.9992104768753052
monitored O O 0.9999517202377319
. O O 0.9999994039535522

consensus O B-DNA 0.6486233472824097
o-tetradecanoylphorbol B-DNA I-DNA 0.5118992924690247
13-acetate I-DNA I-DNA 0.29981735348701477
( I-DNA I-DNA 0.7710802555084229
TPA I-DNA I-DNA 0.4960998594760895
) I-DNA I-DNA 0.5483363270759583
response I-DNA I-DNA 0.7944665551185608
element E-DNA E-DNA 0.9849538803100586
. O O 0.9996391534805298
On O O 0.9999946355819702
the O O 0.999982476234436
other O O 0.9998607635498047
hand O O 0.9995352029800415
, O O 0.9999963045120239
the O O 0.9999785423278809
growth B-protein B-protein 0.8355092406272888
factor E-protein E-protein 0.7859452962875366
does O O 0.9971393346786499
induce O O 0.9999914169311523
the O O 0.9999806880950928
activation O O 0.9986085295677185
of O O 0.99993896484375
STAT3 S-protein S-protein 0.975892186164856
and O O 0.9914741516113281
STAT5 S-protein S-protein 0.9853824377059937
in O O 0.9993730187416077
these O O 0.9996868371963501
cells O O 0.9768487811088562
, O O 0.999937891960144
as O O 0.9999969005584717
has O O 0.9999665021896362
been O O 0.9999198913574219
previously O O 0.9999164342880249
demonstrated O O 0.9999642372131348
. O O 0.9999974966049194
These O O 0.9999316930770874

infected B-cell_type O 0.7083441019058228
CD4+ I-cell_type B-cell_type 0.6601522564888
T-lymphocytes E-cell_type E-cell_type 0.9382144212722778
, O O 0.9937505125999451
as O O 0.9999117851257324
well O O 0.9996104836463928
as O O 0.9999926090240479
systemic O O 0.9871906638145447
effects O O 0.9995524287223816
of O O 0.9999595880508423
chronically O O 0.8901485800743103
elevated O O 0.9703459739685059
cortisol O O 0.9390114545822144
level O O 0.9987062215805054
. O O 0.9999971389770508
Abundant O O 0.9794445037841797
expression O O 0.9978930354118347
of O O 0.9999377727508545
erythroid B-RNA B-protein 0.3570868670940399
transcription I-RNA I-protein 0.7613629102706909
factor I-RNA I-protein 0.8539271354675293
P45 I-RNA I-protein 0.5470629930496216
NF-E2 I-RNA E-protein 0.744365930557251

RA O O 0.919151246547699
: O O 0.9979761242866516
20 O O 0.9951807260513306
% O O 0.9997619986534119
; O O 0.9999083280563354
GM-CSF S-protein O 0.6033362150192261
: O O 0.9990094900131226
12 O O 0.9984446167945862
% O O 0.9997724890708923
; O O 0.9999245405197144

In O O 0.9987479448318481
vitro O O 0.9770307540893555
characterization O O 0.9939761161804199
of O O 0.999893307685852
parasympathetic O O 0.5375689268112183
and O O 0.9319837689399719
sympathetic O O 0.8599885702133179
responses O O 0.9704560041427612
in O O 0.9999403953552246
cyclophosphamide S-Chemical B-Chemical 0.9271309971809387
- O O 0.8722115755081177
induced O O 0.9966602325439453
cystitis O B-Disease 0.9816409945487976
in O O 0.9632217884063721
the O O 0.9906039834022522
rat O O 0.9447099566459656
. O O 0.9999797344207764

) O O 0.7260620594024658
or O O 0.9958464503288269
calpain S-protein O 0.4321918487548828
inhibitor O O 0.5635225176811218
I O O 0.7787913084030151
. O O 0.9956613183021545
These O O 0.9999958276748657
data O O 0.9994006156921387
demonstrate O O 0.999995231628418
that O O 0.9999971389770508
intracellular O O 0.8369591236114502
free O O 0.9567325711250305
calcium O O 0.9150450825691223
and O O 0.9997376799583435
the O O 0.999964714050293
calcium-dependent B-protein B-protein 0.783730149269104
protease E-protein E-protein 0.8601458072662354
, O O 0.9955317974090576
calpain S-protein S-protein 0.6213811635971069
play O O 0.9918375611305237
critical O O 0.9898788928985596
roles O O 0.9977741837501526
in O O 0.9999682903289795
monocytic O O 0.6784631013870239
differentiation O O 0.9290323853492737
. O O 0.9999725818634033
Intracellular O O 0.9472255706787109
calcium O O 0.9440274238586426
appears O O 0.9998766183853149

In O O 0.9997000694274902
this O O 0.999951958656311
latter O O 0.9976279139518738
patient O O 0.9987332224845886
, O O 0.9999899864196777
and O O 0.999972939491272
in O O 0.9998959302902222
2 O O 0.9990226030349731
others O O 0.9999344348907471
, O O 0.999990701675415
the O O 0.9999687671661377
causal O O 0.8426570296287537
relationship O O 0.9562413096427917
between O O 0.9993377327919006
methyldopa S-Chemical B-Chemical 0.9236311316490173
and O O 0.9879233241081238
hepatic O B-Disease 0.5878405570983887
dysfunction O I-Disease 0.9849432706832886
was O O 0.9915536046028137
proved O O 0.9999626874923706
with O O 0.9999889135360718
the O O 0.9999550580978394
recurrence O O 0.9486607909202576
of O O 0.9990442395210266
hepatitis O B-Disease 0.9637073278427124
within O O 0.9855839014053345
2 O O 0.999306321144104
weeks O O 0.9999701976776123
of O O 0.9999854564666748
re O O 0.4991533160209656
- O O 0.8815358877182007
exposure O O 0.9643628001213074
to O O 0.99985671043396
the O O 0.9993791580200195
drug O O 0.9902898669242859
. O O 0.9999933242797852

These O O 0.9997532963752747
data O O 0.9999024868011475
suggest O O 0.9999983310699463
distinct O O 0.9957646131515503
differences O O 0.9891325831413269
in O O 0.9991112351417542
the O O 0.9995859265327454
propensity O O 0.9669420123100281
to O O 0.9997351765632629
develop O O 0.9985032081604004
LIDs B-Disease O 0.9116277694702148
in O O 0.9747139811515808
monkeys O O 0.8654050230979919
with O O 0.9999020099639893
different O O 0.9995313882827759
rates O O 0.9992499947547913
of O O 0.9999080896377563
symptom O O 0.7427670955657959
progression O O 0.7424975633621216
or O O 0.980628490447998
symptom O O 0.5120205879211426
durations O O 0.5963796377182007
prior O O 0.9982384443283081
to O O 0.9999600648880005
levodopa B-Chemical B-Chemical 0.9284837245941162
and O O 0.990862250328064
demonstrate O O 0.9998109936714172
the O O 0.9999642372131348
value O O 0.9993802309036255
of O O 0.9999829530715942
these O O 0.9999532699584961
models O O 0.9982129335403442
for O O 0.9999897480010986
further O O 0.9993202686309814
studying O O 0.9998753070831299
the O O 0.9998446702957153
pathophysiology O O 0.8400128483772278
of O O 0.9979708790779114
LIDs B-Disease O 0.8771137595176697
. O O 0.9994271993637085

FK B-Chemical B-Chemical 0.9319666028022766
506 E-Chemical I-Chemical 0.9471579790115356
decreased O O 0.9486551284790039
eNOS O O 0.7023639678955078
activity O O 0.9304624795913696
and O O 0.9995562434196472
the O O 0.9999102354049683
levels O O 0.999808132648468
of O O 0.9999526739120483
eNOS O O 0.7827115654945374
mRNA O O 0.628080427646637
in O O 0.9999620914459229
the O O 0.9999135732650757
aorta O O 0.8858842253684998
( O O 0.9994681477546692
48 O O 0.9993637204170227
% O O 0.9997928738594055
and O O 0.999924898147583
55 O O 0.9997757077217102
% O O 0.9999375343322754
, O O 0.9999713897705078
respectively O O 0.9999704360961914
) O O 0.9999147653579712
. O O 0.9999963045120239

nuclear O O 0.8383374810218811
localization O O 0.6407532095909119
sequence O O 0.6461177468299866
of O O 0.9955110549926758
NF-kappa B-protein B-protein 0.6107059717178345
B1 I-protein I-protein 0.5594021677970886
dimers E-protein E-protein 0.9624916911125183
and O O 0.9921654462814331
prevents O O 0.9997482895851135
their O O 0.99991774559021
nuclear O O 0.9373612403869629
localization O O 0.9518815875053406
, O O 0.9997772574424744
induces O O 0.9998736381530762
apoptosis O O 0.9806230068206787
in O O 0.9999399185180664
resting B-cell_type B-cell_type 0.6506174802780151
normal I-cell_type I-cell_type 0.5367836952209473
human I-cell_type I-cell_type 0.7076387405395508
PBL E-cell_type E-cell_type 0.9533918499946594
. O O 0.9998218417167664
Inhibition O O 0.9981679916381836
of O O 0.9998548030853271
NF-kappa B-protein B-protein 0.9104209542274475
B E-protein E-protein 0.9972729086875916
resulted O O 0.9998024106025696
in O O 0.9999904632568359
the O O 0.9999659061431885
externalization O O 0.9985491633415222
of O O 0.9999551773071289
phosphatidylserine O O 0.5422784686088562
, O O 0.995554506778717
induction O O 0.9969010353088379
of O O 0.999830961227417
DNA O O 0.7757065296173096
breaks O O 0.7674570679664612
, O O 0.9987021684646606
and O O 0.9996428489685059

physically O O 0.9090153574943542

CONCLUSION O O 0.9987351298332214
: O O 0.9999929666519165
This O O 0.9999768733978271
rat O O 0.9852178692817688
study O O 0.9997678399085999
demonstrated O O 0.999984622001648
a O O 0.9999825954437256
synergistic O O 0.8683162331581116
nephrotoxic B-Disease O 0.7557185888290405
effect O O 0.905569314956665
of O O 0.9995418787002563
CsA B-Chemical B-Chemical 0.915140688419342
plus O O 0.9697529077529907
SRL B-Chemical B-Chemical 0.9126903414726257
, O O 0.9924116730690002
whereas O O 0.999976396560669
FK506 B-Chemical B-Chemical 0.9084048271179199
plus O O 0.9636716842651367
SRL B-Chemical B-Chemical 0.9067600965499878
was O O 0.998529314994812
better O O 0.999479353427887
tolerated O O 0.9991294741630554
. O O 0.9999995231628418

at O O 0.9991182684898376
the O O 0.9999891519546509
S-G2/M O O 0.45233941078186035
boundaries O O 0.843323826789856
. O O 0.999967098236084
5. O O 0.9991851449012756
One O O 0.9998785257339478
of O O 0.9999915361404419
the O O 0.9999891519546509
signaling B-protein B-protein 0.8503137826919556
molecules E-protein E-protein 0.9009976387023926
which O O 0.9992966651916504
mediates O O 0.9959378242492676
programmed O O 0.9262405633926392
cell O O 0.9110360741615295
death O O 0.9481893181800842
is O O 0.9999786615371704
nuclear B-protein B-protein 0.5353703498840332
factor I-protein I-protein 0.49911174178123474

Thus O O 0.9993723034858704
the O O 0.9998552799224854
migraine B-Disease O 0.8829902410507202
- O O 0.5086106061935425
inducing O O 0.8608158230781555
effect O O 0.9540195465087891
of O O 0.9980792999267578
nitroglycerin B-Chemical B-Chemical 0.9347512125968933
seems O O 0.999203622341156
to O O 0.9999493360519409
depend O O 0.999994158744812
on O O 0.9999758005142212
direct O O 0.9961989521980286
stimulation O O 0.9315478801727295
of O O 0.9956004619598389
the O O 0.9991779923439026
habitual O O 0.8278723955154419
site O O 0.9587693810462952
of O O 0.998611330986023
pain B-Disease B-Disease 0.9580777883529663
, O O 0.9935187697410583
suggesting O O 0.9999843835830688
that O O 0.9999852180480957
the O O 0.999884843826294
frontotemporal O O 0.6101756691932678
region O O 0.7078263759613037
is O O 0.9997277855873108
of O O 0.9999699592590332
crucial O O 0.985023021697998
importance O O 0.9545037150382996
in O O 0.9999229907989502
the O O 0.9998892545700073
development O O 0.996802806854248
of O O 0.9999092817306519
a O O 0.9991372227668762
migraine B-Disease O 0.9418484568595886
crisis O O 0.9316446781158447
. O O 0.9997286200523376

with O O 0.9982224106788635
its O O 0.9999212026596069
receptor O O 0.90022212266922
on O O 0.9979520440101624
T-lymphocytes S-cell_type S-cell_type 0.9410336017608643
may O O 0.9995325803756714
play O O 0.9999855756759644
an O O 0.9999943971633911
important O O 0.9996623992919922
role O O 0.9998866319656372
in O O 0.9999903440475464
the O O 0.9999567270278931
regulation O O 0.9995552897453308
of O O 0.9999700784683228
granulomatous O O 0.8483029007911682
reactions O O 0.9009804129600525
, O O 0.9999245405197144
but O O 0.9999896287918091
because O O 0.9999932050704956
these O O 0.9999316930770874
receptors O O 0.6142787933349609
are O O 0.9996269941329956
expressed O O 0.9998425245285034
on O O 0.9997774958610535
different O O 0.992091178894043
lymphocyte B-cell_type B-cell_type 0.5861350297927856
populations E-cell_type E-cell_type 0.9507599472999573
, O O 0.9998332262039185
the O O 0.9999892711639404
net O O 0.9591869711875916

pathway O O 0.9596630930900574
that O O 0.9999744892120361
lead O O 0.9999780654907227
to O O 0.9999927282333374
the O O 0.999985933303833
release O O 0.9983482360839844
of O O 0.9999068975448608
E2F S-protein S-protein 0.9759432673454285
that O O 0.999546468257904
in O O 0.9997541308403015
turn O O 0.9979610443115234
induces O O 0.999976634979248
expression O O 0.994716227054596
of O O 0.9997308850288391
factors O O 0.8789690136909485
required O O 0.999224066734314
for O O 0.9999762773513794
cell O O 0.9378806352615356
cycle O O 0.9339208602905273
progression O O 0.9966388940811157
. O O 0.9999973773956299
In O O 0.9999762773513794
this O O 0.9999649524688721
paper O O 0.9912832975387573

Myopathy O B-Disease 0.9735854864120483
, O O 0.9513612389564514
associated O O 0.9936250448226929
in O O 0.9999295473098755
some O O 0.9999599456787109
cases O O 0.9953392744064331
with O O 0.9999587535858154
myoglobinuria O B-Disease 0.5079834461212158
, O O 0.9619842767715454
and O O 0.999758780002594
in O O 0.9999672174453735
2 O O 0.9960870742797852
cases O O 0.9952077269554138
with O O 0.9999885559082031
transient O B-Disease 0.6925486326217651
renal O I-Disease 0.4634817838668823
failure O I-Disease 0.9795587658882141
, O O 0.9737153053283691
has O O 0.9994725584983826
been O O 0.9998666048049927
rarely O O 0.9997625946998596
reported O O 0.9999568462371826
with O O 0.9999610185623169
lovastatin S-Chemical B-Chemical 0.9309937357902527
, O O 0.9935925602912903
especially O O 0.9992565512657166
in O O 0.999884843826294
patients O O 0.9998189806938171
concomitantly O O 0.9975215792655945
treated O O 0.9999595880508423
with O O 0.9999474287033081
cyclosporin S-Chemical B-Chemical 0.9277101755142212
, O O 0.7664663195610046
gemfibrozil S-Chemical B-Chemical 0.9289534091949463
or O O 0.8466905951499939
niacin S-Chemical B-Chemical 0.9189201593399048
. O O 0.9995625615119934

activated O O 0.9267367720603943
the O O 0.9994515776634216
respiratory O O 0.8965915441513062
burst O O 0.8926478028297424
through O O 0.999288022518158
hTLR2 S-protein S-DNA 0.5511868596076965
. O O 0.9990769624710083
Thus O O 0.9995224475860596
, O O 0.999816358089447
hTLR2 S-protein S-protein 0.7192335724830627
is O O 0.9998021721839905
a O O 0.9999724626541138
molecular O O 0.9248916506767273
link O O 0.9623939990997314
between O O 0.999714195728302
microbial O B-protein 0.7127289175987244
products O E-protein 0.8865851759910583
, O O 0.9957212209701538
apoptosis O O 0.9758239388465881
, O O 0.9992201328277588
and O O 0.9997941851615906
host O O 0.9551020860671997
defense O O 0.9269168972969055
mechanisms O O 0.9942947030067444
. O O 0.9999973773956299
Possible O O 0.9990872144699097
differences O O 0.9989155530929565
in O O 0.9999470710754395
the O O 0.9998745918273926
mechanism O O 0.9930704236030579
( O O 0.9992013573646545

Jurkat I-cell_line B-cell_line 0.52336186170578
T I-cell_line E-cell_line 0.4718533456325531
or I-cell_line O 0.8567831516265869
293 I-cell_line O 0.750869870185852

was O O 0.9950586557388306
greatly O O 0.997517466545105

The O O 0.9995656609535217
epidemiological O O 0.9316744804382324
studies O O 0.9966214895248413
that O O 0.9999983310699463
assessed O O 0.999777615070343
the O O 0.999830961227417
risk O O 0.9980102181434631
of O O 0.9999091625213623
venous O B-Disease 0.5648614168167114
thromboembolism O I-Disease 0.9346718788146973
( O O 0.9146999716758728
VTE O B-Disease 0.9629195928573608
) O O 0.8047670722007751
associated O O 0.9971581697463989
with O O 0.9999847412109375
newer O O 0.9827683568000793
oral B-Chemical B-Chemical 0.7824328541755676
contraceptives E-Chemical I-Chemical 0.9467988014221191
( O O 0.8699230551719666
OC S-Chemical B-Chemical 0.9183443188667297
) O O 0.9622122645378113
did O O 0.9999831914901733
not O O 0.9999829530715942
distinguish O O 0.9999507665634155
between O O 0.999796450138092
patterns O O 0.9911612272262573
of O O 0.9993796348571777
OC S-Chemical B-Chemical 0.9107161164283752
use O O 0.9890233278274536
, O O 0.9999818801879883
namely O O 0.9996069073677063
first O O 0.9995978474617004
- O O 0.9997816681861877
time O O 0.998646080493927
users O O 0.9994097948074341
, O O 0.9999330043792725
repeaters O O 0.9567338824272156
and O O 0.998397171497345
switchers O O 0.9255110025405884
. O O 0.9999856948852539

activate O O 0.9713639616966248
U2 B-RNA B-RNA 0.4088951349258423
snRNA E-RNA E-RNA 0.6801828742027283
transcription O O 0.6139870882034302
in O O 0.9992231130599976
both O O 0.9995704293251038
HeLa B-cell_line B-cell_line 0.9163958430290222
cells E-cell_line E-cell_line 0.9937728047370911
, O O 0.9924076199531555
in O O 0.999956488609314
which O O 0.9999877214431763
only O O 0.9993422627449036
OTF-1 O S-protein 0.8981293439865112
is O O 0.9933712482452393
expressed O O 0.9982134103775024
, O O 0.9998880624771118
and O O 0.9999140501022339
in O O 0.9990597367286682
BJA-B B-cell_line B-cell_line 0.5427808165550232
cells E-cell_line E-cell_line 0.5578244924545288
in O O 0.9991152882575989
which O O 0.998734176158905

5 O O 0.953330397605896
+/- O O 0.9987577199935913
4 O O 0.9984049201011658
fmol/mg O O 0.9595956802368164
respectively O O 0.9999755620956421
. O O 0.9999972581863403
These O O 0.9999973773956299
results O O 0.9999198913574219
show O O 0.9999967813491821
that O O 0.9999971389770508
there O O 0.999984860420227
is O O 0.9999958276748657
no O O 0.9999938011169434
evidence O O 0.9999779462814331
of O O 0.9999920129776001
specific O O 0.9914681911468506
expression O O 0.9981995820999146
of O O 0.9999446868896484
the O O 0.9998012185096741
progesterone B-protein B-protein 0.4348728060722351
receptor E-protein E-protein 0.5863913297653198

be O O 0.9689637422561646

in O O 0.9991291165351868
large O O 0.9997705817222595
part O O 0.9997515082359314
, O O 0.9999865293502808
to O O 0.9999712705612183
changes O O 0.9977746605873108
affecting O O 0.9999709129333496
the O O 0.9998949766159058
viral B-DNA B-DNA 0.4895309805870056
LTR E-DNA E-DNA 0.9797579050064087
. O O 0.9991065859794617
Nucleotide O B-DNA 0.6531438827514648
sequence O E-DNA 0.7650758624076843
and O O 0.9934892654418945
PCR O O 0.33172428607940674

IL-6 B-DNA B-DNA 0.7668336629867554
gene E-DNA E-DNA 0.8675988912582397
transcription O O 0.9361947178840637
and O O 0.9985132813453674
expression O O 0.997459352016449
by O O 0.9999709129333496
IL-4 S-protein S-protein 0.9714995622634888
and O O 0.9869784116744995
IL-10 S-protein S-protein 0.9828569293022156
in O O 0.9996988773345947
human B-cell_line B-cell_line 0.5380023717880249
monocytic I-cell_line I-cell_line 0.31939706206321716
cell I-cell_line I-cell_line 0.6311367154121399
lines E-cell_line E-cell_line 0.9960289001464844
. O O 0.9997711777687073
IL-4 S-protein S-protein 0.9574966430664062
and O O 0.9943291544914246
IL-10 S-protein S-protein 0.9660769104957581
inhibit O O 0.9996985197067261
the O O 0.9999325275421143
cytokine S-protein S-protein 0.9536465406417847
production O O 0.9954859614372253
and O O 0.9997724890708923
mRNA O O 0.6798528432846069
expression O O 0.9901002049446106
by O O 0.9999433755874634
monocytes/macrophages S-cell_type S-cell_type 0.8044731020927429
. O O 0.9992271661758423
To O O 0.9999880790710449
investigate O O 0.9999871253967285
the O O 0.9999864101409912
molecular O O 0.9742141366004944
mechanism O O 0.9972493052482605
of O O 0.9999871253967285
the O O 0.9999724626541138
inhibitory O O 0.9017149209976196
effect O O 0.9988137483596802
on O O 0.9999760389328003
transcriptional O O 0.9012587070465088
or O O 0.9940937161445618
post-transcriptional O O 0.9685233235359192
regulation O O 0.9982523322105408
of O O 0.9999793767929077
IL-6 B-DNA B-DNA 0.7077991962432861
gene E-DNA E-DNA 0.8187554478645325
expression O O 0.9829431772232056
by O O 0.9999561309814453
IL-4 S-protein S-protein 0.9465190172195435
and O O 0.9874373078346252
IL-10 S-protein S-protein 0.894643247127533

. O O 0.9964189529418945
The O O 0.9999496936798096
HTLV-I B-DNA B-DNA 0.3931106925010681
LTR E-DNA E-DNA 0.9841524958610535
contains O O 0.9991900324821472
three O O 0.9978365302085876
conserved O O 0.9163853526115417
regulatory B-DNA B-DNA 0.5635153651237488
elements E-DNA E-DNA 0.9477804899215698
known O O 0.9983691573143005
as O O 0.9999539852142334
21 B-DNA B-DNA 0.670198917388916
base I-DNA I-DNA 0.5687829852104187
pair I-DNA I-DNA 0.42997342348098755
repeats E-DNA E-DNA 0.932439386844635
which O O 0.9990021586418152
are O O 0.9999672174453735
required O O 0.9998890161514282
for O O 0.9999868869781494
stimulation O O 0.9972636699676514
of O O 0.9999287128448486
gene O O 0.9513170123100281
expression O O 0.9986584186553955
by O O 0.9999980926513672
the O O 0.9999598264694214
transactivator B-protein B-protein 0.43279024958610535
protein E-protein I-protein 0.6520251035690308
tax S-protein E-protein 0.9561561942100525
. O O 0.999190628528595
Mutagenesis O O 0.9879265427589417
indicates O O 0.9999773502349854
that O O 0.9999961853027344
the O O 0.9998214840888977
21 B-DNA B-DNA 0.5542871356010437
bp I-DNA I-DNA 0.45114392042160034
repeats E-DNA E-DNA 0.9920344948768616
can O O 0.999402642250061
be O O 0.9999825954437256
subdivided O O 0.9996951818466187
into O O 0.9999474287033081
three O O 0.9851131439208984
motifs O O 0.9019748568534851
, O O 0.9998985528945923
A O O 0.8008926510810852
, O O 0.9448840618133545
B O O 0.6381113529205322

is O O 0.9901347756385803
differentially O O 0.9928902387619019
expressed O O 0.9995601773262024
in O O 0.9997770190238953
murine B-cell_line B-cell_line 0.5319952368736267
Th1 I-cell_line I-cell_line 0.4474455416202545
and I-cell_line I-cell_line 0.49347805976867676
Th2 I-cell_line I-cell_line 0.4321577548980713
cells E-cell_line E-cell_line 0.7540823221206665
and O O 0.9964904189109802
controls O O 0.99802565574646
Th2-specific O O 0.3824380338191986
expression O O 0.8826572895050049
of O O 0.9983816146850586
the O O 0.9998261332511902
interleukin-5 B-DNA B-DNA 0.4353167712688446
gene E-DNA E-DNA 0.9784746766090393
. O O 0.998566210269928
Interleukin-5 S-protein S-protein 0.7949149012565613
( O O 0.8372345566749573

linking O O 0.9912025928497314
BCR S-protein S-protein 0.9697946310043335
-derived O O 0.9951634407043457
signals O O 0.9968717694282532
to O O 0.9999816417694092
the O O 0.9999020099639893
induction O O 0.993716299533844
of O O 0.9995537400245667
CD44 S-protein S-protein 0.9296015501022339
. O O 0.9995539784431458
The O O 0.9999959468841553
relevance O O 0.9991681575775146
of O O 0.9999806880950928
these O O 0.9999616146087646
molecular O O 0.8399854302406311
events O O 0.9306380748748779
to O O 0.9998273253440857
BCR S-protein S-protein 0.5255175828933716
signal O O 0.95424485206604

However O O 0.9990680813789368
, O O 0.9999650716781616
we O O 0.9997996687889099
experienced O O 0.9999425411224365
a O O 0.9998605251312256
case O O 0.9893500208854675
of O O 0.9997217059135437
severe O O 0.9736467003822327
ocular B-Disease B-Disease 0.5860978364944458
and I-Disease I-Disease 0.6785401701927185
orbital I-Disease I-Disease 0.6317151784896851
toxicity I-Disease I-Disease 0.7707516551017761
after O O 0.9805030822753906
intracarotid O O 0.8104255795478821
injection O O 0.7835577726364136
of O O 0.9970701932907104
carboplatin B-Chemical B-Chemical 0.9291713237762451
, O O 0.9755468368530273
which O O 0.9999450445175171
is O O 0.9999815225601196
infrequently O O 0.9985044002532959
reported O O 0.99997878074646
. O O 0.9999973773956299

and I-DNA O 0.8710048198699951
NFIL-2A I-DNA B-DNA 0.31342804431915283
sites E-DNA E-DNA 0.9606871604919434
and O O 0.9975863695144653
Ig O B-DNA 0.6228400468826294
kappa B-DNA I-DNA 0.8404802083969116
B I-DNA I-DNA 0.8737414479255676
site E-DNA E-DNA 0.9918603301048279
, O O 0.9903109073638916
but O O 0.9999421834945679
also O O 0.9999743700027466
the O O 0.9999141693115234
IL-8 S-protein B-DNA 0.5621187686920166
AP-1 S-DNA I-DNA 0.4297912120819092
and O I-DNA 0.6513129472732544
kappa B-DNA I-DNA 0.8362196087837219
B-like I-DNA I-DNA 0.9494836330413818
sites E-DNA E-DNA 0.994360625743866
are O O 0.9993194341659546
terminals O O 0.9301585555076599
of O O 0.9996669292449951
FK506-sensitive O O 0.40645042061805725
pathway O O 0.9454094767570496
involving O O 0.9998113512992859
Ca2+ O O 0.8493879437446594
mobilization O O 0.9921891689300537
. O O 0.9999833106994629
Androgen B-protein B-DNA 0.42285194993019104
binding I-protein I-DNA 0.5233566761016846
sites E-protein E-DNA 0.6970434784889221
in O O 0.9987890124320984
peripheral B-cell_type B-cell_type 0.45261943340301514
human I-cell_type I-cell_type 0.48510465025901794
mononuclear I-cell_type I-cell_type 0.7825325131416321
leukocytes E-cell_type E-cell_type 0.9836912155151367
of O O 0.9953197836875916
healthy O O 0.7941520810127258
males O O 0.9104295969009399
and O O 0.9908918738365173
females O O 0.9249387383460999
. O O 0.9999809265136719
Androgen B-protein B-DNA 0.5591198801994324
binding I-protein I-DNA 0.52742999792099
sites E-protein E-DNA 0.6418036222457886

observed O O 0.9715177416801453

that O O 0.9979774355888367
Jurkat B-cell_line B-cell_line 0.6080346703529358
T I-cell_line I-cell_line 0.8028959631919861
cells E-cell_line E-cell_line 0.9740346074104309
acutely O O 0.9948705434799194
exposed O O 0.9999455213546753
to O O 0.9999569654464722
micromolar O O 0.8059675097465515
concentrations O O 0.9474726319313049
of O O 0.9998233914375305
H2O2 O O 0.5834277868270874
exhibit O O 0.9943881630897522
substantial O O 0.9932340979576111
increases O O 0.9938289523124695
in O O 0.9997524619102478
AP-1 S-protein S-protein 0.9633716940879822
binding O O 0.9409099221229553
activity O O 0.9960001111030579
and O O 0.9999755620956421
the O O 0.9999665021896362
expression O O 0.9949330687522888

of O O 0.9955600500106812
NF-kappa B-protein B-protein 0.704201877117157
B E-protein E-protein 0.9931350946426392
activation O O 0.995410144329071
. O O 0.9999842643737793
A O O 0.9846455454826355
cell B-DNA B-DNA 0.824849009513855
type-specific I-DNA I-DNA 0.6790130734443665
enhancer E-DNA E-DNA 0.9504473209381104
in O O 0.9992814660072327
the O O 0.9999080896377563
human B-DNA B-DNA 0.4193437695503235
B7.1 I-DNA I-DNA 0.6036698222160339
gene E-DNA E-DNA 0.9722946286201477
regulated O O 0.9917917251586914
by O O 0.9999576807022095
NF-kappaB S-protein S-protein 0.9737594127655029
. O O 0.9998291730880737
The O O 0.9999862909317017
costimulatory B-protein B-protein 0.7727112770080566
molecule I-protein I-protein 0.7231718301773071
B7.1 E-protein E-protein 0.692382276058197
provides O O 0.9988069534301758
a O O 0.9999892711639404
second O O 0.9865866899490356
signal O O 0.9880401492118835
critical O O 0.9932408332824707
for O O 0.9996343851089478
T O O 0.6586475372314453

as O O 0.9975776076316833
soluble O O 0.9160358309745789
E-selectin S-protein S-protein 0.8727158308029175
, O O 0.9955816864967346
PAI-1 S-protein S-protein 0.9578582048416138
and O O 0.9961552023887634
vWf S-protein S-protein 0.9817777872085571
to O O 0.9963018894195557
a O O 0.9995038509368896
minimal O O 0.9463834166526794
extent O O 0.9849880337715149
, O O 0.9999042749404907
increased O O 0.9991515874862671
in O O 0.9994731545448303
supernatants O O 0.505051851272583
from O O 0.9995322227478027
HUVEC S-cell_type S-cell_line 0.7686297297477722
cocultured O O 0.5179341435432434

These O O 0.9994562268257141
differences O O 0.9864349365234375
were O O 0.9999631643295288
not O O 0.9999397993087769
observed O O 0.9999219179153442
during O O 0.9999903440475464
puberty O O 0.8174031376838684
. O O 0.9998277425765991

, O O 0.9884883761405945
CsA O O 0.9116486310958862
inhibits O O 0.9997405409812927
lymphocyte B-DNA B-DNA 0.4808636009693146
gene E-DNA E-DNA 0.7835809588432312
activation O O 0.9757906794548035
by O O 0.9999686479568481
inhibiting O O 0.9996819496154785
the O O 0.999739944934845
phosphatase S-protein S-protein 0.7720234990119934
activity O O 0.9959314465522766
of O O 0.9999607801437378
calcineurin S-protein S-protein 0.9438924193382263
( O O 0.9902327060699463
CN S-protein S-protein 0.8958181738853455
) O O 0.9755173325538635
. O O 0.9999698400497437
In O O 0.9999773502349854
clinical O O 0.9893850684165955
use O O 0.9994316697120667
, O O 0.999997615814209
CsA O O 0.8508707284927368
treatment O O 0.9984234571456909
inhibits O O 0.9999911785125732
50-75 O O 0.9405343532562256
% O O 0.9967615008354187
of O O 0.9998996257781982
CN S-protein S-protein 0.7430000305175781
activity O O 0.9814935922622681
in O O 0.9999055862426758

response O O 0.9525406956672668
. O O 0.9998736381530762
Cross-linking O O 0.9945361614227295
of O O 0.9997100234031677
FcR S-protein S-protein 0.9508823752403259
with O O 0.9979477524757385
immune B-protein B-protein 0.834004819393158
complexes E-protein E-protein 0.8895241022109985
leads O O 0.9911118149757385
, O O 0.9999469518661499
first O O 0.9978850483894348
to O O 0.9998558759689331
activation O O 0.9961850047111511
of O O 0.9998431205749512
protein-tyrosine B-protein B-protein 0.335595041513443

However O O 0.9984952211380005
, O O 0.9999603033065796
this O O 0.9998496770858765
difference O O 0.9904907941818237
reached O O 0.9999370574951172
statistical O O 0.994484007358551
significance O O 0.9864734411239624
only O O 0.9999688863754272
with O O 0.9999852180480957
regard O O 0.9996533393859863
to O O 0.9999866485595703
reported O O 0.9974585175514221
pain O B-Disease 0.974128007888794
sensation O O 0.834783136844635
( O O 0.9988040924072266
P O O 0.9988464117050171
= O O 0.9999755620956421
0 O O 0.9998515844345093
. O O 0.9999290704727173
011 O O 0.9832100868225098
) O O 0.9995469450950623
. O O 0.9999959468841553

RESULTS O O 0.9985325336456299
: O O 0.9999864101409912
The O O 0.9999825954437256
percentage O O 0.9997407793998718
of O O 0.9999302625656128
bruising O B-Disease 0.9792317152023315
occurrence O O 0.843319833278656
was O O 0.9976485371589661
64 O O 0.9999382495880127
% O O 0.9999855756759644
with O O 0.999996542930603
the O O 0.9999372959136963
injection O O 0.9830243587493896
of O O 0.9982407093048096
10 O O 0.9981380701065063
seconds O O 0.999576985836029
duration O O 0.997870683670044
and O O 0.9999945163726807
42 O O 0.9997740387916565
% O O 0.9999697208404541
in O O 0.9999915361404419
the O O 0.9999659061431885
30 O O 0.9941100478172302
- O O 0.999505877494812
second O O 0.9981587529182434
injection O O 0.9923821091651917
. O O 0.999997615814209

stimulated O O 0.8784433603286743
Ipr B-cell_line B-cell_line 0.6326684951782227
CD4-8- I-cell_line I-cell_line 0.8793953657150269
T I-cell_line I-cell_line 0.9290803670883179
cells E-cell_line E-cell_line 0.9804915189743042
with O O 0.9997001886367798
that O O 0.9999837875366211
of O O 0.9998841285705566
normal B-cell_type B-cell_type 0.5802621841430664
T I-cell_type I-cell_type 0.614875316619873
lymphocytes E-cell_type E-cell_type 0.9940755367279053
. O O 0.9996808767318726
Levels O O 0.9991864562034607
of O O 0.9997727274894714

transcription B-DNA B-DNA 0.45584142208099365
start I-DNA I-DNA 0.39077410101890564
site E-DNA E-DNA 0.9804650545120239
. O O 0.9998348951339722
Mutation O O 0.9941698312759399
of O O 0.9998024106025696
the O O 0.9999276399612427
E B-DNA B-DNA 0.7753113508224487
box E-DNA E-DNA 0.9639692902565002
abolished O O 0.9883113503456116
USF/c-Myc S-protein S-DNA 0.6452651023864746
-mediated O O 0.9723150134086609
up-regulation O O 0.9954264760017395
of O O 0.9998975992202759
CXCR4 S-protein B-DNA 0.4623323380947113
promoter O E-DNA 0.9427903294563293
activity O O 0.9615969061851501
, O O 0.9998063445091248
and O O 0.9999585151672363
mutation O O 0.9870902895927429
of O O 0.9996777772903442
the O O 0.999809205532074
YY1 B-DNA B-DNA 0.33642280101776123
binding I-DNA I-DNA 0.7545065879821777
site E-DNA E-DNA 0.9379277229309082
was O O 0.9986341595649719
associated O O 0.9999527931213379
with O O 0.9999942779541016
unresponsiveness O O 0.9666329622268677
to O O 0.9988424181938171
YY1 S-protein S-DNA 0.6471055150032043
-mediated O O 0.9748222827911377

ternary O O 0.7512475252151489
IcsA-N-WASP-Arp2/3 B-protein B-protein 0.27255481481552124
complex E-protein E-protein 0.9918701648712158
, O O 0.9941944479942322
which O O 0.9999356269836426
nucleates O O 0.993833065032959
actin S-protein S-protein 0.8572954535484314
polymerization O O 0.9626442193984985
. O O 0.9999798536300659
The O O 0.9999629259109497
Arp2/3 B-protein B-protein 0.34427088499069214
complex E-protein E-protein 0.9833394289016724
is O O 0.9994839429855347
essential O O 0.9999310970306396
in O O 0.9999822378158569
initiation O O 0.9948363304138184
of O O 0.9999020099639893
actin S-protein S-protein 0.7275187373161316

from O O 0.9989854693412781
patients O O 0.9993813037872314
with O O 0.9999876022338867
early O O 0.9104332327842712
untreated O O 0.9683641195297241
RA O O 0.951748788356781
manifest O O 0.9994825124740601
an O O 0.9999545812606812
intrinsic O O 0.9547725915908813
abnormality O O 0.952549934387207
in O O 0.9998855590820312
their O O 0.9999241828918457
ability O O 0.9996366500854492
to O O 0.9999750852584839
differentiate O O 0.9996881484985352
into O O 0.9998705387115479
specific O O 0.9015427231788635
cytokine-producing B-cell_type B-cell_type 0.3272295296192169
effector I-cell_type I-cell_type 0.5175692439079285
cells E-cell_type E-cell_type 0.5680063962936401
that O O 0.9985799789428711
might O O 0.9999978542327881
contribute O O 0.9999979734420776
to O O 0.9999867677688599
the O O 0.9998655319213867
characteristic O O 0.9750884771347046
Th1-dominated O O 0.3814376890659332
chronic O O 0.24885165691375732
( O O 0.6716523170471191
auto O O 0.47821950912475586

Here O O 0.9997488856315613
we O O 0.9999920129776001
show O O 0.9999901056289673
that O O 0.9999969005584717
perceived O O 0.9794794917106628
pain O B-Disease 0.9743223786354065
intensity O O 0.8487026691436768
in O O 0.9842236638069153
secondary O O 0.845913290977478
hyperalgesia O B-Disease 0.8779830932617188
is O O 0.9852625131607056
decreased O O 0.9942027926445007
when O O 0.9999771118164062
attention O O 0.971946656703949
is O O 0.9982228875160217
distracted O O 0.9942798614501953
away O O 0.9999474287033081
from O O 0.9999953508377075
the O O 0.9998632669448853
painful O O 0.9252156019210815
pinprick O O 0.48454058170318604
stimulus O O 0.7527623772621155
with O O 0.9999676942825317
a O O 0.9999246597290039
visual O O 0.9378916621208191
task O O 0.9789630174636841
. O O 0.9999984502792358

II-positive I-cell_line I-cell_line 0.5261608958244324
nonlymphoid I-cell_line I-cell_line 0.40730544924736023
glioblastoma I-cell_line I-cell_line 0.7576743364334106
cell I-cell_line I-cell_line 0.8913908004760742
line E-cell_line E-cell_line 0.9944236874580383
does O O 0.999607503414154
not O O 0.9999790191650391
exhibit O O 0.9997696280479431
interactions O O 0.9978070855140686
at O O 0.9999984502792358
the O O 0.9999444484710693
octamer B-DNA B-DNA 0.4412182867527008
site E-DNA E-DNA 0.9438430666923523
despite O O 0.9999217987060547
the O O 0.9999959468841553
presence O O 0.9998458623886108
of O O 0.9999905824661255
the O O 0.999919056892395
ubiquitous B-protein O 0.6782185435295105
OTF-1 I-protein B-protein 0.27510911226272583
factor E-protein E-protein 0.6280516386032104

Development O O 0.9903616905212402
of O O 0.9994975328445435
levodopa S-Chemical B-Chemical 0.9206150770187378
- O O 0.913496196269989
induced O O 0.9978233575820923
dyskinesias O B-Disease 0.9697564840316772
in O O 0.9842028617858887
parkinsonian O O 0.6386468410491943
monkeys O O 0.6507219076156616
may O O 0.9995864033699036
depend O O 0.9999912977218628
upon O O 0.9999300241470337
rate O O 0.9995885491371155
of O O 0.9997888207435608
symptom O O 0.7228745818138123
onset O O 0.5230060815811157
and O O 0.9972881078720093
/ O O 0.9997240900993347
or O O 0.9998778104782104
duration O O 0.9795457124710083
of O O 0.9987795948982239
symptoms O O 0.597409188747406
. O O 0.9999570846557617

, O O 0.9162858724594116
ie O O 0.9739319086074829
, O O 0.9982509016990662
gelatinase S-protein O 0.8735371828079224
granules O O 0.8665520548820496
, O O 0.9990684390068054
which O O 0.9999891519546509
, O O 0.99994957447052
in O O 0.999968409538269
concert O O 0.9755553007125854

plasma B-protein I-protein 0.6237198710441589
sialyltransferase E-protein E-protein 0.7517469525337219
: O O 0.964992880821228
cortisol O O 0.8889757394790649
ratio O O 0.9113489389419556
reflects O O 0.9999860525131226
HPA O O 0.7763343453407288
axis O O 0.8138520121574402
function O O 0.9968973398208618
, O O 0.9999860525131226
alterations O O 0.9972123503684998
in O O 0.9999517202377319
specific O O 0.9736951589584351
isozyme O S-protein 0.5503624081611633
activity O O 0.9933497309684753
may O O 0.9999790191650391

Age O O 0.9510344862937927
at O O 0.9999343156814575
presentation O O 0.9966698288917542
, O O 0.9999842643737793
time O O 0.9989338517189026
of O O 0.9999209642410278
ictus O O 0.7091723084449768
after O O 0.9662586450576782
intoxication O O 0.5516937971115112
, O O 0.9990503191947937
Hunt O O 0.6325293183326721
and O O 0.9971336126327515
Hess O O 0.8627867102622986
grade O O 0.9851071238517761
of O O 0.9998306035995483
subarachnoid B-Disease O 0.48963025212287903
hemorrhage I-Disease O 0.770066499710083
, O O 0.9877170920372009
size O O 0.9986153841018677
of O O 0.9997506737709045
the O O 0.9996907711029053
aneurysm B-Disease O 0.9010028839111328
, O O 0.9751437902450562
location O O 0.9312307834625244
of O O 0.9950388073921204
the O O 0.9981033802032471
aneurysm B-Disease O 0.9197888970375061
, O O 0.9786282777786255
and O O 0.999861478805542
the O O 0.999962329864502
Glasgow O O 0.8970942497253418
Outcome O O 0.799766480922699
Scale O O 0.9320191740989685
score O O 0.9854810833930969
were O O 0.9999943971633911
assessed O O 0.9999024868011475
and O O 0.9999431371688843
compared O O 0.9998764991760254
. O O 0.9999971389770508

diethyl O O 0.7157526612281799
maleate O O 0.7389475703239441
( O O 0.9983201622962952
DEM O O 0.8840879201889038
) O O 0.9996334314346313
prevented O O 0.9999402761459351
the O O 0.9999854564666748
development O O 0.9998712539672852
of O O 0.9999858140945435
differentiated O O 0.8696677088737488
features O O 0.8814698457717896
in O O 0.9999662637710571
response O O 0.9968442916870117
to O O 0.9999759197235107
phorbol O O 0.8747268915176392
esters O O 0.9228543043136597
, O O 0.9998433589935303
including O O 0.9999879598617554
adherence O O 0.980201780796051

antidiabetic O O 0.49805405735969543

vitro O O 0.8112677335739136
. O O 0.9989950060844421
1 O O 0.9672060608863831
. O O 0.9998449087142944
This O O 0.9999942779541016
study O O 0.999948263168335
was O O 0.9999964237213135
designed O O 0.9999957084655762
to O O 0.9999988079071045
investigate O O 0.9999932050704956
the O O 0.9999815225601196
presence O O 0.9995476603507996
of O O 0.9999865293502808
estrogen O B-protein 0.44454124569892883
type O I-protein 0.64285808801651
I O E-protein 0.5803747773170471
( O O 0.8497897982597351
high O O 0.9127808809280396
affinity O O 0.9063768982887268
, O O 0.99592125415802
low O O 0.9734523892402649
capacity O O 0.9951836466789246
) O O 0.9997236132621765
and O O 0.9999560117721558
type O O 0.8559344410896301
II O O 0.4268708825111389

cells E-cell_type E-cell_type 0.7074171304702759
with O O 0.999492883682251
long O O 0.7287865281105042
neurite O O 0.5686183571815491
processes O O 0.5540245175361633
) O O 0.9951890707015991
, O O 0.9999644756317139
MHC S-protein O 0.38050055503845215
I+/ O O 0.8702837824821472
MHC S-protein O 0.500885546207428
IIbright/CD83+/CD86+/ O O 0.8840535283088684
CD14 S-protein S-protein 0.7374329566955566
- O O 0.997890293598175
surface O O 0.9791204929351807
Ag O O 0.37409427762031555
expression O O 0.971837043762207
, O O 0.9993491768836975
and O O 0.9994581341743469
RelB S-protein S-protein 0.8479607105255127
and O O 0.968482494354248
DC S-cell_type S-protein 0.523301899433136
-CK1 O O 0.40290960669517517
gene O O 0.5989975333213806
expression O O 0.9919185042381287
. O O 0.9999828338623047
Functional O O 0.9042031168937683

that O O 0.9906361699104309
is O O 0.9999150037765503
blocked O O 0.9997636675834656
by O O 0.9999920129776001
cyclosporin O O 0.9375661611557007
A O O 0.7616866230964661
. O O 0.9996254444122314
We O O 0.9999736547470093
have O O 0.9999920129776001
previously O O 0.9998879432678223
identified O O 0.9999744892120361
a O O 0.9998774528503418
promoter B-DNA B-DNA 0.4113450050354004
element E-DNA E-DNA 0.9831347465515137
, O O 0.9962490200996399
kappa B-DNA B-DNA 0.6608194708824158
3 E-DNA E-DNA 0.9600039720535278
, O O 0.9698715209960938
that O O 0.9996906518936157
is O O 0.9999096393585205
required O O 0.9998962879180908
for O O 0.999976396560669
calcium-stimulated O O 0.8373484015464783
, O O 0.9782751798629761
cyclosporin O O 0.8542389869689941
A-sensitive O O 0.8787687420845032

macrophages S-cell_type S-cell_type 0.45628827810287476

dimer E-protein E-protein 0.8032885193824768
of O O 0.9812238216400146
calcineurin B-protein B-protein 0.4460846185684204
A I-protein I-protein 0.8722872138023376
and I-protein I-protein 0.688648521900177
B I-protein I-protein 0.6338051557540894
subunits E-protein E-protein 0.9909958243370056
. O O 0.9998482465744019
Evaluation O O 0.9999337196350098
of O O 0.9999786615371704
monoclonal O B-protein 0.7334383726119995
anti-D O I-protein 0.31840166449546814
reagents O E-protein 0.3843866288661957
using O O 0.9837005734443665
D B-cell_line B-cell_type 0.48627766966819763
variant I-cell_line I-cell_type 0.6962775588035583
cells E-cell_line E-cell_type 0.907110333442688
. O O 0.9998559951782227
Monoclonal B-protein B-protein 0.8134893774986267
anti-D I-protein I-protein 0.3204326331615448
antibodies E-protein E-protein 0.9891574382781982
submitted O O 0.9995943903923035
to O O 0.9999915361404419
the O O 0.9999626874923706
Third O O 0.7762380838394165
Monoclonal O O 0.6351220607757568
International O O 0.5036388635635376
Workshop O O 0.6776040196418762

in O O 0.997312068939209
primary B-cell_type B-cell_type 0.7167286276817322
mouse I-cell_type I-cell_type 0.8778746724128723
T I-cell_type I-cell_type 0.9566851854324341
cells E-cell_type E-cell_type 0.9776597619056702
. O O 0.9994112253189087
In O O 0.9999834299087524
contrast O O 0.9998654127120972
to O O 0.9999901056289673
that O O 0.9998165965080261
reported O O 0.996218740940094
for O O 0.9987499713897705
human B-cell_type O 0.44723767042160034

African O O 0.7546314001083374
populations O O 0.6854100227355957
, O O 0.9996441602706909
after O O 0.9999939203262329
correction O O 0.9965488314628601
for O O 0.9999946355819702
other O O 0.9996337890625
known O O 0.9964421391487122
TNF O O 0.36224564909935
polymorphisms O O 0.3115110695362091
and O O 0.9971476197242737
linked O O 0.9948705434799194
HLA B-DNA O 0.3703222870826721

CD8+CD18bright B-cell_type B-cell_type 0.46308669447898865
T I-cell_type I-cell_type 0.7427945137023926
cells E-cell_type E-cell_type 0.6584569215774536
correlates O O 0.9986831545829773
with O O 0.9999969005584717
the O O 0.9999631643295288
activation O O 0.9947638511657715
of O O 0.999855637550354
the O O 0.999743640422821
stress B-protein B-protein 0.5780105590820312
kinases E-protein E-protein 0.951651930809021
, O O 0.9949076771736145
p38 B-protein S-protein 0.6938202381134033

elevated O O 0.9066793322563171
IgE S-protein S-protein 0.9026299715042114
. O O 0.9995009899139404
This O O 0.9999779462814331
implies O O 0.9999858140945435
that O O 0.9999963045120239
high O O 0.983528733253479
levels O O 0.9990171194076538
of O O 0.9999303817749023
IgE S-protein S-protein 0.9667856693267822
in O O 0.999849796295166
these O O 0.9999576807022095
patients O O 0.9993382096290588
either O O 0.999993085861206
results O O 0.9998251795768738
from O O 0.9999362230300903
B B-cell_type B-cell_type 0.8329416513442993
cells E-cell_type E-cell_type 0.9881886839866638
that O O 0.999267041683197
have O O 0.9999868869781494
already O O 0.9999477863311768
undergone O O 0.9994601607322693
class O O 0.9243724346160889
switching O O 0.9646134972572327
, O O 0.9998360872268677
from O O 0.9999762773513794
Ig O B-protein 0.2384825348854065
class O I-protein 0.6329574584960938

The O O 0.9993570446968079
co O O 0.8271920680999756
- O O 0.9843664169311523
administration O O 0.9992910623550415
of O O 0.9999161958694458
aspirin B-Chemical B-Chemical 0.9285579919815063
with O O 0.9953685998916626
N B-Chemical B-Chemical 0.9613978862762451
- I-Chemical I-Chemical 0.9855329394340515
[ I-Chemical I-Chemical 0.9873073101043701
4 I-Chemical I-Chemical 0.9755532741546631
- I-Chemical I-Chemical 0.9927592277526855
( I-Chemical I-Chemical 0.9913057684898376
5 I-Chemical I-Chemical 0.9864094257354736
- I-Chemical I-Chemical 0.9954133629798889
nitro I-Chemical I-Chemical 0.9697585105895996
- I-Chemical I-Chemical 0.9953289031982422
2 I-Chemical I-Chemical 0.9818791747093201
- I-Chemical I-Chemical 0.9959068298339844
furyl I-Chemical I-Chemical 0.9697704911231995
) I-Chemical I-Chemical 0.972620964050293
- I-Chemical I-Chemical 0.9947875738143921
2 I-Chemical I-Chemical 0.9808167815208435
- I-Chemical I-Chemical 0.9961293935775757
thiazolyl I-Chemical I-Chemical 0.9608455300331116
] I-Chemical I-Chemical 0.9492137432098389
- I-Chemical I-Chemical 0.988006055355072
formamide I-Chemical I-Chemical 0.9463832974433899
( O O 0.8505809307098389
FANFT B-Chemical B-Chemical 0.8725964426994324
) O O 0.8492739200592041
to O O 0.9998688697814941
rats O O 0.9719491004943848
resulted O O 0.9997935891151428
in O O 0.99992835521698
a O O 0.9998863935470581
reduced O O 0.9919177889823914
incidence O O 0.984226405620575
of O O 0.9997227787971497
FANFT B-Chemical B-Chemical 0.9127865433692932
- O O 0.9571341276168823
induced O O 0.9990980625152588
bladder B-Disease B-Disease 0.5725269913673401
carcinomas I-Disease I-Disease 0.9684333205223083
but O O 0.9934013485908508
a O O 0.9999555349349976
concomitant O O 0.9110965132713318
induction O O 0.9032157063484192
of O O 0.9983983635902405
forestomach B-Disease O 0.5906503796577454
tumors I-Disease O 0.7991782426834106
. O O 0.9996793270111084

colony-stimulating I-protein I-protein 0.391927033662796
factor I-protein I-protein 0.8468981385231018
( I-protein I-protein 0.5581126809120178
M-CSF I-protein I-protein 0.4718884527683258
) I-protein I-protein 0.5257596373558044
receptor E-protein E-protein 0.9906636476516724
is O O 0.9981277585029602
expressed O O 0.9999456405639648
in O O 0.9999829530715942
a O O 0.9999653100967407
tissue-specific O O 0.6505829095840454
fashion O O 0.5552887916564941
from O O 0.9997941851615906
two O O 0.9994271993637085
distinct O O 0.9854947328567505
promoters S-DNA S-DNA 0.8830624222755432
in O O 0.998630702495575
monocytes/macrophages S-cell_type S-cell_type 0.8983940482139587
and O O 0.9926020503044128
the O O 0.9993768334388733
placenta O O 0.5232723355293274
. O O 0.9988613128662109
In O O 0.9999728202819824
order O O 0.9998886585235596
to O O 0.9999908208847046
further O O 0.9999650716781616
understand O O 0.9999674558639526
the O O 0.9999698400497437
transcription O B-protein 0.5377614498138428
factors O E-protein 0.9964063763618469
which O O 0.9996504783630371
play O O 0.9999629259109497
a O O 0.9999939203262329
role O O 0.9970377683639526

Due O O 0.9998144507408142
to O O 0.9999735355377197
severe O O 0.9879343509674072
systolic O B-Disease 0.648384690284729
dysfunction O I-Disease 0.9441008567810059
losartan S-Chemical S-Chemical 0.5410894155502319
was O O 0.9632882475852966
prescribed O O 0.9996280670166016
. O O 0.9999990463256836

A O O 0.9970588684082031
respiratory O O 0.5176500678062439
arrest O O 0.9350951910018921
with O O 0.9767441749572754
severe O O 0.9276173710823059
desaturation O B-Disease 0.9133824706077576
and O O 0.9345784783363342
bradycardia O B-Disease 0.983590304851532
occurred O O 0.9616711139678955
. O O 0.999996542930603

, O O 0.9777536392211914
coexpression O O 0.9867576360702515
of O O 0.9997120499610901
the O O 0.9998812675476074
p65 B-protein B-protein 0.5345803499221802
subunit E-protein E-protein 0.938349187374115
of O O 0.9602885246276855
nuclear B-protein B-protein 0.532663106918335
factor I-protein I-protein 0.5915204286575317
( I-protein I-protein 0.6885527968406677
NF I-protein I-protein 0.951473593711853
) I-protein I-protein 0.9609987139701843
-kappa I-protein I-protein 0.9614297151565552
B E-protein E-protein 0.9390857815742493
, O O 0.9540761709213257

546-nucleotide B-DNA O 0.4559118151664734

Following O O 0.9998723268508911
major O O 0.9869982600212097
intracranial O O 0.7837733030319214
surgery O O 0.6833028793334961
in O O 0.997533917427063
a O O 0.9998914003372192
35 O O 0.9987903237342834
- O O 0.9998770952224731
year O O 0.9999316930770874
- O O 0.9998940229415894
old O O 0.9989506006240845
man O O 0.9908400177955627
, O O 0.9999728202819824
sodium B-Chemical B-Chemical 0.9329079985618591
pentothal E-Chemical I-Chemical 0.9312769174575806
was O O 0.9871273040771484
intravenously O O 0.9973759651184082
infused O O 0.9989326596260071
to O O 0.9999591112136841
minimize O O 0.9982982277870178
cerebral O O 0.7161369919776917
ischaemia O O 0.8675804138183594
. O O 0.996711254119873

Evidence O O 0.9960238933563232
is O O 0.9999713897705078
accumulating O O 0.9995384216308594
that O O 0.9999788999557495
lindane S-Chemical B-Chemical 0.9149496555328369
can O O 0.9983893632888794
be O O 0.9999678134918213
toxic O B-Disease 0.8208712339401245
to O I-Disease 0.7246303558349609
the O I-Disease 0.692799985408783
central O I-Disease 0.5290917158126831
nervous O I-Disease 0.9362224340438843
system O I-Disease 0.9893626570701599
and O O 0.7663711309432983
may O O 0.997028648853302
be O O 0.9999380111694336
associated O O 0.9997901320457458
with O O 0.9999839067459106
aplastic O B-Disease 0.6685607433319092
anaemia O I-Disease 0.9436861276626587
. O O 0.9988002777099609

. O O 0.9944546818733215
HIV O O 0.9468957185745239
infection O O 0.9898597598075867
of O O 0.9999243021011353
fresh O B-cell_type 0.43092742562294006
monocytes S-cell_type E-cell_type 0.9017181396484375
failed O O 0.9982910752296448
to O O 0.999971866607666
induce O O 0.9998844861984253
p50/p65 S-protein S-protein 0.8549705147743225
as O O 0.9981220364570618
seen O O 0.9998966455459595
in O O 0.9999065399169922
MDMs S-cell_type S-cell_type 0.8804365992546082
. O O 0.9998397827148438
The O O 0.9999963045120239
replacement O O 0.9926803708076477
of O O 0.9998111128807068
p50 B-protein B-protein 0.5396692752838135
homodimers E-protein E-protein 0.9506722092628479
with O O 0.9991331696510315
transcriptionally O B-protein 0.7490485906600952
active O I-protein 0.757540225982666
heterodimers O E-protein 0.6368306875228882
following O O 0.9994087219238281
time O O 0.9980772733688354
in O O 0.9998610019683838
culture O O 0.9475560188293457
may O O 0.999972939491272
partially O O 0.9999818801879883
explain O O 0.9999926090240479
the O O 0.9999816417694092
progressive O O 0.9637568593025208
increase O O 0.9864266514778137

to O O 0.9780224561691284

use O O 0.9960201382637024
of O O 0.9999605417251587
embryonic B-cell_type B-cell_type 0.5378273129463196
stem I-cell_type I-cell_type 0.6702132821083069
cells E-cell_type E-cell_type 0.9215689301490784
in O O 0.9999047517776489
the O O 0.9999889135360718
analysis O O 0.9996969699859619
of O O 0.9999909400939941
hematopoietic B-DNA O 0.7247717380523682
gene E-DNA O 0.6615089774131775
expression O O 0.9806444048881531
and O O 0.9998586177825928
the O O 0.999983549118042
use O O 0.9999586343765259
of O O 0.9999872446060181
targeted O O 0.9394823908805847
gene O O 0.8592475652694702
disruption O O 0.992108166217804
to O O 0.9999786615371704
analyze O O 0.9999383687973022
the O O 0.9999843835830688
role O O 0.9998044371604919
of O O 0.9999767541885376
transcription B-protein B-protein 0.5698187351226807
factors E-protein E-protein 0.994131863117218
in O O 0.999496579170227
hematopoiesis O O 0.8772132396697998
. O O 0.9998654127120972
Finally O O 0.9996918439865112
, O O 0.9999819993972778
the O O 0.9999802112579346
status O O 0.9987592697143555
of O O 0.9999414682388306
our O O 0.999823272228241
current O O 0.8643723130226135

, O O 0.9769896268844604
complement B-protein O 0.9908251166343689
receptor-1 I-protein B-protein 0.5429067015647888
cell I-protein I-protein 0.470569372177124
surface I-protein I-protein 0.7889936566352844
protein E-protein E-protein 0.9631672501564026
, O O 0.9518219828605652
and O O 0.9977465271949768
TNF-alpha B-protein S-protein 0.980676531791687
protein E-protein O 0.7351523041725159
presence O O 0.9711848497390747
. O O 0.9999563694000244
Monocytes S-cell_type S-cell_type 0.8611247539520264
stimulated O O 0.9964699745178223
with O O 0.9999103546142578
LPS O O 0.9492269158363342
concentrations O O 0.9964178800582886
of O O 0.9999537467956543
1.0 O O 0.9519122838973999
micrograms/ml O O 0.9046381115913391
displayed O O 0.9995602965354919
the O O 0.9999773502349854
above O O 0.9952651262283325
cytotoxic O B-protein 0.7291455268859863
markers O E-protein 0.8629462122917175
, O O 0.9990847110748291
whereas O O 0.9999799728393555
monocytes S-cell_type S-cell_type 0.9664211273193359
stimulated O O 0.9984244108200073
with O O 0.9999244213104248
DHEA O O 0.6404969096183777
alone O O 0.997456967830658
or O O 0.9999536275863647
with O O 0.9999525547027588
LPS O O 0.9682521224021912
at O O 0.9999923706054688
a O O 0.9999788999557495
lower O O 0.9977540373802185
concentration O O 0.9981879591941833
of O O 0.9999326467514038
0.2 O O 0.9100818037986755
ng/ml O O 0.8917095065116882
did O O 0.9999083280563354
not O O 0.9999707937240601
. O O 0.9999915361404419
However O O 0.9998652935028076
, O O 0.9999618530273438
when O O 0.9998462200164795
used O O 0.9961330890655518

an O O 0.9982019662857056
open B-DNA B-DNA 0.7553800940513611
reading I-DNA I-DNA 0.502165675163269
frame E-DNA E-DNA 0.9725134372711182
of O O 0.9986257553100586
900 B-DNA O 0.9736020565032959
amino I-DNA O 0.948879063129425
acids E-DNA O 0.911741316318512
capable O O 0.9994491934776306
of O O 0.999957799911499
encoding O O 0.9990425705909729
a O O 0.9994138479232788
97-kDa B-protein B-protein 0.7149351835250854
protein E-protein E-protein 0.9718464016914368
. O O 0.998241662979126
This O O 0.9999328851699829
protein O O 0.949904203414917
is O O 0.9997430443763733
most O O 0.9999604225158691
similar O O 0.9999172687530518
to O O 0.9999752044677734
the O O 0.999829888343811
105-kDa O B-protein 0.6681123971939087

peptides O O 0.36993226408958435
and O O 0.9902665019035339
IFN B-protein B-protein 0.39523592591285706
gamma E-protein E-protein 0.9338443279266357
, O O 0.9397327303886414
or O O 0.9984109401702881
by O O 0.9998875856399536
LPS O O 0.9306016564369202
. O O 0.999921441078186
Glucocorticoid-mediated O O 0.9336497783660889
repression O O 0.9775782823562622
of O O 0.9995504021644592
cytokine B-DNA B-DNA 0.6870853900909424
gene E-DNA E-DNA 0.8675495982170105
transcription O O 0.832082986831665
in O O 0.9995280504226685
human O B-cell_type 0.8664475083351135

The O O 0.998087465763092
site O O 0.9973865151405334
of O O 0.9999641180038452
common O O 0.9449635744094849
side O O 0.9388570785522461
effects O O 0.990564227104187
of O O 0.9995760321617126
sumatriptan B-Chemical B-Chemical 0.9206790328025818
. O O 0.9991434812545776

selection O O 0.973821759223938
. O O 0.9999706745147705
In O O 0.9999297857284546
clinics O O 0.9986217021942139
these O O 0.9999966621398926
molecules O O 0.9882015585899353
are O O 0.9999688863754272
also O O 0.9999760389328003
used O O 0.9999734163284302
for O O 0.999990701675415
their O O 0.9999380111694336
potencies O O 0.9977502226829529
in O O 0.9999840259552002
inducing O O 0.9963076114654541
apoptosis O O 0.9728025794029236
of O O 0.9997438788414001
malignant B-cell_type B-cell_type 0.5745784640312195
lymphoid I-cell_type I-cell_type 0.8616116642951965
cells E-cell_type E-cell_type 0.9545941948890686
. O O 0.9998062252998352
Glucocorticoids O O 0.949945867061615
are O O 0.9998995065689087
mediating O O 0.9994788765907288
their O O 0.9999250173568726
effects O O 0.9998810291290283
after O O 0.9999954700469971
binding O O 0.972264289855957
to O O 0.9980078339576721

( O O 0.8982967138290405
NFAT S-protein S-protein 0.6108035445213318
) O O 0.718398928642273
, O O 0.9984835982322693
the O O 0.9999798536300659
binding B-DNA B-DNA 0.6419813632965088
site E-DNA E-DNA 0.8397811055183411
of O O 0.9030178785324097
which O O 0.998984158039093
is O O 0.9995348453521729
included O O 0.9998154044151306
in O O 0.9999626874923706
the O O 0.9999096393585205
IL-2 B-DNA B-DNA 0.6452950239181519
gene I-DNA I-DNA 0.6656289100646973
promoter E-DNA E-DNA 0.9903632998466492
. O O 0.999788224697113
The O O 0.999988317489624
activation O O 0.9908588528633118
of O O 0.9990425705909729
NFAT S-protein S-protein 0.894446074962616
was O O 0.9990052580833435

Nine O O 0.9772078394889832
patients O O 0.998689591884613
with O O 0.999931812286377
severe O O 0.9585669040679932
pain B-Disease B-Disease 0.9067116379737854
in O O 0.9790868759155273
their O O 0.9955949187278748
feet O O 0.9917916059494019
, O O 0.9999363422393799
which O O 0.9998980760574341
was O O 0.9999014139175415
registered O O 0.9999032020568848
after O O 0.9999823570251465
transplantation O O 0.9822354316711426
, O O 0.9999607801437378
were O O 0.9999841451644897
investigated O O 0.9999563694000244
. O O 0.9999990463256836

kappaB-regulated B-DNA O 0.8088882565498352
luciferase I-DNA S-protein 0.6285459399223328
encoding I-DNA O 0.8622457385063171
vector E-DNA O 0.6811553239822388
and O O 0.992976725101471
by O O 0.9998816251754761
electrophoretic O O 0.8961108922958374
mobility O O 0.9791123867034912

DNA O O 0.5664993524551392
is O O 0.9993282556533813
required O O 0.9999761581420898
for O O 0.9999868869781494
DNA O O 0.9608626961708069
binding O O 0.9810638427734375
and O O 0.9991555213928223
transcriptional O O 0.9259623885154724
activation O O 0.9859195947647095
and O O 0.9997802376747131
suggest O O 0.9999918937683105
that O O 0.9999967813491821
transcriptional O O 0.9115476012229919
activation O O 0.9715837240219116
mediated O O 0.9996852874755859
by O O 0.9999946355819702
the O O 0.9998664855957031
individual O B-protein 0.9113948941230774
rel-related B-protein I-protein 0.6209030747413635
proteins E-protein E-protein 0.9559611678123474
will O O 0.999854326248169
differ O O 0.9999912977218628
dramatically O O 0.9999452829360962
, O O 0.9999926090240479
depending O O 0.9999961853027344
on O O 0.9999855756759644
the O O 0.9999890327453613
specific O O 0.9743665456771851

432 O O 0.7474687099456787
, O O 0.9693361520767212
435 O O 0.78066086769104
, O O 0.9877507090568542
437 O O 0.3825119435787201
, O O 0.9894282221794128
438 O O 0.529280960559845
, O O 0.9811087250709534
and O O 0.9915323853492737
440 O O 0.31302115321159363
( O O 0.9891276955604553
position B-DNA O 0.7975177764892578
P1 I-DNA S-DNA 0.8096449375152588
, I-DNA O 0.9689448475837708
P4 I-DNA S-DNA 0.9630545973777771
, I-DNA O 0.9895225167274475
P6 I-DNA S-DNA 0.9537100195884705
, I-DNA O 0.9874760508537292
P7 I-DNA S-DNA 0.9470916986465454
, I-DNA O 0.9749886989593506
and I-DNA O 0.9931252002716064
P9 E-DNA S-DNA 0.846153974533081

repeats O E-DNA 0.9194495677947998
, O O 0.9994606375694275
depending O O 0.9999971389770508
on O O 0.9999794960021973
the O O 0.9999303817749023
reconstitution O O 0.909322202205658
conditions O O 0.9822801947593689
. O O 0.999994158744812
In O O 0.9999415874481201
different O O 0.9959617257118225
genes S-DNA O 0.7946911454200745
, O O 0.9999500513076782
the O O 0.9999552965164185
core B-DNA B-DNA 0.7270338535308838
sequences E-DNA E-DNA 0.9571692943572998
are O O 0.9994091987609863
separated O O 0.9990007281303406
by O O 0.9999899864196777
integer O O 0.7121706008911133
numbers O O 0.8533715009689331
of O O 0.9981278777122498
helical O O 0.6272810101509094
turns O O 0.6021183729171753
. O O 0.9998879432678223
Considering O O 0.9999985694885254
the O O 0.9999853372573853
strong O O 0.9879092574119568
positive O O 0.965099036693573
regulatory O O 0.9232740998268127
effect O O 0.9990044236183167
of O O 0.9999804496765137
this O O 0.9998741149902344
element S-DNA O 0.5948400497436523
and O O 0.9982500672340393
its O O 0.9998855590820312
presence O O 0.9972870349884033
in O O 0.9999812841415405
several O O 0.9988952279090881
T-cell-expressed B-DNA B-DNA 0.35364770889282227
cytokine I-DNA I-DNA 0.3828575909137726
genes E-DNA E-DNA 0.9928163290023804
, O O 0.9996222257614136
it O O 0.999969482421875
may O O 0.9999964237213135
be O O 0.9999971389770508
crucial O O 0.9998700618743896

days O O 0.8612930178642273
) O O 0.9808312058448792
post-stimulation O O 0.9927969574928284
. O O 0.9999980926513672
A O O 0.9999940395355225
better O O 0.9997593760490417
understanding O O 0.9998492002487183
of O O 0.9999831914901733
transcriptional O O 0.9436572194099426
regulation O O 0.9972344040870667
at O O 0.9999988079071045
this O O 0.9999935626983643
important O O 0.9977419376373291
stage O O 0.9998098015785217
of O O 0.9999784231185913
T-cell O O 0.7772665023803711
maturation O O 0.9905937314033508
may O O 0.9999960660934448
yield O O 0.9999961853027344
new O O 0.9991928935050964
insights O O 0.9988991022109985
into O O 0.9999934434890747
T-cell O O 0.5619859099388123
development O O 0.9735956192016602
and O O 0.9997453093528748
new O O 0.9855480790138245
immunotherapeutic O O 0.8461750745773315
targets O O 0.5857952833175659
. O O 0.9999827146530151
Involvement O O 0.9998952150344849
of O O 0.9999841451644897
different O O 0.996932864189148
transduction O O 0.81170654296875

. O O 0.9965099692344666
First O O 0.9969205856323242
, O O 0.9999847412109375
we O O 0.9999845027923584
show O O 0.9999966621398926
that O O 0.9999983310699463
persistent O O 0.9852008819580078
HIV O O 0.9384374618530273
infection O O 0.9296567440032959
results O O 0.9998458623886108
in O O 0.999993085861206
the O O 0.9999717473983765

High O O 0.9809895157814026
doses O O 0.998694121837616
of O O 0.9999309778213501
the O O 0.9991683959960938
vitamin B-Chemical B-Chemical 0.9448797106742859
K E-Chemical E-Chemical 0.9254176020622253
antagonist O O 0.6235710978507996
Warfarin S-Chemical B-Chemical 0.9280800223350525
are O O 0.9955320358276367
also O O 0.9999871253967285
known O O 0.9999834299087524
to O O 0.9999039173126221
cause O O 0.9999042749404907
calcification O O 0.8657506704330444
of O O 0.5590015053749084
the O O 0.604928731918335
artery O O 0.9124727845191956
media O O 0.9272215962409973
, O O 0.9499139189720154
but O O 0.999723494052887
at O O 0.9999958276748657
treatment O O 0.999607264995575
times O O 0.9999452829360962
of O O 0.9999873638153076
2 O O 0.9989017248153687
weeks O O 0.9999254941940308
or O O 0.999987006187439
longer O O 0.9999384880065918
yet O O 0.9999803304672241
not O O 0.9999432563781738
at O O 0.9999864101409912
1 O O 0.9994122982025146
week O O 0.999901533126831
. O O 0.9999992847442627

To O O 0.9988048076629639
analyze O O 0.9999110698699951
the O O 0.999945878982544
transformation O O 0.9053551554679871
patterns O O 0.9863172173500061
, O O 0.999992847442627
we O O 0.9999744892120361
classified O O 0.9999173879623413
the O O 0.999890923500061
exencephaly B-Disease O 0.7622048258781433
by O O 0.9828593134880066
size O O 0.9886233806610107
and O O 0.9997166991233826
shape O O 0.9944711923599243
of O O 0.9995648264884949
the O O 0.9998724460601807
exencephalic B-Disease O 0.7461802363395691
tissue O O 0.7926857471466064
into O O 0.9997937083244324
several O O 0.9997075200080872
types O O 0.9988842606544495
at O O 0.9999945163726807
E13 O O 0.9266313910484314
. O O 0.9998785257339478
5 O O 0.9915329813957214
and O O 0.9992654919624329
E18 O O 0.9385119080543518
. O O 0.9999638795852661
5 O O 0.9845448732376099
. O O 0.9998693466186523

The O O 0.9982089996337891
PML B-protein O 0.3062443435192108
gene I-protein O 0.3258903920650482
product E-protein O 0.780867874622345
has O O 0.9992520213127136
been O O 0.9999415874481201
localized O O 0.9998459815979004
to O O 0.9999812841415405
subnuclear B-cell_line O 0.8818820714950562
dot-like I-cell_line O 0.8196563124656677
structures E-cell_line O 0.9191524386405945
variously O O 0.999504804611206
termed O O 0.9994175434112549
PODs O O 0.642098069190979
, O O 0.9940117001533508
ND10s O O 0.5296908020973206
, O O 0.9917173981666565
Kr O O 0.609795868396759
bodies O O 0.8001813888549805
, O O 0.9990628361701965
or O O 0.9998594522476196
PML O O 0.700323760509491
nuclear O O 0.7523454427719116
bodies O O 0.8691727519035339
( O O 0.9994182586669922
PML O O 0.9114693403244019
NBs O O 0.7302398681640625
) O O 0.9989675283432007
. O O 0.9999978542327881

No O O 0.9977062940597534
such O O 0.9999496936798096
obvious O O 0.9935339689254761
upregulation O O 0.8681874871253967
of O O 0.9967465400695801
Pgp O O 0.4857102334499359
was O O 0.9966965913772583
observed O O 0.9999150037765503
in O O 0.9999886751174927
liver O O 0.9308297634124756
sections O O 0.9813207983970642
. O O 0.9999982118606567

Additionally O O 0.9987279772758484
, O O 0.9999691247940063
ritonavir S-Chemical B-Chemical 0.9102275371551514
treatment O O 0.9715636968612671
selectively O O 0.9996225833892822
increased O O 0.9996646642684937
the O O 0.999869704246521
relative O O 0.9948764443397522
levels O O 0.9998365640640259
of O O 0.9999481439590454
PPARgamma O B-RNA 0.6587972044944763
mRNA O E-RNA 0.9874098896980286
, O O 0.999552309513092
a O O 0.9999833106994629
transcription O B-protein 0.7658097743988037
factor O E-protein 0.9155724048614502
responsible O O 0.99765944480896
for O O 0.9999758005142212
the O O 0.9999639987945557
regulation O O 0.9992403984069824
of O O 0.9999470710754395
CD36 O B-RNA 0.6125361323356628
mRNA O E-RNA 0.9795229434967041
expression O O 0.9836465716362
. O O 0.999997615814209

messenger O B-RNA 0.4180770516395569
RNA O E-RNA 0.7759615778923035
splicing O O 0.8766718506813049
, O O 0.999862790107727
B-cell B-protein B-protein 0.5503875613212585
Fc I-protein I-protein 0.47614648938179016
gamma I-protein I-protein 0.47766873240470886
RII E-protein E-protein 0.9788338541984558
contains O O 0.998755931854248
an O O 0.9999885559082031
insertion O O 0.9859340786933899
of O O 0.9997559189796448
47 O O 0.8752670288085938
amino O O 0.617091953754425
acids O O 0.4027789235115051
that O O 0.994261622428894
participates O O 0.9999094009399414
in O O 0.9998168349266052
determining O O 0.9961583018302917
receptor O O 0.9064854383468628
function O O 0.9903126955032349
in O O 0.999897837638855

Bacterial O O 0.6715984344482422

oxidant O O 0.7341645956039429
hypochlorous O O 0.9093005061149597
acid O O 0.9698176980018616
( O O 0.9997583031654358
HOCl O O 0.9558055996894836
; O O 0.9991335272789001
1 O O 0.9993341565132141
to O O 0.9996448755264282
7.5 O O 0.999387264251709
mM O O 0.9980069994926453
) O O 0.9997791647911072
in O O 0.9999722242355347
vitro O O 0.9929081201553345
, O O 0.9997879862785339
and O O 0.9999072551727295
protects O O 0.9997090697288513
from O O 0.9999744892120361
HOCl-mediated O O 0.871119499206543
lung O O 0.8878793716430664
injury O O 0.8261362314224243
in O O 0.9998660087585449
rats O O 0.9704552888870239
. O O 0.9999514818191528
Tyloxapol O O 0.8488298058509827
also O O 0.998494029045105
reduces O O 0.9999257326126099
the O O 0.9996090531349182
viscosity O O 0.9863992929458618
of O O 0.9999005794525146
CF O O 0.5312750935554504
sputum O O 0.6208235621452332
( O O 0.9984800219535828
from O O 0.9999622106552124
463 O O 0.9456696510314941
+/- O O 0.998487114906311
133 O O 0.9978176355361938
to O O 0.9999125003814697
128 O O 0.9982901215553284
+/- O O 0.9998327493667603
52 O O 0.9992671608924866
centipoise O O 0.9789318442344666
) O O 0.9998891353607178
. O O 0.999996542930603
We O O 0.9999967813491821
conclude O O 0.999998927116394
that O O 0.9999988079071045
tyloxapol O O 0.8649152517318726
is O O 0.9999147653579712
potentially O O 0.9999747276306152
useful O O 0.9998763799667358
as O O 0.999998927116394
a O O 0.9999953508377075
new O O 0.9924348592758179
antiinflammatory O O 0.9166989922523499
therapy O O 0.9888250231742859
for O O 0.9999858140945435
CF O O 0.8478119373321533
lung O O 0.9024365544319153
disease O O 0.8638066649436951
, O O 0.9998470544815063
and O O 0.9999344348907471
could O O 0.9999969005584717
possibly O O 0.9999889135360718
promote O O 0.9997476935386658

karyotypes O O 0.2995077967643738
, O O 0.9974229335784912
whereas O O 0.9999942779541016
2 O O 0.9937399625778198
cases O O 0.9989367127418518
had O O 0.9999881982803345
abnormalities O O 0.9811098575592041
of O O 0.9996793270111084
chromosome B-DNA B-DNA 0.41715008020401
17q E-DNA E-DNA 0.976695716381073
: O O 0.992679238319397
1 O O 0.930718719959259
with O O 0.9994076490402222
del B-DNA B-DNA 0.35072004795074463
( I-DNA I-DNA 0.7019035816192627
17 I-DNA I-DNA 0.46212029457092285
) I-DNA I-DNA 0.40685105323791504
( I-DNA I-DNA 0.8556413650512695
q25 I-DNA I-DNA 0.5325945615768433
) E-DNA E-DNA 0.7835047841072083
and O O 0.9832399487495422
the O O 0.9996297359466553
other O O 0.9995940327644348
with O O 0.9991920590400696
t B-DNA B-DNA 0.5559442639350891
( I-DNA I-DNA 0.49060124158859253

. O O 0.9933454990386963
Modulation O O 0.9923227429389954
of O O 0.9997698664665222
the O O 0.9998650550842285
immune O O 0.9497579336166382
response O O 0.9932695031166077
by O O 0.9999886751174927
progesterone-induced B-protein B-protein 0.7428672909736633
lymphocyte I-protein I-protein 0.35887041687965393
factors E-protein E-protein 0.9823696613311768
. O O 0.9997584223747253
Rat O S-protein 0.5195345878601074

, O O 0.9503923654556274

gene E-DNA E-DNA 0.9471341371536255
are O O 0.9995138645172119
unable O O 0.9999157190322876
to O O 0.9999874830245972
transcribe O O 0.9998998641967773
the O O 0.9999196529388428
HLA B-DNA B-DNA 0.4537753760814667
class I-DNA I-DNA 0.5000696182250977
II I-DNA I-DNA 0.3941584527492523
genes E-DNA E-DNA 0.9913210272789001
in O O 0.9997592568397522
response O O 0.9976307153701782
to O O 0.999975323677063
IFN-gamma S-protein S-protein 0.9661061763763428
treatment O O 0.9960483908653259
, O O 0.999983549118042
and O O 0.9999819993972778
reconstitution O O 0.9912416934967041
of O O 0.9993521571159363
functional O O 0.773337721824646
Rb S-protein S-protein 0.40974804759025574

downstream B-DNA B-DNA 0.7409613132476807
regulatory I-DNA I-DNA 0.6337316036224365
element I-DNA I-DNA 0.8728423118591309
1 E-DNA E-DNA 0.9566136002540588
[ O O 0.9899985194206238
DRE B-DNA B-DNA 0.7514914870262146
1 E-DNA E-DNA 0.9555943012237549
] O O 0.8126049041748047
) O O 0.9829522371292114
, O O 0.999805748462677
+195 B-DNA B-DNA 0.7300764918327332
to I-DNA I-DNA 0.7627189755439758
+240 E-DNA E-DNA 0.8654854893684387
, O O 0.9889699220657349
at O O 0.9999740123748779
the O O 0.9999496936798096
boundary O O 0.9774348735809326
of O O 0.9990062117576599
the O O 0.9997203946113586
R/U5 B-DNA B-DNA 0.5437021851539612
region E-DNA E-DNA 0.9304642677307129
of O O 0.9969009160995483
the O O 0.9999035596847534
long B-DNA B-DNA 0.4992803633213043
terminal I-DNA I-DNA 0.7783615589141846
repeat E-DNA E-DNA 0.988805890083313
which O O 0.9974662065505981
is O O 0.999929666519165
required O O 0.9998748302459717
for O O 0.9999728202819824
HTLV-I O O 0.5362555980682373
basal O O 0.6981377005577087
transcription O O 0.901512086391449
. O O 0.9998576641082764
We O O 0.9999732971191406
identified O O 0.9999756813049316
a O O 0.9999648332595825
protein O O 0.6199872493743896
, O O 0.8690445423126221
p37 O S-protein 0.8744264245033264
, O O 0.923513650894165
which O O 0.997119665145874
specifically O O 0.9996616840362549
bound O O 0.9998264908790588
to O O 0.9998846054077148
DRE B-DNA B-DNA 0.41085848212242126
1 E-DNA E-DNA 0.8337281346321106
. O O 0.9987367987632751
An O O 0.9999287128448486
affinity O O 0.9008210897445679
column O O 0.8508853316307068
fraction O O 0.9356213808059692
, O O 0.9997957348823547
containing O O 0.9993582367897034

regulatory I-DNA I-DNA 0.35575419664382935
region E-DNA E-DNA 0.7937424778938293
( O O 0.9929423332214355
LTR S-DNA S-DNA 0.9880417585372925
) O O 0.9873006939888
, O O 0.9999653100967407
we O O 0.9999780654907227
observed O O 0.9999865293502808
that O O 0.9999992847442627
okadaic O O 0.9013310670852661
acid O O 0.8615366816520691
( O O 0.9965046644210815
OKA O O 0.8842348456382751
) O O 0.9947383999824524
activates O O 0.9996936321258545
HIV O O 0.735863208770752
transcription O O 0.8834567070007324
through O O 0.9995482563972473
both O O 0.9998757839202881
the O O 0.9997065663337708
enhancer O S-DNA 0.9288807511329651
, O O 0.9935275912284851
responding O O 0.9994679093360901
to O O 0.9999774694442749
the O O 0.9998283386230469
factor O O 0.9217144250869751
NF-kappa B-protein B-protein 0.519395112991333
B E-protein E-protein 0.9780961275100708
, O O 0.9906417727470398
and O O 0.999758780002594
the O O 0.9999521970748901
promoter B-DNA O 0.6557289361953735
domain E-DNA O 0.49792659282684326
of O O 0.9273593425750732
the O O 0.995097815990448
LTR S-DNA S-DNA 0.9732999801635742
. O O 0.9995653033256531
The O O 0.9999935626983643
inducibility O O 0.9881947040557861
of O O 0.9998714923858643
HIV B-DNA B-DNA 0.6688905358314514
LTR-driven I-DNA I-DNA 0.5031864643096924
luciferase I-DNA I-DNA 0.4237429201602936
expression I-DNA I-DNA 0.8258181810379028
constructs E-DNA E-DNA 0.8377510905265808
in O O 0.9978066086769104
lymphoblastoid B-cell_type B-cell_type 0.6692234873771667
cells E-cell_type E-cell_type 0.8802340626716614
stimulated O O 0.9977904558181763
by O O 0.9999920129776001
OKA O S-protein 0.6313799619674683
depended O O 0.999320387840271
on O O 0.9998959302902222
both O O 0.9996329545974731
functional B-DNA O 0.9026788473129272

human B-DNA B-DNA 0.43713560700416565
class I-DNA I-DNA 0.4244914948940277
II I-DNA I-DNA 0.4320181608200073
transplantation I-DNA I-DNA 0.6064768433570862
gene E-DNA E-DNA 0.9875200986862183
, O O 0.9822521209716797
DRA S-DNA S-DNA 0.9952906370162964
. O O 0.9997257590293884
The O O 0.9999599456787109
promoter O S-DNA 0.947737991809845
of O O 0.9958289265632629
the O O 0.9999222755432129
major B-DNA B-DNA 0.4920262098312378
histocompatibility I-DNA I-DNA 0.6708897948265076
class I-DNA I-DNA 0.797061562538147
II I-DNA I-DNA 0.6725165247917175
gene E-DNA I-DNA 0.9271950721740723
DRA S-DNA E-DNA 0.6209403872489929
contains O O 0.9987756609916687
an O O 0.9998859167098999
octamer B-DNA B-DNA 0.5448698997497559
element E-DNA E-DNA 0.9833065867424011
( O O 0.9887392520904541
ATTTGCAT O S-DNA 0.9829443097114563
) O O 0.9649826884269714
that O O 0.9995993971824646
is O O 0.999971866607666
required O O 0.9999513626098633
for O O 0.99998939037323
efficient O O 0.989604115486145
DRA S-DNA S-DNA 0.6453008651733398
expression O O 0.93243008852005
in O O 0.9996366500854492
B B-cell_type B-cell_type 0.8703944087028503
cells E-cell_type E-cell_type 0.9642314314842224
. O O 0.9995765089988708

the O O 0.9970542192459106
cytoplasm O O 0.7621771097183228
to O O 0.995880126953125
the O O 0.9998273849487305
nucleus O O 0.942188560962677
during O O 0.9997496008872986
T-cell O O 0.7163222432136536
activation O O 0.9854097366333008
. O O 0.9999834299087524
This O O 0.9999599456787109
intracellular O B-protein 0.8167988061904907
signaling O I-protein 0.4992522597312927
complex O E-protein 0.9707905650138855
potently O O 0.9975898265838623
stimulates O O 0.999806821346283
kappa O O 0.6506170034408569
B-directed O O 0.5444268584251404
transcription O O 0.7116749286651611
from O O 0.999037504196167
either O O 0.9999464750289917
the O O 0.998920202255249
HIV-1 B-DNA B-DNA 0.7306792736053467
LTR E-DNA E-DNA 0.9936065673828125
or O O 0.9976654052734375
the O O 0.9997549653053284
IL-2R B-DNA B-DNA 0.7318655848503113
alpha I-DNA I-DNA 0.6690877676010132
promoter E-DNA E-DNA 0.9658787846565247
via O O 0.9729510545730591

METHODS O O 0.99446702003479
: O O 0.9999858140945435
This O O 0.9999877214431763
double O O 0.9846211671829224
- O O 0.9967285394668579
blind O O 0.9802479147911072
study O O 0.9995875954627991
examined O O 0.999987006187439
the O O 0.9999600648880005
incidence O O 0.9723663330078125
and O O 0.9996832609176636
severity O O 0.6612088084220886
of O O 0.9935356378555298
postoperative B-Disease O 0.7687444090843201
nausea I-Disease O 0.5943999886512756
and I-Disease O 0.8653913736343384
vomiting I-Disease O 0.8216142654418945
and O O 0.9363477826118469
pain B-Disease B-Disease 0.9344850778579712
in O O 0.9954386353492737
the O O 0.9998010993003845
first O O 0.9993141889572144
24 O O 0.999634861946106
h O O 0.9812189936637878
after O O 0.9998363256454468
sevoflurane B-Chemical B-Chemical 0.9210123419761658
anaesthesia O O 0.8212110996246338
in O O 0.9977432489395142
216 O O 0.9967373013496399
adult O O 0.895004153251648
day O O 0.9435431361198425
surgery O O 0.5608901977539062
patients O O 0.9960571527481079
. O O 0.9999994039535522

kinase E-protein E-protein 0.9300435781478882
dependent O O 0.87833172082901
and O O 0.9813023209571838
protein B-protein B-protein 0.6350758075714111
kinase I-protein I-protein 0.7222644686698914
C E-protein E-protein 0.9587627053260803
independent O O 0.8636350631713867
. O O 0.998691976070404
BACKGROUND O O 0.9918351173400879
: O O 0.9998326301574707
Tumor B-protein B-protein 0.5655437111854553
necrosis I-protein I-protein 0.8095421195030212
factor I-protein I-protein 0.5041317939758301
alpha E-protein E-protein 0.9836199283599854
( O O 0.9795218110084534
TNF-alpha S-protein S-protein 0.9907797574996948
) O O 0.981871485710144
is O O 0.9999867677688599
an O O 0.999992847442627
important O O 0.998113751411438
mediator O O 0.987038254737854
of O O 0.9996788501739502
septic O O 0.4733748733997345

During O O 0.9998699426651001
the O O 0.9999791383743286
infusion O O 0.9605860710144043
of O O 0.9982653260231018
aminophylline B-Chemical B-Chemical 0.9309382438659668
, O O 0.997778594493866
the O O 0.9999715089797974
ventricular B-Disease O 0.6980491280555725
fibrillation I-Disease O 0.9102790951728821
threshold O O 0.8621865510940552
was O O 0.9997648596763611
reduced O O 0.9996638298034668
by O O 0.9999935626983643
30 O O 0.9998317956924438
to O O 0.999955415725708
40 O O 0.9998862743377686
percent O O 0.9999620914459229
of O O 0.9999535083770752
the O O 0.9999496936798096
control O O 0.9975413084030151
when O O 0.9999910593032837
pH O O 0.4929235875606537
and O O 0.994234025478363
partial O O 0.9895723462104797
pressures O O 0.9787745475769043
of O O 0.9992977380752563
oxygen B-Chemical B-Chemical 0.932528018951416
( O O 0.9345560669898987
PO2 B-Chemical O 0.7958932518959045
) O O 0.8022409677505493
and O O 0.9998546838760376
carbon B-Chemical B-Chemical 0.9295185208320618
dioxide I-Chemical I-Chemical 0.9574058055877686
( O O 0.9660304188728333
CO2 B-Chemical O 0.6310302019119263
) O O 0.9922845363616943
were O O 0.9999948740005493
kept O O 0.9999867677688599
within O O 0.999987006187439
normal O O 0.9885919690132141
limits O O 0.9991815686225891
. O O 0.9999992847442627

depend O O 0.9972363710403442
upon O O 0.9999880790710449
the O O 0.9999260902404785
phosphorylation B-DNA B-DNA 0.6069826483726501
sites E-DNA E-DNA 0.5165974497795105
of O O 0.9980979561805725
NFATp S-protein S-protein 0.9593018293380737
affected O O 0.9985595345497131
by O O 0.9999738931655884
activation O O 0.9941961765289307
. O O 0.9999756813049316
Cross-linking O O 0.9484524130821228
CD40 S-protein S-protein 0.9328815340995789
on O O 0.9978170394897461
B B-cell_type B-cell_type 0.8424783945083618
cells E-cell_type E-cell_type 0.9759311079978943
preferentially O O 0.995445966720581
induces O O 0.9999692440032959
stress-activated B-protein B-protein 0.825456440448761
protein I-protein I-protein 0.4068576395511627
kinases E-protein E-protein 0.9751442074775696
rather O O 0.9937976002693176
than O O 0.9997898936271667
mitogen-activated B-protein B-protein 0.5128838419914246
protein I-protein I-protein 0.6105624437332153
kinases E-protein E-protein 0.9848513007164001
. O O 0.999657154083252
The O O 0.9998384714126587
B B-protein B-cell_type 0.6785695552825928

showed O O 0.9989762306213379
a O O 0.9999877214431763
close O O 0.9659333825111389
, O O 0.9972737431526184
inverse O O 0.9875911474227905
correlation O O 0.9961045980453491
with O O 0.9999949932098389
the O O 0.999891996383667
PMNs S-cell_type O 0.4474751949310303
chemotaxis O O 0.7696496248245239
to O O 0.9974684715270996
FMLP O O 0.6250181794166565
( O O 0.9976129531860352
r O O 0.9941389560699463
= O O 0.9995723366737366
-0.821 O O 0.9992443323135376
p O O 0.9996755123138428
< O O 0.9997816681861877
0.001 O O 0.997265100479126
) O O 0.9997454285621643
. O O 0.999996542930603
Estrogen O O 0.9592215418815613
may O O 0.9999018907546997
modify O O 0.9691187143325806

are O O 0.9985623955726624
inactive O O 0.9870278835296631
on O O 0.999792754650116
1.3E2 B-cell_line B-cell_line 0.48691660165786743
cells E-cell_line E-cell_line 0.9628965258598328
exhibit O O 0.9989493489265442
a O O 0.9999741315841675
sensitivity O O 0.9956055283546448
to O O 0.999988317489624
the O O 0.999903678894043
antioxidant O O 0.8247960209846497
pyrrolidine O O 0.7485343217849731
dithiocarbamate O O 0.5804560780525208
( O O 0.9963288903236389
PDTC O O 0.8554285764694214
) O O 0.9987534284591675
. O O 0.9999910593032837
In O O 0.9999771118164062
contrast O O 0.9977927207946777
, O O 0.999950647354126
stimuli O O 0.970237135887146
such O O 0.9999666213989258
as O O 0.9999920129776001
hyperosmotic O O 0.8595811724662781
shock O O 0.7021055221557617
or O O 0.9867342710494995
phosphatase O O 0.7311228513717651
inhibitors O O 0.8674180507659912
, O O 0.9998615980148315
which O O 0.9999340772628784
use O O 0.9999366998672485

- O O 0.8269416093826294
, O O 0.9553448557853699
CD16 S-protein S-protein 0.7931016087532043
- O O 0.9732232093811035
. O O 0.9999051094055176
Multicolor O O 0.9275887608528137
flow O O 0.956404447555542
cytometric O O 0.9565306305885315
assays O O 0.9993851184844971
confirmed O O 0.9999932050704956
the O O 0.999995231628418
coexpression O O 0.9720057845115662
of O O 0.9992827773094177
myeloid B-protein B-protein 0.32194823026657104
( I-protein I-protein 0.5222625136375427
CD33 I-protein I-protein 0.3463461399078369
, I-protein I-protein 0.3200686573982239

Hepatitis O B-Disease 0.9721235632896423
may O O 0.9732896089553833
develop O O 0.9989697933197021
weeks O O 0.9992938041687012
after O O 0.9999890327453613
discontinuation O O 0.9652367234230042
of O O 0.9986546039581299
the O O 0.9989602565765381
drug O O 0.99152010679245
and O O 0.9998372793197632
may O O 0.9999796152114868
run O O 0.9998786449432373
a O O 0.9999674558639526
prolonged O O 0.9644891619682312
course O O 0.9701793193817139
, O O 0.99996018409729
but O O 0.9999321699142456
complete O O 0.9960175156593323
remission O O 0.9448645114898682
was O O 0.9999409914016724
observed O O 0.9999383687973022
in O O 0.9999970197677612
all O O 0.9999698400497437
reported O O 0.996821403503418
cases O O 0.9976879358291626
. O O 0.9999991655349731

Baseline O O 0.4345046579837799
, O O 0.9971785545349121
liver O O 0.9467249512672424
function O O 0.8634218573570251
tests O O 0.992493748664856
were O O 0.9999936819076538
elevated O O 0.9973567724227905
in O O 0.9999878406524658
two O O 0.9998447895050049
patients O O 0.9997566342353821
( O O 0.9999935626983643
fourth O O 0.9994003772735596
patient O O 0.9983558058738708
: O O 0.9999573230743408
ALT O O 0.7955842018127441
: O O 0.9996483325958252
122 O O 0.999420166015625
IU O O 0.9936763644218445
/ O O 0.9999703168869019
l O O 0.9994679093360901
, O O 0.9999021291732788
AST O O 0.9900192022323608
: O O 0.9999550580978394
111 O O 0.9994962215423584
IU O O 0.9951435327529907
/ O O 0.9999707937240601
l O O 0.9994593262672424
, O O 0.9999669790267944
tenth O O 0.9983794689178467
patient O O 0.9989506006240845
: O O 0.9999561309814453
ALT O O 0.7250946760177612
: O O 0.9990231990814209
294 O O 0.9993707537651062
IU O O 0.9932323694229126
/ O O 0.9999812841415405
l O O 0.9991481304168701
, O O 0.9998288154602051
AST O O 0.9861466288566589
: O O 0.9999446868896484
274 O O 0.9991711378097534
IU O O 0.9917017817497253
/ O O 0.9999635219573975
l O O 0.9981549382209778
, O O 0.9999402761459351
with O O 0.9999946355819702
minimal O O 0.9639167785644531
changes O O 0.9510197043418884
in O O 0.9986341595649719
the O O 0.9985682964324951
liver O O 0.8575581312179565
biopsy O O 0.663604199886322
in O O 0.9996843338012695
both O O 0.9998078942298889
) O O 0.9989098310470581
. O O 0.9999909400939941

the O O 0.9979640245437622
binding O O 0.9875425100326538
of O O 0.9996242523193359
all-trans O O 0.8908350467681885
RA O O 0.750644862651825
or O O 0.9988816380500793
9-cis O O 0.891501247882843
RA O O 0.9315815567970276
. O O 0.9999648332595825
Interestingly O O 0.999096155166626
, O O 0.9999567270278931
residue O O 0.9161226153373718
C-235 O O 0.23586082458496094
is O O 0.9995119571685791
specifically O O 0.9997212290763855
important O O 0.9998818635940552
in O O 0.9999507665634155
antagonist O O 0.6398584246635437
binding O O 0.7242299318313599
. O O 0.9995123147964478

We O O 0.9994749426841736
investigated O O 0.9999303817749023
the O O 0.9999744892120361
diagnostic O O 0.9412043690681458
value O O 0.9883540868759155
of O O 0.9999078512191772
cTnI O O 0.6743007302284241
and O O 0.9931933283805847
cTnT O O 0.5132607817649841
for O O 0.9993708729743958
the O O 0.9999798536300659
diagnosis O O 0.9892628788948059
of O O 0.999897837638855
myocardial B-Disease B-Disease 0.6085581183433533
damage I-Disease I-Disease 0.9868484735488892
in O O 0.9647635221481323
a O O 0.996875524520874
rat O O 0.964208722114563
model O O 0.9975601434707642
of O O 0.9995085000991821
doxorubicin B-Chemical B-Chemical 0.934712290763855
( O O 0.8097183108329773
DOX B-Chemical B-Chemical 0.9202508330345154
) O O 0.5856913328170776
- O O 0.9960659146308899
induced O O 0.9975475668907166
cardiomyopathy B-Disease B-Disease 0.9653552770614624
, O O 0.9880653023719788
and O O 0.9998563528060913
we O O 0.9998952150344849
examined O O 0.999977707862854
the O O 0.9999302625656128
relationship O O 0.9991389513015747
between O O 0.9999755620956421
serial O O 0.9446829557418823
cTnI O O 0.4260524809360504
and O O 0.9941515326499939
cTnT O O 0.5859070420265198
with O O 0.9987962245941162
the O O 0.9999277591705322
development O O 0.9978898167610168
of O O 0.9999581575393677
cardiac B-Disease B-Disease 0.5416273474693298
disorders I-Disease I-Disease 0.9905953407287598
monitored O O 0.9258730411529541
by O O 0.9997468590736389
echocardiography O O 0.8279287219047546
and O O 0.9987503290176392
histological O O 0.9428670406341553
examinations O O 0.9358627796173096
in O O 0.9999628067016602
this O O 0.9999449253082275
model O O 0.9946415424346924
. O O 0.9999953508377075

( O O 0.7351237535476685

Initial O O 0.9940788745880127
cardiopulmonary O O 0.9598685503005981
resuscitation O O 0.6333679556846619
and O O 0.9990099668502808
immediate O O 0.9721506237983704
treatment O O 0.9915608763694763
with O O 0.9999618530273438
adrenaline B-Chemical B-Chemical 0.9295973181724548
( O O 0.8968541026115417
epinephrine B-Chemical B-Chemical 0.9302266240119934
) O O 0.8064112067222595
, O O 0.9982590079307556
atropine B-Chemical B-Chemical 0.9271968007087708
and O O 0.9677507877349854
furosemide B-Chemical B-Chemical 0.9241690635681152
was O O 0.9988018274307251
successful O O 0.999794065952301
. O O 0.9999991655349731

The O O 0.9993595480918884
remaining O O 0.9997351765632629
seven O O 0.9996856451034546
patients O O 0.9992722868919373
had O O 0.9999717473983765
isolated O O 0.9057890772819519
beta O O 0.7029149532318115
2 O O 0.8161152005195618
microglobulinuria O O 0.7249546051025391
. O O 0.9996115565299988

This O O 0.9992006421089172
hemorrhagic B-Disease O 0.7115488648414612
ulcer B-Disease O 0.8142094612121582
and O O 0.9843388795852661
various O O 0.9969338178634644
ulcerogenic O O 0.6088957190513611
parameters O O 0.5540680885314941
were O O 0.9997261166572571
dose O O 0.9987562894821167
- O O 0.9998577833175659
dependently O O 0.9990149736404419
ameliorated O O 0.9955204725265503
by O O 0.999981164932251
daily O O 0.9765396118164062
intragastric O O 0.8854954838752747
verapamil B-Chemical B-Chemical 0.9230338335037231
. O O 0.9996999502182007

that O O 0.9994863271713257
the O O 0.9999535083770752
IL-4R B-protein B-protein 0.5483872890472412
alpha I-protein I-protein 0.8141299486160278
cytoplasmic I-protein I-protein 0.737201988697052
domain E-protein E-protein 0.9804476499557495
is O O 0.9992423057556152
sufficient O O 0.9998807907104492
to O O 0.999974250793457
activate O O 0.9981157779693604
JAK-1 S-protein S-protein 0.9450119137763977
and O O 0.9930106997489929
STAT6 S-protein S-protein 0.9907487034797668
and O O 0.9974578022956848
to O O 0.9999377727508545
induce O O 0.9998962879180908
expression O O 0.9974929094314575
of O O 0.9998657703399658
IL-4 B-DNA B-DNA 0.8398770689964294
target I-DNA I-DNA 0.5512838363647461
genes E-DNA E-DNA 0.979607343673706
, O O 0.9989097118377686
thus O O 0.9999945163726807
identifying O O 0.9999545812606812
a O O 0.9999663829803467
mechanism O O 0.9944401979446411
by O O 0.9999704360961914

c-Rel S-protein S-protein 0.9452009201049805
, O O 0.9946053624153137
p65 S-protein S-protein 0.9132879972457886
( O O 0.9055659770965576
RelA S-protein S-protein 0.9380493760108948
) O O 0.48697760701179504
, O O 0.9859647750854492
and O O 0.9984533786773682
p50 S-protein S-protein 0.854131817817688
( O O 0.917787492275238
NF-kappa B-protein B-protein 0.3641700744628906
B1 E-protein E-protein 0.9270280003547668
) O O 0.778370201587677
) O O 0.9779667854309082
and O O 0.9997958540916443
NF-kappa B-protein B-protein 0.6415367722511292
B E-protein E-protein 0.9713966250419617
DNA O O 0.8716880679130554
binding O O 0.9422798752784729
activity O O 0.9936210513114929
in O O 0.9999700784683228
the O O 0.999937891960144
nucleus O O 0.9366760849952698
. O O 0.9999494552612305
However O O 0.9997128844261169
, O O 0.9999433755874634

B E-protein E-protein 0.9474356770515442
-and O O 0.979778528213501
serum B-protein B-DNA 0.9387788772583008
response I-protein I-DNA 0.8203872442245483
factor E-protein I-DNA 0.8167647123336792
-binding O I-DNA 0.7228104472160339
elements O E-DNA 0.9590821266174316
activates O O 0.999068558216095
an O O 0.9999444484710693
interleukin-2 B-DNA B-DNA 0.4980245530605316
receptor I-DNA I-DNA 0.605255126953125
alpha-chain I-DNA I-DNA 0.8296257257461548
enhancer E-DNA E-DNA 0.9885947704315186
specifically O O 0.9969137907028198
in O O 0.9997861981391907
T B-cell_type B-cell_type 0.8288944363594055
lymphocytes E-cell_type E-cell_type 0.9944614171981812
. O O 0.9998656511306763
We O O 0.9961268305778503

involving O O 0.996164083480835
class O B-cell_line 0.6398757100105286
I-restricted B-cell_line I-cell_line 0.35930654406547546
CTLs E-cell_line E-cell_line 0.791132926940918
in O O 0.9998515844345093
the O O 0.9999210834503174
pathogenesis O O 0.9671182036399841
of O O 0.9998102784156799
autoimmune O O 0.9529578685760498
disease O O 0.9009279012680054
. O O 0.9999886751174927
RFLAT-1 S-protein S-protein 0.8146181702613831
: O O 0.9935033917427063
a O O 0.9998539686203003
new O O 0.9828252196311951
zinc B-protein B-protein 0.3743349313735962
finger I-protein I-protein 0.5029022097587585
transcription I-protein I-protein 0.913798987865448
factor E-protein E-protein 0.9855124354362488
that O O 0.9982826709747314
activates O O 0.9992546439170837
RANTES B-DNA B-DNA 0.3430692255496979
gene E-DNA E-DNA 0.8669618964195251
expression O O 0.9438849091529846
in O O 0.999648928642273
T B-cell_type B-cell_type 0.8958534002304077
lymphocytes E-cell_type E-cell_type 0.9957115650177002
. O O 0.9993322491645813
RANTES S-protein S-protein 0.7126326560974121
( O O 0.9061287045478821
Regulated B-protein O 0.5442154407501221
upon I-protein O 0.4832732081413269

( O O 0.9711965322494507
30 O O 0.9944515824317932
% O O 0.9983136653900146
) O O 0.9981751441955566
is O O 0.999971866607666
found O O 0.999954104423523
in O O 0.9999408721923828
acute O O 0.827667772769928
myeloid O O 0.7498618960380554
leukemia O O 0.8714239001274109
. O O 0.9999215602874756
The O O 0.9999967813491821
presence O O 0.9990839958190918
of O O 0.9999598264694214
ras O O 0.2836284637451172
mutations O O 0.4942528009414673
has O O 0.9998582601547241
been O O 0.9999605417251587
correlated O O 0.9999209642410278
with O O 0.9999972581863403
a O O 0.9999611377716064
poor O O 0.9836644530296326
prognosis O O 0.9824752807617188
and O O 0.9997864365577698
negative O O 0.9395025968551636
clinical O O 0.95796138048172
outcome O O 0.9866527915000916

January O O 0.9947353005409241
1987 O O 0.9997114539146423
and O O 0.9999872446060181
December O O 0.9996356964111328
1988 O O 0.9993300437927246
, O O 0.9999946355819702
were O O 0.9999892711639404
processed O O 0.9990969896316528
for O O 0.9999728202819824
staining O O 0.9585960507392883
by O O 0.9999473094940186
an O O 0.9998974800109863
immunohistochemical O O 0.7691977620124817
procedure O O 0.5303798913955688
( O O 0.9956045150756836
avidin-biotin B-protein B-protein 0.4633857309818268
complex E-protein E-protein 0.97145676612854
) O O 0.9847872853279114
. O O 0.9999899864196777
The O O 0.9999971389770508
median O O 0.9881995916366577
time O O 0.9992454051971436
of O O 0.9999305009841919
observation O O 0.9977498650550842
was O O 0.9999980926513672
42 O O 0.995819091796875
months O O 0.9997760653495789
( O O 0.9999521970748901
range O O 0.9990720748901367

, O O 0.9948615431785583
the O O 0.9999555349349976
inhibitors O O 0.9955279231071472
of O O 0.9999326467514038
these O O 0.9998823404312134
phosphatases S-protein S-protein 0.6918776035308838
, O O 0.9986250400543213
okadaic O O 0.9090332388877869
acid O O 0.932600200176239
and O O 0.9993706345558167
calyculin O O 0.9423680305480957
A O O 0.7437440156936646
, O O 0.9995390176773071
were O O 0.9999958276748657
found O O 0.9999850988388062
to O O 0.9999876022338867
increase O O 0.9999531507492065
the O O 0.9990835189819336
mRNA O O 0.8367384076118469
accumulation O O 0.973642885684967
and O O 0.9997575879096985
cytokine O S-protein 0.9081602096557617
production O O 0.9968186616897583
of O O 0.9999396800994873
interleukin-1 B-protein S-protein 0.5598450899124146

. O O 0.9897184371948242
E3 B-protein B-RNA 0.39120185375213623
transcripts E-protein E-RNA 0.9805293679237366
are O O 0.9989608526229858
present O O 0.9998990297317505
in O O 0.9999644756317139
the O O 0.9993863105773926
myeloid B-cell_type B-cell_type 0.3868951201438904
, I-cell_type I-cell_type 0.4457623064517975
B-lymphoid I-cell_type I-cell_type 0.37901145219802856
, I-cell_type I-cell_type 0.7355620265007019
and I-cell_type I-cell_type 0.8215804100036621
erythroid I-cell_type I-cell_type 0.8656671643257141
lineages E-cell_type E-cell_type 0.9607935547828674
, O O 0.9973426461219788
absent O O 0.9952564835548401
in O O 0.999536395072937
nonhematopoietic B-cell_type B-cell_type 0.725159764289856
cells E-cell_type E-cell_type 0.9332789778709412
, O O 0.9935811758041382
and O O 0.9998893737792969
encode O O 0.998445451259613
a O O 0.999697208404541
highly O O 0.8705430030822754

GR B-RNA B-RNA 0.5702962279319763
precursor I-RNA I-RNA 0.9239569306373596
mRNA E-RNA E-RNA 0.9913058876991272
gives O O 0.9995875954627991
rise O O 0.999338686466217
to O O 0.9999616146087646
two O O 0.9986528158187866
receptor O B-protein 0.8707127571105957
isoforms O E-protein 0.8455063700675964
, O O 0.9987101554870605
termed O O 0.9995482563972473
GRalpha S-protein S-protein 0.8335970640182495
and O O 0.9881347417831421
GRbeta S-protein S-protein 0.8167568445205688

elements E-DNA E-DNA 0.9582973122596741
, O O 0.9978621602058411
with O O 0.9999935626983643
the O O 0.9999914169311523
exception O O 0.9999707937240601
of O O 0.9999879598617554
a O O 0.9999197721481323
weakly O O 0.8400395512580872
active O O 0.8403571248054504
region O O 0.5389919877052307
within O O 0.9994578957557678
the O O 0.9999343156814575
3'-flanking B-DNA B-DNA 0.544884204864502
sequences E-DNA E-DNA 0.9890182018280029
. O O 0.999882698059082
DNase O B-protein 0.4654442071914673
I O E-protein 0.9377154111862183
footprinting O O 0.8981404304504395
assays O O 0.9948446750640869
revealed O O 0.9999884366989136
four O O 0.9984233379364014
distinct O O 0.9821130633354187
sites O O 0.8241924047470093
that O O 0.9998347759246826
bind O O 0.998846173286438
myeloid B-protein B-protein 0.44096046686172485
nuclear I-protein I-protein 0.6996453404426575
proteins E-protein E-protein 0.9838855266571045
( O O 0.9840989708900452
-408 B-DNA O 0.6250962018966675

NF-kappa B-protein B-protein 0.7321255803108215
B E-protein I-protein 0.9656925201416016
binding B-protein I-protein 0.7054811716079712
proteins E-protein E-protein 0.9540905356407166
compared O O 0.9997232556343079
with O O 0.9999943971633911
the O O 0.999944806098938
double B-cell_line O 0.8319145441055298
transfectants E-cell_line O 0.5161113739013672
. O O 0.9998290538787842
The O O 0.9999963045120239
level O O 0.999690055847168
of O O 0.999950647354126
Oct-1 B-protein B-protein 0.900807797908783
binding I-protein I-protein 0.5229586958885193
proteins E-protein E-protein 0.9857564568519592
remained O O 0.9996867179870605
similar O O 0.9999654293060303
in O O 0.9999792575836182
all O O 0.9997857213020325
samples O O 0.9893534183502197
. O O 0.9999946355819702
Super-shift O O 0.9186346530914307
analysis O O 0.9989803433418274
revealed O O 0.9999966621398926
that O O 0.999991774559021
the O O 0.9997889399528503
NF-kappa B-protein B-protein 0.668251633644104
B I-protein I-protein 0.514064610004425
complex E-protein E-protein 0.9527300596237183
of O O 0.9813715815544128
costimulated B-cell_line O 0.3888237476348877

dexamethasone O O 0.6345838308334351

of O O 0.9926290512084961

and O O 0.9722923636436462
lower O O 0.9860159754753113
molecular O O 0.9582814574241638
weight O O 0.9407294988632202
variant O O 0.8161487579345703
in O O 0.9998944997787476
human B-cell_type B-cell_type 0.8192901611328125
monocytes E-cell_type E-cell_type 0.9806188941001892
and O O 0.9873170256614685
monocytes S-cell_type S-cell_type 0.974934995174408
differentiated O O 0.9961579442024231
into O O 0.9996284246444702
macrophages S-cell_type S-cell_type 0.9807521104812622
by O O 0.9998145699501038
culture O O 0.9388648271560669
in O O 0.9997609257698059
macrophage-CSF S-protein B-cell_line 0.2767038941383362
( O I-cell_line 0.4425243139266968
M-CSF S-protein I-cell_line 0.4246433973312378
) O I-cell_line 0.5909383893013

human B-cell_line B-cell_line 0.3144731819629669
B I-cell_line I-cell_line 0.5947156548500061
cell I-cell_line I-cell_line 0.869598925113678
lines E-cell_line E-cell_line 0.9922348260879517
AF10 S-cell_line S-cell_line 0.9495875239372253
and O O 0.9915731549263
Ramos S-cell_line S-cell_line 0.9904875159263611
, O O 0.9739281535148621
respectively O O 0.9999179840087891
. O O 0.9999984502792358
The O O 0.9999920129776001
phorbol O O 0.8702565431594849
ester O O 0.9207073450088501
, O O 0.999871015548706
PMA O O 0.9813920855522156
, O O 0.9998906850814819
was O O 0.9999830722808838
also O O 0.9999873638153076
a O O 0.9999936819076538
potent O O 0.9923140406608582
inducer O O 0.9529619812965393
of O O 0.9987057447433472
Fos B-protein B-protein 0.7399023771286011
kinase E-protein E-protein 0.9089112281799316
activity O O 0.9770317673683167
in O O 0.9999792575836182
all O O 0.9998297691345215
of O O 0.9999327659606934
the O O 0.9999690055847168
above O O 0.9494022727012634
populations O O 0.8612076640129089
, O O 0.9999359846115112

Neither O O 0.998363196849823
patient O O 0.9948373436927795
was O O 0.9999599456787109
considered O O 0.9999780654907227
to O O 0.9998995065689087
have O O 0.9999054670333862
a O O 0.9996780157089233
renal O O 0.8363870978355408
state O O 0.7216749787330627
sufficiently O O 0.9951916933059692
severe O O 0.9915300607681274
enough O O 0.9955612421035767
to O O 0.9999473094940186
explain O O 0.9999654293060303
their O O 0.9999287128448486
presentation O O 0.9994896650314331
. O O 0.9999985694885254

construct E-protein E-DNA 0.8647779226303101
. O O 0.9999096393585205
A O O 0.9990276098251343
Y341 O O 0.893462598323822
-- O O 0.9962961077690125
> O O 0.9993773102760315
F B-protein O 0.9900306463241577
mutant E-protein O 0.7400323152542114
of O O 0.9948429465293884
Syk S-protein S-protein 0.9477667808532715
, O O 0.9887786507606506
which O O 0.9998739957809448
is O O 0.9999071359634399
deficient O O 0.9986597299575806
in O O 0.9999265670776367
its O O 0.9996190071105957
interaction O O 0.9932095408439636
with O O 0.9999157190322876
phospholipase B-protein O 0.49437201023101807
Cy1 E-protein O 0.505483090877533
and O O 0.9011067152023315
Vav S-protein S-protein 0.8979387283325195
, O O 0.9890710115432739
was O O 0.9999442100524902
less O O 0.9998160004615784
efficient O O 0.9969701766967773
than O O 0.9999594688415527
wild-type B-protein B-protein 0.5862042307853699
Syk E-protein E-protein 0.6564322113990784

which O O 0.9819728136062622

Behavioral O O 0.7530617117881775
effects O O 0.9346254467964172
of O O 0.9992490410804749
urotensin B-Chemical B-Chemical 0.935540497303009
- I-Chemical I-Chemical 0.974563717842102
II I-Chemical E-Chemical 0.9266141057014465
centrally O O 0.9478967785835266
administered O O 0.9988389611244202
in O O 0.9999834299087524
mice O O 0.9984378218650818
. O O 0.999998927116394

transcriptionally O O 0.9276334643363953
activates O O 0.9938470721244812
interleukin-6 S-protein S-protein 0.9393502473831177
expression O O 0.9926170706748962
involving O O 0.9999487400054932
NK-chi B-protein B-protein 0.4484593868255615
B E-protein E-protein 0.9670308828353882
and O O 0.9748503565788269
NF-IL6 S-protein S-protein 0.9604722261428833
. O O 0.9996732473373413
Leukotriene O O 0.7825174927711487
B4 O O 0.5019398331642151
( O O 0.9459508657455444
LTB4 O S-protein 0.3855639398097992

of O O 0.9942318797111511
alpha B-protein B-protein 0.45642536878585815
B1 E-protein E-protein 0.9013053774833679
and O O 0.9803277850151062
alpha B-protein B-protein 0.36799561977386475
B2 E-protein E-protein 0.8956291079521179
showed O O 0.9996236562728882
that O O 0.9999970197677612
the O O 0.9999538660049438
promoter O O 0.4930395781993866
activity O O 0.9782847762107849
could O O 0.9999866485595703

These O O 0.9996479749679565
effects O O 0.999631404876709
suggest O O 0.9999970197677612
that O O 0.9999966621398926
the O O 0.9999145269393921
protection O O 0.9888652563095093
from O O 0.9998966455459595
hemolysis B-Disease B-Disease 0.9722751379013062
by O O 0.9864497780799866
tocopherols B-Chemical B-Chemical 0.9099577069282532
is O O 0.9988859295845032
related O O 0.9999706745147705
to O O 0.9999909400939941
a O O 0.9998829364776611
decreased O O 0.9908456206321716
TAM B-Chemical B-Chemical 0.9175724387168884
incorporation O O 0.80635005235672
in O O 0.9992910623550415
condensed O O 0.8946302533149719
membranes O O 0.739499032497406
and O O 0.9998630285263062
the O O 0.9999833106994629
structural O O 0.9493986964225769
damage O O 0.5891638398170471
of O O 0.9768880605697632
the O O 0.9977092742919922
erythrocyte O O 0.6066344976425171
membrane O O 0.4791237711906433
is O O 0.9991693496704102
consequently O O 0.9996353387832642
avoided O O 0.9999309778213501
. O O 0.9999991655349731

In O O 0.9996984004974365
28 O O 0.999887228012085
% O O 0.9999816417694092
of O O 0.9999659061431885
patients O O 0.9970731735229492
proteinuria B-Disease B-Disease 0.9551210999488831
remained O O 0.9649996757507324
unchanged O O 0.9934828877449036
, O O 0.999976396560669
whereas O O 0.9999711513519287
it O O 0.9995830655097961
increased O O 0.9994592070579529
in O O 0.9999692440032959
68 O O 0.9993984699249268
% O O 0.9999762773513794
of O O 0.9999756813049316
patients O O 0.9996660947799683
. O O 0.999998927116394

the O O 0.9962015748023987

Pregnant O O 0.7409393787384033
rats O O 0.9633640646934509
were O O 0.9999669790267944
administered O O 0.9996535778045654
one O O 0.999930739402771
of O O 0.9999709129333496
these O O 0.9999741315841675
calcium S-Chemical B-Chemical 0.930962085723877
channel O O 0.5645790696144104
blockers O O 0.9581757187843323
during O O 0.9999924898147583
the O O 0.9999821186065674
period O O 0.9999809265136719
of O O 0.999991774559021
cardiac O O 0.7530885934829712
morphogenesis O O 0.9169277548789978
and O O 0.9788211584091187
the O O 0.997051477432251
offspring O O 0.9880968332290649
examined O O 0.9999545812606812
on O O 0.9999827146530151
day O O 0.9980250597000122
20 O O 0.9993183612823486
of O O 0.9999499320983887
gestation O O 0.9205894470214844
for O O 0.9994840621948242
cardiovascular O O 0.5015088319778442
malformations O O 0.9654706716537476
. O O 0.9990671277046204

, O O 0.9713330268859863
as O O 0.9996190071105957
cell O B-cell_line 0.7382341027259827
lines O E-cell_line 0.974912703037262
deficient O O 0.9914664030075073
in O O 0.9999570846557617
these O O 0.9999557733535767
factors O O 0.9844560623168945
failed O O 0.9996764659881592
to O O 0.9999771118164062
allow O O 0.9999629259109497
transcription O O 0.943680465221405
from O O 0.9999439716339111
the O O 0.9998713731765747
DM B-DNA B-DNA 0.7860088348388672
promoters E-DNA E-DNA 0.9937728047370911
. O O 0.9996989965438843
In O O 0.9999872446060181
addition O O 0.9999134540557861
, O O 0.999995231628418
in O O 0.9999035596847534
vivo O O 0.9775660634040833
footprint O O 0.980049729347229
analysis O O 0.999715268611908
showed O O 0.9999980926513672
the O O 0.9999775886535645
putative O O 0.8118483424186707
X B-DNA B-DNA 0.2742867171764374
and I-DNA I-DNA 0.6881333589553833
Y I-DNA I-DNA 0.31507816910743713
boxes E-DNA E-DNA 0.9533910751342773
to O O 0.9977375268936157
be O O 0.9999321699142456
occupied O O 0.9999388456344604
by O O 0.9999935626983643
transcription B-protein O 0.5932848453521729

our O O 0.980022668838501

gene O O 0.6427192687988281
expression O O 0.986940324306488
in O O 0.9999780654907227
an O O 0.9999693632125854
indirect O O 0.9591334462165833
manner O O 0.997686505317688
. O O 0.9999983310699463
Epithelial O O 0.9112161993980408
cell-initiated O O 0.9028211832046509
inflammation O O 0.9920825958251953
plays O O 0.9999910593032837
a O O 0.9999958276748657
crucial O O 0.9994176626205444
role O O 0.9998315572738647
in O O 0.9999843835830688
early O O 0.9734954237937927
tissue O O 0.9766935706138611
damage O O 0.9891557097434998
in O O 0.9999740123748779
amebic O O 0.7797456979751587
infection O O 0.9565106630325317
of O O 0.9997943043708801
human O O 0.6944092512130737
intestine O O 0.5708510875701904

the O O 0.9976795315742493
cytokines S-protein S-protein 0.9975608587265015
IL-2 S-protein S-protein 0.9927565455436707
and O O 0.9962342381477356
IL-15 S-protein S-protein 0.9922236204147339
are O O 0.9997943043708801
identical O O 0.9985523819923401
would O O 0.9999876022338867
suggest O O 0.9999942779541016
that O O 0.9999903440475464
these O O 0.9997239708900452
cytokines S-protein S-protein 0.9773867130279541
have O O 0.9999096393585205
redundant O O 0.9848676323890686

Autism B-Disease O 0.9262908101081848
is O O 0.976854145526886
a O O 0.9993095397949219
neurodevelopmental B-Disease O 0.788676917552948
disorder I-Disease O 0.893733561038971
presenting O O 0.989349365234375
before O O 0.9995744824409485
3 O O 0.9990993738174438
years O O 0.9999569654464722
of O O 0.99980229139328
age O O 0.9998828172683716
with O O 0.9999964237213135
deficits B-Disease O 0.6265568733215332
in I-Disease O 0.9804217219352722
communication I-Disease O 0.932736873626709
and I-Disease O 0.9984941482543945
social I-Disease O 0.9715846180915833
skills I-Disease O 0.812760591506958
and O O 0.9993137121200562
repetitive B-Disease O 0.5979472398757935
behaviors I-Disease O 0.8882729411125183
. O O 0.9997147917747498

level O O 0.9826686382293701
of O O 0.9998154044151306
SRF S-protein S-protein 0.9649914503097534
binding O O 0.9840917587280273
in O O 0.9997043013572693
T B-cell_type B-cell_type 0.8843287229537964
cells E-cell_type E-cell_type 0.988881528377533
is O O 0.9995978474617004
functionally O O 0.9951087832450867
important O O 0.9996964931488037
. O O 0.999997615814209
Mutual O O 0.9849091172218323
regulation O O 0.9991146922111511
of O O 0.9999806880950928
the O O 0.9998970031738281
transcriptional B-protein O 0.6417579650878906
activator E-protein O 0.5976507663726807
NF-kappa B-protein B-protein 0.4955737292766571
B E-protein E-protein 0.9859280586242676
and O O 0.9963111281394958
its O O 0.9996516704559326
inhibitor O O 0.9136155843734741
, O O 0.9982106685638428
I B-protein B-protein 0.8348202705383301
kappa I-protein I-protein 0.9711213111877441
B-alpha E-protein E-protein 0.8778448104858398
. O O 0.9974060654640198

and O O 0.9470709562301636
inflammatory B-protein B-protein 0.7935615181922913
cytokines E-protein E-protein 0.9731281399726868
. O O 0.9999371767044067
Here O O 0.9999842643737793
we O O 0.9999986886978149
report O O 0.9999969005584717
that O O 0.9999949932098389
LTB4 O S-protein 0.6728524565696716
induces O O 0.9995074272155762
synthesis O O 0.9762743711471558
of O O 0.9996258020401001
interleukin B-protein B-protein 0.30524274706840515
( I-protein I-protein 0.6768724322319031
IL I-protein I-protein 0.9339174628257751
) I-protein I-protein 0.9331992268562317
-6 E-protein E-protein 0.9797840118408203
by O O 0.9993491768836975
human B-cell_type B-cell_type 0.7195468544960022
blood I-cell_type I-cell_type 0.9471729397773743

CONCLUSIONS O O 0.9962261915206909
: O O 0.9999595880508423
Sub O O 0.884982168674469
- O O 0.9973141551017761
chronic O O 0.9855683445930481
low O O 0.9821367859840393
dose O O 0.9938268065452576
GVG S-Chemical B-Chemical 0.9225097298622131
potentiates O O 0.8539214730262756
and O O 0.9997820258140564
extends O O 0.9998422861099243
the O O 0.9998573064804077
inhibition O O 0.790596067905426
of O O 0.9942929744720459
cocaine S-Chemical B-Chemical 0.9195477366447449
- O O 0.9866458177566528
induced O O 0.9990754127502441
increases O O 0.6555117964744568
in O O 0.781255841255188
dopamine S-Chemical B-Chemical 0.9246544241905212
, O O 0.9970986843109131
effectively O O 0.9997197985649109
reducing O O 0.9987581968307495
cumulative O O 0.8193950057029724
exposures O O 0.7324175238609314
and O O 0.9993488192558289
the O O 0.9999411106109619
risk O O 0.9997108578681946
for O O 0.9999744892120361
VFDS O O 0.915012538433075
. O O 0.9980641007423401

Safety O O 0.8932910561561584
and O O 0.9948487877845764
side O O 0.9947332143783569
- O O 0.9990471005439758
effects O O 0.9984398484230042
of O O 0.9996122717857361
alprazolam B-Chemical B-Chemical 0.9254190325737
. O O 0.9995550513267517

hGR S-protein S-protein 0.5989817976951599

intravenous O O 0.8217061758041382
glucocorticoids O O 0.7955642342567444
and O O 0.9863125681877136
6 O O 0.9579788446426392
who O O 0.9987119436264038
did O O 0.9999392032623291
not O O 0.9997004270553589
) O O 0.9994043111801147
and O O 0.9998781681060791
ten O O 0.9885624647140503
control O O 0.942477822303772
subjects O O 0.8950956463813782
were O O 0.999984622001648
studied O O 0.9999135732650757
. O O 0.9999991655349731
The O O 0.9999840259552002
number O O 0.9871882200241089
and O O 0.9986560344696045
apparent O O 0.9905106425285339
dissociation O O 0.9456236958503723
constant O O 0.9781067967414856
of O O 0.9996994733810425
glucocorticoid B-protein B-protein 0.37549808621406555

( O O 0.9183745980262756
biotinylated B-protein O 0.5644964575767517
MCP-1 E-protein S-protein 0.48267319798469543
) O O 0.7189766764640808
binding O O 0.8764099478721619
to O O 0.9983029365539551
THP-1 B-cell_type B-cell_line 0.7428619265556335
cells E-cell_type E-cell_line 0.9566829204559326
, O O 0.99871826171875
whereas O O 0.9999954700469971
RA O O 0.9590247869491577
had O O 0.9998732805252075
no O O 0.9999650716781616
effect O O 0.999862551689148
. O O 0.9999963045120239
Other O O 0.9995939135551453
peroxisome B-protein B-protein 0.3793348968029022
proliferator I-protein I-protein 0.38872066140174866
activated I-protein I-protein 0.8166723251342773
receptor E-protein E-protein 0.920481264591217
( O O 0.7665601372718811

beta I-DNA E-protein 0.7411515712738037
and I-DNA O 0.9833758473396301
the I-DNA O 0.9998438358306885
simian I-DNA B-DNA 0.8116254806518555
virus I-DNA I-DNA 0.6473914980888367
40 I-DNA I-DNA 0.5848455429077148
enhancer I-DNA I-DNA 0.5712339878082275
elements E-DNA E-DNA 0.9951415061950684
functioned O O 0.9973657727241516
more O O 0.9998243451118469
efficiently O O 0.9995470643043518
in O O 0.999854564666748
monocytes S-cell_type S-cell_type 0.9666419625282288
than O O 0.9980296492576599
in O O 0.9973936080932617
HeLa B-cell_type B-cell_line 0.9436525702476501
cells E-cell_type E-cell_line 0.9964675903320312
, O O 0.9947236776351929
which O O 0.9996906518936157

the O O 0.9980473518371582
HTLV-1 B-protein B-protein 0.328433096408844
transactivator I-protein I-protein 0.48603278398513794
protein E-protein E-protein 0.9805081486701965
, O O 0.9790723919868469
tax S-protein S-protein 0.9813138246536255
, O O 0.9938927888870239
acts O O 0.9992941617965698
as O O 0.9999939203262329
a O O 0.9999430179595947
costimulatory O O 0.7363752126693726
signal O O 0.8020265102386475
for O O 0.9973402619361877
GM-CSF O S-protein 0.8531044721603394
and O O 0.980043888092041
IL-2 O B-DNA 0.761022686958313
gene O E-DNA 0.7573773860931396
transcription O O 0.7414690852165222
, O O 0.9974428415298462
in O O 0.9999849796295166
that O O 0.9999251365661621
it O O 0.9991090893745422
can O O 0.9998414516448975

However O O 0.9987384676933289
, O O 0.9999841451644897
no O O 0.9993357062339783
study O O 0.9998906850814819
in O O 0.9999964237213135
the O O 0.9999399185180664
literature O O 0.9726550579071045
has O O 0.9999669790267944
reported O O 0.9999854564666748
the O O 0.9999737739562988
use O O 0.9999597072601318
of O O 0.9999802112579346
a O O 0.9999489784240723
statistical O O 0.9785061478614807
model O O 0.9972881078720093
to O O 0.9999959468841553
analyze O O 0.9999746084213257
the O O 0.9999009370803833
variables O O 0.9958242177963257
that O O 0.9999719858169556
influence O O 0.9978345036506653
outcome O O 0.9752342700958252
. O O 0.9999955892562866

Heavy O O 0.7976474761962891
proteinuria B-Disease B-Disease 0.9016737341880798
was O O 0.9817107319831848
common O O 0.9989410042762756
after O O 0.999995231628418
the O O 0.9999610185623169
use O O 0.9999619722366333
of O O 0.9998890161514282
SRL B-Chemical B-Chemical 0.9307409524917603
as O O 0.9984205961227417
rescue O O 0.8816986680030823
therapy O O 0.9983792304992676
for O O 0.9999915361404419
renal O O 0.8820768594741821
transplantation O O 0.5608033537864685
. O O 0.9999642372131348

IL-12 S-protein S-protein 0.9915786981582642
-induced O O 0.9977489113807678
phosphorylation O O 0.9883334040641785
of O O 0.9997279047966003
STAT4 S-protein S-protein 0.9730960726737976
( O O 0.9933783411979675
signal B-protein B-protein 0.5230467319488525
transducer I-protein I-protein 0.5804045796394348
and I-protein I-protein 0.6056240200996399
activator I-protein I-protein 0.4821968078613281
of I-protein I-protein 0.8261221051216125
transcription-4 E-protein E-protein 0.9118539094924927
) O O 0.6591206789016724
, O O 0.9991470575332642
a O O 0.9998698234558105
transcription B-protein B-protein 0.47960537672042847
factor E-protein E-protein 0.9793141484260559
that O O 0.9953588843345642
is O O 0.9999504089355469
typically O O 0.9999252557754517
involved O O 0.9999678134918213
in O O 0.9999630451202393
IL-12 S-protein S-protein 0.9652309417724609
signaling O O 0.9914822578430176
. O O 0.9999960660934448
Consequently O O 0.9999884366989136
, O O 0.999966025352478
IL-12 S-protein S-protein 0.9837036728858948
also O O 0.9990288019180298
failed O O 0.9998875856399536
to O O 0.9999873638153076
induce O O 0.9999939203262329
the O O 0.9999593496322632
DNA-binding O O 0.8074885606765747
activity O O 0.991057276725769

The O O 0.9995300769805908
risk O O 0.9989649057388306
of O O 0.9999051094055176
developing O O 0.9864063858985901
renal O B-Disease 0.7511752247810364
papillary O I-Disease 0.5852458477020264
necrosis O I-Disease 0.9216639399528503
or O O 0.831364631652832
cancer O B-Disease 0.9065974950790405
of O O 0.6488985419273376
the O O 0.8745772242546082
renal O O 0.6592199802398682
pelvis O O 0.883324921131134
, O O 0.9110092520713806
ureter O O 0.3657272756099701
or O O 0.9286494255065918
bladder O O 0.5618691444396973
associated O O 0.9615998864173889
with O O 0.9994673132896423
consumption O O 0.9484413266181946
of O O 0.9985690116882324
either O O 0.9952645301818848
phenacetin S-Chemical B-Chemical 0.9317305684089661
or O O 0.9355608224868774
paracetamol S-Chemical B-Chemical 0.9375059008598328
was O O 0.9991379976272583
calculated O O 0.9999966621398926
from O O 0.9999982118606567
data O O 0.9976363182067871
acquired O O 0.9999386072158813
by O O 0.9999949932098389
questionnaire O O 0.9951346516609192
from O O 0.9999932050704956
381 O O 0.9846151471138
cases O O 0.9982833862304688
and O O 0.9999769926071167
808 O O 0.9673672318458557
controls O O 0.9866097569465637
. O O 0.9999977350234985

technique O O 0.8854544758796692
for O O 0.9998685121536255
the O O 0.9999932050704956
rapid O O 0.9860534071922302
, O O 0.998484194278717
sensitive O O 0.9888462424278259
measurement O O 0.9940727353096008
of O O 0.9998212456703186
CIF S-protein S-protein 0.8877967000007629
or O O 0.9899623394012451

of O O 0.9968196153640747
NF-kappa B-protein B-protein 0.7893645763397217
B-related I-protein I-protein 0.6228948831558228
transcription I-protein I-protein 0.7881065607070923
factors E-protein E-protein 0.9976824522018433
to O O 0.9987640380859375
nuclei O O 0.7803497910499573
of O O 0.9864572882652283
adhered O B-cell_type 0.4684707522392273
monocytes O E-cell_type 0.9158105850219727
. O O 0.9997804760932922
The O O 0.9999958276748657
demonstration O O 0.9928311109542847
that O O 0.9997773766517639
NF-kappa B-protein B-protein 0.8641752600669861
B E-protein E-protein 0.9856201410293579
can O O 0.9995251893997192
regulate O O 0.9992351531982422

This O O 0.9994513392448425
literature O O 0.9959406852722168
review O O 0.9998051524162292
suggests O O 0.9999967813491821
that O O 0.9999908208847046
general O O 0.9914018511772156
practitioners O O 0.990988552570343
should O O 0.9999908208847046
prescribe O O 0.9998800754547119
scabicides O O 0.3972747325897217
with O O 0.9995753169059753
increased O O 0.9960684776306152
caution O O 0.9840461015701294
for O O 0.9999443292617798
certain O O 0.9998784065246582
at O O 0.9999836683273315
- O O 0.9995322227478027
risk O O 0.9756404161453247
groups O O 0.9991925358772278
, O O 0.9999945163726807
and O O 0.9999936819076538
give O O 0.9999932050704956
adequate O O 0.9986578226089478
warnings O O 0.9870485663414001
regarding O O 0.9999769926071167
potential O O 0.9824333190917969
toxicity O B-Disease 0.9711189270019531
. O O 0.9988538026809692

regions E-DNA E-DNA 0.6927493214607239
extending O O 0.9985931515693665
from O O 0.999860405921936
approximately O O 0.9938992261886597
-500 B-DNA O 0.8104321956634521
to I-DNA O 0.9422164559364319
+50bp E-DNA O 0.46405452489852905
( O O 0.980419933795929
promoter B-DNA B-DNA 0.8150638937950134
regions E-DNA E-DNA 0.914737343788147
) O O 0.9718382954597473
, O O 0.999622106552124
truncated O B-DNA 0.8080633878707886
delta O I-DNA 0.28281399607658386
and O I-DNA 0.724560022354126
beta B-DNA I-DNA 0.4183063209056854
5 I-DNA I-DNA 0.4317401349544525
' I-DNA I-DNA 0.8159542679786682
flanking I-DNA I-DNA 0.7981316447257996
regions E-DNA E-DNA 0.9949630498886108
extending O O 0.9993662238121033
from O O 0.9998782873153687
approximately O O 0.9935922026634216
-250 B-DNA O 0.8370279669761658
to I-DNA O 0.9515127539634705
+50 I-DNA O 0.9697246551513672
bp E-DNA O 0.5953048467636108
, O O 0.9991273283958435
and O O 0.9996746778488159
chimeric B-DNA B-DNA 0.5327112674713135
promoter I-DNA I-DNA 0.3994132876396179
constructions E-DNA E-DNA 0.9743719696998596
, O O 0.9994413256645203
which O O 0.9999815225601196
consisted O O 0.9999556541442871

and O O 0.9477782249450684

Grade O O 0.9885150790214539
3 O O 0.9844281077384949
- O O 0.9934144020080566
4 O O 0.9967798590660095
adverse O O 0.9494308233261108
effects O O 0.9828749895095825
included O O 0.9998278617858887
myelosuppression B-Disease O 0.9447634816169739
, O O 0.954706609249115
fatigue B-Disease B-Disease 0.9435692429542542
, O O 0.9506173729896545
somnolence B-Disease O 0.9227377772331238
/ O O 0.6329484581947327
depressed B-Disease O 0.6907576322555542
mood I-Disease O 0.5773555040359497
, O O 0.9242469668388367
neuropathy B-Disease O 0.7974393367767334
and O O 0.9622515439987183
dyspnea B-Disease B-Disease 0.926491916179657
. O O 0.9988264441490173

Srl B-Chemical S-Chemical 0.8763496279716492
should O O 0.9970176219940186
be O O 0.9999909400939941
used O O 0.9999948740005493
with O O 0.9999973773956299
ACEi B-Chemical B-Chemical 0.9154057502746582
/ O O 0.6006933450698853
ARB B-Chemical B-Chemical 0.7486960887908936
therapy O O 0.9914349913597107
and O O 0.9999212026596069
patients O O 0.9965506792068481
monitored O O 0.999947190284729
for O O 0.9999686479568481
proteinuria B-Disease B-Disease 0.9745109677314758
and O O 0.9652830362319946
increased O O 0.9834414720535278
renal B-Disease O 0.688292920589447
dysfunction I-Disease O 0.9752536416053772
. O O 0.9978172779083252

Bcl-x B-cell_type O 0.19298164546489716
protected I-cell_type O 0.5157071948051453
B I-cell_type B-cell_type 0.3264271020889282
cells E-cell_type E-cell_type 0.7244405746459961
from O O 0.9995869994163513
Fas-mediated O O 0.8459851741790771
apoptosis O O 0.5641468167304993
in O O 0.999384880065918
the O O 0.9999573230743408
absence O O 0.9986170530319214
of O O 0.9999507665634155
NF-kappaB S-protein S-protein 0.9026955366134644
signaling O O 0.9628890752792358
. O O 0.9999724626541138

negative O O 0.8321768641471863
role O O 0.9617903232574463
for O O 0.9997207522392273
phosphoinositide B-protein B-protein 0.40925168991088867
3-kinase E-protein E-protein 0.9809858202934265
in O O 0.9995417594909668
T-cell B-protein B-protein 0.6575527191162109
antigen I-protein I-protein 0.4706677496433258
receptor E-protein E-protein 0.9068586230278015
function O O 0.9775543808937073
. O O 0.9999487400054932
BACKGROUND O O 0.974380373954773
: O O 0.999637246131897
A O O 0.9997867941856384
delicate O O 0.9715136885643005
balance O O 0.996762752532959
between O O 0.999886155128479
positive O O 0.8829358220100403
and O O 0.9898528456687927
negative O O 0.940078616142273
regulatory O O 0.9309636354446411
mechanisms O O 0.9927476048469543
during O O 0.9999935626983643
T-cell O O 0.6791844367980957
activation O O 0.9900623559951782
determines O O 0.9999853372573853
the O O 0.9999700784683228
specificity O O 0.9965720176696777
and O O 0.999811589717865
magnitude O O 0.9967760443687439
of O O 0.9999499320983887
an O O 0.999873161315918
immune O O 0.9516081809997559
response O O 0.9906153678894043
. O O 0.9999819993972778
Phosphoinositide B-protein B-protein 0.6023151874542236
3-kinase E-protein E-protein 0.9526419639587402
( O O 0.9835222959518433
PI B-protein B-protein 0.3896699547767639
3-kinase E-protein E-protein 0.8911486864089966
) O O 0.9236085414886475

and O O 0.9851111769676208
that O O 0.9999701976776123
, O O 0.9999399185180664
like O O 0.99996018409729
other O O 0.999934196472168
members O O 0.9981772899627686
of O O 0.9999834299087524
this O O 0.999956488609314
family O O 0.9480693936347961
, O O 0.9998494386672974
its O O 0.9999520778656006

identification O O 0.9913008809089661
of O O 0.9999871253967285
minimal O O 0.9414948225021362
residual O O 0.9587308168411255
disease O O 0.9077621102333069
in O O 0.9999585151672363
patients O O 0.9999006986618042
with O O 0.9999860525131226
APL O O 0.8971935510635376
and O O 0.9998121857643127
that O O 0.9999948740005493
cytotoxic O O 0.9139841794967651
chemotherapy O O 0.9785608053207397
following O O 0.9999959468841553
ATRA O O 0.6455399394035339
therapy O O 0.9967889785766602
is O O 0.9999971389770508
required O O 0.9999551773071289

stimuli O O 0.6870099306106567
that O O 0.9998660087585449
mimic O O 0.9994646906852722
the O O 0.9998842477798462
CD40 S-protein S-protein 0.9362297058105469
signaling O O 0.8736412525177002
cascade O O 0.9323911070823669
, O O 0.9997875094413757

thyrotropin O O 0.39616072177886963
( O O 0.9381836652755737
TSH O S-protein 0.6016741394996643
) O O 0.6975660920143127
levels O O 0.9978501796722412
on O O 0.9999336004257202
receptor O O 0.8217591047286987
kinetics O O 0.7208042740821838
. O O 0.9999028444290161
The O O 0.9999966621398926
subjects O O 0.9980727434158325
were O O 0.9999890327453613
exposed O O 0.9998908042907715
to O O 0.9999622106552124
cold O O 0.8709550499916077
air O O 0.9344538450241089
( O O 0.9997156262397766
4 O O 0.9994151592254639
degrees O O 0.997718334197998
C O O 0.9957665205001831
) O O 0.9992678761482239
twice/d O O 0.9840606451034546
, O O 0.9996694326400757
30 O O 0.9954493641853333
min/exposure O O 0.9591967463493347
, O O 0.999733030796051
for O O 0.9999630451202393

. O O 0.9928781390190125
In O O 0.9986673593521118
U-937 B-cell_line B-cell_line 0.8914293646812439
cells E-cell_line E-cell_line 0.9965521097183228
, O O 0.9996030926704407
optimum O O 0.9559376239776611
time O O 0.984811544418335
and O O 0.9995771050453186
dose O O 0.9990490078926086
of O O 0.999834418296814
pretreatment O O 0.985090970993042
with O O 0.9999791383743286
1 O O 0.8506101965904236
, O O 0.9888084530830383
25- O O 0.9963602423667908
( O O 0.9993771910667419
OH O O 0.9844310879707336
) O O 0.9993187189102173
2D3 O O 0.9514328241348267
were O O 0.9999845027923584
determined O O 0.9999788999557495
to O O 0.9999864101409912
be O O 0.9999642372131348

. O O 0.9946606755256653
Autoreactive B-cell_type B-cell_type 0.5633419752120972
B-cells E-cell_type E-cell_type 0.7669638991355896
are O O 0.9990904331207275
eliminated O O 0.9997859597206116
by O O 0.9999967813491821
anti-IgM S-protein S-protein 0.7203389406204224
crosslinking O O 0.7554327249526978
after O O 0.9995649456977844
encountering O O 0.9988196492195129
self-antigens S-protein O 0.3961368501186371
, O O 0.9975157976150513
but O O 0.9999308586120605
precise O O 0.9784548878669739
mechanisms O O 0.9963510036468506
leading O O 0.9999823570251465
to O O 0.999943733215332
B-cell S-cell_type O 0.4921126961708069
apoptosis O O 0.9235391616821289
are O O 0.999940037727356
still O O 0.9999712705612183
not O O 0.9999334812164307
well O O 0.9992696642875671
understood O O 0.9999133348464966
. O O 0.9999983310699463
We O O 0.9999788999557495
report O O 0.9999948740005493
here O O 0.9999916553497314
the O O 0.9999945163726807
cleavage O O 0.6461077928543091

This O O 0.9993517994880676
drug O O 0.9815431237220764
occasionally O O 0.9969032406806946
has O O 0.9998238682746887
been O O 0.998913049697876
associated O O 0.9999244213104248
with O O 0.9999769926071167
acute O O 0.7799367904663086
interstitial B-Disease O 0.5412753224372864
nephritis I-Disease O 0.6655923128128052
in O O 0.9880993962287903
native O O 0.9255973100662231
kidneys O O 0.5654181241989136
. O O 0.9999724626541138

contrast O O 0.8763443231582642

A O O 0.9989629983901978
Phase O O 0.9980829954147339
I O O 0.9943663477897644
study O O 0.9998093247413635
of O O 0.9999221563339233
intravenous O O 0.4760660231113434
( O O 0.9491991400718689
IV O O 0.3976341485977173
) O O 0.953311562538147
bolus O O 0.6556628942489624
4 B-Chemical B-Chemical 0.7230781316757202
' I-Chemical I-Chemical 0.671335756778717
- I-Chemical I-Chemical 0.8332754373550415
0 I-Chemical I-Chemical 0.9663088321685791
- I-Chemical I-Chemical 0.9954078793525696
tetrahydropyranyladriamycin I-Chemical I-Chemical 0.9340721964836121
( O O 0.8457239270210266
Pirarubicin B-Chemical B-Chemical 0.9221720099449158
) O O 0.7004500031471252
was O O 0.9998723268508911
done O O 0.9999734163284302
in O O 0.9999963045120239
55 O O 0.9971343278884888
patients O O 0.9998807907104492
in O O 0.999994158744812
good O O 0.9798758029937744
performance O O 0.9549932479858398
status O O 0.942478597164154
with O O 0.9999860525131226
refractory O O 0.5995586514472961
tumors B-Disease O 0.6684009432792664
. O O 0.9997019171714783

both O O 0.9959444403648376
functionally O O 0.9915243983268738
and O O 0.9983900785446167
structurally O O 0.9925238490104675
to O O 0.9999085664749146
the O O 0.9995818734169006
v-myb B-DNA B-DNA 0.6439618468284607
oncogene E-DNA E-DNA 0.9883992671966553
. O O 0.9995703101158142
Following O O 0.9999942779541016
our O O 0.999984860420227
observations O O 0.9996503591537476
that O O 0.9999970197677612
A-myb S-DNA S-DNA 0.7367634177207947
is O O 0.9986710548400879
expressed O O 0.999925971031189
in O O 0.9999816417694092
a O O 0.999944806098938
restricted O O 0.839286208152771
subset O O 0.8412466049194336
of O O 0.9996312856674194
normal O B-cell_type 0.5676659941673279
mature B-cell_type I-cell_type 0.4318869709968567
human I-cell_type I-cell_type 0.6357818245887756
B I-cell_type I-cell_type 0.8064389824867249
lymphocytes E-cell_type E-cell_type 0.9227493405342102
, O O 0.9988179802894592
with O O 0.9999949932098389
the O O 0.9999804496765137
phenotype O O 0.5772417187690735
CD38+ O O 0.2788284420967102
, O O 0.8792726993560791

The O O 0.9995600581169128
absolute O O 0.8963395357131958
risk O O 0.9959715008735657
for O O 0.9998990297317505
bladder B-Disease B-Disease 0.5112378001213074
cancer I-Disease I-Disease 0.9598394632339478
in O O 0.9798714518547058
the O O 0.9963867664337158
cohort O O 0.58912193775177
reached O O 0.9997497200965881
10 O O 0.9997958540916443
% O O 0.9999896287918091
16 O O 0.999962329864502
years O O 0.9999884366989136
after O O 0.999995231628418
diagnosis O O 0.9822837710380554
of O O 0.9997377991676331
Wegener B-Disease O 0.48618045449256897
' I-Disease O 0.6300646066665649
s I-Disease O 0.637885332107544
granulomatosis I-Disease B-Disease 0.5396150350570679
, O O 0.9846220016479492
and O O 0.9997870326042175
a O O 0.9997482895851135
history O O 0.991878867149353
of O O 0.9998483657836914
bladder B-Disease B-Disease 0.629753828048706
cancer I-Disease I-Disease 0.9560739398002625
was O O 0.9822806715965271
( O O 0.9998594522476196
non O O 0.965110719203949
- O O 0.988197386264801
significantly O O 0.9975996613502502
) O O 0.9997978806495667
twice O O 0.9999738931655884
as O O 0.9999492168426514
common O O 0.999278724193573
as O O 0.999983549118042
expected O O 0.9999057054519653
at O O 0.9999959468841553
the O O 0.9999933242797852
time O O 0.999980092048645
of O O 0.99997878074646
diagnosis O O 0.9520699977874756
of O O 0.9992450475692749
Wegener B-Disease O 0.5293007493019104
' I-Disease O 0.5530012249946594
s I-Disease O 0.5206201076507568
granulomatosis I-Disease O 0.690344512462616
. O O 0.9978298544883728

Pooled O O 0.9870642423629761
data O O 0.9937266111373901
from O O 0.9999867677688599
trials O O 0.9980034232139587
comparing O O 0.9999896287918091
antithrombotic O O 0.6509402394294739
treatment O O 0.9795987606048584
with O O 0.9999582767486572
placebo O O 0.8558508157730103
have O O 0.9998157620429993
shown O O 0.9999926090240479
that O O 0.9999890327453613
warfarin B-Chemical B-Chemical 0.9277157187461853
reduces O O 0.992400050163269
the O O 0.9969257712364197
risk O O 0.9989219903945923
of O O 0.9998667240142822
stroke B-Disease B-Disease 0.9792951345443726
by O O 0.9938656687736511
62 O O 0.9998979568481445
% O O 0.999969482421875
, O O 0.9999797344207764
and O O 0.9999819993972778
that O O 0.9999905824661255
aspirin B-Chemical B-Chemical 0.9305555820465088
alone O O 0.9484841227531433
reduces O O 0.9993149042129517
the O O 0.998258650302887
risk O O 0.998576283454895
by O O 0.9999954700469971
22 O O 0.9999380111694336
% O O 0.9999629259109497
. O O 0.999997615814209

Dexamethasone O B-Chemical 0.897355854511261
is O O 0.9944260120391846
frequently O O 0.9991255402565002
administered O O 0.9999215602874756
to O O 0.9999779462814331
the O O 0.99983811378479
developing O O 0.8796300888061523
fetus O O 0.8727847933769226
to O O 0.9998679161071777
accelerate O O 0.999308705329895
pulmonary O O 0.9576000571250916
development O O 0.8310161828994751
. O O 0.9999892711639404

rapid O O 0.8734488487243652
translocation O O 0.9882768988609314
into O O 0.9999732971191406
the O O 0.9998917579650879
nucleus O O 0.9687110781669617
where O O 0.9998619556427002
it O O 0.9990456700325012
binds O O 0.9997205138206482
to O O 0.9999638795852661
its O O 0.9998327493667603
cognate B-DNA B-DNA 0.7866174578666687
enhancer I-DNA I-DNA 0.34414783120155334
elements E-DNA E-DNA 0.9938608407974243
. O O 0.9998618364334106
Similarly O O 0.9999762773513794
, O O 0.9999918937683105
the O O 0.9999494552612305
p105 B-protein B-protein 0.6271184682846069
precursor E-protein E-protein 0.764850914478302
of O O 0.9823377132415771
the O O 0.9997183680534363
NF-kappa B-protein B-protein 0.5660978555679321
B E-protein I-protein 0.5451226830482483
p50 B-protein I-protein 0.5490189790725708
subunit E-protein E-protein 0.9917029738426208
is O O 0.9994020462036133
also O O 0.9999643564224243
post-translationally O O 0.9284862875938416
processed O O 0.9663781523704529
in O O 0.9992920160293579

is O O 0.9928998947143555
not O O 0.9995218515396118
fully O O 0.9979793429374695
clarified O O 0.9998660087585449
. O O 0.9999982118606567
Recently O O 0.9999042749404907
, O O 0.9999816417694092
we O O 0.9999434947967529
have O O 0.9999839067459106
reported O O 0.9999895095825195
that O O 0.9999961853027344
the O O 0.9999070167541504
histogenesis O O 0.9596070051193237
of O O 0.9995762705802917
B-cell B-cell_type O 0.34225842356681824
lymphomas E-cell_type O 0.5994446277618408
may O O 0.9984126091003418
be O O 0.9999942779541016
assessed O O 0.9999626874923706
by O O 0.9999948740005493
monitoring O O 0.9992504715919495
the O O 0.999940037727356
expression O O 0.9658644199371338
pattern O O 0.9788215160369873
of O O 0.9998028874397278
BCL-6 S-protein S-protein 0.9710909724235535
, O O 0.9990266561508179
a O O 0.9999059438705444
transcription B-protein B-protein 0.5901778340339661
factor E-protein E-protein 0.9750843644142151
expressed O O 0.9976325035095215
in O O 0.9999107122421265
germinal B-cell_type B-cell_line 0.3894524872303009
center I-cell_type I-cell_line 0.4065367877483368
( I-cell_type I-cell_line 0.5099723935127258
GC I-cell_type I-cell_line 0.573520839214325
) I-cell_type I-cell_line 0.5720491409301758
B I-cell_type I-cell_line 0.6030157208442688
cells E-cell_type E-cell_line 0.6254888772964478
, O O 0.9929973483085632
and O O 0.9996433258056641
CD138/syndecan-1 S-protein S-protein 0.6564013957977295
( O O 0.8546256422996521
syn-1 S-protein S-protein 0.49734750390052795
) O O 0.8183518648147583
, O O 0.9992475509643555
a O O 0.9999402761459351
proteoglycan O S-DNA 0.48876863718032837
associated O O 0.974565863609314
with O O 0.9998389482498169
post-GC O O 0.6777364611625671

of O O 0.9926290512084961

This O O 0.9979257583618164
was O O 0.9998136162757874
preceded O O 0.9999704360961914
by O O 0.9999912977218628
altered O O 0.9774527549743652
nephrin O O 0.48684272170066833
expression O O 0.8881893157958984
, O O 0.9999474287033081
supporting O O 0.9999176263809204
its O O 0.9999653100967407
pivotal O O 0.9835383892059326
role O O 0.998643696308136
in O O 0.9999812841415405
podocyte O O 0.7314186692237854
morphology O O 0.7299290299415588
. O O 0.9999916553497314

TCR S-protein S-protein 0.7989045977592468
engagement O O 0.9809390306472778
that O O 0.9999818801879883
are O O 0.9999909400939941
important O O 0.9998637437820435
for O O 0.999980092048645
regulating O O 0.9938008189201355
CD95 B-protein S-protein 0.77713543176651
ligand E-protein O 0.4330310821533203
gene O O 0.6419455409049988
expression O O 0.9910235404968262
. O O 0.9999947547912598
To O O 0.9999512434005737
approach O O 0.9999457597732544
this O O 0.9999901056289673
, O O 0.9999637603759766

S O O 0.27150216698646545
phase O O 0.5036565661430359
in O O 0.9977638721466064
erythroid B-cell_type B-cell_type 0.7864976525306702
cells E-cell_type E-cell_type 0.9869088530540466
. O O 0.999725878238678
We O O 0.9999862909317017
have O O 0.9999927282333374
set O O 0.9999574422836304
out O O 0.999981164932251
to O O 0.9999854564666748
test O O 0.9999861717224121
a O O 0.9999709129333496
model O O 0.9917705059051514
for O O 0.9998587369918823
tissue-specific O O 0.7428122162818909
gene O O 0.5617381930351257
expression O O 0.9685645699501038
that O O 0.999953031539917
relies O O 0.9999054670333862
on O O 0.9999415874481201

Angiotensin S-Chemical B-Chemical 0.9306154847145081
- O O 0.9003341794013977
converting O O 0.9978534579277039
enzyme O O 0.8840078711509705
inhibitors O O 0.7487985491752625
and O O 0.9993366599082947
angiotensin B-Chemical B-Chemical 0.942202627658844
II E-Chemical I-Chemical 0.9580308198928833
receptor O O 0.7566487789154053
- O O 0.8871825933456421
blocking O O 0.9866446852684021
drugs O O 0.9932169318199158
hold O O 0.9999330043792725
promise O O 0.8892048001289368
in O O 0.9996329545974731
atrial O B-Disease 0.7041544318199158
fibrillation O I-Disease 0.9767994284629822
through O O 0.9929025769233704
cardiac O O 0.7512326240539551
remodelling O O 0.8059512376785278
. O O 0.9998459815979004

nuclear B-protein B-protein 0.6694225668907166
NFkappaB E-protein E-protein 0.8027875423431396
correlated O O 0.9992077946662903
with O O 0.9999828338623047
decrease O O 0.99355548620224
in O O 0.9995606541633606
intracellular O O 0.8990808725357056
IL-2 S-protein S-protein 0.750632107257843
receptor O O 0.821742832660675
expression O O 0.9800726175308228
and O O 0.9993645548820496
anti-CD3 S-protein S-protein 0.9848625063896179
-induced O O 0.9949539303779602
proliferation O O 0.9969559907913208
of O O 0.999934196472168
both O O 0.9985172152519226

differences O O 0.9778171181678772
were O O 0.9999856948852539
observed O O 0.999980092048645
between O O 0.9999797344207764
six O O 0.9990109205245972
of O O 0.9999884366989136
the O O 0.9999858140945435
sensitive O O 0.9140690565109253
and O O 0.9750806093215942
resistant O O 0.9638763070106506
patients O O 0.9978023171424866
in O O 0.9999958276748657
the O O 0.9999686479568481
clearance O O 0.9968896508216858
of O O 0.9999772310256958
plasma O O 0.7405060529708862
prednisolone O O 0.5515893697738647
derived O O 0.9989656209945679
from O O 0.9999390840530396
orally O O 0.6091688275337219
administered O O 0.7861607670783997
prednisone O O 0.3792840242385864
. O O 0.9990836381912231
Peripheral B-protein B-cell_type 0.5848996043205261
blood I-protein I-cell_type 0.7403666377067566
mononuclear I-protein I-cell_type 0.9099639058113098

Side O O 0.9612333178520203
effects O O 0.9963351488113403
attributable O O 0.9997729659080505
to O O 0.9998413324356079
mazindol S-Chemical B-Chemical 0.9279816746711731
included O O 0.9952867031097412
decreased O O 0.9211458563804626
appetite O O 0.6011221408843994
( O O 0.9869536757469177
36 O O 0.9991655349731445
% O O 0.9997119307518005
) O O 0.9989629983901978
, O O 0.9999681711196899
dry O B-Disease 0.600648045539856
mouth O I-Disease 0.9774373769760132
( O O 0.9264394640922546
10 O O 0.9976062774658203
% O O 0.9994795918464661
) O O 0.9991658926010132
, O O 0.9999592304229736
behavioral O O 0.7665069103240967
change O O 0.8545842170715332
( O O 0.9924067854881287
22 O O 0.99957674741745
% O O 0.9995928406715393
) O O 0.998021125793457
, O O 0.9998914003372192
and O O 0.999515175819397
gastrointestinal O B-Disease 0.7306199669837952
symptoms O I-Disease 0.9761337041854858
( O O 0.9776440262794495
18 O O 0.9996405839920044
% O O 0.9997394680976868
) O O 0.9992635846138
; O O 0.9999808073043823
mazindol S-Chemical B-Chemical 0.9212055206298828
dosage O O 0.4982120096683502
was O O 0.9998705387115479
reduced O O 0.999342143535614
in O O 0.9999734163284302
43 O O 0.9992914199829102
% O O 0.9999599456787109
of O O 0.9999741315841675
patients O O 0.9997377991676331
. O O 0.9999988079071045

of O O 0.9926290512084961

Increase O O 0.9718737602233887
of O O 0.9970903396606445
Parkinson B-Disease O 0.7526418566703796
disability I-Disease O 0.5741819143295288
after O O 0.9984656572341919
fluoxetine B-Chemical B-Chemical 0.9134691953659058
medication O O 0.9487037062644958
. O O 0.9999955892562866

Acute B-Disease O 0.920854389667511
liver I-Disease B-Disease 0.5876944065093994
failure I-Disease I-Disease 0.9781230092048645
in O O 0.9752492308616638
two O O 0.9983476400375366
patients O O 0.9991056323051453
with O O 0.9999611377716064
regular O O 0.9455614686012268
alcohol B-Chemical B-Chemical 0.9173426032066345
consumption O O 0.8972940444946289
ingesting O O 0.9994626641273499
paracetamol B-Chemical B-Chemical 0.9378029704093933
at O O 0.9991605281829834
therapeutic O O 0.9144266247749329
dosage O O 0.7949053645133972
. O O 0.9999878406524658

, O O 0.9503923654556274

This O O 0.9973344802856445
CAB O O 0.7556610107421875
- O O 0.9519919157028198
induced O O 0.9952783584594727
anemia O B-Disease 0.978570282459259
was O O 0.9814789295196533
normochromic O O 0.7982161641120911
and O O 0.7101634740829468
normocytic O O 0.5687727332115173
. O O 0.9991163611412048

from O O 0.9994056224822998
those O O 0.999984622001648
regulating O O 0.9966773986816406
homotypic O O 0.9381371736526489
aggregation O O 0.9936741590499878
and O O 0.9998559951782227
proliferation O O 0.9981997013092041
. O O 0.9999973773956299
Transcription B-protein B-protein 0.6388816237449646
factor I-protein E-protein 0.8925909399986267
GATA-3 E-protein S-protein 0.4801715314388275

's O O 0.8324022889137268
syndrome O O 0.9241395592689514
( O O 0.9999077320098877
Cushing O O 0.9772023558616638
's O O 0.9938669800758362
disease O O 0.9787065386772156
) O O 0.9998860359191895
and O O 0.9999707937240601
10 O O 0.9962469935417175
healthy O O 0.9743273854255676
controls O O 0.9918117523193359
. O O 0.9999980926513672
Using O O 0.9999847412109375
a O O 0.9998692274093628
whole-cell O O 0.7393119931221008
competitive O O 0.7239434123039246
binding O O 0.5482176542282104
assay O O 0.8983743190765381
and O O 0.9988364577293396
3H-dexamethasone O O 0.5758767127990723
as O O 0.9911941885948181
tracer O O 0.857051432132721
, O O 0.9989467263221741
MNL S-cell_type S-protein 0.3598332405090332
of O O 0.9787261486053467
abdominal O O 0.7696437239646912
obese O O 0.7245059013366699
subjects O O 0.8949347138404846
were O O 0.9999638795852661
found O O 0.9999914169311523
to O O 0.9999905824661255
have O O 0.9999841451644897
4855 O O 0.9151800274848938
+/- O O 0.9944915771484375
1389 O O 0.9766740798950195
sites/cell O O 0.8967427611351013
which O O 0.999968409538269
was O O 0.9999935626983643
significantly O O 0.9998794794082642
lower O O 0.9994094371795654

motifs E-DNA E-DNA 0.45681649446487427
of O O 0.9969981908798218
the O O 0.9999701976776123
beta-globin B-DNA B-DNA 0.508331298828125
locus E-DNA I-DNA 0.746265172958374
LCR S-DNA E-DNA 0.778329074382782
may O O 0.9983000159263611
play O O 0.9999861717224121
a O O 0.9999942779541016
role O O 0.9998985528945923
in O O 0.9999929666519165
the O O 0.9999730587005615
developmental O O 0.9886887669563293
regulation O O 0.9987577199935913
of O O 0.9999834299087524
human O B-DNA 0.7410656809806824
beta-globin B-DNA I-DNA 0.34109747409820557
gene E-DNA E-DNA 0.7820166349411011
expression O O 0.971461296081543
, O O 0.999916672706604
perhaps O O 0.999975323677063
by O O 0.9999876022338867
increasing O O 0.9997897744178772
the O O 0.9999004602432251
probability O O 0.999542236328125
of O O 0.9999707937240601
interaction O O 0.9968749284744263
of O O 0.9999231100082397
the O O 0.9998692274093628
LCR B-protein B-protein 0.41514289379119873
holocomplex E-protein E-protein 0.5327553749084473
with O O 0.9933492541313171
the O O 0.9998531341552734
fetal B-DNA O 0.47108739614486694
or I-DNA O 0.8646490573883057
the I-DNA O 0.989806592464447
adult I-DNA O 0.8268495798110962
globin I-DNA O 0.3296353816986084

The O O 0.9995816349983215
present O O 0.9987389445304871
study O O 0.999768078327179
was O O 0.9999961853027344
done O O 0.9999945163726807
to O O 0.9999988079071045
investigate O O 0.9999697208404541
the O O 0.9999113082885742
protective O O 0.9531356692314148
effect O O 0.9976068735122681
of O O 0.999873161315918
TCR B-Chemical B-Chemical 0.9241271615028381
on O O 0.9944562911987305
experimentally O O 0.9436474442481995
induced O O 0.9928319454193115
myocardial B-Disease B-Disease 0.5802775025367737
infarction I-Disease I-Disease 0.9834238290786743
in O O 0.9600943922996521
rats O O 0.9884980320930481
. O O 0.9999980926513672

Therefore O O 0.9992809891700745
, O O 0.9999909400939941
three O O 0.9997625946998596
novel O O 0.8845545053482056
sigma O O 0.5722823143005371
receptor O O 0.6587693095207214
ligands O O 0.6735339164733887
with O O 0.9997642636299133
antagonist O O 0.6786797046661377
activity O O 0.8308830857276917
were O O 0.9999345541000366
evaluated O O 0.9999929666519165
in O O 0.9999910593032837
Swiss O O 0.970403790473938
Webster O O 0.9270544648170471
mice O O 0.993650496006012
: O O 0.999476969242096
BD1018 B-Chemical B-Chemical 0.9185723066329956
( O O 0.9510732889175415
3S B-Chemical B-Chemical 0.7093408703804016
- I-Chemical I-Chemical 0.986113965511322
1 I-Chemical I-Chemical 0.9792932271957397
- I-Chemical I-Chemical 0.9920908212661743
[ I-Chemical I-Chemical 0.9877070784568787
2 I-Chemical I-Chemical 0.9789543747901917
- I-Chemical I-Chemical 0.9919865131378174
( I-Chemical I-Chemical 0.9868631362915039
3 I-Chemical I-Chemical 0.9836249351501465
, I-Chemical I-Chemical 0.99396812915802
4 I-Chemical I-Chemical 0.9818815588951111
- I-Chemical I-Chemical 0.9955735206604004
dichlorophenyl I-Chemical I-Chemical 0.9612776041030884
) I-Chemical I-Chemical 0.9789854288101196
ethyl I-Chemical I-Chemical 0.9695367217063904
] I-Chemical I-Chemical 0.9735981225967407
- I-Chemical I-Chemical 0.9943618774414062
1 I-Chemical I-Chemical 0.9825317859649658
, I-Chemical I-Chemical 0.9877811670303345
4 I-Chemical I-Chemical 0.9826748967170715
- I-Chemical I-Chemical 0.9961326122283936
diazabicyclo I-Chemical I-Chemical 0.9583125710487366
[ I-Chemical I-Chemical 0.88771653175354
4 I-Chemical I-Chemical 0.9523324370384216
. I-Chemical I-Chemical 0.9752878546714783
3 I-Chemical I-Chemical 0.9859126210212708
. I-Chemical I-Chemical 0.9860438108444214
0 I-Chemical I-Chemical 0.9894098043441772
] I-Chemical I-Chemical 0.9845167994499207
nonane I-Chemical I-Chemical 0.9488982558250427
) O O 0.9183323383331299
, O O 0.634853184223175
BD1063 B-Chemical B-Chemical 0.9226416349411011
( O O 0.8890459537506104
1 B-Chemical B-Chemical 0.7467700839042664
- I-Chemical I-Chemical 0.9896218776702881
[ I-Chemical I-Chemical 0.9872440695762634
2 I-Chemical I-Chemical 0.9801563024520874
- I-Chemical I-Chemical 0.9921616911888123
( I-Chemical I-Chemical 0.9875327944755554
3 I-Chemical I-Chemical 0.9839116334915161
, I-Chemical I-Chemical 0.9936797618865967
4 I-Chemical I-Chemical 0.9822872281074524
- I-Chemical I-Chemical 0.9951995611190796
dichlorophenyl I-Chemical I-Chemical 0.9582364559173584
) I-Chemical I-Chemical 0.9765126705169678
ethyl I-Chemical I-Chemical 0.9704433083534241
] I-Chemical I-Chemical 0.9770522117614746
- I-Chemical I-Chemical 0.9947999715805054
4 I-Chemical I-Chemical 0.9760417938232422
- I-Chemical I-Chemical 0.9952400922775269
methylpiperazine I-Chemical I-Chemical 0.9376200437545776
) O O 0.7776711583137512
, O O 0.9664896130561829
and O O 0.997654139995575
LR132 B-Chemical B-Chemical 0.9399401545524597
( O O 0.9667329788208008
1R O B-Chemical 0.8320345282554626
, O I-Chemical 0.8682988882064819
2S O I-Chemical 0.9621855616569519
- O I-Chemical 0.9875230193138123
( O I-Chemical 0.9744205474853516
+ O I-Chemical 0.8609035611152649
) O I-Chemical 0.6809845566749573
- O I-Chemical 0.7168612480163574
cis O I-Chemical 0.7859064936637878
- O I-Chemical 0.840201735496521
N O I-Chemical 0.9373032450675964
- O I-Chemical 0.9883435964584351
[ O I-Chemical 0.9805586934089661
2 O I-Chemical 0.9742617607116699
- O I-Chemical 0.9909927845001221
( O I-Chemical 0.9778416156768799
3 O I-Chemical 0.9794673323631287
, O I-Chemical 0.9907641410827637
4 O I-Chemical 0.981124997138977
- O I-Chemical 0.9953578114509583
dichlorophenyl O I-Chemical 0.9602488279342651
) O I-Chemical 0.9750873446464539
ethyl O I-Chemical 0.9694647789001465
] O I-Chemical 0.942507266998291
- O I-Chemical 0.9908263087272644
2 O I-Chemical 0.980266273021698
- O I-Chemical 0.9929437041282654
( O I-Chemical 0.9862478375434875
1 O I-Chemical 0.9863474369049072
- O I-Chemical 0.9964210987091064
pyrrolidinyl O I-Chemical 0.9577199816703796
) O I-Chemical 0.9726930260658264
cyclohexylamine O I-Chemical 0.9356887936592102
) O O 0.7083641886711121
. O O 0.9999641180038452

is O O 0.9977896213531494
essential O O 0.9998555183410645
for O O 0.9999762773513794
thymus-dependent O O 0.8569604754447937
humoral O O 0.8877750635147095
immune O O 0.9522141814231873
responses O O 0.9874465465545654
and O O 0.9997716546058655
rescuing O O 0.9419024586677551
B B-cell_type B-cell_type 0.7742971181869507
cells E-cell_type E-cell_type 0.9873203039169312
from O O 0.9997566342353821
apoptosis O O 0.9829724431037903
. O O 0.9999974966049194
Many O O 0.99998939037323
of O O 0.9999940395355225
the O O 0.999991774559021
effects O O 0.9999276399612427
of O O 0.9999527931213379
CD40 S-protein S-protein 0.951252818107605
are O O 0.9995942711830139
believed O O 0.9999696016311646
to O O 0.9999603033065796
be O O 0.9999536275863647
achieved O O 0.9996922016143799
through O O 0.9999810457229614
altered O O 0.920280396938324
gene O O 0.8184983730316162
expression O O 0.9957467913627625

Independent O O 0.9840732216835022
but O O 0.999664306640625
not O O 0.9998840093612671
additive O O 0.9647059440612793
effects O O 0.9963542222976685
of O O 0.9963414072990417
Na S-Chemical B-Chemical 0.9104347229003906
and O O 0.9538763761520386
Ca S-Chemical B-Chemical 0.916989803314209
are O O 0.9972881078720093
shown O O 0.9999920129776001
by O O 0.9999961853027344
decreases O O 0.9931151270866394
in O O 0.9988647699356079
the O O 0.9993329644203186
values O O 0.9987497329711914
of O O 0.9997108578681946
[ O O 0.6157111525535583
verapamil S-Chemical B-Chemical 0.796568751335144
] O O 0.7206724286079407
o O O 0.5828711986541748
needed O O 0.9977992177009583
to O O 0.9999830722808838
reduce O O 0.9989651441574097
BF O O 0.5389385223388672
by O O 0.9981665015220642
30 O O 0.9993723034858704
% O O 0.9999281167984009
( O O 0.9999240636825562
IC30 O O 0.9475911259651184
) O O 0.9991443157196045
with O O 0.9999990463256836
the O O 0.9999934434890747
following O O 0.9999208450317383
order O O 0.99913090467453
of O O 0.999970555305481
inhibitory O O 0.8753107786178589
potency O O 0.769290566444397
: O O 0.9985917210578918
LNa O O 0.509998083114624
> O O 0.9983110427856445
LCa O O 0.6337985396385193
> O O 0.9992177486419678
HCa O O 0.5927273631095886
> O O 0.9985710382461548
N O O 0.8147887587547302
, O O 0.9991999268531799
resulting O O 0.9999281167984009
LNa O O 0.4631655514240265
+ O O 0.9823405742645264
HCa O O 0.499526709318161
similar O O 0.9970494508743286
to O O 0.999941349029541
LNa O O 0.31562376022338867
. O O 0.999382495880127

may O O 0.9933179616928101
provide O O 0.9999967813491821
a O O 0.99998939037323
useful O O 0.9920761585235596
experimental O O 0.9834498763084412
system O O 0.9910780787467957
for O O 0.9999831914901733
studying O O 0.9999555349349976
the O O 0.9999454021453857
molecular O O 0.9526764750480652
mechanisms O O 0.992598295211792
responsible O O 0.9999830722808838
for O O 0.9999866485595703
downmodulation O O 0.9926818013191223
of O O 0.9999232292175293
lineage-restricted O B-protein 0.6612453460693359
transcription B-protein I-protein 0.4689387381076813
factors E-protein E-protein 0.9913890957832336
during O O 0.9995885491371155
hemopoietic O B-cell_type 0.5550577640533447
lineage O E-cell_type 0.7782971262931824

, O O 0.9783510565757751
and O O 0.9997313618659973
the O O 0.9999945163726807
recent O O 0.9986621141433716
demonstration O O 0.9996089339256287
of O O 0.9999842643737793
JAK S-protein S-protein 0.9187784194946289
phosphorylation O O 0.9647972583770752
by O O 0.9999048709869385
IL-12 S-protein S-protein 0.9833789467811584
, O O 0.9994316697120667
identify O O 0.9999730587005615
a O O 0.9999810457229614
rapid O O 0.9590913653373718
signal-transduction O O 0.9463376998901367
pathway O O 0.9964151382446289
likely O O 0.999911904335022
to O O 0.9999887943267822
mediate O O 0.9964160919189453
IL-12 S-protein S-protein 0.9891147613525391
-induced O O 0.9973848462104797
gene O O 0.9735801219940186
expression O O 0.998586893081665
. O O 0.9999986886978149
Temperature-induced O O 0.9714633226394653
down-regulation O O 0.9902309775352478
of O O 0.9997770190238953
the O O 0.9997785687446594
glucocorticoid B-protein B-protein 0.7010431885719299
receptor E-protein E-protein 0.6664177179336548

Seven O O 0.9946148991584778
patients O O 0.9983262419700623
developed O O 0.9995115995407104
glucose O O 0.42436954379081726
tolerance O O 0.7171580195426941
curves O O 0.6241968870162964
characteristic O O 0.9880026578903198
of O O 0.9995794892311096
diabetes O B-Disease 0.9757803678512573
but O O 0.9740676283836365
these O O 0.9997583031654358
were O O 0.9999656677246094
mild O O 0.9921716451644897
, O O 0.9996483325958252
did O O 0.9999126195907593
not O O 0.9998711347579956
require O O 0.9999501705169678
treatment O O 0.9988935589790344
and O O 0.999983549118042
returned O O 0.996068000793457
to O O 0.9995197057723999
normal O O 0.9622092843055725
on O O 0.9997866749763489
ceasing O O 0.9765949845314026
didanosine S-Chemical B-Chemical 0.9197580218315125
. O O 0.9996082186698914

Delirium O B-Disease 0.9572923183441162
was O O 0.9501492977142334
diagnosed O O 0.9990422129631042
in O O 0.9999788999557495
14 O O 0.9977661371231079
( O O 0.9999405145645142
10 O O 0.9998399019241333
. O O 0.9999490976333618
1 O O 0.9996732473373413
% O O 0.9997045397758484
incidence O O 0.5903905034065247
, O O 0.997427761554718
or O O 0.9998164772987366
1 O O 0.9994490742683411
. O O 0.9998964071273804
48 O O 0.9993560910224915
cases O O 0.9982428550720215
/ O O 0.9999760389328003
person O O 0.9998577833175659
- O O 0.999916672706604
years O O 0.999962329864502
of O O 0.9999340772628784
exposure O O 0.7023516297340393
) O O 0.9691011309623718
; O O 0.999616265296936
71 O O 0.9897513389587402
. O O 0.9999912977218628
4 O O 0.9999129772186279
% O O 0.9999698400497437
of O O 0.9999724626541138
cases O O 0.978624165058136
were O O 0.999920129776001
moderate O O 0.6674942970275879
or O O 0.9710067510604858
severe O O 0.9223363995552063
. O O 0.9999209642410278

The O O 0.9996569156646729
acute O O 0.8123922348022461
toxicity B-Disease O 0.8030349016189575
of O O 0.8721773624420166
OPs B-Chemical B-Chemical 0.892302393913269
is O O 0.9990257024765015
the O O 0.9999948740005493
result O O 0.9999927282333374
of O O 0.9999933242797852
their O O 0.9999849796295166
irreversible O O 0.9646632075309753
binding O O 0.9198461771011353
with O O 0.9998065829277039
AChEs O O 0.7319647073745728
in O O 0.9984760880470276
the O O 0.9997629523277283
central O O 0.9658248424530029
nervous O O 0.6651249527931213
system O O 0.5925742983818054
( O O 0.9965033531188965
CNS O O 0.5916616320610046
) O O 0.983060896396637
, O O 0.9999474287033081
which O O 0.9999502897262573
elevates O O 0.9975202679634094
acetylcholine B-Chemical B-Chemical 0.937131404876709
( O O 0.9245789647102356
ACh B-Chemical B-Chemical 0.9159650206565857
) O O 0.7749025225639343
levels O O 0.9993488192558289
. O O 0.9999994039535522

The O O 0.99825519323349
catheters O O 0.8561272025108337
were O O 0.9996592998504639
changed O O 0.9965556859970093
, O O 0.9997674822807312
and O O 0.99981290102005
hemodynamics O O 0.8215742111206055
stabilized O O 0.8957756757736206
at O O 0.9998840093612671
lower O O 0.9986146688461304
catecholamine B-Chemical B-Chemical 0.9217095971107483
doses O O 0.9503974318504333
. O O 0.9999911785125732

the O O 0.9984032511711121
same O O 0.9997904896736145
properties O O 0.9957838654518127
, O O 0.9999797344207764
including O O 0.9999744892120361
GRE S-DNA S-DNA 0.664298951625824
-specific O O 0.9876630902290344
DNA O O 0.9589576721191406
binding O O 0.9675167202949524
, O O 0.9996825456619263
observed O O 0.999834418296814
for O O 0.9999059438705444
glucocorticoid B-protein B-protein 0.5820697546005249
receptor E-protein E-protein 0.9302784204483032
present O O 0.9744061231613159
in O O 0.9998636245727539
cytosolic O O 0.7441739439964294
extracts O O 0.8822983503341675
of O O 0.9995610117912292
mammalian B-cell_type O 0.5944148898124695
cells E-cell_type O 0.7049059867858887
and O O 0.9925008416175842
tissues O O 0.8867819905281067
. O O 0.9999877214431763

age O O 0.9726547002792358

Within O O 0.9997795224189758
14 O O 0.9999003410339355
days O O 0.9999955892562866
of O O 0.999992847442627
the O O 0.9999910593032837
oral O O 0.797617495059967
bisphosphonate S-Chemical B-Chemical 0.9052253365516663
( O O 0.8922680616378784
alendronate B-Chemical B-Chemical 0.9314936399459839
sodium E-Chemical I-Chemical 0.9513275027275085
) O O 0.6294708251953125
administration O O 0.9741025567054749
, O O 0.9999971389770508
the O O 0.9999779462814331
amount O O 0.9999128580093384
of O O 0.9999710321426392
daily O O 0.9609418511390686
urinary O O 0.9697636961936951
protein O O 0.9548110365867615
increased O O 0.9998682737350464
rapidly O O 0.9982095956802368
up O O 0.9997777342796326
to O O 0.9998224377632141
12 O O 0.9995405673980713
. O O 0.9999837875366211
8 O O 0.9998149275779724
g O O 0.9962653517723083
with O O 0.9999715089797974
acute O B-Disease 0.7464302182197571
renal O I-Disease 0.49334579706192017
failure O I-Disease 0.9762516021728516
. O O 0.997527539730072

The O O 0.9995730519294739
incidence O O 0.9965921640396118
of O O 0.9998772144317627
preneoplastic O O 0.6328054070472717
nodules O O 0.7775180339813232
and O O 0.9952542781829834
of O O 0.9998748302459717
hepatocellular B-Disease B-Disease 0.5923253297805786
carcinomas I-Disease I-Disease 0.9614489078521729
was O O 0.9950733780860901
10 O O 0.9999600648880005
% O O 0.9999717473983765
and O O 0.9999755620956421
37 O O 0.9999381303787231
% O O 0.9999810457229614
, O O 0.999984622001648
respectively O O 0.9999898672103882
, O O 0.9999783039093018
in O O 0.9999552965164185
rats O O 0.9968869090080261
fed O O 0.9991735816001892
the O O 0.9999103546142578
plain O O 0.9239110350608826
choline B-Chemical B-Chemical 0.9347586035728455
- O O 0.9822170734405518
devoid O O 0.9898501634597778
diet O O 0.8315181732177734
, O O 0.9996659755706787
and O O 0.9999723434448242
17 O O 0.9998548030853271
% O O 0.9999454021453857
and O O 0.9999545812606812
30 O O 0.9999226331710815
% O O 0.9999758005142212
, O O 0.9999783039093018
in O O 0.9999741315841675
rats O O 0.9974583983421326
fed O O 0.9992794394493103
the O O 0.9999051094055176
phenobarbital B-Chemical O 0.8457246422767639
- O O 0.7320675849914551
containing O O 0.9865350127220154
choline B-Chemical B-Chemical 0.9288828372955322
- O O 0.9813823699951172
devoid O O 0.9986703395843506
diet O O 0.7672346830368042
. O O 0.999972939491272

transcripts E-RNA E-RNA 0.960364580154419
in O O 0.999805748462677
the O O 0.999994158744812
absence O O 0.9988614320755005
of O O 0.9999746084213257
apparent O O 0.9762697815895081
chromosome B-DNA B-DNA 0.5268988013267517
16 E-DNA E-DNA 0.916222333908081
abnormalities O O 0.8585861921310425

Ovariectomy O O 0.7926899194717407
of O O 0.9026563167572021
female O O 0.8659981489181519
DS O O 0.41687360405921936
had O O 0.9975684285163879
no O O 0.999871015548706
effect O O 0.9993657469749451
on O O 0.9999887943267822
intrarenal O O 0.8769238591194153
angiotensinogen O O 0.6304601430892944
expression O O 0.9538078308105469
on O O 0.9999411106109619
either O O 0.9997397065162659
diet O O 0.9737762212753296
. O O 0.9999938011169434

, O O 0.9503923654556274

A O O 0.45929911732673645
and O O 0.9476919174194336
type O O 0.8287264704704285
B O O 0.6468433737754822
EBV O O 0.5052304267883301
carriers O O 0.7843261361122131
. O O 0.9996497631072998
The O O 0.9999861717224121
RAKFKQLLQ-specific O B-DNA 0.5601320266723633
CTL O I-DNA 0.2829033136367798
precursor O I-DNA 0.41545894742012024
frequencies O E-DNA 0.8980790376663208
in O O 0.9995042085647583
all O O 0.9999514818191528
5 O O 0.9752194881439209
persons O O 0.9890848994255066
were O O 0.9999920129776001
at O O 0.9999946355819702

was O O 0.985022246837616
identified O O 0.998953104019165
( O O 0.9995675683021545
CD4+ S-protein O 0.23397493362426758
, O O 0.9334832429885864
CD13 S-protein S-protein 0.5492265820503235
- O O 0.8400611877441406
, O O 0.9763739109039307
CD33+ O O 0.3100610673427582
, O O 0.9574458003044128
CD65s+ O O 0.29754313826560974
) O O 0.7119815945625305
. O O 0.9985660910606384
AF-10 O S-protein 0.761803388595581
was O O 0.9995818734169006
involved O O 0.9999874830245972
in O O 0.9999911785125732
5 O O 0.9890028238296509
of O O 0.9996718168258667
6 O O 0.9004004001617432
evaluable O O 0.9655755758285522

occurred O O 0.9954284429550171
with O O 0.9999960660934448
a O O 0.9999561309814453
parallel O O 0.9709096550941467
activation O O 0.9819414615631104
of O O 0.9994189739227295
c-Jun S-protein S-protein 0.8517176508903503
transactivating O O 0.9293667078018188
functions O O 0.984840452671051
and O O 0.999768078327179
expression O O 0.997204601764679
, O O 0.9999244213104248
was O O 0.9999284744262695
reflected O O 0.9999243021011353
by O O 0.9999743700027466
transfection O O 0.897332489490509
experiments O O 0.9482684135437012
at O O 0.9999920129776001
the O O 0.9999486207962036
IL-2 B-DNA B-DNA 0.6507785320281982
promoter E-DNA E-DNA 0.8181381821632385
level O O 0.920924186706543
, O O 0.9994391798973083
and O O 0.9999597072601318
involved O O 0.9999774694442749
not O O 0.9999750852584839
only O O 0.9999276399612427

T I-cell_line B-cell_type 0.5202776789665222

The O O 0.9995445609092712
mean O O 0.9986127614974976
steady O O 0.994486391544342
- O O 0.9987908005714417
state O O 0.9960405826568604
plasma O O 0.8240936398506165
and O O 0.9919518232345581
CSF O O 0.5573053956031799
methotrexate S-Chemical B-Chemical 0.8810400366783142
concentrations O O 0.9159337878227234
achieved O O 0.999944806098938
were O O 0.9999980926513672
1 O O 0.9990590214729309
. O O 0.9999499320983887
1 O O 0.9996846914291382
X O O 0.9270716905593872
10 O O 0.9474586844444275
( O O 0.999871015548706
- O O 0.9989835619926453
3 O O 0.9983710646629333
) O O 0.9986928105354309
mol O O 0.9915816187858582
/ O O 0.9999212026596069
L O O 0.8866879343986511
and O O 0.9990885257720947
3 O O 0.9991828799247742
. O O 0.9999841451644897
6 O O 0.9997956156730652
X O O 0.9803686738014221
10 O O 0.9944085478782654
( O O 0.9999656677246094
- O O 0.9994602799415588
5 O O 0.9990418553352356
) O O 0.9994156360626221
mol O O 0.9973859190940857
/ O O 0.9999679327011108
L O O 0.9545585513114929
, O O 0.9999006986618042
respectively O O 0.9999938011169434
. O O 0.9999983310699463

The O O 0.9995073080062866
associated O O 0.9925925135612488
urinary O O 0.82732754945755
concentrating O O 0.7743324041366577
defect O O 0.6703281998634338
is O O 0.9938448667526245
reversible O O 0.9985528588294983
only O O 0.9999903440475464
during O O 0.9999865293502808
the O O 0.9999598264694214
early O O 0.9963478446006775
stages O O 0.9999234676361084
of O O 0.9999788999557495
structural O O 0.9046003818511963
damage O O 0.8728252053260803
to O O 0.9134330153465271
the O O 0.9270753860473633
inner O O 0.8896937370300293
medulla O O 0.5320332646369934
. O O 0.9998984336853027

RESULTS O O 0.9980645775794983
: O O 0.9999586343765259
Fourteen O O 0.9960334897041321
subjects O O 0.9992668032646179
completed O O 0.9999533891677856
both O O 0.9999208450317383
treatment O O 0.9948154091835022
arms O O 0.9955947995185852
. O O 0.9999985694885254

glucocorticoids O O 0.5672045946121216
in O O 0.9997972846031189
the O O 0.999881386756897
C O O 0.4531208276748657
and O O 0.8366238474845886
AIDS-C O O 0.3436899781227112
groups O O 0.5191944241523743
( O O 0.9983874559402466
approximately O O 0.9993426203727722
80 O O 0.9888651371002197

gene O O 0.6921088695526123
transcription O O 0.8080919981002808
in O O 0.9996694326400757
THP-1 B-cell_line B-cell_line 0.7958938479423523
cells E-cell_line E-cell_line 0.9595674872398376
starts O O 0.9988065958023071
at O O 0.9999921321868896
multiple O B-DNA 0.9155622124671936
initiation O I-DNA 0.7202799320220947
sites O E-DNA 0.7714869976043701
and O O 0.9988358616828918
that O O 0.9999959468841553
Sp1 S-protein S-protein 0.8782019019126892
and O O 0.9817832112312317
IRBP S-protein S-protein 0.8865548968315125
may O O 0.9997631907463074
be O O 0.9999960660934448
critical O O 0.9955275654792786
factors O O 0.7233092188835144
for O O 0.9998764991760254
modulating O O 0.9984637498855591
the O O 0.9998284578323364
differentiation-dependent O O 0.755553126335144
transcription O O 0.550475001335144

express O O 0.9134554862976074
alpha B-protein B-protein 0.24569183588027954
4 E-protein E-protein 0.779015064239502
. O O 0.9991255402565002
Three O O 0.998936116695404
binding B-DNA B-DNA 0.7877197265625
sites E-DNA E-DNA 0.8361034393310547
for O O 0.9991382360458374
the O O 0.9992673993110657
Ets B-protein B-protein 0.5153658390045166
family E-protein E-protein 0.7860940098762512
of O O 0.8171430230140686

to O O 0.9977274537086487
a O O 0.9997734427452087
heterologous B-DNA B-DNA 0.4713999330997467
promoter E-DNA E-DNA 0.9837064743041992
. O O 0.9997890591621399
That O O 0.999996542930603
the O O 0.9999443292617798
c-myb B-protein B-protein 0.4543853998184204
oncogene I-protein I-protein 0.6050953269004822
product E-protein E-protein 0.8640133738517761
can O O 0.9997041821479797
interact O O 0.9999761581420898
synergistically O O 0.9998763799667358
with O O 0.9999959468841553
an O O 0.9998646974563599
EBV-encoded B-protein B-protein 0.36021801829338074
member E-protein E-protein 0.6237507462501526
of O O 0.7869974970817566

Bupropion S-Chemical B-Chemical 0.9266153573989868
is O O 0.9978523254394531
a O O 0.9999892711639404
monocyclic O O 0.7853406667709351
antidepressant S-Chemical B-Chemical 0.8801252841949463
structurally O O 0.9663722515106201
related O O 0.999771773815155
to O O 0.9999604225158691
amphetamine S-Chemical B-Chemical 0.9304394125938416
. O O 0.9992530941963196

The O O 0.9980050921440125
patient O O 0.9902584552764893
was O O 0.9999032020568848
asymptomatic O O 0.7156007289886475
and O O 0.9824514985084534
the O O 0.9984298348426819
aneurysm O B-Disease 0.9801252484321594
was O O 0.9501892328262329
detected O O 0.9977545142173767
in O O 0.999985933303833
a O O 0.999927282333374
routine O O 0.9282882809638977
control O O 0.9805035591125488
. O O 0.9999939203262329

sites E-DNA E-DNA 0.7099613547325134
showed O O 0.9995872378349304
either O O 0.9999849796295166
no O O 0.9992687106132507
or O O 0.9998276233673096
only O O 0.999796450138092
weak O O 0.9755586981773376
activity O O 0.994388997554779
compared O O 0.9999586343765259
to O O 0.9999338388442993
Jurkat B-cell_line B-cell_line 0.6896153092384338
T I-cell_line I-cell_line 0.8273733854293823
cells E-cell_line E-cell_line 0.98111891746521
. O O 0.9999072551727295
An O O 0.9998754262924194
IL-2 B-DNA B-DNA 0.5268456339836121
promoter E-DNA E-DNA 0.9897580146789551
bearing O O 0.9981535077095032
a O O 0.9999077320098877
defective O O 0.8226523399353027
NF-chi B-DNA B-DNA 0.5742493271827698
B I-DNA I-DNA 0.5445203185081482
site E-DNA E-DNA 0.9753119945526123
was O O 0.998950183391571
completely O O 0.9957517385482788
inactive O O 0.9938448667526245
in O O 0.999870777130127
EBV-transformed B-cell_line B-cell_line 0.6316844820976257
B I-cell_line I-cell_line 0.6893141865730286
cells E-cell_line E-cell_line 0.803322434425354
, O O 0.9958633184432983
while O O 0.9999969005584717
it O O 0.9999382495880127
still O O 0.9997074007987976
had O O 0.9999127388000488
activity O O 0.996055006980896
in O O 0.9999457597732544
Jurkat B-cell_line B-cell_line 0.6624957919120789
T I-cell_line I-cell_line 0.8292234539985657
cells E-cell_line E-cell_line 0.9837486743927002
. O O 0.9999046325683594
In O O 0.9999681711196899
seven O O 0.9991169571876526

lines E-cell_type E-cell_line 0.9812102913856506
and O O 0.9968460202217102
contains O O 0.9998565912246704
an O O 0.999958872795105
essential O O 0.9340396523475647
NF-kappa B-DNA B-DNA 0.6533538699150085
B I-DNA I-DNA 0.5318016409873962
site E-DNA E-DNA 0.9547719359397888
. O O 0.9996421337127686
Epstein-Barr O O 0.8790885806083679
virus O O 0.8537779450416565
( O O 0.9923640489578247
EBV O O 0.9518895745277405
) O O 0.991148829460144
infection O O 0.9900041222572327
of O O 0.9996659755706787
mature O O 0.8716758489608765
, O O 0.6418952345848083
resting B-cell_type B-cell_type 0.5474362373352051
B I-cell_type I-cell_type 0.8690995573997498
cells E-cell_type E-cell_type 0.9532691240310669
drives O O 0.99850994348526
them O O 0.9997382760047913
to O O 0.9999607801437378
become O O 0.999649167060852
lymphoblasts O O 0.5933871269226074
expressing O O 0.9899682402610779
high O O 0.9870174527168274
levels O O 0.9988977909088135

provide O O 0.9982166886329651
direct O O 0.9982832670211792
in O O 0.9998908042907715
vivo O O 0.9872670769691467
evidence O O 0.9995444416999817
to O O 0.9999957084655762
strongly O O 0.9995229244232178
suggest O O 0.9999964237213135
that O O 0.9999978542327881
the O O 0.9999432563781738
modulation O O 0.9964961409568787
of O O 0.9998868703842163
X1 S-DNA O 0.41163888573646545
and O O 0.9669671058654785
X2 S-DNA O 0.35371723771095276
interactions O O 0.9119693636894226
is O O 0.999995231628418
an O O 0.9999969005584717
important O O 0.9947730898857117
constituent O O 0.9791826605796814

general O O 0.5199527144432068
and O O 0.9513940811157227
the O O 0.9994205236434937
association O O 0.9992408752441406
of O O 0.9999791383743286
NF-kappaB S-protein S-protein 0.9926608800888062
activation O O 0.9960694313049316
with O O 0.9999829530715942
cellular/molecular O O 0.860542356967926
events O O 0.9638610482215881
of O O 0.9999282360076904
renal O O 0.8892354369163513
inflammation O O 0.9608230590820312
and O O 0.9988358616828918
fibrosis O O 0.8452727198600769
Expression O O 0.9973986148834229
of O O 0.9999468326568604
transcription B-protein B-protein 0.4770670533180237
factors E-protein E-protein 0.9927147030830383
during O O 0.9998551607131958
sodium O O 0.8448823690414429
phenylacetate O O 0.4139041304588318
induced O O 0.9960368275642395
erythroid O O 0.713737428188324
differentiation O O 0.9580919146537781
in O O 0.9997442364692688
K562 B-cell_line B-cell_line 0.8278927206993103
cells E-cell_line E-cell_line 0.9940255880355835
. O O 0.9999057054519653
During O O 0.9999891519546509
15 O O 0.9975106716156006

SOCS-3 S-protein S-protein 0.8490209579467773
expression O O 0.991425633430481
in O O 0.9999701976776123
response O O 0.9965734481811523
to O O 0.9999171495437622
IL-2 S-protein S-protein 0.9775881767272949
in O O 0.9997445940971375
both O O 0.9981993436813354
T-cell B-cell_line B-cell_line 0.6700015068054199
lines E-cell_line E-cell_line 0.9977948665618896
and O O 0.9981189370155334
human B-cell_type B-cell_type 0.707029402256012
peripheral I-cell_type I-cell_type 0.8174219727516174
blood I-cell_type I-cell_type 0.9267863035202026
lymphocytes E-cell_type E-cell_type 0.9567448496818542
. O O 0.9996345043182373
SOCS-3 S-protein B-protein 0.7374593019485474
protein O E-protein 0.9509121775627136
was O O 0.9989933371543884
detectable O O 0.9993836879730225
as O O 0.9999618530273438
early O O 0.98012375831604
as O O 0.9999343156814575
30 O O 0.9975099563598633
min O O 0.9980744123458862
following O O 0.999976396560669
IL-2 S-protein S-protein 0.938212513923645
stimulation O O 0.9963089823722839
, O O 0.9999892711639404
while O O 0.9999949932098389
CIS S-protein O 0.7864276170730591
was O O 0.9997342228889465
seen O O 0.9999867677688599
only O O 0.9999780654907227
at O O 0.999976634979248
low O O 0.9922361969947815
levels O O 0.9998923540115356
after O O 0.9999982118606567
2 O O 0.9990767240524292
h O O 0.9955541491508484
. O O 0.9999908208847046
Unlike O O 0.9999897480010986
CIS S-protein O 0.6326121091842651
, O O 0.9980701804161072
SOCS-3 S-protein S-protein 0.7554863691329956
was O O 0.9996486902236938
rapidly O O 0.999572217464447

and O O 0.956402063369751
tumour B-protein B-protein 0.6950726509094238
necrosis I-protein I-protein 0.5950877666473389
factor I-protein I-protein 0.5509294867515564
alpha E-protein E-protein 0.9932077527046204
( O O 0.9896417260169983
TNF-alpha S-protein S-protein 0.9942952990531921
) O O 0.9722107648849487
and O O 0.9997583031654358
to O O 0.9999555349349976
expression O O 0.9924654960632324
of O O 0.9997043013572693
the O O 0.9997722506523132
corresponding O O 0.8149868249893188
mRNA S-RNA S-RNA 0.6632106900215149
in O O 0.9969130754470825
human B-cell_type B-cell_type 0.6568005681037903
peripheral I-cell_type I-cell_type 0.8397143483161926
blood I-cell_type I-cell_type 0.9456512331962585
mononuclear I-cell_type I-cell_type 0.9595524668693542
cells E-cell_type E-cell_type 0.9727457165718079
( O O 0.9898495674133301
PBMC S-cell_type S-cell_type 0.9910481572151184
) O O 0.9912681579589844
. O O 0.9999877214431763
Structurally O O 0.9823275804519653
related O O 0.991803765296936
divalent O O 0.8375017046928406
cations O O 0.803602933883667
like O O 0.9966512322425842

step O O 0.8892413973808289
in O O 0.9999840259552002
the O O 0.9999974966049194
study O O 0.9997598528862
of O O 0.9999920129776001
their O O 0.999993085861206
respective O O 0.9989633560180664
roles O O 0.9984555244445801
. O O 0.999997615814209
Control O O 0.9950577020645142
of O O 0.999854326248169
NF-kappa B-protein B-protein 0.7574356198310852
B E-protein E-protein 0.9960231781005859
activity O O 0.9989162683486938
by O O 0.999998927116394
the O O 0.9999686479568481
I B-protein B-protein 0.8071734309196472
kappa I-protein I-protein 0.9454615712165833
B I-protein I-protein 0.7842388153076172
beta I-protein I-protein 0.7839657664299011
inhibitor E-protein E-protein 0.843417763710022
. O O 0.9989027976989746
The O O 0.9999829530715942
transcription B-protein B-protein 0.5935418009757996
factor E-protein E-protein 0.7977995872497559
NF-kappa B-protein B-protein 0.42598944902420044
B E-protein E-protein 0.9954085946083069
is O O 0.9992032647132874
maintained O O 0.9999222755432129
in O O 0.999985933303833
an O O 0.9998960494995117
inactive O O 0.7857192158699036
cytoplasmic O O 0.4703092575073242

IL-12 S-protein S-protein 0.8974494338035583
in O O 0.9998904466629028
a O O 0.999716579914093
human B-cell_line B-cell_line 0.4297633171081543
NK I-cell_line I-cell_line 0.737422525882721
cell I-cell_line I-cell_line 0.9056227803230286
line E-cell_line E-cell_line 0.9929434657096863
. O O 0.9998329877853394
Interferon-gamma S-protein S-protein 0.9822182059288025
( O O 0.9927594661712646
IFN-gamma S-protein S-protein 0.9884169697761536
) O O 0.9701749682426453
is O O 0.9999892711639404
an O O 0.999992847442627
important O O 0.9907649755477905
immunoregulatory B-protein B-protein 0.4842958152294159
protein E-protein E-protein 0.9640522599220276
produced O O 0.9978620409965515
predominantly O O 0.9992081522941589

expression O O 0.9773764610290527
of O O 0.9996128678321838
NF-kappa B-protein B-protein 0.9122341871261597
B E-protein E-protein 0.9946107864379883
. O O 0.9995275735855103
NF-kappa B-protein B-protein 0.8947793245315552
B E-protein E-protein 0.994628369808197
is O O 0.9997313618659973
a O O 0.9999867677688599
rapidly O O 0.9379583597183228
inducible O O 0.9328518509864807
transcriptional B-DNA B-protein 0.7821137309074402
activator E-DNA E-protein 0.947665274143219
that O O 0.9964084029197693
responds O O 0.9999591112136841
to O O 0.9999822378158569
a O O 0.999871015548706
variety O O 0.9976999163627625
of O O 0.999920129776001
signals O O 0.9698401093482971
and O O 0.9986743927001953
influences O O 0.9997805953025818
the O O 0.9999717473983765
expression O O 0.9993124008178711
of O O 0.9999834299087524
many O O 0.9984118938446045
genes O O 0.5291153788566589
involved O O 0.999596893787384
in O O 0.9999804496765137
the O O 0.9998722076416016

IL-4 S-protein S-protein 0.8524147272109985
enhances O O 0.9993425011634827
mRNA S-RNA O 0.7737832069396973
degradation O O 0.98649001121521
and O O 0.9998157620429993
does O O 0.9999796152114868
not O O 0.9999370574951172
suppress O O 0.9996488094329834
cytokine O B-DNA 0.7825527787208557
gene O E-DNA 0.812235414981842
transcription O O 0.9207320213317871
. O O 0.999933123588562
These O O 0.9999957084655762
data O O 0.9997594952583313
indicate O O 0.999997615814209
that O O 0.9999920129776001
IL-10 S-protein S-protein 0.9800840616226196
and O O 0.9940550327301025
IL-4 S-protein S-protein 0.9785544276237488
inhibit O O 0.9994383454322815
cytokine S-protein S-protein 0.9678611159324646
production O O 0.9992142915725708
by O O 0.9999967813491821
different O O 0.998164713382721
mechanisms O O 0.9988833069801331
. O O 0.9999940395355225
LMP-1 S-protein S-protein 0.9594337940216064
activates O O 0.9847981333732605

unable O O 0.9847769737243652
to O O 0.9998154044151306
terminally O O 0.9980620741844177
differentiate O O 0.9987768530845642
, O O 0.9999759197235107
this O O 0.9999772310256958
leads O O 0.9999295473098755
to O O 0.9999899864196777
progenitor O O 0.9020799994468689
proliferation O O 0.9885984659194946
in O O 0.9999840259552002
the O O 0.9997782111167908
spleen O O 0.8933363556861877
and O O 0.9982184767723083
consequently O O 0.9992075562477112
death O O 0.8746288418769836
. O O 0.9999819993972778
Thus O O 0.9832398295402527

A2 E-protein O 0.22773325443267822
and O O 0.9191743731498718
caspase-3/CPP32 S-protein S-protein 0.7435132265090942
, O O 0.9856967926025391
but O O 0.9995977282524109
did O O 0.9999599456787109
not O O 0.9999432563781738
interfere O O 0.9997987151145935
with O O 0.9999749660491943
the O O 0.9999409914016724
activation O O 0.9961264729499817
of O O 0.9998494386672974
NF-kappaB-like B-protein B-protein 0.7778995633125305
transcription I-protein I-protein 0.46762871742248535
factors E-protein E-protein 0.9922013282775879
. O O 0.999782145023346
A O O 0.999919056892395
putative O O 0.950246274471283
function O O 0.9961099028587341
of O O 0.9998910427093506
BHRF1 S-protein S-protein 0.72501140832901

translocation O O 0.8062645792961121
. O O 0.9998714923858643
Mice O O 0.42821991443634033
lacking O O 0.9690945148468018
the O O 0.9985758066177368
transcription B-protein B-protein 0.49067583680152893
factor E-protein E-protein 0.8946103453636169
CIITA S-protein S-protein 0.5406972765922546
-- O O 0.9990900754928589
a O O 0.9999693632125854
second O O 0.9875520467758179
look O O 0.9867276549339294
. O O 0.9999569654464722
We O O 0.9998775720596313
have O O 0.9999802112579346
generated O O 0.999790370464325
a O O 0.9999420642852783
second O O 0.924318253993988
line O O 0.9319717884063721

important O O 0.9752094149589539
regulators B-protein O 0.9412869215011597
of I-protein O 0.9994459748268127
transcription E-protein O 0.9446420073509216
during O O 0.9998601675033569
B-cell O O 0.5504623651504517
maturation O O 0.9828208684921265
. O O 0.9999932050704956
Reconstitution O O 0.9860787987709045
of O O 0.9996259212493896
T O B-protein 0.45465585589408875
cell O I-protein 0.3427914083003998
antigen O E-protein 0.7680122256278992

METHODS O O 0.9861430525779724
: O O 0.9999434947967529
Ninety O O 0.9479706883430481
patients O O 0.9987683892250061
classified O O 0.9999707937240601
as O O 0.9999221563339233
American O O 0.9232592582702637
Society O O 0.9433748722076416
of O O 0.9992951154708862
Anesthesiologists O O 0.7409976720809937
physical O O 0.8804630041122437
status O O 0.5830392837524414
I O O 0.5632048845291138
or O O 0.9976475834846497
II O O 0.6423248052597046
who O O 0.9963310360908508
were O O 0.9999864101409912
scheduled O O 0.9999696016311646
for O O 0.9999865293502808
short O O 0.9891128540039062
gynecologic O O 0.9150137305259705
procedures O O 0.9955639839172363
under O O 0.9999984502792358
spinal O O 0.8958591222763062
anesthesia O O 0.6792396306991577
were O O 0.999727189540863
randomly O O 0.999009370803833
allocated O O 0.9999932050704956
to O O 0.9999947547912598
receive O O 0.9999512434005737
2 O O 0.9634224772453308
. O O 0.9998507499694824
5 O O 0.9997005462646484
ml O O 0.9994022846221924
2 O O 0.9982404708862305
% O O 0.9998573064804077
lidocaine S-Chemical B-Chemical 0.9362534284591675
in O O 0.9981777667999268
7 O O 0.9894990921020508
. O O 0.9999009370803833
5 O O 0.9998371601104736
% O O 0.9998360872268677
glucose S-Chemical B-Chemical 0.9441192150115967
, O O 0.9885597825050354
2 O O 0.9994496703147888
% O O 0.999848484992981
prilocaine S-Chemical B-Chemical 0.9414340853691101
in O O 0.9970827698707581
7 O O 0.988673746585846
. O O 0.9999059438705444
5 O O 0.999782145023346
% O O 0.9998573064804077
glucose S-Chemical B-Chemical 0.9415357708930969
, O O 0.9750174880027771
or O O 0.9997983574867249
0 O O 0.9987264275550842
. O O 0.9999589920043945
5 O O 0.9995361566543579
% O O 0.9997846484184265
bupivacaine S-Chemical B-Chemical 0.9378381967544556
in O O 0.9966222047805786
7 O O 0.9779303073883057
. O O 0.9998037219047546
5 O O 0.9994994401931763
% O O 0.9998156428337097
glucose S-Chemical B-Chemical 0.9309703707695007
. O O 0.9992557168006897

Haemolytic B-Disease B-Disease 0.45869535207748413
- I-Disease I-Disease 0.6688323616981506
uraemic I-Disease I-Disease 0.7714623212814331
syndrome I-Disease I-Disease 0.9902894496917725
after O O 0.9852802157402039
treatment O O 0.9979175925254822
with O O 0.9999884366989136
metronidazole B-Chemical B-Chemical 0.9275362491607666
. O O 0.9994708895683289

chemotaxis O O 0.5733741521835327
and O O 0.9950850605964661
tissue O O 0.9016923308372498
leukostasis O O 0.774238646030426
. O O 0.9998565912246704
Thrombin S-protein S-protein 0.9453731775283813
and O O 0.9885278940200806
thrombin B-protein B-protein 0.3945820927619934
receptor E-protein E-protein 0.8467023372650146
agonist O O 0.8634822964668274
peptide O O 0.8641203045845032

As O O 0.9987947940826416
wider O O 0.9878501296043396
use O O 0.9996784925460815
confirms O O 0.9999746084213257
their O O 0.9999579191207886
safety O O 0.9624406695365906
profile O O 0.9924105405807495
, O O 0.9999872446060181
they O O 0.9998689889907837
will O O 0.999950647354126
gain O O 0.9998559951782227
increasing O O 0.995220959186554
importance O O 0.9808768630027771
in O O 0.9997604489326477
the O O 0.9997784495353699
therapeutic O O 0.9556638598442078
approach O O 0.997763991355896
to O O 0.9999719858169556
hypercholesterolaemia O B-Disease 0.9571207165718079
and O O 0.9468390941619873
its O O 0.9967572093009949
consequences O O 0.9989570379257202
. O O 0.9999991655349731

on O O 0.9974530339241028
tyrosine O O 0.8423740863800049
phosphorylation O O 0.9473900198936462
was O O 0.9999082088470459
globally O O 0.9931092262268066
decreased O O 0.9987950325012207
and O O 0.999958872795105
some O O 0.9998897314071655
phosphorylated O B-protein 0.6287898421287537
substrates O E-protein 0.8473557233810425
were O O 0.9995402097702026
specifically O O 0.9992967844009399
missing O O 0.9986166954040527
. O O 0.9999959468841553
Pervanadate O O 0.7406638264656067
also O O 0.9958504438400269
stimulated O O 0.9959563612937927
transcription O O 0.9585171937942505
of O O 0.9990689158439636
the O O 0.9995007514953613
c-fos B-DNA B-DNA 0.457676500082016
gene E-DNA E-DNA 0.8984178304672241

as O O 0.9951158761978149
efficiently O O 0.9988223910331726
as O O 0.9999966621398926
the O O 0.9999383687973022
hormones O O 0.9350257515907288
alone O O 0.9985163807868958
, O O 0.9999969005584717
providing O O 0.9999862909317017
further O O 0.9999130964279175
evidence O O 0.9999840259552002
to O O 0.9999984502792358
the O O 0.999984622001648
notion O O 0.9999390840530396
that O O 0.9999982118606567
steroid O O 0.7640080451965332
receptor O O 0.4398042857646942
drugs O O 0.7915966510772705
may O O 0.9999852180480957
manifest O O 0.9972236156463623
agonist O O 0.9673873782157898
or O O 0.9951186180114746
antagonist O O 0.9387608170509338
activities O O 0.9967256784439087
depending O O 0.9999980926513672
on O O 0.9999916553497314
the O O 0.9999586343765259
cellular O O 0.9606367945671082
context O O 0.9900065660476685
in O O 0.9999929666519165
which O O 0.9999946355819702
they O O 0.9999146461486816
are O O 0.9999639987945557
studied O O 0.9998095631599426
. O O 0.9999985694885254
Treatment O O 0.99928218126297
with O O 0.9999650716781616
E2 O O 0.32601282000541687
was O O 0.9973509311676025
also O O 0.9999444484710693

interaction O O 0.9887881875038147
of O O 0.9998088479042053
1 O O 0.5694188475608826
, O O 0.4811081290245056
25 O O 0.7006011605262756
( O O 0.8730411529541016
OH O O 0.5537548661231995
) O O 0.8754677772521973
2D3 O O 0.888925313949585

cell O O 0.40827620029449463
differentiation O O 0.9928998947143555
and O O 0.9999051094055176
regulation O O 0.9994674324989319
of O O 0.9999607801437378
cell O O 0.9559214115142822
growth O O 0.9930269122123718
. O O 0.9999969005584717
Inhibition O O 0.9955647587776184
of O O 0.9998296499252319
Th1 O O 0.3154980540275574
development O O 0.9406638741493225
mediated O O 0.9998065829277039
by O O 0.9999902248382568
GATA-3 S-protein S-protein 0.9865089058876038
through O O 0.9998960494995117
an O O 0.9999743700027466
IL-4-independent O O 0.48071348667144775
mechanism O O 0.8325648903846741

In O O 0.9996504783630371
the O O 0.9999346733093262
cohort O O 0.9575849771499634
the O O 0.9987443685531616
cumulative O O 0.8613437414169312
risk O O 0.9680008292198181
of O O 0.9996223449707031
bladder O B-Disease 0.5096019506454468
cancer O I-Disease 0.9436955451965332
after O O 0.9952715039253235
Wegener O O 0.735632598400116
' O O 0.825544536113739
s O O 0.8164801597595215
granulomatosis O B-Disease 0.6282604932785034
, O O 0.9913864135742188
and O O 0.9998296499252319
the O O 0.9999704360961914
relative O O 0.9976152181625366
prevalence O O 0.9943574070930481
of O O 0.9998536109924316
a O O 0.9993680119514465
history O O 0.9946764707565308
of O O 0.9998863935470581
bladder O B-Disease 0.6407307386398315
cancer O I-Disease 0.9661166071891785
at O O 0.997866690158844
the O O 0.9999904632568359
time O O 0.9999704360961914
of O O 0.9999822378158569
diagnosis O O 0.9536978602409363
of O O 0.9994144439697266
Wegener O O 0.5556391477584839
' O O 0.6661069989204407
s O O 0.6405889987945557
granulomatosis O O 0.6082820296287537
, O O 0.9911713004112244
were O O 0.999953031539917
also O O 0.9999794960021973
estimated O O 0.9999957084655762
. O O 0.9999990463256836

Sp1 I-DNA B-DNA 0.8775796294212341
binding I-DNA I-DNA 0.6112887263298035
elements E-DNA E-DNA 0.9900916814804077
and O O 0.9981689453125
the O O 0.9999650716781616
ability O O 0.9997313618659973
of O O 0.9999721050262451
the O O 0.9999409914016724
TATA B-DNA B-DNA 0.4797295331954956
box E-DNA E-DNA 0.9126969575881958
to O O 0.9930675029754639
bind O O 0.9997801184654236
the O O 0.9998723268508911
protein O O 0.7139204144477844
TBP S-protein S-protein 0.5975514054298401
. O O 0.9982934594154358
In O O 0.9999183416366577
both O O 0.9965794682502747
transformed B-cell_type B-cell_line 0.576759934425354
and I-cell_type I-cell_line 0.6715507507324219
normal I-cell_type I-cell_line 0.4592355191707611
lymphocytes E-cell_type E-cell_line 0.6517536044120789
, O O 0.999534010887146
OKA O S-protein 0.6632468104362488
stimulation O O 0.9845272302627563
induced O O 0.9997460246086121
intense O O 0.9778604507446289
phosphorylation O O 0.9802897572517395
of O O 0.9995483756065369
the O O 0.9997978806495667
constitutively O O 0.7127261161804199
expressed O O 0.8017051815986633
Sp1 B-protein B-protein 0.5408706068992615
protein E-protein E-protein 0.8597167730331421

. O O 0.9944022297859192
Enhanced O O 0.9889410138130188
responsiveness O O 0.996182382106781
to O O 0.9999666213989258
nuclear B-protein B-protein 0.6973434090614319
factor I-protein I-protein 0.5245457291603088
kappa I-protein I-protein 0.8953391313552856
B E-protein E-protein 0.9925963878631592
contributes O O 0.9998255372047424
to O O 0.9999924898147583
the O O 0.9999879598617554
unique O O 0.9711397290229797
phenotype O O 0.9111481308937073
of O O 0.9995154142379761
simian O O 0.7631799578666687
immunodeficiency O O 0.7427855730056763
virus O O 0.7207614183425903
variant O O 0.7051516175270081
SIVsmmPBj14 O O 0.26630881428718567
. O O 0.9981454610824585
Infection O O 0.9950554370880127
with O O 0.9999682903289795
a O O 0.999789297580719
variant O O 0.974702775478363
of O O 0.9990373849868774

A O O 0.9980289340019226
conjunction O O 0.9907167553901672
analysis O O 0.9990556836128235
of O O 0.9999760389328003
the O O 0.9999632835388184
encode O O 0.8668226003646851
and O O 0.9977582097053528
recall O O 0.9887354969978333
phases O O 0.9997449517250061
of O O 0.9999874830245972
the O O 0.9999852180480957
task O O 0.9944010376930237
revealed O O 0.9999654293060303
ecstasy B-Chemical B-Chemical 0.9146527647972107
- O O 0.9569952487945557
specific O O 0.9957886338233948
hyperactivity B-Disease O 0.9345682263374329
in O O 0.9840441346168518
bilateral O O 0.8883420825004578
frontal O O 0.742586612701416
regions O O 0.84747314453125
, O O 0.9998958110809326
left O O 0.9880610704421997
temporal O O 0.7638912200927734
, O O 0.9928299784660339
right O O 0.9844345450401306
parietal O O 0.7968702912330627
, O O 0.9897202849388123
bilateral O O 0.8601431250572205
temporal O O 0.6618839502334595
, O O 0.9887591600418091
and O O 0.9993031024932861
bilateral O O 0.9061036705970764
occipital O O 0.806281328201294
brain O O 0.7176711559295654
regions O O 0.9163609147071838
. O O 0.9999979734420776

in O O 0.9985387325286865
myeloproliferative O O 0.8707144260406494
disorders O O 0.7991266846656799
, O O 0.9999417066574097
particularly O O 0.9997621178627014
polycythemia O O 0.8677275776863098
vera O O 0.9166868925094604
and O O 0.9987083673477173
myelodysplastic O O 0.9389461874961853
syndromes O O 0.9337030053138733
. O O 0.9999967813491821
The O O 0.9999964237213135
association O O 0.9994434714317322
of O O 0.9999604225158691
20q B-DNA O 0.3069022595882416
deletions E-DNA O 0.6763315200805664
with O O 0.9997754693031311
myeloid O O 0.5700018405914307
`` O O 0.69870924949646
stem O O 0.41281330585479736
cell O O 0.39762285351753235
'' O O 0.37930360436439514
disorders O O 0.6161720156669617
suggests O O 0.9998761415481567
that O O 0.9999959468841553
the O O 0.9999268054962158
deletions O O 0.9629226922988892
mark O O 0.9997128844261169
the O O 0.9999768733978271

( O O 0.935271680355072
EMSA O O 0.5892189145088196
) O O 0.9533711671829224
and O O 0.998553454875946
supershift O O 0.874129593372345
analyses O O 0.9619618058204651
of O O 0.9998701810836792
this O O 0.9999760389328003
region O O 0.976496160030365
documented O O 0.998489260673523
constitutive O O 0.9842830300331116
binding O O 0.9732459187507629
of O O 0.998170018196106
Sp1 S-protein S-protein 0.93840491771698
in O O 0.9996312856674194
unactivated O O 0.8304740190505981
nuclear O O 0.876301646232605
extracts O O 0.9582093358039856
and O O 0.9993646740913391
inducible O O 0.9522333145141602
binding O O 0.9484924077987671
of O O 0.9973742961883545
p50-p65 B-protein B-protein 0.6269681453704834
NF-kappaB I-protein I-protein 0.44227707386016846
heterodimers E-protein E-protein 0.9845261573791504
after O O 0.9998970031738281
P/I O O 0.6421560645103455

, O O 0.979070782661438
here O O 0.9998421669006348
used O O 0.999990701675415
as O O 0.9999889135360718
positive O O 0.9424187541007996
control O O 0.9846068620681763
. O O 0.9999592304229736
In O O 0.999984622001648
order O O 0.9998915195465088
to O O 0.9999959468841553
elucidate O O 0.9982821941375732
possible O O 0.9918386340141296
mechanisms O O 0.9955142140388489
underlying O O 0.9990774393081665
endothelial B-cell_type O 0.8634640574455261
cell E-cell_type O 0.5824323296546936
activation O O 0.9962491393089294
by O O 0.9999915361404419
xenogeneic O O 0.6869338750839233
serum O O 0.7686835527420044
, O O 0.9993796348571777
we O O 0.9999724626541138
focussed O O 0.9999771118164062
on O O 0.9999783039093018
transcription B-protein B-protein 0.577241063117981
factor I-protein E-protein 0.7812146544456482
NF-kappa I-protein B-protein 0.5617658495903015
B E-protein E-protein 0.9924860000610352
, O O 0.9985178112983704
a O O 0.999968409538269
central O O 0.7856373190879822
regulator O O 0.5289661884307861
for O O 0.9949812293052673
the O O 0.999887228012085
induction O O 0.9961649179458618
of O O 0.9997864365577698
different O O 0.9905402660369873

The O O 0.9993215799331665
involvement O O 0.9998939037322998
of O O 0.9999849796295166
multiple O O 0.8473759293556213
tumor B-protein B-protein 0.3915818929672241
necrosis I-protein I-protein 0.6628269553184509
factor I-protein I-protein 0.5229766964912415
receptor I-protein E-protein 0.9552314877510071
( I-protein O 0.9176343679428101
TNFR I-protein S-protein 0.9508638978004456
) I-protein O 0.8617571592330933
-associated I-protein O 0.931020975112915

BACKGROUND O O 0.9860489368438721
: O O 0.9998186230659485
Cyproterone B-Chemical B-Chemical 0.9120031595230103
acetate E-Chemical I-Chemical 0.9480488300323486
combined O O 0.9680037498474121
with O O 0.9999010562896729
ethinyl B-Chemical B-Chemical 0.9254244565963745
estradiol E-Chemical I-Chemical 0.9494841694831848
( O O 0.9294127225875854
CPA S-Chemical B-Chemical 0.949909508228302
/ O O 0.7497264742851257
EE S-Chemical B-Chemical 0.9175978302955627
) O O 0.8713794350624084
is O O 0.9998134970664978
licensed O O 0.9998722076416016
in O O 0.9999953508377075
the O O 0.9999306201934814
UK O O 0.995461642742157
for O O 0.999993085861206
the O O 0.9999376535415649
treatment O O 0.999919056892395
of O O 0.9999707937240601
women O O 0.995686411857605
with O O 0.9998725652694702
acne O B-Disease 0.9606776237487793
and O O 0.794263482093811
hirsutism O B-Disease 0.9138014912605286
and O O 0.9697130918502808
is O O 0.9997962117195129
also O O 0.9999866485595703
a O O 0.9999860525131226
treatment O O 0.9986612796783447
option O O 0.9998151659965515
for O O 0.9999861717224121
polycystic O B-Disease 0.5580936670303345
ovary O I-Disease 0.8278281688690186
syndrome O I-Disease 0.990110456943512
( O O 0.9645698070526123
PCOS O O 0.9335561394691467
) O O 0.9036768674850464
. O O 0.9999827146530151

In O O 0.9998534917831421
the O O 0.9999818801879883
absence O O 0.9964229464530945
of O O 0.9997357726097107
caffeine S-Chemical B-Chemical 0.9264290928840637
, O O 0.9788926839828491
acetaminophen S-Chemical B-Chemical 0.9368021488189697
( O O 0.9942130446434021
up O O 0.99928879737854
to O O 0.9998451471328735
300 O O 0.9997987151145935
mg O O 0.9996768236160278
/ O O 0.9999754428863525
kg O O 0.9993647933006287
) O O 0.9998527765274048
did O O 0.9999939203262329
not O O 0.9999791383743286
modify O O 0.9994679093360901
the O O 0.999248206615448
seizures O B-Disease 0.9710797071456909
induced O O 0.9552667140960693
by O O 0.9997887015342712
maximal O O 0.959657609462738
electroshock O O 0.39737576246261597
and O O 0.9965986609458923
did O O 0.9999417066574097
not O O 0.999945878982544
alter O O 0.999937891960144
the O O 0.9998825788497925
convulsant O O 0.5971992015838623
dose O O 0.9855490326881409
of O O 0.9995487332344055
pentylenetetrezol S-Chemical B-Chemical 0.9315038919448853
in O O 0.9952681660652161
mice O O 0.9952552318572998
( O O 0.9999806880950928
tests O O 0.9998303651809692
performed O O 0.9999939203262329
by O O 0.9999986886978149
the O O 0.9999457597732544
Anticonvulsant O O 0.795687735080719
Screening O O 0.862053394317627
Project O O 0.9799859523773193
of O O 0.9999152421951294
NINCDS O O 0.7281174063682556
) O O 0.9855853915214539
. O O 0.9999970197677612

Audiograms O O 0.8463360667228699
from O O 0.9996132254600525
15 O O 0.9990880489349365
patients O O 0.9997730851173401
remained O O 0.9999536275863647
abnormal O O 0.5216644406318665
and O O 0.9796740412712097
four O O 0.9984356760978699
patients O O 0.9993083477020264
required O O 0.9999539852142334
hearing O O 0.7674017548561096
aids O O 0.5111550688743591
because O O 0.9997689127922058
of O O 0.9999418258666992
permanent O O 0.8359235525131226
disability O O 0.5904144644737244
. O O 0.9995816349983215

( O O 0.9124572277069092
HIV O O 0.7956573963165283
) O O 0.8899454474449158
replication O O 0.9902288913726807
under O O 0.9999954700469971
the O O 0.999977707862854
biological O O 0.9017492532730103
stimuli O O 0.7841703295707703
of O O 0.9986065030097961
the O O 0.999923586845398
thymic O O 0.6158636808395386
microenvironment O O 0.6428196430206299
. O O 0.9998730421066284
In O O 0.9999943971633911
this O O 0.9999972581863403
report O O 0.999930739402771
we O O 0.999993085861206
demonstrate O O 0.9999946355819702
that O O 0.9999881982803345
interaction O O 0.9930201172828674

Clonality O O 0.8249228000640869
of O O 0.999045193195343
isolated B-cell_type B-cell_type 0.6675887107849121
eosinophils E-cell_type E-cell_type 0.7585901021957397
in O O 0.9997923970222473
the O O 0.9998701810836792
hypereosinophilic O O 0.8678361773490906
syndrome O O 0.872797966003418
. O O 0.9999922513961792
The O O 0.9999938011169434
idiopathic O O 0.895666778087616
hypereosinophilic O O 0.8667812943458557
syndrome O O 0.9471995830535889
( O O 0.9998350143432617
IHES O O 0.8883033990859985
) O O 0.9989356398582458
is O O 0.9999958276748657
a O O 0.9999891519546509
rare O O 0.9855223894119263
disorder O O 0.9600009322166443
characterized O O 0.9999822378158569
by O O 0.9999819993972778
unexplained O O 0.9066907167434692
, O O 0.9885247349739075
persistent O O 0.9482114911079407
eosinophilia O O 0.5967117547988892
associated O O 0.9741740822792053

are O O 0.9984425902366638
necessary O O 0.9999631643295288
for O O 0.9999885559082031
maximal O O 0.9695396423339844
gene O O 0.8029722571372986
activation O O 0.9971864819526672
. O O 0.9999967813491821
Here O O 0.9998960494995117
we O O 0.9999887943267822
demonstrate O O 0.9999732971191406
, O O 0.9999575614929199
with O O 0.9999903440475464
a O O 0.9998767375946045
site-specific O B-protein 0.8482133746147156
antibody O E-protein 0.900007963180542
, O O 0.9958145022392273
that O O 0.999981164932251
STAT3 S-protein S-protein 0.9940005540847778
is O O 0.9995191097259521
phosphorylated O O 0.9445818066596985
on O O 0.9988647699356079
Ser-727 O S-protein 0.37504029273986816
in O O 0.9973291158676147
human B-cell_type B-cell_type 0.7724179029464722
neutrophils E-cell_type E-cell_type 0.9710142016410828
stimulated O O 0.9901794195175171

Whether O O 0.9986522793769836
pentoxifylline S-Chemical B-Chemical 0.9287792444229126
inhibits O O 0.9838528633117676
dipyridamole S-Chemical B-Chemical 0.9305686354637146
- O O 0.9767205119132996
induced O O 0.9996050000190735
coronary O O 0.611773669719696
hyperemia O O 0.6451160311698914
like O O 0.9529338479042053
other O O 0.9974225759506226
methylxanthines S-Chemical O 0.421375036239624
such O O 0.9942527413368225
as O O 0.999774158000946
theophylline S-Chemical B-Chemical 0.9311873912811279
and O O 0.9942466616630554
should O O 0.9998350143432617
be O O 0.9999151229858398
stopped O O 0.9984806180000305
prior O O 0.9999736547470093
to O O 0.999953031539917
dipyridamole S-Chemical B-Chemical 0.9334695339202881
- O O 0.5431305170059204
thallium S-Chemical B-Chemical 0.8352558612823486
- O O 0.5212476849555969
201 O O 0.7193562388420105
imaging O O 0.947525143623352
is O O 0.9999754428863525
unknown O O 0.9986914992332458
. O O 0.9999990463256836

Renal O O 0.6998142004013062
plasma O O 0.5269259810447693
flow O O 0.6762803196907043
increased O O 0.9894070029258728
, O O 0.9998389482498169
but O O 0.9998663663864136
albumin O O 0.43668627738952637
excretion O O 0.6293535232543945
and O O 0.9967340230941772
glomerulosclerosis B-Disease B-Disease 0.9424729943275452
did O O 0.9914352297782898
not O O 0.9997027516365051
change O O 0.9990723133087158
after O O 0.9999837875366211
enalapril B-Chemical B-Chemical 0.9324356317520142
treatment O O 0.9964187145233154
. O O 0.9999992847442627

the O O 0.9989712238311768
suppressive O O 0.981590211391449
effect O O 0.9997798800468445
of O O 0.9999833106994629
V3-BH10 S-protein O 0.5192051529884338
. O O 0.9997395873069763
In O O 0.9999908208847046
addition O O 0.9998408555984497
, O O 0.9999866485595703
V3-BH10 S-protein O 0.4433944523334503
generated O O 0.9983392953872681
the O O 0.9999696016311646
arrest O O 0.9970209002494812
of O O 0.9999585151672363

and O O 0.9675809144973755
blood O O 0.8369067907333374
leukocyte O O 0.6645159125328064
content O O 0.9917436242103577
of O O 0.9998956918716431
glucocorticoid B-protein B-protein 0.5017002820968628
receptors E-protein E-protein 0.9955151677131653
( O O 0.997214138507843
GCR S-protein S-protein 0.9767208695411682
) O O 0.9956121444702148
were O O 0.9999812841415405
assayed O O 0.9999561309814453
in O O 0.9999831914901733
20 O O 0.9982353448867798
patients O O 0.9998923540115356
with O O 0.9999854564666748
deficiency O O 0.9406193494796753
syndromes O O 0.8876351118087769
, O O 0.9999704360961914
10 O O 0.9943249821662903
cold O O 0.9396278858184814

steroid O O 0.7578099966049194
hormones O O 0.9553973078727722
affect O O 0.9999876022338867
the O O 0.9998540878295898
immune O O 0.9813955426216125
system O O 0.9928372502326965
, O O 0.999962568283081
and O O 0.9998873472213745
inflammatory O O 0.9423907995223999
diseases O O 0.8179924488067627
are O O 0.999923586845398
associated O O 0.9999592304229736
with O O 0.9999951124191284
activation O O 0.998610258102417
of O O 0.9999657869338989
the O O 0.9998410940170288
hypothalamic-pituitary-adrenal O O 0.7351656556129456
axis O O 0.44727104902267456
, O O 0.9986734390258789
providing O O 0.9999833106994629
evidence O O 0.9999746084213257
of O O 0.9999927282333374
an O O 0.9999439716339111
immune-endocrine O O 0.8087944984436035
interplay O O 0.7936312556266785
. O O 0.9995275735855103
Function O O 0.9676952958106995

mAb E-protein E-protein 0.9717009663581848
activated O O 0.9980725049972534
both O O 0.9998607635498047
PLD S-protein S-protein 0.7926071882247925
and O O 0.9622235298156738
transcription B-protein B-protein 0.49489104747772217
factor I-protein I-protein 0.8339883089065552
AP-1 E-protein E-protein 0.890129029750824
. O O 0.9993454813957214
Wortmannin O O 0.5804111361503601
, O O 0.9987038373947144
an O O 0.9999561309814453
inhibitor O O 0.9819627404212952
of O O 0.9992673993110657
receptor-coupled O O 0.9092348217964172
PLD S-protein S-protein 0.6404277086257935
activation O O 0.9421858191490173
, O O 0.9993208646774292
blocked O O 0.9997958540916443
the O O 0.9999004602432251

the O O 0.996665894985199
T O O 0.6415041089057922
cell O O 0.4406522214412689
pathway O O 0.9054145812988281
. O O 0.9999922513961792
The O O 0.999995231628418
dominant O O 0.9456842541694641
interference O O 0.9414644241333008
activity O O 0.9945080876350403
of O O 0.9999278783798218
Ikaros B-protein B-protein 0.6173115968704224
isoforms E-protein E-protein 0.9332167506217957
unable O O 0.9989437460899353
to O O 0.9999641180038452
bind O O 0.9977468848228455
DNA O O 0.9350699782371521
and O O 0.9992170333862305
their O O 0.9998739957809448
effects O O 0.9996947050094604
in O O 0.9999405145645142
lymphocyte O O 0.5928832292556763
development O O 0.994022786617279
suggest O O 0.999995231628418
that O O 0.9999909400939941
Ikaros S-protein S-protein 0.9400718212127686
works O O 0.9998461008071899
in O O 0.9999880790710449
concert O O 0.9998279809951782
with O O 0.9999984502792358
other O O 0.9998766183853149
factors O O 0.9828051924705505
. O O 0.9999884366989136
The O O 0.9999974966049194
role O O 0.9996453523635864
of O O 0.9999417066574097

this O O 0.9971005320549011
model O O 0.9891140460968018
system O O 0.9960454106330872
of O O 0.9999567270278931
mechanical O O 0.9501779675483704
ventilation O O 0.9854641556739807
. O O 0.9999959468841553
These O O 0.9999871253967285
mediators O O 0.8550593852996826
were O O 0.9999172687530518
measured O O 0.9998480081558228
in O O 0.9997032284736633
supernatants O S-cell_type 0.6743484139442444
from O O 0.9988073110580444
ventilated B-cell_type B-cell_type 0.4797151982784271
alveolar I-cell_type I-cell_type 0.3233027756214142
macrophages E-cell_type E-cell_type 0.7815558910369873
, O O 0.9948562383651733
monocyte-derived B-cell_type B-cell_type 0.5165870189666748
macrophages E-cell_type E-cell_type 0.9249325394630432
, O O 0.9974154233932495

examined O O 0.9951369166374207
in O O 0.9999855756759644
the O O 0.9999706745147705
leukemic B-cell_line B-cell_line 0.5273181796073914
U937 I-cell_line I-cell_line 0.7835956811904907
cell E-cell_line E-cell_line 0.9451011419296265
. O O 0.9986681938171387
Transfected O O 0.6859801411628723
U937 B-cell_line B-cell_line 0.7587850689888
cells E-cell_line E-cell_line 0.9979616403579712
stably O O 0.9798653721809387
overexpressing O O 0.8719016909599304
PKC-zeta S-protein S-protein 0.764602541923523
displayed O O 0.9992192983627319
a O O 0.9999743700027466
longer O O 0.9928815364837646
doubling O O 0.9487677812576294
time O O 0.9917421340942383
, O O 0.9999730587005615
lower O O 0.9975031018257141
saturation O O 0.952103316783905
density O O 0.9844090342521667
at O O 0.9999957084655762

the O O 0.996955394744873
transcription O O 0.9554744362831116
of O O 0.9988086223602295
TcR B-DNA B-DNA 0.25444602966308594
delta I-DNA I-DNA 0.3719058930873871
locus E-DNA E-DNA 0.8770558834075928
, O O 0.9885140061378479
was O O 0.9999403953552246
analyzed O O 0.9999632835388184
by O O 0.9999963045120239
Northern O O 0.9695578813552856
blot O O 0.8376330137252808
, O O 0.9982402324676514
in O O 0.9999462366104126
cultured O B-cell_line 0.6548931002616882
NK B-cell_line I-cell_line 0.6904784440994263
cell I-cell_line I-cell_line 0.7519447803497314
population E-cell_line E-cell_line 0.7840205430984497
and O O 0.9322890043258667
clones O O 0.7204757332801819
( O O 0.9685995578765869
but O O 0.993829071521759
not O O 0.9947165846824646
in O O 0.9891213774681091

Repeated O O 0.958704948425293
trimipramine B-Chemical B-Chemical 0.9199907183647156
induces O O 0.9948859810829163
dopamine B-Chemical B-Chemical 0.927497386932373
D2 O O 0.6942064762115479
/ O O 0.9894439578056335
D3 O O 0.8393317461013794
and O O 0.9998419284820557
alpha1 O O 0.6362613439559937
- O O 0.922529935836792
adrenergic O O 0.7058147192001343
up O O 0.996711254119873
- O O 0.9992173910140991
regulation O O 0.9988287091255188
. O O 0.9999990463256836

NF-kappa B-protein B-protein 0.6164253354072571

this O O 0.9982742071151733
base O O 0.9686967730522156
exchange O O 0.9322144389152527
( O O 0.9998867511749268
p O O 0.9943693280220032
< O O 0.9994630217552185
0.009 O O 0.9976801872253418
) O O 0.9993539452552795
. O O 0.9999966621398926
The O O 0.9999902248382568
base O O 0.7796423435211182
exchange O O 0.6778385639190674
at O O 0.9986677169799805
-509 O O 0.6520404815673828
( O O 0.986454427242279
from O O 0.9994500279426575
the O O 0.999744713306427
transcription O B-DNA 0.5613085627555847
initiation O I-DNA 0.35348209738731384
site O E-DNA 0.8227978348731995
) O O 0.9800666570663452
in O O 0.9999690055847168
the O O 0.9999446868896484
TGF-beta B-DNA B-DNA 0.5468732714653015
promoter E-DNA E-DNA 0.9880934357643127
also O O 0.9984713196754456
linked O O 0.9999865293502808
to O O 0.9999185800552368
elevated O O 0.9063418507575989
total O O 0.9338114857673645
IgE S-protein S-protein 0.7593964338302612
( O O 0.9884381890296936
p O O 0.9621006846427917
< O O 0.994975209236145
0.01 O O 0.9961052536964417
) O O 0.9988502264022827
. O O 0.9999953508377075
This O O 0.9999313354492188
polymorphism O O 0.9575696587562561
represented O O 0.9999690055847168
a O O 0.9999823570251465
C-to-T O O 0.5713424682617188
base O O 0.5591358542442322
exchange O O 0.6958592534065247
which O O 0.9994268417358398
induced O O 0.9993599057197571

the O O 0.9977184534072876
TATA B-protein B-protein 0.5244179964065552
box I-protein I-protein 0.6291764378547668
binding I-protein I-protein 0.9490817189216614
protein E-protein E-protein 0.9819444417953491
. O O 0.9951842427253723
CIITA S-protein S-protein 0.7510226368904114
is O O 0.9999231100082397
a O O 0.9999852180480957
positive O O 0.8088516592979431
regulator O O 0.5769177675247192
of O O 0.9893375635147095
class B-DNA B-DNA 0.5601595640182495
II I-DNA I-DNA 0.29448992013931274
major I-DNA I-DNA 0.48733463883399963

T-cell O O 0.4382439851760864
stimulation O O 0.9108198285102844
defects O O 0.9773717522621155
associated O O 0.9999628067016602
with O O 0.9999982118606567
the O O 0.9999358654022217
loss O O 0.9944169521331787
of O O 0.9998928308486938
Rel S-protein S-protein 0.9084594249725342
, O O 0.9908145070075989
we O O 0.9998574256896973
have O O 0.9999926090240479
examined O O 0.9999736547470093
the O O 0.9999740123748779
expression O O 0.9988297820091248
of O O 0.9999347925186157
cell B-protein B-protein 0.6263551115989685
surface I-protein I-protein 0.6441474556922913
activation I-protein I-protein 0.759017288684845
markers E-protein E-protein 0.9517460465431213

In O O 0.9998095631599426
this O O 0.9999910593032837
study O O 0.9996793270111084
, O O 0.9999748468399048
long O O 0.9828383922576904
- O O 0.9993637204170227
term O O 0.9994402527809143
cardiac O O 0.6506199240684509
transplant O O 0.501788854598999
patients O O 0.9830290675163269
were O O 0.9999973773956299
switched O O 0.9999604225158691
from O O 0.9999891519546509
cyclosporine B-Chemical B-Chemical 0.9164774417877197
to O O 0.9841751456260681
Srl B-Chemical B-Chemical 0.9094251990318298
- O O 0.7359657883644104
based O O 0.9988723397254944
IS O O 0.9920634627342224
. O O 0.9999945163726807

through O O 0.9990575909614563
a O O 0.9999638795852661
combination O O 0.998602569103241
of O O 0.9999741315841675
impaired O O 0.9384543895721436
recycling O O 0.9656035304069519
, O O 0.9995960593223572
abrogated O O 0.9284029603004456
signalling O O 0.9693046808242798
and O O 0.9991484880447388
normal O O 0.92631995677948
binding O O 0.9525721073150635
to O O 0.9976443648338318
IFNgamma S-protein S-protein 0.9497115015983582
exert O O 0.9991883635520935
a O O 0.9999192953109741
dominant-negative O O 0.9278028607368469
effect O O 0.9984594583511353
. O O 0.9999971389770508
We O O 0.9999855756759644
thus O O 0.9999936819076538
report O O 0.9999934434890747
a O O 0.9999698400497437
hotspot O O 0.9340607523918152
for O O 0.9990909099578857
human B-DNA O 0.6793943047523499
IFNGR1 I-DNA O 0.3427516222000122
small I-DNA O 0.43356120586395264
deletions E-DNA O 0.5997143983840942

used O O 0.9899840354919434
cytokine O S-protein 0.9646374583244324
production O O 0.999009370803833
as O O 0.9999980926513672
a O O 0.9999905824661255
readout O O 0.9849318861961365
for O O 0.9996706247329712
monocyte O O 0.6361120343208313
activation O O 0.9680307507514954
and O O 0.9994428753852844
found O O 0.9999473094940186
that O O 0.9999206066131592
CD15 O S-protein 0.9293427467346191
cross-linking O O 0.9020792245864868
induced O O 0.9932457804679871

Infarcts B-Disease O 0.6305810809135437
in I-Disease O 0.9864364266395569
substantia I-Disease O 0.7943652272224426
nigra I-Disease O 0.45997679233551025
pars I-Disease O 0.8691113591194153
reticulata I-Disease O 0.573206901550293
were O O 0.999007523059845
evoked O O 0.9998610019683838
by O O 0.9999959468841553
prolonged O O 0.9522767663002014
pilocarpine B-Chemical B-Chemical 0.92216557264328
- O O 0.9699035882949829
induced O O 0.9953782558441162
status B-Disease B-Disease 0.787906289100647
epilepticus I-Disease I-Disease 0.9116355776786804
. O O 0.9985246062278748

that O O 0.9993752837181091
the O O 0.9999637603759766
interaction O O 0.997833788394928
between O O 0.9998844861984253
Cbl S-protein S-protein 0.9301575422286987
and O O 0.9929252862930298
PI3-K S-protein S-protein 0.8986419439315796
is O O 0.9994671940803528
not O O 0.9999643564224243
required O O 0.9999669790267944
in O O 0.9999982118606567
the O O 0.9999823570251465
70Z/3 S-protein S-protein 0.5573422908782959
-mediated O O 0.9924886226654053
induction O O 0.998689591884613
of O O 0.9999607801437378
NFAT S-protein S-protein 0.9785683751106262
. O O 0.9999475479125977
Additional O O 0.9993351101875305
mapping O O 0.9884327054023743
studies O O 0.9995940327644348
indicated O O 0.999994158744812
that O O 0.9999880790710449

Blood O O 0.9435942769050598
pressure O O 0.7806772589683533
( O O 0.9997655749320984
BP O O 0.5456074476242065
) O O 0.977790355682373
is O O 0.9999552965164185
more O O 0.9998847246170044
salt S-Chemical B-Chemical 0.8744286298751831
sensitive O O 0.6128592491149902
in O O 0.9989746809005737
men O O 0.9959872364997864
than O O 0.9999825954437256
in O O 0.9998704195022583
premenopausal O O 0.4658612906932831
women O O 0.9146177768707275
. O O 0.9999834299087524

DNA O O 0.8609771728515625
binding O O 0.9238721132278442
and O O 0.9929209351539612
TNF-alpha S-protein S-protein 0.9852746725082397
release O O 0.9823055863380432
in O O 0.9998797178268433
human B-cell_type B-cell_type 0.7126700282096863
monocytes E-cell_type E-cell_type 0.9834960699081421
. O O 0.9997386336326599
Nonspecific O O 0.9244061708450317
protein B-protein B-protein 0.6380073428153992
kinase E-protein E-protein 0.8335278630256653
inhibition O O 0.9072193503379822
inhibited O O 0.9967181086540222
NF-kappaB S-protein S-protein 0.985621988773346
activation O O 0.9960036873817444
and O O 0.9997832179069519
TNF-alpha S-protein S-protein 0.9763728380203247
release O O 0.981023907661438
, O O 0.9999406337738037
while O O 0.9999969005584717
specific O O 0.9880225658416748
PKC S-protein S-protein 0.8744027614593506
inhibition O O 0.9857962131500244
with O O 0.9997665286064148
Bis O S-protein 0.48457714915275574
had O O 0.9948413968086243
no O O 0.9999556541442871
effect O O 0.9999533891677856
on O O 0.9999871253967285
LPS-induced O O 0.9033445119857788
NF-kappaB S-protein S-protein 0.9484678506851196
DNA O O 0.9763936400413513
binding O O 0.9877294898033142
or O O 0.9996159076690674
TNF-alpha S-protein S-protein 0.9521108865737915
release O O 0.9844231009483337
. O O 0.9999881982803345
PTK S-protein S-protein 0.7467339634895325
inhibition O O 0.9889294505119324
with O O 0.9998970031738281
Gen O O 0.4177018105983734
attenuated O O 0.9775741696357727
both O O 0.9995699524879456
LPS-induced O O 0.6324092745780945
NF-kappaB S-protein S-protein 0.57942134141922
DNA O O 0.5441449880599976

cytokines S-protein S-protein 0.5569038987159729
or O O 0.9992369413375854
hematopoietic B-protein B-protein 0.7085249423980713
growth I-protein I-protein 0.525475800037384
factors E-protein E-protein 0.9733234643936157
by O O 0.9997569918632507
recruitment O O 0.9854979515075684
and O O 0.9984685778617859
tyrosine O O 0.903304934501648
phosphorylation O O 0.9411954879760742
of O O 0.9976885318756104
a O O 0.9963931441307068

This O O 0.9996780157089233
low O O 0.9908170700073242
percentage O O 0.9982333183288574
( O O 0.9999798536300659
5 O O 0.9999531507492065
% O O 0.9999068975448608
) O O 0.9998332262039185
of O O 0.9999620914459229
TDFS O B-Chemical 0.7862410545349121
must O O 0.9977812170982361
be O O 0.9999901056289673
evaluated O O 0.9999909400939941
with O O 0.9999969005584717
respect O O 0.9998086094856262
to O O 0.9999959468841553
the O O 0.9999402761459351
efficacy O O 0.9973861575126648
of O O 0.9997147917747498
ifosfamide S-Chemical B-Chemical 0.9289592504501343
in O O 0.997867226600647
the O O 0.9998034834861755
treatment O O 0.9994189739227295
of O O 0.9999845027923584
mesenchymal O B-Disease 0.687231719493866
tumors O I-Disease 0.9178094863891602
in O O 0.9829851984977722
children O O 0.9993089437484741
. O O 0.9999990463256836

, O O 0.981410026550293
CD16- O O 0.4750681519508362
myeloid/natural O O 0.397083580493927
killer O O 0.4094974994659424
cell O O 0.44709089398384094
acute O O 0.5649166107177734
leukemia O O 0.5754685401916504
: O O 0.9790839552879333
a O O 0.9997462630271912
previously O O 0.9926199316978455
unrecognized O O 0.988792359828949
form O O 0.9847109913825989
of O O 0.9999393224716187
acute O O 0.868765652179718
leukemia O O 0.696691632270813
potentially O O 0.9979422688484192
misdiagnosed O O 0.9996150732040405
as O O 0.999995231628418
French-American-British O O 0.7239720225334167
acute O O 0.8116521835327148
myeloid O O 0.712202250957489
leukemia-M3 O O 0.3322869539260864
[ O O 0.978890597820282
see O O 0.9990660548210144
comments O O 0.9980071187019348
] O O 0.9999270439147949
We O O 0.9997257590293884
have O O 0.9999853372573853
identified O O 0.9998786449432373
and O O 0.999902606010437
characterized O O 0.9999179840087891
a O O 0.9999237060546875
previously O O 0.9857078194618225
unrecognized O O 0.9797396063804626
form O O 0.9677726626396179

Interactive O O 0.9066430926322937
effects O O 0.9917469024658203
of O O 0.9997302889823914
variations O O 0.9464618563652039
in O O 0.9987325072288513
[ O O 0.756859540939331
Na B-Chemical B-Chemical 0.9156761169433594
] O O 0.515670895576477
o O O 0.6053259968757629
and O O 0.9657388925552368
[ O O 0.9805660247802734
Ca B-Chemical B-Chemical 0.9065946340560913
] O O 0.6904577612876892
o O O 0.9600166082382202
on O O 0.9996563196182251
rat O O 0.7023528218269348
atrial O O 0.7105147838592529
spontaneous O O 0.5322290658950806
frequency O O 0.687440812587738
. O O 0.9999223947525024

kinase O I-cell_line 0.5666317939758301
C-depleted O I-cell_line 0.2662453353404999
endothelial B-cell_type I-cell_line 0.5246176719665527
cells E-cell_type E-cell_line 0.6372305154800415
. O O 0.9997832179069519
A O O 0.99998939037323
number O O 0.9998428821563721
of O O 0.9999959468841553
our O O 0.9999783039093018
studies O O 0.99991774559021
indicate O O 0.999997615814209
that O O 0.9999959468841553
cAMP O O 0.8148347735404968
is O O 0.9999133348464966
the O O 0.9999946355819702
second O O 0.9973301887512207
messenger O O 0.952512800693512
for O O 0.9997026324272156
the O O 0.9999659061431885
effects O O 0.9999043941497803
of O O 0.9999804496765137
MM-LDL S-protein O 0.4845565855503082
cited O O 0.9953820109367371
above O O 0.9994956254959106
. O O 0.9999814033508301
Incubation O O 0.9808176755905151
of O O 0.9994857311248779
endothelial B-cell_type B-cell_type 0.8021463751792908
cells E-cell_type E-cell_type 0.9873959422111511
with O O 0.999293327331543

Choreatiform O O 0.7820248603820801
hyperkinesias O O 0.43443045020103455
are O O 0.9843735694885254
known O O 0.9997996687889099
to O O 0.9999573230743408
be O O 0.9999675750732422
occasional O O 0.9822202920913696
movement O O 0.6381287574768066
abnormalities O O 0.6840612888336182
during O O 0.9975960850715637
intoxications O O 0.8078193664550781
with O O 0.9989575147628784
cocaine S-Chemical B-Chemical 0.9163243174552917
but O O 0.993791401386261
not O O 0.9997327923774719
opiates O O 0.8669272065162659
. O O 0.999991774559021

Ultimately O O 0.9965530633926392
, O O 0.9999867677688599
an O O 0.9999232292175293
arteriography O O 0.5747567415237427
showed O O 0.9996448755264282
a O O 0.9999772310256958
70 O O 0.9638393521308899
- O O 0.9985538125038147
80 O O 0.9967796206474304
% O O 0.9997023940086365
renal B-Disease B-Disease 0.7651374340057373
artery I-Disease I-Disease 0.7166553139686584
stenosis I-Disease I-Disease 0.8855701088905334
. O O 0.9989089965820312

monocytes E-cell_type E-cell_type 0.7508644461631775
to O O 0.998854398727417
alveolar O B-protein 0.6276785731315613
macrophage O I-protein 0.3338782489299774
nuclear O I-protein 0.5247110724449158
proteins O E-protein 0.9875340461730957
resulted O O 0.9999077320098877
in O O 0.9999932050704956
a O O 0.9999561309814453
marked O O 0.9958131909370422
increase O O 0.9957857728004456
in O O 0.9996169805526733
AP-1 S-protein S-protein 0.8927074074745178
DNA O O 0.8443620800971985
binding O O 0.9948458671569824
. O O 0.9999943971633911
These O O 0.9999891519546509
studies O O 0.9999336004257202
strongly O O 0.9999643564224243
suggest O O 0.9999934434890747

a O O 0.9978240728378296
cytoplasmic B-protein O 0.6912368535995483
proteic I-protein O 0.35974299907684326
inhibitor E-protein O 0.8091950416564941
, O O 0.9973447918891907
the O O 0.9998670816421509
IkB S-protein S-protein 0.885012686252594
. O O 0.9983934760093689
Treatment O O 0.9989016056060791
of O O 0.999893307685852
T B-cell_type B-cell_type 0.838966429233551
cells E-cell_type E-cell_type 0.988089382648468
with O O 0.9985961318016052
mitogens O S-protein 0.8858140110969543
( O O 0.9949485063552856
phorbol O O 0.8488094210624695
esters O O 0.6368059515953064
) O O 0.9679621458053589
or O O 0.9993948936462402
cytokines S-protein S-protein 0.9660013318061829
( O O 0.998626708984375
TNF B-protein B-protein 0.5839425325393677
alpha E-protein E-protein 0.8520809412002563

The O O 0.999733030796051
possible O O 0.9990808963775635
additive O O 0.9814671874046326
role O O 0.9975156784057617
of O O 0.9999597072601318
pharmacologic O O 0.8642522692680359
agents O O 0.967114269733429
in O O 0.9999334812164307
precipitating O O 0.993753969669342
cardiac B-Disease O 0.542301595211029
disturbances I-Disease O 0.9649749994277954
in O O 0.9642465114593506
patients O O 0.9993194341659546
with O O 0.9999227523803711
respiratory B-Disease O 0.7263309359550476
failure I-Disease O 0.9484440088272095
has O O 0.9887623190879822
only O O 0.9996034502983093
recently O O 0.9998683929443359
been O O 0.9999110698699951
emphasized O O 0.9999436140060425
. O O 0.9999991655349731

. O O 0.9974802136421204
Inhibition O O 0.9978360533714294
of O O 0.9999233484268188
rat B-cell_type O 0.3637714982032776
splenocyte E-cell_type O 0.5152809619903564
proliferation O O 0.9381245970726013
with O O 0.9998563528060913
methylprednisolone O O 0.7128991484642029
: O O 0.9937472343444824
in O O 0.9998530149459839
vivo O O 0.9811136722564697
effect O O 0.9990267753601074

inactive O O 0.7395098209381104
and O O 0.9752218723297119
may O O 0.9995959401130676
compete O O 0.9999856948852539
with O O 0.9999868869781494
Stat3alpha S-protein S-protein 0.9392374753952026
for O O 0.9953332543373108
Stat3 B-DNA B-DNA 0.8552148938179016
binding I-DNA I-DNA 0.43003690242767334
sites E-DNA E-DNA 0.7325457334518433
in O O 0.9996224641799927
these O O 0.9999631643295288
terminally B-cell_type B-cell_type 0.5841321349143982
differentiated I-cell_type I-cell_type 0.5988457798957825
myeloid I-cell_type I-cell_type 0.4778873026371002
cells E-cell_type E-cell_type 0.755217432975769
Association O O 0.9773344397544861
between O O 0.9994805455207825
expression O O 0.9951131939888
of O O 0.9997517466545105
intercellular B-protein B-protein 0.3738994598388672
adhesion I-protein I-protein 0.7024440765380859
molecule-1 E-protein E-protein 0.9787105917930603
and O O 0.9832183122634888

During O O 0.9994019269943237
treatment O O 0.9994039535522461
, O O 0.9999942779541016
adverse O O 0.9466661214828491
cardiac O O 0.6372033953666687
effects O O 0.7632567286491394
were O O 0.9994526505470276
observed O O 0.9998219609260559
in O O 0.999985933303833
14 O O 0.9982923865318298
patients O O 0.9998332262039185
( O O 0.9999896287918091
18 O O 0.999944806098938
% O O 0.999933123588562
) O O 0.9998101592063904
. O O 0.9999972581863403

Behavioral O O 0.7411223649978638
effects O O 0.9141271710395813
of O O 0.9978038668632507
diazepam S-Chemical B-Chemical 0.9185032844543457
and O O 0.9667870402336121
propranolol S-Chemical B-Chemical 0.9298998713493347
in O O 0.9986878037452698
patients O O 0.9997226595878601
with O O 0.9999722242355347
panic O B-Disease 0.5070785284042358
disorder O I-Disease 0.9874082803726196
and O O 0.9363438487052917
agoraphobia O B-Disease 0.9697328209877014
. O O 0.998941957950592

to O O 0.9943141341209412
surrounding O O 0.9906700849533081
interfollicular O O 0.753618061542511
zones O O 0.7114424705505371
. O O 0.9999462366104126
This O O 0.9999785423278809
prompted O O 0.999957799911499
a O O 0.9999939203262329
study O O 0.9998291730880737
of O O 0.9999619722366333
follicular O O 0.7783212661743164
borders O O 0.7925442457199097
with O O 0.999778687953949
Bcl-6 S-protein S-protein 0.8938491344451904
staining O O 0.9723418354988098
in O O 0.9998078942298889
reactive O O 0.7833467125892639
follicular O O 0.5906425714492798
hyperplasias O O 0.5739957094192505
and O O 0.9921861886978149
follicular O O 0.8245848417282104
lymphomas O O 0.6382460594177246
to O O 0.9995208978652954
compare O O 0.9999747276306152
with O O 0.9999620914459229
AITL/GC O O 0.5914081335067749

The O O 0.9996129870414734
possibility O O 0.9998296499252319
of O O 0.9999929666519165
a O O 0.9999834299087524
clinically O O 0.9810312390327454
relevant O O 0.9984114170074463
dopamine B-Chemical B-Chemical 0.9219106435775757
- O O 0.9908376336097717
antagonistic O O 0.766200065612793
capacity O O 0.9660645723342896
of O O 0.9996775388717651
fluoxetine B-Chemical B-Chemical 0.9253988265991211
in O O 0.9995848536491394
Parkinson B-Disease O 0.8801077604293823
' I-Disease O 0.802947461605072
s I-Disease O 0.5326963663101196
disease I-Disease O 0.966910183429718
patients O O 0.7660678625106812
must O O 0.9999319314956665
be O O 0.9999879598617554
considered O O 0.9999890327453613
. O O 0.9999988079071045

adhesion I-protein I-protein 0.5922567844390869
molecule I-protein I-protein 0.7499344944953918
1 E-protein E-protein 0.9912428855895996
( O O 0.9900239109992981
ICAM-1 S-protein S-protein 0.990832507610321
) O O 0.9830008745193481
] O O 0.9994000196456909
. O O 0.99998939037323
We O O 0.9999852180480957
therefore O O 0.9999946355819702
determined O O 0.9999970197677612
whether O O 0.9999951124191284
corticosteroids O O 0.8078736066818237
suppress O O 0.9995735287666321
inflammation O O 0.9240007400512695

The O O 0.9994736313819885
normalized O O 0.8898330926895142
reflex O O 0.6141926646232605
amplitude O O 0.5855288505554199
was O O 0.9993125200271606
significantly O O 0.9998490810394287
higher O O 0.9990112781524658
during O O 0.9999583959579468
pain B-Disease O 0.938215970993042
, O O 0.9905164837837219
but O O 0.9997590184211731
only O O 0.9998249411582947
at O O 0.9999772310256958
faster O O 0.9829127788543701
stretches O O 0.9881921410560608
in O O 0.9999494552612305
the O O 0.9997367262840271
painful B-Disease O 0.6795575022697449
muscle I-Disease O 0.5057995915412903
. O O 0.9999480247497559

, I-RNA I-RNA 0.49352261424064636
c-myc I-RNA I-RNA 0.45048218965530396
, I-RNA I-RNA 0.6972109079360962
junB I-RNA I-RNA 0.6535401344299316
, I-RNA I-RNA 0.5410836935043335
and I-RNA I-RNA 0.5008119940757751
fra-1 I-RNA I-RNA 0.7400676608085632
mRNAs E-RNA E-RNA 0.9852628707885742
was O O 0.9986571073532104
increased O O 0.9997714161872864
in O O 0.9995105266571045
activated O B-cell_type 0.5487877130508423
peripheral B-cell_type I-cell_type 0.4882422983646393
blood I-cell_type I-cell_type 0.7665132284164429
lymphocytes E-cell_type E-cell_type 0.8061299324035645
incubated O O 0.9993671774864197
with O O 0.9999862909317017
ciprofloxacin O O 0.7226060628890991
compared O O 0.999367892742157
to O O 0.999970555305481
that O O 0.9999270439147949
in O O 0.9990523457527161
untreated O O 0.779158353805542
controls O O 0.7848420739173889
. O O 0.9999580383300781
Ciprofloxacin O O 0.7080697417259216
increased O O 0.9987439513206482
CAT S-protein S-protein 0.9447380900382996
activity O O 0.9976346492767334
in O O 0.999915599822998
stimulated O B-cell_type 0.3880433142185211
lymphocytes O E-cell_type 0.5399260520935059
transfected O O 0.9601091146469116
with O O 0.9997981190681458
plasmids S-cell_type O 0.47489258646965027
containing O O 0.9921435117721558
either O O 0.9997327923774719
the O O 0.9993718266487122

accompanied O O 0.995388388633728
by O O 0.9999759197235107
IL-10 S-protein S-protein 0.9780987501144409
production O O 0.9892235994338989
and O O 0.9997904896736145
a O O 0.9999228715896606
block O O 0.9618428945541382
in O O 0.9995040893554688
JNK S-protein S-protein 0.9510066509246826
activity O O 0.9951560497283936
. O O 0.9999963045120239
The O O 0.9999960660934448
ability O O 0.9997053742408752
to O O 0.9999762773513794
induce O O 0.9998506307601929
anergy O O 0.9055690169334412
in O O 0.9995468258857727
antigen-specific B-cell_type B-cell_type 0.5135836005210876
T I-cell_type I-cell_type 0.7503418922424316
cells E-cell_type E-cell_type 0.8975805044174194
has O O 0.9997054934501648
potential O O 0.9988507032394409
therapeutic O O 0.9913823008537292
value O O 0.99715256690979
for O O 0.9999734163284302
altering O O 0.9666520953178406

1 E-protein O 0.5562892556190491
overexpression O O 0.9579982161521912
and O O 0.9982309937477112
activation O O 0.9940943121910095
induced O O 0.9999755620956421
by O O 0.9999806880950928
interferon B-protein B-protein 0.5496732592582703
beta E-protein E-protein 0.9427943825721741
in O O 0.9976553916931152
human B-cell_type B-cell_type 0.6636181473731995
T I-cell_type I-cell_type 0.8416680097579956
lymphocytes E-cell_type E-cell_type 0.9873849153518677
: O O 0.9964779019355774
an O O 0.9999576807022095
ISGF3 S-protein S-protein 0.943417489528656
-independent O O 0.9913190007209778
response O O 0.9981977343559265
. O O 0.9999939203262329
Interferons S-protein S-protein 0.846019983291626
exert O O 0.9989380240440369
their O O 0.999975323677063
antiviral O O 0.9435018301010132
, O O 0.9924851059913635
antiproliferative O O 0.9750878810882568
and O O 0.9971747398376465
immunoregulatory S-protein O 0.9572184681892395
activities O O 0.9939536452293396
by O O 0.9999912977218628
stimulating O O 0.9990072846412659
the O O 0.9997314810752869
expression O O 0.9990463852882385
of O O 0.9999725818634033
several O O 0.9889877438545227
genes O O 0.464888334274292
. O O 0.9999383687973022
Such O O 0.9995853304862976
genes O O 0.6973105072975159

studied O O 0.9954901337623596
using O O 0.999962329864502
limited O O 0.9687729477882385
proteolytic O O 0.8948432803153992
digestion O O 0.9845277667045593
by O O 0.9999831914901733
trypsin S-protein S-protein 0.7325467467308044
. O O 0.9998397827148438
Partial O O 0.9741214513778687
proteolysis O O 0.9417359232902527
of O O 0.9993029832839966
androgen-bound B-protein B-protein 0.5100034475326538
receptor I-protein I-protein 0.6551640629768372
protein E-protein E-protein 0.9846165180206299
resulted O O 0.9997044205665588
in O O 0.9999951124191284
a O O 0.9998779296875
29-kDa B-protein B-protein 0.5017876029014587
proteolysis-resisting I-protein I-protein 0.6888585686683655
fragment E-protein E-protein 0.5412186980247498
, O O 0.9945836663246155
whereas O O 0.9999834299087524
antiandrogen O O 0.5676046013832092
binding O O 0.622421145439148
stabilised O O 0.9893879890441895
a O O 0.9995280504226685

In O O 0.9998369216918945
this O O 0.9999921321868896
experimental O O 0.9913657903671265
study O O 0.9998109936714172
we O O 0.9999961853027344
used O O 0.9999947547912598
30 O O 0.9966008067131042
Sprague O O 0.9848771095275879
- O O 0.9991075396537781
Dawley O O 0.9697965383529663
rats O O 0.9974849224090576
, O O 0.9999861717224121
27 O O 0.9994888305664062
of O O 0.9998946189880371
which O O 0.9999784231185913
had O O 0.9999533891677856
gentamicin B-Chemical B-Chemical 0.9157984256744385
instilled O O 0.9591441750526428
into O O 0.9994822144508362
the O O 0.9995007514953613
middle O O 0.9876794815063477
ear O O 0.9924721717834473
. O O 0.9999990463256836

STUDY O O 0.9969958066940308
DESIGN O O 0.9991711378097534
AND O O 0.9999438524246216
METHODS O O 0.9947181344032288
: O O 0.9999673366546631
Plasma O O 0.9296400547027588
samples O O 0.9765125513076782
from O O 0.9999692440032959
before O O 0.9993009567260742
and O O 0.999883770942688
after O O 0.9999759197235107
CPB O O 0.7668270468711853
were O O 0.9991075396537781
analyzed O O 0.9999762773513794
postoperatively O O 0.9998911619186401
for O O 0.9999853372573853
argatroban S-Chemical B-Chemical 0.9175918102264404
concentration O O 0.8128269910812378
using O O 0.9998925924301147
a O O 0.9999696016311646
modified O O 0.9770210385322571
ecarin O O 0.3941669762134552
clotting O O 0.7873848676681519
time O O 0.9694226384162903
( O O 0.9994795918464661
ECT O O 0.9470616579055786
) O O 0.9982984662055969
assay O O 0.9989217519760132
. O O 0.9999992847442627

Western O O 0.9252843260765076

cell I-cell_line O 0.4758114814758301
variant E-cell_line O 0.37572187185287476
) O O 0.9752855896949768
; O O 0.9998587369918823
trypsin S-protein O 0.5146644711494446
digestion O O 0.9519938230514526
of O O 0.9996126294136047
antiandrogen-bound B-protein B-protein 0.43287333846092224
mutated I-protein I-protein 0.6483011841773987
receptor E-protein E-protein 0.9543874859809875
also O O 0.9923420548439026
resulted O O 0.9999638795852661
in O O 0.9999936819076538
a O O 0.999895453453064
29-kDa B-protein B-DNA 0.4228360056877136
fragment E-protein E-DNA 0.4043791890144348

ICAM I-protein I-protein 0.299942284822464
) I-protein I-protein 0.48287510871887207
-1 E-protein E-protein 0.934800922870636
, O O 0.9588331580162048
vascular B-protein B-protein 0.7760443091392517
cell I-protein I-protein 0.5425686836242676
adhesion I-protein I-protein 0.5645569562911987
molecule I-protein I-protein 0.9740732908248901
( I-protein I-protein 0.9762560725212097
VCAM I-protein I-protein 0.8308175802230835
) I-protein I-protein 0.6854701638221741
-1 E-protein E-protein 0.9558645486831665
and O O 0.9891124367713928
endothelial B-protein O 0.5155456066131592
leukocyte I-protein O 0.27094778418540955

of O O 0.9926290512084961

We O O 0.9993036985397339
observed O O 0.9998243451118469
the O O 0.9999421834945679
exencephaly B-Disease O 0.8729842901229858
induced O O 0.8110582232475281
by O O 0.9553893804550171
5 B-Chemical B-Chemical 0.8341112732887268
- I-Chemical I-Chemical 0.9954437017440796
azacytidine I-Chemical E-Chemical 0.923418402671814
at O O 0.9957635402679443
embryonic O O 0.5429988503456116
day O O 0.6675902605056763
13 O O 0.9469664692878723
. O O 0.999943733215332
5 O O 0.9929854273796082
( O O 0.9999618530273438
E13 O O 0.9792223572731018
. O O 0.9996387958526611
5 O O 0.9974236488342285
) O O 0.9978055357933044
, O O 0.9999918937683105
let O O 0.9996103644371033
the O O 0.9999434947967529
embryos O O 0.9745274782180786
develop O O 0.9996500015258789
exo O O 0.8998790979385376
utero O O 0.8894376158714294
until O O 0.9999902248382568
E18 O O 0.904361367225647
. O O 0.9998693466186523
5 O O 0.9954784512519836
, O O 0.9995378255844116
and O O 0.9999300241470337
re O O 0.9262798428535461
- O O 0.9984440207481384
observed O O 0.9998407363891602
the O O 0.9999727010726929
same O O 0.9998770952224731
embryos O O 0.8776156902313232
at O O 0.9999679327011108
E18 O O 0.8999263644218445
. O O 0.9999700784683228
5 O O 0.992203950881958
. O O 0.9999388456344604

From O O 0.9997031092643738
January O O 0.9994022846221924
1986 O O 0.9999523162841797
to O O 0.9999909400939941
January O O 0.9999936819076538
2009 O O 0.9999790191650391
, O O 0.9999963045120239
1223 O O 0.999529242515564
consecutive O O 0.99982750415802
ALF B-Disease O 0.8668822646141052
patients O O 0.9652602672576904
were O O 0.9999861717224121
evaluated O O 0.9999912977218628
: O O 0.999982476234436
ATT O O 0.4042641818523407
alone O O 0.9928366541862488
was O O 0.9999899864196777
the O O 0.9999878406524658
cause O O 0.9993341565132141
in O O 0.9999959468841553
70 O O 0.9959020018577576
( O O 0.9998502731323242
5 O O 0.9998934268951416
. O O 0.9998927116394043
7 O O 0.9998338222503662
% O O 0.9997274279594421
) O O 0.9965654015541077
patients O O 0.9995829463005066
. O O 0.9999992847442627

activity O O 0.9810116291046143
. O O 0.999985933303833
The O O 0.9999549388885498
spi-1 B-cell_line B-cell_line 0.4616382122039795
transfected I-cell_line I-cell_line 0.41768118739128113
cells E-cell_line E-cell_line 0.9391834139823914
showed O O 0.9998661279678345
reduced O O 0.992601215839386
growth O O 0.9523090720176697
rates O O 0.9961344003677368
and O O 0.999964714050293
reduced O O 0.9950233697891235
clonogenic O O 0.823000431060791
cell O O 0.6176097393035889
growth O O 0.9867700338363647
. O O 0.9999942779541016
When O O 0.9999948740005493
the O O 0.999840497970581
erythroid O O 0.5181866884231567
and O O 0.9191383719444275
monocytic O O 0.7602976560592651
differentiation O O 0.8812417387962341
markers O O 0.5246328711509705
were O O 0.9998652935028076
analyzed O O 0.9997186064720154
, O O 0.9999876022338867
spi-1 S-protein S-protein 0.7902892231941223
overexpression O O 0.9935996532440186
resulted O O 0.9999818801879883
in O O 0.9999815225601196
opposite O O 0.990559458732605
effects O O 0.9995279312133789
: O O 0.9999831914901733
erythroid O O 0.8382057547569275
differentiation O O 0.9868567585945129
was O O 0.9999697208404541
significantly O O 0.9997519850730896
inhibited O O 0.9995848536491394
in O O 0.9998947381973267
spi-1 B-cell_line B-cell_line 0.3318163752555847
transfectants E-cell_line E-cell_line 0.8312519192695618
, O O 0.9991424083709717
while O O 0.9999947547912598
spi-1 S-protein S-protein 0.8527157306671143
overexpression O O 0.9932189583778381
increased O O 0.9999551773071289
the O O 0.9999406337738037
monocytic O O 0.8057416677474976
differentiation O O 0.9738882780075073
of O O 0.9997449517250061

cytokines S-protein S-protein 0.5813173651695251
induced O O 0.9988933205604553
STAT6 S-protein S-protein 0.9203656315803528
, O O 0.9811397790908813
STAT3 S-protein S-protein 0.9705519676208496
and O O 0.994220495223999
STAT5 S-protein S-protein 0.9648551344871521
activation O O 0.9890947937965393
in O O 0.9996345043182373
B B-cell_type B-cell_type 0.8918454051017761
cells E-cell_type E-cell_type 0.9864482283592224
. O O 0.999526858329773
In O O 0.9999921321868896
spite O O 0.9999078512191772
of O O 0.9999940395355225
this O O 0.9999812841415405
similar O O 0.9956851005554199
downstream O O 0.8693496584892273
signalling O O 0.942850649356842
, O O 0.9986087679862976
IL4 S-protein S-protein 0.8230398893356323
and O O 0.9870380163192749
IL13 S-protein S-protein 0.7755004167556763

c-fos S-DNA S-DNA 0.6311108469963074
well O O 0.5666385889053345
. O O 0.9999090433120728
That O O 0.9999828338623047
synergy O O 0.9867725968360901
of O O 0.999583899974823
signaling O O 0.9046670794487
pathways O O 0.9807625412940979
is O O 0.9999910593032837
relevant O O 0.9998456239700317
for O O 0.9999945163726807
the O O 0.9999608993530273
anti-Ig S-protein S-protein 0.6539010405540466
induction O O 0.9157094359397888
of O O 0.9979137778282166
c-fos S-DNA S-DNA 0.9428809285163879
is O O 0.9981330037117004
supported O O 0.9999679327011108
by O O 0.9999970197677612
the O O 0.9999903440475464
fact O O 0.9991472959518433
that O O 0.9999909400939941
cAMP-inducing O O 0.5516384243965149
agents O O 0.5772044658660889
and O O 0.9977537989616394
okadaic O O 0.6204763650894165

seen O O 0.9963449835777283
in O O 0.9999252557754517
IL-2 S-protein S-protein 0.9172072410583496
-driven O O 0.992484986782074
cell O O 0.9671558737754822
growth O O 0.9939743876457214
of O O 0.9999020099639893
CD8-positive B-cell_type B-cell_type 0.5837268233299255
lymphocytes E-cell_type E-cell_type 0.8055680394172668
purified O O 0.9962137341499329
from O O 0.9999808073043823
7-day B-cell_type O 0.8007368445396423
PHA-blasts E-cell_type O 0.3875594139099121
, O O 0.9919660091400146
indicating O O 0.9999871253967285
that O O 0.9999933242797852
CD4 B-protein B-protein 0.6426615118980408
molecules E-protein E-protein 0.9578337073326111
were O O 0.9997299313545227
not O O 0.999941349029541
required O O 0.9999451637268066
for O O 0.9999936819076538
the O O 0.9999277591705322
suppression O O 0.9872363805770874
. O O 0.9999922513961792
The O O 0.9999943971633911
treatment O O 0.9996402263641357
with O O 0.9999885559082031
anti-V3 B-protein B-protein 0.6020763516426086
loop I-protein I-protein 0.5174784660339355
monoclonal I-protein I-protein 0.5527026653289795
antibody E-protein E-protein 0.9644719958305359
( O O 0.9738203287124634
902 B-protein B-protein 0.6460195779800415
antibody E-protein E-protein 0.8689185380935669
) O O 0.9126274585723877
completely O O 0.9990703463554382

. O O 0.9963762164115906
These O O 0.9999969005584717
data O O 0.9998577833175659
suggest O O 0.999998927116394
a O O 0.9999954700469971
model O O 0.9949778914451599
in O O 0.999953031539917
which O O 0.999969482421875
CD30 S-protein S-protein 0.9596545100212097
limits O O 0.9992745518684387
its O O 0.9999176263809204
own O O 0.9957873225212097
ability O O 0.9995881915092468
to O O 0.9999841451644897
transduce O O 0.9981067180633545
cell O O 0.9596707820892334
survival O O 0.9700490832328796
signals O O 0.9978151321411133
through O O 0.9999959468841553
signal-coupled O O 0.8614708781242371
depletion O O 0.9788414835929871
of O O 0.9995629191398621
TRAF2 S-protein S-protein 0.6937752366065979

region O E-DNA 0.6487113833427429
is O O 0.998978853225708
downstream O O 0.9978861212730408
of O O 0.9999758005142212
the O O 0.9999213218688965
BOX1 B-protein B-DNA 0.5411335229873657
motif E-protein E-DNA 0.848363995552063
and O O 0.9706120491027832
contains O O 0.9994250535964966
a O O 0.9966655373573303

which O O 0.9939203262329102
is O O 0.9999842643737793
essential O O 0.9999300241470337
for O O 0.9999823570251465
productive O O 0.9661997556686401
infection O O 0.9508283734321594
, O O 0.9999532699584961
has O O 0.9999860525131226
also O O 0.9999608993530273
been O O 0.9999818801879883
shown O O 0.9999706745147705

interactions O O 0.9759668707847595
mediating O O 0.9993942975997925
IFN-beta S-protein S-protein 0.9377762079238892
induction O O 0.9874207377433777
, O O 0.999872088432312
positive B-protein B-protein 0.8802380561828613
regulatory I-protein I-protein 0.4957362115383148
domain I-protein I-protein 0.855819821357727
( I-protein I-protein 0.7351728081703186
PRD I-protein I-protein 0.46956437826156616
) I-protein I-protein 0.8142663836479187
II I-protein I-protein 0.7652591466903687
binding I-protein I-protein 0.812622606754303
proteins E-protein E-protein 0.9925455451011658
were O O 0.9996457099914551
purified O O 0.9991528987884521
from O O 0.9999794960021973
phorbol O O 0.5738250017166138
ester O O 0.4606846272945404
induced O O 0.8482483625411987
Jurkat B-cell_line B-cell_line 0.6577214002609253
T-cells E-cell_line E-cell_line 0.949414074420929
and O O 0.9972133040428162
from O O 0.9996777772903442
IFN B-cell_line S-protein 0.32268694043159485
primed I-cell_line O 0.42645400762557983
, I-cell_line O 0.8196395039558411
cycloheximide/polyinosinic-polycytidylic I-cell_line O 0.4403987526893616
acid I-cell_line O 0.40841910243034363
treated I-cell_line O 0.7723579406738281
HeLa I-cell_line B-cell_line 0.48281341791152954
S3 I-cell_line I-cell_line 0.791795015335083
cells E-cell_line E-cell_line 0.9975355863571167
. O O 0.999647855758667
From O O 0.999909520149231
HeLa B-cell_line B-cell_line 0.8518757820129395
cells E-cell_line E-cell_line 0.9952418804168701
, O O 0.9996287822723389
two O O 0.9995121955871582
major O O 0.9361110329627991
proteins O O 0.4915314316749573

Age O O 0.9334515333175659
- O O 0.9978638291358948
dependent O O 0.9956902861595154
sensitivity O O 0.8291349411010742
of O O 0.9834907650947571
the O O 0.9953912496566772
rat O O 0.9603543877601624
to O O 0.9995641112327576
neurotoxic B-Disease O 0.7500013709068298
effects O O 0.7321491837501526
of O O 0.9969960451126099
streptomycin B-Chemical B-Chemical 0.9179751873016357
. O O 0.9996287822723389

All O O 0.9996416568756104
the O O 0.9999809265136719
patients O O 0.9993259906768799
were O O 0.9999946355819702
skin O O 0.5575887560844421
test O O 0.8364364504814148
negative O O 0.9146955609321594
to O O 0.9989901185035706
BPO B-Chemical B-Chemical 0.9082122445106506
; O O 0.996619701385498
49 O O 0.9993250370025635
of O O 0.99996018409729
51 O O 0.9969610571861267
( O O 0.9999321699142456
96 O O 0.9998053908348083
% O O 0.999921441078186
) O O 0.9997805953025818
were O O 0.9999934434890747
also O O 0.9999347925186157
negative O O 0.9934777021408081
to O O 0.9998224377632141
MDM B-Disease O 0.4000778794288635
, O O 0.9926010966300964
and O O 0.9999642372131348
44 O O 0.999875545501709
of O O 0.9999772310256958
46 O O 0.996772825717926
( O O 0.999922513961792
96 O O 0.9997984766960144
% O O 0.999907374382019
) O O 0.9993108510971069
to O O 0.9998488426208496
PG B-Chemical B-Chemical 0.9254192113876343
. O O 0.9989596605300903

Habitual O O 0.715611457824707
use O O 0.96016925573349
of O O 0.9993721842765808
acetaminophen B-Chemical B-Chemical 0.9257158041000366
as O O 0.9994069337844849
a O O 0.9999700784683228
risk O O 0.9863828420639038
factor O O 0.9880844950675964
for O O 0.9999644756317139
chronic B-Disease B-Disease 0.8284342885017395
renal I-Disease I-Disease 0.593955934047699
failure I-Disease I-Disease 0.9672366976737976
: O O 0.9862696528434753
a O O 0.9998430013656616
comparison O O 0.9998144507408142
with O O 0.9999932050704956
phenacetin B-Chemical B-Chemical 0.9165717959403992
. O O 0.9993487000465393

Differences O O 0.8769042491912842
in O O 0.9955739974975586
the O O 0.9991494417190552
labelling O O 0.8170642852783203
pattern O O 0.9370133280754089
occurred O O 0.9997280240058899
with O O 0.999997615814209
different O O 0.9994118213653564
antibodies O O 0.72500079870224
which O O 0.9995321035385132
apparently O O 0.9995228052139282
depended O O 0.9999767541885376
on O O 0.9999316930770874
molecular O O 0.9537193179130554
weight O O 0.9273127317428589
class O O 0.9500467777252197
of O O 0.9986275434494019
NFs O O 0.34659433364868164
and O O 0.9918681979179382
phosphorylation O O 0.7200703024864197
state O O 0.8487945795059204
. O O 0.999992847442627

gene O E-DNA 0.6602353453636169

the O O 0.9986786246299744
presence O O 0.9993762373924255
of O O 0.9999790191650391
cycloheximide O O 0.816017210483551
and O O 0.9964113831520081
is O O 0.9999051094055176
fully O O 0.9983701109886169
suppressed O O 0.9996799230575562
by O O 0.9999949932098389
CyA O O 0.6742848753929138
. O O 0.9998490810394287
The O O 0.9999754428863525
PILOT S-protein B-protein 0.38418829441070557
protein O E-protein 0.9451547861099243
has O O 0.9984954595565796
a O O 0.9999059438705444
calculated O O 0.8935841917991638
M O O 0.18206630647182465
( O O 0.5292428135871887
r O O 0.34339600801467896

of O O 0.9941871166229248
fusion B-protein B-protein 0.5720078349113464
proteins E-protein E-protein 0.9687105417251587
and O O 0.993540346622467
B-lymphocyte B-cell_type B-cell_type 0.5707706809043884
cells E-cell_type E-cell_type 0.9386566877365112
using O O 0.9993689656257629
magnetic O O 0.906792163848877
separation O O 0.9799298048019409
. O O 0.9999929666519165
A O O 0.9999679327011108
new O O 0.9974551796913147
approach O O 0.9999539852142334
to O O 0.9999793767929077
facilitate O O 0.9992201328277588
immobilization O O 0.9952331185340881
and O O 0.999915361404419
affinity O O 0.9412079453468323
purification O O 0.98067307472229

silencer O O 0.6217275261878967
mechanism O O 0.8840283751487732
to O O 0.9998457431793213
down-regulate O O 0.9925474524497986
CD4 B-DNA B-DNA 0.6943041086196899
gene E-DNA E-DNA 0.8200811147689819
expression O O 0.979697048664093
. O O 0.9999841451644897
Unexpectedly O O 0.9995993971824646
, O O 0.9999922513961792
the O O 0.9999791383743286
CD4 B-DNA B-protein 0.4302637577056885
silencer E-DNA E-protein 0.6046410799026489
is O O 0.9954788684844971
also O O 0.9999426603317261
active O O 0.9985358715057373
in O O 0.9997299313545227
CD4+ B-cell_type B-cell_line 0.7119265794754028
CD8int/- I-cell_type I-cell_line 0.7182144522666931
cells E-cell_type E-cell_line 0.567747950553894
of O O 0.9964207410812378
the O O 0.9999082088470459
thymus O O 0.6070572733879089
, O O 0.9937995076179504
implying O O 0.9999809265136719
that O O 0.9999946355819702
an O O 0.999887228012085
anti-silencer O S-protein 0.6956482529640198
may O O 0.9986031651496887
be O O 0.9999822378158569
required O O 0.9996342658996582
to O O 0.9998055100440979

All O O 0.9977439641952515
rats O O 0.9899616241455078
in O O 0.999901294708252
the O O 0.9996261596679688
sodium B-Chemical B-Chemical 0.9336661100387573
- O O 0.8093892335891724
depleted O O 0.8232261538505554
group O O 0.9797484278678894
had O O 0.9999444484710693
histopathological O O 0.890995442867279
evidence O O 0.9542140364646912
of O O 0.9994165897369385
patchy O O 0.9425943493843079
tubular O O 0.7838795781135559
cytoplasmic O O 0.46446600556373596
degeneration O O 0.8085618615150452
in O O 0.9921271800994873
tubules O O 0.5924656391143799
that O O 0.9974278807640076
was O O 0.9998606443405151
not O O 0.9999077320098877
observed O O 0.9997981190681458
in O O 0.9999896287918091
any O O 0.999884843826294
normal O O 0.9014022350311279
- O O 0.9950215816497803
salt O O 0.6263572573661804
or O O 0.9969460368156433
salt O O 0.7727141380310059
- O O 0.9817885756492615
loaded O O 0.9959551095962524
rat O O 0.9781635999679565
. O O 0.9999912977218628

Nifedipine B-Chemical B-Chemical 0.9221869111061096
significantly O O 0.9971457123756409
improved O O 0.996713399887085
kidney O O 0.9009698033332825
function O O 0.7906414866447449
as O O 0.9998341798782349
indicated O O 0.9999133348464966
by O O 0.9999938011169434
a O O 0.9999434947967529
significant O O 0.9994513392448425
lowering O O 0.9914113283157349
of O O 0.9971864819526672
serum O O 0.9659498333930969
creatinine B-Chemical B-Chemical 0.9245001077651978
levels O O 0.9971174001693726
at O O 0.9999992847442627
6 O O 0.9997949004173279
and O O 0.9999113082885742
12 O O 0.9999222755432129
months O O 0.9999797344207764
. O O 0.9999991655349731

, O O 0.8891003131866455
but O O 0.9860990047454834
not O O 0.9888923764228821
Jak1 S-protein S-protein 0.9758768081665039
, O O 0.9953712821006775
Jak2 S-protein S-protein 0.9783198833465576
, O O 0.9894816875457764
and O O 0.9951362013816833
Jak3 S-protein S-protein 0.9862982630729675
. O O 0.9997929930686951
In O O 0.9999886751174927
addition O O 0.9999109506607056
, O O 0.999997615814209
the O O 0.9999750852584839
transcription B-protein B-protein 0.6458054780960083
factor E-protein E-protein 0.9451638460159302
Stat-3 S-protein S-protein 0.7455559372901917
was O O 0.999749481678009
tyrosine O O 0.8173466920852661
phosphorylated O O 0.8608797788619995
in O O 0.9996155500411987
the O O 0.9997782111167908
cytoplasm O O 0.8358446359634399
and O O 0.9956564903259277
subsequently O O 0.9992852807044983
translocated O O 0.9963153004646301
to O O 0.9998869895935059
the O O 0.9992287158966064

can O O 0.9612979292869568

In O O 0.9995124340057373
female O O 0.9037109017372131
rats O O 0.9900537729263306
, O O 0.9999929666519165
only O O 0.9999873638153076
a O O 0.9998636245727539
weak O O 0.9882318377494812
tendency O O 0.9320552349090576
toward O O 0.9997316002845764
aggressiveness O B-Disease 0.9583181142807007
was O O 0.9897797703742981
found O O 0.9999731779098511
. O O 0.9999984502792358

i.e O O 0.5194112062454224
. O O 0.9995025396347046
HHV-8+/EBV- B-cell_line B-protein 0.6048856973648071
PEL E-cell_line E-protein 0.3431554436683655
in O O 0.9915885329246521
the O O 0.9999738931655884
case O O 0.9984967708587646
of O O 0.9999492168426514
CRO-AP/3 B-cell_line S-protein 0.48032334446907043
and I-cell_line O 0.982109546661377
HHV-8+/EBV+ I-cell_line B-protein 0.5439965724945068
PEL E-cell_line E-protein 0.5159057378768921
in O O 0.9927143454551697
the O O 0.9998494386672974

tyrosine O O 0.671492338180542
phosphorylation O O 0.865864098072052
is O O 0.9999227523803711
required O O 0.9999825954437256
for O O 0.9999922513961792
complex O O 0.946193516254425
formation O O 0.9925064444541931
. O O 0.9999861717224121
IL-3 S-protein S-protein 0.9450318217277527
and O O 0.9815022349357605

B E-protein E-protein 0.9596725106239319
activation O O 0.9935925602912903
by O O 0.9999879598617554
the O O 0.9998446702957153
T B-protein B-protein 0.3946530520915985
cell I-protein I-protein 0.6972041130065918
receptor I-protein I-protein 0.6495175957679749
complex E-protein E-protein 0.9832073450088501
: O O 0.995527446269989
role O O 0.9945348501205444
of O O 0.9988189339637756

structural O O 0.9096754789352417
similarity O O 0.9914224743843079
with O O 0.9999909400939941
the O O 0.9999068975448608
v-rel B-protein B-protein 0.4699440896511078
oncogene I-protein I-protein 0.36034509539604187
product E-protein E-protein 0.984838604927063
. O O 0.9996908903121948
Nuclear O O 0.9634789228439331
expression O O 0.9929887652397156
of O O 0.9998981952667236
these O O 0.9997233748435974
proteins O O 0.6367684006690979
is O O 0.9993364214897156
induced O O 0.9998106360435486
with O O 0.9999799728393555
distinctly O O 0.9616950154304504
biphasic O O 0.7908148169517517
kinetics O O 0.5962434411048889
following O O 0.9998923540115356
phorbol O O 0.9024354815483093
ester O O 0.9428822994232178
activation O O 0.9972890615463257
of O O 0.9998431205749512
T B-cell_type B-cell_type 0.8212178945541382
cells E-cell_type E-cell_type 0.9731962084770203

FLA B-Chemical B-Chemical 0.9161849617958069
- I-Chemical I-Chemical 0.9591864347457886
63 E-Chemical I-Chemical 0.9563454389572144
, O O 0.9038994312286377
a O O 0.9979496598243713
dopamine S-Chemical B-Chemical 0.9310423731803894
- O O 0.8209275603294373
beta O O 0.9369767904281616
- O O 0.9824504256248474
oxidase O O 0.6216246485710144
inhibitor O O 0.6735925078392029
, O O 0.9993886947631836
did O O 0.9999452829360962
not O O 0.9998766183853149
have O O 0.9999436140060425
any O O 0.9998736381530762
effect O O 0.9984180927276611
on O O 0.999966025352478
the O O 0.9991426467895508
hypotension O O 0.9468434453010559
, O O 0.907992959022522
bradycardia O O 0.9207285046577454
or O O 0.888127326965332
reflex O O 0.5391008257865906
- O O 0.9796977639198303
enhancing O O 0.9936779141426086
effect O O 0.9941737055778503
of O O 0.9996664524078369
L B-Chemical B-Chemical 0.8753142356872559
- I-Chemical I-Chemical 0.9889547824859619
dopa E-Chemical I-Chemical 0.958080530166626
. O O 0.9994319081306458

81 B-DNA B-DNA 0.5110294222831726
bp I-DNA I-DNA 0.392753005027771
EBNA2 I-DNA I-DNA 0.3317476511001587
responsive I-DNA I-DNA 0.4424373209476471
region E-DNA E-DNA 0.9142104983329773
between O O 0.9975479245185852
-258 O B-DNA 0.4568004608154297
and O I-DNA 0.6943830251693726
-177 O E-DNA 0.8888168334960938
relative O O 0.96904057264328
to O O 0.9996852874755859
the O O 0.9997969269752502
TP1 B-DNA B-DNA 0.2903968095779419
RNA I-DNA I-DNA 0.27012044191360474
start I-DNA I-DNA 0.5857500433921814
site E-DNA E-DNA 0.9911728501319885
. O O 0.9997908473014832
The O O 0.9999707937240601
element O O 0.6287864446640015
worked O O 0.999210000038147
in O O 0.9999686479568481
either O O 0.9990333318710327
orientation O O 0.9684245586395264
and O O 0.9996187686920166
could O O 0.9999934434890747
mediate O O 0.9979815483093262
EBNA2 S-protein S-protein 0.7494143843650818
dependent O O 0.9719222187995911
transactivation O O 0.980818510055542
on O O 0.9999678134918213
a O O 0.9998051524162292
heterologous B-DNA B-DNA 0.6388214826583862
promoter E-DNA E-DNA 0.9858951568603516
. O O 0.9996293783187866
Electrophoretic O O 0.9662542939186096
mobility O O 0.9837544560432434
shift O O 0.998245120048523
assays O O 0.9996090531349182
revealed O O 0.999994158744812
three O O 0.9989221096038818
specific O O 0.9601835608482361
protein-DNA B-protein B-protein 0.6034783720970154
complexes E-protein E-protein 0.9820069670677185
formed O O 0.9986121654510498
with O O 0.9999723434448242

in O O 0.9970675110816956
human B-cell_type B-cell_type 0.664603054523468
lymphocytes E-cell_type E-cell_type 0.9939477443695068
. O O 0.9998152852058411
Interleukin B-protein B-protein 0.7126609086990356
12 E-protein E-protein 0.9663887619972229
( O O 0.9781033992767334
IL-12 S-protein S-protein 0.9729099869728088
) O O 0.9612820744514465
is O O 0.9999866485595703
an O O 0.9999922513961792
important O O 0.9894862174987793
immunoregulatory B-protein B-protein 0.6101248264312744
cytokine E-protein E-protein 0.9193153977394104
whose O O 0.9924554824829102
receptor O O 0.704157292842865
is O O 0.9984048008918762
a O O 0.9999619722366333
member O O 0.9932743310928345
of O O 0.9997095465660095
the O O 0.9998867511749268
hematopoietin B-protein S-protein 0.702335000038147

CD11b S-protein S-protein 0.7055391669273376
. O O 0.9996719360351562
No O O 0.9997323155403137
upregulation O O 0.9957721829414368
of O O 0.9998138546943665
megakaryocyte B-protein B-protein 0.2055109590291977
or I-protein I-protein 0.8147153854370117
lymphoid I-protein I-protein 0.41537854075431824
markers E-protein E-protein 0.6565952301025391

Deletion O O 0.9669045805931091
of O O 0.9997668862342834
the O O 0.999962568283081
PLZF B-protein B-protein 0.29541081190109253
POZ I-protein I-protein 0.6579136848449707
domain E-protein E-protein 0.8903735280036926
partially O O 0.9937887787818909
abrogated O O 0.9997946619987488
the O O 0.9999828338623047
inhibitory O O 0.9655869603157043
effect O O 0.9994534850120544
of O O 0.9999817609786987
PLZF-RAR B-protein B-protein 0.3859228491783142
alpha E-protein E-protein 0.9739930629730225
on O O 0.9992990493774414
RA-induced O O 0.8070797920227051
differentiation O O 0.9758729934692383
and O O 0.999818742275238
on O O 0.9996827840805054
RA-mediated O B-protein 0.8029809594154358
type B-protein I-protein 0.7489564418792725
II I-protein I-protein 0.4707362651824951
TGase E-protein E-protein 0.8388400673866272
up-regulation O O 0.992500364780426
, O O 0.9999802112579346
suggesting O O 0.9999959468841553
that O O 0.9999889135360718
POZ-mediated O O 0.8271605372428894
protein O O 0.5446733236312866
interactions O O 0.9748100638389587
might O O 0.9999958276748657
be O O 0.9999961853027344
responsible O O 0.9999485015869141
for O O 0.9999933242797852
the O O 0.9999620914459229
inhibitory O O 0.8638733625411987
transcriptional O O 0.7616469860076904

Methamphetamine S-Chemical B-Chemical 0.9234547019004822
( O O 0.9584640860557556
METH S-Chemical B-Chemical 0.9130868315696716
) O O 0.7356700301170349
damages O O 0.9634596109390259
dopamine S-Chemical B-Chemical 0.9184092879295349
( O O 0.9081686735153198
DA S-Chemical B-Chemical 0.9206769466400146
) O O 0.8255528211593628
nerve O O 0.49880996346473694
endings O O 0.5380996465682983
by O O 0.9997178912162781
a O O 0.9999845027923584
process O O 0.9994933605194092
that O O 0.9999880790710449
has O O 0.9999673366546631
been O O 0.9997159838676453
linked O O 0.9999856948852539
to O O 0.9999899864196777
microglial O O 0.779156506061554
activation O O 0.658070981502533
but O O 0.9997164607048035
the O O 0.9999775886535645
signaling O O 0.9505488872528076
pathways O O 0.966151237487793
that O O 0.99997878074646
mediate O O 0.9994543194770813
this O O 0.9997703433036804
response O O 0.9978936314582825
have O O 0.99998939037323
not O O 0.9998946189880371
yet O O 0.9999808073043823
been O O 0.9998341798782349
delineated O O 0.9992595314979553
. O O 0.9999991655349731

; O O 0.9922630786895752
the O O 0.9999685287475586
interassay O O 0.5970327854156494
coefficient O O 0.441988468170166
of O O 0.9504155516624451
variation O O 0.9768203496932983
is O O 0.9999674558639526
11 O O 0.9983916878700256
% O O 0.9996732473373413
. O O 0.9999850988388062
To O O 0.9999850988388062
validate O O 0.9997729659080505
the O O 0.9999843835830688
method O O 0.9939045310020447
, O O 0.9999841451644897
we O O 0.9999459981918335
made O O 0.9998925924301147
use O O 0.9999479055404663
of O O 0.9999916553497314
earlier O O 0.9755945801734924
receptor O O 0.808297872543335
binding O O 0.8065974712371826
studies O O 0.9825002551078796
indicating O O 0.9999808073043823
that O O 0.9999822378158569
normal B-cell_type B-cell_type 0.5256704688072205
human I-cell_type I-cell_type 0.5359969735145569
monocytes E-cell_type E-cell_type 0.9846316576004028
and O O 0.9911110401153564
activated O O 0.5351364016532898
, O O 0.5596442222595215
but O O 0.8497605323791504
not O O 0.8131788372993469
resting O O 0.4650568962097168
, O O 0.9706379175186157
lymphocytes S-cell_type S-cell_type 0.880972146987915
expressed O O 0.998755931854248
the O O 0.9999585151672363
VDR S-protein S-protein 0.5376272201538086
. O O 0.9979819059371948
The O O 0.9999887943267822
concentration O O 0.99678635597229
of O O 0.9998477697372437
the O O 0.998917818069458
VDR B-RNA B-RNA 0.8243499398231506
mRNA E-RNA E-RNA 0.9566377401351929

Does O O 0.9988850951194763
smoking B-Chemical B-Chemical 0.9235280752182007
during O O 0.9974972605705261
pregnancy O O 0.6986162662506104
affect O O 0.9993140697479248
the O O 0.9998695850372314
amplitudes O O 0.9396309852600098
of O O 0.9992184638977051
transient O O 0.6131181120872498
evoked O O 0.9379391670227051
otoacoustic O O 0.5903081297874451
emissions O O 0.924605667591095
in O O 0.9880126714706421
newborns O O 0.7527356743812561
? O O 0.9996732473373413

partly O O 0.985605776309967
blocked O O 0.9996203184127808
the O O 0.9999872446060181
calyculin B-protein B-protein 0.5711623430252075
A E-protein E-protein 0.9335271716117859
-induced O O 0.9853546619415283
STAT3 S-protein S-protein 0.8145272135734558
phosphorylation O O 0.9064193964004517
, O O 0.9996476173400879
whereas O O 0.9999934434890747
inhibitors O O 0.9950826168060303
of O O 0.9998757839202881
serine/threonine B-protein B-protein 0.46024683117866516
kinases E-protein E-protein 0.982559323310852
, O O 0.9937919974327087
such O O 0.999955415725708
as O O 0.9999620914459229
mitogen-activated B-protein B-protein 0.6422210335731506
protein I-protein I-protein 0.4816713035106659
kinase-1 I-protein I-protein 0.9495292901992798
extracellular-regulated I-protein I-protein 0.7186442613601685
kinase-kinase E-protein E-protein 0.7308095097541809
, O O 0.9732897281646729
mitogen-activated B-protein B-protein 0.6216108798980713
protein I-protein I-protein 0.6568121314048767
p38 I-protein I-protein 0.37724989652633667
kinase E-protein E-protein 0.9820815920829773
, O O 0.9853760600090027
and O O 0.9991422891616821
phosphatidylinositol B-protein B-protein 0.6017295122146606
3-kinase E-protein E-protein 0.9699295163154602
, O O 0.9906884431838989

GG O O 0.534725546836853
at O O 0.9992075562477112
0.1-10 O O 0.9390255212783813
micromol/L O O 0.907884955406189
enhanced O O 0.9932002425193787
NK O B-cell_line 0.4897766709327698
cell-mediated O I-cell_line 0.6662925481796265
K562 B-cell_line I-cell_line 0.3207971751689911
cancer I-cell_line I-cell_line 0.6450639963150024
cell E-cell_line I-cell_line 0.6295362710952759
killing O I-cell_line 0.5614086985588074

had O O 0.9978177547454834
a O O 0.9999681711196899
slightly O O 0.9958866238594055
higher O O 0.9980081915855408
promoter O O 0.4767979681491852
activity O O 0.9876874089241028
and O O 0.9998581409454346
viral O O 0.919221043586731
replication O O 0.9681994915008545
rate O O 0.9993095397949219
than O O 0.9999951124191284
the O O 0.9999558925628662
isogenic B-DNA B-DNA 0.5426964163780212
control I-DNA I-DNA 0.5016347765922546
LTR E-DNA E-DNA 0.9392587542533875
with O O 0.9993890523910522
three O O 0.9889969825744629

Tissue O O 0.7682183384895325
lipid O O 0.8126897811889648
peroxidation O O 0.4186291992664337
was O O 0.9997128844261169
measured O O 0.9999517202377319
in O O 0.9999768733978271
whole O O 0.9892693161964417
homogenates O O 0.5152010917663574
as O O 0.9990888833999634
well O O 0.9998084902763367
as O O 0.9999858140945435
in O O 0.9998397827148438
lipid O O 0.7490571141242981
extracts O O 0.80672687292099
from O O 0.9994294047355652
homogenates O O 0.4293896555900574
as O O 0.9991809725761414
thiobarbituric B-Chemical B-Chemical 0.8361659049987793
acid E-Chemical I-Chemical 0.9446573257446289
reactive O O 0.4071532189846039
substances O O 0.7231664657592773
. O O 0.9999533891677856

The O O 0.9995506405830383
mechanisms O O 0.9995580315589905
of O O 0.9998217225074768
sirolimus B-Chemical B-Chemical 0.9211598038673401
- O O 0.9240666031837463
associated O O 0.9900986552238464
proteinuria B-Disease B-Disease 0.9677554965019226
are O O 0.9854016304016113
multifactorial O O 0.8044188618659973
and O O 0.9903820157051086
may O O 0.9998447895050049
be O O 0.9999858140945435
due O O 0.999992847442627
to O O 0.9999802112579346
an O O 0.9998137354850769
increase O O 0.9426634907722473
in O O 0.9841752648353577
glomerular O O 0.9197827577590942
capillary O O 0.7969663739204407
pressure O O 0.8990561366081238
following O O 0.9999884366989136
calcineurin O O 0.698270320892334
inhibitor O O 0.6274980902671814
withdrawal O O 0.8570991158485413
. O O 0.9999862909317017

in O O 0.9945907592773438
NK3.3 B-cell_line B-cell_line 0.7814692258834839
cells E-cell_line E-cell_line 0.9805124998092651
compared O O 0.9995119571685791
with O O 0.9999901056289673
preactivated B-cell_line B-cell_type 0.5614923238754272
primary I-cell_line I-cell_type 0.37503689527511597
NK I-cell_line I-cell_type 0.6988207101821899
cells E-cell_line E-cell_type 0.7338192462921143
. O O 0.999804675579071
In O O 0.999830961227417
NK3.3 B-cell_line B-cell_line 0.4549534320831299

transcription O O 0.7671817541122437
. O O 0.9994822144508362
Liposomal O O 0.8920300602912903
transfection O O 0.9789738059043884
of O O 0.9998509883880615
a O O 0.9999006986618042
double-stranded O O 0.7071191072463989
kappaB O O 0.22165265679359436
phosphorothioate O O 0.3215300738811493
oligonucleotide O O 0.2766847312450409
, O O 0.9738030433654785
but O O 0.9995943903923035
not O O 0.9997566342353821
of O O 0.9999290704727173
the O O 0.9999454021453857
mutated O O 0.782285213470459
form O O 0.6950308680534363
, O O 0.9926398992538452
inhibited O O 0.994997501373291
MCP-1 S-protein S-protein 0.9233089685440063
secretion O O 0.9712754487991333
and O O 0.9996210336685181
surface O O 0.9523869156837463
expression O O 0.9946094751358032
of O O 0.9998775720596313
ICAM-1 S-protein S-protein 0.9007644057273865
on O O 0.9969915151596069
activated O O 0.8326149582862854
endothelium O O 0.7130864262580872
( O O 0.9940297603607178
P O O 0.9597080945968628
< O O 0.9972478747367859
0.05 O O 0.9984700083732605

These O O 0.9995786547660828
rats O O 0.9974683523178101
also O O 0.999991774559021
showed O O 0.9999850988388062
declines O O 0.7903618216514587
in O O 0.9614229798316956
left O O 0.9508368372917175
ventricular O O 0.945232629776001
systolic O O 0.9352961182594299
pressure O O 0.8331450819969177
, O O 0.9996293783187866
maximum O O 0.9979660511016846
and O O 0.9998718500137329
minimum O O 0.9988528490066528
rate O O 0.9998989105224609
of O O 0.999854326248169
developed O O 0.9959471821784973
left O O 0.9831297993659973
ventricular O O 0.936354398727417
pressure O O 0.5424134731292725
, O O 0.9965590834617615
and O O 0.9999195337295532
elevation O O 0.9148639440536499
of O O 0.986346423625946
left O O 0.9546530842781067
ventricular O O 0.922082245349884
end O O 0.9334174990653992
- O O 0.997739315032959
diastolic O O 0.9216610789299011
pressure O O 0.7785962820053101
and O O 0.9988721013069153
ST O O 0.6701244115829468
- O O 0.9475041627883911
segment O O 0.9910515546798706
. O O 0.9999982118606567

a O O 0.9982965588569641
small O O 0.979512095451355
, O O 0.9978019595146179
Ras-like B-protein B-protein 0.6172381043434143
GTPase E-protein E-protein 0.6682628989219666
whose O O 0.9838008284568787
function O O 0.9961955547332764
and O O 0.9998422861099243
regulation O O 0.9981899857521057
are O O 0.99998939037323
still O O 0.9999239444732666
largely O O 0.9992116689682007
unknown O O 0.999518632888794
. O O 0.9999978542327881
We O O 0.9999822378158569
have O O 0.9999910593032837
developed O O 0.9999654293060303
a O O 0.9999892711639404
novel O O 0.9821537733078003
assay O O 0.9935891628265381
to O O 0.9999788999557495
monitor O O 0.9999428987503052
the O O 0.9998216032981873
active O O 0.9472924470901489
, O O 0.9848900437355042
GTP-bound B-protein O 0.605324387550354
form E-protein O 0.5094093084335327
of O O 0.9889302849769592

with O O 0.9983260035514832
the O O 0.9999884366989136
induction O O 0.9982051849365234
of O O 0.999897837638855
Bcl-xL S-protein S-protein 0.9354546070098877
. O O 0.9996722936630249
Treatment O O 0.9997047781944275
of O O 0.9999508857727051
human B-cell_line B-cell_line 0.47238343954086304
promyelocytic I-cell_line I-cell_line 0.47687625885009766
leukemia I-cell_line I-cell_line 0.575249195098877
HL-60 I-cell_line I-cell_line 0.7776400446891785
cells E-cell_line E-cell_line 0.989517867565155
with O O 0.9998618364334106
phorbol O O 0.8952418565750122
esters O O 0.9568464756011963
ultimately O O 0.9999576807022095
induces O O 0.9999885559082031
the O O 0.9999580383300781
differentiation O O 0.9976668357849121
of O O 0.999944806098938
these O O 0.9994877576828003
cells O O 0.9403184056282043
along O O 0.9998177886009216

induction O O 0.9703622460365295
. O O 0.9999535083770752
To O O 0.9999933242797852
study O O 0.9999837875366211
the O O 0.9999865293502808
influence O O 0.9996805191040039
of O O 0.9999812841415405
NFkappaB S-protein S-protein 0.9957714676856995
activity O O 0.9988118410110474
on O O 0.9999791383743286
apoptosis O O 0.9309583902359009

the O O 0.9981112480163574
binding O O 0.9848735332489014
of O O 0.9996410608291626
ubiquitous B-protein O 0.8404874205589294
AP-1 I-protein B-protein 0.6895363330841064
factors E-protein E-protein 0.9563210010528564
to O O 0.9975571632385254
this O O 0.9996824264526367
element O O 0.6235518455505371
. O O 0.9999097585678101
TPA O O 0.4210681915283203
induction O O 0.9809455871582031
inhibits O O 0.9999328851699829
the O O 0.9999624490737915
binding O O 0.9937264919281006
of O O 0.999803364276886
the O O 0.9998425245285034
lineage B-protein B-protein 0.6822205781936646
limited I-protein I-protein 0.721660315990448
transcription I-protein I-protein 0.41293683648109436
factor E-protein E-protein 0.920769214630127
NF-E2 S-protein S-protein 0.615312933921814
to O O 0.9930140376091003

, O O 0.9395045638084412
K562 S-cell_line S-cell_line 0.7931181192398071
( O O 0.8046509027481079
erythroblasts S-cell_line S-cell_line 0.7978730797767639
) O O 0.38008883595466614
, O O 0.8994795083999634
and O O 0.9863167405128479
S-LB1 S-cell_line S-cell_line 0.8317447900772095
( O O 0.9503063559532166
HTLV-1-transfected B-cell_line B-cell_line 0.4610713720321655
T I-cell_line I-cell_line 0.569056510925293
lymphocytes E-cell_line E-cell_line 0.7966058254241943
) O O 0.9781985282897949
. O O 0.9999411106109619
Receptor B-RNA B-RNA 0.6459348797798157
transcripts E-RNA E-RNA 0.8944903016090393
were O O 0.9997512698173523
4.6 O O 0.9445381760597229
kilobases O O 0.8265674114227295
( O O 0.9976569414138794
kb O O 0.9752461314201355
) O O 0.9936872124671936
, O O 0.9999538660049438
and O O 0.9999730587005615
no O O 0.9996391534805298
variant O O 0.858794093132019
sizes O O 0.781243085861206
were O O 0.9998971223831177
observed O O 0.9998316764831543
. O O 0.9999977350234985
All O O 0.9974969029426575
cell O B-cell_line 0.7250463962554932
lines O E-cell_line 0.9772713780403137

CIITA S-protein S-protein 0.6873258948326111
was O O 0.9998140931129456
able O O 0.9999803304672241
to O O 0.9999909400939941
stimulate O O 0.9998891353607178
elongation O O 0.9926435351371765
of O O 0.9994499087333679
transcription O O 0.9310933351516724
. O O 0.9994674324989319
Overall O O 0.9998373985290527
the O O 0.9999765157699585
mechanism O O 0.9994975328445435
of O O 0.9999399185180664
transactivation O O 0.9889758825302124
by O O 0.9999926090240479
the O O 0.9997901320457458

and O O 0.9477782249450684

also O O 0.9782857894897461
enhanced O O 0.9964435696601868
. O O 0.9999855756759644
When O O 0.9999052286148071
isolated O O 0.6582515835762024
PBMC S-cell_type S-cell_type 0.8785288333892822
were O O 0.9996325969696045
first O O 0.9997877478599548
cultured O O 0.9993276596069336
for O O 0.9999953508377075
20 O O 0.9942225813865662
h O O 0.9839389324188232
in O O 0.9999353885650635
the O O 0.9999608993530273
presence O O 0.9990655779838562
of O O 0.9999731779098511
IL-10 S-protein S-protein 0.9726430773735046
on O O 0.9991827607154846
Teflon O O 0.334304541349411
to O O 0.9897884726524353
prevent O O 0.9992071986198425
adherence O O 0.9942521452903748
, O O 0.9998935461044312
washed O O 0.9863406419754028
to O O 0.9995303153991699
remove O O 0.9971107244491577
IL-10 S-protein S-protein 0.9651688933372498
and O O 0.9967300891876221
then O O 0.9993671774864197
further O O 0.999298095703125
cultured O O 0.9964041709899902
in O O 0.9998964071273804
plastic O O 0.7232926487922668
dishes O O 0.7196983695030212
for O O 0.9999420642852783
an O O 0.9999799728393555
additional O O 0.999163031578064
20 O O 0.9805296659469604
h O O 0.9700725078582764
in O O 0.9998461008071899
the O O 0.9999343156814575
presence O O 0.9980132579803467
of O O 0.999958872795105
LPS O O 0.8401509523391724
or O O 0.998878538608551
IL-1beta S-protein S-protein 0.8600555658340454
, O O 0.9981762170791626
an O O 0.99997878074646
enhanced O O 0.9859399795532227
release O O 0.9746454954147339

for O O 0.9979240894317627
biological O O 0.9874876737594604
effects O O 0.9996988773345947
of O O 0.999977707862854
isoflavones O O 0.5143394470214844
, O O 0.9995810389518738
such O O 0.9999898672103882
as O O 0.9999904632568359
estrogen O B-protein 0.5417922735214233
receptor O E-protein 0.8796237707138062
binding O O 0.72053462266922
and O O 0.9918069243431091
natural B-cell_type O 0.8196294903755188
killer I-cell_type O 0.536342203617096
cell E-cell_type O 0.6001443862915039
( O O 0.8048005104064941
NK O O 0.43159419298171997
) O O 0.44170618057250977
activation O O 0.8315483927726746
or O O 0.9973734617233276
inhibition O O 0.9716001152992249
. O O 0.9998286962509155
DG O O 0.4839269816875458
and O O 0.9327348470687866
GG O O 0.39179667830467224
were O O 0.9979152083396912
synthesized O O 0.999152421951294
using O O 0.9999104738235474

and O O 0.9783918261528015
Candida O O 0.976134181022644
albicans O O 0.9454172849655151
on O O 0.9999058246612549
HIV O O 0.8611167073249817
expression O O 0.9812397956848145
in O O 0.9998612403869629
monocytic B-cell_type B-cell_type 0.7232699394226074
cells E-cell_type E-cell_type 0.9524930119514465
was O O 0.9989892840385437
examined O O 0.9999092817306519
. O O 0.999997615814209
Stimulation O O 0.997554361820221
of O O 0.9999313354492188
the O O 0.9995772242546082
latently O B-cell_line 0.686112105846405
HIV-infected B-cell_line I-cell_line 0.5081486701965332
myelomonocytic I-cell_line I-cell_line 0.541149914264679
cell I-cell_line I-cell_line 0.9121231436729431
line E-cell_line I-cell_line 0.9410552382469177
OM-10.1 O E-cell_line 0.543578028678894
with O O 0.9978353381156921
C. O O 0.4466337561607361

family O E-protein 0.8927821516990662
and O O 0.9761101007461548
is O O 0.9998182654380798
known O O 0.9999858140945435
to O O 0.9999856948852539
be O O 0.999990701675415
an O O 0.9999890327453613
important O O 0.9992050528526306
step O O 0.9984575510025024
in O O 0.9999725818634033
NF-kappa B-protein B-protein 0.4978703260421753
B E-protein E-protein 0.987033486366272
activation O O 0.9963834285736084
in O O 0.9999747276306152

Methamphetamine B-Chemical B-Chemical 0.9234547019004822
( O O 0.9584640860557556
METH B-Chemical B-Chemical 0.9130868315696716
) O O 0.7356700301170349
damages O O 0.9634597301483154
dopamine B-Chemical B-Chemical 0.9184092879295349
( O O 0.9081686735153198
DA B-Chemical B-Chemical 0.9206763505935669
) O O 0.8255528211593628
nerve O O 0.49880990386009216
endings O O 0.538103461265564
by O O 0.9997178912162781
a O O 0.9999845027923584
process O O 0.9994933605194092
that O O 0.9999880790710449
has O O 0.9999673366546631
been O O 0.9997159838676453
linked O O 0.9999856948852539
to O O 0.9999899864196777
microglial O O 0.779156506061554
activation O O 0.658070981502533
but O O 0.9997164607048035
the O O 0.9999775886535645
signaling O O 0.9505488872528076
pathways O O 0.966151237487793
that O O 0.99997878074646
mediate O O 0.9994543194770813
this O O 0.9997703433036804
response O O 0.9978936314582825
have O O 0.99998939037323
not O O 0.9998946189880371
yet O O 0.9999808073043823
been O O 0.9998341798782349
delineated O O 0.9992595314979553
. O O 0.9999991655349731

were O O 0.9980265498161316
identified O O 0.9999600648880005
leading O O 0.9999582767486572
to O O 0.9999911785125732
the O O 0.9999878406524658
suggestion O O 0.9999591112136841
that O O 0.9999988079071045
the O O 0.999968409538269
expression O O 0.9985954165458679
of O O 0.9999382495880127
the O O 0.9998903274536133
gene O O 0.8727807402610779
encoding O O 0.942420244216919
for O O 0.9990826845169067
the O O 0.9999085664749146
nuclear B-protein B-protein 0.6396834254264832
autoantigen I-protein I-protein 0.46582600474357605
La/SS-B E-protein E-protein 0.8459161520004272
alters O O 0.5207106471061707
in O O 0.9991470575332642
dependence O O 0.9792670011520386
on O O 0.9998980760574341
disease O O 0.95074462890625
conditions O O 0.9971492886543274
. O O 0.999997615814209
Cross-linking O O 0.9707418084144592
CD40 S-protein S-protein 0.8927260041236877
on O O 0.9956485629081726
B B-cell_type B-cell_type 0.9067245125770569

pathways O O 0.8874683380126953
with O O 0.9999791383743286
differential O O 0.9797590970993042
sensitivity O O 0.9911054968833923
to O O 0.9999442100524902
Bcl-2 S-protein S-protein 0.9683716893196106
and O O 0.9966596364974976
interleukin-1beta-converting O B-protein 0.645541787147522
enzyme O I-protein 0.491183876991272
family O I-protein 0.4791446626186371
protease O E-protein 0.7168810963630676
inhibitors O O 0.7506137490272522
. O O 0.9993829727172852
Since O O 0.9997888207435608
T B-cell_type B-cell_type 0.7742842435836792
cells E-cell_type E-cell_type 0.9801756739616394
normally O O 0.9955850839614868
express O O 0.9993828535079956
Bcl-2 S-protein S-protein 0.9843901991844177
and O O 0.9942368268966675
Bcl-xL S-protein S-protein 0.9904962778091431
following O O 0.999255359172821
activation O O 0.996260941028595
, O O 0.9999896287918091
their O O 0.9999890327453613
inability O O 0.9980752468109131
to O O 0.9999490976333618
block O O 0.9993979930877686
Fas S-protein S-protein 0.9982439279556274
-mediated O O 0.990740180015564
apoptosis O O 0.9793503880500793
may O O 0.9999945163726807
allow O O 0.9999921321868896
for O O 0.9999634027481079

product E-protein E-protein 0.8984653353691101
. O O 0.9996968507766724
The O O 0.9999648332595825
NF-kappa B-protein B-protein 0.659925639629364
B I-protein I-protein 0.5772979259490967
p65 I-protein I-protein 0.4629000425338745
subunit E-protein E-protein 0.9951961636543274
provides O O 0.9996293783187866
the O O 0.9999828338623047
transactivation O O 0.8798098564147949
activity O O 0.9868039488792419
in O O 0.9999516010284424
this O O 0.9998760223388672
complex O O 0.7685127854347229
and O O 0.9775764346122742
serves O O 0.9991663694381714
as O O 0.999990701675415
an O O 0.9999686479568481
intracellular O O 0.7805033922195435
receptor O O 0.7869532704353333
for O O 0.9882319569587708
a O O 0.99981290102005
cytoplasmic O O 0.5737971663475037
inhibitor O O 0.7527918219566345
of O O 0.9625447392463684
NF-kappa B-protein B-protein 0.7134426236152649

. O O 0.9962537288665771
The O O 0.9999953508377075
results O O 0.9998149275779724
are O O 0.9999970197677612
discussed O O 0.9999935626983643
in O O 0.9999964237213135
the O O 0.999997615814209
context O O 0.9999414682388306
of O O 0.9999961853027344
a O O 0.9999808073043823
model O O 0.9890044331550598
relating O O 0.9998486042022705
the O O 0.9999827146530151
two O O 0.9873435497283936
nuclear O B-protein 0.750528872013092
NF-AT B-protein I-protein 0.46433180570602417
complexes E-protein E-protein 0.9930928945541382
to O O 0.9974539875984192
NF-ATp S-protein S-protein 0.9765577912330627
. O O 0.9998992681503296
Cell O O 0.9500179290771484
cycle O O 0.9676326513290405
analysis O O 0.9992977380752563
of O O 0.9999768733978271
E2F S-protein S-protein 0.6456140279769897

fibroblasts S-cell_type E-cell_type 0.7670506834983826
. O O 0.9996975660324097
This O O 0.9999821186065674
differential O O 0.9759868383407593
expression O O 0.9636431336402893
model O O 0.9720252156257629
will O O 0.9999951124191284
be O O 0.9999969005584717
valuable O O 0.9997902512550354
in O O 0.9999946355819702
the O O 0.999984860420227
dissection O O 0.9965307116508484
of O O 0.9999377727508545
the O O 0.9999648332595825
dual O O 0.8159092664718628
signal O O 0.8985684514045715
pathway O O 0.9950443506240845
in O O 0.9998929500579834
T B-cell_type B-cell_type 0.8375737071037292
cells E-cell_type E-cell_type 0.9745104908943176

effects O O 0.9981428384780884
of O O 0.9999881982803345
okadaic O O 0.8731585741043091
acid O O 0.9282816052436829
on O O 0.9998854398727417
TNF-alpha B-RNA B-RNA 0.5094617009162903
mRNA E-RNA E-RNA 0.9375539422035217
levels O O 0.9955683350563049
. O O 0.9999980926513672
Treatment O O 0.9996190071105957
with O O 0.9999822378158569
okadaic O O 0.8630658984184265
acid O O 0.9410812258720398
resulted O O 0.9999274015426636
in O O 0.9999877214431763
a O O 0.9999699592590332
striking O O 0.9857860803604126
increase O O 0.9956172704696655
in O O 0.9993711113929749
TNF-alpha B-RNA B-RNA 0.7782132625579834
mRNA E-RNA I-RNA 0.5209521055221558
transcripts O E-RNA 0.9842462539672852
within O O 0.9995550513267517
1 O O 0.99138343334198
h O O 0.9900630116462708
of O O 0.9996205568313599
stimulation O O 0.9755645990371704
and O O 0.9997351765632629
large O O 0.9775000214576721
amounts O O 0.9987488985061646
of O O 0.9999513626098633
TNF-alpha S-protein S-protein 0.9829879999160767
were O O 0.9994205236434937
released O O 0.9999386072158813
into O O 0.9999653100967407
the O O 0.9997374415397644
culture O O 0.9693902730941772
media O O 0.9931548833847046
. O O 0.9999966621398926
Although O O 0.999992847442627
okadaic O O 0.9488770365715027
acid O O 0.9771966934204102
provides O O 0.9999504089355469
a O O 0.9999890327453613
potent O O 0.9902774095535278
inductive O O 0.8879784345626831
signal O O 0.9659485220909119

its O O 0.9946957230567932

cells E-cell_type E-cell_type 0.727277934551239
( O O 0.9961569905281067
Bob1/OBF-1/OCA-B S-protein S-protein 0.5982733368873596
) O O 0.9250001311302185
represent O O 0.9999347925186157
two O O 0.9991074204444885
B B-protein B-protein 0.5969427824020386
cell-specific I-protein I-protein 0.39980798959732056
transcriptional I-protein I-protein 0.5925942063331604
coactivators E-protein E-protein 0.9490481615066528
. O O 0.9985538125038147
CIITA S-protein S-protein 0.8068364262580872
and O O 0.9729549884796143
Bob1 S-protein S-protein 0.9173065423965454
interact O O 0.998251736164093
with O O 0.9999508857727051
proteins O O 0.8415926098823547
that O O 0.9991827607154846
bind O O 0.9996108412742615
to O O 0.9999548196792603
conserved B-DNA O 0.8828294277191162
upstream I-DNA B-DNA 0.46352824568748474
sequences E-DNA E-DNA 0.9303417801856995
in O O 0.9994189739227295
promoters S-DNA S-DNA 0.9087784886360168
of O O 0.9985159039497375
class B-DNA B-DNA 0.4319252073764801
II I-DNA I-DNA 0.5218325853347778
major I-DNA I-DNA 0.7698009610176086
histocompatibility I-DNA I-DNA 0.8875148296356201
genes E-DNA E-DNA 0.9921470284461975
and O O 0.995724081993103
octamer-binding B-protein B-protein 0.3068851828575134
transcription I-protein I-protein 0.6687227487564087
factors E-protein E-protein 0.9903644919395447
Oct-1 S-protein S-protein 0.9799067378044128
and O O 0.9949548840522766
Oct-2 S-protein S-protein 0.9738094806671143

This O O 0.9996780157089233
low O O 0.9908170700073242
percentage O O 0.9982333183288574
( O O 0.9999798536300659
5 O O 0.9999531507492065
% O O 0.9999068975448608
) O O 0.9998332262039185
of O O 0.9999620914459229
TDFS O B-Chemical 0.7862410545349121
must O O 0.9977812170982361
be O O 0.9999901056289673
evaluated O O 0.9999909400939941
with O O 0.9999969005584717
respect O O 0.9998086094856262
to O O 0.9999959468841553
the O O 0.9999402761459351
efficacy O O 0.9973861575126648
of O O 0.9997147917747498
ifosfamide B-Chemical B-Chemical 0.9289592504501343
in O O 0.997867226600647
the O O 0.9998034834861755
treatment O O 0.9994189739227295
of O O 0.9999845027923584
mesenchymal B-Disease B-Disease 0.687231719493866
tumors I-Disease I-Disease 0.9178094863891602
in O O 0.9829851984977722
children O O 0.9993089437484741
. O O 0.9999990463256836

activation O O 0.9634504318237305
. O O 0.9999145269393921
Mutation O O 0.9955151677131653
of O O 0.9998080134391785
Ser184 O O 0.35386228561401367
also O O 0.9856958985328674
diminished O O 0.9954842329025269
transactivation O O 0.9620153903961182
function O O 0.9950516819953918
in O O 0.9998175501823425
B B-cell_type B-cell_type 0.9220142960548401
cells E-cell_type E-cell_type 0.984228253364563
, O O 0.9974157810211182
suggesting O O 0.9999914169311523
that O O 0.9999889135360718
the O O 0.9998180270195007
activating O O 0.6902680397033691

The O O 0.996809184551239
[ O O 0.9755659699440002
verapamil B-Chemical B-Chemical 0.8746825456619263
] O O 0.58701491355896
o O O 0.787714958190918
that O O 0.9959115982055664
arrested O O 0.9840412139892578
atrial O O 0.6728775501251221
beating O O 0.7801908254623413
( O O 0.9920511841773987
AC O O 0.5851157307624817
) O O 0.9487545490264893
was O O 0.9999539852142334
also O O 0.999991774559021
potentiated O O 0.9999583959579468
with O O 0.9999963045120239
the O O 0.9999644756317139
order O O 0.9774869084358215
LNa O O 0.7557487487792969
= O O 0.9858200550079346
LNa O B-Chemical 0.8989062905311584
+ O O 0.9367737174034119
LCa O O 0.8216151595115662
= O O 0.9649702310562134
LNa O O 0.8726341724395752
+ O O 0.9624857306480408
HCa O O 0.8727996945381165
= O O 0.9501467347145081
LCa O O 0.800813615322113
> O O 0.9892252087593079
HCa O O 0.7481622099876404
= O O 0.9967600703239441
N O O 0.7125235795974731
. O O 0.9999228715896606

In O O 0.9993649125099182
conclusion O O 0.9993820190429688
, O O 0.9999982118606567
ENaC O O 0.8544979691505432
mRNA O O 0.904335618019104
expression O O 0.9790282845497131
, O O 0.9999661445617676
especially O O 0.9999103546142578
alphaENaC O O 0.3737854063510895
, O O 0.9974300265312195
is O O 0.9999793767929077
increased O O 0.9991869330406189
in O O 0.9999624490737915
the O O 0.9999176263809204
very O O 0.9995675683021545
early O O 0.9982927441596985
phase O O 0.9999607801437378
of O O 0.9999313354492188
the O O 0.9999499320983887
experimental O O 0.9561238288879395
model O O 0.99720698595047
of O O 0.99954754114151
PAN B-Chemical B-Chemical 0.9122527241706848
- O O 0.9591469168663025
induced O O 0.9993916749954224
nephrotic B-Disease B-Disease 0.7607349753379822
syndrome I-Disease I-Disease 0.9904692769050598
in O O 0.9784123301506042
rats O O 0.978687584400177
, O O 0.9998238682746887
but O O 0.9999133348464966
appears O O 0.9996986389160156
to O O 0.9995143413543701
escape O O 0.9651474356651306
from O O 0.9996291399002075
the O O 0.9997383952140808
regulation O O 0.9948887228965759
by O O 0.9999809265136719
aldosterone B-Chemical B-Chemical 0.9065520167350769
after O O 0.9993382096290588
day O O 0.9992165565490723
3 O O 0.9986528158187866
. O O 0.9999971389770508

surface O O 0.7744753360748291

on O O 0.9971593618392944
cellular O O 0.9779213070869446
uptake O O 0.9977315068244934
of O O 0.9999771118164062
LPS O O 0.8689593076705933
and O O 0.998114824295044
LPS-induced O O 0.878394365310669
proinflammatory O O 0.8510845303535461
functions O O 0.9809331893920898
. O O 0.9999910593032837
Human B-cell_type B-cell_type 0.609806478023529
phagocytes E-cell_type E-cell_type 0.9596520066261292
recognize O O 0.9991106390953064

17beta B-Chemical B-Chemical 0.9451815485954285
- I-Chemical I-Chemical 0.9885899424552917
Estradiol I-Chemical I-Chemical 0.951739490032196
reduced O O 0.9840519428253174
the O O 0.9982972741127014
argyrophilic O O 0.6248272657394409
neurons O O 0.5880880355834961
in O O 0.999479353427887
the O O 0.9998292922973633
CA1 O O 0.7842432260513306
and O O 0.9950397610664368
CA3 O O 0.8781930208206177
- O O 0.9941469430923462
C O O 0.9748255610466003
sectors O O 0.9976046085357666
of O O 0.9999278783798218
ovariectomized O O 0.6721936464309692
rats O O 0.9539655447006226
. O O 0.999996542930603

directly O O 0.9736829996109009
to O O 0.9998995065689087
the O O 0.9999115467071533
tyrosine O O 0.6795281767845154
phosphorylation O O 0.5605472326278687
of O O 0.9655359387397766
p80c-rel S-protein S-protein 0.9719484448432922
. O O 0.9989941716194153
Thus O O 0.9990200996398926
, O O 0.9999423027038574
the O O 0.9999582767486572
tyrosine B-protein B-protein 0.5616521239280701
kinase E-protein E-protein 0.9215619564056396
activated O O 0.9531941413879395
by O O 0.9997064471244812
G-CSF S-protein S-protein 0.784492552280426

METHODS O O 0.9835764765739441
: O O 0.9997668862342834
Tremor O B-Disease 0.9683020710945129
was O O 0.9512802362442017
measured O O 0.9995181560516357
using O O 0.9999955892562866
a O O 0.9999299049377441
laser O O 0.928274393081665
pointer O O 0.8672569394111633
technique O O 0.9890643954277039
. O O 0.9999988079071045

of O O 0.996791660785675
a O O 0.9998853206634521
repressor S-protein O 0.7090029716491699
from O O 0.9990378618240356
that O O 0.9999697208404541
same O O 0.999786913394928
site O O 0.9836320877075195
. O O 0.9999821186065674
We O O 0.999971866607666
have O O 0.9999946355819702
identified O O 0.9999810457229614
a O O 0.999935507774353
`` B-protein B-protein 0.7801222801208496
two-handed I-protein I-protein 0.6582854986190796
'' I-protein I-protein 0.6685609221458435
zinc I-protein I-protein 0.539945662021637
finger I-protein I-protein 0.7178831100463867
protein E-protein E-protein 0.9862761497497559
, O O 0.9948337078094482
denoted O O 0.993756890296936
ZEB S-protein S-protein 0.7244861125946045
, O O 0.9891719222068787
the O O 0.9989575147628784

BACKGROUND O O 0.9873342514038086
: O O 0.999616265296936
TEE O O 0.7400945425033569
is O O 0.9979648590087891
a O O 0.9999901056289673
semi O O 0.9824305772781372
- O O 0.9988552331924438
invasive O O 0.9833400845527649
tool O O 0.9942761063575745
broadly O O 0.9990412592887878
used O O 0.9999867677688599
and O O 0.9999845027923584
its O O 0.9999068975448608
utilization O O 0.9917448163032532
associated O O 0.9997808337211609
to O O 0.9999192953109741
sedatives O O 0.7273763418197632
drugs O O 0.840794026851654
might O O 0.9992479681968689
to O O 0.9999819993972778
affect O O 0.9999831914901733
the O O 0.9997318387031555
procedure O O 0.9978895783424377
safety O O 0.9887939095497131
. O O 0.9999980926513672

modulation O O 0.9486766457557678

no O O 0.9962183833122253
intrinsic O O 0.9733533263206482
DNA-binding O O 0.857097864151001
activity O O 0.9959516525268555
and O O 0.9999443292617798
recognizes O O 0.9999517202377319
the O O 0.999958872795105
POU B-protein B-protein 0.38244616985321045
domains E-protein E-protein 0.835222065448761
of O O 0.9874130487442017
Oct-1 S-protein S-protein 0.9929499626159668
and O O 0.9932976365089417
Oct-2 S-protein S-protein 0.9936256408691406
, O O 0.9959874749183655
but O O 0.9998809099197388
not O O 0.999777615070343
those O O 0.9999463558197021
of O O 0.9996119141578674
Oct-4 S-protein S-protein 0.9912844896316528
and O O 0.9914926886558533
Oct-6 S-protein S-protein 0.9879897236824036
. O O 0.9998461008071899
The O O 0.999902606010437
OBF-1 B-RNA S-protein 0.5599601864814758

cycloheximide O O 0.44485101103782654
displayed O O 0.9997835755348206
a O O 0.9999865293502808
similar O O 0.9991822838783264
capacity O O 0.9994654059410095
to O O 0.9999929666519165
enhance O O 0.9995536208152771
TNF-alpha S-protein S-protein 0.9781770706176758
induced O O 0.9954342246055603
neutrophil O O 0.7358431816101074
apoptosis O O 0.9106820225715637

through O O 0.9990839958190918
a O O 0.9999852180480957
common O O 0.9782871603965759
mechanism O O 0.996966540813446
involving O O 0.9999959468841553
the O O 0.9999741315841675
synthesis O O 0.9852140545845032
of O O 0.9995670914649963
ROI O S-DNA 0.6854865550994873
. O O 0.9976658821105957
ROI O O 0.33550897240638733
appear O O 0.9935210347175598
to O O 0.9999527931213379
serve O O 0.9999786615371704
as O O 0.9999711513519287
messengers O O 0.6748650074005127
mediating O O 0.9906718730926514
directly O O 0.9986823201179504
or O O 0.9998406171798706
indirectly O O 0.9994893074035645
the O O 0.9999765157699585
release O O 0.9786608219146729
of O O 0.9995343685150146
the O O 0.999895453453064
inhibitory B-protein B-protein 0.47991055250167847
subunit E-protein E-protein 0.8900582194328308
I B-protein B-protein 0.6004578471183777
kappa I-protein I-protein 0.9304528832435608
B E-protein E-protein 0.9553248286247253
from O O 0.9931858777999878
NF-kappa B-protein B-protein 0.7553527355194092
B E-protein E-protein 0.9578611850738525
. O O 0.9984142780303955
Inhibition O O 0.9900494813919067
of O O 0.9987665414810181

growth O O 0.9142599105834961
arrest O O 0.9885157346725464
, O O 0.9998887777328491
and O O 0.9999468326568604
expression O O 0.9976919889450073
of O O 0.9999299049377441
the O O 0.999776303768158
c-fms B-DNA B-DNA 0.6463558673858643
gene E-DNA E-DNA 0.9795836806297302
. O O 0.9996306896209717
Studies O O 0.9998931884765625
were O O 0.9999927282333374
also O O 0.9999871253967285
performed O O 0.9999833106994629
with O O 0.9999912977218628
an O O 0.9997050166130066
HL-60/vinc B-cell_line B-cell_line 0.5843930840492249
revertant E-cell_line I-cell_line 0.7469260096549988
( O I-cell_line 0.8745387196540833
HL-60/vinc/R S-cell_line I-cell_line 0.9753339290618896
) O I-cell_line 0.9641673564910889
line O E-cell_line 0.8895577788352966

The O O 0.9995372295379639
basal O O 0.9262728691101074
tone O O 0.943077027797699
of O O 0.9988411068916321
the O O 0.999955415725708
right O O 0.9921032786369324
coronary O O 0.9056062698364258
artery O O 0.38740578293800354
was O O 0.9995599389076233
significantly O O 0.9998698234558105
lower O O 0.9994992017745972
than O O 0.9999843835830688
that O O 0.9999558925628662
of O O 0.9995325803756714
the O O 0.9997748732566833
left O O 0.962486207485199
coronary O O 0.9150424599647522
artery O O 0.7829970717430115
. O O 0.9999891519546509

Based O O 0.9990697503089905
on O O 0.999984860420227
a O O 0.9999617338180542
score O O 0.9993818998336792
of O O 0.9999587535858154
8 O O 0.9912576675415039
on O O 0.9999690055847168
the O O 0.9999110698699951
Naranjo O O 0.730332612991333
adverse O O 0.699955940246582
drug O O 0.6262466907501221
reaction O O 0.7199707627296448
probability O O 0.6053944230079651
scale O O 0.8964611887931824
, O O 0.9999258518218994
telithromycin S-Chemical B-Chemical 0.9284171462059021
was O O 0.9992398023605347
the O O 0.9999935626983643
probable O O 0.9990423321723938
cause O O 0.9997418522834778
of O O 0.9999635219573975
acute O O 0.6909949779510498
hepatitis O O 0.5842366218566895
in O O 0.9755812883377075
this O O 0.9981600642204285
patient O O 0.9911131262779236
, O O 0.9999212026596069
and O O 0.9999473094940186
pathological O O 0.8432397246360779
findings O O 0.9088752865791321
suggested O O 0.9988484382629395
drug O O 0.8974417448043823
- O O 0.9730290770530701
induced O O 0.9977923631668091
toxic O B-Disease 0.5236982703208923
hepatitis O I-Disease 0.8147621154785156
. O O 0.9976033568382263

rapamycin O O 0.5380799770355225
, O O 0.9994982481002808
an O O 0.9999783039093018
inhibitor O O 0.9863216876983643
of O O 0.9994475245475769
pp70S6K S-protein S-protein 0.9329015612602234
activation O O 0.9844919443130493
, O O 0.9997172951698303
had O O 0.9999737739562988
no O O 0.9999711513519287
effect O O 0.9999308586120605
on O O 0.999984860420227
induction O O 0.9955344200134277
of O O 0.9998528957366943
EGR-1 S-DNA S-protein 0.6769396066665649
expression O O 0.9925103187561035
. O O 0.9999890327453613
In O O 0.9999364614486694
contrast O O 0.9975467324256897
, O O 0.9999797344207764
analysis O O 0.999723494052887
of O O 0.9999518394470215
pp90rsk S-protein S-protein 0.8278682231903076
activity O O 0.9972104430198669
by O O 0.9999812841415405
phosphorylation O O 0.9308512210845947
of O O 0.9972562193870544
a O O 0.9925829172134399

We O O 0.9988740086555481
used O O 0.9999948740005493
an O O 0.9999850988388062
in O O 0.998843789100647
vitro O O 0.9794712662696838
model O O 0.9970570802688599
of O O 0.9999196529388428
chemotherapy O O 0.6752592921257019
induced O O 0.9606379866600037
peripheral B-Disease B-Disease 0.566970705986023
neuropathy I-Disease I-Disease 0.924943208694458
that O O 0.9805396795272827
closely O O 0.9973379969596863
mimic O O 0.9978141784667969
the O O 0.9992296695709229
in O O 0.9995249509811401
vivo O O 0.8748956322669983
condition O O 0.7486264705657959
by O O 0.9999463558197021
exposing O O 0.9985772371292114
primary O O 0.8461209535598755
cultures O O 0.9307963848114014
of O O 0.9996898174285889
dorsal O O 0.9113486409187317
root O O 0.8516459465026855
ganglion O O 0.4497365653514862
( O O 0.9981409311294556
DRG O O 0.40111956000328064
) O O 0.9617624878883362
sensory O O 0.8806406855583191
neurons O O 0.6764846444129944
to O O 0.9993461966514587
paclitaxel B-Chemical B-Chemical 0.9220775365829468
and O O 0.9325734376907349
cisplatin B-Chemical B-Chemical 0.9239166378974915
, O O 0.9940781593322754
two O O 0.9992930889129639
widely O O 0.9592586755752563
used O O 0.994621992111206
and O O 0.9991909861564636
highly O O 0.9731712937355042
effective O O 0.980144739151001
chemotherapeutic O O 0.821969747543335
drugs O O 0.9094101190567017
. O O 0.9999929666519165

to O O 0.9930318593978882
be O O 0.9994016885757446
expressed O O 0.9992395639419556
by O O 0.9999476671218872
mesenchymal B-cell_type B-cell_type 0.7058802247047424
cells E-cell_type E-cell_type 0.9698117971420288
, O O 0.9984056353569031
including O O 0.9999459981918335
human B-cell_type B-cell_type 0.5102553963661194
fibroblasts E-cell_type E-cell_type 0.9891848564147949
. O O 0.9997888207435608
Little O O 0.9996212720870972
is O O 0.9999823570251465
known O O 0.9999933242797852
about O O 0.9999972581863403
the O O 0.9999880790710449
role O O 0.9989482760429382
of O O 0.9998487234115601
CD40 S-protein S-protein 0.9700244069099426
in O O 0.9987030029296875

isolated O O 0.8354125618934631

This O O 0.9996551275253296
is O O 0.9999973773956299
the O O 0.9999972581863403
first O O 0.9998027682304382
case O O 0.9989823698997498
report O O 0.9997805953025818
of O O 0.9994493126869202
pseudoacromegaly O B-Chemical 0.6932345628738403
as O O 0.9931806325912476
a O O 0.9999353885650635
side O O 0.9919818043708801
effect O O 0.9995836615562439
of O O 0.9998152852058411
minoxidil S-Chemical B-Chemical 0.9319060444831848
use O O 0.8512694835662842
. O O 0.9999980926513672

0.20 O O 0.9567047357559204
fmol/10 O O 0.9816330671310425
( O O 0.9994920492172241
6 O O 0.9993701577186584
) O O 0.995844304561615
cells O O 0.933513343334198
) O O 0.999824583530426
. O O 0.9999932050704956
Conversely O O 0.9997791647911072
, O O 0.9998792409896851
glucocorticoid B-protein B-protein 0.590498149394989
receptor E-protein E-protein 0.9396951794624329
affinity O O 0.9386869668960571
was O O 0.9999701976776123
significantly O O 0.9999215602874756
decreased O O 0.9996638298034668
in O O 0.9999496936798096
anorexia O O 0.8823277950286865

. O O 0.9965881109237671
In O O 0.9999943971633911
this O O 0.9999953508377075
report O O 0.9998119473457336
, O O 0.9999935626983643
we O O 0.9999923706054688
describe O O 0.9999938011169434
the O O 0.9999867677688599
cloning O O 0.9654154777526855
of O O 0.9990211725234985
human B-protein B-protein 0.33006641268730164
GATA-4 E-protein E-protein 0.9260066151618958
( O O 0.9392231702804565
hGATA-4 S-protein S-protein 0.7612113952636719
) O O 0.9679094552993774
and O O 0.9985816478729248

Visual O O 0.8134129047393799
and O O 0.9356838464736938
auditory O O 0.7467076182365417
neurotoxicity O O 0.5128241777420044
was O O 0.9970001578330994
previously O O 0.9999594688415527
documented O O 0.9999899864196777
in O O 0.9999932050704956
42 O O 0.9995763897895813
of O O 0.9999593496322632
89 O O 0.9974988102912903
patients O O 0.9997671246528625
with O O 0.9999691247940063
transfusion O O 0.7568528652191162
- O O 0.8535991907119751
dependent O O 0.9483654499053955
anemia O B-Disease 0.9513788819313049
who O O 0.9699792861938477
were O O 0.9999423027038574
receiving O O 0.9999631643295288
iron S-Chemical B-Chemical 0.8935748338699341
chelation O I-Chemical 0.9447296857833862
therapy O O 0.9888399243354797
with O O 0.999996542930603
daily O O 0.979060173034668
subcutaneous O O 0.9348558187484741
deferoxamine S-Chemical B-Chemical 0.9274554252624512
. O O 0.9995365142822266

Long O O 0.9035142064094543
- O O 0.9945236444473267
term O O 0.9985380172729492
follow O O 0.9946644306182861
- O O 0.9979286193847656
up O O 0.9999309778213501
of O O 0.9997954964637756
ifosfamide S-Chemical B-Chemical 0.913587212562561
renal O B-Disease 0.437595009803772
toxicity O I-Disease 0.8761641979217529
in O O 0.9745298624038696
children O O 0.9976309537887573
treated O O 0.9999890327453613
for O O 0.9999865293502808
malignant O O 0.6897158026695251
mesenchymal O O 0.41917791962623596
tumors O O 0.8708745241165161
: O O 0.9977989792823792
an O O 0.9999973773956299
International O O 0.9933522939682007
Society O O 0.9908663630485535
of O O 0.9998195767402649
Pediatric O O 0.927325427532196
Oncology O O 0.8581967353820801
report O O 0.9986178874969482
. O O 0.9999992847442627

Light O O 0.8865645527839661
microscopic O O 0.9421055912971497
analysis O O 0.986220121383667
showed O O 0.9999957084655762
a O O 0.9999856948852539
significant O O 0.999629020690918
protection O O 0.9942330718040466
against O O 0.9998594522476196
ADR B-Chemical B-Chemical 0.9022226333618164
- O O 0.9847848415374756
induced O O 0.9987581968307495
cardiac B-Disease O 0.707048237323761
morphological I-Disease O 0.5042712092399597
alterations I-Disease O 0.7155693173408508
. O O 0.9998905658721924

pretreated O O 0.9877903461456299
with O O 0.9998729228973389
dimaprit O O 0.5337735414505005
showed O O 0.9999417066574097
a O O 0.999977707862854
decrease O O 0.9979464411735535
in O O 0.9998989105224609
the O O 0.9998582601547241
cAMP O O 0.589026927947998
response O O 0.9755406975746155
to O O 0.9998763799667358
subsequent O O 0.9990504384040833
addition O O 0.9997907280921936
of O O 0.9999769926071167
H2 O O 0.6432249546051025
agonists O O 0.6818374991416931
, O O 0.9997885823249817
whereas O O 0.999997615814209
the O O 0.999975323677063
cAMP O O 0.6973033547401428
response O O 0.9820859432220459
to O O 0.9997742772102356
prostaglandin O O 0.7000179290771484
E2 O O 0.3470991253852844
remained O O 0.9982896447181702
unaltered O O 0.9993133544921875
. O O 0.9999990463256836
This O O 0.9999884366989136
homologous O O 0.9379723072052002
mechanism O O 0.9942839741706848
of O O 0.9999452829360962
H2 B-protein O 0.6573542356491089
receptor E-protein O 0.6650774478912354
desensitization O O 0.9890767335891724
was O O 0.9999954700469971
time O O 0.9961997866630554

Patients O O 0.9954980611801147
who O O 0.9999616146087646
present O O 0.9999668598175049
with O O 0.999875545501709
stress O B-Disease 0.671256959438324
incontinence O I-Disease 0.9701087474822998
while O O 0.9965093731880188
taking O O 0.999342143535614
prazosin S-Chemical B-Chemical 0.934598445892334
should O O 0.9996658563613892
change O O 0.9999736547470093
their O O 0.9998730421066284
antihypertensive O O 0.6804317831993103
medication O O 0.874542772769928
before O O 0.9999797344207764
considering O O 0.9999778270721436
surgery O O 0.9791101813316345
, O O 0.9999735355377197
because O O 0.9999936819076538
their O O 0.9997915625572205
incontinence O B-Disease 0.9554032683372498
may O O 0.9869807362556458
resolve O O 0.9979904890060425
spontaneously O O 0.9586277008056641
with O O 0.9999438524246216
a O O 0.9997838139533997
change O O 0.9973340034484863
in O O 0.9997599720954895
drug O O 0.9276425838470459
therapy O O 0.9678910374641418
. O O 0.9999985694885254

B I-cell_type B-cell_type 0.2752472758293152
cells E-cell_type E-cell_type 0.8806299567222595
. O O 0.9995483756065369
The O O 0.9999945163726807
activation O O 0.9894595146179199
is O O 0.9998262524604797
rapid O O 0.990368127822876
and O O 0.9985867738723755
transient O O 0.9738359451293945
and O O 0.9994798302650452
is O O 0.9999659061431885
mediated O O 0.999518871307373
through O O 0.9999933242797852
a O O 0.9999023675918579
cyclosporin O O 0.49980440735816956
A-insensitive O O 0.5105834603309631
pathway O O 0.9657617807388306
. O O 0.9999891519546509
Furthermore O O 0.9999942779541016
, O O 0.999993085861206
this O O 0.99996018409729
signaling O O 0.9628442525863647
pathway O O 0.9978514909744263
appears O O 0.9999903440475464
not O O 0.9999892711639404
to O O 0.999975323677063
rely O O 0.9999769926071167
on O O 0.9999042749404907
protein B-protein O 0.8233058452606201

addition O O 0.9846519231796265
, O O 0.999975323677063
two O O 0.9994789958000183
mutations O O 0.9766373634338379
between O O 0.9997469782829285
-93 B-DNA B-DNA 0.438407838344574
and I-DNA I-DNA 0.5170406103134155
-76 E-DNA E-DNA 0.6506823301315308
and O O 0.9074361324310303
between O O 0.9879927635192871
-75 B-DNA B-DNA 0.6402991414070129
and I-DNA I-DNA 0.7732276320457458
-58 E-DNA E-DNA 0.5654625296592712
were O O 0.9865918755531311
utilized O O 0.9983524084091187
, O O 0.9999631643295288
since O O 0.9999958276748657
they O O 0.999988317489624
affect O O 0.9999879598617554
the O O 0.9998190999031067
nuclear B-DNA B-protein 0.8157207369804382
factor I-DNA I-protein 0.5118520259857178
kappa I-DNA I-protein 0.5088958144187927
B I-DNA E-protein 0.8831345438957214
( I-DNA O 0.8718809485435486
NF-kappa I-DNA B-protein 0.3181609511375427
B I-DNA E-protein 0.8413944840431213
) I-DNA O 0.46381524205207825
- I-DNA O 0.7967298626899719
and I-DNA O 0.9260434508323669
Sp1-binding I-DNA B-DNA 0.26893267035484314
sites E-DNA E-DNA 0.872840940952301
and O O 0.9971188306808472
were O O 0.9999685287475586
expected O O 0.9999771118164062
to O O 0.9999806880950928
diminish O O 0.999519944190979
viral O O 0.9341477155685425
replication O O 0.9787565469741821
. O O 0.9999940395355225
Our O O 0.999997615814209
results O O 0.9999629259109497
suggest O O 0.9999973773956299
that O O 0.9999972581863403
while O O 0.9999374151229858
transfection O O 0.9482780694961548
analyses O O 0.9818165302276611
offer O O 0.9999973773956299
an O O 0.9999947547912598
adequate O O 0.9981860518455505
approximation O O 0.9982324242591858
of O O 0.9999600648880005
the O O 0.9999521970748901
effects O O 0.9998742341995239
of O O 0.9999791383743286
the O O 0.9999001026153564

. O O 0.9861313104629517
Cortivazol O O 0.5969861745834351
mediated O O 0.989436149597168
induction O O 0.9979981780052185
of O O 0.9999281167984009
glucocorticoid B-RNA B-protein 0.6907320022583008
receptor I-RNA E-protein 0.896673858165741
messenger I-RNA O 0.5863139033317566
ribonucleic I-RNA O 0.8018759489059448
acid E-RNA O 0.902880847454071
in O O 0.9997251629829407
wild-type S-cell_line B-cell_line 0.32655099034309387
and O I-cell_line 0.5006331205368042
dexamethasone-resistant B-cell_line I-cell_line 0.44187915325164795
human I-cell_line I-cell_line 0.8313650488853455
leukemic I-cell_line I-cell_line 0.9416689276695251
( I-cell_line I-cell_line 0.9652323126792908
CEM I-cell_line I-cell_line 0.9804116487503052
) I-cell_line I-cell_line 0.9667378664016724
cells E-cell_line E-cell_line 0.9727765321731567

The O O 0.9996258020401001
overall O O 0.987576961517334
response O O 0.9955992698669434
rate O O 0.9998323917388916
was O O 0.9999954700469971
26 O O 0.9999402761459351
% O O 0.9999793767929077
( O O 0.9999849796295166
95 O O 0.9998804330825806
% O O 0.9999737739562988
confidence O O 0.976635217666626
interval O O 0.9923635721206665
, O O 0.999976396560669
15 O O 0.9999523162841797
- O O 0.9998931884765625
41 O O 0.9999158382415771
% O O 0.9999674558639526
) O O 0.9997884631156921
. O O 0.9999978542327881

( O O 0.9687272310256958
i.e. O O 0.9806923270225525
, O O 0.9995564818382263
CsA O O 0.8001536130905151
with O O 0.9997599720954895
cyclophilin B-protein O 0.7046938538551331
A E-protein O 0.6522092223167419
and O O 0.9809500575065613
FK506 O O 0.7864794731140137
with O O 0.9987547397613525
FKBP12 S-protein O 0.5222698450088501
) O O 0.9865707755088806
to O O 0.9999529123306274
form O O 0.9993749260902405
protein/drug O B-protein 0.6196039915084839
complexes O E-protein 0.9782020449638367
that O O 0.9996263980865479
suppress O O 0.9999372959136963
the O O 0.9996795654296875
immune O O 0.982991099357605
system O O 0.9922349452972412
by O O 0.9999982118606567
preventing O O 0.9997251629829407
activation O O 0.9979676604270935
of O O 0.9998971223831177

Urinary O O 0.9035180807113647
excretion O O 0.6675167679786682
of O O 0.9892193675041199
Pirarubicin S-Chemical B-Chemical 0.9339922070503235
in O O 0.9963566064834595
the O O 0.9999499320983887
first O O 0.9996960163116455
24 O O 0.9998431205749512
hours O O 0.9999113082885742
was O O 0.9999991655349731
less O O 0.9999746084213257
than O O 0.9999598264694214
or O O 0.9997100234031677
equal O O 0.9999520778656006
to O O 0.9999566078186035
10 O O 0.9998846054077148
% O O 0.9999600648880005
. O O 0.9999958276748657

Physicians O O 0.9916704893112183
should O O 0.99998939037323
be O O 0.9999899864196777
aware O O 0.9999780654907227
of O O 0.9999700784683228
this O O 0.9999386072158813
potential O O 0.9975044131278992
interaction O O 0.9770132303237915
and O O 0.9999600648880005
use O O 0.9999768733978271
caution O O 0.993206262588501
when O O 0.9999949932098389
prescribing O O 0.9984398484230042
levofloxacin B-Chemical B-Chemical 0.9385083317756653
to O O 0.9953552484512329
patients O O 0.9990978240966797
taking O O 0.9999738931655884
warfarin B-Chemical B-Chemical 0.9280941486358643
. O O 0.9995679259300232

naive B-cell_type B-cell_type 0.37082433700561523
T I-cell_type I-cell_type 0.6619970798492432
cells E-cell_type E-cell_type 0.873412013053894
and O O 0.9968389272689819
allogeneic O B-cell_type 0.72865229845047
DC S-cell_type E-cell_type 0.9337079524993896
resulted O O 0.999790608882904
in O O 0.9999927282333374
a O O 0.9999854564666748
profound O O 0.9953716397285461
inhibition O O 0.9964436888694763
of O O 0.9999375343322754
alloreactive O O 0.7900187373161316
responses O O 0.9725558161735535
, O O 0.9999434947967529
which O O 0.9999783039093018
could O O 0.9999959468841553
be O O 0.9999669790267944

The O O 0.9981364011764526
patient O O 0.9970721006393433
recovered O O 0.9997488856315613
spontaneously O O 0.9607473611831665
in O O 0.9998413324356079
3 O O 0.9989739656448364
hours O O 0.9992350339889526
under O O 0.9999899864196777
surveillance O O 0.9961793422698975
in O O 0.9999699592590332
the O O 0.9997603297233582
hospital O O 0.9962815642356873
. O O 0.9999983310699463

its O O 0.9892783761024475
own O O 0.9778668284416199
promoter S-DNA O 0.4386620819568634
. O O 0.9995935559272766
While O O 0.9999967813491821
this O O 0.9999619722366333
expectation O O 0.9995959401130676
may O O 0.9999958276748657
be O O 0.9999926090240479
realized O O 0.9998906850814819
in O O 0.9999943971633911
some O O 0.9999786615371704
cases O O 0.9998418092727661
, O O 0.9999951124191284
we O O 0.9999806880950928
have O O 0.9999938011169434
not O O 0.9999488592147827
found O O 0.9999878406524658
evidence O O 0.9998924732208252
for O O 0.9999954700469971
it O O 0.999349057674408

Sirolimus S-Chemical B-Chemical 0.9170256853103638
is O O 0.9986478686332703
a O O 0.9999555349349976
novel O O 0.8478823304176331
immunosuppressant O O 0.4522145986557007
with O O 0.9976491332054138
potent O O 0.9936942458152771
antiproliferative O O 0.9092627167701721
actions O O 0.6205726861953735
through O O 0.9998230338096619
its O O 0.9999637603759766
ability O O 0.9997686743736267
to O O 0.9999804496765137
inhibit O O 0.9998599290847778
the O O 0.9998672008514404
raptor O O 0.8934409022331238
- O O 0.9982329607009888
containing O O 0.9998680353164673
mammalian O O 0.6370001435279846
target O O 0.9233794808387756
of O O 0.9995003938674927
rapamycin S-Chemical B-Chemical 0.9299185872077942
protein O O 0.7610806226730347
kinase O O 0.38581857085227966
. O O 0.9991699457168579

regulation O O 0.9829062223434448
were O O 0.9999738931655884
not O O 0.9999566078186035
altered O O 0.9999098777770996
by O O 0.9999918937683105
EC S-cell_type S-cell_type 0.9496465921401978
, O O 0.9992018342018127
although O O 0.9999905824661255
NFAT-DNA B-protein B-protein 0.45148250460624695
complexes E-protein E-protein 0.9931655526161194
migrated O O 0.9992942810058594
at O O 0.9999973773956299
a O O 0.9999531507492065
slightly O O 0.9976412057876587
different O O 0.9989110231399536
mobility O O 0.9941133856773376
. O O 0.9999969005584717
In O O 0.9999806880950928
summary O O 0.9990680813789368
, O O 0.9999958276748657
our O O 0.9999661445617676
data O O 0.9997621178627014
suggest O O 0.9999979734420776
that O O 0.9999949932098389
changes O O 0.9992882609367371
in O O 0.9999333620071411
the O O 0.9995586276054382
composition O O 0.975062370300293

After O O 0.9998443126678467
6 O O 0.9994630217552185
weeks O O 0.9999674558639526
of O O 0.9999414682388306
treatment O O 0.9961263537406921
, O O 0.999987006187439
renal O O 0.88655686378479
hemodynamics O O 0.7169377207756042
( O O 0.9965747594833374
glomerular O O 0.5859476923942566
filtration O O 0.7688702940940857
rate O O 0.9930042624473572
and O O 0.999915361404419
renal O O 0.9245670437812805
plasma O O 0.6738812327384949
flow O O 0.7941812872886658
) O O 0.9980271458625793
were O O 0.9999880790710449
measured O O 0.9999703168869019
in O O 0.9999806880950928
the O O 0.9998774528503418
anesthetized O O 0.636765718460083
rats O O 0.9829639196395874
. O O 0.9999980926513672

RESULTS O O 0.9980411529541016
: O O 0.9999724626541138
One O O 0.9998788833618164
hundred O O 0.9997177720069885
patients O O 0.9996192455291748
were O O 0.9999885559082031
enrolled O O 0.9994692206382751
. O O 0.9999988079071045

Many O O 0.9993312358856201
of O O 0.9999796152114868
these O O 0.9999529123306274
patients O O 0.9978413581848145
are O O 0.999996542930603
taking O O 0.9998014569282532
pentoxifylline S-Chemical B-Chemical 0.9278179407119751
( O O 0.9672391414642334
Trental S-Chemical B-Chemical 0.9009224772453308
) O O 0.5724058151245117
, O O 0.9988259673118591
a O O 0.9998984336853027
methylxanthine S-Chemical B-Chemical 0.9192121624946594
derivative O O 0.8227732181549072
which O O 0.9978291392326355
may O O 0.9999947547912598
improve O O 0.9999353885650635
intermittent O O 0.8915585875511169
claudication O O 0.39660483598709106
. O O 0.9999203681945801

to O O 0.9816917181015015
IFN-gamma S-protein S-protein 0.9827501773834229
. O O 0.9997710585594177
When O O 0.9999300241470337
freshly O O 0.6612899899482727
isolated O O 0.6920787692070007
, O O 0.9823440313339233
highly O O 0.7313135862350464
enriched O O 0.6163220405578613
( O O 0.9022413492202759
> O O 0.9848004579544067
98 O O 0.9938185811042786
% O O 0.9985325336456299
) O O 0.9950807094573975
T B-cell_type B-cell_type 0.6061663627624512
cells E-cell_type E-cell_type 0.9674669504165649
are O O 0.9996320009231567
examined O O 0.9999512434005737
for O O 0.9999938011169434
IFN-gamma S-protein S-protein 0.9691122174263
responsiveness O O 0.9906206130981445
; O O 0.999936580657959
these O O 0.9999490976333618
cells O O 0.9697598814964294
can O O 0.9999861717224121
respond O O 0.9999808073043823
to O O 0.9998952150344849
IFN-gamma S-protein S-protein 0.9903942942619324
and O O 0.997560977935791

However O O 0.9988340735435486
, O O 0.999964714050293
multiple O O 0.9908370971679688
regression O O 0.799026608467102
for O O 0.9990729093551636
the O O 0.999919056892395
daily O O 0.9937918782234192
dosage O O 0.9908559322357178
, O O 0.9999940395355225
duration O O 0.9981358051300049
of O O 0.9998292922973633
phenytoin S-Chemical B-Chemical 0.93023282289505
treatment O O 0.9492347836494446
and O O 0.9999105930328369
cerebellar O O 0.677973747253418
volume O O 0.959850013256073
revealed O O 0.9999901056289673
a O O 0.9999648332595825
correlation O O 0.9917026162147522
of O O 0.9992486834526062
these O O 0.9999704360961914
parameters O O 0.9934787750244141
. O O 0.9999979734420776

activates O O 0.9804232120513916
many O O 0.9988547563552856
B B-DNA B-DNA 0.36771002411842346
cell I-DNA I-DNA 0.4382022023200989
and I-DNA I-DNA 0.7439937591552734
myeloid I-DNA I-DNA 0.37007156014442444
genes E-DNA E-DNA 0.9486267566680908
, O O 0.9944251775741577
and O O 0.99986732006073
is O O 0.999990701675415
critical O O 0.9998061060905457
for O O 0.9999914169311523
development O O 0.9997068047523499
of O O 0.9999822378158569
both O O 0.999946117401123
of O O 0.9999299049377441
these O O 0.9997444748878479
lineages O O 0.8768038749694824
. O O 0.9999843835830688
Our O O 0.9999974966049194
previous O O 0.9996562004089355
studies O O 0.999863862991333
( O O 0.9999828338623047
Chen O O 0.9622196555137634
, O O 0.9995235204696655
H.M. O O 0.9939269423484802
, O O 0.9998327493667603
Ray-Gallet O O 0.9928464293479919
, O O 0.9998934268951416
D. O O 0.9980354905128479
, O O 0.9999758005142212
Zhang O O 0.9780576825141907

replication O O 0.932555615901947
is O O 0.9998641014099121
controlled O O 0.9998385906219482
by O O 0.9999984502792358
a O O 0.9999676942825317
complex O O 0.9302525520324707
array O O 0.8754088282585144
of O O 0.999393105506897
virally B-protein B-protein 0.580866813659668
encoded I-protein I-protein 0.380966454744339
and I-protein I-protein 0.7048730254173279
cellular I-protein I-protein 0.576561689376831
proteins E-protein E-protein 0.988166332244873
. O O 0.9998296499252319
A O O 0.999983549118042
wide O O 0.9819506406784058
spectrum O O 0.9937206506729126
of O O 0.9999439716339111
levels O O 0.9990419745445251
of O O 0.9999215602874756
HIV-1 O O 0.3945114314556122
expression O O 0.9835929870605469
have O O 0.9999798536300659
been O O 0.9998904466629028

The O O 0.9994897842407227
maintenance O O 0.9986135959625244
of O O 0.9999697208404541
lymphocyte O O 0.48134228587150574
homeostasis O O 0.7859037518501282
by O O 0.999936580657959
apoptosis O O 0.9868969321250916
is O O 0.9999984502792358
a O O 0.9999964237213135
critical O O 0.9917603135108948
regulatory O O 0.9116355776786804
mechanism O O 0.979598879814148
in O O 0.999992847442627
the O O 0.9999008178710938
normal O O 0.8981622457504272
immune O O 0.9359756708145142
system O O 0.9648803472518921
. O O 0.9999984502792358
The O O 0.9999878406524658
transcription B-protein B-protein 0.5233327746391296
factor E-protein E-protein 0.9560168385505676
NF-kappaB S-protein S-protein 0.87480229139328
has O O 0.9997110962867737
been O O 0.9999526739120483
shown O O 0.999977707862854
to O O 0.9999833106994629
play O O 0.9999125003814697
a O O 0.9999371767044067

In O O 0.999697208404541
35 O O 0.9981303811073303
patients O O 0.9995484948158264
( O O 0.9999878406524658
ages O O 0.9999537467956543
20 O O 0.9999549388885498
to O O 0.9998621940612793
86 O O 0.999495267868042
yr O O 0.998897910118103
) O O 0.9992067217826843
receiving O O 0.9999076128005981
cimetidine S-Chemical B-Chemical 0.9312589168548584
therapeutically O O 0.9705302119255066
two O O 0.9998273253440857
serum O O 0.9857174158096313
samples O O 0.9942122101783752
and O O 0.9999915361404419
all O O 0.999863862991333
urine O O 0.7445497512817383
formed O O 0.9986733198165894
in O O 0.9999902248382568
the O O 0.9999728202819824
interim O O 0.9987955093383789
were O O 0.9999959468841553
collected O O 0.9999853372573853
for O O 0.9999971389770508
analysis O O 0.9935122132301331
of O O 0.9997538924217224
cimetidine S-Chemical B-Chemical 0.9328426718711853
by O O 0.9990553259849548
high O O 0.9819840788841248
- O O 0.9983031749725342
pressure O O 0.9666935801506042
liquid O O 0.76817387342453
chromatography O O 0.5165086388587952
and O O 0.9994871616363525
for O O 0.9999325275421143
creatinine S-Chemical B-Chemical 0.8800660371780396
. O O 0.9991733431816101

Severe O O 0.9597044587135315
and O O 0.9943547248840332
clinically O O 0.9720155596733093
evident O O 0.9879001379013062
anemia O B-Disease 0.9800652861595154
was O O 0.979335367679596
easily O O 0.9972122311592102
corrected O O 0.9998024106025696
by O O 0.9999955892562866
subcutaneous O O 0.7394809722900391
injections O O 0.7738527059555054
( O O 0.9998780488967896
3 O O 0.9999449253082275
times O O 0.9999078512191772
/ O O 0.9999862909317017
week O O 0.999967098236084
for O O 0.99998939037323
1 O O 0.9998409748077393
month O O 0.9999333620071411
) O O 0.999969482421875
of O O 0.9999809265136719
recombinant O O 0.9125058650970459
erythropoietin O O 0.7174462676048279
( O O 0.9837390184402466
rHuEPO O O 0.5959972739219666
- O O 0.6991745233535767
beta O O 0.7664626240730286
) O O 0.9246916174888611
. O O 0.9999879598617554

impaired O O 0.8734196424484253

lipopolysaccharide O O 0.4215914011001587
( O O 0.9513112902641296
LPS O O 0.7246119976043701
) O O 0.9020392894744873
induction O O 0.9965888261795044
of O O 0.9999644756317139
two O O 0.9981449842453003
immediate O B-DNA 0.7368998527526855
early O I-DNA 0.4222530424594879
genes O E-DNA 0.9305383563041687
c-fos S-DNA S-DNA 0.9762701392173767
and O O 0.9871800541877747
c-jun S-DNA S-DNA 0.9952357411384583
. O O 0.9995836615562439
These O O 0.9999594688415527
genes O O 0.7098832726478577
encode O O 0.9979410767555237
proteins O O 0.949782133102417
that O O 0.9999370574951172
form O O 0.9983610510826111

altered O O 0.9566137194633484
by O O 0.999795138835907
PHA S-protein S-protein 0.9609625339508057
activation O O 0.9962978959083557
in O O 0.9999737739562988
the O O 0.9999533891677856
absence O O 0.9953560829162598
or O O 0.9998451471328735
presence O O 0.9991466999053955
of O O 0.9999475479125977
EC S-cell_type S-cell_type 0.9244867563247681
. O O 0.9997534155845642
In O O 0.9999376535415649
contrast O O 0.998214602470398
, O O 0.999744713306427
c-fos B-RNA B-RNA 0.8465445637702942
mRNA E-RNA E-RNA 0.9982069730758667
is O O 0.999068558216095
absent O O 0.9998478889465332
from O O 0.9999001026153564
resting O B-cell_type 0.6838428974151611
T B-cell_type I-cell_type 0.8189891576766968
cells E-cell_type E-cell_type 0.9764020442962646
and O O 0.9911318421363831
is O O 0.999958872795105
induced O O 0.9999583959579468
on O O 0.9999563694000244
PHA S-protein S-protein 0.7429553270339966
activation O O 0.9917498230934143
. O O 0.9999775886535645
EC S-cell_type S-cell_type 0.9039528369903564

of O O 0.995701014995575
active O O 0.8938014507293701
NF-kappa B-protein B-protein 0.6297799348831177
B E-protein E-protein 0.9883257150650024
. O O 0.9995940327644348
The O O 0.9999936819076538
cloning O O 0.972179114818573
of O O 0.999395489692688
the O O 0.9998376369476318
complementary B-DNA B-DNA 0.6943830847740173
DNA E-DNA E-DNA 0.9207280874252319
for O O 0.9964091181755066
the O O 0.9998737573623657
50K B-protein B-protein 0.36159875988960266
subunit E-protein E-protein 0.9305732846260071
helped O O 0.9964396357536316
to O O 0.9999611377716064
identify O O 0.9999896287918091
an O O 0.9999808073043823
exclusively O O 0.9711270332336426
cytoplasmic B-protein B-protein 0.6244246363639832
105K I-protein I-protein 0.45248815417289734
precursor E-protein E-protein 0.70030677318573

and O O 0.9852868318557739
the O O 0.9997735619544983
SH2 B-protein B-protein 0.36809781193733215
domain E-protein E-protein 0.9209715127944946
of O O 0.931570291519165
STAT1alpha S-protein S-protein 0.9843562245368958
. O O 0.9998511075973511
We O O 0.9999781847000122
demonstrate O O 0.9999936819076538
that O O 0.9999959468841553
, O O 0.9991911053657532
in O O 0.9996389150619507

Proteinuria O B-Disease 0.9731019735336304
correlated O O 0.9373003244400024
most O O 0.9988791346549988
strongly O O 0.9993785619735718
with O O 0.9999889135360718
sirolimus S-Chemical B-Chemical 0.9311968684196472
therapy O O 0.9852954149246216
when O O 0.9999918937683105
compared O O 0.9999345541000366
to O O 0.999984622001648
other O O 0.999573290348053
demographic O O 0.7054618000984192
and O O 0.8754518032073975
clinical O O 0.8200668096542358
variables O O 0.9326454997062683
. O O 0.9999974966049194

transcriptional O O 0.5622560381889343

levels O O 0.9871019124984741
of O O 0.9999836683273315
the O O 0.9999306201934814
apoptosis O B-protein 0.7509680390357971
effector O I-protein 0.6240546107292175
proteins O E-protein 0.9347521662712097
Bak S-protein S-protein 0.947517454624176
and O O 0.9667502641677856
Bad S-protein S-protein 0.9115349054336548
were O O 0.9992064833641052
enhanced O O 0.9979838132858276
, O O 0.9999582767486572
whereas O O 0.9999871253967285
there O O 0.9999892711639404
was O O 0.999995231628418
a O O 0.9999887943267822
slight O O 0.9935073852539062
down-regulation O O 0.9894513487815857
of O O 0.9998382329940796
the O O 0.9998323917388916
apoptosis B-protein B-protein 0.7111902236938477
suppressor I-protein I-protein 0.4081974923610687
protein E-protein E-protein 0.8064165711402893

Extracorporeal O O 0.8280787467956543
lithotripsy O O 0.39292487502098083
successfully O O 0.9879475235939026
removed O O 0.9995291233062744
a O O 0.9999446868896484
renal B-Disease O 0.9456923604011536
calculus I-Disease O 0.6363349556922913
in O O 0.9996857643127441
one O O 0.9999663829803467
patient O O 0.9995900988578796
and O O 0.9999808073043823
surgery O O 0.8655998706817627
removed O O 0.9997716546058655
a O O 0.999968409538269
staghorn O O 0.5214799642562866
calculus B-Disease O 0.7441760897636414
in O O 0.999908447265625
another O O 0.9999141693115234
, O O 0.9999713897705078
permitting O O 0.9999369382858276
continued O O 0.9953159093856812
treatment O O 0.9989868998527527
. O O 0.9999992847442627

retinoic O O 0.769737958908081
acid O O 0.9179103374481201
. O O 0.9997178912162781
Neutrophil S-cell_type O 0.6314261555671692
maturation O O 0.9871975183486938
occurs O O 0.9999641180038452
in O O 0.9999666213989258
well O O 0.9033827185630798
defined O O 0.9666801691055298
morphological O O 0.9501321911811829
stages O O 0.9917391538619995
that O O 0.999991774559021
correlate O O 0.9999492168426514
with O O 0.9999927282333374
the O O 0.9999492168426514
acquisition O O 0.997685432434082
of O O 0.9999595880508423
molecular B-protein O 0.8201487064361572
markers E-protein O 0.6123242974281311
associated O O 0.9988629817962646
with O O 0.9999828338623047
neutrophil O O 0.5471435785293579
function O O 0.9680789113044739
. O O 0.9999818801879883
A O O 0.9999728202819824
variety O O 0.9983329176902771
of O O 0.9999713897705078
factors O O 0.9777684807777405
are O O 0.9999525547027588
known O O 0.9999685287475586
to O O 0.9999152421951294
play O O 0.998847484588623

effector I-protein I-DNA 0.36055612564086914
site E-protein E-DNA 0.7564056515693665
, O O 0.994734525680542
TES2 S-protein S-DNA 0.8110257983207703
. O O 0.9995591044425964
A O O 0.9998836517333984
yeast O O 0.9703574180603027
two-hybrid O O 0.8269391655921936
screen O O 0.530204176902771
identified O O 0.9966014623641968
TES2 B-protein B-protein 0.6441009044647217
interacting I-protein I-protein 0.6774570941925049
proteins E-protein E-protein 0.9419699907302856
, O O 0.9945672750473022
including O O 0.9998925924301147

. O O 0.9959357976913452
No O O 0.999839186668396
difference O O 0.9996957778930664
of O O 0.9999568462371826
VDR S-protein S-protein 0.9217993021011353
retention O O 0.9929028153419495
in O O 0.9999415874481201
pulse O O 0.30199864506721497
and O O 0.8741213083267212
pulse/chase-experiments O O 0.2756440341472626
was O O 0.9989633560180664
seen O O 0.9999902248382568
in O O 0.9999008178710938
PBL S-cell_type S-cell_type 0.8289691209793091
, O O 0.9974404573440552
where O O 0.9999430179595947
VDR S-protein O 0.33538150787353516
halflife O O 0.44537419080734253
was O O 0.9999617338180542
approximately O O 0.9999291896820068
30 O O 0.9944657683372498
min O O 0.998826801776886

nearly O O 0.9868072867393494
90 O O 0.9948481321334839
% O O 0.9993367791175842
decrease O O 0.9985761642456055
in O O 0.9997957348823547
promoter O O 0.7393438816070557
activity O O 0.9952539205551147
compared O O 0.9999816417694092
with O O 0.9999934434890747
expression O O 0.998245358467102
from O O 0.9999971389770508
an O O 0.9999500513076782
alpha-globin B-DNA B-DNA 0.5667365193367004
promoter E-DNA E-DNA 0.9544032216072083
retaining O O 0.983320415019989
this O O 0.9997699856758118
region O O 0.9885381460189819
. O O 0.9999957084655762
These O O 0.9999961853027344
results O O 0.9999693632125854
suggest O O 0.9999985694885254
that O O 0.9999982118606567
the O O 0.9999125003814697
alpha-globin B-DNA B-DNA 0.3623805344104767
G I-DNA I-DNA 0.2959316074848175
+ I-DNA I-DNA 0.5934696793556213
C-rich I-DNA I-DNA 0.5117343664169312
5 I-DNA I-DNA 0.45182955265045166

in O O 0.9988163709640503
response O O 0.9995402097702026
to O O 0.9999849796295166
phorbol O O 0.9122885465621948
12-myristate O O 0.9627199172973633
13-acetate O O 0.9318791031837463
( O O 0.9997175335884094
PMA O O 0.9690278768539429
) O O 0.9994799494743347
. O O 0.9999648332595825
EL-4 B-cell_line B-cell_line 0.7481579184532166
cells E-cell_line E-cell_line 0.9752878546714783
also O O 0.9996832609176636
produce O O 0.9999923706054688
low O O 0.9863124489784241
levels O O 0.9981009364128113
of O O 0.9999419450759888
IL-5 S-protein S-protein 0.9666828513145447
when O O 0.999634861946106
stimulated O O 0.9968956708908081
by O O 0.999990701675415
PMA O O 0.962935209274292
alone O O 0.999575674533844
; O O 0.9999877214431763
however O O 0.9999860525131226
, O O 0.9999901056289673
cAMP O O 0.9199153780937195
greatly O O 0.9997898936271667
augments O O 0.9993523955345154
PMA-dependent O O 0.8455239534378052
IL-5 S-protein S-protein 0.9271563291549683
production O O 0.9976477026939392
. O O 0.9999982118606567
A O O 0.9998838901519775
transient O O 0.934163510799408
transfection O O 0.9543014168739319
assay O O 0.9993450045585632
revealed O O 0.9999929666519165
that O O 0.9999963045120239
two O O 0.991730272769928
signals O O 0.9702693223953247
, O O 0.9991017580032349
PMA O O 0.8264755010604858
and O O 0.9864876866340637
cAMP O O 0.6168140769004822
, O O 0.9951283931732178
are O O 0.9999831914901733
required O O 0.9999713897705078
for O O 0.9999940395355225
optimal O O 0.9780241250991821
activation O O 0.9961745738983154
of O O 0.9999642372131348
the O O 0.9989307522773743
IL-5 B-DNA B-DNA 0.5791895985603333
promoter E-DNA E-DNA 0.9862136244773865
. O O 0.9993539452552795
In O O 0.9999641180038452
contrast O O 0.999268114566803
, O O 0.9999713897705078

Dipyridamole B-Chemical B-Chemical 0.9146379828453064
significantly O O 0.996661901473999
increased O O 0.9928326606750488
coronary O O 0.912987232208252
blood O O 0.7045823931694031
flow O O 0.7018496990203857
before O O 0.9995381832122803
and O O 0.9999138116836548
after O O 0.9999561309814453
7 O O 0.9990278482437134
. O O 0.9999462366104126
5 O O 0.9997422099113464
or O O 0.9999758005142212
15 O O 0.9998966455459595
mm O O 0.9999145269393921
/ O O 0.9999904632568359
kg O O 0.9990271329879761
i O O 0.9993269443511963
. O O 0.999900221824646
v O O 0.9885240197181702
. O O 0.9991006851196289
pentoxifylline B-Chemical B-Chemical 0.9231868982315063
( O O 0.9897825717926025
p O O 0.9791432619094849
less O O 0.9973254203796387
than O O 0.9999657869338989
0 O O 0.9996289014816284
. O O 0.9996359348297119
002 O O 0.9727846384048462
) O O 0.9994828701019287
. O O 0.9999948740005493

Thymic B-cell_type B-cell_type 0.424012690782547
dendritic I-cell_type I-cell_type 0.5851197838783264
cells E-cell_type E-cell_type 0.7171363830566406
( O O 0.9522738456726074
DC S-cell_type S-cell_type 0.9632992148399353
) O O 0.9930354952812195
mediate O O 0.9941835999488831
negative O O 0.9549973607063293
selection O O 0.9831924438476562
at O O 0.9999958276748657
a O O 0.9999891519546509
relatively O O 0.9947839379310608
late O O 0.9975075721740723
stage O O 0.9997102618217468

Early O O 0.9475626349449158
onset O O 0.8717998266220093
migraine O B-Disease 0.9665106534957886
attacks O O 0.5730646252632141
were O O 0.9976721405982971
induced O O 0.9996625185012817
by O O 0.9999862909317017
nitroglycerin S-Chemical B-Chemical 0.9344486594200134
in O O 0.9989653825759888
seven O O 0.999887228012085
out O O 0.9999548196792603
of O O 0.9999779462814331
10 O O 0.9996265172958374
patients O O 0.999627947807312
versus O O 0.9999885559082031
no O O 0.9983969330787659
patient O O 0.9974982142448425
in O O 0.9999758005142212
the O O 0.9997978806495667
placebo O O 0.9355948567390442
group O O 0.9953983426094055
. O O 0.9999990463256836

element E-DNA E-DNA 0.9435950517654419
to O O 0.9970441460609436
generate O O 0.9995637536048889
transgenic O O 0.869202196598053
mice O O 0.968268632888794
expressing O O 0.9997901320457458
the O O 0.9999545812606812
Pebp2beta S-protein B-protein 0.3800160586833954
Smmhc B-protein I-protein 0.6903302073478699
chimeric I-protein I-protein 0.8754580020904541
fusion I-protein I-protein 0.9093683362007141
protein E-protein E-protein 0.9907494187355042
in O O 0.9992161989212036
myeloid B-cell_type B-cell_type 0.6645194888114929
cells E-cell_type E-cell_type 0.9699832201004028
. O O 0.9995532631874084
Neutrophil O O 0.596119225025177
maturation O O 0.9851324558258057
was O O 0.9999538660049438
impaired O O 0.9996782541275024
in O O 0.9999556541442871
PEBP2betaMYH11 S-protein O 0.2496962696313858
transgenic O O 0.5391291975975037
mice O O 0.7220168709754944
. O O 0.9999397993087769
Although O O 0.9997097849845886

expression O O 0.9801441431045532
of O O 0.999886155128479
these O O 0.9999617338180542
genes S-DNA O 0.6513547301292419
in O O 0.9997041821479797
human B-cell_type B-cell_type 0.6232074499130249
cells E-cell_type E-cell_type 0.9796482920646667
in O O 0.9992901086807251
continuous O O 0.7735884785652161
culture O O 0.4821075201034546
. O O 0.9998887777328491
We O O 0.9999716281890869
have O O 0.9999942779541016
previously O O 0.9999454021453857
reported O O 0.9999877214431763
the O O 0.9999903440475464
presence O O 0.9997299313545227
of O O 0.9999759197235107
a O O 0.9998430013656616
transcriptional B-DNA B-DNA 0.7415561079978943
control I-DNA I-DNA 0.460988312959671
element E-DNA E-DNA 0.9513422846794128
with O O 0.9993984699249268
the O O 0.9999643564224243
properties O O 0.9959126114845276
of O O 0.9999681711196899
a O O 0.9996646642684937
silencer S-DNA O 0.5123261213302612
extending O O 0.9934658408164978
from O O 0.9994567036628723
-392 B-DNA O 0.4875270128250122
to I-DNA O 0.8151528239250183

factors E-protein E-protein 0.9874885678291321
. O O 0.9997135996818542
This O O 0.9999747276306152
suggests O O 0.9999793767929077
that O O 0.9999933242797852
in O O 0.9997976422309875
these O O 0.9994982481002808
cells O O 0.9684361219406128
GR S-protein S-protein 0.8196204304695129
within O O 0.9997313618659973
the O O 0.9999639987945557
nucleus O O 0.8994553089141846
interacts O O 0.9992658495903015
with O O 0.9999911785125732
cytokine-stimulated B-protein B-protein 0.5700427889823914
transcription I-protein I-protein 0.4534436762332916
factors E-protein E-protein 0.9941089153289795
by O O 0.9998856782913208
the O O 0.9999865293502808
process O O 0.9996135830879211
of O O 0.9999774694442749
cross O O 0.9249894618988037
coupling O O 0.9715357422828674
. O O 0.9999873638153076
This O O 0.9999613761901855
may O O 0.9999837875366211
be O O 0.9999972581863403
an O O 0.999995231628418
important O O 0.995259702205658
molecular O O 0.9480004906654358
site O O 0.9076354503631592
of O O 0.9997842907905579
steroid O O 0.899524450302124
action O O 0.9973872303962708
. O O 0.9999988079071045
Differential O O 0.9914801120758057
induction O O 0.9992917776107788
of O O 0.9999607801437378
the O O 0.9998072981834412

are O O 0.9971411228179932
shared O O 0.9993355870246887
between O O 0.9998507499694824
different O O 0.9937142729759216
cell O O 0.9533088803291321
types O O 0.9102632999420166
, O O 0.999984860420227
it O O 0.9999791383743286
appears O O 0.9999934434890747
that O O 0.999997615814209
cell-specific B-protein B-protein 0.8442177176475525
factors E-protein E-protein 0.9415247440338135
can O O 0.9998700618743896
influence O O 0.9999793767929077
the O O 0.9999449253082275
response O O 0.9992747902870178
to O O 0.9999939203262329
a O O 0.999925971031189
given O O 0.9964491128921509
apoptotic O O 0.8231906890869141
stimuli O O 0.700579047203064
. O O 0.9999167919158936
Characterization O O 0.9969841837882996
and O O 0.9998183846473694
understanding O O 0.9952471852302551

cortisol O O 0.5914567708969116
. O O 0.999607264995575
We O O 0.9999526739120483
also O O 0.9999780654907227
observed O O 0.9999780654907227
that O O 0.9999903440475464
ketoconazole O O 0.7852523326873779
was O O 0.9998301267623901
a O O 0.9999743700027466
weak O O 0.9712368845939636
competitor O O 0.9422576427459717

cells E-cell_type E-cell_type 0.7036719918251038
. O O 0.9997463822364807
In O O 0.9999878406524658
a O O 0.9998362064361572
T-cell B-cell_line B-cell_line 0.669358491897583
clone E-cell_line E-cell_line 0.9047486782073975
specific O O 0.89768385887146
for O O 0.9996938705444336
pigeon B-protein B-protein 0.6281302571296692
cytochrome I-protein I-protein 0.42345333099365234
c E-protein E-protein 0.6397353410720825
in O O 0.995574951171875
the O O 0.9999562501907349
context O O 0.9996423721313477
of O O 0.9999805688858032
I-Ek S-protein S-protein 0.919344961643219
, O O 0.9962350726127625
Oct-2 S-protein S-protein 0.9791832566261292
was O O 0.9996703863143921
induced O O 0.9999361038208008
by O O 0.999980092048645
antigen O O 0.8325375318527222
stimulation O O 0.987174391746521
, O O 0.9999322891235352
with O O 0.999996542930603
the O O 0.9999880790710449
increase O O 0.9985021352767944
in O O 0.9997679591178894
Oct-2 B-protein S-protein 0.9358969330787659
protein E-protein O 0.7986639738082886
seen O O 0.9989700317382812
first O O 0.9993374943733215
at O O 0.9999970197677612
3 O O 0.9986316561698914
h O O 0.9978445768356323
after O O 0.9999597072601318
activation O O 0.9951871633529663
and O O 0.9999070167541504
continuing O O 0.9949530363082886
for O O 0.9999089241027832
at O O 0.9992693066596985
least O O 0.999078631401062
24 O O 0.9980003237724304
h O O 0.9907292723655701
. O O 0.9999746084213257
Oct-2 B-RNA B-RNA 0.8835361003875732
mRNA E-RNA E-RNA 0.9974262118339539
induction O O 0.9972785115242004
during O O 0.9999794960021973
antigen-driven O O 0.8150649666786194
T-cell S-cell_type O 0.49794650077819824
activation O O 0.9801591634750366
was O O 0.9999743700027466

and O O 0.9829418063163757
that O O 0.9999370574951172
curcumin O O 0.429535835981369
affects O O 0.9998119473457336
a O O 0.9999779462814331
common O O 0.9911496639251709
step O O 0.9951699376106262
, O O 0.9999812841415405
presumably O O 0.9999871253967285
involving O O 0.9999926090240479
a O O 0.999947190284729
modulation O O 0.9903723001480103
of O O 0.9996715784072876
the O O 0.9998999834060669
AP-1 S-protein B-protein 0.9044457674026489
transcription B-protein I-protein 0.425673246383667
factor E-protein E-protein 0.9631784558296204
. O O 0.9950292706489563
Interleukin-7 S-protein S-protein 0.9577035903930664
upregulates O O 0.9985558390617371
the O O 0.999901294708252
interleukin-2-gene S-DNA S-DNA 0.631472647190094
expression O O 0.8738886117935181
in O O 0.9994175434112549
activated B-cell_type B-cell_type 0.4643813669681549
human I-cell_type I-cell_type 0.44535529613494873
T I-cell_type I-cell_type 0.7149074673652649
lymphocytes E-cell_type E-cell_type 0.9145740866661072
at O O 0.9997418522834778
the O O 0.9999555349349976
transcriptional O O 0.7787802219390869

1 B-protein I-protein 0.4621596336364746
, I-protein I-protein 0.9002026915550232
25 I-protein I-protein 0.7281631827354431
( I-protein I-protein 0.8816390633583069
OH I-protein I-protein 0.6399385929107666
) I-protein I-protein 0.5905332565307617
2D3 I-protein I-protein 0.8394269943237305
receptors E-protein E-protein 0.9973350167274475
in O O 0.9997825026512146
myeloid B-cell_type B-cell_type 0.6670136451721191
cells E-cell_type E-cell_type 0.926551103591919

for O O 0.9977936744689941
breast/ovarian O O 0.9047134518623352
cancer O O 0.9679508805274963
. O O 0.999996542930603
Four O O 0.9998219609260559
of O O 0.9999790191650391
six O O 0.9971827268600464
truncating O O 0.7927724719047546
mutations O O 0.6268748641014099
were O O 0.9997811913490295
novel O O 0.9531015753746033
, O O 0.999066174030304
and O O 0.999927282333374
two O O 0.9972905516624451
mutations O O 0.9405847787857056
were O O 0.999923586845398
recurrent O O 0.996235191822052
. O O 0.9999984502792358
Four O O 0.9996386766433716
patients O O 0.9997209906578064
( O O 0.9999724626541138
22 O O 0.999657392501831
% O O 0.9997662901878357
) O O 0.9998884201049805
had O O 0.9999884366989136
a O O 0.9999347925186157
family O O 0.9635188579559326
history O O 0.9956817626953125
of O O 0.9999704360961914
breast/ovarian O O 0.7612895369529724
cancer O O 0.8852505683898926
in O O 0.9999722242355347
at O O 0.9999457597732544
least O O 0.9996351003646851

, O O 0.9882671236991882
we O O 0.9999275207519531
have O O 0.999993085861206
analyzed O O 0.9999133348464966
the O O 0.9999524354934692
human B-DNA B-DNA 0.5090382695198059
genomic I-DNA I-DNA 0.6316345930099487
DNA I-DNA I-DNA 0.4658467173576355
sequence E-DNA E-DNA 0.9734545350074768
upstream O O 0.9278621673583984
of O O 0.999929666519165
the O O 0.9999420642852783
B29 S-protein B-DNA 0.3811448812484741
ATG B-DNA I-DNA 0.39438942074775696
start I-DNA I-DNA 0.505315899848938
codon E-DNA E-DNA 0.851320743560791
for O O 0.9918394088745117
transcriptional O O 0.907907247543335
control O O 0.9327502250671387
activity O O 0.994013249874115
. O O 0.999995231628418
The O O 0.999962329864502
human O B-DNA 0.5511468648910522
B29 B-DNA I-DNA 0.6463547348976135
gene E-DNA E-DNA 0.9759482741355896
lacks O O 0.9773992300033569
either O O 0.9999347925186157

Nuclear O O 0.9053347110748291
factor O O 0.8336809873580933
kappa O O 0.6520596146583557
B O O 0.45880717039108276
( O O 0.9837990999221802
NFkappaB O O 0.46646660566329956
) O O 0.9726491570472717
is O O 0.9999895095825195
a O O 0.9999855756759644
sensor O O 0.9582067728042603
of O O 0.9984322190284729
oxidative O O 0.8494583964347839
stress O O 0.5889613628387451
and O O 0.9981630444526672
participates O O 0.9943872690200806
in O O 0.9996200799942017
memory O O 0.8640544414520264
formation O O 0.5744353532791138
that O O 0.997734546661377
could O O 0.9999856948852539
be O O 0.9999525547027588
involved O O 0.9999508857727051
in O O 0.9999556541442871
drug O O 0.925983726978302
toxicity B-Disease O 0.45949655771255493
and O O 0.9687137603759766
addiction O O 0.5302433371543884
mechanisms O O 0.8182281255722046
. O O 0.9999951124191284

The O O 0.9992961883544922
typical O O 0.9158192873001099
fluoxetine S-Chemical B-Chemical 0.922204852104187
- O O 0.9841861128807068
induced O O 0.9978132247924805
symptoms O O 0.5747660994529724
of O O 0.9015011787414551
restlessness O O 0.9108133316040039
, O O 0.983859658241272
constant O O 0.9306662082672119
pacing O O 0.6099198460578918
, O O 0.9894750118255615
purposeless O O 0.7938823103904724
movements O O 0.45218944549560547
of O O 0.909964919090271
the O O 0.9524993300437927
feet O O 0.8888350129127502
and O O 0.9940958023071289
legs O O 0.6770759224891663
, O O 0.9991806149482727
and O O 0.9998849630355835
marked O O 0.9880021810531616
anxiety O B-Disease 0.9628782868385315
were O O 0.9937454462051392
indistinguishable O O 0.9680782556533813
from O O 0.9998685121536255
those O O 0.9999827146530151
of O O 0.9998927116394043
neuroleptic O O 0.6168524622917175
- O O 0.6719937324523926
induced O O 0.9549335241317749
akathisia O B-Disease 0.9628634452819824
. O O 0.9987125396728516

. O O 0.9942219853401184
These O O 0.9999417066574097
cells O O 0.9782228469848633
showed O O 0.9999912977218628
G1 O O 0.915643572807312
phase O O 0.9784149527549744
arrest O O 0.9959017634391785
and O O 0.9999886751174927
the O O 0.9999505281448364
clonogenicity O O 0.9158241748809814
was O O 0.9999330043792725
reduced O O 0.999531626701355
. O O 0.9999972581863403
The O O 0.9999897480010986
growth-modulating O O 0.8416045904159546
effect O O 0.9985153079032898
was O O 0.9999901056289673
dose-dependent O O 0.9970003962516785
and O O 0.999779999256134
not O O 0.9997239708900452

repeat-KB I-DNA I-DNA 0.26841434836387634
enhancer I-DNA I-DNA 0.7712652683258057
sequence E-DNA E-DNA 0.9804143905639648
located O O 0.9986302852630615
in O O 0.9999889135360718
the O O 0.9999536275863647
long B-DNA B-DNA 0.4751143157482147
terminal I-DNA I-DNA 0.7678169012069702
repeat E-DNA E-DNA 0.9954217076301575
. O O 0.9995854496955872
PMA O O 0.801582932472229
treatment O O 0.9919867515563965
, O O 0.9999258518218994
and O O 0.9999022483825684
not O O 0.9998587369918823
retinoic O O 0.9053646326065063
acid O O 0.8244082927703857
treatment O O 0.9916593432426453
of O O 0.9999288320541382
the O O 0.9999122619628906
U937 B-cell_line B-cell_line 0.863329291343689
cells E-cell_line E-cell_line 0.992468535900116
acts O O 0.9973836541175842
in O O 0.9999775886535645
inducing O O 0.9939210414886475
NF-KB S-protein S-protein 0.960927426815033
expression O O 0.9969942569732666
in O O 0.9999817609786987
the O O 0.9999045133590698
nuclei O O 0.888925313949585
. O O 0.999711811542511
In O O 0.9998666048049927
nuclear O O 0.9369087815284729
extracts O O 0.9871542453765869
from O O 0.9999399185180664
monocytes S-cell_type S-cell_type 0.8993738293647766

Elevations O O 0.9195610284805298
in O O 0.9982497096061707
the O O 0.9990490078926086
serum O O 0.989728569984436
GOT O O 0.4853849411010742
and O O 0.9952770471572876
GPT O O 0.7757419943809509
were O O 0.9995813965797424
maximum O O 0.9955956339836121
in O O 0.9999418258666992
the O O 0.9997865557670593
sedentary O O 0.9507198333740234
- O O 0.9925941824913025
isoproterenols S-Chemical O 0.7458935379981995
and O O 0.9988196492195129
minimum O O 0.991615355014801
in O O 0.999977707862854
the O O 0.9999067783355713
exercise O O 0.9791223406791687
- O O 0.9995424747467041
controls O O 0.9990441203117371
. O O 0.9999991655349731

Two O O 0.9980015158653259
groups O O 0.9999021291732788
of O O 0.9999840259552002
22 O O 0.9993778467178345
similar O O 0.9839941263198853
patients O O 0.9984051585197449
were O O 0.9999884366989136
studied O O 0.9999173879623413
: O O 0.9999778270721436
one O O 0.9997001886367798
group O O 0.9995008707046509
received O O 0.999985933303833
6 O O 0.9954761862754822
mL O O 0.997318685054779
prilocaine S-Chemical B-Chemical 0.9409436583518982
2 O O 0.9590337872505188
% O O 0.9997220635414124
; O O 0.9999510049819946
and O O 0.9999638795852661
the O O 0.9999604225158691
other O O 0.9999663829803467
received O O 0.9999107122421265
3 O O 0.9974327683448792
mL O O 0.991215705871582
bupivacaine S-Chemical B-Chemical 0.9444360136985779
0 O O 0.9143298864364624
. O O 0.9999704360961914
5 O O 0.9997735619544983
% O O 0.9999217987060547
. O O 0.9999856948852539

Organelles O O 0.42732006311416626
of O O 0.9374345541000366
these O O 0.9966699481010437
cells O O 0.987065315246582
, O O 0.9999586343765259
in O O 0.9999878406524658
particular O O 0.9999654293060303
the O O 0.9998794794082642
mitochondria O O 0.7802767753601074
( O O 0.9780879020690918
increased O O 0.9808979630470276
number O O 0.9744071960449219
and O O 0.9980217218399048
size O O 0.9942551255226135
, O O 0.9998961687088013
distinct O O 0.993686854839325
degeneration O O 0.6992159485816956
of O O 0.9557351469993591
their O O 0.9909232258796692
matrix O O 0.842445433139801
and O O 0.997945249080658
cristae O O 0.49875473976135254
) O O 0.9887027740478516
and O O 0.9999505281448364
Golgi O O 0.9100642204284668
apparatus O O 0.9636952877044678
were O O 0.9999847412109375
altered O O 0.9994574189186096
. O O 0.9999991655349731

The O O 0.9994438290596008
neurologic O O 0.928976833820343
evaluation O O 0.9892101883888245
revealed O O 0.9999568462371826
loss B-Disease O 0.7295240759849548
of I-Disease O 0.7218357920646667
sensation I-Disease O 0.7922424077987671
in O O 0.9836804866790771
the O O 0.9939325451850891
saddle O O 0.9072819948196411
area O O 0.9906159043312073
and O O 0.9999715089797974
medial O O 0.9702975749969482
aspect O O 0.9929170608520508
of O O 0.9994736313819885
her O O 0.9986559152603149
right O O 0.9798439741134644
leg O O 0.9504948854446411
. O O 0.9999973773956299

that O O 0.9994958639144897
the O O 0.9999644756317139
phosphorylation O O 0.9668132066726685
does O O 0.9999631643295288
not O O 0.999974250793457
necessarily O O 0.9999903440475464
constitute O O 0.9999967813491821
the O O 0.9999877214431763
signal-induced O O 0.9708006978034973
event O O 0.9847599864006042
which O O 0.9999393224716187
targets O O 0.9999208450317383
the O O 0.999883770942688
molecule O O 0.9455268979072571
for O O 0.9967080354690552
proteolysis O O 0.9236125946044922
. O O 0.9999402761459351
Agonistic O O 0.923368513584137
activity O O 0.9935583472251892
of O O 0.9999358654022217
a O O 0.9998853206634521
CD40-specific B-protein B-protein 0.40162935853004456
single-chain I-protein I-protein 0.613948404788971
Fv E-protein E-protein 0.6463747620582581
constructed O O 0.7752803564071655
from O O 0.9997884631156921
the O O 0.9997219443321228
variable B-protein O 0.8574893474578857

T I-cell_line B-cell_type 0.3700883388519287
cells E-cell_line E-cell_type 0.8693857192993164
activated O O 0.9975681900978088
by O O 0.9999889135360718
cross-linking O B-protein 0.8218647837638855
cell B-protein I-protein 0.7192499041557312
surface I-protein I-protein 0.6002626419067383
CD3 E-protein E-protein 0.8491085171699524
. O O 0.9982293248176575
Cell O O 0.9442155957221985
activation O O 0.9966908693313599
resulted O O 0.9999891519546509
in O O 0.9999969005584717
a O O 0.999987006187439
delayed O O 0.9927524328231812
induction O O 0.998713493347168
of O O 0.9999076128005981
STAT S-protein S-protein 0.7683246731758118
DNA-binding O O 0.5728352665901184

class O O 0.43121668696403503
of O O 0.9709067344665527
self-antigens S-protein O 0.2967405617237091
that O O 0.9977020621299744
deserve O O 0.9999055862426758
further O O 0.9992647767066956
consideration O O 0.9999058246612549
as O O 0.9999978542327881
tumor B-protein B-protein 0.44487303495407104
Ag E-protein E-protein 0.9841527342796326
in O O 0.9997562766075134
epithelial O O 0.7582013010978699
cancers O O 0.808745801448822
. O O 0.9999608993530273
Induction O O 0.9956798553466797
of O O 0.9999270439147949
the O O 0.9998534917831421
pro-myelocytic B-DNA B-DNA 0.4719010293483734
leukaemia I-DNA I-DNA 0.49471673369407654
gene E-DNA E-DNA 0.9849121570587158
by O O 0.9996258020401001
type B-protein B-protein 0.5593604445457458
I I-protein I-protein 0.6979364156723022
and I-protein I-protein 0.7381902933120728

Microscopic O O 0.8106920123100281
observation O O 0.7981517314910889
showed O O 0.9999078512191772
the O O 0.9999713897705078
configuration O O 0.9972339272499084
of O O 0.9998481273651123
exencephaly O O 0.5048761963844299
at O O 0.994084894657135
E13 O O 0.8627423048019409
. O O 0.9998855590820312
5 O O 0.9863852858543396
, O O 0.9997828602790833
frequent O O 0.9858361482620239
hemorrhaging O O 0.6304299831390381
and O O 0.987942636013031
detachment O O 0.7559254169464111
of O O 0.9735584259033203
the O O 0.9967281818389893
neural O O 0.9250491261482239
plate O O 0.9327707886695862
from O O 0.9998993873596191
surface O O 0.9368225336074829
ectoderm O O 0.750919759273529
in O O 0.9996798038482666
the O O 0.9997770190238953
exencephalic O O 0.479092001914978
head O O 0.5444265007972717
at O O 0.9993371367454529
E15 O O 0.8944686651229858
. O O 0.9998898506164551
5 O O 0.9862739443778992
, O O 0.9997081160545349
and O O 0.999957799911499
multiple O O 0.9964922070503235
modes O O 0.9981081485748291
of O O 0.9998168349266052
reduction O O 0.8943065404891968
in O O 0.9934875965118408
the O O 0.9970183372497559
exencephalic O O 0.7378866076469421
tissue O O 0.6541489958763123
at O O 0.9999552965164185
E18 O O 0.8772494792938232
. O O 0.9999392032623291
5 O O 0.9902966618537903
. O O 0.9999403953552246

RESULTS O O 0.9980870485305786
: O O 0.9999874830245972
The O O 0.9999899864196777
reported O O 0.999352753162384
use O O 0.9996379613876343
of O O 0.9999080896377563
antibacterials O O 0.7235239744186401
increased O O 0.9901509284973145
during O O 0.9998899698257446
pregnancy O O 0.9678999781608582
, O O 0.9999690055847168
peaking O O 0.9997615218162537
during O O 0.9999955892562866
the O O 0.9999780654907227
third O O 0.9997703433036804
month O O 0.9999765157699585
. O O 0.9999990463256836

Testosterone S-Chemical B-Chemical 0.9325379729270935
contributes O O 0.9982419013977051
to O O 0.9999228715896606
the O O 0.9997269511222839
development O O 0.9952374696731567
of O O 0.9998143315315247
hypertension O B-Disease 0.9690076112747192
and O O 0.9554777145385742
renal O B-Disease 0.5311696529388428
injury O I-Disease 0.9848965406417847
in O O 0.9264136552810669
male O O 0.9570210576057434
DS O O 0.6537660956382751
rats O O 0.9720343947410583
on O O 0.9999632835388184
HS O O 0.6892390847206116
diet O O 0.8548429608345032
possibly O O 0.9997039437294006
through O O 0.9999949932098389
upregulation O O 0.9487519860267639
of O O 0.9991962313652039
the O O 0.9998856782913208
intrarenal O O 0.9112803339958191
renin O O 0.7232411503791809
- O O 0.981515645980835
angiotensin S-Chemical B-Chemical 0.9257395267486572
system O O 0.6069574952125549
. O O 0.9999862909317017

clones O E-cell_line 0.7975344061851501
isolated O O 0.9977301955223083
from O O 0.999982476234436
0.75 O O 0.7671955227851868
x O O 0.9754661321640015
10 O O 0.9949754476547241
( O O 0.9997263550758362
6 O O 0.9992544054985046
) O O 0.9975218176841736
yeast O O 0.9848695993423462
colonies O O 0.8965263366699219
, O O 0.9999619722366333

has O O 0.9932653903961182
shown O O 0.9999812841415405
that O O 0.9999972581863403
RA O O 0.9576114416122437
can O O 0.9999662637710571
enhance O O 0.9996596574783325
in O O 0.9966872334480286
vitro O O 0.9818414449691772
polyclonal O O 0.9685550928115845
B O O 0.9670088291168213
cell O O 0.9648039937019348
immunoglobulin S-protein O 0.6081066727638245
( O O 0.9850524067878723
Ig O S-protein 0.8990926146507263
) O O 0.9415286779403687
response O O 0.9912658333778381
. O O 0.9999868869781494
Investigating O O 0.9993839263916016
cytokines S-protein S-protein 0.9807829260826111
known O O 0.9997313618659973
to O O 0.9999399185180664
affect O O 0.9998108744621277
B O O 0.6235234141349792
cell O O 0.6081262230873108
differentiation O O 0.9816208481788635
, O O 0.9999303817749023
we O O 0.9999560117721558
have O O 0.9999946355819702

and O O 0.9821951985359192
suggest O O 0.9999797344207764
that O O 0.9999992847442627
different O O 0.9980581402778625
species O O 0.9950972199440002
of O O 0.9998725652694702
heterodimers S-protein O 0.4963763952255249
involving O O 0.9983179569244385
RXR-alpha S-protein S-protein 0.9763832092285156
may O O 0.999601423740387
control O O 0.9999146461486816
the O O 0.9999129772186279
acquisition O O 0.9990524649620056
of O O 0.9999810457229614
different O O 0.9973064661026001
features O O 0.9948535561561584
of O O 0.999841570854187
mature O O 0.8432308435440063
monocyte/macrophage O O 0.3616354465484619
function O O 0.9810669422149658
. O O 0.9999785423278809
Transcriptional O O 0.9268995523452759
activation O O 0.9921633005142212
of O O 0.9998854398727417
the O O 0.9998171925544739
vascular B-DNA B-DNA 0.47972139716148376
cell I-DNA I-DNA 0.4355902373790741
adhesion I-DNA I-DNA 0.49595919251441956
molecule-1 I-DNA I-DNA 0.5575181841850281
gene E-DNA E-DNA 0.9760189056396484
in O O 0.9972575306892395
T B-cell_type B-cell_type 0.8357881903648376
lymphocytes E-cell_type E-cell_type 0.9914793372154236
expressing O O 0.9918212890625
human B-protein B-protein 0.7090831398963928
T-cell I-protein I-protein 0.5495317578315735
leukemia I-protein I-protein 0.4595300853252411
virus I-protein I-protein 0.4283180832862854
type I-protein I-protein 0.7200675010681152
1 I-protein I-protein 0.7362847328186035
Tax I-protein I-protein 0.7119163274765015
protein E-protein E-protein 0.9932286739349365
. O O 0.9996539354324341
Recruitment O O 0.994211733341217
and O O 0.9989470839500427
extravasation O O 0.9794323444366455
of O O 0.9989519119262695
T B-cell_type B-cell_type 0.9318675398826599
cells E-cell_type E-cell_type 0.995166540145874
through O O 0.9998270869255066
the O O 0.9999556541442871

of O O 0.9979234933853149
a O O 0.9998931884765625
murine B-protein B-protein 0.5388437509536743
transcription I-protein I-protein 0.6003305315971375
factor E-protein E-protein 0.9774370193481445
, O O 0.9934322834014893
PEBP2 S-protein S-protein 0.9147745370864868
, O O 0.9924334287643433
which O O 0.9997660517692566
is O O 0.9999221563339233
implicated O O 0.9997064471244812
as O O 0.9999176263809204
a O O 0.9992659687995911

Although O O 0.9996631145477295
clinical O O 0.9783907532691956
experience O O 0.986287534236908
with O O 0.9999716281890869
omeprazole S-Chemical B-Chemical 0.9292784929275513
is O O 0.9970008730888367
still O O 0.9999587535858154
limited O O 0.9986856579780579
, O O 0.9999948740005493
many O O 0.9999493360519409
controlled O O 0.9907083511352539
studies O O 0.9997057318687439
have O O 0.9999992847442627
established O O 0.9999918937683105
the O O 0.9999821186065674
short O O 0.9928731918334961
- O O 0.9990108013153076
term O O 0.9998393058776855
safety O O 0.9975022673606873
of O O 0.9999442100524902
this O O 0.9996449947357178
drug O O 0.9937897324562073
. O O 0.9999972581863403

IL-2 S-protein S-protein 0.9513075351715088
synthesis O O 0.9837835431098938
and O O 0.9998736381530762
on O O 0.9997879862785339
the O O 0.9999477863311768
activation O O 0.9920931458473206
of O O 0.9996553659439087
the O O 0.999748170375824
nuclear B-protein B-protein 0.5085116624832153
factor I-protein I-protein 0.6635611057281494
kappaB E-protein E-protein 0.8205751776695251
( O O 0.6008012294769287

urinary O O 0.8418768048286438
cortisol O O 0.9315979480743408
was O O 0.9998809099197388
not O O 0.9999668598175049
affected O O 0.9999223947525024
until O O 0.9999988079071045
the O O 0.9999979734420776
second O O 0.9984667301177979
week O O 0.9999386072158813
of O O 0.9999821186065674
treatment O O 0.9995414018630981
. O O 0.9999982118606567
In O O 0.9998925924301147
conclusion O O 0.9997015595436096
, O O 0.9999955892562866
intranasal O O 0.7421521544456482
glucocorticoids O O 0.7728838324546814
at O O 0.9999470710754395
clinically O O 0.959186315536499
recommended O O 0.9908367395401001
doses O O 0.9987342953681946
have O O 0.9999935626983643
not O O 0.9998853206634521
only O O 0.9999423027038574
significant O O 0.9990921020507812
systemic O O 0.9851999282836914
effects O O 0.998887836933136
on O O 0.9999635219573975
adrenal O O 0.9184833765029907
function O O 0.9868120551109314
, O O 0.9998692274093628
but O O 0.9999661445617676
also O O 0.9999836683273315
have O O 0.9999874830245972
an O O 0.9999792575836182
effect O O 0.9999336004257202
on O O 0.9999895095825195
specific O O 0.979778528213501
gene O O 0.9135082364082336
expression O O 0.9972143769264221
in O O 0.9999617338180542
peripheral B-cell_type B-cell_type 0.7354536056518555
lymphocytes E-cell_type E-cell_type 0.9859734773635864
. O O 0.9997954964637756
These O O 0.9999942779541016
effects O O 0.9998799562454224
are O O 0.999990701675415
receptor-dependent O O 0.9867291450500488

gene E-DNA O 0.6684125065803528
expression O O 0.9688490629196167
and O O 0.999504804611206
NF-kappa B-protein B-protein 0.7634322643280029
B E-protein E-protein 0.9932812452316284
activation O O 0.9963347911834717
through O O 0.9999597072601318
CD28 S-protein S-protein 0.9281530380249023
requires O O 0.9997227787971497
reactive O O 0.9691131114959717
oxygen O O 0.7972333431243896
production O O 0.9989135265350342
by O O 0.9999886751174927
5-lipoxygenase S-protein O 0.5325562953948975
. O O 0.9992415904998779
Activation O O 0.9882404804229736

blocked O O 0.9782880544662476
by O O 0.9998264908790588
CD3 S-protein S-protein 0.9667069315910339
depletion O O 0.994515061378479
, O O 0.999983549118042
indicating O O 0.9999868869781494
the O O 0.9999842643737793
importance O O 0.9998595714569092
of O O 0.9999890327453613
such O O 0.9977468848228455
cell B-protein B-protein 0.8932592272758484
surface I-protein I-protein 0.582009494304657
molecules E-protein E-protein 0.9707326889038086
in O O 0.999757707118988
biological O O 0.9142305254936218
responses O O 0.9858905076980591
to O O 0.9998985528945923
UV O O 0.6864244341850281
. O O 0.9998107552528381
In O O 0.9996534585952759
nonlymphoid B-cell_type B-cell_type 0.45673665404319763
cells E-cell_type E-cell_type 0.8069918751716614
, O O 0.999808132648468
the O O 0.9999922513961792
epidermal B-protein B-protein 0.6945323348045349
growth I-protein I-protein 0.46364662051200867
factor I-protein I-protein 0.5999670028686523
receptor E-protein E-protein 0.9779160618782043
displayed O O 0.9992382526397705
increased O O 0.9967549443244934
tyrosine O O 0.7812697291374207
phosphorylation O O 0.9042592644691467
within O O 0.9999434947967529
seconds O O 0.9990643858909607

cell I-cell_type O 0.5429204106330872
types E-cell_type O 0.7183781862258911
of O O 0.9996053576469421
prostate O O 0.6725777983665466
epithelia O O 0.3975798785686493
, O O 0.9886109232902527
and O O 0.9995442032814026
neuron-specific B-protein O 0.8174791932106018
enolase E-protein O 0.3062065839767456
and O O 0.9614459276199341
serotonin O O 0.5012243390083313
, O O 0.9976903200149536
associated O O 0.9998138546943665
with O O 0.9999518394470215
neuroendocrine B-cell_type B-cell_type 0.6157291531562805
cells E-cell_type E-cell_type 0.9317222833633423

work O O 0.9786449670791626
, O O 0.9999738931655884
we O O 0.9999780654907227
identified O O 0.9999873638153076
an O O 0.9999901056289673
essential O O 0.9223431944847107
site O O 0.7069787383079529
in O O 0.9998284578323364
the O O 0.9998340606689453
c-sis/PDGF-B B-DNA B-DNA 0.6533874273300171
promoter E-DNA E-DNA 0.9922509789466858
, O O 0.9965943694114685
Tax-responsive B-DNA B-DNA 0.4636900722980499
element I-DNA I-DNA 0.5267077684402466
1 E-DNA E-DNA 0.9819303154945374
( O O 0.9868284463882446
TRE1 S-DNA S-DNA 0.9937984347343445
) O O 0.9635250568389893
, O O 0.9995595812797546
necessary O O 0.9995331764221191
for O O 0.9998196959495544
transactivation O O 0.9830899238586426
by O O 0.999782145023346
Tax S-protein S-protein 0.9973986148834229
. O O 0.9998248219490051
We O O 0.9999313354492188
also O O 0.9999538660049438
identified O O 0.9997928738594055
Sp1 S-protein S-protein 0.9369205832481384
, O O 0.9660468697547913
Sp3 O S-protein 0.96939617395401
, O O 0.9802170395851135
and O O 0.9939145445823669
NGFI-A/Egr-1 S-protein S-protein 0.9715222716331482
as O O 0.9998480081558228
the O O 0.9999750852584839
primary B-protein O 0.8916729092597961
nuclear I-protein B-protein 0.755560576915741
transcription I-protein I-protein 0.47189173102378845
factors E-protein E-protein 0.984149158000946
binding O O 0.9929677248001099
to O O 0.9998462200164795
TRE1 S-DNA S-DNA 0.8355004191398621
which O O 0.999639630317688
mediate O O 0.9977627992630005
Tax S-protein S-protein 0.9902424216270447
responsiveness O O 0.9957295060157776
. O O 0.9999959468841553
In O O 0.9991027116775513

Time O O 0.9917901754379272
course O O 0.9995841383934021
of O O 0.9999672174453735
lipid O O 0.6755244731903076
peroxidation O O 0.43120554089546204
in O O 0.9993404746055603
puromycin B-Chemical B-Chemical 0.9342907667160034
aminonucleoside E-Chemical I-Chemical 0.9327922463417053
- O O 0.7267429232597351
induced O O 0.9949498176574707
nephropathy O B-Disease 0.9875243902206421
. O O 0.9984458088874817

The O O 0.9997357726097107
addition O O 0.9997242093086243
of O O 0.9996861219406128
ephedrine S-Chemical B-Chemical 0.9321774244308472
to O O 0.958842933177948
propofol S-Chemical B-Chemical 0.9292037487030029
appears O O 0.9932217597961426
to O O 0.9999599456787109
be O O 0.9999867677688599
an O O 0.9999816417694092
effective O O 0.996369481086731
method O O 0.9997585415840149
of O O 0.9999449253082275
obtunding O O 0.9542578458786011
the O O 0.992988646030426
hypotensive O O 0.9001137018203735
response O O 0.585436999797821
to O O 0.9965554475784302
propofol S-Chemical B-Chemical 0.9288430213928223
at O O 0.9995445609092712
all O O 0.9998877048492432
doses O O 0.9996869564056396
used O O 0.9999878406524658
in O O 0.999996542930603
this O O 0.9999911785125732
study O O 0.9999328851699829
. O O 0.9999990463256836

type O O 0.44632476568222046
1 O O 0.4504075348377228
( O O 0.8482847213745117
HSV-1 O O 0.51716548204422
) O O 0.4247908890247345
activates O O 0.9437289237976074
expression O O 0.9955228567123413
of O O 0.9999669790267944
the O O 0.9997325539588928
human O O 0.5047050714492798
immunodeficiency O O 0.4130251109600067
virus O O 0.5144391059875488
type O O 0.47115835547447205
1 O O 0.3899914026260376
( O O 0.8283321857452393
HIV-1 O O 0.5878158807754517
) O O 0.787723958492279
provirus O O 0.7221781611442566
in O O 0.9996138215065002
T B-cell_type B-cell_type 0.8984978795051575
cells E-cell_type E-cell_type 0.9912569522857666
. O O 0.9996858835220337
Activation O O 0.9990066885948181
of O O 0.9999719858169556
the O O 0.999607503414154
HIV-1 O O 0.5189939141273499
provirus O O 0.44602513313293457

Associations O O 0.983002245426178
between O O 0.9994612336158752
use O O 0.999786913394928
of O O 0.9998154044151306
benzodiazepines B-Chemical B-Chemical 0.9133095741271973
or O O 0.9955381155014038
related O O 0.9714188575744629
drugs O O 0.8495948314666748
and O O 0.9984973669052124
health O O 0.9103484749794006
, O O 0.9975033402442932
physical O O 0.960785984992981
abilities O O 0.7811881303787231
and O O 0.9986207485198975
cognitive O O 0.8911113142967224
function O O 0.6431443691253662
: O O 0.9992818236351013
a O O 0.9999856948852539
non O O 0.9824396371841431
- O O 0.9985178112983704
randomised O O 0.9766196608543396
clinical O O 0.9918006062507629
study O O 0.9995802044868469
in O O 0.9999942779541016
the O O 0.9997900128364563
elderly O O 0.9179052710533142
. O O 0.9999876022338867

that O O 0.9967107772827148
mediate O O 0.9929240942001343
interleukin O O 0.668811023235321
responsiveness O O 0.9416971206665039
of O O 0.9998093247413635
the O O 0.9999697208404541
mouse B-DNA B-DNA 0.5316634774208069
IL-2R I-DNA I-DNA 0.4952021837234497
alpha I-DNA I-DNA 0.4747278392314911
gene E-DNA E-DNA 0.9911973476409912
using O O 0.999620795249939
a O O 0.9997760653495789
thymic B-cell_line B-cell_line 0.5843760967254639
lymphoma-derived I-cell_line I-cell_line 0.40635183453559875
hybridoma E-cell_line E-cell_line 0.75295490026474
( O O 0.9768983125686646
PC60 S-cell_line O 0.4206460118293762
) O O 0.9867087602615356
. O O 0.9999786615371704
The O O 0.9999961853027344
transcriptional O O 0.8964031338691711
response O O 0.9758663773536682
of O O 0.9995611310005188
the O O 0.9996145963668823
IL-2R B-DNA B-DNA 0.5768905878067017

the O O 0.9993290901184082
first O O 0.9908971190452576
description O O 0.9987838864326477
of O O 0.9999867677688599
a O O 0.9999239444732666
negative B-DNA B-DNA 0.7514861822128296
regulatory I-DNA I-DNA 0.45284295082092285
region E-DNA E-DNA 0.7631889581680298
responsive O O 0.9886888861656189
to O O 0.9998995065689087
glucocorticoids O O 0.7530730962753296
in O O 0.999839186668396
a O O 0.9998188614845276
cytokine B-DNA B-DNA 0.4856569170951843
gene E-DNA E-DNA 0.9883536100387573
. O O 0.9997569918632507
Interaction O O 0.9983614087104797
of O O 0.9999349117279053
transcription B-protein B-protein 0.49468761682510376
factors E-protein E-protein 0.9927122592926025
RFX1 S-protein S-protein 0.9719575643539429
and O O 0.9956315755844116
MIBP1 S-protein S-protein 0.9835705757141113
with O O 0.9987188577651978

level O O 0.9768041968345642
in O O 0.9997931122779846
monocyte-derived B-cell_type B-cell_type 0.41480350494384766
macrophages E-cell_type E-cell_type 0.8216865658760071
, O O 0.9982459545135498
and O O 0.9999774694442749
this O O 0.9999837875366211
occurred O O 0.9999650716781616
whether O O 0.9999978542327881
these O O 0.9999755620956421

proteins E-protein E-protein 0.9329124689102173
have O O 0.9997908473014832
been O O 0.9999648332595825
suggested O O 0.999953031539917
to O O 0.9999793767929077
play O O 0.9998815059661865
an O O 0.9999868869781494
important O O 0.9994189739227295
role O O 0.9997939467430115
in O O 0.9999877214431763
gene O O 0.9773361086845398
transcription O O 0.9924265146255493
of O O 0.9999178647994995
inflammatory B-protein B-protein 0.5092898607254028
mediators E-protein E-protein 0.8640272617340088
when O O 0.9994572997093201
monocytes S-cell_type S-cell_type 0.9841411113739014
are O O 0.9995050430297852
stimulated O O 0.9984762072563171
with O O 0.9999809265136719
lipopolysaccharide O O 0.9166591167449951
. O O 0.9999643564224243
Nonsteroidal O O 0.9078612327575684

or O O 0.9832704663276672
HIV-1 B-protein O 0.8575149178504944
gp120 E-protein O 0.34639662504196167
could O O 0.9995642304420471
all O O 0.999984860420227
trigger O O 0.999768078327179
activation O O 0.9979090690612793
of O O 0.9999569654464722
the O O 0.999883770942688
protein B-protein B-protein 0.5824865698814392
tyrosine I-protein I-protein 0.703657865524292
kinases E-protein E-protein 0.989346444606781
p56lck S-protein S-protein 0.9709751605987549
and O O 0.9882867932319641
p59fyn S-protein S-protein 0.9474563598632812
and O O 0.9860644340515137
phosphorylation O O 0.9461084604263306
of O O 0.9982022047042847
the O O 0.9996588230133057
Shc B-protein B-protein 0.6294678449630737
adaptor I-protein I-protein 0.6694788336753845
protein E-protein E-protein 0.9843367338180542
, O O 0.9916292428970337
which O O 0.9999405145645142
mediates O O 0.99871826171875
signals O O 0.9708665013313293
to O O 0.9968223571777344
Ras S-protein S-protein 0.9472158551216125
, O O 0.988946259021759
they O O 0.9998494386672974
differed O O 0.9996285438537598
significantly O O 0.9999282360076904
in O O 0.9999631643295288
their O O 0.9999237060546875
ability O O 0.9995455145835876
to O O 0.9999731779098511
activate O O 0.9983140230178833
NF-AT S-protein S-protein 0.9893295168876648
. O O 0.9999411106109619
Lack O O 0.9968098998069763
of O O 0.9995613694190979
full O O 0.9738540053367615
activation O O 0.9886965751647949

Beginning O O 0.9983924031257629
on O O 0.9999699592590332
day O O 0.9995852112770081
22 O O 0.9988754391670227
, O O 0.9999961853027344
all O O 0.9999548196792603
rats O O 0.9962418079376221
were O O 0.9999805688858032
maintained O O 0.999940037727356
on O O 0.9999736547470093
ad O O 0.8991889953613281
libitum O O 0.7795405983924866
chow O O 0.9271955490112305
. O O 0.9999972581863403

the O O 0.9962015748023987

) O O 0.626071572303772
in O O 0.9985546469688416
peripheral B-cell_type B-cell_type 0.6374212503433228
leukocytes E-cell_type E-cell_type 0.9782061576843262
was O O 0.9996645450592041
determined O O 0.9999936819076538
by O O 0.9999936819076538
radioligand-binding O O 0.9454055428504944
assay O O 0.9978377223014832
in O O 0.9999778270721436
extrinsic O O 0.6563294529914856
and O O 0.8847288489341736
intrinsic O O 0.7842242121696472
asthmatics O O 0.8097019791603088
. O O 0.999985933303833
Their O O 0.9999964237213135
corresponding O O 0.9692659378051758
plasma O O 0.8829785585403442
cortisol O O 0.758691132068634
levels O O 0.9995519518852234
were O O 0.9999969005584717
assessed O O 0.9999464750289917

rapamycin O O 0.31972524523735046
and O O 0.9938389658927917
RAD O S-protein 0.6624680757522583
. O O 0.9994534850120544
Clonality O O 0.972165048122406
analysis O O 0.9992710947990417
using O O 0.9999774694442749
X-chromosome S-DNA O 0.6060833930969238
inactivation O O 0.9052071571350098
at O O 0.9999350309371948
the O O 0.9999445676803589
human B-DNA B-DNA 0.43148767948150635
androgen I-DNA I-DNA 0.49318087100982666

PKC S-protein S-protein 0.5451542139053345
) O O 0.9732481837272644
, O O 0.9999444484710693
we O O 0.9999947547912598
examined O O 0.9999443292617798
translocation O O 0.9916096329689026
of O O 0.9998379945755005
PKC S-protein S-protein 0.9341681599617004
from O O 0.9998273849487305
the O O 0.999742329120636
cytosol O O 0.8285012245178223
to O O 0.998254120349884
the O O 0.9996720552444458
membrane O O 0.8458541631698608
fraction O O 0.8267974853515625
. O O 0.9998906850814819
Although O O 0.9999289512634277
HL-60 S-cell_line S-cell_line 0.8873924612998962
and O O 0.8761874437332153
HL-60/vinc/R B-cell_line B-cell_line 0.3999592661857605
cells E-cell_line E-cell_line 0.9494694471359253
demonstrated O O 0.9987419247627258
translocation O O 0.9940084218978882
of O O 0.9999040365219116
PKC S-protein S-protein 0.9704656600952148
activity O O 0.9982629418373108
, O O 0.9999972581863403
this O O 0.9999780654907227
subcellular O O 0.930530309677124
redistribution O O 0.9816717505455017
was O O 0.9999462366104126
undetectable O O 0.998889148235321
in O O 0.9998334646224976
HL-60/vinc B-cell_line B-cell_line 0.801429271697998
cells E-cell_line E-cell_line 0.9732394814491272
. O O 0.9999053478240967
Activity O O 0.999562680721283
of O O 0.999962329864502
the O O 0.9999063014984131
mitogen-activated B-protein B-protein 0.49224990606307983
protein I-protein E-protein 0.734264612197876

phosphatase E-protein O 0.4890578091144562
specific O O 0.8490225076675415
inhibitor O O 0.7895234823226929
pervanadate O O 0.6015855669975281
is O O 0.9998701810836792
a O O 0.9999866485595703
potent O O 0.988017201423645
activator O O 0.8662130236625671
of O O 0.9956685304641724
T B-cell_type B-cell_type 0.7480313777923584
lymphocytes E-cell_type E-cell_type 0.996044397354126
through O O 0.9996352195739746
induction O O 0.9922899603843689
of O O 0.9998389482498169
tyrosine B-protein O 0.5516170263290405
phosphorylation E-protein O 0.6809121966362
and O O 0.9800352454185486
downstream O O 0.8586785793304443
events O O 0.9723233580589294
of O O 0.9997003078460693
the O O 0.9999722242355347
activation O O 0.8736059665679932
cascade O O 0.8578307628631592
. O O 0.9998533725738525
Using O O 0.9997220635414124
CD45- B-cell_line O 0.4619998037815094
or I-cell_line O 0.8924460411071777
CD3-negative I-cell_line O 0.49648168683052063
variants E-cell_line O 0.42838194966316223
of O O 0.9993513226509094
the O O 0.999624490737915
Jurkat B-cell_line B-cell_line 0.577994704246521

gp120 S-protein S-protein 0.8228058815002441
to O O 0.9988672733306885
the O O 0.9999046325683594
cell O B-protein 0.8624612092971802
surface O I-protein 0.5809755325317383
molecule O E-protein 0.9542144536972046
( O O 0.984442412853241
s O O 0.8983717560768127
) O O 0.8967434167861938
appears O O 0.999927282333374
to O O 0.9999922513961792
affect O O 0.9999926090240479
intracellular O O 0.9193888902664185
IL-2 S-protein S-protein 0.8807671070098877
signaling O O 0.9683936238288879
, O O 0.9998096823692322
which O O 0.9999765157699585
leads O O 0.9999721050262451
to O O 0.9999896287918091
the O O 0.9999392032623291
suppression O O 0.9966598749160767
of O O 0.9999290704727173
IL-2 S-protein S-protein 0.9817419648170471
-induced O O 0.9944288730621338
T O O 0.7732790112495422
cell O O 0.6699879765510559
growth O O 0.9082621335983276
A O O 0.9519870281219482

phosphatase E-protein S-protein 0.5691187977790833
activity O O 0.9940620064735413
, O O 0.9999761581420898
inhibits O O 0.9998520612716675
H2O2 O O 0.38943567872047424
release O O 0.8623508810997009
from O O 0.9995006322860718
human B-cell_type B-cell_type 0.7147834897041321
peripheral I-cell_type I-cell_type 0.865458607673645
blood I-cell_type I-cell_type 0.9595649838447571
mononuclear I-cell_type I-cell_type 0.9681812524795532
cells E-cell_type E-cell_type 0.9733251929283142
( O O 0.9633987545967102

after O O 0.9959633350372314
replating O O 0.9968230724334717
on O O 0.9995738863945007
2M-1 B-cell_line B-cell_line 0.7626885175704956
cells E-cell_line E-cell_line 0.9723641872406006
. O O 0.9998979568481445
In O O 0.9996572732925415
agar O B-cell_line 0.42775505781173706
cultures O E-cell_line 0.9749861359596252
, O O 0.999591052532196
47.10 B-cell_line B-cell_line 0.797715425491333
cells E-cell_line E-cell_line 0.934794545173645
form O O 0.9984548091888428
7- O O 0.988628625869751
and O O 0.9990831613540649
14-day O O 0.9866073131561279

Manic O B-Disease 0.8168097734451294
excitement O I-Disease 0.9375922679901123
was O O 0.9544568657875061
coincident O O 0.9792429208755493
with O O 0.9999927282333374
the O O 0.9999635219573975
duration O O 0.999066174030304
of O O 0.9999655485153198
action O O 0.9308156967163086
of O O 0.9960414171218872
triazolam S-Chemical B-Chemical 0.9215074777603149
. O O 0.9992843270301819

) O O 0.6935757398605347
. O O 0.9983141422271729
YJ B-cell_line B-cell_line 0.8495299816131592
cells E-cell_line E-cell_line 0.9760190844535828
treated O O 0.9994745850563049
in O O 0.9999221563339233
vitro O O 0.9894317388534546
with O O 0.9999814033508301
2 O O 0.9905773401260376
microM O O 0.9804650545120239
RA O O 0.9256311058998108
differentiated O O 0.9962298274040222
into O O 0.9992868304252625
metamyelocytes S-cell_type S-cell_type 0.975642204284668
and O O 0.9912446141242981
band B-cell_type B-cell_type 0.37641167640686035
neutrophils E-cell_type E-cell_type 0.8912674188613892
, O O 0.9985032081604004
and O O 0.9999765157699585
increased O O 0.9997085928916931
the O O 0.9997603297233582

the O O 0.9975244402885437
cultures O O 0.932174026966095
with O O 0.9999916553497314
high O O 0.986403226852417
doses O O 0.9987939596176147
of O O 0.9999362230300903
IL-2 O S-protein 0.9488179087638855
reverted O O 0.9988967180252075
anti- O O 0.9125893712043762
TNF-alpha S-protein S-protein 0.746726393699646
inhibition O O 0.994771420955658
of O O 0.9999493360519409
cell O O 0.9526360034942627
proliferation O O 0.9933218359947205
but O O 0.9999817609786987
did O O 0.9999790191650391
not O O 0.9999833106994629
affect O O 0.9999922513961792
the O O 0.9999167919158936
inhibition O O 0.9953755140304565
of O O 0.9999473094940186
HIV O B-protein 0.588612973690033
p24 B-protein I-protein 0.5802363753318787
antigen E-protein E-protein 0.939927339553833

The O O 0.9979023933410645
patient O O 0.9965667724609375
was O O 0.9998983144760132
successfully O O 0.9985300302505493
treated O O 0.9999412298202515
with O O 0.9999912977218628
a O O 0.9994217157363892
graft O O 0.7737761735916138
stent O O 0.6541889309883118
. O O 0.9999780654907227

Fasciculations B-Disease O 0.9119621515274048
in O O 0.9736179113388062
the O O 0.9963966012001038
six O O 0.9985601305961609
areas O O 0.999914288520813
and O O 0.9999966621398926
the O O 0.9999685287475586
total O O 0.9831318855285645
fasciculation B-Disease O 0.7766292095184326
score O O 0.7750096321105957
were O O 0.999863862991333
related O O 0.9999794960021973
directly O O 0.9999551773071289
to O O 0.9999847412109375
the O O 0.9998965263366699
rate O O 0.9999532699584961
of O O 0.9998857975006104
infusion O O 0.845450758934021
. O O 0.99993896484375

A O O 0.9898943305015564
patient O O 0.9985509514808655
is O O 0.9999476671218872
reported O O 0.9998608827590942
who O O 0.9997537732124329
developed O O 0.9980931878089905
progressive O O 0.7526114583015442
cardiomyopathy B-Disease B-Disease 0.5759010314941406
two O O 0.9354991912841797
and O O 0.9991291165351868
one O O 0.9999099969863892
- O O 0.9999182224273682
half O O 0.9999279975891113
years O O 0.9999890327453613
after O O 0.9999879598617554
receiving O O 0.9998685121536255
580 O O 0.9975727200508118
mg O O 0.998794436454773
/ O O 0.9998877048492432
m2 O O 0.9956218600273132
which O O 0.9999780654907227
apparently O O 0.9998086094856262
represents O O 0.9999575614929199
late O O 0.9834776520729065
, O O 0.9992747902870178
late O O 0.98661208152771
cardiotoxicity B-Disease O 0.9321039915084839
. O O 0.9989696741104126

induction O O 0.9697011113166809
of O O 0.999380350112915
NF-AT S-protein S-protein 0.9859842658042908
, O O 0.9927638173103333
AP-1 S-protein S-protein 0.9865555763244629
, O O 0.9897668957710266
and O O 0.9985529780387878
NF-kappaB S-protein S-protein 0.9972894191741943
as O O 0.9986727237701416
well O O 0.9987542629241943
as O O 0.9999821186065674
IL-2 S-protein S-protein 0.9687759876251221
production O O 0.994628369808197
. O O 0.9999915361404419
Using O O 0.9999520778656006
selective O O 0.947262704372406
inhibitors O O 0.9070810079574585
, O O 0.999954104423523
we O O 0.9999616146087646
investigated O O 0.9999767541885376
the O O 0.999962568283081
signaling O O 0.9125425219535828

The O O 0.9995984435081482
65 O O 0.9895003437995911
dogs O O 0.9936987161636353
in O O 0.9999908208847046
the O O 0.9999641180038452
study O O 0.9986328482627869
received O O 0.9999040365219116
injections O O 0.7667147517204285
in O O 0.9993171691894531
the O O 0.9998266100883484
subarachnoid O O 0.7117193341255188
space O O 0.9507035613059998
as O O 0.9999434947967529
follows O O 0.9998538494110107
: O O 0.9999780654907227
6 O O 0.9995594620704651
to O O 0.9998716115951538
8 O O 0.9998384714126587
ml O O 0.9983553290367126
of O O 0.9976823329925537
bupivacaine B-Chemical B-Chemical 0.9410313963890076
( O O 0.9851992130279541
N O O 0.7021550536155701
= O O 0.7726843953132629
15 O O 0.7112271189689636
) O O 0.5398877263069153
, O O 0.9867695569992065
2 B-Chemical B-Chemical 0.5904967188835144
- I-Chemical I-Chemical 0.9708501100540161
chloroprocaine I-Chemical I-Chemical 0.9369456171989441
- I-Chemical I-Chemical 0.97589510679245
CE I-Chemical I-Chemical 0.9277202486991882
( O O 0.9616146683692932
N O O 0.7898060083389282
= O O 0.9897204041481018
20 O O 0.9733771681785583
) O O 0.9977418184280396
, O O 0.9999943971633911
low O O 0.9788805842399597
pH O O 0.7490370869636536
normal O O 0.9681112170219421
saline O O 0.7087917923927307
( O O 0.9996860027313232
pH O O 0.9399697780609131
3 O O 0.9816182255744934
. O O 0.999734103679657
0 O O 0.999000608921051
) O O 0.9984999895095825
( O O 0.9999862909317017
N O O 0.9944656491279602
= O O 0.9997879862785339
20 O O 0.9976108074188232
) O O 0.9996077418327332
, O O 0.9999858140945435
or O O 0.9999417066574097
normal O O 0.9528803825378418
saline O O 0.9047831892967224
( O O 0.9999003410339355
N O O 0.9769279956817627
= O O 0.9997014403343201
10 O O 0.9990166425704956
) O O 0.9997908473014832
. O O 0.999997615814209

acts O O 0.7129485011100769
in O O 0.9998881816864014
biological O O 0.948215126991272
systems O O 0.9621228575706482
mainly O O 0.9999657869338989
as O O 0.9999951124191284
an O O 0.9999239444732666
oxidant O O 0.8829330205917358
, O O 0.9990823268890381
and O O 0.9999765157699585
through O O 0.9999891519546509
its O O 0.9999773502349854
role O O 0.9990304708480835
in O O 0.99998939037323
the O O 0.9999825954437256
plasma O O 0.9120446443557739
membrane O O 0.8716384768486023
redox O O 0.7997393012046814
system O O 0.9674947261810303
exerts O O 0.9999251365661621
different O O 0.9987900853157043
effects O O 0.9997851252555847
on O O 0.9999788999557495
the O O 0.9997305274009705
cell O O 0.9715620875358582
. O O 0.9999672174453735
We O O 0.999984622001648
have O O 0.9999963045120239
investigated O O 0.9999843835830688
the O O 0.9999792575836182
role O O 0.9998526573181152
of O O 0.9999812841415405
ascorbate O O 0.5455541014671326
, O O 0.9880984425544739
AFR O S-protein 0.6967456340789795
and O O 0.989974319934845
dehydroascorbate O O 0.7375630140304565
( O O 0.9932147264480591
DHA O O 0.6141567230224609
) O O 0.9909511804580688
in O O 0.9999798536300659
the O O 0.9999514818191528
activation O O 0.959703803062439

, O O 0.9737632274627686
LANDs O S-protein 0.5426000952720642
could O O 0.9994657635688782
be O O 0.9999850988388062
visualized O O 0.9987255930900574
in O O 0.9999412298202515
HeLa B-cell_line B-cell_line 0.9108655452728271
cells E-cell_line E-cell_line 0.9955213069915771
by O O 0.999930739402771
transfection O O 0.9902053475379944
of O O 0.9998599290847778
a O O 0.9993002414703369
LYSP100 B-DNA B-DNA 0.4947538673877716
cDNA E-DNA E-DNA 0.967431366443634
. O O 0.9993826150894165
Immunoelectron O O 0.7203912734985352
microscopy O O 0.8581055402755737
revealed O O 0.9983941912651062
LANDs O O 0.38872674107551575
to O O 0.9972547888755798
be O O 0.999760091304779
globular O O 0.7210872173309326

P O O 0.942979097366333
= O O 0.9993252754211426
0.045 O O 0.9997896552085876
; O O 0.9999732971191406
P O O 0.9985367059707642
= O O 0.9998610019683838
0.029 O O 0.9995469450950623
) O O 0.9997445940971375
. O O 0.9999910593032837
CONCLUSIONS O O 0.9991027116775513
: O O 0.9999796152114868
The O O 0.9999879598617554
increased O O 0.9881046414375305
number O O 0.99285489320755
and O O 0.9997566342353821
apparent O O 0.9937871694564819
dissociation O O 0.9736685156822205
constant O O 0.9898354411125183
of O O 0.9998996257781982
glucocorticoid B-protein B-protein 0.6269832253456116
receptor E-protein E-protein 0.9866494536399841
are O O 0.9993466734886169
closely O O 0.9977317452430725
associated O O 0.9999446868896484
with O O 0.9999972581863403
the O O 0.9999662637710571
effectiveness O O 0.9997538924217224
of O O 0.9999829530715942
glucocorticoid O O 0.8631160259246826
therapy O O 0.9931760430335999
. O O 0.9999967813491821
The O O 0.9999951124191284
measurement O O 0.9958111047744751
of O O 0.9998705387115479
the O O 0.9999316930770874
number O O 0.9632651209831238
and O O 0.9948776960372925
apparent O O 0.9900366067886353
dissociation O O 0.9474275708198547
constant O O 0.9488365650177002
of O O 0.9993632435798645
glucocorticoid B-protein B-protein 0.7557055354118347
receptor E-protein E-protein 0.951163649559021
may O O 0.9954138398170471

RNA S-RNA E-RNA 0.8947041034698486
through O O 0.9997456669807434
the O O 0.9999700784683228
intervening O O 0.902706503868103
DNA S-DNA O 0.6020007729530334
and O O 0.9807353615760803
the O O 0.9994879961013794
gene O O 0.9527611136436462
by O O 0.9999741315841675
a O O 0.9998513460159302
tracking O O 0.9050003290176392
and O O 0.9751771092414856
transcription O O 0.8949835300445557
mechanism O O 0.9702028036117554
, O O 0.9999951124191284
the O O 0.9999812841415405
HS2 B-DNA B-DNA 0.45451539754867554
enhancer E-DNA E-DNA 0.9879746437072754
may O O 0.9985270500183105
( O O 0.9998997449874878
i O O 0.9978498220443726
) O O 0.9990164041519165
open O O 0.9996131062507629
up O O 0.999970555305481
the O O 0.9999005794525146
chromatin B-DNA O 0.2792483866214752
structure E-DNA O 0.48375383019447327
of O O 0.9911784529685974

expression O O 0.9874237179756165
of O O 0.9999316930770874
other O O 0.9944701194763184
monocytic B-DNA B-DNA 0.33406421542167664
genes E-DNA E-DNA 0.9621909856796265
( O O 0.9920164346694946
TNF-alpha S-DNA S-protein 0.6594313979148865
, O O 0.9733359217643738
IL-1beta S-DNA S-protein 0.6563916802406311
, O O 0.9907786846160889
IL-6 S-DNA S-protein 0.8745948076248169
, O O 0.9935585856437683
IL-8 S-DNA S-protein 0.8923029899597168
, O O 0.9933269023895264
IL-10 S-DNA S-protein 0.811289370059967
, O O 0.9941282272338867
ICAM-1 S-DNA S-protein 0.5139179825782776
) O O 0.9792055487632751
activated O O 0.9970510005950928
by O O 0.9999887943267822
exposure O O 0.9947581887245178
to O O 0.99996018409729
a O O 0.9997319579124451
pro-inflammatory O O 0.7476082444190979
stimulus O O 0.6647264361381531
( O O 0.9958310723304749
lipopolysaccharide O O 0.9022364020347595
, O O 0.996009349822998

agent O O 0.7755164504051208
that O O 0.9997420907020569
promotes O O 0.9988086223602295
eosinophil S-cell_type O 0.7038633823394775
apoptosis O O 0.9532442092895508
while O O 0.9999688863754272
inhibiting O O 0.997917115688324
neutrophil S-cell_type O 0.7204374670982361
apoptosis O O 0.9558659791946411
, O O 0.9998334646224976
and O O 0.9999634027481079
thus O O 0.9999836683273315
presents O O 0.999988317489624
a O O 0.9999909400939941
novel O O 0.9860246777534485
approach O O 0.9997407793998718
to O O 0.999993085861206
the O O 0.9999860525131226
study O O 0.9996334314346313
of O O 0.9999548196792603
control O O 0.9892264008522034
of O O 0.999826967716217
apoptosis O O 0.9654481410980225
in O O 0.9999727010726929
these O O 0.9996672868728638

more O O 0.9972634315490723
than O O 0.9999631643295288
4 O O 0.9989954829216003
weeks O O 0.9997748732566833
. O O 0.9999864101409912
hGR S-protein S-protein 0.8857650756835938
levels O O 0.9968020915985107
were O O 0.9999935626983643
determined O O 0.999984860420227
from O O 0.9999768733978271
isolated O O 0.7728940844535828
cytosol O O 0.712934136390686
of O O 0.9974793791770935
peripheral B-cell_type B-cell_type 0.5595143437385559
blood I-cell_type I-cell_type 0.814918041229248
mononuclear I-cell_type I-cell_type 0.9085244536399841
cells E-cell_type E-cell_type 0.9259132146835327
( O O 0.97053062915802
PBMCs S-cell_type S-cell_type 0.764622688293457
) O O 0.9881922602653503
or O O 0.999843955039978
mucosal O O 0.6533095836639404
biopsies O O 0.4698529541492462
using O O 0.9995218515396118
a O O 0.9999065399169922
radioassay O O 0.7363683581352234
with O O 0.999019980430603
[ O O 0.945044994354248
3H O O 0.7353165745735168
] O O 0.75858473777771
-dexamethasone O O 0.46335071325302124
. O O 0.9996975660324097

and O O 0.9805651307106018
whether O O 0.999893069267273
antibodies S-protein O 0.49088218808174133
to O O 0.9796975255012512
T-antigen S-protein S-protein 0.3591580092906952
, O O 0.9008492231369019
DNA O O 0.5540124177932739
, O O 0.9908004403114319
and O O 0.9990891218185425
to O O 0.9998598098754883
TBP S-protein S-protein 0.7913092374801636
and O O 0.9861041903495789
CREB S-protein S-protein 0.8576963543891907
are O O 0.9998089671134949
linked O O 0.9999364614486694
to O O 0.9999936819076538
such O O 0.9997569918632507
events O O 0.9984184503555298
. O O 0.9999974966049194
Both O O 0.9999788999557495
within O O 0.9992947578430176
and O O 0.999762237071991
among O O 0.9999759197235107
these O O 0.9999359846115112
SLE O O 0.4591478407382965
patients O O 0.9597947597503662
, O O 0.9999909400939941
frequent O O 0.9753550291061401
polyomavirus O O 0.776534914970398
reactivations O O 0.9672621488571167
were O O 0.999988317489624
observed O O 0.999911904335022
that O O 0.9999886751174927
could O O 0.9999920129776001
not O O 0.9999639987945557
be O O 0.9998999834060669

Two O O 0.996498703956604
patients O O 0.9992293119430542
are O O 0.9999938011169434
presented O O 0.9999836683273315
with O O 0.9999867677688599
tingling O O 0.7496824264526367
or O O 0.9000973701477051
burning O O 0.6599080562591553
sensations O O 0.812508761882782
limited O O 0.9509868025779724
to O O 0.9990403056144714
areas O O 0.9994768500328064
of O O 0.9998840093612671
heat O O 0.633592963218689
exposure O O 0.8410009145736694
or O O 0.9680742025375366
sunburn O O 0.9333745837211609
. O O 0.9986572265625

, O O 0.961359977722168
DHEA O O 0.4442691206932068
and O O 0.993051290512085
LPS O O 0.9079203009605408
0.2 O O 0.9145777821540833
ng/ml O O 0.7951645255088806
displayed O O 0.9998811483383179
a O O 0.9999603033065796
synergistic O O 0.9716038703918457
effect O O 0.9988762736320496
on O O 0.9999850988388062
monocyte O O 0.6326925158500671
cytotoxicity O O 0.7720016241073608

monocytic B-protein O 0.6554874777793884
IkappaB I-protein S-protein 0.6642747521400452
kinase E-protein O 0.7586379647254944
signalsome O O 0.3727213144302368
activation O O 0.9214997887611389
and O O 0.9975800514221191
IkappaB S-protein S-protein 0.9108293652534485
proteolysis O O 0.8962001204490662
. O O 0.9999169111251831
The O O 0.9999905824661255
inflammatory O O 0.7521718144416809
mediators O O 0.5995651483535767
lipopolysaccharide O O 0.660298764705658
( O O 0.9749271869659424
LPS O O 0.8248829245567322
) O O 0.9648891091346741

compared O O 0.991432785987854

is O O 0.9954869151115417
unclear O O 0.9993440508842468
. O O 0.9999971389770508
Steroid O O 0.9514204859733582
resistance O O 0.9952865242958069
can O O 0.9999912977218628
not O O 0.9999833106994629
be O O 0.9999903440475464
explained O O 0.9998834133148193
by O O 0.9999918937683105
pharmacokinetic O O 0.9191838502883911
mechanisms O O 0.9765800833702087
, O O 0.9999793767929077
by O O 0.999997615814209
a O O 0.9999072551727295
defect O O 0.9975237250328064
in O O 0.9999901056289673
the O O 0.9997968077659607
binding O O 0.9834457039833069
of O O 0.9997957348823547
steroids O O 0.8811250329017639
to O O 0.9990647435188293
glucocorticoid B-protein B-protein 0.4315880537033081
receptors E-protein E-protein 0.9886128306388855
, O O 0.9976760745048523
nor O O 0.999858021736145
by O O 0.9999891519546509
defective O O 0.946108877658844
nuclear O O 0.9215870499610901
translocation O O 0.9570525884628296
of O O 0.9987607002258301
this O O 0.9999423027038574

' I-DNA I-DNA 0.7777763605117798
62 I-DNA I-DNA 0.7604284882545471
base I-DNA I-DNA 0.6094893217086792
pairs E-DNA E-DNA 0.8410813212394714
are O O 0.9994601607322693
needed O O 0.9999942779541016
for O O 0.9999932050704956
erythroid-specific O O 0.7905799150466919
reporter O O 0.4158996641635895
expression O O 0.9770104885101318
. O O 0.999987006187439
These O O 0.9999977350234985
findings O O 0.9999512434005737
demonstrate O O 0.9999940395355225
differential O O 0.9907875657081604
lineage O O 0.9716385006904602
requirements O O 0.9972921013832092
for O O 0.9999816417694092
expression O O 0.9986414313316345
within O O 0.9999946355819702
the O O 0.9999659061431885
HS B-DNA B-DNA 0.6762869954109192
I I-DNA I-DNA 0.6330175995826721
element E-DNA E-DNA 0.9886844754219055
. O O 0.9997527003288269
Non-steroidal O O 0.9459049701690674
anti-inflammatory O O 0.924572765827179
drugs O O 0.9840606451034546
inhibit O O 0.9996806383132935

product O E-protein 0.8100696802139282
of O O 0.9939947724342346
the O O 0.9999059438705444
c-rel B-DNA B-DNA 0.2737584710121155
protooncogene E-DNA E-DNA 0.5110265016555786
( O O 0.8964598774909973
c-Rel S-protein S-protein 0.865801215171814
) O O 0.5927618741989136
. O O 0.9998340606689453
Recent O O 0.9993243217468262
biochemical O O 0.9792113304138184
studies O O 0.9985981583595276
have O O 0.9999983310699463
shown O O 0.9999957084655762
that O O 0.9999891519546509
p65 S-protein S-protein 0.9548888802528381
and O O 0.9589970707893372
p50 S-protein S-protein 0.9476256966590881
form O O 0.9882245063781738
the O O 0.9999109506607056
prototypical O O 0.7032062411308289
NF-kappa B-protein B-protein 0.6436808109283447
B I-protein I-protein 0.5578261613845825
complex E-protein E-protein 0.9912171363830566
, O O 0.9971006512641907
which O O 0.9999589920043945
is O O 0.9999680519104004
rapidly O O 0.9978546500205994
translocated O O 0.9944522976875305
from O O 0.9999352693557739

A O O 0.9983661770820618
detailed O O 0.9956421852111816
clinical O O 0.9944361448287964
history O O 0.99470055103302
, O O 0.9999960660934448
together O O 0.9999971389770508
with O O 0.9999945163726807
skin O O 0.9407787322998047
tests O O 0.9950768351554871
, O O 0.9999916553497314
RAST O O 0.440469890832901
( O O 0.997718334197998
radioallergosorbent O O 0.6743331551551819
test O O 0.9337579607963562
) O O 0.9996052384376526
, O O 0.9999812841415405
and O O 0.9999686479568481
controlled O O 0.9733980298042297
challenge O O 0.9691247344017029
tests O O 0.9985346794128418
, O O 0.9999959468841553
was O O 0.9999585151672363
used O O 0.9999958276748657
to O O 0.9999933242797852
establish O O 0.9999901056289673
whether O O 0.9999874830245972
patients O O 0.9988059997558594
allergic B-Disease O 0.5111638903617859
to O O 0.980340301990509
beta B-Chemical B-Chemical 0.6258143782615662
- I-Chemical I-Chemical 0.9145315289497375
lactam I-Chemical E-Chemical 0.9241805076599121
antibiotics O O 0.7909113168716431
had O O 0.9996219873428345
selective O O 0.9687870740890503
immediate O O 0.9666531085968018
allergic B-Disease O 0.7180793285369873
responses O O 0.727282702922821
to O O 0.9988332390785217
amoxicillin B-Chemical B-Chemical 0.9344285726547241
( O O 0.8565577864646912
AX B-Chemical B-Chemical 0.9103286266326904
) O O 0.9389845132827759
or O O 0.9999184608459473
were O O 0.9999756813049316
cross O O 0.9678201079368591
- O O 0.9942994117736816
reacting O O 0.9987261891365051
with O O 0.9999948740005493
other O O 0.9997445940971375
penicillin B-Chemical B-Chemical 0.9038195013999939
derivatives O O 0.680164635181427
. O O 0.9999550580978394

tonsillar I-cell_type B-cell_type 0.41544395685195923
mononuclear I-cell_type I-cell_type 0.6704361438751221
cells E-cell_type E-cell_type 0.881597638130188
: O O 0.9931864738464355
role O O 0.9977794289588928
in O O 0.9999409914016724
transient O O 0.8796103596687317
up-regulation O O 0.9844265580177307
of O O 0.9998015761375427
the O O 0.9993433356285095
interleukin-4-induced B-RNA B-RNA 0.638716459274292
CD23b I-RNA I-RNA 0.9510794281959534
mRNA E-RNA E-RNA 0.991858184337616
. O O 0.999535083770752
Stimulation O O 0.9974451065063477
of O O 0.9999158382415771
human B-cell_type B-cell_type 0.4533461928367615
tonsillar I-cell_type I-cell_type 0.45045793056488037
mononuclear I-cell_type I-cell_type 0.659652829170227
cells E-cell_type E-cell_type 0.8126505613327026
with O O 0.9988497495651245
interleukin-4 S-protein S-protein 0.9702506065368652
( O O 0.9910898208618164
IL-4 S-protein S-protein 0.9918184280395508
) O O 0.9880459308624268
and O O 0.9996968507766724
interferon-gamma S-protein S-protein 0.9684619307518005
( O O 0.9890696406364441
IFN-gamma S-protein S-protein 0.9930167198181152
) O O 0.9808484315872192
rapidly O O 0.9986251592636108
induced O O 0.9999496936798096
the O O 0.9999451637268066
activation O O 0.997999370098114
of O O 0.9999557733535767
distinct O O 0.916101336479187
nuclear B-protein B-protein 0.48941168189048767
factors E-protein E-protein 0.9555158019065857
with O O 0.9979519248008728
different O O 0.9960873126983643
mobilities O O 0.9865596294403076
, O O 0.9999768733978271
both O O 0.9999772310256958

activation O O 0.9362528324127197

maturation O O 0.973249614238739
and O O 0.9996035695075989
function O O 0.9985648989677429
of O O 0.9998748302459717
the O O 0.9998074173927307
immune O O 0.9317298531532288
system O O 0.9730628132820129
as O O 0.9999384880065918
well O O 0.9997058510780334
as O O 0.9999934434890747
differentiation O O 0.993751585483551
of O O 0.999870777130127
skeletal O O 0.7569576501846313
muscle O O 0.7663807272911072
. O O 0.9998325109481812
Here O O 0.9999510049819946
we O O 0.9999929666519165
examine O O 0.999817430973053
molecular O O 0.8129715323448181

study O O 0.9961346387863159
is O O 0.9999971389770508
the O O 0.9999977350234985
first O O 0.9999752044677734
to O O 0.9999936819076538
demonstrate O O 0.999990701675415
the O O 0.9999784231185913
expression O O 0.9994683861732483
of O O 0.9999643564224243
CD14 S-protein S-protein 0.9603574275970459
in O O 0.9994449019432068
human B-cell_type B-cell_type 0.5405240654945374
gingival I-cell_type I-cell_type 0.7447057962417603
fibroblasts E-cell_type E-cell_type 0.908775269985199
and O O 0.9970625042915344
to O O 0.9999649524688721
show O O 0.9999908208847046
that O O 0.9999985694885254
the O O 0.9999346733093262
signal-transducing O O 0.9235436320304871
pathway O O 0.9818602204322815
of O O 0.9997968077659607
P-LPS O S-protein 0.5651205778121948
in O O 0.9984254837036133
the O O 0.9994736313819885
cells O O 0.9695269465446472
is O O 0.9999536275863647
mediated O O 0.9996931552886963
by O O 0.9999759197235107
CD14 S-protein S-protein 0.9085533618927002
. O O 0.9994444251060486
rel S-protein S-protein 0.6999450325965881
Is O O 0.9923068881034851
rapidly O O 0.9623072147369385
tyrosine-phosphorylated O O 0.7469247579574585
following O O 0.9948523640632629
granulocyte-colony B-protein O 0.6856234073638916

Grade O O 0.9727862477302551
less O O 0.9945482611656189
than O O 0.9992730021476746
or O O 0.9995002746582031
equal O O 0.9998124241828918
to O O 0.9997357726097107
2 O O 0.9967898726463318
nausea O O 0.8722116351127625
and O O 0.8826148509979248
vomiting O O 0.8095454573631287
occurred O O 0.946123480796814
in O O 0.9998118281364441
66 O O 0.9981574416160583
% O O 0.999948263168335
courses O O 0.9965588450431824
and O O 0.9999587535858154
phlebitis O O 0.6556333899497986
in O O 0.9820095896720886
the O O 0.9966399669647217
infusion O O 0.8660752177238464
arm O O 0.9374245405197144
in O O 0.9998517036437988
37 O O 0.9987198114395142
% O O 0.9999363422393799
. O O 0.999995231628418

at O O 0.9983466863632202
least O O 0.9999203681945801
some O O 0.9999964237213135
cases O O 0.9998934268951416
of O O 0.9999864101409912
ATLL O O 0.3912583589553833
does O O 0.99974125623703
not O O 0.9999736547470093
require O O 0.9999922513961792
the O O 0.9999713897705078
constitutive O O 0.9576924443244934
, O O 0.9931569695472717
but O O 0.9986520409584045
may O O 0.9998531341552734
require O O 0.9999406337738037
IL-2 S-protein S-protein 0.9985288381576538
-induced O O 0.9960142374038696
, O O 0.9997732043266296
activation O O 0.9979826211929321
of O O 0.9999079704284668
the O O 0.9997815489768982
IL-2R S-protein S-protein 0.48044532537460327
Jak/STAT S-protein S-protein 0.31286880373954773
pathway O O 0.8183769583702087

granulocyte/macrophage B-protein B-protein 0.3530265688896179
colony-stimulating I-protein I-protein 0.8300237059593201
factor E-protein E-protein 0.9654026031494141
, O O 0.9640994668006897
IL-6 S-protein S-protein 0.9933151602745056
, O O 0.9945015907287598
or O O 0.9995115995407104
transforming O B-protein 0.8020381927490234
growth O I-protein 0.4290914833545685
factor O I-protein 0.4472781717777252
beta O E-protein 0.9675558805465698
suppressed O O 0.9739692211151123
activation O O 0.9926481246948242
of O O 0.9997835755348206
STAT6 S-protein S-protein 0.9838083386421204
by O O 0.9993782043457031
IL-4 S-protein S-protein 0.9681389927864075
. O O 0.9993521571159363

were O O 0.9982593655586243
evaluated O O 0.9999551773071289
against O O 0.9999934434890747
a O O 0.9998291730880737
number O O 0.9989832043647766
of O O 0.9999593496322632
D B-cell_line B-cell_type 0.6548669338226318
variant I-cell_line I-cell_type 0.7981246709823608
cells E-cell_line E-cell_type 0.9494970440864563
using O O 0.9995688796043396
standard O O 0.9727814793586731
serological O O 0.9474602937698364
techniques O O 0.9927256107330322
. O O 0.9999983310699463
The O O 0.9999887943267822
monoclonal B-protein B-protein 0.731062114238739
antibodies E-protein E-protein 0.917550265789032
were O O 0.9997925162315369
able O O 0.9999899864196777
to O O 0.9999823570251465
discriminate O O 0.9997150301933289

CNS O O 0.6846070289611816
toxic O O 0.6882621645927429
effects O O 0.9815548062324524
of O O 0.9997684359550476
the O O 0.9995588660240173
antineoplastic O O 0.772307813167572
agent O O 0.8618964552879333
ifosfamide S-Chemical B-Chemical 0.9297595024108887
( O O 0.9785115122795105
IFX S-Chemical B-Chemical 0.9239351749420166
) O O 0.9739179015159607
are O O 0.9999606609344482
frequent O O 0.9974645376205444
and O O 0.9999662637710571
include O O 0.9999911785125732
a O O 0.9996755123138428
variety O O 0.9968181848526001
of O O 0.9999313354492188
neurological O O 0.5055675506591797
symptoms O O 0.8976199626922607
that O O 0.989124059677124
can O O 0.9999257326126099
limit O O 0.9982209801673889
drug O O 0.8697707056999207
use O O 0.7900831699371338
. O O 0.9999868869781494

One O O 0.9995539784431458
of O O 0.9999861717224121
the O O 0.9999700784683228
twins O O 0.9664708971977234
developed O O 0.9989907145500183
complete O O 0.957311749458313
heart B-Disease O 0.764833927154541
block I-Disease O 0.866108775138855
and O O 0.9442530274391174
dilated B-Disease O 0.7589464783668518
cardiomyopathy I-Disease O 0.6390088200569153
related O O 0.9625104665756226
to O O 0.9995194673538208
lopinavir B-Chemical B-Chemical 0.9357378482818604
/ I-Chemical I-Chemical 0.9766018986701965
ritonavir I-Chemical I-Chemical 0.9332392811775208
therapy O O 0.9730944037437439
, O O 0.9999943971633911
a O O 0.9999517202377319
boosted O O 0.9875473976135254
protease O O 0.8888545036315918
- O O 0.9940035939216614
inhibitor O O 0.9724467992782593
agent O O 0.967344343662262
, O O 0.9999140501022339
while O O 0.9999819993972778
the O O 0.9999709129333496
other O O 0.9997578263282776
twin O O 0.9367049932479858
developed O O 0.9990277290344238
mild O O 0.8933722376823425
bradycardia B-Disease B-Disease 0.8848690986633301
. O O 0.9983685612678528

endothelial I-cell_type B-cell_type 0.324558287858963
cells E-cell_type E-cell_type 0.8936911821365356
( O O 0.9949211478233337
HUVEC S-cell_type S-cell_line 0.8815513253211975
) O O 0.962962806224823
, O O 0.9999369382858276
CoCl2 O O 0.6646440625190735
at O O 0.9989321827888489
2 O O 0.9853905439376831
mM O O 0.9629391431808472
concentration O O 0.9950343370437622
induced O O 0.9999678134918213
the O O 0.9999603033065796
surface O O 0.9707667231559753
expression O O 0.9958440661430359
of O O 0.9998534917831421
a O O 0.9997126460075378
subset O O 0.9700009226799011
of O O 0.9982708692550659
CAMs S-protein S-protein 0.6162502765655518
( O O 0.960986316204071
VCAM-1 S-protein S-protein 0.8611181974411011
) O O 0.9801915884017944
and O O 0.9997671246528625
activation O O 0.9826272130012512
of O O 0.9983439445495605
transcription B-protein B-protein 0.5038533806800842
factor E-protein E-protein 0.8345168232917786
NF-kappaB S-protein S-protein 0.45525452494621277

within O O 0.9969103932380676
30 O O 0.9965893030166626
min O O 0.9994785189628601
of O O 0.9999396800994873
monocyte O O 0.5900548696517944
adherence O O 0.9495658278465271
would O O 0.9999868869781494
result O O 0.9999771118164062
from O O 0.9999910593032837
NF-kappa B-protein B-protein 0.6804370880126953
B E-protein E-protein 0.9983001351356506
-dependent O O 0.9947952628135681
transcriptional O O 0.9562041759490967
stimulation O O 0.9940071105957031
of O O 0.999968409538269
the O O 0.9999351501464844
I B-DNA B-DNA 0.5138190388679504
kappa I-DNA I-DNA 0.759795606136322
B I-DNA I-DNA 0.4308880567550659
alpha/MAD-3 I-DNA I-DNA 0.3361845910549164
gene E-DNA E-DNA 0.983132004737854
. O O 0.9996248483657837
Nuclear O O 0.9063585996627808
run-on O O 0.7379526495933533
analyses O O 0.9263696670532227
indicated O O 0.9998874664306641
that O O 0.9999912977218628
, O O 0.998752236366272
instead O O 0.9998728036880493
, O O 0.999967098236084
while O O 0.9999853372573853
several O O 0.9991699457168579
immediate-early B-DNA O 0.7263083457946777
cytokine I-DNA S-protein 0.4002549946308136

T3SO4 O S-protein 0.2512352466583252
displayed O O 0.9945002794265747
about O O 0.9996947050094604
0.5 O O 0.9921604990959167
% O O 0.9996986389160156
the O O 0.9999089241027832
activity O O 0.9981393814086914
of O O 0.9999191761016846
T3 O O 0.3354837894439697
at O O 0.9983275532722473
72 O O 0.9780915379524231
h O O 0.9706823825836182
. O O 0.9999629259109497
Human B-cell_type B-cell_type 0.5610761046409607
fibroblasts E-cell_type E-cell_type 0.9376883506774902
contained O O 0.99875807762146
roughly O O 0.9997420907020569
the O O 0.9999736547470093
same O O 0.999935507774353
level O O 0.9994562268257141
of O O 0.9998326301574707
microsomal O O 0.46433040499687195

family I-protein I-protein 0.298980176448822
proteins E-protein E-protein 0.99564528465271
( O O 0.9962615370750427
c-Rel S-protein S-protein 0.9970295429229736
, O O 0.9889959096908569
p65 S-protein S-protein 0.9935370087623596
, O O 0.9825489521026611
p50 S-protein S-protein 0.9949123859405518
, O O 0.9684275984764099
and O O 0.9724225401878357
p49 S-protein S-protein 0.9822699427604675
) O O 0.9212707877159119
. O O 0.999955415725708
Furthermore O O 0.9999887943267822
, O O 0.9999943971633911
we O O 0.9999567270278931
confirmed O O 0.9999834299087524
the O O 0.9999939203262329
previous O O 0.999811589717865
report O O 0.9999514818191528
that O O 0.9999924898147583
FK506 O O 0.6981924772262573
suppressed O O 0.999308705329895
the O O 0.9998867511749268
PMA/ionomycin-induced O O 0.6347259879112244
activation O O 0.9166523218154907
through O O 0.999319314956665
authentic O O 0.8473906517028809
kappa B-DNA B-DNA 0.5002520084381104
B I-DNA I-DNA 0.31699338555336
site E-DNA E-DNA 0.6922076344490051
of O O 0.9747171998023987
immunoglobulin B-DNA B-DNA 0.3232017457485199
( I-DNA I-DNA 0.6380709409713745
Ig I-DNA I-DNA 0.806471586227417
) I-DNA I-DNA 0.7846779227256775
gene E-DNA E-DNA 0.9904700517654419
, O O 0.9957636594772339
to O O 0.9999349117279053
which O O 0.9999872446060181
NF-kappa B-protein B-protein 0.5685187578201294
B E-protein E-protein 0.9439801573753357
binding O O 0.9331057071685791
was O O 0.9997860789299011
also O O 0.9999557733535767
decreased O O 0.9992486834526062
by O O 0.9999706745147705

Suxamethonium B-Chemical B-Chemical 0.9222872853279114
- O O 0.9586203694343567
induced O O 0.9993664622306824
cardiac B-Disease B-Disease 0.5757330656051636
arrest I-Disease I-Disease 0.9719113707542419
and O O 0.9068861603736877
death B-Disease B-Disease 0.9537093639373779
following O O 0.9975486397743225
5 O O 0.9984654188156128
days O O 0.9999406337738037
of O O 0.9998854398727417
immobilization O O 0.7874427437782288
. O O 0.9997192025184631

of O O 0.9928602576255798
genes O O 0.6833540201187134
such O O 0.9995676875114441
as O O 0.9999778270721436
cytokines S-protein S-protein 0.9903839826583862
, O O 0.9967504739761353
proto-oncogenes S-DNA S-protein 0.5217814445495605
, O O 0.9501327276229858
and O O 0.9826815724372864
transcription B-protein B-protein 0.45573869347572327
factors E-protein E-protein 0.9950370192527771
. O O 0.9995373487472534
AU-DD S-DNA S-protein 0.6888949871063232
is O O 0.9995352029800415
an O O 0.9999840259552002
AU-motif-directed B-DNA O 0.4925132691860199
differential I-DNA O 0.6584348082542419

Because O O 0.9998692274093628
of O O 0.9999644756317139
the O O 0.9999663829803467
extreme O O 0.9120429158210754
toxicity B-Disease O 0.8862210512161255
of O O 0.907598078250885
vitamin B-Chemical B-Chemical 0.9517444372177124
D3 I-Chemical E-Chemical 0.9229906797409058
in O O 0.99872225522995
pregnant O O 0.9229204058647156
Jersey O O 0.9140849709510803
cows O O 0.9672273397445679
and O O 0.9999775886535645
the O O 0.9999463558197021
low O O 0.9748309850692749
margin O O 0.9570011496543884
of O O 0.9938469529151917
safety O O 0.8484527468681335
between O O 0.9962181448936462
doses O O 0.9994896650314331
of O O 0.9998670816421509
vitamin B-Chemical B-Chemical 0.9556503295898438
D3 I-Chemical E-Chemical 0.9171862006187439
that O O 0.988223135471344
prevent O O 0.9996544122695923
milk B-Disease O 0.7841376662254333
fever I-Disease O 0.8541209697723389
and O O 0.926011860370636
doses O O 0.9550274610519409
that O O 0.9997780919075012
induce O O 0.9998701810836792
milk B-Disease O 0.7706127166748047
fever I-Disease O 0.8737145066261292
, O O 0.9943357110023499
we O O 0.9999345541000366
concluded O O 0.9999939203262329
that O O 0.9999961853027344
vitamin B-Chemical B-Chemical 0.9565481543540955
D3 I-Chemical E-Chemical 0.9247464537620544
cannot O O 0.9957634210586548
be O O 0.999804675579071
used O O 0.9999886751174927
practically O O 0.9999746084213257
to O O 0.9999808073043823
prevent O O 0.9995383024215698
milk B-Disease O 0.7895189523696899
fever I-Disease O 0.9100316166877747
when O O 0.9875470995903015
injected O O 0.9889408946037292
several O O 0.9998455047607422
weeks O O 0.9994574189186096
prepartum O O 0.6188528537750244
. O O 0.9999865293502808

intracellular O O 0.7967188358306885
signaling O O 0.938758909702301
pathways O O 0.9949913620948792
in O O 0.9999507665634155
CD34+ B-cell_type B-cell_type 0.620728611946106
progenitor E-cell_type E-cell_type 0.408034086227417
to O O 0.8915985226631165
dendritic O O 0.4886247515678406
cell O O 0.5165591835975647
differentiation O O 0.9427353143692017
from O O 0.9999266862869263
a O O 0.9997925162315369
human O B-cell_line 0.5133308172225952
cell O I-cell_line 0.8020700812339783
line O E-cell_line 0.9055781960487366

zinc-binding B-protein B-protein 0.27679377794265747
proteins E-protein E-protein 0.9932520985603333
and O O 0.9986366629600525
to O O 0.9998602867126465
iron-sulfur B-protein O 0.5958775281906128
centers E-protein O 0.5559248328208923
of O O 0.9954195022583008
ferredoxins S-protein O 0.3290872275829315
. O O 0.9997753500938416
Two O O 0.9995449185371399
homologues O O 0.8318080902099609
of O O 0.9990360736846924
the O O 0.9998687505722046
rhombotin B-DNA B-DNA 0.34670913219451904
gene E-DNA E-DNA 0.9609426856040955
have O O 0.9983030557632446
now O O 0.9999291896820068
been O O 0.9998866319656372
isolated O O 0.9991903901100159
. O O 0.9999988079071045
One O O 0.9999696016311646
of O O 0.9999946355819702
these O O 0.9998539686203003
, O O 0.9989548921585083
designated O O 0.9753081798553467
Rhom-2 S-DNA S-DNA 0.5737321376800537
, O O 0.9002483487129211
is O O 0.9992955923080444

inhibitors O O 0.6425782442092896
of O O 0.9997856020927429
cytosolic B-protein O 0.8352037668228149
phospholipase I-protein O 0.5189723968505859
A2 E-protein O 0.7828267812728882
. O O 0.9986618757247925
In O O 0.9998456239700317
monocytes S-cell_type S-cell_type 0.9746367931365967
, O O 0.9989137649536133
lipopolysaccharide O O 0.9237459301948547
induces O O 0.9998143315315247
synthesis O O 0.9825032949447632
and O O 0.9993973970413208
activity O O 0.9967026114463806
of O O 0.9999358654022217
the O O 0.9997413754463196
85-kDa O B-protein 0.5805754661560059
cytosolic B-protein I-protein 0.7820160388946533
phospholipase I-protein I-protein 0.7964320778846741
A2 E-protein E-protein 0.9018523097038269
. O O 0.9983532428741455
This O O 0.9999058246612549
enzyme O O 0.7102559208869934

or I-protein O 0.944656491279602

mRNA E-RNA E-RNA 0.7896403074264526
and O O 0.9977378845214844
subsequent O O 0.9983429908752441
release O O 0.9971976280212402
of O O 0.9999237060546875
bioactive O B-protein 0.7869256138801575
M-CSF B-protein I-protein 0.40373897552490234
protein E-protein E-protein 0.9873868823051453
as O O 0.9995236396789551
demonstrated O O 0.9999316930770874
by O O 0.9999916553497314
ELISA O O 0.7481442093849182
and O O 0.9976820945739746
inhibition O O 0.981105625629425
of O O 0.9988588094711304
IL-2 S-protein S-protein 0.9488820433616638
induced O O 0.9917215704917908
release O O 0.9863522052764893
of O O 0.9995487332344055
an O O 0.992336094379425

In O O 0.9995585083961487
this O O 0.9999957084655762
study O O 0.9999434947967529
, O O 0.9999959468841553
we O O 0.9999861717224121
report O O 0.9999977350234985
that O O 0.9999978542327881
both O O 0.9996694326400757
Exosurf O O 0.37989991903305054
and O O 0.9550198912620544
Survanta O O 0.4624162018299103
suppress O O 0.9983880519866943
TNF B-RNA B-RNA 0.7601513266563416
mRNA E-RNA E-RNA 0.9905815124511719
and O O 0.997962236404419
secretion O O 0.9678279161453247
( O O 0.9995322227478027
85 O O 0.970755934715271
+/- O O 0.9988188147544861
4 O O 0.9985364675521851
% O O 0.9990013241767883
mean O O 0.9978004097938538
percent O O 0.9984477758407593
inhibition O O 0.9741724729537964
+/- O O 0.9918658137321472
SEM O O 0.7253130078315735
by O O 0.9998939037322998
Exosurf O O 0.810680627822876
; O O 0.9982325434684753
71 O O 0.9936240911483765
+/- O O 0.9997745156288147
6 O O 0.9997729659080505
% O O 0.9996424913406372
by O O 0.9999749660491943
Survanta O O 0.5517024993896484
) O O 0.9961234927177429
by O O 0.9999949932098389
endotoxin-stimulated B-cell_line B-protein 0.63275545835495
THP-1 E-cell_line E-protein 0.5868949294090271
, O O 0.9946770668029785
a O O 0.9999114274978638
human B-cell_line O 0.377906858921051

for O O 0.9969493746757507
diagnosis O O 0.997983455657959

Since O O 0.9996943473815918
it O O 0.9997178912162781
takes O O 0.9999912977218628
three O O 0.9995865225791931
to O O 0.999936580657959
12 O O 0.999910831451416
months O O 0.9999198913574219
to O O 0.9999864101409912
achieve O O 0.9998419284820557
maximal O O 0.9593588709831238
effects O O 0.9708280563354492
, O O 0.9999443292617798
those O O 0.9999687671661377
patients O O 0.9993385672569275
who O O 0.9999958276748657
are O O 0.9999912977218628
unable O O 0.9987793564796448
to O O 0.9999088048934937
continue O O 0.9999151229858398
the O O 0.9998212456703186
drug O O 0.9438061714172363
receive O O 0.9997850060462952
little O O 0.9997897744178772
benefit O O 0.9975706934928894
from O O 0.9999830722808838
it O O 0.9981915354728699
. O O 0.9999982118606567

S6 S-protein O 0.2609036862850189
on O O 0.9632480144500732
SDS-PAGE O S-DNA 0.6310386061668396
is O O 0.9987310767173767
consistent O O 0.9999502897262573
with O O 0.9999964237213135
the O O 0.9999760389328003
estimated O O 0.9863308668136597
molecular O O 0.9368309378623962
mass O O 0.914020836353302
for O O 0.9988616704940796
TBP7 S-protein S-protein 0.778862476348877
, O O 0.9994333386421204
we O O 0.9999898672103882
conclude O O 0.9999969005584717
that O O 0.9999972581863403
subunit B-protein B-protein 0.7933735847473145
6 E-protein E-protein 0.8918583393096924
of O O 0.989674985408783
the O O 0.9996084570884705
26S B-protein B-protein 0.3819608986377716
protease E-protein E-protein 0.9600681662559509
is O O 0.9985248446464539
TBP7 S-protein S-protein 0.9153723120689392
. O O 0.9997677206993103
Hypoxia O O 0.9487437009811401
causes O O 0.9999263286590576
the O O 0.9999549388885498
activation O O 0.9980031847953796
of O O 0.999890923500061
nuclear B-protein B-protein 0.6468074321746826
factor I-protein I-protein 0.776111900806427
kappa I-protein I-protein 0.8923890590667725

cytokines S-protein S-protein 0.699648916721344
and O O 0.9992585778236389
growth B-protein B-protein 0.7126603722572327
factors E-protein E-protein 0.9765213131904602
act O O 0.9957402944564819
through O O 0.9999946355819702
an O O 0.9999648332595825
induction O O 0.9899874329566956
of O O 0.9995898604393005
gene O O 0.9136135578155518
expression O O 0.9962489008903503
mediated O O 0.9993543028831482
by O O 0.9999212026596069

affect O O 0.9958643913269043
IL-6 S-protein S-protein 0.9807239770889282
expression O O 0.9990372657775879
. O O 0.999997615814209
However O O 0.9999697208404541
, O O 0.9999744892120361
for O O 0.9998779296875
IL-4 S-protein S-protein 0.9782231450080872
this O O 0.999616265296936
was O O 0.9999760389328003
accompanied O O 0.9999533891677856
with O O 0.9999949932098389
a O O 0.999977707862854
reduction O O 0.9973049163818359
of O O 0.9997900128364563
AP-1 O S-protein 0.9552009105682373
and O O 0.9911443591117859
NF-IL6 O S-protein 0.9677116870880127
binding O O 0.9804885387420654
activity O O 0.9982237219810486
whereas O O 0.999995231628418
IL-10 S-protein S-protein 0.9594529867172241
only O O 0.9992623925209045
inhibited O O 0.9985445737838745
AP-1 S-protein S-protein 0.9765086770057678
binding O O 0.9568796753883362
activity O O 0.997814416885376
. O O 0.9999973773956299
Regulation O O 0.9989746809005737
of O O 0.9999046325683594
GM-CSF B-DNA B-DNA 0.6865125894546509
gene E-DNA E-DNA 0.8252255916595459

study O O 0.9952667951583862
was O O 0.999990701675415
performed O O 0.9999879598617554
to O O 0.9999961853027344
increase O O 0.9999656677246094
our O O 0.9999616146087646
understanding O O 0.9998847246170044
of O O 0.9999927282333374
the O O 0.9999351501464844
immunosuppressive O O 0.9429476261138916
activity O O 0.9971731901168823
of O O 0.9999856948852539
heparin O O 0.4684193432331085
by O O 0.9998235106468201
investigation O O 0.999761164188385
of O O 0.9999648332595825
potential O O 0.958824098110199
antagonism O O 0.9042061567306519

it O O 0.9805461764335632
exerts O O 0.999976396560669
its O O 0.9999778270721436
costimulatory O O 0.8634254336357117
actions O O 0.9863808751106262
are O O 0.9999884366989136
less O O 0.9999562501907349
clear O O 0.9996752738952637
. O O 0.9999982118606567
In O O 0.9999879598617554
many O O 0.9998912811279297
circumstances O O 0.9999344348907471
it O O 0.9999970197677612
is O O 0.9999964237213135
difficult O O 0.9999454021453857
to O O 0.9999849796295166
distinguish O O 0.9998935461044312
the O O 0.9999196529388428
effects O O 0.9999520778656006
of O O 0.9999779462814331
CD28 S-protein S-protein 0.957491934299469
from O O 0.9999159574508667
subsequent O O 0.9951415061950684
actions O O 0.9993143081665039
of O O 0.9999712705612183
cytokines S-protein S-protein 0.9932855367660522
, O O 0.9992691874504089
such O O 0.9999814033508301
as O O 0.9999749660491943
IL-2 S-protein S-protein 0.988701343536377
, O O 0.9979565143585205
on O O 0.999813973903656
T O O 0.612442135810852
cell O O 0.6117720007896423
proliferation O O 0.9702380299568176
. O O 0.9999902248382568
Here O O 0.9997542500495911
, O O 0.9999940395355225
we O O 0.9999914169311523
report O O 0.9999971389770508
a O O 0.9999909400939941
model O O 0.9950025677680969
of O O 0.9997995495796204
CD28 S-protein S-protein 0.9310939311981201
costimulation O O 0.9402465224266052
using O O 0.9998000264167786
PMA O O 0.7078810334205627
plus O O 0.9854869842529297
the O O 0.9990684390068054
natural B-protein O 0.7674955129623413

GR S-protein S-protein 0.7639923691749573
) O O 0.9367954730987549
was O O 0.9998712539672852
analyzed O O 0.9999653100967407
in O O 0.9999352693557739
human B-cell_type B-cell_type 0.6679327487945557
peripheral I-cell_type I-cell_type 0.7938676476478577
blood I-cell_type I-cell_type 0.9274676442146301
mononuclear I-cell_type I-cell_type 0.9488733410835266
cells E-cell_type E-cell_type 0.9853491187095642
by O O 0.9997280240058899
gel O O 0.8794333934783936
mobility O O 0.9437758326530457
shift O O 0.9653811454772949
assays O O 0.9961494207382202
. O O 0.9999892711639404
TNF-alpha O S-protein 0.9185606241226196
, O O 0.9805902242660522
IL-1 O B-protein 0.3800649344921112
beta O E-protein 0.9139707088470459
and O O 0.9808253645896912
phorbol O O 0.8463220000267029
myristate O O 0.8186120986938477
acetate O O 0.8596956729888916
( O O 0.993606448173523

2-dependent I-DNA I-DNA 0.7441235184669495
enhancer E-DNA E-DNA 0.9559235572814941
. O O 0.9996408224105835
Immune O O 0.9624051451683044
response O O 0.9907221794128418
of O O 0.9998972415924072
peripheral B-cell_type B-cell_type 0.6632996201515198
blood I-cell_type I-cell_type 0.9148380160331726
mononuclear I-cell_type I-cell_type 0.9676694273948669
cells E-cell_type E-cell_type 0.9871097803115845
to O O 0.9985514283180237
HBx-antigen S-protein O 0.43797561526298523
of O O 0.9973000884056091
hepatitis O O 0.877680778503418
B O O 0.8800800442695618
virus O O 0.9687818884849548
. O O 0.9999637603759766
The O O 0.9999756813049316

During O O 0.9998699426651001
the O O 0.9999791383743286
infusion O O 0.9605860710144043
of O O 0.9982653260231018
aminophylline S-Chemical B-Chemical 0.9309382438659668
, O O 0.997778594493866
the O O 0.9999715089797974
ventricular O O 0.6980491280555725
fibrillation O O 0.9102790951728821
threshold O O 0.8621865510940552
was O O 0.9997648596763611
reduced O O 0.9996638298034668
by O O 0.9999935626983643
30 O O 0.9998317956924438
to O O 0.999955415725708
40 O O 0.9998862743377686
percent O O 0.9999620914459229
of O O 0.9999535083770752
the O O 0.9999496936798096
control O O 0.9975413084030151
when O O 0.9999910593032837
pH O O 0.4929235875606537
and O O 0.994234025478363
partial O O 0.9895723462104797
pressures O O 0.9787745475769043
of O O 0.9992977380752563
oxygen S-Chemical B-Chemical 0.932528018951416
( O O 0.9345560669898987
PO2 S-Chemical O 0.7958932518959045
) O O 0.8022409677505493
and O O 0.9998546838760376
carbon B-Chemical B-Chemical 0.9295185208320618
dioxide E-Chemical I-Chemical 0.9574058055877686
( O O 0.9660304188728333
CO2 S-Chemical O 0.6310302019119263
) O O 0.9922845363616943
were O O 0.9999948740005493
kept O O 0.9999867677688599
within O O 0.999987006187439
normal O O 0.9885919690132141
limits O O 0.9991815686225891
. O O 0.9999992847442627

gp130 S-protein S-protein 0.7620317935943604
fused O O 0.9902513027191162
to O O 0.9999250173568726
the O O 0.999914288520813
extracellular B-protein B-protein 0.5202699899673462
domain E-protein E-protein 0.8609141707420349
of O O 0.9843922853469849
the O O 0.9998193383216858
epidermal B-protein B-DNA 0.3651899993419647
growth I-protein I-DNA 0.3549394905567169

to O O 0.995322048664093
distinct O O 0.9740940928459167
nuclear O O 0.8168720602989197
foci O O 0.2600780725479126
. O O 0.9949636459350586
Previously O O 0.9998249411582947
we O O 0.9999103546142578
have O O 0.9999933242797852
shown O O 0.9999880790710449
( O O 0.9999209642410278
W.Q. O O 0.9956343770027161
Jiang O O 0.9883331656455994
, O O 0.9999078512191772
L.Szekely O O 0.9972907900810242
, O O 0.9999407529830933
V.Wendel-Hansen O O 0.9989942908287048
, O O 0.9999802112579346
N.Ringertz O O 0.9981305003166199
, O O 0.9999815225601196
G.Klein O O 0.9953175783157349
, O O 0.9999536275863647
and O O 0.9999731779098511
A. O O 0.9993077516555786
Rosen O O 0.9971791505813599
, O O 0.9999815225601196
Exp.Cell O O 0.9707902073860168

Comparison O O 0.9963079690933228
of O O 0.9999256134033203
the O O 0.9999643564224243
respiratory O O 0.7319167852401733
effects O O 0.9725778102874756
of O O 0.9997342228889465
i O O 0.954094648361206
. O O 0.999342143535614
v O O 0.9831472039222717
. O O 0.9996343851089478
infusions O O 0.9782503247261047
of O O 0.9992755055427551
morphine S-Chemical B-Chemical 0.9199250340461731
and O O 0.9779568910598755
regional O O 0.9110196828842163
analgesia O O 0.6109405755996704
by O O 0.9984720349311829
extradural O O 0.6012051105499268
block O O 0.712746798992157
. O O 0.9990298748016357

DC S-cell_type S-cell_type 0.6568254232406616
characteristics O O 0.863922119140625
include O O 0.9999886751174927
fluid O O 0.9050742387771606
phase O O 0.9033534526824951
macromolecule O O 0.727803111076355
uptake O O 0.9861477017402649
( O O 0.9997908473014832
FITC-dextran O O 0.4924790859222412
) O O 0.9783169627189636
and O O 0.9996137022972107
activation O O 0.9873989820480347
of O O 0.9994392991065979
resting B-cell_type B-cell_type 0.7896967530250549
T I-cell_type I-cell_type 0.8970300555229187
cells E-cell_type E-cell_type 0.9752194881439209
. O O 0.9996436834335327
Comparison O O 0.990351140499115

Fundus O O 0.6500905752182007
fluorescein S-Chemical B-Chemical 0.8473015427589417
angiography O O 0.41354691982269287
confirmed O O 0.9976009726524353
macular O O 0.9115185141563416
capillary O O 0.7103416919708252
closure O O 0.5049548745155334
and O O 0.9957659244537354
telangiectasis O B-Disease 0.9651014804840088
. O O 0.9991201758384705

transfected O O 0.8966202735900879
with O O 0.9997019171714783
a O O 0.9997298121452332
control O B-DNA 0.8635196685791016
plasmid O E-DNA 0.8191459774971008
. O O 0.9997197985649109
Our O O 0.9999963045120239
results O O 0.9999474287033081
suggest O O 0.9999979734420776
that O O 0.9999974966049194
the O O 0.9999017715454102
TNFalpha B-DNA B-DNA 0.672377347946167
gene E-DNA E-DNA 0.9621160626411438
could O O 0.9998086094856262
be O O 0.9999980926513672
one O O 0.9999867677688599
of O O 0.9999945163726807
the O O 0.9999852180480957
targets O O 0.9954407215118408

normal O O 0.8917625546455383
controls O O 0.9865610003471375
. O O 0.9999961853027344
Using O O 0.9998278617858887
RT-PCR O O 0.29147809743881226
we O O 0.9453967809677124
were O O 0.999971866607666
able O O 0.9999912977218628
to O O 0.9999902248382568
identify O O 0.9999905824661255
both O O 0.9999752044677734
the O O 0.9997808337211609
full B-protein O 0.9603049159049988
length I-protein O 0.9347390532493591
wild-type I-protein O 0.6465978026390076
form E-protein O 0.7048494815826416
and O O 0.9970784187316895
an O O 0.9998536109924316
isoform O O 0.7087104916572571
of O O 0.9700588583946228
the O O 0.9975355863571167
ER S-protein S-protein 0.6140043139457703
which O O 0.9827327728271484
precisely O O 0.9995061159133911
lacks O O 0.998626708984375
exon B-DNA B-DNA 0.5226128101348877
V E-DNA I-DNA 0.30022215843200684

( I-cell_line I-cell_line 0.8081191182136536
Th I-cell_line I-cell_line 0.37971845269203186
) I-cell_line I-cell_line 0.44083449244499207
clones E-cell_line E-cell_line 0.9512388110160828
( O O 0.9982166886329651
Th1 S-cell_line S-cell_line 0.8534963726997375
and O O 0.8710108399391174
Th2 S-cell_line S-cell_line 0.7409388422966003
) O O 0.9040069580078125
are O O 0.9999200105667114
defined O O 0.9998773336410522
on O O 0.9999775886535645
the O O 0.9999891519546509
basis O O 0.9999376535415649
of O O 0.9999953508377075
different O O 0.9988178610801697
patterns O O 0.9975857734680176
of O O 0.9999327659606934
cytokine S-protein S-protein 0.8727691173553467
( O O 0.9673041701316833
lymphokine S-protein O 0.5220072865486145
) O O 0.872904360294342
secretion O O 0.9762952327728271
. O O 0.9999837875366211
They O O 0.9999954700469971
determine O O 0.9999643564224243

domain E-protein E-protein 0.9009988903999329
essential O O 0.9730527400970459
for O O 0.9994741082191467
B-cell S-cell_type O 0.46765539050102234
immortalization O O 0.9379485845565796
and O O 0.9982226490974426
interaction O O 0.9893660545349121
with O O 0.9999121427536011
the O O 0.9998903274536133
tumor B-protein B-protein 0.5286002159118652
necrosis I-protein I-protein 0.6245288848876953
factor I-protein I-protein 0.673743486404419
receptor E-protein E-protein 0.9208337664604187
signaling O O 0.7554882764816284
pathway O O 0.9927043914794922
. O O 0.9999959468841553
Nevertheless O O 0.9999964237213135
, O O 0.9999916553497314
the O O 0.9999738931655884
simian B-protein O 0.7595525979995728
EBV I-protein O 0.4813651442527771
LMP1s E-protein S-protein 0.3725430965423584
retain O O 0.9972521662712097
most O O 0.9990149736404419
functions O O 0.9985619187355042
in O O 0.9999548196792603

Omitting O O 0.9734141826629639
fentanyl B-Chemical B-Chemical 0.9171081781387329
reduces O O 0.9537602066993713
nausea B-Disease O 0.8917964100837708
and O O 0.6662314534187317
vomiting B-Disease O 0.6032302379608154
, O O 0.983322262763977
without O O 0.9997102618217468
increasing O O 0.9677591323852539
pain B-Disease B-Disease 0.9272032380104065
, O O 0.9918884634971619
after O O 0.9999467134475708
sevoflurane B-Chemical B-Chemical 0.9310178756713867
for O O 0.9974769949913025
day O O 0.9816139936447144
surgery O O 0.8966169953346252
. O O 0.9999959468841553

and I-DNA O 0.8735992312431335
Sp1 I-DNA B-DNA 0.7407909631729126
binding I-DNA I-DNA 0.43128344416618347
sites E-DNA E-DNA 0.923247754573822
. O O 0.9998903274536133
The O O 0.9999761581420898
interleukin-2 B-protein B-protein 0.5306313633918762
IL-2 I-protein I-protein 0.33298733830451965
receptor I-protein I-protein 0.46816951036453247
beta-chain E-protein E-protein 0.9625091552734375
( O O 0.9821479320526123
IL-2Rbeta S-protein S-protein 0.9824284911155701
) O O 0.9670434594154358
is O O 0.9999736547470093
an O O 0.999992847442627
essential O O 0.9768986105918884
component O O 0.9725651741027832
of O O 0.9998644590377808
the O O 0.9999512434005737
receptors O O 0.6709797978401184
for O O 0.9897915124893188
IL-2 S-protein S-protein 0.9906626343727112
and O O 0.9941112399101257
IL-15 S-protein S-protein 0.9933912754058838
. O O 0.9997454285621643
Although O O 0.9999781847000122
IL-2Rbeta S-protein S-protein 0.9843270182609558
is O O 0.9992617964744568
constitutively O O 0.999006450176239
expressed O O 0.9994823932647705
by O O 0.9999392032623291
lymphocytes O S-cell_type 0.9683104753494263
, O O 0.9995754361152649
its O O 0.9999161958694458
expression O O 0.9996126294136047
can O O 0.9999953508377075
be O O 0.9999938011169434
further O O 0.9999215602874756
induced O O 0.9999619722366333
by O O 0.9999951124191284
a O O 0.9999393224716187
number O O 0.9993020296096802
of O O 0.9999550580978394
stimuli O O 0.8136956095695496
, O O 0.9973226189613342

This O O 0.9993491768836975
supports O O 0.9999306201934814
the O O 0.9999939203262329
assumption O O 0.9998480081558228
that O O 0.9999978542327881
differences O O 0.9872791767120361
in O O 0.9995028972625732
renal O O 0.9678289294242859
ACE O O 0.5854807496070862
activity O O 0.9563279747962952
predispose O O 0.9989312291145325
to O O 0.9999574422836304
a O O 0.9999129772186279
less O O 0.999211311340332
favourable O O 0.9980612397193909
course O O 0.9991610050201416
of O O 0.9998655319213867
renal B-Disease O 0.8254014849662781
damage I-Disease O 0.9430580735206604
. O O 0.9989055395126343

A O O 0.9891799688339233
61 O O 0.9959118366241455
- O O 0.9997755885124207
year O O 0.9999622106552124
- O O 0.9999417066574097
old O O 0.9992141723632812
man O O 0.9900215268135071
was O O 0.9999216794967651
treated O O 0.9999948740005493
with O O 0.9999909400939941
combination O O 0.9579324722290039
chemotherapy O O 0.5276679992675781
incorporating O O 0.9982408285140991
cisplatinum S-Chemical B-Chemical 0.9370841979980469
, O O 0.8914064168930054
etoposide S-Chemical B-Chemical 0.9339565634727478
, O O 0.9942680597305298
high O O 0.9925135970115662
- O O 0.9973837733268738
dose O O 0.9968208074569702
5 B-Chemical B-Chemical 0.9487447738647461
- I-Chemical I-Chemical 0.9942055344581604
fluorouracil E-Chemical E-Chemical 0.9257880449295044
( O O 0.899641752243042
2 O O 0.8440077900886536
, O O 0.9782293438911438
250 O O 0.997468113899231
mg O O 0.9997944235801697
/ O O 0.9999804496765137
m2 O O 0.9999366998672485
/ O O 0.9999856948852539
24 O O 0.9999200105667114
hours O O 0.9995396137237549
) O O 0.9997424483299255
and O O 0.9999687671661377
folinic B-Chemical B-Chemical 0.9086833000183105
acid E-Chemical I-Chemical 0.9520031213760376
for O O 0.9965534210205078
an O O 0.999885082244873
inoperable O O 0.9252740740776062
gastric O O 0.5316842198371887
adenocarcinoma O O 0.9030577540397644
. O O 0.9971023201942444

The O O 0.9985846281051636
recently O O 0.9523471593856812
cloned O O 0.940959095954895
TCL1 B-DNA B-DNA 0.3697649836540222
gene E-DNA E-DNA 0.9805923700332642
, O O 0.9818934202194214
also O O 0.9989877343177795
involved O O 0.9999263286590576
in O O 0.9999148845672607
translocations O O 0.9241493344306946
and O O 0.9982738494873047
inversions O O 0.9672790765762329
associated O O 0.9998570680618286
with O O 0.999970555305481
T-cell O O 0.7053596377372742
proliferations O O 0.6331659555435181
, O O 0.9997757077217102
codes O O 0.9926403164863586
for O O 0.999985933303833
a O O 0.9998977184295654
14-kD B-protein B-protein 0.39313435554504395
protein E-protein E-protein 0.9144355058670044
that O O 0.9979432225227356

IL-12R B-protein B-protein 0.777032196521759
complex E-protein E-protein 0.9916349649429321
and O O 0.9991305470466614
the O O 0.9999172687530518
IL-12 S-protein S-protein 0.9599389433860779
signal O O 0.9559912085533142
transduction O O 0.9512332081794739
pathway O O 0.9983062744140625
in O O 0.9999440908432007
cytotoxic B-cell_type B-cell_type 0.5281577110290527
T I-cell_type I-cell_type 0.7272390723228455
cells E-cell_type E-cell_type 0.8875203728675842
, O O 0.9981420040130615
we O O 0.9999858140945435
studied O O 0.9999161958694458
a O O 0.9999488592147827
number O O 0.9989645481109619
of O O 0.9999754428863525
human B-cell_line B-cell_line 0.4999850392341614
T I-cell_line I-cell_line 0.3441811203956604
cell I-cell_line I-cell_line 0.623864471912384
lines E-cell_line E-cell_line 0.991425633430481
that O O 0.999161958694458
had O O 0.999968409538269
been O O 0.9998277425765991
transformed O O 0.9993060827255249
to O O 0.9999815225601196
permanent O O 0.8998428583145142
growth O O 0.9560033082962036
with O O 0.9999377727508545
Herpesvirus O O 0.944015622138977
saimiri O O 0.9501435160636902
, O O 0.9999514818191528
an O O 0.9999862909317017
oncogenic O O 0.8612315654754639
virus O O 0.8709226846694946
of O O 0.9971401691436768
nonhuman O O 0.5171276926994324

apoptosis O O 0.5982048511505127
inducers O O 0.49439728260040283
. O O 0.9992792010307312
Sequencing O O 0.9808973670005798
of O O 0.9995216131210327
the O O 0.9997724890708923
GR B-DNA B-DNA 0.6439862251281738
cDNA E-DNA E-DNA 0.97222501039505
and O O 0.9743462800979614
gene O O 0.6777008771896362
including O O 0.9987661838531494
the O O 0.9997150301933289
2.3-kb O B-DNA 0.497804194688797
coding O I-DNA 0.6246935725212097
region O E-DNA 0.8748008608818054
, O O 0.9994584918022156
the O O 0.9999172687530518
intron/exon O O 0.2884112596511841
junctions O O 0.5306854248046875

expression O O 0.9813660383224487
was O O 0.9999808073043823
also O O 0.9999804496765137
evident O O 0.9999915361404419
during O O 0.999998927116394
the O O 0.9999955892562866
peak O O 0.9996565580368042
of O O 0.9999915361404419
an O O 0.9999736547470093
acute O O 0.9140834808349609
HIV-1 O O 0.930155873298645
infection O O 0.9788778424263
of O O 0.9999152421951294
HL-60 B-cell_line B-cell_line 0.5762754082679749
promyelocytes E-cell_line E-cell_line 0.6484773755073547
. O O 0.9998753070831299
Although O O 0.9999830722808838
TR55 S-protein S-protein 0.6905174255371094
expression O O 0.9956037998199463
was O O 0.9999852180480957

Myocardial B-Disease B-Disease 0.510708212852478
infarction I-Disease I-Disease 0.9779722690582275
following O O 0.9950987696647644
sublingual O O 0.9290884733200073
administration O O 0.8977319002151489
of O O 0.997717022895813
isosorbide B-Chemical B-Chemical 0.9192760586738586
dinitrate I-Chemical I-Chemical 0.928574800491333
. O O 0.9993320107460022

-- O O 0.9856132864952087
basic O O 0.9870448708534241
research O O 0.998110294342041
and O O 0.9998074173927307
clinical O O 0.9916979074478149
perspectives O O 0.9988945126533508
for O O 0.9999833106994629
gastroenterology O O 0.9712104797363281
. O O 0.999996542930603
Tissue O O 0.9640145897865295
specific O O 0.9970424771308899
regulation O O 0.9993730187416077
of O O 0.9999632835388184
gene O O 0.9292459487915039
expression O O 0.9979265928268433
by O O 0.9999916553497314
transcription B-protein B-protein 0.5911165475845337
factors E-protein E-protein 0.9967562556266785
is O O 0.9996059536933899
a O O 0.9999722242355347

of O O 0.995070219039917
ICAM-1 S-protein S-protein 0.9467229247093201
and O O 0.9892483353614807
LFA-3 S-protein S-protein 0.9554142951965332
by O O 0.9992864727973938
Tax1 S-protein S-protein 0.947317361831665
of O O 0.9980610013008118
human O O 0.7899457216262817
T-cell O O 0.7352983355522156
leukemia O O 0.8044666051864624
virus O O 0.9008071422576904
type O O 0.8365290760993958
1 O O 0.847415030002594
and O O 0.9797611236572266
mechanism O O 0.9904009699821472
of O O 0.9996581077575684
down-regulation O O 0.9774601459503174
of O O 0.9996351003646851
ICAM-1 S-protein S-protein 0.8198933601379395
or O O 0.9911882877349854
LFA-1 S-protein S-protein 0.8902120590209961
in O O 0.9990609288215637
adult-T-cell-leukemia B-cell_line B-cell_line 0.3856908082962036
cell I-cell_line I-cell_line 0.5906570553779602
lines E-cell_line E-cell_line 0.9900633692741394
. O O 0.9999483823776245

the O O 0.9950737357139587
beta-globin B-DNA B-DNA 0.34616976976394653
locus E-DNA E-DNA 0.940366804599762
. O O 0.9997149109840393
Estrogen O O 0.9605405330657959
decreases O O 0.9996311664581299
TNF S-protein S-protein 0.8207982182502747
gene O O 0.6315523982048035
expression O O 0.9921966791152954
by O O 0.9999921321868896
blocking O O 0.9978128671646118
JNK S-protein S-protein 0.9487834572792053
activity O O 0.995309054851532
and O O 0.9999315738677979
the O O 0.9999837875366211
resulting O O 0.9990623593330383
production O O 0.9987291693687439
of O O 0.999937891960144
c-Jun S-protein S-protein 0.9527735710144043
and O O 0.9910709857940674
JunD S-protein S-protein 0.9666850566864014
. O O 0.9993013143539429
Central O O 0.9674329161643982
to O O 0.9994169473648071
the O O 0.999860405921936
bone-sparing O O 0.8861212730407715
effect O O 0.9988265633583069
of O O 0.999971866607666
estrogen O O 0.6925334930419922
( O O 0.9906677603721619
E O O 0.6779193878173828
( O O 0.9647385478019714
2 O O 0.9388716816902161
) O O 0.9763203859329224

scrambled B-DNA B-DNA 0.6270825266838074
sequence E-DNA E-DNA 0.7729787826538086
, O O 0.9922695159912109
was O O 0.9999401569366455
specifically O O 0.9997677206993103
bound O O 0.9999582767486572
by O O 0.9999901056289673
nuclear B-protein B-protein 0.7136110067367554
proteins E-protein E-protein 0.9774437546730042
from O O 0.9992306232452393
IFN-gamma B-cell_line S-protein 0.6776275038719177
treated I-cell_line O 0.8347428441047668
U937 I-cell_line B-cell_line 0.8317062258720398
cells E-cell_line E-cell_line 0.9977046847343445
. O O 0.9999288320541382
Gel O O 0.6667568683624268

tyrosine O O 0.4313756227493286

promonocytic I-cell_line O 0.44651344418525696

Clinical O O 0.9385870099067688
experiences O O 0.9768841862678528
in O O 0.9999778270721436
an O O 0.9999563694000244
open O O 0.9882529377937317
and O O 0.9994229078292847
a O O 0.9999576807022095
double O O 0.9629349708557129
- O O 0.9943114519119263
blind O O 0.8075963258743286
trial O O 0.9643182158470154
. O O 0.9999983310699463

. O O 0.997098445892334
After O O 0.9999845027923584
5-day O O 0.9331374764442444
anti-CD3 S-protein S-protein 0.898389458656311
/IL-2 S-protein S-protein 0.9154962301254272
activation O O 0.9978770017623901
, O O 0.9999890327453613
levels O O 0.9998596906661987
of O O 0.9999021291732788
p56lck S-protein S-protein 0.8654077649116516
and O O 0.9772278666496277
p59fyn S-protein S-protein 0.9019066095352173
and O O 0.9868032336235046
protein O B-protein 0.7365706562995911
tyrosine O I-protein 0.7603026628494263
kinase O E-protein 0.8585985898971558
activity O O 0.9828501343727112
increased O O 0.9998841285705566
. O O 0.9999971389770508

in O O 0.995029866695404
G1 O O 0.3623444139957428
, O O 0.9689977765083313
but O O 0.9992699027061462
was O O 0.999943733215332
without O O 0.9999421834945679
effect O O 0.9994783997535706
on O O 0.9999873638153076
the O O 0.9998356103897095
cell O O 0.9171569347381592
growth O O 0.9796022176742554
of O O 0.9995161294937134
MOLT-4 B-cell_line S-cell_line 0.9020934700965881
and I-cell_line O 0.9174821376800537
CEM I-cell_line B-cell_line 0.7063421010971069
cells E-cell_line E-cell_line 0.969863772392273

Ultimately O O 0.9965530633926392
, O O 0.9999867677688599
an O O 0.9999232292175293
arteriography O O 0.5747576355934143
showed O O 0.9996448755264282
a O O 0.9999772310256958
70 O O 0.9638393521308899
- O O 0.9985538125038147
80 O O 0.9967796206474304
% O O 0.9997023940086365
renal O B-Disease 0.7651374340057373
artery O I-Disease 0.7166553139686584
stenosis O I-Disease 0.8855701088905334
. O O 0.9989089965820312

domain E-protein E-protein 0.9636927247047424
. O O 0.9996685981750488
A O O 0.9989674091339111
mutation O O 0.9956133365631104
of O O 0.9998704195022583
the O O 0.999841570854187
glucocorticoid B-protein B-protein 0.7344433665275574
receptor E-protein E-protein 0.9652373790740967
in O O 0.9988133907318115
primary O O 0.6799156069755554
cortisol O O 0.7063877582550049
resistance O O 0.9826738238334656
. O O 0.9999901056289673
The O O 0.9999964237213135
precise O O 0.9663098454475403
molecular O O 0.9276475310325623
abnormalities O O 0.9604321122169495
that O O 0.9999830722808838
cause O O 0.9998656511306763
primary O O 0.8758102655410767
cortisol O O 0.6143231391906738
resistance O O 0.9847180247306824

A O O 0.9964849948883057
47 O O 0.9950699806213379
- O O 0.9995216131210327
year O O 0.9999319314956665
- O O 0.9998693466186523
old O O 0.9985435009002686
patient O O 0.9977350234985352
suffering O O 0.9997788071632385
from O O 0.9997480511665344
coronary O B-Disease 0.6265116333961487
artery O I-Disease 0.7095464468002319
disease O I-Disease 0.9961127638816833
was O O 0.9773972630500793
admitted O O 0.9997169375419617
to O O 0.9999372959136963
the O O 0.9995847344398499
CCU O O 0.5483995079994202
in O O 0.9956985712051392
shock O O 0.890842616558075
with O O 0.9934502840042114
III O O 0.6112247109413147
. O O 0.9998371601104736

independent O O 0.7713276147842407
sites O O 0.6954410672187805
. O O 0.99989914894104
We O O 0.9999816417694092
determined O O 0.999992847442627
that O O 0.9999964237213135
an O O 0.9997854828834534
initiator-like B-DNA B-DNA 0.5205811262130737
sequence E-DNA E-DNA 0.8664637207984924
present O O 0.9887239933013916
at O O 0.9999966621398926
the O O 0.9998506307601929
cap B-DNA B-DNA 0.6769015192985535
site E-DNA E-DNA 0.9677425026893616
and O O 0.9979856014251709
an O O 0.999754011631012
Ets B-DNA B-DNA 0.6940178275108337
consensus I-DNA I-DNA 0.8378477692604065

After O O 0.9997411370277405
35 O O 0.9982755184173584
days O O 0.9998749494552612
in O O 0.9999747276306152
the O O 0.9997755885124207
TG O O 0.5350985527038574
+ O O 0.9567126035690308
HAART O O 0.6621427536010742
cohort O O 0.8371767401695251
, O O 0.9999688863754272
left O O 0.9220304489135742
ventricular O O 0.7094473242759705
mass O O 0.8165295124053955
increased O O 0.9848606586456299
160 O O 0.9989370703697205
% O O 0.9998736381530762
by O O 0.9999773502349854
echocardiography O O 0.7258543968200684
. O O 0.9999833106994629

Modafinil S-Chemical B-Chemical 0.9189537763595581
was O O 0.9964411854743958
associated O O 0.9998136162757874
with O O 0.999976634979248
increased O O 0.995781421661377
daytime O O 0.9070526361465454
sleep O O 0.47283950448036194
latency O O 0.565534770488739
, O O 0.9992376565933228
as O O 0.9999548196792603
measured O O 0.9999098777770996
by O O 0.9999905824661255
the O O 0.9999363422393799
Multiple O O 0.9692471027374268
Sleep O O 0.7765709757804871
Latency O O 0.8532534837722778
Test O O 0.9554914236068726
, O O 0.9999690055847168
and O O 0.9999830722808838
a O O 0.9999496936798096
nearly O O 0.9988971948623657
significant O O 0.9987331032752991
decrease O O 0.9295324087142944
in O O 0.9920613765716553
subjective O O 0.935021162033081
daytime O O 0.6084816455841064
sleepiness O O 0.8669896721839905
. O O 0.9992008805274963

possibility O O 0.9872194528579712
that O O 0.9999967813491821
the O O 0.9999892711639404
effect O O 0.9999819993972778
of O O 0.9999831914901733
CIITA S-protein S-protein 0.8440490961074829
on O O 0.9997996687889099
promoter O O 0.7147192358970642
occupation O O 0.9248700141906738
is O O 0.9999923706054688
mediated O O 0.9999635219573975
by O O 0.9999974966049194
an O O 0.9999802112579346
effect O O 0.9999570846557617
on O O 0.9999935626983643
the O O 0.9998829364776611
cooperative O O 0.9142772555351257

-73 B-DNA O 0.6428310871124268

MR S-protein O 0.703152596950531
, O O 0.9941926598548889
242 O O 0.9977689981460571
+/- O O 0.9999107122421265
79 O O 0.998924195766449
; O O 0.9999605417251587
SPD O O 0.9327887892723083
, O O 0.9997628331184387
14.0 O O 0.9984108209609985
+/- O O 0.9998819828033447
4 O O 0.9998842477798462
mV O O 0.9977224469184875
) O O 0.9997945427894592
. O O 0.9999938011169434
Aldosterone O O 0.950482964515686
levels O O 0.9996985197067261
returned O O 0.9999701976776123
to O O 0.9999438524246216
normal O O 0.9514645338058472
nonpregnant O O 0.9136432409286499
values O O 0.9868465065956116
after O O 0.9999921321868896
delivery O O 0.9996205568313599
. O O 0.999998927116394
These O O 0.9999536275863647

Angiosarcoma O B-Disease 0.8857064247131348
was O O 0.9058705568313599
also O O 0.9992533326148987
present O O 0.9999675750732422
within O O 0.9999847412109375
pulmonary O O 0.8405462503433228
and O O 0.9160756468772888
renal O O 0.6403024792671204
arteries O O 0.7510970234870911
. O O 0.9998997449874878

to O O 0.993735134601593
vaso-occlusion O O 0.9527960419654846
in O O 0.9998133778572083
SCD O O 0.4185607135295868
. O O 0.9978678226470947
Signal O O 0.8343102931976318
transduction O O 0.8367252349853516
abnormalities O O 0.9356436729431152
in O O 0.9998177886009216
T B-cell_type B-cell_type 0.881662130355835
lymphocytes E-cell_type E-cell_type 0.9973837733268738
from O O 0.9997594952583313
patients O O 0.9998989105224609
with O O 0.9999909400939941
advanced O O 0.9719932675361633
renal O O 0.9306445717811584
carcinoma O O 0.6471590399742126
: O O 0.9997696280479431
clinical O O 0.9755008816719055
relevance O O 0.9885671138763428
and O O 0.9998862743377686

The O O 0.9989513158798218
drug O O 0.9609917998313904
was O O 0.9985330104827881
still O O 0.9999585151672363
present O O 0.9999711513519287
in O O 0.9999940395355225
measurable O O 0.9973368048667908
quantities O O 0.9993902444839478
after O O 0.9999991655349731
24 O O 0.9995113611221313
h O O 0.9812421798706055
even O O 0.9997503161430359
with O O 0.9999943971633911
the O O 0.9999061822891235
smallest O O 0.9985470175743103
dose O O 0.9995618462562561
. O O 0.9999979734420776

is O O 0.9960707426071167
delayed O O 0.9992363452911377
a O O 0.9999881982803345
further O O 0.9995231628417969
1-2 O O 0.9932612776756287
hr O O 0.987403154373169
when O O 0.9999918937683105
mononuclear B-cell_line B-cell_line 0.6087846755981445
cell I-cell_line I-cell_line 0.44564762711524963
cultures E-cell_line E-cell_line 0.9408174753189087
are O O 0.9998756647109985
stimulated O O 0.9998987913131714
by O O 0.9999991655349731
an O O 0.999914288520813
antigen O O 0.784286618232727
which O O 0.9981613755226135
requires O O 0.9999631643295288
processing O O 0.9977013468742371
. O O 0.999995231628418
Appearance O O 0.9986264705657959
of O O 0.9998743534088135
the O O 0.9998544454574585

Effect O O 0.9963125586509705
of O O 0.9999676942825317
humoral O O 0.8630881309509277
modulators O O 0.8720541596412659
of O O 0.9970321655273438
morphine S-Chemical B-Chemical 0.927334725856781
- O O 0.9823394417762756
induced O O 0.9949270486831665
increase O O 0.5112290978431702
in O O 0.6156184673309326
locomotor O O 0.6283161044120789
activity O O 0.9448375701904297
of O O 0.6333109736442566
mice O O 0.7288995385169983
. O O 0.9999810457229614

could O O 0.9986177682876587
involve O O 0.9999985694885254
the O O 0.9999871253967285
activation O O 0.9982067346572876
of O O 0.9998676776885986
PKC O S-protein 0.9657296538352966
. O O 0.9999117851257324
An O O 0.9999057054519653
11-base-pair O B-DNA 0.6324341893196106
DNA O I-DNA 0.44669872522354126
sequence O I-DNA 0.5438323020935059
motif O E-DNA 0.7837646007537842

expressed O O 0.9870922565460205
during O O 0.999988317489624
the O O 0.9999880790710449
lectin S-protein S-protein 0.9676519632339478
-induced O O 0.995733916759491
switch O O 0.9918364882469177
of O O 0.9997685551643372
lymphocytes S-cell_type S-cell_type 0.9761156439781189
from O O 0.9998024106025696
the O O 0.9998741149902344
G0 O O 0.5706842541694641
to O O 0.9939141869544983
the O O 0.9998137354850769
G1 O O 0.7510882616043091
phases O O 0.9515723586082458
of O O 0.9999157190322876
the O O 0.9999855756759644
cell O O 0.959105372428894
cycle O O 0.9784541130065918
. O O 0.9999978542327881
This O O 0.9999938011169434
paper O O 0.9996140599250793
presents O O 0.9999969005584717
studies O O 0.9999145269393921
of O O 0.9999819993972778
G0S2 S-DNA S-DNA 0.6689643263816833
, O O 0.9967703819274902
a O O 0.9998787641525269
member O O 0.9605878591537476

They O O 0.9987618923187256
were O O 0.9999721050262451
followed O O 0.9999774694442749
up O O 0.999981164932251
during O O 0.9999949932098389
and O O 0.9997487664222717
for O O 0.9999566078186035
8 O O 0.999782383441925
weeks O O 0.9999803304672241
after O O 0.999995231628418
CT O O 0.535496711730957
. O O 0.9997449517250061

Disulfiram S-Chemical B-Chemical 0.9066249132156372
- O O 0.8331555128097534
like O O 0.9269098043441772
syndrome O O 0.5003928542137146
after O O 0.9997780919075012
hydrogen B-Chemical B-Chemical 0.9045557975769043
cyanamide E-Chemical I-Chemical 0.9300073981285095
professional O O 0.5324379205703735
skin O O 0.6134950518608093
exposure O O 0.5413183569908142
: O O 0.9996906518936157
two O O 0.999946117401123
case O O 0.9926128387451172
reports O O 0.9995631575584412
in O O 0.9999940395355225
France O O 0.9595161080360413
. O O 0.999997615814209

In O O 0.9998124241828918
this O O 0.9999927282333374
study O O 0.9999022483825684
, O O 0.9999872446060181
cancer O O 0.8215059638023376
patients O O 0.9183213114738464
who O O 0.9998220801353455
have O O 0.999951958656311
solid O O 0.8384002447128296
and O O 0.9254570007324219
hematological O O 0.5857660174369812
malignancies O O 0.601808488368988
with O O 0.9995074272155762
chronic O O 0.8031461238861084
HBV O O 0.41279199719429016
infection O O 0.9100240468978882
received O O 0.9959789514541626
the O O 0.9998061060905457
antiviral O O 0.6459349989891052
agent O O 0.6449841260910034
lamivudine S-Chemical B-Chemical 0.9330018162727356
prior O O 0.9830116033554077
and O O 0.9999431371688843
during O O 0.9999071359634399
CT O O 0.6313232779502869
compared O O 0.998759388923645
with O O 0.9999966621398926
historical O O 0.9613542556762695
control O O 0.9275138974189758
group O O 0.9845969080924988
who O O 0.9999290704727173
did O O 0.9999852180480957
not O O 0.9998705387115479
receive O O 0.9997648596763611
lamivudine S-Chemical B-Chemical 0.9251114130020142
. O O 0.9997037053108215

Mean O O 0.9763948917388916
peak O O 0.8937596082687378
forced O O 0.9871975183486938
expiratory O O 0.945254385471344
volume O O 0.6936489343643188
in O O 0.9980411529541016
1 O O 0.9969742298126221
second O O 0.9985170960426331
( O O 0.9999392032623291
FEV1 O O 0.8917604088783264
) O O 0.9912570714950562
increases O O 0.9386171102523804
over O O 0.9981366395950317
baseline O O 0.9801315665245056
and O O 0.9999371767044067
the O O 0.9999264478683472
proportion O O 0.999864935874939
of O O 0.999958872795105
patients O O 0.9994972944259644
attaining O O 0.9999192953109741
at O O 0.9988147020339966
least O O 0.9998071789741516
a O O 0.999980092048645
15 O O 0.9903988838195801
% O O 0.9995802044868469
increase O O 0.9074440598487854
in O O 0.9973957538604736
the O O 0.9992713332176208
FEV1 O O 0.6144981980323792
( O O 0.9952632188796997
responders O O 0.9883784651756287
) O O 0.9998049139976501
were O O 0.9999971389770508
31 O O 0.9998782873153687
% O O 0.9999672174453735
and O O 0.9999791383743286
90 O O 0.9999421834945679
% O O 0.999984622001648
, O O 0.9999892711639404
respectively O O 0.9999929666519165
, O O 0.9999788999557495
for O O 0.9998801946640015
ipratropium S-Chemical B-Chemical 0.9298359751701355
and O O 0.9920867085456848
17 O O 0.9993071556091309
% O O 0.9999253749847412
and O O 0.9999573230743408
50 O O 0.9998323917388916
% O O 0.9999653100967407
, O O 0.9999837875366211
respectively O O 0.9999890327453613
, O O 0.9999819993972778
for O O 0.9999406337738037
theophylline S-Chemical B-Chemical 0.9162827730178833
. O O 0.9994087219238281

show O O 0.8454949855804443

Ketoconazole B-Chemical B-Chemical 0.9084023833274841
induced O O 0.9444996118545532
torsades B-Disease O 0.765705406665802
de I-Disease O 0.7098243832588196
pointes I-Disease O 0.8683075308799744
without O O 0.9984728693962097
concomitant O O 0.9351507425308228
use O O 0.9934167861938477
of O O 0.9998584985733032
QT O O 0.4901367425918579
interval O O 0.7935585379600525
- O O 0.9958208799362183
prolonging O O 0.977516770362854
drug O O 0.9532676935195923
. O O 0.9999700784683228

Amiloride B-Chemical B-Chemical 0.9161187410354614
reduced O O 0.9733455181121826
the O O 0.9888958930969238
drinking O O 0.8330013155937195
and O O 0.9914590120315552
urine O O 0.9491178393363953
volume O O 0.9825353622436523
of O O 0.9994971752166748
rats O O 0.97468501329422
in O O 0.9998437166213989
an O O 0.9998797178268433
acute O O 0.8291418552398682
( O O 0.9944307208061218
6 O O 0.9990516304969788
or O O 0.9999339580535889
12 O O 0.9995772242546082
h O O 0.985741376876831
) O O 0.9951410293579102
and O O 0.9999408721923828
a O O 0.9999136924743652
subacute O O 0.48478707671165466
( O O 0.963064968585968
3 O O 0.9958447813987732
days O O 0.9995065927505493
) O O 0.9996349811553955
experiment O O 0.9986799359321594
. O O 0.9999994039535522

enhancement O O 0.9703458547592163
of O O 0.9997146725654602
Ig-secreting B-cell_type B-cell_line 0.44432884454727173
cells E-cell_type E-cell_line 0.5037989020347595
after O O 0.9996410608291626
PWM S-protein S-protein 0.7023106217384338
stimulation O O 0.9946544170379639
. O O 0.999995231628418
In O O 0.9999880790710449
this O O 0.9999939203262329
study O O 0.9999063014984131
the O O 0.9999946355819702
effect O O 0.9999864101409912
of O O 0.9999908208847046
anti-estrogen O O 0.7559621334075928
( O O 0.9834680557250977
toremifene O O 0.6916371583938599
) O O 0.9666705131530762
therapy O O 0.9977450966835022
on O O 0.9999908208847046
serum B-protein B-protein 0.667113184928894
immunoglobulin E-protein E-protein 0.906930685043335
( O O 0.9678189754486084
IgA S-protein S-protein 0.444576621055603

In O O 0.9996057152748108
conclusion O O 0.9725257158279419
mitochondrial O B-Disease 0.5993982553482056
toxicity O I-Disease 0.760428786277771
is O O 0.9914239048957825
an O O 0.9999574422836304
early O O 0.9815722703933716
common O O 0.990908145904541
event O O 0.9922298789024353
both O O 0.9999871253967285
in O O 0.9998853206634521
paclitaxel S-Chemical B-Chemical 0.9257186651229858
and O O 0.9403597712516785
cisplatin S-Chemical B-Chemical 0.9280386567115784
induced O O 0.9373301267623901
neurotoxicity O B-Disease 0.9836624264717102
. O O 0.9989224672317505

genes O E-DNA 0.7708772420883179
encoding O O 0.935772716999054
proteins O O 0.6725079417228699
involved O O 0.9998025298118591
in O O 0.9999237060546875
DNA O O 0.9240500926971436
replication O O 0.9842483401298523
, O O 0.9997950196266174
binding O O 0.9660852551460266
, O O 0.9956250786781311
transcription O O 0.9386760592460632
and O O 0.9945042133331299
translation O O 0.9784139394760132
were O O 0.9998778104782104
induced O O 0.9997499585151672
. O O 0.9999967813491821
Large O O 0.9946964979171753
part O O 0.9928567409515381
of O O 0.9999116659164429
the O O 0.9999359846115112
activated B-DNA B-DNA 0.7528790235519409
genes E-DNA E-DNA 0.8546609878540039
were O O 0.9991279244422913
under O O 0.9999850988388062
very O O 0.9963891506195068
stringent O O 0.9887091517448425
regulation O O 0.9967265129089355
being O O 0.9999294281005859
expressed O O 0.9997351765632629
only O O 0.9999769926071167
after O O 0.9999736547470093
stimulation O O 0.9974180459976196
. O O 0.9999978542327881
The O O 0.999990701675415
mechanism O O 0.9973823428153992
and O O 0.9998704195022583
function O O 0.9992817044258118
of O O 0.9999468326568604
the O O 0.9998723268508911
expressed B-DNA B-DNA 0.732797384262085
genes E-DNA E-DNA 0.8994261622428894
during O O 0.998992383480072
lymphocyte O O 0.42868220806121826

hyperproliferative O O 0.8636085987091064
disorders O O 0.7773406505584717
including O O 0.9997993111610413
psoriasis O O 0.9279436469078064
and O O 0.9997292160987854
cancer O O 0.8901745676994324
. O O 0.9999955892562866
Here O O 0.9999593496322632
we O O 0.9999951124191284
demonstrate O O 0.9999933242797852
that O O 0.9999961853027344
these O O 0.999929666519165
analogs O O 0.749140739440918
, O O 0.9988344311714172
as O O 0.9999091625213623
well O O 0.9992990493774414
as O O 0.999983549118042
the O O 0.9998512268066406
6-cis-locked O O 0.3465953469276428
conformer O O 0.30593177676200867
, O O 0.924480140209198
1alpha B-cell_line O 0.30595794320106506
, I-cell_line O 0.9380715489387512

i O O 0.7778573632240295
following O O 0.9990874528884888
thapsigargin O O 0.4576868414878845
treatment O O 0.9944456815719604
. O O 0.9999836683273315
NF-kappaB S-protein S-protein 0.9693492650985718
regulatory O O 0.9071735739707947
effect O O 0.9984217882156372
of O O 0.9999716281890869
alpha-lipoate O O 0.4367245137691498
and O O 0.991331934928894
N-acetylcysteine O O 0.7562168836593628
appeared O O 0.999841570854187
to O O 0.9999791383743286
be O O 0.9999880790710449
, O O 0.9998754262924194

are O O 0.9992102384567261
true O O 0.9999635219573975
for O O 0.9999936819076538
the O O 0.999943733215332
Epstein-Barr O O 0.5739502906799316
virus O O 0.42117375135421753
( O O 0.9314501881599426
EBV O O 0.7203741073608398
) O O 0.9398192763328552
. O O 0.9988994598388672
B B-cell_type B-cell_type 0.7963852882385254
cells E-cell_type E-cell_type 0.9844926595687866
and O O 0.9923661351203918
epithelial B-cell_type B-cell_type 0.7810550928115845
cells E-cell_type E-cell_type 0.9784380197525024
have O O 0.999589741230011

this O O 0.9994214773178101
study O O 0.9999836683273315
, O O 0.9999983310699463
the O O 0.9999895095825195
region O O 0.9719618558883667
upstream O O 0.9750032424926758
of O O 0.9995948672294617
Cp S-DNA S-DNA 0.9923239946365356
was O O 0.9987778067588806
analyzed O O 0.9999451637268066
for O O 0.9999957084655762
the O O 0.9999920129776001
presence O O 0.9989400506019592
of O O 0.999951958656311
cis O B-DNA 0.2815505862236023
elements O E-DNA 0.9778876900672913
involved O O 0.9993987083435059
in O O 0.9999666213989258
regulating O O 0.9979004859924316
the O O 0.9998108744621277
activities O O 0.9997971653938293
of O O 0.9999821186065674
the O O 0.9997254014015198

. O O 0.99189692735672
In O O 0.9999837875366211
contrast O O 0.9997835755348206
, O O 0.9999905824661255
deletion O O 0.9982209801673889
of O O 0.9999061822891235
the O O 0.9998706579208374
upstream B-DNA B-DNA 0.4972420036792755
portion E-DNA E-DNA 0.8274998664855957
of O O 0.9963973164558411
the O O 0.9999090433120728
delta B-DNA B-DNA 0.5451924800872803
promoter E-DNA E-DNA 0.9916651844978333
led O O 0.9993565678596497
to O O 0.9999924898147583
a O O 0.9999377727508545
10 O O 0.8387877345085144
fold O O 0.918592095375061
decrease O O 0.9754353165626526
in O O 0.9991542100906372
expression O O 0.996610701084137
. O O 0.9999908208847046
Coupling O O 0.980922520160675
of O O 0.9992782473564148
the O O 0.9998238682746887
upstream B-DNA B-DNA 0.42707934975624084
beta I-DNA I-DNA 0.46027326583862305
globin I-DNA I-DNA 0.7198175191879272
sequence E-DNA E-DNA 0.987355649471283
from O O 0.9996745586395264
approximately O O 0.9947867393493652
-500 O O 0.7729323506355286
to O O 0.9240934252738953
-250 O O 0.9301725625991821
bp O O 0.634554922580719
to O O 0.9976987242698669
the O O 0.9998040795326233
truncated O B-DNA 0.6615713834762573
delta B-DNA I-DNA 0.33237388730049133

Vitamin B-Chemical B-Chemical 0.9475151896476746
B12 E-Chemical I-Chemical 0.9455735087394714
and O O 0.9724007844924927
folinic B-Chemical B-Chemical 0.8383078575134277
acid E-Chemical I-Chemical 0.9564072489738464
supplementation O O 0.9347548484802246
of O O 0.9994516968727112
ZDV S-Chemical B-Chemical 0.9214195013046265
therapy O O 0.9795837998390198
does O O 0.9999982118606567
not O O 0.9999542236328125
seem O O 0.9999935626983643
useful O O 0.9998399019241333
in O O 0.9999524354934692
preventing O O 0.9963488578796387
or O O 0.999189555644989
reducing O O 0.9985427856445312
ZDV S-Chemical B-Chemical 0.9181634783744812
- O O 0.9190335273742676
induced O O 0.9967613816261292
myelotoxicity O B-Disease 0.9830355644226074
in O O 0.9760273098945618
the O O 0.994101345539093
overall O O 0.953178346157074
treated O O 0.9676937460899353
population O O 0.9322463274002075
, O O 0.9999730587005615
although O O 0.9999978542327881
a O O 0.9999881982803345
beneficial O O 0.9818848967552185
effect O O 0.9985761642456055
in O O 0.9999943971633911
certain O O 0.9992144107818604
subgroups O O 0.9690971970558167
of O O 0.9981533885002136
patients O O 0.9991670846939087
cannot O O 0.9999812841415405
be O O 0.9999294281005859
excluded O O 0.9998452663421631
. O O 0.9999992847442627

Carmofur S-Chemical B-Chemical 0.9236560463905334
- O O 0.9329223036766052
induced O O 0.9984365105628967
organic O B-Disease 0.6038907766342163
mental O I-Disease 0.4997609257698059
disorders O I-Disease 0.984831690788269
. O O 0.9973383545875549

TRAF6 S-protein S-protein 0.7289662957191467
) O O 0.978306770324707
. O O 0.999987006187439
The O O 0.9999878406524658
human O O 0.6333795189857483
homologue O O 0.6091219782829285
of O O 0.9867653846740723
Drosophila B-protein B-protein 0.7320084571838379
Toll E-protein E-protein 0.7889861464500427
( O O 0.9495001435279846
hToll S-protein S-protein 0.4476233422756195
) O O 0.808375895023346
is O O 0.9990012049674988
a O O 0.9999926090240479
recently O O 0.9791412949562073
cloned O O 0.939570963382721
receptor O O 0.5397252440452576
of O O 0.9940102100372314
the O O 0.9996833801269531
interleukin B-protein B-protein 0.37087351083755493
1 I-protein I-protein 0.4249432682991028
receptor I-protein I-protein 0.8071343898773193
( I-protein I-protein 0.5823084712028503
IL-1R I-protein I-protein 0.5982646346092224
) I-protein I-protein 0.6459841728210449
superfamily E-protein E-protein 0.9240137338638306
, O O 0.9635977745056152
and O O 0.9995700716972351
has O O 0.9999693632125854
been O O 0.999906063079834
implicated O O 0.999869704246521
in O O 0.9998061060905457

revealed O O 0.9972608089447021
a O O 0.9999881982803345
transient O O 0.9559983015060425
up-regulation O O 0.9901095628738403
of O O 0.999853253364563
the O O 0.9997451901435852
IL-4-induced B-RNA B-RNA 0.7555186748504639
CD23 I-RNA I-RNA 0.9371939301490784
mRNA E-RNA E-RNA 0.9912149906158447
by O O 0.9993245601654053
IFN-gamma S-protein S-protein 0.9647200107574463
within O O 0.9987862706184387
2 O O 0.9952829480171204
h O O 0.994404673576355
of O O 0.9998906850814819
IFN-gamma S-protein S-protein 0.9088008403778076
treatment O O 0.9854023456573486
in O O 0.9999638795852661
these O O 0.9997015595436096
tonsillar B-cell_type B-cell_type 0.5193068385124207
cells E-cell_type E-cell_type 0.8724344372749329
. O O 0.9998098015785217
The O O 0.9999988079071045
results O O 0.9999877214431763
suggest O O 0.9999978542327881
that O O 0.9999947547912598
the O O 0.9998350143432617

During O O 0.999879002571106
these O O 0.999984860420227
two O O 0.9999450445175171
episodes O O 0.997840404510498
, O O 0.9999871253967285
his O O 0.9997952580451965
blood O O 0.9479018449783325
pressure O O 0.8214370608329773
diminished O O 0.994759738445282
but O O 0.9999388456344604
no O O 0.9998772144317627
severe O O 0.9674022197723389
hypotension B-Disease B-Disease 0.9316520094871521
was O O 0.9577667713165283
noted O O 0.9998669624328613
. O O 0.9999978542327881

Sham O O 0.3643847703933716
- O O 0.9725643992424011
operated O O 0.9956870675086975
rats O O 0.9959272742271423
served O O 0.9999799728393555
as O O 0.999987006187439
normotensive O O 0.48326122760772705
controls O O 0.8575957417488098
( O O 0.9999527931213379
128 O O 0.9991610050201416
+ O O 0.9999556541442871
/ O O 0.9999967813491821
- O O 0.9999890327453613
3 O O 0.9999405145645142
mm O O 0.9999498128890991
Hg O O 0.9741048216819763
, O O 0.9999585151672363
n O O 0.9998225569725037
= O O 0.9999589920043945
8 O O 0.9990750551223755
) O O 0.999794065952301
. O O 0.9999971389770508

HS O O 0.6620082259178162
diet O O 0.8451220393180847
for O O 0.9998456239700317
4 O O 0.9462341666221619
wk O O 0.7183109521865845
caused O O 0.999923586845398
a O O 0.9998214840888977
progressive O O 0.9508028030395508
increase O O 0.6326390504837036
in O O 0.8425963521003723
BP O O 0.42836230993270874
, O O 0.9885600209236145
protein O O 0.8321675658226013
and O O 0.9971672892570496
albumin O O 0.38791510462760925
excretion O O 0.5807113647460938
, O O 0.9980894923210144
and O O 0.9997416138648987
glomerular B-Disease B-Disease 0.5225520133972168
sclerosis I-Disease I-Disease 0.96627277135849
in O O 0.9702976942062378
male O O 0.9652196168899536
DS O O 0.7790515422821045
rats O O 0.9838663935661316
, O O 0.9999788999557495
which O O 0.9999699592590332
were O O 0.9999850988388062
attenuated O O 0.9994183778762817
by O O 0.9999926090240479
castration O O 0.9627839922904968
. O O 0.9999979734420776

in O O 0.9971413016319275
cell O O 0.968947172164917
proliferation O O 0.9952827095985413
and O O 0.9998717308044434
cytokine S-protein S-protein 0.9689210057258606
production O O 0.9983805418014526
and O O 0.9999692440032959
to O O 0.9999796152114868
increased O O 0.9969466328620911
cell O O 0.9724308848381042
apoptosis O O 0.9910762310028076
in O O 0.9999853372573853
response O O 0.9907128214836121
to O O 0.9999440908432007
mitogenic O O 0.8382577300071716
stimuli O O 0.8202016353607178
, O O 0.9995530247688293
but O O 0.999954342842102
not O O 0.9998743534088135
to O O 0.9998227953910828
abnormal O O 0.7442557215690613
thymopoiesis O O 0.4666746258735657
. O O 0.9998689889907837
To O O 0.9999909400939941
understand O O 0.9999853372573853
the O O 0.9999951124191284
role O O 0.9998915195465088
of O O 0.9999655485153198
NF-kappa B-protein B-protein 0.8572972416877747
B E-protein I-protein 0.8400413393974304
complexes O E-protein 0.9953916072845459
in O O 0.999880313873291
T O O 0.5530123114585876
cell O O 0.4686663746833801
development O O 0.9813736081123352

in O O 0.9974502921104431
comparison O O 0.9998810291290283
with O O 0.9999948740005493
healthy O O 0.9583826065063477
controls O O 0.9938082098960876
. O O 0.9999984502792358
A O O 0.9999916553497314
possible O O 0.9971332550048828
correlation O O 0.9964448809623718
between O O 0.9997050166130066
immune O O 0.9322056174278259
and O O 0.9912123084068298
clinical O O 0.9827362298965454
parameters O O 0.9863536357879639
was O O 0.9999890327453613
analysed O O 0.9999774694442749
in O O 0.999911904335022

for O O 0.9924771189689636
X O O 0.3420291244983673
inactivation O O 0.9192769527435303
analysis O O 0.998360812664032
has O O 0.9999972581863403
however O O 0.999982476234436
given O O 0.9999825954437256
rise O O 0.999705970287323
to O O 0.9999905824661255
new O O 0.9958418011665344
controversies O O 0.9883736371994019
, O O 0.999994158744812
one O O 0.9999954700469971
of O O 0.9999942779541016
the O O 0.9999933242797852
more O O 0.9993292093276978

blood I-cell_type O 0.4454498887062073
leukocyte E-cell_type O 0.7215232253074646
, O O 0.9703212976455688
while O O 0.9999547004699707
the O O 0.9999722242355347
skeletal O O 0.8660040497779846
muscle O O 0.7779943346977234
expressed O O 0.9971051812171936
primarily O O 0.9927600622177124
NFATx2 S-protein S-protein 0.7696191668510437
. O O 0.9994675517082214
In O O 0.9996683597564697
Jurkat B-cell_line B-cell_line 0.8629639148712158
cells E-cell_line E-cell_line 0.9884876608848572
, O O 0.9995868802070618
transcription O O 0.9617452025413513
from O O 0.9996598958969116
the O O 0.9996912479400635
NFAT B-DNA B-DNA 0.6419014930725098
site E-DNA E-DNA 0.9792600274085999
of O O 0.996084451675415
the O O 0.9998711347579956
IL-2 B-DNA B-DNA 0.6661849617958069
promoter E-DNA E-DNA 0.9948433637619019
is O O 0.998376727104187
activated O O 0.9997156262397766
strongly O O 0.9999815225601196
by O O 0.9999889135360718
NFATx1 S-protein S-protein 0.7874224185943604
but O O 0.9909906387329102

Inhibition O O 0.8864893913269043
of O O 0.997536301612854
NO S-Chemical B-Chemical 0.9349162578582764
- O O 0.6067790985107422
synthase O O 0.34889110922813416
induced O O 0.9985703229904175
a O O 0.9997395873069763
reversible O O 0.9454075694084167
hypertension O B-Disease 0.9717614054679871
accompanied O O 0.9867820739746094
by O O 0.9999498128890991
depressed O O 0.8005669713020325
Na S-Chemical B-Chemical 0.9254570007324219
+ O O 0.7914895415306091
- O O 0.9873467087745667
extrusion O O 0.6043155193328857
from O O 0.9996517896652222
cardiac O O 0.5502738356590271
cells O O 0.5342034101486206
as O O 0.9999312162399292
a O O 0.9999974966049194
consequence O O 0.9998500347137451
of O O 0.9999915361404419
deteriorated O O 0.9380245208740234
Na S-Chemical B-Chemical 0.9256693124771118
+ O O 0.8357579708099365
- O O 0.9968012571334839
binding O O 0.9825261831283569
properties O O 0.9975963234901428
of O O 0.9998730421066284
the O O 0.99739670753479
( O O 0.9221689701080322
Na S-Chemical B-Chemical 0.9368335604667664
, O O 0.8129861950874329
K S-Chemical B-Chemical 0.9261298179626465
) O O 0.456102192401886
- O O 0.963701069355011
ATPase O O 0.47661858797073364
. O O 0.999957799911499

and O O 0.9699838757514954
normal O O 0.9664597511291504
subjects O O 0.9954969882965088
( O O 0.9999935626983643
2.0 O O 0.9980891346931458
+/- O O 0.9999639987945557
0.8 O O 0.9999209642410278
nmol/L O O 0.9984222650527954
; O O 0.9999843835830688
P O O 0.9989461302757263
< O O 0.9999347925186157
0.01 O O 0.99947589635849
) O O 0.9998681545257568
. O O 0.9999958276748657
IFN B-protein B-protein 0.5114893317222595
alpha E-protein E-protein 0.9881823658943176
levels O O 0.9984239339828491
were O O 0.9999967813491821
increased O O 0.9999508857727051
in O O 0.9999912977218628
the O O 0.9999418258666992
AIDS-GR O O 0.5511558651924133
group O O 0.9072057604789734
( O O 0.9998953342437744
17 O O 0.9993104934692383
+/- O O 0.9998914003372192
6 O O 0.9993416666984558
vs O O 0.9993894100189209
. O O 0.9999568462371826
4 O O 0.9963538646697998

IL-2 S-protein S-protein 0.9187527894973755
. O O 0.9998476505279541
In O O 0.9999969005584717
this O O 0.9999967813491821
report O O 0.9999182224273682
we O O 0.9999920129776001
show O O 0.9999972581863403
that O O 0.9999983310699463
the O O 0.9999359846115112
functional O O 0.9625768661499023
synergy O O 0.9838641881942749
between O O 0.9996091723442078
IL-12 S-protein S-protein 0.9646735191345215
and O O 0.9902759790420532
IL-2 S-protein S-protein 0.9734042286872864
in O O 0.9990604519844055

the O O 0.9996104836463928
underlying O O 0.9970492720603943
degree O O 0.9998828172683716
of O O 0.9999886751174927
mucosal O O 0.8246012330055237
inflammation O O 0.9642086029052734
Tobacco O O 0.961397647857666
smoke O O 0.9682880640029907
induces O O 0.9995920062065125
coordinate O O 0.99754399061203
activation O O 0.9991137385368347
of O O 0.9999654293060303
HSF S-protein S-protein 0.8797335028648376
and O O 0.9884212017059326
inhibition O O 0.9844225645065308
of O O 0.9992951154708862
NFkappaB S-protein S-protein 0.9915364980697632
in O O 0.9996556043624878
human B-cell_type B-cell_type 0.8020302057266235
monocytes E-cell_type E-cell_type 0.9852433204650879
: O O 0.9768701791763306
effects O O 0.9997953772544861
on O O 0.9999716281890869
TNFalpha S-protein S-protein 0.9703146815299988
release O O 0.992107093334198
. O O 0.9999939203262329
Tobacco O O 0.9611781239509583
smoke O O 0.9595073461532593
( O O 0.9978100657463074
TS O O 0.9451796412467957
) O O 0.9980365633964539
exposure O O 0.999514102935791
is O O 0.999998927116394
a O O 0.9999954700469971
major O O 0.9933096170425415
risk O O 0.997183620929718
factor O O 0.9784101843833923
for O O 0.9998239874839783

Two O O 0.9972502589225769
subsets O O 0.9855526089668274
of O O 0.9981462955474854
patients O O 0.9989131689071655
were O O 0.9999891519546509
identified O O 0.9999384880065918
from O O 0.999994158744812
this O O 0.9999053478240967
latter O O 0.9987815022468567
group O O 0.9996596574783325
: O O 0.9999970197677612
the O O 0.9999885559082031
first O O 0.9998853206634521
included O O 0.9999535083770752
four O O 0.999695897102356
patients O O 0.9998599290847778
( O O 0.9999946355819702
5 O O 0.9999614953994751
% O O 0.9999829530715942
of O O 0.9999754428863525
the O O 0.9999200105667114
total O O 0.9758484363555908
population O O 0.9394500851631165
) O O 0.9991636276245117
who O O 0.9998674392700195
developed O O 0.9979534149169922
major O O 0.758197009563446
toxicity O B-Disease 0.7133011221885681
resulting O O 0.9541541934013367
in O O 0.9993090629577637
Fanconi O B-Disease 0.4831753969192505
' O I-Disease 0.5368797183036804
s O I-Disease 0.7686783671379089
syndrome O I-Disease 0.987188994884491
( O O 0.9588695764541626
TDFS O B-Disease 0.9699190855026245
) O O 0.9024621844291687
; O O 0.9996656179428101
and O O 0.9999725818634033
the O O 0.9999704360961914
second O O 0.9986145496368408
group O O 0.999480664730072
included O O 0.9999878406524658
five O O 0.9990050196647644
patients O O 0.9997835755348206
with O O 0.9999862909317017
elevated O O 0.9074839353561401
beta O O 0.7274084687232971
2 O O 0.8076193332672119
microglobulinuria O O 0.8043700456619263
and O O 0.9871117472648621
low O O 0.9618951678276062
phosphate S-Chemical B-Chemical 0.9207851886749268
reabsorption O O 0.47397512197494507
. O O 0.9998641014099121

those O O 0.9966163039207458
in O O 0.9999693632125854
young O O 0.9480817317962646
. O O 0.999896764755249
Examination O O 0.9998248219490051
of O O 0.999984860420227
IkappaB B-protein B-protein 0.6407623887062073
alpha E-protein E-protein 0.9687009453773499
regulation O O 0.9955665469169617
revealed O O 0.9999940395355225
that O O 0.9999923706054688
TNF-alpha S-protein S-protein 0.997856080532074
-mediated O O 0.9958685636520386
degradation O O 0.9975956082344055
of O O 0.999950647354126
IkappaB B-protein B-protein 0.6238786578178406
alpha E-protein E-protein 0.968845784664154
in O O 0.9990143775939941
both O O 0.9997805953025818
memory B-cell_type O 0.7195492386817932
and I-cell_type O 0.6394525766372681

The O O 0.998365581035614
infusion O O 0.8370062708854675
was O O 0.9958147406578064
discontinued O O 0.9979479908943176
either O O 0.9999916553497314
when O O 0.999951958656311
there O O 0.9999450445175171
was O O 0.9999803304672241
no O O 0.999930739402771
muscular O O 0.8360503911972046
response O O 0.8069168329238892
to O O 0.9985899329185486
tetanic B-Disease O 0.6122671961784363
stimulation O O 0.7505975961685181
of O O 0.9896306395530701
the O O 0.9978808760643005
ulnar O O 0.6726532578468323
nerve O O 0.7365013360977173
or O O 0.986846387386322
when O O 0.9999085664749146
Sch B-Chemical B-Chemical 0.887279748916626
120 O O 0.8778275847434998
mg O O 0.5314182043075562
was O O 0.99978107213974
exceeded O O 0.9999663829803467
. O O 0.9999994039535522

. O O 0.996147632598877
In O O 0.9999955892562866
this O O 0.9999964237213135
study O O 0.9999125003814697
, O O 0.9999958276748657
we O O 0.9999117851257324
cloned O O 0.9984753727912903
two O O 0.9915446043014526
cDNAs S-DNA S-DNA 0.9720482230186462
encoding O O 0.9790375232696533
proteins O O 0.8281932473182678
which O O 0.9997847676277161
bind O O 0.9996823072433472
to O O 0.9999725818634033
an O O 0.9997870326042175
oligonucleotide O O 0.3752889037132263
in O O 0.9958441853523254
silencer B-DNA O 0.8513160943984985
I E-DNA O 0.26503926515579224
containing O O 0.9339588284492493
a O O 0.9943451881408691

to O O 0.9940282106399536
T-cell O O 0.5784357190132141
activation O O 0.9864298105239868
. O O 0.9999732971191406
When O O 0.9999610185623169
bound O O 0.9993851184844971
to O O 0.9999419450759888
cyclophilin S-protein S-protein 0.7927007079124451
, O O 0.9977607727050781
cyclosporin O O 0.8607569336891174
A O O 0.5024672150611877
binds O O 0.9704583287239075
and O O 0.9987524747848511
inactivates O O 0.9995973706245422
the O O 0.999808132648468
key O O 0.9358020424842834
signalling O O 0.9319536685943604
intermediate O O 0.8614720106124878
calcineurin S-protein S-protein 0.9367206692695618
. O O 0.9998132586479187
To O O 0.9999896287918091
identify O O 0.9999653100967407
potential O O 0.9892113208770752
cellular O O 0.910873532295227
homologues O O 0.6204013824462891
of O O 0.9986521601676941
cyclosporin O O 0.5432288646697998
A O O 0.486406534910202

nucleotide O O 0.6024920344352722
polymorphism O O 0.5836969017982483
( O O 0.9949789643287659
SNP O O 0.7276215553283691
) O O 0.9954707622528076
that O O 0.9999827146530151
causes O O 0.9999728202819824
the O O 0.9998045563697815
helix-turn-helix O B-protein 0.34685149788856506
transcription B-protein I-protein 0.656294047832489
factor E-protein E-protein 0.925513505935669
OCT-1 O S-protein 0.6937065720558167
to O O 0.9992144107818604
bind O O 0.9910616278648376

Impotence B-Disease O 0.8842063546180725
was O O 0.9690231084823608
more O O 0.996711015701294
common O O 0.99391770362854
among O O 0.9998823404312134
male O O 0.8171690702438354
patients O O 0.9937981963157654
than O O 0.9999916553497314
controls O O 0.9827637672424316
and O O 0.9999377727508545
was O O 0.999919056892395
found O O 0.9998881816864014
to O O 0.9999434947967529
be O O 0.9999537467956543
associated O O 0.9998464584350586
with O O 0.9999891519546509
co O O 0.5385376214981079
- O O 0.8385498523712158
morbidity O O 0.49991893768310547
and O O 0.9963096976280212
the O O 0.9996381998062134
taking O O 0.9996022582054138
of O O 0.9997357726097107
methotrexate B-Chemical B-Chemical 0.9219061136245728
. O O 0.9995898604393005

New O O 0.9977376461029053
strategies O O 0.9997844099998474
for O O 0.999994158744812
long O O 0.9896872639656067
- O O 0.9987087249755859
term O O 0.998114824295044
immunosuppression O O 0.648356556892395
may O O 0.9993102550506592
be O O 0.9999879598617554
needed O O 0.9999912977218628
to O O 0.9999730587005615
decrease O O 0.9983336329460144
this O O 0.998374342918396
complication O O 0.8789549469947815
. O O 0.9999887943267822

Ezetimibe B-Chemical B-Chemical 0.9121150374412537
undergoes O O 0.9989803433418274
extensive O O 0.9863700866699219
glucuronidation O O 0.7298427820205688
by O O 0.9982289671897888
uridine B-Chemical B-Chemical 0.9202466607093811
diphosphate I-Chemical I-Chemical 0.9426301717758179
glucoronosyltransferases O O 0.813574492931366
( O O 0.9794712662696838
UGT O O 0.46584025025367737
) O O 0.9791009426116943
in O O 0.9998950958251953
the O O 0.9995402097702026
intestine O O 0.6947722434997559
and O O 0.9978141784667969
liver O O 0.7687710523605347
and O O 0.983903169631958
may O O 0.99972003698349
have O O 0.9999654293060303
inhibited O O 0.9994193315505981
the O O 0.9997034668922424
glucuronidation O O 0.5676453113555908
of O O 0.9949337840080261
simvastatin B-Chemical B-Chemical 0.9049027562141418
hydroxy I-Chemical I-Chemical 0.9361276626586914
acid I-Chemical I-Chemical 0.945132851600647
, O O 0.9960162043571472
resulting O O 0.9999260902404785
in O O 0.9999357461929321
increased O O 0.9938271641731262
simvastatin B-Chemical S-Chemical 0.8967970013618469
exposure O O 0.7997496128082275
and O O 0.998596727848053
subsequent O O 0.9698240160942078
hepatotoxicity B-Disease B-Disease 0.9511500597000122
. O O 0.9987820982933044

and O O 0.9547727704048157
immunohistochemistry O O 0.8788774013519287
( O O 0.9970207810401917
IH O O 0.8901994228363037
) O O 0.9977157115936279
. O O 0.9999957084655762
Of O O 0.9999992847442627
the O O 0.9999979734420776
23 O O 0.9973425269126892
cases O O 0.9996121525764465
, O O 0.9999934434890747
19 O O 0.9830577969551086
were O O 0.9999303817749023
classified O O 0.9996482133865356
as O O 0.9997995495796204
NK-cell O O 0.4612370729446411
and O O 0.9520741105079651

Antiemetic O O 0.522667646408081
requirements O O 0.7399302124977112
were O O 0.9996935129165649
reduced O O 0.9997392296791077
from O O 0.9999938011169434
24 O O 0.9999029636383057
% O O 0.9999722242355347
and O O 0.9999840259552002
31 O O 0.9998646974563599
% O O 0.999972939491272
to O O 0.9999788999557495
7 O O 0.9999616146087646
% O O 0.999984622001648
( O O 0.9999873638153076
P O O 0.9998701810836792
= O O 0.9999834299087524
0 O O 0.9999043941497803
. O O 0.9999736547470093
0012 O O 0.9856380820274353
) O O 0.9995799660682678
. O O 0.9999953508377075

Given O O 0.9997642636299133
its O O 0.9999294281005859
excellent O O 0.9908517003059387
tolerance O O 0.887636125087738
profile O O 0.9517490863800049
and O O 0.9998760223388672
low O O 0.7555326223373413
toxicity O B-Disease 0.7944219708442688
, O O 0.9959631562232971
further O O 0.9996944665908813
evaluation O O 0.9997773766517639
of O O 0.9999687671661377
VNB S-Chemical B-Chemical 0.893020510673523
in O O 0.9968340992927551
combination O O 0.839034914970398
therapy O O 0.9964536428451538
is O O 0.9999949932098389
warranted O O 0.9999555349349976
. O O 0.9999992847442627

to O O 0.976373553276062
50 B-protein B-protein 0.8922587633132935
kDa I-protein I-protein 0.5991981029510498
NF-kappa I-protein I-protein 0.5361325740814209
B I-protein I-protein 0.8028678894042969
protein E-protein E-protein 0.9845684766769409
) O O 0.9877374172210693
reacted O O 0.9999699592590332
with O O 0.9999945163726807
the O O 0.9999520778656006
p50 S-protein S-protein 0.7204659581184387
of O O 0.7847232222557068
NF-GM2 S-protein S-protein 0.4785761833190918
, O O 0.9969673752784729
indicating O O 0.9999904632568359
that O O 0.9999971389770508
the O O 0.9999052286148071
NF-GM2 B-protein S-protein 0.47661733627319336
polypeptide E-protein O 0.3078288733959198
can O O 0.9988160133361816
not O O 0.9999808073043823
be O O 0.9999680519104004
immunologically O O 0.9089660048484802
differentiated O O 0.9898697733879089

OBJECTIVES O O 0.9723162651062012
: O O 0.9999613761901855
To O O 0.9999862909317017
study O O 0.9999676942825317
the O O 0.9999637603759766
long O O 0.9808552861213684
- O O 0.9972666501998901
term O O 0.9991113543510437
effects O O 0.9994118213653564
of O O 0.9999493360519409
androgen O B-Chemical 0.9342102408409119
treatment O O 0.9793072938919067
on O O 0.9999798536300659
atherosclerosis B-Disease B-Disease 0.9726883172988892
in O O 0.9911077618598938
postmenopausal O O 0.717179000377655
women O O 0.7354338765144348
. O O 0.9999856948852539

virus O O 0.8124087452888489
type O O 0.7303750514984131
2 O O 0.7564463019371033
( O O 0.9930248260498047
HIV-2 O O 0.9257598519325256
) O O 0.9960141181945801
, O O 0.9999139308929443
like O O 0.9998863935470581
HIV-1 O O 0.7889755368232727
, O O 0.997831404209137
causes O O 0.9997983574867249
AIDS O O 0.7931385040283203
and O O 0.9992608428001404
is O O 0.9999517202377319
associated O O 0.9999734163284302
with O O 0.9999954700469971
AIDS O O 0.8649946451187134
cases O O 0.99400794506073
primarily O O 0.9999752044677734
in O O 0.9999818801879883
West O O 0.9844446182250977
Africa O O 0.9992635846138
. O O 0.9999973773956299
HIV-1 O O 0.6121550798416138
and O O 0.9747720956802368

, O O 0.9162757396697998
or O O 0.9930540919303894
CsA O O 0.7357181310653687
. O O 0.9998776912689209
Hence O O 0.9952908754348755
, O O 0.9999074935913086
integration O O 0.998052716255188
of O O 0.9998652935028076
signals O O 0.965894341468811
that O O 0.9998363256454468
lead O O 0.9998692274093628
to O O 0.9999053478240967
T O O 0.8342941403388977
cell O O 0.746223509311676
activation O O 0.9931638836860657
occurs O O 0.999970555305481
at O O 0.9999984502792358
the O O 0.999991774559021
level O O 0.999891996383667
of O O 0.9999456405639648
JNK S-protein S-protein 0.7805076837539673

variant O O 0.47752538323402405
ER S-protein S-protein 0.7612265348434448
forms O O 0.6810336112976074
remain O O 0.9998108744621277
to O O 0.9999384880065918
be O O 0.9998948574066162
elucidated O O 0.9897633790969849
. O O 0.9999350309371948
p21ras S-protein S-protein 0.6624230742454529
initiates O O 0.9965051412582397
Rac-1 S-protein S-protein 0.9337996244430542
but O O 0.9961124062538147
not O O 0.9989184141159058
phosphatidyl B-protein B-protein 0.7860183715820312
inositol I-protein I-protein 0.6251006126403809
3 I-protein I-protein 0.7134738564491272
kinase/PKB E-protein E-protein 0.7487956285476685
, O O 0.9920440912246704
mediated O O 0.9843936562538147
signaling O O 0.9493361115455627
pathways O O 0.9846694469451904
in O O 0.9998512268066406
T B-cell_type B-cell_type 0.7619443535804749
lymphocytes E-cell_type E-cell_type 0.9935742020606995
. O O 0.9991803765296936
p21ras S-protein S-protein 0.6167563796043396
is O O 0.998421311378479
activated O O 0.9989196062088013
by O O 0.9999949932098389
the O O 0.999931812286377
T B-protein B-protein 0.46843114495277405
cell I-protein I-protein 0.7664933204650879
antigen I-protein I-protein 0.615510106086731
receptor E-protein E-protein 0.9874124526977539
( O O 0.9807425737380981
TCR S-protein S-protein 0.9952561259269714
) O O 0.9852843880653381
and O O 0.9990519881248474
then O O 0.9998161196708679
co-ordinates O O 0.9995467066764832
important O O 0.9892476201057434
signaling O O 0.9503942131996155
pathways O O 0.9950283169746399
for O O 0.9999411106109619
T B-protein O 0.7150266766548157
lymphocyte E-protein O 0.8119320869445801
activation O O 0.9878968000411987
. O O 0.9999895095825195
Effector O O 0.9611310958862305
pathways O O 0.9967345595359802
for O O 0.9999904632568359
this O O 0.9999371767044067
guanine B-protein B-protein 0.45111438632011414
nucleotide I-protein I-protein 0.7164409756660461
binding I-protein I-protein 0.891322135925293
protein E-protein E-protein 0.980975866317749
in O O 0.9983541965484619
T B-cell_type B-cell_type 0.917595624923706
cells E-cell_type E-cell_type 0.9879335761070251
are O O 0.999344527721405
mediated O O 0.9993032217025757

TH O O 0.31839051842689514
action O O 0.9883085489273071
depending O O 0.9999911785125732
on O O 0.9999725818634033
TRE S-DNA O 0.33284544944763184
structure O O 0.6658340096473694
and O O 0.99673992395401
THR B-protein O 0.47646015882492065
isotype E-protein O 0.6499761939048767
. O O 0.9996728897094727
Comparison O O 0.9997968077659607
of O O 0.9999872446060181
retinoic O O 0.7547095417976379
acid O O 0.7888807654380798
and O O 0.9957740902900696
phorbol O O 0.9290794134140015
myristate O O 0.9460296630859375
acetate O O 0.983826220035553
as O O 0.9999707937240601
inducers O O 0.8963273167610168
of O O 0.9980852603912354
monocytic O O 0.7920306921005249
differentiation O O 0.9703155755996704
. O O 0.9999843835830688
Several O O 0.9997926354408264
human B-cell_line B-cell_line 0.45757418870925903
myeloid I-cell_line I-cell_line 0.4680594205856323
leukemia I-cell_line I-cell_line 0.7850427627563477
cell I-cell_line I-cell_line 0.8570205569267273
lines E-cell_line E-cell_line 0.9986995458602905
growing O O 0.9977103471755981
in O O 0.9988580942153931
vitro O O 0.991936445236206
can O O 0.9998425245285034
be O O 0.9999740123748779
induced O O 0.9993897676467896
to O O 0.9999605417251587
differentiate O O 0.999333918094635
to O O 0.9996675252914429
more O O 0.9976321458816528
mature O O 0.6256982088088989

Peripheral O B-Disease 0.6010442972183228
neuropathy O I-Disease 0.8728281259536743
due O O 0.9944655299186707
to O O 0.9999308586120605
nutritional O O 0.8949282169342041
deficiency O O 0.8249912261962891
of O O 0.8617342710494995
thiamine S-Chemical B-Chemical 0.9279803037643433
and O O 0.946331262588501
riboflavin S-Chemical B-Chemical 0.9324831366539001
was O O 0.9958886504173279
common O O 0.9987503290176392
( O O 0.9999713897705078
10 O O 0.9998828172683716
. O O 0.9999247789382935
1 O O 0.9999287128448486
% O O 0.9997962117195129
) O O 0.9989456534385681
and O O 0.9999425411224365
presented O O 0.9998829364776611
mainly O O 0.9997212290763855
as O O 0.9999613761901855
sensory O O 0.7807424068450928
and O O 0.9874868392944336
sensori O O 0.611626923084259
- O O 0.9367166757583618
motor O O 0.7039097547531128
neuropathy O O 0.8803059458732605
. O O 0.9988131523132324

, O O 0.9929266571998596
we O O 0.9999631643295288
analyzed O O 0.9996426105499268
regulatory B-DNA B-DNA 0.8156732320785522
regions E-DNA E-DNA 0.7276954650878906
of O O 0.997330904006958
B B-DNA B-DNA 0.3469308912754059
cell-specific I-DNA I-DNA 0.4881417155265808
genes E-DNA E-DNA 0.9849576950073242
for O O 0.9995872378349304
potential O O 0.9788848161697388
AML1-binding B-DNA B-DNA 0.7469924688339233
sites E-DNA E-DNA 0.9739865064620972
and O O 0.9975104331970215
have O O 0.9999877214431763
identified O O 0.9999630451202393
a O O 0.9999772310256958
putative O O 0.6992120742797852
AML1-binding B-DNA B-DNA 0.6109011173248291
site E-DNA E-DNA 0.9743106365203857
in O O 0.9995442032814026
the O O 0.9999393224716187
promoter O S-DNA 0.9605085253715515
of O O 0.995500385761261
the O O 0.999806821346283
B B-DNA B-DNA 0.38848674297332764
cell-specific I-DNA I-DNA 0.5002719759941101
tyrosine I-DNA I-DNA 0.6042090654373169
kinase I-DNA I-DNA 0.5674093961715698
gene I-DNA E-DNA 0.9368974566459656

be O O 0.9987917542457581
a O O 0.9999849796295166
mouse O O 0.8417089581489563
homologue O O 0.47659599781036377
of O O 0.9958316683769226
human B-protein B-protein 0.45942866802215576
BAF170 E-protein E-protein 0.6837093234062195
. O O 0.9956148862838745
Immunoprecipitation O O 0.9959652423858643
of O O 0.9998624324798584
cell O O 0.9424513578414917
extract O O 0.9561008214950562
with O O 0.9998788833618164
the O O 0.9999462366104126
antiserum O O 0.8705797791481018
against O O 0.9980953335762024
the O O 0.999850869178772
mouse B-protein B-protein 0.5990117788314819
SRG3 E-protein E-protein 0.627106249332428
also O O 0.9834367036819458
brought O O 0.999956488609314
down O O 0.9997848868370056
a O O 0.9998261332511902
195-kD B-protein B-protein 0.5231447815895081
protein E-protein E-protein 0.9566717743873596
that O O 0.995717465877533
could O O 0.9999903440475464
be O O 0.9999659061431885
recognized O O 0.9999097585678101
by O O 0.9999961853027344
an O O 0.9999074935913086
antiserum O O 0.7592648863792419
raised O O 0.988639235496521
against O O 0.9997101426124573
human B-protein B-protein 0.7119964957237244
SWI2 I-protein I-protein 0.3483307659626007
protein E-protein E-protein 0.9814250469207764
. O O 0.9994934797286987
The O O 0.9999964237213135
results O O 0.9999709129333496
suggest O O 0.9999948740005493

Sulpiride B-Chemical B-Chemical 0.9040021300315857
induced O O 0.997381865978241
only O O 0.9996498823165894
SOCS O O 0.6215475797653198
- O O 0.9305366277694702
1 O O 0.9800976514816284
in O O 0.9999713897705078
the O O 0.9999473094940186
medial O O 0.9804564714431763
preoptic O O 0.6973791122436523
area O O 0.96037358045578
, O O 0.999983549118042
where O O 0.9999713897705078
GnRH O O 0.7888967990875244
neurons O O 0.8081350922584534
are O O 0.9998552799224854
regulated O O 0.9989846348762512
, O O 0.9999666213989258
but O O 0.9999748468399048
in O O 0.999967098236084
the O O 0.9998581409454346
arcuate O O 0.9098183512687683
nucleus O O 0.8971148729324341
and O O 0.9997459053993225
choroid O O 0.7773692011833191
plexus O O 0.5799227952957153
, O O 0.9995130300521851
PRL O O 0.9784844517707825
- O O 0.9981409311294556
R O O 0.9950636029243469
, O O 0.9999679327011108
SOCS O O 0.9819617867469788
- O O 0.9967854022979736
3 O O 0.983283519744873
, O O 0.9999539852142334
and O O 0.9999440908432007
CIS O O 0.9636390209197998
mRNA O O 0.9876664876937866
levels O O 0.999958872795105
were O O 0.9999959468841553
also O O 0.9999628067016602
induced O O 0.9998703002929688
. O O 0.9999988079071045

OBJECTIVE O O 0.9376941323280334
: O O 0.9998434782028198
Maternal O O 0.9904295206069946
tobacco O O 0.7071762084960938
smoking S-Chemical B-Chemical 0.9291199445724487
has O O 0.9995885491371155
negative O O 0.9612326622009277
effects O O 0.9846746921539307
on O O 0.9998646974563599
fetal O O 0.8899349570274353
growth O O 0.5908756852149963
. O O 0.999873161315918

Nonhematologic O O 0.5726324915885925
toxicities O O 0.6694327592849731
were O O 0.9923446774482727
mild O O 0.9669608473777771
. O O 0.9999881982803345

T I-cell_type B-cell_type 0.520277738571167

cells E-cell_type E-cell_type 0.7346687912940979
from O O 0.999735414981842
non-tumorous O O 0.8722866773605347
cavity O O 0.8289826512336731
fluids O O 0.8067948818206787
. O O 0.9999781847000122
The O O 0.9999963045120239
detection O O 0.9974848031997681
of O O 0.999942421913147
estrogen S-protein B-protein 0.30352720618247986
and O I-protein 0.8138421773910522
progesterone B-protein I-protein 0.42962905764579773
receptors E-protein E-protein 0.9918068647384644
( O O 0.9911069273948669
ER S-protein S-protein 0.9891306161880493
and O O 0.9902690649032593
PR S-protein S-protein 0.9843757748603821
) O O 0.9925538897514343
localized O O 0.9950695037841797
in O O 0.9999030828475952
the O O 0.9998639822006226
cell O O 0.9566569328308105
nucleus O O 0.9324982762336731
can O O 0.9999648332595825
be O O 0.9999895095825195
achieved O O 0.9999854564666748
by O O 0.9999977350234985
the O O 0.9999898672103882
same O O 0.9998347759246826
assay O O 0.9865385293960571

erythroblasts E-cell_line E-cell_type 0.6804522275924683
coexpressing O O 0.9881101846694946
the O O 0.9997691512107849
v-erbA B-protein B-protein 0.5368298292160034
oncoprotein E-protein E-protein 0.9079912304878235
and O O 0.9939285516738892
the O O 0.9996852874755859
c-erbA/T3 B-protein B-protein 0.39672863483428955
receptor E-protein E-protein 0.8500593900680542
at O O 0.9956846237182617
an O O 0.9999426603317261
approximately O O 0.9902225732803345

restored O O 0.921231746673584
apoptosis O O 0.9477195739746094
sensitivity O O 0.9979351758956909
. O O 0.9999985694885254
These O O 0.9999961853027344
data O O 0.9998045563697815
suggest O O 0.9999979734420776
that O O 0.9999984502792358
inhibition O O 0.9974888563156128
of O O 0.9999083280563354
NFkappaB S-protein S-protein 0.9937894940376282
activation O O 0.9988600015640259
may O O 0.9999974966049194
provide O O 0.9999983310699463
a O O 0.9999948740005493
molecular O O 0.9741029143333435
approach O O 0.9989414811134338
to O O 0.9999872446060181
increase O O 0.9995691180229187
apoptosis O O 0.9625194072723389
sensitivity O O 0.9976196885108948
in O O 0.9999840259552002
anticancer O O 0.7708044648170471
treatment O O 0.9806929230690002
. O O 0.9999878406524658
Loss- O O 0.9459195733070374
and O O 0.9851638078689575
gain-of-function O O 0.9472606778144836
mutations O O 0.9436241388320923
reveal O O 0.9999988079071045
an O O 0.9999831914901733
important O O 0.9965314269065857
role O O 0.9995309114456177
of O O 0.9998960494995117
BSAP S-protein S-protein 0.7598978281021118
( O O 0.8111844658851624
Pax-5 S-protein S-protein 0.8162139654159546
) O O 0.807908296585083

of O O 0.994685173034668
inducing O O 0.9950889945030212
certain O O 0.9981412887573242
characteristics O O 0.9955667853355408
of O O 0.9998130202293396
activated B-cell_type B-cell_type 0.5477390885353088
B I-cell_type I-cell_type 0.5822332501411438
cells E-cell_type E-cell_type 0.9442710280418396
, O O 0.9975601434707642
strongly O O 0.9991998076438904
suggesting O O 0.9999915361404419
that O O 0.9999914169311523
LMP1 S-protein S-protein 0.9773262143135071
can O O 0.9990841150283813
also O O 0.9999719858169556
activate O O 0.9834206700325012
cells O O 0.7021327018737793
independently O O 0.999943733215332
of O O 0.9999620914459229
NF-kappaB S-protein S-protein 0.9927391409873962
. O O 0.9998600482940674
Models O O 0.9989618062973022
of O O 0.9998021721839905
lineage O O 0.6954953074455261
switching O O 0.9968728423118591
in O O 0.9997475743293762
hematopoietic O O 0.5575764179229736
development O O 0.9393597841262817
: O O 0.9991292357444763

A O O 0.9823638200759888
significant O O 0.9995449185371399
up O O 0.999925971031189
- O O 0.9998453855514526
regulation O O 0.9982280135154724
of O O 0.9998571872711182
alphaENaC O O 0.5139278769493103
and O O 0.99859219789505
betaENaC O O 0.9338361620903015
mRNA O O 0.9790098667144775
abundance O O 0.96944260597229
on O O 0.9999498128890991
days O O 0.9996961355209351
1 O O 0.9991808533668518
and O O 0.9997904896736145
2 O O 0.995280921459198
preceded O O 0.9999300241470337
sodium B-Chemical B-Chemical 0.9189925193786621
retention O O 0.7854205965995789
on O O 0.9999122619628906
days O O 0.9998857975006104
2 O O 0.9999103546142578
and O O 0.9998663663864136
3 O O 0.9973583817481995
. O O 0.9999933242797852

NF-kappaB S-protein S-protein 0.9726481437683105
and O O 0.9964906573295593
Tat S-protein S-protein 0.9885890483856201
in O O 0.9996138215065002
transcriptional O O 0.9326989054679871
activation O O 0.988549530506134
of O O 0.9997760653495789
HIV-1 O O 0.560802698135376
, O O 0.9859055280685425
and O O 0.9993826150894165
enhance O O 0.999288022518158
HIV-1 O O 0.8455514907836914
replication O O 0.9705270528793335
in O O 0.999786913394928
T B-cell_type B-cell_type 0.8952397108078003
cells E-cell_type E-cell_type 0.9914925694465637
. O O 0.9996774196624756
These O O 0.9999945163726807
results O O 0.9998457431793213
link O O 0.9998772144317627
regulatory B-protein B-protein 0.8361758589744568
factors E-protein E-protein 0.9362740516662598

Prolonged O O 0.8427872657775879
apnea O O 0.5735137462615967
in O O 0.9670639038085938
our O O 0.9970595240592957
case O O 0.7209320068359375
ensued O O 0.9947072267532349
because O O 0.999993085861206
the O O 0.9999715089797974
information O O 0.9987003803253174
about O O 0.9999804496765137
suicidal O O 0.5348255038261414
attempt O O 0.7835168242454529
by O O 0.9993460774421692
OP B-Chemical O 0.8288282752037048
compound E-Chemical O 0.5358337163925171
was O O 0.9998490810394287
concealed O O 0.9990491271018982
from O O 0.9999959468841553
the O O 0.9999271631240845
treating O O 0.9849318265914917
team O O 0.9980456829071045
. O O 0.9999979734420776

Tax S-protein S-protein 0.9316050410270691
was O O 0.9997349381446838
able O O 0.9999864101409912
to O O 0.9999886751174927
significantly O O 0.9998986721038818
increase O O 0.9998847246170044
the O O 0.9997547268867493
transcriptional O O 0.9516432881355286
activity O O 0.9973205924034119
of O O 0.9999792575836182
a O O 0.9999547004699707
template O O 0.9145373702049255
containing O O 0.9998303651809692
the O O 0.9997919201850891
-257 B-DNA B-DNA 0.6553885340690613
to I-DNA I-DNA 0.5807363986968994
+74 I-DNA I-DNA 0.3345821499824524
region E-DNA E-DNA 0.9343618154525757
of O O 0.9961024522781372
the O O 0.9994115829467773
c-sis/PDGF-B B-DNA B-DNA 0.6744080781936646
promoter E-DNA E-DNA 0.9956690073013306
. O O 0.9996727705001831
Electrophoretic O O 0.9573838710784912
mobility O O 0.9862783551216125
shift O O 0.9993621706962585
assay O O 0.995766282081604
analysis O O 0.9999022483825684
showed O O 0.9999984502792358
that O O 0.9999886751174927
Tax S-protein S-protein 0.9965956807136536
increased O O 0.9998152852058411
the O O 0.999927282333374
DNA O O 0.9567362666130066
binding O O 0.9468902945518494
activity O O 0.9973286390304565
of O O 0.9999517202377319
both O O 0.9994009733200073

Preoperative O O 0.9513269662857056
assessment O O 0.9932021498680115
should O O 0.9999942779541016
focus O O 0.9999843835830688
on O O 0.9999403953552246
cardiovascular O O 0.7997488379478455
status O O 0.6437581181526184
and O O 0.9966603517532349
serum O O 0.9775822758674622
potassium S-Chemical B-Chemical 0.9249892234802246
level O O 0.9907676577568054
. O O 0.9999942779541016

the O O 0.9974116683006287
hypertension O O 0.9096343517303467
and O O 0.9985608458518982
altered O O 0.9668235778808594
MR S-protein S-protein 0.8613100051879883
status O O 0.9931737780570984
. O O 0.9999946355819702
Structure O O 0.9646472334861755
function O O 0.988162100315094
analysis O O 0.9995563626289368
of O O 0.9999876022338867
vitamin O B-protein 0.5292915105819702
D O I-protein 0.41495823860168457
analogs O E-protein 0.8113691806793213
with O O 0.9986236095428467
C-ring O O 0.34074029326438904
modifications O O 0.7499289512634277
. O O 0.9999215602874756
Analogs O O 0.9909994006156921
of O O 0.9997437596321106
1 O O 0.9229973554611206
alpha O O 0.7342588305473328
, O O 0.995631217956543
25-dihydroxyvitamin O O 0.9209111332893372
D3 O O 0.8448873162269592
( O O 0.9890661239624023
1 O O 0.9775257706642151

47 B-protein B-protein 0.7785926461219788
kDa I-protein I-protein 0.47678202390670776
protein I-protein I-protein 0.6694984436035156
factor E-protein E-protein 0.9706576466560364
to O O 0.9937856197357178
the O O 0.9996473789215088
SRE B-DNA B-DNA 0.6906018257141113
sequence E-DNA E-DNA 0.9577890634536743
. O O 0.9997593760490417
Based O O 0.9997420907020569
upon O O 0.9999769926071167
these O O 0.999984622001648
results O O 0.9998013377189636
we O O 0.9999969005584717
propose O O 0.9999972581863403
that O O 0.9999967813491821
this O O 0.9998661279678345
factor O O 0.9824166297912598
may O O 0.9999399185180664
have O O 0.9999935626983643
a O O 0.9999743700027466
role O O 0.9998403787612915
in O O 0.9999735355377197
pathophysiology O O 0.9901815056800842
of O O 0.999963641166687
chronic O O 0.9215677380561829
myeloid O O 0.8878364562988281
leukaemia O O 0.9446629285812378
. O O 0.9999802112579346
Cloning O O 0.8557471632957458
and O O 0.9864648580551147
characterization O O 0.9981219172477722
of O O 0.9999064207077026

and O O 0.9615461826324463
in O O 0.9992249011993408
monocyte-derived B-cell_type B-cell_type 0.4974216818809509
macrophages E-cell_type E-cell_type 0.8526360988616943
( O O 0.9957864880561829
MDMs S-cell_type S-cell_type 0.897608757019043
) O O 0.9908592104911804
. O O 0.9999779462814331
Constitutive O O 0.9708443880081177
DNA O O 0.9084275364875793
binding O O 0.9457050561904907
activity O O 0.9962685108184814
consisting O O 0.9999876022338867
of O O 0.9999796152114868
p50 B-protein B-protein 0.37827160954475403
homodimers E-protein E-protein 0.9538244009017944
was O O 0.9991422891616821
detected O O 0.9999474287033081
in O O 0.9999638795852661
nuclear O O 0.9149637222290039
extracts O O 0.9592725038528442
from O O 0.9999465942382812
both O O 0.9997274279594421
cell O O 0.9242958426475525
types O O 0.7128583192825317
. O O 0.9999818801879883
An O O 0.9999784231185913
additional O O 0.9890154004096985
complex O O 0.9006475806236267
composed O O 0.9988848567008972
of O O 0.9999029636383057
p50/RelA B-protein S-protein 0.5104498267173767
( I-protein O 0.5015712380409241

of O O 0.9926290512084961

lines E-cell_line E-cell_line 0.9876531362533569
leading O O 0.9997594952583313
to O O 0.9999819993972778
enhanced O O 0.9873256683349609
HIV-1 O O 0.864634096622467
replication O O 0.9782335758209229
can O O 0.9999743700027466
be O O 0.999983549118042
induced O O 0.9998069405555725
by O O 0.9999841451644897
antigens S-protein S-protein 0.8161760568618774
, O O 0.9793171882629395
mitogens O S-protein 0.9185013771057129
, O O 0.990022599697113
and O O 0.9979119896888733
cytokines S-protein S-protein 0.9924560785293579
( O O 0.9984789490699768
tumor B-protein B-protein 0.5947959423065186
necrosis I-protein I-protein 0.910221517086029
factor I-protein I-protein 0.4896095097064972
alpha E-protein E-protein 0.9247127771377563

multiple O B-DNA 0.8500036597251892
regulatory O I-DNA 0.5725159049034119
sites O E-DNA 0.9486438632011414
. O O 0.9998165965080261
Interleukin O B-protein 0.7028577923774719
2 O E-protein 0.9806704521179199
( O O 0.9815234541893005
IL-2 S-protein S-protein 0.9878381490707397
) O O 0.9835501909255981
is O O 0.9999864101409912
an O O 0.9999898672103882
important O O 0.9899390339851379
lymphokine S-protein S-protein 0.7220948338508606
required O O 0.9966511130332947
in O O 0.9999817609786987
the O O 0.9998975992202759
process O O 0.9987169504165649
of O O 0.9999802112579346
T O O 0.8040510416030884
cell O O 0.6403992772102356
activation O O 0.991316556930542
, O O 0.9998093247413635
proliferation O O 0.9950670003890991
, O O 0.999723494052887
clonal O O 0.9546780586242676
expansion O O 0.9922983050346375
and O O 0.9996813535690308
differentiation O O 0.9960495829582214
. O O 0.9999922513961792
The O O 0.9999080896377563
IL-2 B-DNA B-DNA 0.733315110206604
gene E-DNA E-DNA 0.9651753306388855
displays O O 0.9958486557006836
both O O 0.9999068975448608
T O O 0.6328897476196289
cell O O 0.4613286256790161
specific O O 0.8282129764556885
and O O 0.9854340553283691
inducible O O 0.8529428243637085
expression O O 0.9614752531051636
: O O 0.9991462230682373
it O O 0.9994565844535828
is O O 0.9999188184738159
only O O 0.9998990297317505
expressed O O 0.9996317625045776
in O O 0.9997404217720032
CD4+ B-cell_type B-cell_type 0.847478985786438
T I-cell_type I-cell_type 0.9228654503822327
cells E-cell_type E-cell_type 0.9043310880661011
after O O 0.9995821118354797
antigenic O O 0.9326363801956177
or O O 0.9964849948883057
mitogenic O O 0.913882315158844
stimulation O O 0.9896323680877686
. O O 0.9999967813491821
Several O O 0.9997938275337219
cis-acting B-DNA B-DNA 0.4519732892513275

Possible O O 0.9850409626960754
teratogenicity O O 0.8425111770629883
of O O 0.9373748898506165
sulphasalazine S-Chemical B-Chemical 0.929044783115387
. O O 0.9990878105163574

accumulation O O 0.9630439877510071
, O O 0.9998044371604919
and O O 0.9999744892120361
the O O 0.9999812841415405
expression O O 0.9979435801506042
of O O 0.9998904466629028
genes O O 0.5778675079345703
characteristic O O 0.988654375076294
for O O 0.9998607635498047
immature B-cell_type B-cell_type 0.5567618012428284
cells E-cell_type E-cell_type 0.8460126519203186

dermal B-cell_type B-cell_type 0.31195783615112305
fibroblasts E-cell_type E-cell_type 0.9417382478713989
. O O 0.9998071789741516
Cloning O O 0.8473331332206726
of O O 0.9960950016975403
the O O 0.99968421459198
5 B-DNA B-DNA 0.5559402704238892
' I-DNA I-DNA 0.6830563545227051
and I-DNA I-DNA 0.5027623176574707
3 I-DNA I-DNA 0.557305097579956
' I-DNA I-DNA 0.7597072124481201
untranslated I-DNA I-DNA 0.854530394077301
region E-DNA E-DNA 0.9677819609642029
( O O 0.9924983382225037
UTR S-DNA S-DNA 0.6682330369949341

Mitochondrial B-Disease O 0.581855833530426
abnormalities I-Disease O 0.9288070201873779
have O O 0.9706704616546631
been O O 0.9979566335678101
associated O O 0.9999648332595825
with O O 0.9999933242797852
several O O 0.9997910857200623
aspects O O 0.9999215602874756
of O O 0.9998995065689087
epileptogenesis O O 0.9348538517951965
, O O 0.9871401190757751
such O O 0.9999247789382935
as O O 0.9999806880950928
energy O O 0.7549325227737427
generation O O 0.906882643699646
, O O 0.999745786190033
control O O 0.9890760183334351
of O O 0.9989363551139832
cell O O 0.966528058052063
death B-Disease O 0.4847855567932129
, O O 0.9973408579826355
neurotransmitter O O 0.7249673008918762
synthesis O O 0.8275642991065979
, O O 0.9850910902023315
and O O 0.9993543028831482
free O O 0.9891437888145447
radical O O 0.9651228189468384
( O O 0.9969007968902588
FR O O 0.8699875473976135
) O O 0.9903755784034729
production O O 0.9949735403060913
. O O 0.9999985694885254

Recurarization O O 0.8609283566474915
in O O 0.9996955394744873
the O O 0.9999386072158813
recovery O O 0.9564177393913269
room O O 0.9958642721176147
. O O 0.9999988079071045

the O O 0.9979602098464966
results O O 0.9991468191146851
obtained O O 0.9999810457229614
with O O 0.9999895095825195
purified O B-protein 0.8801449537277222
Jurkat O I-protein 0.4216340184211731
protein O E-protein 0.9795483350753784
, O O 0.985628604888916
was O O 0.999964714050293
decreased O O 0.9999339580535889
by O O 0.9999957084655762
introduction O O 0.9992983341217041
of O O 0.9999396800994873
site-specific O O 0.7459200620651245
mutations O O 0.7344238758087158
in O O 0.9999691247940063
the O O 0.999962329864502
DRE B-DNA B-DNA 0.4657118022441864
1 I-DNA I-DNA 0.6028491258621216
regulatory I-DNA I-DNA 0.8560325503349304
sequence E-DNA E-DNA 0.99013352394104
. O O 0.9997860789299011
In O O 0.9992117881774902

and O O 0.9315347075462341
alpha B-protein B-protein 0.47667619585990906
B2 E-protein E-protein 0.9134703874588013
( O O 0.9941363334655762
two O O 0.9963653087615967
alpha B-protein B-protein 0.7515153288841248
B-encoded I-protein I-protein 0.4265389144420624
isomers E-protein E-protein 0.8668760061264038
) O O 0.9564623236656189
for O O 0.9999464750289917
their O O 0.9999619722366333
effects O O 0.9998776912689209
on O O 0.9999920129776001
the O O 0.9998520612716675
GM-CSF B-DNA B-DNA 0.6607476472854614
promoter E-DNA E-DNA 0.9959689378738403
. O O 0.9994984865188599
PEBP2 B-protein B-protein 0.3253287971019745
alpha I-protein I-protein 0.767795979976654
A1 E-protein E-protein 0.9041928052902222
, O O 0.9889238476753235
alpha B-protein B-protein 0.38364505767822266
B1 E-protein E-protein 0.9397267699241638
, O O 0.9743820428848267
and O O 0.9981051683425903
alpha B-protein B-protein 0.43802404403686523
B2 I-protein I-protein 0.5793707966804504
proteins E-protein E-protein 0.9868849515914917
bound O O 0.9994958639144897
the O O 0.9999769926071167

FANFT B-Chemical S-Chemical 0.8923074007034302
- O O 0.8223796486854553
induced O O 0.9984849095344543
cell O O 0.9632556438446045
proliferation O O 0.8505259156227112
in O O 0.9995105266571045
the O O 0.999508261680603
bladder O O 0.6163020730018616
was O O 0.9992493987083435
significantly O O 0.999948263168335
suppressed O O 0.9991527795791626
by O O 0.9999938011169434
aspirin B-Chemical B-Chemical 0.9330629110336304
co O O 0.6881669759750366
- O O 0.8329078555107117
administration O O 0.9971098303794861
after O O 0.9999973773956299
4 O O 0.9995781779289246
weeks O O 0.9999711513519287
but O O 0.999984622001648
not O O 0.9999439716339111
after O O 0.9999761581420898
12 O O 0.9998713731765747
weeks O O 0.9999845027923584
. O O 0.9999988079071045

A O O 0.950981080532074
polymorphism O O 0.94034743309021
that O O 0.9999505281448364
affects O O 0.9999710321426392
OCT-1 S-protein S-protein 0.8521397709846497
binding O O 0.8681085705757141
to O O 0.9993855953216553
the O O 0.9998289346694946
TNF B-DNA B-DNA 0.5376691222190857
promoter I-DNA I-DNA 0.6445806622505188
region E-DNA E-DNA 0.9831122756004333
is O O 0.9997057318687439
associated O O 0.999975323677063
with O O 0.9999960660934448
severe O O 0.9918482303619385
malaria O O 0.6643451452255249
[ O O 0.9992478489875793
see O O 0.9999713897705078
comments O O 0.9963555335998535

required O O 0.9879137873649597
for O O 0.9999327659606934
differentiation O O 0.9979890584945679
of O O 0.9999449253082275
tissues O O 0.9408531188964844
such O O 0.9996596574783325
as O O 0.9999737739562988
the O O 0.9994511008262634
central O O 0.9245526790618896
nervous O O 0.9019448161125183
system O O 0.9650381803512573
and O O 0.9991361498832703
muscle O O 0.7986262440681458
. O O 0.9984803795814514
ZEB S-protein S-protein 0.8604016304016113
, O O 0.9982471466064453
a O O 0.999881386756897
vertebrate O O 0.7266908884048462
homolog O O 0.5534967184066772
of O O 0.8142741918563843
Zfh-1 S-protein S-protein 0.8100919127464294
, O O 0.9861035346984863
binds O O 0.9997220635414124
a O O 0.9999182224273682
subset O O 0.9906691312789917
of O O 0.9993776679039001
E B-DNA B-DNA 0.36573275923728943
boxes E-DNA E-DNA 0.8802299499511719
and O O 0.9795868992805481
blocks O O 0.964392364025116

enhancers E-DNA E-DNA 0.8827414512634277
, O O 0.9986053109169006
in O O 0.9999796152114868
transcription O O 0.8792005181312561
activation O O 0.973935067653656
we O O 0.9997051358222961
have O O 0.9999879598617554
prepared O O 0.9964683055877686
somatic O B-cell_line 0.6346434950828552
cell O I-cell_line 0.5451220273971558
hybrids O E-cell_line 0.9725717306137085
between O O 0.9995808005332947
IARC B-cell_line B-cell_line 0.660010814666748
301.5 E-cell_line E-cell_line 0.9754727482795715
and O O 0.9973405003547668
a O O 0.9995624423027039
murine B-cell_line O 0.6838490962982178
myeloma E-cell_line O 0.41441836953163147
. O O 0.9994046688079834
Most O O 0.9921467900276184
hybrids O O 0.45884475111961365
express O O 0.9989796280860901
both O O 0.9996620416641235
KBF1 S-protein S-protein 0.8795140385627747
and O O 0.9934341907501221
NF-kappa B-protein B-protein 0.7066180109977722
B E-protein E-protein 0.9885966181755066
in O O 0.9995321035385132
their O O 0.9997759461402893
nuclei O O 0.7560246586799622
, O O 0.9868118166923523
but O O 0.9997338652610779
one O O 0.9996476173400879
hybrid O O 0.5424623489379883
expresses O O 0.9883275628089905
only O O 0.9996634721755981
KBF1 S-protein S-protein 0.5818649530410767
. O O 0.9997816681861877
The O O 0.9999679327011108
kappa B-DNA B-DNA 0.5675660371780396
B I-DNA I-DNA 0.8011952638626099
enhancer E-DNA E-DNA 0.9848868250846863
of O O 0.9957952499389648
the O O 0.9999023675918579
gene O O 0.9053655862808228
encoding O O 0.9929147958755493
the O O 0.9997084736824036
interleukin-2 B-protein B-protein 0.7127103805541992
( I-protein I-protein 0.5659133195877075
IL-2 I-protein I-protein 0.46092766523361206
) I-protein I-protein 0.49318748712539673
receptor I-protein I-protein 0.45532989501953125
alpha I-protein I-protein 0.5507121682167053
chain E-protein E-protein 0.9940117001533508
( O O 0.9971621632575989
IL-2R B-protein B-protein 0.4720069169998169
alpha E-protein E-protein 0.9249986410140991
) O O 0.6452822089195251
is O O 0.999754011631012

Causes O O 0.9967197775840759
of O O 0.999221920967102
death B-Disease B-Disease 0.9585244059562683
, O O 0.9871193170547485
with O O 0.999930739402771
special O O 0.9701293110847473
reference O O 0.9856845140457153
to O O 0.9998096823692322
cerebral B-Disease B-Disease 0.6488161683082581
haemorrhage I-Disease I-Disease 0.8947387337684631
, O O 0.9865520596504211
among O O 0.999951958656311
240 O O 0.999085545539856
patients O O 0.9995357990264893
with O O 0.9999866485595703
pathologically O O 0.839641273021698
verified O O 0.9827628135681152
Parkinson B-Disease B-Disease 0.706901490688324
' I-Disease I-Disease 0.6284639835357666
s I-Disease I-Disease 0.6213245987892151
disease I-Disease I-Disease 0.9855279326438904
were O O 0.9911773204803467
investigated O O 0.9998528957366943
using O O 0.9999926090240479
the O O 0.9999737739562988
Annuals O O 0.8420534729957581
of O O 0.9989282488822937
the O O 0.9999314546585083
Pathological O O 0.8352470993995667
Autopsy O O 0.7867155075073242
Cases O O 0.9676283001899719
in O O 0.9999899864196777
Japan O O 0.9948694705963135
from O O 0.9999988079071045
1981 O O 0.9998666048049927
to O O 0.9999512434005737
1985 O O 0.9998096823692322
. O O 0.9999995231628418

Electron O O 0.6917406916618347
microscopy O O 0.7952694296836853
disclosed O O 0.9998469352722168
many O O 0.999725878238678
secretory O O 0.8138187527656555
granules O O 0.674831748008728
, O O 0.9992648959159851
slightly O O 0.9765675663948059
distorted O O 0.9618148803710938
rough O O 0.8462820053100586
endoplasmic O O 0.8456418514251709
reticulum O O 0.6721400022506714
, O O 0.9994055032730103
and O O 0.9999101161956787
partially O O 0.9166076183319092
dilated O O 0.9688215255737305
Golgi O O 0.7690168023109436
cisternae O O 0.24628907442092896
in O O 0.9993446469306946
the O O 0.9998346567153931
prolactinoma O O 0.6305392384529114
cells O O 0.6453250646591187
. O O 0.9998904466629028

examined O O 0.9844776391983032
, O O 0.9999433755874634
by O O 0.9999641180038452
denaturing O O 0.896160900592804
gradient-gel O O 0.8388980627059937
electrophoresis O O 0.9336084127426147
and O O 0.9983541965484619
DNA B-DNA O 0.9067407846450806
sequence E-DNA O 0.7589558959007263
analysis O O 0.9839876890182495
, O O 0.999994158744812
the O O 0.9999967813491821
possible O O 0.9988203644752502
presence O O 0.9996873140335083
of O O 0.9999768733978271
a O O 0.9998602867126465
codon B-DNA B-DNA 0.41165658831596375
10 I-DNA I-DNA 0.4772243797779083
polymorphic I-DNA I-DNA 0.49540975689888
site E-DNA E-DNA 0.9049518704414368
in O O 0.9993645548820496
normal O O 0.8394249677658081
oestrogen O O 0.6091848611831665
target O O 0.9072377681732178
organs O O 0.8021873831748962
and O O 0.9973078966140747
cells O O 0.948103129863739
such O O 0.9999252557754517
as O O 0.9999774694442749
the O O 0.9987163543701172
uterus O O 0.8631953001022339
( O O 0.9981566071510315
myometrium O O 0.6540051102638245
and O O 0.9838146567344666
endometrium O O 0.8000084161758423
) O O 0.9902192950248718
, O O 0.9999197721481323

( O O 0.735123872756958

segment O O 0.5913717150688171
polarity O O 0.9660900235176086
; O O 0.9999752044677734
in O O 0.999969482421875
Xenopus O O 0.4050118625164032
it O O 0.9715790748596191
controls O O 0.9999206066131592
the O O 0.9999841451644897
definition O O 0.9995228052139282
of O O 0.9999674558639526
the O O 0.9999419450759888
body O O 0.7904751896858215
axis O O 0.7733817100524902

) O O 0.7880282998085022
, O O 0.9997056126594543
an O O 0.9999872446060181
inhibitor O O 0.9736155271530151
of O O 0.9995899796485901
myosin B-protein B-protein 0.3948957026004791
light I-protein I-protein 0.5079680681228638
chain I-protein I-protein 0.4754546582698822
kinase E-protein E-protein 0.9781233668327332
, O O 0.9899685978889465
induces O O 0.9997642636299133
differentiation O O 0.9916998147964478
of O O 0.9998341798782349
monocytoid B-cell_line B-cell_line 0.38773787021636963
leukemia I-cell_line I-cell_line 0.5570527911186218
cell I-cell_line I-cell_line 0.8218271136283875
lines E-cell_line E-cell_line 0.9776240587234497
U937 S-cell_line S-cell_line 0.9610763788223267
and O O 0.9916241765022278
THP-1 S-cell_line S-cell_line 0.9874299168586731

A I-protein O 0.9530214071273804
macrophage I-protein B-protein 0.7377886772155762
scavenger I-protein I-protein 0.4776920676231384
receptor I-protein E-protein 0.985590934753418
( I-protein O 0.9940599799156189
MSR I-protein S-protein 0.9829453825950623
) E-protein O 0.9940449595451355
contributes O O 0.999983549118042
to O O 0.999988317489624
the O O 0.9999188184738159
uptake O O 0.9967377781867981
of O O 0.9999347925186157
modified B-protein O 0.9456623792648315
low I-protein B-protein 0.9148639440536499
density I-protein I-protein 0.8532741069793701
lipoproteins I-protein E-protein 0.9630018472671509
( I-protein O 0.9949106574058533
LDL I-protein S-protein 0.871195912361145
) E-protein O 0.9955893754959106
by O O 0.9999774694442749
macrophages S-cell_type S-cell_type 0.8545820116996765

sequence O O 0.5001484155654907

5 B-Chemical B-Chemical 0.9219973087310791
- I-Chemical I-Chemical 0.9940694570541382
azacytidine E-Chemical I-Chemical 0.932986319065094
potentiates O O 0.7702623605728149
initiation O O 0.6005799174308777
induced O O 0.9332367181777954
by O O 0.9978036284446716
carcinogens O O 0.6873409152030945
in O O 0.9926425814628601
rat O O 0.729675829410553
liver O O 0.4642861485481262
. O O 0.999767005443573

, O O 0.9503923654556274

These O O 0.9990394711494446
data O O 0.9979830980300903
implicate O O 0.999858021736145
TRAFs S-protein S-protein 0.7952195405960083
in O O 0.9996412992477417
STP-C488 S-protein S-protein 0.9240087866783142
-mediated O O 0.9946838021278381
transformation O O 0.993191659450531
of O O 0.9998660087585449
human B-cell_type B-cell_type 0.658294141292572
lymphocytes E-cell_type E-cell_type 0.9862158298492432
and O O 0.9925433397293091
rodent O B-cell_type 0.5796688199043274
fibroblasts S-cell_type E-cell_type 0.982097327709198
. O O 0.9999082088470459
Other O O 0.9998899698257446
factors O O 0.989118218421936

Treatment O O 0.9847941994667053
duration O O 0.9975144863128662
longer O O 0.9999783039093018
than O O 0.9999905824661255
1 O O 0.998950719833374
year O O 0.9999229907989502
was O O 0.9999879598617554
associated O O 0.9999656677246094
with O O 0.9999923706054688
an O O 0.9999195337295532
eightfold O O 0.9942513704299927
increased O O 0.9546403288841248
risk O O 0.9660734534263611
( O O 0.9999375343322754
OR O O 0.9827407002449036
= O O 0.9996250867843628
7 O O 0.9998983144760132
. O O 0.9999710321426392
7 O O 0.9997839331626892
, O O 0.9999415874481201
95 O O 0.9997816681861877
% O O 0.9999721050262451
CI O O 0.8382394909858704
0 O O 0.9892087578773499
. O O 0.9999556541442871
9 O O 0.999900221824646
to O O 0.999618649482727
69 O O 0.9962724447250366
) O O 0.9997233748435974
. O O 0.9999973773956299

interleukin-4-induced O O 0.7544627785682678
tyrosine O O 0.6812964081764221
phosphorylation O O 0.8343964219093323
of O O 0.9963725805282593
insulin O B-protein 0.36220309138298035
receptor O I-protein 0.5801876783370972
substrate O E-protein 0.9099184274673462
and O O 0.9427934885025024
Stat6 S-protein B-protein 0.8844515085220337
signaling B-protein I-protein 0.5821259021759033
molecules E-protein E-protein 0.9795185923576355
. O O 0.9998251795768738
The O O 0.9997056126594543
Jak1 B-protein S-protein 0.7957179546356201
, I-protein O 0.8843068480491638
Jak2 I-protein S-protein 0.8526298999786377
, I-protein O 0.9716991782188416
Jak3 I-protein S-protein 0.9390829205513
, I-protein O 0.9873892068862915
and I-protein O 0.9972807168960571
Fes I-protein B-protein 0.5346443057060242
tyrosine I-protein I-protein 0.6835373044013977
kinases E-protein E-protein 0.9816341996192932
have O O 0.9996778964996338
been O O 0.9999387264251709
demonstrated O O 0.9999332427978516
to O O 0.999954342842102
undergo O O 0.999606192111969

ancillary I-DNA I-protein 0.5926211476325989
DNA-binding I-DNA I-protein 0.4236341118812561
domain E-DNA E-protein 0.9225316643714905
in O O 0.9992813467979431
all O O 0.9996432065963745
E2A-HLF B-protein B-cell_line 0.48122143745422363
chimeras E-protein E-cell_line 0.5851860642433167
and O O 0.9597775936126709
were O O 0.9998195767402649
further O O 0.9998977184295654
exacerbated O O 0.9999616146087646
by O O 0.9999971389770508
a O O 0.9999462366104126
zipper O O 0.5531478524208069
mutation O O 0.7030267715454102
in O O 0.9998830556869507
one O O 0.9994412064552307
isolate O O 0.97580885887146
. O O 0.9999730587005615
Both O O 0.9998745918273926
wild-type S-protein B-cell_line 0.2902360260486603
and O I-cell_line 0.7895514369010925
chimeric B-protein I-cell_line 0.6364580988883972
HLF I-protein I-cell_line 0.5555019378662109

that O O 0.994199275970459
is O O 0.9999504089355469
morphologically O O 0.9835594296455383
and O O 0.997768759727478
biochemically O O 0.9753825664520264
distinct O O 0.9993823766708374
from O O 0.9999885559082031
PML S-cell_type B-cell_line 0.2567044794559479
NBs O I-cell_line 0.28910398483276367

granulocytes S-cell_type E-cell_type 0.7527911067008972
. O O 0.999603807926178
To O O 0.999991774559021
investigate O O 0.9999873638153076
the O O 0.9999847412109375
transcriptional O O 0.9445592761039734
regulation O O 0.9957876801490784
of O O 0.9999549388885498
these O O 0.9999097585678101
genes O O 0.7119536995887756
we O O 0.9996985197067261
cotransfected O O 0.835857629776001
constructs O O 0.7365785837173462
expressing O O 0.9882396459579468
CAT S-protein S-protein 0.8546410799026489
under O O 0.9985553622245789
control O O 0.998985230922699
of O O 0.999977707862854
the O O 0.999933123588562
MRP14 B-DNA B-DNA 0.42797499895095825
promoter E-DNA E-DNA 0.9713549613952637
and O O 0.9808618426322937
expression O O 0.926922082901001
constructs O O 0.5153914093971252
of O O 0.9996272325515747
C/EBP B-protein B-protein 0.4272070527076721
alpha E-protein E-protein 0.9553118944168091
and O O 0.9469971656799316
v-myb S-protein S-DNA 0.8263019323348999
, O O 0.998239278793335
two O O 0.99896240234375
transcription B-protein B-protein 0.4898008108139038
factors E-protein E-protein 0.9902119040489197
involved O O 0.9991633892059326
in O O 0.9999277591705322
myeloid/monocytic O O 0.7854034304618835
differentiation O O 0.9815054535865784
. O O 0.9999785423278809
Transfection O O 0.8863651752471924

Moreover O O 0.9952991008758545
, O O 0.9999717473983765
a O O 0.9999579191207886
positive O O 0.9610075354576111
correlation O O 0.9595233798027039
of O O 0.9994015693664551
histamine B-Chemical B-Chemical 0.9200670123100281
to O O 0.998776376247406
gastric B-Disease B-Disease 0.5813712477684021
hemorrhage I-Disease I-Disease 0.9173924326896667
and O O 0.9642848372459412
to O O 0.9965416789054871
ulcer B-Disease O 0.9044026732444763
was O O 0.9321685433387756
found O O 0.9996166229248047
in O O 0.9999624490737915
those O O 0.9999027252197266
atherosclerotic B-Disease O 0.8653706312179565
rats O O 0.6790849566459656
. O O 0.9999895095825195

protein E-protein E-protein 0.9702146649360657
( O O 0.9819651246070862
BSAP S-protein S-protein 0.9682589173316956
) O O 0.9909634590148926
in O O 0.9999399185180664
the O O 0.9999523162841797
promoter B-DNA B-DNA 0.5746229290962219
region E-DNA E-DNA 0.9452205896377563
of O O 0.997036337852478
the O O 0.999916672706604
human O B-DNA 0.5225841999053955
CD19 B-DNA I-DNA 0.7104145288467407
gene E-DNA E-DNA 0.9860386252403259
which O O 0.9971810579299927
is O O 0.999980092048645
similar O O 0.9999486207962036
to O O 0.9999864101409912
the O O 0.9999626874923706
consensus B-DNA B-DNA 0.5921775102615356
Ah I-DNA I-DNA 0.637219250202179
receptor I-DNA I-DNA 0.6949923634529114
DNA I-DNA I-DNA 0.8312618136405945
binding I-DNA I-DNA 0.9530085325241089
site E-DNA E-DNA 0.9826767444610596
. O O 0.9998378753662109
These O O 0.9999926090240479
results O O 0.9994770884513855

with O O 0.9971997737884521
PAF S-protein S-protein 0.9933352470397949
binding O O 0.9950891137123108
to O O 0.9999580383300781
its O O 0.9998980760574341
membrane B-protein B-protein 0.6712462902069092
receptors E-protein E-protein 0.9721217751502991
. O O 0.9994315505027771
CONCLUSIONS O O 0.999910831451416
: O O 0.9999872446060181
Our O O 0.9999809265136719
results O O 0.9998949766159058
show O O 0.9999959468841553
that O O 0.9999939203262329
glucocorticoids O O 0.8966313004493713
at O O 0.9998360872268677
clinically O O 0.966432511806488
relevant O O 0.9764808416366577
concentrations O O 0.9955559372901917
exert O O 0.9999716281890869
specific O O 0.9950435161590576
actions O O 0.9995453953742981
on O O 0.999987006187439
expression O O 0.9961696267127991
of O O 0.9996697902679443

Postmortem O O 0.893409252166748
cytoarchitectural O O 0.8225600719451904
features O O 0.9626189470291138
identifying O O 0.9996691942214966
A1 O O 0.44800272583961487
were O O 0.9995256662368774
correlated O O 0.9999064207077026
with O O 0.9999966621398926
the O O 0.9999382495880127
electrophysiologic O O 0.8712179064750671
data O O 0.9685679078102112
. O O 0.9999982118606567

5-trisphosphate/calcium O O 0.3787058889865875
pathway O O 0.9844990372657776
which O O 0.9999696016311646
responds O O 0.9999575614929199
over O O 0.9999788999557495
the O O 0.9999617338180542
same O O 0.9998955726623535
rapid O O 0.9650731682777405
time O O 0.9917667508125305
course O O 0.9978801012039185
. O O 0.9999990463256836
Such O O 0.9999741315841675
changes O O 0.9995617270469666
clearly O O 0.9999923706054688
can O O 0.999996542930603
not O O 0.9999861717224121
be O O 0.9999902248382568
explained O O 0.9999223947525024
by O O 0.9999592304229736

inhibitory O O 0.9044095277786255
action O O 0.998247504234314
of O O 0.9999654293060303
alpha-lipoic O O 0.8086767196655273
acid O O 0.9226618409156799
was O O 0.9999480247497559
found O O 0.9999898672103882
to O O 0.9999890327453613
be O O 0.9999830722808838
very O O 0.9986928105354309
potent O O 0.9985640645027161
as O O 0.9999960660934448
only O O 0.9997683167457581
4 O O 0.9880701899528503
mM O O 0.9180709719657898
was O O 0.9999287128448486
needed O O 0.9999927282333374
for O O 0.9999978542327881
a O O 0.9999648332595825
complete O O 0.9794983267784119
inhibition O O 0.9872832298278809
, O O 0.9999864101409912
whereas O O 0.9999948740005493
20 O O 0.9638818502426147
mM O O 0.8491348028182983
was O O 0.999862790107727

Both O O 0.9992600083351135
active O O 0.8307738900184631
treatments O O 0.9862205982208252
were O O 0.9999915361404419
well O O 0.9988682270050049
tolerated O O 0.9981374740600586
. O O 0.9999995231628418

CsA O O 0.54332035779953
and O O 0.9676768779754639
FK506 O O 0.5284044742584229
operate O O 0.9982132911682129
as O O 0.99997878074646
prodrugs O O 0.5644549131393433
: O O 0.9957346320152283
they O O 0.9999613761901855
bind O O 0.9981776475906372
endogenous B-protein B-protein 0.8329668641090393
intracellular I-protein I-protein 0.5261654853820801
receptors E-protein E-protein 0.9764845967292786
, O O 0.9983479976654053
the O O 0.9998962879180908
immunophilins S-protein S-protein 0.9150305986404419
, O O 0.9937791228294373
and O O 0.9997790455818176
the O O 0.9999257326126099
resulting O O 0.9577059745788574
complex O O 0.5984031558036804
targets O O 0.9386851787567139
the O O 0.9998045563697815
protein B-protein B-protein 0.5708139538764954
phosphatase I-protein E-protein 0.9319877028465271
, E-protein O 0.9854841828346252
calcineurin S-protein S-protein 0.9762399196624756
, O O 0.9832942485809326
to O O 0.9995026588439941
exert O O 0.999037504196167
the O O 0.9996287822723389
immunosuppressive O O 0.7118419408798218

Older O O 0.9732598066329956
subjects O O 0.9969897270202637
tended O O 0.999991774559021
to O O 0.9999570846557617
display O O 0.9999228715896606
more O O 0.9995576739311218
side O O 0.9785470366477966
effects O O 0.9937577247619629
. O O 0.9999988079071045

The O O 0.9996441602706909
enhanced O O 0.9871383309364319
alpha B-Chemical B-Chemical 0.48358026146888733
- I-Chemical I-Chemical 0.831750750541687
methyldopa E-Chemical I-Chemical 0.9309046268463135
hypotension O B-Disease 0.9363194704055786
in O O 0.9860579371452332
Ovx O O 0.8260025978088379
rats O O 0.9857634902000427
was O O 0.999962568283081
paralleled O O 0.9999356269836426
with O O 0.9999947547912598
further O O 0.9979996085166931
reduction O O 0.9646212458610535
in O O 0.9903837442398071
SDRR O O 0.34918177127838135
and O O 0.995819091796875
a O O 0.9995998740196228
reduced O O 0.9832846522331238
locomotor O O 0.7617734670639038
activity O O 0.6814010739326477
. O O 0.999974250793457

gain O O 0.5202150344848633
in O O 0.9995272159576416
transcriptional O O 0.845193088054657
signal O O 0.9082472324371338
ordinarily O O 0.9971389770507812
used O O 0.9999377727508545
for O O 0.9999771118164062
a O O 0.9999146461486816
T B-protein B-protein 0.6375219225883484
helper I-protein I-protein 0.37362611293792725
1-type I-protein I-protein 0.5033249258995056
cytokine E-protein E-protein 0.955222487449646
( O O 0.9868545532226562
IFN-gamma S-protein S-protein 0.9883390665054321
) O O 0.9825165271759033
in O O 0.9999614953994751
combination O O 0.9888317584991455
with O O 0.9999548196792603
allergy-driven O O 0.7920892238616943
overproduction O O 0.8566007614135742
of O O 0.9908664226531982

factors E-protein E-protein 0.9874301552772522
? O O 0.999560534954071
Finally O O 0.99989914894104
, O O 0.9999810457229614
it O O 0.9999772310256958
would O O 0.9999953508377075
be O O 0.999996542930603
useful O O 0.9998728036880493
to O O 0.9999830722808838
know O O 0.9999961853027344
what O O 0.9999983310699463
the O O 0.9999719858169556
inhibitory O O 0.9539420008659363
effects O O 0.999485969543457
of O O 0.999984860420227
CyA O O 0.6313202381134033
are O O 0.9999139308929443
on O O 0.9997549653053284
tolerance O O 0.9698702692985535
and O O 0.9998509883880615
negative O O 0.9263203740119934
regulatory O O 0.8965138792991638
events O O 0.9813287258148193
. O O 0.9999940395355225
Stimulation O O 0.9943825006484985
of O O 0.9995593428611755
B B-cell_type B-cell_type 0.6608290076255798
and I-cell_type I-cell_type 0.7175436615943909
T I-cell_type I-cell_type 0.8939295411109924

sites E-DNA E-DNA 0.6786525845527649
mediated O O 0.9933221936225891
basal O O 0.8284560441970825
expression O O 0.9900534749031067
in O O 0.9999771118164062
uninduced B-cell_type B-cell_type 0.3803214728832245
cells E-cell_type E-cell_type 0.5446962714195251
. O O 0.9997588992118835
The O O 0.9999969005584717
two O O 0.9976192116737366
AP-1 B-DNA B-DNA 0.6448188424110413
sites E-DNA E-DNA 0.9189185500144958
bound O O 0.9857008457183838
c-Fos/c-Jun B-protein B-protein 0.49637603759765625
heterodimers E-protein E-protein 0.925483763217926
in O O 0.9989846348762512
both O O 0.9991348385810852
unstimulated B-cell_type B-cell_line 0.39633217453956604
and I-cell_type I-cell_line 0.5098525881767273
LPS-stimulated I-cell_type I-cell_line 0.35412001609802246
cells E-cell_type E-cell_line 0.8003130555152893
. O O 0.9999046325683594
Maximal O O 0.9339007139205933
LPS O O 0.9170753955841064

is O O 0.9924706220626831

of O O 0.9967875480651855
monocyte B-protein B-protein 0.47526824474334717
chemotactic I-protein I-protein 0.5503130555152893
protein-1 E-protein E-protein 0.9929392337799072
( O O 0.975567102432251
MCP-1 S-protein S-protein 0.9845882058143616
) O O 0.9859670996665955
and O O 0.9996974468231201
tumor B-protein B-protein 0.5340213179588318
necrosis I-protein I-protein 0.7851518392562866

constitutively O O 0.9865142703056335
represses O O 0.9996028542518616
transcription O O 0.95089191198349
of O O 0.9994814991950989
certain O O 0.9916799664497375
erythrocyte B-DNA B-DNA 0.44401365518569946
genes E-DNA E-DNA 0.9815770983695984
, O O 0.9983023405075073
suggesting O O 0.9999897480010986
a O O 0.9999762773513794
normal O O 0.9888008832931519
function O O 0.998896598815918
of O O 0.9999662637710571
the O O 0.999718964099884
proto-oncogene B-DNA B-DNA 0.3427315056324005
c-erbA E-DNA E-DNA 0.6966825723648071
in O O 0.9927391409873962
erythropoiesis O O 0.9035617113113403
. O O 0.9991884827613831

mediate O O 0.9292021989822388
overexpression O O 0.9608086347579956
of O O 0.9987418055534363
the O O 0.9999089241027832
gene O O 0.9304748773574829
. O O 0.9997686743736267
Atopy O O 0.5741453766822815
, O O 0.9942272901535034
which O O 0.9999241828918457
predisposes O O 0.9998188614845276
individuals O O 0.9968833327293396
to O O 0.9999706745147705
develop O O 0.9995284080505371
asthma O O 0.8943400382995605
, O O 0.9998883008956909
severe O O 0.9886761903762817
systemic O O 0.9776281714439392
anaphylaxis O O 0.9355780482292175
, O O 0.999927282333374
and O O 0.9998070597648621
atopic O O 0.958024263381958
dermatitis O O 0.826467752456665
, O O 0.9999312162399292
is O O 0.9999889135360718
usually O O 0.9999344348907471
associated O O 0.9998785257339478
with O O 0.9999911785125732
dramatically O O 0.9865113496780396
elevated O O 0.9809094071388245
total O O 0.9617863297462463
serum O O 0.9568015933036804
IgE S-protein S-protein 0.90473872423172
levels O O 0.998736560344696

the O O 0.9987214207649231
Epstein-Barr B-protein B-protein 0.5059860944747925
virus I-protein I-protein 0.5605258345603943
nuclear I-protein I-protein 0.6569374799728394
antigen I-protein I-protein 0.6345102190971375
2 E-protein E-protein 0.9889562726020813
( O O 0.9824807047843933
EBNA-2 S-protein S-protein 0.9894043207168579
) O O 0.9842233061790466
: O O 0.9998157620429993
evidence O O 0.9998310804367065
for O O 0.9999896287918091
complex O O 0.9121115803718567
formation O O 0.9594550132751465
by O O 0.9997755885124207

stromal I-cell_type I-cell_type 0.29639092087745667
cells E-cell_type E-cell_type 0.6796115636825562
actively O O 0.9774873852729797
secreting O O 0.9281330704689026
PRL S-protein S-protein 0.7344677448272705
, O O 0.9898410439491272
but O O 0.9996417760848999
did O O 0.999948263168335
not O O 0.999923586845398
allow O O 0.9998339414596558
transcription O O 0.9371072053909302
in O O 0.9997125267982483
undifferentiated O B-cell_line 0.39706188440322876
non-PRL-secreting B-cell_type I-cell_line 0.33726614713668823
endometrial I-cell_type I-cell_line 0.6053627133369446
stromal I-cell_type I-cell_line 0.6460599303245544
cells E-cell_type E-cell_line 0.5488051176071167
. O O 0.9997363686561584
Activation O O 0.999049961566925
of O O 0.9999594688415527
the O O 0.9998027682304382
dPRL B-DNA B-DNA 0.6285719275474548
promoter E-DNA I-DNA 0.814401388168335
construct O E-DNA 0.9801363945007324
in O O 0.999250590801239
these O O 0.9998522996902466
undifferentiated O B-cell_line 0.33542025089263916
cells O E-cell_line 0.5267338752746582
could O O 0.9996674060821533
however O O 0.9999880790710449
be O O 0.9999910593032837
induced O O 0.9999310970306396
by O O 0.9999966621398926
the O O 0.9999840259552002
addition O O 0.9999176263809204
of O O 0.9999797344207764
cAMP O O 0.7426936626434326
, O O 0.9984569549560547
in O O 0.9999904632568359
the O O 0.9999785423278809
absence O O 0.9995580315589905
of O O 0.9999802112579346
progesterone O O 0.8205191493034363
, O O 0.9983123540878296
suggesting O O 0.9999935626983643
that O O 0.9999926090240479
a O O 0.9998841285705566
signal O O 0.9732708930969238
transduced O O 0.9943886399269104
through O O 0.9999563694000244
the O O 0.9996473789215088
cAMP O O 0.3790883719921112
signaling O O 0.6039060354232788
pathway O O 0.9711208343505859
is O O 0.9999456405639648

Ten-day O O 0.7993893623352051
exposure O O 0.9852054715156555
to O O 0.9997387528419495
Epo S-protein S-protein 0.9603700041770935
induced O O 0.9950424432754517
mature B-cell_type B-cell_type 0.4674489498138428
erythroblasts E-cell_type E-cell_type 0.9024848937988281
and O O 0.972836434841156
red B-cell_type B-cell_type 0.6567278504371643
cells E-cell_type E-cell_type 0.8906989693641663
. O O 0.999687910079956
These O O 0.9999912977218628
benzidine-positive B-cell_line O 0.41074055433273315
cells E-cell_line O 0.6287931203842163
were O O 0.9997487664222717
positive O O 0.997816801071167
for O O 0.9999872446060181
hemoglobin S-protein O 0.7105156779289246
F O O 0.3793199956417084
staining O O 0.9426777958869934
. O O 0.9999767541885376

( O O 0.9647173285484314
' O O 0.9696127772331238
HMG B-protein O 0.5405845046043396
box E-protein O 0.5567631125450134
' O O 0.421970397233963
) O O 0.544131338596344
transcription B-protein B-protein 0.4099288284778595
factors E-protein E-protein 0.9971611499786377
that O O 0.9996984004974365
control O O 0.9988266825675964
developmental O O 0.9584206938743591
events O O 0.9834046959877014
in O O 0.9999700784683228
yeast O O 0.6000049710273743
, O O 0.96904456615448

We O O 0.9993021488189697
report O O 0.9999958276748657
the O O 0.9999936819076538
case O O 0.9953629970550537
of O O 0.9998149275779724
a O O 0.9998816251754761
63 O O 0.9921149611473083
- O O 0.9993566870689392
year O O 0.9999539852142334
- O O 0.9998965263366699
old O O 0.9991231560707092
female O O 0.974929928779602
who O O 0.9988855719566345
was O O 0.9992499947547913
treated O O 0.9999774694442749
with O O 0.9999651908874512
methylphenidate B-Chemical B-Chemical 0.9315228462219238
due O O 0.9994882345199585
to O O 0.999893307685852
hyperactivity B-Disease B-Disease 0.9643903970718384
and O O 0.9638184309005737
suffered O O 0.9878103733062744
from O O 0.9995935559272766
multiple O O 0.8255088329315186
ischaemic B-Disease B-Disease 0.4683842957019806
strokes I-Disease I-Disease 0.962867021560669
. O O 0.9985893368721008

factor I-protein I-protein 0.5511214137077332
kappaB E-protein E-protein 0.868224024772644
( O O 0.8436505198478699
NF-kappaB S-protein S-protein 0.9477092027664185
) O O 0.8986396789550781
activation O O 0.9900980591773987
were O O 0.9999819993972778
also O O 0.9999282360076904

normoxia O O 0.323273241519928
) O O 0.6868848204612732
ICAM-1 S-protein S-protein 0.8776457905769348
expression O O 0.9989550113677979
. O O 0.9999985694885254
Combinations O O 0.9992027878761292
of O O 0.9999738931655884
hypoxia O O 0.8288502097129822
and O O 0.9984038472175598
LPS O O 0.9439274668693542
significantly O O 0.9996013045310974
increased O O 0.9982000589370728
lymphocyte O O 0.49353498220443726
binding O O 0.9472147822380066
, O O 0.9996559619903564
and O O 0.9999673366546631
such O O 0.9998868703842163
increases O O 0.9982112646102905
were O O 0.999988317489624
inhibited O O 0.999724805355072
by O O 0.999995231628418
addition O O 0.9994572997093201
of O O 0.9999040365219116
anti-ICAM-1 B-protein S-protein 0.6307212114334106

of O O 0.9984142780303955
acute O O 0.8877381682395935
leukemia O O 0.6774551868438721
that O O 0.9995854496955872
shares O O 0.9991132616996765
features O O 0.9951317310333252
of O O 0.9999352693557739
both O O 0.9980453252792358
myeloid B-cell_type B-cell_type 0.549606204032898
and I-cell_type I-cell_type 0.4931742548942566
natural I-cell_type I-cell_type 0.5864278078079224
killer I-cell_type I-cell_type 0.6999030709266663
( I-cell_type I-cell_type 0.8165073394775391
NK I-cell_type I-cell_type 0.8287534713745117
) I-cell_type I-cell_type 0.8681378960609436
cells E-cell_type E-cell_type 0.8746288418769836
. O O 0.9993083477020264
From O O 0.9999960660934448
a O O 0.9999728202819824
consecutive O O 0.9978602528572083
series O O 0.994455873966217
of O O 0.9999817609786987
350 O O 0.9794607162475586
cases O O 0.99250328540802
of O O 0.9999637603759766
adult O O 0.9165417551994324
de O O 0.9709715843200684
novo O O 0.9831709265708923
acute O O 0.9677802324295044
myeloid O O 0.9544129967689514
leukemia O O 0.9581355452537537
( O O 0.9996542930603027
AML O O 0.8630325198173523
) O O 0.9991589784622192
, O O 0.9999924898147583
we O O 0.9999855756759644
identified O O 0.9999716281890869
20 O O 0.9959630370140076
cases O O 0.9985730648040771
( O O 0.9999740123748779
6 O O 0.999531626701355
% O O 0.9990898370742798
) O O 0.9997654557228088
with O O 0.9999945163726807
a O O 0.9999294281005859
unique O O 0.9230452179908752
immunophenotype O O 0.7047178745269775
: O O 0.9845810532569885
CD33+ O B-cell_line 0.463886559009552
, O I-cell_line 0.9500814080238342
CD56+ O I-cell_line 0.2646026015281677
, O I-cell_line 0.907176673412323
CD11a+ O I-cell_line 0.3064100444316864
, O I-cell_line 0.8680384159088135
CD13lo O I-cell_line 0.547892689704895
, O I-cell_line 0.912380039691925
CD15lo O I-cell_line 0.4353673756122589
, O I-cell_line 0.8268288969993591
CD34+/- O I-cell_line 0.5414959788322449
, O I-cell_line 0.7981953024864197
HLA-DR S-protein I-cell_line 0.6446901559829712

Further O O 0.9954356551170349
observations O O 0.9984573125839233
on O O 0.9999960660934448
the O O 0.9998834133148193
electrophysiologic O O 0.7798877954483032
effects O O 0.9959703683853149
of O O 0.9999737739562988
oral O O 0.5196740627288818
amiodarone B-Chemical B-Chemical 0.9025203585624695
therapy O O 0.9834617376327515
. O O 0.9999988079071045

. O O 0.9915071725845337
In O O 0.9999816417694092
contrast O O 0.999914288520813
to O O 0.9999970197677612
the O O 0.9999772310256958
purely O O 0.9769506454467773
enhancer-dependent O O 0.9668566584587097
effect O O 0.9997994303703308
of O O 0.9999878406524658
cytokines S-protein S-protein 0.9749880433082581
such O O 0.9999080896377563
as O O 0.999968409538269
TNF S-protein S-protein 0.9855754375457764
on O O 0.9996751546859741
the O O 0.999941349029541
activity O O 0.9973721504211426
of O O 0.9999393224716187
the O O 0.9996951818466187
HIV B-DNA B-DNA 0.5299621224403381

an O O 0.9968530535697937
active O O 0.9921417236328125
role O O 0.9991737008094788
in O O 0.999982476234436
NF-kappa B-protein B-protein 0.6782669425010681
B E-protein E-protein 0.9988850951194763
-mediated O O 0.9879064559936523
signal O O 0.9511035680770874
transduction O O 0.9893026947975159
. O O 0.9999897480010986
The O O 0.9999597072601318
Rel/NF-kappa B-protein B-protein 0.5467386245727539
B I-protein I-protein 0.5662287473678589
family E-protein E-protein 0.9533479809761047
of O O 0.9845273494720459
transcription B-protein B-protein 0.49554765224456787
factors E-protein E-protein 0.9935899972915649
is O O 0.9992139339447021
composed O O 0.9999843835830688
of O O 0.9999901056289673
two O O 0.9979121088981628
distinct O O 0.9893139004707336
subgroups O O 0.918082594871521
, O O 0.9990577101707458
proteins O O 0.8746293783187866
that O O 0.9988352656364441
undergo O O 0.999479353427887
proteolytic O O 0.9148830771446228
processing O O 0.9906964302062988
and O O 0.9997633099555969
contain O O 0.9997950196266174
SWI6/ankyrin B-protein B-DNA 0.49652111530303955
repeats E-protein E-DNA 0.6923002004623413
in O O 0.9996830224990845
their O O 0.9995755553245544
carboxyl B-protein O 0.6851250529289246
termini E-protein O 0.3512899875640869
( O O 0.858101487159729
p105 S-protein S-protein 0.40680941939353943
, O O 0.6313272714614868

This O O 0.9986016154289246
led O O 0.9999575614929199
us O O 0.9999679327011108
to O O 0.9999532699584961
hypothesize O O 0.9949707984924316
that O O 0.9999819993972778
a O O 0.9998487234115601
metabolite O O 0.9602206945419312
of O O 0.9988101720809937
cocaine B-Chemical B-Chemical 0.9225413203239441
may O O 0.9994214773178101
be O O 0.99998939037323
responsible O O 0.999942421913147
for O O 0.9999856948852539
some O O 0.9999759197235107
of O O 0.9999786615371704
those O O 0.9999496936798096
delayed O O 0.9124060273170471
sequelae O O 0.6581799983978271
. O O 0.9992901086807251

An O O 0.9995580315589905
unusual O O 0.9714270830154419
toxic O O 0.6215115785598755
reaction O O 0.8928048014640808
to O O 0.9279399514198303
axillary O O 0.5205539464950562
block O O 0.8887835741043091
by O O 0.9836013913154602
mepivacaine S-Chemical B-Chemical 0.9228360056877136
with O O 0.9983940720558167
adrenaline S-Chemical B-Chemical 0.9297516345977783
. O O 0.9996368885040283

showed O O 0.9987738728523254
strong O O 0.9954047203063965
AP-1 S-protein S-protein 0.9748424291610718
activity O O 0.9967942833900452
by O O 0.9999911785125732
gel-shift O O 0.9195516109466553
analysis O O 0.9969504475593567
, O O 0.9999885559082031
and O O 0.9999655485153198
supershift O O 0.9483654499053955
analysis O O 0.9989079236984253
showed O O 0.9999983310699463
the O O 0.9999738931655884
AP-1 B-protein B-protein 0.6920233368873596
complexes E-protein E-protein 0.935941755771637
contained O O 0.9989474415779114
specific O O 0.9757044315338135
members O O 0.9510082602500916
of O O 0.9997771382331848
both O O 0.9998593330383301
the O O 0.997599184513092
jun B-DNA B-DNA 0.667025625705719
and I-DNA I-DNA 0.6277596354484558
fos I-DNA I-DNA 0.5580742359161377
gene I-DNA I-DNA 0.5227230191230774
families E-DNA E-DNA 0.7941362261772156
. O O 0.9997525811195374
These O O 0.9999974966049194
data O O 0.9997841715812683
indicate O O 0.9999974966049194
that O O 0.9999938011169434
, O O 0.9993415474891663
in O O 0.9999839067459106
contrast O O 0.9998394250869751
to O O 0.9999934434890747
most O O 0.9985998272895813
LPS O O 0.7281144857406616
effects O O 0.9971318244934082
, O O 0.9999765157699585
AP-1 S-protein S-protein 0.9695118069648743
, O O 0.9935594797134399
but O O 0.9994831085205078
not O O 0.9992846846580505
nuclear B-protein B-protein 0.506088137626648
factor-kappaB E-protein E-protein 0.9547333717346191
, O O 0.9739248752593994
mediates O O 0.984580397605896

Selective O O 0.9500356912612915
activation O O 0.9918367266654968
and O O 0.9993245601654053
functional O O 0.9909077882766724
significance O O 0.9995297193527222
of O O 0.9999817609786987
p38alpha B-protein B-protein 0.9153136610984802
mitogen-activated I-protein I-protein 0.5726314783096313
protein I-protein I-protein 0.40935617685317993
kinase E-protein E-protein 0.9731801748275757
in O O 0.9985085129737854
lipopolysaccharide-stimulated B-cell_line B-cell_type 0.47197121381759644
neutrophils E-cell_line E-cell_type 0.7089411616325378
. O O 0.9996846914291382
Activation O O 0.9977505803108215
of O O 0.9998821020126343
leukocytes S-cell_type S-cell_type 0.9902477860450745
by O O 0.9994804263114929
proinflammatory O O 0.8229988217353821
stimuli O O 0.6194437742233276
selectively O O 0.9977282881736755
initiates O O 0.9998082518577576
intracellular O O 0.896842360496521
signal O O 0.9424761533737183
transduction O O 0.9860906600952148
via O O 0.9998680353164673
sequential O O 0.8991276025772095
phosphorylation O O 0.9108318090438843
of O O 0.9970155954360962
kinases S-protein S-protein 0.5847840309143066

and O O 0.9278270602226257
MAD3 S-protein S-protein 0.4943277835845947
, O O 0.9952484965324402
with O O 0.9999884366989136
the O O 0.9999744892120361
end O O 0.9939340949058533
result O O 0.9997244477272034
of O O 0.9999918937683105
persistent O O 0.9781391024589539
NF-kappa O B-protein 0.6640207767486572
B O E-protein 0.9969028830528259
activation O O 0.9953717589378357
and O O 0.9999136924743652
viral O O 0.8950079679489136
persistence O O 0.9541388154029846
. O O 0.9999887943267822
Furthermore O O 0.9999657869338989
, O O 0.9999809265136719
persistent O O 0.976996123790741
HIV O O 0.9511926770210266
infection O O 0.986190915107727
of O O 0.9997501969337463
monocytes S-cell_type S-cell_type 0.9926833510398865
and O O 0.9921891689300537
macrophages S-cell_type S-cell_type 0.9893960356712341
provides O O 0.9998120665550232
a O O 0.9999803304672241
useful O O 0.9914990067481995
model O O 0.9982878565788269
with O O 0.999991774559021

did O O 0.9985664486885071
not O O 0.9999749660491943
affect O O 0.9999871253967285
the O O 0.9999291896820068
proliferation O O 0.9964619278907776
of O O 0.9999289512634277
B B-cell_type B-cell_type 0.9020975828170776
cells E-cell_type E-cell_type 0.9841024279594421
investigated O O 0.9977737069129944
. O O 0.9999970197677612
Altogether O O 0.9999501705169678
, O O 0.9999948740005493
our O O 0.9999778270721436
data O O 0.9995835423469543
demonstrate O O 0.9999922513961792
that O O 0.999990701675415
: O O 0.998932421207428
( O O 0.9995830655097961
a O O 0.9995015859603882
) O O 0.9996892213821411
the O O 0.9999692440032959
ability O O 0.9998243451118469
of O O 0.9999196529388428
B B-cell_type B-cell_type 0.8693861365318298
cells E-cell_type E-cell_type 0.9900782108306885
to O O 0.9980727434158325
release O O 0.9994181394577026
TNF-alpha S-protein S-protein 0.98842453956604
after O O 0.999588668346405
triggering O O 0.995598316192627
of O O 0.9998995065689087
HLA-DR B-protein B-protein 0.27575093507766724
antigens E-protein E-protein 0.9894010424613953
depends O O 0.9999407529830933
on O O 0.9999860525131226
their O O 0.9999737739562988
stage O O 0.9983193278312683
of O O 0.9997349381446838
differentiation O O 0.9943038821220398
; O O 0.9999476671218872
( O O 0.9995835423469543
b O O 0.9970008730888367
) O O 0.9995119571685791
levels O O 0.9998427629470825
of O O 0.9999276399612427
released O O 0.9231809973716736
TNF-alpha S-protein S-protein 0.9589174389839172
seem O O 0.9968926906585693

of O O 0.9968423843383789
the O O 0.9999737739562988
alphabeta B-cell_type B-cell_type 0.46220651268959045
lineage E-cell_type E-cell_type 0.8272470831871033
was O O 0.9988920092582703
reduced O O 0.9992075562477112
, O O 0.9999734163284302
and O O 0.9999780654907227
the O O 0.9999375343322754
remaining O O 0.9943506121635437
TCRhigh B-cell_type O 0.3652136027812958
population E-cell_type O 0.3150913417339325
contained O O 0.9985775947570801
an O O 0.9999731779098511
unusually O O 0.9648741483688354
high O O 0.9958667755126953
proportion O O 0.9995399713516235
of O O 0.999964714050293
double-positive B-cell_line B-cell_type 0.5397297143936157
cells E-cell_line E-cell_type 0.7654693722724915

matrix-associated B-DNA I-protein 0.5484570860862732
region E-DNA E-protein 0.6590725183486938
of O O 0.9874029159545898
the O O 0.9993991851806641
J-C B-DNA B-DNA 0.4517444968223572
intron E-DNA E-DNA 0.8451863527297974
. O O 0.9987468719482422
The O O 0.9999909400939941
binding O O 0.8922725915908813
activity O O 0.9917722344398499
is O O 0.9999772310256958
greatly O O 0.9997133612632751
inducible O O 0.9986520409584045
in O O 0.9999449253082275
pre-B B-cell_type B-cell_type 0.8334903717041016
cells E-cell_type E-cell_type 0.9685105681419373
by O O 0.9997521042823792
bacterial O O 0.8597216606140137
lipopolysaccharide O O 0.48513734340667725
and O O 0.9680156707763672
interleukin-1 S-protein S-protein 0.9315227270126343
but O O 0.9959814548492432
specific O O 0.9931679368019104
complexes O O 0.5903506278991699
are O O 0.9999548196792603
found O O 0.9999392032623291

solely O O 0.997445821762085
by O O 0.9999964237213135
the O O 0.9999892711639404
transition O O 0.9993433356285095
from O O 0.9999935626983643
inactive O O 0.8142262101173401
to O O 0.994358479976654
active O O 0.9029580950737
functional O O 0.9119654893875122
state O O 0.9602323174476624
of O O 0.9997952580451965
a O O 0.9999229907989502
positive B-protein B-protein 0.8234801888465881
transcription I-protein I-protein 0.40712693333625793
factor E-protein E-protein 0.9798564910888672
binding O O 0.9648100733757019
to O O 0.9998196959495544
these O O 0.9992768168449402
promoter O O 0.3690411448478699

enhancer O E-DNA 0.854007363319397
activity O O 0.9740864038467407
in O O 0.999957799911499
the O O 0.9999691247940063
third B-DNA O 0.9650055766105652
intron E-DNA O 0.3871496915817261
of O O 0.991682767868042
TNF-alpha S-protein S-protein 0.8597902655601501
. O O 0.9996862411499023
We O O 0.999977707862854
describe O O 0.9999929666519165
an O O 0.999948263168335
enhancer O B-DNA 0.5479263663291931
site O E-DNA 0.9512410759925842
in O O 0.9995710253715515
the O O 0.9999545812606812
third B-DNA O 0.9259657263755798
intron E-DNA O 0.4713808000087738
of O O 0.9885324239730835
tumor B-protein B-protein 0.3810277581214905
necrosis I-protein I-protein 0.5899634957313538
factor I-protein I-protein 0.4101872146129608
alpha E-protein E-protein 0.8627417683601379

microM O O 0.5586549043655396

Treatment O O 0.9981461763381958
of O O 0.9999574422836304
previously O O 0.9868143796920776
treated O O 0.9872931241989136
metastatic O O 0.6145826578140259
breast B-Disease O 0.5842113494873047
cancer I-Disease O 0.9196425676345825
by O O 0.9913849830627441
mitoxantrone B-Chemical B-Chemical 0.9408175945281982
and O O 0.9891343712806702
48 O O 0.9813745617866516
- O O 0.999184787273407
hour O O 0.9994716048240662
continuous O O 0.9709718227386475
infusion O O 0.8244607448577881
of O O 0.9914570450782776
high O O 0.9916908740997314
- O O 0.9976676106452942
dose O O 0.9974479675292969
5 B-Chemical B-Chemical 0.9682108759880066
- I-Chemical I-Chemical 0.994629979133606
FU I-Chemical E-Chemical 0.9275954365730286
and O O 0.8723564147949219
leucovorin B-Chemical B-Chemical 0.9281627535820007
( O O 0.9441676139831543
MFL B-Chemical B-Chemical 0.9355606436729431
) O O 0.8034265041351318
: O O 0.999937891960144
low O O 0.9878615140914917
palliative O O 0.9332817792892456
benefit O O 0.8780539035797119
and O O 0.9995331764221191
high O O 0.9723221063613892
treatment O O 0.989170491695404
- O O 0.9996623992919922
related O O 0.9908574223518372
toxicity B-Disease B-Disease 0.9762444496154785
. O O 0.9986433386802673

B-dependent O O 0.6605903506278992
manner O O 0.8756551146507263
. O O 0.9998310804367065
We O O 0.9999818801879883
found O O 0.9999929666519165
that O O 0.9999960660934448
transactivation O O 0.9909452199935913
of O O 0.9998695850372314
the O O 0.9997919201850891
HIV-1 B-DNA B-DNA 0.5154936909675598
LTR E-DNA E-DNA 0.980309247970581
by O O 0.9992508292198181
v-src S-DNA S-DNA 0.9378405809402466
was O O 0.999121367931366
more O O 0.9998843669891357
sensitive O O 0.9993288516998291
to O O 0.9999762773513794
mutations O O 0.9809526801109314
of O O 0.9998551607131958
the O O 0.9998767375946045
proximal O O 0.6748226284980774
, O O 0.9107327461242676
rather O O 0.9840752482414246
than O O 0.9992744326591492
the O O 0.9998844861984253
distal O O 0.7667896151542664
, O O 0.9866001009941101
kappa B-DNA B-DNA 0.607338547706604
B I-DNA I-DNA 0.6502001285552979

subfamilies E-protein O 0.4348210096359253
; O O 0.9991729855537415
however O O 0.9999785423278809
, O O 0.9999797344207764
E2A-HLF S-protein B-protein 0.7381691932678223
proteins O E-protein 0.9796192646026611
were O O 0.9999032020568848
significantly O O 0.9998466968536377
less O O 0.9999364614486694
tolerant O O 0.9966012239456177
of O O 0.9999849796295166
certain O O 0.9990535378456116
deviations O O 0.9932564496994019
from O O 0.9999966621398926
the O O 0.9999688863754272
HLF B-DNA B-DNA 0.44065791368484497
consensus I-DNA I-DNA 0.7154276967048645
binding I-DNA I-DNA 0.9178900122642517
site E-DNA E-DNA 0.9742400050163269
. O O 0.9998648166656494
These O O 0.9999953508377075
differences O O 0.9995506405830383
were O O 0.9999971389770508
directly O O 0.9997871518135071
attributable O O 0.9999850988388062
to O O 0.9999926090240479
loss O O 0.9968723654747009
of O O 0.9998084902763367
an O O 0.9997316002845764
HLF B-DNA B-DNA 0.2340715080499649

examined O O 0.9971767663955688
the O O 0.9999915361404419
effect O O 0.9999738931655884
of O O 0.9999891519546509
cytokines S-protein S-protein 0.9711815714836121
on O O 0.9999001026153564
IL-2 S-protein S-protein 0.8120030760765076
deprivation-induced O O 0.8994301557540894
apoptosis O O 0.9579479098320007
of O O 0.99955815076828
human B-cell_line B-cell_line 0.545367956161499
antigen-specific I-cell_line I-cell_line 0.5989270806312561
T I-cell_line I-cell_line 0.776279091835022
helper I-cell_line I-cell_line 0.7844186425209045
clones E-cell_line E-cell_line 0.9248319864273071
with O O 0.9996750354766846
different O O 0.9958884119987488

Renal O O 0.6998143196105957
plasma O O 0.5269255042076111
flow O O 0.6762803196907043
increased O O 0.9894070029258728
, O O 0.9998389482498169
but O O 0.9998663663864136
albumin O O 0.43668627738952637
excretion O O 0.6293535232543945
and O O 0.9967340230941772
glomerulosclerosis O B-Disease 0.9424729943275452
did O O 0.9914352297782898
not O O 0.9997027516365051
change O O 0.9990723133087158
after O O 0.9999837875366211
enalapril S-Chemical B-Chemical 0.9324356317520142
treatment O O 0.9964187145233154
. O O 0.9999992847442627

B-1 I-cell_type B-cell_line 0.3227514922618866
cells E-cell_type E-cell_line 0.5494922399520874
but O O 0.9981510043144226
only O O 0.999855637550354
inducibly O O 0.9985610842704773
expressed O O 0.9999067783355713
in O O 0.9997116923332214
conventional O B-cell_type 0.5977687835693359
B B-cell_type I-cell_type 0.5597043037414551
lymphocytes E-cell_type E-cell_type 0.9775009155273438
[ O O 0.9964587092399597
see O O 0.9997525811195374
comments O O 0.9925946593284607
] O O 0.9990267753601074
Cytokine S-protein S-protein 0.6500867009162903
and O O 0.9837835431098938
growth B-protein B-protein 0.7094849348068237
factor I-protein I-protein 0.4302106499671936
receptor E-protein E-protein 0.8044057488441467
engagement O O 0.9423666596412659

is O O 0.9943187832832336
regulated O O 0.9992184638977051
in O O 0.9999760389328003
vivo O O 0.9849012494087219
at O O 0.9999825954437256
the O O 0.9999947547912598
level O O 0.9998471736907959
of O O 0.9999791383743286
constitutive O O 0.9339762926101685
and O O 0.9910340905189514
inducible O O 0.9751350283622742
protein/DNA O O 0.46308770775794983
interactions O O 0.9337509870529175
. O O 0.9999744892120361
We O O 0.9999867677688599
propose O O 0.9999982118606567
a O O 0.9999939203262329
model O O 0.9972264170646667
where O O 0.9999713897705078
basal O O 0.8948058485984802
transcription O O 0.9095104932785034
is O O 0.999491810798645
maintained O O 0.9999370574951172
by O O 0.9999951124191284
binding O O 0.9884496927261353
of O O 0.9997742772102356
various O O 0.9912541508674622
transcription B-protein B-protein 0.535777747631073
factors E-protein E-protein 0.9875888228416443

Features O O 0.9929225444793701
of O O 0.9999327659606934
organic B-Disease B-Disease 0.7560044527053833
mental I-Disease I-Disease 0.5853074789047241
disorder I-Disease I-Disease 0.977813720703125
( O O 0.9021421074867249
delirium B-Disease B-Disease 0.8911911845207214
) O O 0.7780289053916931
were O O 0.9994972944259644
not O O 0.9999306201934814
present O O 0.9999594688415527
. O O 0.9999990463256836

Warfarin B-Chemical B-Chemical 0.9141606688499451
is O O 0.9988204836845398
the O O 0.9999885559082031
most O O 0.9956735968589783
widely O O 0.9900083541870117
used O O 0.999180018901825
oral O O 0.6396110653877258
anticoagulant O O 0.7108744978904724
and O O 0.9943453073501587
is O O 0.9999785423278809
indicated O O 0.9999805688858032
for O O 0.9999936819076538
many O O 0.9996694326400757
clinical O O 0.9927750825881958
conditions O O 0.9921543002128601
. O O 0.9999990463256836

segregated O O 0.9315419793128967
with O O 0.9996254444122314
Vbeta O S-protein 0.8988670110702515
usage O O 0.9802870154380798
. O O 0.999990701675415
We O O 0.9999910593032837
thus O O 0.9999901056289673
propose O O 0.9999943971633911
that O O 0.9999963045120239
during O O 0.9998681545257568
an O O 0.9999762773513794
in O O 0.9991397857666016
vivo O O 0.9874618649482727
chronic O O 0.9648928046226501
response O O 0.989732563495636
, O O 0.9999873638153076
a O O 0.9999873638153076
narrow O O 0.9542843699455261
range O O 0.9926540851593018
of O O 0.9997275471687317
avidity O O 0.9511684775352478
of O O 0.9986239671707153
the O O 0.9996672868728638
TCR-CD8 B-protein S-protein 0.3533216118812561

Features O O 0.9929225444793701
of O O 0.9999327659606934
organic O B-Disease 0.7560044527053833
mental O I-Disease 0.5853074789047241
disorder O I-Disease 0.977813720703125
( O O 0.9021421074867249
delirium O B-Disease 0.8911911845207214
) O O 0.7780289053916931
were O O 0.9994972944259644
not O O 0.9999306201934814
present O O 0.9999594688415527
. O O 0.9999990463256836

enhancer E-DNA E-DNA 0.9342092871665955
as O O 0.9991151690483093
judged O O 0.9999281167984009
by O O 0.9999885559082031
gel O O 0.9031715989112854
retardation O O 0.9568992853164673
and O O 0.99818354845047
methylation O O 0.8674642443656921
interference O O 0.9316861629486084
assays O O 0.9895764589309692
. O O 0.9999760389328003
With O O 0.998468816280365

RESULTS O O 0.9968793392181396
: O O 0.9999736547470093
Sensitivity O O 0.9301876425743103
to O O 0.9993693232536316
several O O 0.9995275735855103
convulsion O O 0.7599930763244629
endpoints O O 0.5163139700889587
induced O O 0.9980273842811584
by O O 0.9999206066131592
nicotine S-Chemical B-Chemical 0.9244503974914551
, O O 0.9652611613273621
carbachol S-Chemical B-Chemical 0.9291900396347046
, O O 0.9578824639320374
and O O 0.9969297051429749
neostigmine S-Chemical B-Chemical 0.925512969493866
were O O 0.9991180300712585
significantly O O 0.9998536109924316
greater O O 0.9999138116836548
in O O 0.9999749660491943
WSR O O 0.4971901476383209
versus O O 0.9956842660903931
WSP O O 0.5643237233161926
mice O O 0.9766317009925842
. O O 0.9999990463256836

cell I-cell_line O 0.3951442539691925

erythroid O O 0.692894458770752
development O O 0.9726063013076782
is O O 0.999967098236084
mediated O O 0.999933123588562
by O O 0.9999983310699463
a O O 0.9998624324798584
distal B-DNA B-DNA 0.655894935131073
enhancer E-DNA E-DNA 0.969626247882843
, O O 0.9963076114654541
HS-40 S-DNA S-DNA 0.9546973705291748
. O O 0.9997865557670593
Previous O O 0.9997977614402771
protein-DNA O O 0.7991384863853455
binding O O 0.6832289099693298
studies O O 0.9313129782676697
have O O 0.9999843835830688
shown O O 0.999995231628418
that O O 0.999993085861206
HS-40 S-DNA S-protein 0.5175309777259827
consists O O 0.9989839196205139
of O O 0.999948263168335

One O O 0.999607264995575
hour O O 0.9995265007019043
after O O 0.9999969005584717
the O O 0.9999814033508301
administration O O 0.9990504384040833
of O O 0.9997914433479309
gamma B-Chemical B-Chemical 0.9422041177749634
- I-Chemical I-Chemical 0.9919911026954651
HCH I-Chemical I-Chemical 0.9570973515510559
, O O 0.9969911575317383
the O O 0.9999457597732544
activity O O 0.9944543242454529
of O O 0.9997889399528503
seizure B-Disease B-Disease 0.9696441888809204
- O O 0.7169003486633301
inducing O O 0.9432406425476074
agents O O 0.9241757988929749
was O O 0.9998694658279419
increased O O 0.9986286163330078
, O O 0.9999672174453735
regardless O O 0.9999494552612305
of O O 0.9999188184738159
their O O 0.9998114705085754
mechanism O O 0.9967321157455444
, O O 0.9999915361404419
while O O 0.9999966621398926
24 O O 0.9985483288764954
h O O 0.9887237548828125
after O O 0.9999016523361206
gamma B-Chemical B-Chemical 0.9247428774833679
- I-Chemical I-Chemical 0.9927281141281128
HCH I-Chemical I-Chemical 0.9518718719482422
a O O 0.9772911667823792
differential O O 0.9783740043640137
response O O 0.9951719641685486
was O O 0.9999839067459106
observed O O 0.9999347925186157
. O O 0.9999990463256836

Our O O 0.9988518953323364
observations O O 0.997001588344574
demonstrated O O 0.9999805688858032
an O O 0.9999730587005615
association O O 0.9942173957824707
of O O 0.99981290102005
hearing O B-Disease 0.6726744771003723
loss O I-Disease 0.9886926412582397
with O O 0.9736552834510803
a O O 0.9993797540664673
higher O O 0.9990136623382568
incidence O O 0.9969788789749146
of O O 0.9998683929443359
perinatal O O 0.6113571524620056
complications O O 0.9340009093284607
. O O 0.9988971948623657

and O O 0.9223719835281372
cortisol O O 0.8530457615852356
from O O 0.9997335076332092
homologous O O 0.6588749289512634
and O O 0.9514904618263245
heterologous O O 0.8979101777076721
competition O O 0.9606195092201233
curves O O 0.9470264911651611
for O O 0.9999550580978394
specific O O 0.9839910268783569
[ O O 0.9547185897827148
3H O O 0.6795816421508789
] O O 0.8573830127716064
dexamethasone O B-DNA 0.737182080745697
binding O I-DNA 0.44992944598197937
sites O E-DNA 0.5628994107246399
on O O 0.9976529479026794
HML S-cell_type S-cell_type 0.31040576100349426
isolated O O 0.6689021587371826
from O O 0.9975715279579163
the O O 0.9994614720344543
blood O O 0.902649998664856
of O O 0.9980826377868652
normotensive O O 0.4076440632343292
volunteers O O 0.5929672122001648
and O O 0.9869205951690674
subjects O O 0.9974396228790283
with O O 0.9999892711639404
essential O O 0.8626028299331665
hypertension O O 0.8223346471786499
. O O 0.9988890290260315

which O O 0.9913538098335266
displayed O O 0.999258816242218
differential O O 0.9798428416252136
binding O O 0.9821182489395142
with O O 0.9999480247497559
respect O O 0.9998399019241333
to O O 0.9999958276748657
the O O 0.9999735355377197
other O O 0.9988052845001221
protein O O 0.7879704833030701
, O O 0.9944790601730347
little O O 0.9986751675605774
to O O 0.9998824596405029
no O O 0.9997137188911438
binding O O 0.9830579161643982
was O O 0.9997709393501282
observed O O 0.9999336004257202
with O O 0.9999914169311523
the O O 0.9998668432235718
heterodimeric B-protein B-protein 0.5883604288101196
NF-kappa I-protein I-protein 0.5971518754959106
B I-protein I-protein 0.5969241857528687
complex E-protein E-protein 0.9935705661773682
. O O 0.999769389629364
Similarly O O 0.9999110698699951
, O O 0.9999663829803467
in O O 0.9999167919158936
transfection O O 0.8450170755386353
experiments O O 0.932292640209198
in O O 0.9999872446060181
which O O 0.9999967813491821
the O O 0.9998202919960022
selective B-DNA O 0.8881776928901672
kappa I-DNA B-DNA 0.3637961149215698
B I-DNA I-DNA 0.471780002117157
binding I-DNA I-DNA 0.8479955196380615
sites E-DNA E-DNA 0.9845260381698608
were O O 0.9996022582054138
used O O 0.9999693632125854
to O O 0.9999837875366211
drive O O 0.9998515844345093
the O O 0.999721348285675
expression O O 0.9885114431381226

whereas O O 0.9989687204360962
the O O 0.9999750852584839
RAR S-protein S-protein 0.543890655040741
antagonist O O 0.6776068210601807
completely O O 0.9719457626342773
blocked O O 0.9987491369247437
all-trans O O 0.9644132256507874
RA-induced O O 0.9280650019645691
differentiation O O 0.9927871823310852
and O O 0.9998579025268555
apoptosis O O 0.9614275097846985
of O O 0.9990641474723816
the O O 0.999710738658905
cells O O 0.9624494910240173
. O O 0.9999896287918091
Additional O O 0.9992683529853821
experiments O O 0.9997338652610779
showed O O 0.9999974966049194
that O O 0.9999938011169434
levels O O 0.9992949962615967
of O O 0.999920129776001
BCL-2 B-protein B-protein 0.8553390502929688
protein E-protein E-protein 0.9368996620178223
decreased O O 0.9986203908920288
during O O 0.9999643564224243

of O O 0.9973520040512085
IL-2-independent B-cell_line B-cell_line 0.7181121110916138
cell I-cell_line I-cell_line 0.8101102113723755
lines E-cell_line E-cell_line 0.9988412261009216
( O O 0.9991316199302673
Hut102 S-cell_line S-cell_line 0.9929972290992737
, O O 0.9783152341842651
Molt-4 S-cell_line S-cell_line 0.9938299059867859
, O O 0.9233903288841248
and O O 0.9957629442214966
Jurkat S-cell_line S-cell_line 0.9986215829849243
) O O 0.9053270220756531
. O O 0.9999769926071167
This O O 0.9999909400939941
suppressive O O 0.9443792104721069
effect O O 0.9995421171188354
was O O 0.9999954700469971
also O O 0.9999333620071411

Neonatal O O 0.8252959251403809
pyridoxine B-Chemical S-Chemical 0.9018998146057129
responsive O O 0.8177462816238403
convulsions B-Disease O 0.6377028822898865
due O O 0.9989221096038818
to O O 0.9999605417251587
isoniazid B-Chemical B-Chemical 0.9262192249298096
therapy O O 0.9841394424438477
. O O 0.9999983310699463

Sexual O B-Disease 0.5643086433410645
dysfunction O I-Disease 0.9861114025115967
among O O 0.9489342570304871
patients O O 0.9882264733314514
with O O 0.9999189376831055
arthritis O B-Disease 0.9732505679130554
. O O 0.9990713596343994

In O O 0.9992449283599854
control O O 0.9717611074447632
rats O O 0.9899514317512512
, O O 0.9999853372573853
intravenous O O 0.8612754344940186
bromocriptine S-Chemical B-Chemical 0.9378412961959839
( O O 0.991969883441925
150 O O 0.9949110150337219
microg O O 0.990871250629425
/ O O 0.9998781681060791
kg O O 0.9959418177604675
) O O 0.9997895359992981
induced O O 0.9998362064361572
significant O O 0.9865520000457764
hypotension O B-Disease 0.9745020270347595
and O O 0.932368814945221
tachycardia O B-Disease 0.9651781916618347
. O O 0.9976921081542969

TIMP O O 0.9318851232528687
mRNA O O 0.9602274894714355
and O O 0.9999496936798096
tissue O O 0.7343121767044067
levels O O 0.9613791704177856
did O O 0.9998903274536133
not O O 0.9999167919158936
differ O O 0.9999493360519409
obviously O O 0.9995253086090088
among O O 0.9999959468841553
the O O 0.9999231100082397
three O O 0.9989594221115112
aortic O O 0.5352379083633423
segments O O 0.7747507691383362
. O O 0.9999896287918091

Twenty O O 0.9917263984680176
- O O 0.9992331266403198
six O O 0.9996809959411621
had O O 0.9999006986618042
minimal O O 0.9845527410507202
prior O O 0.9776397943496704
therapy O O 0.9943247437477112
( O O 0.9999865293502808
good O O 0.9795073866844177
risk O O 0.9622770547866821
) O O 0.9993247985839844
, O O 0.9999632835388184
23 O O 0.9923986792564392
had O O 0.9998583793640137
extensive O O 0.9952438473701477
prior O O 0.9872366189956665
therapy O O 0.9917165637016296
( O O 0.9999864101409912
poor O O 0.9010390043258667
risk O O 0.9079360365867615
) O O 0.9979081153869629
, O O 0.9999140501022339
and O O 0.9999523162841797
six O O 0.9928065538406372
had O O 0.9984588623046875
renal O O 0.5215253233909607
and O O 0.6983935832977295
/ O O 0.7715067863464355
or O O 0.9377167820930481
hepatic O O 0.5953447818756104
dysfunction O O 0.9588896036148071
. O O 0.9989546537399292

recombination O O 0.8894318342208862

ionomycin O O 0.44277799129486084
and O O 0.9976873397827148
phorbol O O 0.953197181224823
myristate O O 0.9837105870246887
acetate O O 0.997603714466095
( O O 0.9999872446060181
PMA O O 0.9865220189094543
) O O 0.9999021291732788
. O O 0.9999947547912598
The O O 0.999997615814209
inhibitory O O 0.9424799680709839
effect O O 0.9991196990013123
of O O 0.9999656677246094
CaM-K B-protein B-protein 0.3526782989501953
II E-protein E-protein 0.9456150531768799
on O O 0.9983941912651062
IL-2 B-DNA B-DNA 0.5417745113372803
promoter E-DNA E-DNA 0.9948549270629883
was O O 0.9987492561340332
associated O O 0.9999619722366333
with O O 0.9999974966049194
decreased O O 0.9931007623672485
transcription O O 0.9782483577728271
of O O 0.9993818998336792
its O O 0.9997859597206116
AP-1 O S-protein 0.7660320401191711
and O O 0.9217627644538879
NF-AT O S-protein 0.8530669808387756
transactivating O O 0.8892048001289368
pathways O O 0.9795240759849548
. O O 0.9999949932098389

BACKGROUND O O 0.988330602645874
: O O 0.9998912811279297
Fibrin O O 0.8147932887077332
sealants O O 0.5263576507568359
( O O 0.9998084902763367
FS O O 0.6903309226036072
) O O 0.9963778853416443
derived O O 0.999871015548706
from O O 0.9999580383300781
human O O 0.8384665250778198
plasma O O 0.5589981079101562
are O O 0.9986900687217712
frequently O O 0.9998394250869751
used O O 0.9999765157699585
in O O 0.9999788999557495
neurosurgery O O 0.6182979345321655
. O O 0.9999191761016846

ROS O O 0.39623504877090454
activity O O 0.9720302224159241
and O O 0.9996300935745239
antioxidant O O 0.9026984572410583
defence O O 0.9913183450698853
to O O 0.9999730587005615
inflammatory O O 0.9186580777168274
diseases O O 0.8019949197769165
and O O 0.999816358089447
attempts O O 0.999937891960144
to O O 0.9999595880508423
draw O O 0.9999523162841797
parallels O O 0.9936538934707642
with O O 0.9999752044677734
periodontitis O O 0.8112056851387024
, O O 0.9999115467071533
in O O 0.9999731779098511
an O O 0.9997957348823547

high O O 0.8975666165351868

minor O O 0.8706085681915283
importance O O 0.99687659740448
after O O 0.9999977350234985
influenza O O 0.9524134397506714
infection O O 0.992377758026123
since O O 0.9999986886978149
in O O 0.9997970461845398
apoptosisprone B-cell_type B-cell_type 0.5044669508934021
cells E-cell_type E-cell_type 0.6771835088729858
an O O 0.9998043179512024
immediate O O 0.9920042157173157
availability O O 0.9983237385749817
of O O 0.999875545501709
transcription B-protein B-protein 0.46778109669685364
factor I-protein E-protein 0.8369748592376709

Lipopolysaccharide S-Chemical B-Chemical 0.9139310121536255
pretreatment O O 0.8365524411201477
did O O 0.999908447265625
not O O 0.9999699592590332
affect O O 0.9999860525131226
the O O 0.9997401833534241
basal O O 0.969613254070282
body O O 0.9686592817306519
temperature O O 0.9211034774780273
or O O 0.9999140501022339
methamphetamine S-Chemical B-Chemical 0.9181679487228394
- O O 0.9640356302261353
elicited O O 0.9908549785614014
hyperthermia O B-Disease 0.9862110018730164
three O O 0.9863125681877136
days O O 0.9999309778213501
later O O 0.9999936819076538
. O O 0.9999991655349731

mononuclear I-cell_type I-cell_type 0.4094548225402832
cells E-cell_type E-cell_type 0.9124706983566284
as O O 0.9998797178268433
a O O 0.9999964237213135
prognostic O O 0.9207479953765869
parameter O O 0.8981128931045532
for O O 0.9997745156288147
the O O 0.9999817609786987
course O O 0.9994949102401733
of O O 0.9999778270721436
breast O O 0.9277515411376953
cancer O O 0.6771153807640076
: O O 0.999863862991333
a O O 0.9999641180038452
prospective O O 0.9356789588928223
longitudinal O O 0.5830429792404175

X-SCID O O 0.24021808803081512
) O O 0.9364160895347595
. O O 0.9999358654022217
The O O 0.9999834299087524
gamma B-protein B-protein 0.4478006362915039
( I-protein I-protein 0.8468374013900757
c I-protein I-protein 0.9594653844833374
) I-protein I-protein 0.6812554597854614
subunit E-protein E-protein 0.9822677969932556
can O O 0.9992490410804749
be O O 0.9999843835830688
employed O O 0.9999816417694092
in O O 0.9999525547027588
receptor B-protein O 0.8571128249168396
complexes E-protein O 0.829862654209137
for O O 0.9991740584373474
IL-2 B-protein B-protein 0.9442498683929443
, I-protein I-protein 0.9155797958374023
-4 I-protein I-protein 0.3964006006717682
, I-protein I-protein 0.5769153833389282
-7 I-protein I-protein 0.418304443359375
, I-protein I-protein 0.8531495928764343
-9 I-protein I-protein 0.559827446937561
, I-protein I-protein 0.8350816965103149
and I-protein I-protein 0.9280446767807007
-15 E-protein E-protein 0.8685900568962097
, O O 0.8603242635726929
and O O 0.9733536243438721

These O O 0.9994099140167236
data O O 0.9999138116836548
suggest O O 0.9999980926513672
that O O 0.9999961853027344
NF-kappa B-protein B-protein 0.774231493473053
B E-protein E-protein 0.9888980984687805
may O O 0.9998111128807068
be O O 0.9999991655349731
an O O 0.9999940395355225
important O O 0.9977390766143799
molecular O O 0.9385798573493958
mediator O O 0.6881074905395508
of O O 0.9995521903038025
Pb-induced O O 0.7799500823020935
immunotoxicity O O 0.9258779287338257
. O O 0.9999146461486816
Tyrosine B-protein B-protein 0.6805436611175537
kinase E-protein E-protein 0.9274247884750366
and O O 0.973466157913208
cAMP-dependent B-protein B-protein 0.513806939125061
protein I-protein I-protein 0.4807535409927368
kinase E-protein E-protein 0.8906983733177185
activities O O 0.9043685793876648
in O O 0.9998979568481445
CD40-activated B-cell_line B-cell_line 0.624101459980011
human I-cell_line I-cell_line 0.7510554790496826
B I-cell_line I-cell_line 0.8264632821083069
lymphocytes E-cell_line E-cell_line 0.7957891821861267

) O O 0.6980689764022827
and O O 0.9804859161376953
receptor O O 0.736829936504364
numbers O O 0.6116675138473511
( O O 0.9980795383453369
Ro O O 0.5173422694206238
) O O 0.9736264944076538
in O O 0.9999775886535645
the O O 0.9999231100082397
monocytes S-cell_type S-cell_type 0.923113226890564
of O O 0.998325526714325
these O O 0.9999837875366211
two O O 0.9993663430213928
groups O O 0.9984455704689026
of O O 0.9999634027481079
subjects O O 0.9968969821929932
. O O 0.9999982118606567
The O O 0.9999964237213135
concentration O O 0.9958850741386414
of O O 0.9998934268951416
corticosteroid O O 0.5902475118637085
producing O O 0.9719236493110657
50 O O 0.8313400149345398
% O O 0.9771602153778076
inhibition O O 0.9728881120681763
( O O 0.9997814297676086
IC50 O O 0.8362752795219421
) O O 0.998217761516571
was O O 0.9999969005584717
600 O O 0.9925641417503357
nM O O 0.9943104982376099
, O O 0.9999086856842041
70 O O 0.9975225329399109
nM O O 0.9944772124290466
, O O 0.9997991919517517
and O O 0.9998668432235718
0.5 O O 0.9932239055633545
nM O O 0.9953439831733704
for O O 0.9998993873596191
hydrocortisone O O 0.8680077195167542
, O O 0.9987468719482422
methylprednisolone O O 0.8568287491798401
, O O 0.9968671202659607
and O O 0.9996942281723022

Heart O O 0.877971887588501
rate O O 0.9777550101280212
( O O 0.9998323917388916
HR O O 0.8488499522209167
) O O 0.9924737215042114
, O O 0.9999388456344604
MAP O O 0.5618115067481995
, O O 0.9976587295532227
stroke B-Disease O 0.5005791187286377
volume O O 0.6065188050270081
( O O 0.9992325305938721
SV O O 0.6479853391647339
) O O 0.969636082649231
, O O 0.9998767375946045
cardiac O O 0.8798072934150696
output O O 0.6027386784553528
( O O 0.9985768795013428
CO O O 0.6841979622840881
) O O 0.9869499802589417
, O O 0.9999184608459473
and O O 0.9999229907989502
frontal O O 0.9342420697212219
lobe O O 0.7264467477798462
oxygenation O O 0.7330767512321472
( O O 0.9965425133705139
S O O 0.9840494394302368
( O O 0.9990665316581726
c O O 0.9982495903968811
) O O 0.9995712637901306
O O O 0.9978119134902954
( O O 0.9998936653137207
2 O O 0.9986175298690796
) O O 0.9985421895980835
) O O 0.9998846054077148
were O O 0.9999938011169434
registered O O 0.9999485015869141
. O O 0.9999991655349731

Egr-3 S-protein S-protein 0.838900089263916
, O O 0.9984452128410339
regulates O O 0.9992007613182068
FasL S-protein S-protein 0.9852369427680969
expression O O 0.997494101524353
in O O 0.9998446702957153
activated O B-cell_type 0.4963894784450531
normal O I-cell_type 0.45564159750938416
T B-cell_type I-cell_type 0.7236860394477844
cells E-cell_type E-cell_type 0.9237895607948303
, O O 0.988976776599884
and O O 0.9997289776802063
Egr-2 S-protein S-protein 0.8566591143608093
is O O 0.9994621872901917
likely O O 0.9997819066047668
to O O 0.9999319314956665

of O O 0.9925994873046875
PU.1 S-protein S-protein 0.9193791747093201
, O O 0.9989768266677856
indicating O O 0.999982476234436
that O O 0.9999898672103882
PU.1 S-protein S-protein 0.9833057522773743
can O O 0.9997523427009583
block O O 0.9997681975364685
erythroid O O 0.7809698581695557
differentiation O O 0.9869993329048157
. O O 0.9999881982803345
Here O O 0.9999315738677979
we O O 0.9999969005584717
investigate O O 0.9999949932098389
the O O 0.9999876022338867
mechanism O O 0.9987654685974121
by O O 0.999993085861206
which O O 0.9999774694442749
PU.1 S-protein S-protein 0.9422969222068787
interferes O O 0.9992852807044983
with O O 0.9999736547470093
erythroid O O 0.7300480604171753
differentiation O O 0.9744200706481934
. O O 0.9999823570251465
We O O 0.9999852180480957
find O O 0.999997615814209
that O O 0.9999920129776001
PU.1 S-protein S-protein 0.9121359586715698
interacts O O 0.9989386200904846
directly O O 0.9999099969863892
with O O 0.9999806880950928
GATA-1 S-protein S-protein 0.9617792963981628
, O O 0.9994122982025146
a O O 0.9999560117721558
zinc B-protein B-protein 0.48369789123535156
finger I-protein I-protein 0.6989059448242188
transcription I-protein I-protein 0.922586977481842
factor E-protein E-protein 0.9568249583244324

the O O 0.9967191815376282
ecto-5'-nucleotidase B-DNA B-DNA 0.6303454041481018
promoter E-DNA E-DNA 0.9971895813941956
. O O 0.999359667301178
Role O O 0.9370652437210083
of O O 0.9974831938743591
the O O 0.9998052716255188
camp B-DNA B-DNA 0.4453947842121124
response I-DNA I-DNA 0.6455407738685608
element I-DNA I-DNA 0.7046566605567932
site E-DNA E-DNA 0.9720485806465149
in O O 0.998815655708313
mediating O O 0.9756594896316528
repression O O 0.9817725419998169
by O O 0.9999861717224121
the O O 0.9997608065605164
upstream B-DNA B-DNA 0.4779534637928009
regulatory I-DNA I-DNA 0.6946687698364258
region E-DNA E-DNA 0.9106404185295105
. O O 0.9998853206634521
We O O 0.9955394864082336

accumulation O O 0.9736851453781128

1 O O 0.5791164636611938

primary B-DNA O 0.7274308800697327
restriction I-DNA O 0.9236526489257812
elements E-DNA O 0.5569460391998291
for O O 0.9996262788772583
lectin-like O O 0.5451037287712097
, O O 0.9598860144615173
gliadin O O 0.8062490820884705
peptides O O 0.94328773021698
while O O 0.9999947547912598
the O O 0.9999958276748657
degree O O 0.9995878338813782
of O O 0.999955415725708
immune O O 0.9436658620834351
suppression O O 0.969897985458374
( O O 0.9994428753852844
or O O 0.999496579170227

METHODS O O 0.9826622009277344
: O O 0.9998891353607178
Cholinergic O O 0.5727805495262146
convulsant O O 0.5335874557495117
sensitivity O O 0.5433791279792786
was O O 0.9996408224105835
examined O O 0.9999551773071289
in O O 0.9999871253967285
alcohol B-Chemical B-Chemical 0.9209275245666504
- O O 0.7702841758728027
na O B-Chemical 0.6675372123718262
ve O O 0.9312517642974854
Withdrawal O O 0.7445789575576782
Seizure B-Disease O 0.5119621157646179
- O O 0.9259858131408691
Prone O O 0.7962216734886169
( O O 0.9996069073677063
WSP O O 0.6159791350364685
) O O 0.9913978576660156
and O O 0.9999270439147949
- O O 0.9993163347244263
Resistant O O 0.9738171696662903
( O O 0.9998787641525269
WSR O O 0.8185524940490723
) O O 0.9920951724052429
mice O O 0.9976656436920166
. O O 0.9999994039535522

Comparison O O 0.9964190721511841
of O O 0.9998760223388672
developmental O O 0.9631202816963196
toxicity O O 0.761056125164032
of O O 0.8688497543334961
selective O O 0.8581874370574951
and O O 0.9920777678489685
non O O 0.989093542098999
- O O 0.9992102384567261
selective O O 0.9669773578643799
cyclooxygenase O O 0.6671923398971558
- O O 0.7283908724784851
2 O O 0.7536669373512268
inhibitors O O 0.5737836956977844
in O O 0.9995216131210327
CRL O O 0.6738366484642029
: O O 0.9408676028251648
( O O 0.9984374642372131
WI O O 0.7953916788101196
) O O 0.9960711002349854
WUBR O O 0.8922336101531982
Wistar O O 0.8715941309928894
rats O O 0.9990853071212769
- O O 0.9920533895492554
- O O 0.961137592792511
DFU S-Chemical B-Chemical 0.48800382018089294
and O O 0.989593505859375
piroxicam S-Chemical B-Chemical 0.9258498549461365
study O O 0.9789966344833374
. O O 0.9999929666519165

polyamides O O 0.43565693497657776
inhibit O O 0.9987142086029053
virus O O 0.9408298134803772
replication O O 0.9883670210838318
by O O 0.999990701675415
> O O 0.9992782473564148
99 O O 0.9952859282493591
% O O 0.9995706677436829
in O O 0.9997528195381165
isolated B-cell_type B-cell_type 0.49237945675849915
human I-cell_type I-cell_type 0.5442146062850952
peripheral I-cell_type I-cell_type 0.7756695747375488
blood I-cell_type I-cell_type 0.8761946558952332
lymphocytes E-cell_type E-cell_type 0.8783040046691895
, O O 0.9963783621788025
with O O 0.999983549118042
no O O 0.9970856308937073

activation O O 0.9743044972419739
of O O 0.999680757522583
an O O 0.999862790107727
H7-inhibitable O O 0.6092147827148438
pathway O O 0.9097248315811157
. O O 0.9999653100967407
By O O 0.99996018409729
using O O 0.9999591112136841
the O O 0.9999731779098511
protein O O 0.7760691046714783
synthesis O O 0.6836662292480469
inhibitor O O 0.6953164339065552
cycloheximide O O 0.7524102330207825
, O O 0.9997139573097229
it O O 0.9999790191650391
was O O 0.9999808073043823
shown O O 0.9999891519546509
that O O 0.9999929666519165
G O O 0.7109516263008118
( O O 0.9859603643417358
Anh O O 0.9676089286804199
) O O 0.9980579018592834
MTetra-induced O O 0.9340308904647827
IL-6 B-RNA B-RNA 0.3947772979736328
mRNA E-RNA E-RNA 0.9815865159034729
expression O O 0.9898542761802673
depends O O 0.9999973773956299
on O O 0.999985933303833
the O O 0.9999594688415527
synthesis O O 0.9623256325721741

These O O 0.9996470212936401
observations O O 0.9988558292388916
suggest O O 0.9999967813491821
that O O 0.9999724626541138
rigidity O B-Disease 0.9791712164878845
should O O 0.9783635139465332
be O O 0.9996994733810425
prevented O O 0.9996689558029175
when O O 0.9999918937683105
alfentanil S-Chemical B-Chemical 0.9250349402427673
, O O 0.9716196060180664
and O O 0.9997232556343079
, O O 0.999920129776001
presumably O O 0.9999220371246338
, O O 0.9999758005142212
other O O 0.9998200535774231
opiates O O 0.9061873555183411
, O O 0.9998663663864136
are O O 0.9999890327453613
used O O 0.9999685287475586
in O O 0.9999887943267822
the O O 0.9998096823692322
anesthetic O O 0.7232738733291626
management O O 0.9592056274414062
of O O 0.9985628724098206
patients O O 0.9995841383934021
with O O 0.9999935626983643
ICP O O 0.8178508877754211
problems O O 0.9265730977058411
. O O 0.999710738658905

She O O 0.9328680634498596
was O O 0.9988422989845276
treated O O 0.9999933242797852
with O O 0.999984860420227
heparin B-Chemical B-Chemical 0.9255302548408508
, O O 0.9209973812103271
dipyridamole B-Chemical B-Chemical 0.930414617061615
and O O 0.9835091233253479
hemodialysis O O 0.9331322312355042
; O O 0.9866983890533447
and O O 0.9998006224632263
after O O 0.9997333884239197
more O O 0.9999089241027832
than O O 0.9999608993530273
three O O 0.9999780654907227
months O O 0.9999467134475708
, O O 0.9999912977218628
her O O 0.9992700219154358
urinary O O 0.9677643775939941
output O O 0.9588518142700195
rose O O 0.9995808005332947
above O O 0.9995166063308716
500 O O 0.9983118772506714
ml O O 0.9981231093406677
; O O 0.9999802112579346
and O O 0.9999853372573853
six O O 0.9999525547027588
months O O 0.9999728202819824
after O O 0.9999967813491821
the O O 0.9999843835830688
onset O O 0.9873372912406921
of O O 0.9996101260185242
anuria B-Disease B-Disease 0.9674919247627258
, O O 0.9908059239387512
dialysis O O 0.577150821685791
treatment O O 0.9320879578590393
was O O 0.9999626874923706
stopped O O 0.9988340735435486
. O O 0.9999986886978149

[ I-DNA I-DNA 0.7967976927757263
AP-1 I-DNA I-DNA 0.696306586265564
] I-DNA I-DNA 0.5246613025665283
site E-DNA E-DNA 0.9526523351669312
at O O 0.9997130036354065
-72 S-DNA O 0.6005775928497314
abolished O O 0.9490779638290405
basal B-DNA O 0.8273735642433167
promoter E-DNA O 0.5844787955284119
activity O O 0.9670119285583496
and O O 0.9996902942657471
LPS/zymosan O O 0.35438719391822815
inducibility O O 0.935935378074646
, O O 0.9998794794082642
while O O 0.9999693632125854
mutagenesis O O 0.9493604898452759
of O O 0.9991707801818848
an O O 0.9981573224067688

identified O O 0.9961611032485962
as O O 0.9999721050262451
the O O 0.9999376535415649
main O O 0.9661570191383362
cellular O O 0.9325571656227112
source O O 0.9461987018585205
for O O 0.9996711015701294
critical O B-protein 0.9271318912506104
inflammatory B-protein I-protein 0.7052473425865173
mediators E-protein E-protein 0.9234864115715027
such O O 0.9993483424186707
as O O 0.9999836683273315
tumor B-protein B-protein 0.41176319122314453
necrosis I-protein I-protein 0.8386840224266052
factor-alpha E-protein E-protein 0.9721437692642212
, O O 0.9964002370834351
the O O 0.9998544454574585
chemokines S-protein B-protein 0.8222700953483582
interleukin B-protein I-protein 0.41596296429634094
( I-protein I-protein 0.839625895023346
IL I-protein I-protein 0.6081759929656982
) I-protein I-protein 0.7957163453102112
-8 I-protein I-protein 0.9351638555526733
and I-protein I-protein 0.8085037469863892
-6 E-protein E-protein 0.8708692789077759
, O O 0.9463251829147339
and O O 0.9947264790534973
matrix B-protein B-protein 0.5063736438751221
metalloproteinase-9 E-protein E-protein 0.8487921953201294
in O O 0.9963259100914001

Their O O 0.9985925555229187
affinity O O 0.9943775534629822
for O O 0.9999561309814453
the O O 0.999927282333374
vitamin B-protein B-protein 0.4552668631076813
D-binding I-protein I-protein 0.9059987664222717
protein E-protein E-protein 0.9870070219039917
, O O 0.9965059757232666
however O O 0.9999091625213623
, O O 0.9999631643295288
increased O O 0.9996997117996216
up O O 0.9991102814674377
to O O 0.9995999932289124
4-fold O O 0.9970747232437134
. O O 0.9999969005584717
The O O 0.9999958276748657
biological O O 0.9784076809883118
activity O O 0.9991044402122498
of O O 0.9999808073043823
11 O O 0.8953826427459717
alpha-methyl-1 O O 0.8198179006576538
alpha O O 0.5438781380653381
, O O 0.9949502944946289
25- O O 0.9919219017028809
( O O 0.9981396198272705
OH O O 0.9772989153862
) O O 0.9980658888816833
2D3 O O 0.9776588082313538
closely O O 0.9975391626358032
resembled O O 0.9998996257781982
that O O 0.9999934434890747
of O O 0.9999568462371826
the O O 0.9999010562896729
natural O O 0.8579432368278503
hormone O O 0.8308690190315247
on O O 0.9976752400398254
normal O O 0.49372628331184387
and O O 0.8481142520904541
leukemic B-cell_type O 0.4837127923965454
cell E-cell_type O 0.39135679602622986

Immunohistochemistry O O 0.6024976372718811
with O O 0.9989404082298279
monoclonal O O 0.8967568278312683
antibodies O O 0.5576893091201782
against O O 0.9990381002426147
neurofilament O O 0.3467998504638672
( O O 0.9720662236213684
NF O O 0.7744297981262207
) O O 0.9684208631515503
proteins O O 0.7537481188774109
of O O 0.9926180243492126
middle O O 0.9018351435661316
and O O 0.9934971332550049
high O O 0.9801586270332336
molecular O O 0.9447475075721741
weight O O 0.9104186296463013
class O O 0.8409810066223145
, O O 0.9996933937072754
NF O O 0.9562250971794128
- O O 0.994350016117096
M O O 0.9643032550811768
and O O 0.9998939037322998
NF O O 0.955980122089386
- O O 0.9919501543045044
H O O 0.8314003348350525
, O O 0.9998158812522888
was O O 0.9999719858169556
used O O 0.9999957084655762
to O O 0.9999971389770508
study O O 0.9997327923774719
axonal B-Disease O 0.6258590221405029
injury I-Disease O 0.8729274272918701
in O O 0.9787527322769165
the O O 0.9922412633895874
borderzone O O 0.7994206547737122
of O O 0.9933674931526184
focal O O 0.6702027320861816
lesions O O 0.8019216656684875
in O O 0.9949015378952026
rats O O 0.9939263463020325
. O O 0.9999977350234985

of O O 0.9920989274978638
Stat3 S-protein S-protein 0.9917207956314087
but O O 0.9971368312835693
not O O 0.9992918968200684
for O O 0.9995967745780945
Stat1 S-protein S-protein 0.9897260069847107
or O O 0.9975453019142151
Stat5 S-protein S-protein 0.9815633296966553
. O O 0.9998592138290405
Twelve O O 0.9989122152328491
amino O O 0.8925803899765015
acid O O 0.7218697667121887
peptides O O 0.5579120516777039
encompassing O O 0.9993234872817993
either O O 0.9999417066574097
of O O 0.9999768733978271
these O O 0.9999834299087524
two O O 0.9931591153144836
tyrosine O O 0.6112199425697327
residues O O 0.7360851764678955
in O O 0.999408483505249
phosphorylated B-protein O 0.6289919018745422
form E-protein O 0.5336533784866333
coprecipitated O O 0.9194579124450684
Stat3 S-protein S-protein 0.8660624623298645

their O O 0.9901922941207886
transcription B-protein B-protein 0.6023284196853638
factors E-protein E-protein 0.9946867227554321
, O O 0.9991710186004639
and O O 0.9999939203262329
that O O 0.9999982118606567
the O O 0.9999825954437256
commitment O O 0.9968516230583191
to O O 0.9999128580093384
fetal O O 0.8295045495033264
or O O 0.9805033206939697
adult O O 0.9453386664390564
program O O 0.9905104041099548
occurs O O 0.9999432563781738
at O O 0.9999991655349731
a O O 0.9999909400939941
very O O 0.9979591369628906
early O O 0.9751920700073242
differentiation O O 0.9566720724105835
stage O O 0.9885038733482361

cellular B-DNA B-DNA 0.6311143636703491
genes E-DNA E-DNA 0.9840369820594788
. O O 0.9998812675476074
In O O 0.9999936819076538
this O O 0.9999954700469971
study O O 0.9999160766601562
, O O 0.9999933242797852
we O O 0.9999176263809204
show O O 0.9999963045120239
that O O 0.9999958276748657
MIP-1alpha S-protein S-protein 0.9658502340316772
is O O 0.999081015586853
selectively O O 0.9973554611206055
expressed O O 0.9994217157363892
and O O 0.9998860359191895
secreted O O 0.9970455765724182
in O O 0.9999563694000244
the O O 0.9998942613601685
tax B-cell_line B-cell_line 0.4159682095050812
transfected I-cell_line I-cell_line 0.4690555930137634
Jurkat I-cell_line I-cell_line 0.5329279899597168
cell I-cell_line I-cell_line 0.7387322187423706
line E-cell_line E-cell_line 0.9867047071456909
upon O O 0.9989743232727051
mitogen S-protein O 0.33254799246788025
stimulation O O 0.9601228833198547
. O O 0.9999673366546631
Expression O O 0.9982615113258362
of O O 0.999813973903656
MIP-1alpha-R B-RNA B-RNA 0.9368611574172974
mRNA E-RNA E-RNA 0.9964743256568909
in O O 0.9991894364356995
these O O 0.9995446801185608
cells O O 0.9743874669075012
suggests O O 0.9999935626983643
an O O 0.9999920129776001
autocrine O O 0.9379978775978088
role O O 0.9864349365234375
for O O 0.9999589920043945
this O O 0.9998618364334106
chemokine S-protein S-protein 0.9289228320121765
in O O 0.9996476173400879
HTLV-I B-cell_type B-cell_type 0.3603537678718567
infected I-cell_type I-cell_type 0.45565372705459595
T-cells E-cell_type E-cell_type 0.635532021522522
. O O 0.999708354473114
Induced O O 0.9925966262817383
MIP-1alpha S-protein S-protein 0.9664554595947266
expression O O 0.996964156627655
and O O 0.9998893737792969
secretion O O 0.9750969409942627
in O O 0.9996132254600525
PMA/PHA B-cell_line S-cell_line 0.730346143245697
stimulated I-cell_line O 0.9066804051399231

a O O 0.99791020154953
similar O O 0.9996100068092346
degree O O 0.9996517896652222
of O O 0.999962568283081
reduction O O 0.9933759570121765
in O O 0.9992474317550659
lymphocyte O O 0.7161888480186462
proliferation O O 0.9696826338768005
and O O 0.9993526339530945
IFN-gamma S-protein S-protein 0.9854126572608948
production O O 0.9986445307731628
in O O 0.9999765157699585
the O O 0.9997127652168274
allogeneic B-cell_line B-cell_line 0.3796321153640747
mixed I-cell_line I-cell_line 0.3601374328136444
lymphocyte I-cell_line I-cell_line 0.42701396346092224
cultures E-cell_line E-cell_line 0.9787771701812744
. O O 0.9999148845672607
These O O 0.9999966621398926
data O O 0.9992695450782776
support O O 0.9999940395355225
the O O 0.9999980926513672
conclusion O O 0.9999940395355225
that O O 0.9999973773956299
CN S-protein S-protein 0.917564332485199
activity O O 0.9977073669433594
is O O 0.9999959468841553
rate-limiting O O 0.9990617632865906
for O O 0.9999903440475464
the O O 0.9999450445175171
activation O O 0.9886670112609863
of O O 0.9997987151145935
primary B-cell_type B-cell_type 0.7841795682907104
human I-cell_type I-cell_type 0.8380934596061707
T I-cell_type I-cell_type 0.9337835311889648
lymphocytes E-cell_type E-cell_type 0.9730479121208191
. O O 0.9997515082359314

Acetaminophen S-Chemical B-Chemical 0.9252976775169373
- O O 0.9387425184249878
induced O O 0.9972561001777649
hypotension O B-Disease 0.9850785732269287
. O O 0.9980685114860535

A O O 0.9903443455696106
single O O 0.9943912625312805
MPEP S-Chemical B-Chemical 0.9241288900375366
( O O 0.9854304790496826
5 O O 0.9975782036781311
mg O O 0.999396800994873
/ O O 0.999954342842102
kg O O 0.9993219375610352
ip O O 0.9190537333488464
) O O 0.9928273558616638
injection O O 0.9836544394493103
reduced O O 0.9995545744895935
the O O 0.9998382329940796
basal O O 0.9734708666801453
extracellular O O 0.9683836698532104
dopamine S-Chemical B-Chemical 0.9306299686431885
level O O 0.9939664602279663
in O O 0.999992847442627
the O O 0.9997414946556091
striatum O O 0.6821396350860596
, O O 0.999285876750946
as O O 0.9999852180480957
well O O 0.9998195767402649
as O O 0.9999916553497314
dopamine S-Chemical B-Chemical 0.9286659359931946
release O O 0.9407575130462646
stimulated O O 0.9967166781425476
either O O 0.9999200105667114
by O O 0.9998927116394043
methamphetamine S-Chemical B-Chemical 0.931133508682251
( O O 0.9911045432090759
10 O O 0.9992460012435913
mg O O 0.9996479749679565
/ O O 0.999972939491272
kg O O 0.999755322933197
sc O O 0.9915748238563538
) O O 0.9996410608291626
or O O 0.9999825954437256
by O O 0.9999808073043823
intrastriatally O O 0.9043528437614441
administered O O 0.9590480327606201
veratridine S-Chemical B-Chemical 0.9370087385177612
( O O 0.9924730062484741
100 O O 0.9969623684883118
microM O O 0.9868592023849487
) O O 0.9995179176330566
. O O 0.9999979734420776

autologous B-cell_type B-cell_type 0.5866875648498535
CD4+ I-cell_type I-cell_type 0.49291980266571045
T I-cell_type I-cell_type 0.8005567193031311
cells E-cell_type E-cell_type 0.6818031668663025
were O O 0.9994003772735596
isolated O O 0.9984839558601379
from O O 0.9999591112136841
peripheral O O 0.527959406375885
blood O O 0.5105219483375549
by O O 0.9976547956466675
a O O 0.9999419450759888
series O O 0.9820894002914429
of O O 0.9994412064552307
density-gradient O O 0.7123885154724121
centrifugations O O 0.5829971432685852
or O O 0.997564435005188
magnetic O O 0.7063473463058472
bead O O 0.4981271028518677
separations O O 0.7316777110099792
( O O 0.9970462918281555
or O O 0.9997256398200989
both O O 0.999872088432312
) O O 0.9986053109169006
. O O 0.9999634027481079
Peptides O O 0.4646569490432739
corresponding O O 0.9994608759880066
to O O 0.9999655485153198
residues O O 0.9403855800628662
of O O 0.9972903728485107
the O O 0.9993636012077332

analysis O O 0.9857251644134521

. O O 0.9947293400764465
Moreover O O 0.999903678894043
, O O 0.9999810457229614
in O O 0.9999839067459106
a O O 0.9999674558639526
physiological O O 0.9243989586830139
coculture O O 0.9019001126289368
cellular O O 0.9628227949142456
assay O O 0.9863595366477966
system O O 0.9883795976638794
, O O 0.9999958276748657
we O O 0.9999746084213257
show O O 0.9999972581863403
that O O 0.999996542930603
membrane-bound B-protein O 0.6530489921569824
TNF-alpha E-protein S-protein 0.6599435806274414
and O O 0.9848158359527588
LT-alpha1beta2 S-protein S-protein 0.6862905025482178
act O O 0.7443680167198181
virtually O O 0.9995309114456177
identically O O 0.998138427734375
to O O 0.9990062117576599

Male O O 0.9311547875404358
rats O O 0.993687093257904
that O O 0.9999858140945435
received O O 0.9998363256454468
prenatal O O 0.8805469274520874
dexamethasone B-Chemical B-Chemical 0.9215061664581299
on O O 0.9988526105880737
days O O 0.9998812675476074
15 O O 0.999798595905304
and O O 0.9998691082000732
16 O O 0.9990704655647278
, O O 0.9999697208404541
17 O O 0.9996108412742615
and O O 0.9998657703399658
18 O O 0.9975711703300476
, O O 0.9999139308929443
and O O 0.9999368190765381
13 O O 0.9973580241203308
and O O 0.9998691082000732
14 O O 0.9983749389648438
of O O 0.9997958540916443
gestation O O 0.7415791153907776
had O O 0.9967153072357178
elevated B-Disease O 0.9790985584259033
blood I-Disease O 0.8631533980369568
pressures I-Disease O 0.5184355974197388
at O O 0.9998596906661987
6 O O 0.9996685981750488
months O O 0.9999725818634033
of O O 0.9999600648880005
age O O 0.999908447265625
; O O 0.999997615814209
the O O 0.9999697208404541
latter O O 0.9992340803146362
group O O 0.9994107484817505
did O O 0.9999946355819702
not O O 0.9999326467514038
have O O 0.9999892711639404
a O O 0.9997355341911316
reduction B-Disease O 0.9439650774002075
in I-Disease O 0.9924060702323914
glomerular I-Disease O 0.7373781204223633
number I-Disease O 0.7358256578445435
. O O 0.9999464750289917

H2O2 O O 0.24197033047676086
treatment O O 0.9694406986236572
of O O 0.9995483756065369
cells O O 0.9355853796005249
from O O 0.9999700784683228
its O O 0.9999333620071411
inactive B-protein O 0.8884585499763489
cytoplasmic I-protein O 0.6533282995223999
form E-protein O 0.7103895545005798
. O O 0.9994456171989441
N-acetyl-L-cysteine O O 0.7547661066055298
( O O 0.9909363389015198
NAC O O 0.7914860248565674
) O O 0.987646222114563
, O O 0.9998441934585571
a O O 0.9998353719711304

Jaundice B-Disease B-Disease 0.9509932994842529
disappeared O O 0.578163743019104
within O O 0.9969750642776489
3 O O 0.9985160231590271
months O O 0.9997288584709167
but O O 0.9999510049819946
was O O 0.9998202919960022
followed O O 0.9999943971633911
by O O 0.9999889135360718
prolonged O O 0.9717403650283813
anicteric O O 0.7240654230117798
cholestasis B-Disease O 0.6808924674987793
marked O O 0.9696609973907471
by O O 0.9996761083602905
pruritus B-Disease O 0.48596256971359253
and O O 0.9865285158157349
high O O 0.9284408688545227
levels O O 0.9854553937911987
of O O 0.9997661709785461
alkaline O O 0.7290589213371277
phosphatase O O 0.64597487449646
and O O 0.995521068572998
gammaglutamyltransferase O O 0.4112163186073303
activities O O 0.9300119280815125
. O O 0.9999970197677612

human B-cell_type B-cell_type 0.40351927280426025
epithelial I-cell_type I-cell_type 0.8991972804069519
cells E-cell_type E-cell_type 0.9506036043167114
will O O 0.9994303584098816
benefit O O 0.9997634291648865
. O O 0.9999972581863403
Reverse O O 0.944851815700531
transcription-PCR O O 0.8768836855888367
analysis O O 0.9993607401847839
showed O O 0.9999978542327881
that O O 0.9999988079071045
all O O 0.9998481273651123
seven O O 0.9961836934089661
EBV-positive O B-protein 0.33648139238357544
tumour O I-protein 0.4288942217826843
tissues O E-protein 0.6536556482315063
constitutively O O 0.8496386408805847
expressed O O 0.9882670044898987
EBV B-RNA B-RNA 0.7854774594306946
nuclear I-RNA I-RNA 0.9289225339889526
antigen I-RNA I-RNA 0.9799652099609375
( I-RNA I-RNA 0.9808701872825623
EBNA I-RNA I-RNA 0.9959487915039062
) I-RNA I-RNA 0.9950311183929443
1 I-RNA I-RNA 0.9851862788200378
mRNA E-RNA E-RNA 0.9487341642379761
, O O 0.9921563863754272
but O O 0.9998310804367065
not O O 0.998874843120575
EBNA2 B-RNA B-RNA 0.8941364884376526
mRNA E-RNA E-RNA 0.9971857666969299
. O O 0.999819815158844
The O O 0.9999924898147583
EBNA S-protein S-protein 0.435585618019104
transcription O O 0.5083397626876831
was O O 0.9963194131851196
initiated O O 0.9999598264694214

in O O 0.9981371164321899
terminal B-cell_type O 0.8054739236831665
granulocyte E-cell_type O 0.4762806296348572
differentiation O O 0.9786348342895508
or O O 0.9996926784515381
in O O 0.9995595812797546
regulating O O 0.9605947732925415
granulocyte S-cell_type O 0.5282076597213745
functionality O O 0.975411593914032
. O O 0.9999866485595703
The O O 0.999963641166687
29-kDa B-protein B-protein 0.5677911043167114
proteins E-protein E-protein 0.9876282215118408
phosphorylated O O 0.8934917449951172
in O O 0.9995673298835754
thrombin-activated B-cell_line B-cell_line 0.5006784200668335
human I-cell_line I-cell_line 0.6692419648170471
platelets E-cell_line E-cell_line 0.617283284664154
are O O 0.999461829662323
forms O O 0.999392032623291
of O O 0.9999749660491943
the O O 0.999924898147583
estrogen B-protein B-protein 0.31370121240615845
receptor-related I-protein I-protein 0.48017504811286926
27-kDa I-protein I-protein 0.5505513548851013
heat I-protein I-protein 0.7947308421134949
shock I-protein I-protein 0.9063899517059326
protein E-protein E-protein 0.9833667278289795
. O O 0.998289167881012
Thrombin S-protein S-protein 0.9883520007133484
plays O O 0.9966891407966614
a O O 0.9998981952667236

T-cell I-cell_line I-cell_line 0.2083369493484497
clones E-cell_line E-cell_line 0.9826739430427551
stably O O 0.9973136782646179
expressing O O 0.9996840953826904
the O O 0.9998362064361572
tax O B-DNA 0.4722250699996948
gene O E-DNA 0.9846732020378113
. O O 0.999864935874939
The O O 0.9999967813491821
effect O O 0.999866247177124
of O O 0.9999514818191528
Tax S-protein S-protein 0.9863110184669495
on O O 0.9993657469749451
VCAM-1 S-protein B-DNA 0.620262086391449
gene O E-DNA 0.8712987899780273
transcription O O 0.8605765700340271
was O O 0.9998699426651001
next O O 0.9999657869338989
confirmed O O 0.9999287128448486
in O O 0.9999693632125854
JPX-9 B-cell_line B-cell_line 0.5022000074386597

We O O 0.9993357062339783
now O O 0.9999985694885254
advocate O O 0.9999860525131226
that O O 0.9999881982803345
before O O 0.9995675683021545
age O O 0.9998477697372437
50 O O 0.9998774528503418
years O O 0.9999802112579346
testosterone S-Chemical B-Chemical 0.9266831874847412
be O O 0.9994718432426453
determined O O 0.9999910593032837
only O O 0.9999982118606567
in O O 0.99998939037323
cases O O 0.9995753169059753
of O O 0.9999629259109497
low O O 0.9084423780441284
sexual O O 0.7008174657821655
desire O O 0.9493674635887146
and O O 0.9531196355819702
abnormal O O 0.9386719465255737
physical O O 0.8984043598175049
examination O O 0.813564658164978
but O O 0.9998319149017334
that O O 0.9999942779541016
it O O 0.9998897314071655
be O O 0.9999856948852539
measured O O 0.9999394416809082
in O O 0.9999852180480957
all O O 0.9999644756317139
men O O 0.9970158338546753
older O O 0.9999192953109741
than O O 0.9999760389328003
50 O O 0.9999291896820068
years O O 0.9999867677688599
. O O 0.999998927116394

memory B-cell_type B-cell_type 0.3997139036655426
T I-cell_type I-cell_type 0.8305762410163879
cells E-cell_type E-cell_type 0.9585868716239929
are O O 0.999349057674408
not O O 0.9999457597732544
significantly O O 0.9999243021011353
altered O O 0.9998107552528381
in O O 0.9999804496765137
their O O 0.9998679161071777
responsiveness O O 0.9987978935241699
to O O 0.9999871253967285
TNF-alpha S-protein S-protein 0.9980815649032593
-mediated O O 0.9959463477134705
induction O O 0.9991093277931213
of O O 0.9999548196792603
NFkappaB S-protein S-protein 0.9885126352310181
. O O 0.9998095631599426
Although O O 0.9999821186065674
treatment O O 0.9995457530021667
with O O 0.9999812841415405
TNF-alpha S-protein S-protein 0.9915192723274231
induced O O 0.9962347149848938
nuclear O O 0.9214733839035034
localization O O 0.958122730255127
of O O 0.9987319111824036

immune O O 0.874965250492096
response O O 0.9914692044258118
. O O 0.9999845027923584
Protein O B-protein 0.8258119821548462
tyrosine B-protein I-protein 0.4500542879104614
kinases E-protein E-protein 0.972011387348175
transmit O O 0.9638509750366211
signals O O 0.9923186302185059
from O O 0.9999630451202393
cytokine B-protein S-protein 0.93611741065979
and I-protein O 0.9893205165863037
immune I-protein B-protein 0.7657626867294312
receptors E-protein E-protein 0.9662164449691772
. O O 0.9995520710945129
Very O O 0.9987358450889587
little O O 0.9983770847320557
information O O 0.9988716244697571
exists O O 0.9999641180038452
linking O O 0.999955415725708
these O O 0.9999299049377441
two O O 0.9993754029273987
important O O 0.9945055842399597
classes O O 0.9797109961509705
of O O 0.9992489218711853
signaling B-protein B-protein 0.6377755403518677
molecules E-protein E-protein 0.986362636089325
. O O 0.9998364448547363
We O O 0.9999724626541138
now O O 0.9999984502792358
demonstrate O O 0.9999959468841553
that O O 0.9999881982803345
v-src S-DNA S-DNA 0.6644367575645447
expression O O 0.9921489953994751
correlates O O 0.9999550580978394
with O O 0.9999833106994629
nuclear O O 0.8900983333587646
expression O O 0.9672064781188965
of O O 0.9992673993110657
a O O 0.9994407296180725
kappa B-protein B-protein 0.5010080933570862
B I-protein I-protein 0.47398877143859863
binding I-protein I-protein 0.6301999688148499
complex E-protein E-protein 0.7965651750564575
similar O O 0.8256496787071228

PML S-protein S-cell_type 0.3426416218280792

Out O O 0.9992796778678894
of O O 0.9999850988388062
these O O 0.999987006187439
67 O O 0.9735749363899231
proteins O O 0.9658877849578857
, O O 0.9999772310256958
LID B-Disease O 0.494710773229599
significantly O O 0.9981985688209534
changed O O 0.9991500377655029
the O O 0.9996486902236938
expression O O 0.9297735095024109
level O O 0.9992685914039612
of O O 0.999982476234436
five O O 0.9964602589607239
proteins O O 0.9871705174446106
: O O 0.99989914894104
alphabeta O O 0.8769540786743164
- O O 0.9618455171585083
crystalin O O 0.4800361096858978
, O O 0.9975735545158386
gamma O O 0.7073680758476257
- O O 0.6254125833511353
enolase O O 0.9246481657028198
, O O 0.9109421968460083
guanidoacetate O O 0.830177903175354
methyltransferase O O 0.8791243433952332
, O O 0.9666932225227356
vinculin O O 0.5991064310073853
, O O 0.9889501929283142
and O O 0.9998629093170166
proteasome O O 0.6135711073875427
alpha O O 0.51848965883255
- O O 0.7206254601478577
2 O O 0.7801930904388428
subunit O O 0.5727090835571289
. O O 0.9999752044677734

Hepatitis B-Disease O 0.6392108798027039
B I-Disease O 0.842095136642456
virus O O 0.8919010758399963
( O O 0.8755896687507629
HBV O O 0.42912617325782776
) O O 0.9196063876152039
is O O 0.9997404217720032
one O O 0.9999902248382568
of O O 0.9999904632568359
the O O 0.9999672174453735
major O O 0.995112955570221
causes O O 0.9989596605300903
of O O 0.9999809265136719
chronic O O 0.8567346930503845
liver B-Disease O 0.7458251118659973
disease I-Disease O 0.9421932101249695
worldwide O O 0.855056881904602
. O O 0.9999802112579346

. O O 0.9961372017860413
We O O 0.9999858140945435
report O O 0.9999972581863403
here O O 0.9999949932098389
that O O 0.9999994039535522
the O O 0.999971866607666
second O O 0.9771960973739624
alteration O O 0.9923892617225647
, O O 0.9999810457229614
at O O 0.9999889135360718
threonine O O 0.8312605619430542
78 O O 0.5631044507026672
, O O 0.995303750038147
also O O 0.9999302625656128
plays O O 0.9999575614929199
an O O 0.9999910593032837
important O O 0.99796462059021
, O O 0.9994193315505981
although O O 0.9995436072349548

Paget O O 0.8807862997055054
's O O 0.974266529083252
disease O O 0.9477008581161499
showed O O 0.9999924898147583
positive O O 0.977828860282898
reactions O O 0.978678286075592
for O O 0.9999632835388184
HER-2/neu S-protein S-protein 0.6528525948524475
. O O 0.9986829161643982
Basement O O 0.8999554514884949
membrane O O 0.8751358985900879
immunoreactivity O O 0.9889761209487915
for O O 0.9998792409896851
type B-protein O 0.7711241841316223
IV I-protein O 0.47059890627861023
collagen E-protein O 0.5794574022293091
and O O 0.9696691632270813
laminin S-protein O 0.49697554111480713
was O O 0.9996237754821777
discontinuous O O 0.9963346719741821
in O O 0.9999783039093018
most O O 0.9993676543235779
examples O O 0.9995750784873962
of O O 0.9999645948410034
IDC O O 0.33727335929870605
regardless O O 0.9997770190238953
of O O 0.9998973608016968
type O O 0.9013229012489319
, O O 0.997687578201294
with O O 0.9999874830245972
a O O 0.9998550415039062
trend O O 0.9981258511543274
toward O O 0.9999879598617554
more O O 0.9993321299552917
intense O O 0.9759490489959717
staining O O 0.9732426404953003
in O O 0.999599039554596
comedo O O 0.5162931084632874
than O O 0.9895692467689514
in O O 0.9978140592575073

lymphocytes E-cell_type E-cell_type 0.7980253100395203

In O O 0.9994984865188599
independent O O 0.9540678262710571
groups O O 0.9948915243148804
, O O 0.9999868869781494
morphine S-Chemical B-Chemical 0.9276087284088135
inhibited O O 0.9977604150772095
the O O 0.99973064661026
intestinal O O 0.8360687494277954
transit O O 0.5038174986839294
in O O 0.9990621209144592
48 O O 0.9984878301620483
+ O O 0.9999473094940186
/ O O 0.9999929666519165
- O O 0.9999650716781616
4 O O 0.9999455213546753
% O O 0.9999589920043945
and O O 0.9999741315841675
38 O O 0.9998583793640137
+ O O 0.9999767541885376
/ O O 0.9999958276748657
- O O 0.9999803304672241
4 O O 0.9999727010726929
% O O 0.9999717473983765
after O O 0.9999868869781494
acute O O 0.8129667639732361
and O O 0.9888498187065125
chronic O O 0.7336229681968689
treatment O O 0.9535602927207947
, O O 0.9999797344207764
respectively O O 0.9999730587005615
, O O 0.9999732971191406
suggesting O O 0.9999854564666748
that O O 0.9998587369918823
tolerance O O 0.5523898601531982
did O O 0.999007523059845
not O O 0.9998173117637634
develop O O 0.998306393623352
to O O 0.9999257326126099
the O O 0.9997360110282898
constipating O O 0.5066030621528625
effects O O 0.9571511745452881
. O O 0.9999964237213135

sequence E-DNA E-DNA 0.8874676823616028
are O O 0.9995083808898926
required O O 0.9998973608016968
for O O 0.9999912977218628
full O O 0.9900981783866882
promoter S-DNA O 0.8129782676696777
function O O 0.9936375617980957
. O O 0.9999947547912598
We O O 0.9999833106994629
also O O 0.9999939203262329
demonstrate O O 0.9999967813491821
that O O 0.999998927116394
the O O 0.9999173879623413
Myc-associated B-protein B-protein 0.45387792587280273
zinc I-protein I-protein 0.8266826868057251
finger I-protein I-protein 0.7458804845809937
protein E-protein E-protein 0.9941871166229248
( O O 0.990278422832489
MAZ S-protein S-protein 0.9880222082138062
) O O 0.9934349060058594
appears O O 0.9999303817749023
to O O 0.9999815225601196
be O O 0.9999558925628662

NF I-protein B-protein 0.428899347782135

are O O 0.9982621073722839
tandem B-DNA O 0.8690078854560852
CRE I-DNA B-DNA 0.6809722781181335
motifs E-DNA E-DNA 0.9206734299659729
, O O 0.9994518160820007
a O O 0.9995848536491394
Sp1 B-DNA B-DNA 0.5699202418327332
site E-DNA E-DNA 0.9710745215415955
, O O 0.9986530542373657
an O O 0.9999371767044067
overlapping O O 0.6931623816490173
Egr-1/Sp1 B-DNA B-DNA 0.4070023000240326

as O O 0.9995229244232178
subsequent O O 0.9906436800956726
monocytic O O 0.7119070291519165
cell O O 0.478302925825119
adhesion O O 0.9647766947746277
to O O 0.9995995163917542
endothelial B-cell_type B-cell_type 0.73637855052948
cells E-cell_type E-cell_type 0.9739313721656799
stimulated O O 0.9985222220420837
by O O 0.9999909400939941
TNF S-protein S-protein 0.9687923192977905
. O O 0.9999613761901855
Inhibition O O 0.9938685297966003
studies O O 0.9997783303260803
indicate O O 0.9999978542327881
that O O 0.9999880790710449

Valvular O O 0.5198904871940613
heart O O 0.6333394050598145
abnormalities O O 0.9625598192214966
have O O 0.9637925028800964
been O O 0.9986625909805298
reported O O 0.9999351501464844
in O O 0.9999598264694214
patients O O 0.9999288320541382
with O O 0.999969482421875
Parkinson O B-Disease 0.7835744619369507
' O I-Disease 0.6862521171569824
s O I-Disease 0.5865103602409363
disease O I-Disease 0.9831962585449219
( O O 0.8996163010597229
PD O B-Disease 0.9814531803131104
) O O 0.7014486193656921
treated O O 0.9799115061759949
with O O 0.9999462366104126
pergolide S-Chemical B-Chemical 0.9285843372344971
. O O 0.9996135830879211

Here O O 0.9980930685997009
, O O 0.9999957084655762
we O O 0.9999831914901733
show O O 0.9999957084655762
that O O 0.9999971389770508
ectopic O O 0.9175952672958374
expression O O 0.9924025535583496
of O O 0.9997299313545227
GATA-3 S-protein S-protein 0.9776232838630676
is O O 0.9997280240058899
sufficient O O 0.9999450445175171
to O O 0.9999778270721436
drive O O 0.9975179433822632
IL-5 S-protein S-protein 0.9836558103561401
but O O 0.9974159002304077
not O O 0.9995338916778564

nor O O 0.9718596935272217
the O O 0.9998465776443481
morphology O O 0.979273796081543
of O O 0.9996047616004944
apoptosis O O 0.9754343032836914
was O O 0.999966025352478
observed O O 0.9998472929000854
. O O 0.9999990463256836
These O O 0.9999959468841553
findings O O 0.9998255372047424
demonstrate O O 0.9999867677688599

Capsaicin S-Chemical B-Chemical 0.9330109357833862
( O O 0.988831102848053
10 O O 0.9930055737495422
micro O O 0.994744062423706
g O O 0.9927895665168762
) O O 0.9952221512794495
was O O 0.9999808073043823
injected O O 0.9998468160629272
into O O 0.9999865293502808
the O O 0.9995074272155762
masseter O O 0.944845974445343
muscle O O 0.9561918377876282
to O O 0.9999337196350098
induce O O 0.9989483952522278
pain O B-Disease 0.9690623879432678
in O O 0.9900450110435486
11 O O 0.9970340728759766
healthy O O 0.8633794784545898
volunteers O O 0.9900416731834412
. O O 0.9999985694885254

There O O 0.9997406601905823
was O O 0.999987006187439
a O O 0.9999873638153076
significant O O 0.9995144605636597
40 O O 0.9953327775001526
% O O 0.9995375871658325
improvement O O 0.9712883830070496
in O O 0.9984194040298462
the O O 0.9989417195320129
dyskinesia O O 0.9451409578323364
score O O 0.6162381768226624
without O O 0.999312162399292
increase O O 0.8318822979927063
of O O 0.9807842969894409
parkinsonian O O 0.5067641139030457
motor O O 0.5711922645568848
disability O O 0.9655953645706177
. O O 0.9979329109191895

Toxicity O B-Disease 0.9836925268173218
was O O 0.9827370643615723
mild O O 0.9805567264556885
. O O 0.9999903440475464

a O O 0.9944285154342651
transcription B-protein B-protein 0.725605845451355
factor E-protein E-protein 0.9770557880401611
( O O 0.9785147309303284
EGR1 S-protein S-protein 0.8827399611473083
) O O 0.9604433178901672
that O O 0.9999274015426636
links O O 0.9993775486946106
B-cell B-protein B-protein 0.47627484798431396
antigen I-protein I-protein 0.46164679527282715
receptor E-protein E-protein 0.9656869769096375
( O O 0.9594045281410217
BCR S-protein S-protein 0.9560767412185669
) O O 0.9502303600311279
signals O O 0.9851831793785095
to O O 0.9997181296348572

Five O O 0.9965147376060486
females O O 0.9828521609306335
and O O 0.9990715980529785
6 O O 0.9989387392997742
males O O 0.9922468662261963
, O O 0.9999572038650513
21 O O 0.9995076656341553
- O O 0.9998283386230469
59 O O 0.9998476505279541
years O O 0.9999817609786987
of O O 0.9998078942298889
age O O 0.9999167919158936
, O O 0.9999873638153076
were O O 0.9999849796295166
examined O O 0.999971866607666
with O O 0.9999816417694092
a O O 0.9995893836021423
1 O O 0.949044942855835
. O O 0.9982625842094421
5 O O 0.989596426486969
- O O 0.9929372668266296
T O O 0.9872952103614807
whole O O 0.9988683462142944
- O O 0.9997146725654602
body O O 0.9926168322563171
system O O 0.9966586828231812
using O O 0.9999954700469971
a O O 0.999894380569458
circular O O 0.8991952538490295
polarized O O 0.6875215768814087
head O O 0.8099485039710999
coil O O 0.5775856375694275
. O O 0.9999223947525024

SIR S-DNA S-protein 0.2847622036933899
( O O 0.9766808152198792
suppressor B-DNA O 0.6611760258674622
of I-DNA O 0.9768843054771423
immune I-DNA B-DNA 0.8396391272544861
response I-DNA I-DNA 0.7041320204734802
genes E-DNA E-DNA 0.9365723729133606
) O O 0.9846771955490112
, O O 0.9998769760131836
does O O 0.999985933303833
not O O 0.9999630451202393
act O O 0.9999762773513794
directly O O 0.9999608993530273
on O O 0.9999864101409912
the O O 0.9999395608901978
transcription O O 0.8503900766372681
of O O 0.9968585968017578
class B-DNA B-DNA 0.5939606428146362
II I-DNA I-DNA 0.7624838352203369
genes E-DNA E-DNA 0.9956569671630859
, O O 0.997546374797821
but O O 0.9999735355377197
instead O O 0.9999974966049194
on O O 0.9999890327453613
the O O 0.9999537467956543
transcription O O 0.9017238616943359
of O O 0.9983683228492737
the O O 0.9994361996650696
AIR-1 B-DNA B-DNA 0.5996034145355225
gene E-DNA E-DNA 0.9781790375709534
, O O 0.9958433508872986

The O O 0.9995073080062866
associated O O 0.9925925135612488
urinary O O 0.82732754945755
concentrating O O 0.7743324041366577
defect O O 0.6703281998634338
is O O 0.9938448667526245
reversible O O 0.9985528588294983
only O O 0.9999903440475464
during O O 0.9999865293502808
the O O 0.9999598264694214
early O O 0.9963478446006775
stages O O 0.9999234676361084
of O O 0.9999788999557495
structural O O 0.9046016335487366
damage O O 0.8728234171867371
to O O 0.9134343266487122
the O O 0.9270763993263245
inner O O 0.8896947503089905
medulla O O 0.5320323705673218
. O O 0.9998984336853027

activating I-protein I-protein 0.6324298977851868
factor E-protein E-protein 0.9281623363494873
and O O 0.8627167344093323
FMLP S-protein S-protein 0.8375644087791443
. O O 0.9994804263114929
Stimulation O O 0.9967969059944153
of O O 0.9998487234115601
human B-cell_type B-cell_type 0.5162349939346313
neutrophils E-cell_type E-cell_type 0.9755164980888367
with O O 0.9989802241325378
chemoattractants S-protein O 0.5130475163459778
FMLP S-protein S-protein 0.4087299406528473
or O O 0.9866805672645569
platelet B-protein B-protein 0.5647045373916626
activating I-protein I-protein 0.6234214901924133
factor E-protein E-protein 0.9233918786048889
( O O 0.9208617210388184
PAF S-protein S-protein 0.9546126127243042
) O O 0.915823221206665
results O O 0.9993472695350647
in O O 0.9999845027923584
different O O 0.997163712978363
but O O 0.9987030029296875
overlapping O O 0.9278895854949951
functional O O 0.9454475045204163
responses O O 0.9934593439102173
. O O 0.9999961853027344
We O O 0.9999872446060181
questioned O O 0.9999878406524658
whether O O 0.9999986886978149
these O O 0.999988317489624
differences O O 0.9993784427642822
might O O 0.9999980926513672
reflect O O 0.9999922513961792
patterns O O 0.9974648952484131
of O O 0.9999494552612305
intracellular O O 0.8861951231956482
signal O O 0.9368566870689392
transduction O O 0.9894222617149353
. O O 0.999993085861206
Stimulation O O 0.9960684776306152
with O O 0.9999597072601318
either O O 0.9993320107460022
PAF S-protein S-protein 0.9161308407783508
or O O 0.992280125617981
FMLP S-protein O 0.5085337162017822
resulted O O 0.9996065497398376
in O O 0.9999818801879883
equivalent O O 0.9695937633514404
phosphorylation O O 0.9783211946487427
and O O 0.9996834993362427
activation O O 0.9871729612350464

DISCUSSION O O 0.9943506121635437
: O O 0.9999498128890991
Quantifying O O 0.9275863766670227
tremor O B-Disease 0.9617908596992493
by O O 0.9889888167381287
using O O 0.9998840093612671
an O O 0.9999290704727173
inexpensive O O 0.8665889501571655
laser O O 0.8085072636604309
pointer O O 0.7663799524307251
is O O 0.9998968839645386
, O O 0.9999819993972778
with O O 0.9999945163726807
the O O 0.9999862909317017
exception O O 0.9999210834503174
of O O 0.9999526739120483
children O O 0.9982328414916992
( O O 0.9999788999557495
< O O 0.999916672706604
12 O O 0.9998883008956909
years O O 0.9997972846031189
) O O 0.9999179840087891
a O O 0.9999799728393555
sensitive O O 0.9406481385231018
and O O 0.99273681640625
reproducible O O 0.9461292624473572
method O O 0.9942111372947693
. O O 0.9999978542327881

In O O 0.9995170831680298
the O O 0.999967098236084
transient-transfection O O 0.915446400642395
assay O O 0.9764129519462585
, O O 0.9999337196350098
ICP0 S-protein S-protein 0.86397784948349
, O O 0.9957297444343567
but O O 0.9998244643211365
not O O 0.9994240999221802
ICP4 S-protein S-protein 0.7391690015792847
, O O 0.9981301426887512
activated O O 0.9997134804725647
the O O 0.999944806098938
HIV-1 B-DNA B-DNA 0.4494672119617462
long I-DNA I-DNA 0.7078768610954285
terminal I-DNA I-DNA 0.8635522723197937
repeat I-DNA I-DNA 0.7852003574371338
promoter I-DNA E-DNA 0.9360023140907288

therapeutic O O 0.8968271613121033
effect O O 0.9982424974441528
in O O 0.9999899864196777
the O O 0.9998189806938171
T B-cell_type B-cell_type 0.6091204881668091
lymphocytes E-cell_type E-cell_type 0.9897791743278503
of O O 0.9954952001571655
acquired O O 0.8607228994369507
immunodeficiency O O 0.8425245881080627
syndrome O O 0.961852490901947
patients O O 0.9989655017852783
. O O 0.9999990463256836
Simple O O 0.9931638836860657
derivation O O 0.9982738494873047
of O O 0.9999686479568481
TFIID-dependent O B-protein 0.47427451610565186
RNA B-protein I-protein 0.25380802154541016
polymerase I-protein I-protein 0.3767920434474945
II E-protein E-protein 0.9443756937980652
transcription O O 0.7570177912712097
systems O O 0.7528417110443115
from O O 0.9999637603759766
Schizosaccharomyces O O 0.7550951242446899
pombe O O 0.436699777841568
and O O 0.9507839679718018
other O O 0.9951590895652771
organisms O O 0.9628044366836548
, O O 0.999750554561615
and O O 0.9999086856842041
factors O O 0.9735844135284424
required O O 0.9997190833091736

specific O O 0.9569892287254333
DNA O O 0.950660228729248
binding O O 0.972104549407959
. O O 0.9997268319129944
Spi-B S-protein S-protein 0.6086338758468628
binds O O 0.9662059545516968
DNA B-DNA B-DNA 0.7932667136192322
sequences E-DNA E-DNA 0.8939852714538574
containing O O 0.9982200264930725
a O O 0.9970735311508179
core O B-DNA 0.5927621126174927
5'-GGAA-3 O I-DNA 0.49798232316970825
' O I-DNA 0.5668443441390991
and O I-DNA 0.5535402297973633

were O O 0.9973235726356506
detected O O 0.9997777342796326
in O O 0.9999591112136841
certain O O 0.9944930076599121
subclones O O 0.7541581988334656
of O O 0.9970089793205261
THP-1 S-cell_line S-cell_line 0.9165779948234558
and O O 0.8988229632377625
HL-60 B-cell_line B-cell_line 0.6004286408424377
cells E-cell_line E-cell_line 0.9744731783866882
and O O 0.9990842342376709
in O O 0.9994850158691406
primary O B-cell_type 0.7489385604858398
monocytes S-cell_type E-cell_type 0.9557209014892578
, O O 0.998691737651825
in O O 0.9999871253967285
each O O 0.9999862909317017
case O O 0.9980769157409668
correlating O O 0.999270498752594
with O O 0.9999052286148071
the O O 0.9994093179702759
truncated O O 0.5634369850158691
from O O 0.986182689666748

affecting O O 0.9901785850524902
T O O 0.7202171087265015
cell O O 0.4967356324195862
function O O 0.9708529114723206
, O O 0.9997100234031677
T B-cell_line B-cell_line 0.47898992896080017
leukemia I-cell_line I-cell_line 0.5990782976150513
cell I-cell_line I-cell_line 0.532424807548523
lines E-cell_line E-cell_line 0.9972410202026367
were O O 0.9997003078460693
stably O O 0.998744010925293
transduced O O 0.9996647834777832
with O O 0.9999974966049194
a O O 0.999832034111023
retroviral B-DNA B-DNA 0.6503337025642395
vector E-DNA E-DNA 0.6235414147377014
encoding O O 0.9281736612319946
a O O 0.9979548454284668
transdominant O O 0.583861768245697
mutant O O 0.31734737753868103

Hypotension B-Disease B-Disease 0.9694478511810303
following O O 0.9968271851539612
the O O 0.9999299049377441
initiation O O 0.989569902420044
of O O 0.9993016719818115
tizanidine B-Chemical B-Chemical 0.9349794983863831
in O O 0.9986425042152405
a O O 0.9998737573623657
patient O O 0.9993152618408203
treated O O 0.9999803304672241
with O O 0.9999957084655762
an O O 0.9992735981941223
angiotensin B-Chemical B-Chemical 0.9320361614227295
converting O O 0.6222946047782898
enzyme O O 0.4981197118759155
inhibitor O O 0.7133768796920776
for O O 0.999301552772522
chronic O O 0.6732289791107178
hypertension B-Disease O 0.5756438970565796
. O O 0.9987989664077759

human B-DNA B-DNA 0.4286438524723053
interleukin-1 I-DNA I-DNA 0.5641849040985107
beta I-DNA I-DNA 0.47921568155288696
promoter E-DNA E-DNA 0.9967336654663086
confers O O 0.9981523156166077
preferential O O 0.9441372156143188
transcriptional O O 0.9102845191955566
activity O O 0.9911900758743286
in O O 0.9999351501464844
keratinocytes S-cell_type S-cell_type 0.9459327459335327
. O O 0.9997890591621399
To O O 0.9999825954437256
investigate O O 0.9999737739562988
the O O 0.9999817609786987
mechanisms O O 0.9994385838508606
of O O 0.9999814033508301
transcriptional O O 0.9338161945343018
activation O O 0.9851952791213989
of O O 0.9995970129966736
interleukin-1beta S-protein S-protein 0.9766293168067932
( O O 0.984596312046051
IL-1beta S-protein S-protein 0.991162896156311
) O O 0.9791873693466187
in O O 0.9998002648353577
non-monocytic O B-cell_type 0.6403883695602417
cells O E-cell_type 0.9446045756340027
, O O 0.9993341565132141
we O O 0.999964714050293
constructed O O 0.9995661377906799
a O O 0.9999492168426514
series O O 0.9853134751319885
of O O 0.9994961023330688
reporter O B-DNA 0.6356519460678101
plasmids O E-DNA 0.9300090074539185
with O O 0.9997016787528992
the O O 0.9999641180038452
bacterial O B-DNA 0.6489904522895813
chloramphenicol O I-DNA 0.32911521196365356
acetyltransferase O I-DNA 0.42155343294143677
gene O E-DNA 0.9704006314277649
linked O O 0.9926844835281372

Although O O 0.9998431205749512
the O O 0.9999628067016602
explanation O O 0.99932861328125
for O O 0.9999856948852539
the O O 0.9999613761901855
association O O 0.9432846903800964
between O O 0.9989345669746399
artery B-Disease O 0.49688398838043213
calcification I-Disease O 0.9317600727081299
and O O 0.9821473360061646
growth O O 0.750045657157898
status O O 0.6507772207260132
cannot O O 0.9996944665908813
be O O 0.9999709129333496
determined O O 0.9999892711639404
from O O 0.9999982118606567
the O O 0.9999911785125732
present O O 0.99960857629776
study O O 0.9999480247497559
, O O 0.9999971389770508
there O O 0.9999939203262329
was O O 0.9999911785125732
a O O 0.9999467134475708
relationship O O 0.9985117316246033
between O O 0.9999436140060425
higher O O 0.9902279376983643
serum O O 0.9559036493301392
phosphate B-Chemical B-Chemical 0.915535032749176
and O O 0.9960220456123352
susceptibility O O 0.6682240962982178
to O O 0.994792640209198
artery B-Disease O 0.5278982520103455
calcification I-Disease O 0.9596132636070251
, O O 0.991716206073761
with O O 0.9999860525131226
30 O O 0.9976187348365784
% O O 0.9998045563697815
higher O O 0.9964973330497742
levels O O 0.9992864727973938
of O O 0.9999637603759766
serum O O 0.9172095656394958
phosphate B-Chemical B-Chemical 0.8892635703086853
in O O 0.9989526271820068
young O O 0.9839290380477905
, O O 0.9992044568061829
ad O O 0.9793933629989624
libitum O O 0.7701162099838257
- O O 0.9964906573295593
fed O O 0.9969080090522766
rats O O 0.9972944855690002
compared O O 0.9999969005584717
with O O 0.9999945163726807
either O O 0.9999185800552368
of O O 0.9999291896820068
the O O 0.9999352693557739
groups O O 0.9992638230323792
that O O 0.9999939203262329
was O O 0.9999375343322754
resistant O O 0.9977789521217346
to O O 0.9998632669448853
Warfarin B-Chemical B-Chemical 0.9274666905403137
- O O 0.9264956116676331
induced O O 0.9991793036460876
artery B-Disease B-Disease 0.6931084394454956
calcification I-Disease I-Disease 0.9508752226829529
, O O 0.9428026080131531
ie O O 0.9881420731544495
, O O 0.9999330043792725
the O O 0.9999908208847046
10 O O 0.9971305727958679
- O O 0.9997307658195496
month O O 0.9999003410339355
- O O 0.9999566078186035
old O O 0.9949122071266174
rats O O 0.9984026551246643
and O O 0.9999881982803345
the O O 0.9999624490737915
restricted O O 0.9896498918533325
- O O 0.9979827404022217
diet O O 0.9449918866157532
, O O 0.9998434782028198
growth O O 0.8314781188964844
- O O 0.9724217653274536
inhibited O O 0.9935657382011414
young O O 0.9124108552932739
rats O O 0.9784576296806335
. O O 0.9999984502792358

this O O 0.9987245202064514
possibility O O 0.999929666519165
, O O 0.9999984502792358
we O O 0.9999966621398926
examined O O 0.9999868869781494
the O O 0.9999938011169434
expression O O 0.9990648627281189
of O O 0.9999676942825317
markers O O 0.868747353553772
for O O 0.9982605576515198
B-cell O O 0.5947304964065552
activation O O 0.9437469244003296
, O O 0.9993298053741455
differentiation O O 0.9937235713005066
, O O 0.9998251795768738
and O O 0.9997586607933044

( O O 0.984618067741394
the O O 0.9996289014816284
transcriptional B-DNA B-protein 0.7513492703437805
regulatory I-DNA I-protein 0.6297994256019592
domain E-DNA E-protein 0.9737358689308167
) O O 0.9762105941772461
of O O 0.9999271631240845
the O O 0.9999189376831055
HIV-1 B-DNA B-DNA 0.5318878889083862
LTR E-DNA E-DNA 0.9922044277191162
. O O 0.9997416138648987
Cotransfection O O 0.9796136617660522
of O O 0.999315619468689
an O O 0.9999089241027832
hGATA-3 B-DNA S-protein 0.6080231070518494
expression I-DNA O 0.929142951965332

The O O 0.999437153339386
authors O O 0.9998617172241211
report O O 0.999992847442627
2 O O 0.9994706511497498
cases O O 0.997105062007904
of O O 0.9998453855514526
premature O O 0.5961787104606628
neonates O O 0.7145407795906067
who O O 0.9705105423927307
had O O 0.9995437264442444
enterocutaneous O O 0.5801102519035339
fistula B-Disease O 0.7794811129570007
complicating O O 0.8318760991096497
necrotizing B-Disease O 0.4186525344848633
enterocolitis I-Disease B-Disease 0.6290116906166077
. O O 0.999479353427887

with O O 0.9946276545524597
SLP-76 S-protein S-protein 0.8426406979560852
but O O 0.9938843846321106
not O O 0.9986236095428467
with O O 0.9997237324714661
Sos1 S-protein S-protein 0.7284260988235474
or O O 0.9960783123970032
Sos2 S-protein S-protein 0.38275009393692017
from O O 0.9954343438148499
Jurkat B-cell_line B-cell_line 0.5093290209770203
cell E-cell_line I-cell_line 0.47761619091033936
lysates O E-cell_line 0.9160158038139343
. O O 0.9998629093170166
In O O 0.9999926090240479
contrast O O 0.999790608882904
, O O 0.9999808073043823
Grb2 S-protein S-protein 0.980922281742096
can O O 0.9998267292976379
be O O 0.9999774694442749
coimmunoprecipitated O O 0.986935555934906
with O O 0.9998737573623657
Sos1 S-protein S-protein 0.7972157001495361
and O O 0.985328733921051
Sos2 S-protein S-protein 0.6437269449234009
but O O 0.992919385433197
not O O 0.9992626309394836
with O O 0.9998332262039185

delta I-cell_line I-cell_line 0.23573583364486694
cells E-cell_line E-cell_line 0.6120774149894714
in O O 0.999934196472168
a O O 0.9999343156814575
fetal B-cell_line O 0.8694577813148499
thymic I-cell_line O 0.812258780002594
organ I-cell_line O 0.8218957781791687
culture E-cell_line O 0.738939106464386
( O O 0.9995835423469543
FTOC S-cell_line O 0.892815887928009
) O O 0.9835193753242493
. O O 0.999983549118042
Here O O 0.9999836683273315
we O O 0.9999967813491821
document O O 0.9999839067459106
that O O 0.9999970197677612
overexpression O O 0.9858679175376892
of O O 0.9994131326675415
Id3 S-protein S-protein 0.9600353240966797
, O O 0.9962939620018005
in O O 0.9998165965080261
progenitors S-cell_type O 0.6893242001533508
that O O 0.9812690615653992
have O O 0.9999165534973145
initiated O O 0.9952040910720825
TCR B-DNA B-DNA 0.6017575860023499
gene I-DNA I-DNA 0.817756175994873
rearrangements E-DNA E-DNA 0.8659766912460327
( O O 0.9973236322402954
pre-T B-cell_type B-cell_type 0.4431566596031189
cells E-cell_type E-cell_type 0.8441985845565796
) O O 0.9650357365608215
, O O 0.9998002648353577
inhibits O O 0.9999206066131592
development O O 0.9985866546630859
into O O 0.9999641180038452
TCRalpha B-cell_line B-protein 0.3290838897228241
beta E-cell_line E-protein 0.9340193271636963
but O O 0.9906249642372131
not O O 0.9997351765632629
into O O 0.9993150234222412
TCRgamma B-cell_line B-cell_line 0.4449305236339569

from O O 0.9993301630020142
the O O 0.999963641166687
classical O B-protein 0.8924906253814697
1 B-protein I-protein 0.8446199893951416
, I-protein I-protein 0.9853958487510681
25 I-protein I-protein 0.9512315988540649
( I-protein I-protein 0.989972710609436
OH I-protein I-protein 0.8490850329399109
) I-protein I-protein 0.9277554750442505
2D3 I-protein I-protein 0.7096557021141052
receptor E-protein E-protein 0.9433218240737915
and O O 0.9922488927841187
, O O 0.9998894929885864
similar O O 0.9997887015342712
to O O 0.9999731779098511
the O O 0.9999094009399414
classical O B-protein 0.8069447875022888
1 B-protein I-protein 0.6995580196380615
, I-protein I-protein 0.9474167823791504
25 I-protein I-protein 0.8827425241470337
( I-protein I-protein 0.9808340668678284
OH I-protein I-protein 0.7525056004524231
) I-protein I-protein 0.8728459477424622
2D3 I-protein I-protein 0.6164315342903137
receptor E-protein E-protein 0.9390902519226074
, O O 0.9939372539520264
was O O 0.9999427795410156
upregulated O O 0.9982122182846069
in O O 0.9999711513519287
a O O 0.9998509883880615
dose-dependent O O 0.8962923288345337
fashion O O 0.9618542790412903
by O O 0.9998835325241089
1 O O 0.9456610083580017
, O O 0.9902157783508301

The O O 0.9994039535522461
results O O 0.9999139308929443
indicate O O 0.999996542930603
that O O 0.999993085861206
the O O 0.999799907207489
deprived O O 0.9639703631401062
area O O 0.9893879890441895
of O O 0.9999167919158936
A1 O O 0.5384874939918518
undergoes O O 0.9997355341911316
extensive O O 0.991259753704071
reorganization O O 0.872696578502655
and O O 0.9992201328277588
becomes O O 0.9996459484100342
responsive O O 0.9989175796508789
to O O 0.9999836683273315
intact O O 0.9843413233757019
cochlear O O 0.7221478819847107
frequencies O O 0.7649505138397217
. O O 0.9999920129776001

NF-kappa B-protein B-protein 0.6249357461929321
B E-protein E-protein 0.9921475052833557
by O O 0.9993152618408203
targeting O O 0.9996597766876221
the O O 0.9999620914459229
inhibitory B-protein B-protein 0.7708702683448792
molecule I-protein E-protein 0.8095129728317261
I I-protein B-protein 0.48924583196640015
kappa I-protein I-protein 0.8911279439926147
B I-protein I-protein 0.598633348941803
alpha E-protein E-protein 0.9828038215637207
. O O 0.9969736337661743
LMP-1 S-protein S-protein 0.9466105699539185
, O O 0.9988592863082886
an O O 0.9998739957809448
Epstein-Barr B-protein B-protein 0.5379486083984375
virus I-protein I-protein 0.585729718208313
membrane I-protein I-protein 0.8024990558624268
protein E-protein E-protein 0.9817334413528442
expressed O O 0.9982101917266846
during O O 0.999976634979248
latent O O 0.9232092499732971
infection O O 0.9455042481422424
, O O 0.999875545501709
has O O 0.9999790191650391
oncogenic O O 0.8295956254005432
properties O O 0.9259059429168701
, O O 0.9998927116394043
as O O 0.9999896287918091

the O O 0.9969995617866516
adenylate B-protein B-protein 0.6409515738487244
cyclase E-protein E-protein 0.9492817521095276
or O O 0.994239330291748
PKA S-protein S-protein 0.7632884979248047
on O O 0.9974712133407593
two O O 0.9966159462928772
parallel O O 0.9046475887298584
mitogen-activated O B-protein 0.5890653133392334
protein O I-protein 0.31653761863708496
kinase O E-protein 0.9123647212982178
signaling O O 0.8309900760650635
pathways O O 0.987040102481842
mediated O O 0.9999656677246094
by O O 0.999993085861206
extracellular B-protein B-protein 0.7346174716949463
signal-regulated I-protein I-protein 0.4756130874156952
kinase E-protein E-protein 0.9408599734306335
( O O 0.8891063332557678
ERK S-protein S-protein 0.9412869215011597
) O O 0.8362668752670288
and O O 0.9864354729652405
c-Jun B-protein B-protein 0.7868147492408752
N-terminal I-protein I-protein 0.8319017887115479
kinase E-protein E-protein 0.9583464860916138
. O O 0.9984116554260254
Using O O 0.9999222755432129
a O O 0.9996275901794434
PKC S-protein S-protein 0.35529688000679016

PPARs S-protein S-protein 0.7621018886566162
) O O 0.9683204889297485
, O O 0.9997630715370178
members O O 0.9987266659736633
of O O 0.9999654293060303
the O O 0.99991774559021
nuclear B-protein B-protein 0.5193759202957153
receptor I-protein I-protein 0.6434106826782227
superfamily E-protein E-protein 0.9147955179214478
of O O 0.9120818376541138
transcription B-protein B-protein 0.5566632747650146
factors E-protein E-protein 0.9947062134742737
, O O 0.9941229224205017
are O O 0.9999752044677734
activated O O 0.9956527948379517
by O O 0.9998418092727661

Morphometric O O 0.6485217213630676
analysis O O 0.9814884662628174
revealed O O 0.9999932050704956
that O O 0.9999943971633911
the O O 0.9998617172241211
volume O O 0.9864287972450256
density O O 0.995088517665863
of O O 0.999919056892395
secretory O O 0.8481792211532593
granules O O 0.8176151514053345
increased O O 0.998826801776886
, O O 0.99991774559021
while O O 0.9999954700469971
the O O 0.9999171495437622
volume O O 0.987386167049408
density O O 0.9943668246269226
of O O 0.9999363422393799
cytoplasmic O O 0.7452293038368225
microtubules O O 0.5131295919418335
decreased O O 0.9989751577377319
. O O 0.999997615814209

At O O 0.9998799562454224
six O O 0.9998613595962524
months O O 0.9999700784683228
post O O 0.9996366500854492
- O O 0.9971197843551636
CAB O O 0.6987640261650085
, O O 0.9994414448738098
patients O O 0.9996918439865112
with O O 0.9999805688858032
severe O O 0.9225385785102844
anemia B-Disease O 0.8574159741401672
had O O 0.9898706078529358
a O O 0.9998407363891602
Hb O O 0.8683655858039856
mean O O 0.9837540984153748
value O O 0.990967333316803
of O O 0.9997941851615906
10 O O 0.9989060163497925
. O O 0.9999967813491821
2 O O 0.9999592304229736
+ O O 0.9999830722808838
/ O O 0.9999972581863403
- O O 0.9999717473983765
0 O O 0.9999688863754272
. O O 0.9999954700469971
1 O O 0.9998756647109985
g O O 0.9996649026870728
/ O O 0.9999804496765137
dl O O 0.999173104763031
( O O 0.9999525547027588
X O O 0.996898889541626
+ O O 0.999969482421875
/ O O 0.9999829530715942
- O O 0.9998457431793213
SE O O 0.8936846256256104
) O O 0.9978715181350708
, O O 0.999992847442627
whereas O O 0.9999982118606567
the O O 0.9999864101409912
other O O 0.9999514818191528
patients O O 0.9998658895492554
had O O 0.999977707862854
mild O O 0.9672250151634216
anemia B-Disease O 0.9046629071235657
with O O 0.984283447265625
Hb O O 0.7008711099624634
mean O O 0.9911274313926697
value O O 0.9947648048400879
of O O 0.9999228715896606
13 O O 0.9981701374053955
. O O 0.9999949932098389
2 O O 0.9999536275863647
+ O O 0.9999833106994629
/ O O 0.9999990463256836
- O O 0.999976396560669
0 O O 0.9999685287475586
. O O 0.9999920129776001
17 O O 0.9996227025985718
( O O 0.9999759197235107
X O O 0.9993939399719238
+ O O 0.9999809265136719
/ O O 0.9999921321868896
- O O 0.99992835521698
SE O O 0.922218382358551
) O O 0.9991927742958069
. O O 0.999995231628418

Iatrogenically O O 0.9112048149108887
induced O O 0.9977385997772217
intractable O O 0.9391228556632996
atrioventricular B-Disease O 0.696535587310791
reentrant I-Disease O 0.5063977837562561
tachycardia I-Disease O 0.5771165490150452
after O O 0.9879549741744995
verapamil B-Chemical B-Chemical 0.9287861585617065
and O O 0.9681658148765564
catheter O O 0.516013503074646
ablation O O 0.5000298023223877
in O O 0.9995759129524231
a O O 0.9999220371246338
patient O O 0.999602735042572
with O O 0.9999938011169434
Wolff B-Disease O 0.6255613565444946
- I-Disease O 0.9086366295814514
Parkinson I-Disease O 0.5554223656654358
- I-Disease O 0.9017788171768188
White I-Disease O 0.7025816440582275
syndrome I-Disease O 0.8916410207748413
and O O 0.9885284304618835
idiopathic B-Disease O 0.6276146173477173
dilated I-Disease O 0.4891906976699829
cardiomyopathy I-Disease O 0.6810984015464783
. O O 0.9989551305770874

The O O 0.9989763498306274
deformations B-Disease O 0.8537595272064209
caused O O 0.990980327129364
by O O 0.9998642206192017
both O O 0.9937410950660706
coniine B-Chemical B-Chemical 0.9256714582443237
and O O 0.9730145931243896
nicotine B-Chemical B-Chemical 0.9156631231307983
sulfate O O 0.8624333739280701
were O O 0.999294638633728
excessive B-Disease O 0.8474184274673462
flexion I-Disease O 0.3607008755207062
or I-Disease O 0.9974496960639954
extension I-Disease O 0.9294729828834534
of I-Disease O 0.9822970032691956
one I-Disease O 0.988731324672699
or I-Disease O 0.9996163845062256
more I-Disease O 0.9997304081916809
toes I-Disease O 0.9268089532852173
. O O 0.9999910593032837

, O O 0.9928181171417236
the O O 0.9999833106994629
function O O 0.9998379945755005
of O O 0.9999861717224121
this O O 0.9999383687973022
receptor O O 0.7195976376533508
remains O O 0.9995737671852112
poorly O O 0.9963729381561279
defined O O 0.9998034834861755
in O O 0.9999402761459351
vivo O O 0.9856211543083191
. O O 0.9999734163284302
We O O 0.9999723434448242
show O O 0.9999933242797852
here O O 0.9999910593032837
that O O 0.999996542930603
at O O 0.999937891960144
levels O O 0.9997881054878235
relevant O O 0.9998676776885986
to O O 0.9999867677688599
human O O 0.7635604739189148
disease O O 0.7976853847503662

There O O 0.9996175765991211
was O O 0.9999823570251465
one O O 0.9999876022338867
treatment O O 0.9992412328720093
- O O 0.9999281167984009
related O O 0.9954980611801147
death O B-Disease 0.9775721430778503
. O O 0.9980570673942566

. O O 0.9971298575401306
Recently O O 0.9999234676361084
, O O 0.999995231628418
a O O 0.9999566078186035
multivalent O O 0.7182660102844238
guanylhydrazone O O 0.41874170303344727
( O O 0.9890522360801697
CNI-1493 O O 0.5238694548606873
) O O 0.9887661337852478
developed O O 0.9999550580978394
as O O 0.9999988079071045
an O O 0.9999696016311646
inhibitor O O 0.9866243600845337
of O O 0.9997814297676086
macrophage O O 0.41470634937286377
activation O O 0.9143338203430176
was O O 0.9995952248573303
shown O O 0.9999878406524658
to O O 0.9999927282333374
suppress O O 0.9998422861099243
TNF S-protein S-protein 0.9721161723136902
production O O 0.9975215792655945
and O O 0.9999203681945801
protect O O 0.9996705055236816
against O O 0.9999514818191528
tissue O O 0.9311639070510864
inflammation O O 0.951554000377655
and O O 0.9996687173843384
endotoxin O O 0.4943086802959442

all O O 0.9991992115974426
the O O 0.9999872446060181
isoforms S-protein O 0.5778557658195496
are O O 0.9996040463447571
able O O 0.9999701976776123
to O O 0.9999830722808838
activate O O 0.9999195337295532
an O O 0.999942421913147
octamer S-DNA O 0.6483336091041565
containing O O 0.9233680963516235
promoter B-DNA B-DNA 0.6165903806686401
element E-DNA E-DNA 0.9384490847587585
in O O 0.9957935810089111
fibroblasts O O 0.5508847236633301
revealing O O 0.9969737529754639
an O O 0.9998973608016968
unexpected O O 0.9810650944709778
functional O O 0.9184881448745728
redundancy O O 0.5559022426605225
. O O 0.9999184608459473

critical O O 0.9407300353050232
for O O 0.9990585446357727
T O O 0.6275742650032043
lymphocyte O O 0.7678453326225281
function O O 0.9726689457893372
and O O 0.9994667172431946
is O O 0.9999916553497314
a O O 0.9999905824661255
strong O O 0.9883044958114624
inducer O O 0.9807230830192566
of O O 0.9996955394744873
HIV-LTR S-DNA S-protein 0.470111221075058
activation O O 0.9768205881118774
. O O 0.9999650716781616
We O O 0.9999833106994629
demonstrate O O 0.9999946355819702
that O O 0.9999945163726807
Pb O S-protein 0.5785015225410461
at O O 0.9974320530891418
physiologically O O 0.9522507190704346
relevant O O 0.951848566532135
concentrations O O 0.9618682861328125
activates O O 0.9999161958694458
NF-kappa B-protein B-protein 0.7683082222938538
B E-protein E-protein 0.9870613217353821
in O O 0.9997060894966125
primary B-cell_type B-cell_type 0.778152585029602
human I-cell_type I-cell_type 0.8051883578300476
CD4+ I-cell_type I-cell_type 0.8712714910507202
T I-cell_type I-cell_type 0.9129412174224854

sequence O E-DNA 0.7209200263023376
of O O 0.9984808564186096
the O O 0.9999713897705078
FY*B B-DNA B-DNA 0.581576406955719
allele E-DNA E-DNA 0.9721554517745972
of O O 0.9964691400527954
the O O 0.9999470710754395
Duffy B-DNA B-DNA 0.4691351652145386
chemokine I-DNA I-DNA 0.6097872853279114
receptor I-DNA I-DNA 0.6857906579971313
gene E-DNA E-DNA 0.9891543984413147
is O O 0.9987589120864868
associated O O 0.9999686479568481
with O O 0.9999967813491821
an O O 0.999940037727356
altered O O 0.9017960429191589
erythrocyte O O 0.5161502361297607

complex O E-protein 0.9664099812507629
with O O 0.9997393488883972
the O O 0.9999821186065674
same O O 0.999828577041626
electrophoretic O O 0.8674789071083069
mobility O O 0.9098274111747742
as O O 0.9999246597290039
the O O 0.9999734163284302
NF-kappa B-protein B-protein 0.6385761499404907
B-DNA I-protein I-protein 0.8325252532958984
complex E-protein E-protein 0.9945446252822876
. O O 0.9998037219047546
Therefore O O 0.9999966621398926
the O O 0.999976396560669
rel-related B-protein B-protein 0.6350675821304321
65-kD I-protein I-protein 0.6468129754066467
protein E-protein E-protein 0.9849534034729004
may O O 0.999778687953949
represent O O 0.9999977350234985
the O O 0.9999895095825195
p65 B-protein B-protein 0.4536229074001312
subunit E-protein E-protein 0.9610099792480469
of O O 0.9864979982376099
the O O 0.9996532201766968
active B-protein O 0.8670779466629028
NF-kappa I-protein B-protein 0.70558100938797
B I-protein I-protein 0.9322707653045654
transcription I-protein I-protein 0.4688999652862549
factor I-protein I-protein 0.7962083220481873
complex E-protein E-protein 0.9936861395835876
. O O 0.9998776912689209
The O O 0.9999715089797974
human B-cell_line B-cell_line 0.3995043933391571
myelomonocytic I-cell_line I-cell_line 0.7616151571273804
cell I-cell_line I-cell_line 0.9461179375648499
line I-cell_line I-cell_line 0.8042070269584656
U-937 E-cell_line E-cell_line 0.7422124147415161
as O O 0.9991090893745422
a O O 0.9999717473983765
model O O 0.9888198971748352

In O O 0.9995591044425964
contrast O O 0.9997983574867249
, O O 0.9999693632125854
SSR103800 S-Chemical B-Chemical 0.901856541633606
failed O O 0.9868723154067993
to O O 0.9997920393943787
affect O O 0.9998548030853271
hyperactivity O B-Disease 0.982058048248291
induced O O 0.9074528813362122
by O O 0.997179388999939
amphetamine S-Chemical B-Chemical 0.934363603591919
or O O 0.985859215259552
naturally O O 0.9504417181015015
observed O O 0.9936050772666931
in O O 0.9998704195022583
dopamine S-Chemical B-Chemical 0.9305601716041565
transporter O O 0.5986533761024475
( O O 0.9986565113067627
DAT O O 0.4648815989494324
( O O 0.9966186285018921
- O O 0.9991118311882019
/ O O 0.9998607635498047
- O O 0.999103844165802
) O O 0.9988188147544861
) O O 0.9997044205665588
knockout O O 0.540360152721405
mice O O 0.9552321434020996
( O O 0.9999691247940063
10 O O 0.9997164607048035
- O O 0.9997590184211731
30 O O 0.9998181462287903
mg O O 0.9997949004173279
/ O O 0.9999891519546509
kg O O 0.9995545744895935
p O O 0.9983788728713989
. O O 0.9999706745147705
o O O 0.9999405145645142
. O O 0.9996106028556824
) O O 0.9996634721755981
. O O 0.9999903440475464

affect O O 0.9987921118736267
basal O O 0.9390084147453308
LTR S-DNA S-DNA 0.6430658102035522
function O O 0.9838378429412842
and O O 0.9997935891151428
transcription B-protein B-protein 0.6434547901153564
factor E-protein E-protein 0.9203579425811768
recruitment O O 0.9587874412536621
, O O 0.9998747110366821
which O O 0.9999856948852539
may O O 0.9999922513961792
, O O 0.9999643564224243
in O O 0.9999717473983765
turn O O 0.9981728792190552
, O O 0.9999485015869141

Acute O O 0.8111125826835632
myocarditis O B-Disease 0.8519713878631592
associated O O 0.985069990158081
with O O 0.9998711347579956
clozapine S-Chemical B-Chemical 0.92645263671875
. O O 0.9995965361595154

in O O 0.9957149624824524
leukemic B-cell_type B-cell_type 0.6255452036857605
cells E-cell_type E-cell_type 0.9196698069572449
carrying O O 0.9982329607009888
a O O 0.9986771941184998
t O B-DNA 0.49057838320732117
( O I-DNA 0.7708315253257751
14 O I-DNA 0.701609194278717
; O I-DNA 0.590241014957428
14 O I-DNA 0.6396732926368713
) O I-DNA 0.5046417713165283
( O I-DNA 0.6781644821166992
q11 O I-DNA 0.7922945022583008
; O I-DNA 0.896882176399231
q32 O I-DNA 0.9557347297668457
) O I-DNA 0.532217800617218
chromosome O E-DNA 0.9199966788291931
translocation O O 0.5374171137809753
or O O 0.998603880405426
a O O 0.9973803162574768
inv O B-DNA 0.4652910828590393
( O I-DNA 0.6788378357887268
14 O I-DNA 0.5987046957015991
) O I-DNA 0.4341106414794922
( O I-DNA 0.6667765974998474
q11 O I-DNA 0.713148295879364
; O I-DNA 0.9432946443557739
q32 O I-DNA 0.9500840902328491
) O I-DNA 0.5673892498016357
chromosome O E-DNA 0.894017219543457
inversion O O 0.7882720828056335
. O O 0.9999598264694214
The O O 0.9999717473983765
cognate B-DNA B-DNA 0.6718466281890869
cDNA I-DNA I-DNA 0.5769909024238586
sequence E-DNA E-DNA 0.970563530921936
reveals O O 0.9992601275444031

Thyroid O O 0.3215980529785156
- O O 0.8079704642295837
stimulating O O 0.9170342087745667
hormone O O 0.4745067358016968
, O O 0.9924754500389099
magnesium S-Chemical B-Chemical 0.9253681898117065
, O O 0.9902589321136475
and O O 0.9997124075889587
potassium S-Chemical B-Chemical 0.9313668608665466
levels O O 0.9943068623542786
were O O 0.9999978542327881
within O O 0.9999135732650757
normal O O 0.9876304268836975
limits O O 0.9965862035751343
, O O 0.9999909400939941
urine O O 0.7370936274528503
drug O O 0.9304493069648743
screen O O 0.8940642476081848
was O O 0.9997513890266418
negative O O 0.9762553572654724
, O O 0.9998956918716431
and O O 0.9998781681060791
alcohol S-Chemical B-Chemical 0.9204682111740112
use O O 0.9775267839431763
was O O 0.9999427795410156
denied O O 0.9995054006576538
. O O 0.9999985694885254

was O O 0.9891545176506042
prepared O O 0.9968315958976746
, O O 0.9999704360961914
which O O 0.9999725818634033
lacks O O 0.9999873638153076
the O O 0.9999350309371948
calmodulin-binding B-protein B-protein 0.5291216373443604
domain E-protein E-protein 0.8942963480949402
, O O 0.9536386728286743
autoinhibitory B-protein B-protein 0.45746609568595886
domain E-protein E-protein 0.9679459929466248
and O O 0.9962638020515442
most O O 0.999568521976471
of O O 0.9999189376831055
its O O 0.9999117851257324
catalytic O O 0.6263859868049622
core O O 0.4278123080730438

that O O 0.990145206451416
fail O O 0.9990794658660889
to O O 0.9999878406524658
activate O O 0.9998787641525269
either O O 0.9999247789382935
ATF S-protein S-protein 0.8638123869895935
-or O O 0.9918036460876465
NF-kappaB-dependent B-DNA O 0.5280773639678955

Patients O O 0.9898311495780945
treated O O 0.9999303817749023
with O O 0.999982476234436
alkylating B-Chemical B-Chemical 0.8958410620689392
agents I-Chemical E-Chemical 0.9012848734855652
have O O 0.9986610412597656
an O O 0.9999432563781738
increased O O 0.9769311547279358
risk O O 0.994828999042511
of O O 0.9997950196266174
development O O 0.9624921679496765
of O O 0.9989001750946045
acute B-Disease O 0.7203471064567566
nonlymphocytic I-Disease O 0.502471387386322
leukemia I-Disease O 0.7796502709388733
, O O 0.9868384003639221
and O O 0.9999262094497681
both O O 0.9998099207878113
alkylating B-Chemical B-Chemical 0.9010534882545471
agents I-Chemical E-Chemical 0.8965742588043213
and O O 0.8669426441192627
azathioprine B-Chemical B-Chemical 0.9277050495147705
are O O 0.9949510097503662
associated O O 0.9999104738235474
with O O 0.9999910593032837
the O O 0.9997684359550476
development O O 0.9961716532707214
of O O 0.9999332427978516
non B-Disease O 0.834859311580658
- I-Disease O 0.9405191540718079
Hodgkin I-Disease O 0.7735888361930847
' I-Disease O 0.8483050465583801
s I-Disease O 0.8012694716453552
lymphoma I-Disease O 0.824024498462677
. O O 0.9994420409202576

There O O 0.9998154044151306
were O O 0.9999945163726807
no O O 0.9999758005142212
suggestions O O 0.9998992681503296
of O O 0.9999512434005737
interactions O O 0.9262077212333679
between O O 0.997330904006958
clonidine S-Chemical B-Chemical 0.929103434085846
and O O 0.9652354121208191
methylphenidate S-Chemical B-Chemical 0.9262888431549072
regarding O O 0.9966675639152527
cardiovascular O O 0.7657468914985657
outcomes O O 0.6370129585266113
. O O 0.9999107122421265

correlated O O 0.9726210832595825
with O O 0.9999547004699707
the O O 0.9999827146530151
ability O O 0.9998753070831299
of O O 0.9999687671661377
CD40 S-protein S-protein 0.9669311046600342
to O O 0.9988740086555481
induce O O 0.9998496770858765
Ab O S-protein 0.8450512886047363
secretion O O 0.988973081111908
and O O 0.999924898147583
the O O 0.9999903440475464
up-regulation O O 0.9961876273155212
of O O 0.9996981620788574
ICAM-1 S-protein S-protein 0.6946439146995544

There O O 0.9998154044151306
were O O 0.9999945163726807
no O O 0.9999758005142212
suggestions O O 0.9998992681503296
of O O 0.9999512434005737
interactions O O 0.9262077212333679
between O O 0.997330904006958
clonidine B-Chemical B-Chemical 0.929103434085846
and O O 0.9652354121208191
methylphenidate B-Chemical B-Chemical 0.9262888431549072
regarding O O 0.9966675639152527
cardiovascular O O 0.7657468914985657
outcomes O O 0.6370129585266113
. O O 0.9999107122421265

used O O 0.9805842638015747

Hypertension O O 0.938715934753418
was O O 0.9661850333213806
observed O O 0.9995750784873962
in O O 0.9999716281890869
animals O O 0.9726952910423279
that O O 0.999921441078186
had O O 0.9998321533203125
a O O 0.9997386336326599
reduction O O 0.9478471875190735
in O O 0.9774852991104126
glomeruli O O 0.4852489233016968
as O O 0.9929713606834412
well O O 0.9978464841842651
as O O 0.9999710321426392
in O O 0.9999269247055054
a O O 0.9997485280036926
group O O 0.9980431795120239
that O O 0.9999792575836182
did O O 0.9999097585678101
not O O 0.99981290102005
have O O 0.9999780654907227
a O O 0.9998063445091248
reduction O O 0.9526969194412231
in O O 0.9854651093482971
glomerular O O 0.8507753014564514
number O O 0.7408814430236816
, O O 0.9995716214179993
suggesting O O 0.9999924898147583
that O O 0.9999935626983643
a O O 0.99985671043396
reduction O O 0.9741165041923523
in O O 0.9918176531791687
glomerular O O 0.8736996650695801
number O O 0.7489174008369446
is O O 0.9995163679122925
not O O 0.9999648332595825
the O O 0.9999854564666748
sole O O 0.9995999932289124
cause O O 0.9998906850814819
for O O 0.9999699592590332
the O O 0.9997792840003967
development O O 0.9939448237419128
of O O 0.99972003698349
hypertension O B-Disease 0.9792345762252808
. O O 0.9990646243095398

Pethidine S-Chemical B-Chemical 0.9233375191688538
- O O 0.9623544812202454
associated O O 0.9927681684494019
seizure O B-Disease 0.9891901016235352
in O O 0.9776196479797363
a O O 0.9979087114334106
healthy O O 0.7553240060806274
adolescent O O 0.6864646077156067
receiving O O 0.9951335787773132
pethidine S-Chemical B-Chemical 0.9254270792007446
for O O 0.999014139175415
postoperative O O 0.8450449109077454
pain O O 0.6604788303375244
control O O 0.7772186994552612
. O O 0.9999717473983765

In O O 0.9997524619102478
both O O 0.9997887015342712
ecstasy B-Chemical B-Chemical 0.8890414834022522
and O O 0.989840030670166
cannabis B-Chemical B-Chemical 0.8795492053031921
groups O O 0.7978104948997498
brain O O 0.8908886313438416
activation O O 0.8218721151351929
was O O 0.9997733235359192
decreased O O 0.998050332069397
in O O 0.9999569654464722
the O O 0.9998127818107605
right O O 0.9951828122138977
medial O O 0.993391752243042
frontal O O 0.9520611763000488
gyrus O O 0.5707066655158997
, O O 0.9993258714675903
left O O 0.9482237100601196
parahippocampal O O 0.6150510907173157
gyrus O O 0.7386609315872192
, O O 0.9946187734603882
left O O 0.9081270098686218
dorsal O O 0.8939263820648193
cingulate O O 0.9005747437477112
gyrus O O 0.38664954900741577
, O O 0.9971309304237366
and O O 0.9999617338180542
left O O 0.9814592599868774
caudate O O 0.7980524897575378
. O O 0.9999902248382568

permanent O O 0.8663603663444519

A O O 0.9989629983901978
Phase O O 0.9980829954147339
I O O 0.9943663477897644
study O O 0.9998093247413635
of O O 0.9999221563339233
intravenous O O 0.4760660231113434
( O O 0.9491991400718689
IV O O 0.3976341485977173
) O O 0.9533119201660156
bolus O O 0.6556634902954102
4 B-Chemical B-Chemical 0.7230751514434814
' I-Chemical I-Chemical 0.6713324189186096
- I-Chemical I-Chemical 0.8332774043083191
0 I-Chemical I-Chemical 0.9663092494010925
- I-Chemical I-Chemical 0.9954078793525696
tetrahydropyranyladriamycin E-Chemical I-Chemical 0.9340721964836121
( O O 0.8457258939743042
Pirarubicin S-Chemical B-Chemical 0.922173261642456
) O O 0.7004500031471252
was O O 0.9998723268508911
done O O 0.9999734163284302
in O O 0.9999963045120239
55 O O 0.9971343278884888
patients O O 0.9998807907104492
in O O 0.999994158744812
good O O 0.9798758029937744
performance O O 0.9549932479858398
status O O 0.942478597164154
with O O 0.9999860525131226
refractory O O 0.5995648503303528
tumors O O 0.6683942079544067
. O O 0.9997019171714783

examined O O 0.996600329875946
in O O 0.9999901056289673
this O O 0.999993085861206
group O O 0.9951053857803345
also O O 0.9999465942382812
expressed O O 0.9999078512191772
1 B-protein B-protein 0.5836743712425232
, I-protein I-protein 0.6347231864929199
25 I-protein I-protein 0.5021989345550537
( I-protein I-protein 0.8574258089065552
OH I-protein I-protein 0.6501409411430359
) I-protein I-protein 0.5878228545188904
2D3 I-protein I-protein 0.842924177646637
receptors E-protein E-protein 0.9904336929321289
. O O 0.9998121857643127
Most O O 0.9918138980865479
B B-cell_line B-cell_type 0.7683615684509277

the O O 0.9962015748023987

However O O 0.9991186261177063
, O O 0.9999805688858032
for O O 0.9999295473098755
recipients O O 0.9987916350364685
of O O 0.9999313354492188
organ O O 0.8829566240310669
transplantation O O 0.8789271116256714
, O O 0.9999654293060303
removing O O 0.9995693564414978
the O O 0.9997794032096863
inciting O O 0.6033163070678711
agent O O 0.771938145160675
is O O 0.9997684359550476
not O O 0.999963641166687
without O O 0.9999569654464722
the O O 0.9998664855957031
attendant O O 0.9777892231941223
risk O O 0.9966514706611633
of O O 0.9998874664306641
precipitating O O 0.9967161417007446
acute O O 0.7853883504867554
rejection O O 0.6335218548774719
and O O 0.9919825196266174
graft O O 0.7589876651763916
loss O O 0.956878662109375
. O O 0.9971733093261719

At O O 0.9998807907104492
the O O 0.9999929666519165
highest O O 0.9952694773674011
effective O O 0.9936742782592773
doses O O 0.9992327690124512
, O O 0.9999926090240479
PG B-Chemical B-Chemical 0.9477234482765198
- I-Chemical I-Chemical 0.9856739640235901
9 I-Chemical I-Chemical 0.9325998425483704
did O O 0.9872785806655884
not O O 0.9999686479568481
produce O O 0.9999573230743408
any O O 0.9998811483383179
collateral O O 0.7710235714912415
symptoms O O 0.5207037329673767
as O O 0.99922776222229
revealed O O 0.9998549222946167
by O O 0.9999973773956299
the O O 0.999963641166687
Irwin O O 0.9192784428596497
test O O 0.9954568147659302
, O O 0.9999929666519165
and O O 0.9999895095825195
it O O 0.9999430179595947
did O O 0.9999885559082031
not O O 0.9999465942382812
modify O O 0.9998252987861633
spontaneous O O 0.8730157017707825
motility O O 0.6727392673492432
and O O 0.9990410208702087
inspection O O 0.9557435512542725
activity O O 0.9544879198074341
, O O 0.9999545812606812
as O O 0.9999942779541016
revealed O O 0.9999434947967529
by O O 0.9999939203262329
the O O 0.9999486207962036
hole O O 0.9975021481513977
- O O 0.9999151229858398
board O O 0.9989901185035706
test O O 0.9995623230934143
. O O 0.9999988079071045

The O O 0.9992868304252625
Multiple O O 0.9703773260116577
Sleep O O 0.582545816898346
Latency O O 0.5087327361106873
Test O O 0.9431905150413513
was O O 0.9999808073043823
performed O O 0.9999985694885254
at O O 0.9999986886978149
11 O O 0.9998807907104492
: O O 0.9999793767929077
30 O O 0.9999741315841675
a O O 0.9999858140945435
. O O 0.999992847442627
m O O 0.9995027780532837
. O O 0.9999563694000244
, O O 0.9999653100967407
2 O O 0.9999246597290039
: O O 0.9999864101409912
00 O O 0.9999607801437378
p O O 0.9998728036880493
. O O 0.9999909400939941
m O O 0.9982041120529175
. O O 0.9999287128448486
, O O 0.9999198913574219
and O O 0.9999731779098511
4 O O 0.9997867941856384
: O O 0.9999607801437378
30 O O 0.9999454021453857
p O O 0.9997206330299377
. O O 0.9999897480010986
m O O 0.9953977465629578
. O O 0.9999197721481323
on O O 0.999970555305481
days O O 0.9999456405639648
2 O O 0.9999674558639526
, O O 0.9999583959579468
8 O O 0.999783456325531
, O O 0.9999231100082397
and O O 0.9999228715896606
15 O O 0.9987988471984863
. O O 0.999988317489624

T-cell O O 0.4686809480190277
function O O 0.9771923422813416
, O O 0.9997754693031311
and O O 0.9999731779098511
uncover O O 0.9997816681861877
a O O 0.999946117401123
previously O O 0.9921269416809082
unrecognized O O 0.9899594783782959
function O O 0.9982808828353882
for O O 0.9999773502349854
PI B-protein B-protein 0.47795820236206055
3-kinase E-protein E-protein 0.980692446231842
in O O 0.9990515112876892
T B-cell_type B-cell_type 0.8885233998298645
cells E-cell_type E-cell_type 0.9897359609603882
as O O 0.9997830986976624
a O O 0.9999864101409912
selective O O 0.9351362586021423

heterologous B-protein B-protein 0.636469841003418
viral I-protein I-protein 0.44062748551368713
transcription-activating I-protein I-protein 0.7298063039779663
domain E-protein E-protein 0.9770075082778931
. O O 0.9997746348381042
The O O 0.9999974966049194
specificity O O 0.9981396198272705
of O O 0.9999204874038696
CIITA S-protein S-protein 0.5945284962654114
for O O 0.999524712562561
three O O 0.9983680844306946
major O O 0.9304049015045166
MHC B-DNA B-DNA 0.2993888556957245
class I-DNA I-DNA 0.582783579826355
II I-DNA I-DNA 0.47469717264175415
genes E-DNA E-DNA 0.9796455502510071
, O O 0.9979161620140076
DR S-DNA S-DNA 0.8910924792289734
, O O 0.9711355566978455

response O O 0.8237086534500122
element-binding O O 0.6667780876159668
activity O O 0.9947106838226318
, O O 0.9999909400939941
indicating O O 0.9999974966049194
that O O 0.9999984502792358
the O O 0.9999526739120483
PAS B-protein B-protein 0.2968064248561859
domain E-protein E-protein 0.8487231135368347
may O O 0.9995456337928772
be O O 0.9999982118606567
important O O 0.9999160766601562
for O O 0.9999821186065674
DNA-binding O O 0.7511552572250366
affinity O O 0.7831229567527771
and/or O O 0.4146758019924164
specificity O O 0.9653716087341309

Evaluation O O 0.9966643452644348
of O O 0.9999420642852783
cardiac O O 0.9333240985870361
troponin O O 0.5874722599983215
I O O 0.6169978380203247
and O O 0.998573899269104
T O O 0.6881769895553589
levels O O 0.9956100583076477
as O O 0.9999971389770508
markers O O 0.9799374938011169
of O O 0.9996665716171265
myocardial O B-Disease 0.677647590637207
damage O I-Disease 0.9826650023460388
in O O 0.9285551309585571
doxorubicin S-Chemical B-Chemical 0.9357352256774902
- O O 0.9012459516525269
induced O O 0.9965190887451172
cardiomyopathy O B-Disease 0.9524046778678894
rats O O 0.6680194735527039
, O O 0.9995620846748352
and O O 0.9999523162841797
their O O 0.9997757077217102
relationship O O 0.9971080422401428
with O O 0.9999856948852539
echocardiographic O O 0.69148188829422
and O O 0.9355340003967285
histological O O 0.8133508563041687
findings O O 0.8700695633888245
. O O 0.999991774559021

CD34 S-protein S-protein 0.8682448863983154
, O O 0.9888078570365906
CD41a S-protein S-protein 0.9516963958740234
, O O 0.9879617094993591
and O O 0.9984453320503235
glycophorin B-protein B-protein 0.5490526556968689
A I-protein I-protein 0.46389496326446533
antigens E-protein E-protein 0.9823040962219238
. O O 0.9989978671073914
Ultrastructurally O O 0.9917669892311096
, O O 0.9998944997787476
the O O 0.9998455047607422
cells O O 0.9718555212020874
had O O 0.9999656677246094
alpha-granules O O 0.48347362875938416
, O O 0.983717679977417
demarcation O O 0.8218031525611877
membranes O O 0.6585836410522461
, O O 0.9967926144599915
and O O 0.9997182488441467
platelet B-protein O 0.6267929077148438
peroxidase E-protein O 0.45360690355300903
activity O O 0.9719688296318054

likely O O 0.9745791554450989
plays O O 0.9998676776885986
a O O 0.9999929666519165
role O O 0.9998997449874878
in O O 0.9999866485595703
regulating O O 0.9900009632110596
lymphocyte O O 0.5211982131004333
homeostasis O O 0.47475695610046387
. O O 0.9999020099639893
Differential O O 0.9332019090652466
nuclear O O 0.8909341096878052
localization O O 0.958016037940979
of O O 0.9983559250831604
p50 S-protein S-protein 0.9577127695083618
, O O 0.9439385533332825
p52 S-protein S-protein 0.9629563093185425
, O O 0.9621841311454773
and O O 0.9850409626960754
RelB S-protein B-protein 0.9241730570793152
proteins O E-protein 0.9513899683952332
in O O 0.9994524121284485
human B-cell_type B-cell_type 0.6492083072662354
accessory I-cell_type I-cell_type 0.8079873323440552
cells E-cell_type E-cell_type 0.9603183269500732
of O O 0.9951017498970032
the O O 0.9998334646224976
immune O O 0.574629008769989

of O O 0.9974080920219421
the O O 0.9999613761901855
kappaB-Sp1 B-DNA B-DNA 0.3761174976825714
composite I-DNA I-DNA 0.654790997505188
site E-DNA E-DNA 0.9878913164138794
in O O 0.9993532299995422
P/I-inducible B-DNA B-DNA 0.5888722538948059
fas I-DNA I-DNA 0.3786124885082245
promoter E-DNA E-DNA 0.9405565857887268
activation O O 0.9121513366699219
was O O 0.9997739195823669
verified O O 0.9999370574951172
by O O 0.9999916553497314
using O O 0.9991876482963562
kappaB- O B-protein 0.8301752805709839
Sp1 S-protein I-protein 0.2369668036699295
concatamers O E-protein 0.5063501596450806
( O O 0.9721415042877197
-295 B-DNA B-DNA 0.6608168482780457
to I-DNA I-DNA 0.6742497086524963
-286 E-DNA E-DNA 0.910397469997406
) O O 0.9501554369926453
in O O 0.9999802112579346
a O O 0.9999372959136963
thymidine B-DNA B-DNA 0.42820224165916443
kinase I-DNA I-DNA 0.3687683641910553
promoter-driven I-DNA I-DNA 0.6541407704353333
reporter I-DNA I-DNA 0.6285380125045776
construct E-DNA E-DNA 0.984798014163971
and O O 0.9871496558189392
native B-DNA B-DNA 0.4896943271160126
promoter I-DNA I-DNA 0.761849045753479
constructs E-DNA E-DNA 0.9940136075019836
in O O 0.9993636012077332
Jurkat B-cell_line B-cell_line 0.8361755013465881
cells E-cell_line E-cell_line 0.9781156182289124

treatment O O 0.9911064505577087
of O O 0.999941349029541
HL-60/vinc B-cell_line B-cell_line 0.6040985584259033
cells E-cell_line E-cell_line 0.9100713133811951
with O O 0.9998750686645508
okadaic O O 0.9217739105224609
acid O O 0.9583152532577515
, O O 0.9999303817749023
an O O 0.9999873638153076
inhibitor O O 0.9883120656013489
of O O 0.999792754650116
serine/threonine B-protein B-protein 0.6211229562759399
protein I-protein I-protein 0.39341551065444946
phosphatases E-protein E-protein 0.958145260810852
, O O 0.9979721903800964
induces O O 0.9999040365219116
c-jun S-DNA S-DNA 0.8756413459777832
transcription O O 0.9203383326530457
, O O 0.9990805387496948

CONCLUSION O O 0.998612642288208
: O O 0.9999874830245972
When O O 0.9999319314956665
performing O O 0.9992349147796631
intracarotid O O 0.7755011916160583
injection O O 0.9395752549171448
of O O 0.999535083770752
carboplatin B-Chemical B-Chemical 0.9260398745536804
, O O 0.9938848614692688
we O O 0.9999542236328125
must O O 0.9999939203262329
be O O 0.9999878406524658
aware O O 0.9999691247940063
of O O 0.9999613761901855
its O O 0.9999121427536011
potentially O O 0.9890916347503662
blinding O O 0.9114996790885925
ocular B-Disease B-Disease 0.5039301514625549
toxicity I-Disease I-Disease 0.7986410856246948
. O O 0.998281717300415

a O O 0.9756313562393188

the O O 0.9977322816848755
transcriptional B-DNA B-DNA 0.7578955888748169
initiation I-DNA I-DNA 0.5080814361572266
site E-DNA E-DNA 0.9301026463508606
in O O 0.9996428489685059
the O O 0.9999483823776245
U3 B-DNA B-DNA 0.6235256195068359
region E-DNA E-DNA 0.978029191493988
of O O 0.9968666434288025
the O O 0.9998194575309753
LTR S-DNA S-DNA 0.9494391083717346

promyelocytic O O 0.42455407977104187

( O O 0.9263529777526855
gamma B-protein B-protein 0.21390755474567413
B*CaM-K E-protein E-protein 0.9336606860160828
and O O 0.9702789783477783
delta B-protein B-protein 0.51875239610672
CaM-AI E-protein E-protein 0.9517617225646973
, O O 0.9822423458099365
respectively O O 0.9996836185455322
) O O 0.9998326301574707
to O O 0.9999867677688599
explore O O 0.9999843835830688
their O O 0.9999808073043823
relative O O 0.988746702671051
role O O 0.9986050724983215
in O O 0.9999761581420898
cytokine B-DNA B-DNA 0.4823932945728302
gene E-DNA E-DNA 0.780949056148529

mb-1 B-DNA B-DNA 0.45946988463401794
promoter E-DNA E-DNA 0.9949648976325989
. O O 0.9996861219406128
The O O 0.999927282333374
cDNA S-DNA S-DNA 0.8074526190757751
hybridized O O 0.4943615794181824
to O O 0.9838771224021912
multiple O O 0.871794581413269
transcripts O O 0.712550938129425
in O O 0.9980840682983398
pre-B B-cell_line B-cell_line 0.3592807352542877
and I-cell_line I-cell_line 0.43961626291275024
B-cell I-cell_line I-cell_line 0.5771085619926453
lines E-cell_line E-cell_line 0.990304172039032
, O O 0.9972112774848938
but O O 0.9998996257781982
transcripts O O 0.5607560873031616
were O O 0.999921441078186
not O O 0.9999023675918579
detected O O 0.9998660087585449
at O O 0.9999955892562866
significant O O 0.9951972365379333
levels O O 0.9996594190597534
in O O 0.9999525547027588
plasmacytoma S-cell_line O 0.4948744475841522
, O O 0.9883316159248352

OCA-B S-protein S-protein 0.5547218322753906
for O O 0.9965327978134155
the O O 0.9999514818191528
transcriptional O O 0.9579442739486694
regulation O O 0.9977679252624512
of O O 0.9999829530715942
other O O 0.9988412261009216
tissue-specific B-DNA B-DNA 0.42870232462882996
promoters E-DNA E-DNA 0.9707508087158203
. O O 0.9991455078125
SCL S-protein S-protein 0.7153063416481018
and O O 0.9278842210769653
related O O 0.9344562292098999
hemopoietic B-protein B-protein 0.6158418655395508
helix-loop-helix I-protein I-protein 0.3986576795578003
transcription I-protein I-protein 0.7534435391426086
factors E-protein E-protein 0.9953617453575134
. O O 0.9997166991233826
The O O 0.9998927116394043
helix-loop-helix B-protein B-protein 0.23579593002796173
( I-protein I-protein 0.34435033798217773
HLH I-protein I-protein 0.544567883014679
) I-protein I-protein 0.6029862761497498

etiological O O 0.8565444946289062
agent O O 0.9280737638473511
of O O 0.9998902082443237
adult O O 0.887661337852478
T-cell O O 0.7965694069862366
leukemia O O 0.8132610321044922
( O O 0.9954251646995544
ATL O O 0.9320762753486633
) O O 0.9991981387138367
. O O 0.9999940395355225
We O O 0.9999550580978394
showed O O 0.9999939203262329
here O O 0.9999878406524658
by O O 0.9999923706054688
mobility-shift O O 0.8588595986366272
assay O O 0.9893574118614197
that O O 0.9999839067459106
T-cell B-cell_line O 0.530993640422821

She O O 0.9918067455291748
noticed O O 0.9990861415863037
hoarseness B-Disease O 0.9253497123718262
and O O 0.9206015467643738
distally O O 0.5115318298339844
accentuated O O 0.7891643047332764
motor O O 0.4332197308540344
and O O 0.921019434928894
sensory O O 0.6390078663825989
dysfunction O O 0.896093487739563
after O O 0.9939128756523132
she O O 0.9988058805465698
had O O 0.9996464252471924
recovered O O 0.9994470477104187
from O O 0.9999722242355347
this O O 0.9996172189712524
state O O 0.9966089725494385
. O O 0.9999990463256836

OBJECTIVE O O 0.955470621585846
: O O 0.9996011853218079
To O O 0.9999830722808838
examine O O 0.999988317489624
the O O 0.9999500513076782
effect O O 0.9999058246612549
of O O 0.9998059868812561
raloxifene S-Chemical B-Chemical 0.9335042238235474
on O O 0.9993909597396851
major O O 0.9491899013519287
adverse O O 0.8216082453727722
events O O 0.5771062970161438
that O O 0.995907187461853
occur O O 0.9996339082717896
with O O 0.9999972581863403
postmenopausal O O 0.8326853513717651
estrogen S-Chemical B-Chemical 0.8832871317863464
therapy O O 0.9495823979377747
or O O 0.9999165534973145
tamoxifen S-Chemical B-Chemical 0.9201098084449768
. O O 0.9994369149208069

The O O 0.9995564818382263
expression O O 0.994327962398529
of O O 0.9997578263282776
arginine B-Chemical B-Chemical 0.9234592914581299
vasopressin I-Chemical I-Chemical 0.9368522763252258
( O O 0.8372121453285217
AVP B-Chemical B-Chemical 0.8266106247901917
) O O 0.5422973036766052
gene O O 0.5031558871269226
in O O 0.9994044303894043
the O O 0.9997631907463074
paraventricular O O 0.595828652381897
( O O 0.9872437119483948
PVN O O 0.5949393510818481
) O O 0.9786027073860168
and O O 0.9997556805610657
supraoptic O O 0.7908483743667603
nuclei O O 0.4330649673938751
( O O 0.998569130897522
SON O O 0.4685487449169159
) O O 0.9642777442932129
was O O 0.9999504089355469
investigated O O 0.9999896287918091
in O O 0.9999886751174927
rats O O 0.9976420402526855
with O O 0.9999624490737915
lithium B-Chemical B-Chemical 0.9322528839111328
( O O 0.8326398134231567
Li B-Chemical B-Chemical 0.9208586812019348
) O O 0.6487323641777039
- O O 0.9745714068412781
induced O O 0.9977760910987854
polyuria B-Disease B-Disease 0.9881755113601685
, O O 0.9760286211967468
using O O 0.9997486472129822
in O O 0.9998835325241089
situ O O 0.918052077293396
hybridization O O 0.9117313623428345
histochemistry O O 0.719412624835968
and O O 0.9994472861289978
radioimmunoassay O O 0.3681345283985138
. O O 0.999841570854187

in O O 0.996503472328186
inhibition O O 0.9678394198417664
rather O O 0.9993921518325806
than O O 0.999925971031189
activation O O 0.9928681254386902
of O O 0.9998897314071655
NF-kappa B-DNA B-DNA 0.4824698567390442
B-regulated I-DNA I-DNA 0.6482946872711182
inflammatory I-DNA I-DNA 0.6845502257347107
cytokine I-DNA I-DNA 0.7609067559242249
genes E-DNA E-DNA 0.9868801832199097
. O O 0.999897837638855
Consequently O O 0.999993085861206
, O O 0.9999957084655762
these O O 0.9999905824661255
results O O 0.9999148845672607
suggest O O 0.999997615814209
that O O 0.9999953508377075
physiologically O O 0.9396018981933594
relevant O O 0.9922469854354858
concentrations O O 0.9992170333862305
of O O 0.9999567270278931
ethanol O O 0.85005784034729
may O O 0.999914288520813
affect O O 0.9999957084655762
production O O 0.9991014003753662
of O O 0.999972939491272
inflammatory B-protein B-protein 0.7142986059188843
cytokines E-protein E-protein 0.9738453030586243
, O O 0.9994470477104187
such O O 0.9999887943267822
as O O 0.9999650716781616

Chronic O O 0.8622780442237854
enalapril S-Chemical B-Chemical 0.922787606716156
treatment O O 0.988545835018158
reduced O O 0.9977220892906189
blood O O 0.9641637206077576
pressure O O 0.6697314381599426
without O O 0.9997606873512268
reducing O O 0.9962992072105408
albuminuria O O 0.926038920879364
in O O 0.9908011555671692
group O O 0.9566990733146667
4 O O 0.9791194796562195
. O O 0.9999842643737793

EC-Mn O B-protein 0.14893507957458496

One O O 0.9941973686218262
patient O O 0.9994021654129028
had O O 0.9998972415924072
focal O O 0.6208867430686951
seizures O O 0.7236265540122986
and O O 0.9778233766555786
transient O O 0.7288217544555664
hemiparesis O O 0.4998749792575836
but O O 0.9816746115684509
recovered O O 0.9968175888061523
completely O O 0.9986716508865356
. O O 0.9999974966049194

Delirium B-Disease B-Chemical 0.791799783706665
, O O 0.9447214603424072
which O O 0.9992979764938354
may O O 0.9999644756317139
be O O 0.9999701976776123
induced O O 0.9996957778930664
by O O 0.9999817609786987
tricyclic O O 0.7910210490226746
drug O O 0.8194519281387329
therapy O O 0.968309760093689
in O O 0.9999184608459473
the O O 0.9992932081222534
elderly O O 0.9416744112968445
, O O 0.9995230436325073
can O O 0.9996016621589661
be O O 0.9999620914459229
caused O O 0.9995548129081726
by O O 0.9999350309371948
tricyclics O O 0.4004316031932831
with O O 0.9994819760322571
low O O 0.920772135257721
anticholinergic O O 0.4894023537635803
potency O O 0.6646916270256042
. O O 0.999942421913147

and O O 0.966045618057251
fibrosis O O 0.7979322075843811
of O O 0.9989087581634521
the O O 0.9999585151672363
tubulointerstitium O O 0.3679947555065155
, O O 0.9787237644195557
with O O 0.9999444484710693
the O O 0.9999889135360718
subsequent O O 0.997443437576294
loss O O 0.9846416115760803

The O O 0.9995577931404114
results O O 0.9999035596847534
suggest O O 0.9999951124191284
that O O 0.9999573230743408
rigidity O B-Disease 0.9699532985687256
, O O 0.9640026092529297
which O O 0.9994797110557556
is O O 0.9999457597732544
assumed O O 0.9999268054962158
to O O 0.999944806098938
be O O 0.9999330043792725
due O O 0.9999847412109375
to O O 0.9999804496765137
an O O 0.9999063014984131
action O O 0.9962576627731323
of O O 0.9980782270431519
morphine S-Chemical B-Chemical 0.9278395175933838
in O O 0.9983273148536682
the O O 0.9997507929801941
striatum O O 0.6451032757759094
, O O 0.9992938041687012
can O O 0.9999412298202515
be O O 0.999953031539917
antagonized O O 0.9971470236778259
by O O 0.9999895095825195
another O O 0.9999709129333496
process O O 0.999647855758667
leading O O 0.9999847412109375
to O O 0.9999697208404541
dopaminergic O O 0.4356171488761902
activation O O 0.6719129681587219
in O O 0.9995957016944885
the O O 0.9997435212135315
striatum O O 0.7618558406829834
. O O 0.9999668598175049

Effect O O 0.9966661334037781
of O O 0.999663233757019
aspirin S-Chemical B-Chemical 0.9385254383087158
on O O 0.9437060952186584
N B-Chemical B-Chemical 0.961871325969696
- I-Chemical I-Chemical 0.9860068559646606
[ I-Chemical I-Chemical 0.9885355830192566
4 I-Chemical I-Chemical 0.9796159267425537
- I-Chemical I-Chemical 0.9939025640487671
( I-Chemical I-Chemical 0.9947957396507263
5 I-Chemical I-Chemical 0.9881696701049805
- I-Chemical I-Chemical 0.9959396123886108
nitro I-Chemical I-Chemical 0.9709875583648682
- I-Chemical I-Chemical 0.9956876635551453
2 I-Chemical I-Chemical 0.9835019707679749
- I-Chemical I-Chemical 0.9965684413909912
furyl I-Chemical I-Chemical 0.9712055325508118
) I-Chemical I-Chemical 0.978408932685852
- I-Chemical I-Chemical 0.9953793287277222
2 I-Chemical I-Chemical 0.9829853177070618
- I-Chemical I-Chemical 0.9967709183692932
thiazolyl I-Chemical I-Chemical 0.9614372253417969
] I-Chemical I-Chemical 0.9719588160514832
- I-Chemical I-Chemical 0.9920256733894348
formamide E-Chemical E-Chemical 0.9235017895698547
- O O 0.5581722855567932
induced O O 0.9970887303352356
epithelial O O 0.7080180644989014
proliferation O O 0.8971096873283386
in O O 0.9732093214988708
the O O 0.9921369552612305
urinary O O 0.9247432947158813
bladder O O 0.6150785088539124
and O O 0.9986496567726135
forestomach O O 0.6031287908554077
of O O 0.9232693910598755
the O O 0.9804019331932068
rat O O 0.9243402481079102
. O O 0.9999626874923706

infection O O 0.9344964027404785
of O O 0.9994763731956482
human B-cell_type B-cell_type 0.6576899886131287
thymocytes E-cell_type E-cell_type 0.9920217990875244
: O O 0.9958615899085999
simultaneous O O 0.983424961566925
early O O 0.9457994103431702
expression O O 0.9932470321655273
of O O 0.999785840511322
BZLF-1 S-protein S-protein 0.9271656274795532
and O O 0.9967101812362671
its O O 0.999715268611908
repressor O B-protein 0.7949302792549133
RAZ S-protein E-protein 0.6536864042282104
. O O 0.9959295392036438
Epstein-Barr O O 0.901200532913208
virus O O 0.8877911567687988
( O O 0.9968788623809814
EBV O O 0.974728524684906
) O O 0.9989892840385437
is O O 0.9999868869781494
known O O 0.999897837638855
to O O 0.9993212223052979

Total O O 0.9869855046272278
cumulative O O 0.9551054239273071
doses O O 0.9912619590759277
were O O 0.9999533891677856
36 O O 0.9986318945884705
or O O 0.9999790191650391
60 O O 0.9998576641082764
g O O 0.9997319579124451
/ O O 0.9999568462371826
m2 O O 0.9994156360626221
of O O 0.9987614154815674
ifosfamide B-Chemical B-Chemical 0.9352999329566956
( O O 0.9671890735626221
six O O 0.9952882528305054
or O O 0.9999427795410156
10 O O 0.9997175335884094
cycles O O 0.9979821443557739
of O O 0.9987506866455078
ifosfamide B-Chemical B-Chemical 0.9375385046005249
, I-Chemical O 0.5035101175308228
vincristine I-Chemical B-Chemical 0.8181422352790833
, I-Chemical O 0.5009910464286804
and I-Chemical O 0.8342025279998779
dactinomycin I-Chemical B-Chemical 0.8822623491287231
[ O O 0.7604087591171265
IVA B-Chemical B-Chemical 0.9194903373718262
] O O 0.7471736669540405
) O O 0.9973533153533936
. O O 0.9999977350234985

kinase-1 E-protein E-protein 0.7334683537483215
but O O 0.9802360534667969
upstream O O 0.9186443090438843
of O O 0.997536301612854
MAPK S-protein S-protein 0.9744201898574829
and O O 0.9971010088920593
suggest O O 0.9999477863311768
that O O 0.9999958276748657
, O O 0.9996752738952637
in O O 0.9999557733535767
the O O 0.9998836517333984
signaling O O 0.9678415656089783
pathway O O 0.9944593906402588
of O O 0.9999629259109497
the O O 0.9999657869338989
apoptotic O O 0.7855043411254883
process O O 0.8724833130836487
induced O O 0.9997857213020325
by O O 0.9999709129333496
bufalin O O 0.49359792470932007
, O O 0.9998422861099243
the O O 0.9999861717224121
transcriptional O O 0.9479497075080872
activity O O 0.9955167174339294
of O O 0.9999349117279053
activator B-protein B-protein 0.4865042567253113
protein-1 E-protein E-protein 0.9842661619186401
may O O 0.9995787739753723
be O O 0.9999805688858032
down-regulated O O 0.9976574182510376
through O O 0.9999898672103882
the O O 0.9999090433120728

These O O 0.9998624324798584
findings O O 0.9999688863754272
suggest O O 0.9999984502792358
that O O 0.9999942779541016
estrogen S-Chemical B-Chemical 0.9345711469650269
downregulates O O 0.9824923276901245
alpha2 O O 0.3929036259651184
- O O 0.9196642637252808
but O O 0.9997746348381042
not O O 0.9998929500579834
I1 O O 0.8291880488395691
- O O 0.9941978454589844
receptor O O 0.9812582731246948
- O O 0.9994518160820007
mediated O O 0.9953468441963196
hypotension O B-Disease 0.9819544553756714
and O O 0.9836709499359131
highlight O O 0.9991810917854309
a O O 0.9999626874923706
role O O 0.9989150762557983
for O O 0.9999904632568359
the O O 0.9999170303344727
cardiac O O 0.8946199417114258
autonomic O O 0.7337218523025513
control O O 0.7203634977340698
in O O 0.999352753162384
alpha B-Chemical B-Chemical 0.5071155428886414
- I-Chemical I-Chemical 0.9508031606674194
methyldopa E-Chemical I-Chemical 0.954124391078949
- O I-Chemical 0.8552687764167786
estrogen S-Chemical I-Chemical 0.8391295075416565
interaction O O 0.9119124412536621
. O O 0.9999864101409912

chelating O O 0.573093831539154
activities O O 0.9916483163833618
, O O 0.999991774559021
we O O 0.9999866485595703
tested O O 0.999968409538269
the O O 0.9999775886535645
effects O O 0.9999074935913086
of O O 0.9999842643737793
N-acetyl-L-cysteine O O 0.82748943567276
( O O 0.9965649247169495
NAC O O 0.8974279165267944
) O O 0.9951221346855164
( O O 0.9998530149459839
antioxidant O O 0.9102782011032104
) O O 0.9871273040771484
or O O 0.999790608882904
o-phenanthroline O O 0.8158251643180847
( O O 0.9894842505455017
OP O O 0.7867850065231323
) O O 0.9779520034790039
( O O 0.9997469782829285
metal-ion O O 0.8554313778877258
chelator O O 0.7163209915161133
) O O 0.9419615268707275
on O O 0.9997854828834534
the O O 0.9999301433563232
induction O O 0.9965066313743591
of O O 0.9999290704727173
apoptosis O O 0.9793457984924316
. O O 0.999990701675415
Pretreatment O O 0.9788525700569153
of O O 0.9994155168533325
HL-60 O B-cell_line 0.7087578773498535
cells O E-cell_line 0.9622260928153992
or O O 0.9971053004264832
thymocytes S-cell_type S-cell_type 0.9679347276687622
with O O 0.9994007349014282

as O O 0.9994831085205078
a O O 0.9999932050704956
mucolytic O O 0.8727011680603027
agent O O 0.8824382424354553
in O O 0.9999558925628662
adult O O 0.8987367749214172
chronic O O 0.9415282607078552
bronchitis O O 0.9361533522605896
. O O 0.9999912977218628
Tyloxapol O O 0.8877047300338745
inhibits O O 0.9991523027420044
activation O O 0.9978697299957275
of O O 0.9998867511749268
the O O 0.9996210336685181
transcription B-protein B-protein 0.5092973709106445
factor I-protein E-protein 0.866665244102478
nuclear I-protein B-protein 0.3691338002681732
factor-kappa I-protein I-protein 0.7465541958808899
B E-protein E-protein 0.9320094585418701
( O O 0.9441272020339966
NK-kappa B-protein B-protein 0.674863338470459
B E-protein E-protein 0.9394361972808838
) O O 0.8895745277404785
, O O 0.9977430105209351

The O O 0.9997064471244812
purpose O O 0.9997155070304871
of O O 0.9999957084655762
this O O 0.9999899864196777
study O O 0.9999071359634399
was O O 0.9999979734420776
to O O 0.9999940395355225
investigate O O 0.9999773502349854
the O O 0.9998724460601807
influence O O 0.9976044297218323
of O O 0.9997826218605042
calcium S-Chemical B-Chemical 0.9319673180580139
channel O O 0.4725143015384674
blockers O O 0.8157631158828735
on O O 0.999839186668396
bupivacaine S-Chemical B-Chemical 0.9223223924636841
- O O 0.9638893008232117
induced O O 0.9995480179786682
acute O O 0.5620005130767822
toxicity O B-Disease 0.5229941010475159
. O O 0.9988596439361572

A O O 0.9938033819198608
novel O O 0.9554102420806885
transcription B-protein B-protein 0.5915685892105103
factor E-protein E-protein 0.9880437254905701
regulates O O 0.9986061453819275
expression O O 0.9985514283180237
of O O 0.9999624490737915
the O O 0.9998162388801575
vacuolar B-protein B-protein 0.3806396722793579
H+-ATPase I-protein I-protein 0.4971032738685608
B2 I-protein I-protein 0.4440898299217224
subunit E-protein E-protein 0.980065643787384
through O O 0.9990493655204773
AP-2 B-DNA B-DNA 0.6574642658233643
sites E-DNA E-DNA 0.8552054166793823
during O O 0.9995206594467163
monocytic O O 0.7793139219284058
differentiation O O 0.9735825061798096
. O O 0.9999816417694092
During O O 0.9998785257339478
monocyte-to-macrophage O O 0.70332270860672
differentiation O O 0.9885148406028748
, O O 0.9999843835830688
the O O 0.9999908208847046
cellular O O 0.9428175687789917
content O O 0.9822027683258057
of O O 0.9997870326042175
vacuolar B-protein B-protein 0.4902312755584717
H+-ATPase E-protein E-protein 0.8953283429145813
( O O 0.9677209854125977
V-ATPase S-protein S-protein 0.48702046275138855

the O O 0.9972004890441895
RANTES B-DNA B-DNA 0.4658319056034088
promoter I-DNA I-DNA 0.8924974203109741
region E-DNA E-DNA 0.987281858921051
was O O 0.9991903901100159
analyzed O O 0.9999736547470093
by O O 0.9999939203262329
transient O O 0.8411723375320435
expression O O 0.9345192313194275
and O O 0.9969907999038696
gel-mobility O O 0.8134874105453491
shift O O 0.8916420936584473
assays O O 0.9600151777267456
. O O 0.999994158744812
We O O 0.9999809265136719
demonstrate O O 0.9999951124191284
that O O 0.9999960660934448
: O O 0.9988998174667358
1 O O 0.9968434572219849
) O O 0.9947029948234558
RANTES S-protein B-DNA 0.4248296022415161
promoter O E-DNA 0.9430553913116455
activity O O 0.9769744277000427
is O O 0.9999841451644897
up-regulated O O 0.9995940327644348
by O O 0.9999939203262329
PMA O O 0.8688974380493164
plus O O 0.9918647408485413

PU.1 S-protein S-protein 0.9035550951957703
and O O 0.991163969039917
Spi-B S-protein S-protein 0.9580799341201782
may O O 0.9993669390678406
bind O O 0.9997058510780334
to O O 0.9999878406524658
similar O O 0.9890594482421875
DNA O B-DNA 0.822015106678009
control O I-DNA 0.620372474193573
elements O E-DNA 0.9586199522018433
and O O 0.9987564086914062
have O O 0.9999892711639404
redundancy O O 0.9959957599639893
of O O 0.9996582269668579
transactivation O O 0.8611260652542114
function O O 0.9748858213424683

One O O 0.9995163679122925
week O O 0.9999605417251587
later O O 0.9999819993972778
, O O 0.9999241828918457
by O O 0.999893307685852
mistake O O 0.9643619060516357
, O O 0.9998565912246704
losartan S-Chemical B-Chemical 0.9269310235977173
was O O 0.9938338994979858
prescribed O O 0.999853253364563
again O O 0.9999507665634155
and O O 0.9999855756759644
after O O 0.9999796152114868
the O O 0.9999860525131226
second O O 0.9991955161094666
dose O O 0.9996962547302246
of O O 0.9999648332595825
50 O O 0.9930296540260315
mg O O 0.9934481978416443
, O O 0.9999916553497314
the O O 0.9999772310256958
patient O O 0.999357283115387
developed O O 0.999906063079834
a O O 0.9998632669448853
second O O 0.9955793023109436
episode O O 0.9383748769760132
of O O 0.9979140162467957
transient O O 0.7774097323417664
anuria O B-Disease 0.7081683278083801
lasting O O 0.984135091304779
10 O O 0.9995948672294617
hours O O 0.9999569654464722
. O O 0.9999991655349731

cis B-DNA B-DNA 0.20630773901939392
element E-DNA E-DNA 0.9719233512878418
binds O O 0.9976270794868469
a O O 0.9999696016311646
protein O B-protein 0.7564505934715271
complex O E-protein 0.9736126661300659
referred O O 0.9995843768119812
to O O 0.9999483823776245
as O O 0.9998401403427124
HRF S-protein S-protein 0.9014120101928711
( O O 0.9691283106803894
heme-responsive B-protein B-protein 0.5558272004127502
factor E-protein E-protein 0.8905488848686218
) O O 0.49267566204071045
, O O 0.9935684204101562
which O O 0.9999057054519653
is O O 0.9999468326568604
greatly O O 0.9995818734169006
enhanced O O 0.999690055847168
both O O 0.9999821186065674
in O O 0.9991124272346497
heme-treated O B-cell_line 0.5802319049835205
FLCs S-cell_line E-cell_line 0.8901175260543823
and O O 0.997579038143158
during O O 0.998863935470581
monocyte-to-macrophage O O 0.4486527144908905
differentiation O O 0.9498040676116943

This O O 0.9992006421089172
hemorrhagic O O 0.7115488648414612
ulcer O O 0.8142092227935791
and O O 0.9843388795852661
various O O 0.9969338178634644
ulcerogenic O O 0.6088957190513611
parameters O O 0.5540680885314941
were O O 0.9997261166572571
dose O O 0.9987562894821167
- O O 0.9998577833175659
dependently O O 0.9990149736404419
ameliorated O O 0.9955204725265503
by O O 0.999981164932251
daily O O 0.9765396118164062
intragastric O O 0.8854954838752747
verapamil S-Chemical B-Chemical 0.9230338335037231
. O O 0.9996999502182007

were O O 0.9970349073410034
also O O 0.9999070167541504
detected O O 0.9998519420623779
in O O 0.9999629259109497
this O O 0.9996300935745239
subset O O 0.9630421996116638
in O O 0.9999505281448364
addition O O 0.9994934797286987
to O O 0.9999338388442993
c-kit S-protein S-protein 0.9049133062362671
and O O 0.9952303171157837
flt-3 S-protein S-protein 0.8611359000205994
, O O 0.9916191101074219
receptors O O 0.6656248569488525
known O O 0.999403715133667
to O O 0.9998176693916321
be O O 0.9999161958694458
expressed O O 0.9995343685150146
on O O 0.999767005443573
progenitor B-cell_type O 0.3925659954547882

fashion O O 0.7517736554145813
, O O 0.9996044039726257
the O O 0.9999778270721436
nuclear O O 0.927284300327301
accumulation O O 0.9589192271232605
of O O 0.9993517994880676
the O O 0.9998540878295898
JunB B-protein B-protein 0.678058385848999
protein E-protein E-protein 0.9753409624099731
. O O 0.9991961121559143
In O O 0.9999947547912598
this O O 0.9999943971633911
study O O 0.999915361404419
, O O 0.9999955892562866
we O O 0.9999504089355469
demonstrated O O 0.9999818801879883
that O O 0.9999867677688599
IL-6 S-protein S-protein 0.9820111989974976
regulation O O 0.9980205297470093
occurred O O 0.9999841451644897
exclusively O O 0.9999818801879883
at O O 0.9999963045120239
the O O 0.999969482421875
transcriptional O O 0.9146832823753357
level O O 0.9983029365539551
and O O 0.9999849796295166
that O O 0.9999979734420776
the O O 0.999956488609314
bimodal O O 0.8458384871482849
increase O O 0.9938004612922668
of O O 0.999687910079956
junB B-RNA B-RNA 0.932207465171814
mRNA E-RNA E-RNA 0.9849467277526855
and O O 0.9965832829475403
JunB B-protein B-protein 0.5384156703948975
protein E-protein E-protein 0.7360398173332214

demonstrate O O 0.9932977557182312

cells E-cell_type E-cell_type 0.7172908186912537
. O O 0.9996840953826904
In O O 0.9999891519546509
addition O O 0.9997896552085876
, O O 0.9999957084655762
an O O 0.9999306201934814
adenocarcinoma B-protein B-protein 0.41719016432762146
reactive I-protein I-protein 0.6861113905906677
human-mouse I-protein I-protein 0.4941994249820709
chimeric I-protein I-protein 0.4751536548137665
monoclonal I-protein I-protein 0.6777169704437256
antibody E-protein E-protein 0.9959481358528137
( O O 0.991353452205658
ING-1 S-protein S-protein 0.9899829030036926
) O O 0.9907435774803162
was O O 0.9999455213546753
able O O 0.9999822378158569
to O O 0.9999786615371704
significantly O O 0.999850869178772
boost O O 0.9987665414810181
in O O 0.9994619488716125
vivo O O 0.987062394618988
generated O O 0.9947475790977478
LAK O O 0.419575572013855
cell-mediated O O 0.5809681415557861
lysis O O 0.6924976110458374
of O O 0.9706501364707947
control B-cell_line O 0.8953137397766113
, I-cell_line O 0.993831992149353
E2-treated I-cell_line O 0.30848366022109985
, I-cell_line O 0.5486568808555603
and I-cell_line O 0.8621613383293152
TAM-treated I-cell_line O 0.34939366579055786

was O O 0.9949374198913574
confirmed O O 0.9999666213989258
by O O 0.999997615814209
specific O O 0.991619348526001
antibody O O 0.8744796514511108
induction O O 0.9918140172958374
of O O 0.9998898506164551
supershifts O O 0.6081590056419373
in O O 0.9993277788162231
mobility O O 0.9286101460456848
assays O O 0.9943221807479858
. O O 0.9999974966049194
These O O 0.9999963045120239
results O O 0.9999127388000488
are O O 0.9999967813491821
the O O 0.9999955892562866
first O O 0.9999696016311646
to O O 0.9999881982803345
suggest O O 0.9999957084655762
that O O 0.9999909400939941
surfactant O O 0.8146983981132507
's O O 0.9849916100502014
suppressive O O 0.9470115303993225
effects O O 0.9983974099159241
on O O 0.9999905824661255
inflammatory B-protein O 0.9333446025848389
cytokine E-protein S-protein 0.5053665637969971
production O O 0.9991946816444397
may O O 0.9999985694885254
involve O O 0.999998927116394
transcriptional O O 0.9671598672866821
regulation O O 0.9974673986434937
through O O 0.9999933242797852
inhibition O O 0.9733021259307861

only O O 0.9936082363128662
64.1 S-protein O 0.400386244058609
induced O O 0.9411340355873108
NF-AT S-protein S-protein 0.8474186062812805
in O O 0.999775230884552
the O O 0.9999223947525024
nucleus O O 0.887486457824707
, O O 0.9990298748016357
correlating O O 0.9954895377159119
with O O 0.9999605417251587
its O O 0.9999512434005737
ability O O 0.9993185997009277
to O O 0.9999306201934814
activate O O 0.9740986227989197
T B-cell_type B-cell_type 0.703838586807251
cells E-cell_type E-cell_type 0.9841340184211731
. O O 0.9997045397758484
Thus O O 0.9996538162231445
, O O 0.9998224377632141
NF-AT S-protein S-protein 0.9924026727676392
induction O O 0.9989303946495056
and O O 0.9999263286590576
IL-2 S-protein S-protein 0.9288509488105774
secretion O O 0.9810933470726013
were O O 0.9999872446060181
correlated O O 0.999887228012085
with O O 0.9999972581863403
the O O 0.9999799728393555
levels O O 0.9997300505638123
of O O 0.9999723434448242
inositol O O 0.6794570088386536
phosphate O O 0.6527920961380005
release O O 0.9742465615272522

testosterone O O 0.7198287844657898
had O O 0.9998186230659485
no O O 0.9999773502349854
effect O O 0.9998564720153809
. O O 0.9999957084655762
YT-N17 S-cell_line O 0.28753381967544556
contained O O 0.9955256581306458
11.8 O O 0.8896966576576233
fmol/mg O O 0.7561120390892029
protein O O 0.8085852861404419
of O O 0.9707204699516296
estrogen B-protein B-protein 0.35486382246017456
receptor E-protein E-protein 0.9834679365158081
( O O 0.9935322999954224
mean O O 0.9907523393630981
of O O 0.9988019466400146
two O O 0.9944033622741699
independent O O 0.9556657075881958
assays O O 0.9518516063690186
) O O 0.9975458979606628
, O O 0.999968409538269
a O O 0.999790608882904

; O O 0.953732430934906
and O O 0.9977109432220459
, O O 0.9998229146003723
finally O O 0.999578058719635
, O O 0.9999840259552002
that O O 0.9999842643737793
interferon B-protein B-protein 0.47833359241485596
gamma I-protein E-protein 0.9523226022720337
, I-protein O 0.9728182554244995
but I-protein O 0.9991866946220398
not I-protein O 0.9991518259048462
alpha I-protein B-protein 0.46984022855758667
or I-protein I-protein 0.8711273670196533
beta E-protein E-protein 0.7198846340179443
, O O 0.8758944869041443
induces O O 0.9996746778488159
maturation O O 0.9868059158325195
and O O 0.9996412992477417
growth O O 0.9354349374771118
suppression O O 0.985094428062439
of O O 0.9998669624328613

progression O O 0.9893943667411804
. O O 0.9999933242797852
In O O 0.9999951124191284
this O O 0.9999954700469971
study O O 0.9999551773071289
, O O 0.9999973773956299
we O O 0.9999527931213379
investigated O O 0.9999817609786987
the O O 0.99997878074646
effects O O 0.9999575614929199
of O O 0.9999853372573853
IL-10 S-protein S-protein 0.9754697680473328
on O O 0.9995139837265015
the O O 0.9999239444732666
activation O O 0.9921646118164062
of O O 0.9999256134033203
HIV-1 O O 0.5808044672012329
from O O 0.9963454604148865
infected B-cell_type B-cell_type 0.5905994772911072
monocytes E-cell_type E-cell_type 0.7701913118362427
and O O 0.9842022657394409
macrophages S-cell_type S-cell_type 0.9924910664558411
. O O 0.9997976422309875
Although O O 0.9999768733978271
IL-10 S-protein S-protein 0.9776435494422913
alone O O 0.9942883253097534
did O O 0.9999945163726807
not O O 0.9999868869781494
induce O O 0.9999282360076904
HIV-1 O O 0.8651260137557983
replication O O 0.9827786087989807
, O O 0.9999825954437256
in O O 0.9999856948852539
the O O 0.9999822378158569
presence O O 0.999417781829834
of O O 0.9999709129333496
TNF-alpha S-protein S-protein 0.8375940322875977

Treated O O 0.9659448266029358
rats O O 0.975527286529541
were O O 0.9999792575836182
then O O 0.9999872446060181
evaluated O O 0.9999880790710449
for O O 0.9999867677688599
incidence O O 0.7631902694702148
, O O 0.996856689453125
latency O O 0.5334352254867554
, O O 0.9830273389816284
and O O 0.9980644583702087
seizure B-Disease O 0.924927294254303
pattern O O 0.7853493690490723
or O O 0.9819290637969971
for O O 0.9994303584098816
locomotor O O 0.8646036982536316
activity O O 0.7527573108673096
in O O 0.9948733448982239
animals O O 0.9566508531570435
without O O 0.9999150037765503
seizures B-Disease B-Disease 0.9622147083282471
. O O 0.9994654059410095

( O O 0.7351237535476685

Manifestations O O 0.8818671703338623
regressed O O 0.9763187766075134
spontaneously O O 0.9626034498214722
under O O 0.9997013211250305
surveillance O O 0.9926915764808655
in O O 0.9999779462814331
the O O 0.9998924732208252
hospital O O 0.9932757616043091
. O O 0.9999977350234985

decreased O O 0.9806037545204163

the O O 0.9962015748023987

that O O 0.9992098808288574
the O O 0.9999812841415405
effects O O 0.9999672174453735
of O O 0.9999915361404419
the O O 0.9999817609786987
inactive B-protein O 0.904810905456543
CaMKIV E-protein O 0.3259897530078888
on O O 0.992285966873169
activation O O 0.9946869611740112
are O O 0.9999815225601196
reversible O O 0.9989625215530396
. O O 0.999997615814209
Our O O 0.9999971389770508
results O O 0.999934196472168
suggest O O 0.9999974966049194
that O O 0.9999954700469971
CaMKIV S-protein O 0.44865503907203674
may O O 0.9997147917747498
represent O O 0.9999960660934448
a O O 0.9999897480010986
physiologically O O 0.8784048557281494
relevant O O 0.9697833061218262
CREB B-protein B-protein 0.5695353150367737
kinase E-protein E-protein 0.9507323503494263
in O O 0.9984513521194458
T B-cell_type B-cell_type 0.9147644639015198
cells E-cell_type E-cell_type 0.98929762840271
and O O 0.9977725148200989
that O O 0.9999985694885254
the O O 0.9999350309371948
enzyme O O 0.7109624743461609
is O O 0.999043881893158
also O O 0.9999685287475586
required O O 0.9999532699584961
to O O 0.9999924898147583
ensure O O 0.9999879598617554
normal O O 0.9780208468437195
expansion O O 0.9977784752845764
of O O 0.9998722076416016
T B-cell_type B-cell_type 0.853896975517273
cells E-cell_type E-cell_type 0.9932785630226135
in O O 0.9996767044067383
the O O 0.9997368454933167
thymus O O 0.784858763217926
. O O 0.9996114373207092
Whereas O O 0.9999971389770508
the O O 0.999950647354126
pathway O O 0.9931759238243103
responsible O O 0.9996672868728638
for O O 0.9999895095825195
this O O 0.9999608993530273
latter O O 0.9896354079246521
role O O 0.997657060623169
is O O 0.999990701675415
yet O O 0.9999610185623169
to O O 0.9999743700027466
be O O 0.999914288520813
elucidated O O 0.9987382292747498
, O O 0.999985933303833

made O O 0.978018581867218
in O O 0.9997995495796204
hemo-lymphoid B-cell_type B-cell_type 0.5589250922203064
progenitors E-cell_type E-cell_type 0.884207546710968
and O O 0.9735280871391296
precursors S-cell_type O 0.8742908239364624
as O O 0.9998750686645508
they O O 0.9999704360961914
give O O 0.9999128580093384
rise O O 0.9989509582519531
to O O 0.9999804496765137
the O O 0.999560534954071
cells O O 0.9824017882347107

pulmonary O O 0.8461999893188477
heart O O 0.9085468649864197
disease O O 0.9247545003890991
] O O 0.999886155128479
In O O 0.9999402761459351
order O O 0.9998891353607178
to O O 0.9999953508377075
inquire O O 0.9998947381973267
into O O 0.9999644756317139
the O O 0.999829888343811
functional O O 0.9515587687492371
state O O 0.9820044636726379

acquisition O O 0.9740832448005676

In O O 0.9995643496513367
six O O 0.9996145963668823
conscious O O 0.9481150507926941
, O O 0.9975737929344177
trained O O 0.9402209520339966
dogs O O 0.9037154912948608
, O O 0.9999216794967651
maintained O O 0.9976805448532104
on O O 0.9998109936714172
a O O 0.9997060894966125
normal O O 0.9729368686676025
sodium B-Chemical B-Chemical 0.9281004667282104
intake O O 0.5508817434310913
of O O 0.9931545257568359
2 O O 0.9941151142120361
to O O 0.9997979998588562
4 O O 0.9996575117111206
mEq O O 0.9953041076660156
/ O O 0.9999767541885376
kg O O 0.9987894892692566
/ O O 0.9999871253967285
day O O 0.9999473094940186
, O O 0.9999970197677612
sympathetic O O 0.9215601086616516
activity O O 0.9067129492759705
was O O 0.99986732006073
assessed O O 0.9999593496322632
as O O 0.999997615814209
the O O 0.9999254941940308
release O O 0.9967724680900574
rate O O 0.9997599720954895
of O O 0.9998331069946289
norepinephrine B-Chemical B-Chemical 0.9249498844146729
and O O 0.9576542973518372
epinephrine B-Chemical B-Chemical 0.9336001873016357
during O O 0.9995908141136169
15 O O 0.9995648264884949
- O O 0.9998538494110107
minute O O 0.9999164342880249
i O O 0.9999032020568848
. O O 0.9998041987419128
v O O 0.9926767349243164
. O O 0.999804675579071
infusions O O 0.9852220416069031
of O O 0.9998779296875
human O O 0.7178623080253601
alpha O O 0.6284812688827515
- O O 0.9655733704566956
atrial O O 0.9545599818229675
natriuretic O O 0.882077693939209
factor O O 0.5025664567947388
. O O 0.9987514019012451

Although O O 0.9997292160987854
the O O 0.9998171925544739
transaminases O O 0.5094053149223328
gradually O O 0.9893229603767395
returned O O 0.9979362487792969
to O O 0.9998268485069275
baseline O O 0.9783840179443359
after O O 0.9999790191650391
withholding O O 0.9972283244132996
the O O 0.9993492960929871
beta B-Chemical B-Chemical 0.6745359897613525
lactam I-Chemical E-Chemical 0.84670090675354
antibiotic O O 0.7416641116142273
, O O 0.9993520379066467
there O O 0.9999953508377075
was O O 0.9999873638153076
a O O 0.9999656677246094
gradual O O 0.9935146570205688
increase O O 0.8922451734542847
in O O 0.9776169061660767
serum O O 0.9479056000709534
bilirubin B-Chemical B-Chemical 0.9135579466819763
and O O 0.9983265995979309
a O O 0.9994340538978577
decrease O O 0.9478650689125061
in O O 0.9790863394737244
hemoglobin O O 0.6010261178016663
concentration O O 0.8304339647293091
caused O O 0.9994298815727234
by O O 0.9999829530715942
an O O 0.9998799562454224
autoimmune B-Disease O 0.8686157464981079
hemolytic I-Disease O 0.5227649211883545
anemia I-Disease O 0.7896835207939148
and O O 0.9721242785453796
erythroblastocytopenia B-Disease B-Disease 0.9576342701911926
. O O 0.9982578158378601

in O O 0.9985204339027405
the O O 0.9999749660491943
HLA-DQ B-DNA B-DNA 0.2802976071834564
sequence E-DNA E-DNA 0.9616935849189758
that O O 0.9989904761314392
are O O 0.9999791383743286
localized O O 0.9980244636535645
within O O 0.9999444484710693
sites O O 0.9889302849769592
suitable O O 0.999904990196228
for O O 0.9999700784683228
peptide O O 0.8559619188308716
recognition O O 0.9856824278831482
. O O 0.999988317489624
The O O 0.9999887943267822
polymorphism O O 0.9053427577018738
at O O 0.9996576309204102
residue O O 0.8550920486450195
57 O O 0.41323158144950867
of O O 0.9888392090797424
the O O 0.999698281288147
DQB1 O B-DNA 0.2929440140724182
polypeptide O E-DNA 0.37948471307754517
is O O 0.9921344518661499
of O O 0.9999548196792603
particular O O 0.998683512210846
interest O O 0.9937397241592407

Two O O 0.9994238615036011
weeks O O 0.9999847412109375
after O O 0.9999901056289673
terminating O O 0.9936462640762329
the O O 0.9993360638618469
treatment O O 0.999893069267273
, O O 0.9999973773956299
the O O 0.9998190999031067
SBP O O 0.7507722973823547
recovered O O 0.9985718727111816
to O O 0.9999271631240845
control O O 0.9991926550865173
value O O 0.9945183396339417
. O O 0.999996542930603

These O O 0.999772846698761
results O O 0.9999309778213501
suggest O O 0.9999979734420776
that O O 0.9999895095825195
PGE1 B-Chemical B-Chemical 0.9142612218856812
may O O 0.9994174242019653
be O O 0.9999963045120239
preferable O O 0.999945878982544
to O O 0.9999849796295166
TMP B-Chemical B-Chemical 0.8888006210327148
for O O 0.996268630027771
hypotensive B-Disease O 0.7174330353736877
anaesthesia O O 0.8723073601722717
in O O 0.9889799356460571
spinal O O 0.8310413360595703
surgery O O 0.7005458474159241
because O O 0.9988786578178406
TMP B-Chemical B-Chemical 0.8762452006340027
decreased O O 0.9415173530578613
EBF O O 0.6220064163208008
. O O 0.9995593428611755

DNA O O 0.8508385419845581
binding O O 0.9630128145217896
capacity O O 0.9990670084953308
was O O 0.9999855756759644
affected O O 0.9997820258140564
as O O 0.9999921321868896
well O O 0.9992231130599976
, O O 0.9999942779541016
A O O 0.9976932406425476
strong O O 0.9940999150276184
reduction O O 0.9982103109359741
was O O 0.9999560117721558
observed O O 0.9999113082885742
in O O 0.9999884366989136
the O O 0.9998880624771118
LPS-induced O O 0.8046479821205139
DNA-binding O O 0.8366678357124329
activity O O 0.9933144450187683
of O O 0.9999488592147827
AP-1 S-protein S-protein 0.967934787273407
in O O 0.9996917247772217
the O O 0.9999361038208008
presence O O 0.9988623857498169
of O O 0.999969482421875
IFN-gamma S-protein S-protein 0.968579113483429
. O O 0.9995235204696655
LPS-stimulated B-cell_type B-cell_type 0.4995689392089844
monocytes E-cell_type E-cell_type 0.5591257214546204
showed O O 0.9998227953910828
an O O 0.9999946355819702
increased O O 0.9939303398132324
expression O O 0.9988319277763367
of O O 0.9997245669364929
p105 B-RNA B-RNA 0.9302483201026917
mRNA E-RNA E-RNA 0.9966020584106445
, O O 0.9992709755897522
the O O 0.9999938011169434
precursor O O 0.9927992820739746
of O O 0.9998214840888977
the O O 0.999913215637207
p50 B-protein B-protein 0.4868340790271759
subunit E-protein E-protein 0.9633635878562927
of O O 0.9862971305847168
the O O 0.9993041753768921
transcription B-protein B-protein 0.48101383447647095
factor I-protein I-protein 0.8566896319389343
nuclear I-protein I-protein 0.3803788125514984
factor-kappa I-protein I-protein 0.6735397577285767
B E-protein E-protein 0.7424350380897522

Dexamethasone B-Chemical B-Chemical 0.9213511943817139
( O O 0.9933792352676392
10 O O 0.9984169006347656
microg O O 0.9858672022819519
/ O O 0.9998782873153687
kg O O 0.9993908405303955
per O O 0.9999157190322876
day O O 0.9998801946640015
, O O 0.9999912977218628
s O O 0.9993264675140381
. O O 0.9998303651809692
c O O 0.9963514804840088
. O O 0.9995937943458557
) O O 0.9977030158042908
or O O 0.9999663829803467
saline O O 0.5381852388381958
was O O 0.9995556473731995
started O O 0.9998788833618164
after O O 0.9999970197677612
4 O O 0.9992653727531433
days O O 0.9999452829360962
in O O 0.9999488592147827
Ato B-Chemical B-Chemical 0.9105844497680664
- O O 0.7774658799171448
treated O O 0.9969184398651123
and O O 0.99993896484375
non O O 0.9421355128288269
- O O 0.9938234090805054
treated O O 0.9967166781425476
rats O O 0.9882636070251465
and O O 0.9999418258666992
continued O O 0.9992662072181702
for O O 0.9999793767929077
11 O O 0.9993398785591125
- O O 0.9997313618659973
13 O O 0.9997506737709045
days O O 0.9999892711639404
. O O 0.9999990463256836

METHODS O O 0.9844240546226501
AND O O 0.9999209642410278
RESULTS O O 0.999625563621521
: O O 0.9999781847000122
To O O 0.9999798536300659
test O O 0.9999531507492065
whether O O 0.9999892711639404
clonidine B-Chemical B-Chemical 0.9205173254013062
elicits O O 0.9819456934928894
pharmacological O O 0.8778271079063416
effects O O 0.9562428593635559
independent O O 0.9997488856315613
of O O 0.9998849630355835
alpha2 O O 0.49357011914253235
- O O 0.8127872943878174
adrenoceptors O O 0.49003326892852783
, O O 0.9998557567596436
we O O 0.999825656414032
have O O 0.9999771118164062
generated O O 0.9995226860046387
mice O O 0.9950888752937317
with O O 0.9999938011169434
a O O 0.9999481439590454
targeted O O 0.9879865050315857
deletion O O 0.9633210301399231
of O O 0.9992921352386475
all O O 0.9999388456344604
3 O O 0.9617842435836792
alpha2 O O 0.8938745856285095
- O O 0.988416314125061
adrenoceptor O O 0.7888196706771851
subtypes O O 0.874130129814148
( O O 0.9999591112136841
alpha2ABC O O 0.952251672744751
- O O 0.9964078068733215
/ O O 0.9999370574951172
- O O 0.9994218349456787
) O O 0.999779999256134
. O O 0.9999951124191284

We O O 0.9989513158798218
then O O 0.9999803304672241
examined O O 0.9999821186065674
the O O 0.9999567270278931
morphology O O 0.908534586429596
, O O 0.9999086856842041
expression O O 0.9893450140953064
of O O 0.9998890161514282
beclin O O 0.7543018460273743
1 O O 0.8490612506866455
gene O O 0.8907196521759033
, O O 0.9997360110282898
mitochondrial O O 0.8057729601860046
permeability O O 0.5809117555618286
transition O O 0.8568382859230042
( O O 0.9997983574867249
MPT O O 0.7609561681747437
) O O 0.9940920472145081
, O O 0.9999603033065796
and O O 0.999647855758667
Na O B-Chemical 0.9243406653404236
+ O O 0.9738378524780273
- O O 0.9887790679931641
K B-Chemical B-Chemical 0.9083383083343506
+ O O 0.9660149216651917
ATPase O O 0.4799887537956238
activity O O 0.9059076309204102
in O O 0.9999040365219116
vivo O O 0.9299198389053345
. O O 0.9999886751174927

and O O 0.8714001774787903
T B-cell_type B-cell_type 0.5250882506370544
cells E-cell_type E-cell_type 0.9795859456062317
. O O 0.9993329644203186
This O O 0.9999845027923584
activity O O 0.998670220375061
is O O 0.9999862909317017
further O O 0.9996278285980225
inducible O O 0.9981980919837952
in O O 0.9998151659965515
activated O B-cell_type 0.5218051075935364
T B-cell_type I-cell_type 0.5922309756278992
cells E-cell_type E-cell_type 0.9387689232826233

adhesion I-protein I-protein 0.5716165900230408
molecule I-protein I-protein 0.7651137113571167
1 E-protein E-protein 0.9923128485679626
( O O 0.9897604584693909
VCAM-1 S-protein S-protein 0.9932780861854553
) O O 0.9833911657333374
by O O 0.9999219179153442
interleukin-4 S-protein S-protein 0.9815534353256226
( O O 0.9827136993408203
IL-4 S-protein S-protein 0.9961764812469482
) O O 0.9804710149765015
on O O 0.9995818734169006
endothelial B-cell_type B-cell_type 0.729107141494751
cells E-cell_type E-cell_type 0.9830678105354309
. O O 0.9998738765716553
We O O 0.9970550537109375

site E-DNA E-DNA 0.8418853282928467
was O O 0.9992597699165344
active O O 0.9995678067207336
in O O 0.9999879598617554
the O O 0.9999245405197144
LT-producing B-cell_line B-cell_line 0.616287350654602
C81-66-45 I-cell_line I-cell_line 0.8063451647758484
cell I-cell_line I-cell_line 0.8847388625144958
line E-cell_line E-cell_line 0.989738404750824
, O O 0.9655534029006958
which O O 0.9997772574424744
contains O O 0.9999324083328247
defective O O 0.8792301416397095
HTLV-I O O 0.3458307087421417
but O O 0.9500590562820435
expresses O O 0.9982761144638062
tax S-protein S-protein 0.9677987098693848
. O O 0.999776303768158
The O O 0.9999960660934448
observation O O 0.9989472031593323
that O O 0.9999971389770508
a O O 0.9997813105583191
mutated B-DNA O 0.8068683743476868
LT-kappa I-DNA B-DNA 0.3294680714607239
B I-DNA I-DNA 0.5091125965118408
construct E-DNA E-DNA 0.8149405121803284
( O O 0.9879734516143799
M1-CAT S-DNA S-protein 0.568528950214386
) O O 0.9567616581916809
was O O 0.9999066591262817
inactive O O 0.9981986880302429
in O O 0.9999434947967529
C81-66-45 S-cell_line S-cell_line 0.8181623816490173
, O O 0.9641436338424683
confirmed O O 0.9998040795326233
the O O 0.9999492168426514

is O O 0.9924706220626831

Alterations O O 0.9698143601417542
in O O 0.9989205598831177
hepatocyte O O 0.5958693623542786
TJs O O 0.44458314776420593
were O O 0.9999452829360962
assessed O O 0.9999778270721436
by O O 0.9999972581863403
double O O 0.9934240579605103
- O O 0.9979901313781738
immunolabeling O O 0.8846367597579956
for O O 0.9998268485069275
7H6 O O 0.6221126317977905
and O O 0.9983513355255127
ZO O O 0.8381086587905884
- O O 0.9825484752655029
1 O O 0.9797565340995789
using O O 0.9999902248382568
a O O 0.9999679327011108
confocal O O 0.9284770488739014
laser O O 0.9046831727027893
scanning O O 0.9665261507034302
microscope O O 0.9589625000953674
. O O 0.9999969005584717

affecting O O 0.9967509508132935
the O O 0.999910831451416
E2F-binding B-DNA B-DNA 0.5738282799720764
sites E-DNA E-DNA 0.974048376083374
. O O 0.9997960925102234
In O O 0.9999791383743286
addition O O 0.9998341798782349
, O O 0.9999815225601196
Tax S-protein S-protein 0.9978969097137451
also O O 0.998978853225708
stimulates O O 0.999932050704956
the O O 0.999924898147583
transcription O O 0.9604727029800415
of O O 0.9992411136627197
the O O 0.9997686743736267
E2F-1 B-DNA B-DNA 0.390527606010437
gene E-DNA E-DNA 0.8984375596046448
itself O O 0.5520634055137634
. O O 0.9998733997344971
Using O O 0.9981891512870789
Tax S-protein B-protein 0.7307978868484497
mutants O E-protein 0.8670464158058167

function O O 0.9906575679779053
as O O 0.9999880790710449
a O O 0.9999830722808838
cyclosporin-sensitive B-DNA B-DNA 0.46476656198501587
promoter I-DNA I-DNA 0.5590842366218567
element E-DNA E-DNA 0.9898502826690674
in O O 0.9970972537994385
T B-cell_type B-cell_type 0.8218752145767212
cells E-cell_type E-cell_type 0.9902175068855286
by O O 0.9997014403343201
virtue O O 0.9955111742019653
of O O 0.9999703168869019
its O O 0.9999802112579346
ability O O 0.9993199110031128
to O O 0.9999568462371826
bind O O 0.9990549683570862
NFATp S-protein S-protein 0.9846794009208679
. O O 0.9999414682388306
The O O 0.9999972581863403
involvement O O 0.9999018907546997
of O O 0.9999802112579346
NFATp S-protein S-protein 0.9828283190727234
in O O 0.9998918771743774
transcriptional O O 0.9157962799072266
activation O O 0.9825209975242615
of O O 0.9997139573097229
both O O 0.9998922348022461
the O O 0.9982560276985168
interleukin-2 S-protein S-protein 0.6701179146766663
and O O 0.7120459675788879

Such O O 0.9966913461685181
organophosphorus B-Chemical B-Chemical 0.8198530673980713
( O O 0.8390423655509949
OP B-Chemical B-Chemical 0.8025435209274292
) O O 0.5528755784034729
compounds O O 0.7801076173782349
as O O 0.9995737671852112
diisopropylfluorophosphate B-Chemical B-Chemical 0.9312757849693298
( O O 0.949344277381897
DFP B-Chemical B-Chemical 0.9209628105163574
) O O 0.9037464261054993
, O O 0.9998283386230469
sarin B-Chemical B-Chemical 0.9320803880691528
and O O 0.9209532141685486
soman B-Chemical B-Chemical 0.9192127585411072
are O O 0.9827589392662048
potent O O 0.993097722530365
inhibitors O O 0.993075966835022
of O O 0.9996121525764465
acetylcholinesterases O O 0.7268905639648438
( O O 0.9765002727508545
AChEs O O 0.6953636407852173
) O O 0.8603094220161438
and O O 0.9992314577102661
butyrylcholinesterases O O 0.6371275186538696
( O O 0.9838467836380005
BChEs O O 0.45209431648254395
) O O 0.9886741042137146
. O O 0.9999953508377075

to O O 0.9847789406776428
express O O 0.9854361414909363
Ig O S-protein 0.9127835035324097
, O O 0.9976905584335327
all O O 0.9999300241470337
other O O 0.9998623132705688
tested O O 0.9682867527008057
B B-DNA B-DNA 0.3121717572212219
lymphocyte-specific I-DNA I-DNA 0.5757648348808289
genes E-DNA E-DNA 0.9893378019332886
also O O 0.9990111589431763
remain O O 0.9999761581420898
active O O 0.9958018660545349
. O O 0.9999939203262329
The O O 0.9999332427978516

of O O 0.9947039484977722
detectable O O 0.9724705815315247
Tax S-protein S-protein 0.9866076707839966
expression O O 0.9988884329795837
. O O 0.9999969005584717
Interestingly O O 0.9997872710227966
, O O 0.9999943971633911
the O O 0.9999539852142334
NF-kappaB S-protein S-protein 0.9535942077636719
in O O 0.9984155893325806
TL-Om1 O S-cell_line 0.725928783416748
consists O O 0.9947163462638855
of O O 0.9999642372131348
p50/p50 S-protein S-protein 0.9248437285423279
and O O 0.9669981002807617
p50/p65 S-protein S-protein 0.8814976215362549
like O O 0.9883099794387817
that O O 0.9998382329940796
in O O 0.9995169639587402
fresh O B-cell_type 0.6059232950210571
primary B-cell_type I-cell_type 0.41967904567718506
leukemic I-cell_type I-cell_type 0.6614833474159241
cells E-cell_type E-cell_type 0.8743799328804016
. O O 0.9997559189796448
Our O O 0.9999984502792358
results O O 0.9999809265136719
suggest O O 0.9999986886978149
that O O 0.9999970197677612
activation O O 0.9974464178085327
of O O 0.9997169375419617
NF-kappaB S-protein S-protein 0.9938328266143799
occurs O O 0.9997462630271912
through O O 0.9999895095825195
a O O 0.9997871518135071
Tax S-protein S-protein 0.9949532151222229
-independent O O 0.9830517768859863
mechanism O O 0.9982914328575134
in O O 0.9999929666519165

In O O 0.9998841285705566
a O O 0.9999815225601196
risk O O 0.9986259937286377
analysis O O 0.998375654220581
of O O 0.999963641166687
neuropsychiatric O O 0.5801381468772888
side O O 0.5320544838905334
effects O O 0.6732082366943359
in O O 0.9992344379425049
Germany O O 0.9032447338104248
, O O 0.999947190284729
it O O 0.9999768733978271
is O O 0.9999939203262329
estimated O O 0.9999986886978149
that O O 0.9999884366989136
one O O 0.9999372959136963
of O O 0.9999665021896362
8 O O 0.9873681664466858
, O O 0.9991208910942078
000 O O 0.9985049962997437
mefloquine S-Chemical B-Chemical 0.9271778464317322
users O O 0.792444109916687
suffers O O 0.9997270703315735
from O O 0.9998860359191895
such O O 0.9988180994987488
reactions O O 0.9639698266983032
. O O 0.9999972581863403

NB4 B-cell_line S-protein 0.34303176403045654

MAIN O O 0.9732970595359802
OUTCOME O O 0.9910104274749756
MEASURE O O 0.9996556043624878
( O O 0.9998912811279297
S O O 0.9858616590499878
) O O 0.9983958601951599
: O O 0.9999794960021973
Central O O 0.983601987361908
retinal O O 0.8158593773841858
vein O O 0.7772613167762756
occlusion O O 0.9177941083908081
after O O 0.9670732617378235
ovulation O O 0.6950502395629883
induction O O 0.9728436470031738
with O O 0.9999619722366333
CC S-Chemical B-Chemical 0.9168814420700073
. O O 0.998721182346344

CASE O O 0.9520755410194397
SUMMARIES O O 0.994210958480835
: O O 0.9999372959136963
Two O O 0.9990226030349731
patients O O 0.9994483590126038
developed O O 0.9993064403533936
prolonged O O 0.8977175951004028
cholestatic O B-Disease 0.5488933324813843
hepatitis O I-Disease 0.9284119009971619
after O O 0.9900581240653992
receiving O O 0.9995068311691284
ticlopidine S-Chemical B-Chemical 0.9293003082275391
following O O 0.9998691082000732
percutaneous O O 0.9381546378135681
coronary O O 0.7328892350196838
angioplasty O O 0.7118481397628784
, O O 0.9983762502670288
with O O 0.999980092048645
complete O O 0.985748827457428
remission O O 0.9111423492431641
during O O 0.9999774694442749
the O O 0.9999876022338867
follow O O 0.9992270469665527
- O O 0.9998313188552856
up O O 0.9999581575393677
period O O 0.9999955892562866
. O O 0.9999995231628418

step-wise O O 0.8103747367858887
increasing O O 0.9953834414482117
physical O O 0.9718374013900757
exercise O O 0.9873719215393066
to O O 0.9999516010284424
maximal O O 0.8805814981460571
( O O 0.9922329187393188
MPE O O 0.8850757479667664
) O O 0.9987836480140686
; O O 0.9999828338623047
the O O 0.9999924898147583
second O O 0.997380793094635
involved O O 0.9999597072601318
prolonged O O 0.9268503189086914
( O O 0.9962078332901001
35 O O 0.9943806529045105
min O O 0.9967153072357178
) O O 0.9983972907066345
submaximal O O 0.9499148726463318
physical O O 0.952511191368103
exercise O O 0.9858372211456299

induction O O 0.9704270362854004
of O O 0.9994745850563049
NF-ATc S-protein S-protein 0.9819524884223938
during O O 0.9998032450675964
T O O 0.877128541469574
cell O O 0.8036327362060547
activation O O 0.9954853653907776
. O O 0.999985933303833
NF-ATc S-protein S-protein 0.98023521900177
, O O 0.9987152814865112
an O O 0.9999637603759766
inducibly O O 0.9090784788131714
expressed O O 0.8981680870056152
transcription B-protein B-protein 0.49957507848739624
factor E-protein E-protein 0.9862930774688721
, O O 0.9935895204544067
controls O O 0.9994168281555176
gene O O 0.9486261606216431
expression O O 0.9928849339485168
in O O 0.9998716115951538
T B-cell_type B-cell_type 0.8630532026290894
lymphocytes E-cell_type E-cell_type 0.9938347339630127
and O O 0.987779974937439
cardiomyocytes S-cell_type S-cell_type 0.9346615672111511
. O O 0.9997238516807556
We O O 0.9998908042907715
show O O 0.999987006187439
here O O 0.9999850988388062
that O O 0.9999960660934448
the O O 0.9997628331184387

RA O O 0.7826465964317322
in O O 0.9998513460159302
the O O 0.999863862991333
immune O O 0.9444143176078796
response O O 0.989577054977417
. O O 0.9999921321868896
Involvement O O 0.9999141693115234
of O O 0.9999856948852539
an O O 0.9999657869338989
SAF-like B-protein B-protein 0.3424522876739502
transcription I-protein I-protein 0.6506535410881042
factor E-protein E-protein 0.9639254212379456
in O O 0.9988265633583069
the O O 0.9999085664749146

inhibiting O O 0.9639893174171448

inositol O O 0.6472539305686951
turnover O O 0.9379526972770691
, O O 0.9996331930160522
or O O 0.9999542236328125
expression O O 0.9969525337219238
of O O 0.9996294975280762
Egr-1 B-RNA B-RNA 0.9600530862808228
mRNA E-RNA E-RNA 0.9940614104270935
, O O 0.9987340569496155
whereas O O 0.9999926090240479
2.06 S-protein O 0.833669900894165
plus O O 0.9938507080078125
GAM S-protein S-protein 0.6676826477050781
induced O O 0.9995757937431335
an O O 0.9999641180038452
increase O O 0.9957089424133301
in O O 0.9993513226509094

elevated O O 0.929100513458252
E2A B-protein S-protein 0.6994144916534424
protein E-protein O 0.7476240992546082
concentrations O O 0.8803009390830994
in O O 0.9999140501022339
these O O 0.9992676377296448
cells O O 0.9676534533500671
. O O 0.999984860420227
Hypertension O O 0.9928635954856873
in O O 0.999976634979248
pregnancy O O 0.9969196319580078
. O O 0.9999985694885254
Pregnancy-induced O O 0.9799321293830872
hypertension O O 0.9740098118782043
( O O 0.9998829364776611
PIH O O 0.9061989784240723
) O O 0.9989457726478577
is O O 0.9999884366989136
a O O 0.9999655485153198

activity O O 0.9859985113143921
in O O 0.9999667406082153
a O O 0.9998840093612671
dose-dependent O O 0.9566876888275146
manner O O 0.9946401715278625
. O O 0.9999978542327881
The O O 0.9999819993972778
mycotoxins O O 0.6829156279563904
alpha-zearalenol O O 0.8470189571380615
and O O 0.9943441152572632
zearalenone O O 0.8392475843429565
both O O 0.9996237754821777
exhibited O O 0.999454915523529
full O O 0.9888483285903931
agonist O O 0.9788880944252014
activity O O 0.9957420229911804
, O O 0.9999804496765137
but O O 0.9999058246612549

Because O O 0.9997945427894592
of O O 0.9999749660491943
the O O 0.99997878074646
rapid O O 0.9928021430969238
systemic O O 0.984012246131897
clearance O O 0.9947303533554077
of O O 0.9993300437927246
BCNU S-Chemical B-Chemical 0.9409583806991577
( O O 0.8858870267868042
1 B-Chemical B-Chemical 0.7910641431808472
, I-Chemical I-Chemical 0.9760105013847351
3 I-Chemical I-Chemical 0.9792560338973999
- I-Chemical I-Chemical 0.9905626773834229
bis I-Chemical I-Chemical 0.9691653847694397
- I-Chemical I-Chemical 0.9922782182693481
( I-Chemical I-Chemical 0.9901973009109497
2 I-Chemical I-Chemical 0.9852922558784485
- I-Chemical I-Chemical 0.9956445693969727
chloroethyl I-Chemical I-Chemical 0.9567528367042542
) I-Chemical I-Chemical 0.9706013798713684
- I-Chemical I-Chemical 0.9934195876121521
1 I-Chemical I-Chemical 0.9741259813308716
- I-Chemical I-Chemical 0.9952558875083923
nitrosourea E-Chemical I-Chemical 0.9293705224990845
) O O 0.768722653388977
, O O 0.9807305335998535
intra O O 0.42646944522857666
- O O 0.7061895728111267
arterial O O 0.7941015958786011
administration O O 0.929290235042572
should O O 0.9999629259109497
provide O O 0.9999957084655762
a O O 0.9999734163284302
substantial O O 0.9994144439697266
advantage O O 0.998838484287262
over O O 0.9999874830245972
intravenous O O 0.8357661366462708
administration O O 0.8725646734237671
for O O 0.9998067021369934
the O O 0.9998998641967773
treatment O O 0.9998250603675842
of O O 0.9999920129776001
malignant O O 0.6717824339866638
gliomas O O 0.7213699221611023
. O O 0.999076247215271

of O O 0.9983049631118774
a O O 0.9996103644371033
NF-kappa B-protein B-protein 0.7865738272666931
B I-protein E-protein 0.9079205989837646
regulated I-protein O 0.7266634702682495
chemokine E-protein S-protein 0.5401879549026489
, O O 0.9931060671806335
IL-8 S-protein S-protein 0.985079824924469
, O O 0.9989394545555115
a O O 0.9999202489852905
known O O 0.9905229210853577
inducer O O 0.8873237371444702
of O O 0.9960002303123474
CD11b/CD18 S-protein S-protein 0.8134777545928955
expression O O 0.9960338473320007
. O O 0.9999929666519165
Thus O O 0.9997038245201111
the O O 0.9999403953552246
suppression O O 0.9599754214286804

We O O 0.9996817111968994
conclude O O 0.9999946355819702
that O O 0.9999959468841553
noxious O O 0.847412645816803
stimulation O O 0.7427600026130676
of O O 0.9981765747070312
facial O O 0.8771034479141235
mucosa O O 0.5901932716369629
increases O O 0.9917279481887817
intracranial O O 0.9163116812705994
blood O O 0.694320023059845
flow O O 0.6324468851089478
and O O 0.9924464821815491
lacrimation O O 0.7423654198646545
via O O 0.9948923587799072
a O O 0.9992976188659668
trigemino O O 0.7671484351158142
- O O 0.8914253115653992
parasympathetic O O 0.676655650138855
reflex O O 0.6536405086517334
. O O 0.9999876022338867

of O O 0.9936382174491882
NF-kB S-protein S-protein 0.9615058898925781
in O O 0.9995473027229309
human B-cell_type B-cell_type 0.4814041554927826
T I-cell_type I-cell_type 0.5401598215103149
cell I-cell_type I-cell_type 0.406974196434021
thymic I-cell_type I-cell_type 0.6544673442840576
progenitors E-cell_type E-cell_type 0.8733201026916504
. O O 0.9996448755264282
We O O 0.9999785423278809
report O O 0.9999843835830688
differences O O 0.9991779923439026
in O O 0.9998959302902222
( O O 0.9987502098083496
Ca2+ O O 0.9742372035980225
) O O 0.9985278844833374
i O O 0.9980021119117737
requirement O O 0.9996323585510254
for O O 0.9999912977218628
NF-kB S-protein S-protein 0.9683037400245667
activation O O 0.994429349899292
in O O 0.9998418092727661
thymocytes S-cell_type S-cell_type 0.9804065227508545
as O O 0.9996715784072876

that O O 0.9913894534111023
is O O 0.9999523162841797
essential O O 0.9999474287033081
for O O 0.9999901056289673
the O O 0.9999747276306152
generation O O 0.9956252574920654
of O O 0.9999456405639648
a O O 0.9997814297676086
diversified O O 0.9183717966079712
B B-cell_type O 0.5257500410079956
cell I-cell_type O 0.3927535116672516
repertoire E-cell_type O 0.3796725571155548
in O O 0.9997753500938416
the O O 0.999920129776001
chicken O O 0.7563887238502502
. O O 0.9993951320648193
We O O 0.9999849796295166
describe O O 0.9999852180480957
here O O 0.999956488609314
a O O 0.9999871253967285
novel O O 0.8845622539520264
gene O O 0.6685339212417603
preferentially O O 0.946247935295105
expressed O O 0.9989435076713562
in O O 0.9995793700218201
bursal B-cell_type B-cell_type 0.4075597822666168
B I-cell_type I-cell_type 0.6244809031486511
cells E-cell_type E-cell_type 0.754662036895752
. O O 0.9995607733726501
The O O 0.9999796152114868
gene O O 0.9381066560745239
encodes O O 0.9945608973503113
an O O 0.9997780919075012

Here O O 0.9996569156646729
, O O 0.9999963045120239
we O O 0.9999834299087524
report O O 0.9999948740005493
two O O 0.9999724626541138
cases O O 0.9979789853096008
of O O 0.9999574422836304
severely O O 0.8939998745918274
immunocompromised O O 0.6954253315925598
HIV O B-Disease 0.5288242101669312
- O I-Disease 0.8026250004768372
infected O I-Disease 0.9853231906890869
patients O O 0.5445073843002319
who O O 0.9980699419975281
developed O O 0.9970830082893372
severe O O 0.9689261317253113
intrahepatic O B-Disease 0.5443944334983826
cholestasis O I-Disease 0.8863399028778076
, O O 0.9827588200569153
and O O 0.9998477697372437
in O O 0.9999724626541138
one O O 0.9998810291290283
patient O O 0.976362407207489
lesions O O 0.9393160343170166
mimicking O O 0.9989451766014099
liver O O 0.836087167263031
abscess O O 0.566130518913269
formation O O 0.7724823355674744
on O O 0.9999145269393921
radiologic O O 0.8950592279434204
exams O O 0.9312707781791687
, O O 0.9999920129776001
during O O 0.9999628067016602
co B-Chemical B-Chemical 0.6336520314216614
- I-Chemical I-Chemical 0.9768937230110168
trimoxazole E-Chemical I-Chemical 0.9313674569129944
treatment O O 0.9915609955787659
for O O 0.9999862909317017
PCP O B-Chemical 0.7546808123588562
. O O 0.999447762966156

GAD S-protein O 0.3638956546783447

Butyrylcholinesterase O O 0.7186905145645142
gene O O 0.3765827417373657
mutations O O 0.7551857829093933
in O O 0.9997590184211731
patients O O 0.9998745918273926
with O O 0.9999638795852661
prolonged O O 0.7406384944915771
apnea O O 0.576423704624176
after O O 0.9794142842292786
succinylcholine S-Chemical B-Chemical 0.933443009853363
for O O 0.9929178357124329
electroconvulsive O O 0.5836879014968872
therapy O O 0.8965650796890259
. O O 0.9999966621398926

of O O 0.9897155165672302
FasL S-protein S-protein 0.9793012142181396
and O O 0.9924308657646179
blocks O O 0.9942580461502075
paclitaxel-induced O O 0.931902289390564
apoptosis O O 0.9857412576675415
. O O 0.9999955892562866
The O O 0.9999978542327881
mechanism O O 0.9995706677436829
of O O 0.9999897480010986
this O O 0.9999635219573975
effect O O 0.9999278783798218
is O O 0.9999958276748657
that O O 0.9999946355819702
Bcl-2 S-protein S-protein 0.9897270798683167
prevents O O 0.9997833371162415
the O O 0.9999459981918335
nuclear O O 0.9482005834579468
translocation O O 0.9613337516784668
of O O 0.9981403350830078
NFAT S-protein S-protein 0.9787427186965942
( O O 0.9867181181907654
nuclear B-protein B-protein 0.5340049862861633
factor I-protein I-protein 0.7536372542381287
of I-protein I-protein 0.9799307584762573
activated I-protein I-protein 0.986428439617157
T I-protein I-protein 0.8218028545379639

Estradiol S-Chemical B-Chemical 0.9067919254302979
enhanced O O 0.9906461238861084
these O O 0.9995751976966858
effects O O 0.9991942048072815
on O O 0.9999890327453613
SOCS O O 0.5120047926902771
- O O 0.7457559108734131
3 O O 0.48127540946006775
and O O 0.9890211224555969
CIS O O 0.5337893962860107
. O O 0.999910831451416

. O O 0.9979491829872131
Prior O O 0.9972696900367737
studies O O 0.9997634291648865
have O O 0.9999986886978149
shown O O 0.9999905824661255
MCP-1 S-protein S-protein 0.9564144611358643
expression O O 0.9970177412033081
is O O 0.9999885559082031
modulated O O 0.9996552467346191
by O O 0.9999960660934448
a O O 0.999893069267273
variety O O 0.997222900390625
of O O 0.9999436140060425
ligands O O 0.9039843082427979
that O O 0.9992693066596985
act O O 0.999510645866394
through O O 0.9999765157699585
extracellular B-protein B-protein 0.7898423671722412
receptors E-protein E-protein 0.9638106822967529
. O O 0.9998006224632263
In O O 0.9999841451644897
the O O 0.9999957084655762
current O O 0.9985694885253906
study O O 0.9999459981918335
, O O 0.999984622001648

transactivation O O 0.9603092670440674
of O O 0.9997623562812805
the O O 0.9999566078186035
reporter B-DNA B-DNA 0.5061548352241516
gene I-DNA I-DNA 0.758179247379303
luciferase E-DNA E-DNA 0.5086394548416138
, O O 0.9966807961463928
suggesting O O 0.9999861717224121
direct O O 0.9958712458610535
control O O 0.998242974281311
of O O 0.9999438524246216
Bcl-2 S-protein S-protein 0.9228602051734924
expression O O 0.9964996576309204
by O O 0.9999803304672241
Aiolos S-protein S-protein 0.6152429580688477
. O O 0.9995287656784058
Co-transfection O O 0.9381256699562073
experiments O O 0.9885411262512207
confirm O O 0.9999922513961792
that O O 0.9999932050704956

well O O 0.9213616251945496

Most O O 0.9971262812614441
side O O 0.9963139891624451
effects O O 0.9990692734718323
were O O 0.9999843835830688
mild O O 0.9584073424339294
and O O 0.9991835951805115
related O O 0.9994394183158875
to O O 0.999906063079834
the O O 0.9995095729827881
GI O O 0.49990221858024597
tract O O 0.8642213940620422
. O O 0.9999955892562866

Of O O 0.9998075366020203
those O O 0.9999923706054688
, O O 0.9999872446060181
13 O O 0.9994939565658569
( O O 0.9999569654464722
26 O O 0.9999456405639648
% O O 0.9999490976333618
) O O 0.9997027516365051
developed O O 0.9990975856781006
biliary O O 0.5379772782325745
pathology O O 0.8818349242210388
. O O 0.9998676776885986

germline S-DNA S-DNA 0.6529666781425476
C O O 0.6550963521003723
epsilon O O 0.7948081493377686
transcription O O 0.9570712447166443
. O O 0.999954342842102
Second O O 0.9979118704795837
, O O 0.9999661445617676
we O O 0.9999758005142212
studied O O 0.9999436140060425
the O O 0.9999815225601196
effect O O 0.9999706745147705
of O O 0.9999898672103882
NAC O O 0.8311678171157837
on O O 0.9997947812080383
IgE S-protein S-protein 0.9343534111976624
synthesis O O 0.9731252193450928
in O O 0.9999611377716064
human O B-cell_type 0.6747643947601318
normal O I-cell_type 0.7280945777893066
B O I-cell_type 0.8327077627182007
cells O E-cell_type 0.9139359593391418
costimulated O O 0.9906870722770691
with O O 0.9999141693115234
IL-4 S-protein S-protein 0.9035896062850952
and O O 0.9884986281394958
anti-CD40 B-protein B-protein 0.39253920316696167
mAb E-protein E-protein 0.8970191478729248

two O O 0.9918122291564941
novel O B-cell_line 0.8938422203063965
lymphoma B-cell_line I-cell_line 0.3511744439601898
cell I-cell_line I-cell_line 0.6236512064933777
lines E-cell_line E-cell_line 0.9977408647537231
( O O 0.9993608593940735
CRO-AP/3 S-cell_line S-cell_line 0.9914665222167969
and O O 0.9767276644706726
CRO-AP/5 S-cell_line S-cell_line 0.9946961402893066
) O O 0.9345110058784485
which O O 0.9995563626289368
carry O O 0.9998657703399658
infection O O 0.9022839665412903

tissues O O 0.8007820844650269
as O O 0.9999018907546997
ovulation O O 0.8841540813446045
markers O O 0.7056493759155273
we O O 0.9999667406082153
studied O O 0.9999426603317261
the O O 0.999985933303833
behaviour O O 0.99790358543396
of O O 0.9999779462814331
Albuminemia O O 0.5557326078414917
, O O 0.9954362511634827
Platelet B-protein B-protein 0.5871424674987793
Factor I-protein I-protein 0.4423418939113617
IV E-protein E-protein 0.9698024392127991
( O O 0.99565190076828
as O O 0.9999197721481323
indicator O O 0.9982733726501465
of O O 0.9998975992202759
Platelet O O 0.5978267788887024
Aggregation O O 0.6647545695304871
) O O 0.9613897204399109
, O O 0.9996272325515747
Type B-protein B-protein 0.47400516271591187
II I-protein I-protein 0.6157037019729614
estrogenic I-protein I-protein 0.9096920490264893
receptors E-protein E-protein 0.9900145530700684
in O O 0.9996138215065002

with O O 0.9967928528785706
alveolar O B-cell_type 0.5297990441322327
macrophages O E-cell_type 0.9935926795005798
. O O 0.9997732043266296
We O O 0.9999762773513794
also O O 0.999977707862854
found O O 0.9999804496765137
differential O O 0.992805540561676
expression O O 0.9988904595375061
of O O 0.9999784231185913
the O O 0.9999096393585205
Ca2+-independent B-protein B-protein 0.5283622741699219
isoforms E-protein E-protein 0.9521143436431885
in O O 0.9993032217025757
alveolar B-cell_type B-cell_type 0.6708730459213257
macrophages E-cell_type E-cell_type 0.9858799576759338
compared O O 0.9992330074310303
with O O 0.9999840259552002
monocytes S-cell_type S-cell_type 0.9773150682449341
. O O 0.9997664093971252
One O O 0.9904767274856567

, O O 0.9725931286811829
which O O 0.9997076392173767
can O O 0.9999814033508301
interact O O 0.9999643564224243
with O O 0.9999908208847046
the O O 0.9998695850372314
IL-4R B-protein B-protein 0.6577546000480652
alpha I-protein I-protein 0.48939740657806396
chain E-protein E-protein 0.9935992956161499
to O O 0.9988800883293152
mediate O O 0.982860803604126
signaling O O 0.9844314455986023
, O O 0.9996114373207092
is O O 0.99993896484375
expressed O O 0.9996556043624878
on O O 0.999555766582489
cells O O 0.9617307782173157
lacking O O 0.9989637136459351
gamma B-protein B-protein 0.40183600783348083
( I-protein I-protein 0.4214785695075989
c I-protein I-protein 0.7645345330238342

plus B-cell_line I-cell_line 0.8512107729911804
clones E-cell_line E-cell_line 0.7628329992294312
, O O 0.9978803396224976
as O O 0.9999631643295288
demonstrated O O 0.9997324347496033
in O O 0.9999908208847046
the O O 0.9999958276748657
case O O 0.9991610050201416
of O O 0.9999877214431763
cathepsin B-protein B-protein 0.7561860084533691
G E-protein E-protein 0.7683249711990356
. O O 0.9924525618553162
In O O 0.9999814033508301
addition O O 0.9998403787612915
, O O 0.9999939203262329
these O O 0.999972939491272
proteases O O 0.7711908221244812

C E-protein O 0.2992040812969208
pathway O O 0.895287811756134
is O O 0.9999167919158936
not O O 0.9999698400497437
involved O O 0.9999812841415405
in O O 0.9999904632568359
the O O 0.9999499320983887
potentiation O O 0.9884725213050842
of O O 0.9994310736656189
aggregation O O 0.8210878372192383
. O O 0.9999676942825317

TCR S-protein S-protein 0.896699070930481
engagement O O 0.9945244789123535
. O O 0.9999963045120239
Stimulation O O 0.9966566562652588
of O O 0.9997872710227966
resting B-cell_type B-cell_type 0.6630350351333618
human I-cell_type I-cell_type 0.7079166769981384
T I-cell_type I-cell_type 0.8671994209289551
cells E-cell_type E-cell_type 0.9568815231323242
with O O 0.9995495676994324
the O O 0.9999773502349854
CD28-specific B-protein B-protein 0.6715826988220215
mAb I-protein I-protein 0.7903781533241272
BW I-protein I-protein 0.332817018032074
828 E-protein E-protein 0.9097736477851868
induces O O 0.9987519979476929
proliferation O O 0.9952189326286316
and O O 0.9996786117553711
cytokine S-protein S-protein 0.9507299661636353
synthesis O O 0.9920810461044312
without O O 0.9999884366989136
further O O 0.9987492561340332
requirement O O 0.9996234178543091
for O O 0.9999802112579346
TCR S-protein S-protein 0.9452847242355347
coengagement O O 0.9895983934402466
. O O 0.9999948740005493
This O O 0.9999864101409912
observation O O 0.9996249675750732
prompted O O 0.9999834299087524
us O O 0.9999258518218994
to O O 0.9999736547470093
postulate O O 0.999806821346283
that O O 0.9999310970306396
signal O B-protein 0.6921958327293396
2 O E-protein 0.7593551278114319
( O O 0.9237856268882751
costimulatory O O 0.7329629063606262
signal O O 0.672635018825531
) O O 0.94380122423172
alone O O 0.9976761937141418

to O O 0.969537615776062
IL-13 S-protein S-protein 0.9751257300376892
. O O 0.9998372793197632
Within O O 0.9999629259109497
1 O O 0.9958985447883606
min O O 0.999092698097229
of O O 0.9997920393943787
activation O O 0.9830853343009949
, O O 0.9998282194137573
JAK2 S-protein S-protein 0.9346503019332886
was O O 0.9993727803230286
phosphorylated O O 0.8026862144470215
, O O 0.9929590225219727
and O O 0.9998558759689331
peaked O O 0.997306227684021
in O O 0.9997219443321228
10 O O 0.9834428429603577
min O O 0.9935199618339539
. O O 0.9999762773513794
In O O 0.9999572038650513
addition O O 0.997366726398468
, O O 0.9998332262039185
IL-13 S-protein B-protein 0.8620086908340454
phosphorylated O I-protein 0.8379907011985779
insulin B-protein I-protein 0.5649354457855225
response I-protein I-protein 0.7265757918357849
substrate-1 E-protein E-protein 0.9253706336021423
, O O 0.9788895845413208
IL-4R B-protein B-protein 0.6069531440734863
p140 E-protein E-protein 0.891304612159729
, O O 0.9460127353668213
JAK1 S-protein S-protein 0.956848680973053
, O O 0.9830790758132935
and O O 0.9966070652008057
Tyk2 S-protein S-protein 0.942606508731842
, O O 0.988754391670227
but O O 0.9994799494743347
not O O 0.9995999932289124
JAK3 B-protein B-protein 0.7239198088645935
kinase E-protein E-protein 0.7475732564926147
. O O 0.9961720108985901

However O O 0.999066174030304
, O O 0.9999837875366211
the O O 0.9999756813049316
observation O O 0.9979815483093262
that O O 0.9999903440475464
antagonists O O 0.9341297745704651
of O O 0.9582415819168091
the O O 0.9932251572608948
glutamate S-Chemical B-Chemical 0.9415494799613953
N B-Chemical B-Chemical 0.6286947131156921
- I-Chemical I-Chemical 0.9814002513885498
methyl I-Chemical I-Chemical 0.9589909315109253
- I-Chemical I-Chemical 0.9897339940071106
D I-Chemical I-Chemical 0.9530531764030457
- I-Chemical I-Chemical 0.9917987585067749
aspartate E-Chemical I-Chemical 0.9460589289665222
( O O 0.771605908870697
NMDA S-Chemical B-Chemical 0.9204904437065125
) O O 0.6335978507995605
receptor O O 0.8491472601890564
produce O O 0.997082531452179
schizophrenic O O 0.8910107016563416
- O O 0.6048159599304199
like O O 0.5042938590049744
symptoms O O 0.6817807555198669
in O O 0.9930770397186279
humans O O 0.8946556448936462
has O O 0.9997702240943909
led O O 0.9999263286590576
to O O 0.9999715089797974
the O O 0.9999603033065796
idea O O 0.9998037219047546
of O O 0.9999891519546509
a O O 0.9999346733093262
dysfunctioning O O 0.7232308387756348
of O O 0.9742109179496765
the O O 0.9931269884109497
glutamatergic O O 0.42860090732574463
system O O 0.8368430137634277
via O O 0.9998972415924072
its O O 0.9999282360076904
NMDA S-Chemical B-Chemical 0.9285804033279419
receptor O O 0.42135927081108093
. O O 0.9996259212493896

EBNA B-DNA B-DNA 0.30260634422302246
gene I-DNA I-DNA 0.7224369645118713
promoters E-DNA E-DNA 0.9908163547515869
in O O 0.9986329674720764
established O B-cell_line 0.7690077424049377
in B-cell_line I-cell_line 0.9536462426185608
vitro I-cell_line I-cell_line 0.776350200176239
immortalized I-cell_line I-cell_line 0.7265045642852783
lymphoblastoid I-cell_line I-cell_line 0.4454743564128876
cell I-cell_line I-cell_line 0.8320936560630798
lines E-cell_line E-cell_line 0.9963082671165466
( O O 0.9982349872589111
LCLs S-cell_line S-cell_line 0.9741160273551941
) O O 0.9384457468986511
. O O 0.9999734163284302
It O O 0.9999394416809082
was O O 0.9999836683273315
determined O O 0.9999972581863403
that O O 0.9999852180480957
oriP S-DNA S-DNA 0.8142787218093872
, O O 0.9955710768699646
the O O 0.9999136924743652
origin O O 0.9854534268379211
for O O 0.9998722076416016
episomal O O 0.8699944019317627
maintenance O O 0.9872722029685974
during O O 0.9999462366104126
latency O O 0.9677102565765381
, O O 0.9999301433563232
is O O 0.9999929666519165
essential O O 0.9999573230743408
for O O 0.9999817609786987
efficient O O 0.9881324172019958
transcription O O 0.9165695905685425
initiation O O 0.9910625219345093
from O O 0.9999839067459106
either O O 0.999306321144104

a O O 0.9756313562393188

Curcumin S-Chemical B-Chemical 0.9146416187286377
ameliorates O O 0.9750372171401978
cognitive O O 0.71059650182724
dysfunction O O 0.9722257852554321
and O O 0.9271877408027649
oxidative O O 0.7045421004295349
damage O O 0.8649324774742126
in O O 0.983763575553894
phenobarbitone S-Chemical B-Chemical 0.9309981465339661
and O O 0.7483589053153992
carbamazepine S-Chemical B-Chemical 0.9280346035957336
administered O O 0.8976857662200928
rats O O 0.9641937613487244
. O O 0.9999933242797852

Such O O 0.9988505840301514
disparity O O 0.7488939762115479
suggests O O 0.999839186668396
an O O 0.9999814033508301
inhibition O O 0.9439148306846619
of O O 0.9989981055259705
creatine B-Chemical S-Chemical 0.8819630146026611
phosphokinase O O 0.44620198011398315
. O O 0.9992095232009888

subsequent O O 0.9844818115234375

Twenty O O 0.9932326078414917
- O O 0.999482274055481
three O O 0.999908447265625
h O O 0.8886052966117859
postoperatively O O 0.9650387763977051
he O O 0.996605396270752
developed O O 0.9993942975997925
a O O 0.9998571872711182
brief O O 0.9262574315071106
self O O 0.8159253597259521
- O O 0.9871468544006348
limited O O 0.977084219455719
seizure B-Disease B-Disease 0.9818060398101807
. O O 0.9981056451797485

( O O 0.973280668258667
P O O 0.9627861976623535
< O O 0.9961704611778259
0.025 O O 0.996595561504364
) O O 0.9982990622520447
and O O 0.9999265670776367
to O O 0.9986938834190369
IL-1 B-cell_line S-protein 0.847426176071167
beta-stimulated I-cell_line O 0.9324368834495544
HUVEC E-cell_line S-cell_line 0.727408230304718
by O O 0.9978461265563965
56 O O 0.9927835464477539
% O O 0.9997250437736511
( O O 0.9999163150787354
P O O 0.9974067807197571
< O O 0.9997075200080872
0.010 O O 0.9992356300354004
) O O 0.9996156692504883

Schneider O O 0.6122027039527893
et O O 0.9365147352218628
al. O O 0.9985471367835999
1990 O O 0.9965329170227051
) O O 0.9999178647994995
. O O 0.9999972581863403
The O O 0.9999990463256836
fact O O 0.9995529055595398
that O O 0.9999948740005493
BCL-6 S-protein S-protein 0.8275704979896545
rearrangements O O 0.6086188554763794
identify O O 0.9999161958694458
biologically O O 0.9502950310707092
and O O 0.9885750412940979
clinically O O 0.9831830263137817

absent O O 0.9844815731048584
in O O 0.9999462366104126
most O O 0.9995623230934143
of O O 0.999950647354126
the O O 0.999930739402771
other O O 0.9960434436798096
cells O O 0.9367503523826599
or O O 0.9995889067649841
tissues O O 0.9736782312393188
tested O O 0.9997811913490295
. O O 0.999997615814209
Furthermore O O 0.9999818801879883
, O O 0.999991774559021
expression O O 0.9978461265563965
of O O 0.9998773336410522
OBF-1 S-protein S-protein 0.966659665107727
in O O 0.9989448189735413
HeLa B-cell_line B-cell_line 0.8505580425262451
cells E-cell_line E-cell_line 0.9910278916358948
selectively O O 0.9989622831344604
stimulates O O 0.999834418296814

Inhibition O O 0.9923970103263855
of O O 0.9999604225158691
phorbol O O 0.6757031679153442
ester-induced O O 0.9536822438240051
monocytic O O 0.8760428428649902
differentiation O O 0.9745873808860779
by O O 0.9999833106994629
dexamethasone O O 0.8447687029838562
is O O 0.9995909333229065
associated O O 0.9999550580978394
with O O 0.999994158744812
down-regulation O O 0.9927940368652344
of O O 0.9997870326042175
c-fos S-DNA S-DNA 0.8450955748558044
and O O 0.9299868941307068
c-jun S-DNA S-DNA 0.869369387626648
( O O 0.9917186498641968
AP-1 S-DNA S-protein 0.7654673457145691
) O O 0.9770506620407104
. O O 0.9999852180480957
Previous O O 0.9999752044677734
studies O O 0.9999147653579712
have O O 0.9999985694885254
shown O O 0.9999955892562866
that O O 0.999996542930603
treatment O O 0.9979105591773987
of O O 0.9999538660049438
human B-cell_type B-cell_type 0.5182620286941528
myeloid I-cell_type I-cell_type 0.6177100539207458
leukemia I-cell_type I-cell_type 0.7571104764938354
cells E-cell_type E-cell_type 0.7665016651153564
with O O 0.9995736479759216
12-O-tetradecanoylphorbol-13-acetate O O 0.821950376033783
( O O 0.9958778619766235
TPA O O 0.9432440400123596
) O O 0.9992891550064087
is O O 0.9999889135360718
associated O O 0.9999847412109375
with O O 0.9999977350234985
induction O O 0.9962630867958069
of O O 0.9997960925102234
monocytic O O 0.6392874121665955
differentiation O O 0.9319263100624084
and O O 0.999377965927124
expression O O 0.989494264125824

Stroke B-Disease O 0.8250806927680969
followed O O 0.9849615097045898
cocaine B-Chemical B-Chemical 0.9150205254554749
use O O 0.992867112159729
by O O 0.9999873638153076
inhalation O O 0.6822498440742493
, O O 0.991195559501648
intranasal O O 0.7181439995765686
, O O 0.9603067636489868
intravenous O O 0.7169627547264099
, O O 0.9735740423202515
and O O 0.9969249367713928
intramuscular O O 0.5895205736160278
routes O O 0.8382587432861328
. O O 0.9999911785125732

Attenuation O O 0.7607643604278564
of O O 0.9948275685310364
methamphetamine B-Chemical B-Chemical 0.9218358993530273
- O O 0.9486401677131653
induced O O 0.9994210004806519
nigrostriatal O O 0.6625758409500122
dopaminergic O O 0.3711738586425781
neurotoxicity B-Disease O 0.5663391947746277
in O O 0.9940022826194763
mice O O 0.9972811937332153
by O O 0.9999943971633911
lipopolysaccharide B-Chemical B-Chemical 0.9216005206108093
pretreatment O O 0.48449358344078064
. O O 0.9999362230300903

Patients O O 0.9923152923583984
developing O O 0.9990941286087036
ESRD B-Disease B-Disease 0.7855167984962463
had O O 0.9968224763870239
a O O 0.9999771118164062
6 O O 0.9928370118141174
- O O 0.9995111227035522
year O O 0.9996439218521118
survival O O 0.9970460534095764
after O O 0.9999827146530151
onset O O 0.9910963773727417
of O O 0.9997707009315491
ESRD B-Disease O 0.9135301113128662
of O O 0.8484280109405518
27 O O 0.9940409064292908
% O O 0.999935507774353
for O O 0.9999672174453735
the O O 0.9998277425765991
patients O O 0.9993436932563782
receiving O O 0.9999662637710571
hemodialysis O O 0.8988450169563293
versus O O 0.9950975775718689
71 O O 0.9789733290672302
. O O 0.9999890327453613
4 O O 0.9999467134475708
% O O 0.9999604225158691
for O O 0.9999570846557617
the O O 0.999906063079834
patients O O 0.9995156526565552
developing O O 0.9997010827064514
ESRD B-Disease B-Disease 0.970308244228363
who O O 0.9753486514091492
subsequently O O 0.9998185038566589
received O O 0.9998644590377808
kidney O O 0.772682785987854
transplants O O 0.8888824582099915
. O O 0.9999961853027344

types O O 0.7536191344261169
of O O 0.9990077614784241
TNF B-protein B-protein 0.7118065357208252
receptors E-protein E-protein 0.9859029054641724
. O O 0.9994515776634216
METHODS O O 0.8591485619544983
: O O 0.9871336221694946
TNF S-protein S-protein 0.9391360282897949
receptor O O 0.6081215739250183
surface O O 0.8399839401245117
expression O O 0.9925343990325928
was O O 0.9999772310256958
determined O O 0.9999914169311523
by O O 0.999992847442627
specific O O 0.9827848076820374
monoclonal B-protein O 0.9012735486030579
antibody E-protein O 0.7222297787666321
recognition O O 0.9596530795097351
and O O 0.9963294863700867
flow O O 0.9434653520584106
cytometry O O 0.8943655490875244
, O O 0.9995926022529602
and O O 0.9999065399169922
signal O O 0.956800103187561
transduction O O 0.9739624261856079
was O O 0.9998553991317749
detected O O 0.9999510049819946
by O O 0.9999923706054688
gel O O 0.9451406598091125
shift O O 0.9718086123466492
analysis O O 0.9991108775138855
. O O 0.9999977350234985
HIV-1 O O 0.7925170063972473
activation O O 0.9895567297935486
and O O 0.9997525811195374
expression O O 0.9986717700958252
was O O 0.9999849796295166

line E-cell_line E-cell_line 0.7576447129249573
ZAP-70 S-protein S-cell_line 0.6393819451332092
mutated O O 0.9540098905563354
on O O 0.9995396137237549
Tyr-492 O O 0.6404411792755127
and O O 0.9736484885215759
Tyr-493 O S-cell_line 0.711093544960022
in O O 0.9971829652786255
the O O 0.9999486207962036
putative O O 0.8322474360466003
regulatory O O 0.6715129017829895
loop O O 0.4864259362220764
of O O 0.9911589026451111
its O O 0.9997500777244568
kinase B-protein B-protein 0.5629792213439941
domain E-protein E-protein 0.8342106342315674
. O O 0.9990473389625549
This O O 0.9990468621253967

between O O 0.992986261844635
-95 B-DNA O 0.89496910572052
and I-DNA O 0.9480531811714172
-73 E-DNA O 0.3805125951766968
is O O 0.9988111257553101
essential O O 0.9998989105224609
for O O 0.9999798536300659
transcriptional O O 0.9621279835700989
activation O O 0.9963171482086182
in O O 0.9999903440475464
response O O 0.9979044198989868
to O O 0.9999103546142578
PMA/A23187 O O 0.6485281586647034
. O O 0.9996381998062134
This O O 0.9999527931213379
region O O 0.9972732663154602
contains O O 0.9999910593032837
two O O 0.9984057545661926
DNA-binding B-DNA B-DNA 0.37820690870285034
motifs E-DNA E-DNA 0.7788618803024292
, O O 0.9846640229225159
GM2 S-DNA S-DNA 0.7543448209762573
and O O 0.853455662727356
GC-box S-DNA S-DNA 0.4712240993976593
. O O 0.9954468607902527

1 O O 0.7316756844520569
) O O 0.8824728727340698
VZV B-DNA B-DNA 0.5587124228477478
gE I-DNA I-DNA 0.41329488158226013
protein I-DNA I-DNA 0.5313258171081543
coding I-DNA I-DNA 0.5667976140975952
sequences E-DNA E-DNA 0.9821183681488037
along O O 0.9993709921836853
with O O 0.9999713897705078
the O O 0.9995999932289124
promoter B-protein B-DNA 0.43754616379737854
region E-protein E-DNA 0.9744964838027954
were O O 0.9994493126869202
inserted O O 0.9997839331626892
into O O 0.9999587535858154
the O O 0.9994243383407593
thymidine B-DNA B-protein 0.6012805700302124
kinase I-DNA E-protein 0.4848254919052124
( I-DNA O 0.4370308518409729

the O O 0.996895432472229
pol B-DNA B-DNA 0.42625436186790466
gene E-DNA E-DNA 0.9909005165100098
( O O 0.9993458390235901
E. O O 0.9841761589050293
Verdin O O 0.9818345904350281
, O O 0.9999724626541138
J. O O 0.9962244033813477
Virol. O O 0.999599277973175
65 O O 0.9992434978485107
: O O 0.9999343156814575
6790-6799 O O 0.9988893866539001
, O O 0.9999773502349854
1991 O O 0.9888417720794678
) O O 0.9998292922973633
. O O 0.9999951124191284
In O O 0.9999958276748657
the O O 0.9999909400939941
present O O 0.9955452680587769
report O O 0.9929181933403015
, O O 0.9996832609176636
high-resolution O O 0.9176159501075745
mapping O O 0.9639692902565002
of O O 0.9990766048431396
this O O 0.9998524188995361
site O O 0.9263443946838379
with O O 0.9995915293693542
DNase B-protein B-DNA 0.33227282762527466
I E-protein E-DNA 0.4628463089466095
and O O 0.9371774792671204
micrococcal B-protein B-protein 0.5511228442192078
nuclease E-protein E-protein 0.6165101528167725
identified O O 0.9890540838241577
a O O 0.9998636245727539
nucleosome-free B-DNA O 0.6477251052856445
region E-DNA O 0.49309489130973816
centered O O 0.9928058981895447
around O O 0.9998039603233337
nucleotides B-DNA O 0.2600153386592865
( I-DNA O 0.8548779487609863
nt I-DNA O 0.2654595971107483
) I-DNA O 0.31686463952064514

We O O 0.9992120265960693
report O O 0.9999942779541016
the O O 0.999995231628418
case O O 0.9979088306427002
of O O 0.9998965263366699
a O O 0.9999362230300903
70 O O 0.984541654586792
- O O 0.998872697353363
year O O 0.9998693466186523
- O O 0.9998509883880615
old O O 0.9984807372093201
hypertensive B-Disease O 0.9182451963424683
man O O 0.5481856465339661
with O O 0.9985148310661316
a O O 0.9981359243392944
solitary O O 0.6580655574798584
kidney O O 0.7367547750473022
and O O 0.9505646824836731
chronic B-Disease O 0.8176676630973816
renal I-Disease O 0.5869618058204651
insufficiency I-Disease O 0.9703346490859985
who O O 0.8959468603134155
developed O O 0.9980432987213135
two O O 0.9992314577102661
episodes O O 0.9835243225097656
of O O 0.999445378780365
transient O O 0.7991867065429688
anuria B-Disease B-Disease 0.7548304796218872
after O O 0.9777956008911133
losartan B-Chemical B-Chemical 0.9149092435836792
administration O O 0.9726311564445496
. O O 0.9999947547912598

METHOD O O 0.962775468826294
: O O 0.9989618062973022
Open O O 0.967634379863739
, O O 0.9997252821922302
case O O 0.9934659600257874
series O O 0.9869019985198975
design O O 0.9979239702224731
. O O 0.9999979734420776

proteins E-protein E-protein 0.9431056380271912
. O O 0.9997599720954895
Notably O O 0.999893307685852
, O O 0.9999796152114868
no O O 0.9996095299720764
activation O O 0.9910146594047546
of O O 0.9986605644226074
Jak1 S-protein S-protein 0.9573819041252136
, O O 0.9828654527664185
Jak2 S-protein S-protein 0.9580775499343872
, O O 0.9945328235626221
Tyk2 S-protein S-protein 0.9392509460449219
, O O 0.9956737160682678
Stat1 S-protein S-protein 0.86134272813797

correlates O O 0.75467449426651
with O O 0.9999608993530273
cellular O O 0.9672083854675293
expression O O 0.9959161877632141
of O O 0.9999616146087646
the O O 0.9999629259109497
retinoic B-protein B-protein 0.5802331566810608
acid I-protein I-protein 0.7978442907333374
receptors E-protein E-protein 0.9847139716148376
. O O 0.9993058443069458
OBJECTIVES O O 0.9398971199989319
: O O 0.9982739686965942
To O O 0.9999377727508545
analyze O O 0.9999762773513794
the O O 0.9999814033508301
effect O O 0.9999675750732422
of O O 0.9999887943267822
retinoic O O 0.8257567882537842
acids O O 0.6861362457275391
( O O 0.9880834221839905
RA O O 0.8687416315078735
) O O 0.9911577105522156

and O O 0.9815707802772522
that O O 0.9999160766601562
RpoS S-protein S-protein 0.6925268769264221
likely O O 0.9976502060890198
regulates O O 0.9994958639144897
genes O O 0.7820855379104614
that O O 0.9998410940170288
enable O O 0.9999750852584839
it O O 0.9996703863143921
to O O 0.999964714050293
survive O O 0.999969482421875
in O O 0.9999308586120605
the O O 0.9993818998336792
environment O O 0.998579740524292
within O O 0.9999839067459106
protozoa O O 0.632682204246521
. O O 0.999782383441925
Our O O 0.9999977350234985
data O O 0.9996936321258545
indicate O O 0.9999974966049194
that O O 0.9999978542327881
the O O 0.9999703168869019
role O O 0.9996323585510254
of O O 0.9999375343322754
rpoS S-DNA S-DNA 0.8543029427528381
in O O 0.9990039467811584
L. O O 0.8053972125053406
pneumophila O O 0.699000895023346
is O O 0.9997134804725647
very O O 0.9997223019599915
different O O 0.9998773336410522
from O O 0.9999808073043823

cells E-cell_line E-cell_type 0.6165165901184082

ACE B-Chemical O 0.6257032155990601
inhibitor E-Chemical O 0.6637874841690063
and O O 0.9936413168907166
angiotensin B-Chemical B-Chemical 0.9309021830558777
- I-Chemical O 0.6830127835273743
releasing I-Chemical O 0.9827776551246643
blocker E-Chemical O 0.9149904847145081
( O O 0.9982458353042603
ARB S-Chemical O 0.6587996482849121
) O O 0.8299965262413025
therapy O O 0.9967772364616394
reduced O O 0.9976164102554321
proteinuria O O 0.8779422044754028
development O O 0.5701465010643005
. O O 0.9999630451202393

compared O O 0.991432785987854

and O O 0.9186884760856628
fibroblastic B-cell_line B-cell_line 0.4435664415359497
cell I-cell_line I-cell_line 0.7189623117446899
lines E-cell_line E-cell_line 0.9983958601951599
. O O 0.9999412298202515
Genetic O O 0.9802614450454712
mapping O O 0.9803001880645752
studies O O 0.9980812072753906
within O O 0.9999926090240479
the O O 0.9998956918716431
E1A B-DNA B-DNA 0.5303182601928711
gene E-DNA E-DNA 0.9848107099533081
demonstrated O O 0.9994564652442932
that O O 0.999994158744812
expression O O 0.9980915188789368
of O O 0.9999144077301025
only O O 0.9998489618301392
the O O 0.9995891451835632
first O O 0.8855307698249817
exon O S-DNA 0.6658024191856384
of O O 0.9432550668716431
E1A S-DNA S-DNA 0.6531099081039429
was O O 0.9978875517845154

is O O 0.9915224313735962
rapidly O O 0.9887458682060242
degraded O O 0.9975398778915405
. O O 0.9999979734420776
Overexpression O O 0.9964045286178589
of O O 0.999864935874939
p65 S-protein S-protein 0.9343702793121338
increases O O 0.9988502264022827
endogenous O O 0.9236840009689331
I B-protein B-protein 0.7068029046058655
kappa I-protein I-protein 0.9342990517616272
B E-protein I-protein 0.8462350368499756
protein O E-protein 0.9723491668701172
in O O 0.999679446220398
both O O 0.9948217868804932
carcinoma B-cell_type O 0.4325065016746521
and I-cell_type O 0.8691321611404419
lymphoid I-cell_type B-cell_type 0.6139245629310608
cells E-cell_type E-cell_type 0.9874134063720703
by O O 0.9999165534973145
two O O 0.9993748068809509
mechanisms O O 0.9961821436882019
: O O 0.9999479055404663
protein O O 0.8862441778182983
stabilization O O 0.98454350233078
and O O 0.9996922016143799

) O O 0.7139992713928223
or O O 0.997170627117157
PP2B S-protein S-protein 0.8284879922866821
( O O 0.9944846034049988
cyclosporine O O 0.8341050744056702
A O O 0.4057658314704895
) O O 0.9206349849700928
. O O 0.9999146461486816
Pretreatment O O 0.9830988049507141
with O O 0.999871015548706
the O O 0.9999675750732422
broad O O 0.9089648127555847
serine/threonine O O 0.6155605912208557
kinase O O 0.6783480048179626
inhibitor O O 0.5897627472877502
staurosporine O O 0.5087806582450867

by O O 0.99834144115448
Ficoll O O 0.8917983770370483
density O O 0.936409056186676
gradient O O 0.9354310631752014
. O O 0.9999690055847168
This O O 0.9999549388885498
ANG B-protein B-protein 0.39290082454681396
II E-protein E-protein 0.79390549659729
effect O O 0.9786810278892517
was O O 0.9999815225601196
blocked O O 0.9999459981918335
by O O 0.9999986886978149
the O O 0.9999589920043945
angiotensin O B-protein 0.4851652979850769
AT1 O I-protein 0.5962513089179993
receptor O E-protein 0.8151236772537231
antagonist O O 0.3724881708621979
losartan O O 0.605339765548706
. O O 0.9966639876365662
Specificity O O 0.998180627822876
of O O 0.999933123588562
ANG B-protein B-protein 0.4187128245830536
II E-protein E-protein 0.9775345325469971
-induced O O 0.992536187171936
NF-kappaB S-protein S-protein 0.9888174533843994
activation O O 0.9966892600059509
was O O 0.9999861717224121
ascertained O O 0.9999767541885376
by O O 0.9999955892562866
supershift O O 0.9207122921943665
and O O 0.9938251972198486
competition O O 0.9866505861282349

Acute O O 0.8336473107337952
confusion B-Disease B-Disease 0.8474389910697937
induced O O 0.9876855611801147
by O O 0.9998905658721924
a O O 0.9999136924743652
high O O 0.9978806972503662
- O O 0.9994269609451294
dose O O 0.9987228512763977
infusion O O 0.9337087273597717
of O O 0.9981822967529297
5 B-Chemical B-Chemical 0.9017757773399353
- I-Chemical I-Chemical 0.9936002492904663
fluorouracil I-Chemical I-Chemical 0.9319395422935486
and O O 0.8376477956771851
folinic B-Chemical B-Chemical 0.9338383078575134
acid I-Chemical I-Chemical 0.9467141628265381
. O O 0.9991748929023743

effect O O 0.9958451390266418
on O O 0.9999853372573853
the O O 0.9998303651809692
immune O O 0.9709345102310181
system O O 0.9785823822021484
. O O 0.9999986886978149
These O O 0.9999982118606567
apparent O O 0.9896601438522339
inconsistencies O O 0.9961263537406921
reflect O O 0.9999982118606567
the O O 0.9999920129776001
complexity O O 0.9948683977127075
of O O 0.9999257326126099

-177 I-DNA B-DNA 0.534278392791748
bp E-DNA E-DNA 0.9546787142753601
relative O O 0.9871282577514648
to O O 0.9999381303787231
the O O 0.9998258948326111
cap B-DNA B-DNA 0.521567702293396
site E-DNA E-DNA 0.9636863470077515
of O O 0.9972782731056213
the O O 0.9999347925186157
human B-DNA B-DNA 0.5518918633460999
epsilon-globin-encoding I-DNA I-DNA 0.6974850296974182
gene E-DNA E-DNA 0.9726641774177551
[ O O 0.9900345206260681
Cao O O 0.6019196510314941
et O O 0.4294152855873108
al. O O 0.8708551526069641
, O O 0.9998451471328735
Proc.Natl.Acad.Sci.USA O O 0.8471333980560303
86 O O 0.5413228273391724
( O O 0.9953852295875549
1989 O O 0.9824026823043823
) O O 0.9955026507377625
5306-5309 O O 0.9478164911270142
] O O 0.9991440773010254
. O O 0.9999929666519165
We O O 0.99996018409729
also O O 0.9999879598617554
showed O O 0.999996542930603
that O O 0.9999984502792358
this O O 0.9999058246612549
silencer S-DNA O 0.7366398572921753
has O O 0.9998593330383301
stronger O O 0.9916001558303833
inhibitory O O 0.9393117427825928
activity O O 0.9801125526428223
in O O 0.9999387264251709
HeLa B-cell_line B-cell_line 0.91058748960495
cells E-cell_line E-cell_line 0.9950172305107117
, O O 0.9973580241203308
as O O 0.9999865293502808
compared O O 0.999896764755249
to O O 0.9999583959579468
K562 B-cell_line B-cell_line 0.6344959139823914
human I-cell_line I-cell_line 0.7312922477722168
erythroleukemia I-cell_line I-cell_line 0.8217471837997437
cells E-cell_line E-cell_line 0.8617361187934875
. O O 0.9999321699142456

known O O 0.989590585231781

binding O O 0.7913153171539307
, O O 0.9919962286949158
transcriptional O O 0.9105032682418823
activation O O 0.9714060425758362
, O O 0.9994617104530334
and O O 0.9999182224273682
inhibition O O 0.9945726990699768
by O O 0.9999916553497314
an O O 0.9996405839920044
I B-protein B-protein 0.8632067441940308
kappa I-protein I-protein 0.9641302227973938
B-alpha E-protein E-protein 0.9599979519844055
( O O 0.9599505066871643
MAD-3 S-protein S-protein 0.9152882099151611
) O O 0.9492567181587219
. O O 0.9999463558197021
Inducible O O 0.9714762568473816
expression O O 0.9977426528930664
of O O 0.9998326301574707

of O O 0.9926290512084961

For O O 0.9994935989379883
both O O 0.9998904466629028
experiments O O 0.9979992508888245
the O O 0.9999721050262451
drug O O 0.9472827911376953
intake O O 0.9879383444786072
led O O 0.9999698400497437
to O O 0.9999794960021973
significant O O 0.9970952272415161
increases O O 0.9009371995925903
in O O 0.971462607383728
PRL O O 0.6875482201576233
secretion O O 0.8157371282577515
, O O 0.99988853931427
acting O O 0.9987634420394897
preferentially O O 0.9994490742683411
on O O 0.9999748468399048
tonic O O 0.9203925728797913
secretion O O 0.7881477475166321
as O O 0.9999533891677856
pulse O O 0.8946923017501831
amplitude O O 0.7950989603996277
and O O 0.9992756247520447
frequency O O 0.9579116702079773
did O O 0.9998764991760254
not O O 0.9998828172683716
differ O O 0.9999704360961914
significantly O O 0.9999306201934814
from O O 0.9999943971633911
corresponding O O 0.9886825680732727
control O O 0.9853879809379578
values O O 0.9939942955970764
. O O 0.999998927116394

the O O 0.9939623475074768
gene O O 0.9436550140380859
has O O 0.9998509883880615
been O O 0.9999332427978516
characterized O O 0.9998979568481445
. O O 0.9999951124191284
Two O O 0.9986540079116821
interferon-stimulated B-DNA B-DNA 0.6208338737487793
response I-DNA I-DNA 0.5453957915306091
elements E-DNA E-DNA 0.9830008745193481
( O O 0.9745506048202515
ISRE S-DNA S-DNA 0.9865618348121643
) O O 0.9715456366539001

these O O 0.99172443151474
cells O O 0.9033540487289429
. O O 0.9999806880950928
IL-2 S-protein S-protein 0.8765611052513123
binding O O 0.8102895021438599
analysis O O 0.9948029518127441
demonstrated O O 0.9999873638153076
that O O 0.9999942779541016
IL-2 S-protein S-protein 0.9755585193634033
markedly O O 0.997778594493866
increased O O 0.9997767806053162
the O O 0.9999306201934814
number O O 0.9991668462753296
of O O 0.9999704360961914
low O O 0.8800099492073059
affinity O O 0.6920289397239685
IL-2Rs S-protein S-protein 0.6679661870002747
on O O 0.9994184970855713
the O O 0.9995693564414978
leukemia B-cell_type B-cell_type 0.5555428862571716
cells E-cell_type E-cell_type 0.9679868817329407
, O O 0.9985460042953491
without O O 0.9999970197677612
an O O 0.9999871253967285
effect O O 0.999931812286377
on O O 0.9999942779541016
the O O 0.9999096393585205
number O O 0.9971796274185181
of O O 0.9999043941497803
high-affinity B-protein O 0.5181694626808167

One O O 0.9996572732925415
week O O 0.9999740123748779
later O O 0.9999933242797852
, O O 0.9999823570251465
the O O 0.999622106552124
patient O O 0.9975443482398987
was O O 0.9999611377716064
again O O 0.9997244477272034
extubated O O 0.9693843126296997
and O O 0.999896764755249
3 O O 0.9972296357154846
days O O 0.9999701976776123
later O O 0.9999747276306152
was O O 0.9999639987945557
transferred O O 0.9999628067016602
to O O 0.9999881982803345
a O O 0.9998570680618286
peripheral O O 0.956989586353302
ward O O 0.9899263381958008
. O O 0.9999988079071045

non-B O O 0.2798224091529846
, O O 0.7951074838638306
non-T O O 0.4109492301940918
) O O 0.4362852871417999
phenotypes O O 0.5986239910125732
although O O 0.9997177720069885
immunogenotypic O O 0.9314547777175903
studies O O 0.9937007427215576
documented O O 0.9999494552612305
their O O 0.999937891960144
B-cell B-cell_type O 0.5506442189216614
origin E-cell_type O 0.35626259446144104
. O O 0.999946117401123
Both O O 0.9999189376831055
cell B-cell_line B-cell_line 0.725123941898346
lines E-cell_line E-cell_line 0.9772850275039673
are O O 0.9997206330299377

PURPOSE O O 0.9842178821563721
: O O 0.9999701976776123
To O O 0.9999834299087524
assess O O 0.999944806098938
the O O 0.9999191761016846
incidence O O 0.9961219429969788
of O O 0.9999045133590698
postoperative O O 0.9129848480224609
emetic O O 0.722809910774231
side O O 0.8123511075973511
effects O O 0.9733181595802307
after O O 0.9999923706054688
the O O 0.9999573230743408
administration O O 0.9968032836914062
of O O 0.9993411898612976
methylprednisolone B-Chemical B-Chemical 0.9294449687004089
and O O 0.9399781227111816
gentamicin B-Chemical B-Chemical 0.9282109141349792
into O O 0.9957866072654724
the O O 0.9998925924301147
posterior O O 0.8563761115074158
sub O O 0.9902219772338867
- O O 0.9996979236602783
Tenon O O 0.9814445972442627
' O O 0.991866409778595
s O O 0.9864158630371094
space O O 0.9968400001525879
at O O 0.999998927116394
the O O 0.9999457597732544
end O O 0.999295711517334
of O O 0.9999880790710449
routine O O 0.839497983455658
cataract B-Disease O 0.5542410016059875
surgery O O 0.6088681817054749
. O O 0.9999701976776123

a O O 0.9965426325798035
group O O 0.9986026883125305
of O O 0.9999607801437378
age- O O 0.9624193906784058
and O O 0.9794929623603821
sex-matched O O 0.9311859011650085
controls O O 0.968726634979248
. O O 0.9999943971633911
While O O 0.9999973773956299
there O O 0.9999864101409912
was O O 0.9999940395355225
a O O 0.9999865293502808
significant O O 0.9992127418518066
increase O O 0.9971664547920227
in O O 0.9989635944366455
plasma O O 0.8998948335647583
cortisol O O 0.8524447679519653
levels O O 0.9996600151062012
in O O 0.9999948740005493
the O O 0.9999171495437622
depressed O O 0.7213387489318848
group O O 0.9210605025291443
, O O 0.99997878074646
there O O 0.9999955892562866
were O O 0.9999974966049194
no O O 0.9999847412109375
changes O O 0.9994822144508362
in O O 0.999984622001648
the O O 0.999769389629364
lymphocyte O O 0.4986276924610138
GR S-protein O 0.3391951322555542
binding O O 0.4772796034812927
parameters O O 0.5822370052337646
( O O 0.9918117523193359
K O O 0.6627947688102722
( O O 0.9482945799827576
m O O 0.9318602681159973
) O O 0.9708858132362366
and O O 0.9987949132919312
Bmax O O 0.5092896223068237
) O O 0.9635074734687805

Tonotopic O O 0.5414085984230042
organization O O 0.5121683478355408
is O O 0.9995799660682678
an O O 0.9999959468841553
essential O O 0.9984167814254761
feature O O 0.9996323585510254
of O O 0.9999618530273438
the O O 0.9999574422836304
primary O O 0.926548182964325
auditory O O 0.8977017402648926
area O O 0.9761127829551697
( O O 0.9999010562896729
A1 O O 0.8165825605392456
) O O 0.9987097978591919
of O O 0.9999666213989258
primate O O 0.6857885718345642
cortex O O 0.7917435765266418
. O O 0.99986732006073

This O O 0.9997538924217224
study O O 0.9999890327453613
suggests O O 0.9999960660934448
that O O 0.9999902248382568
for O O 0.9993908405303955
healthy O O 0.8508764505386353
older O O 0.9585837125778198
adults O O 0.992746889591217
who O O 0.9999637603759766
are O O 0.9999722242355347
not O O 0.9989909529685974
suffering O O 0.9997534155845642
from O O 0.9999247789382935
chronic B-Disease O 0.7743785381317139
pain I-Disease O 0.695119321346283
, O O 0.9844160676002502
neurocognitive O O 0.5098810791969299
and O O 0.7977274060249329
pharmacodynamic O O 0.549733579158783
changes O O 0.8363405466079712
in O O 0.9982764720916748
response O O 0.9987179040908813
to O O 0.9999878406524658
a O O 0.9999523162841797
10 O O 0.9881122708320618
- O O 0.9992369413375854
mg O O 0.9984172582626343
dose O O 0.9998339414596558
of O O 0.9999524354934692
immediate O O 0.9808754920959473
- O O 0.9977549910545349
release O O 0.9952414035797119
oxycodone B-Chemical B-Chemical 0.9300733804702759
are O O 0.9996204376220703
similar O O 0.9999500513076782
to O O 0.9999886751174927
those O O 0.9999842643737793
observed O O 0.9999116659164429
for O O 0.9999873638153076
middle O O 0.9807424545288086
- O O 0.9952514171600342
aged O O 0.9985706806182861
adults O O 0.9976423382759094
. O O 0.9999988079071045

Evaluation O O 0.998139500617981
of O O 0.9999812841415405
adverse O O 0.9337442517280579
reactions O O 0.8496630787849426
of O O 0.9991925358772278
aponidine B-Chemical B-Chemical 0.9163841605186462
hydrochloride I-Chemical E-Chemical 0.9143801927566528
ophthalmic O O 0.41207849979400635
solution O O 0.7047603726387024
. O O 0.9999693632125854

In O O 0.9997524619102478
both O O 0.9997887015342712
ecstasy S-Chemical B-Chemical 0.8890414834022522
and O O 0.989840030670166
cannabis S-Chemical B-Chemical 0.8795492053031921
groups O O 0.7978104948997498
brain O O 0.8908886313438416
activation O O 0.8218721151351929
was O O 0.9997733235359192
decreased O O 0.998050332069397
in O O 0.9999569654464722
the O O 0.9998127818107605
right O O 0.9951828122138977
medial O O 0.993391752243042
frontal O O 0.9520611763000488
gyrus O O 0.5707066655158997
, O O 0.9993258714675903
left O O 0.9482237100601196
parahippocampal O O 0.6150510907173157
gyrus O O 0.7386609315872192
, O O 0.9946187734603882
left O O 0.9081270098686218
dorsal O O 0.8939263820648193
cingulate O O 0.9005747437477112
gyrus O O 0.38664954900741577
, O O 0.9971309304237366
and O O 0.9999617338180542
left O O 0.9814592599868774
caudate O O 0.7980524897575378
. O O 0.9999902248382568

. O O 0.9936544895172119
Erythroid B-protein B-protein 0.7490485906600952
Kruppel-like I-protein I-protein 0.7452030181884766
factor E-protein E-protein 0.9688576459884644
( O O 0.9780262112617493
EKLF S-protein S-protein 0.9709773063659668
) O O 0.9503947496414185
, O O 0.9995217323303223
which O O 0.9999517202377319
binds O O 0.9997199177742004
to O O 0.9999105930328369
the O O 0.9997566342353821
CACCC O B-DNA 0.6946243047714233
box O E-DNA 0.9839695692062378
in O O 0.9991872906684875
the O O 0.9999122619628906
beta-globin B-DNA B-DNA 0.7312715649604797
promoter E-DNA E-DNA 0.9776340126991272
, O O 0.9719967246055603
is O O 0.9999580383300781
required O O 0.9999434947967529
for O O 0.9999927282333374
the O O 0.9999778270721436
expression O O 0.9979920387268066
of O O 0.9999521970748901
the O O 0.9999040365219116
beta-globin B-DNA B-DNA 0.6972728371620178
gene E-DNA E-DNA 0.9664196968078613
in O O 0.9972677230834961
adult B-cell_type O 0.5070854425430298

Tyrosine O O 0.5021924376487732

The O O 0.9993124008178711
effects O O 0.9992640614509583
of O O 0.9993466734886169
sevoflurane B-Chemical B-Chemical 0.9350964426994324
on O O 0.9319494962692261
lidocaine B-Chemical B-Chemical 0.9263812303543091
- O O 0.9835197329521179
induced O O 0.9956256151199341
convulsions B-Disease B-Disease 0.969254732131958
. O O 0.9986819624900818

of O O 0.9952554106712341
transcription B-protein B-protein 0.5827681422233582
factors E-protein E-protein 0.9972477555274963
in O O 0.9997480511665344
early O O 0.7688513994216919
hematopoietic O O 0.6766833662986755
differentiation O O 0.9641320109367371
has O O 0.9998641014099121
not O O 0.9998863935470581
yet O O 0.9999704360961914
been O O 0.9999278783798218
explored O O 0.999942421913147
. O O 0.9999988079071045
The O O 0.9999855756759644
DNA-binding B-protein B-protein 0.4152321517467499
protein E-protein E-protein 0.9312787652015686
GATA-1 S-protein S-protein 0.5192669630050659
is O O 0.9996492862701416
required O O 0.9999494552612305
for O O 0.999990701675415
normal O O 0.9325404763221741
erythroid O O 0.7669610381126404
development O O 0.9810196757316589
and O O 0.9994070529937744
regulates O O 0.9989933371543884
erythroid-expressed B-DNA B-DNA 0.45410045981407166
genes E-DNA E-DNA 0.9613777995109558

receptors E-protein E-protein 0.9696834087371826
and O O 0.9987459182739258
rapid O O 0.9653378129005432
non-genomic O O 0.9688290357589722
actions O O 0.9979941844940186
of O O 0.9999711513519287
mineralocorticoids O O 0.34205836057662964
. O O 0.9993463158607483
Functional O O 0.9860267639160156
studies O O 0.9989687204360962
in O O 0.9999189376831055
extrarenal B-cell_type B-cell_type 0.6259229183197021
, I-cell_type I-cell_type 0.5347458124160767
non-epithelial I-cell_type I-cell_type 0.6802573800086975
cells E-cell_type E-cell_type 0.8352969288825989
such O O 0.9976553916931152
as O O 0.9998854398727417
smooth B-cell_type B-cell_type 0.46959546208381653
muscle I-cell_type I-cell_type 0.7185836434364319
cells E-cell_type E-cell_type 0.9163820743560791
and O O 0.9943013191223145
more O O 0.995103120803833
recently O O 0.9138869643211365
circulating B-cell_type O 0.8037825226783752
human I-cell_type B-cell_type 0.45860961079597473
lymphocytes E-cell_type E-cell_type 0.9777201414108276
have O O 0.9994187355041504
provided O O 0.9999850988388062

tyrosine-phosphorylated O O 0.5441759824752808
by O O 0.99552983045578
GM-CSF S-protein S-protein 0.9723953604698181
and O O 0.9943317174911499
FMLP O S-protein 0.9003050923347473
, O O 0.9966102242469788
and O O 0.9989550113677979
Sos1 S-protein S-protein 0.9109552502632141
and O O 0.989147424697876
c-Raf-1 S-protein S-protein 0.9784949421882629
were O O 0.9997168183326721
not O O 0.9998142123222351
phosphorylated O O 0.9511275291442871
by O O 0.9995889067649841
GM-CSF S-protein S-protein 0.9703246355056763
, O O 0.9958550333976746
IL-3 O S-protein 0.9888849258422852
, O O 0.9951122403144836
TNF O S-protein 0.9914737939834595
, O O 0.993047297000885
and O O 0.9988217949867249
FMLP O S-protein 0.9170636534690857
in O O 0.9973949193954468
monocytes S-cell_type S-cell_type 0.8853768110275269

chimeric B-protein B-protein 0.36965638399124146
CD8alpha/IL-4Ralpha I-protein I-protein 0.45849087834358215
receptor E-protein E-protein 0.9852793216705322
, O O 0.9757201671600342
which O O 0.9998507499694824
is O O 0.9998874664306641
expressed O O 0.9996664524078369
on O O 0.9998155236244202
the O O 0.9997822642326355
cell O O 0.8781068325042725
surface O O 0.9382468461990356
as O O 0.9998856782913208
a O O 0.9999406337738037
homodimer S-protein O 0.3582399785518646
, O O 0.9461206793785095
constitutively O O 0.9277555346488953
expressed O O 0.9919313788414001
Cepsilon B-RNA B-RNA 0.6400914788246155
germline I-RNA I-RNA 0.9343346953392029
transcripts E-RNA E-RNA 0.9934592247009277
. O O 0.9996408224105835
These O O 0.9999966621398926
results O O 0.9999686479568481
suggest O O 0.9999982118606567
that O O 0.9999946355819702
homodimerization O O 0.9946210384368896
of O O 0.9998177886009216
the O O 0.9995868802070618
IL-4Ralpha B-protein S-protein 0.37561413645744324

alpha I-DNA I-DNA 0.5347628593444824
gene E-DNA E-DNA 0.9715850353240967
in O O 0.9962522387504578
B B-cell_type B-cell_type 0.8793094754219055
cells E-cell_type E-cell_type 0.9747409820556641
and O O 0.9769432544708252
T B-cell_type B-cell_type 0.868793249130249
cells E-cell_type E-cell_type 0.9911653399467468
by O O 0.9992544054985046
NFATp S-protein S-protein 0.9385305047035217
and O O 0.9967286586761475
ATF-2/JUN S-protein O 0.5420506596565247
. O O 0.999868631362915
The O O 0.999988317489624
human B-DNA B-protein 0.5782751441001892
tumor I-DNA I-protein 0.30578336119651794
necrosis I-DNA I-protein 0.5187837481498718
factor I-DNA I-protein 0.5667625069618225
alpha I-DNA E-protein 0.8564205169677734

DNA B-DNA B-DNA 0.63960200548172
binding I-DNA I-DNA 0.5229199528694153
sites E-DNA E-DNA 0.6963119506835938
for O O 0.9991897940635681
IL-13-induced B-protein B-protein 0.38014936447143555
regulatory I-protein I-protein 0.7042133808135986
factors E-protein E-protein 0.9889963865280151
in O O 0.9990885257720947
monocytes S-cell_type S-cell_type 0.9839019179344177
. O O 0.9995436072349548
In O O 0.9999754428863525
order O O 0.9998980760574341
to O O 0.9999967813491821
study O O 0.9999842643737793
the O O 0.9999465942382812
transcriptional O O 0.9575531482696533
control O O 0.9940010905265808
of O O 0.9998800754547119
15-LO S-protein S-protein 0.5418350696563721
expression O O 0.992550253868103
, O O 0.9999608993530273

expressions O O 0.9867933392524719

of I-protein O 0.9789236187934875
activated I-protein B-cell_type 0.5703325867652893
T I-protein I-cell_type 0.5522323846817017
cells E-protein E-cell_type 0.8151136040687561
( O O 0.9809905290603638
NF-AT S-protein S-protein 0.9935824275016785
) O O 0.9872006177902222
denotes O O 0.9998466968536377
a O O 0.9999518394470215
family O O 0.9832473397254944
of O O 0.9988561868667603
transcription B-protein B-protein 0.6188725233078003
factors E-protein E-protein 0.9942582845687866
that O O 0.9995405673980713
regulate O O 0.9999614953994751
the O O 0.999808132648468
activation-dependent O O 0.9257564544677734
expression O O 0.9901487827301025
of O O 0.9999139308929443
many O O 0.992497980594635
immunologically B-protein B-protein 0.7902646660804749
important I-protein I-protein 0.8547367453575134
proteins E-protein E-protein 0.8728567361831665
. O O 0.9995200634002686
At O O 0.9999849796295166
least O O 0.9994003772735596
four O O 0.9998207688331604
distinct O O 0.9892271757125854
genes O O 0.4580307602882385
encode O O 0.9997441172599792
the O O 0.9999057054519653
various O O 0.9896920323371887
family O O 0.9197225570678711
members O O 0.5371753573417664
, O O 0.9993342757225037
and O O 0.9999532699584961
several O O 0.9990837574005127

beta-phorbol O O 0.6681864261627197
12-myristate O O 0.9201843738555908
13-acetate O O 0.9262775182723999
( O O 0.9989359974861145
PMA O O 0.9526913166046143
) O O 0.9984666109085083
addition O O 0.9998326301574707
of O O 0.9999853372573853
DM O O 0.5366355776786804
to O O 0.9970539808273315
the O O 0.999790608882904
cultures O O 0.946459174156189
resulted O O 0.9999830722808838
in O O 0.999991774559021
a O O 0.9999797344207764
60 O O 0.9539311528205872
% O O 0.9960877895355225
reduction O O 0.9939188957214355
in O O 0.9993423819541931
IL-2R B-protein B-protein 0.3463245630264282
alpha E-protein E-protein 0.94454425573349
and O O 0.9973788261413574
a O O 0.9999536275863647
30 O O 0.9528704285621643
% O O 0.9954356551170349
reduction O O 0.9936892986297607
in O O 0.9996514320373535
IL-2R B-protein B-protein 0.3070013225078583
beta E-protein E-protein 0.8119626045227051
membrane O O 0.3977169692516327
expression O O 0.9817912578582764
compared O O 0.9998534917831421

activation O O 0.9801260828971863
of O O 0.9997716546058655
dominant-negative O O 0.6998950242996216
RXR S-protein S-protein 0.7468175292015076
-retinoic O B-protein 0.9477663636207581
acid O I-protein 0.8749642968177795
receptor O I-protein 0.4952084422111511
alpha403 O I-protein 0.359851211309433
heterodimers O E-protein 0.9835395812988281
is O O 0.9994578957557678
developmentally O O 0.9777551293373108
regulated O O 0.9979649782180786
during O O 0.9999816417694092
myeloid O O 0.7775351405143738
differentiation O O 0.9774653911590576
. O O 0.9999886751174927
The O O 0.9999963045120239
multiple O O 0.9462234973907471
biologic O O 0.921879231929779
activities O O 0.9968129992485046
of O O 0.9999889135360718
retinoic O O 0.8107597231864929
acid O O 0.7996354699134827
( O O 0.9950534701347351
RA O O 0.9607317447662354
) O O 0.999150276184082
are O O 0.9999902248382568
mediated O O 0.9997252821922302
through O O 0.9999815225601196
RAR S-protein S-protein 0.6667096614837646
and O O 0.972022533416748
retinoid B-protein B-protein 0.7335376739501953
X I-protein I-protein 0.6485934257507324
receptor I-protein E-protein 0.9405927658081055
( I-protein O 0.8954600691795349

mechanisms O O 0.9575109481811523

catalytically B-protein O 0.8158984780311584
inactive I-protein O 0.9155023694038391
form E-protein O 0.7553101181983948
of O O 0.9995892643928528
Ca2+/calmodulin-dependent B-protein B-protein 0.5541898608207703
protein I-protein I-protein 0.4839252531528473
kinase I-protein I-protein 0.7184688448905945
IV E-protein E-protein 0.985676646232605
( O O 0.9911425113677979
CaMKIV S-protein S-protein 0.9531776905059814
) O O 0.9872767329216003
specifically O O 0.999868631362915
in O O 0.9998335838317871
thymic B-cell_type B-cell_type 0.5659499168395996
T I-cell_type I-cell_type 0.7220602035522461
cells E-cell_type E-cell_type 0.824465811252594
. O O 0.9997766613960266
The O O 0.9999982118606567
presence O O 0.9993869066238403
of O O 0.9999737739562988
this O O 0.9999148845672607
protein O O 0.748305082321167

less O O 0.9883346557617188
dependent O O 0.9997218251228333
on O O 0.9999865293502808
the O O 0.9999454021453857
Src B-protein B-protein 0.48290780186653137
family I-protein I-protein 0.5959917902946472
kinase E-protein E-protein 0.9617024064064026
Lck S-protein S-protein 0.9489712715148926
than O O 0.9996377229690552
the O O 0.9999493360519409
activation O O 0.9680131077766418
of O O 0.9965957999229431
Zap S-protein S-protein 0.9233056902885437

No O O 0.9968309998512268
changes O O 0.9975073933601379
in O O 0.9998811483383179
haloperidol B-Chemical B-Chemical 0.9359320402145386
- O O 0.8655640482902527
induced O O 0.9972276091575623
catalepsy B-Disease B-Disease 0.9444698095321655
or O O 0.9803630709648132
MK B-Chemical B-Chemical 0.9446499943733215
- I-Chemical I-Chemical 0.9840100407600403
801 I-Chemical I-Chemical 0.9322687983512878
- O O 0.5543361306190491
induced O O 0.995104193687439
locomotion O O 0.9083673357963562
were O O 0.9918488264083862
seen O O 0.9999651908874512
following O O 0.9999814033508301
PD O O 0.7323647737503052
. O O 0.9996531009674072

CD33 S-protein S-protein 0.8299397230148315
and O O 0.9949126243591309
were O O 0.999891996383667
negative O O 0.9958064556121826
for O O 0.9997900128364563
CD34 S-protein S-protein 0.9601213335990906
, O O 0.989797830581665
CD16 S-protein S-protein 0.9797690510749817
and O O 0.9937331080436707
CD23 S-protein S-protein 0.971307635307312
. O O 0.9997102618217468
The O O 0.9999884366989136
eosinophilic O O 0.7358121871948242
characteristics O O 0.8615849018096924
of O O 0.9997969269752502
YJ B-cell_line B-cell_line 0.5867002606391907
cells E-cell_line E-cell_line 0.9350485801696777
were O O 0.9999054670333862

that O O 0.9989916682243347
other O O 0.9995038509368896
genes O O 0.7685917615890503
are O O 0.9999204874038696
likely O O 0.9999358654022217
to O O 0.9999856948852539
be O O 0.9999747276306152
adversely O O 0.9989299178123474
affected O O 0.9999716281890869
by O O 0.9999974966049194
loss O O 0.9915340542793274
of O O 0.9997888207435608
C/EBPalpha S-protein S-protein 0.9858043193817139
. O O 0.9998849630355835
Here O O 0.999964714050293
we O O 0.9999972581863403
demonstrate O O 0.9999818801879883
loss O O 0.9851332902908325
of O O 0.9995474219322205
interleukin B-protein B-protein 0.4730066955089569
6 I-protein I-protein 0.9429337382316589
( I-protein I-protein 0.8674681782722473
IL-6 I-protein I-protein 0.8430886268615723
) I-protein I-protein 0.6499342918395996
receptor E-protein E-protein 0.9146508574485779
and O O 0.9778472185134888
IL-6-responsive B-protein B-protein 0.4243587851524353
colony-forming I-protein I-protein 0.678014874458313
units E-protein E-protein 0.7825870513916016
( O O 0.995662271976471
CFU-IL6 S-protein S-protein 0.3752201497554779
) O O 0.9783318638801575
in O O 0.9999234676361084
C/EBPalpha S-protein S-protein 0.5707204341888428
-/- O O 0.8900136351585388

The O O 0.9992695450782776
combination O O 0.9725607633590698
inhibited O O 0.9964250922203064
intestinal O O 0.8458682298660278
transit O O 0.7211003303527832
similar O O 0.9728934168815613
to O O 0.9982969164848328
that O O 0.9993270635604858
produced O O 0.9998931884765625
by O O 0.9999730587005615
morphine S-Chemical B-Chemical 0.9395011067390442
regardless O O 0.9996172189712524
of O O 0.9999667406082153
the O O 0.9999935626983643
time O O 0.9999449253082275
of O O 0.9999508857727051
treatment O O 0.9965278506278992
, O O 0.9999946355819702
suggesting O O 0.9999873638153076
that O O 0.9999313354492188
metamizol S-Chemical B-Chemical 0.9306215643882751
did O O 0.9990083575248718
not O O 0.9999276399612427
potentiate O O 0.9979259967803955
morphine S-Chemical B-Chemical 0.9359354376792908
- O O 0.9657385945320129
induced O O 0.9982129335403442
constipation O B-Disease 0.9689221382141113
. O O 0.9982158541679382

immune O O 0.8948113918304443
response O O 0.993309497833252
to O O 0.9998843669891357
Ad O O 0.46164700388908386
in O O 0.9977918863296509
BALB/c O O 0.4451373517513275
mice O O 0.936779260635376
was O O 0.9999805688858032
more O O 0.9999068975448608
complex O O 0.9770587086677551
. O O 0.9999756813049316
CTLs S-cell_type S-cell_type 0.8517449498176575
from O O 0.9994869232177734
BALB/c O O 0.39279651641845703
mice O O 0.8593865633010864
inoculated O O 0.9990922212600708
i.p. O O 0.9772966504096985
with O O 0.9999781847000122
wild-type O O 0.6603046655654907
Ad O O 0.4079406261444092
recognized O O 0.8642818331718445
E1B S-DNA S-protein 0.600249707698822
in O O 0.9981495141983032

The O O 0.9991130232810974
EF O O 0.41516396403312683
was O O 0.9992613196372986
40 O O 0.9999278783798218
% O O 0.9999899864196777
, O O 0.999985933303833
in O O 0.999984622001648
the O O 0.9998643398284912
group O O 0.9992927312850952
with O O 0.9999942779541016
MP O O 0.6169508695602417
and O O 0.9748461842536926
44 O O 0.9984316229820251
% O O 0.9999687671661377
in O O 0.9999771118164062
the O O 0.9998112320899963
group O O 0.9982469081878662
with O O 0.999993085861206
severe O O 0.9825291633605957
MR O O 0.925581693649292
and O O 0.8425217866897583
it O O 0.9845402836799622
can O O 0.9997413754463196
be O O 0.999994158744812
a O O 0.9999463558197021
factor O O 0.9816833734512329
associated O O 0.9998356103897095
with O O 0.9999904632568359
clinical O O 0.9742020964622498
events O O 0.9100750684738159
in O O 0.9998589754104614
the O O 0.9999102354049683
last O O 0.999232292175293
group O O 0.9997053742408752
. O O 0.999998927116394

stimulates O O 0.9825407862663269
transcription O O 0.9633076190948486
mediated O O 0.9993470311164856
by O O 0.9999953508377075
these O O 0.9999788999557495
factors O O 0.9717934727668762
. O O 0.999937891960144
HIV B-protein B-protein 0.8606376647949219
glycoprotein I-protein I-protein 0.5298141837120056
120 E-protein E-protein 0.8523105382919312
enhances O O 0.9936743974685669
intercellular B-protein B-protein 0.8513578772544861
adhesion I-protein I-protein 0.7298181653022766
molecule-1 E-protein E-protein 0.7580364942550659
gene O O 0.7530583739280701
expression O O 0.9456039667129517
in O O 0.9997339844703674
glial B-cell_type B-cell_type 0.7786435484886169
cells E-cell_type E-cell_type 0.9538426995277405
. O O 0.9998302459716797
Involvement O O 0.9998409748077393
of O O 0.9999774694442749
Janus B-protein B-protein 0.7815811634063721
kinase E-protein I-protein 0.7940491437911987
/signal B-protein I-protein 0.42300188541412354
transducer I-protein E-protein 0.586304247379303

of O O 0.9935868978500366
sIgD S-protein S-protein 0.6696463823318481
. O O 0.9980676770210266
Egr-1 B-RNA B-RNA 0.784783661365509
mRNA E-RNA E-RNA 0.9956905245780945
expression O O 0.9814794659614563
induced O O 0.9999512434005737
by O O 0.9999667406082153
sIgM- O O 0.645996630191803
and O O 0.8684446215629578
sIgD-crosslinking O O 0.4952584207057953
was O O 0.9966983199119568
inhibited O O 0.9998342990875244
by O O 0.99998939037323
H7 S-protein O 0.6175366640090942
, O O 0.9939345717430115
erbstatin O O 0.7799533605575562
and O O 0.9987921118736267
genistein O O 0.8648608326911926
, O O 0.998478353023529
but O O 0.99994957447052
not O O 0.9997462630271912
by O O 0.9998663663864136
HA1004 O O 0.6512385010719299
. O O 0.9996509552001953
Erbstatin O O 0.9231151938438416
and O O 0.9983168840408325
genistein O O 0.8558928966522217
inhibited O O 0.9999040365219116
the O O 0.9999123811721802
sIg-crosslinking-induced O O 0.7871664762496948
Egr-1 B-RNA B-RNA 0.33256927132606506
mRNA E-RNA E-RNA 0.9655092358589172
expression O O 0.9910092353820801
in O O 0.9999879598617554
a O O 0.9999141693115234
dose-dependent O O 0.817125678062439
manner O O 0.8687064051628113
parallel O O 0.9804108738899231
to O O 0.9997743964195251
that O O 0.9994077682495117
observed O O 0.9872121214866638
in O O 0.9999008178710938
the O O 0.9998615980148315
inhibition O O 0.9394950866699219
of O O 0.9984132051467896

Analysis O O 0.9964614510536194
of O O 0.9998836517333984
neurotransmitter O O 0.4268401861190796
concentration O O 0.7747905850410461
in O O 0.9990010857582092
some O O 0.999948263168335
brain O O 0.8462934494018555
regions O O 0.8909313678741455
on O O 0.9998841285705566
the O O 0.9999667406082153
test O O 0.9976205229759216
day O O 0.9999384880065918
showed O O 0.9999986886978149
that O O 0.9999774694442749
dopamine S-Chemical B-Chemical 0.9287477731704712
concentration O O 0.9701565504074097
of O O 0.9995100498199463
the O O 0.999578058719635
vehicle O O 0.6945412755012512
/ O O 0.9726109504699707
scopolamine S-Chemical B-Chemical 0.9338353276252747
group O O 0.9084471464157104
was O O 0.9999927282333374
significantly O O 0.9999315738677979
lower O O 0.9998934268951416
than O O 0.9999922513961792
that O O 0.9999697208404541
of O O 0.9997552037239075
the O O 0.9997332692146301
vehicle O O 0.9646905064582825
/ O O 0.9995421171188354
vehicle O O 0.9904312491416931
group O O 0.9987183809280396
, O O 0.9999927282333374
but O O 0.9999861717224121
this O O 0.9998522996902466
phenomenon O O 0.9403400421142578
was O O 0.9998759031295776
reversed O O 0.9997339844703674
when O O 0.9999898672103882
s B-Chemical B-Chemical 0.5569224953651428
- I-Chemical I-Chemical 0.9840917587280273
limonene E-Chemical E-Chemical 0.925160825252533
or O O 0.8910863995552063
s B-Chemical B-Chemical 0.6872110962867737
- I-Chemical I-Chemical 0.9865034818649292
perillyl I-Chemical I-Chemical 0.9518952965736389
alcohol E-Chemical I-Chemical 0.9317707419395447
were O O 0.9923580288887024
administered O O 0.9999208450317383
before O O 0.9999971389770508
the O O 0.9999814033508301
injection O O 0.984205424785614
of O O 0.999347984790802
scopolamine S-Chemical B-Chemical 0.9343544244766235
. O O 0.9995001554489136

measuring O O 0.9538325071334839
[ O O 0.9881238341331482
3H O O 0.9076119661331177
] O O 0.9758386015892029
dexamethasone O O 0.9069880247116089
binding O O 0.9878939986228943
and O O 0.9999277591705322
the O O 0.9999874830245972
effect O O 0.9999572038650513
of O O 0.9999901056289673
dexamethasone O O 0.9542574286460876
on O O 0.9997699856758118
[ O O 0.9970571994781494
3H O O 0.942798912525177
] O O 0.9965062141418457
thymidine O O 0.8563628196716309
incorporation O O 0.9990082383155823
, O O 0.9999897480010986
which O O 0.9999892711639404
is O O 0.9999972581863403
one O O 0.9999898672103882
of O O 0.9999949932098389
the O O 0.9999864101409912
effects O O 0.9999210834503174
of O O 0.9999821186065674

shown O O 0.9910408854484558

The O O 0.9993595480918884
remaining O O 0.9997351765632629
seven O O 0.9996856451034546
patients O O 0.9992722868919373
had O O 0.9999717473983765
isolated O O 0.9057885408401489
beta O O 0.7029145359992981
2 O O 0.8161144852638245
microglobulinuria O O 0.7249539494514465
. O O 0.9996115565299988

Relationship O O 0.9865202903747559
between O O 0.9991545677185059
those O O 0.9998224377632141
markers O O 0.9459275007247925
and O O 0.9990160465240479
demographic O O 0.5470643639564514
characteristics O O 0.6921386122703552
were O O 0.9995254278182983
investigated O O 0.9998569488525391
. O O 0.9999990463256836

syndrome I-protein O 0.7665508985519409
toxin-I E-protein O 0.5617730617523193
or O O 0.9970736503601074
staphylococcal B-protein B-protein 0.851447582244873
enterotoxin I-protein I-protein 0.43370309472084045
B E-protein E-protein 0.9693265557289124
, O O 0.9961622953414917
regulate O O 0.9999281167984009
the O O 0.9998086094856262
NF-kappa B-protein B-protein 0.7123681306838989
B E-protein E-protein 0.9905279874801636
binding O O 0.9477314352989197
activity O O 0.9963171482086182
. O O 0.9999958276748657
Regulation O O 0.9993539452552795
of O O 0.9999688863754272
inosine-5'-monophosphate B-protein B-DNA 0.46667253971099854
dehydrogenase I-protein I-DNA 0.3888297379016876
type I-protein I-DNA 0.6543348431587219
II E-protein I-DNA 0.7035542130470276
gene O E-DNA 0.6718155145645142
expression O O 0.9002993702888489
in O O 0.9997215867042542
human B-cell_type B-cell_type 0.7770705819129944
T I-cell_type I-cell_type 0.9000149369239807
cells E-cell_type E-cell_type 0.9861189126968384
. O O 0.9996657371520996
Role O O 0.8822284936904907
for O O 0.9964166879653931
a O O 0.9976791739463806

. O O 0.9983271956443787
Human B-protein B-protein 0.8724457025527954
immunodeficiency I-protein I-protein 0.8468509912490845
virus I-protein I-protein 0.8665437698364258
type I-protein I-protein 0.7782690525054932
1 I-protein I-protein 0.7959710955619812
Tat E-protein E-protein 0.8233048915863037
upregulates O O 0.9717185497283936
interleukin-2 S-protein S-protein 0.8216907382011414
secretion O O 0.8961963057518005
in O O 0.999357283115387
activated B-cell_type B-cell_type 0.5460017323493958
T I-cell_type I-cell_type 0.6315514445304871
cells E-cell_type E-cell_type 0.946877121925354
. O O 0.9997487664222717
Dysregulation O O 0.9985674619674683
of O O 0.9999427795410156
cytokines S-protein S-protein 0.9936704635620117
secreted O O 0.9990018010139465
by O O 0.9998611211776733
T B-cell_type B-cell_type 0.8258066177368164
cells E-cell_type E-cell_type 0.9865463972091675
may O O 0.9995312690734863
play O O 0.9999932050704956
an O O 0.9999943971633911
important O O 0.9996681213378906
role O O 0.999829888343811
in O O 0.9999897480010986
the O O 0.9999144077301025
pathogenesis O O 0.960845410823822

the O O 0.9970760345458984
acute B-cell_line B-cell_line 0.5158499479293823
lymphoblastic I-cell_line I-cell_line 0.47088366746902466
leukemia I-cell_line I-cell_line 0.8876409530639648
cell I-cell_line I-cell_line 0.9331264495849609
line I-cell_line I-cell_line 0.9051646590232849
REH E-cell_line E-cell_line 0.6376484036445618
. O O 0.9995051622390747
The O O 0.9999966621398926
function O O 0.9997305274009705
of O O 0.9999796152114868
the O O 0.9999039173126221
transactivation B-protein B-protein 0.44674450159072876
domain E-protein E-protein 0.9393258094787598
is O O 0.9988794922828674
negatively O O 0.9872156381607056
regulated O O 0.9993495345115662
by O O 0.999988317489624
adjacent O B-DNA 0.7693116664886475
sequences O E-DNA 0.7808052897453308
from O O 0.9997349381446838
the O O 0.9999494552612305
extreme B-protein B-DNA 0.7212941646575928
C-terminus E-protein E-DNA 0.4041249752044678
. O O 0.9973552227020264
The O O 0.9999773502349854
activating O B-protein 0.8385576605796814
and O I-protein 0.9216599464416504
inhibitory O I-protein 0.644924521446228
domains O E-protein 0.8655328154563904
function O O 0.9993127584457397
together O O 0.9999898672103882
as O O 0.9999980926513672
an O O 0.9999821186065674
independent O O 0.8712807297706604
regulatory O O 0.5729210376739502
module O O 0.3809701204299927
in O O 0.9985197186470032

physiological O O 0.9292920827865601
relevance O O 0.9974695444107056
of O O 0.9999872446060181
this O O 0.9999854564666748
phenomenon O O 0.9908732175827026
is O O 0.9999945163726807
emphasized O O 0.9999669790267944
by O O 0.9999961853027344
similar O O 0.9943345785140991

that O O 0.9991660118103027
these O O 0.9999486207962036
phosphoproteins S-protein S-protein 0.7377567887306213
may O O 0.9998805522918701
be O O 0.9999969005584717
directly O O 0.9957481026649475
involved O O 0.9999312162399292
in O O 0.9999603033065796
regulating O O 0.9975618124008179
the O O 0.9996323585510254
transcriptional O O 0.9233134388923645
response O O 0.9920114874839783
to O O 0.999950647354126
cellular O O 0.963922381401062
activation O O 0.9974272847175598
by O O 0.9999961853027344
external O O 0.9609178304672241
stimuli O O 0.9214246869087219
. O O 0.9999675750732422
Inactivation O O 0.9978436231613159
of O O 0.9998946189880371
IkappaBbeta S-protein S-protein 0.9866868257522583
by O O 0.999940037727356
the O O 0.9999630451202393
tax B-protein B-protein 0.36051198840141296
protein E-protein E-protein 0.991764485836029
of O O 0.9990911483764648
human O O 0.6890580058097839
T-cell O O 0.5442593693733215
leukemia O O 0.5523164868354797
virus O O 0.763903796672821

and I-protein O 0.9477782249450684

Each O O 0.9998131394386292
course O O 0.9998520612716675
of O O 0.9999719858169556
chemotherapy O O 0.7035802602767944
was O O 0.9991763234138489
given O O 0.9999970197677612
every O O 0.9999986886978149
4 O O 0.9998311996459961
weeks O O 0.9999847412109375
. O O 0.9999991655349731

deficient O O 0.9553089737892151
in O O 0.9995489716529846
FasL S-protein S-protein 0.9864361882209778
expression O O 0.9982364177703857
and O O 0.9999392032623291
apoptosis O O 0.9748942255973816
induced O O 0.999873161315918
upon O O 0.9997338652610779
TCR S-protein S-protein 0.9392697811126709
triggering O O 0.9823516011238098
, O O 0.9999198913574219
although O O 0.999992847442627
their O O 0.9984367489814758

Indomethacin B-Chemical B-Chemical 0.9211902618408203
- O O 0.9568770527839661
induced O O 0.998484194278717
renal B-Disease B-Disease 0.5777917504310608
insufficiency I-Disease I-Disease 0.9767051339149475
: O O 0.9241100549697876
recurrence O O 0.5166225433349609
on O O 0.9933196306228638
rechallenge O O 0.5670971870422363
. O O 0.9997827410697937

show O O 0.8454952239990234

NF-kappaB S-protein S-protein 0.790188729763031

Thus O O 0.9868523478507996
, O O 0.9998372793197632
FS O O 0.5460668206214905
containing O O 0.9908246397972107
47 O O 0.9553827047348022
. O O 0.9999722242355347
5 O O 0.9977340698242188
mg O O 0.9990999698638916
/ O O 0.9999595880508423
ml O O 0.9931291341781616
tAMCA B-Chemical B-Chemical 0.9165781140327454
evoked O O 0.9979948997497559
generalized B-Disease O 0.8567414283752441
seizures I-Disease B-Disease 0.9159951210021973
in O O 0.9906358122825623
all O O 0.9998199343681335
tested O O 0.9837550520896912
rats O O 0.9931619167327881
( O O 0.9999922513961792
n O O 0.9983698725700378
= O O 0.9999207258224487
6 O O 0.9975733160972595
) O O 0.9998692274093628
while O O 0.9999994039535522
the O O 0.9999825954437256
lowest O O 0.9975946545600891
concentration O O 0.9965947270393372
of O O 0.9996815919876099
tAMCA B-Chemical B-Chemical 0.9383776187896729
( O O 0.9890111684799194
0 O O 0.9993898868560791
. O O 0.9999175071716309
5 O O 0.9999203681945801
mg O O 0.9998332262039185
/ O O 0.9999817609786987
ml O O 0.9995538592338562
) O O 0.9993921518325806
only O O 0.9999914169311523
evoked O O 0.9998725652694702
brief O O 0.962699830532074
episodes O O 0.9837493896484375
of O O 0.9997894167900085
jerk O O 0.5063291192054749
- O O 0.9330480694770813
correlated O O 0.9946215152740479
convulsive B-Disease O 0.5670904517173767
potentials O O 0.7366413474082947
in O O 0.9994989633560181
1 O O 0.9965277314186096
of O O 0.9999103546142578
6 O O 0.9992407560348511
rats O O 0.996780276298523
. O O 0.9999988079071045

High O O 0.9835267663002014
doses O O 0.9989587068557739
of O O 0.9998838901519775
vitamin B-Chemical B-Chemical 0.9524526000022888
D E-Chemical I-Chemical 0.9327855706214905
are O O 0.9777496457099915
known O O 0.9999743700027466
to O O 0.9999558925628662
cause O O 0.9999065399169922
calcification O O 0.8638442754745483
of O O 0.5984136462211609
the O O 0.6561484336853027
artery O O 0.9431949257850647
media O O 0.950333297252655
in O O 0.9363491535186768
as O O 0.9976814985275269
little O O 0.9998101592063904
as O O 0.9999912977218628
3 O O 0.9996539354324341
to O O 0.9998515844345093
4 O O 0.9998533725738525
days O O 0.9999799728393555
. O O 0.9999994039535522

retarget O O 0.4958451986312866
NF-kappa B-protein B-protein 0.2557006776332855
B I-protein I-protein 0.8498238921165466
p65 E-protein E-protein 0.9491546750068665
from O O 0.9982088804244995
the O O 0.9998117089271545
nucleus O O 0.8897820711135864
to O O 0.9977883100509644
the O O 0.9996604919433594
cytoplasm O O 0.6254040002822876
, O O 0.927688479423523
3 O O 0.9066929221153259
) O O 0.9460586309432983
selective O O 0.9766030311584473
deletion O O 0.9931934475898743
of O O 0.999931812286377
the O O 0.9999310970306396
functional O O 0.8635052442550659
nuclear O O 0.6549752950668335
localization O O 0.5274664759635925
signal O O 0.6692213416099548
present O O 0.9632004499435425
in O O 0.9999605417251587
the O O 0.9999144077301025
Rel B-protein B-protein 0.47701987624168396
homology I-protein I-protein 0.548481285572052
domain E-protein E-protein 0.9417640566825867
of O O 0.9908924102783203
NF-kappa B-protein B-protein 0.8373793363571167
B I-protein E-protein 0.9162759184837341

postmenopausal O O 0.6764355301856995
woman O O 0.8979560136795044
with O O 0.9996936321258545
a O O 0.9992178678512573
Y B-DNA O 0.8749622702598572
; I-DNA O 0.9687857031822205
15 I-DNA O 0.9572821259498596
translocation E-DNA O 0.8936838507652283
in O O 0.9995552897453308
peripheral B-cell_type B-cell_type 0.5119389295578003
blood I-cell_type I-cell_type 0.7764971852302551
lymphocytes E-cell_type E-cell_type 0.9755555391311646
and O O 0.998601496219635
a O O 0.9996956586837769
t O O 0.7345152497291565
( O O 0.9649484753608704
Y O O 0.9477741718292236
; O O 0.9860885739326477
15 O O 0.9907150268554688
) O O 0.9968452453613281
/45 O O 0.9968069791793823
, O O 0.9999120235443115
X O O 0.9317238330841064
Turner O O 0.9418429732322693
mosaic O O 0.9310945868492126
pattern O O 0.9639247059822083
in O O 0.9998626708984375
skin B-cell_type B-cell_type 0.521817147731781
fibroblasts E-cell_type E-cell_type 0.9589020013809204
. O O 0.999871015548706
We O O 0.9999910593032837
report O O 0.9999988079071045
an O O 0.9999942779541016
unusual O O 0.9945712685585022
case O O 0.9988190531730652
of O O 0.9999896287918091
a O O 0.9998784065246582
55 O O 0.8609915375709534
year O O 0.9673320651054382
old O O 0.9930525422096252
Japanese O O 0.9810598492622375
woman O O 0.9981367588043213
with O O 0.9999876022338867
a O O 0.9993199110031128
seminoma O O 0.5206135511398315
but O O 0.9980429410934448
relatively O O 0.9934319853782654
normal O O 0.919867753982544

. O O 0.9927908182144165
They O O 0.9999803304672241
also O O 0.9999741315841675
display O O 0.9998383522033691
constitutively O O 0.9557012915611267
high O O 0.9897052645683289
levels O O 0.9993035793304443
of O O 0.9999097585678101
p59fyn S-protein S-protein 0.8316819667816162
and O O 0.9723160266876221
CD3 B-protein O 0.5098572969436646
zeta E-protein O 0.6622872948646545
tyrosine O O 0.7537224888801575
phosphorylation O O 0.9510492086410522
. O O 0.9999295473098755
The O O 0.9999938011169434
generation O O 0.994759738445282
of O O 0.9998325109481812
second O O 0.8683823347091675
messengers O O 0.4694896340370178
in O O 0.9984889030456543
T B-cell_type B-cell_type 0.8989489078521729
cells E-cell_type E-cell_type 0.9874445199966431
normally O O 0.9980924725532532
leads O O 0.999982476234436
to O O 0.9999905824661255
downstream O O 0.8861716389656067
signaling O O 0.9575211405754089
that O O 0.9998770952224731
results O O 0.9999510049819946
in O O 0.999971866607666
transcriptional O O 0.9443581700325012
activation O O 0.9837861657142639

but O O 0.9767722487449646
not O O 0.9932520985603333
Stat1 S-protein S-protein 0.9880005717277527
and O O 0.9981445074081421
blocked O O 0.9824569225311279
IL-10 S-protein S-protein 0.9946263432502747
-induced O O 0.9978793859481812
Stat3 S-protein S-protein 0.971318781375885
phosphorylation O O 0.9900206327438354
in O O 0.9999904632568359
a O O 0.9999154806137085
cell-free O O 0.7997441291809082
system O O 0.5169380307197571
. O O 0.9999765157699585
In O O 0.9999877214431763
contrast O O 0.9983705878257751
, O O 0.9999215602874756
tyrosine-phosphorylated O O 0.7456014752388
peptides O O 0.533514142036438
containing O O 0.9988157749176025
Tyr374 O O 0.5166164040565491
or O O 0.9927145838737488
Tyr396 O O 0.6142364740371704
did O O 0.9995429515838623
not O O 0.9999701976776123
interact O O 0.9995865225791931

to O O 0.9931736588478088
present O O 0.9992074370384216
TG S-protein O 0.3519206643104553
to O O 0.9410122036933899
T B-cell_type B-cell_type 0.8287268877029419
cells E-cell_type E-cell_type 0.9921627640724182
. O O 0.9993809461593628
Proliferation O O 0.9977535605430603
in O O 0.9999403953552246
response O O 0.9954965114593506
to O O 0.9999070167541504
TG S-protein O 0.36817699670791626
was O O 0.9986007809638977
observed O O 0.9998886585235596
in O O 0.9997839331626892
T B-cell_type B-cell_type 0.8904014229774475
cells E-cell_type E-cell_type 0.9883251190185547
from O O 0.9996768236160278
only O O 0.9999051094055176
1 O O 0.9929198622703552
of O O 0.9999191761016846
5 O O 0.9856614470481873
Hashimoto O O 0.8074364066123962

1.3 O O 0.8731187582015991
, O O 0.9931545257568359
respectively O O 0.999788224697113
) O O 0.99977046251297
, O O 0.9999921321868896
indicating O O 0.9999973773956299
an O O 0.9999895095825195
increased O O 0.9974028468132019
rate O O 0.9997537732124329
of O O 0.9999129772186279
apoptosis O O 0.9494357705116272
in O O 0.999971866607666
80.5 O O 0.9310195446014404
% O O 0.998654842376709

the O O 0.9983119964599609
opposite O O 0.9880954027175903
effect O O 0.9992994070053101
, O O 0.9999775886535645
and O O 0.9999752044677734
it O O 0.9999716281890869
strengthens O O 0.9998225569725037
the O O 0.9999086856842041
response O O 0.9971668124198914
of O O 0.9999265670776367
cells O O 0.9429751634597778
to O O 0.9999421834945679
the O O 0.9999301433563232
growth-inhibitory O O 0.9218218922615051
effect O O 0.9980058073997498
of O O 0.9999489784240723
TGF-beta1 S-protein S-protein 0.930131733417511
. O O 0.9997203946113586
By O O 0.9981939196586609

erythroleukemia O O 0.3623437285423279
by O O 0.9974675178527832
efficiently O O 0.9731956720352173
arresting O O 0.9863098859786987
differentiation O O 0.9931528568267822
of O O 0.9998903274536133
red B-cell_type B-cell_type 0.45126333832740784
cell I-cell_type I-cell_type 0.37700074911117554
progenitors E-cell_type E-cell_type 0.6585874557495117
and O O 0.9906365275382996
by O O 0.9999078512191772
suppressing O O 0.970719575881958
transcription O O 0.9341307282447815
of O O 0.9980289340019226
erythrocyte-specific B-DNA B-DNA 0.47366899251937866
genes E-DNA E-DNA 0.9887024164199829
. O O 0.999850869178772
Here O O 0.999782383441925
, O O 0.9999901056289673
we O O 0.999931812286377
show O O 0.9999871253967285
that O O 0.9999788999557495
v-erbA S-protein S-protein 0.5771231055259705
and O O 0.9226756691932678
c-erbA S-protein S-protein 0.6306703090667725
bind O O 0.9211916327476501
directly O O 0.9984586238861084
to O O 0.9999097585678101
sequences O O 0.9318041801452637
within O O 0.9999523162841797
the O O 0.9998466968536377
promoter S-DNA S-DNA 0.9062628149986267
of O O 0.9692298769950867

peripheral B-cell_type B-cell_type 0.39071476459503174
blood I-cell_type I-cell_type 0.7904168367385864
mononuclear I-cell_type I-cell_type 0.9160099029541016
cells E-cell_type E-cell_type 0.9755846858024597
from O O 0.9997696280479431
normal O O 0.7872242331504822
individuals O O 0.9649916887283325
and O O 0.9983483552932739
lupus O O 0.7843839526176453
patients O O 0.9878283739089966

of O O 0.996907651424408
the O O 0.9999581575393677
interleukin-1 B-DNA B-DNA 0.37850937247276306
genes E-DNA E-DNA 0.9930742979049683
. O O 0.9998822212219238
Stimulation O O 0.9965575933456421
of O O 0.9998766183853149
interleukin-1 B-DNA B-DNA 0.5180358290672302
gene E-DNA E-DNA 0.9041840434074402
transcription O O 0.8477422595024109
may O O 0.9998301267623901
be O O 0.9999839067459106

TNF S-protein S-protein 0.6013581156730652

. O O 0.9948891401290894
The O O 0.9998551607131958
Syk S-protein S-protein 0.993339478969574
-mediated O O 0.9920238256454468
T B-protein B-protein 0.7967144250869751
cell I-protein I-protein 0.5181249976158142
antigen I-protein I-protein 0.4418722987174988
receptor E-protein E-protein 0.9909263849258423
-induced O O 0.9840233325958252
MAPK S-protein S-protein 0.9691759943962097
activation O O 0.9940989017486572
was O O 0.9999721050262451
detectable O O 0.9986729621887207
within O O 0.9999587535858154
1 O O 0.9800414443016052
min O O 0.9958562254905701

, O O 0.9503923654556274

In O O 0.9997325539588928
these O O 0.9999133348464966
patients O O 0.9993583559989929
, O O 0.9999963045120239
the O O 0.9999862909317017
magnitude O O 0.9906038641929626
of O O 0.9997790455818176
proteinuria O B-Disease 0.9754828214645386
was O O 0.9854686856269836
assessed O O 0.999951958656311
on O O 0.9999943971633911
morning O O 0.9892562627792358
urine O O 0.9357196688652039
samples O O 0.9972254037857056
by O O 0.9999986886978149
turbidometric O O 0.929738461971283
measurement O O 0.9690098762512207
or O O 0.9999387264251709
random O O 0.9549262523651123
urine O O 0.9000440835952759
protein O O 0.9234734773635864
: O O 0.9998596906661987
creatinine S-Chemical B-Chemical 0.887304425239563
ratios O O 0.8185366988182068
, O O 0.9999861717224121
an O O 0.9999957084655762
estimate O O 0.9999074935913086
of O O 0.9999358654022217
grams O O 0.9784034490585327
of O O 0.998683512210846
proteinuria O O 0.784337043762207
/ O O 0.9732811450958252
day O O 0.9963053464889526
. O O 0.9999983310699463

Pretreatment O O 0.7936221361160278
with O O 0.9986625909805298
either O O 0.9896343946456909
VPU B-Chemical B-Chemical 0.9219210147857666
( O O 0.9618425965309143
50 O O 0.9745217561721802
and O O 0.9993667006492615
100 O O 0.9996163845062256
mg O O 0.9998313188552856
/ O O 0.9999749660491943
kg O O 0.9991540908813477
) O O 0.9997149109840393
or O O 0.9999792575836182
VPA B-Chemical B-Chemical 0.9326984882354736
( O O 0.9803885221481323
300 O O 0.9965831637382507
and O O 0.9999058246612549
600 O O 0.9997748732566833
mg O O 0.9997957348823547
/ O O 0.9999734163284302
kg O O 0.9991494417190552
) O O 0.9997642636299133
completely O O 0.9956626296043396
abolished O O 0.9675728678703308
pilocarpine B-Chemical B-Chemical 0.9290186166763306
- O O 0.9783014059066772
evoked O O 0.9991274476051331
increases O O 0.8894844055175781
in O O 0.9853081107139587
extracellular O O 0.9515169858932495
glutamate B-Chemical B-Chemical 0.922321617603302
and O O 0.9854980707168579
aspartate B-Chemical B-Chemical 0.9243601560592651
. O O 0.9997005462646484

Sulfonamides B-Chemical O 0.4885514974594116
were O O 0.9852778315544128
associated O O 0.9997381567955017
with O O 0.9999561309814453
anencephaly B-Disease B-Chemical 0.9034186601638794
( O O 0.9470910429954529
adjusted O O 0.9800644516944885
OR O O 0.9300280213356018
[ O O 0.9836079478263855
AOR O O 0.694267213344574
] O O 0.9395918846130371
= O O 0.999849796295166
3 O O 0.9996127486228943
. O O 0.9999178647994995
4 O O 0.9975113868713379
; O O 0.9999666213989258
95 O O 0.9990953207015991
% O O 0.9999493360519409
confidence O O 0.8170663714408875
interval O O 0.8589332699775696
[ O O 0.990227460861206
CI O O 0.490063339471817
] O O 0.9851195216178894
, O O 0.9999532699584961
1 O O 0.9998569488525391
. O O 0.9999649524688721
3 O O 0.9997625946998596
- O O 0.9982888102531433
8 O O 0.999243974685669
. O O 0.999841570854187
8 O O 0.9970397353172302
) O O 0.9953964352607727
, O O 0.9999121427536011
hypoplastic B-Disease B-Disease 0.8854308128356934
left I-Disease I-Disease 0.8759588599205017
heart I-Disease I-Disease 0.9652466177940369
syndrome I-Disease I-Disease 0.9991794228553772
( O O 0.9834725856781006
AOR O O 0.532096266746521
= O O 0.9908168315887451
3 O O 0.9991230368614197
. O O 0.9999556541442871
2 O O 0.9995095729827881
; O O 0.9999501705169678
95 O O 0.9994480013847351
% O O 0.9999544620513916
CI O O 0.552994430065155
, O O 0.9981690645217896
1 O O 0.9997572302818298
. O O 0.9999558925628662
3 O O 0.9998251795768738
- O O 0.9989319443702698
7 O O 0.9995864033699036
. O O 0.9999363422393799
6 O O 0.9993496537208557
) O O 0.9970472455024719
, O O 0.9999686479568481
coarctation B-Disease O 0.668433666229248
of I-Disease O 0.9376521110534668
the I-Disease O 0.9884054660797119
aorta I-Disease O 0.6825854778289795
( O O 0.9987359642982483
AOR O O 0.8804357647895813
= O O 0.9990456700325012
2 O O 0.999731719493866
. O O 0.9999611377716064
7 O O 0.9993033409118652
; O O 0.9999517202377319
95 O O 0.9993896484375
% O O 0.9999567270278931
CI O O 0.6007587909698486
, O O 0.9985561966896057
1 O O 0.9997602105140686
. O O 0.9999608993530273
3 O O 0.9998223185539246
- O O 0.9988911747932434
5 O O 0.9996076226234436
. O O 0.9999183416366577
6 O O 0.9990146160125732
) O O 0.9966555833816528
, O O 0.999976396560669
choanal B-Disease O 0.42516714334487915
atresia I-Disease O 0.6476658582687378
( O O 0.981671154499054
AOR O O 0.6224464774131775
= O O 0.9964930415153503
8 O O 0.9996545314788818
. O O 0.9999699592590332
0 O O 0.9997020363807678
; O O 0.9999622106552124
95 O O 0.9996874332427979
% O O 0.9999561309814453
CI O O 0.6442663073539734
, O O 0.9988800883293152
2 O O 0.9998160004615784
. O O 0.9999517202377319
7 O O 0.999817430973053
- O O 0.9984115362167358
23 O O 0.998812198638916
. O O 0.9999634027481079
5 O O 0.999193012714386
) O O 0.9978356957435608
, O O 0.9999816417694092
transverse B-Disease O 0.5440521836280823
limb I-Disease O 0.49722880125045776
deficiency I-Disease O 0.7579013705253601
( O O 0.9962722063064575
AOR O O 0.7296164035797119
= O O 0.9980713725090027
2 O O 0.9997190833091736
. O O 0.9999634027481079
5 O O 0.9993281364440918
; O O 0.9999450445175171
95 O O 0.999552309513092
% O O 0.9999575614929199
CI O O 0.5081281065940857
, O O 0.9980077147483826
1 O O 0.9997636675834656
. O O 0.9999558925628662
0 O O 0.9998809099197388
- O O 0.9990960359573364
5 O O 0.9996722936630249
. O O 0.9999102354049683
9 O O 0.9987486600875854
) O O 0.9960302710533142
, O O 0.9999433755874634
and O O 0.9998693466186523
diaphragmatic B-Disease O 0.7168505787849426
hernia I-Disease O 0.915221095085144
( O O 0.9804209470748901
AOR O O 0.7219071984291077
= O O 0.9958125948905945
2 O O 0.999575674533844
. O O 0.9999693632125854
4 O O 0.9995540976524353
; O O 0.9999586343765259
95 O O 0.99972003698349
% O O 0.9999701976776123
CI O O 0.6926813125610352
, O O 0.9988889098167419
1 O O 0.999855637550354
. O O 0.999972939491272
1 O O 0.9998944997787476
- O O 0.9994478821754456
5 O O 0.9997604489326477
. O O 0.9999250173568726
4 O O 0.9992119073867798
) O O 0.9988604784011841
. O O 0.9999915361404419

None O O 0.9995753169059753
of O O 0.9999899864196777
the O O 0.9999649524688721
animals O O 0.9617026448249817
that O O 0.9997761845588684
received O O 0.998084545135498
bupivacaine S-Chemical B-Chemical 0.9339373111724854
, O O 0.9919281005859375
normal O O 0.9733730554580688
saline O O 0.7795912027359009
, O O 0.9986141920089722
or O O 0.9999324083328247
normal O O 0.9566990733146667
saline O O 0.7375127673149109
titrated O O 0.9346073865890503
to O O 0.9994039535522461
a O O 0.9987144470214844
pH O O 0.8679795265197754
3 O O 0.9687381982803345
. O O 0.9997956156730652
0 O O 0.9973899722099304
developed O O 0.9975348711013794
hind O O 0.6389855742454529
- O O 0.913711667060852
limb O O 0.45340439677238464
paralysis O O 0.7055338621139526
. O O 0.9993879795074463

from O O 0.9992203712463379
maturation O O 0.9700321555137634
occurring O O 0.9998039603233337
upon O O 0.9999290704727173
activation O O 0.9986063838005066
of O O 0.9999630451202393
other O O 0.9968440532684326
PKC B-protein B-protein 0.370821475982666
subfamilies E-protein E-protein 0.7174638509750366
induced O O 0.9973229765892029

regulation O O 0.9864155650138855
. O O 0.9999860525131226
Forced O O 0.9917680025100708
expression O O 0.9986020922660828
of O O 0.999950647354126
E2F1 S-protein S-protein 0.969565749168396
could O O 0.9998277425765991
induce O O 0.9999526739120483
expression O O 0.9985756874084473
of O O 0.9999619722366333
all O O 0.9995456337928772
members O O 0.9687507152557373
of O O 0.9998894929885864
the O O 0.9999204874038696
endogenous B-DNA B-DNA 0.5668603181838989
MCM I-DNA I-DNA 0.28734493255615234
genes E-DNA E-DNA 0.9890479445457458
in O O 0.9993900060653687
rat B-cell_line B-cell_line 0.4187948405742645
embryonal I-cell_line I-cell_line 0.42522507905960083
fibroblast I-cell_line I-cell_line 0.5524242520332336
REF52 I-cell_line I-cell_line 0.7942283153533936
cells E-cell_line E-cell_line 0.9847456216812134
. O O 0.9998857975006104
Our O O 0.9999978542327881
results O O 0.9999586343765259
demonstrated O O 0.9999916553497314
that O O 0.9999963045120239
the O O 0.9999163150787354
growth-regulated O O 0.8993045091629028
expression O O 0.9882165789604187
of O O 0.9998657703399658
mammalian B-DNA B-DNA 0.31342974305152893
MCM5 I-DNA I-DNA 0.5353544354438782
and I-DNA I-DNA 0.5688972473144531
MCM6 I-DNA I-DNA 0.5991817116737366
genes E-DNA E-DNA 0.995997428894043
, O O 0.9964255690574646
and O O 0.9999058246612549
presumably O O 0.9998626708984375
other O O 0.9996969699859619

Treatments O O 0.9943585991859436
have O O 0.9999938011169434
included O O 0.9999740123748779
discontinuation O O 0.8674942851066589
or O O 0.995776355266571
reduction O O 0.9825351238250732
of O O 0.9955220222473145
cyclosporine B-Chemical B-Chemical 0.9212895035743713
dose O O 0.9538859724998474
with O O 0.9997976422309875
or O O 0.9994199275970459
without O O 0.9999861717224121
concurrent O O 0.9839375615119934
plasma O O 0.8544397950172424
exchange O O 0.8066325187683105
, O O 0.9996943473815918
plasma O O 0.8867751359939575
infusion O O 0.6063638925552368
, O O 0.9916551113128662
anticoagulation O O 0.6439830660820007
, O O 0.9984064698219299
and O O 0.9998867511749268
intravenous O O 0.9458590149879456
immunoglobulin O O 0.39282041788101196
G O O 0.4427676200866699
infusion O O 0.9563663005828857
. O O 0.9999667406082153

mechanism O O 0.9246217608451843

in O O 0.9985564351081848
the O O 0.9999362230300903
adenovirus B-DNA B-DNA 0.3823331594467163
E1A I-DNA I-DNA 0.42246776819229126
and I-DNA I-DNA 0.5733083486557007
hexon I-DNA I-DNA 0.6409715414047241
genes E-DNA E-DNA 0.9970989227294922
. O O 0.999795138835907
The O O 0.9999587535858154
E1A B-DNA B-DNA 0.6990851759910583
and I-DNA I-DNA 0.5854361653327942
hexon I-DNA I-DNA 0.6641831994056702
primers E-DNA E-DNA 0.9800204038619995
amplified O O 0.9918988943099976
DNA O O 0.9062397480010986
from O O 0.999930739402771
representative O O 0.9209606647491455
adenoviral O O 0.6517014503479004
serotypes O O 0.518142819404602
in O O 0.9998863935470581
all O O 0.9999151229858398
six O O 0.9853701591491699
adenoviral O O 0.5124269127845764
groups O O 0.555986762046814
( O O 0.9859926104545593

1 O O 0.6518294811248779
. O O 0.9989583492279053

found O O 0.9974306225776672
in O O 0.9999619722366333
I B-protein B-protein 0.4527314305305481
kappa I-protein I-protein 0.867505669593811
B I-protein I-protein 0.5270349979400635
proteins E-protein E-protein 0.9911069273948669
in O O 0.9995461106300354
which O O 0.9999974966049194
the O O 0.9998904466629028
ankyrin B-protein B-protein 0.2635848820209503
repeat E-protein I-protein 0.4845189154148102
domain O E-protein 0.928578794002533
is O O 0.9996668100357056
thought O O 0.9999868869781494
to O O 0.9999804496765137
be O O 0.999961256980896
directly O O 0.991081953048706
involved O O 0.9998704195022583
in O O 0.9999325275421143

leads O O 0.9969480633735657
to O O 0.9999780654907227
exocytosis O O 0.974930465221405
of O O 0.9998279809951782
the O O 0.9998812675476074
cytotoxic B-cell_type B-cell_line 0.4627167284488678
NK I-cell_type I-cell_line 0.442518025636673
cell I-cell_type I-cell_line 0.5910633206367493

The O O 0.9994994401931763
objectives O O 0.9986854195594788
were O O 0.9999924898147583
to O O 0.9999864101409912
assess O O 0.9999550580978394
the O O 0.999843955039978
efficacy O O 0.9954137206077576
of O O 0.9995470643043518
lamivudine S-Chemical B-Chemical 0.927778959274292
in O O 0.9987236857414246
reducing O O 0.9967622756958008
the O O 0.9983559250831604
incidence O O 0.9973770380020142
of O O 0.9998970031738281
HBV O O 0.4624260365962982
reactivation O O 0.7153218388557434
, O O 0.9970020651817322
and O O 0.9997203946113586
diminishing O O 0.9669113755226135
morbidity O O 0.5274545550346375
and O O 0.9752932190895081
mortality O O 0.5505430698394775
during O O 0.9998325109481812
CT O O 0.801519513130188
. O O 0.9995703101158142

A O O 0.997538685798645
second O O 0.9984562397003174
echocardiography O O 0.5990099906921387
was O O 0.9946776628494263
performed O O 0.9999518394470215
( O O 0.999992847442627
median O O 0.9968767166137695
interval O O 0.9917083382606506
: O O 0.999929666519165
13 O O 0.999881386756897
months O O 0.9999306201934814
) O O 0.999890923500061
after O O 0.9999862909317017
pergolide B-Chemical B-Chemical 0.9216328263282776
withdrawal O O 0.5840673446655273
( O O 0.9987899661064148
n O O 0.9974006414413452
= O O 0.9999476671218872
10 O O 0.9997400641441345
patients O O 0.9998039603233337
) O O 0.9999727010726929
. O O 0.9999978542327881

mIL-2rE S-DNA S-protein 0.44234129786491394
) O O 0.8959819674491882
. O O 0.999948263168335
This O O 0.9999744892120361
putative O B-protein 0.8088572025299072
human B-DNA I-protein 0.4462944269180298
IL-2rE E-DNA E-protein 0.7865150570869446
, O O 0.9854282736778259
designated O O 0.9964995384216309
PRRIII S-DNA S-DNA 0.8297779560089111
, O O 0.9925811290740967
confers O O 0.9997729659080505
IL-2 S-protein S-protein 0.9102200269699097
responsiveness O O 0.9511849880218506
on O O 0.9998428821563721
a O O 0.9982666969299316

The O O 0.9993962049484253
effect O O 0.9997760653495789
of O O 0.9997662901878357
amantadine B-Chemical B-Chemical 0.9300166368484497
hydrochloride E-Chemical I-Chemical 0.9352228045463562
, O O 0.9872194528579712
injected O O 0.9972634315490723
i O O 0.9981346130371094
. O O 0.9996985197067261
p O O 0.9848092198371887
. O O 0.9999655485153198
in O O 0.999946117401123
6 O O 0.9935212731361389
increments O O 0.996612012386322
of O O 0.9999463558197021
100 O O 0.9863499999046326
mg O O 0.9991043210029602
/ O O 0.9999535083770752
kg O O 0.9994006156921387
each O O 0.9999510049819946
over O O 0.9999285936355591
30 O O 0.9985743761062622
hr O O 0.9972733855247498
, O O 0.9999769926071167
on O O 0.9999309778213501
mouse O O 0.8182511925697327
motility O O 0.8508409857749939
and O O 0.9993031024932861
whole O O 0.9878488779067993
brain O O 0.9317914247512817
content O O 0.9920996427536011
of O O 0.9999418258666992
selected O O 0.9255988597869873
biogenic O O 0.7509379982948303
amines S-Chemical O 0.7475802898406982
and O O 0.9860590100288391
major O O 0.9143226146697998
metabolites O O 0.7319890856742859
was O O 0.9997988343238831
studied O O 0.9999521970748901
in O O 0.9999802112579346
4 O O 0.9892634749412537
strains O O 0.9847425222396851
of O O 0.9994308352470398
mice O O 0.9862465858459473
. O O 0.9999980926513672

was O O 0.9932004809379578
confirmed O O 0.9999303817749023
by O O 0.9999927282333374
base-substitution O O 0.8978772759437561
mutations O O 0.6974413990974426
. O O 0.999984860420227
The O O 0.9999886751174927
plasmids O S-DNA 0.7490347623825073
carrying O O 0.9978588223457336
multiple O O 0.9604520201683044
copies O O 0.8788872361183167
of O O 0.9997252821922302
the O O 0.9998152852058411
P B-DNA B-DNA 0.5803049206733704
sequence E-DNA E-DNA 0.9847410321235657
showed O O 0.9997547268867493
higher O O 0.9933304190635681
responsiveness O O 0.9965864419937134
to O O 0.9999847412109375
the O O 0.9998329877853394
stimulation O O 0.9936673045158386
. O O 0.9999936819076538
The O O 0.9999696016311646
binding B-protein B-protein 0.5753766894340515
protein E-protein E-protein 0.9293304681777954
( O O 0.8370026350021362
s O O 0.5145195722579956
) O O 0.7118328213691711

The O O 0.9992831349372864
mechanism O O 0.998100221157074
by O O 0.999992847442627
which O O 0.9999737739562988
omeprazole B-Chemical B-Chemical 0.9319002032279968
caused O O 0.9979236125946045
the O O 0.9988958835601807
patient O O 0.9584420919418335
' O O 0.9813354015350342
s O O 0.9813774228096008
hemolytic B-Disease O 0.6112080812454224
anemia I-Disease O 0.8894753456115723
is O O 0.9911319613456726
uncertain O O 0.9916514754295349
, O O 0.9999760389328003
but O O 0.9999734163284302
physicians O O 0.9977989792823792
should O O 0.9999895095825195
be O O 0.9999911785125732
alerted O O 0.999940037727356
to O O 0.9999899864196777
this O O 0.9999068975448608
possible O O 0.9975343942642212
adverse O O 0.9346998929977417
effect O O 0.9847532510757446
. O O 0.9999970197677612

elements E-DNA E-DNA 0.932726263999939
may O O 0.9997332692146301
constitute O O 0.9999972581863403
a O O 0.9999788999557495
minimal O O 0.9117709398269653
region O O 0.6726904511451721
responsible O O 0.999762237071991
for O O 0.9999905824661255
CTL-specific O O 0.9162594079971313
expression O O 0.9909880757331848
of O O 0.9997896552085876
perforin S-protein S-protein 0.5131523013114929
. O O 0.9984074234962463
The O O 0.9999655485153198
Oct-2 B-protein B-protein 0.84630286693573
transcription I-protein I-protein 0.6357970833778381
factor E-protein E-protein 0.9732922315597534
. O O 0.9968670010566711
The O O 0.9999743700027466
Oct-2 B-protein B-protein 0.8681910037994385
transcription I-protein I-protein 0.5827994346618652
factor E-protein E-protein 0.9630441665649414
is O O 0.9966436624526978
a O O 0.9999878406524658
member O O 0.996619701385498
of O O 0.9998859167098999
the O O 0.9998917579650879
POU B-protein B-protein 0.34898874163627625
( I-protein I-protein 0.7204503417015076
Pit-Oct-Unc I-protein I-protein 0.9370737075805664
) I-protein I-protein 0.9010083079338074
family E-protein E-protein 0.7976073026657104

of O O 0.9979429841041565
the O O 0.999976396560669
G0 O O 0.49778640270233154
and O O 0.9167023301124573
G1 O O 0.6213502287864685
phases O O 0.8833878636360168
of O O 0.9998143315315247
the O O 0.9999854564666748
cell O O 0.9537825584411621
cycle O O 0.9821164011955261
and O O 0.9996969699859619
regulation O O 0.9992998838424683
of O O 0.9999712705612183
apoptosis O O 0.9886422753334045
. O O 0.9999943971633911
In O O 0.9999144077301025
EBV O O 0.9137176871299744
infection O O 0.9814980030059814
most O O 0.9999735355377197
of O O 0.9999879598617554
the O O 0.9999877214431763
changes O O 0.9984238147735596
, O O 0.9999921321868896
including O O 0.9999890327453613
the O O 0.9999326467514038
early O O 0.9728585481643677
induction O O 0.9968829154968262
of O O 0.9999254941940308
cyclin B-protein B-protein 0.2626250982284546
D2 E-protein E-protein 0.8899092674255371
, O O 0.990506112575531
are O O 0.9999735355377197
dependent O O 0.99994957447052
on O O 0.9999743700027466
expression O O 0.9958174824714661
of O O 0.9998741149902344
EBV B-DNA B-DNA 0.4994843006134033
genes E-DNA E-DNA 0.9906855225563049
, O O 0.9983674883842468
but O O 0.9999864101409912
an O O 0.9999803304672241
alteration O O 0.9956417083740234
in O O 0.9998181462287903

, O O 0.9503923654556274

. O O 0.9964020252227783

164 O O 0.952390193939209
patients O O 0.9996256828308105
( O O 0.9999970197677612
mean O O 0.9999326467514038
age O O 0.9990992546081543
+ O O 0.9999805688858032
/ O O 0.9999945163726807
- O O 0.9999116659164429
standard O O 0.9974108338356018
deviation O O 0.9719167947769165
[ O O 0.9986822009086609
SD O O 0.4788832366466522
] O O 0.9608577489852905
81 O O 0.9924924969673157
. O O 0.9999949932098389
6 O O 0.9999054670333862
+ O O 0.9999874830245972
/ O O 0.9999984502792358
- O O 0.999961256980896
6 O O 0.9999479055404663
. O O 0.9999876022338867
8 O O 0.9999308586120605
years O O 0.999967098236084
) O O 0.9999483823776245
were O O 0.9999924898147583
admitted O O 0.9998908042907715
. O O 0.9999990463256836

regulated O O 0.9058516025543213

is O O 0.9981359243392944
ATRA O O 0.6125510334968567
inducible O O 0.9667755365371704
in O O 0.9998539686203003
myeloid B-cell_type B-cell_type 0.5417486429214478
leukemia I-cell_type I-cell_type 0.7519281506538391
cells E-cell_type E-cell_type 0.8067047595977783
and O O 0.9959051609039307
normal B-cell_type O 0.5188641548156738
CD34+ I-cell_type B-cell_type 0.3965894281864166
bone I-cell_type I-cell_type 0.7959394454956055
marrow I-cell_type I-cell_type 0.8458880186080933
cells E-cell_type E-cell_type 0.9278691411018372
. O O 0.9998114705085754
This O O 0.9999884366989136
effect O O 0.9999716281890869
is O O 0.9999974966049194
independent O O 0.9992857575416565
of O O 0.9998748302459717
differentiation O O 0.9945000410079956
and O O 0.9998020529747009
is O O 0.9999350309371948
mediated O O 0.9993176460266113
by O O 0.999962329864502

Age O O 0.9510344862937927
at O O 0.9999343156814575
presentation O O 0.9966698288917542
, O O 0.9999842643737793
time O O 0.9989338517189026
of O O 0.9999209642410278
ictus O O 0.7091723084449768
after O O 0.9662586450576782
intoxication O O 0.5516937971115112
, O O 0.9990503191947937
Hunt O O 0.6325293183326721
and O O 0.9971336126327515
Hess O O 0.8627867102622986
grade O O 0.9851071238517761
of O O 0.9998306035995483
subarachnoid O O 0.48963025212287903
hemorrhage O O 0.770066499710083
, O O 0.9877169728279114
size O O 0.9986153841018677
of O O 0.9997506737709045
the O O 0.9996907711029053
aneurysm O O 0.9010028839111328
, O O 0.9751437902450562
location O O 0.9312307834625244
of O O 0.9950388073921204
the O O 0.9981033802032471
aneurysm O O 0.9197888970375061
, O O 0.9786282777786255
and O O 0.999861478805542
the O O 0.999962329864502
Glasgow O O 0.8970942497253418
Outcome O O 0.799766480922699
Scale O O 0.9320191740989685
score O O 0.9854810833930969
were O O 0.9999943971633911
assessed O O 0.9999024868011475
and O O 0.9999431371688843
compared O O 0.9998764991760254
. O O 0.9999971389770508

Early O O 0.9561314582824707
adjuvant O O 0.7315029501914978
adriamycin S-Chemical B-Chemical 0.9176054000854492
in O O 0.9992088675498962
superficial O B-Disease 0.7238606810569763
bladder O I-Disease 0.5220203995704651
carcinoma O I-Disease 0.9464161992073059
. O O 0.9977566599845886

The O O 0.9995809197425842
aggravated O O 0.7712903022766113
risk O O 0.9269187450408936
on O O 0.999351441860199
intracerebral B-Disease B-Disease 0.6242335438728333
hemorrhage I-Disease I-Disease 0.9242015480995178
( O O 0.9191622138023376
ICH B-Disease B-Disease 0.9414180517196655
) O O 0.8918604850769043
with O O 0.9997774958610535
drugs O O 0.9496119618415833
used O O 0.999906063079834
for O O 0.9999419450759888
stroke B-Disease B-Disease 0.9517065286636353
patients O O 0.8297263383865356
should O O 0.9999384880065918
be O O 0.9999972581863403
estimated O O 0.9999960660934448
carefully O O 0.9998921155929565
. O O 0.9999991655349731

a O O 0.9975827932357788
wild-type O O 0.6494007706642151
level O O 0.967768669128418
in O O 0.9999101161956787
peripheral B-cell_line B-cell_line 0.4968578517436981
blood I-cell_line I-cell_line 0.8193716406822205
mononuclear I-cell_line I-cell_line 0.9078960418701172
cell I-cell_line I-cell_line 0.5983229279518127
cultures E-cell_line E-cell_line 0.6860851645469666
in O O 0.9998558759689331
50 O O 0.9931138157844543
to O O 0.9997597336769104
100 O O 0.9987860321998596
% O O 0.9998593330383301
of O O 0.9999895095825195
the O O 0.9999667406082153
experiments O O 0.9985872507095337
. O O 0.999998927116394
One O O 0.9998934268951416
group O O 0.9970875382423401
of O O 0.9999122619628906
mutants O O 0.6305158734321594
replicated O O 0.9900626540184021
very O O 0.9776369333267212

In O O 0.9971756935119629
MM B-cell_line B-cell_line 0.7037723660469055
cells E-cell_line E-cell_line 0.9502256512641907
that O O 0.9994819760322571
proliferated O O 0.9992332458496094
in O O 0.9999620914459229
response O O 0.9943282008171082
to O O 0.9998193383216858
IL-6 S-protein S-protein 0.9746870398521423
, O O 0.9982820749282837
exogenous O O 0.8642998933792114
IL-6 S-protein S-protein 0.7948455810546875
downregulated O O 0.9550782442092896
dephosphorylated B-protein B-protein 0.7060242295265198
pRB E-protein E-protein 0.4618314802646637

lines O E-cell_line 0.9743157029151917

by O O 0.9989578723907471
the O O 0.9999959468841553
addition O O 0.9998990297317505
of O O 0.9999853372573853
CTLA4Ig O S-protein 0.6209211349487305
. O O 0.9994452595710754
The O O 0.9999923706054688
control O O 0.9916303753852844
of O O 0.9998136162757874
lytic O O 0.8178094029426575
replication O O 0.9289996027946472
of O O 0.9995712637901306
Epstein-Barr O O 0.6024720072746277
virus O O 0.5270779132843018
in O O 0.9768983125686646
B B-cell_type B-cell_type 0.8069066405296326
lymphocytes E-cell_type E-cell_type 0.9853532910346985
( O O 0.986257791519165
Review O O 0.6247944235801697
) O O 0.9534319639205933

The O O 0.9995576739311218
primary O O 0.9442994594573975
response O O 0.9749312996864319
variable O O 0.9892237782478333
was O O 0.9999847412109375
based O O 0.9999947547912598
on O O 0.9999938011169434
central O O 0.9937604069709778
reading O O 0.9957236051559448
of O O 0.9999778270721436
24 O O 0.9718272686004639
hour O O 0.988996148109436
ambulatory O O 0.971335768699646
electrocardiographic O O 0.9607325196266174
recordings O O 0.9845923781394958
and O O 0.9999793767929077
was O O 0.9999791383743286
defined O O 0.9999713897705078
as O O 0.9999958276748657
the O O 0.9999579191207886
occurrence O O 0.9985021352767944
of O O 0.9999685287475586
30 O O 0.985056459903717
or O O 0.9993641972541809
more O O 0.999839186668396
single O O 0.988969087600708
premature O O 0.8979141712188721
ventricular O O 0.7383369207382202
complexes O O 0.5845562219619751
in O O 0.9996503591537476
any O O 0.9999637603759766
two O O 0.9995052814483643
consecutive O O 0.999929666519165
30 O O 0.9942341446876526
minute O O 0.996877908706665
blocks O O 0.9965590834617615
or O O 0.9999591112136841
one O O 0.9991497993469238
or O O 0.9998719692230225
more O O 0.9998652935028076
runs O O 0.991970419883728
of O O 0.9997813105583191
two O O 0.9960097074508667
or O O 0.999559223651886
more O O 0.9996090531349182
premature O O 0.8392531275749207
ventricular O O 0.5991789102554321
complexes O O 0.4730588495731354
in O O 0.9994816184043884
the O O 0.9999550580978394
entire O O 0.9954469799995422
24 O O 0.9643277525901794
hour O O 0.9915549159049988
electrocardiographic O O 0.8360075354576111
recording O O 0.9300423264503479
. O O 0.9999889135360718

Whether O O 0.9986522793769836
pentoxifylline B-Chemical B-Chemical 0.9287792444229126
inhibits O O 0.9838528633117676
dipyridamole B-Chemical B-Chemical 0.9305686354637146
- O O 0.9767202734947205
induced O O 0.9996050000190735
coronary O O 0.611773669719696
hyperemia B-Disease O 0.6451160311698914
like O O 0.9529334902763367
other O O 0.9974225759506226
methylxanthines B-Chemical O 0.421375036239624
such O O 0.9942527413368225
as O O 0.999774158000946
theophylline B-Chemical B-Chemical 0.9311873912811279
and O O 0.9942466616630554
should O O 0.9998350143432617
be O O 0.9999151229858398
stopped O O 0.9984806180000305
prior O O 0.9999736547470093
to O O 0.999953031539917
dipyridamole B-Chemical B-Chemical 0.9334695339202881
- O O 0.5431305170059204
thallium B-Chemical B-Chemical 0.8352558612823486
- O O 0.5212476849555969
201 O O 0.7193562388420105
imaging O O 0.947525143623352
is O O 0.9999754428863525
unknown O O 0.9986914992332458
. O O 0.9999990463256836

. O O 0.9942091703414917
Upon O O 0.9987842440605164
HBsAg S-protein O 0.5235857963562012
stimulation O O 0.9773592352867126
, O O 0.9999551773071289
expression O O 0.9977952241897583
of O O 0.9997413754463196
IFN-gamma S-protein S-protein 0.9821715354919434
, O O 0.9895929098129272
IL-2 S-protein S-protein 0.9921414852142334
, O O 0.9956122636795044
IL-4 S-protein S-protein 0.9904710054397583
, O O 0.9912818670272827
and O O 0.9981963038444519
IL-10 S-protein S-protein 0.977245032787323
was O O 0.9996060729026794
detected O O 0.9999542236328125
in O O 0.9999136924743652
41 O O 0.9682580232620239
% O O 0.9977337121963501
, O O 0.9999232292175293
8 O O 0.9985114932060242
% O O 0.9995929598808289
, O O 0.9998230338096619
41 O O 0.9932221174240112
% O O 0.9996662139892578

stage O O 0.8832048177719116
. O O 0.9999247789382935
We O O 0.9999730587005615
have O O 0.999988317489624
isolated O O 0.9984299540519714
a O O 0.9998356103897095
human B-DNA B-DNA 0.4091692268848419
cDNA I-DNA I-DNA 0.3637247681617737
clone E-DNA E-DNA 0.9482812881469727
encoding O O 0.9979840517044067
a O O 0.9998682737350464
zinc B-protein B-protein 0.5817579030990601
finger I-protein I-protein 0.847848653793335
protein E-protein E-protein 0.9867667555809021
( O O 0.9839887022972107
NF-E1 S-protein S-protein 0.989479124546051
) O O 0.9921700358390808
that O O 0.9999427795410156
binds O O 0.9975922107696533

and O O 0.9633212089538574
cell O O 0.9332008957862854
proliferation O O 0.9967660903930664
. O O 0.9999983310699463
In O O 0.999990701675415
the O O 0.9999924898147583
present O O 0.9986977577209473
study O O 0.9998242259025574
, O O 0.9999964237213135
the O O 0.999991774559021
role O O 0.9996378421783447
of O O 0.9999743700027466
IL-2R S-protein S-protein 0.9544793963432312
signaling O O 0.9775516390800476
in O O 0.9999622106552124
the O O 0.9999213218688965
growth O O 0.9827825427055359
of O O 0.9999003410339355
CD8+ B-cell_line B-cell_line 0.442734956741333
T I-cell_line I-cell_line 0.5710437893867493
cell I-cell_line I-cell_line 0.38939154148101807
prolymphocytic I-cell_line I-cell_line 0.3955993056297302
leukemia I-cell_line I-cell_line 0.40853211283683777
( I-cell_line I-cell_line 0.5919392108917236
T-PLL I-cell_line I-cell_line 0.7600044012069702
) I-cell_line I-cell_line 0.5910748839378357

, O O 0.9851425290107727
PKB/Akt S-protein S-protein 0.9412335157394409
activity O O 0.9957746863365173
alone O O 0.999819815158844
did O O 0.9999924898147583
not O O 0.9999804496765137
protect O O 0.9999294281005859
these O O 0.999553382396698
cells O O 0.9633424878120422
from O O 0.9999572038650513
apoptosis O O 0.9893152713775635
. O O 0.9999972581863403
Treatment O O 0.9994447827339172
of O O 0.999940037727356
HCD57 B-cell_line B-cell_line 0.7458418011665344
cells E-cell_line E-cell_line 0.9742039442062378
with O O 0.9997022747993469
SCF S-protein S-protein 0.7824097275733948
also O O 0.9954162836074829
activated O O 0.9942084550857544
PKB/Akt S-protein S-protein 0.9282121658325195
, O O 0.9960219264030457
but O O 0.9998406171798706
did O O 0.9999439716339111
not O O 0.9999455213546753
protect O O 0.9998714923858643
from O O 0.9998514652252197
apoptosis O O 0.9830016493797302
. O O 0.9999967813491821
This O O 0.9999825954437256
result O O 0.9998220801353455
suggested O O 0.9999971389770508
that O O 0.9999899864196777
PKB/PI3-kinase S-protein S-protein 0.8336533308029175
activity O O 0.9964286684989929
is O O 0.9999921321868896
necessary O O 0.9999516010284424
but O O 0.999942421913147
not O O 0.9997366070747375
sufficient O O 0.9997484087944031
to O O 0.999980092048645
promote O O 0.9997217059135437
viability O O 0.9865714907646179
and/or O O 0.919312596321106
proliferation O O 0.9978829026222229
. O O 0.9999960660934448
Constitutive O O 0.9502760171890259
STAT5 S-protein S-protein 0.9437259435653687
activity O O 0.9956607222557068
, O O 0.9999508857727051
activated O O 0.9755843877792358
through O O 0.9998764991760254
an O O 0.999233603477478

soluble O O 0.8037113547325134
peptide O O 0.9336945414543152
. O O 0.9999377727508545
Copyright O O 0.9743672013282776
1998 O O 0.9754835963249207
Academic O O 0.9956758618354797
Press O O 0.9860240817070007
. O O 0.9999934434890747
Upregulation O O 0.9975448250770569
of O O 0.9999076128005981
interleukin B-protein S-protein 0.44102275371551514

There O O 0.9997007846832275
was O O 0.9999734163284302
only O O 0.9999598264694214
one O O 0.9999731779098511
case O O 0.9900287985801697
of O O 0.9992988109588623
dementia O B-Disease 0.9865661263465881
possibly O O 0.8675932288169861
due O O 0.9996585845947266
to O O 0.9998396635055542
cimetidine S-Chemical B-Chemical 0.9368952512741089
( O O 0.9938435554504395
with O O 0.9999420642852783
a O O 0.9996398687362671
drug O O 0.9198887348175049
level O O 0.9912681579589844
of O O 0.9995536208152771
1 O O 0.9985587000846863
. O O 0.9999083280563354
9 O O 0.9998342990875244
microgram O O 0.9969865679740906
/ O O 0.9999407529830933
ml O O 0.9995355606079102
6 O O 0.9998629093170166
hr O O 0.999344527721405
after O O 0.999997615814209
a O O 0.9999780654907227
dose O O 0.9997820258140564
) O O 0.9999333620071411
in O O 0.9999955892562866
a O O 0.9999498128890991
group O O 0.9996441602706909
of O O 0.9999662637710571
13 O O 0.9825962781906128
patients O O 0.9989432692527771
without O O 0.999782383441925
liver O B-Disease 0.5473366379737854
or O I-Disease 0.693770170211792
kidney O I-Disease 0.6416608691215515
disease O I-Disease 0.988813579082489
who O O 0.947745144367218
had O O 0.9991298317909241
cimetidine S-Chemical B-Chemical 0.9401828050613403
levels O O 0.9878397583961487
above O O 0.9999381303787231
1 O O 0.9991484880447388
. O O 0.9999663829803467
25 O O 0.999729335308075
microgram O O 0.9972092509269714
/ O O 0.9999741315841675
ml O O 0.9975425004959106
. O O 0.999985933303833

assays O O 0.9083459973335266
we O O 0.9995693564414978
show O O 0.9999963045120239
that O O 0.9999994039535522
the O O 0.9999351501464844
H4 B-DNA B-DNA 0.3689539432525635
promoter E-DNA E-DNA 0.9884470105171204
contains O O 0.9993273019790649
two O O 0.9992601275444031
ATF/ O B-DNA 0.494734525680542
CREB S-protein I-DNA 0.19986592233181
recognition O I-DNA 0.4362644851207733
motifs O E-DNA 0.8468611240386963
which O O 0.9990377426147461
interact O O 0.9999445676803589
with O O 0.9999361038208008
CREB S-protein S-protein 0.7170013189315796
, O O 0.9901974201202393
ATF1 S-protein S-protein 0.6966235041618347
, O O 0.963017463684082

histocompatibility I-DNA O 0.5799719095230103
complex I-DNA O 0.3860015571117401
gene E-DNA O 0.7127498388290405
transcription O O 0.7097259759902954
that O O 0.9983389377593994
has O O 0.999984860420227
been O O 0.9998788833618164
found O O 0.9999340772628784
to O O 0.9994018077850342

interactions O O 0.9805657863616943
with O O 0.9999499320983887
CREB S-protein S-protein 0.9200764894485474
. O O 0.999860405921936
The O O 0.9999961853027344
ability O O 0.9997722506523132
to O O 0.9999784231185913
regulate O O 0.9991351962089539
AR B-DNA B-DNA 0.5561737418174744
gene E-DNA E-DNA 0.8624176383018494
transcription O O 0.9048275351524353
via O O 0.9997815489768982
the O O 0.9999617338180542
second O O 0.9627121686935425
messenger O O 0.8480548858642578
pathway O O 0.989144504070282
is O O 0.9999856948852539
lost O O 0.998842716217041
in O O 0.9999489784240723
the O O 0.9993832111358643
PC-3 B-cell_line S-cell_line 0.9281378388404846
and I-cell_line O 0.9048833250999451
DU-145 I-cell_line B-cell_line 0.6562056541442871
cell I-cell_line I-cell_line 0.7352171540260315
lines E-cell_line E-cell_line 0.99839848279953
. O O 0.9999433755874634

We O O 0.9995449185371399
describe O O 0.9999828338623047
a O O 0.9999890327453613
25 O O 0.9922381043434143
- O O 0.9994487166404724
year O O 0.999941349029541
- O O 0.9998871088027954
old O O 0.9991920590400696
woman O O 0.9989915490150452
with O O 0.9999972581863403
pre O O 0.994507372379303
- O O 0.99924635887146
existing O O 0.9972041845321655
mitral B-Disease O 0.6464235782623291
valve I-Disease O 0.5860668420791626
prolapse I-Disease O 0.7283987402915955
who O O 0.9866379499435425
developed O O 0.999363362789154
intractable O O 0.9476698040962219
ventricular B-Disease B-Disease 0.5342069864273071
fibrillation I-Disease I-Disease 0.9875608086585999
after O O 0.9825454950332642
consuming O O 0.9927547574043274
a O O 0.9992414712905884
" O O 0.9881581664085388
natural O O 0.9696866273880005
energy O O 0.9440202116966248
" O O 0.9984139204025269
guarana O O 0.840160608291626
health O O 0.9733269810676575
drink O O 0.9408156871795654
containing O O 0.9999626874923706
a O O 0.9998892545700073
high O O 0.9818521738052368
concentration O O 0.9802209138870239
of O O 0.9991658926010132
caffeine B-Chemical B-Chemical 0.9232745170593262
. O O 0.9995107650756836

whereas O O 0.9985933899879456
all O O 0.999993085861206
these O O 0.9999809265136719
signaling O O 0.8692407011985779
molecules O O 0.8352760672569275
were O O 0.999729335308075
affected O O 0.9968087077140808
and/or O S-protein 0.46152111887931824
utilized O O 0.9848580360412598
by O O 0.9998835325241089
GM-CSF S-protein S-protein 0.98575758934021
in O O 0.9996768236160278
MO7e B-cell_type B-cell_line 0.6869533061981201
cells E-cell_type E-cell_line 0.9152796864509583
. O O 0.9998149275779724
In O O 0.9999908208847046
contrast O O 0.9997027516365051
to O O 0.9999743700027466
neutrophils S-cell_type S-cell_type 0.98970627784729
, O O 0.999415397644043
p38 S-protein S-protein 0.9153763651847839
was O O 0.9984531402587891
constitutively O O 0.9851039052009583
phosphorylated O O 0.8503313660621643
and O O 0.9939991235733032
agonist-dependent O O 0.9639567732810974
phosphorylation O O 0.9694914221763611
and O O 0.9997876286506653
activation O O 0.991211473941803
was O O 0.999913215637207
not O O 0.9997746348381042
detected O O 0.9996435642242432
in O O 0.9997245669364929
human B-cell_type B-cell_type 0.8354266881942749

of O O 0.9969671368598938
the O O 0.9999558925628662
VCAM B-DNA B-DNA 0.6893596649169922
promoter E-DNA E-DNA 0.9942079782485962
. O O 0.9995548129081726
This O O 0.9999815225601196
effect O O 0.9999053478240967
is O O 0.9999905824661255
blocked O O 0.9997873902320862
by O O 0.999990701675415
anti-VCAM B-protein B-protein 0.3408777415752411
antibodies E-protein E-protein 0.9898362755775452
. O O 0.9997304081916809
After O O 0.9998486042022705

suggest O O 0.9987447261810303
an O O 0.9999942779541016
important O O 0.9992883801460266
role O O 0.9993581175804138
for O O 0.9999828338623047
abnormalities O O 0.9642491340637207
in O O 0.9998902082443237
mineralocorticoid O O 0.8126497864723206
effector O O 0.6789592504501343
mechanisms O O 0.9513843655586243
in O O 0.9999850988388062
the O O 0.9999376535415649
etiology O O 0.9805417060852051
of O O 0.9998831748962402
preeclampsia O O 0.7893852591514587
and O O 0.9967015385627747
could O O 0.9999837875366211
be O O 0.9999920129776001
an O O 0.9999819993972778
useful O O 0.9845775961875916
marker O O 0.9459599256515503

cells E-cell_line E-cell_type 0.7291171550750732
in O O 0.9995043277740479
vitro O O 0.9817905426025391
, O O 0.9993977546691895
in O O 0.9998801946640015
liquid O O 0.7164484262466431
culture O O 0.5924662947654724
as O O 0.9994854927062988
well O O 0.9996945858001709
as O O 0.999982476234436
in O O 0.9993915557861328
clonogenic O O 0.7930678725242615
assay O O 0.9011349081993103
, O O 0.9984754920005798
and O O 0.999886155128479
in O O 0.9994838237762451
vivo O O 0.9894089698791504
, O O 0.9999450445175171
after O O 0.9999912977218628
bone O O 0.9474856853485107
marrow O O 0.980981707572937
transplantation O O 0.9979408383369446
in O O 0.9999693632125854
lethally O B-cell_type 0.6365953683853149
irradiated O I-cell_type 0.7177724242210388

system O O 0.5279231071472168
provides O O 0.9998612403869629
a O O 0.9999880790710449
complex O O 0.9529421925544739
and O O 0.986689567565918
interesting O O 0.9844767451286316
model O O 0.9948461055755615
of O O 0.9999573230743408
the O O 0.9999649524688721
regulation O O 0.9981998205184937
of O O 0.999937891960144
transcription B-protein B-protein 0.4901639521121979
factors E-protein E-protein 0.9941376447677612
by O O 0.9995588660240173
hsp90 S-protein S-protein 0.8239458203315735
. O O 0.9997228980064392
Induction O O 0.9969124794006348
of O O 0.9998282194137573
transcription B-protein B-protein 0.5747306942939758
factors E-protein E-protein 0.9961349964141846
in O O 0.9995360374450684
human B-cell_type B-cell_type 0.7975192666053772
T I-cell_type I-cell_type 0.9165425300598145
lymphocytes E-cell_type E-cell_type 0.9919896721839905
by O O 0.9989209175109863

induction O O 0.969632625579834
of O O 0.9995571970939636
programmed O O 0.8514341711997986
cell O O 0.8273893594741821
death O O 0.8325144052505493
( O O 0.9991587400436401
PCD O O 0.934146523475647
) O O 0.9997342228889465
have O O 0.9999903440475464
been O O 0.9999624490737915
identified O O 0.9999659061431885
, O O 0.9999908208847046
but O O 0.9999847412109375
little O O 0.9999138116836548
is O O 0.9999909400939941
known O O 0.9999924898147583
about O O 0.9999933242797852
specific O O 0.9695281982421875
extracellular O O 0.6365106105804443

the O O 0.9962015748023987

The O O 0.9983940720558167
patient O O 0.9884483218193054
' O O 0.9948273301124573
s O O 0.9891090393066406
clinical O O 0.9704980850219727
course O O 0.9929399490356445
is O O 0.9999866485595703
described O O 0.9999854564666748
and O O 0.9999606609344482
correlated O O 0.999850869178772
with O O 0.9999979734420776
initial O O 0.9970037341117859
urodynamic O O 0.8014185428619385
studies O O 0.9866567254066467
while O O 0.9999949932098389
on O O 0.9998629093170166
prazosin B-Chemical B-Chemical 0.916738748550415
and O O 0.9912058711051941
subsequent O O 0.997373104095459
studies O O 0.9997718930244446
while O O 0.9999959468841553
taking O O 0.999637246131897
verapamil B-Chemical B-Chemical 0.9208351969718933
. O O 0.9994447827339172

. O O 0.9967076778411865
Northern O O 0.9878275394439697
blotting O O 0.9767640829086304
experiments O O 0.9986516833305359
indicated O O 0.9999938011169434
that O O 0.9999923706054688
regulation O O 0.9981769323348999
predominantly O O 0.9997040629386902
occurred O O 0.9999008178710938
at O O 0.9999969005584717
the O O 0.9999392032623291
mRNA O O 0.7279078364372253
level O O 0.9926487803459167
. O O 0.9999977350234985
Comparison O O 0.9998742341995239
of O O 0.9999897480010986
the O O 0.9999947547912598
different O O 0.998845100402832
combinations O O 0.9971871972084045
of O O 0.999925971031189
GC O O 0.47948455810546875
and O O 0.9784324169158936
cytokines S-protein S-protein 0.9805120229721069
/LPS O O 0.5508869886398315
revealed O O 0.9998279809951782
differences O O 0.9985076785087585
in O O 0.9999392032623291
the O O 0.9999319314956665
level O O 0.9995635151863098
of O O 0.9999387264251709
GC-dependent O O 0.7506518959999084
enhancement O O 0.9677649736404419
of O O 0.9997619986534119
sialoadhesin S-protein S-protein 0.8487274050712585
expression O O 0.9984656572341919
, O O 0.9999856948852539

nuclear O O 0.9502920508384705
extracts O O 0.997063934803009
with O O 0.999977707862854
sodium O O 0.9235965609550476
deoxycholate O O 0.9623037576675415
restored O O 0.9998853206634521
their O O 0.9999765157699585
ability O O 0.9997987151145935
to O O 0.9999819993972778
form O O 0.9997988343238831
the O O 0.9998036026954651
heterodimer S-protein S-protein 0.7151951193809509
, O O 0.9595943689346313

interactions O O 0.9653233885765076
. O O 0.9999747276306152
T O O 0.7455987930297852
cell O O 0.6288676261901855
responses O O 0.9836772680282593
to O O 0.9999434947967529
some O O 0.999955415725708
nuclear O O 0.8219260573387146
antigens O O 0.6086094975471497
, O O 0.9975008368492126
particularly O O 0.9998407363891602
U1RNP S-protein O 0.47580280900001526
, O O 0.991666853427887
have O O 0.9999706745147705
been O O 0.9997574687004089
detected O O 0.9997871518135071
in O O 0.9999861717224121
patients O O 0.9999275207519531
with O O 0.9999822378158569
systemic O O 0.8791108131408691
lupus O O 0.43407127261161804
erythematosus O O 0.7835625410079956
( O O 0.9866020679473877
SLE O O 0.9226233959197998
) O O 0.8825004696846008
and O O 0.9993878602981567
in O O 0.9999139308929443
healthy O O 0.77513587474823
subjects O O 0.9724035859107971
. O O 0.9999946355819702

Current O O 0.9752746224403381
clinical O O 0.9924351572990417
experience O O 0.9962672591209412
. O O 0.999998927116394

pharmacokinetic O O 0.7281225919723511
behaviors O O 0.7567641735076904
. O O 0.9999678134918213
In O O 0.999988317489624
addition O O 0.9999181032180786
, O O 0.999996542930603
increased O O 0.9969744682312012
amounts O O 0.9996531009674072
of O O 0.9998705387115479
arsenic O B-Chemical 0.8764954209327698
appeared O O 0.9684938192367554
in O O 0.9998533725738525
the O O 0.9995812773704529
urine O O 0.8864166140556335
, O O 0.9995423555374146
with O O 0.9999969005584717
a O O 0.9999542236328125
daily O O 0.979775071144104
excretion O O 0.9380808472633362
accounting O O 0.9999023675918579
for O O 0.9999724626541138
approximately O O 0.9999018907546997
1 O O 0.999785840511322
% O O 0.9999560117721558
to O O 0.9999598264694214
8 O O 0.9999206066131592
% O O 0.9999833106994629
of O O 0.9999767541885376
the O O 0.99996018409729
total O O 0.9777880311012268
daily O O 0.8974912762641907
dose O O 0.9949502944946289
administered O O 0.9981212019920349
. O O 0.9999947547912598

of O O 0.9926290512084961

positive O O 0.8479018211364746
for O O 0.9930620789527893
TCF-1 S-protein S-protein 0.959258496761322
and O O 0.9910928606987
GATA-3 S-protein S-protein 0.9712082147598267
, O O 0.9976346492767334
which O O 0.9999741315841675
are O O 0.9999955892562866
the O O 0.9999762773513794
transcription B-protein B-protein 0.6374983191490173
factors E-protein E-protein 0.980290412902832
for O O 0.9972825050354004
promoters O S-DNA 0.9475361704826355
for O O 0.9992259740829468
several O O 0.9994986057281494
T-cell-restricted B-protein B-protein 0.4876832365989685
markers E-protein E-protein 0.9246415495872498
, O O 0.9961913824081421
including O O 0.9998859167098999
CD2 S-protein S-protein 0.942906379699707
, O O 0.9868250489234924
CD3 S-protein S-protein 0.9551378488540649
, O O 0.9907149076461792
TcR S-protein S-protein 0.9542365074157715
, O O 0.9767223000526428
and O O 0.9926860332489014
lck S-protein S-protein 0.7353019714355469
. O O 0.9965781569480896
The O O 0.999991774559021
absence O O 0.9991438388824463
of O O 0.9999417066574097
BSAP S-protein S-protein 0.8513947129249573
, O O 0.9867095351219177
TCF-1 S-protein S-protein 0.8812030553817749
, O O 0.9840887784957886
and O O 0.996924102306366
GATA-3 S-protein S-protein 0.921126127243042
clearly O O 0.9941613078117371
indicates O O 0.9999922513961792
an O O 0.9999732971191406

of O O 0.9960322976112366
IL-2 S-protein S-protein 0.9585731625556946
expression O O 0.995897650718689
, O O 0.9999920129776001
we O O 0.999958872795105
next O O 0.9996054768562317
analysed O O 0.999915599822998
its O O 0.9999829530715942
nuclear O O 0.8900498747825623
translocation O O 0.8634171485900879
in O O 0.9996718168258667
neonatal B-cell_type B-cell_type 0.7513052225112915
and I-cell_type I-cell_type 0.5704038739204407
adult I-cell_type I-cell_type 0.6752942800521851
T I-cell_type I-cell_type 0.9103198051452637
cells E-cell_type E-cell_type 0.9801008701324463
using O O 0.999560534954071
the O O 0.9999635219573975
electrophoretic O O 0.8843404054641724
mobility O O 0.9676582217216492

3 O O 0.6174454092979431
. O O 0.9989400506019592

the O O 0.9927642941474915
liver O O 0.9189022183418274
and O O 0.9875170588493347
kidney O O 0.9282459616661072
. O O 0.9999563694000244
Plasma O O 0.8719413876533508
TPO S-protein S-protein 0.8071609139442444
levels O O 0.998736560344696
are O O 0.9999929666519165
regulated O O 0.9998924732208252
by O O 0.9999918937683105
the O O 0.9999053478240967
platelet O O 0.45274975895881653
and O O 0.9736320376396179
megakaryocyte O O 0.6478453278541565
mass O O 0.6814122796058655
through O O 0.9964146614074707
Mpl B-protein O 0.4664991497993469
receptor E-protein O 0.6235779523849487
binding O O 0.5797131657600403
, O O 0.9926028847694397

members O O 0.8691791892051697
of O O 0.999679684638977
NF-AT S-protein S-protein 0.942932665348053
, O O 0.9558913707733154
NF-kB S-protein S-protein 0.960747241973877
and O O 0.9823411703109741
AP-1 B-protein B-protein 0.8469584584236145
factor I-protein I-protein 0.41567057371139526
families E-protein E-protein 0.9111114740371704
. O O 0.9993852376937866
Naive B-cell_type B-cell_type 0.5613664984703064
( I-cell_type I-cell_type 0.42713096737861633
CD45RA+ I-cell_type I-cell_type 0.5698161125183105
) I-cell_type I-cell_type 0.5346563458442688
T I-cell_type I-cell_type 0.5587553977966309
lymphocytes E-cell_type E-cell_type 0.7059184908866882
are O O 0.9998224377632141
more O O 0.99973064661026
sensitive O O 0.9977878332138062
to O O 0.9999680519104004
oxidative O O 0.8640347719192505
stress-induced O O 0.9528151154518127
signals O O 0.9855318665504456
than O O 0.9999650716781616

Also O O 0.9875540733337402
, O O 0.9999128580093384
there O O 0.9999659061431885
appears O O 0.9999680519104004
to O O 0.9999750852584839
be O O 0.999977707862854
an O O 0.9999085664749146
adaptation O O 0.9044796228408813
by O O 0.9991174340248108
the O O 0.9993651509284973
rats O O 0.9966481328010559
to O O 0.9999704360961914
the O O 0.9998304843902588
chronic O O 0.7476816773414612
ingestion O O 0.6033003926277161
of O O 0.9915595650672913
aspirin B-Chemical B-Chemical 0.9249565005302429
. O O 0.9994603991508484

( O O 0.8192139267921448
GC O O 0.2778421640396118
) O O 0.49469807744026184
-insensitive O O 0.8906072378158569
asthma O O 0.9368078112602234
is O O 0.9999815225601196
a O O 0.999994158744812
challenging O O 0.9727229475975037
clinical O O 0.9802657961845398
problem O O 0.991570234298706
that O O 0.9999932050704956
can O O 0.9999178647994995

24 O O 0.8994956016540527
h O O 0.954371452331543
with O O 0.9996881484985352
methylprednisolone O O 0.7400275468826294
, O O 0.997184693813324
dexamethasone O O 0.864037036895752
, O O 0.99776291847229
and O O 0.9998212456703186
hydrocortisone O O 0.8699415326118469
, O O 0.998715877532959
but O O 0.9999418258666992
not O O 0.9998267292976379
the O O 0.9998869895935059
nonglucocorticoid O O 0.6930256485939026
steroids O O 0.7563378810882568
aldosterone O O 0.7443979382514954
, O O 0.9966511130332947
estradiol O O 0.7671903967857361
, O O 0.9844329357147217
and O O 0.9980787038803101
progesterone O O 0.7904427647590637
, O O 0.9933267831802368
potentiated O O 0.9755635857582092
phagocytosis O O 0.91866135597229
of O O 0.999187171459198
apoptotic B-cell_type B-cell_type 0.6163259744644165
neutrophils E-cell_type E-cell_type 0.9889304041862488
. O O 0.9998109936714172
These O O 0.9999966621398926
effects O O 0.9999041557312012
were O O 0.9999938011169434
specific O O 0.9998706579208374
in O O 0.9999655485153198
that O O 0.9999412298202515
the O O 0.9997559189796448
potentiated O O 0.9140849709510803
phagocytosis O O 0.766951858997345

IL-4 I-DNA B-DNA 0.7155368328094482
promoter E-DNA E-DNA 0.9938499331474304
. O O 0.9990611672401428
In O O 0.999981164932251
the O O 0.9999641180038452
mouse B-DNA B-DNA 0.4557701349258423
IL-4 I-DNA I-DNA 0.7012236714363098
promoter E-DNA E-DNA 0.9938390851020813
, O O 0.9977939128875732
there O O 0.999988317489624
are O O 0.9999942779541016
five O O 0.9949110150337219
elements O O 0.8044205904006958
homologous O O 0.8885721564292908
to O O 0.9995713829994202
the O O 0.9992868304252625
human O B-DNA 0.5376332402229309
P B-DNA I-DNA 0.6933492422103882
sequence E-DNA E-DNA 0.9479902982711792
designated O O 0.9686354994773865
conserved B-DNA O 0.8467995524406433
lymphokine I-DNA B-DNA 0.32294684648513794
element I-DNA I-DNA 0.6641790270805359
0 E-DNA E-DNA 0.851348876953125
( O O 0.9576550126075745
CLE0 S-DNA S-DNA 0.9693592190742493
) O O 0.9738039374351501
, O O 0.9994053840637207
P S-DNA S-DNA 0.9590596556663513
, O O 0.9845190048217773
P2 S-DNA S-DNA 0.984889566898346
, O O 0.9942136406898499
P3 S-DNA S-DNA 0.9768475294113159
and O O 0.9906708002090454
P4 S-DNA S-DNA 0.9562381505966187
. O O 0.999035120010376

, O O 0.9938593506813049
a O O 0.9999629259109497
pancreatic O B-protein 0.7112363576889038
beta-cell O I-protein 0.41247865557670593
type-specific O I-protein 0.5967966318130493
complex O E-protein 0.9756906628608704
believed O O 0.9991257786750793
to O O 0.999980092048645
regulate O O 0.9997592568397522
insulin O S-protein 0.8336319923400879
expression O O 0.9974416494369507
, O O 0.9999794960021973
is O O 0.9999837875366211
demonstrated O O 0.9999583959579468
to O O 0.9999843835830688
consist O O 0.9999864101409912
of O O 0.9999649524688721
at O O 0.9994319081306458
least O O 0.9988686442375183
two O O 0.9995276927947998
distinct O O 0.9931259155273438
species O O 0.9726861715316772
, O O 0.9999401569366455
one O O 0.9999855756759644
of O O 0.9999927282333374
which O O 0.9999686479568481
does O O 0.9999691247940063
not O O 0.9998217225074768

in O O 0.9986637830734253
the O O 0.9999521970748901
TCR-alpha B-DNA B-DNA 0.6206801533699036
and I-DNA I-DNA 0.7686880826950073
CD3-epsilon I-DNA I-DNA 0.633507490158081
enhancers E-DNA E-DNA 0.9963222742080688
imply O O 0.9990251064300537
an O O 0.9999839067459106
important O O 0.9981476068496704
role O O 0.9993541836738586
for O O 0.9999518394470215
TCF-1 S-protein S-protein 0.9739766716957092
in O O 0.999813973903656
the O O 0.9999842643737793
establishment O O 0.9980225563049316
of O O 0.999968409538269
the O O 0.9999033212661743
mature B-cell_type O 0.7430233955383301
T I-cell_type O 0.5867249369621277
cell I-cell_type O 0.5057340264320374
phenotype E-cell_type O 0.2928157448768616
. O O 0.9987834095954895
Cloning O O 0.9102599620819092
of O O 0.9980258941650391
a O O 0.9990221261978149
human B-DNA B-DNA 0.3197244703769684

; O O 0.9840030074119568
this O O 0.9999700784683228
may O O 0.999994158744812
be O O 0.999997615814209
due O O 0.9999957084655762
in O O 0.9999927282333374
part O O 0.9999583959579468
to O O 0.9999978542327881
the O O 0.9999816417694092
suppression O O 0.9971241354942322
of O O 0.9999430179595947
NFkappaB S-protein S-protein 0.9579153060913086
entry O O 0.9878573417663574
into O O 0.9999790191650391
the O O 0.9999380111694336
nucleus O O 0.942021906375885
. O O 0.9999254941940308
Molecular O O 0.8200316429138184

Impotence O O 0.884206235408783
was O O 0.9690231680870056
more O O 0.996711015701294
common O O 0.99391770362854
among O O 0.9998823404312134
male O O 0.8171690702438354
patients O O 0.9937981963157654
than O O 0.9999916553497314
controls O O 0.9827638864517212
and O O 0.9999377727508545
was O O 0.999919056892395
found O O 0.9998881816864014
to O O 0.9999434947967529
be O O 0.9999537467956543
associated O O 0.9998464584350586
with O O 0.9999891519546509
co O O 0.5385376214981079
- O O 0.8385498523712158
morbidity O O 0.4999224543571472
and O O 0.9963098168373108
the O O 0.9996381998062134
taking O O 0.9996022582054138
of O O 0.9997357726097107
methotrexate S-Chemical B-Chemical 0.9219061136245728
. O O 0.9995898604393005

various O O 0.9708861708641052

Since O O 0.9998225569725037
adverse O O 0.903044581413269
reactions O O 0.712990403175354
are O O 0.9963300824165344
frequent O O 0.9833477139472961
, O O 0.9999786615371704
less O O 0.9998341798782349
than O O 0.9999046325683594
50 O O 0.9995530247688293
percent O O 0.9999850988388062
of O O 0.999958872795105
patients O O 0.999431312084198
are O O 0.9999979734420776
able O O 0.9999594688415527
to O O 0.9999597072601318
continue O O 0.9999390840530396
a O O 0.9998753070831299
particular O O 0.9821957945823669
drug O O 0.9936867356300354
for O O 0.9999797344207764
more O O 0.9999438524246216
than O O 0.9998983144760132
one O O 0.9999421834945679
year O O 0.9998986721038818
. O O 0.9999994039535522

% O O 0.9598737955093384
fetal O O 0.7970125675201416
bovine O O 0.5457931160926819
serum O O 0.5288394093513489
, O O 0.9928234815597534
most O O 0.9990264177322388
YJ B-cell_line B-cell_line 0.761393666267395
cells E-cell_line E-cell_line 0.940319299697876
were O O 0.9997326731681824
myeloblastoid O O 0.7870545387268066
with O O 0.9991732239723206
a O O 0.9998507499694824
small O O 0.9905367493629456
number O O 0.9914275407791138
of O O 0.9998961687088013
the O O 0.9996780157089233
cells O O 0.9671311378479004
having O O 0.9998749494552612
eosinophilic O O 0.6351295709609985
granules O O 0.4486945867538452
. O O 0.9994531273841858
Cell B-protein B-protein 0.7976595163345337
surface I-protein I-protein 0.5823899507522583
markers E-protein E-protein 0.9059562683105469
in O O 0.9994770884513855

the O O 0.9949357509613037
c-fos B-DNA B-DNA 0.8149058222770691
gene E-DNA E-DNA 0.9879329800605774
. O O 0.9996720552444458
Run-on O O 0.9214071035385132
analysis O O 0.9976285099983215
demonstrated O O 0.9999737739562988
detectable O O 0.9851264953613281
levels O O 0.9981358051300049
of O O 0.9999203681945801
c-jun S-DNA S-DNA 0.8895317316055298
transcription O O 0.9033457636833191
in O O 0.9996614456176758
U-937 B-cell_line B-cell_line 0.8220939636230469
cells E-cell_line E-cell_line 0.987211287021637
and O O 0.9991158843040466
that O O 0.9999986886978149
this O O 0.999951958656311
rate O O 0.999502420425415
is O O 0.99997878074646
increased O O 0.9994962215423584
approximately O O 0.9999064207077026
40-fold O O 0.9968332648277283
following O O 0.9999923706054688
okadaic O O 0.8799251317977905
acid O O 0.8829160332679749
exposure O O 0.9976518750190735
. O O 0.9999879598617554
c-jun B-RNA B-RNA 0.7158582210540771
mRNA E-RNA E-RNA 0.9497128129005432
levels O O 0.9949604272842407
were O O 0.9999896287918091
superinduced O O 0.9989651441574097
in O O 0.9997482895851135
cells O O 0.9841346144676208
treated O O 0.9998975992202759
with O O 0.9999918937683105

core O B-DNA 0.6328853964805603
region O E-DNA 0.8962914943695068
show O O 0.9973020553588867
little O O 0.9989233613014221
conservation O O 0.9990178346633911
with O O 0.9999927282333374
consensus B-DNA B-DNA 0.5433263182640076
sites E-DNA E-DNA 0.9735022783279419
. O O 0.9997314810752869
Nonetheless O O 0.9987541437149048
, O O 0.9997017979621887
CREB S-protein S-protein 0.885750949382782
, O O 0.9801187515258789
Ets-1 S-protein S-protein 0.9200108051300049
, O O 0.9765050411224365
and O O 0.9944762587547302
AML1 S-protein S-protein 0.9584864377975464
bind O O 0.950503408908844
and O O 0.9971466660499573
activate O O 0.9992376565933228
cooperatively O O 0.9981510043144226
and O O 0.9998425245285034
very O O 0.9995694756507874
efficiently O O 0.9993438124656677
through O O 0.9999926090240479
the O O 0.9998433589935303

mimic O O 0.8177929520606995
of O O 0.9964436888694763
granulocyte-colony-stimulating B-protein B-protein 0.4914502203464508
factor E-protein E-protein 0.9540854096412659
[ O O 0.9856413006782532
see O O 0.994196891784668
commetns O O 0.7657655477523804
] O O 0.988811731338501
A O O 0.9962559938430786
nonpeptidyl O O 0.9155267477035522
small O O 0.9250675439834595
molecule O O 0.768987774848938
SB O O 0.7478852272033691
247464 O O 0.45053720474243164
, O O 0.9920781254768372
capable O O 0.9982783794403076
of O O 0.9998314380645752

is O O 0.9974554181098938
essential O O 0.9999043941497803
in O O 0.9999943971633911
the O O 0.9999872446060181
TPA O O 0.31564760208129883
maturation O O 0.7796108722686768
response O O 0.9730798602104187
. O O 0.9999371767044067
Neutrophil S-cell_type O 0.6640779376029968
maturation O O 0.9850229620933533
and O O 0.99989914894104
the O O 0.9999923706054688
role O O 0.9998726844787598
of O O 0.9999552965164185

rat O O 0.35856524109840393
and O O 0.9017544984817505
mouse O O 0.85590660572052
tissues O O 0.9424758553504944
have O O 0.9999673366546631
detected O O 0.9995367527008057
ubiquitously O O 0.6439475417137146
expressed O O 0.9016510844230652
Pan O B-RNA 0.3237725794315338
transcripts O E-RNA 0.8397573232650757
, O O 0.9978996515274048
but O O 0.9999904632568359
the O O 0.9999830722808838
abundance O O 0.9880947470664978
, O O 0.9981381893157959
distribution O O 0.9899870753288269
, O O 0.9987903237342834
and O O 0.9994074106216431
form O O 0.9720101356506348
of O O 0.9989483952522278
Pan B-protein B-protein 0.4827299118041992
proteins E-protein E-protein 0.9910987019538879
have O O 0.9997437596321106
not O O 0.9999222755432129
been O O 0.9999568462371826
clearly O O 0.9992581009864807
defined O O 0.9998071789741516
. O O 0.9999979734420776
Studies O O 0.9999032020568848
of O O 0.9999228715896606
cell B-cell_line B-cell_line 0.6912147998809814
lines E-cell_line E-cell_line 0.9636263251304626

physiologically O O 0.8704596161842346
relevant O O 0.985335111618042
stimulation O O 0.9966970682144165
, O O 0.9999864101409912
PHA S-protein S-protein 0.7191707491874695
stimulates O O 0.998781144618988
productive O O 0.9719422459602356
LAI O O 0.4049392342567444
replication O O 0.9282980561256409
in O O 0.9998695850372314
both O O 0.9984567165374756
naive B-cell_type B-cell_type 0.701666533946991
and I-cell_type I-cell_type 0.6948019862174988
memory I-cell_type I-cell_type 0.8762532472610474
T I-cell_type I-cell_type 0.974245548248291
cells E-cell_type E-cell_type 0.9560865759849548
. O O 0.9994730353355408

STAT3 S-protein S-protein 0.982320249080658
, O O 0.9892957806587219
STAT4 S-protein S-protein 0.9972454309463501
, O O 0.9866428375244141
STAT5a S-protein S-protein 0.9957261085510254
, O O 0.975936233997345
and O O 0.993713915348053
STAT5b S-protein S-protein 0.992470383644104
. O O 0.9987121820449829
IL-12 S-protein S-protein 0.9872209429740906
induced O O 0.9956433773040771
STAT4 S-protein S-protein 0.9729757905006409
and O O 0.9915339350700378
IL-2 S-protein S-protein 0.9826148748397827
and O O 0.9943678975105286
IL-15 S-protein S-protein 0.9739012718200684
induced O O 0.9931963682174683
STAT5 S-protein S-protein 0.8651920557022095
binding O O 0.9474462866783142
to O O 0.9993823766708374
the O O 0.9996892213821411
GAS B-DNA B-DNA 0.5115078091621399
elements E-DNA E-DNA 0.9940139651298523
. O O 0.999817430973053
Taken O O 0.9999496936798096
together O O 0.9999793767929077
, O O 0.9999935626983643
our O O 0.9985285997390747

the O O 0.9962015748023987

leading O O 0.9851440787315369
to O O 0.9996569156646729
gene O O 0.9460609555244446
transcription O O 0.9610770344734192
and O O 0.9984101057052612
translation O O 0.9802473783493042
in O O 0.9991983771324158
leukocytes S-cell_type S-cell_type 0.993809163570404
. O O 0.9998399019241333
Transcription B-protein B-protein 0.5332150459289551
factors E-protein E-protein 0.9973201155662537
, O O 0.998868465423584
such O O 0.9998947381973267

inhibitory O O 0.7760142087936401

Oct-binding B-protein B-protein 0.6697374582290649
factor I-protein I-protein 0.5815861821174622
1 E-protein E-protein 0.9851749539375305
( O O 0.9794079065322876
OBF-1 S-protein S-protein 0.9763385653495789
) O O 0.9699208736419678
, O O 0.9999399185180664
a O O 0.9999370574951172
novel O B-protein 0.8299534320831299
protein O E-protein 0.8551685214042664
that O O 0.9966183304786682
specifically O O 0.9999078512191772
associates O O 0.9998754262924194
with O O 0.9997850060462952
Oct-1 S-protein S-protein 0.9946521520614624
and O O 0.9971330165863037
Oct-2 S-protein S-protein 0.9934472441673279
. O O 0.9998660087585449
Biochemical O O 0.9844861030578613
studies O O 0.999509334564209
demonstrate O O 0.9999966621398926
that O O 0.9999686479568481
OBF-1 S-protein S-protein 0.9543770551681519
has O O 0.9996306896209717

limitation O O 0.9647376537322998
. O O 0.9998995065689087
Phytohemagglutinin S-protein O 0.40622156858444214
( O O 0.9690735936164856
PHA S-protein S-protein 0.6283531785011292
) O O 0.6904795169830322
-induced O O 0.9435998201370239
proliferation O O 0.9942080974578857
of O O 0.9999454021453857
peripheral B-cell_type B-cell_type 0.6436511874198914
blood I-cell_type I-cell_type 0.8901461362838745
T I-cell_type I-cell_type 0.9551702737808228
lymphocytes E-cell_type E-cell_type 0.9917677640914917
from O O 0.9996548891067505
the O O 0.9998443126678467
sensitive O O 0.9048992395401001
but O O 0.9945486187934875
not O O 0.9990731477737427
the O O 0.9998089671134949
resistant O O 0.9127923250198364
asthmatic O O 0.5970517992973328
patients O O 0.9657734632492065
was O O 0.999980092048645
significantly O O 0.9999586343765259
( O O 0.9999338388442993
p O O 0.9986114501953125
less O O 0.9996414184570312
than O O 0.9998844861984253
0.01 O O 0.9957873225212097
) O O 0.9993302822113037
inhibited O O 0.9996941089630127
by O O 0.9999880790710449
dexamethasone O O 0.8608702421188354
( O O 0.9989151954650879
10 O O 0.998110294342041
( O O 0.9996030926704407
-7 O O 0.9989579916000366
) O O 0.9988308548927307
mol/L O O 0.9761996865272522
) O O 0.9997919201850891
, O O 0.9999878406524658

is O O 0.9977206587791443
secondary O O 0.9986571073532104
to O O 0.9999918937683105
the O O 0.9998960494995117
phosphorylation O O 0.9397567510604858
and O O 0.99793541431427
subsequent O O 0.9974133372306824
degradation O O 0.9947328567504883
of O O 0.9999475479125977
the O O 0.9996808767318726
NF-kappaB B-protein B-protein 0.9605967402458191
inhibitory I-protein I-protein 0.7917676568031311
molecule E-protein E-protein 0.8623949289321899
IkappaBalpha S-protein S-protein 0.8511934876441956
. O O 0.9998283386230469
Tyrosine B-protein B-protein 0.6261981725692749
kinase E-protein E-protein 0.9536596536636353
-dependent O O 0.8321489095687866
, O O 0.9905946254730225
and O O 0.9983828067779541
not O O 0.9992201328277588
protein B-protein B-protein 0.59981769323349
kinase I-protein I-protein 0.7109408378601074
C E-protein E-protein 0.9948465824127197
-dependent O O 0.9880693554878235
, O O 0.9997792840003967
pathways O O 0.8894823789596558
mediate O O 0.9669585227966309
CD23 S-protein S-protein 0.9751831293106079
-triggered O O 0.9977462887763977
NF-kappaB S-protein S-protein 0.9900795221328735
activation O O 0.9947695136070251
but O O 0.99989914894104
do O O 0.9999685287475586
not O O 0.999885082244873

initiation I-DNA I-DNA 0.7427611947059631
site E-DNA E-DNA 0.8366028666496277
without O O 0.9997410178184509
a O O 0.9999376535415649
TATA B-DNA B-DNA 0.7801727056503296
box E-DNA E-DNA 0.9920127987861633
. O O 0.9998007416725159
Transient O O 0.9754791855812073
transfections O O 0.9781842827796936
of O O 0.9999053478240967
CAT B-DNA B-DNA 0.48249000310897827
reporter I-DNA I-DNA 0.5761253237724304
gene I-DNA I-DNA 0.7373819947242737
constructs E-DNA E-DNA 0.9931314587593079
containing O O 0.9991010427474976
various O O 0.9775846600532532
Fc B-DNA B-DNA 0.5900327563285828
gamma I-DNA I-DNA 0.4326140582561493
RIC I-DNA I-DNA 0.6631431579589844
promoter I-DNA I-DNA 0.4764661192893982
sequences E-DNA E-DNA 0.9944532513618469
into O O 0.9992682337760925
U937 B-cell_line B-cell_line 0.8133220076560974
cells E-cell_line E-cell_line 0.9970492720603943
revealed O O 0.9997699856758118
that O O 0.999998927116394
a O O 0.999850869178772
20-bp B-DNA B-DNA 0.6346636414527893
region E-DNA E-DNA 0.9470661282539368
surrounding O O 0.9966597557067871

OBJECTIVE O O 0.9483484029769897
: O O 0.9996912479400635
In O O 0.9997922778129578
vitro O O 0.9852684140205383
work O O 0.9947634935379028
has O O 0.9999681711196899
demonstrated O O 0.9999212026596069
that O O 0.9999845027923584
cinacalcet S-Chemical B-Chemical 0.9183692336082458
is O O 0.9950590133666992
a O O 0.9999933242797852
strong O O 0.9930958151817322
inhibitor O O 0.995541512966156
of O O 0.9998894929885864
cytochrome O O 0.5358815789222717
P450 O O 0.4322996139526367
isoenzyme O O 0.3923065960407257
( O O 0.9882777333259583
CYP O O 0.5473073124885559
) O O 0.9463761448860168
2D6 O O 0.700320303440094
. O O 0.9999324083328247

these O O 0.9994304776191711
studies O O 0.9999628067016602
demonstrate O O 0.9999973773956299
that O O 0.9999982118606567
the O O 0.9999339580535889
processing O O 0.9946192502975464
and O O 0.9991719722747803
inducible O O 0.9868344664573669
degradation O O 0.9942883253097534
of O O 0.999911904335022
p105 S-protein S-protein 0.903680145740509
are O O 0.9984825253486633
differentially O O 0.9968696236610413
regulated O O 0.9987726807594299
. O O 0.9999970197677612
Identification O O 0.9996337890625
of O O 0.9999703168869019
an O O 0.9999531507492065
inducible B-protein O 0.9218225479125977
regulator E-protein O 0.7547442317008972
of O O 0.9953201413154602
c-myb S-DNA S-DNA 0.9601784944534302
expression O O 0.9938109517097473
during O O 0.9999839067459106
T-cell S-cell_type O 0.6190719604492188
activation O O 0.9783118963241577
. O O 0.999950647354126
Resting B-cell_type B-cell_type 0.5894902944564819
T I-cell_type I-cell_type 0.7325690388679504
cells E-cell_type E-cell_type 0.9228081107139587
express O O 0.9974396228790283
very O O 0.9832223057746887
low O O 0.9904218912124634

These O O 0.999772846698761
results O O 0.9999309778213501
suggest O O 0.9999979734420776
that O O 0.9999895095825195
PGE1 S-Chemical B-Chemical 0.9142616987228394
may O O 0.9994174242019653
be O O 0.9999963045120239
preferable O O 0.999945878982544
to O O 0.9999849796295166
TMP S-Chemical B-Chemical 0.8888006210327148
for O O 0.996268630027771
hypotensive O O 0.7174330353736877
anaesthesia O O 0.8723073601722717
in O O 0.9889799356460571
spinal O O 0.8310413360595703
surgery O O 0.7005458474159241
because O O 0.9988786578178406
TMP S-Chemical B-Chemical 0.8762452006340027
decreased O O 0.9415173530578613
EBF O O 0.6220064163208008
. O O 0.9995593428611755

We O O 0.9994444251060486
recommend O O 0.9999909400939941
caution O O 0.973084032535553
in O O 0.9999037981033325
the O O 0.9998928308486938
use O O 0.9997692704200745
of O O 0.9999067783355713
lopinavir B-Chemical B-Chemical 0.9262431263923645
/ I-Chemical O 0.8314019441604614
ritonavir I-Chemical B-Chemical 0.4896586537361145
in O O 0.9992008805274963
the O O 0.9999686479568481
immediate O O 0.9758520722389221
neonatal O O 0.8276723027229309
period O O 0.9985901713371277
. O O 0.9999994039535522

the O O 0.9958475232124329
interfollicular O O 0.8819621205329895
areas O O 0.8957868814468384
. O O 0.9999958276748657
An O O 0.9999778270721436
occasional O O 0.9895414710044861
GC O O 0.5356864333152771
with O O 0.9982151985168457
an O O 0.9998610019683838
ill-defined O O 0.892375648021698
border O O 0.9301965236663818
was O O 0.9996380805969238
invariably O O 0.9999697208404541
surrounded O O 0.999934196472168
by O O 0.9999915361404419
a O O 0.9994837045669556
broad O O 0.7662512063980103
mantle O O 0.746283769607544
zone O O 0.6421831250190735
; O O 0.9997377991676331
those O O 0.9999874830245972
with O O 0.9999536275863647
indistinct O O 0.9345601201057434
mantle O O 0.7937765717506409
zones O O 0.7950353026390076
had O O 0.999903678894043

CONCLUSION O O 0.9972614049911499
: O O 0.999976634979248
In O O 0.9998396635055542
patients O O 0.9998206496238708
with O O 0.9999886751174927
risk O O 0.934219241142273
factors O O 0.8905543684959412
, O O 0.9998471736907959
e O O 0.9666032195091248
. O O 0.9990550875663757
g O O 0.9289854764938354
. O O 0.9997349381446838
regular O O 0.993977427482605
consumption O O 0.9972532391548157
of O O 0.9998904466629028
alcohol B-Chemical B-Chemical 0.9161754846572876
, O O 0.9946731925010681
liver B-Disease O 0.6486399173736572
failure I-Disease O 0.9668087363243103
is O O 0.9818315505981445
possible O O 0.9997523427009583
when O O 0.999996542930603
therapeutic O O 0.8747611045837402
doses O O 0.9819844365119934
are O O 0.9999185800552368
ingested O O 0.9984886646270752
. O O 0.9999988079071045

are O O 0.9985361099243164
discussed O O 0.9999747276306152
. O O 0.9999979734420776
Induction O O 0.9970274567604065
of O O 0.9998657703399658
IL-8 S-protein S-protein 0.9717985391616821
expression O O 0.9976492524147034
in O O 0.9998884201049805

a O O 0.9871195554733276
promoter O O 0.6921917796134949
when O O 0.9993894100189209
located O O 0.9998204112052917
between O O 0.9997703433036804
the O O 0.9999803304672241
two O O 0.9979223608970642
in O O 0.9998903274536133
a O O 0.9998419284820557
chromatin-integrated B-DNA B-DNA 0.5165274143218994
construct E-DNA E-DNA 0.8879481554031372
. O O 0.9995881915092468
We O O 0.9999740123748779
propose O O 0.999997615814209
that O O 0.9999947547912598
BEAD-1 S-DNA S-protein 0.6073901653289795
functions O O 0.9522201418876648
as O O 0.999995231628418
a O O 0.9999935626983643
boundary O O 0.9740964770317078
that O O 0.999881386756897
separates O O 0.9970928430557251

CNBr S-protein S-protein 0.8275387287139893
and O O 0.9983443021774292
three O O 0.9987926483154297
internal O O 0.9715328216552734
peptides O O 0.8676031827926636
were O O 0.9999114274978638
sequenced O O 0.9998835325241089
. O O 0.9999980926513672
A O O 0.999974250793457
comparison O O 0.9987485408782959
with O O 0.9999781847000122
known O O 0.9907628893852234
proteins O O 0.7245305180549622
in O O 0.9995573163032532
Genbank O O 0.4300317168235779
revealed O O 0.9995697140693665
that O O 0.9999973773956299
all O O 0.999904990196228
three O O 0.9973904490470886
S6 S-protein O 0.5739726424217224
peptides O O 0.39756929874420166
match O O 0.9997572302818298
the O O 0.9999942779541016
predicted O O 0.9810391664505005
sequence O O 0.9268879294395447
of O O 0.9997137188911438
TBP7 S-protein S-protein 0.7326666116714478
, O O 0.9962008595466614
Tat-binding B-protein B-protein 0.4755991995334625
protein I-protein I-protein 0.49468109011650085
7 E-protein E-protein 0.9943147301673889
. O O 0.99893718957901
Based O O 0.9995793700218201
on O O 0.9999182224273682
peptide O O 0.8061253428459167
matches O O 0.9272490739822388
covering O O 0.9999369382858276
more O O 0.9993784427642822

The O O 0.9994766116142273
role O O 0.999058187007904
of O O 0.9999264478683472
nicotine S-Chemical B-Chemical 0.924435019493103
in O O 0.9983308911323547
smoking O B-Chemical 0.919601559638977
- O O 0.9246537089347839
related O O 0.9971672892570496
cardiovascular O B-Disease 0.6554532051086426
disease O I-Disease 0.9820366501808167
. O O 0.9973614811897278

Seizures B-Disease B-Disease 0.9817766547203064
induced O O 0.9262162446975708
by O O 0.9992499947547913
the O O 0.9970506429672241
cocaine B-Chemical B-Chemical 0.9142752289772034
metabolite O O 0.8449983596801758
benzoylecgonine B-Chemical B-Chemical 0.91492760181427
in O O 0.9985402822494507
rats O O 0.991631805896759
. O O 0.9999977350234985

promoters E-DNA E-DNA 0.7362157106399536

for O O 0.997383177280426
the O O 0.9999727010726929

shown O O 0.9924830794334412
to O O 0.9999426603317261
express O O 0.9999662637710571
the O O 0.9998830556869507
chimeric B-protein B-protein 0.48543062806129456
receptor E-protein E-protein 0.9729572534561157
on O O 0.9988908171653748
the O O 0.9998551607131958
cell O O 0.8775968551635742
surface O O 0.928693413734436
and O O 0.9983024597167969

after O O 0.9988106489181519
multi-agent O O 0.9689934253692627
therapy O O 0.9986880421638489
, O O 0.9999979734420776
suggesting O O 0.9999672174453735
overlapping O O 0.9595309495925903
mechanisms O O 0.997479259967804
of O O 0.9999485015869141
action O O 0.999261200428009
, O O 0.9999938011169434
and O O 0.9999734163284302
focusing O O 0.9998335838317871
attention O O 0.9994953870773315
on O O 0.9999953508377075
the O O 0.9999624490737915
determinants O O 0.9952621459960938
of O O 0.9998756647109985
the O O 0.9999456405639648
threshold O O 0.99578458070755

is O O 0.9896031022071838
also O O 0.9997501969337463
mediated O O 0.9998328685760498
by O O 0.9999896287918091
sequences O O 0.9425268769264221
in O O 0.999984622001648
a O O 0.9999115467071533
region B-DNA B-DNA 0.7613332271575928
II E-DNA E-DNA 0.9642849564552307
( O O 0.994659960269928
bp O O 0.5511021614074707
-88 O O 0.6226015686988831
to O O 0.9266551733016968
- O O 0.9489671587944031
59 O O 0.523781418800354
) O O 0.9344974756240845
, O O 0.9992098808288574
which O O 0.9998058676719666
lies O O 0.9992871880531311
10 B-DNA B-DNA 0.8149034380912781
bp I-DNA I-DNA 0.378020316362381
upstream E-DNA E-DNA 0.9633185863494873
from O O 0.9994699358940125
the O O 0.9997026324272156
PU.1-binding B-DNA B-DNA 0.7263906002044678
site E-DNA E-DNA 0.9872998595237732
. O O 0.9996873140335083
When O O 0.9999866485595703
analyzed O O 0.9943671822547913
by O O 0.9997424483299255

opposite O O 0.9269807934761047
phenotypes O O 0.38148564100265503
were O O 0.9996945858001709
found O O 0.9999181032180786
, O O 0.9999679327011108
which O O 0.9999347925186157
depended O O 0.9999629259109497
on O O 0.999971866607666
the O O 0.999954104423523
intracellular O O 0.9176852703094482
localization O O 0.9525777101516724
of O O 0.9980473518371582
Nef S-protein S-protein 0.9943564534187317
. O O 0.9992716908454895
Expressed O O 0.9994070529937744
in O O 0.9998663663864136
the O O 0.9998792409896851
cytoplasm O O 0.7664823532104492
or O O 0.9909226298332214
on O O 0.9993243217468262
the O O 0.9998396635055542
cell O O 0.897280216217041
surface O O 0.9501752853393555
, O O 0.9998775720596313
the O O 0.9999667406082153
chimera S-protein O 0.3537173569202423
inhibited O O 0.9461262822151184
or O O 0.9942575693130493
activated O O 0.9926511645317078
early O O 0.8688389658927917
signaling O O 0.8644424080848694
events O O 0.98492032289505

) O O 0.7159895300865173
has O O 0.9995658993721008
been O O 0.9999749660491943
shown O O 0.9999935626983643
to O O 0.9999895095825195
down-regulate O O 0.9996362924575806
the O O 0.9997972846031189
transcription B-protein B-protein 0.6325063705444336
factors E-protein E-protein 0.9781519770622253
NF-kappa B-protein B-protein 0.8352177739143372
B E-protein E-protein 0.9946304559707642
and O O 0.9911360740661621
AP-1 S-protein S-protein 0.9884299039840698
in O O 0.9988238215446472
vitro O O 0.9916459918022156
. O O 0.9999814033508301
To O O 0.9999924898147583
define O O 0.9999469518661499
the O O 0.9999802112579346
mechanism O O 0.9994508624076843
of O O 0.999981164932251
action O O 0.9987770915031433
of O O 0.9999399185180664
the O O 0.9998030066490173
Nef S-protein B-protein 0.7605472207069397
protein O E-protein 0.9724677801132202
, O O 0.9987149238586426
the O O 0.9999865293502808
signal O O 0.8871482610702515
transduction O O 0.8676170110702515
pathways O O 0.993901252746582
which O O 0.9999819993972778
may O O 0.9999897480010986
be O O 0.9999830722808838
affected O O 0.9991312623023987
in O O 0.9997766613960266
T B-cell_type B-cell_type 0.9202919006347656
cells E-cell_type E-cell_type 0.9952523708343506
by O O 0.9998058676719666
constitutive O O 0.9569827318191528
expression O O 0.9952168464660645
of O O 0.999843955039978
the O O 0.9997931122779846

enhancer O E-DNA 0.7763194441795349

Disulfiram B-Chemical B-Chemical 0.9066249132156372
- O O 0.8331555128097534
like O O 0.9269098043441772
syndrome O O 0.5003944635391235
after O O 0.9997780919075012
hydrogen B-Chemical B-Chemical 0.9045557975769043
cyanamide I-Chemical I-Chemical 0.9300073981285095
professional O O 0.5324378609657288
skin O O 0.6134950518608093
exposure O O 0.5413183569908142
: O O 0.9996906518936157
two O O 0.999946117401123
case O O 0.9926128387451172
reports O O 0.9995631575584412
in O O 0.9999940395355225
France O O 0.9595161080360413
. O O 0.999997615814209

In O O 0.9993478655815125
individuals O O 0.9987214207649231
with O O 0.9999899864196777
preexisting O O 0.8953378200531006
, O O 0.9926510453224182
high O O 0.9934982061386108
- O O 0.9980925917625427
grade O O 0.9966429471969604
coronary O O 0.8637028932571411
arterial O O 0.7087514400482178
narrowing O O 0.5912685394287109
, O O 0.9992751479148865
acute B-Disease O 0.8311373591423035
myocardial I-Disease O 0.6999073028564453
infarction I-Disease O 0.9568734169006348
may O O 0.9931801557540894
result O O 0.999914288520813
from O O 0.99998939037323
an O O 0.9998095631599426
increase O O 0.91026371717453
in O O 0.958943784236908
myocardial O O 0.8790112137794495
oxygen B-Chemical B-Chemical 0.9098130464553833
demand O O 0.9823306798934937
associated O O 0.9999045133590698
with O O 0.9999874830245972
cocaine B-Chemical B-Chemical 0.9175085425376892
- O O 0.9747728705406189
induced O O 0.997262716293335
increase O O 0.7544591426849365
in O O 0.8098809719085693
rate O O 0.9480383992195129
- O O 0.9913076758384705
pressure O O 0.9093591570854187
product O O 0.9720212817192078
. O O 0.9999977350234985

Regional O O 0.9625340104103088
localization O O 0.9343962669372559
of O O 0.9986433386802673
the O O 0.9997040629386902
antagonism O O 0.5073667764663696
of O O 0.9759248495101929
amphetamine B-Chemical B-Chemical 0.9314458966255188
- O O 0.9334254860877991
induced O O 0.9991180300712585
hyperactivity B-Disease B-Disease 0.9812769889831543
by O O 0.9949018955230713
intracerebral O O 0.7799372673034668
calcitonin B-Chemical B-Chemical 0.9128413200378418
injections O O 0.9355781674385071
. O O 0.9999885559082031

for O O 0.9988815188407898
5 O O 0.9983452558517456
hours O O 0.999943733215332
before O O 0.9999938011169434
LPS O O 0.9146324992179871
activation O O 0.9980998635292053
, O O 0.9999945163726807
both O O 0.9999423027038574
the O O 0.99928879737854
c-fos O S-DNA 0.8118892908096313
and O O 0.9661551117897034
the O O 0.9978067278862
c-jun O B-RNA 0.61919766664505
mRNA O E-RNA 0.8657492995262146
expression O O 0.9719045162200928
was O O 0.9999649524688721
decreased O O 0.9997876286506653
. O O 0.9999973773956299
The O O 0.9999915361404419
inhibition O O 0.9952996969223022
of O O 0.9997909665107727
c-fos S-DNA S-DNA 0.7023435831069946
and O O 0.9087492227554321
c-jun O S-DNA 0.9291338920593262
expression O O 0.994060218334198
by O O 0.9999891519546509
IL-4 S-protein S-protein 0.9874027967453003
in O O 0.999534010887146
LPS-treated B-cell_type B-cell_line 0.48083633184432983
cells E-cell_type E-cell_line 0.7131193280220032
was O O 0.9997268319129944
shown O O 0.9999947547912598
to O O 0.9999368190765381

The O O 0.9995434880256653
duration O O 0.9889348149299622
of O O 0.9992050528526306
apnea O B-Disease 0.9771421551704407
was O O 0.983796238899231
compared O O 0.9999740123748779
with O O 0.9999982118606567
published O O 0.997718095779419
data O O 0.9993213415145874
on O O 0.9999891519546509
normal O O 0.9153354167938232
subjects O O 0.9943844079971313
. O O 0.9999983310699463

RESULTS O O 0.9972230195999146
: O O 0.9999406337738037
Immunofluorescence O O 0.4443477392196655
staining O O 0.8914120197296143
with O O 0.999805748462677
the O O 0.9998713731765747
MRP2 O O 0.5476815104484558
antibody O O 0.7807024717330933
was O O 0.9999755620956421
found O O 0.9999936819076538
to O O 0.9999806880950928
label O O 0.9999548196792603
a O O 0.9998400211334229
high O O 0.9918348789215088
number O O 0.9985175728797913
of O O 0.9999233484268188
microvessels O O 0.6524978280067444
throughout O O 0.9990944862365723
the O O 0.9991704225540161
brain O O 0.9673329591751099
in O O 0.999984622001648
normal O O 0.9421473741531372
Wistar O O 0.777958333492279
rats O O 0.991685688495636
, O O 0.9999918937683105
whereas O O 0.9999979734420776
such O O 0.9999361038208008
labeling O O 0.9030008316040039
was O O 0.9998952150344849
absent O O 0.9996627569198608
in O O 0.9999738931655884
TR O O 0.6266217827796936
( O O 0.930841326713562
- O O 0.9645572900772095
) O O 0.9905982613563538
rats O O 0.9970384836196899
. O O 0.9999982118606567

, O O 0.9051101803779602
differentiated B-cell_type O 0.5243341326713562
DC E-cell_type S-cell_type 0.41974738240242004
, O O 0.9743714928627014
and O O 0.9955893754959106
monocyte-derived B-cell_line B-cell_type 0.401582807302475
DC E-cell_line E-cell_type 0.7111364006996155
. O O 0.9995168447494507
Immunohistochemical O O 0.9447463750839233
staining O O 0.9838922023773193
demonstrated O O 0.9997419714927673
RelB S-protein S-protein 0.9831812977790833
within O O 0.9997767806053162
the O O 0.9999721050262451
differentiated B-cell_type O 0.8502832651138306
lymph I-cell_type O 0.5050356984138489
node I-cell_type O 0.32350990176200867
interdigitating I-cell_type O 0.381690114736557
DC E-cell_type S-cell_type 0.4287721514701843
and O O 0.9899887442588806
follicular B-cell_type B-cell_type 0.5689393281936646
DC E-cell_type E-cell_type 0.8617368936538696
, O O 0.9880015254020691
but O O 0.9987364411354065
not O O 0.9984355568885803
undifferentiated B-cell_type O 0.6001801490783691
DC E-cell_type S-cell_type 0.569141149520874
in O O 0.9990488886833191
normal O O 0.7881510853767395
skin O O 0.7823175191879272
. O O 0.9997363686561584
Active O O 0.8959765434265137

previously O O 0.9830159544944763
established O O 0.9989006519317627
a O O 0.9998676776885986
critical O O 0.9966939687728882
role O O 0.9993731379508972
for O O 0.9999951124191284
the O O 0.9999557733535767
transcription B-protein B-protein 0.5599555373191833
factor E-protein E-protein 0.8996273875236511
GATA-3 S-protein S-protein 0.5196484327316284
in O O 0.9996838569641113
IL-5 B-DNA B-DNA 0.559126079082489
promoter E-DNA E-DNA 0.9608525633811951
activation O O 0.9630122184753418

a O O 0.9962116479873657
CD2 S-protein S-protein 0.9714376330375671
-based O O 0.9866297245025635
signaling O O 0.9747971296310425
pathway O O 0.9982954859733582
which O O 0.9999926090240479
, O O 0.999954104423523
in O O 0.9999761581420898
contrast O O 0.9998050332069397
to O O 0.9999817609786987
that O O 0.9999511241912842
of O O 0.9999080896377563
the O O 0.999805748462677
T B-protein B-protein 0.37722674012184143
cell I-protein I-protein 0.6127554774284363
receptor E-protein E-protein 0.834479033946991
, O O 0.9644350409507751

Infusion O O 0.7736157774925232
regimens O O 0.864152729511261
were O O 0.9999686479568481
designed O O 0.9999912977218628
that O O 0.999996542930603
rapidly O O 0.9961463212966919
achieved O O 0.9990936517715454
and O O 0.9997212290763855
maintained O O 0.9987878203392029
target O O 0.9874976873397827
- O O 0.9994320273399353
free O O 0.9982579350471497
concentrations O O 0.9971796274185181
of O O 0.9999430179595947
these O O 0.999886155128479
drugs O O 0.9954699277877808
in O O 0.9999561309814453
plasma O O 0.9035106897354126
and O O 0.996547520160675
data O O 0.9855506420135498
on O O 0.9999619722366333
the O O 0.999890923500061
relationship O O 0.998110294342041
between O O 0.9999197721481323
free O O 0.9810904860496521
concentration O O 0.990196943283081
and O O 0.9999468326568604
changes O O 0.9821056127548218
in O O 0.9985760450363159
MAPD O O 0.4664708077907562
were O O 0.9986132383346558
obtained O O 0.9999653100967407
for O O 0.9999940395355225
these O O 0.999942421913147
compounds O O 0.9932730197906494
. O O 0.9999979734420776

signalling O O 0.9523802399635315
. O O 0.9999369382858276
Gender O O 0.9694573879241943
and O O 0.9936925172805786
vascular O O 0.9650248885154724
reactivity O O 0.9907224178314209
. O O 0.9999961853027344
Estrogen B-protein B-protein 0.6034058928489685
receptors E-protein E-protein 0.9892367720603943
are O O 0.9996254444122314
found O O 0.9999328851699829
on O O 0.999809205532074
vascular B-cell_type B-cell_type 0.4585950970649719
endothelial I-cell_type I-cell_type 0.5246133208274841
and I-cell_type I-cell_type 0.56971675157547
smooth I-cell_type I-cell_type 0.5048842430114746
muscle I-cell_type I-cell_type 0.6094452738761902
cells E-cell_type E-cell_type 0.9111824631690979
; O O 0.999468982219696
their O O 0.9999809265136719
expression O O 0.9997450709342957
is O O 0.9999867677688599

) O O 0.7832449078559875
are O O 0.9999511241912842
a O O 0.9999979734420776
good O O 0.9992052912712097
model O O 0.9995657801628113
for O O 0.9999955892562866
studies O O 0.9998548030853271
of O O 0.9999823570251465
GR S-protein S-protein 0.98145592212677
in O O 0.9997584223747253
humans O O 0.965339720249176
. O O 0.9999483823776245
Glucocorticoids O O 0.9320849776268005
are O O 0.9999009370803833
important O O 0.9997909665107727
for O O 0.999972939491272
maintaining O O 0.9956177473068237
cellular O O 0.9126723408699036
and O O 0.9806650876998901
humoral O O 0.9323444366455078
homeostasis O O 0.9057507514953613
and O O 0.9997581839561462
are O O 0.9999959468841553
key O O 0.9984036087989807
mediators O O 0.9952137470245361
of O O 0.9999666213989258
neuroendocrine-immune O O 0.9198122620582581
regulatory O O 0.9306306838989258
interactions O O 0.993181049823761
. O O 0.9999985694885254
The O O 0.9999982118606567
increase O O 0.998943030834198
of O O 0.999909520149231
cortisol O O 0.7644352912902832

because O O 0.9983989596366882
heterozygosity O O 0.9614537358283997
at O O 0.999962568283081
distal B-DNA O 0.8863270878791809
markers E-DNA O 0.7133432030677795
was O O 0.9999284744262695
retained O O 0.9997896552085876
and O O 0.999993085861206
because O O 0.9999969005584717
quantitative O O 0.966742217540741
Southern O O 0.8638529181480408
blotting O O 0.9444201588630676
demonstrated O O 0.9998708963394165

Passive O O 0.9191239476203918
avoidance O O 0.8322963118553162
paradigm O O 0.7972771525382996
and O O 0.999758780002594
elevated O O 0.9408926963806152
plus O O 0.9698392152786255
maze O O 0.942907452583313
test O O 0.9989953637123108
were O O 0.9999949932098389
used O O 0.9999873638153076
to O O 0.9999936819076538
assess O O 0.9998530149459839
cognitive O O 0.878380298614502
function O O 0.5075728893280029
. O O 0.9999288320541382

factors E-protein E-protein 0.9869518280029297
: O O 0.9992107152938843
a O O 0.9999821186065674
novel O O 0.9649712443351746
experimental O O 0.9512491822242737
model O O 0.9833366274833679
for O O 0.9999316930770874
hemopoietic O O 0.737707793712616
lineage O O 0.4527188241481781
restriction O O 0.9852188229560852
. O O 0.999991774559021
The O O 0.9999591112136841
human B-cell_line B-cell_line 0.4863150715827942
erythroleukemia I-cell_line I-cell_line 0.8057361245155334
cell I-cell_line I-cell_line 0.9291278123855591
line I-cell_line I-cell_line 0.8923139572143555
K562 E-cell_line E-cell_line 0.8203431963920593
can O O 0.9970126152038574
be O O 0.9999258518218994
induced O O 0.9987025260925293

spliced O B-RNA 0.7558113932609558
transcripts O E-RNA 0.9297860860824585
. O O 0.9995567202568054
Whether O O 0.9999939203262329
the O O 0.9999282360076904
detected O O 0.9388478398323059
transcripts O O 0.4742986857891083
are O O 0.9996387958526611
translated O O 0.9992451667785645
into O O 0.9999573230743408
functional O B-protein 0.8686341643333435
receptor O I-protein 0.49334368109703064
proteins O E-protein 0.9721121788024902
remains O O 0.999477207660675
to O O 0.9999839067459106
be O O 0.99997878074646
determined O O 0.9999873638153076
. O O 0.999997615814209
In O O 0.9994049072265625
vitro O O 0.9923000335693359
stimulation O O 0.998221218585968
did O O 0.9999953508377075
not O O 0.9999858140945435
affect O O 0.9999357461929321
ER B-RNA B-RNA 0.7253966927528381
mRNA E-RNA E-RNA 0.988940417766571
expression O O 0.9936072826385498
. O O 0.9999982118606567
The O O 0.9999959468841553
presence O O 0.999281108379364
of O O 0.999963641166687
variants O O 0.9612011313438416
did O O 0.9999568462371826
not O O 0.9999589920043945
correlate O O 0.9997872710227966

protein E-protein E-protein 0.9615486264228821
. O O 0.9987165927886963
Further O O 0.9993751645088196
, O O 0.9999089241027832
Tax1 S-protein S-protein 0.9915695786476135
coimmunoprecipitated O O 0.9933441877365112
with O O 0.9999303817749023
NF-Y S-protein S-protein 0.9720209836959839
from O O 0.9996730089187622
nuclear O O 0.924913763999939
extracts O O 0.9751136302947998
of O O 0.9996716976165771
HTLV-1-transformed B-cell_type B-cell_line 0.602820873260498
cells E-cell_type E-cell_line 0.7656394839286804
, O O 0.99796462059021
providing O O 0.9999760389328003
evidence O O 0.9999325275421143
for O O 0.9999954700469971
in O O 0.9998028874397278
vivo O O 0.9867059588432312
interaction O O 0.9985846281051636
of O O 0.9998884201049805
Tax1 S-protein S-protein 0.9910888671875
and O O 0.9959367513656616
NF-YB S-protein S-protein 0.9895528554916382
. O O 0.9998645782470703
We O O 0.9999698400497437
further O O 0.9999825954437256
demonstrate O O 0.9999878406524658
that O O 0.9999690055847168
Tax1 S-protein S-protein 0.9949548840522766
specifically O O 0.9995224475860596
activated O O 0.9998971223831177
the O O 0.999933123588562
NF-Y-responsive B-DNA B-DNA 0.6440690755844116
DQbeta I-DNA I-DNA 0.6801557540893555
promoter E-DNA E-DNA 0.960084855556488

accumulation O O 0.9886471629142761
of O O 0.9999202489852905
its O O 0.9996147155761719
mRNA S-RNA S-RNA 0.9862029552459717
as O O 0.9963787198066711
well O O 0.9992069602012634
as O O 0.9999923706054688
several O O 0.9998748302459717
other O O 0.9998190999031067
hallmarks O O 0.9926756024360657
of O O 0.9998121857643127
T-lymphocyte S-cell_type O 0.3383687138557434
activation O O 0.8643829822540283
such O O 0.998358428478241

receptor E-protein E-protein 0.971015989780426
( O O 0.9826840758323669
EpoR S-protein S-protein 0.9546663165092468
) O O 0.983728289604187
by O O 0.9999812841415405
the O O 0.9999784231185913
spleen B-protein O 0.6802355051040649
focus I-protein O 0.7495154738426208
forming I-protein O 0.9633639454841614
virus I-protein O 0.9024143218994141

paralleling O O 0.933222234249115
differentiation O O 0.9930170774459839
. O O 0.9999934434890747
The O O 0.9999902248382568
generation O O 0.9965766072273254
of O O 0.9998335838317871
AP-1 B-protein B-protein 0.6954282522201538
complexes E-protein E-protein 0.9925726652145386
, O O 0.9986740350723267
as O O 0.9999845027923584
measured O O 0.9996964931488037
by O O 0.9999815225601196
DNA O O 0.9192408919334412
binding O O 0.8872689604759216
activity O O 0.9909377098083496
, O O 0.9999464750289917
closely O O 0.9993274211883545
parallels O O 0.9993964433670044
morphological O O 0.9779987335205078
differentiation O O 0.9973167777061462
. O O 0.9999984502792358
Furthermore O O 0.9999679327011108
, O O 0.9999947547912598
the O O 0.9999845027923584
ability O O 0.9998981952667236
of O O 0.9999843835830688
these O O 0.9999630451202393
complexes O O 0.9323620796203613

Administration O O 0.9970701932907104
of O O 0.9998389482498169
salvianolic B-Chemical B-Chemical 0.9240649342536926
acid I-Chemical I-Chemical 0.9430556297302246
A E-Chemical I-Chemical 0.9328867197036743
for O O 0.9889340996742249
a O O 0.9999518394470215
period O O 0.9999839067459106
of O O 0.999976396560669
8 O O 0.9993651509284973
days O O 0.9998929500579834
significantly O O 0.9997310042381287
attenuated O O 0.873502790927887
isoproterenol S-Chemical B-Chemical 0.9292783737182617
- O O 0.9772549271583557
induced O O 0.9993669390678406
cardiac O B-Disease 0.5326676964759827
dysfunction O I-Disease 0.9898548126220703
and O O 0.9222758412361145
myocardial O B-Disease 0.6051185727119446
injury O I-Disease 0.9829441905021667
and O O 0.958816409111023
improved O O 0.9863873720169067
mitochondrial O O 0.8681800365447998
respiratory O O 0.7276678681373596
function O O 0.7817942500114441
. O O 0.9997193217277527

Norepinephrine S-Chemical B-Chemical 0.9030469655990601
signaling O O 0.9202987551689148
through O O 0.9998311996459961
beta O O 0.6643306016921997
- O O 0.8547465205192566
adrenergic O O 0.4695131778717041
receptors O O 0.837462306022644
is O O 0.9999645948410034
critical O O 0.9996989965438843
for O O 0.9999831914901733
expression O O 0.9783385396003723
of O O 0.9995895028114319
cocaine S-Chemical B-Chemical 0.9142664074897766
- O O 0.9742999076843262
induced O O 0.9985890984535217
anxiety O B-Disease 0.9585961699485779
. O O 0.9979408383369446

Reversibility O O 0.7964271903038025
of O O 0.9943705201148987
captopril B-Chemical B-Chemical 0.9270493388175964
- O O 0.9663021564483643
induced O O 0.9992101192474365
renal B-Disease B-Disease 0.5321815013885498
insufficiency I-Disease I-Disease 0.9804306626319885
after O O 0.9899281859397888
prolonged O O 0.8974663615226746
use O O 0.9914581179618835
in O O 0.9999871253967285
an O O 0.9999432563781738
unusual O O 0.9449970126152039
case O O 0.9576504230499268
of O O 0.9995723366737366
renovascular B-Disease B-Disease 0.5647480487823486
hypertension I-Disease I-Disease 0.8239902257919312
. O O 0.9981516003608704

is O O 0.9912446141242981
polymorphic O O 0.8837844729423523
. O O 0.9995719790458679
Haplotypes O O 0.40598684549331665
containing O O 0.9979761242866516
HLA B-DNA B-protein 0.2706778645515442
DQA1*0501 E-DNA E-protein 0.7716404795646667
, O O 0.9736060500144958
but O O 0.9995349645614624
not O O 0.9997678399085999
HLA B-DNA B-protein 0.32517310976982117
DQA1*0201 E-DNA E-protein 0.8581910133361816
, O O 0.9923875331878662
together O O 0.9999880790710449
with O O 0.9999696016311646
HLA B-DNA B-protein 0.5622080564498901
DQB1*0201 E-DNA E-protein 0.813389241695404
are O O 0.9985688924789429
associated O O 0.9999810457229614
with O O 0.9999973773956299
Grave O O 0.9532310962677002
's O O 0.9864975810050964
disease O O 0.9653887152671814
and O O 0.999961256980896
celiac O O 0.8093419075012207

cytoplasm O O 0.6707157492637634

regulation O O 0.9772768020629883

only O O 0.9935061931610107
weakly O O 0.9873067140579224
active O O 0.9879926443099976
in O O 0.9997146725654602
one O O 0.9967971444129944
B B-cell_line B-cell_line 0.7067669630050659
clone E-cell_line E-cell_line 0.8479973077774048
and O O 0.991657555103302
not O O 0.9991111159324646
at O O 0.9999845027923584
all O O 0.9998290538787842

, O O 0.9940127730369568
we O O 0.9999744892120361
evaluated O O 0.9998226761817932
expression O O 0.9974822402000427
of O O 0.9999175071716309
protein B-protein B-protein 0.5074051022529602
kinase I-protein I-protein 0.7713652849197388
C I-protein I-protein 0.9640635251998901
( I-protein I-protein 0.8677568435668945
PKC I-protein I-protein 0.9559928774833679
) I-protein I-protein 0.7938469648361206
isoforms E-protein E-protein 0.9286881685256958
. O O 0.9998095631599426
We O O 0.9999887943267822
found O O 0.9999958276748657
an O O 0.9999920129776001
increase O O 0.9985337257385254
in O O 0.9998456239700317
Ca2+-dependent B-protein B-protein 0.5696518421173096
PKC I-protein I-protein 0.46321234107017517
isoforms E-protein E-protein 0.935863196849823
in O O 0.9997207522392273
monocytes O S-cell_type 0.9037540555000305
compared O O 0.9941376447677612

and I-cell_type O 0.9528379440307617
type I-cell_type B-cell_line 0.7094497680664062
I I-cell_type I-cell_line 0.4359169006347656
human I-cell_type I-cell_line 0.5454273819923401
T-cell I-cell_type I-cell_line 0.8254216909408569
leukemia I-cell_type I-cell_line 0.9236249327659607
virus-infected I-cell_type I-cell_line 0.9351699352264404
human I-cell_type I-cell_line 0.9631834030151367
T I-cell_type I-cell_line 0.9757862687110901
cells E-cell_type E-cell_line 0.9616575241088867
. O O 0.999880313873291
The O O 0.9999960660934448
tax O B-protein 0.3334256410598755
gene O I-protein 0.49564844369888306
product O E-protein 0.9071170091629028
of O O 0.9963710308074951
the O O 0.9999347925186157
type O O 0.7809308767318726
I O O 0.6783815026283264
human O O 0.6087629199028015
T-cell O O 0.4892861843109131
leukemia O O 0.4449293315410614
virus O O 0.44023171067237854
( O O 0.931580662727356
HTLV-I O O 0.4881134331226349
) O O 0.9018861651420593

TES1 S-protein S-protein 0.4427105188369751

B I-DNA I-DNA 0.5710179805755615
promoter E-DNA E-DNA 0.9798319935798645
demonstrated O O 0.9989176988601685
that O O 0.999996542930603
both O O 0.9997429251670837
sites O O 0.9935065507888794
participate O O 0.9999873638153076
in O O 0.9999749660491943
dexamethasone-mediated O O 0.9508638978004456
inhibition O O 0.9912420511245728
of O O 0.9999210834503174
the O O 0.9998557567596436
granzyme B-DNA B-DNA 0.5413104891777039
B I-DNA I-DNA 0.46928346157073975
promoter E-DNA E-DNA 0.9435413479804993
activity O O 0.9747812747955322
. O O 0.9999723434448242
Electromobility O O 0.8945541977882385
shift O O 0.9795066118240356
assay O O 0.9917889833450317

Chronic O O 0.8994854092597961
carbamazepine S-Chemical B-Chemical 0.9243865013122559
treatment O O 0.9848125576972961
in O O 0.9999641180038452
the O O 0.9997425675392151
rat O O 0.9653321504592896
: O O 0.9995999932289124
efficacy O O 0.9386463165283203
, O O 0.9990561604499817
toxicity O B-Disease 0.9516475200653076
, O O 0.9487531781196594
and O O 0.9982498288154602
effect O O 0.9835244417190552
on O O 0.9997417330741882
plasma O O 0.7386235594749451
and O O 0.9797617197036743
tissue O O 0.9341358542442322
folate S-Chemical B-Chemical 0.934455394744873
concentrations O O 0.8350840210914612
. O O 0.9999785423278809

It O O 0.9983153343200684
is O O 0.9999945163726807
necessary O O 0.9999830722808838
that O O 0.9999973773956299
both O O 0.9997996687889099
oncologists O O 0.995147168636322
and O O 0.9996711015701294
neurologists O O 0.9941799640655518
be O O 0.9999680519104004
fully O O 0.9996949434280396
aware O O 0.9999874830245972
of O O 0.9999769926071167
this O O 0.9999521970748901
unusual O O 0.8931460380554199
complication O O 0.7302478551864624
. O O 0.9999852180480957

promoter E-DNA E-DNA 0.9297749400138855
after O O 0.9981637597084045
proteolytically O O 0.8614085912704468
activated O O 0.9328675270080566
receptor-1 O O 0.40344691276550293
activation O O 0.986248791217804
. O O 0.99997878074646
Differential O O 0.9667928218841553
inhibition O O 0.9906327724456787
of O O 0.9995195865631104
Smad6 S-protein S-protein 0.9511070251464844
and O O 0.989734411239624
Smad7 S-protein S-protein 0.9551779627799988
on O O 0.9973090887069702

Controls O O 0.8345115780830383
were O O 0.9993610978126526
age O O 0.9983193278312683
- O O 0.9997716546058655
and O O 0.9998642206192017
sex O O 0.8143078684806824
- O O 0.9941237568855286
matched O O 0.9999204874038696
non O O 0.9822390079498291
- O O 0.9894580841064453
PD O B-Disease 0.9484964609146118
patients O O 0.8948182463645935
referred O O 0.9999809265136719
to O O 0.9999932050704956
the O O 0.9999687671661377
cardiology O O 0.7889091372489929
department O O 0.9868667125701904
. O O 0.9999991655349731

motifs O E-DNA 0.5168973803520203
that O O 0.9989509582519531
contribute O O 0.999991774559021
to O O 0.9999921321868896
this O O 0.9999383687973022
antiapoptotic O O 0.9279511570930481
effect O O 0.9987244009971619
, O O 0.999996542930603
we O O 0.9999662637710571
constructed O O 0.9997527003288269
a O O 0.9999469518661499
panel O O 0.992672324180603
of O O 0.9998056292533875
E2A-HLF B-protein B-protein 0.31792235374450684
mutants E-protein E-protein 0.7642989158630371
and O O 0.997329592704773
programmed O O 0.998812198638916
their O O 0.9999220371246338
expression O O 0.9962486624717712
in O O 0.9999595880508423
IL-3-dependent B-cell_line B-cell_line 0.7577977180480957
murine I-cell_line I-cell_line 0.8166264295578003
pro-B I-cell_line I-cell_line 0.8722304105758667
cells E-cell_line E-cell_line 0.9127832651138306
( O O 0.9930439591407776
FL5.12 B-cell_line B-cell_line 0.5306944251060486
line E-cell_line E-cell_line 0.9801604151725769
) O O 0.962784469127655
, O O 0.9997641444206238
using O O 0.9999419450759888
a O O 0.9997320771217346
zinc-inducible O B-DNA 0.31970569491386414
vector O E-DNA 0.8195061683654785
. O O 0.9994068145751953
Neither O O 0.9999841451644897
the O O 0.9999226331710815
E12 S-protein S-protein 0.45140358805656433
nor O O 0.9139444231987
the O O 0.9904389381408691
E47 S-protein B-protein 0.33866119384765625
product O E-protein 0.8567861318588257
of O O 0.9821072220802307
the O O 0.9995666146278381
E2A B-DNA B-DNA 0.39171040058135986
gene E-DNA E-DNA 0.9779613018035889
nor O O 0.9925343990325928
the O O 0.9999270439147949
wild-type B-protein B-protein 0.5119670629501343
HLF I-protein I-protein 0.5392948389053345
protein E-protein E-protein 0.9693148732185364
was O O 0.9994627833366394

in O O 0.9956735968589783
T B-cell_type B-cell_type 0.706932544708252
effector I-cell_type I-cell_type 0.7722212672233582
cells E-cell_type E-cell_type 0.9124872088432312
. O O 0.9997873902320862
The O O 0.999995231628418
relative O O 0.9762411713600159
low O O 0.9805132746696472
binding O O 0.9565770626068115
affinity O O 0.9821373820304871
of O O 0.9998069405555725
cleavage B-protein B-protein 0.39640262722969055
stimulation I-protein I-protein 0.6250110864639282
factor E-protein I-protein 0.8582621812820435
CstF-64 S-protein E-protein 0.8013774752616882
to O O 0.9943714737892151
the O O 0.9998039603233337
proximal B-DNA B-DNA 0.48074302077293396
polyA I-DNA I-DNA 0.6818124651908875
site E-DNA E-DNA 0.9668975472450256
seems O O 0.9991099238395691
to O O 0.9999881982803345
contribute O O 0.9999896287918091

MDS1/EVI1 S-DNA S-protein 0.5904786586761475
and O O 0.9688790440559387
AML1/MDS1/EVI1 S-protein S-protein 0.4539170563220978
) O O 0.8580634593963623
physically O O 0.9980732202529907
interacts O O 0.9999479055404663
with O O 0.9999760389328003
SMAD3 S-protein S-protein 0.9013913869857788
, O O 0.9950258135795593
which O O 0.9999587535858154
is O O 0.9999920129776001
an O O 0.9999895095825195
intracellular O O 0.8053452968597412
mediator O O 0.46663686633110046
of O O 0.9890433549880981
TGF-beta1 S-protein S-protein 0.8336540460586548
signaling O O 0.9685741066932678
. O O 0.9999605417251587
Finally O O 0.9998362064361572
, O O 0.9999827146530151
we O O 0.9998708963394165
have O O 0.999985933303833
correlated O O 0.9997468590736389
the O O 0.9999380111694336
response O O 0.9869412779808044

Lastly O O 0.9991704225540161
, O O 0.9999909400939941
we O O 0.9999436140060425
measured O O 0.9993255138397217
PRL O O 0.8993794322013855
- O O 0.9854176044464111
R O O 0.9724876880645752
and O O 0.9998883008956909
suppressor O O 0.9091925024986267
of O O 0.9969096779823303
cytokine O O 0.777511477470398
signaling O O 0.8754094243049622
( O O 0.9999369382858276
SOCS O O 0.950273334980011
- O O 0.9775887727737427
1 O O 0.979550302028656
and O O 0.9995244741439819
- O O 0.9944472312927246
3 O O 0.9790987968444824
and O O 0.999930739402771
CIS O O 0.7669112682342529
, O O 0.9994149208068848
which O O 0.9999905824661255
reflect O O 0.9999867677688599
the O O 0.9999520778656006
level O O 0.9997474551200867
of O O 0.9999368190765381
prolactin O O 0.5725102424621582
signaling O O 0.9032323360443115
) O O 0.9972286820411682
mRNAs O O 0.5455051064491272
in O O 0.9997325539588928
response O O 0.9980545043945312
to O O 0.9999544620513916
sulpiride S-Chemical B-Chemical 0.9124695062637329
and O O 0.9590277671813965
estradiol S-Chemical B-Chemical 0.9299225211143494
. O O 0.9991828799247742

Similar O O 0.9962785840034485
to O O 0.9997386336326599
rats O O 0.9633647203445435
, O O 0.9999227523803711
systemic O O 0.9716460704803467
pilocarpine B-Chemical B-Chemical 0.9150875210762024
injection O O 0.9606330394744873
causes O O 0.9993467926979065
status B-Disease B-Disease 0.6087921857833862
epilepticus I-Disease I-Disease 0.9420758485794067
( O O 0.9380444884300232
SE B-Disease O 0.9293719530105591
) O O 0.6549162268638611
and O O 0.9972831010818481
the O O 0.9998701810836792
eventual O O 0.9985252022743225
development O O 0.9957107305526733
of O O 0.9999206066131592
spontaneous O O 0.6887332201004028
seizures B-Disease B-Disease 0.6969759464263916
and O O 0.976257860660553
mossy O O 0.8914671540260315
fiber O O 0.5763131380081177
sprouting O O 0.6684921979904175
in O O 0.9992920160293579
C57BL O O 0.8790238499641418
/ O O 0.9991500377655029
6 O O 0.9791309237480164
and O O 0.999839186668396
CD1 O O 0.8462267518043518
mice O O 0.9853211045265198
, O O 0.9999890327453613
but O O 0.9999953508377075
the O O 0.9999834299087524
physiological O O 0.9051274657249451
correlates O O 0.9741922616958618
of O O 0.9997320771217346
these O O 0.9999449253082275
events O O 0.9719178080558777
have O O 0.999947190284729
not O O 0.999903678894043
been O O 0.9999703168869019
identified O O 0.999921441078186
in O O 0.9999904632568359
mice O O 0.9988535642623901
. O O 0.999998927116394

expression O O 0.9834678173065186
does O O 0.9999866485595703
not O O 0.9999665021896362
associate O O 0.999961256980896
with O O 0.9999533891677856
p100 S-protein S-protein 0.8310948014259338
. O O 0.991316556930542
( O O 0.9989062547683716
ABSTRACT O O 0.9482558369636536
TRUNCATED O O 0.9968032836914062
AT O O 0.9999700784683228
250 O O 0.9847372174263

The O O 0.9995771050453186
present O O 0.9988352656364441
study O O 0.9998823404312134
was O O 0.9999970197677612
undertaken O O 0.9999949932098389
to O O 0.9999977350234985
investigate O O 0.9999607801437378
the O O 0.9998581409454346
effects O O 0.9998384714126587
of O O 0.9998806715011597
TET S-Chemical B-Chemical 0.9334295392036438
and O O 0.9594120979309082
FAN S-Chemical B-Chemical 0.9266141057014465
on O O 0.9965494871139526
the O O 0.9997125267982483
experimental O O 0.8845014572143555
thrombosis O O 0.7857694029808044
induced O O 0.8761934041976929
by O O 0.9986793398857117
collagen O O 0.6657091975212097
plus O O 0.846231997013092
epinephrine S-Chemical B-Chemical 0.9262549877166748
( O O 0.9588487148284912
EP S-Chemical B-Chemical 0.9382282495498657
) O O 0.832790732383728
in O O 0.9999634027481079
mice O O 0.9955116510391235
, O O 0.9999674558639526
and O O 0.9998618364334106
platelet O O 0.6700670123100281
aggregation O O 0.7746273279190063
and O O 0.9790797233581543
blood O O 0.7187669277191162
coagulation O O 0.8972679972648621
in O O 0.994446873664856
vitro O O 0.9331618547439575
. O O 0.9999876022338867

primary O O 0.7355659008026123
translocation O O 0.9594396352767944
alone O O 0.9998220801353455
. O O 0.9999990463256836
Some O O 0.9999358654022217
expression O O 0.9990707039833069
of O O 0.9999200105667114
TCL1 S-protein S-protein 0.8526695966720581
could O O 0.9997820258140564
also O O 0.999990701675415
be O O 0.9999734163284302
detected O O 0.9998905658721924
in O O 0.9999113082885742
randomly O O 0.7363152503967285
selected O O 0.9533565640449524
A-T O O 0.24458149075508118

Pre O O 0.7842515110969543
- O O 0.9945911169052124
and O O 0.9999169111251831
posttransplant O O 0.8557325005531311
crossmatching O O 0.4025735557079315
was O O 0.999018669128418
done O O 0.9999762773513794
when O O 0.9999984502792358
possible O O 0.999804675579071
. O O 0.9999979734420776

ACE B-Chemical O 0.6257033348083496
inhibitor I-Chemical O 0.6637874841690063
and O O 0.9936413168907166
angiotensin B-Chemical B-Chemical 0.9309026598930359
- I-Chemical O 0.6830127835273743
releasing I-Chemical O 0.9827777743339539
blocker I-Chemical O 0.9149906039237976
( O O 0.9982458353042603
ARB B-Chemical O 0.6587996482849121
) O O 0.8299965262413025
therapy O O 0.9967772364616394
reduced O O 0.9976164102554321
proteinuria B-Disease O 0.8779422044754028
development O O 0.5701465010643005
. O O 0.9999630451202393

of O O 0.9970213770866394
the O O 0.9999735355377197
HIV-1 B-DNA B-DNA 0.5039055347442627
enhancer E-DNA E-DNA 0.9875478744506836
following O O 0.9975996613502502
T-cell O O 0.6935832500457764
stimulation O O 0.9783046245574951
is O O 0.9999442100524902
mediated O O 0.9989120960235596
largely O O 0.9999328851699829
through O O 0.999967098236084
binding O O 0.981360673904419
of O O 0.9995695948600769
the O O 0.9998764991760254
transcription B-protein B-protein 0.5184904336929321
factor E-protein E-protein 0.8218504786491394
NF-kappa B-protein B-protein 0.42163583636283875
B E-protein E-protein 0.9863712191581726
to O O 0.997606635093689
two O O 0.9955741167068481
adjacent O O 0.8527103662490845
kappa B-DNA B-DNA 0.36361438035964966
B I-DNA I-DNA 0.7787173390388489
sites E-DNA E-DNA 0.9803046584129333
in O O 0.9997497200965881
the O O 0.9999402761459351
HIV-1 B-DNA B-DNA 0.44949766993522644
long I-DNA I-DNA 0.7635720372200012
terminal I-DNA I-DNA 0.8886699676513672
repeat E-DNA E-DNA 0.994093120098114
, O O 0.9977352619171143
activation O O 0.989095151424408
of O O 0.9998019337654114
the O O 0.9996024966239929
HIV-2 B-DNA B-DNA 0.5929368734359741
enhancer E-DNA E-DNA 0.9869426488876343
in O O 0.9957706332206726
monocytes S-cell_type S-cell_type 0.9590327739715576
and O O 0.978459358215332
T B-cell_type B-cell_type 0.7821283936500549
cells E-cell_type E-cell_type 0.9753492474555969
is O O 0.9991330504417419
dependent O O 0.9999719858169556
on O O 0.9999879598617554
four O O 0.9905829429626465
cis-acting B-DNA B-DNA 0.5747517943382263
elements E-DNA E-DNA 0.9951918125152588
: O O 0.9991162419319153
a O O 0.999840259552002
single O O 0.8996665477752686
kappa B-DNA B-DNA 0.6011617183685303
B I-DNA I-DNA 0.8134289383888245
site E-DNA E-DNA 0.987751841545105
, O O 0.9982871413230896
two O O 0.9895564913749695
purine-rich B-DNA B-DNA 0.5573681592941284
binding I-DNA I-DNA 0.7168111205101013
sites E-DNA E-DNA 0.9543914198875427
, O O 0.9927733540534973
PuB1 S-DNA S-DNA 0.9708869457244873
and O O 0.973990261554718
PuB2 S-DNA S-DNA 0.9620094299316406
, O O 0.9794237613677979
and O O 0.9989577531814575
a O O 0.9975020289421082
pets B-DNA B-DNA 0.4127308428287506
site E-DNA E-DNA 0.9462857246398926
. O O 0.9994142055511475
We O O 0.9997678399085999
have O O 0.9999885559082031

A O O 0.9918317198753357
34 O O 0.9978752136230469
- O O 0.9997625946998596
year O O 0.999956488609314
- O O 0.9998944997787476
old O O 0.9986349940299988
lady O O 0.9969287514686584
developed O O 0.9999010562896729
a O O 0.9998531341552734
constellation O O 0.9551048874855042
of O O 0.997645914554596
dermatitis B-Disease B-Disease 0.977523684501648
, O O 0.9019282460212708
fever B-Disease O 0.6221783757209778
, O O 0.8655502200126648
lymphadenopathy B-Disease O 0.7240565419197083
and O O 0.8817415833473206
hepatitis B-Disease B-Disease 0.8571029305458069
, O O 0.9715297818183899
beginning O O 0.9994022846221924
on O O 0.9999767541885376
the O O 0.9999411106109619
17th O O 0.9989994168281555
day O O 0.9999921321868896
of O O 0.9999946355819702
a O O 0.9999840259552002
course O O 0.9994895458221436
of O O 0.9999688863754272
oral O O 0.8240464329719543
sulphasalazine B-Chemical B-Chemical 0.9229174256324768
for O O 0.9953108429908752
sero O O 0.38480934500694275
- O O 0.7807844281196594
negative O O 0.7912308573722839
rheumatoid B-Disease O 0.5573844909667969
arthritis I-Disease O 0.9226073622703552
. O O 0.9985187649726868

the O O 0.9954127669334412
Rch1/importin B-protein B-protein 0.3161100149154663
( I-protein I-protein 0.6872599124908447
karyopherin I-protein I-protein 0.6638302206993103
) I-protein I-protein 0.7362566590309143
-beta I-protein I-protein 0.5892876386642456
heterodimer E-protein E-protein 0.9795243144035339
expressed O O 0.9983327984809875
in O O 0.9998509883880615
Jurkat B-cell_line B-cell_line 0.7377731800079346
T I-cell_line I-cell_line 0.874716579914093
cells E-cell_line E-cell_line 0.9847058653831482
. O O 0.9997990727424622
Taken O O 0.9999778270721436
together O O 0.9999908208847046
, O O 0.9999972581863403
these O O 0.9999816417694092
data O O 0.9860952496528625

pathway O O 0.9533703923225403
per O O 0.9993669390678406
se O O 0.9829955697059631
is O O 0.9999672174453735
not O O 0.9999260902404785
sufficient O O 0.9999349117279053
for O O 0.9999721050262451
proliferation O O 0.9946979284286499
induction O O 0.9997126460075378
. O O 0.9999983310699463
To O O 0.999995231628418
determine O O 0.9999966621398926
the O O 0.9999922513961792
contribution O O 0.9998363256454468
of O O 0.9999880790710449
the O O 0.9999431371688843
cytoplasmic B-protein B-protein 0.5624244213104248
domain E-protein E-protein 0.9564445614814758
of O O 0.9912406802177429
the O O 0.9996938705444336
IL-7 B-protein B-protein 0.608832836151123
receptor I-protein I-protein 0.5341988205909729
alpha I-protein I-protein 0.49461108446121216
chain E-protein E-protein 0.996338963508606
( O O 0.9971030354499817
IL-7R B-protein B-protein 0.47753265500068665
alpha E-protein E-protein 0.9720068573951721
) O O 0.871807336807251
to O O 0.9995112419128418
activation O O 0.9838175773620605

a O O 0.9984320998191833
powerful O O 0.9483132362365723
PTPase S-protein S-protein 0.6262111663818359
inhibitor O O 0.5987252593040466
, O O 0.999659538269043
vanadate O O 0.9497644901275635
peroxide O O 0.9472873210906982
( O O 0.9993665814399719
pervanadate O O 0.948725700378418
) O O 0.9988299012184143
, O O 0.999940037727356
on O O 0.9999572038650513
the O O 0.9999116659164429
activation O O 0.9293230772018433
cascade O O 0.8148502707481384
of O O 0.9989686012268066
Jurkat B-cell_line B-cell_line 0.5875348448753357
human I-cell_line I-cell_line 0.7412936687469482
leukaemic I-cell_line I-cell_line 0.9263109564781189
T-cells E-cell_line E-cell_line 0.9064609408378601
. O O 0.9997108578681946
Pervanadate O O 0.6371525526046753
induced O O 0.9952855706214905
activation O O 0.9943825006484985
of O O 0.9998705387115479
the O O 0.9990412592887878
tyrosine B-protein B-protein 0.46652740240097046
kinases E-protein E-protein 0.9537160396575928
lck S-protein S-protein 0.7201781868934631
and O O 0.9217237830162048
fyn S-protein S-protein 0.5944367051124573
( O O 0.9113448858261108
4- O O 0.755866289138794
and O O 0.8378030061721802
3-fold O O 0.5934761762619019
respectively O O 0.9942933320999146
) O O 0.9988125562667847
and O O 0.9999557733535767
a O O 0.9999456405639648
dramatic O O 0.9880592226982117
increase O O 0.9931209683418274
in O O 0.9995711445808411
tyrosine O O 0.8210921883583069
phosphorylation O O 0.9138148427009583
of O O 0.9986999034881592
cellular B-protein B-protein 0.6575434803962708
proteins E-protein E-protein 0.9630438685417175
, O O 0.9983224272727966
notably O O 0.9998981952667236
phospholipase B-protein B-protein 0.31641924381256104
C I-protein E-protein 0.5598507523536682

that O O 0.9986422657966614
VDR S-protein S-protein 0.6016259789466858
polymorphism O O 0.687257707118988
does O O 0.99994957447052
not O O 0.9999880790710449
affect O O 0.9999943971633911
the O O 0.9999579191207886
abundance O O 0.9980093836784363
of O O 0.9999127388000488
the O O 0.9983526468276978
VDR B-RNA B-RNA 0.9338340759277344
mRNA E-RNA E-RNA 0.9976683259010315
. O O 0.9995110034942627
Oncogenic O O 0.8898327350616455
forms O O 0.8475322127342224
of O O 0.9996747970581055
NOTCH1 S-protein S-protein 0.6171735525131226
lacking O O 0.9971386194229126
either O O 0.9999544620513916
the O O 0.9998559951782227

extent O O 0.8874732851982117
. O O 0.9999066591262817
They O O 0.9999682903289795
fail O O 0.9993875026702881
to O O 0.9999642372131348
induce O O 0.9998551607131958
mRNA S-RNA S-RNA 0.9750780463218689
of O O 0.9912354946136475
TNF-alpha S-protein S-protein 0.9569615125656128
after O O 0.9993118047714233
3 O O 0.9904877543449402
h O O 0.9873666763305664
of O O 0.9995790123939514
culture O O 0.9594571590423584
. O O 0.9999819993972778
Therefore O O 0.9999910593032837
, O O 0.9999823570251465
monokine O O 0.5225805044174194
induction O O 0.997256338596344
is O O 0.9999977350234985
a O O 0.9999949932098389
zinc-specific O O 0.8047822713851929
effect O O 0.9946495890617371
influenced O O 0.9999399185180664
by O O 0.9999942779541016
the O O 0.9999487400054932
physicochemical O O 0.8691471815109253
properties O O 0.8403194546699524
of O O 0.999937891960144
the O O 0.9999357461929321
ion O B-DNA 0.4489169716835022

super O I-protein 0.5962287187576294
family O E-protein 0.860321581363678
, O O 0.9817715883255005
and O O 0.9997214674949646
the O O 0.9999655485153198
LPS O O 0.5806659460067749
signaling O O 0.7381998300552368
cascade O O 0.43681612610816956
uses O O 0.999398946762085
an O O 0.9999843835830688
analogous O O 0.9005890488624573
molecular O O 0.8676890134811401
framework O O 0.7752423882484436
for O O 0.9986963868141174
signaling O O 0.9939547181129456
as O O 0.9999428987503052
IL-1 S-protein S-protein 0.9875438213348389
in O O 0.9993152618408203
mononuclear B-cell_type B-cell_type 0.7740288376808167
phagocytes E-cell_type E-cell_type 0.9766521453857422
and O O 0.9912282228469849
endothelial B-cell_type B-cell_type 0.7122523188591003
cells E-cell_type E-cell_type 0.9795324206352234
. O O 0.9997182488441467
Signal O O 0.9079238176345825
transduction O O 0.9540824890136719
through O O 0.9987939596176147
interferon-gamma B-protein B-protein 0.6794587969779968
receptor E-protein E-protein 0.9605320692062378
on O O 0.996997594833374
human B-cell_type B-cell_type 0.6899121403694153
eosinophils E-cell_type E-cell_type 0.9860633015632629
. O O 0.9991399049758911
BACKGROUND O O 0.9890828132629395
: O O 0.9997528195381165
We O O 0.9999176263809204
reported O O 0.999981164932251
on O O 0.9999618530273438
the O O 0.9999511241912842
constitutive O O 0.9105654358863831
interferon-gamma B-protein B-protein 0.27633732557296753
receptor E-protein E-protein 0.9391773343086243
( O O 0.9257587194442749
IFN-gammaR S-protein S-protein 0.9242520928382874
) O O 0.9045023322105408
expression O O 0.9948798418045044
on O O 0.9998879432678223
eosinophils S-cell_type S-cell_type 0.9873746633529663
. O O 0.9998088479042053
But O O 0.9998862743377686
signal O O 0.9420726895332336
transduction O O 0.9627671837806702
through O O 0.9996495246887207
IFN-gammaR S-protein S-protein 0.8995777368545532
on O O 0.9955287575721741
eosinophils S-cell_type S-cell_type 0.9755831360816956
remains O O 0.9989018440246582
to O O 0.9999644756317139
be O O 0.999922513961792
elucidated O O 0.9954087138175964

This O O 0.9996663331985474
case O O 0.998921275138855
study O O 0.9999700784683228
reveals O O 0.9999978542327881
an O O 0.9999864101409912
unusual O O 0.9940885305404663
finding O O 0.9991815686225891
of O O 0.9999815225601196
rapidly O O 0.9660457372665405
proliferative O O 0.9202438592910767
crescentic O O 0.585992157459259
glomerulonephritis B-Disease O 0.48486945033073425
in O O 0.98475581407547
a O O 0.9987026453018188
patient O O 0.9992319345474243
treated O O 0.9999808073043823
with O O 0.9999874830245972
rifampin B-Chemical B-Chemical 0.9256068468093872
who O O 0.9853357076644897
had O O 0.9999508857727051
no O O 0.9998970031738281
other O O 0.9998574256896973
identifiable O O 0.9945249557495117
causes O O 0.9685149192810059
for O O 0.9998416900634766
developing O O 0.992708683013916
this O O 0.9942756295204163
disease O O 0.7879350781440735
. O O 0.9999821186065674

inhibit O O 0.976962685585022
leukocyte S-cell_type O 0.32707086205482483
-endothelial B-cell_type O 0.9426045417785645
cell E-cell_type O 0.9302474856376648
interaction O O 0.9987645149230957
. O O 0.9999986886978149
An O O 0.9999849796295166
early O O 0.9046398997306824
event O O 0.9912371635437012
in O O 0.9999641180038452
acute O O 0.8354465961456299
and O O 0.9800706505775452
chronic O O 0.9707660675048828
inflammation O O 0.9548561573028564
and O O 0.9998007416725159
associated O O 0.9798148274421692
diseases O O 0.9411907196044922
such O O 0.9998956918716431
as O O 0.9999709129333496
atherosclerosis O O 0.7467158436775208
and O O 0.999382734298706
rheumatoid O O 0.8299582600593567
arthritis O O 0.6777343153953552

activation O O 0.9362528324127197

cascade O O 0.6100272536277771
involved O O 0.9992837309837341
is O O 0.9999964237213135
the O O 0.9999750852584839
inositol O O 0.659242570400238
1 O O 0.6386470794677734
, O O 0.9693996906280518
4 O O 0.9591829180717468
, O O 0.9962189793586731
5-trisphosphate/calcium O O 0.9579135775566101
pathway O O 0.9988971948623657
which O O 0.9999833106994629
responds O O 0.9999492168426514
over O O 0.9999866485595703
the O O 0.9999680519104004
same O O 0.999846339225769
rapid O O 0.9665447473526001
time O O 0.9873948097229004
course O O 0.9973810315132141
. O O 0.9999991655349731
Such O O 0.9999581575393677
changes O O 0.9993062019348145
clearly O O 0.999980092048645
can O O 0.9999949932098389
not O O 0.9999418258666992

, O O 0.8788255453109741
and O O 0.9766789078712463
cRel S-protein S-protein 0.8702379465103149
correlate O O 0.9996781349182129
with O O 0.9999934434890747
positive O O 0.9734410643577576
regulation O O 0.9980175495147705
whereas O O 0.9999982118606567
the O O 0.9999880790710449
presence O O 0.9996292591094971
of O O 0.9999419450759888
p50 S-protein S-protein 0.9274612665176392
correlates O O 0.9842219352722168
with O O 0.9999949932098389
negative O O 0.9559155106544495
regulation O O 0.9969460368156433
. O O 0.999997615814209
Ii B-DNA B-protein 0.785990834236145
kappa I-DNA I-protein 0.358383446931839
B-2 E-DNA E-protein 0.7497946619987488
is O O 0.9995272159576416
a O O 0.9999939203262329
site O O 0.9910141825675964
of O O 0.9998067021369934
positive O O 0.9251319169998169
regulation O O 0.9873389005661011
in O O 0.9999569654464722

cell O O 0.44725897908210754
types O O 0.6202858686447144
as O O 0.9991487264633179
shown O O 0.9999854564666748
by O O 0.9999947547912598
fusion O O 0.8837391138076782
to O O 0.9978044629096985
the O O 0.9997592568397522
GAL4 B-protein B-protein 0.5477045774459839
DNA I-protein I-protein 0.3421064615249634
binding I-protein I-protein 0.6435950994491577
domain E-protein E-protein 0.919213593006134
. O O 0.999663233757019
The O O 0.9999960660934448
same O O 0.9997978806495667
arrangement O O 0.9993409514427185
of O O 0.999925971031189
positively B-DNA O 0.7180801033973694
and I-DNA O 0.924490213394165
negatively I-DNA O 0.918931245803833
acting I-DNA O 0.9159802794456482
sequences E-DNA O 0.6572374701499939
has O O 0.9998658895492554
been O O 0.9999523162841797

is O O 0.9972967505455017
critical O O 0.9992700219154358
for O O 0.9999891519546509
this O O 0.999935507774353
activity O O 0.9992651343345642
. O O 0.9999986886978149
Possible O O 0.9986972212791443
role O O 0.9987455606460571
of O O 0.9999308586120605
nuclear B-protein B-protein 0.5996690988540649
factor-kappa I-protein I-protein 0.7167994976043701
B E-protein E-protein 0.9863502383232117
activity O O 0.9948668479919434
in O O 0.9999785423278809
germline S-DNA S-DNA 0.9111518859863281
C O O 0.788291335105896
epsilon O O 0.6964734196662903
transcription O O 0.9751063585281372
in O O 0.9999687671661377
a O O 0.9996991157531738
human B-cell_line B-cell_line 0.5863674283027649
Burkitt I-cell_line I-cell_line 0.8370025753974915
lymphoma I-cell_line I-cell_line 0.9199102520942688
B I-cell_line I-cell_line 0.9837191700935364
cell I-cell_line I-cell_line 0.958562433719635
line E-cell_line E-cell_line 0.9666879773139954

Cushing O O 0.9025981426239014
's O O 0.980061948299408
disease O O 0.9584540128707886
patients O O 0.9995825886726379
were O O 0.9999983310699463
within O O 0.9999867677688599
the O O 0.9999573230743408
normal O O 0.9667586088180542
range O O 0.9983569979667664
. O O 0.9999979734420776
At O O 0.9999984502792358
the O O 0.9999997615814209
same O O 0.9999973773956299
time O O 0.9999889135360718
, O O 0.9999760389328003
3-O-MG O O 0.7209656834602356
transport O O 0.9296382069587708
was O O 0.9999771118164062
determined O O 0.9999943971633911
in O O 0.9999890327453613
the O O 0.9999796152114868
same O O 0.9999451637268066
subjects O O 0.9991492033004761
. O O 0.9999984502792358
In O O 0.9998873472213745
Cushing O O 0.8898988962173462
's O O 0.9711083769798279
disease O O 0.9717401266098022
, O O 0.9999607801437378
3-O-MG O O 0.6815519332885742
transport O O 0.919090211391449
was O O 0.9999790191650391
within O O 0.9999903440475464
the O O 0.9999649524688721

and I-cell_type O 0.8946488499641418
nonerythroid I-cell_type B-cell_type 0.392673134803772
cells E-cell_type E-cell_type 0.9624225497245789
. O O 0.9998278617858887
Coproporphyrinogen B-protein B-protein 0.8993640542030334
oxidase E-protein E-protein 0.8913217782974243
( O O 0.9884772300720215
CPO S-protein S-protein 0.92536860704422
) O O 0.9876185655593872
catalyzes O O 0.9995700716972351
the O O 0.9999581575393677
sixth O O 0.9734591245651245
step O O 0.9848451018333435
of O O 0.9997556805610657
the O O 0.9999274015426636
heme S-protein B-DNA 0.2905527353286743

no O O 0.9943336248397827
recognizable O O 0.9965137839317322
association O O 0.9983125925064087
of O O 0.9999573230743408
cytokine B-protein S-protein 0.8481476902961731
patterns E-protein O 0.9371679425239563
with O O 0.9999606609344482
AST/ALT O S-protein 0.7518131732940674
levels O O 0.9953371286392212
. O O 0.9999945163726807
In O O 0.9999454021453857
conclusion O O 0.9996325969696045
, O O 0.9999955892562866
production O O 0.9994194507598877
of O O 0.9999741315841675
a O O 0.999352753162384
Th1 B-protein B-protein 0.31757643818855286
cytokine E-protein E-protein 0.921235978603363
, O O 0.9912631511688232
IFN-gamma S-protein S-protein 0.9899076223373413
, O O 0.9959426522254944
by O O 0.9999041557312012
HBsAg S-protein S-protein 0.8268370032310486
-reactive O O 0.8339709639549255
cells O O 0.6772672533988953
was O O 0.9995725750923157
associated O O 0.999897837638855

factor E-protein E-protein 0.920651376247406
( O O 0.9100052118301392
I-factor S-protein S-protein 0.4425506591796875
) O O 0.4443851709365845
in O O 0.99880051612854
mouse B-cell_line B-cell_line 0.43498751521110535
myeloid I-cell_line I-cell_line 0.43477386236190796
leukemia I-cell_line I-cell_line 0.7075045108795166
M1 I-cell_line I-cell_line 0.8112844824790955
cells E-cell_line E-cell_line 0.9576476216316223
as O O 0.9999659061431885
a O O 0.9999948740005493
murine B-protein B-protein 0.44450506567955017
homolog E-protein E-protein 0.6361335515975952
of O O 0.9514856934547424
the O O 0.9985560774803162
human B-protein B-protein 0.3861575722694397
nm23-H2 I-protein I-protein 0.42886534333229065
gene I-protein I-protein 0.5864686965942383
product E-protein E-protein 0.9261147975921631
. O O 0.9994713664054871
nm23 B-DNA B-DNA 0.3852073848247528
genes E-DNA E-DNA 0.9855322241783142

Azathioprine S-Chemical B-Chemical 0.9184789657592773
treatment O O 0.9923195242881775
benefited O O 0.9997982382774353
19 O O 0.9979038238525391
( O O 0.9999300241470337
66 O O 0.9999344348907471
% O O 0.9999256134033203
) O O 0.999792754650116
out O O 0.9999819993972778
of O O 0.9999910593032837
29 O O 0.9946118593215942
patients O O 0.9991451501846313
suffering O O 0.9999604225158691
from O O 0.9998714923858643
severe O O 0.9647823572158813
psoriasis O B-Disease 0.9503697752952576
. O O 0.9988424181938171

all-trans O O 0.8747107982635498
retinoic O O 0.9355385899543762
acid O O 0.9763619303703308
. O O 0.9999538660049438
Differential O O 0.9669526219367981
utilization O O 0.9941087961196899
of O O 0.9998809099197388
Janus B-protein B-protein 0.7192132472991943
kinase E-protein E-protein 0.9609235525131226
-signal O O 0.8880307078361511
transducer O O 0.7861558198928833
activator O O 0.48470112681388855
of O O 0.9685127139091492
transcription O O 0.7125949859619141
signaling O O 0.8058859705924988
pathways O O 0.9864287972450256
in O O 0.9999786615371704
the O O 0.999935507774353
stimulation O O 0.9863220453262329
of O O 0.9998552799224854
human B-cell_type B-cell_type 0.5851300954818726
natural I-cell_type I-cell_type 0.6746810078620911
killer I-cell_type I-cell_type 0.8765878081321716
cells E-cell_type E-cell_type 0.9593895673751831
by O O 0.9994785189628601
IL-2 S-protein S-protein 0.9554861187934875
, O O 0.9922102689743042
IL-12 S-protein S-protein 0.9642430543899536
, O O 0.991258442401886
and O O 0.9990386962890625
IFN-alpha S-protein S-protein 0.9179645776748657

Associated O O 0.9796446561813354
factors O O 0.9830544590950012
were O O 0.9999871253967285
co O O 0.9698970913887024
- O O 0.9974047541618347
treatment O O 0.9998049139976501
with O O 0.9999979734420776
other O O 0.9998321533203125
centrally O O 0.9783570170402527
antimuscarinic O O 0.3530828356742859
agents O O 0.6161569356918335
, O O 0.9999407529830933
poor O O 0.9475371241569519
clinical O O 0.9492679834365845
outcome O O 0.8972637057304382
, O O 0.9994193315505981
older O O 0.9953130483627319
age O O 0.9966391324996948
, O O 0.9999644756317139
and O O 0.9998025298118591
longer O O 0.997277557849884
hospitalization O O 0.6145864725112915
( O O 0.998002827167511
by O O 0.9999521970748901
17 O O 0.9999209642410278
. O O 0.9999845027923584
5 O O 0.9998915195465088
days O O 0.9999688863754272
, O O 0.9999897480010986
increasing O O 0.992226243019104
cost O O 0.9734495282173157
) O O 0.9969780445098877
; O O 0.9999269247055054
sex O O 0.9226967692375183
, O O 0.9983869791030884
diagnosis O O 0.8880704641342163
or O O 0.9991680383682251
medical O O 0.9633785486221313
co O O 0.7139062881469727
- O O 0.8283784985542297
morbidity O O 0.5795931220054626
, O O 0.9951510429382324
and O O 0.9998325109481812
daily O O 0.9908706545829773
clozapine S-Chemical B-Chemical 0.9212996959686279
dose O O 0.9849143624305725
, O O 0.9999587535858154
which O O 0.9999266862869263
fell O O 0.9994879961013794
with O O 0.9999772310256958
age O O 0.9989294409751892
, O O 0.9999895095825195
were O O 0.9999773502349854
unrelated O O 0.9969112277030945
. O O 0.9999974966049194

by O O 0.9970728158950806
mAb S-protein S-protein 0.9242161512374878
and O O 0.9766562581062317
SE O S-protein 0.9147365689277649
triggers O O 0.9988254904747009
a O O 0.9999884366989136
rapid O O 0.969434380531311
, O O 0.9941279888153076
PP1 S-protein S-protein 0.987546980381012
-sensitive O O 0.993083119392395
tyrosine O O 0.9475533962249756
and O O 0.9996762275695801
serine O O 0.8960367441177368
phosphorylation O O 0.8713356256484985
of O O 0.99540776014328
Stat3 S-protein S-protein 0.9949175119400024
in O O 0.9997041821479797
human B-cell_type B-cell_type 0.5663778781890869
CD4+ I-cell_type I-cell_type 0.6624820828437805
T I-cell_type I-cell_type 0.7713676691055298
cells E-cell_type E-cell_type 0.7567352056503296
. O O 0.9997250437736511
Moreover O O 0.9946948885917664

Such O O 0.9945856928825378
treatment O O 0.9937374591827393
did O O 0.9999760389328003
not O O 0.9999134540557861
diminish O O 0.9994668364524841
the O O 0.9999043941497803
ADR B-Chemical O 0.8305262327194214
antitumor O O 0.3229716718196869
activity O O 0.6584921479225159
in O O 0.9988906979560852
L1210 B-Disease O 0.4974188506603241
leukemia I-Disease O 0.5178971290588379
and O O 0.9940511584281921
in O O 0.9998918771743774
Ehrlich B-Disease O 0.7056726217269897
ascites I-Disease O 0.6522403359413147
tumor I-Disease B-Disease 0.8232831358909607
. O O 0.9990792274475098

stimulate O O 0.9907179474830627
humoral O O 0.9486775398254395
immunity O O 0.9817304611206055
, O O 0.9999911785125732
whereas O O 0.999996542930603
this O O 0.9999430179595947
response O O 0.9986135959625244
is O O 0.9999815225601196
not O O 0.9998123049736023
detected O O 0.9997645020484924
in O O 0.999907374382019
cortisol-resistant O O 0.356969952583313

Comprehensive O O 0.9653375744819641
clinical O O 0.9872598648071289
and O O 0.9987213015556335
developmental O O 0.9945911169052124
measurements O O 0.9916771650314331
were O O 0.999994158744812
done O O 0.9999779462814331
. O O 0.9999995231628418

-NF-Y S-protein S-protein 0.8752399682998657
interaction O O 0.99600750207901
may O O 0.9999926090240479
play O O 0.9999829530715942
a O O 0.9999947547912598
critical O O 0.9983198046684265
role O O 0.9998794794082642
in O O 0.9999665021896362
causing O O 0.9994590878486633
cellular O O 0.9684980511665344
transformation O O 0.9805082678794861
and O O 0.9998607635498047
HTLV-1 O O 0.5570844411849976
pathogenesis O O 0.9430446028709412
. O O 0.9999932050704956
High O O 0.9830688238143921
levels O O 0.9989776611328125

. O O 0.9967103004455566
The O O 0.9999574422836304
BAT B-DNA B-DNA 0.4725191593170166
box E-DNA E-DNA 0.959579348564148
and O O 0.9884060621261597
Oct-2 S-protein S-DNA 0.6508288979530334
were O O 0.998736560344696
also O O 0.9999760389328003
implicated O O 0.9999548196792603
in O O 0.9999926090240479
the O O 0.999971866607666
induction O O 0.9966333508491516
of O O 0.9998062252998352
CD20 S-protein S-protein 0.7636080384254456
in O O 0.9996899366378784
the O O 0.9999383687973022
pre-B B-cell_line B-cell_line 0.4971778392791748
cell I-cell_line I-cell_line 0.6228516101837158
line E-cell_line E-cell_line 0.9533448219299316
, O O 0.9957215785980225
PB-697 S-cell_line S-cell_line 0.9869148135185242
, O O 0.974612295627594
via O O 0.9990885257720947
phorbol O O 0.72108393907547
esters O O 0.8092784285545349
. O O 0.9999581575393677
The O O 0.9999725818634033

Therefore O O 0.9988969564437866
, O O 0.9999616146087646
patients O O 0.9993313550949097
with O O 0.9999533891677856
glioblastoma B-Disease B-Disease 0.9579547643661499
sometimes O O 0.9852718114852905
have O O 0.9999572038650513
intracarotid O O 0.6869759559631348
injection O O 0.7632275223731995
of O O 0.9929428100585938
carcinostatics O O 0.5563607215881348
added O O 0.9955501556396484
to O O 0.9999597072601318
the O O 0.9994193315505981
treatment O O 0.9958836436271667
regimen O O 0.9984229803085327
. O O 0.9999992847442627

The O O 0.9994059801101685
clinical O O 0.9947248101234436
course O O 0.9987707734107971
and O O 0.9999834299087524
histopathological O O 0.9566186666488647
results O O 0.9967785477638245
of O O 0.9999821186065674
the O O 0.9999947547912598
two O O 0.999951958656311
cases O O 0.9984394907951355
are O O 0.9999954700469971
presented O O 0.9999856948852539
. O O 0.9999990463256836

of O O 0.9942611455917358
NF-kappa B-protein B-protein 0.7475888133049011
B E-protein E-protein 0.9889981150627136
. O O 0.9995131492614746
Previously O O 0.9999196529388428
, O O 0.9999825954437256
we O O 0.999188244342804
and O O 0.9997952580451965
others O O 0.9993914365768433
have O O 0.9999899864196777
demonstrated O O 0.9999876022338867
that O O 0.9999929666519165
NF-kappa B-protein B-protein 0.7180277109146118
B E-protein E-protein 0.9780941605567932
regulates O O 0.9979363679885864
the O O 0.9999063014984131
NF-kappa B-DNA B-DNA 0.6480400562286377
B1 I-DNA I-DNA 0.30696332454681396
gene E-DNA E-DNA 0.9826181530952454
. O O 0.9996633529663086
In O O 0.9999821186065674
this O O 0.9999691247940063
manuscript O O 0.9717817902565002
we O O 0.9996034502983093

. O O 0.9918600916862488
As O O 0.9992178678512573
occurs O O 0.9984652996063232
for O O 0.9999759197235107
HL-60 O B-cell_line 0.5639215707778931
cell O E-cell_line 0.7852532267570496
differentiation O O 0.9109150171279907
induced O O 0.9995930790901184
by O O 0.9999845027923584
high O O 0.9664289355278015
phorbol O O 0.894682765007019
ester O O 0.9325217008590698
concentration O O 0.9976557493209839
, O O 0.9999983310699463
the O O 0.9999946355819702
ciprofibrate-induced O O 0.8087785243988037
phorbol O O 0.7606284022331238
ester-dependent O O 0.8745766878128052
differentiation O O 0.9904848337173462
of O O 0.9999279975891113
HL-60 B-cell_line B-cell_line 0.6989487409591675
cells E-cell_line E-cell_line 0.9747255444526672
proceeded O O 0.9997262358665466
through O O 0.9999949932098389
the O O 0.9999731779098511
monocytic/macrophage O O 0.6403781771659851
pathway O O 0.9406505823135376
and O O 0.9995467066764832
induced O O 0.9998041987419128
the O O 0.9997357726097107
phosphorylation O O 0.9628803730010986
of O O 0.9987829327583313
proteins O O 0.8653236031532288
with O O 0.9996886253356934
similar O O 0.9920675754547119
molecular O O 0.8626401424407959
weights O O 0.8051728010177612
suggesting O O 0.999583899974823
that O O 0.9999860525131226
increased O O 0.9891306161880493
protein B-protein O 0.876916229724884

Due O O 0.9998144507408142
to O O 0.9999735355377197
severe O O 0.9879343509674072
systolic B-Disease B-Disease 0.648384690284729
dysfunction I-Disease I-Disease 0.9441008567810059
losartan B-Chemical S-Chemical 0.5410913228988647
was O O 0.9632882475852966
prescribed O O 0.9996280670166016
. O O 0.9999990463256836

ringed B-cell_type O 0.657898485660553
sideroblasts E-cell_type O 0.4760310649871826
exclusively O O 0.9983394145965576
showed O O 0.9999948740005493
one O O 0.9998471736907959
pattern O O 0.9883190393447876
dominant O O 0.9903096556663513
in O O 0.9999051094055176
those O O 0.9999430179595947
of O O 0.9998552799224854
PMNCs S-cell_type S-cell_type 0.8884869813919067
. O O 0.9997912049293518
Our O O 0.9999973773956299
findings O O 0.9999746084213257
suggest O O 0.9999967813491821
that O O 0.9999856948852539
non-clonal B-cell_type B-cell_type 0.522537887096405
progenitor I-cell_type I-cell_type 0.7909425497055054
cells E-cell_type E-cell_type 0.9612450003623962

a O O 0.996625542640686
peptide O B-protein 0.7194358706474304
antigen O E-protein 0.9468531012535095
which O O 0.9968493580818176
interacts O O 0.9997923970222473
with O O 0.9999469518661499
DQ B-protein B-protein 0.6141600012779236
molecules E-protein E-protein 0.8951970934867859
encoded O O 0.9990956783294678
by O O 0.9999843835830688
both O O 0.9996141195297241
parental O B-cell_type 0.7470184564590454
haplotypes O E-cell_type 0.8737878203392029
. O O 0.999757707118988
Markedly O O 0.993658721446991
impaired O O 0.9729821085929871
binding O O 0.9784188270568848
was O O 0.9998759031295776
observed O O 0.9998366832733154
, O O 0.999991774559021
consistent O O 0.9999141693115234
with O O 0.9999935626983643
both O O 0.9999492168426514
the O O 0.9999455213546753
use O O 0.9998319149017334
of O O 0.9998730421066284
different O O 0.9920507073402405

of O O 0.9972901344299316
HB24 S-DNA S-DNA 0.6293107867240906
expression O O 0.9782814383506775
in O O 0.9998071789741516
lymphoid O O 0.4262067973613739
and O O 0.8986581563949585
select O O 0.9286078810691833
developing O O 0.9524843692779541
tissues O O 0.9679523706436157
was O O 0.9999707937240601
performed O O 0.9999536275863647
by O O 0.9999912977218628
in O O 0.9984766840934753
situ O O 0.9284384846687317
hybridization O O 0.9760017395019531
. O O 0.9999920129776001
Positive O O 0.943207859992981
hybridization O O 0.9852702021598816
was O O 0.9999768733978271
found O O 0.999974250793457
in O O 0.9998975992202759
thymus O O 0.31551316380500793
, O O 0.9187129139900208
tonsil O O 0.6738188862800598
, O O 0.9746814966201782
bone O O 0.8971458673477173
marrow O O 0.9245923161506653
, O O 0.9934560656547546
developing O O 0.9200815558433533
vessels O O 0.8956954479217529
, O O 0.9988131523132324
and O O 0.9998106360435486
in O O 0.999534010887146
fetal O O 0.5644181370735168
brain O O 0.4746938943862915
. O O 0.9957993626594543
HB24 S-DNA S-protein 0.2185104936361313

Our O O 0.960589587688446

h O O 0.4926449954509735

No O O 0.9872955679893494
association O O 0.994491457939148
was O O 0.9999672174453735
found O O 0.9999761581420898
for O O 0.9999709129333496
hormone O O 0.732965886592865
use O O 0.9558420181274414
less O O 0.9992653727531433
than O O 0.9999821186065674
1 O O 0.998938262462616
year O O 0.9997877478599548
. O O 0.9999979734420776

element E-DNA E-DNA 0.8281519412994385

protein E-protein E-protein 0.9312186241149902
that O O 0.9988881945610046
may O O 0.9999909400939941
be O O 0.9999876022338867
involved O O 0.9999819993972778
in O O 0.9999861717224121
the O O 0.9999717473983765
regulation O O 0.9993565678596497
of O O 0.9999728202819824
myeloid O O 0.6793428063392639
differentiation O O 0.9749503135681152
. O O 0.9999920129776001
Our O O 0.9987660646438599

Oral O O 0.8785349130630493
administration O O 0.9473682045936584
of O O 0.9964033365249634
CBZ S-Chemical B-Chemical 0.9306431412696838
as O O 0.9988793730735779
an O O 0.9999667406082153
aqueous O O 0.47775959968566895
suspension O O 0.41500362753868103
every O O 0.9995372295379639
8 O O 0.9997342228889465
h O O 0.9982001781463623
at O O 0.9999964237213135
a O O 0.9999545812606812
dose O O 0.9994737505912781
of O O 0.9999443292617798
250 O O 0.9950436353683472
mg O O 0.9995484948158264
/ O O 0.9999291896820068
kg O O 0.9978229999542236
was O O 0.9999834299087524
continuously O O 0.99953293800354
protective O O 0.9982750415802002
against O O 0.9999656677246094
HFDE S-Chemical B-Chemical 0.913051426410675
- O O 0.9547420144081116
induced O O 0.9962424039840698
seizures O B-Disease 0.987151026725769
and O O 0.9663414359092712
was O O 0.9987658262252808
minimally O O 0.9803072810173035
toxic O O 0.6643166542053223
as O O 0.9942164421081543
measured O O 0.9994908571243286
by O O 0.9999678134918213
weight O O 0.6698221564292908
gain O O 0.8464298248291016
over O O 0.994828999042511
8 O O 0.9994786381721497
weeks O O 0.9999557733535767
of O O 0.9999679327011108
treatment O O 0.9992939233779907
. O O 0.9999994039535522

Some O O 0.9991023540496826
other O O 0.9999439716339111
mechanism O O 0.9988827109336853
than O O 0.9999948740005493
those O O 0.9999792575836182
being O O 0.9999063014984131
reported O O 0.9999781847000122
herein O O 0.9996172189712524
should O O 0.9999873638153076
be O O 0.9999850988388062
further O O 0.9993984699249268
investigated O O 0.999862790107727
. O O 0.9999988079071045

Significant O O 0.9946969747543335
disfiguring O O 0.6927769184112549
changes O O 0.509655773639679
occur O O 0.9866201877593994
as O O 0.9999711513519287
a O O 0.9999891519546509
result O O 0.9999760389328003
of O O 0.9999663829803467
bone O O 0.8872070908546448
, O O 0.9837784767150879
cartilage O O 0.4273505210876465
, O O 0.9942721128463745
and O O 0.9995697140693665
soft O O 0.8940327167510986
tissue O O 0.6761995553970337
hypertrophy O O 0.7675830125808716
, O O 0.9941686391830444
including O O 0.9999607801437378
the O O 0.9996737241744995
thickening O O 0.6461054086685181
of O O 0.8695041537284851
the O O 0.9141535758972168
skin O O 0.41959846019744873
, O O 0.9983124732971191
coarsening O O 0.6223869323730469
of O O 0.9492768049240112
facial O O 0.8367369174957275
features O O 0.6748005151748657
, O O 0.9990273714065552
and O O 0.9998455047607422
cutis O O 0.5767741799354553
verticis O O 0.7203270196914673
gyrata O O 0.8244369626045227
. O O 0.9992384910583496

Chronic O O 0.8622782230377197
enalapril B-Chemical B-Chemical 0.9227876663208008
treatment O O 0.988545835018158
reduced O O 0.9977220892906189
blood O O 0.9641637206077576
pressure O O 0.6697331070899963
without O O 0.9997606873512268
reducing O O 0.9962992072105408
albuminuria B-Disease O 0.9260390400886536
in O O 0.9908013939857483
group O O 0.9566990733146667
4 O O 0.9791194796562195
. O O 0.9999842643737793

scanning O O 0.9757328033447266
confocal O O 0.834930419921875
microscopy O O 0.8592033982276917
in O O 0.9998993873596191
human B-cell_line B-cell_line 0.40530672669410706
CD14-transfected I-cell_line I-cell_line 0.3950484097003937
Chinese I-cell_line I-cell_line 0.5265762209892273
hamster I-cell_line I-cell_line 0.6314119696617126
ovary I-cell_line I-cell_line 0.6993045806884766
fibroblasts E-cell_line E-cell_line 0.8581863045692444
( O O 0.9947949051856995
CHO-CD14 B-cell_line B-cell_line 0.6087160110473633
cells E-cell_line E-cell_line 0.9580422043800354
) O O 0.9910677075386047
and O O 0.9999037981033325

OBJECTIVE O O 0.9652315378189087
: O O 0.9997966885566711
To O O 0.9999866485595703
examine O O 0.9999841451644897
the O O 0.999919056892395
safety O O 0.9829591512680054
and O O 0.9980154037475586
tolerability O O 0.936086893081665
of O O 0.998580813407898
clonidine B-Chemical B-Chemical 0.9325547814369202
used O O 0.98665452003479
alone O O 0.9993485808372498
or O O 0.9999918937683105
with O O 0.9999438524246216
methylphenidate B-Chemical B-Chemical 0.9274399280548096
in O O 0.9989429116249084
children O O 0.9996211528778076
with O O 0.999976396560669
attention B-Disease O 0.9319248795509338
- I-Disease O 0.9645163416862488
deficit I-Disease O 0.6499208211898804
/ I-Disease O 0.9778822064399719
hyperactivity I-Disease B-Disease 0.7693014740943909
disorder I-Disease I-Disease 0.981572151184082
( O O 0.9825400710105896
ADHD B-Disease B-Disease 0.9749696850776672
) O O 0.9491358399391174
. O O 0.9999898672103882

monocyte O O 0.45003145933151245
arrest O O 0.9875993728637695
and O O 0.9998356103897095
emigration O O 0.9916695356369019
in O O 0.9999258518218994
shear O O 0.6322963237762451
flow O O 0.8619040846824646
and O O 0.9979087114334106
thus O O 0.9998476505279541
for O O 0.9999517202377319
monocyte O O 0.5843894481658936
infiltration O O 0.9792490601539612
in O O 0.9999233484268188
atherosclerotic O O 0.7109063863754272
plaques O O 0.6403574347496033
. O O 0.9999091625213623
Recognition O O 0.9993336796760559
of O O 0.9999467134475708
NFATp/AP-1 B-DNA B-DNA 0.632577121257782
composite I-DNA I-DNA 0.522606372833252
elements E-DNA E-DNA 0.9896847009658813
within O O 0.9978917241096497
genes O O 0.5089235901832581
induced O O 0.9989510774612427
upon O O 0.999150276184082

alpha- B-protein B-protein 0.5616603493690491
and I-protein I-protein 0.8558710813522339
beta- I-protein I-protein 0.5674921870231628
bound I-protein I-protein 0.5149253010749817
complexes E-protein E-protein 0.9751748442649841
, O O 0.9980888962745667
resembling O O 0.999866247177124
the O O 0.9999592304229736
pattern O O 0.9899132251739502
seen O O 0.9999374151229858
in O O 0.999911904335022
chronically B-cell_type B-cell_type 0.5166546106338501
activated I-cell_type I-cell_type 0.43730926513671875
cells E-cell_type E-cell_type 0.6951926350593567
and O O 0.9932407140731812
not O O 0.9995790123939514
of O O 0.9994024038314819
senescent B-cell_type O 0.4574786126613617

The O O 0.9965482354164124
promoters S-DNA S-DNA 0.9085744619369507
were O O 0.9994662404060364
used O O 0.9999096393585205
without O O 0.9996774196624756
enhancers S-DNA S-DNA 0.9708884358406067
, O O 0.9946016073226929
or O O 0.9995338916778564
with O O 0.9995946288108826
enhancers S-DNA S-DNA 0.9706944227218628
derived O O 0.9977931976318359
from O O 0.9999479055404663
the O O 0.9996765851974487
beta-globin B-DNA B-DNA 0.46394431591033936
locus I-DNA I-DNA 0.4273928701877594
control I-DNA I-DNA 0.8033896088600159
region E-DNA E-DNA 0.9631422758102417
and O O 0.9982689619064331
the O O 0.9998726844787598
alpha-globin B-DNA B-DNA 0.5583759546279907
HS-40 I-DNA I-DNA 0.8158068060874939
enhancer E-DNA E-DNA 0.9926064014434814
. O O 0.9994598031044006
When O O 0.9999680519104004
transfected O O 0.8131986856460571
into O O 0.9983065128326416
K562 B-cell_line B-cell_line 0.8462101221084595
cells E-cell_line E-cell_line 0.9973945617675781
, O O 0.998871386051178
which O O 0.9999778270721436
express O O 0.9993384480476379
zeta-globin S-protein S-protein 0.8390697836875916
, O O 0.9916493892669678

after O O 0.999485969543457
the O O 0.9999957084655762
0.5-Gy O O 0.7391707897186279
exposure O O 0.9791280627250671
. O O 0.9999871253967285
The O O 0.9999949932098389
expression O O 0.9975692629814148
of O O 0.9999066591262817
the O O 0.9996912479400635
p50 B-protein S-protein 0.7785735726356506
and I-protein O 0.8566415905952454
p65 I-protein B-protein 0.7390848398208618
NF-kappa I-protein I-protein 0.6805701851844788
B I-protein I-protein 0.6539800763130188
subunits E-protein E-protein 0.9817952513694763
was O O 0.999840259552002

Comparison O O 0.9928863644599915
of O O 0.9998387098312378
i O O 0.9880239367485046
. O O 0.9993163347244263
v O O 0.9525611400604248
. O O 0.9990399479866028
glycopyrrolate B-Chemical B-Chemical 0.9157282114028931
and O O 0.9270079731941223
atropine B-Chemical B-Chemical 0.9200873970985413
in O O 0.9968422651290894
the O O 0.9999077320098877
prevention O O 0.9947068095207214
of O O 0.9998435974121094
bradycardia B-Disease O 0.9460875988006592
and O O 0.7768422961235046
arrhythmias B-Disease O 0.7262610197067261
following O O 0.9970679879188538
repeated O O 0.9865220189094543
doses O O 0.9989399313926697
of O O 0.999825656414032
suxamethonium B-Chemical B-Chemical 0.9271049499511719
in O O 0.9897602200508118
children O O 0.998246431350708
. O O 0.9999984502792358

on O O 0.9968296885490417
IL-2 S-protein S-protein 0.9757678508758545
expression O O 0.9958422780036926
, O O 0.9999914169311523
the O O 0.9999386072158813
activated B-cell_type O 0.7070071697235107
cell E-cell_type O 0.4593315124511719
destroys O O 0.9774633646011353
its O O 0.9996639490127563
own O O 0.969340443611145
chromatin S-DNA S-DNA 0.628368079662323
. O O 0.9994737505912781
The O O 0.999975323677063
genes O O 0.6866350769996643
that O O 0.9996809959411621
need O O 0.9999476671218872
to O O 0.9999221563339233
be O O 0.9999303817749023
induced O O 0.9996417760848999
for O O 0.999993085861206
this O O 0.9999759197235107

stimuli O O 0.5935772061347961
. O O 0.9999185800552368
Previously O O 0.9997848868370056
, O O 0.9999902248382568
an O O 0.9999510049819946
inducible B-DNA B-DNA 0.8331781625747681
enhancer E-DNA E-DNA 0.8323978781700134
between O O 0.993716299533844
nucleotides B-DNA B-DNA 0.5207879543304443
-299 I-DNA I-DNA 0.5292285084724426
and I-DNA I-DNA 0.6678121089935303
-228 E-DNA E-DNA 0.8699281811714172
that O O 0.9810382723808289
contains O O 0.9997941851615906
NF-kappa B-DNA B-DNA 0.453511506319046
B I-DNA I-DNA 0.7750526070594788
and I-DNA I-DNA 0.8563673496246338
CArG I-DNA I-DNA 0.3363105356693268
motifs E-DNA E-DNA 0.8791810274124146
was O O 0.9992499947547913
identified O O 0.9999841451644897
. O O 0.9999986886978149
We O O 0.9999843835830688
now O O 0.9999985694885254
report O O 0.9999970197677612
the O O 0.999990701675415
characterization O O 0.9995218515396118
of O O 0.9999691247940063
a O O 0.9999133348464966
second O O 0.9643339514732361
essential B-DNA O 0.9508708119392395
positive I-DNA O 0.8455777168273926
regulatory I-DNA O 0.5642325282096863

or O O 0.9769969582557678
PMA O O 0.9270460605621338
responded O O 0.9999347925186157
comparably O O 0.9999572038650513
to O O 0.9999737739562988
untreated O O 0.8869232535362244
samples O O 0.9155510067939758
. O O 0.9999910593032837
We O O 0.9999780654907227
detected O O 0.9999575614929199
an O O 0.9999744892120361
association O O 0.9988327622413635
between O O 0.9999092817306519
the O O 0.9998425245285034
reduced O O 0.9748126864433289
mitogenic O O 0.8143647909164429
response O O 0.9335377812385559
and O O 0.9981581568717957
low O O 0.9788596630096436
expression O O 0.9963065385818481
of O O 0.9999576807022095
both O O 0.9993348717689514
interleukin-2 S-protein S-protein 0.4912797808647156

class O O 0.40123552083969116
switching O O 0.9132208824157715
to O O 0.9980587363243103
IgE S-protein S-protein 0.9506839513778687
by O O 0.9996881484985352
cytokines S-protein S-protein 0.9806380271911621
is O O 0.9999268054962158
mediated O O 0.99997878074646
by O O 0.9999938011169434
STAT B-protein S-protein 0.8517690896987915
transcription I-protein O 0.7650824189186096

lineage- O O 0.7094897031784058
and O O 0.9884331822395325
stage-specific O O 0.9849995970726013
expression O O 0.9979150891304016
of O O 0.9999228715896606
CD20 S-protein S-protein 0.9676381349563599
in O O 0.9978064894676208
B B-cell_type B-cell_type 0.8177202939987183
lymphocytes E-cell_type E-cell_type 0.9909636974334717
. O O 0.9992157220840454
CD20 S-protein S-protein 0.7323924899101257
is O O 0.9997618794441223
a O O 0.9999556541442871
B-lineage-specific B-DNA B-DNA 0.45063042640686035
gene E-DNA E-DNA 0.9155712127685547
expressed O O 0.9922055602073669
at O O 0.9999946355819702
the O O 0.9999853372573853
pre-B-cell O O 0.7819533348083496
stage O O 0.9676676392555237
of O O 0.9997017979621887
B-cell O O 0.5924198627471924
development O O 0.9725633859634399

Thirty O O 0.9974276423454285
- O O 0.9997420907020569
six O O 0.9997668862342834
patients O O 0.9995951056480408
were O O 0.9999877214431763
treated O O 0.9999582767486572
with O O 0.999988317489624
BCNU B-Chemical B-Chemical 0.9310030341148376
every O O 0.9988294243812561
6 O O 0.99985671043396
to O O 0.999893307685852
8 O O 0.9998816251754761
weeks O O 0.9999544620513916
, O O 0.9999933242797852
either O O 0.9999984502792358
by O O 0.9999818801879883
transfemoral O O 0.8605049252510071
catheterization O O 0.8412633538246155
of O O 0.9948803186416626
the O O 0.9990845918655396
internal O O 0.9823487401008606
carotid O O 0.5398788452148438
or O O 0.9783681631088257
vertebral O O 0.6538513898849487
artery O O 0.7995074987411499
or O O 0.989149272441864
through O O 0.9999589920043945
a O O 0.9999229907989502
fully O O 0.9867660999298096
implantable O O 0.9717616438865662
intracarotid O O 0.37087389826774597
drug O O 0.5997626781463623
delivery O O 0.9357874393463135
system O O 0.9815002679824829
, O O 0.9999852180480957
beginning O O 0.9999690055847168
with O O 0.9999953508377075
a O O 0.9999370574951172
dose O O 0.9997771382331848
of O O 0.9999469518661499
200 O O 0.9545792937278748
mg O O 0.996674656867981
/ O O 0.9997157454490662
sq O O 0.9996838569641113
m O O 0.999129593372345
body O O 0.9832360148429871
surface O O 0.9708408713340759
area O O 0.9991725087165833
. O O 0.9999995231628418

, O O 0.9804947376251221
peripheral O B-cell_type 0.7776278257369995
blood B-cell_type I-cell_type 0.6348409056663513
lymphocytes E-cell_type E-cell_type 0.982752799987793
were O O 0.9997658133506775
stimulated O O 0.9996938705444336
with O O 0.9999896287918091
phytohemagglutinin S-protein S-protein 0.9014764428138733
( O O 0.9975294470787048
PHA S-protein O 0.6521390676498413
) O O 0.9864440560340881
. O O 0.9999141693115234
IL-2R O B-protein 0.5307775735855103
chains O E-protein 0.9835057854652405
were O O 0.9997445940971375
measured O O 0.99983811378479
by O O 0.9999802112579346
flow O O 0.9332394003868103
cytometry O O 0.9042560458183289
, O O 0.9995902180671692
and O O 0.9998866319656372
Jaks/Stats S-protein O 0.45068612694740295
by O O 0.9993311166763306
sodium O O 0.848468542098999

FINDINGS O O 0.9865651726722717
: O O 0.99980229139328
FS O O 0.5314950346946716
containing O O 0.9950894713401794
tAMCA B-Chemical B-Chemical 0.8990769982337952
caused O O 0.9964495897293091
paroxysmal O O 0.7440342903137207
brain O O 0.763403058052063
activity O O 0.5394444465637207
which O O 0.9973586201667786
was O O 0.9997519850730896
associated O O 0.9999468326568604
with O O 0.9999953508377075
distinct O O 0.9873397350311279
convulsive B-Disease O 0.5391152501106262
behaviours O O 0.8420354127883911
. O O 0.9998294115066528

OBJECTIVES O O 0.963911235332489
: O O 0.9999349117279053
To O O 0.9999629259109497
estimate O O 0.9999494552612305
the O O 0.9996517896652222
frequency O O 0.9643526077270508
and O O 0.9988111257553101
severity O O 0.8312512636184692
of O O 0.9970840811729431
valvular B-Disease O 0.6460792422294617
heart I-Disease O 0.4149637222290039
abnormality I-Disease O 0.9375487565994263
and O O 0.9864686727523804
its O O 0.999758780002594
possible O O 0.9977098703384399
reversibility O O 0.6033249497413635
after O O 0.9996538162231445
drug O O 0.8913620114326477
withdrawal O O 0.5651987791061401
in O O 0.9996751546859741
a O O 0.999974250793457
case O O 0.9933122992515564
- O O 0.9997437596321106
control O O 0.9962073564529419
study O O 0.9998494386672974
. O O 0.9999984502792358

family O E-protein 0.8605379462242126
have O O 0.9989014863967896
been O O 0.9999276399612427
isolated O O 0.9959391355514526
from O O 0.9999735355377197
invertebrates O O 0.8390341997146606
as O O 0.9990878105163574
well O O 0.9993865489959717
as O O 0.9999750852584839
vertebrates O O 0.8296478390693665
. O O 0.9999473094940186
We O O 0.9996129870414734
isolated O O 0.9773741960525513
mouse B-protein O 0.6321491003036499

activity O O 0.9777486324310303
constitutively O O 0.9992885589599609
expressed O O 0.9998660087585449
in O O 0.9992953538894653
T B-cell_type B-cell_type 0.9052553176879883
cells E-cell_type E-cell_type 0.9914212822914124
from O O 0.9994627833366394
RCC O O 0.638985812664032
patients O O 0.9551642537117004
is O O 0.9999657869338989
composed O O 0.999983549118042
mostly O O 0.9999915361404419
of O O 0.999961256980896
the O O 0.9998185038566589
NF-kappa B-protein B-protein 0.7835670709609985
B1 I-protein I-protein 0.8561450242996216
( I-protein I-protein 0.787623405456543
p50 I-protein I-protein 0.44093748927116394
) I-protein I-protein 0.4271402359008789
subunit E-protein E-protein 0.9793828725814819
. O O 0.9996008276939392
The O O 0.9999961853027344
second O O 0.9733961224555969
abnormality O O 0.9889784455299377
in O O 0.9999617338180542
kappa O O 0.6547582149505615
B-binding O O 0.43222931027412415
activity O O 0.9771239161491394
in O O 0.9999052286148071

in O O 0.9993624091148376
most O O 0.9991100430488586
cases O O 0.9988394379615784
of O O 0.999991774559021
Hodgkin O O 0.9634462594985962
's O O 0.973199725151062
disease O O 0.8538660407066345
( O O 0.999855637550354
HD O O 0.7640207409858704
) O O 0.9976761937141418
have O O 0.9999860525131226
been O O 0.9999337196350098
recently O O 0.9993832111358643
recognized O O 0.9998008608818054
to O O 0.9999570846557617
originate O O 0.9997599720954895
from O O 0.9999210834503174
the O O 0.9992104768753052
B-cell B-cell_type B-cell_type 0.4898837208747864
lineage E-cell_type E-cell_type 0.8312922716140747
, O O 0.9982388019561768
but O O 0.9999902248382568
their O O 0.9999880790710449
precise O O 0.9738465547561646
differentiation O O 0.9635738730430603
stage O O 0.993791401386261

viral O O 0.822966456413269
infections O O 0.9508211016654968
and O O 0.9998441934585571
viral O O 0.9731768369674683
clearance O O 0.9944736361503601
. O O 0.9999985694885254
This O O 0.9999929666519165
study O O 0.9999687671661377
was O O 0.9999951124191284
initiated O O 0.9999966621398926
to O O 0.9999953508377075
investigate O O 0.9999935626983643
whether O O 0.9999967813491821
a O O 0.9999381303787231
cytokine S-protein S-protein 0.6491491794586182
imbalance O O 0.8314691781997681
oriented O O 0.9962177872657776
toward O O 0.999945878982544
Th2 O O 0.4368012547492981
type O O 0.4337962567806244
response O O 0.9463772773742676
plays O O 0.9999192953109741
a O O 0.9999969005584717
role O O 0.9998633861541748
in O O 0.9999891519546509
chronic O O 0.921441376209259
hepatitis O O 0.8719673156738281
B O O 0.8443156480789185
. O O 0.9998922348022461
Cytokine B-protein O 0.532870352268219
profiles E-protein O 0.6179997324943542
of O O 0.9986805319786072
peripheral B-cell_type B-cell_type 0.6125436425209045
blood I-cell_type I-cell_type 0.9121199250221252

Although O O 0.9989263415336609
paralysis O B-Disease 0.9756010174751282
after O O 0.9896718263626099
magnesium S-Chemical B-Chemical 0.9337418675422668
administration O O 0.9290700554847717
has O O 0.9998617172241211
been O O 0.999907374382019
described O O 0.9999713897705078
in O O 0.9999898672103882
patients O O 0.9997480511665344
with O O 0.9999666213989258
known O O 0.9933613538742065
myasthenia O B-Disease 0.9156817197799683
gravis O I-Disease 0.9672634601593018
, O O 0.9888651371002197
it O O 0.9996975660324097
has O O 0.9999754428863525
not O O 0.9998972415924072
previously O O 0.9999600648880005
been O O 0.999861478805542
reported O O 0.999934196472168
to O O 0.9999656677246094
be O O 0.9998188614845276
the O O 0.9997838139533997
initial O O 0.9952240586280823
or O O 0.9995235204696655
only O O 0.9998998641967773
manifestation O O 0.9531962871551514
of O O 0.9991490840911865
the O O 0.9984044432640076
disease O O 0.7878075838088989
. O O 0.9999769926071167

a O O 0.9756313562393188

with O O 0.9992165565490723
multiple O O 0.9859511256217957
organ O O 0.9269699454307556
dysfunction O O 0.7484261393547058
due O O 0.9999616146087646
to O O 0.9999889135360718
eosinophilic O O 0.9040175676345825
tissue O O 0.9565980434417725
infiltration O O 0.9977594614028931
. O O 0.999997615814209
In O O 0.9999890327453613
the O O 0.9999879598617554
absence O O 0.9997023940086365
of O O 0.9999805688858032
karyotypic O O 0.8088391423225403
abnormalities O O 0.8860939741134644
, O O 0.9999426603317261
there O O 0.999997615814209
is O O 0.9999972581863403
no O O 0.999994158744812
specific O O 0.9983624815940857
test O O 0.9994080066680908
to O O 0.999992847442627
detect O O 0.9997506737709045
clonal O O 0.8592904210090637
eosinophilia O O 0.5025761127471924
in O O 0.999477207660675
IHES O O 0.4155725836753845
. O O 0.9999145269393921
Analysis O O 0.9998530149459839
of O O 0.9999756813049316
X-chromosome S-DNA O 0.4003182053565979
inactivation O O 0.7876611948013306
patterns O O 0.9733307361602783
can O O 0.9999876022338867
be O O 0.9999929666519165
used O O 0.9999772310256958
to O O 0.9999938011169434
determine O O 0.9999942779541016
whether O O 0.9999841451644897
proliferative O O 0.9232520461082458
disorders O O 0.8587456345558167
are O O 0.9999524354934692
clonal O O 0.8599153757095337
in O O 0.9957329630851746
origin O O 0.9593315720558167
. O O 0.999980092048645
Methylation O O 0.9544165134429932
of O O 0.9988763928413391
HpaII B-DNA S-protein 0.6401179432868958
and I-DNA O 0.9581964015960693
Hha I-DNA B-DNA 0.2901247441768646
I I-DNA I-DNA 0.7845635414123535
sites E-DNA E-DNA 0.7541263103485107
near O O 0.9980559349060059

cryptococcal O O 0.77418452501297
stimulation O O 0.9836376905441284
. O O 0.9999901056289673
In O O 0.9999834299087524
contrast O O 0.9997751116752625
, O O 0.99998939037323
inhibition O O 0.9964138865470886
of O O 0.9997861981391907
IL-1 B-RNA B-RNA 0.908897340297699
beta I-RNA I-RNA 0.9349130392074585
mRNA E-RNA E-RNA 0.9944440722465515
was O O 0.9996587038040161
of O O 0.9999732971191406
lesser O O 0.9937853813171387
magnitude O O 0.9410175681114197
and O O 0.99977046251297
occurred O O 0.9992334842681885
only O O 0.9999831914901733
when O O 0.9999765157699585
IL-10 S-protein S-protein 0.9139546155929565
was O O 0.999750554561615
added O O 0.9998623132705688
within O O 0.9999809265136719
2 O O 0.9976363182067871
h O O 0.9964845180511475
of O O 0.9998830556869507
cryptococcal O O 0.6640236973762512
stimulation O O 0.5516827702522278
. O O 0.9999600648880005

. O O 0.9980831146240234
The O O 0.9997755885124207
NF B-DNA B-protein 0.647412121295929
kappa I-DNA I-protein 0.8654823303222656
B I-DNA I-protein 0.7865290641784668
independent I-DNA I-protein 0.5313183665275574
cis-acting I-DNA I-protein 0.4018884599208832

Moreover O O 0.9848312139511108
, O O 0.9992544054985046
L O O 0.6862082481384277
- O O 0.8589971661567688
NOArg O O 0.9460569024085999
and O O 0.9418224096298218
7 O O 0.7097245454788208
- O O 0.5390830039978027
NI O O 0.8826119899749756
but O O 0.9983124732971191
not O O 0.999870777130127
L O O 0.748060941696167
- O O 0.7767195701599121
NIL O O 0.7566653490066528
intensify O O 0.9927108287811279
antihyperalgesic O O 0.6166003942489624
activity O O 0.7590159177780151
of O O 0.9988024234771729
HOE B-Chemical B-Chemical 0.9416011571884155
140 I-Chemical I-Chemical 0.9417906999588013
or O O 0.8396773934364319
des B-Chemical B-Chemical 0.9233010411262512
- I-Chemical I-Chemical 0.9913382530212402
Arg10HOE I-Chemical I-Chemical 0.9448297023773193
140 I-Chemical E-Chemical 0.9232202172279358
in O O 0.9967039227485657
toxic B-Disease B-Disease 0.5250484943389893
neuropathy I-Disease I-Disease 0.9001536965370178
. O O 0.9990112781524658

CASE O O 0.9868955016136169
SUMMARY O O 0.9996225833892822
: O O 0.9999536275863647
A O O 0.9998636245727539
40 O O 0.9993935823440552
- O O 0.9998906850814819
year O O 0.9999755620956421
- O O 0.999911904335022
old O O 0.9976717829704285
woman O O 0.9958235025405884
with O O 0.9999698400497437
major O O 0.7224370837211609
depression O B-Disease 0.5583648085594177
took O O 0.995868444442749
an O O 0.9993900060653687
overdose O O 0.9414172172546387
of O O 0.7879539132118225
venlafaxine S-Chemical B-Chemical 0.9336392879486084
in O O 0.9995276927947998
an O O 0.9999387264251709
apparent O O 0.9486454725265503
suicide O O 0.8336527347564697
attempt O O 0.7073463201522827
. O O 0.9999707937240601

BACKGROUND O O 0.9952954649925232
: O O 0.9999902248382568
We O O 0.9999884366989136
report O O 0.9999960660934448
on O O 0.9999927282333374
the O O 0.9999231100082397
manifestation O O 0.9869057536125183
of O O 0.9996285438537598
a O O 0.9874003529548645
levetiracetam B-Chemical B-Chemical 0.9327883720397949
( O O 0.8328848481178284
LEV B-Chemical B-Chemical 0.9265474081039429
) O O 0.6847711801528931
- O O 0.9950085878372192
induced O O 0.997011661529541
encephalopathy B-Disease B-Disease 0.9865466356277466
. O O 0.9987127780914307

% O O 0.9879063367843628
+/- O O 0.9994175434112549
4.7 O O 0.9996999502182007
% O O 0.999911904335022
, O O 0.9999779462814331
respectively O O 0.9999847412109375
by O O 0.9999926090240479
13-cis O O 0.9809079170227051
RA O O 0.991442859172821
. O O 0.9999911785125732
IgE S-protein S-protein 0.9530342817306519
synthesis O O 0.984459638595581
was O O 0.9999886751174927
even O O 0.99994957447052
more O O 0.999629020690918
markedly O O 0.9967057108879089
inhibited O O 0.9997848868370056
by O O 0.9999940395355225
RA O O 0.9627184867858887
starting O O 0.9996764659881592
at O O 0.9999704360961914
concentrations O O 0.9973440766334534
of O O 0.9998205304145813
> O O 0.9983035326004028
10 O O 0.9967727065086365
( O O 0.9998143315315247
-14 O O 0.9975860118865967
) O O 0.997502863407135
mol/L O O 0.9092925786972046
for O O 0.9989169836044312
B B-cell_type B-cell_type 0.7565584182739258
cells E-cell_type E-cell_type 0.9780239462852478
and O O 0.9973813891410828
> O O 0.9989714622497559
10 O O 0.9964266419410706
( O O 0.9996230602264404
-10 O O 0.9971515536308289
) O O 0.9982395172119141
mol/L O O 0.8968144059181213
for O O 0.9994687438011169
PBMC S-cell_type S-cell_type 0.9921575784683228
. O O 0.9999080896377563
Maximal O O 0.9575166702270508
inhibition O O 0.9916845560073853
of O O 0.9997512698173523

kinases E-protein E-protein 0.919439435005188
. O O 0.9988633394241333
We O O 0.9999041557312012
show O O 0.9999879598617554
here O O 0.9999877214431763
that O O 0.9999932050704956
c-Raf S-protein S-protein 0.9827422499656677
, O O 0.9959576725959778
which O O 0.9998751878738403
is O O 0.9998888969421387
at O O 0.999991774559021
the O O 0.9999666213989258
helm O O 0.9985841512680054
of O O 0.9999781847000122
the O O 0.9999518394470215
classic O O 0.8700543642044067
MAP- O O 0.7384023070335388
Erk S-protein O 0.42411404848098755
cascade O O 0.46624600887298584
, O O 0.9984672665596008
contributes O O 0.9999945163726807
to O O 0.9999552965164185
IL-2 S-protein S-protein 0.9667708873748779
induction O O 0.9971868395805359
through O O 0.9999940395355225
a O O 0.9996256828308105

to O O 0.9939172863960266
induce O O 0.9999657869338989
any O O 0.9999698400497437
of O O 0.99996018409729
these O O 0.9999679327011108
effects O O 0.9997661709785461
in O O 0.9999879598617554
the O O 0.9999121427536011
same O O 0.9997405409812927
cells O O 0.9625827074050903
. O O 0.9999964237213135
Activation O O 0.9977179765701294
of O O 0.9998974800109863
the O O 0.9999163150787354
erythropoietin B-protein B-protein 0.536608874797821
receptor E-protein E-protein 0.9440553784370422
caused O O 0.996651828289032
specific O O 0.9874390959739685
DNA-binding O O 0.8792368769645691
of O O 0.989528238773346
Stat B-protein S-protein 0.6193877458572388

I B-protein B-protein 0.6929122805595398
kappa I-protein I-protein 0.9249788522720337
B I-protein I-protein 0.7767118215560913
alpha E-protein E-protein 0.9126802086830139
( O O 0.9579097032546997
MAD3 S-protein O 0.39724069833755493
) O O 0.6256325244903564
- O O 0.9816790819168091
NF-kappa B-protein B-protein 0.462712824344635
B E-protein E-protein 0.9591699838638306
dissociation O O 0.9703283309936523
in O O 0.999976634979248
the O O 0.9998669624328613
cytosol O O 0.5906631946563721

Verapamil S-Chemical B-Chemical 0.9213675260543823
- O O 0.8747895359992981
induced O O 0.998572826385498
carbamazepine S-Chemical B-Chemical 0.9102438688278198
neurotoxicity O B-Disease 0.9923040270805359
. O O 0.9989433884620667

' O O 0.8534495830535889
of O O 0.9979388117790222
the O O 0.9998906850814819
human B-DNA B-DNA 0.36995700001716614
GM-CSF I-DNA I-DNA 0.47028854489326477
TATA I-DNA I-DNA 0.6389169692993164
box E-DNA E-DNA 0.9917097687721252
( O O 0.9921689629554749
bp B-DNA S-DNA 0.9325488805770874
-34 I-DNA O 0.5318891406059265

develop O O 0.9752824306488037
predominantly O O 0.9909077882766724
to O O 0.9982964396476746
T B-cell_type B-cell_type 0.843612015247345
cells E-cell_type E-cell_type 0.9929469227790833
in O O 0.9995014667510986
the O O 0.9998764991760254
thymus O O 0.7003087401390076
. O O 0.9996065497398376
The O O 0.9999934434890747
mechanisms O O 0.9994173049926758
controlling O O 0.9997910857200623
this O O 0.9998635053634644

, O O 0.9310181736946106
Tat S-protein S-protein 0.7364300489425659
is O O 0.9995307922363281
not O O 0.9998476505279541
otherwise O O 0.9999315738677979
absolutely O O 0.9985077977180481
required O O 0.9999076128005981
for O O 0.999953031539917
synthesis O O 0.9733573794364929
of O O 0.9997623562812805
full-length B-RNA B-RNA 0.5827670693397522
HIV I-RNA I-RNA 0.4006321430206299
transcripts E-RNA E-RNA 0.9408570528030396
and O O 0.9972988963127136
assembly O O 0.9570432901382446
of O O 0.9992579817771912
virus O O 0.7653796076774597
particles O O 0.6855171918869019
. O O 0.999908447265625
Direct O O 0.9947633743286133
sequencing O O 0.9947630763053894
of O O 0.9999208450317383
the O O 0.9998759031295776
viral B-DNA B-DNA 0.4964938461780548

7 O O 0.6208069324493408

the O O 0.9960306286811829
IL-2 B-protein B-protein 0.6732332706451416
receptor E-protein E-protein 0.9541361927986145
( O O 0.9615605473518372
IL-2R S-protein S-protein 0.9856448173522949
) O O 0.9647011160850525
. O O 0.999984860420227
Analysis O O 0.9999306201934814
of O O 0.9999898672103882
intracellular O O 0.9041680693626404
Ca2+ O O 0.8754512667655945
mobilization O O 0.9965710639953613
suggested O O 0.999990701675415
that O O 0.9999985694885254
the O O 0.9999006986618042
CD3 S-protein S-protein 0.8995874524116516
/ O O 0.9832795858383179
TcR S-protein S-protein 0.9712812900543213
-dependent O O 0.9950346946716309
signal O O 0.9823517203330994
transduction O O 0.9924076199531555
was O O 0.9999620914459229
impaired O O 0.9994351267814636
in O O 0.9999041557312012
PMA/Bt2cAMP-treated B-cell_line B-cell_line 0.8072910904884338
cells E-cell_line E-cell_line 0.9341530203819275
. O O 0.9998890161514282
Remarkably O O 0.9992470741271973

lymphoma O O 0.44389137625694275
( O O 0.9813335537910461
PEL S-cell_line O 0.6105441451072693
) O O 0.977554440498352
. O O 0.9999275207519531
These O O 0.9999971389770508
two O O 0.9986410737037659
cell B-cell_line B-cell_line 0.7977634072303772
lines E-cell_line E-cell_line 0.9690005779266357
are O O 0.9997350573539734
representative O O 0.9998917579650879
of O O 0.9999812841415405
different O O 0.9968245029449463
virologic O O 0.7322841286659241
subtypes O O 0.5076186060905457
of O O 0.9932246804237366
PEL S-cell_line S-protein 0.43697312474250793
, O O 0.9394438862800598

mechanisms O O 0.9353242516517639
controlling O O 0.9998650550842285
the O O 0.9999263286590576
pattern O O 0.9967026114463806
of O O 0.999754011631012
alpha B-protein B-protein 0.5730419158935547
4 E-protein E-protein 0.9340084195137024
expression O O 0.9967489242553711
. O O 0.9999977350234985
The O O 0.9999964237213135
activity O O 0.9975632429122925
of O O 0.9998692274093628
constructs O O 0.8868491649627686
containing O O 0.9986248016357422
5 B-DNA O 0.715495765209198

mobility O O 0.8952924013137817
shift O O 0.9625517725944519
assays O O 0.9956556558609009
( O O 0.9999783039093018
EMSA O O 0.967748761177063
) O O 0.9998574256896973
. O O 0.9999921321868896
Transfection O O 0.9890088438987732
of O O 0.9997343420982361
EL-4 B-cell_line B-cell_line 0.7647912502288818
cells E-cell_line E-cell_line 0.9796834588050842
with O O 0.999839186668396
the O O 0.9999469518661499
IL-4 B-DNA B-DNA 0.4207251965999603
promoter-reporter I-DNA I-DNA 0.45225784182548523
constructs E-DNA E-DNA 0.9941237568855286
carrying O O 0.9938755631446838
mutated B-DNA O 0.7333008646965027
P-like I-DNA B-DNA 0.4175683856010437
elements E-DNA E-DNA 0.9933727979660034
showed O O 0.9997510313987732
that O O 0.9999982118606567
four O O 0.9847978949546814
P-like B-DNA B-DNA 0.505770742893219
elements E-DNA E-DNA 0.9867608547210693
, O O 0.9965143799781799
CLE0 S-DNA S-DNA 0.9830971956253052
, O O 0.9935738444328308
P S-DNA S-DNA 0.9427937269210815
, O O 0.9479215145111084

of O O 0.9923849105834961
intact O O 0.928870677947998
USA O O 0.604673445224762
in O O 0.999566376209259
the O O 0.9999370574951172
assay O O 0.9574810266494751
system O O 0.9872224926948547
. O O 0.9999974966049194
Consistent O O 0.999906063079834
with O O 0.9999947547912598
the O O 0.9999891519546509
requirement O O 0.9995228052139282
for O O 0.9999525547027588
PC4 S-protein S-protein 0.7833118438720703
in O O 0.9997031092643738
the O O 0.9999769926071167
reconstituted O O 0.9058846831321716
system O O 0.9196174740791321
, O O 0.9999454021453857
OCA-B S-protein S-protein 0.9415526390075684
was O O 0.9991416931152344
found O O 0.9999446868896484
to O O 0.9999713897705078
interact O O 0.9999681711196899
directly O O 0.9999125003814697
with O O 0.9999743700027466
PC4 S-protein S-protein 0.7974008917808533
. O O 0.999779999256134
Surprisingly O O 0.9994522929191589
, O O 0.9999799728393555
however O O 0.9999678134918213
, O O 0.9999691247940063

The O O 0.9950590133666992
K S-Chemical B-Chemical 0.9155840873718262
( O O 0.8000501990318298
Na S-Chemical S-Chemical 0.9014604687690735
) O O 0.7383270263671875
value O O 0.9919813275337219
for O O 0.9998894929885864
Na S-Chemical B-Chemical 0.9206634759902954
+ O O 0.8840882778167725
returned O O 0.99808669090271
to O O 0.9999563694000244
control O O 0.9979356527328491
value O O 0.9975175857543945
. O O 0.9999984502792358

of O O 0.9926290512084961

shift O O 0.8414299488067627
assays O O 0.9920713305473328
with O O 0.9999938011169434
various O O 0.9942225813865662
mutant O B-DNA 0.6824288368225098
probes O E-DNA 0.8089626431465149
and O O 0.9884860515594482
B O O 0.4389318823814392
cell O O 0.31630486249923706
nuclear O O 0.685102641582489
extracts O O 0.9176098108291626
demonstrated O O 0.9999251365661621
that O O 0.9999982118606567
the O O 0.9999237060546875
core O B-DNA 0.7887687683105469
sequence O E-DNA 0.8681937456130981
TAAT O S-DNA 0.788322925567627
was O O 0.9996163845062256
essential O O 0.9999161958694458
for O O 0.9999626874923706
binding O O 0.9909830093383789
to O O 0.999889612197876
this O O 0.9995465874671936
site O O 0.9471635818481445
. O O 0.9998705387115479
Cross O O 0.9357445240020752
competition O O 0.9554349184036255
experiments O O 0.9860174059867859
with O O 0.999996542930603
an O O 0.9997782111167908
octamer O B-DNA 0.5667294859886169
sequence O E-DNA 0.9840466380119324
from O O 0.9995679259300232
the O O 0.9998019337654114

There O O 0.9997866749763489
is O O 0.999994158744812
evidence O O 0.9999774694442749
that O O 0.9999985694885254
all O O 0.9998772144317627
four O O 0.9995463490486145
immunosuppressive O O 0.6089057922363281
drugs O O 0.8197517395019531
can O O 0.9996238946914673
reduce O O 0.9966939687728882
synovitis B-Disease B-Disease 0.965747594833374
, O O 0.9823247194290161
but O O 0.9997403025627136
disease O O 0.7478803992271423
activity O O 0.7960206866264343
almost O O 0.9982396364212036
always O O 0.9997567534446716
recurs O O 0.9684429168701172
after O O 0.9996966123580933
therapy O O 0.9958898425102234
is O O 0.9999819993972778
stopped O O 0.9978260397911072
. O O 0.9999988079071045

PBMC S-cell_type S-cell_type 0.9158749580383301
from O O 0.999822199344635
Graves O O 0.8728671073913574
' O O 0.9482186436653137
patients O O 0.9942188262939453
before O O 0.9999979734420776
RAI O O 0.9265040159225464
therapy O O 0.9996517896652222
were O O 0.9999986886978149
less O O 0.9999330043792725
than O O 0.9999277591705322
those O O 0.9999825954437256
in O O 0.999929666519165
the O O 0.9997541308403015
presurgical O O 0.589773952960968

The O O 0.9987560510635376
aorta O O 0.8513785600662231
/ O O 0.9980440139770508
serum O O 0.9832507967948914
- O O 0.9974844455718994
ratio O O 0.9992039799690247
and O O 0.9999872446060181
the O O 0.9998524188995361
radioactive O O 0.6750057339668274
build O O 0.6274288296699524
- O O 0.9745015501976013
up O O 0.9991545677185059
24 O O 0.9994687438011169
and O O 0.9999608993530273
48 O O 0.9996966123580933
hours O O 0.9999799728393555
after O O 0.9999927282333374
injection O O 0.9846596717834473
of O O 0.9995235204696655
131I O B-Chemical 0.8416223526000977
- O I-Chemical 0.8098916411399841
HSA O I-Chemical 0.9390506744384766
was O O 0.9984371066093445
reduced O O 0.9990553259849548
in O O 0.9999551773071289
animals O O 0.9821346998214722
treated O O 0.9998743534088135
with O O 0.9999892711639404
D B-Chemical B-Chemical 0.8358327746391296
- I-Chemical I-Chemical 0.9786239862442017
pen E-Chemical I-Chemical 0.968375027179718
for O O 0.9854340553283691
42 O O 0.9970634579658508
days O O 0.9999759197235107
, O O 0.9999977350234985
indicating O O 0.9999971389770508
an O O 0.9999843835830688
impeded O O 0.9922032356262207
transmural O O 0.7332814931869507
transport O O 0.8440618515014648
of O O 0.9940902590751648
tracer O O 0.7197877764701843
which O O 0.9947754144668579
may O O 0.9999346733093262
be O O 0.9999607801437378
caused O O 0.9997093081474304
by O O 0.9999743700027466
a O O 0.9998918771743774
steric O O 0.8412622809410095
exclusion O O 0.7583908438682556
effect O O 0.9966688752174377
of O O 0.9999548196792603
abundant O O 0.8538914918899536
hyaluronate S-Chemical B-Chemical 0.7908071875572205
. O O 0.9995213747024536

proliferation O O 0.9683554768562317
. O O 0.9999439716339111
AR B-protein B-protein 0.7452846765518188
protein E-protein E-protein 0.9505371451377869
decreased O O 0.9993916749954224
by O O 0.9999921321868896
70 O O 0.9962939620018005
% O O 0.9995573163032532
and O O 0.9998610019683838
PSA S-protein O 0.6233276724815369
levels O O 0.9989256262779236
in O O 0.9997771382331848
supernatants O O 0.5911669731140137
from O O 0.9979336261749268
LNCaP B-cell_line B-cell_line 0.6090188026428223
cells E-cell_line E-cell_line 0.9005406498908997
were O O 0.9998624324798584
reduced O O 0.9999053478240967
by O O 0.99998939037323
approximately O O 0.9999531507492065
80 O O 0.9994068145751953
% O O 0.9998272061347961
following O O 0.9999936819076538
treatment O O 0.9998769760131836
with O O 0.9999873638153076
MCM O O 0.7735025882720947
. O O 0.9999583959579468
We O O 0.9999735355377197
focused O O 0.9999908208847046
on O O 0.9999805688858032
the O O 0.9999638795852661
contribution O O 0.9998672008514404
of O O 0.999990701675415
two O O 0.99791020154953
major O O 0.9313691258430481
products O O 0.5709724426269531
of O O 0.9900913238525391
activated O B-cell_type 0.7187167406082153
monocytes S-cell_type E-cell_type 0.8376224040985107
, O O 0.9964836835861206
prostaglandin O B-protein 0.3103996813297272
E2 O E-protein 0.8518183827400208
and O O 0.9877814054489136
interleukin B-protein B-protein 0.6096969842910767
1beta E-protein E-protein 0.9863271713256836
( O O 0.9892906546592712
IL-1beta S-protein S-protein 0.9793365597724915
) O O 0.9820189476013184
, O O 0.9998620748519897
to O O 0.9999921321868896
the O O 0.9999641180038452
MCM O O 0.3307925760746002
modulatory O O 0.37555554509162903
action O O 0.8356611132621765
. O O 0.999581515789032
LNCaP B-cell_line S-protein 0.5098196864128113

in O O 0.9980416297912598
patients O O 0.9996742010116577
. O O 0.9999984502792358
Infection O O 0.9805818200111389
of O O 0.9989666938781738
human B-cell_type B-cell_type 0.6864539980888367
peripheral I-cell_type I-cell_type 0.9066303372383118
blood I-cell_type I-cell_type 0.979404091835022

MMP O O 0.5702898502349854
- O O 0.9426848292350769
TIMP O O 0.7984628677368164
and O O 0.9995771050453186
ADAM O O 0.5986401438713074
mRNAs O O 0.7922388315200806
were O O 0.9999656677246094
semi O O 0.9785413146018982
- O O 0.9993390440940857
quantitatively O O 0.9979946613311768
analyzed O O 0.9994788765907288
and O O 0.9999778270721436
protein O O 0.9304221272468567
expressions O O 0.9750996828079224
were O O 0.9999943971633911
determined O O 0.999995231628418
by O O 0.9999898672103882
immunohistochemistry O O 0.8401692509651184
. O O 0.9999878406524658

Electrophysiological O O 0.9067040085792542
recordings O O 0.8812439441680908
showed O O 0.9999717473983765
that O O 0.9999814033508301
microinjection O O 0.6408209204673767
of O O 0.9914891719818115
neurotensin B-Chemical B-Chemical 0.925442636013031
induced O O 0.9430312514305115
excitation O O 0.4946446716785431
of O O 0.9787043333053589
pallidal O O 0.49946093559265137
neurons O O 0.6503461599349976
in O O 0.9991518259048462
the O O 0.9998806715011597
presence O O 0.9976404905319214
of O O 0.9999637603759766
systemic O O 0.8934151530265808
haloperidol B-Chemical B-Chemical 0.9150863885879517
administration O O 0.9809577465057373
. O O 0.9999920129776001

RESULTS O O 0.9988382458686829
: O O 0.9999792575836182
Twenty O O 0.9996034502983093
- O O 0.9995087385177612
eight O O 0.9995003938674927
patients O O 0.9991934895515442
( O O 0.9999935626983643
24 O O 0.9999697208404541
% O O 0.9999674558639526
) O O 0.9996713399887085
developed O O 0.9993422627449036
increased O O 0.9669380187988281
proteinuria O B-Disease 0.9791895151138306
from O O 0.9624233245849609
baseline O O 0.8580572605133057
during O O 0.9999624490737915
their O O 0.9999749660491943
post O O 0.9992077946662903
- O O 0.9995816349983215
transplantation O O 0.9046186804771423
course O O 0.9946893453598022
. O O 0.9999990463256836

RESULTS O O 0.9984626770019531
: O O 0.9999909400939941
The O O 0.9999902248382568
selected O O 0.9977005124092102
doses O O 0.9998074173927307
of O O 0.999560534954071
WR242511 B-Chemical B-Chemical 0.9228944778442383
, O O 0.9788499474525452
which O O 0.9999538660049438
produced O O 0.9998095631599426
significant O O 0.9946034550666809
methemoglobinemia B-Disease B-Disease 0.9506284594535828
in O O 0.949444055557251
beagle O O 0.6716981530189514
dogs O O 0.8962414860725403
in O O 0.9999629259109497
earlier O O 0.9993495345115662
studies O O 0.999382734298706
conducted O O 0.9999953508377075
elsewhere O O 0.9999551773071289
, O O 0.9999643564224243
produced O O 0.9997852444648743
very O O 0.9880006909370422
little O O 0.9944652915000916
MHb O O 0.5245735049247742
( O O 0.9826707243919373
mean O O 0.995864987373352
< O O 0.9992176294326782
2 O O 0.9997040629386902
. O O 0.9999403953552246
0 O O 0.9997718930244446
% O O 0.999835729598999
) O O 0.9986705780029297
in O O 0.9999809265136719
the O O 0.999858021736145
rhesus O O 0.660639762878418
monkey O O 0.47855162620544434
. O O 0.999846339225769

the O O 0.9979314804077148
peripheral O B-cell_type 0.7205990552902222
blood O I-cell_type 0.5746052265167236
lymphocytes O E-cell_type 0.9889580011367798
of O O 0.9977185726165771
one O O 0.9981513619422913
B-cell O O 0.44881317019462585
chronic O O 0.5972179174423218
lymphocytic O O 0.3815898597240448
leukemia O O 0.6923732757568359
( O O 0.7212984561920166
B-CLL O O 0.7659326195716858
) O O 0.5404346585273743
patient O O 0.7511911988258362
using O O 0.999792754650116
DNA O O 0.7854088544845581
transfer O O 0.7530741095542908
and O O 0.9987776875495911
a O O 0.9998817443847656
mouse O O 0.6590036153793335
tumorigenicity O O 0.585036039352417
assay O O 0.9891919493675232
. O O 0.9999958276748657
The O O 0.9999406337738037
Bcd S-DNA B-DNA 0.26491329073905945
proto-oncogene S-DNA E-DNA 0.9128836989402771
was O O 0.9976650476455688
activated O O 0.999610960483551
by O O 0.9999972581863403
a O O 0.9994192123413086
truncation O O 0.8903459310531616
in O O 0.9994503855705261
the O O 0.999751627445221
5 B-DNA B-DNA 0.5508868098258972
' I-DNA I-DNA 0.6997645497322083
UTR E-DNA E-DNA 0.9005064964294434
. O O 0.9992320537567139
It O O 0.9999427795410156
predicts O O 0.9999785423278809
for O O 0.9999752044677734

The O O 0.9995613694190979
effect O O 0.9998581409454346
of O O 0.9999865293502808
high O O 0.9803157448768616
dose O O 0.9798500537872314
D B-Chemical B-Chemical 0.9360114932060242
- I-Chemical I-Chemical 0.9885002374649048
penicillamine I-Chemical I-Chemical 0.924177348613739
treatment O O 0.9648560285568237
on O O 0.9999390840530396
aortic O O 0.7681459784507751
permeability O O 0.5798465609550476
to O O 0.996425211429596
albumin O B-Chemical 0.8814061880111694
and O O 0.9798406958580017
on O O 0.9996901750564575
the O O 0.9997562766075134
ultrastructure O O 0.9285263419151306
of O O 0.9965925812721252
the O O 0.9995669722557068
vessel O O 0.9783117175102234
. O O 0.9999843835830688

Proteomic O O 0.8070239424705505
analysis O O 0.9382457733154297
of O O 0.999665379524231
striatal O O 0.8101857304573059
proteins O O 0.8489313125610352
in O O 0.9999418258666992
the O O 0.9999175071716309
rat O O 0.9731742143630981
model O O 0.9985760450363159
of O O 0.9997643828392029
L B-Chemical B-Chemical 0.8996172547340393
- I-Chemical I-Chemical 0.9905080795288086
DOPA I-Chemical I-Chemical 0.9499967098236084
- O O 0.9013947248458862
induced O O 0.9973018169403076
dyskinesia B-Disease B-Disease 0.9843294620513916
. O O 0.9988412261009216

OBJECTIVE O O 0.9551928639411926
: O O 0.9997578263282776
This O O 0.9996262788772583
is O O 0.9999279975891113
to O O 0.9999816417694092
present O O 0.9999675750732422
reversible O O 0.9852890372276306
inferior O O 0.77866530418396
colliculus O O 0.36825209856033325
lesions O O 0.611298680305481
in O O 0.9978679418563843
metronidazole S-Chemical B-Chemical 0.9267206788063049
- O O 0.9093936681747437
induced O O 0.9961420893669128
encephalopathy O B-Disease 0.987036943435669
, O O 0.98678058385849
to O O 0.9997343420982361
focus O O 0.999756395816803
on O O 0.9999639987945557
the O O 0.9998542070388794
diffusion O O 0.8281771540641785
- O O 0.994143545627594
weighted O O 0.9812886714935303
imaging O O 0.9701898694038391
( O O 0.999848484992981
DWI O O 0.7015244364738464
) O O 0.9934523105621338
and O O 0.999903678894043
fluid O O 0.8042383193969727
attenuated O O 0.8909265398979187
inversion O O 0.9004454016685486
recovery O O 0.9528669714927673
( O O 0.9993064403533936
FLAIR O O 0.8897835612297058
) O O 0.9958057403564453
imaging O O 0.991216778755188
. O O 0.9999985694885254

of O O 0.9931437969207764
c-Rel S-protein S-protein 0.9577328562736511
and O O 0.9939291477203369
Rel B-protein B-protein 0.4789731800556183
A E-protein E-protein 0.9648838043212891
were O O 0.9991447925567627
normal O O 0.9677872657775879
in O O 0.9998315572738647
freshly O O 0.7797935009002686
isolated O O 0.9274482727050781
tumor-draining O O 0.650599479675293
LN O O 0.3873363733291626
, O O 0.9386385679244995
as O O 0.9998809099197388
was O O 0.9999333620071411
nuclear O B-protein 0.8152844905853271
kappaB S-protein E-protein 0.7936776876449585
DNA-binding O O 0.9012196063995361
activity O O 0.9934006929397583
induced O O 0.9999270439147949
by O O 0.9999791383743286
anti-CD3 B-protein S-protein 0.5914989113807678

Neither O O 0.9990835189819336
cardiac O O 0.7351381182670593
vagal O O 0.6512975096702576
nor O O 0.8725236058235168
sympathetic O O 0.7789868712425232
tone O O 0.6753581762313843
was O O 0.9985705614089966
altered O O 0.9997020363807678
by O O 0.999995231628418
isoproterenol B-Chemical B-Chemical 0.9244873523712158
pretreatment O O 0.7564677596092224
. O O 0.999975323677063

bp E-DNA E-DNA 0.6763396859169006
) O O 0.8705697059631348
contained O O 0.9999512434005737
an O O 0.9999516010284424
overlapping O O 0.7778164148330688
Sp1/Egr-1 B-DNA B-DNA 0.3469260036945343
site E-DNA E-DNA 0.9801730513572693
, O O 0.9928916692733765
and O O 0.999573290348053
region B-DNA B-DNA 0.6851468086242676
II E-DNA E-DNA 0.9863324761390686
( O O 0.9938589930534363
-119 B-DNA B-DNA 0.7056673169136047
to I-DNA I-DNA 0.8093522191047668
-88 E-DNA E-DNA 0.9803117513656616
) O O 0.9224421977996826
contained O O 0.9994219541549683
CRE S-DNA S-DNA 0.9147188067436218
and O O 0.9359817504882812
NF-kappaB B-DNA B-DNA 0.46130621433258057
( I-DNA I-DNA 0.8685327172279358
designated I-DNA I-DNA 0.8226017355918884
kappaB3 I-DNA I-DNA 0.5210904479026794
) I-DNA I-DNA 0.3520810604095459
sites E-DNA E-DNA 0.9631986618041992
. O O 0.9998108744621277
In O O 0.9999674558639526
unstimulated O O 0.7923340201377869
THP-1 S-cell_line S-protein 0.45948702096939087
, O O 0.9849468469619751
CRE-binding B-protein B-protein 0.4692021906375885
protein E-protein E-protein 0.9583243727684021
and O O 0.970017671585083
, O O 0.9940680265426636

the O O 0.9962015748023987

This O O 0.9997580647468567
study O O 0.9999855756759644
tested O O 0.9999946355819702
the O O 0.9999535083770752
hypothesis O O 0.9503719210624695
that O O 0.9999245405197144
activation O O 0.9578220248222351
of O O 0.9989621639251709
nociceptive B-Disease O 0.6524769067764282
muscle I-Disease O 0.6653146743774414
afferent O O 0.8874366879463196
fibers O O 0.7778365015983582
would O O 0.999931812286377
be O O 0.999980092048645
linked O O 0.9999711513519287
to O O 0.999990701675415
an O O 0.9999345541000366
increased O O 0.9859210848808289
excitability O O 0.7904613018035889
of O O 0.9915395379066467
the O O 0.9991798996925354
human O O 0.9324712157249451
jaw O O 0.8771657347679138
- O O 0.9959917664527893
stretch O O 0.9867470264434814
reflex O O 0.7776437401771545
and O O 0.9992520213127136
whether O O 0.9999973773956299
this O O 0.9999161958694458
process O O 0.9998466968536377
would O O 0.9999979734420776
be O O 0.9999672174453735
sensitive O O 0.9907751679420471
to O O 0.9997523427009583
length O O 0.9591167569160461
and O O 0.997780978679657
velocity O O 0.7610283493995667
of O O 0.9890539646148682
the O O 0.9994487166404724
stretch O O 0.9902791380882263
. O O 0.9999977350234985

molecular O O 0.8332499265670776
target O O 0.8662471771240234
for O O 0.999569833278656
SR O O 0.7338857054710388
31747A O O 0.5318921804428101
in O O 0.9995941519737244
mammalian O O 0.7578930258750916
tissues O O 0.8868810534477234
, O O 0.9993496537208557
which O O 0.9999727010726929
could O O 0.9999959468841553
be O O 0.999992847442627
critical O O 0.9977915287017822
for O O 0.9999423027038574
T O O 0.7671763300895691
cell O O 0.5729883313179016
proliferation O O 0.9941879510879517
. O O 0.9999970197677612
Phospholipase B-protein B-protein 0.7241503000259399
C I-protein I-protein 0.3979727029800415
gamma I-protein E-protein 0.6404736042022705

Prenatal O O 0.6361101865768433
exposure O O 0.685500979423523
to O O 0.9977374076843262
selective O O 0.9481736421585083
COX O O 0.5278691649436951
- O O 0.8965368270874023
2 O O 0.9115738272666931
inhibitors O O 0.7523202896118164
does O O 0.9999814033508301
not O O 0.9998784065246582
increase O O 0.9991866946220398
the O O 0.9995061159133911
risk O O 0.9995288848876953
of O O 0.9999688863754272
ventricular O O 0.6323856115341187
septal O O 0.8147830367088318
and O O 0.6749569177627563
midline O O 0.510167121887207
defects O O 0.8514391779899597
in O O 0.9805444478988647
rat O O 0.838171124458313
when O O 0.9992192983627319
compared O O 0.9999390840530396
to O O 0.9999769926071167
non O O 0.9453879594802856
- O O 0.9922153353691101
selective O O 0.9394242763519287
drugs O O 0.9412109851837158
and O O 0.9997658133506775
historic O O 0.9151148200035095
control O O 0.8689778447151184
. O O 0.9999845027923584

Thus O O 0.9958051443099976
, O O 0.9999289512634277
A-myb S-DNA S-protein 0.5592280030250549
expression O O 0.9899216294288635
, O O 0.9999760389328003
unlike O O 0.9999932050704956
that O O 0.9999864101409912
of O O 0.9997846484184265
c-myb S-DNA S-DNA 0.8275848031044006
and O O 0.9408619999885559
B-myb S-DNA S-DNA 0.817072868347168
, O O 0.9931424856185913
is O O 0.999980092048645
restricted O O 0.99958735704422
to O O 0.9999837875366211
a O O 0.9998118281364441
subset O O 0.980453610420227
of O O 0.9996629953384399
B-cell O O 0.30187729001045227
neoplasias O O 0.4525909721851349
( O O 0.8826120495796204
in O O 0.9977830052375793

Laboratory O O 0.9725825190544128
evaluations O O 0.9942135214805603
, O O 0.9999970197677612
including O O 0.9999946355819702
head O O 0.9779798984527588
CT O O 0.8928316831588745
scan O O 0.9635290503501892
, O O 0.999671220779419
were O O 0.9999707937240601
normal O O 0.9975691437721252
. O O 0.999998927116394

isoforms O O 0.4490869343280792

During O O 0.9984278678894043
monitoring O O 0.9957388639450073
, O O 0.9999217987060547
visual O O 0.886670708656311
hallucinations O O 0.7376929521560669
did O O 0.9980155229568481
not O O 0.9999312162399292
correlate O O 0.9999719858169556
with O O 0.9999891519546509
EEG O O 0.4466896951198578
readings O O 0.8359463810920715
, O O 0.999941349029541
nor O O 0.9999014139175415
did O O 0.9999823570251465
video O O 0.9798938632011414
recording O O 0.9895644187927246
capture O O 0.999783456325531
any O O 0.9999865293502808
of O O 0.999983549118042
the O O 0.999985933303833
described O O 0.9934965372085571
events O O 0.9847788214683533
. O O 0.9999927282333374

of O O 0.997404158115387
their O O 0.9999479055404663
C O O 0.6068349480628967
terminal O O 0.4735106825828552
peptides O O 0.29502224922180176
and O O 0.9654332399368286
mode O O 0.9465939998626709
of O O 0.9934508800506592
synthesis O O 0.9759682416915894
. O O 0.9999815225601196
Due O O 0.9999936819076538
to O O 0.9999923706054688
a O O 0.999958872795105
switch O O 0.9932732582092285
from O O 0.9999594688415527
the O O 0.9998518228530884
use O O 0.9993500113487244
of O O 0.9999356269836426
a O O 0.9989603757858276
3 B-DNA B-DNA 0.6330498456954956
' I-DNA I-DNA 0.6677944660186768
polyA I-DNA I-DNA 0.5164030194282532
site E-DNA E-DNA 0.9588121175765991
to O O 0.9956661462783813

RelB S-protein S-protein 0.9420149326324463
are O O 0.9998370409011841
restricted O O 0.9948280453681946
to O O 0.9998317956924438
accessory B-cell_type B-cell_type 0.5829899907112122
cells E-cell_type E-cell_type 0.932046115398407
of O O 0.9943358302116394
the O O 0.9997259974479675
immune O O 0.9475587606430054
system O O 0.9590284824371338
, O O 0.9999512434005737
which O O 0.999983549118042
include O O 0.9999812841415405
FDC S-cell_type S-cell_type 0.6920565366744995
in O O 0.9981297850608826
GC O O 0.3474647104740143
, O O 0.7515605092048645
and O O 0.9407341480255127
DC S-cell_type S-cell_type 0.9706801176071167
and O O 0.9931514263153076
macrophages O S-cell_type 0.985601007938385
in O O 0.9995704293251038

FINDINGS O O 0.9930411577224731
: O O 0.9999774694442749
A O O 0.9999091625213623
temporal O O 0.6993439793586731
relationship O O 0.8428289294242859
was O O 0.9996334314346313
found O O 0.9999817609786987
between O O 0.9997723698616028
topical O O 0.9506614208221436
papaverine S-Chemical B-Chemical 0.8994919657707214
and O O 0.9944362640380859
BAEP O O 0.4428815543651581
changes O O 0.9489638805389404
leading O O 0.9998148083686829
to O O 0.9999912977218628
complete O O 0.9935570359230042
waveform O O 0.5825999975204468
loss O O 0.7547232508659363
. O O 0.9997972846031189

interleukin-3 B-cell_line S-protein 0.5961552262306213
( I-cell_line O 0.945015013217926
IL-3 I-cell_line S-protein 0.9635144472122192
) I-cell_line O 0.8651934862136841
-dependent I-cell_line O 0.9661762714385986
murine I-cell_line B-cell_type 0.6285601854324341
pro-B I-cell_line I-cell_type 0.6393195986747742
cells E-cell_line E-cell_type 0.9292970299720764
after O O 0.9996974468231201
IL-3 S-protein S-protein 0.9704260230064392
withdrawal O O 0.9945259094238281
suggests O O 0.9999905824661255
that O O 0.9999934434890747
it O O 0.9997479319572449
disrupts O O 0.9997453093528748
signaling O O 0.9607203006744385
pathways O O 0.9939541220664978
normally O O 0.9999611377716064
responsible O O 0.9999678134918213
for O O 0.999981164932251
cell O O 0.9773436784744263
suicide O O 0.9899095296859741
, O O 0.9999920129776001
allowing O O 0.9999618530273438
the O O 0.9998832941055298

extracts O O 0.9416410326957703
of O O 0.9997780919075012
peripheral B-cell_type B-cell_type 0.5561151504516602
blood I-cell_type I-cell_type 0.7740049362182617
T I-cell_type I-cell_type 0.9406577348709106
cells E-cell_type E-cell_type 0.9854164719581604
stimulated O O 0.9976010918617249
with O O 0.9999654293060303
PMA O O 0.8317208886146545
plus O O 0.9958603978157043
alphaCD28 S-protein S-protein 0.804075300693512
. O O 0.9996373653411865
Peripheral B-cell_type B-cell_type 0.5537466406822205
blood I-cell_type I-cell_type 0.7877883315086365
T I-cell_type I-cell_type 0.9549844264984131
cells E-cell_type E-cell_type 0.9908954501152039
stimulated O O 0.9984288811683655
with O O 0.9999721050262451
PMA O O 0.49639105796813965
/alphaCD28 S-protein S-protein 0.6783391237258911

Tissues O O 0.5630380511283875
were O O 0.9986213445663452
analyzed O O 0.9999719858169556
at O O 0.9999978542327881
0 O O 0.9989683628082275
, O O 0.9998040795326233
5 O O 0.9996591806411743
, O O 0.9998917579650879
7 O O 0.9996317625045776
, O O 0.9998931884765625
11 O O 0.9996076226234436
, O O 0.999919056892395
21 O O 0.9996090531349182
, O O 0.9998974800109863
45 O O 0.9991931319236755
, O O 0.9998218417167664
80 O O 0.998955249786377
and O O 0.9999161958694458
126 O O 0.9997346997261047
days O O 0.9999593496322632
after O O 0.9999867677688599
PAN S-Chemical B-Chemical 0.9138646721839905
injection O O 0.957086980342865
so O O 0.9998660087585449
as O O 0.9999895095825195
to O O 0.9999220371246338
include O O 0.9999611377716064
both O O 0.9999065399169922
the O O 0.9998791217803955
acute O O 0.8719265460968018
phase O O 0.9832721948623657
of O O 0.9994643330574036
proteinuria O B-Disease 0.9796567559242249
associated O O 0.9296299815177917
with O O 0.9996201992034912
foot O O 0.9239561557769775
process O O 0.9144986867904663
effacement O O 0.7792924046516418
( O O 0.9998496770858765
days O O 0.9998914003372192
5 O O 0.9998776912689209
- O O 0.9917353391647339
11 O O 0.9744349122047424
) O O 0.998630940914154
and O O 0.9999830722808838
the O O 0.9999556541442871
chronic O O 0.8993457555770874
phase O O 0.9866270422935486
of O O 0.9995607733726501
proteinuria O B-Disease 0.9823653101921082
associated O O 0.9242147207260132
with O O 0.9991063475608826
glomerulosclerosis O B-Disease 0.9783304333686829
( O O 0.9765331149101257
days O O 0.9987249970436096
45 O O 0.9993783235549927
- O O 0.9926751255989075
126 O O 0.7875758409500122
) O O 0.9968770742416382
. O O 0.9999980926513672

for O O 0.9951985478401184
activation O O 0.9966499209403992
of O O 0.9998531341552734
JAK-1 S-protein S-protein 0.9510706663131714
and O O 0.9963087439537048
STAT6 S-protein S-protein 0.9882793426513672
and O O 0.9980788230895996
the O O 0.9999438524246216
induction O O 0.9975553154945374
of O O 0.9998682737350464
IL-4 S-protein S-protein 0.9754394888877869
-specific O O 0.9852247834205627
gene O O 0.9492805600166321
expression O O 0.9990394711494446
. O O 0.9999973773956299
The O O 0.9999828338623047
common B-protein B-protein 0.8322753310203552
gamma-chain E-protein I-protein 0.4232460856437683
( O I-protein 0.6535683274269104
gamma B-protein I-protein 0.42977991700172424
( I-protein I-protein 0.7489568591117859
c I-protein I-protein 0.9028621912002563
) E-protein E-protein 0.9595599174499512
) O O 0.5040802955627441
is O O 0.9997947812080383
a O O 0.9999840259552002
functional O O 0.9312131404876709
component O O 0.7601709365844727
of O O 0.9994487166404724
the O O 0.9997125267982483
IL-4R S-protein S-protein 0.71882563829422
, O O 0.8719050288200378

the O O 0.9980450868606567
antioxidant O O 0.8581861853599548
had O O 0.9992362260818481
no O O 0.9999717473983765
appreciable O O 0.9966703057289124
effect O O 0.9999098777770996
when O O 0.9999991655349731
an O O 0.9998910427093506
oligomer O O 0.6074684858322144
corresponding O O 0.981726348400116
to O O 0.9997671246528625
the O O 0.9999488592147827
consensus B-DNA B-DNA 0.5852364897727966
NF-kappa I-DNA I-DNA 0.49072200059890747
B I-DNA I-DNA 0.4469076693058014
binding I-DNA I-DNA 0.8821986317634583
site E-DNA E-DNA 0.9720447063446045
of O O 0.9959073066711426
the O O 0.9998295307159424
E-selectin B-DNA B-DNA 0.693020761013031
gene E-DNA E-DNA 0.9823499917984009
( O O 0.9899425506591797
E-selectin S-protein B-DNA 0.8056381940841675
-NF-kappa B-protein I-DNA 0.3368465304374695
B E-protein E-DNA 0.6631504893302917
) O O 0.9316820502281189
was O O 0.9997937083244324
used O O 0.9999637603759766
. O O 0.9999986886978149
Because O O 0.9999707937240601
NF-kappa B-protein B-protein 0.6464596390724182
B E-protein E-protein 0.955464243888855
has O O 0.9991563558578491
been O O 0.9999485015869141
reported O O 0.9998750686645508
to O O 0.9983710646629333

that O O 0.9993308782577515
classical O B-protein 0.8765312433242798
protein B-protein I-protein 0.6102241277694702
kinase I-protein I-protein 0.41343334317207336
C I-protein I-protein 0.9719632863998413
( I-protein I-protein 0.9356192946434021
PKC I-protein I-protein 0.9481459856033325
) I-protein I-protein 0.8323442935943604
isoenzymes E-protein E-protein 0.8360521793365479
were O O 0.9997178912162781
not O O 0.9999620914459229
involved O O 0.9999889135360718
in O O 0.999996542930603
the O O 0.9999825954437256
HIV-mediated O O 0.9308890700340271
NF-kappa B-protein B-protein 0.42791152000427246
B E-protein E-protein 0.9876623153686523
activation O O 0.9954008460044861
. O O 0.9999949932098389
In O O 0.9999939203262329
this O O 0.9999955892562866
study O O 0.999911904335022
, O O 0.9999927282333374
we O O 0.9998971223831177
have O O 0.9999945163726807
focused O O 0.9999887943267822
on O O 0.9999706745147705
atypical O B-protein 0.8756794333457947
PKC B-protein I-protein 0.5699648261070251
isoenzymes E-protein E-protein 0.9659498333930969
. O O 0.999785840511322
PKC-zeta S-protein S-protein 0.956028401851654
belongs O O 0.9994532465934753
to O O 0.9999861717224121
this O O 0.9999411106109619

IL-1 S-DNA S-protein 0.9506993889808655
, O O 0.992836058139801
and O O 0.9985195994377136
IL-6 S-DNA S-protein 0.991384744644165
. O O 0.9997875094413757
Electrophoretic O O 0.9683772921562195
mobility O O 0.9882182478904724
shift O O 0.9992148876190186
assays O O 0.9998323917388916
showed O O 0.9999971389770508
that O O 0.9999974966049194
both O O 0.9996769428253174
surfactants O O 0.8850671648979187
decreased O O 0.9983428716659546
activation O O 0.9977905750274658
of O O 0.9998949766159058
NF-kappa B-protein B-protein 0.8590114712715149
B E-protein E-protein 0.9933352470397949
. O O 0.9995716214179993
The O O 0.9999970197677612
presence O O 0.9993360638618469
of O O 0.9999775886535645
both O O 0.9993513226509094
p65 S-protein S-protein 0.7847200036048889
and O O 0.8882827162742615
p50 S-protein B-protein 0.6521829962730408
NF-kappa B-protein I-protein 0.5892979502677917
B I-protein I-protein 0.8721840977668762
components E-protein E-protein 0.867224395275116
in O O 0.9995859265327454
LPS-activated O B-cell_line 0.6596963405609131
THP-1 B-cell_line I-cell_line 0.7188051342964172
cells E-cell_line E-cell_line 0.9944713115692139

METHODS O O 0.9794262051582336
: O O 0.9999756813049316
The O O 0.9999890327453613
Multiple O O 0.984107494354248
Outcomes O O 0.9712444543838501
of O O 0.9992165565490723
Raloxifene B-Chemical S-Chemical 0.9010008573532104
Evaluation O O 0.84977126121521
, O O 0.99996018409729
a O O 0.9999836683273315
multicenter O O 0.9428958892822266
, O O 0.9969205856323242
randomized O O 0.9714158177375793
, O O 0.9990962743759155
double O O 0.9839370846748352
- O O 0.9980012774467468
blind O O 0.951599657535553
trial O O 0.9945762157440186
, O O 0.9999896287918091
enrolled O O 0.9994686245918274
7 O O 0.9062893390655518
, O O 0.9961048364639282
705 O O 0.9986469149589539
postmenopausal O O 0.5612866282463074
women O O 0.9398500323295593
with O O 0.9996998310089111
osteoporosis B-Disease O 0.9332704544067383
. O O 0.9986763596534729

internalization O O 0.9730121493339539

both O O 0.9980506896972656
rheumatoid O O 0.7590150237083435
and O O 0.9264166355133057
osteoarthritis O O 0.9399943351745605
. O O 0.9999908208847046
A O O 0.9985960125923157
significant O O 0.9991196990013123
( O O 0.9995606541633606
P O O 0.996644914150238
< O O 0.9998542070388794
0.001 O O 0.9990719556808472
and O O 0.9998503923416138
< O O 0.999708354473114
0.05 O O 0.9995317459106445
, O O 0.9998370409011841
respectively O O 0.9998013377189636
) O O 0.999618649482727
increase O O 0.9982006549835205
in O O 0.9998587369918823
the O O 0.9999405145645142
percentage O O 0.9975022673606873
of O O 0.9999102354049683
cells O O 0.9562836289405823
with O O 0.9999494552612305
nuclear O O 0.8766559958457947
staining O O 0.8181629180908203
was O O 0.9996472597122192
seen O O 0.9999831914901733

thymocytes E-cell_type E-cell_type 0.7180845737457275
. O O 0.999778687953949
Tumor B-protein B-protein 0.5933916568756104
necrosis I-protein I-protein 0.8392046093940735
factor E-protein E-protein 0.94107985496521
( O O 0.9215121269226074
TNF S-protein S-protein 0.9644991755485535
) O O 0.9197125434875488
and O O 0.9950671195983887
interleukin-7 S-protein S-protein 0.985822856426239
( O O 0.9851084351539612
IL-7 S-protein S-protein 0.9972971081733704
) O O 0.978243350982666
, O O 0.9997833371162415
secreted O O 0.9854534268379211
during O O 0.999845027923584
this O O 0.9998798370361328
interaction O O 0.9976171851158142
, O O 0.9999823570251465
are O O 0.9999891519546509
critical O O 0.9939467310905457

THP S-Chemical B-Chemical 0.7701917290687561
exhibited O O 0.99244225025177
an O O 0.9999260902404785
antipsychotic O O 0.6906288266181946
- O O 0.9294644594192505
like O O 0.9658668041229248
profile O O 0.9727888107299805
by O O 0.9999746084213257
potentiating O O 0.6312642693519592
haloperidol S-Chemical B-Chemical 0.9240548610687256
- O O 0.9349544048309326
induced O O 0.9987342953681946
catalepsy O B-Disease 0.9754976034164429
, O O 0.9922024011611938
reducing O O 0.996722400188446
amphetamine S-Chemical B-Chemical 0.9322397112846375
- O O 0.9064251780509949
induced O O 0.9987797141075134
hyperactivity O B-Disease 0.9833452105522156
and O O 0.9714739918708801
reducing O O 0.9952588677406311
apomorphine S-Chemical B-Chemical 0.9256635904312134
- O O 0.9624714851379395
induced O O 0.9986085295677185
climbing O O 0.8764037489891052
in O O 0.9672436118125916
mice O O 0.9912191033363342
. O O 0.999998927116394

resulting O O 0.9954029321670532
from O O 0.9999438524246216
T O O 0.632565975189209
cell O O 0.5342515110969543
triggering O O 0.9455488920211792
with O O 0.9997594952583313
alpha B-protein B-protein 0.5169479250907898
CD3 E-protein E-protein 0.9517976641654968
, O O 0.9972535967826843
but O O 0.999945878982544
at O O 0.9999958276748657
later O O 0.9855948686599731
time O O 0.9989325404167175
points O O 0.9972112774848938
prevents O O 0.9999738931655884
the O O 0.9999510049819946
appearance O O 0.9996452331542969
of O O 0.9999790191650391
functional O O 0.8955776691436768
NF-AT1 B-protein S-protein 0.9293881058692932
transcription I-protein B-protein 0.783456027507782
factor I-protein I-protein 0.6680585741996765
complexes E-protein E-protein 0.9920694828033447
in O O 0.9998449087142944
T O O 0.5514414310455322
cell O O 0.4523983895778656
nuclear O O 0.8099034428596497
extracts O O 0.9248668551445007
. O O 0.9999890327453613
These O O 0.9999959468841553
findings O O 0.9997742772102356
are O O 0.9999974966049194
consistent O O 0.9999860525131226
with O O 0.9999985694885254
the O O 0.9999700784683228
postulated O O 0.9544853568077087
role O O 0.9907817244529724
for O O 0.9998632669448853
TN S-protein S-protein 0.7195696234703064
as O O 0.9990717172622681
a O O 0.9999827146530151
natural O O 0.8710893392562866
antagonist O O 0.9058862328529358

population O O 0.7751490473747253
of O O 0.9964916110038757
thymocytes S-cell_type S-cell_type 0.9872350096702576
were O O 0.999809205532074
undergoing O O 0.999771773815155
apoptosis O O 0.9904850721359253
. O O 0.9999985694885254
The O O 0.9999872446060181
spleen O O 0.8883089423179626
exhibited O O 0.9997373223304749
a O O 0.999964714050293
marked O O 0.9938502311706543
reduction O O 0.9964525699615479
in O O 0.9995185136795044
splenic B-cell_type O 0.627670407295227

A O O 0.9255287051200867
chi O O 0.9286484718322754
- O O 0.9961912631988525
square O O 0.9848312139511108
test O O 0.9994888305664062
was O O 0.9999935626983643
used O O 0.9999948740005493
to O O 0.9999961853027344
assess O O 0.999984860420227
the O O 0.9999275207519531
statistical O O 0.9951813817024231
significance O O 0.9988338351249695
of O O 0.9999768733978271
results O O 0.9992349147796631
. O O 0.999998927116394

transcription O O 0.7354481220245361
from O O 0.9998477697372437
a O O 0.9998753070831299
reporter O B-DNA 0.8181047439575195
construct O E-DNA 0.9228427410125732
containing O O 0.9963136315345764
GAL4 B-DNA B-DNA 0.43916597962379456
sites E-DNA E-DNA 0.9780077338218689
in O O 0.9997686743736267
a O O 0.999945878982544
cotransfection O O 0.7015668153762817
assay O O 0.8781894445419312
in O O 0.9999463558197021
the O O 0.999889612197876
Raji B-cell_line B-cell_line 0.734671950340271
human I-cell_line I-cell_line 0.8233892321586609
B I-cell_line I-cell_line 0.947564959526062
cell I-cell_line I-cell_line 0.9646811485290527
line E-cell_line E-cell_line 0.9863396883010864
. O O 0.9996962547302246
However O O 0.9999494552612305
, O O 0.9999933242797852
these O O 0.9999748468399048
plasmids S-DNA O 0.47888508439064026
produced O O 0.9993348717689514
transcriptional O O 0.9141600728034973
activity O O 0.9929866194725037
in O O 0.999984860420227
HeLa B-cell_line B-cell_line 0.742071270942688

cultured O O 0.9421724677085876
in O O 0.9998958110809326
the O O 0.9999687671661377
presence O O 0.9988117218017578
of O O 0.9999791383743286
the O O 0.9997071623802185
IL-4 S-protein S-protein 0.9312102198600769
or O O 0.9599880576133728
IL-13 S-protein S-protein 0.940396249294281
but O O 0.9937259554862976
not O O 0.9982555508613586
by O O 0.9997605681419373
IL-10 S-protein S-protein 0.9933775067329407
. O O 0.9997962117195129
When O O 0.9999245405197144
peripheral O O 0.5853679776191711

Increased O O 0.9879056215286255
production O O 0.9877382516860962
of O O 0.9985652565956116
FRs O O 0.7463218569755554
may O O 0.9993581175804138
cause O O 0.9999574422836304
mtDNA O O 0.6628173589706421
damage O O 0.9435863494873047
leading O O 0.9675083756446838
to O O 0.9997726082801819
decreased O O 0.987711489200592
activities O O 0.9909121990203857
of O O 0.9997721314430237
oxidative O O 0.9313517808914185
phosphorylation O O 0.7947164177894592
complexes O O 0.9486564993858337
containing O O 0.9999097585678101
mtDNA O O 0.704315721988678
- O O 0.964057981967926
encoded O O 0.9978328347206116
subunits O O 0.9647850394248962
. O O 0.9999909400939941

The O O 0.999392032623291
nicotine B-Chemical B-Chemical 0.9131946563720703
lozenge O O 0.6424919366836548
and O O 0.994782030582428
nicotine B-Chemical B-Chemical 0.9158197045326233
gum O O 0.7229049205780029
were O O 0.9997196793556213
equally O O 0.999358594417572
well O O 0.9973413348197937
tolerated O O 0.9955190420150757
, O O 0.9999920129776001
despite O O 0.999990701675415
increased O O 0.9985079169273376
nicotine B-Chemical B-Chemical 0.9116761088371277
exposure O O 0.9599301815032959
from O O 0.99986732006073
the O O 0.9990841150283813
lozenge O O 0.7292248606681824
. O O 0.9999359846115112

transcription O O 0.6482393145561218
, O O 0.9972020387649536
and O O 0.9999532699584961
that O O 0.9999947547912598
the O O 0.9998939037322998
5'-untranslated B-DNA B-DNA 0.4777691662311554
region E-DNA E-DNA 0.847042441368103
of O O 0.9960970282554626
the O O 0.9998219609260559
B2 B-DNA B-DNA 0.7538360953330994
gene E-DNA E-DNA 0.9545906186103821
, O O 0.9880967140197754
containing O O 0.999954104423523
multiple O O 0.9236687421798706
consensus B-DNA B-DNA 0.5216736793518066
binding I-DNA I-DNA 0.733721911907196
sites E-DNA E-DNA 0.9763500094413757
for O O 0.9994623064994812
the O O 0.9999425411224365
transcription B-protein B-protein 0.4152720868587494
factors E-protein E-protein 0.9761151671409607
AP-2 S-protein S-protein 0.8909686803817749

the O O 0.9962015748023987

Skin O O 0.6667981743812561
tests O O 0.9819121360778809
were O O 0.9999902248382568
performed O O 0.9999967813491821
with O O 0.9999877214431763
benzylpenicilloyl B-Chemical B-Chemical 0.9378367066383362
- I-Chemical I-Chemical 0.9248962998390198
poly I-Chemical I-Chemical 0.9560528993606567
- I-Chemical I-Chemical 0.9901768565177917
L I-Chemical I-Chemical 0.9564194679260254
- I-Chemical I-Chemical 0.992381751537323
lysine E-Chemical I-Chemical 0.9467281699180603
( O O 0.8158678412437439
BPO B-Chemical B-Chemical 0.9141931533813477
- I-Chemical I-Chemical 0.9878780841827393
PLL E-Chemical I-Chemical 0.9585098624229431
) O O 0.6204102635383606
, O O 0.9805287718772888
benzylpenicilloate S-Chemical B-Chemical 0.9354921579360962
, O O 0.9227174520492554
benzylpenicillin S-Chemical B-Chemical 0.9422023296356201
( O O 0.8735318779945374
PG S-Chemical B-Chemical 0.9446520209312439
) O O 0.6826424598693848
, O O 0.9906084537506104
ampicillin S-Chemical B-Chemical 0.9446828365325928
( O O 0.9225549697875977
AMP S-Chemical B-Chemical 0.9291045665740967
) O O 0.7322916388511658
, O O 0.9982499480247498
and O O 0.9975207448005676
AX S-Chemical B-Chemical 0.9240367412567139
. O O 0.9993863105773926

and O O 0.9477782249450684

. O O 0.9977317452430725
Fewer O O 0.9997283816337585
apoptotic B-cell_type O 0.6571762561798096
cell I-cell_type O 0.6027144193649292
bodies E-cell_type O 0.5430819392204285
were O O 0.9996281862258911
present O O 0.9998921155929565
in O O 0.999983549118042
ectopic O O 0.8330186605453491
pregnancy O O 0.9784587621688843
. O O 0.9999953508377075
The O O 0.999996542930603
use O O 0.999828577041626
of O O 0.9999707937240601
tissue O O 0.9529387354850769
obtained O O 0.9996998310089111
from O O 0.9999836683273315
ectopic O O 0.7003869414329529
pregnancy O O 0.859166145324707
may O O 0.9996474981307983

agent O O 0.8197898864746094
for O O 0.9990621209144592
adult O O 0.8486343622207642
T O O 0.7321664094924927
cell O O 0.615372359752655
leukemia O O 0.6813230514526367
and O O 0.9928845763206482
tropical O O 0.8118706345558167
spastic O O 0.6992379426956177
paraparesis O O 0.46162500977516174
( O O 0.9801028370857239
also O O 0.9924180507659912

events O O 0.9457249641418457
that O O 0.9999533891677856
follow O O 0.9998466968536377
irradiation O O 0.9938734769821167
. O O 0.9999936819076538
Detection O O 0.9985527396202087
of O O 0.9999562501907349
adenovirus B-DNA B-DNA 0.3294364809989929
DNA E-DNA E-DNA 0.9699518084526062
in O O 0.9988549947738647
peripheral B-cell_type B-cell_type 0.7468906044960022
blood I-cell_type I-cell_type 0.9453746676445007
mononuclear I-cell_type I-cell_type 0.9769672155380249
cells E-cell_type E-cell_type 0.9745712280273438

EBV O O 0.802863597869873
can O O 0.9998244643211365
up-regulate O O 0.9998052716255188
IL-1beta S-protein S-protein 0.9664968848228455
expression O O 0.9971551895141602
, O O 0.9999619722366333
possibly O O 0.9999150037765503
by O O 0.9999719858169556
using O O 0.9994258880615234
RBP S-protein S-protein 0.9457907676696777
, O O 0.9900239109992981
NF-kappaB S-protein S-protein 0.9874489307403564
, O O 0.9868242144584656
or O O 0.9990070462226868
both O O 0.9996918439865112
. O O 0.9999498128890991
Copyright O O 0.9719218611717224
1998 O O 0.9621348977088928
Academic O O 0.991152822971344
Press O O 0.9516647458076477
. O O 0.9998843669891357
CD27 S-protein S-protein 0.9339050650596619
/CD70 O S-protein 0.8414148092269897
interaction O O 0.9911683797836304
augments O O 0.9995207786560059

the O O 0.9986903071403503
amount O O 0.9998544454574585
of O O 0.9999412298202515
active O O 0.8307223916053772
and O O 0.9782590866088867
inactive O O 0.9510841369628906
NF-kappa B-protein B-protein 0.3368504047393799
B E-protein E-protein 0.9192389845848083
and O O 0.983029305934906
NF-kappa B-RNA B-RNA 0.5296333432197571
B I-RNA I-RNA 0.5539005398750305
mRNA E-RNA E-RNA 0.9709148406982422
, O O 0.9967052340507507
in O O 0.9999099969863892
Porphyromonas O B-cell_line 0.446636825799942
gingivalis O I-cell_line 0.4066758155822754
lipopolysaccharide-stimulated B-cell_line I-cell_line 0.6423746943473816
human I-cell_line I-cell_line 0.8634757399559021
monocytic I-cell_line I-cell_line 0.9685039520263672
cells E-cell_line E-cell_line 0.9769852161407471
was O O 0.9991280436515808
assessed O O 0.9999759197235107
. O O 0.9999988079071045
High O O 0.9873560070991516
doses O O 0.9990655779838562
of O O 0.999930739402771
sodium O O 0.6883512735366821
salicylate O O 0.6445915699005127
suppressed O O 0.9820451140403748
NF-kappa B-protein B-RNA 0.5532738566398621
B E-protein I-RNA 0.50339275598526
p65 B-RNA I-RNA 0.7201762795448303
mRNA E-RNA E-RNA 0.9805158376693726
accumulation O O 0.9815395474433899
, O O 0.999980092048645
resulting O O 0.9999902248382568
in O O 0.9999727010726929
suppression O O 0.9750595688819885

and O O 0.9484092593193054
TLCK O S-protein 0.32797765731811523
did O O 0.999459445476532
not O O 0.9999779462814331
block O O 0.9998681545257568
induction O O 0.9972769618034363
of O O 0.9998958110809326
an O O 0.9998799562454224
immediate-early B-DNA B-DNA 0.45136651396751404
gene E-DNA E-DNA 0.9385426640510559
encoding O O 0.9658734202384949
the O O 0.9991051554679871
transcription B-protein B-protein 0.5186086893081665
factor E-protein E-protein 0.9491862058639526
, O O 0.9710642099380493
Egr-1 S-protein S-protein 0.9629997611045837
. O O 0.999563992023468
Taken O O 0.9999675750732422
together O O 0.9999819993972778
, O O 0.9999958276748657
these O O 0.9999721050262451
data O O 0.9841444492340088

) O O 0.6561011672019958
induces O O 0.9994156360626221
NF-kB S-protein S-protein 0.9510090947151184
nuclear O O 0.9746809601783752
translocation O O 0.9916490316390991
and O O 0.9999399185180664
the O O 0.9999939203262329
subsequent O O 0.9989854693412781
expression O O 0.9994052648544312
of O O 0.9999468326568604
NF-kB B-DNA S-protein 0.8950785398483276
dependent I-DNA O 0.9377350211143494
T I-DNA B-DNA 0.642963707447052
cell I-DNA I-DNA 0.49399587512016296
genes E-DNA E-DNA 0.9767491817474365
. O O 0.9999181032180786
Here O O 0.9999492168426514
we O O 0.999994158744812
examined O O 0.9999821186065674
the O O 0.9999699592590332
activation O O 0.9610977172851562

cytokines S-protein S-protein 0.7638399004936218
IL-6 S-protein S-protein 0.9817972183227539
and O O 0.9968504309654236
IL-8 S-protein S-protein 0.9918490648269653
. O O 0.9995248317718506
IFN-gamma-primed B-cell_line B-cell_line 0.4558631181716919
lung I-cell_line I-cell_line 0.49068722128868103
fibroblasts E-cell_line E-cell_line 0.7545369863510132
costimulate O O 0.9589500427246094
T O B-cell_type 0.6418312788009644
lymphocyte O E-cell_type 0.8486773371696472
proliferation O O 0.8832511305809021
utilizing O O 0.9953049421310425
CD40 S-protein S-protein 0.8599456548690796
, O O 0.9737364649772644
but O O 0.9989686012268066
not O O 0.9995463490486145
the O O 0.9996649026870728

Haematological O O 0.6531026363372803
complications O O 0.8113754391670227
were O O 0.9969155788421631
not O O 0.9998741149902344
troublesome O O 0.9971269965171814
and O O 0.9999916553497314
results O O 0.9999208450317383
of O O 0.9999828338623047
biochemical O O 0.969819962978363
liver O O 0.923235297203064
function O O 0.839911937713623
tests O O 0.9963494539260864
remained O O 0.9999710321426392
normal O O 0.9884493947029114
. O O 0.9999980926513672

CONCLUSIONS O O 0.9973606467247009
: O O 0.999968409538269
Sirolimus B-Chemical S-Chemical 0.9004524946212769
induces O O 0.9350267052650452
or O O 0.9982481002807617
aggravates O O 0.9900270104408264
pre O O 0.9895137548446655
- O O 0.9982288479804993
existing O O 0.9903249740600586
proteinuria B-Disease B-Disease 0.9620633125305176
in O O 0.9842990636825562
an O O 0.9995198249816895
unpredictable O O 0.6295125484466553
subset O O 0.7816717624664307
of O O 0.9976668357849121
renal O O 0.7585329413414001
allograft O O 0.466064989566803
recipients O O 0.8395007252693176
. O O 0.9999892711639404

hLH-2 S-DNA S-protein 0.5648601651191711
expression O O 0.9961069226264954
in O O 0.9999905824661255
all O O 0.999825656414032
cases O O 0.995165228843689
of O O 0.9999681711196899
CML O O 0.5283090472221375
, O O 0.9985583424568176
expression O O 0.9961637258529663
was O O 0.9999691247940063
observed O O 0.9998986721038818
in O O 0.999883770942688
lymphoid O O 0.4864891767501831
malignancies O O 0.3974205255508423
and O O 0.9740424156188965
myeloid B-cell_line B-cell_line 0.42580223083496094
cell I-cell_line I-cell_line 0.4346308708190918
lines E-cell_line E-cell_line 0.9872440695762634
, O O 0.9953923225402832
but O O 0.9998748302459717
not O O 0.999580442905426
in O O 0.9994470477104187
primary O O 0.5585460662841797
cases O O 0.8573600649833679
of O O 0.9998928308486938
acute O O 0.8658385276794434
myelogenous O O 0.8775864243507385
leukaemia O O 0.9177443981170654
. O O 0.9999843835830688
The O O 0.999997615814209
role O O 0.9996005892753601
of O O 0.99996018409729
hLH-2 S-DNA S-protein 0.574920117855072
in O O 0.9989538192749023
the O O 0.9999028444290161
development O O 0.9920501112937927
or O O 0.9993195533752441

4 O O 0.6221673488616943
. O O 0.9988880753517151

Renal O O 0.6115111708641052
function O O 0.6156233549118042
remained O O 0.9826828241348267
normal O O 0.968336820602417
in O O 0.9998728036880493
all O O 0.9997588992118835
patients O O 0.999788224697113
. O O 0.9999994039535522

. O O 0.9955021739006042
These O O 0.9999977350234985
findings O O 0.9999232292175293
thus O O 0.9999972581863403
emphasize O O 0.9999903440475464
the O O 0.999987006187439
importance O O 0.9998799562454224
of O O 0.9999662637710571
IFN-alpha S-protein S-protein 0.9937736988067627
as O O 0.9998914003372192
a O O 0.9999761581420898
T-cell B-protein O 0.4629824757575989
regulatory I-protein O 0.30659741163253784

Administration O O 0.9983364939689636
of O O 0.9999548196792603
50 O O 0.980857253074646
mg O O 0.997908353805542
/ O O 0.9999161958694458
kg O O 0.9280345439910889
PDTC B-Chemical B-Chemical 0.926717221736908
( O O 0.9891061186790466
low O O 0.9948588609695435
- O O 0.9982156753540039
dose O O 0.9984444975852966
) O O 0.9997145533561707
did O O 0.9999935626983643
not O O 0.9999617338180542
exert O O 0.9999047517776489
major O O 0.9901200532913208
effects O O 0.9904029369354248
on O O 0.9999704360961914
the O O 0.9998353719711304
development O O 0.9951861500740051
of O O 0.9999229907989502
a O O 0.9997807145118713
status B-Disease O 0.636867344379425
epilepticus I-Disease O 0.788070797920227
or O O 0.9787889719009399
the O O 0.9987226128578186
mortality O O 0.8425552248954773
rate O O 0.9966446161270142
. O O 0.9999992847442627

Vehicle O O 0.9486850500106812
/ O O 0.9920223951339722
drugs O O 0.9686573147773743
were O O 0.9999591112136841
administered O O 0.9999610185623169
daily O O 0.9998694658279419
for O O 0.9999964237213135
21days O O 0.9770484566688538
to O O 0.9998179078102112
male O O 0.989737331867218
Wistar O O 0.7643263936042786
rats O O 0.9882209300994873
. O O 0.999998927116394

that O O 0.9959533214569092
exhibited O O 0.9998593330383301
a O O 0.9999170303344727
microdeletion O O 0.9123260378837585
in O O 0.999884843826294
the O O 0.99994957447052
short B-DNA O 0.8398135900497437
arm I-DNA O 0.5419098734855652
of I-DNA O 0.9956503510475159
Chr I-DNA B-DNA 0.5068478584289551
20 E-DNA E-DNA 0.39634329080581665
encompassing O O 0.8647711873054504
bands O O 0.6827573180198669
p11.23 B-DNA O 0.26891353726387024
to I-DNA O 0.8499705791473389
p12.3 E-DNA S-DNA 0.41928645968437195
with O O 0.9949353337287903
rodent B-cell_line B-cell_line 0.7778021693229675
thermosensitive I-cell_line I-cell_line 0.5865284204483032
mutant I-cell_line I-cell_line 0.3499985337257385
cells E-cell_line E-cell_line 0.5251762866973877
( O O 0.951411783695221
CHOtsH1-1 S-cell_line S-cell_line 0.8611971735954285
) O O 0.6440322995185852
deficient O O 0.8222231864929199
in-leucyl-tRNA B-protein B-protein 0.43622085452079773
synthetase E-protein E-protein 0.8442894220352173
, O O 0.9982866644859314
we O O 0.9999310970306396
isolated O O 0.9983829259872437
a O O 0.9998316764831543
somatic B-cell_line B-cell_line 0.5976682901382446
cell I-cell_line I-cell_line 0.4205785393714905
hybrid E-cell_line E-cell_line 0.8955193161964417
segregating O O 0.969996452331543
the O O 0.9992087483406067
deleted O B-DNA 0.8021582961082458
human O I-DNA 0.39488738775253296
Chr B-DNA I-DNA 0.5078017115592957
20 E-DNA E-DNA 0.5915471911430359
. O O 0.9938873648643494
This O O 0.9999111890792847
hybrid O O 0.6941566467285156
clone O O 0.6813147664070129
, O O 0.9950972199440002
designated O O 0.9970430731773376
NR2 S-cell_line S-DNA 0.6584159731864929
, O O 0.9815477132797241
was O O 0.9999285936355591
characterized O O 0.9999591112136841
by O O 0.9999954700469971
several O O 0.9994587302207947
methods O O 0.9976723790168762
, O O 0.999944806098938
including O O 0.9999418258666992
PCR O S-protein 0.5485292077064514
, O O 0.992060661315918
with O O 0.9999349117279053
eight O O 0.987882137298584
pairs O O 0.9517804980278015
of O O 0.9997918009757996
oligonucleotides O O 0.3782689869403839
mapped O O 0.9967606663703918
to O O 0.9998971223831177
Chr B-DNA O 0.5969879627227783
20 E-DNA O 0.4071740508079529
: O O 0.970109760761261
D20S5 S-DNA O 0.5890144109725952
, O O 0.9928532242774963

from O O 0.9984115362167358
class B-protein B-protein 0.734404444694519
II I-protein I-protein 0.5586425065994263
molecules E-protein E-protein 0.9909088015556335
for O O 0.9993252754211426
antigenic O O 0.8472896218299866
peptides O O 0.8105723261833191
. O O 0.9999572038650513
HLA-DO S-protein S-protein 0.5210162997245789
is O O 0.9996626377105713
a O O 0.9999887943267822
second O B-protein 0.9578003287315369
class B-protein I-protein 0.711143970489502
II-like I-protein I-protein 0.7192785143852234
molecule E-protein E-protein 0.9864185452461243
that O O 0.998963475227356
physically O O 0.9992166757583618
associates O O 0.9993357062339783
with O O 0.99994957447052
HLA-DM S-protein O 0.49460262060165405
in O O 0.9971799850463867
B B-cell_type B-cell_type 0.8683105111122131
cells E-cell_type E-cell_type 0.9879844188690186
. O O 0.9995089769363403
HLA-DO S-protein O 0.4074467718601227
was O O 0.9958382844924927
shown O O 0.9999762773513794
to O O 0.9999854564666748
block O O 0.9997053742408752
HLA-DM S-protein O 0.43606433272361755
function O O 0.9898227453231812
. O O 0.9999921321868896
Purified O B-protein 0.8465014100074768
HLA-DM-DO B-protein I-protein 0.22000935673713684
complexes E-protein E-protein 0.9788966774940491

( O O 0.9769353866577148
p O O 0.9771157503128052
< O O 0.9977779984474182
0.05 O O 0.9991827607154846
) O O 0.9994920492172241
than O O 0.9999713897705078
controls O O 0.9928414821624756
( O O 0.999947190284729
6234 O O 0.9840688109397888
+/- O O 0.9996650218963623
1568 O O 0.9986741542816162
sites/cell O O 0.9746258854866028
) O O 0.9997696280479431
, O O 0.9999938011169434
although O O 0.9999983310699463
no O O 0.9993977546691895

at O O 0.9992638230323792
high O O 0.9883865714073181
levels O O 0.9997251629829407
in O O 0.9999945163726807
certain O O 0.9999091625213623
areas O O 0.9988693594932556
of O O 0.9999542236328125
tissue O O 0.8580814003944397
insult O O 0.8444437384605408
such O O 0.9997460246086121
as O O 0.9999818801879883
tumor O O 0.4688221216201782
matrices O O 0.2654702067375183
and O O 0.9308149814605713
sites O O 0.8729222416877747
of O O 0.9975571632385254
wound O O 0.7805085182189941

the O O 0.9965732097625732
gammac B-protein B-protein 0.4905063807964325
chain E-protein E-protein 0.9713259339332581
may O O 0.9995597004890442
involve O O 0.9999942779541016
signaling O O 0.9993701577186584
via O O 0.9999145269393921
the O O 0.9997366070747375
IL-13R S-protein S-protein 0.9133889675140381
. O O 0.999010443687439
Alternatively O O 0.999941349029541
, O O 0.9999892711639404
the O O 0.9999575614929199
IL-4Ralpha B-protein B-protein 0.5304863452911377
chain E-protein E-protein 0.9790133237838745
may O O 0.9997915625572205
transduce O O 0.9999271631240845
intracellular O O 0.8574526309967041
signals O O 0.8792126178741455
that O O 0.9998536109924316
lead O O 0.9999743700027466
to O O 0.9999703168869019
Cepsilon B-DNA B-DNA 0.33823397755622864
gene E-DNA E-DNA 0.6399844884872437

In O O 0.9995105266571045
this O O 0.9999948740005493
study O O 0.9999569654464722
, O O 0.9999970197677612
we O O 0.9999501705169678
investigated O O 0.9999873638153076
the O O 0.9999825954437256
effect O O 0.9999701976776123
of O O 0.9999864101409912
ER B-protein B-protein 0.2277929186820984
alpha E-protein E-protein 0.9759408831596375
( O O 0.9928187727928162
referred O O 0.9987389445304871
to O O 0.9998418092727661
throughout O O 0.9992495179176331
as O O 0.9998486042022705
ER S-protein S-protein 0.7310207486152649
) O O 0.9923781156539917
on O O 0.9999502897262573
DNA-binding O O 0.729993462562561
activities O O 0.9849047660827637
of O O 0.99983811378479
transcription B-protein O 0.49807947874069214

Oct-1 S-protein S-protein 0.9503974318504333
and O O 0.9935557246208191
Oct-2 S-protein S-protein 0.8470987677574158
for O O 0.9983200430870056
the O O 0.9999349117279053
variant O B-DNA 0.8652952909469604
octamer B-DNA I-DNA 0.3866027295589447
motif E-DNA E-DNA 0.8984078168869019
and O O 0.9981278777122498
determined O O 0.9998635053634644
the O O 0.9999748468399048
functional O O 0.9851640462875366
role O O 0.9985608458518982
of O O 0.9999686479568481
this O O 0.9998750686645508
octamer B-DNA B-DNA 0.42473316192626953
motif E-DNA E-DNA 0.8783496618270874
in O O 0.999334990978241
transcriptional O O 0.8759713172912598
activation O O 0.9743530750274658
. O O 0.9999740123748779
We O O 0.9999805688858032
find O O 0.9999958276748657
that O O 0.9999933242797852
, O O 0.9996778964996338
although O O 0.999990701675415
the O O 0.9999690055847168
variant O O 0.7991139888763428
octamer B-DNA B-DNA 0.3983643651008606
motif E-DNA E-DNA 0.7318127155303955

acid O O 0.5799277424812317
substitutions O O 0.9753129482269287
. O O 0.9999940395355225
One O O 0.9999200105667114
patient O O 0.9992352724075317
with O O 0.999967098236084
incomplete O O 0.9429980516433716
androgen O O 0.7475244998931885
insensitivity O O 0.9495620727539062
was O O 0.9999945163726807
a O O 0.9999775886535645
mosaic O O 0.7927790880203247

with O O 0.9971883893013

these O O 0.9944466352462769
cells O O 0.9489889740943909
have O O 0.9999841451644897
been O O 0.9999430179595947
impossible O O 0.9993174076080322
to O O 0.999954104423523
generate O O 0.9998654127120972
given O O 0.9999895095825195
the O O 0.9999802112579346
requirement O O 0.9998667240142822
of O O 0.9999831914901733
GATA-1 S-protein S-protein 0.9480896592140198
for O O 0.9993915557861328
Epo B-protein B-protein 0.7128412127494812
receptor E-protein E-protein 0.9423439502716064
expression O O 0.9883660674095154
and O O 0.9998465776443481
red B-cell_type O 0.54884272813797
cell E-cell_type O 0.440406858921051
viability O O 0.9082162976264954
( O O 0.9997815489768982
C. O O 0.9867421984672546
Simon O O 0.9605709910392761
and O O 0.9993718266487122

cell O O 0.4950529634952545
growth O O 0.9687132239341736
and O O 0.9992848038673401
differentiation O O 0.9981468915939331
. O O 0.9999982118606567
In O O 0.9999897480010986
this O O 0.9999949932098389
study O O 0.9998828172683716
, O O 0.9999932050704956
we O O 0.9997120499610901
generated O O 0.998481810092926
transgenic O O 0.8343039155006409
mice O O 0.9537032842636108
carrying O O 0.9998713731765747
the O O 0.9998306035995483
human B-DNA B-DNA 0.46550941467285156
IRF-1 I-DNA I-DNA 0.544944167137146
gene E-DNA E-DNA 0.9879876375198364
linked O O 0.99784255027771
to O O 0.9999886751174927
the O O 0.9996234178543091
human B-DNA B-DNA 0.41069918870925903
immunoglobulin I-DNA I-DNA 0.5078786611557007
heavy-chain I-DNA I-DNA 0.7031583189964294

, O O 0.934887170791626
size O O 0.8845869302749634
, O O 0.9964220523834229
lymph-node O O 0.5518999099731445
involvement O O 0.9847280979156494
, O O 0.9998409748077393
hormonal O O 0.8879894614219666
receptor O O 0.4731125831604004
presence O O 0.9300430417060852
, O O 0.9995761513710022
proliferation O O 0.983123779296875
activity O O 0.9957411289215088
or O O 0.9999245405197144
p53 S-protein S-protein 0.8924878835678101
protein O O 0.7761654853820801
expression O O 0.9851374626159668
was O O 0.999967098236084
detected O O 0.9999191761016846
. O O 0.999998927116394
These O O 0.9999951124191284
results O O 0.9999700784683228
indicate O O 0.9999991655349731
the O O 0.9999885559082031
utility O O 0.99037766456604
of O O 0.9993498921394348

not O O 0.8676725625991821
derived O O 0.9961525797843933
from O O 0.9999657869338989
the O O 0.9997699856758118
malignant B-cell_line B-cell_line 0.4839496910572052
clone E-cell_line E-cell_line 0.7646116614341736
. O O 0.9985997080802917
Therefore O O 0.9999921321868896
, O O 0.9999973773956299
the O O 0.9999860525131226
human B-protein B-protein 0.6411789059638977
androgen I-protein I-protein 0.4069438576698303
receptor E-protein E-protein 0.7174383997917175
assay O O 0.8629655838012695
( O O 0.9992269277572632
HUMARA O O 0.5157188773155212
) O O 0.9935604333877563
was O O 0.9999758005142212
used O O 0.999977707862854
to O O 0.9999924898147583
determine O O 0.9999717473983765
granulocyte O O 0.6177920699119568
clonality O O 0.8051769733428955
. O O 0.9999715089797974
In O O 0.9998706579208374
21 O O 0.974912703037262
of O O 0.9997957348823547

both O O 0.9982402324676514
a O O 0.9999618530273438
rapid O O 0.9707353115081787
and O O 0.9947556257247925
concentration-dependent O O 0.9857602715492249
manner O O 0.9988540410995483
by O O 0.9999990463256836
the O O 0.9999723434448242
fungal O O 0.7417858839035034
metabolite O O 0.6994417309761047
gliotoxin O O 0.6745749711990356
, O O 0.9913948178291321
but O O 0.9999372959136963
not O O 0.9998268485069275
by O O 0.9999746084213257
its O O 0.9999573230743408
inactive O O 0.8869960308074951
analog O O 0.7336293458938599
methylthiogliotoxin O S-protein 0.5752849578857422
. O O 0.9989916682243347
This O O 0.9999649524688721
induction O O 0.9989838004112244
of O O 0.9999532699584961
apoptosis O O 0.9766393303871155
was O O 0.9999593496322632
abolished O O 0.999944806098938
by O O 0.9999977350234985
the O O 0.9999090433120728
caspase O S-protein 0.7926918864250183
inhibitor O O 0.6672039031982422
zVAD-fmk O S-protein 0.736556351184845
, O O 0.9970197081565857
correlated O O 0.9997921586036682
with O O 0.9999940395355225
the O O 0.9999485015869141
inhibition O O 0.9871789216995239
of O O 0.9993815422058105
nuclear B-protein B-protein 0.5527486205101013
factor-kappa I-protein I-protein 0.8848869800567627
B E-protein E-protein 0.9070942401885986
( O O 0.7813105583190918

also O O 0.9818436503410339

7-day B-cell_line O 0.6673113107681274
PHA-blasts E-cell_line O 0.2530379593372345
, O O 0.9678332805633545
and O O 0.9989296793937683
fresh B-cell_type B-cell_type 0.7641393542289734
peripheral I-cell_type I-cell_type 0.5622272491455078
blood I-cell_type I-cell_type 0.5995877981185913
mononuclear I-cell_type I-cell_type 0.8065871000289917
cells E-cell_type E-cell_type 0.909679651260376
] O O 0.9950262904167175
tested O O 0.9998983144760132
, O O 0.9999861717224121
whereas O O 0.9999953508377075
it O O 0.9998818635940552
did O O 0.9999574422836304
not O O 0.9999563694000244
suppress O O 0.9999098777770996
the O O 0.9994999170303345
cell O O 0.9435725212097168
growth O O 0.9512146711349487

of O O 0.9913589954376221
E2 O S-protein 0.3905884921550751
. O O 0.9953693747520447
On O O 0.9999727010726929
the O O 0.9999768733978271
contrary O O 0.9992050528526306
, O O 0.9999896287918091
other O O 0.9998605251312256
steroid O O 0.7883153557777405
hormones O O 0.714259922504425
such O O 0.9989187717437744
as O O 0.9999638795852661
Tx O O 0.4159846305847168
, O O 0.9796466827392578
progesterone O O 0.7188703417778015
, O O 0.9833648800849915
and O O 0.9985653758049011

Offspring O O 0.9467567801475525
of O O 0.9991635084152222
rats O O 0.9278044104576111
administered O O 0.995776891708374
dexamethasone B-Chemical B-Chemical 0.9294148087501526
on O O 0.9957073926925659
days O O 0.9995051622390747
15 O O 0.9994989633560181
and O O 0.9998993873596191
16 O O 0.9980307221412659
gestation O O 0.8551344275474548
had O O 0.9999065399169922
a O O 0.9999381303787231
20 O O 0.990548312664032
% O O 0.9993928670883179
reduction B-Disease O 0.9410554766654968
in I-Disease O 0.9869396686553955
glomerular I-Disease O 0.8006506562232971
number I-Disease O 0.6765033006668091
compared O O 0.9996250867843628
with O O 0.9999918937683105
control O O 0.9885967373847961
at O O 0.9999909400939941
6 O O 0.9997394680976868
to O O 0.9999032020568848
9 O O 0.9998677968978882
months O O 0.9999775886535645
of O O 0.9999598264694214
age O O 0.9997618794441223
( O O 0.9999934434890747
22 O O 0.9998658895492554
527 O O 0.999492883682251
+ O O 0.9999748468399048
/ O O 0.9999967813491821
- O O 0.9999130964279175
509 O O 0.9984651803970337
versus O O 0.9999874830245972
28 O O 0.9996631145477295
050 O O 0.9998281002044678
+ O O 0.9999710321426392
/ O O 0.9999943971633911
- O O 0.9999127388000488
561 O O 0.9985429048538208
, O O 0.9999897480010986
P O O 0.996865451335907
< O O 0.9998693466186523
0 O O 0.9998964071273804
. O O 0.9998793601989746
05 O O 0.9974890947341919
) O O 0.9993038177490234
, O O 0.9999825954437256
which O O 0.9999105930328369
was O O 0.9999513626098633
comparable O O 0.9999923706054688
to O O 0.9999912977218628
the O O 0.999943733215332
percent O O 0.9993987083435059
reduction O O 0.9712086915969849
in O O 0.9950647950172424
glomeruli O O 0.4058971703052521
measured O O 0.9845133423805237
at O O 0.999971866607666
3 O O 0.9998307228088379
weeks O O 0.9999536275863647
of O O 0.9999160766601562
age O O 0.9998301267623901
. O O 0.9999991655349731

beta E-protein E-protein 0.7788002490997314
and O O 0.9187042117118835
interleukin-1 B-protein B-protein 0.2888849675655365
alpha E-protein E-protein 0.9814024567604065
. O O 0.9992451667785645
The O O 0.9999974966049194
increased O O 0.9900963306427002
mRNA S-RNA O 0.844693660736084
accumulation O O 0.9790175557136536
was O O 0.9999810457229614
found O O 0.9999630451202393
to O O 0.9999902248382568
be O O 0.9999915361404419
primarily O O 0.9995619654655457
because O O 0.9999953508377075
of O O 0.9999735355377197
the O O 0.999985933303833
increase O O 0.9987367987632751
in O O 0.9999266862869263
the O O 0.9997058510780334
transcription O O 0.7602543830871582

Further O O 0.995434582233429
studies O O 0.9999362230300903
on O O 0.9999862909317017
the O O 0.9997606873512268
effects O O 0.9997314810752869
of O O 0.9999611377716064
certain O O 0.9983004927635193
irrigating O O 0.5126217007637024
fluids O O 0.7422235608100891
on O O 0.9824016690254211
the O O 0.9921036958694458
rat O O 0.9586211442947388
bladder O O 0.6351053714752197
for O O 0.999849796295166
18 O O 0.9997468590736389
hours O O 0.9999648332595825
are O O 0.9999974966049194
reported O O 0.9999796152114868
. O O 0.9999980926513672

We O O 0.9995836615562439
conducted O O 0.9999796152114868
a O O 0.9999954700469971
12 O O 0.9896261692047119
- O O 0.9991798996925354
month O O 0.9993347525596619
controlled O O 0.9878147840499878
trial O O 0.9899995923042297
of O O 0.9997491240501404
mazindol B-Chemical B-Chemical 0.9258279800415039
, O O 0.986047625541687
a O O 0.9998130202293396
putative O O 0.920230507850647
growth O O 0.9290514588356018
hormone O O 0.8507317304611206
secretion O O 0.9565715193748474
inhibitor O O 0.955028235912323
, O O 0.9999589920043945
in O O 0.9999886751174927
83 O O 0.9895422458648682
boys O O 0.9965415596961975
with O O 0.9999837875366211
Duchenne B-Disease B-Disease 0.611436128616333
dystrophy I-Disease I-Disease 0.9880698323249817
. O O 0.9990936517715454

OBJECTIVE O O 0.9566773176193237
: O O 0.9998531341552734
The O O 0.9999932050704956
goal O O 0.9998087286949158
of O O 0.9999961853027344
this O O 0.999994158744812
study O O 0.9998877048492432
was O O 0.9999977350234985
to O O 0.9999979734420776
compare O O 0.9999924898147583
the O O 0.9998809099197388
efficacy O O 0.9786790013313293
and O O 0.999542236328125
side O O 0.9870299696922302
effects O O 0.9994632601737976
of O O 0.9999871253967285
two O O 0.9997707009315491
doses O O 0.9997602105140686
of O O 0.9997449517250061
haloperidol B-Chemical B-Chemical 0.9315645098686218
and O O 0.9786620736122131
placebo O O 0.7732892632484436
in O O 0.9985558390617371
the O O 0.9997332692146301
treatment O O 0.9995291233062744
of O O 0.9999639987945557
psychosis B-Disease B-Disease 0.9747989773750305
and O O 0.9450740814208984
disruptive B-Disease O 0.5482522249221802
behaviors I-Disease O 0.9239079356193542
in O O 0.9838964939117432
patients O O 0.9997443556785583
with O O 0.9999794960021973
Alzheimer B-Disease B-Disease 0.6386993527412415
' I-Disease I-Disease 0.5587953329086304
s I-Disease I-Disease 0.6425053477287292
disease I-Disease I-Disease 0.9841423630714417
. O O 0.9985108971595764

Thirty O O 0.9978067278862
- O O 0.9997840523719788
four O O 0.9998701810836792
patients O O 0.9992628693580627
with O O 0.9999526739120483
juvenile O B-Disease 0.6920737624168396
rheumatoid O I-Disease 0.5122817158699036
arthritis O I-Disease 0.975009024143219
, O O 0.9688348174095154
who O O 0.9988951086997986
were O O 0.9999775886535645
treated O O 0.9999599456787109
with O O 0.9999654293060303
flurbiprofen S-Chemical B-Chemical 0.9339237809181213
at O O 0.9982134103775024
a O O 0.9999761581420898
maximum O O 0.9986392855644226
dose O O 0.9997608065605164
of O O 0.9999464750289917
4 O O 0.9991157650947571
mg O O 0.9995286464691162
/ O O 0.9999715089797974
kg O O 0.9989988207817078
/ O O 0.9999849796295166
day O O 0.9998667240142822
, O O 0.9999934434890747
had O O 0.9999688863754272
statistically O O 0.9905875325202942
significant O O 0.9959726929664612
decreases O O 0.9035643935203552
from O O 0.9989930987358093
baseline O O 0.9192250370979309
in O O 0.9994062185287476
6 O O 0.9919129610061646
arthritis O B-Disease 0.9478553533554077
indices O O 0.777167022228241
after O O 0.9996836185455322
12 O O 0.9999161958694458
weeks O O 0.9999852180480957
of O O 0.9999755620956421
treatment O O 0.9995548129081726
. O O 0.9999995231628418

however O O 0.9922161102294922

Large O O 0.9932235479354858
differences O O 0.9733535647392273
, O O 0.9999017715454102
regarded O O 0.999961256980896
as O O 0.9999842643737793
statistically O O 0.9931668639183044
significant O O 0.998033344745636
, O O 0.9998680353164673
between O O 0.9999113082885742
the O O 0.9998012185096741
mexiletine S-Chemical B-Chemical 0.9178302884101868
and O O 0.9740145802497864
placebo O O 0.7368968725204468
groups O O 0.9819602966308594
were O O 0.9999908208847046
noted O O 0.9999970197677612
in O O 0.9999924898147583
that O O 0.9999839067459106
end O O 0.9971747398376465
point O O 0.9990196228027344
at O O 0.9999996423721313
months O O 0.9999309778213501
1 O O 0.9998027682304382
and O O 0.9998610019683838
4 O O 0.998664140701294
, O O 0.9999653100967407
but O O 0.9999852180480957
only O O 0.9999327659606934
trends O O 0.9967868328094482
were O O 0.9999850988388062
observed O O 0.9998382329940796
at O O 0.9999985694885254
month O O 0.9995404481887817
12 O O 0.9996998310089111
. O O 0.9999974966049194

For O O 0.997665524482727
glyburide S-Chemical B-Chemical 0.9169395565986633
, O O 0.997175931930542
a O O 0.9999591112136841
second O O 0.9986741542816162
- O O 0.999386191368103
generation O O 0.9986155033111572
sulfonylurea S-Chemical B-Chemical 0.9111683964729309
, O O 0.9970341920852661
only O O 0.9999843835830688
two O O 0.9999145269393921
brief O O 0.9977473616600037
reports O O 0.998110294342041
of O O 0.999896764755249
hepatotoxicity O B-Disease 0.9707857370376587
exist O O 0.880608320236206
. O O 0.9999876022338867

In O O 0.9996694326400757
previous O O 0.9999028444290161
experiments O O 0.9996658563613892
we O O 0.9999979734420776
found O O 0.9999926090240479
that O O 0.9999736547470093
decreases O O 0.9356244802474976
in O O 0.9522936344146729
food O O 0.8566903471946716
intake O O 0.835631251335144
were O O 0.9997616410255432
induced O O 0.9998632669448853
by O O 0.9999924898147583
local O O 0.9820685982704163
administration O O 0.9886198043823242
of O O 0.9995720982551575
calcitonin B-Chemical B-Chemical 0.9156465530395508
into O O 0.9961720108985901
several O O 0.9987418055534363
hypothalamic O O 0.6157106161117554
sites O O 0.5826822519302368
and O O 0.9995346069335938
into O O 0.9999716281890869
the O O 0.9997716546058655
nucleus O O 0.9247141480445862
accumbens O O 0.922819972038269
. O O 0.9999924898147583

kinase I-protein I-protein 0.32028356194496155
family E-protein E-protein 0.9549858570098877
with O O 0.9994089603424072
associated O O 0.940241813659668
phosphorylation O O 0.9202619194984436
of O O 0.9969915151596069
c-Jun B-protein S-protein 0.7651811838150024
Y-peptide E-protein O 0.3012414276599884

activity O O 0.9892727136611938
of O O 0.9999552965164185
the O O 0.9999322891235352
IgH-luciferase B-DNA B-DNA 0.5675404071807861
construct E-DNA E-DNA 0.9493284821510315
was O O 0.9990710020065308
induced O O 0.9999548196792603
upon O O 0.999798595905304
ligation O O 0.9927797913551331
of O O 0.999808132648468
the O O 0.9998536109924316
full-length B-protein B-protein 0.6338634490966797
chimeric I-protein I-protein 0.5090034604072571
receptor E-protein E-protein 0.9574275612831116
but O O 0.9931461811065674
not O O 0.9993278980255127
by O O 0.9999051094055176
truncated B-protein B-protein 0.818500280380249
gp130 I-protein I-protein 0.41015273332595825
receptors E-protein E-protein 0.9934589266777039
. O O 0.9998254179954529
Moreover O O 0.999895453453064
, O O 0.9999896287918091
the O O 0.9999252557754517
gp130 S-protein S-protein 0.7343989014625549
-induced O O 0.9914659261703491
activity O O 0.996852457523346
of O O 0.9999502897262573
this O O 0.9997510313987732
reporter B-DNA B-DNA 0.6346201300621033
gene E-DNA E-DNA 0.9407892823219299
was O O 0.997901201248169
abrogated O O 0.9996471405029297
by O O 0.9999932050704956
Stat3EE S-protein S-protein 0.5849176049232483
, O O 0.9982330799102783
a O O 0.9999146461486816
mutant O O 0.4886939823627472
Stat3 S-protein S-protein 0.36704352498054504
incapable O O 0.707088053226471

metabolites O O 0.45303940773010254
were O O 0.9997060894966125
present O O 0.9999630451202393
. O O 0.9999982118606567
Statistically O O 0.9893727898597717
significant O O 0.9988694787025452
correlations O O 0.9949911236763
could O O 0.9999963045120239
be O O 0.999990701675415
established O O 0.9999431371688843
between O O 0.9995668530464172
patient/histopathology O O 0.8603977560997009
data O O 0.9754669666290283
and O O 0.9999390840530396
the O O 0.9999954700469971
results O O 0.9999197721481323
of O O 0.9999946355819702
the O O 0.9999903440475464
platelet S-cell_type O 0.571161150932312
aggregation O O 0.7673156261444092
assays O O 0.9892461895942688
, O O 0.9999887943267822
e.g. O O 0.9984923601150513
between O O 0.9978081583976746
menopausal O O 0.6175078749656677

and O O 0.9293610453605652
kappaB S-protein S-protein 0.9581388235092163
-dependent O O 0.9974256157875061
transcriptional O O 0.9639613032341003
activity O O 0.9963138699531555
was O O 0.9999845027923584
enhanced O O 0.9996899366378784
in O O 0.9999715089797974
the O O 0.9999457597732544
presence O O 0.9987227320671082
of O O 0.9999059438705444
activated B-cell_type B-cell_type 0.551402747631073
platelets E-cell_type E-cell_type 0.9348011016845703
. O O 0.9995166063308716
In O O 0.9999666213989258
addition O O 0.9985436201095581
, O O 0.9999260902404785
ADP-activated B-cell_type B-cell_type 0.37290969491004944
platelets E-cell_type E-cell_type 0.8635668158531189
induced O O 0.9938054084777832
MCP-1 O S-protein 0.8850855231285095
and O O 0.9874857068061829
ICAM-1 O S-protein 0.8991202712059021
promoter-dependent O O 0.8962957262992859

Electrophoretically O O 0.9068698883056641

inflammation O O 0.884721040725708

At O O 0.9993115663528442
doses O O 0.9994470477104187
where O O 0.9999746084213257
alone O O 0.9954386353492737
, O O 0.9999402761459351
they O O 0.9998635053634644
produced O O 0.999842643737793
no O O 0.9997989535331726
significant O O 0.9982971549034119
effects O O 0.9958631992340088
on O O 0.9998751878738403
locomotion O O 0.8005485534667969
, O O 0.9731864333152771
BD1018 B-Chemical B-Chemical 0.9136393666267395
, O O 0.9263263940811157
BD1063 B-Chemical B-Chemical 0.9068747758865356
and O O 0.9577232599258423
LR132 B-Chemical B-Chemical 0.9052998423576355
significantly O O 0.9967028498649597
attenuated O O 0.9987597465515137
the O O 0.9996705055236816
locomotor O O 0.8510892391204834
stimulatory O O 0.7814875841140747
effects O O 0.9897994995117188
of O O 0.9998818635940552
cocaine B-Chemical B-Chemical 0.9175443649291992
. O O 0.9996033310890198

a O O 0.9955698847770691
MPC11 B-cell_line O 0.3897363841533661
plasmacytoma I-cell_line O 0.2723153531551361
x I-cell_line O 0.27204629778862
fibroblast I-cell_line O 0.3906429708003998
environment E-cell_line O 0.7028176188468933
, O O 0.9998315572738647
the O O 0.999941349029541
IgH B-DNA B-DNA 0.5513298511505127
3 I-DNA I-DNA 0.5971154570579529
' I-DNA I-DNA 0.8078827857971191
enhancer E-DNA E-DNA 0.9935752749443054
is O O 0.9983963370323181
transcriptionally O O 0.9647803902626038
inactive O O 0.9882957935333252
. O O 0.9999938011169434
Furthermore O O 0.9999861717224121
, O O 0.9999935626983643
we O O 0.9999594688415527
demonstrate O O 0.9999957084655762
that O O 0.9999957084655762
binding O O 0.9863861799240112
of O O 0.999488353729248
several O O 0.9949064254760742

protease S-protein O 0.49053260684013367

the O O 0.9987990856170654
same O O 0.9997279047966003
chimeric O O 0.8044842481613159
animals O O 0.7684901356697083
suggested O O 0.9999450445175171
that O O 0.9999974966049194
the O O 0.9999058246612549
ES B-cell_type B-cell_line 0.30742159485816956
cell-derived I-cell_type I-cell_line 0.3874306082725525
reticulocytes E-cell_type E-cell_line 0.7802932262420654
were O O 0.9998248219490051
present O O 0.9998581409454346

phase O O 0.9723502993583679
of O O 0.9996578693389893
allergic O O 0.9412027597427368
inflammation O O 0.980767011642456
. O O 0.9999988079071045
This O O 0.9999821186065674
review O O 0.9997914433479309
will O O 0.9999933242797852
focus O O 0.999967098236084
on O O 0.999976396560669

Among O O 0.9996243715286255
the O O 0.9999668598175049
2000 O O 0.9967256784439087
spots O O 0.998307466506958
compared O O 0.9999943971633911
for O O 0.999995231628418
statistical O O 0.9910468459129333
difference O O 0.9914994835853577
, O O 0.9999874830245972
67 O O 0.9931086301803589
spots O O 0.9986384510993958
were O O 0.9999902248382568
significantly O O 0.9999175071716309
changed O O 0.9994829893112183
in O O 0.9999558925628662
abundance O O 0.9625000953674316
and O O 0.9998403787612915
identified O O 0.9998445510864258
using O O 0.9999047517776489
matrix O O 0.9076934456825256
- O O 0.9993579983711243
assisted O O 0.994963526725769
laser O O 0.9442858695983887
desorption O O 0.8032929301261902
/ O O 0.9992973804473877
ionization O O 0.9809316992759705
time O O 0.9991698265075684
- O O 0.9999607801437378
of O O 0.9999022483825684
- O O 0.999058187007904
flight O O 0.9942386150360107
MS O O 0.8090971112251282
, O O 0.9998297691345215
atmospheric O O 0.9217133522033691
pressure O O 0.859642505645752
matrix O O 0.9251796007156372
- O O 0.9995443224906921
assisted O O 0.996600329875946
laser O O 0.9477366805076599
desorption O O 0.8196889162063599
/ O O 0.99936443567276
ionization O O 0.879772424697876
and O O 0.9998032450675964
HPLC O O 0.5460973978042603
coupled O O 0.9899841547012329
tandem O O 0.8260390162467957
MS O O 0.6945326924324036
( O O 0.9995750784873962
LC O O 0.8438044190406799
/ O O 0.9995206594467163
MS O O 0.9645039439201355
/ O O 0.999763548374176
MS O O 0.9254665970802307
) O O 0.9992671608924866
. O O 0.9999974966049194

In O O 0.9996802806854248
the O O 0.9999009370803833
vitro O O 0.9583749771118164
human O O 0.8761010766029358
platelet B-Disease O 0.7238413095474243
aggregations I-Disease O 0.6570914387702942
induced O O 0.9988757967948914
by O O 0.9999871253967285
the O O 0.9995075464248657
agonists O O 0.9270064830780029
used O O 0.9999237060546875
in O O 0.9999831914901733
tests O O 0.9996545314788818
, O O 0.9999908208847046
TET B-Chemical B-Chemical 0.9118174314498901
and O O 0.9636706113815308
FAN B-Chemical B-Chemical 0.9116925597190857
showed O O 0.9986059069633484
the O O 0.9999703168869019
inhibitions O O 0.7969458103179932
dose O O 0.9974640607833862
dependently O O 0.99982088804245
. O O 0.9999972581863403

The O O 0.9981406927108765
block O O 0.9596182107925415
was O O 0.9995121955871582
successful O O 0.9997493624687195
and O O 0.9999552965164185
surgery O O 0.876984179019928
was O O 0.9997777342796326
conducted O O 0.9999722242355347
as O O 0.9999954700469971
scheduled O O 0.9998500347137451
despite O O 0.9999903440475464
persisting O O 0.998537540435791
atrial O B-Disease 0.7178317308425903
fibrillation O I-Disease 0.9770167469978333
. O O 0.9979827404022217

Jurkat B-cell_line B-cell_line 0.5236190557479858
cells E-cell_line E-cell_line 0.9496181011199951
, O O 0.995922327041626
whereas O O 0.9999898672103882
stimulation O O 0.9975448250770569
with O O 0.9999961853027344
the O O 0.9999847412109375
same O O 0.9998207688331604
stimuli O O 0.9528982043266296
resulted O O 0.9999669790267944
in O O 0.9999809265136719
partial O O 0.9840800166130066
inhibition O O 0.996347963809967
of O O 0.9999308586120605
LTR S-DNA S-DNA 0.91862952709198
activation O O 0.9847837686538696
in O O 0.9999576807022095
Nef+ B-cell_line B-cell_line 0.5060527324676514
Jurkat I-cell_line I-cell_line 0.7568866610527039
cells E-cell_line E-cell_line 0.988263726234436
. O O 0.9999021291732788
This O O 0.9999815225601196
inhibition O O 0.9965407252311707
was O O 0.9999868869781494
not O O 0.9999500513076782

The O O 0.9990206956863403
hypotensive O B-Disease 0.9674437642097473
episodes O O 0.7607254981994629
were O O 0.9988856911659241
severe O O 0.9931249022483826
enough O O 0.9992413520812988
to O O 0.9999762773513794
require O O 0.999970555305481
vasopressor O B-Chemical 0.9021294116973877
administration O O 0.9702059030532837
. O O 0.999988317489624

region E-protein E-DNA 0.633392870426178
. O O 0.9997572302818298
GrpL S-protein S-protein 0.9611285328865051
can O O 0.9995699524879456
be O O 0.9999712705612183
coimmunoprecipitated O O 0.9925238490104675

unique O O 0.9060450196266174
characteristic O O 0.9947595000267029
among O O 0.9999728202819824
nuclear O B-protein 0.7558985352516174
factors O E-protein 0.9557693600654602
implicated O O 0.9985559582710266
in O O 0.9999476671218872
the O O 0.9999750852584839
control O O 0.9918434023857117
of O O 0.9997963309288025
IL-2 S-protein B-DNA 0.7725737690925598
gene O E-DNA 0.8483829498291016
expression O O 0.9791887402534485
. O O 0.9999821186065674
Transcriptional O O 0.8787509202957153
basis O O 0.9598942399024963
for O O 0.9994826316833496
hyporesponsiveness O O 0.9243199825286865
of O O 0.9993813037872314
the O O 0.9998204112052917
human B-DNA B-DNA 0.4584988057613373
inducible I-DNA I-DNA 0.4086865186691284
nitric I-DNA I-DNA 0.5727735161781311
oxide I-DNA I-DNA 0.6854177713394165
synthase I-DNA I-DNA 0.5354263186454773
gene E-DNA E-DNA 0.9608672261238098

Myasthenia O B-Disease 0.7581347227096558
gravis O I-Disease 0.9548436403274536
caused O O 0.967516303062439
by O O 0.9996098875999451
penicillamine S-Chemical B-Chemical 0.9362030625343323
and O O 0.9226622581481934
chloroquine S-Chemical B-Chemical 0.9280591607093811
therapy O O 0.9774593710899353
for O O 0.9999648332595825
rheumatoid O B-Disease 0.5324686765670776
arthritis O I-Disease 0.9590961933135986
. O O 0.9975149631500244

) O O 0.8821107745170593
a O O 0.9997835755348206
characteristic O O 0.9898204803466797
competitive O O 0.9696643352508545
binding O O 0.9515589475631714
profile O O 0.9861345887184143
for O O 0.9999903440475464
other O O 0.9994723200798035
steroid O O 0.7428090572357178
hormones O O 0.6223968863487244
( O O 0.998846173286438
relative O O 0.9911559820175171
binding O O 0.9788291454315186
affinities O O 0.9870953559875488
: O O 0.9999672174453735
testosterone O O 0.9226499795913696
= O O 0.9985300302505493
dihydrotestosterone O O 0.9345546960830688
> O O 0.9997056126594543
17 O O 0.9952455163002014
beta-estradiol O O 0.971321702003479
> O O 0.9996134638786316
progesterone O O 0.9526308178901672
, O O 0.9998633861541748
whereas O O 0.9999960660934448
aldosterone O O 0.920458197593689
, O O 0.9986754059791565
17-hydroxy-progesterone O O 0.9544408321380615
and O O 0.9992319345474243
cortisol O O 0.9786275029182434
did O O 0.9999551773071289
not O O 0.9999487400054932
compete O O 0.9998732805252075
appreciably O O 0.9998778104782104
) O O 0.9999141693115234
. O O 0.9999935626983643
Furthermore O O 0.9996283054351807
the O O 0.9999936819076538
number O O 0.9990906715393066
of O O 0.999950647354126
binding B-protein B-DNA 0.6697728037834167
sites E-protein E-DNA 0.6712694764137268
determined O O 0.9994810223579407
using O O 0.9999558925628662
[ O O 0.9914857745170593
3H O O 0.9084925651550293
] O O 0.9856862425804138
dihydrotestosterone O O 0.9513083100318909
, O O 0.9998797178268433
[ O O 0.9990614056587219
3H O O 0.9852913618087769
] O O 0.9987843632698059
RU-1881 O O 0.8924949169158936
, O O 0.9998874664306641
or O O 0.9999732971191406
[ O O 0.997283935546875
3H O O 0.9740172028541565
] O O 0.9977545142173767
testosterone O O 0.7734069228172302

neutrophils E-cell_type S-cell_type 0.523672342300415
. O O 0.9998632669448853
Binding O O 0.9641215801239014
of O O 0.9914460182189941
interferon-gamma S-protein S-protein 0.9506728649139404
( O O 0.9899492263793945
IFN-gamma S-protein S-protein 0.9904612898826599
) O O 0.9694547057151794
to O O 0.9999377727508545
its O O 0.9998588562011719
heterodimeric O B-protein 0.5149905681610107
receptor O E-protein 0.9578519463539124
induces O O 0.9962666630744934
activation O O 0.9950876832008362
of O O 0.9998477697372437
the O O 0.9996923208236694
tyrosine B-protein B-protein 0.40899258852005005
kinases E-protein E-protein 0.9332332611083984

transduction/transcription B-protein B-protein 0.47335922718048096
factors E-protein E-protein 0.9919478297233582
. O O 0.9997465014457703
The O O 0.9999924898147583
remaining O O 0.9981052875518799
86 O O 0.9368759393692017
% O O 0.991661548614502
correspond O O 0.9998399019241333
to O O 0.9999676942825317
unknown O O 0.94782954454422
genes S-DNA O 0.4899422526359558
of O O 0.9996963739395142
which O O 0.9999948740005493
92 O O 0.9654590487480164
% O O 0.9953286647796631
have O O 0.9999693632125854
been O O 0.999790370464325
confirmed O O 0.9995693564414978
to O O 0.9999516010284424
be O O 0.9998821020126343
differentially O O 0.9941138625144958
expressed O O 0.9995942711830139
. O O 0.9999983310699463
These O O 0.9999938011169434
data O O 0.9997119307518005
demonstrate O O 0.9999970197677612
the O O 0.9999845027923584
efficiency O O 0.9995208978652954
of O O 0.9999595880508423
the O O 0.9999022483825684
system O O 0.9950039982795715
and O O 0.9999560117721558
support O O 0.9998971223831177
the O O 0.9999873638153076
notion O O 0.999863862991333
that O O 0.9999983310699463
numerous O O 0.9918163418769836
genes S-DNA O 0.5028070211410522
falling O O 0.9991065859794617
into O O 0.9999767541885376
those O O 0.9999240636825562
categories O O 0.9944539666175842
remain O O 0.9999736547470093

at O O 0.9991881251335144
the O O 0.9999918937683105
nonpermissive O O 0.9187472462654114
temperature O O 0.9829543232917786
because O O 0.9999778270721436
they O O 0.9999860525131226
express O O 0.9999512434005737
a O O 0.9996631145477295
human B-DNA B-DNA 0.3933406174182892
BCL-2 I-DNA I-DNA 0.46740904450416565
gene E-DNA E-DNA 0.9869492650032043
. O O 0.9997285008430481
Our O O 0.9999980926513672
studies O O 0.9999314546585083
reveal O O 0.9999982118606567
that O O 0.9999963045120239
inactivation O O 0.9952084422111511
of O O 0.9998223185539246
the O O 0.9987431168556213
v-abl B-protein B-protein 0.5207482576370239
protein I-protein I-protein 0.5006598234176636
tyrosine I-protein I-protein 0.7156245708465576
kinase E-protein E-protein 0.9846014976501465
triggers O O 0.9985160231590271
high-frequency O O 0.9398346543312073
rearrangement O O 0.9804912805557251
of O O 0.9997482895851135
kappa B-DNA O 0.39127784967422485
and I-DNA O 0.9720577001571655
lambda I-DNA O 0.752644419670105
light-chain I-DNA O 0.4875296652317047

Proteinuria O B-Disease 0.961043655872345
increased O O 0.9017924070358276
significantly O O 0.9962930083274841
from O O 0.9999691247940063
a O O 0.9999148845672607
median O O 0.9997950196266174
of O O 0.9999040365219116
0 O O 0.9994756579399109
. O O 0.9999803304672241
13 O O 0.9998599290847778
g O O 0.9996739625930786
/ O O 0.9999791383743286
day O O 0.9999507665634155
( O O 0.9999852180480957
range O O 0.9996901750564575
0 O O 0.9997524619102478
- O O 0.9989864230155945
5 O O 0.9995095729827881
. O O 0.999957799911499
7 O O 0.9997091889381409
) O O 0.9988514184951782
preswitch O O 0.8744227886199951
to O O 0.9979724287986755
0 O O 0.9991415739059448
. O O 0.9999724626541138
23 O O 0.9998188614845276
g O O 0.9997805953025818
/ O O 0.9999884366989136
day O O 0.9999604225158691
( O O 0.999992847442627
0 O O 0.9999514818191528
- O O 0.9996353387832642
9 O O 0.9998407363891602
. O O 0.9998955726623535
88 O O 0.9983968138694763
) O O 0.9994462132453918
at O O 0.9999990463256836
24 O O 0.999699592590332
months O O 0.9999613761901855
postswitch O O 0.9941752552986145
( O O 0.9999840259552002
p O O 0.9998792409896851
= O O 0.9999772310256958
0 O O 0.9999077320098877
. O O 0.999923825263977
0024 O O 0.9711387157440186
) O O 0.9996479749679565
. O O 0.9999953508377075

AML O O 0.23930098116397858
by O O 0.9961678385734558
modulating O O 0.9989835619926453
the O O 0.9999208450317383
activity O O 0.9988890290260315
of O O 0.9999604225158691
transcription B-protein B-protein 0.5434625744819641
factors E-protein E-protein 0.9945076107978821
that O O 0.9996153116226196
are O O 0.9999865293502808
pivotal O O 0.9918402433395386
for O O 0.9998735189437866
normal O O 0.9663891792297363
myeloid O O 0.9029866456985474
development O O 0.9984537363052368
. O O 0.9999990463256836
Copyright O O 0.9613911509513855
1999 O O 0.9742431640625
Academic O O 0.9936385750770569
Press O O 0.9776170253753662
. O O 0.9999635219573975
NF-ATc B-protein B-protein 0.6710408329963684
isoforms E-protein E-protein 0.9783610105514526
are O O 0.9996258020401001
differentially O O 0.9956225752830505
expressed O O 0.9989325404167175
and O O 0.9997692704200745
regulated O O 0.9959142804145813
in O O 0.9996424913406372
murine B-cell_type B-cell_type 0.6417043209075928
T I-cell_type I-cell_type 0.5070661902427673
and I-cell_type I-cell_type 0.7989832162857056
mast I-cell_type I-cell_type 0.851140558719635
cells E-cell_type E-cell_type 0.9598723649978638
. O O 0.9996840953826904
NF B-protein B-protein 0.45704904198646545

engagement O O 0.9527340531349182
and O O 0.9992838501930237
exposure O O 0.9970445036888123
to O O 0.9999366998672485
IL-4 S-protein S-protein 0.923169732093811
synergistically O O 0.9253358244895935
induced O O 0.9934629201889038
gamma O B-protein 0.378477543592453
3 O E-protein 0.8761923909187317
ECS-dependent O O 0.8554554581642151
luciferase B-DNA B-DNA 0.28493714332580566
reporter I-DNA I-DNA 0.367563396692276
gene E-DNA E-DNA 0.9128466844558716
activation O O 0.9678671360015869
. O O 0.9999638795852661
Targeted O O 0.9241297841072083
mutational O O 0.9677730202674866
analysis O O 0.999161958694458
demonstrated O O 0.9999914169311523
that O O 0.9999970197677612
a O O 0.9997679591178894
tandem O O 0.7756878733634949
NF-kappa B-DNA B-DNA 0.20580941438674927
B/Rel I-DNA I-DNA 0.4220356345176697
binding I-DNA I-DNA 0.6316432952880859
motif E-DNA E-DNA 0.5213277339935303
is O O 0.9996442794799805
critical O O 0.9994458556175232
for O O 0.9999874830245972
the O O 0.999824583530426
gamma B-DNA B-protein 0.44100990891456604
3 I-DNA E-protein 0.6263346076011658

The O O 0.9983001351356506
magnesium B-Chemical B-Chemical 0.903244137763977
was O O 0.993759274482727
stopped O O 0.999783456325531
and O O 0.9999837875366211
she O O 0.9992386102676392
recovered O O 0.9996126294136047
over O O 0.9999921321868896
a O O 0.9999241828918457
few O O 0.9999295473098755
days O O 0.9999651908874512
. O O 0.9999990463256836

which O O 0.9952623844146729
significantly O O 0.9997721314430237
increase O O 0.9992565512657166
in O O 0.9992420673370361
number O O 0.9837708473205566
during O O 0.999966025352478
pregnancy O O 0.997473418712616
, O O 0.9999947547912598
might O O 0.9999889135360718
play O O 0.9999927282333374
a O O 0.9999957084655762
role O O 0.9998325109481812
in O O 0.9999949932098389
recognition O O 0.9995662569999695
of O O 0.999982476234436
fetal B-protein B-protein 0.6243008971214294
antigens E-protein E-protein 0.8741629719734192
and O O 0.9897212386131287
also O O 0.9994321465492249

when O O 0.9989448189735413

addition O O 0.9812901616096497
to O O 0.9996256828308105
NB4 O B-cell_line 0.6691445112228394
cells O E-cell_line 0.9595969915390015
, O O 0.99964439868927
ATRA O O 0.7482067942619324
also O O 0.9993233680725098
activated O O 0.9970263838768005
IRF-1 B-DNA B-DNA 0.6399917006492615
gene E-DNA E-DNA 0.8886260986328125
expression O O 0.9821804761886597
in O O 0.9999299049377441
HL-60 S-cell_line S-cell_line 0.9400620460510254
, O O 0.9344437718391418
U937 S-cell_line S-cell_line 0.8596314787864685

function O O 0.9816511869430542
of O O 0.9997208714485168
LEF-1 S-protein S-protein 0.9621455073356628
is O O 0.9994390606880188
dependent O O 0.9999129772186279
, O O 0.9999750852584839
in O O 0.9999812841415405
part O O 0.9988380074501038
, O O 0.9999721050262451
on O O 0.9999784231185913
the O O 0.9998801946640015
HMG B-protein B-protein 0.5119155049324036
domain E-protein E-protein 0.8893582820892334
that O O 0.9968850016593933
induces O O 0.9999570846557617
a O O 0.9999127388000488
sharp O O 0.9339437484741211
bend O O 0.7328853011131287
in O O 0.999210000038147
the O O 0.9997953772544861
DNA O O 0.8157660365104675
helix O O 0.4542865753173828
, O O 0.99399334192276
and O O 0.9999048709869385
on O O 0.9999558925628662
an O O 0.9998989105224609
activation B-protein B-protein 0.7524886727333069
domain E-protein E-protein 0.9505094289779663
that O O 0.9985345602035522
stimulates O O 0.9997296929359436
transcription O O 0.9391440153121948
only O O 0.999171257019043
in O O 0.9999624490737915
a O O 0.9996939897537231
specific O O 0.8828414678573608

. O O 0.9960487484931946
NF-kappa B-protein B-protein 0.7947544455528259
B E-protein E-protein 0.9969858527183533
activation O O 0.9974125027656555
by O O 0.999983549118042
TNF B-protein B-protein 0.438649982213974
alpha E-protein E-protein 0.9931449890136719
was O O 0.9993867874145508
not O O 0.999896764755249
correlated O O 0.9995719790458679
with O O 0.99998939037323
cell O O 0.9670498371124268
differentiation O O 0.9950222969055176
or O O 0.9999306201934814
proliferation O O 0.994243323802948
. O O 0.9999817609786987
However O O 0.9997150301933289
, O O 0.9999287128448486
reagents O O 0.8387864232063293
such O O 0.9998188614845276
as O O 0.9999748468399048
nerve B-protein B-protein 0.6867297887802124
growth I-protein I-protein 0.5098612308502197
factor E-protein E-protein 0.9132459759712219
( O O 0.9580690264701843
NGF S-protein S-protein 0.8965248465538025
) O O 0.935739278793335
and O O 0.9996318817138672
the O O 0.9999034404754639
phorbol O O 0.7821494936943054
ester O O 0.8645613789558411
phorbol O O 0.9168508052825928
12-myristate O O 0.9697372317314148
13-acetate O O 0.9681218266487122
( O O 0.9998137354850769
PMA O O 0.9762291312217712
) O O 0.999826967716217
, O O 0.9999843835830688
which O O 0.9999946355819702
induce O O 0.9999665021896362
phenotypical O O 0.9551270008087158
differentiation O O 0.9928170442581177
of O O 0.9998868703842163

On O O 0.9994588494300842
the O O 0.9999727010726929
other O O 0.9999744892120361
hand O O 0.9999744892120361
, O O 0.9999911785125732
BNP O O 0.6710731983184814
did O O 0.9997017979621887
not O O 0.9997515082359314
increase O O 0.991533100605011
in O O 0.9975903034210205
the O O 0.9986868500709534
patients O O 0.9986124038696289
without O O 0.9999709129333496
heart O B-Disease 0.5315168499946594
failure O I-Disease 0.9755265116691589
given O O 0.9463119506835938
DNR S-Chemical B-Chemical 0.8814660906791687
, O O 0.9828422665596008
even O O 0.9991353154182434
at O O 0.999993085861206
more O O 0.9996874332427979
than O O 0.9999321699142456
700 O O 0.9986157417297363
mg O O 0.9997840523719788
/ O O 0.9999911785125732
m O O 0.9998874664306641
( O O 0.9998902082443237
2 O O 0.9997085928916931
) O O 0.9993003606796265
. O O 0.9999966621398926

Ab E-protein E-protein 0.9350329637527466
, O O 0.9953923225402832
the O O 0.9998865127563477
band O O 0.9701804518699646
was O O 0.9996210336685181
supershifted O O 0.9988741278648376
. O O 0.9999958276748657
Thus O O 0.9996893405914307
, O O 0.9999799728393555
we O O 0.999932050704956
demonstrated O O 0.9999557733535767
that O O 0.9999775886535645
IL-5 S-protein S-protein 0.9834266901016235
activated O O 0.9964728951454163
the O O 0.9998596906661987
Jak B-protein B-protein 0.3692335784435272
2 E-protein E-protein 0.892983078956604
-STAT B-protein B-protein 0.4088975191116333
1 E-protein E-protein 0.8899074792861938
signaling O O 0.8471206426620483
pathway O O 0.9901350140571594
in O O 0.9999663829803467

its O O 0.9970505237579346
metabolic O O 0.9175789952278137
activity O O 0.9749177694320679
in O O 0.9998619556427002
B B-cell_type B-cell_type 0.8609607815742493
cells E-cell_type E-cell_type 0.9885336756706238
. O O 0.9994753003120422
These O O 0.9999985694885254
findings O O 0.9999675750732422
suggest O O 0.9999971389770508
that O O 0.9999980926513672
although O O 0.9998303651809692
human B-cell_type B-cell_type 0.46757760643959045
B I-cell_type I-cell_type 0.7713585495948792
lymphocytes E-cell_type E-cell_type 0.976043164730072
can O O 0.9996261596679688
express O O 0.9998183846473694
VDR B-RNA B-RNA 0.8152238726615906
mRNA E-RNA E-RNA 0.9848259091377258
and O O 0.9956592321395874
protein S-protein O 0.7788251638412476
, O O 0.9980760812759399
they O O 0.9999814033508301
exhibit O O 0.9999220371246338
a O O 0.9999250173568726
functional O O 0.9532374739646912
block O O 0.7819876074790955
for O O 0.9979619979858398

expression O O 0.9731996059417725
. O O 0.9999271631240845
IFN-alpha S-protein S-protein 0.9522823095321655
also O O 0.9943336248397827
sensitized B-cell_line O 0.9420648813247681
T I-cell_line B-cell_type 0.7893174886703491
cells E-cell_line E-cell_type 0.9853616952896118
to O O 0.9965201616287231
IL-2 S-protein S-protein 0.9962887763977051
-induced O O 0.9945582151412964
proliferation O O 0.9977505803108215
, O O 0.9999867677688599
further O O 0.9999339580535889
suggesting O O 0.9999924898147583
that O O 0.9999620914459229
IFN-alpha S-protein S-protein 0.9983439445495605
may O O 0.999887228012085
be O O 0.9999949932098389
involved O O 0.9999825954437256
in O O 0.9999909400939941
the O O 0.9999721050262451
regulation O O 0.99439537525177

Ca O O 0.28237396478652954
( O O 0.8085746169090271
2+ O O 0.6534813046455383
) O O 0.5156376957893372
-dependent O O 0.95414137840271
membrane O O 0.9076189994812012
potential O O 0.986775815486908
changes O O 0.9977079629898071
are O O 0.9999850988388062
not O O 0.9997771382331848
involved O O 0.9999185800552368
in O O 0.9999512434005737
human O O 0.5897800922393799
T B-cell_type O 0.3711552023887634
or I-cell_type O 0.9376773834228516
B I-cell_type O 0.902093768119812
cell E-cell_type O 0.8753513693809509
activation O O 0.996421217918396
and O O 0.9999258518218994
proliferation O O 0.9960970282554626
. O O 0.9999945163726807
The O O 0.9999949932098389
involvement O O 0.9998757839202881
of O O 0.999977707862854
ion O B-protein 0.5487426519393921
channels O E-protein 0.8078343272209167
in O O 0.9979968667030334
B O B-cell_type 0.6066950559616089
and O I-cell_type 0.5819201469421387
T O I-cell_type 0.4868377149105072
lymphocyte O E-cell_type 0.8212643265724182
activation O O 0.9697043895721436
is O O 0.9998942613601685
supported O O 0.9999871253967285
by O O 0.9999963045120239
many O O 0.9997056126594543
reports O O 0.9994630217552185
of O O 0.999976634979248
changes O O 0.991104245185852
in O O 0.9993705153465271
ion O O 0.7934479117393494
fluxes O O 0.6053380370140076
and O O 0.998339056968689
membrane O O 0.7537201046943665
potential O O 0.9358208179473877
after O O 0.9998600482940674
mitogen S-protein O 0.5669146776199341
binding O O 0.9371162056922913
. O O 0.9999223947525024
Human B-cell_type B-cell_type 0.5776504278182983
T I-cell_type I-cell_type 0.5957468748092651
and I-cell_type I-cell_type 0.7952699661254883
B I-cell_type I-cell_type 0.848114550113678
lymphocytes E-cell_type E-cell_type 0.9510265588760376
demonstrate O O 0.9997859597206116
an O O 0.9999891519546509
early O O 0.9423328042030334
and O O 0.9893009066581726
transient O O 0.9476702213287354

necessary O O 0.9923431277275085
to O O 0.9999507665634155
target O O 0.9998668432235718
the O O 0.9999697208404541
appropriate O O 0.979679524898529
switch O O 0.9453492760658264
region O O 0.5567865371704102
for O O 0.9996515512466431
recombination O O 0.9824749827384949
and O O 0.9988961219787598
switching O O 0.99310702085495
. O O 0.9999895095825195
Different O O 0.9963880777359009
cytokines S-protein S-protein 0.9891840219497681
activate O O 0.9991002082824707
transcription O O 0.9091658592224121
at O O 0.9994687438011169
the O O 0.9999494552612305
appropriate O O 0.9167131185531616
germline B-DNA B-DNA 0.5387573838233948
promoter E-DNA E-DNA 0.9652767181396484
. O O 0.9996799230575562
Because O O 0.9999884366989136
binding B-DNA O 0.8406203985214233
sites E-DNA O 0.76253342628479
for O O 0.9986600875854492
B-cell-specific B-protein O 0.3928081691265106

To O O 0.9994742274284363
test O O 0.9999701976776123
the O O 0.999970555305481
validity O O 0.9978433847427368
of O O 0.999980092048645
the O O 0.9999774694442749
hypothesis O O 0.9115775227546692
that O O 0.9998294115066528
hypomethylation O O 0.6625416278839111
of O O 0.9151058793067932
DNA O O 0.36601144075393677
plays O O 0.9990642666816711
an O O 0.9999932050704956
important O O 0.9996721744537354
role O O 0.9994333386421204
in O O 0.9999896287918091
the O O 0.9999464750289917
initiation B-Disease O 0.9794785380363464
of I-Disease O 0.9996414184570312
carcinogenic I-Disease O 0.553272545337677
process I-Disease O 0.8853866457939148
, O O 0.999685525894165
5 B-Chemical B-Chemical 0.9269994497299194
- I-Chemical I-Chemical 0.9964373111724854
azacytidine I-Chemical I-Chemical 0.9325476288795471
( O O 0.7903629541397095
5 B-Chemical B-Chemical 0.7477676868438721
- I-Chemical I-Chemical 0.9923722743988037
AzC I-Chemical I-Chemical 0.9499750137329102
) O O 0.7868655920028687
( O O 0.9954645037651062
10 O O 0.9997230172157288
mg O O 0.9995821118354797
/ O O 0.9999741315841675
kg O O 0.9988754391670227
) O O 0.9996629953384399
, O O 0.9999979734420776
an O O 0.999966025352478
inhibitor O O 0.9846560955047607
of O O 0.9996820688247681
DNA O O 0.6801041960716248
methylation O O 0.6305203437805176
, O O 0.9998230338096619
was O O 0.9999649524688721
given O O 0.9999921321868896
to O O 0.9999709129333496
rats O O 0.9919376969337463
during O O 0.9999902248382568
the O O 0.9999827146530151
phase O O 0.9998581409454346
of O O 0.9998952150344849
repair O O 0.7225396633148193
synthesis O O 0.5677118301391602
induced O O 0.9939634203910828
by O O 0.9999539852142334
the O O 0.999913215637207
three O O 0.9995343685150146
carcinogens O O 0.6605308055877686
, O O 0.9989288449287415
benzo B-Chemical B-Chemical 0.9374470710754395
[ I-Chemical I-Chemical 0.9132001399993896
a I-Chemical I-Chemical 0.9759435057640076
] I-Chemical I-Chemical 0.9824113249778748
- I-Chemical I-Chemical 0.9923530220985413
pyrene I-Chemical I-Chemical 0.9335994720458984
( O O 0.9536024332046509
200 O O 0.9985671043395996
mg O O 0.9989016056060791
/ O O 0.9999704360961914
kg O O 0.99790358543396
) O O 0.9988149404525757
, O O 0.9997296929359436
N B-Chemical B-Chemical 0.9074666500091553
- I-Chemical I-Chemical 0.9899939894676208
methyl I-Chemical I-Chemical 0.9640936851501465
- I-Chemical I-Chemical 0.9899107813835144
N I-Chemical I-Chemical 0.9482529759407043
- I-Chemical I-Chemical 0.9935378432273865
nitrosourea I-Chemical E-Chemical 0.9196011424064636
( O O 0.9467118978500366
60 O O 0.9971724152565002
mg O O 0.9992521405220032
/ O O 0.9999561309814453
kg O O 0.9985633492469788
) O O 0.9996901750564575
and O O 0.9999184608459473
1 B-Chemical B-Chemical 0.779883861541748
, I-Chemical I-Chemical 0.6941440105438232
2 I-Chemical I-Chemical 0.9642737507820129
- I-Chemical I-Chemical 0.9958815574645996
dimethylhydrazine I-Chemical E-Chemical 0.919253945350647
( O O 0.7524694204330444
1 B-Chemical B-Chemical 0.5030330419540405
, I-Chemical I-Chemical 0.8549525737762451
2 I-Chemical I-Chemical 0.9709967374801636
- I-Chemical I-Chemical 0.9944559931755066
DMH I-Chemical I-Chemical 0.9430916905403137
) O O 0.5803616046905518
( O O 0.9989824891090393
100 O O 0.9998769760131836
mg O O 0.9996604919433594
/ O O 0.9999890327453613
kg O O 0.9992733597755432
) O O 0.9999345541000366
. O O 0.9999982118606567

It O O 0.9988994598388672
has O O 0.9999749660491943
also O O 0.9999675750732422
been O O 0.9999738931655884
suggested O O 0.999991774559021
that O O 0.9999784231185913
sirolimus B-Chemical B-Chemical 0.9244985580444336
directly O O 0.9881850481033325
causes O O 0.9995180368423462
increased O O 0.9870296716690063
glomerular O O 0.6843656897544861
permeability O O 0.6292272806167603
/ O O 0.9685031771659851
injury O O 0.7579644918441772
, O O 0.9940145611763
but O O 0.9999057054519653
evidence O O 0.9997467398643494
for O O 0.9999932050704956
this O O 0.9998133778572083
mechanism O O 0.995604395866394
is O O 0.9999935626983643
currently O O 0.9999717473983765
inconclusive O O 0.9972647428512573
. O O 0.9999991655349731

( O O 0.9269282817840576
polypryrimidine-binding B-protein B-protein 0.3437778055667877
factor E-protein E-protein 0.9514288306236267
, O O 0.9621898531913757
PYBF S-protein S-protein 0.9576981067657471
) O O 0.9651740789413452
binds O O 0.9990310668945312
to O O 0.9999772310256958
a O O 0.9996613264083862
pyrimidine-rich B-DNA B-DNA 0.5051557421684265
region E-DNA E-DNA 0.7879229784011841
1 B-DNA O 0.8495440483093262
kb I-DNA O 0.6845138072967529
upstream E-DNA O 0.596035361289978
from O O 0.9999241828918457
the O O 0.9996764659881592
human B-DNA B-DNA 0.5344971418380737
delta-globin-encoding I-DNA I-DNA 0.8306286334991455
gene E-DNA E-DNA 0.9719811081886292
( O O 0.9859360456466675
HBD S-DNA S-DNA 0.9606472253799438
) O O 0.9879970550537109
. O O 0.9999827146530151
The O O 0.9999946355819702
developmental O O 0.9730244278907776
stage-specificity O O 0.9890949130058289
of O O 0.9998144507408142
PYBF S-protein S-protein 0.9073443412780762
and O O 0.9971945285797119
the O O 0.9998928308486938
location O O 0.9927177429199219
of O O 0.9994631409645081

cells E-cell_line E-cell_type 0.7021031379699707
. O O 0.999502420425415
Neutrophils O S-cell_type 0.8340601325035095
pretreated O O 0.9983416795730591
with O O 0.9999630451202393
NH2Cl O O 0.7527019381523132
( O O 0.9966294169425964
30-50 O O 0.9581228494644165
microM O O 0.8206469416618347
) O O 0.9720099568367004
showed O O 0.9999936819076538
a O O 0.999980092048645
marked O O 0.9908062815666199
decrease O O 0.9948244094848633
in O O 0.9997610449790955
the O O 0.9997441172599792
respiratory O O 0.9405942559242249
burst O O 0.9306513071060181
activity O O 0.9969634413719177
induced O O 0.9999576807022095
by O O 0.9999891519546509
phorbol O O 0.9444983005523682
12-myristate O O 0.9832929968833923
13-acetate O O 0.9815580248832703
( O O 0.9998950958251953
PMA O O 0.969224750995636
) O O 0.9997087121009827
, O O 0.9999691247940063
which O O 0.9999834299087524
is O O 0.9999918937683105
a O O 0.9999839067459106
potent O O 0.9881840944290161
PKC S-protein B-protein 0.7492020130157471
activator O E-protein 0.8497603535652161
. O O 0.999201238155365
These O O 0.9999439716339111
cells O O 0.9792789220809937
, O O 0.9998680353164673
however O O 0.9999321699142456
, O O 0.9999650716781616
were O O 0.9999902248382568
viable O O 0.9993213415145874
and O O 0.9999622106552124
showed O O 0.9999809265136719

protein O E-protein 0.9482945799827576
, O O 0.997814416885376
the O O 0.9999843835830688
activity O O 0.9985787868499756
of O O 0.9999687671661377
the O O 0.9998912811279297
double-stranded B-protein B-protein 0.6245866417884827
RNA-dependent I-protein I-protein 0.6303861737251282
protein I-protein I-protein 0.5733079314231873
kinase E-protein E-protein 0.9871439337730408
( O O 0.988195538520813
PKR S-protein S-protein 0.9974865913391113
) O O 0.9926631450653076
and O O 0.9999113082885742
the O O 0.9999682903289795
intracellular O O 0.887534499168396
levels O O 0.9842368960380554
of O O 0.9996843338012695
NF-kappaB B-protein B-protein 0.593268632888794
subunits E-protein E-protein 0.973055899143219
in O O 0.9997718930244446
the O O 0.999743640422821
PLB-985 S-cell_line S-cell_line 0.860418438911438
and O O 0.8461437225341797
U937 B-cell_line B-cell_line 0.5087963342666626
myeloid I-cell_line I-cell_line 0.934611976146698
cell I-cell_line I-cell_line 0.8959212899208069

region O O 0.4125613272190094
of O O 0.9962009787559509
IL-2 B-DNA B-DNA 0.8627632260322571
gene E-DNA E-DNA 0.9140655398368835
in O O 0.9982187151908875
vitro O O 0.9594170451164246
and O O 0.9951817393302917
stimulation O O 0.9823623299598694

( O O 0.9316486120223999
probucol O O 0.5656483769416809
) O O 0.9092234969139099
inhibited O O 0.999748170375824
these O O 0.9999843835830688
events O O 0.99928879737854
. O O 0.9999980926513672
Additionally O O 0.9999436140060425
, O O 0.9999725818634033
preincubation O O 0.9971355199813843
of O O 0.999931812286377
HUVEC S-cell_line S-cell_type 0.5564084053039551
with O O 0.9986196756362915
a O O 0.9999521970748901
synthetic O O 0.9165510535240173
peptide O O 0.8671666979789734
Arg-Gly-Asp O O 0.3559064567089081
( O O 0.9845150709152222
RGD O O 0.5094659328460693
) O O 0.948531448841095
that O O 0.99988853931427
prevents O O 0.999841570854187
vWf S-protein S-protein 0.9619367718696594
-mediated O O 0.993870735168457
adhesion O O 0.9943172335624695
of O O 0.9998769760131836
SS B-cell_type B-cell_type 0.6185197830200195
RBC E-cell_type E-cell_type 0.7308468818664551
reduced O O 0.977792501449585

Plasma O O 0.9133541584014893
PRL O O 0.6493505239486694
concentrations O O 0.9882252216339111
were O O 0.9999958276748657
analysed O O 0.9999953508377075
at O O 0.9999990463256836
10 O O 0.9989847540855408
min O O 0.9995076656341553
intervals O O 0.997610330581665
and O O 0.9999873638153076
underlying O O 0.9963186979293823
secretory O O 0.8175721764564514
rates O O 0.9901633858680725
calculated O O 0.9999724626541138
by O O 0.9999974966049194
a O O 0.9999806880950928
deconvolution O O 0.8790919780731201
procedure O O 0.9813024401664734
. O O 0.9999974966049194

NF B-protein B-protein 0.5824313163757324
kappa I-protein I-protein 0.9068729281425476
B E-protein E-protein 0.9838374257087708
remain O O 0.998683512210846
unaltered O O 0.9974018335342407
during O O 0.9999885559082031
aging O O 0.9921419620513916
. O O 0.9999940395355225
These O O 0.999996542930603
results O O 0.9999592304229736
suggest O O 0.9999988079071045
that O O 0.9999986886978149
an O O 0.9999545812606812
age-associated O O 0.9774134755134583
decline O O 0.9890151619911194
in O O 0.999883770942688
the O O 0.99986732006073
induction O O 0.9970170259475708
of O O 0.9999518394470215
NF B-protein B-protein 0.5796098113059998
kappa I-protein I-protein 0.8717383146286011
B E-protein E-protein 0.984567403793335
in O O 0.9990170001983643
activated O B-cell_type 0.5670255422592163
T B-cell_type I-cell_type 0.6535847783088684
cells E-cell_type E-cell_type 0.9768331050872803
from O O 0.9998006224632263
elderly O O 0.8938941955566406
individuals O O 0.9951390027999878
may O O 0.9999978542327881
be O O 0.9999985694885254
attributable O O 0.9999878406524658
to O O 0.9999949932098389
altered O O 0.9886744618415833
regulation O O 0.9992952346801758
of O O 0.9999700784683228
the O O 0.9998288154602051

hypothesis O O 0.8392362594604492

activity O O 0.9818364977836609
. O O 0.9999852180480957
Together O O 0.999991774559021
, O O 0.9999948740005493
these O O 0.9999940395355225
findings O O 0.9999417066574097
suggest O O 0.9999979734420776
that O O 0.9999972581863403
the O O 0.9998558759689331
nuclear O O 0.810940682888031
localization O O 0.5394894480705261
signal O O 0.49923020601272583
and O O 0.9547397494316101
transactivation B-protein B-protein 0.5124853849411011
domain E-protein E-protein 0.971676766872406
of O O 0.9913034439086914
NF-kappa B-protein B-protein 0.8466944098472595

B E-protein E-protein 0.9291955232620239
through O O 0.9990605711936951
the O O 0.9999479055404663
phosphorylation O O 0.9674558043479919
of O O 0.9994567036628723
I B-protein B-protein 0.8024230599403381
kappa I-protein I-protein 0.8865174055099487
B I-protein I-protein 0.593666672706604
alpha E-protein E-protein 0.9784114360809326
on O O 0.9986452460289001
tyrosine O O 0.7676069736480713
residues O O 0.8854011297225952
. O O 0.9999502897262573
The O O 0.9999960660934448
response O O 0.9957756400108337
of O O 0.9999290704727173
mammalian B-cell_type B-cell_type 0.6289148926734924
cells E-cell_type E-cell_type 0.8808364272117615
to O O 0.9979636669158936
stress O O 0.9273226261138916
is O O 0.9999322891235352
controlled O O 0.9996618032455444
by O O 0.9999942779541016
transcriptional B-protein B-protein 0.8114660978317261
regulatory I-protein I-protein 0.5490567088127136
proteins E-protein E-protein 0.994013249874115
such O O 0.9996795654296875
as O O 0.9999868869781494
nuclear B-protein B-protein 0.5480391979217529
factor I-protein I-protein 0.6248953938484192
kappa I-protein I-protein 0.9390889406204224
B E-protein E-protein 0.9721693396568298
( O O 0.9873619079589844
NF-kappa B-protein B-protein 0.8556281924247742
B E-protein E-protein 0.9661555886268616
) O O 0.9402543306350708
to O O 0.9998980760574341
induce O O 0.9999662637710571
a O O 0.9998997449874878
wide O O 0.9344333410263062

promoter O E-DNA 0.9171308279037476
contains O O 0.9988192915916443
a O O 0.9998874664306641
sequence O O 0.8401979804039001
GGGGACGTCCCC O S-DNA 0.7318907976150513
, O O 0.9830159544944763
named O O 0.9913175106048584
B2 S-DNA S-DNA 0.9494653344154358
, O O 0.9829902648925781
which O O 0.9997770190238953
is O O 0.9999581575393677
similar O O 0.999931812286377
to O O 0.9999792575836182
the O O 0.9998407363891602
kappa B-DNA B-DNA 0.7840645909309387
B I-DNA I-DNA 0.7783140540122986
sequence E-DNA E-DNA 0.9559292197227478
GGGGACTTTCC O S-DNA 0.7075245976448059
, O O 0.9937267303466797
the O O 0.9997578263282776
binding O B-DNA 0.6817833781242371
site O E-DNA 0.7440145611763
of O O 0.984815239906311
the O O 0.9996739625930786
transcription B-protein B-protein 0.48116081953048706
factor E-protein I-protein 0.6936607360839844
nuclear B-protein I-protein 0.5928249359130859
factor I-protein I-protein 0.7326611280441284
( I-protein I-protein 0.4621473252773285
NF I-protein I-protein 0.8098194003105164
) I-protein I-protein 0.8985769748687744
-kappa I-protein I-protein 0.9222363233566284
B E-protein E-protein 0.961389422416687
. O O 0.997201681137085
Activation O O 0.9953606724739075
of O O 0.9992187023162842
T B-cell_type B-cell_type 0.7987089157104492

. O O 0.9958121180534363
The O O 0.9999940395355225
regulation O O 0.9995959401130676
of O O 0.999975323677063
IL-6 S-protein S-protein 0.9859198331832886
is O O 0.9998546838760376
dependent O O 0.9999880790710449
on O O 0.9999948740005493
various O O 0.9970126152038574
stimuli O O 0.9524449110031128
that O O 0.9999641180038452
include O O 0.9999877214431763
lipopolysaccharide O O 0.9068228006362915
( O O 0.9984937906265259
LPS O O 0.9711011648178101
) O O 0.9995928406715393
, O O 0.9999808073043823
viruses O O 0.9162654280662537

of O O 0.9975976347923279
the O O 0.9999728202819824
IL-2mRNA S-RNA S-protein 0.6315088272094727
synthesis O O 0.7139993906021118
in O O 0.9994480013847351
splenic B-cell_line B-cell_line 0.42862939834594727
T-lymphocytes I-cell_line I-cell_line 0.38530194759368896
culture E-cell_line E-cell_line 0.8590720295906067
in O O 0.9992006421089172
normal O O 0.9091276526451111
conditions O O 0.9879394769668579
were O O 0.9999760389328003
shown O O 0.9999876022338867
. O O 0.9999990463256836
The O O 0.9999963045120239
protective O O 0.974773108959198
effect O O 0.9994121789932251
of O O 0.9999473094940186
SP S-protein O 0.31472596526145935
and O O 0.9678911566734314

confocal O O 0.7827468514442444
laser O O 0.8235533237457275
scanning O O 0.9293110966682434
microscopy O O 0.8865258097648621
( O O 0.9980043768882751
CLSM O O 0.4251973628997803
) O O 0.9868539571762085
and O O 0.9995633959770203
flow O O 0.8582915663719177
cytometry O O 0.7047016620635986
, O O 0.9993368983268738
respectively O O 0.9999834299087524
. O O 0.9999957084655762
Binding O O 0.9790942072868347
of O O 0.9993748068809509
the O O 0.9999434947967529
plasma O B-protein 0.643398106098175
membrane O I-protein 0.48821553587913513
impermeable O I-protein 0.6996260285377502
testosterone-BSA B-protein I-protein 0.3795032799243927
conjugate E-protein E-protein 0.8106347322463989
induces O O 0.9986273050308228
a O O 0.9999475479125977
rapid O O 0.9636235237121582
rise O O 0.9928585290908813
( O O 0.9998538494110107
< O O 0.9990748167037964
5 O O 0.9992693066596985
s O O 0.9977599382400513
) O O 0.998071014881134
in O O 0.9999147653579712
[ O O 0.9735249876976013
Ca2+ O O 0.8757152557373047
] O O 0.9913522005081177

The O O 0.9997479319572449
maximal O O 0.9870895743370056
NGF O O 0.5674322247505188
contents O O 0.9585683345794678
obtained O O 0.9999821186065674
by O O 0.9999954700469971
PG B-Chemical B-Chemical 0.9397240877151489
- I-Chemical I-Chemical 0.9894579648971558
9 E-Chemical I-Chemical 0.9620262384414673
were O O 0.8861519694328308
17 O O 0.9955015778541565
. O O 0.9999822378158569
6 O O 0.999000608921051
- O O 0.9992300271987915
fold O O 0.9989727735519409
of O O 0.9994897842407227
the O O 0.99993896484375
control O O 0.9797026515007019
value O O 0.9922095537185669
. O O 0.9999966621398926

We O O 0.9997015595436096
conclude O O 0.9999920129776001
that O O 0.9999918937683105
lidocaine B-Chemical B-Chemical 0.9255081415176392
reduces O O 0.9874073266983032
the O O 0.9965925812721252
incidence O O 0.9543441534042358
and O O 0.9993240833282471
severity O O 0.7040078639984131
of O O 0.9933266639709473
propofol B-Chemical B-Chemical 0.9158678650856018
injection O O 0.8317355513572693
pain B-Disease O 0.8519500494003296
in O O 0.9959533214569092
ambulatory O O 0.6387804746627808
patients O O 0.9634218215942383
whereas O O 0.999984622001648
thiopentone B-Chemical B-Chemical 0.9288074374198914
only O O 0.9979591369628906
reduces O O 0.9972071051597595
its O O 0.9980429410934448
severity O O 0.9294837713241577
. O O 0.9999935626983643

B E-protein E-protein 0.9195996522903442
. O O 0.9968609809875488
A O O 0.9999465942382812
phosphoform O O 0.8331064581871033
of O O 0.9966250658035278
newly O O 0.8839311003684998
synthesized O O 0.9484466910362244
I B-protein B-protein 0.6865495443344116
kappa I-protein I-protein 0.8618180751800537
B I-protein I-protein 0.4950602650642395
alpha E-protein E-protein 0.9929537177085876
is O O 0.9996277093887329
visible O O 0.9995371103286743
when O O 0.999996542930603
degradation O O 0.9933264255523682
by O O 0.9999949932098389
the O O 0.9996235370635986
proteasome S-protein O 0.44340842962265015
is O O 0.9969933032989502
inhibited O O 0.9961672425270081
and O O 0.9998401403427124
new O O 0.9897281527519226
I B-protein B-protein 0.4587531089782715

In O O 0.9997442364692688
the O O 0.9999189376831055
twin O O 0.7079651355743408
pregnancy O O 0.6395618915557861
, O O 0.9998051524162292
the O O 0.9998722076416016
mother O O 0.9961729645729065
had O O 0.999902606010437
Crohn B-Disease B-Disease 0.73012775182724
' I-Disease I-Disease 0.6227898597717285
s I-Disease I-Disease 0.544695258140564
disease I-Disease I-Disease 0.9799021482467651
. O O 0.9958516359329224

binding I-protein I-protein 0.7137260437011719
factors E-protein E-protein 0.9731489419937134
by O O 0.9998358488082886
electrophoretic O O 0.9379298090934753
mobility O O 0.9846922159194946
shift O O 0.9981856942176819
assays O O 0.9996920824050903
show O O 0.999995231628418
that O O 0.9999974966049194
ISGF3 S-protein S-protein 0.9330893754959106
is O O 0.9993159770965576
induced O O 0.9999340772628784
by O O 0.9999786615371704
IFN-alpha S-protein S-protein 0.9788417220115662
within O O 0.9992750287055969
6 O O 0.9958035349845886
h O O 0.9908638596534729
from O O 0.9999648332595825
undetectable O O 0.9475648999214172
basal O O 0.9051966667175293
levels O O 0.9961679577827454
in O O 0.9999719858169556
untreated O O 0.609171986579895
U937 B-cell_line B-cell_line 0.6969260573387146
cells E-cell_line E-cell_line 0.994882345199585
. O O 0.999910831451416
Activation O O 0.9984272718429565
of O O 0.999884843826294
ISGF3 B-protein B-protein 0.4089581370353699
alpha E-protein E-protein 0.9550108313560486
, O O 0.9946603178977966
the O O 0.9999198913574219
latent O O 0.8910623788833618

inflammatory O O 0.7440700531005859
diseases O O 0.8162738680839539
in O O 0.9999595880508423
Japan O O 0.9873237013816833
, O O 0.9999641180038452
cepharanthine O O 0.7709977626800537
should O O 0.9999270439147949
be O O 0.9999898672103882
further O O 0.999943733215332
pursued O O 0.9998674392700195
for O O 0.9999966621398926
its O O 0.999963641166687
chemotherapeutic O O 0.9070902466773987
potential O O 0.9721075892448425

gp41 S-protein S-protein 0.8068028092384338
failed O O 0.9988177418708801
to O O 0.9999825954437256
stimulate O O 0.9998869895935059
NF-kappaB S-protein S-protein 0.9951700568199158
binding O O 0.9896971583366394
activity O O 0.9990085959434509
in O O 0.9999878406524658
as O O 0.9996213912963867
much O O 0.9997531771659851
as O O 0.9999521970748901
no O O 0.9926359057426453
NF-kappaB S-protein S-protein 0.9141514897346497
bound O O 0.9979425072669983
to O O 0.9999850988388062
the O O 0.9998626708984375
main B-DNA O 0.8105400204658508
NF-kappaB-binding I-DNA B-DNA 0.7242037653923035
site E-DNA I-DNA 0.9133962988853455
2 O E-DNA 0.9500950574874878
of O O 0.9969128370285034
the O O 0.9998065829277039
IL-10 B-DNA B-DNA 0.7653676867485046
promoter E-DNA E-DNA 0.9897667765617371
after O O 0.9986464381217957
addition O O 0.9996901750564575
of O O 0.999964714050293
gp41 S-protein S-protein 0.8330870866775513
. O O 0.9993788003921509
We O O 0.9999401569366455
also O O 0.9999771118164062
examined O O 0.9999858140945435
the O O 0.9999861717224121
involvement O O 0.9999538660049438
of O O 0.9999939203262329
other O O 0.9982326030731201
signal O O 0.8485965132713318
transduction O O 0.8373380899429321
pathways O O 0.9901514649391174
. O O 0.9999953508377075
Specific O O 0.9921417236328125
inhibitors O O 0.9716719388961792
of O O 0.9995566010475159
p70 B-protein B-protein 0.5441627502441406
( I-protein I-protein 0.5502939820289612
S6 I-protein I-protein 0.9021880030632019
) I-protein I-protein 0.7838670611381531
-kinase E-protein E-protein 0.9428732991218567
( O O 0.9049527645111084

Plasma O O 0.8978744149208069
cortisol S-Chemical B-Chemical 0.9179030060768127
concentrations O O 0.8772134780883789
were O O 0.9999788999557495
significantly O O 0.999967098236084
raised O O 0.9999020099639893
during O O 0.9999973773956299
the O O 0.9999697208404541
active O O 0.9952823519706726
phase O O 0.9998441934585571
( O O 0.9999856948852539
323 O O 0.9996500015258789
+ O O 0.9999600648880005
/ O O 0.9999959468841553
- O O 0.9999716281890869
43 O O 0.9998577833175659
to O O 0.9999457597732544
1082 O O 0.9997028708457947
+ O O 0.9999696016311646
/ O O 0.9999938011169434
- O O 0.9999815225601196
245 O O 0.9997979998588562
mmol O O 0.9991395473480225
/ O O 0.9999738931655884
L O O 0.9983872175216675
, O O 0.9999567270278931
P O O 0.9964526891708374
< O O 0.9999141693115234
0 O O 0.999761164188385
. O O 0.9999140501022339
05 O O 0.9968515038490295
) O O 0.9996814727783203
. O O 0.9999972581863403

Details O O 0.9899605512619019
of O O 0.9998586177825928
spinal O O 0.9267626404762268
puncture O O 0.6063576340675354
, O O 0.9906657934188843
extension O O 0.9626140594482422
and O O 0.9968854784965515
regression O O 0.8269609212875366
of O O 0.989029049873352
spinal O O 0.8685630559921265
block O O 0.7305698394775391
, O O 0.9772278666496277
and O O 0.9996687173843384
the O O 0.9999418258666992
times O O 0.999841570854187
to O O 0.9999855756759644
reach O O 0.999931812286377
discharge O O 0.9179880619049072
criteria O O 0.9964145421981812
were O O 0.999996542930603
noted O O 0.9999943971633911
. O O 0.9999983310699463

not O O 0.9753894805908203
involve O O 0.9999462366104126
expression O O 0.9987467527389526
of O O 0.9999679327011108
members O O 0.9370979070663452
of O O 0.9993718266487122
the O O 0.9998900890350342
immediate-early B-DNA B-protein 0.4263383746147156
activation I-DNA I-protein 0.534071683883667
genes I-DNA I-protein 0.7681912183761597
family E-DNA E-protein 0.6983022093772888
( O O 0.9576654434204102
egr-1 S-DNA S-DNA 0.9036865830421448
, O O 0.9552823901176453
c-fos S-DNA S-DNA 0.8787394762039185
, O O 0.9781680703163147
and O O 0.9936594367027283
junB S-DNA S-DNA 0.9198259115219116
) O O 0.9768337607383728
, O O 0.9998421669006348
AP-1 S-protein S-protein 0.8078216910362244
transcriptional O O 0.8789473176002502
activity O O 0.9832795858383179
, O O 0.9996986389160156
or O O 0.9995797276496887
bcl-2 S-DNA S-protein 0.4835573732852936
expression O O 0.9793809056282043
. O O 0.9999754428863525
This O O 0.9999843835830688
indicates O O 0.9999794960021973
that O O 0.9999879598617554
functional O O 0.9679655432701111
differences O O 0.994745135307312
observed O O 0.9999688863754272
in O O 0.999957799911499
IL-2- B-cell_line O 0.316479355096817

) O O 0.7025075554847717
and O O 0.9851773977279663
antibody O O 0.538645327091217
to O O 0.937913179397583
CD3 S-protein S-protein 0.8007330298423767
( O O 0.9822385311126709
IC50 O S-protein 0.6399447917938232
of O O 0.9833342432975769
10 O O 0.9757709503173828
ng/ml O O 0.884985625743866
) O O 0.991229772567749
, O O 0.9999697208404541
and O O 0.999962329864502
with O O 0.9999772310256958
PMA O O 0.8239482641220093
and O O 0.9980067610740662
ionomycin O O 0.6412721276283264

plus O O 0.9469948410987854
anti-CD28 S-protein S-protein 0.9244985580444336
and O O 0.9951478838920593
PMA O O 0.743518054485321
plus O O 0.9807939529418945
ionomycin O O 0.43394866585731506
resulted O O 0.9998031258583069
in O O 0.999945878982544
nuclear B-protein O 0.8247329592704773
NFAT E-protein S-protein 0.7230522632598877
. O O 0.9997554421424866
Surprisingly O O 0.9998013377189636
, O O 0.999997615814209
the O O 0.9999872446060181
PMA-ionomycin-induced O O 0.8375569581985474
synthesis O O 0.9449967741966248
of O O 0.9992520213127136
NFATc S-protein S-protein 0.9190447926521301
that O O 0.9987867474555969
was O O 0.9999121427536011
detected O O 0.999824583530426
by O O 0.9999797344207764
immunoprecipitation O O 0.9783754944801331
was O O 0.9999253749847412
not O O 0.9999357461929321
mirrored O O 0.9998363256454468
in O O 0.9999815225601196
the O O 0.9999349117279053
DNA O O 0.8962298035621643
binding O O 0.8049603700637817

Rats O O 0.9384629726409912
were O O 0.9999120235443115
treated O O 0.9999958276748657
with O O 0.9999954700469971
the O O 0.9997310042381287
vehicle O O 0.9971035122871399
( O O 0.9999918937683105
2 O O 0.9997811913490295
mL O O 0.999496579170227
/ O O 0.9999817609786987
kg O O 0.9998432397842407
of O O 0.9998953342437744
distilled O O 0.6540180444717407
water O O 0.4731343686580658
and O O 0.9983207583427429
5 O O 0.9996716976165771
% O O 0.9999703168869019
w O O 0.9997374415397644
/ O O 0.9999645948410034
v O O 0.9998610019683838
cellulose O O 0.8854304552078247
, O O 0.9365604519844055
10 O O 0.9992938041687012
days O O 0.9999111890792847
) O O 0.999835729598999
, O O 0.9999921321868896
gum B-Chemical B-Chemical 0.8709126710891724
Arabic E-Chemical I-Chemical 0.9650735259056091
( O O 0.9694696068763733
2 O O 0.9993334412574768
mL O O 0.9986286163330078
/ O O 0.9999831914901733
kg O O 0.9998016953468323
of O O 0.9998775720596313
a O O 0.9999326467514038
10 O O 0.9965723752975464
% O O 0.9999436140060425
w O O 0.9993937015533447
/ O O 0.9999611377716064
v O O 0.9997387528419495
aqueous O O 0.4985135495662689
suspension O O 0.8659959435462952
of O O 0.9949179887771606
gum B-Chemical B-Chemical 0.8207017779350281
Arabic E-Chemical I-Chemical 0.9537354707717896
powder O I-Chemical 0.9553067684173584
, O O 0.9307193756103516
orally O O 0.9956247210502625
for O O 0.9999635219573975
10 O O 0.9994392991065979
days O O 0.9999037981033325
) O O 0.9998900890350342
, O O 0.9999918937683105
or O O 0.9999675750732422
gum B-Chemical O 0.47750645875930786
Arabic E-Chemical O 0.864387571811676
concomitantly O O 0.9732248187065125
with O O 0.9999648332595825
GM S-Chemical B-Chemical 0.935813844203949
( O O 0.9819106459617615
80mg O O 0.9934318661689758
/ O O 0.9998595714569092
kg O O 0.9990060925483704
/ O O 0.9999878406524658
day O O 0.9999370574951172
intramuscularly O O 0.9951913356781006
, O O 0.9999507665634155
during O O 0.9999927282333374
the O O 0.9999828338623047
last O O 0.9999563694000244
six O O 0.9999327659606934
days O O 0.9999871253967285
of O O 0.9999812841415405
the O O 0.9999715089797974
treatment O O 0.9985693693161011
period O O 0.9999847412109375
) O O 0.9999735355377197
. O O 0.9999974966049194

nuclei O O 0.810600757598877
of O O 0.9978048205375671
IL-4- B-cell_line B-cell_line 0.3724227845668793
, I-cell_line I-cell_line 0.6238462328910828
IL-5- I-cell_line I-cell_line 0.7321673035621643
, I-cell_line I-cell_line 0.8428720235824585
or I-cell_line I-cell_line 0.7859683036804199
ionomycin-stimulated I-cell_line I-cell_line 0.9089509844779968
eosinophils E-cell_line E-cell_line 0.9510464072227478
. O O 0.9993427395820618
Only O O 0.9983903169631958
NF-AT1 S-protein S-protein 0.9294372200965881
and O O 0.9791443943977356
NF-AT4 S-protein S-protein 0.9651705622673035
, O O 0.9928473830223083
but O O 0.9996868371963501
not O O 0.9992052912712097
NF-AT2 S-protein S-protein 0.8799890875816345

Secondary B-Disease O 0.9520077705383301
hyperalgesia I-Disease B-Disease 0.9648039937019348
shares O O 0.9483796954154968
clinical O O 0.952359676361084
characteristics O O 0.9666210412979126
with O O 0.999983549118042
neurogenic B-Disease O 0.5141681432723999
hyperalgesia I-Disease O 0.7271973490715027
in O O 0.9828625321388245
patients O O 0.9998838901519775
with O O 0.9999634027481079
neuropathic B-Disease O 0.619217574596405
pain I-Disease O 0.924282431602478
. O O 0.9992597699165344

B B-protein B-protein 0.3528238534927368
cell I-protein I-protein 0.38073626160621643
110-kDa I-protein I-protein 0.4319363534450531
nuclear I-protein I-protein 0.8877707719802856
protein E-protein E-protein 0.9872716069221497
. O O 0.9989783763885498
Expression O O 0.990365743637085
studies O O 0.9994450211524963
as O O 0.9999769926071167
well O O 0.9997242093086243
as O O 0.9999935626983643
the O O 0.9999641180038452
use O O 0.9997422099113464
of O O 0.9999700784683228
transgenic O O 0.7512566447257996
animals O O 0.7296736240386963
have O O 0.9999502897262573
demonstrated O O 0.9999945163726807
that O O 0.9999980926513672
the O O 0.9999327659606934
A-MYB S-protein B-protein 0.521703839302063
transcription B-protein I-protein 0.5460755825042725
factor E-protein E-protein 0.917903482913971

process O O 0.9320357441902161
. O O 0.9999754428863525
The O O 0.99994957447052
CD34+ B-cell_line B-cell_line 0.6014918684959412
myelomonocytic I-cell_line I-cell_line 0.8738473653793335
cell I-cell_line I-cell_line 0.9266139268875122
line E-cell_line I-cell_line 0.9075320959091187
KG1 S-cell_line E-cell_line 0.5489192605018616
differentiates O O 0.9822489023208618
into O O 0.9993639588356018
dendritic-like O B-cell_type 0.49187415838241577
cells O E-cell_type 0.6096324324607849
in O O 0.9990804195404053
response O O 0.9962922930717468
to O O 0.9999392032623291
granulocyte-macrophage B-protein O 0.6568071842193604
CSF E-protein S-protein 0.5886945128440857
plus O O 0.9832733869552612
TNF-alpha S-protein S-protein 0.9133666753768921
, O O 0.9903165698051453
or O O 0.9995183944702148
PMA O O 0.6917534470558167
( O O 0.9832434058189392
with O O 0.9992815852165222
or O O 0.9989392161369324
without O O 0.999953031539917
the O O 0.9999232292175293
calcium O O 0.7221953272819519
ionophore O O 0.5702102184295654
ionomycin O O 0.4571364223957062

in O O 0.9983102083206177
Epstein-Barr O O 0.49558788537979126
virus-mediated O O 0.5808848142623901
oncogenesis O O 0.7547992467880249
. O O 0.9996654987335205
Identification O O 0.9989874958992004
of O O 0.9999539852142334
human B-DNA B-DNA 0.5280167460441589
TR2 I-DNA I-DNA 0.24374854564666748
orphan I-DNA I-DNA 0.3324664235115051
receptor I-DNA I-DNA 0.42322930693626404
response I-DNA I-DNA 0.8386321663856506
element E-DNA E-DNA 0.9810549020767212
in O O 0.9993541836738586
the O O 0.9999412298202515
transcriptional B-DNA B-DNA 0.733872652053833
initiation I-DNA I-DNA 0.4631357789039612
site E-DNA E-DNA 0.8184697031974792
of O O 0.994240403175354
the O O 0.999729573726654

lipopolysaccharide O O 0.3675786554813385
) O O 0.9338858127593994
repeatedly O O 0.9997379183769226
then O O 0.9999911785125732
the O O 0.9999920129776001
initially O O 0.9903404116630554
high O O 0.989061713218689
expression O O 0.9943391680717468
of O O 0.999932050704956
the O O 0.9999196529388428
TNF B-DNA B-DNA 0.5763231515884399
( I-DNA I-DNA 0.7603644728660583
tumor I-DNA I-DNA 0.3533245921134949
necrosis I-DNA I-DNA 0.5352292060852051
factor I-DNA I-DNA 0.41885271668434143
) I-DNA I-DNA 0.7148658633232117
gene E-DNA E-DNA 0.9894880056381226
is O O 0.9983385801315308
only O O 0.999970555305481
very O O 0.9994221925735474
low O O 0.9961238503456116
, O O 0.999908447265625
i.e. O O 0.9996022582054138
the O O 0.9998759031295776
cells O O 0.968716561794281
are O O 0.9999773502349854
tolerant O O 0.9873371720314026
to O O 0.9998076558113098
LPS O O 0.916752815246582
. O O 0.9998717308044434
Tolerant O O 0.6910053491592407
cells O O 0.46691983938217163
still O O 0.9990662932395935
express O O 0.9999808073043823
the O O 0.9998044371604919
CD14 B-protein S-protein 0.6870537996292114

and O O 0.9302959442138672
NF-kappaB S-protein S-protein 0.9772593975067139
DNA O O 0.9716265797615051
binding O O 0.9978649020195007
increased O O 0.9999372959136963
. O O 0.9999635219573975
IL-10 S-protein S-protein 0.9562799334526062
pretreatment O O 0.9823609590530396
prevented O O 0.9995365142822266
LPS-induced O O 0.855936586856842
decreases O O 0.9808510541915894
in O O 0.999739944934845
IkappaB-alpha S-protein S-protein 0.9691892266273499
protein O O 0.6424651145935059
levels O O 0.9988992214202881
and O O 0.9999574422836304
attenuated O O 0.9336081147193909
NF-kappaB S-protein S-protein 0.9606437087059021
DNA O O 0.9608734846115112
binding O O 0.9933786392211914
. O O 0.9999582767486572
IL-10 S-protein S-protein 0.9761451482772827
appears O O 0.999135434627533
to O O 0.9999849796295166
prevent O O 0.999948263168335
activation O O 0.9987173080444336
of O O 0.9999188184738159
NF-kappaB S-protein S-protein 0.9954211115837097
by O O 0.9998321533203125
preserving O O 0.9963703155517578
IkappaB-alpha S-protein S-protein 0.9593485593795776
protein O O 0.4621807932853699
levels O O 0.9986605644226074
, O O 0.9999866485595703

cells O E-cell_type 0.641126275062561
did O O 0.9997537732124329
not O O 0.9999847412109375
produce O O 0.9998986721038818
IgE S-protein S-protein 0.988430380821228
. O O 0.9994207620620728
CD27 S-protein S-protein 0.9795448780059814
/CD70 O S-protein 0.935581624507904
interaction O O 0.9944440722465515
enhanced O O 0.9992239475250244
B B-cell_type O 0.6971424221992493
cell E-cell_type O 0.4705122709274292
proliferation O O 0.9880204796791077
in O O 0.9999810457229614
the O O 0.9999648332595825
presence O O 0.9986475110054016
of O O 0.9999525547027588
IL-4 S-protein S-protein 0.8928014636039734
or O O 0.9955775737762451
IL-4 S-protein S-protein 0.6187363862991333

observed O O 0.9762027859687805
for O O 0.9996961355209351
NF-kB2/p52 O S-protein 0.9313931465148926
. O O 0.9997822642326355
Constitutive O O 0.9908932447433472
binding O O 0.9873907566070557
of O O 0.9997552037239075
further O O 0.9823437929153442
factor B-protein O 0.879907488822937
proteins E-protein O 0.7549628615379333
to O O 0.9981808662414551
DNA O O 0.7812359929084778
, O O 0.9973093271255493
such O O 0.9999246597290039
as O O 0.9999417066574097
JunD S-protein S-protein 0.7916553616523743
, O O 0.9786231517791748
c-Fos S-protein S-protein 0.9035583734512329
and O O 0.9920830726623535
FosB S-protein S-protein 0.9315798282623291
, O O 0.9961554408073425
was O O 0.9999423027038574
detected O O 0.9999566078186035
in O O 0.9999861717224121
several O O 0.9994920492172241
patients O O 0.9997262358665466
whereas O O 0.9999964237213135
the O O 0.9999696016311646
localisation O O 0.9850026965141296
and O O 0.9987956285476685
DNA O O 0.9739691019058228
binding O O 0.9908509850502014
of O O 0.9999079704284668
other O O 0.9981794357299805
factors O O 0.9442048072814941
such O O 0.9997506737709045
as O O 0.999924898147583
c-Jun S-protein S-protein 0.9319027066230774

& I-cell_type O 0.9354609847068787
H I-cell_type B-cell_type 0.6524925231933594
cells E-cell_type E-cell_type 0.779678463935852
) O O 0.9859622120857239
and O O 0.9999687671661377
its O O 0.9999842643737793
relationship O O 0.9994413256645203
with O O 0.999990701675415
germinal O O 0.8274083733558655
centers O O 0.819365382194519
. O O 0.9999912977218628
Forty-one O O 0.991718053817749
HD O O 0.7842287421226501
samples O O 0.7306578159332275
( O O 0.9999191761016846
19 O O 0.995422899723053
NLPHD O O 0.875987708568573
, O O 0.9992875456809998
12 O O 0.996263325214386
nodular O O 0.8690831065177917

element O E-DNA 0.9749005436897278
. O O 0.9998294115066528
The O O 0.9999746084213257
multimerized B-protein B-DNA 0.6526427268981934
recognition I-protein I-DNA 0.41056162118911743
motif E-protein E-DNA 0.7400735020637512
of O O 0.9848300218582153
TCF-1 S-protein S-protein 0.6595332026481628
constituted O O 0.9996071457862854
a O O 0.9998939037322998
T O B-DNA 0.5474038124084473
cell-specific O I-DNA 0.41120803356170654
enhancer O E-DNA 0.9871582388877869
. O O 0.9998558759689331
Subsequent O O 0.9995231628417969
cloning O O 0.993901252746582
of O O 0.9998182654380798
TCF-1 S-protein S-protein 0.8214103579521179
identified O O 0.9987910389900208
three O O 0.9985874891281128
splice B-protein O 0.6685513257980347
alternatives E-protein O 0.4586995840072632
. O O 0.998646080493927
TCF-1 S-protein S-protein 0.8199305534362793
contained O O 0.9951915740966797
a O O 0.9993888139724731

, O O 0.9683424234390259
which O O 0.9997925162315369
is O O 0.9999468326568604
downregulated O O 0.9992762207984924
as O O 0.9999961853027344
a O O 0.9999886751174927
response O O 0.9986801743507385
to O O 0.9999760389328003
induced O O 0.9905450344085693
differentiation O O 0.9935745596885681
along O O 0.9999663829803467
the O O 0.9997507929801941
erythroid O O 0.5240119099617004
and O O 0.9433071613311768
megakaryocytic O O 0.7775269150733948
pathways O O 0.9225075840950012
. O O 0.9999926090240479
We O O 0.9999310970306396
now O O 0.9999984502792358
demonstrate O O 0.999983549118042

Use O O 0.9994240999221802
of O O 0.9996392726898193
BZDs B-Chemical B-Chemical 0.9095461964607239
/ O O 0.9059156775474548
RDs O O 0.38480469584465027
tended O O 0.9998741149902344
to O O 0.9999768733978271
be O O 0.9999591112136841
associated O O 0.9997552037239075
with O O 0.9999877214431763
a O O 0.9998472929000854
reduced O O 0.9889311194419861
ability O O 0.9878816604614258
to O O 0.9997379183769226
walk O O 0.9986568689346313
and O O 0.9999595880508423
shorter O O 0.9996418952941895
night O O 0.9987731575965881
- O O 0.9999005794525146
time O O 0.9988303780555725
sleep O O 0.995646059513092
during O O 0.9999990463256836
the O O 0.9999922513961792
week O O 0.9999780654907227
prior O O 0.9999977350234985
to O O 0.999994158744812
admission O O 0.9966875910758972
. O O 0.9999992847442627

( O O 0.9720582365989685
KD O O 0.9324383735656738
= O O 0.9984140396118164
69.1 O O 0.998867392539978
pM O O 0.99429851770401
) O O 0.9995574355125427
than O O 0.9999892711639404
does O O 0.9999665021896362
the O O 0.9999725818634033
approximately O O 0.9845218062400818
50-kDa O B-protein 0.5546137690544128
protein O E-protein 0.8709523677825928
NFKB1 B-protein S-protein 0.5261474251747131
( I-protein O 0.902947187423706
p50 I-protein S-protein 0.9288706183433533
) E-protein O 0.7609899640083313
derived O O 0.9995447993278503
from O O 0.999944806098938
p105 S-protein S-protein 0.33789271116256714
( O O 0.6561853289604187
KD O O 0.46083545684814453
= O O 0.9121970534324646
3.9 O O 0.9528108835220337
pM O O 0.904735803604126
) O O 0.9904721975326538

Ocular B-Disease O 0.49701055884361267
and I-Disease O 0.9350306391716003
auditory I-Disease O 0.7893600463867188
toxicity I-Disease O 0.5198031067848206
in O O 0.9884231686592102
hemodialyzed O O 0.6488608121871948
patients O O 0.9190760850906372
receiving O O 0.9998196959495544
desferrioxamine B-Chemical B-Chemical 0.928920567035675
. O O 0.9995972514152527

. O O 0.995186984539032
In O O 0.9999923706054688
this O O 0.9999938011169434
study O O 0.9997900128364563
three O O 0.9996920824050903
novel O O 0.9077399373054504
clones O O 0.40690430998802185
were O O 0.9999005794525146
constructed O O 0.9994768500328064
in O O 0.9999830722808838
which O O 0.9999858140945435
the O O 0.9996441602706909
ZEBRA B-protein S-DNA 0.6195632815361023

have O O 0.999183714389801
some O O 0.9999873638153076
effects O O 0.9999314546585083
not O O 0.9999668598175049
directly O O 0.99947589635849
related O O 0.9999768733978271
to O O 0.9999951124191284
the O O 0.9999444484710693
suppression O O 0.9965674877166748
of O O 0.9999676942825317
IL-2 S-protein S-protein 0.9754945039749146
production O O 0.9960213303565979
. O O 0.9999879598617554
Cell O O 0.9368054866790771
separation O O 0.973064124584198
experiments O O 0.9992994070053101
suggest O O 0.9999986886978149
that O O 0.9999957084655762
IL-10 S-protein S-protein 0.9885879755020142
can O O 0.999583899974823
effect O O 0.9996138215065002
purified O O 0.7676100730895996
CD4 B-cell_type B-cell_type 0.3902885615825653
( I-cell_type I-cell_type 0.7265881299972534
+ I-cell_type I-cell_type 0.7773844003677368
) I-cell_type I-cell_type 0.8102774024009705
T I-cell_type I-cell_type 0.8939169645309448
cells E-cell_type E-cell_type 0.8991771340370178
directly O O 0.9966301321983337
, O O 0.9999868869781494
providing O O 0.9999746084213257
functional O O 0.9861461520195007
evidence O O 0.9996488094329834
for O O 0.9999960660934448
the O O 0.9999862909317017
presence O O 0.9995792508125305
of O O 0.9999678134918213
IL-10 S-protein S-protein 0.749110996723175

A O O 0.9926631450653076
starting O O 0.9948016405105591
dose O O 0.9991683959960938
of O O 0.9999315738677979
1 O O 0.9963585734367371
mg O O 0.9972341656684875
/ O O 0.9999823570251465
day O O 0.9998601675033569
with O O 0.999995231628418
gradual O O 0.9800815582275391
, O O 0.9992066025733948
upward O O 0.9892410635948181
dose O O 0.990425169467926
titration O O 0.7164891958236694
is O O 0.9998440742492676
recommended O O 0.9999756813049316
. O O 0.9999991655349731

. O O 0.993960976600647
Glucocorticoid B-protein B-protein 0.544577419757843
receptor E-protein E-protein 0.9822367429733276
in O O 0.9995946288108826
patients O O 0.999879002571106
with O O 0.9999891519546509
lupus O O 0.9195466041564941
nephritis O O 0.841614842414856
: O O 0.9998676776885986
relationship O O 0.9966139197349548
between O O 0.9996042847633362
receptor O O 0.835938036441803
levels O O 0.9969351291656494
in O O 0.9999476671218872
mononuclear B-cell_type B-cell_type 0.5702923536300659
leukocytes E-cell_type E-cell_type 0.9771396517753601
and O O 0.9961628913879395
effect O O 0.9991894364356995
of O O 0.9999691247940063
glucocorticoid O O 0.860720694065094
therapy O O 0.9911094903945923
. O O 0.9999970197677612
We O O 0.9999722242355347
investigated O O 0.9999881982803345
the O O 0.9999890327453613
clinical O O 0.9871814846992493
significance O O 0.9994469285011292
of O O 0.9999881982803345
glucocorticoid B-protein B-protein 0.4985482692718506
receptor E-protein E-protein 0.9226981997489929
determination O O 0.9802215099334717
in O O 0.9999889135360718
20 O O 0.9988465309143066
patients O O 0.9998942613601685
with O O 0.9999920129776001
systemic O O 0.959114134311676
lupus O O 0.8343839049339294

human I-cell_line B-cell_line 0.4330199956893921
T I-cell_line I-cell_line 0.41030237078666687
cell I-cell_line I-cell_line 0.799040675163269
line E-cell_line E-cell_line 0.9961286783218384
caused O O 0.9998570680618286
the O O 0.9999856948852539
accumulation O O 0.9988709092140198
of O O 0.999922513961792
class B-protein B-protein 0.6145890951156616
II-CLIP I-protein I-protein 0.6959112286567688
complexes E-protein E-protein 0.9962192177772522
, O O 0.9994797110557556
indicating O O 0.9999960660934448
that O O 0.9999916553497314
HLA-DO S-protein O 0.31604084372520447
blocked O O 0.9866155385971069
DM O O 0.5848323106765747
function O O 0.9901233315467834
in O O 0.9999685287475586
vivo O O 0.9749543070793152
and O O 0.9992126226425171
suggesting O O 0.9999850988388062
that O O 0.9999852180480957
HLA-DO S-protein S-protein 0.43869176506996155
is O O 0.999573290348053
an O O 0.9999929666519165
important O O 0.9962694644927979
modulator O O 0.9245830774307251
of O O 0.9926490187644958
class O O 0.6547144651412964

CONCLUSION O O 0.9980803728103638
: O O 0.9998629093170166
Raloxifene S-Chemical B-Chemical 0.9201221466064453
was O O 0.9958515167236328
associated O O 0.9997310042381287
with O O 0.9999709129333496
an O O 0.9996777772903442
increased O O 0.97413569688797
risk O O 0.9963441491127014
for O O 0.9999020099639893
venous O B-Disease 0.5231726765632629
thromboembolism O I-Disease 0.9207713007926941
, O O 0.9779645204544067
but O O 0.999782145023346
there O O 0.9999881982803345
was O O 0.9999622106552124
no O O 0.9999637603759766
increased O O 0.9891585111618042
risk O O 0.9975376129150391
for O O 0.9998782873153687
cataracts O B-Disease 0.9706456661224365
, O O 0.9764184355735779
gallbladder O B-Disease 0.5283323526382446
disease O I-Disease 0.981777548789978
, O O 0.9463592767715454
endometrial O B-Disease 0.5343358516693115
hyperplasia O I-Disease 0.8812860250473022
, O O 0.9240325689315796
or O O 0.9962730407714844
endometrial O B-Disease 0.5684708952903748
cancer O I-Disease 0.9247027039527893
. O O 0.9985401630401611

twin O O 0.8243277668952942
pair O O 0.8303882479667664
with O O 0.9999350309371948
Fabry O O 0.9233500957489014
disease O O 0.7870333790779114
and O O 0.9988038539886475
discordant O O 0.913946807384491
expression O O 0.9850829839706421
of O O 0.9998708963394165
a O O 0.999680757522583
novel O O 0.8200196027755737
mutation O O 0.6992166042327881
in O O 0.9998764991760254
the O O 0.9999247789382935
alpha-galactosidase B-DNA B-DNA 0.4485001564025879
A I-DNA I-DNA 0.6135047674179077
gene E-DNA E-DNA 0.983669102191925
. O O 0.9995989203453064
We O O 0.9999579191207886
describe O O 0.9999721050262451

a O O 0.9956159591674805
functional O O 0.9372082352638245
CAEV B-DNA B-DNA 0.408883661031723
LTR E-DNA E-DNA 0.9931282997131348
and O O 0.9980158805847168
a O O 0.9997523427009583
heterologous B-DNA B-DNA 0.5687313079833984
promoter E-DNA E-DNA 0.9870702028274536
. O O 0.9997465014457703
The O O 0.9999794960021973
cellular O O 0.8211188912391663
factor O O 0.730553388595581
that O O 0.9792937636375427
binds O O 0.9989672899246216
to O O 0.9999531507492065
the O O 0.9993246793746948
GAS B-DNA B-DNA 0.6777704358100891
element E-DNA E-DNA 0.9923305511474609
is O O 0.9994334578514099
present O O 0.9999589920043945
from O O 0.9999936819076538
5 O O 0.9817713499069214
min O O 0.9959923624992371
to O O 0.999392032623291
14 O O 0.9978308081626892
h O O 0.9952768087387085
after O O 0.9999436140060425
stimulation O O 0.997677743434906
with O O 0.99998939037323
IFN-gamma S-protein S-protein 0.9388251900672913
. O O 0.999622106552124
Binding O O 0.9303798675537109

Thus O O 0.9957013726234436
, O O 0.9999828338623047
our O O 0.9999798536300659
results O O 0.999923586845398
suggest O O 0.9999983310699463
that O O 0.9999924898147583
CD40 S-protein S-protein 0.9970780611038208
-mediated O O 0.9855373501777649
cell O O 0.9816656708717346
survival O O 0.9975194334983826
proceeds O O 0.9998539686203003
through O O 0.9999768733978271
NF-kappaB S-protein S-protein 0.9954575300216675
-dependent O O 0.9975500702857971

cell O O 0.5047488808631897
activation O O 0.9883390665054321
of O O 0.9998515844345093
naive O B-cell_type 0.6573938131332397
CD4+ B-cell_type I-cell_type 0.7414308786392212
T I-cell_type I-cell_type 0.8784529566764832
cells E-cell_type E-cell_type 0.822077751159668
using O O 0.9984660148620605
Ab O O 0.40493258833885193
cross-linking O O 0.849891722202301
. O O 0.9993993043899536
CTLA-4 S-protein S-protein 0.859805166721344
ligation O O 0.9169618487358093
inhibited O O 0.9970661997795105
CD3/ O O 0.331023246049881
CD28 S-protein S-protein 0.7249950766563416
-induced O O 0.9902698993682861
IL-2 B-RNA B-RNA 0.6384216547012329
mRNA E-RNA E-RNA 0.9916040301322937
accumulation O O 0.9810178279876709
by O O 0.9999920129776001
inhibiting O O 0.9985859394073486
IL-2 S-protein S-protein 0.9093512296676636
transcription O O 0.926293134689331
, O O 0.9992285966873169
which O O 0.9999653100967407
appears O O 0.9999728202819824
to O O 0.999947190284729
be O O 0.9999734163284302
mediated O O 0.9992671608924866
in O O 0.9999841451644897
part O O 0.998619794845581
through O O 0.999985933303833
decreasing O O 0.9885274171829224
NF-AT S-protein S-protein 0.917019784450531

-mediated O O 0.9121111631393433

sIg-crosslinking-induced O O 0.7385119199752808
protein O O 0.49037283658981323
tyrosine O O 0.6797832250595093
phosphorylation O O 0.8970600962638855
. O O 0.999790608882904
Phorbol O O 0.801548182964325
myristate O O 0.8212773203849792
acetate O O 0.8678752779960632
induced O O 0.9947258830070496
Egr-1 B-RNA B-RNA 0.7172254920005798
mRNA E-RNA E-RNA 0.9812262058258057
expression O O 0.9875693917274475
but O O 0.9999253749847412
forskolin O O 0.595661997795105
and O O 0.9847909808158875
dibutyryl O O 0.8805316090583801
cyclic O O 0.9513921141624451
AMP O O 0.9228342771530151
did O O 0.9999477863311768
not O O 0.9999717473983765
. O O 0.9999951124191284
These O O 0.999996542930603
findings O O 0.9999783039093018
suggest O O 0.9999982118606567
that O O 0.9999961853027344
the O O 0.9994692206382751
Egr-1 B-RNA B-RNA 0.8033014535903931
mRNA E-RNA E-RNA 0.9891360998153687
activating O O 0.9185770153999329
signals O O 0.9827852845191956
through O O 0.999937891960144
sIgM S-protein S-protein 0.8598936200141907
and O O 0.9682340025901794

CONCLUSIONS O O 0.9976874589920044
: O O 0.999993085861206
The O O 0.9999828338623047
combination O O 0.994621992111206
of O O 0.9996539354324341
paclitaxel S-Chemical B-Chemical 0.9235741496086121
, O O 0.930624783039093
cisplatin S-Chemical B-Chemical 0.9314110279083252
, O O 0.9642063975334167
and O O 0.9969005584716797
gemcitabine S-Chemical B-Chemical 0.9216748476028442
is O O 0.9967145919799805
well O O 0.9979756474494934
tolerated O O 0.9949734210968018
and O O 0.9999761581420898
shows O O 0.9999867677688599
high O O 0.9798921942710876
activity O O 0.9409905672073364
in O O 0.9994530081748962
metastatic O O 0.7666659355163574
NSCLC O B-Disease 0.8736324310302734
. O O 0.9990918636322021

a O O 0.9878443479537964
site O O 0.9622159004211426
required O O 0.9998700618743896
for O O 0.9999905824661255
expression O O 0.9988728165626526
of O O 0.999961256980896
the O O 0.9999518394470215
transcriptional O O 0.744060218334198
transrepressive O O 0.6603853106498718
activity O O 0.980156660079956
of O O 0.9998379945755005
this O O 0.9998795986175537
molecule O O 0.7443054914474487
. O O 0.9996053576469421
Moreover O O 0.9998849630355835
, O O 0.9999885559082031
its O O 0.9999854564666748
rapid O O 0.9836683869361877
activation O O 0.9985191226005554
suggests O O 0.999993085861206
it O O 0.999901294708252
may O O 0.999995231628418
have O O 0.9999887943267822

d O O 0.9276412725448608
- O O 0.9899412989616394
1 O O 0.9798731803894043
given O O 0.9999239444732666
for O O 0.9999819993972778
4 O O 0.9991610050201416
weeks O O 0.9999041557312012
, O O 0.9999897480010986
elevated O O 0.9847006797790527
blood O O 0.9707509875297546
pressure O O 0.9281815886497498
from O O 0.999972939491272
102 O O 0.9975099563598633
+ O O 0.9999555349349976
/ O O 0.9999959468841553
- O O 0.9999586343765259
13 O O 0.9998396635055542
to O O 0.9999769926071167
152 O O 0.9997594952583313
+ O O 0.9999709129333496
/ O O 0.9999929666519165
- O O 0.9999538660049438
15 O O 0.9997684359550476
mm O O 0.9995611310005188
Hg O O 0.7408479452133179
and O O 0.9967918992042542
increased O O 0.9976478219032288
the O O 0.9994893074035645
synthesis O O 0.8831492066383362
of O O 0.998299777507782
ET O O 0.7343525886535645
- O O 0.9491134285926819
1 O O 0.9553636908531189
and O O 0.9998387098312378
the O O 0.9999597072601318
levels O O 0.9999274015426636
of O O 0.9999719858169556
ET O O 0.7747127413749695
- O O 0.9911795258522034
1 O O 0.998460054397583
mRNA O O 0.946606457233429
in O O 0.9999727010726929
the O O 0.9998810291290283
mesenteric O O 0.712920606136322
artery O O 0.6211801767349243
( O O 0.9989168643951416
240 O O 0.9997296929359436
% O O 0.9999010562896729
and O O 0.9999536275863647
230 O O 0.9998006224632263
% O O 0.9999507665634155
, O O 0.9999737739562988
respectively O O 0.9999796152114868
) O O 0.9999071359634399
. O O 0.9999959468841553

of O O 0.9945847392082214
Th1 B-cell_type B-cell_type 0.7369177937507629
cells E-cell_type E-cell_type 0.90445476770401
, O O 0.9965291619300842
which O O 0.9999451637268066
are O O 0.9999922513961792
a O O 0.9999774694442749
primary O O 0.9542930126190186
source O O 0.9889124631881714
of O O 0.9999040365219116
interferon B-protein B-protein 0.5012036561965942
gamma E-protein E-protein 0.9411808252334595
( O O 0.956976056098938
IFNgamma S-protein S-protein 0.9376872181892395
) O O 0.9141711592674255
, O O 0.9989169836044312

its O O 0.9964814186096191
interaction O O 0.9987146854400635
with O O 0.9999924898147583
the O O 0.9999109506607056
upstream B-DNA B-DNA 0.433601975440979
regulatory I-DNA I-DNA 0.7483879327774048
element E-DNA E-DNA 0.9958280920982361
. O O 0.9998871088027954
The O O 0.9999498128890991
CRE B-DNA B-DNA 0.6542050242424011
site E-DNA E-DNA 0.9876304268836975
in O O 0.9990506768226624
the O O 0.9998422861099243
bcl-2 B-DNA B-DNA 0.6196114420890808
promoter E-DNA E-DNA 0.9913555979728699
appears O O 0.9972124695777893
to O O 0.9999736547470093
play O O 0.9999794960021973
a O O 0.9999804496765137
major O O 0.9972148537635803
role O O 0.9998003840446472
in O O 0.9999929666519165
the O O 0.9999736547470093
induction O O 0.9986155033111572
of O O 0.9999397993087769
bcl-2 S-protein S-protein 0.5682821869850159
expression O O 0.9948114156723022
during O O 0.9999916553497314
the O O 0.9999861717224121
activation O O 0.994091808795929
of O O 0.999750554561615
mature B-cell_type B-cell_type 0.6130572557449341
B I-cell_type I-cell_type 0.8105403780937195
cells E-cell_type E-cell_type 0.9437100291252136

Recurarization O O 0.8609283566474915
in O O 0.9996955394744873
the O O 0.9999386072158813
recovery O O 0.9564176201820374
room O O 0.9958642721176147
. O O 0.9999988079071045

Five O O 0.9943694472312927
patients O O 0.9990455508232117
with O O 0.9998260140419006
carcinoma B-Disease O 0.9392557740211487
developed O O 0.9689379334449768
thrombotic B-Disease B-Disease 0.5821759700775146
microangiopathy I-Disease I-Disease 0.9197660684585571
( O O 0.9514796137809753
characterized O O 0.9826396703720093
by O O 0.9994044303894043
renal B-Disease O 0.7905504703521729
insufficiency I-Disease O 0.9453970193862915
, O O 0.9652919173240662
microangiopathic B-Disease B-Disease 0.6439066529273987
hemolytic I-Disease I-Disease 0.6860755681991577
anemia I-Disease I-Disease 0.9498298764228821
, O O 0.9085743427276611
and O O 0.9961692690849304
usually O O 0.9983083009719849
thrombocytopenia B-Disease B-Disease 0.9523460865020752
) O O 0.7758474946022034
after O O 0.9991925358772278
treatment O O 0.9997283816337585
with O O 0.9999793767929077
cisplatin B-Chemical B-Chemical 0.9298872947692871
, O O 0.8711114525794983
bleomycin B-Chemical B-Chemical 0.9193437099456787
, O O 0.962573230266571
and O O 0.9988881945610046
a O O 0.998508632183075
vinca B-Chemical B-Chemical 0.8880217671394348
alkaloid I-Chemical I-Chemical 0.8970946073532104
. O O 0.9984299540519714

The O O 0.9990562796592712
male O O 0.9775102734565735
Wistar O O 0.5909808278083801
rats O O 0.9371237754821777
consuming O O 0.9996373653411865
a O O 0.9998807907104492
diet O O 0.9757550358772278
that O O 0.9999514818191528
contained O O 0.9969774484634399
LiCl S-Chemical B-Chemical 0.9231469631195068
( O O 0.9824793338775635
60 O O 0.9952994585037231
mmol O O 0.9977729916572571
/ O O 0.9999610185623169
kg O O 0.9981465339660645
) O O 0.9998968839645386
for O O 0.9999955892562866
4 O O 0.9991515874862671
weeks O O 0.9998295307159424
developed O O 0.9997238516807556
marked O O 0.9850260615348816
polyuria O B-Disease 0.9833008050918579
. O O 0.997956395149231

The O O 0.9991024732589722
rats O O 0.9937880635261536
received O O 0.9999076128005981
AChE O O 0.8505584597587585
reactivator O O 0.7685125470161438
pralidoxime B-Chemical B-Chemical 0.9248397350311279
- I-Chemical I-Chemical 0.9486351609230042
2 I-Chemical I-Chemical 0.9622127413749695
- I-Chemical I-Chemical 0.9938408136367798
chloride E-Chemical I-Chemical 0.9489560127258301
( O O 0.8927342891693115
2PAM S-Chemical B-Chemical 0.9362354874610901
) O O 0.7451788783073425
( O O 0.9930427074432373
30 O O 0.998767614364624
. O O 0.9999407529830933
0 O O 0.9999080896377563
mg O O 0.999823272228241
/ O O 0.9999533891677856
kg O O 0.9995504021644592
BW O O 0.9399118423461914
) O O 0.9977443218231201
, O O 0.9999798536300659
anticonvulsant O O 0.8843267560005188
diazepam S-Chemical B-Chemical 0.5587691068649292
( O O 0.9871668219566345
2 O O 0.994843602180481
. O O 0.9996429681777954
0 O O 0.9999092817306519
mg O O 0.9998331069946289
/ O O 0.9999727010726929
kg O O 0.9995859265327454
BW O O 0.9792906045913696
) O O 0.9992172718048096
, O O 0.9999748468399048
A O O 0.715639054775238
( O O 0.9950333833694458
1 O O 0.9924681782722473
) O O 0.9861867427825928
- O O 0.9966967105865479
adenosine S-Chemical B-Chemical 0.9344961047172546
receptor O O 0.47658810019493103
agonist O O 0.9398738145828247
N B-Chemical B-Chemical 0.9527754783630371
( I-Chemical I-Chemical 0.9097427725791931
6 I-Chemical I-Chemical 0.9822800755500793
) I-Chemical I-Chemical 0.9604805707931519
- I-Chemical I-Chemical 0.9824270009994507
cyclopentyl I-Chemical I-Chemical 0.9571455121040344
adenosine E-Chemical I-Chemical 0.8777599334716797
( O O 0.9229636192321777
CPA S-Chemical B-Chemical 0.934488832950592
) O O 0.9172129034996033
( O O 0.9998666048049927
2 O O 0.9989302754402161
. O O 0.9999227523803711
0 O O 0.9999253749847412
mg O O 0.99985671043396
/ O O 0.9999775886535645
kg O O 0.999666690826416
BW O O 0.9756694436073303
) O O 0.9994291663169861
, O O 0.999991774559021
NMDA S-Chemical B-Chemical 0.9234409928321838
- O O 0.887670636177063
receptor O O 0.9728711843490601
antagonist O O 0.9790241718292236
dizocilpine B-Chemical B-Chemical 0.9372761249542236
maleate E-Chemical I-Chemical 0.9498337507247925
( O O 0.9397293925285339
+ O O 0.9948076605796814
- O O 0.9972832202911377
MK801 O O 0.72597336769104
hydrogen O O 0.536677360534668
maleate O O 0.8349971175193787
) O O 0.9591798186302185
( O O 0.9999662637710571
2 O O 0.9995740056037903
. O O 0.9999077320098877
0 O O 0.9998915195465088
mg O O 0.9998456239700317
/ O O 0.9999676942825317
kg O O 0.9996242523193359
BW O O 0.9478335976600647
) O O 0.9994264841079712
or O O 0.9999918937683105
their O O 0.9999154806137085
combinations O O 0.9967063069343567
with O O 0.9999960660934448
cholinolytic O O 0.6940092444419861
drug O O 0.9027565717697144
atropine B-Chemical B-Chemical 0.9288655519485474
sulfate E-Chemical I-Chemical 0.9527770280838013
( O O 0.980518102645874
50 O O 0.9990021586418152
. O O 0.9999632835388184
0 O O 0.9999091625213623
mg O O 0.9998780488967896
/ O O 0.9999769926071167
kg O O 0.9996742010116577
BW O O 0.9813719987869263
) O O 0.9996699094772339
immediately O O 0.9999909400939941
or O O 0.999995231628418
30 O O 0.9996802806854248
min O O 0.999681830406189
after O O 0.9999972581863403
the O O 0.9999954700469971
single O O 0.9966656565666199
SC O O 0.41428276896476746
injection O O 0.9543495178222656
of O O 0.9998652935028076
DFP S-Chemical B-Chemical 0.9003137946128845
. O O 0.999458372592926

in O O 0.9979909658432007
PHA S-protein S-protein 0.9617804884910583
-induced O O 0.9954931735992432
proliferation O O 0.9979945421218872
of O O 0.9999376535415649
PBMCs S-cell_type S-cell_type 0.9587998390197754
depended O O 0.9998956918716431
upon O O 0.999976396560669
the O O 0.9999451637268066
tumour O O 0.7416221499443054
burden O O 0.962738037109375
as O O 0.9999767541885376

Ranitidine B-Chemical B-Chemical 0.9187899231910706
- O O 0.9741645455360413
induced O O 0.9997193217277527
acute O O 0.7253834009170532
interstitial B-Disease O 0.43249404430389404
nephritis I-Disease O 0.5956443548202515
in O O 0.9915424585342407
a O O 0.9997861981391907
cadaveric O O 0.5551968216896057
renal O O 0.661750853061676
allograft O O 0.43996551632881165
. O O 0.9999163150787354

of O O 0.9959080219268799
the O O 0.9999179840087891
IL-2 B-DNA B-DNA 0.6366941332817078
gene E-DNA E-DNA 0.9723184108734131
. O O 0.9987390637397766
We O O 0.9996639490127563
, O O 0.9999730587005615
therefore O O 0.9999823570251465
, O O 0.9999849796295166
compared O O 0.9999599456787109
the O O 0.9999401569366455
activation O O 0.9290140867233276
state O O 0.9153363108634949
of O O 0.9995923638343811
the O O 0.9996421337127686
IL-2 B-DNA B-DNA 0.60284024477005
gene I-DNA I-DNA 0.5078257322311401
promoter I-DNA I-DNA 0.5488258600234985
region E-DNA E-DNA 0.9726003408432007
in O O 0.9993817806243896
freshly O O 0.7699518203735352
isolated O O 0.7312917709350586
and O O 0.6276599764823914

Therapeutic O O 0.92606121301651
ranges O O 0.9849360585212708
for O O 0.9998700618743896
antidepressants B-Chemical B-Chemical 0.911811351776123
that O O 0.9907442927360535
have O O 0.9999834299087524
been O O 0.9998674392700195
derived O O 0.9999517202377319
from O O 0.9999847412109375
general O O 0.980180025100708
adult O O 0.9834482669830322
population O O 0.9860625863075256
studies O O 0.999424934387207
may O O 0.999997615814209
not O O 0.9999804496765137
be O O 0.9999889135360718
appropriate O O 0.9998038411140442
for O O 0.9999756813049316
the O O 0.9993464350700378
elderly O O 0.9562156200408936
. O O 0.999996542930603

tested O O 0.9960320591926575
by O O 0.9999903440475464
cocultivation O O 0.9902438521385193
of O O 0.9998401403427124
BZLF B-cell_type B-cell_line 0.5138716101646423
1-expressing I-cell_type I-cell_line 0.5734300017356873
R59Z I-cell_type I-cell_line 0.3650648295879364
activator I-cell_type I-cell_line 0.8194767236709595
cells E-cell_type E-cell_line 0.9669634103775024
with O O 0.9997251629829407
the O O 0.9999643564224243
R7-57 B-cell_line B-cell_line 0.39800378680229187
reporter I-cell_line I-cell_line 0.4663711190223694
line E-cell_line E-cell_line 0.9815400242805481
. O O 0.9998692274093628
No O O 0.9986525774002075
lytic O O 0.5458060503005981

can O O 0.9954816102981567
influence O O 0.9999386072158813
the O O 0.9999914169311523
involvement O O 0.9999159574508667
of O O 0.9999779462814331
glial B-cell_type B-cell_type 0.7092312574386597
cells E-cell_type E-cell_type 0.9751951098442078
in O O 0.9998306035995483
the O O 0.9999613761901855
pathogenesis O O 0.9663804769515991
of O O 0.9996414184570312
AIDS O O 0.8095225095748901
dementia O O 0.8973919153213501
complex O O 0.7101049423217773
. O O 0.9995524287223816
IL-10 S-protein S-protein 0.9851490259170532
cooperates O O 0.9990240335464478
with O O 0.9999819993972778
TNF-alpha S-protein S-protein 0.9942649006843567
to O O 0.999291181564331
activate O O 0.9989063739776611
HIV-1 O O 0.6845738291740417
from O O 0.9960707426071167
latently B-cell_type O 0.6085243821144104
and I-cell_type O 0.8866248726844788
acutely I-cell_type O 0.6042546629905701
infected I-cell_type O 0.6602493524551392

with O O 0.9991289973258972
a O O 0.9999402761459351
calcium O O 0.9157028198242188
ionophore O O 0.7493254542350769
. O O 0.9996119141578674
Expression O O 0.999256432056427
of O O 0.9999420642852783
the O O 0.9998505115509033
MAP B-protein B-protein 0.4749312400817871
kinase-specific I-protein I-protein 0.6916657090187073
phosphatase E-protein E-protein 0.9788517951965332
, O O 0.9866902828216553
MKP-1 S-protein S-protein 0.9766464829444885
, O O 0.9947665929794312
which O O 0.9999470710754395
blocks O O 0.9993566870689392
ERK S-protein S-protein 0.9418965578079224
activation O O 0.9853260517120361
, O O 0.9995143413543701
inhibited O O 0.9947294592857361
IL-2 B-DNA B-DNA 0.6280698776245117
promoter E-DNA E-DNA 0.9817620515823364
and O O 0.9835295081138611
NF-AT S-protein S-protein 0.7894629240036011
-driven O O 0.9934864044189453
transcription O O 0.9781821966171265
stimulated O O 0.9992395639419556
by O O 0.9999949932098389
a O O 0.9998878240585327
calcium O O 0.8305091857910156
ionophore O O 0.7297237515449524
and O O 0.9938742518424988
PMA O O 0.9322559833526611
, O O 0.9990231990814209
and O O 0.9999346733093262
in O O 0.9999723434448242
addition O O 0.999581515789032
, O O 0.9999415874481201
MKP-1 S-protein S-protein 0.9481241703033447
neutralized O O 0.9970980882644653
the O O 0.9998786449432373
transcriptional O O 0.9187821745872498
enhancement O O 0.9686130881309509
caused O O 0.999875545501709
by O O 0.9999860525131226
active O O 0.953725278377533
Raf-1 O S-protein 0.957672119140625
and O O 0.9959296584129333
MEK1 O S-protein 0.9617095589637756
expression O O 0.9984109401702881
. O O 0.9999963045120239
We O O 0.9999891519546509
conclude O O 0.9999984502792358
that O O 0.9999986886978149
the O O 0.9999368190765381
MAP B-protein B-protein 0.3879719376564026
kinase E-protein E-protein 0.8628360629081726
signal O O 0.8527951240539551
transduction O O 0.9275728464126587
pathway O O 0.9976474642753601
consisting O O 0.999991774559021
of O O 0.999962568283081
Raf-1 S-protein S-protein 0.9374996423721313

( I-DNA I-DNA 0.6053482294082642
IL-2 I-DNA I-DNA 0.4831661581993103
) I-DNA I-DNA 0.46550750732421875
receptor I-DNA I-DNA 0.5737312436103821
alpha I-DNA I-DNA 0.740223228931427
chain I-DNA I-DNA 0.7602177262306213
gene E-DNA E-DNA 0.9599472880363464
is O O 0.9985438585281372
potently O O 0.9993253946304321
upregulated O O 0.9964381456375122
by O O 0.9999915361404419
its O O 0.9999017715454102
own O O 0.9807916283607483
ligand O O 0.8432824611663818
, O O 0.9978943467140198
IL-2 S-protein S-protein 0.9835139513015747
. O O 0.9997337460517883
In O O 0.9999885559082031
this O O 0.9999903440475464
study O O 0.9998736381530762
, O O 0.9999895095825195
we O O 0.9997372031211853
characterize O O 0.999872088432312

of O O 0.9881574511528015
C/EBPbeta S-protein B-RNA 0.7335028052330017
and O I-RNA 0.8426259160041809
MZF-1 B-RNA I-RNA 0.957436740398407
mRNA E-RNA E-RNA 0.9954751133918762
occurred O O 0.9986830353736877
with O O 0.9999867677688599
neutrophilic O O 0.8608863353729248
differentiation O O 0.9897180795669556
. O O 0.9999948740005493
The O O 0.9999569654464722
YJ B-cell_line B-cell_line 0.850090503692627
cell I-cell_line I-cell_line 0.854023814201355
line E-cell_line E-cell_line 0.9954113364219666
should O O 0.9989023208618164
be O O 0.9999778270721436

Naloxone S-Chemical B-Chemical 0.9230556488037109
alone O O 0.8815917372703552
did O O 0.9999735355377197
not O O 0.999913215637207
affect O O 0.9999463558197021
either O O 0.9998431205749512
blood O O 0.9596176743507385
pressure O O 0.8503308892250061
or O O 0.9994563460350037
heart O O 0.8512737154960632
rate O O 0.942593514919281
. O O 0.9999948740005493

) O O 0.7381255030632019
does O O 0.9997636675834656
not O O 0.9999587535858154
bind O O 0.9997593760490417
to O O 0.9999780654907227
the O O 0.9998966455459595
interferon-stimulated O B-DNA 0.5095999240875244
response O I-DNA 0.6492195129394531
element O E-DNA 0.9691389799118042
( O O 0.987271249294281
ISRE O S-DNA 0.9962788224220276
) O O 0.9875243902206421
. O O 0.9999889135360718
In O O 0.9999806880950928
this O O 0.9999606609344482

of O O 0.9950407147407532
K562 O O 0.25287026166915894
targets O O 0.3791556656360626
by O O 0.9994826316833496
PBLs S-cell_type S-cell_type 0.9146429896354675
. O O 0.9998296499252319
These O O 0.9999854564666748
phenomena O O 0.9227568507194519
are O O 0.9999175071716309
in O O 0.9999735355377197
a O O 0.9999414682388306
dose-dependent O O 0.9462535977363586
manner O O 0.9939987659454346
comparable O O 0.9999449253082275
to O O 0.9999765157699585
that O O 0.9999712705612183
seen O O 0.9999170303344727
with O O 0.9999743700027466
rIL-12 S-protein S-protein 0.5858374834060669
. O O 0.9994434714317322
We O O 0.9999809265136719
have O O 0.9999922513961792
also O O 0.9999819993972778
shown O O 0.9999946355819702
that O O 0.9999974966049194
tyrosine O O 0.9268856644630432
phosphorylation O O 0.977502167224884
of O O 0.9997451901435852
the O O 0.9999165534973145
STAT B-protein B-protein 0.6698343753814697
4 I-protein I-protein 0.8117252588272095
transcription I-protein I-protein 0.6881222724914551
factor E-protein E-protein 0.9614486694335938
, O O 0.989281177520752
which O O 0.9999344348907471
has O O 0.9999748468399048
been O O 0.9999109506607056
shown O O 0.9999812841415405
to O O 0.9999841451644897
be O O 0.9999674558639526
unique O O 0.9942201375961304
to O O 0.9999243021011353
the O O 0.9998255372047424
IL-12 S-protein S-protein 0.9119077920913696
signaling O O 0.8948094844818115
pathway O O 0.9937403202056885
, O O 0.9999638795852661
occurs O O 0.9999632835388184
with O O 0.9999891519546509
Flexi-12 S-protein S-protein 0.9085451364517212
at O O 0.9994862079620361
levels O O 0.9996702671051025
similar O O 0.9999856948852539
to O O 0.9999818801879883
those O O 0.999963641166687
seen O O 0.9999686479568481
with O O 0.9999793767929077
rIL-12 S-protein S-protein 0.6045235991477966
. O O 0.999337375164032
We O O 0.9999643564224243
have O O 0.9999871253967285
packaged O O 0.9850290417671204
Flexi-12 S-protein S-protein 0.649519145488739
into O O 0.9986966252326965
a O O 0.999919056892395
recombinant O O 0.8245571851730347
adeno-associated O O 0.8193814754486084
virus O O 0.7779797315597534
( O O 0.9919198751449585
AAV O O 0.8707913160324097
) O O 0.9946134686470032
and O O 0.9998660087585449
used O O 0.9999265670776367
this O O 0.9999021291732788
vector O O 0.9469833970069885
to O O 0.9999085664749146
infect O O 0.9984020590782166
acute B-cell_type B-cell_type 0.5790047645568848
myeloid I-cell_type I-cell_type 0.5183029770851135
leukemic I-cell_type I-cell_type 0.6759498119354248
( I-cell_type I-cell_type 0.5977323651313782
AML I-cell_type I-cell_type 0.4968360662460327
) I-cell_type I-cell_type 0.5258742570877075
blasts E-cell_type E-cell_type 0.7365780472755432
. O O 0.9997788071632385
Infected O O 0.7342326641082764
AML B-cell_type B-cell_type 0.3599323630332947
blasts E-cell_type E-cell_type 0.8686400651931763
produced O O 0.9992727637290955
between O O 0.9995335340499878
2 O O 0.9806334376335144
and O O 0.9991651773452759
6 O O 0.9995137453079224
ng O O 0.9916915893554688
of O O 0.9998408555984497
IL-12/10 O O 0.4063573181629181
( O O 0.7488259673118591
6 O O 0.9134976863861084
) O O 0.9373384118080139
cells O O 0.5277739763259888
per O O 0.9998663663864136
ml O O 0.994946300983429
per O O 0.9998231530189514
48 O O 0.9970731735229492
hr O O 0.9949393272399902
. O O 0.999994158744812
These O O 0.9999984502792358
studies O O 0.999968409538269
also O O 0.9999979734420776
confirm O O 0.9999971389770508
that O O 0.9999949932098389
AAV O O 0.5764232277870178
is O O 0.9998966455459595
an O O 0.9999901056289673
efficient O O 0.9745760560035706
delivery O O 0.9677363634109497
vehicle O O 0.9611836075782776
for O O 0.9999349117279053
cytokines S-protein S-protein 0.9908962845802307
to O O 0.9993144273757935
leukemic O B-cell_type 0.7150077819824219
cells O E-cell_type 0.9860965609550476
. O O 0.9997981190681458
Direct O O 0.9991764426231384
analysis O O 0.999822199344635
of O O 0.9999723434448242
these O O 0.9998000264167786
modified O O 0.7423796057701111
cells O O 0.5325936079025269
acting O O 0.9950804710388184
as O O 0.9999754428863525
tumor O O 0.5599556565284729
vaccines O O 0.5147583484649658
is O O 0.9996238946914673
underway O O 0.9999792575836182
. O O 0.9999984502792358
Plasma O O 0.8444536924362183
sialyltransferase S-protein S-protein 0.49661552906036377
levels O O 0.9987478256225586
in O O 0.9999744892120361
psychiatric O O 0.9103853106498718
disorders O O 0.6371164321899414
as O O 0.9999521970748901
a O O 0.9999984502792358
possible O O 0.9995511174201965
indicator O O 0.9996321201324463
of O O 0.9999533891677856

a O O 0.9984728693962097
much O O 0.9971023201942444
higher O O 0.9989026784896851
intracellular O O 0.9673800468444824
activity O O 0.9961976408958435
of O O 0.999970555305481
this O O 0.999765932559967
enzyme S-protein S-protein 0.6289753913879395
, O O 0.991256594657898
and O O 0.9996236562728882
higher O O 0.959679365158081
thymidine B-RNA B-RNA 0.46909528970718384
kinase I-RNA I-RNA 0.513569176197052
mRNA E-RNA E-RNA 0.8768938779830933
expression O O 0.9878194332122803

Coniine B-Chemical B-Chemical 0.9223281741142273
, O O 0.9712561368942261
an O O 0.9996660947799683
alkaloid O O 0.5437762141227722
from O O 0.9953371286392212
Conium O O 0.9332157969474792
maculatum O O 0.8211216926574707
( O O 0.9979057312011719
poison O O 0.5401908755302429
hemlock O O 0.5053001642227173
) O O 0.8490873575210571
, O O 0.9992388486862183
has O O 0.9999703168869019
been O O 0.999850869178772
shown O O 0.9999827146530151
to O O 0.9999788999557495
be O O 0.9998806715011597
teratogenic O O 0.6955054402351379
in O O 0.9847354888916016
livestock O O 0.48349398374557495
. O O 0.9996545314788818

endothelial-leukocyte B-protein B-protein 0.38385701179504395
adhesion I-protein I-protein 0.4642469882965088
molecule-1 E-protein E-protein 0.9841200709342957
and O O 0.9926148653030396
intercellular B-protein B-protein 0.6865488886833191
adhesion I-protein I-protein 0.7146857380867004
molecule-1 E-protein E-protein 0.9903956055641174
. O O 0.999521017074585
The O O 0.9999982118606567
aim O O 0.999818742275238
of O O 0.9999936819076538
the O O 0.9999954700469971
present O O 0.9845308065414429
study O O 0.9996936321258545
was O O 0.9999961853027344
to O O 0.999996542930603
investigate O O 0.9999946355819702
whether O O 0.9999783039093018

of O O 0.9970725774765015
a O O 0.9998894929885864
TATA B-DNA B-DNA 0.6996100544929504
sequence E-DNA E-DNA 0.9900924563407898
is O O 0.9969412684440613
located O O 0.9999452829360962
in O O 0.999972939491272
the O O 0.9998390674591064
-30 B-DNA B-DNA 0.6403958797454834
promoter I-DNA I-DNA 0.4974791705608368
region E-DNA E-DNA 0.9896180033683777
upstream O O 0.9372231960296631
of O O 0.9999270439147949
a O O 0.9999517202377319
cluster O O 0.9561774730682373
of O O 0.9982782602310181
heterogeneous O O 0.6305232644081116
transcription O O 0.3144541084766388

Using O O 0.9947391152381897
mRNA O O 0.8600183725357056
differential O O 0.8894094228744507
display O O 0.9781936407089233
we O O 0.9998846054077148
demonstrated O O 0.9996435642242432
abnormally O O 0.9785659909248352
high O O 0.9955052137374878
expression O O 0.9986155033111572
of O O 0.9999721050262451
the O O 0.9998773336410522
signal B-protein B-protein 0.6299452185630798
transducer I-protein I-protein 0.4167531430721283
and I-protein I-protein 0.5309617519378662
activator I-protein I-protein 0.5987354516983032
of I-protein I-protein 0.9318295121192932
transcription E-protein E-protein 0.8106529712677002
( O O 0.7939136028289795
STAT1alpha S-protein S-protein 0.9072576761245728
) O O 0.6535836458206177
in O O 0.9990680813789368
monocytes S-cell_type S-cell_type 0.9880673885345459
from O O 0.9995254278182983
the O O 0.9997854828834534
proband B-cell_line B-protein 0.5897042751312256
II-2 E-cell_line E-protein 0.694223165512085
. O O 0.9978523254394531
Expression O O 0.9986683130264282
of O O 0.9999127388000488
gamma-interferon B-protein B-protein 0.39549121260643005
inducible I-protein I-protein 0.6180403828620911
protein I-protein I-protein 0.6312844753265381
10 E-protein E-protein 0.8203267455101013

In O O 0.9990068078041077
A1 O O 0.7766638994216919
of O O 0.9939467906951904
macaque O O 0.48313215374946594
monkeys O O 0.6763287782669067
, O O 0.9975528120994568
low O O 0.9561529159545898
frequencies O O 0.7998736500740051
are O O 0.9997716546058655
represented O O 0.9999202489852905
rostrolaterally O O 0.9005150198936462
and O O 0.9986011385917664
high O O 0.9753513932228088
frequencies O O 0.8569768667221069
are O O 0.9998960494995117
represented O O 0.9999449253082275
caudomedially O O 0.9131168127059937
. O O 0.9999822378158569

A O O 0.9880302548408508
placebo O O 0.9620729088783264
had O O 0.999448835849762
no O O 0.9998821020126343
effect O O 0.9983577132225037
, O O 0.9999897480010986
but O O 0.9998483657836914
niacinamide S-Chemical B-Chemical 0.9302246570587158
was O O 0.9990449547767639
as O O 0.9999909400939941
effective O O 0.9998329877853394
as O O 0.9999866485595703
pyridoxine S-Chemical B-Chemical 0.923782229423523
. O O 0.9996325969696045

The O O 0.999437153339386
authors O O 0.9998617172241211
report O O 0.999992847442627
2 O O 0.9994706511497498
cases O O 0.997105062007904
of O O 0.9998453855514526
premature O O 0.5961787104606628
neonates O O 0.7145407795906067
who O O 0.9705105423927307
had O O 0.9995437264442444
enterocutaneous O O 0.5801102519035339
fistula O O 0.7794837355613708
complicating O O 0.8318719267845154
necrotizing O O 0.41864824295043945
enterocolitis O B-Disease 0.6290149092674255
. O O 0.999479353427887

A O O 0.994012176990509
patient O O 0.9987824559211731
with O O 0.9999551773071289
sinuatrial O B-Disease 0.5779546499252319
disease O I-Disease 0.9858453273773193
and O O 0.9214399456977844
implanted O O 0.7919495105743408
pacemaker O O 0.4986419081687927
was O O 0.9912516474723816
treated O O 0.9999698400497437
with O O 0.9999587535858154
amiodarone S-Chemical B-Chemical 0.9370115399360657
( O O 0.9937852621078491
maximum O O 0.9603908658027649
dose O O 0.9896937012672424
1000 O O 0.997999370098114
mg O O 0.9979773163795471
, O O 0.9999762773513794
maintenance O O 0.9865491986274719
dose O O 0.9984331727027893
800 O O 0.9989983439445496
mg O O 0.9994675517082214
daily O O 0.9995692372322083
) O O 0.9999493360519409
for O O 0.9999969005584717
10 O O 0.9997809529304504
months O O 0.9999527931213379
, O O 0.9999969005584717
for O O 0.9999836683273315
control O O 0.986940324306488
of O O 0.9991208910942078
supraventricular O O 0.5526387691497803
tachyarrhythmias O O 0.8240984678268433
. O O 0.9985927939414978

Dissociated O O 0.8586621284484863
learning O O 0.9396502375602722
of O O 0.9987902045249939
rats O O 0.9428171515464783
in O O 0.9997497200965881
the O O 0.999815046787262
normal O O 0.9559713006019592
state O O 0.9975898265838623
and O O 0.9999934434890747
the O O 0.9999387264251709
state O O 0.9985136389732361
of O O 0.9998308420181274
amnesia B-Disease B-Disease 0.9812272787094116
produced O O 0.9752840995788574
by O O 0.9997833371162415
pentobarbital B-Chemical B-Chemical 0.9342542290687561
( O O 0.9761168956756592
15 O O 0.9984270334243774
mg O O 0.9994021654129028
/ O O 0.9999651908874512
kg O O 0.9993155002593994
, O O 0.9999637603759766
ip O O 0.9934245347976685
) O O 0.9995644688606262
was O O 0.9999885559082031
carried O O 0.999984860420227
out O O 0.9999960660934448
. O O 0.9999990463256836

In O O 0.9996589422225952
24 O O 0.9988505840301514
patients O O 0.9992399215698242
with O O 0.9999723434448242
this O O 0.9981589913368225
complication O O 0.8191693425178528
, O O 0.99979168176651
the O O 0.9998948574066162
marked O O 0.9958627223968506
slowing O O 0.9423840641975403
of O O 0.9921637773513794
motor O O 0.9147472381591797
nerve O O 0.8196030855178833
conduction O O 0.7479103803634644
velocity O O 0.41812077164649963
and O O 0.9994170665740967
the O O 0.999894380569458
electromyographic O O 0.5813320279121399
changes O O 0.7067165970802307
imply O O 0.9964936375617981
mainly O O 0.9953575730323792
a O O 0.9995290040969849
demyelinating O B-Disease 0.5999458432197571
disorder O I-Disease 0.9686221480369568
. O O 0.9986048340797424

. O O 0.9947644472122192
Function O O 0.9983866214752197
of O O 0.9998962879180908
NF-kappa B-DNA B-DNA 0.46680960059165955
B/Rel I-DNA I-DNA 0.7253167033195496
binding I-DNA I-DNA 0.45440948009490967
sites E-DNA E-DNA 0.8712239861488342
in O O 0.9997246861457825
the O O 0.9999786615371704
major B-DNA B-DNA 0.6348896026611328
histocompatibility I-DNA I-DNA 0.4253711700439453
complex I-DNA I-DNA 0.47913941740989685
class I-DNA I-DNA 0.790367066860199
II I-DNA I-DNA 0.5954112410545349
invariant I-DNA I-DNA 0.8483676910400391
chain I-DNA I-DNA 0.6781427264213562
promoter E-DNA E-DNA 0.9915294647216797
is O O 0.9976590871810913
dependent O O 0.9999544620513916
on O O 0.9999727010726929
cell-specific O O 0.9274978637695312
binding O O 0.9110774397850037
of O O 0.9970179796218872
different O O 0.9962594509124756
NF-kappa B-protein B-protein 0.7136443257331848
B/Rel I-protein I-protein 0.7188062071800232
subunits E-protein E-protein 0.991028904914856
. O O 0.9998886585235596
The O O 0.999966025352478

we O O 0.9977405071258545
examined O O 0.9999850988388062
the O O 0.9999853372573853
ability O O 0.9998471736907959
of O O 0.9999836683273315
type O B-protein 0.7003095746040344
I O I-protein 0.60731041431427
and O I-protein 0.5960777997970581
type O I-protein 0.8933655619621277
II O I-protein 0.8337143063545227
IFNs S-protein E-protein 0.9527818560600281
to O O 0.9971344470977783
regulate O O 0.9997492432594299
activation O O 0.997094988822937
of O O 0.9999051094055176
STAT6 S-protein S-protein 0.9917795062065125
by O O 0.9996397495269775
IL-4 S-protein S-protein 0.992562472820282
in O O 0.9996579885482788
primary B-cell_type B-cell_type 0.5826387405395508
human I-cell_type I-cell_type 0.6780453324317932
monocytes E-cell_type E-cell_type 0.9829822182655334
. O O 0.9998170733451843
Pretreatment O O 0.9912146329879761
of O O 0.9995173215866089
monocytes S-cell_type S-cell_type 0.9736526012420654
with O O 0.9979956150054932
IFN-beta S-protein S-protein 0.9751855134963989
or O O 0.9943769574165344
IFN-gamma S-protein S-protein 0.9875417351722717
, O O 0.9944486618041992
but O O 0.9995493292808533
not O O 0.9982794523239136
IL-1 S-protein S-protein 0.9820729494094849
, O O 0.9959518909454346
IL-2 S-protein S-protein 0.9804456830024719
, O O 0.9959749579429626
macrophage B-protein B-protein 0.5437091588973999
colony-stimulating I-protein I-protein 0.8261682987213135
factor E-protein E-protein 0.8136383295059204

BCL-6 B-RNA B-RNA 0.6828095316886902
mRNA E-RNA E-RNA 0.9994805455207825
. O O 0.9994390606880188
Stimulation O O 0.9985185265541077
of O O 0.9999207258224487
mouse B-cell_type B-cell_type 0.41124090552330017
B I-cell_type I-cell_type 0.6742590665817261
cells E-cell_type E-cell_type 0.8336943984031677
with O O 0.9991999268531799
anti-IgM B-protein S-protein 0.8874924778938293
or I-protein O 0.9683444499969482
IgD I-protein B-protein 0.47623947262763977
antibodies E-protein E-protein 0.9886052012443542
, O O 0.9987885355949402
bacterial O O 0.7655974626541138
lipopolysaccharide O O 0.41317304968833923
, O O 0.9928152561187744
phorbol O O 0.8860301971435547
12-myristate O O 0.9311308264732361
13-acetate O O 0.8915873169898987
plus O O 0.9944179058074951
ionomycin O O 0.6006014943122864
, O O 0.9985834360122681
or O O 0.9998383522033691
CD40 B-protein B-protein 0.43804818391799927
ligand E-protein E-protein 0.8909935355186462
led O O 0.9981270432472229
to O O 0.9999661445617676
a O O 0.9999133348464966
five-fold O O 0.9077123999595642
to O O 0.9657584428787231

NF-kappaB S-protein S-protein 0.9876006841659546
activation O O 0.9989200830459595
is O O 0.9999921321868896
evident O O 0.9999741315841675
in O O 0.9999939203262329
patients O O 0.9997779726982117
with O O 0.999985933303833
diabetic O O 0.8813210725784302
nephropathy O O 0.7848955988883972
we O O 0.9999204874038696
used O O 0.9999877214431763
an O O 0.9999839067459106
Electrophoretic O O 0.8869404196739197
Mobility O O 0.8357490301132202
Shift O O 0.8313236832618713
Assay O O 0.6764237284660339
based O O 0.9797189235687256
semiquantitative O O 0.9307257533073425
detection O O 0.9554061889648438
system O O 0.9742911458015442
which O O 0.999988317489624
enabled O O 0.9999535083770752
us O O 0.9999079704284668
to O O 0.9999767541885376
determine O O 0.9999704360961914
NF-kappaB S-protein S-protein 0.9930903315544128
activation O O 0.9984991550445557
in O O 0.9999876022338867
ex O O 0.8405624628067017
vivo O O 0.8548967838287354
isolated B-cell_type O 0.8516829609870911
peripheral I-cell_type B-cell_type 0.45895692706108093
blood I-cell_type I-cell_type 0.7533531188964844
mononuclear I-cell_type I-cell_type 0.8804841041564941

There O O 0.9996199607849121
is O O 0.9999850988388062
still O O 0.9999850988388062
no O O 0.9999805688858032
proof O O 0.999894380569458
of O O 0.999964714050293
causative O O 0.5234729647636414
effect O O 0.9282032251358032
of O O 0.99904865026474
VPA S-Chemical B-Chemical 0.9094730019569397
in O O 0.9995883107185364
patients O O 0.9996392726898193
with O O 0.9998959302902222
encephalopathy O B-Disease 0.985526442527771
, O O 0.9863813519477844
but O O 0.9999088048934937
only O O 0.9999852180480957
of O O 0.9999659061431885
an O O 0.9999016523361206
association O O 0.9949257373809814
with O O 0.9999864101409912
an O O 0.999721109867096
assumed O O 0.9938377737998962
causal O O 0.8410529494285583
relation O O 0.8331629633903503
. O O 0.9999855756759644

unaltered O O 0.8807569742202759
in O O 0.9991753697395325
DMSO-treated O B-cell_line 0.7994301915168762
cells O E-cell_line 0.9100756049156189
. O O 0.9998656511306763
The O O 0.9999983310699463
generality O O 0.9969255328178406
of O O 0.9999779462814331
this O O 0.9999743700027466
finding O O 0.9982662796974182
was O O 0.9999880790710449
confirmed O O 0.9999865293502808
by O O 0.9999951124191284
the O O 0.9999805688858032
induction O O 0.9970648884773254
of O O 0.9997826218605042
Bcl-xL S-protein S-protein 0.955307126045227
in O O 0.9996752738952637
human B-cell_line B-cell_line 0.49039044976234436
myeloid I-cell_line I-cell_line 0.4489150643348694
U-937 I-cell_line I-cell_line 0.6778886318206787
cells E-cell_line E-cell_line 0.9379829168319702
, O O 0.9994511008262634
human B-cell_type B-cell_type 0.8341968655586243

Although O O 0.9997552037239075
most O O 0.999523401260376
cases O O 0.9899255037307739
of O O 0.9997937083244324
antibiotic O O 0.5148193836212158
induced O O 0.8688988089561462
acute O O 0.7820196747779846
interstitial O O 0.41794538497924805
nephritis O O 0.7478944063186646
are O O 0.9895793795585632
benign O O 0.6495963931083679
and O O 0.9839389324188232
self O O 0.9055566787719727
- O O 0.9935550093650818
limited O O 0.9882610440254211
, O O 0.9999059438705444
some O O 0.999958872795105
patients O O 0.9994914531707764
are O O 0.9999897480010986
at O O 0.999881386756897
risk O O 0.999800980091095
for O O 0.9999856948852539
permanent O O 0.9254384636878967
renal O O 0.6819541454315186
injury O O 0.9688392281532288
. O O 0.9974381923675537

multiple O B-DNA 0.8051477074623108
genes O E-DNA 0.8674026131629944
in O O 0.9986801743507385
human B-cell_type B-cell_type 0.7074807286262512
monocytes E-cell_type E-cell_type 0.9871206879615784
. O O 0.9993597865104675
However O O 0.9999243021011353
, O O 0.9999914169311523
the O O 0.9999862909317017
mechanism O O 0.9991102814674377
by O O 0.9999884366989136
which O O 0.9999861717224121
IFNs S-protein S-protein 0.873825192451477
mediate O O 0.9994631409645081
this O O 0.9999314546585083
inhibition O O 0.9893839955329895
has O O 0.9999791383743286
not O O 0.999886155128479
been O O 0.9999531507492065
defined O O 0.9994878768920898
. O O 0.9999758005142212
IL-4 S-protein S-protein 0.9754830598831177
activates O O 0.9955647587776184
gene O O 0.9588229656219482
expression O O 0.9988377690315247
by O O 0.99998939037323
inducing O O 0.9897470474243164

Butyrylcholinesterase O O 0.7186905145645142
gene O O 0.3765827417373657
mutations O O 0.7551857829093933
in O O 0.9997590184211731
patients O O 0.9998745918273926
with O O 0.9999638795852661
prolonged O O 0.7406384944915771
apnea B-Disease O 0.576423704624176
after O O 0.9794142842292786
succinylcholine B-Chemical B-Chemical 0.933443009853363
for O O 0.9929178357124329
electroconvulsive O O 0.5836879014968872
therapy O O 0.8965650796890259
. O O 0.9999966621398926

on O O 0.9949164390563965

regulatory I-DNA I-DNA 0.4309239685535431
region E-DNA E-DNA 0.7640554308891296
has O O 0.9993975162506104
been O O 0.9999821186065674
identified O O 0.9999814033508301
that O O 0.9999958276748657
conferred O O 0.9953378438949585
lymphocyte-specific O O 0.736699640750885
negative O O 0.6543595790863037
regulation O O 0.9679991602897644
in O O 0.9999788999557495
a O O 0.9999632835388184
heterologous O O 0.6474329233169556
system O O 0.6885359883308411
with O O 0.999977707862854
a O O 0.999923825263977
244-bp B-DNA B-DNA 0.4777551293373108
deoxycytidine I-DNA I-DNA 0.47753602266311646
kinase I-DNA I-DNA 0.6752686500549316
core I-DNA I-DNA 0.6431970000267029
promoter E-DNA E-DNA 0.995036780834198
. O O 0.9997383952140808
DNase B-protein B-protein 0.4992048740386963
I E-protein E-protein 0.9144866466522217
footprinting O O 0.8981765508651733
identified O O 0.9985806941986084

There O O 0.9995433688163757
was O O 0.9999850988388062
widespread O O 0.9987584352493286
metastatic O O 0.7680171132087708
calcification O O 0.5062865614891052
in O O 0.9826231002807617
the O O 0.9954258799552917
cows O O 0.9567052721977234
that O O 0.9997902512550354
died O O 0.9718833565711975
. O O 0.9999951124191284

IL-2-secreting B-cell_line B-cell_line 0.43073326349258423
cells E-cell_line E-cell_line 0.7747156620025635
consisting O O 0.9999032020568848
mainly O O 0.9999618530273438
of O O 0.999974250793457
heterodimeric B-protein B-protein 0.6323392391204834
p50/p65 I-protein I-protein 0.4954347610473633
complexes E-protein E-protein 0.9965977072715759
. O O 0.9998792409896851
A O O 0.9992689490318298
weaker O O 0.934426486492157
chi B-DNA B-protein 0.6060662269592285
B E-DNA I-protein 0.7589401602745056
complex O E-protein 0.9223281741142273
formation O O 0.9017171859741211
and O O 0.9972113966941833
faster-migrating O B-protein 0.6689984202384949
complexes O E-protein 0.9629128575325012
were O O 0.9992089867591858
detected O O 0.9998530149459839
in O O 0.9998717308044434
non-IL-2-secreting B-cell_line B-cell_line 0.6384008526802063
cells E-cell_line E-cell_line 0.7007815837860107
. O O 0.9997962117195129
These O O 0.9999946355819702
results O O 0.9999582767486572
demonstrate O O 0.9999970197677612
that O O 0.9999971389770508
the O O 0.999852180480957
IL-2 B-DNA B-DNA 0.7138119339942932
NF-chi I-DNA I-DNA 0.47281399369239807
B I-DNA I-DNA 0.46357133984565735
site E-DNA E-DNA 0.9805551171302795
is O O 0.9995162487030029
indispensable O O 0.9982057809829712
for O O 0.9999507665634155

proteins E-protein E-protein 0.9470123648643494
, O O 0.9957764744758606
principally O O 0.9890404343605042
GA-binding B-protein B-protein 0.6952241659164429
protein E-protein E-protein 0.981826663017273
and O O 0.9692784547805786
Elf-1 S-protein S-protein 0.9847474694252014
and O O 0.9909830093383789
could O O 0.9998987913131714
be O O 0.9999487400054932
transactivated O O 0.9945912957191467
by O O 0.9999405145645142
GABPalpha S-protein B-protein 0.9633491039276123
and O I-protein 0.9596742987632751
-beta S-protein E-protein 0.6086986660957336
synergistically O O 0.7588447332382202
. O O 0.9992756247520447
These O O 0.9999455213546753

Immunological O O 0.9717122316360474
studies O O 0.999004065990448
in O O 0.9999899864196777
human O O 0.8202705979347229
immunodeficiency O O 0.8495414853096008
virus O O 0.8766464591026306
( O O 0.9911770820617676
HIV O O 0.9607232809066772
) O O 0.98869788646698
-positive O O 0.9918702840805054
patients O O 0.9996985197067261
suggest O O 0.999998927116394
that O O 0.9999991655349731
the O O 0.9999439716339111
disease O O 0.9777839779853821
progression O O 0.999038577079773
is O O 0.9999927282333374
accompanied O O 0.9999651908874512
by O O 0.9999969005584717
a O O 0.9999717473983765
defective O O 0.983768880367279
production O O 0.9968955516815186
of O O 0.9999579191207886
type O B-protein 0.6898221373558044
1 B-protein I-protein 0.5275460481643677
cytokines E-protein E-protein 0.932494044303894
( O O 0.9953818917274475
interleukin-2 S-protein S-protein 0.7255938649177551

It O O 0.9988736510276794
may O O 0.9999959468841553
be O O 0.9999977350234985
concluded O O 0.9999858140945435
that O O 0.9999943971633911
, O O 0.9998737573623657
like O O 0.9998389482498169
other O O 0.9999136924743652
tricyclic O O 0.42766356468200684
antidepressants B-Chemical B-Chemical 0.6380555033683777
studied O O 0.997519314289093
previously O O 0.9999872446060181
, O O 0.9999576807022095
TRI B-Chemical B-Chemical 0.9146563410758972
given O O 0.9847261309623718
repeatedly O O 0.9974207878112793
increases O O 0.9973605275154114
the O O 0.9984697699546814
responsiveness O O 0.9924834370613098
of O O 0.999868631362915
brain O O 0.942386269569397
dopamine B-Chemical B-Chemical 0.930178165435791
D2 O O 0.8123075366020203
and O O 0.9912364482879639
D3 O O 0.4908556342124939
( O O 0.9989309906959534
locomotor O O 0.886468231678009
activity O O 0.7184586524963379
but O O 0.9980931878089905
not O O 0.9996401071548462
stereotypy O O 0.38554954528808594
) O O 0.9728713035583496
as O O 0.9999573230743408
well O O 0.9998608827590942
as O O 0.9999964237213135
alpha1 O O 0.6606706976890564
- O O 0.9778239727020264
adrenergic O O 0.672888994216919
receptors O O 0.7723777890205383
to O O 0.9995089769363403
their O O 0.9995328187942505
agonists O O 0.9693658351898193
. O O 0.9999943971633911

We O O 0.9992941617965698
found O O 0.9999879598617554
that O O 0.9999932050704956
the O O 0.9999551773071289
most O O 0.999883770942688
- O O 0.9998418092727661
frequent O O 0.9935539960861206
cause O O 0.9957042336463928
of O O 0.9998683929443359
thrombotic B-Disease B-Disease 0.5233843922615051
microangiopathy I-Disease I-Disease 0.8457801342010498
was O O 0.9941317439079285
drug O O 0.8504140973091125
related O O 0.5497328639030457
, O O 0.9892093539237976
secondary O O 0.9822622537612915
mainly O O 0.9968205690383911
to O O 0.999751627445221
cyclosporine B-Chemical B-Chemical 0.9181695580482483
. O O 0.9995431900024414

There O O 0.9996175765991211
was O O 0.9999823570251465
one O O 0.9999876022338867
treatment O O 0.9992412328720093
- O O 0.9999281167984009
related O O 0.9954980611801147
death B-Disease B-Disease 0.9775721430778503
. O O 0.9980570673942566

. O O 0.99409419298172
Rel/NF-kappa B-protein B-protein 0.5875660181045532
B E-protein E-protein 0.9793041944503784
transcription B-protein B-protein 0.610163688659668
factors E-protein E-protein 0.9950957298278809
and O O 0.9990965127944946
the O O 0.9999884366989136
control O O 0.9946237802505493
of O O 0.9997676014900208
apoptosis O O 0.9826533198356628
. O O 0.9999885559082031
The O O 0.9999974966049194
process O O 0.9996458292007446
of O O 0.9999767541885376
apoptosis O O 0.9819230437278748
is O O 0.9999738931655884
used O O 0.9999001026153564

lymphocyte O O 0.7104805111885071
differentiation O O 0.9845440983772278
and O O 0.9996721744537354
activation O O 0.9977242350578308
. O O 0.9999953508377075
Hence O O 0.9892404675483704
in O O 0.9999661445617676
the O O 0.9999700784683228
absence O O 0.9990211725234985
of O O 0.9999507665634155
p56 S-protein S-protein 0.8552002310752869
, O O 0.9816317558288574
T B-protein B-protein 0.6902547478675842
cell I-protein I-protein 0.4342442452907562
receptor E-protein E-protein 0.9666510224342346
triggered O O 0.98968106508255
activation O O 0.9936330318450928
does O O 0.9999799728393555
not O O 0.9999442100524902
occur O O 0.999921441078186
. O O 0.9999983310699463
We O O 0.9999769926071167
now O O 0.9999985694885254
provide O O 0.9999960660934448
evidence O O 0.9999074935913086
for O O 0.9999862909317017

treated O O 0.9922573566436768
with O O 0.9999682903289795
prostaglandin O O 0.8105079531669617
E2 O O 0.5929579138755798
showed O O 0.9998888969421387
neither O O 0.999980092048645
a O O 0.9999743700027466
reduction O O 0.9972570538520813
in O O 0.9994938373565674
proliferation O O 0.9856902956962585
nor O O 0.9966357350349426

is O O 0.9982377290725708
accompanied O O 0.9999719858169556
by O O 0.999997615814209
a O O 0.9999667406082153
decrease O O 0.9953461289405823

morphological O O 0.8734853863716125
changes O O 0.9938997030258179
consistent O O 0.9999860525131226
with O O 0.9999884366989136
apoptosis O O 0.9871705174446106
. O O 0.9999971389770508
DNA O O 0.9375917315483093
fragmentation O O 0.9796324968338013
was O O 0.9999830722808838
efficiently O O 0.9992586970329285
blocked O O 0.9999485015869141
by O O 0.9999982118606567
the O O 0.9999277591705322
caspase B-protein S-protein 0.8754127025604248
inhibitor E-protein O 0.8223940134048462
Z-VAD-fmk S-protein S-protein 0.7021663784980774
and O O 0.982249915599823
partially O O 0.9906957149505615
blocked O O 0.9996904134750366
by O O 0.9999854564666748
Ac-DEVD-fmk S-protein S-protein 0.746604323387146
, O O 0.99868243932724
suggesting O O 0.9999946355819702
that O O 0.9999967813491821
SN50-mediated O O 0.866614580154419
apoptosis O O 0.9814483523368835
is O O 0.9999818801879883
caspase S-protein S-protein 0.959265947341919
-dependent O O 0.9962790608406067
. O O 0.9999891519546509
Interestingly O O 0.9989087581634521
, O O 0.9999676942825317
apoptosis O O 0.9523462057113647

Lesions O O 0.7513416409492493
of O O 0.8383538722991943
the O O 0.9800194501876831
capillary O O 0.6242544651031494
included O O 0.9981409311294556
necrosis B-Disease O 0.7890216708183289
of O O 0.8566116094589233
endothelial O O 0.5796399712562561
cells O O 0.7969748973846436
. O O 0.9998652935028076

CD34+Thy-1+ B-cell_line B-cell_type 0.31964364647865295
subset E-cell_line E-cell_type 0.6844949126243591
. O O 0.9994046688079834
Messenger B-RNA B-RNA 0.5263385772705078
RNA E-RNA E-RNA 0.7604733109474182
( O O 0.9643317461013794
mRNA S-RNA O 0.7680754065513611
) O O 0.9317182898521423
levels O O 0.9993360638618469
for O O 0.9999934434890747
the O O 0.9999756813049316
granulocyte-colony B-protein B-protein 0.4746019244194031
stimulating I-protein I-protein 0.6104636788368225
factor I-protein I-protein 0.8282365798950195
( I-protein I-protein 0.4907934367656708
G-CSF I-protein I-protein 0.5316162109375
) I-protein I-protein 0.5911810398101807
receptor E-protein E-protein 0.934154748916626
, O O 0.9368108510971069
granulocyte-macrophage B-protein B-protein 0.3276892304420471
( I-protein I-protein 0.6549422144889832
GM I-protein I-protein 0.9112457036972046
) I-protein I-protein 0.8650996088981628
-CSF I-protein I-protein 0.518204391002655
receptor I-protein I-protein 0.6389865875244141
alpha I-protein I-protein 0.7202548384666443
subunit E-protein E-protein 0.950109601020813
and O O 0.9922243356704712
tumor B-protein B-protein 0.45795944333076477
necrosis I-protein I-protein 0.8056527376174927
factor I-protein I-protein 0.8479292988777161
( I-protein I-protein 0.5851174592971802
TNF I-protein I-protein 0.6475775241851807
) I-protein I-protein 0.740581750869751
receptors I-protein E-protein 0.8994053602218628
I I-protein B-protein 0.7988330125808716
( I-protein I-protein 0.6250877976417542
p55 I-protein I-protein 0.8854740858078003
) I-protein I-protein 0.4336341619491577
and I-protein I-protein 0.8541638255119324
II I-protein I-protein 0.5085646510124207
( I-protein I-protein 0.5416638851165771
p75 I-protein I-protein 0.5024312138557434
) E-protein I-protein 0.47418642044067383

RESULTS O O 0.9979608058929443
: O O 0.9999712705612183
Progressive O O 0.836950957775116
abstinence O O 0.4286355674266815
from O O 0.995918333530426
cocaine B-Chemical B-Chemical 0.9097431898117065
was O O 0.9971912503242493
associated O O 0.9998676776885986
with O O 0.9999587535858154
worsening O O 0.9006662964820862
of O O 0.9781166315078735
all O O 0.9989138841629028
measured O O 0.9749899506568909
polysomnographic O O 0.6316800713539124
sleep O O 0.7759011387825012
outcomes O O 0.538776159286499
. O O 0.9999723434448242

the O O 0.9978982210159302
dPRL B-DNA B-DNA 0.6009094715118408
promoter E-DNA E-DNA 0.995005190372467
did O O 0.9990954399108887
not O O 0.9999632835388184
contain O O 0.9999600648880005
elements O O 0.8858177065849304
restricting O O 0.9987558126449585
expression O O 0.9966220855712891
to O O 0.9999675750732422
only O O 0.9992380142211914
those O O 0.9998787641525269
lymphocytes S-cell_type S-cell_type 0.8326828479766846
that O O 0.9962672591209412
produce O O 0.9997034668922424
PRL O S-protein 0.8298153281211853
but O O 0.9963511228561401
allowed O O 0.9995214939117432
expression O O 0.9975082874298096
of O O 0.9999101161956787
fusion O B-DNA 0.3298340439796448
reporter O I-DNA 0.4605467617511749
genes O E-DNA 0.9927273988723755
irrespective O O 0.9996562004089355
of O O 0.9999874830245972
the O O 0.9999698400497437
status O O 0.9931064248085022
of O O 0.9999067783355713
the O O 0.9996428489685059
endogenous O B-DNA 0.43315088748931885
PRL B-DNA I-DNA 0.41878050565719604
gene E-DNA E-DNA 0.9851194024085999
. O O 0.9995686411857605
This O O 0.9994367957115173

RELEVANCE O O 0.9881844520568848
TO O O 0.9999457597732544
CLINICAL O O 0.9898810982704163
PRACTICE O O 0.999319314956665
: O O 0.999992847442627
When O O 0.9999576807022095
administering O O 0.9965848922729492
subcutaneous O O 0.9528229832649231
heparin B-Chemical B-Chemical 0.9234548807144165
injections O O 0.8866561651229858
, O O 0.9999607801437378
it O O 0.9999891519546509
is O O 0.9999982118606567
important O O 0.9999816417694092
to O O 0.9999847412109375
extend O O 0.9999535083770752
the O O 0.9999539852142334
duration O O 0.9993038177490234
of O O 0.9999874830245972
the O O 0.9999319314956665
injection O O 0.9752893447875977
. O O 0.9999918937683105

, O O 0.9320672154426575
but O O 0.9955092668533325
not O O 0.9964170455932617
in O O 0.9987533092498779
fibroblasts S-cell_type S-cell_type 0.9125009775161743
. O O 0.9997232556343079
In O O 0.9999569654464722
addition O O 0.9998264908790588
to O O 0.9999833106994629
the O O 0.9999581575393677
already O O 0.9982419013977051

a O O 0.9972044825553894
complex O O 0.9742127656936646
role O O 0.9940681457519531
for O O 0.9999316930770874
VitD3 O S-protein 0.8784677386283875
in O O 0.9976972937583923

Ophthalmological O O 0.8854847550392151
examinations O O 0.9489412903785706
in O O 0.9999517202377319
over O O 0.9998887777328491
1100 O O 0.9986774325370789
patients O O 0.9984503984451294
treated O O 0.9999690055847168
with O O 0.9999758005142212
one O O 0.99947589635849
or O O 0.9999672174453735
the O O 0.9999598264694214
other O O 0.9997749924659729
agent O O 0.9979312419891357
have O O 0.9999891519546509
revealed O O 0.9999775886535645
no O O 0.9999538660049438
evidence O O 0.9999189376831055
of O O 0.9999637603759766
significant O O 0.9980177879333496
short O O 0.9948240518569946
term O O 0.9937121868133545
( O O 0.99951171875
up O O 0.9998379945755005
to O O 0.9997797608375549
2 O O 0.9996834993362427
years O O 0.9996285438537598
) O O 0.999016523361206
cataractogenic O O 0.6185566782951355
potential O O 0.6423848271369934
. O O 0.9999587535858154

and O O 0.9659799933433533
developmental O O 0.9857749938964844
stage-specific O O 0.9954773783683777
manner O O 0.9988240599632263
. O O 0.9999983310699463
We O O 0.9999116659164429
have O O 0.999993085861206

entering O O 0.9780713319778442
the O O 0.999362051486969
cell O O 0.9490757584571838
, O O 0.9991275668144226
and O O 0.9999098777770996
consequently O O 0.9998759031295776
inhibit O O 0.9996656179428101
their O O 0.9999005794525146
peptidyl B-protein O 0.6416329741477966
prolyl I-protein O 0.3794420063495636
cis-trans I-protein O 0.31463325023651123
isomerase E-protein O 0.6791333556175232
activities O O 0.9722456932067871
. O O 0.999990701675415
The O O 0.9999957084655762
two O O 0.9982403516769409
structurally O O 0.9395045638084412
distinct O O 0.9861673712730408
immunophilin-drug B-protein B-protein 0.543565034866333
complexes E-protein E-protein 0.9734722375869751
bind O O 0.9941887855529785
to O O 0.999681830406189
, O O 0.9974441528320312
and O O 0.9995575547218323
inhibit O O 0.9956241250038147
, O O 0.9999216794967651
the O O 0.9999359846115112
phosphatase S-protein S-protein 0.7816194295883179
activity O O 0.98775315284729
of O O 0.9998447895050049
calcineurin S-protein S-protein 0.961006224155426
. O O 0.9992465972900391
p105 S-protein S-protein 0.8911528587341309
and O O 0.9418885111808777
p98 S-protein B-protein 0.8118815422058105
precursor B-protein I-protein 0.43819087743759155
proteins E-protein E-protein 0.9732147455215454
play O O 0.9919998645782471

replication O O 0.9333248734474182
from O O 0.9999163150787354
the O O 0.9998514652252197
latently B-cell_type B-cell_type 0.5786123275756836
infected I-cell_type I-cell_type 0.573695182800293
cells E-cell_type E-cell_type 0.922897219657898
. O O 0.9997580647468567
Gold O O 0.8930160403251648
compounds O O 0.8682866096496582
have O O 0.9999616146087646
been O O 0.9999574422836304
effectively O O 0.9998645782470703
used O O 0.9999709129333496
for O O 0.9999905824661255
many O O 0.9994142055511475
decades O O 0.999862790107727
in O O 0.9999911785125732
the O O 0.9999456405639648
treatment O O 0.9995496869087219
of O O 0.999988317489624
rheumatoid O O 0.8963464498519897
arthritis O O 0.9231326580047607
. O O 0.999988317489624
We O O 0.9999566078186035
previously O O 0.999971866607666
reported O O 0.9999946355819702
that O O 0.9999916553497314
gold O O 0.8366934061050415
compounds O O 0.7655854821205139
, O O 0.9998363256454468
especially O O 0.9994238615036011
aurothioglucose O O 0.5384034514427185
( O O 0.9768348336219788
AuTG O S-protein 0.7369993329048157
) O O 0.9654335975646973
containing O O 0.9992412328720093
monovalent O O 0.7314159274101257
gold O O 0.6623508334159851
ion O O 0.41562530398368835
, O O 0.9885890483856201
inhibited O O 0.9994505047798157
the O O 0.9997630715370178
DNA-binding O B-protein 0.4399802088737488

specific B-DNA O 0.9214718341827393
promoter I-DNA B-DNA 0.7007359862327576
sequences E-DNA E-DNA 0.9772367477416992
. O O 0.9997876286506653
STAT3 S-protein S-protein 0.9816408753395081
expression O O 0.9967460632324219
in O O 0.99997878074646
particular O O 0.9998364448547363
has O O 0.9999798536300659
been O O 0.9999537467956543
associated O O 0.9999727010726929
with O O 0.9999809265136719
Abl S-protein O 0.5466148853302002
, O O 0.9812235832214355
Src S-protein S-protein 0.7780360579490662
, O O 0.98894202709198
and O O 0.9990684390068054
HTLV-1 O O 0.8140335083007812
transformation O O 0.991268515586853
of O O 0.9997871518135071
normal B-cell_type B-cell_type 0.6478465795516968
cells E-cell_type E-cell_type 0.9362239837646484

by O O 0.9984241724014282
inhibiting O O 0.9984866380691528
generation O O 0.9903016686439514
of O O 0.9996318817138672
oxidized O B-protein 0.7609761953353882
LDL O E-protein 0.6580989360809326
-- O O 0.9962284564971924
a O O 0.9999728202819824
putative O O 0.9187735915184021
triggering O O 0.8288254737854004
molecule O O 0.8403446078300476
in O O 0.9995827078819275
the O O 0.9998937845230103
atherosclerotic O O 0.8023427128791809
process O O 0.9143821597099304
. O O 0.9999784231185913
Our O O 0.9999934434890747
results O O 0.9998760223388672
point O O 0.9999746084213257
to O O 0.999997615814209
a O O 0.9999843835830688
novel O O 0.9773101806640625
alternative O O 0.9689756035804749
mechanism O O 0.9957014918327332
of O O 0.9999421834945679
action O O 0.9955156445503235
of O O 0.9997976422309875
alpha-tcp O S-protein 0.3935879170894623
. O O 0.9937735795974731
Central B-cell_type O 0.904701828956604
nervous I-cell_type B-cell_type 0.7664848566055298
system-derived I-cell_type I-cell_type 0.7008714079856873
cells E-cell_type E-cell_type 0.8343801498413086
express O O 0.9995587468147278
a O O 0.9999608993530273
kappa O O 0.5026280879974365
B-binding O O 0.3167915642261505
activity O O 0.8299844264984131
that O O 0.9998528957366943
enhances O O 0.9998633861541748
human O O 0.7652466297149658
immunodeficiency O O 0.7625086307525635

This O O 0.999618649482727
study O O 0.999947190284729
should O O 0.9999969005584717
be O O 0.9999899864196777
repeated O O 0.9999173879623413
on O O 0.999995231628418
a O O 0.9999645948410034
larger O O 0.9955651164054871
sample O O 0.9988505840301514
. O O 0.999998927116394

To O O 0.9994217157363892
determine O O 0.9999663829803467
if O O 0.9999345541000366
the O O 0.9999328851699829
addition O O 0.9998636245727539
of O O 0.9999750852584839
a O O 0.9998738765716553
buffering O O 0.4834238290786743
solution O O 0.9550876021385193
to O O 0.9999362230300903
adjust O O 0.999502420425415
the O O 0.9994901418685913
pH O O 0.9074798226356506
of O O 0.9845287203788757
lidocaine B-Chemical B-Chemical 0.9283438920974731
into O O 0.998700737953186
the O O 0.999821126461029
physiologic O O 0.6950336694717407
range O O 0.9469429850578308
would O O 0.9999622106552124
reduce O O 0.998691976070404
pain B-Disease B-Disease 0.9533013105392456
during O O 0.9940846562385559
injection O O 0.9220930933952332
, O O 0.9997380375862122
we O O 0.9999464750289917
performed O O 0.9999747276306152
a O O 0.9999909400939941
blinded O O 0.9594544172286987
randomized O O 0.9277157187461853
study O O 0.9969786405563354
in O O 0.9999924898147583
patients O O 0.9998739957809448
undergoing O O 0.9999319314956665
cardiac O O 0.7181249260902405
catheterization O O 0.802343487739563
. O O 0.9998881816864014

first O O 0.9363037347793579
identified O O 0.9997370839118958
as O O 0.9999916553497314
a O O 0.999897837638855
protein O O 0.8979063034057617
stored O O 0.9962433576583862
in O O 0.9999425411224365
specific O O 0.9105937480926514
granules O O 0.6990231871604919
of O O 0.9984567165374756
the O O 0.9995155334472656
human B-cell_type B-cell_type 0.4582475423812866
neutrophil E-cell_type E-cell_type 0.8976029753684998
. O O 0.9993877410888672
The O O 0.9999836683273315
protein O O 0.9265931248664856
is O O 0.9989526271820068
believed O O 0.999987006187439
to O O 0.9999912977218628
bind O O 0.9992882609367371
small O O 0.9186957478523254
lipophilic O O 0.7709790468215942
substances O O 0.8596252202987671
such O O 0.9997259974479675
as O O 0.9999223947525024

In O O 0.9998764991760254
a O O 0.9999796152114868
double O O 0.9926726222038269
- O O 0.9992563128471375
blind O O 0.959267258644104
6 O O 0.9879930019378662
- O O 0.999426007270813
week O O 0.999935507774353
trial O O 0.9958395957946777
, O O 0.9999954700469971
458 O O 0.9946404099464417
patients O O 0.9997202754020691
with O O 0.9999600648880005
acute O O 0.6065430045127869
schizophrenia B-Disease O 0.5494309663772583
were O O 0.996478259563446
randomly O O 0.9965841770172119
assigned O O 0.9999595880508423
to O O 0.9999676942825317
fixed O O 0.9972953200340271
- O O 0.9996042847633362
dose O O 0.9983164072036743
treatment O O 0.9997004270553589
with O O 0.9999814033508301
asenapine B-Chemical B-Chemical 0.9346389770507812
at O O 0.9993641972541809
5 O O 0.9990994930267334
mg O O 0.9996185302734375
twice O O 0.9999210834503174
daily O O 0.9976175427436829
( O O 0.9999868869781494
BID O O 0.539229691028595
) O O 0.9829712510108948
, O O 0.9999326467514038
asenapine B-Chemical B-Chemical 0.9367981553077698
at O O 0.9979919195175171
10 O O 0.9970989227294922
mg O O 0.9996566772460938
BID O O 0.4343538284301758
, O O 0.9980987906455994
placebo O O 0.7526678442955017
, O O 0.993759036064148
or O O 0.9996793270111084
haloperidol B-Chemical B-Chemical 0.9272431135177612
at O O 0.9984837174415588
4 O O 0.9976794123649597
mg O O 0.9992851614952087
BID O O 0.6336353421211243
( O O 0.9991790652275085
to O O 0.999954342842102
verify O O 0.9994909763336182
assay O O 0.7563936710357666
sensitivity O O 0.7805019021034241
) O O 0.9992406368255615
. O O 0.9999960660934448

on O O 0.9950424432754517
GATA-1 S-protein S-protein 0.8719483017921448
alone O O 0.9882424473762512
. O O 0.9999957084655762
Rather O O 0.9999321699142456
, O O 0.9999594688415527
hEpoR S-protein S-protein 0.8333231210708618
transcription O O 0.975792407989502
activity O O 0.9988890290260315
depends O O 0.9999988079071045
on O O 0.9999819993972778
coordination O O 0.9989142417907715
between O O 0.9998701810836792
Sp1 S-protein S-protein 0.9795385003089905
and O O 0.993111252784729
GATA-1 S-protein S-protein 0.988503634929657
with O O 0.9997654557228088
other O O 0.9989737272262573
cell-specific B-protein B-protein 0.7871301174163818
factors E-protein E-protein 0.978477954864502
, O O 0.9979912042617798
including O O 0.9999815225601196
possibly O O 0.99933260679245
other O O 0.9993255138397217
Sp1-like B-protein B-protein 0.3436105251312256

Hippocampal O O 0.5473508238792419
ACh S-Chemical B-Chemical 0.8378660082817078
also O O 0.9948062300682068
was O O 0.9999699592590332
measured O O 0.9999285936355591
during O O 0.9999929666519165
testing O O 0.9991353154182434
for O O 0.9999830722808838
handling O O 0.9198707938194275
- O O 0.996772825717926
induced O O 0.9932749271392822
convulsions O B-Disease 0.9658107161521912
. O O 0.9986043572425842

cells O E-cell_type 0.6165165901184082

human B-cell_type B-cell_type 0.4429410398006439
umbilical I-cell_type I-cell_type 0.5854135751724243
arterial I-cell_type I-cell_type 0.7217956781387329
endothelial I-cell_type I-cell_type 0.7513507008552551
cells E-cell_type E-cell_type 0.8351737856864929
) O O 0.9888268709182739
and O O 0.999859094619751
mRNA O O 0.793962836265564
expression O O 0.9779368042945862
( O O 0.9998243451118469
by O O 0.9999667406082153
70 O O 0.9938527345657349
% O O 0.999790370464325
at O O 0.9999911785125732
100 O O 0.9669189453125
mumol/L O O 0.9367594718933105
PDTC O O 0.7139368057250977
) O O 0.9968695044517517
in O O 0.9999735355377197

that O O 0.9943300485610962
underwent O O 0.9991534948348999
hyperphosphorylation O O 0.9512748718261719
upon O O 0.9989287257194519
antigen B-protein B-protein 0.7642742991447449
receptor E-protein E-protein 0.8717295527458191
costimulation O O 0.9219116568565369
. O O 0.999829888343811
Tyrosine B-protein O 0.8150535225868225
kinase E-protein O 0.7578666806221008
inhibition O O 0.9733181595802307
by O O 0.9999288320541382
herbimycin O O 0.8856544494628906
A O O 0.9377142786979675
diminished O O 0.9891237020492554
J393/CD43 S-protein S-protein 0.8059695363044739
-mediated O O 0.9905941486358643
apoptosis O O 0.9844106435775757
, O O 0.9999524354934692
whereas O O 0.99998939037323
inhibition O O 0.9966727495193481
of O O 0.9999253749847412
phosphotyrosine B-protein B-protein 0.4066413938999176
phosphatase E-protein E-protein 0.8342918157577515
activity O O 0.9941808581352234
by O O 0.9999727010726929
bis O O 0.711586058139801
( O O 0.9757080674171448
maltolato O O 0.6028664112091064
) O O 0.9154039621353149
oxovanadium-IV O O 0.3303722143173218
enhanced O O 0.9755265116691589
cell O O 0.9551569819450378
death O O 0.9735880494117737
. O O 0.9999899864196777
Signal O O 0.926132082939148
transduction O O 0.9771533012390137
through O O 0.9998469352722168
tyrosine O B-protein 0.5988640785217285
kinase O E-protein 0.9487531781196594
activation O O 0.9823330044746399
may O O 0.9999784231185913
lead O O 0.9999912977218628
to O O 0.99998939037323
altered O O 0.9536541700363159
gene O O 0.9011746048927307
expression O O 0.9991119503974915
, O O 0.999994158744812
as O O 0.9999752044677734
J393/ O O 0.5562232732772827
CD43 S-protein S-protein 0.7767745852470398
ligation O O 0.9779860377311707
prompted O O 0.9999418258666992
decreases O O 0.997837245464325
in O O 0.9999440908432007
the O O 0.9998424053192139
nuclear O O 0.9624491930007935
localization O O 0.9751027226448059
of O O 0.9994131326675415
the O O 0.9997532963752747

35S O O 0.5007117390632629

glucocorticoid B-protein B-protein 0.3499164283275604
receptor E-protein E-protein 0.9908111095428467
and O O 0.9945766925811768
its O O 0.9998632669448853
hormone O O 0.961794912815094
. O O 0.9998006224632263
Such O O 0.9999284744262695
alterations O O 0.9967899918556213
may O O 0.9999932050704956
have O O 0.9999873638153076
clinical O O 0.9917882084846497
consequences O O 0.9992584586143494
, O O 0.9999978542327881
including O O 0.9999966621398926
the O O 0.9999921321868896
possibility O O 0.9999299049377441
of O O 0.9999822378158569
a O O 0.9999282360076904
relatively O O 0.9939467310905457
longer O O 0.99875807762146
life O O 0.9969063401222229
span O O 0.9995653033256531
of O O 0.9999685287475586

TNF-alpha S-protein S-protein 0.5063226819038391
; O O 0.9919294118881226
10 O O 0.9930859804153442
U/ml O O 0.9742916226387024
, O O 0.9997112154960632
6 O O 0.9992101192474365
h O O 0.9951194524765015
) O O 0.9976759552955627
or O O 0.9999420642852783
interleukin-1 B-protein B-protein 0.47429758310317993
beta E-protein E-protein 0.8209037780761719
( O O 0.9843856692314148
IL-1 B-protein B-protein 0.38845396041870117
beta E-protein E-protein 0.8230221271514893
; O O 0.9831425547599792
10 O O 0.9966549873352051
U/ml O O 0.9950268864631653
, O O 0.9998977184295654
6 O O 0.9996538162231445
h O O 0.9976763129234314
) O O 0.9991641044616699
. O O 0.9999850988388062
Cytokine-stimulated O O 0.7254404425621033
cell O O 0.7042438983917236
surface O O 0.770206868648529
expression O O 0.9838162064552307
of O O 0.9996843338012695
vascular B-protein B-protein 0.4274367690086365

inactivation O O 0.9760832786560059
of O O 0.9995846152305603
Rb S-protein S-protein 0.9764560461044312
can O O 0.9997727274894714
be O O 0.9999866485595703
inhibited O O 0.9997501969337463
specifically O O 0.9999659061431885
by O O 0.9999880790710449
neutralizing B-protein O 0.9800310134887695
Abs E-protein S-protein 0.6490069627761841
to O O 0.9993473887443542
basic B-protein B-protein 0.8044227361679077
fibroblast I-protein I-protein 0.3774261474609375
growth I-protein I-protein 0.698506772518158
factor E-protein E-protein 0.9369791746139526
( O O 0.9466657638549805
bFGF S-protein S-protein 0.9641558527946472
) O O 0.9302982091903687
, O O 0.999733030796051
suggesting O O 0.9999920129776001
a O O 0.9999878406524658
role O O 0.9985163807868958
for O O 0.9998691082000732
FGF B-protein B-protein 0.6269859671592712
receptors E-protein E-protein 0.9834765195846558
in O O 0.9997027516365051
the O O 0.9999701976776123
signaling O O 0.9291519522666931
process O O 0.9894606471061707
. O O 0.9999949932098389
Signaling O O 0.9985191226005554
through O O 0.9998821020126343
HLA B-protein O 0.4607965052127838

RESULTS O O 0.9977980852127075
: O O 0.9998975992202759
Sub O O 0.9514403343200684
- O O 0.9973446726799011
chronic O O 0.9720776081085205
GVG B-Chemical B-Chemical 0.8691429495811462
exposure O O 0.8085842728614807
inhibited O O 0.998347282409668
the O O 0.9996731281280518
effect O O 0.9998031258583069
of O O 0.999742329120636
cocaine B-Chemical B-Chemical 0.9244834184646606
for O O 0.9990148544311523
3 O O 0.9979268312454224
days O O 0.9998124241828918
, O O 0.999992847442627
which O O 0.9999650716781616
exceeded O O 0.9996067881584167
in O O 0.9997068047523499
magnitude O O 0.9149024486541748
and O O 0.9986691474914551
duration O O 0.9940633177757263
the O O 0.9999454021453857
identical O O 0.9780706763267517
acute O O 0.618705153465271
dose O O 0.873461127281189
. O O 0.9999788999557495

Although O O 0.9992837309837341
generally O O 0.9912440776824951
consisted O O 0.999036431312561
safe O O 0.9903319478034973
when O O 0.9998935461044312
given O O 0.9998942613601685
intramuscularly O O 0.8495845794677734
, O O 0.9982455968856812
intravenous O O 0.6346186399459839
administration O O 0.9045993685722351
is O O 0.9997519850730896
known O O 0.9999786615371704
to O O 0.999880313873291
cause O O 0.9996795654296875
respiratory O O 0.7735901474952698
and O O 0.8727514743804932
cardiovascular O O 0.6874316930770874
depression O O 0.8871791362762451
. O O 0.9992613196372986

cell O I-cell_line 0.43503281474113464
lines O E-cell_line 0.9962126016616821
expressed O O 0.9996577501296997
increased O O 0.9974270462989807
levels O O 0.9993880987167358
of O O 0.999819815158844
mRNAs S-RNA S-RNA 0.9391555786132812
encoding O O 0.993035614490509
the O O 0.9996069073677063
AP-1 B-protein B-protein 0.8120256066322327
proteins E-protein E-protein 0.9658496379852295
, O O 0.9840056896209717
c-Fos S-protein S-protein 0.9842889904975891
, O O 0.9914960861206055
Fra-1 S-protein S-protein 0.983521580696106
, O O 0.9887722134590149
c-Jun S-protein S-protein 0.9904519319534302
, O O 0.9910702705383301
JunB S-protein S-protein 0.9914754629135132
, O O 0.9793633818626404
and O O 0.9930998086929321
JunD S-protein S-protein 0.9897421598434448
. O O 0.9997537732124329
Previously O O 0.9998192191123962
, O O 0.9999759197235107
transcription O O 0.9427539706230164
of O O 0.9980762004852295
the O O 0.9997590184211731
c-fos B-DNA B-DNA 0.6786702871322632
gene E-DNA E-DNA 0.9667035937309265
has O O 0.9982483386993408
been O O 0.9998843669891357
reported O O 0.9999432563781738
to O O 0.9998718500137329
be O O 0.999671220779419
transactivated O O 0.960213303565979

No O O 0.9980656504631042
underlying O O 0.9930214285850525
infective O O 0.884739339351654
or O O 0.9633648991584778
biochemical O O 0.855657696723938
cause O O 0.9126808047294617
could O O 0.9998986721038818
be O O 0.9999630451202393
found O O 0.9999842643737793
. O O 0.9999988079071045

Pulmonary B-Disease O 0.6542420983314514
hypertension I-Disease O 0.7147819399833679
developed O O 0.9849764108657837
after O O 0.9999778270721436
administration O O 0.9968801736831665
of O O 0.9998421669006348
a O O 0.999497652053833
somatostatin O B-Chemical 0.9094654321670532
analogue O O 0.701297402381897
, O O 0.9946510195732117
octreotide B-Chemical B-Chemical 0.917865514755249
, O O 0.9877958297729492
to O O 0.9999619722366333
enhance O O 0.9980331063270569
resolution O O 0.977374255657196
of O O 0.9988546371459961
the O O 0.9994382262229919
fistula B-Disease O 0.5666959881782532
. O O 0.9998393058776855

by O O 0.9988721013069153
RA O O 0.9829667806625366
. O O 0.9999909400939941
The O O 0.9999881982803345
SS O O 0.5554556846618652
Oct-1 S-protein S-protein 0.7899938821792603
DNA-binding O O 0.8956666588783264
abnormality O O 0.9820919632911682
correlated O O 0.999941349029541
significantly O O 0.9999734163284302
with O O 0.9999949932098389
an O O 0.9999507665634155
inability O O 0.9952411651611328
of O O 0.9997860789299011
cells O O 0.9527670741081238
to O O 0.999882698059082
exit O O 0.9997747540473938
the O O 0.9999457597732544
Gzero/G1 O O 0.4479368329048157
cell O O 0.4783530831336975
cycle O O 0.7625526785850525
phase O O 0.9745966792106628
when O O 0.9999722242355347
stimulated O O 0.9422076940536499
in O O 0.9991773962974548
vitro O O 0.9928682446479797
. O O 0.9999933242797852
Importantly O O 0.9995630383491516
, O O 0.9999279975891113
nucleoprotein O O 0.366170734167099
extracts O O 0.9283997416496277
showing O O 0.999790370464325
decreased O O 0.9867991805076599
DNA-binding O O 0.671049177646637

genes O E-DNA 0.915063738822937
seem O O 0.9989469647407532
to O O 0.9999521970748901
become O O 0.9999573230743408
methylated O O 0.9929758310317993
during O O 0.9999970197677612
the O O 0.9999858140945435
progression O O 0.9993398785591125
of O O 0.9999834299087524
leukemias O O 0.7776423692703247
( O O 0.9979822635650635
HIC1 O O 0.4992015063762665
, O O 0.995465874671936
c-abl O S-DNA 0.696817934513092
) O O 0.9849848747253418
. O O 0.9999874830245972
The O O 0.999976634979248

to I-DNA I-DNA 0.6263952255249023
-16 E-DNA E-DNA 0.6501654386520386
) O O 0.7855563759803772
that O O 0.9998183846473694
did O O 0.9999825954437256
not O O 0.9999877214431763
include O O 0.9999951124191284
the O O 0.9999548196792603
cluster O O 0.9568248391151428
of O O 0.9978469610214233
c-Myb B-DNA B-DNA 0.30576732754707336
sites E-DNA E-DNA 0.8396208882331848
. O O 0.9999105930328369
A O O 0.9992805123329163
4-bp O O 0.475642591714859
mutation O O 0.5320876836776733
of O O 0.9976471066474915

The O O 0.9994544386863708
risk O O 0.9983989596366882
of O O 0.9999120235443115
bladder B-Disease B-Disease 0.513417661190033
cancer I-Disease I-Disease 0.9517844319343567
doubled O O 0.9547958374023438
for O O 0.999893069267273
every O O 0.9999854564666748
10 O O 0.9997192025184631
g O O 0.9968416690826416
increment O O 0.9837628602981567
in O O 0.999786913394928
cyclophosphamide B-Chemical B-Chemical 0.9329819679260254
( O O 0.9855119585990906
OR O O 0.6958333253860474
= O O 0.9968315958976746
2 O O 0.9996808767318726
. O O 0.9999754428863525
0 O O 0.9997650980949402
, O O 0.9999417066574097
95 O O 0.9994408488273621
% O O 0.9999545812606812
confidence O O 0.7997907996177673
interval O O 0.827782392501831
( O O 0.9992815852165222
CI O O 0.8240417242050171
) O O 0.9926140308380127
0 O O 0.9996933937072754
. O O 0.9999780654907227
8 O O 0.9998819828033447
to O O 0.9998615980148315
4 O O 0.999859094619751
. O O 0.9999140501022339
9 O O 0.9989520311355591
) O O 0.998710036277771
. O O 0.9999912977218628

, O O 0.9573137164115906
25 O O 0.9402225017547607
( O O 0.9950529932975769
OH O O 0.9470353722572327
) O O 0.9900360107421875
2D3 O O 0.9331918358802795
is O O 0.9999061822891235
known O O 0.9999707937240601
to O O 0.9999381303787231
be O O 0.9999297857284546
produced O O 0.9998307228088379
at O O 0.99998939037323
sites O O 0.9950902462005615
of O O 0.9999417066574097
granulomatous O O 0.8463758826255798
reactions O O 0.9147666692733765
. O O 0.9999843835830688
In O O 0.9999741315841675
order O O 0.9998599290847778
to O O 0.99998939037323
characterize O O 0.9999183416366577
the O O 0.9998853206634521
cell O O 0.914608895778656
types O O 0.9538458585739136

parameter O O 0.3677883744239807
maintained O O 0.9991206526756287
its O O 0.999976396560669
prognostic O O 0.9746014475822449
significance O O 0.995000422000885
when O O 0.9999990463256836
the O O 0.9999892711639404
patients O O 0.9990806579589844
were O O 0.9999957084655762
stratified O O 0.999596893787384
according O O 0.9999912977218628
to O O 0.9999532699584961
lymph O O 0.7882545590400696
node O O 0.778712272644043
involvement O O 0.9790185689926147
, O O 0.999812662601471
menopausal O O 0.8445889949798584
status O O 0.8884168863296509
, O O 0.9983822107315063
and O O 0.999683141708374
nuclear B-protein B-protein 0.8061228394508362
estrogen I-protein I-protein 0.5455183982849121
receptor E-protein E-protein 0.8545526266098022
content O O 0.7803294658660889
. O O 0.9997169375419617
CONCLUSIONS O O 0.9997790455818176
. O O 0.9999873638153076
Tumor O O 0.41544634103775024

how O O 0.9948261380195618
RA O O 0.8549067974090576
and O O 0.9838878512382507
RARs S-protein S-protein 0.5029608607292175
are O O 0.9995537400245667
involved O O 0.9999715089797974
in O O 0.9999755620956421
regulating O O 0.9936701059341431
normal O O 0.9314098954200745
hematopoietic O O 0.8346708416938782
differentiation O O 0.9929353594779968
. O O 0.9999960660934448
To O O 0.9999788999557495
make O O 0.9999754428863525
clear O O 0.999160647392273
the O O 0.9999780654907227

gamma B-RNA B-RNA 0.5902125835418701
mRNA E-RNA E-RNA 0.9953715205192566
were O O 0.9997076392173767
determined O O 0.9999969005584717
. O O 0.9999985694885254
The O O 0.9999971389770508
effects O O 0.9999189376831055
of O O 0.9999899864196777
RA O O 0.9857432246208191
on O O 0.9999468326568604
IL-2-alpha O S-protein 0.9146385192871094
receptor O O 0.7570610642433167
expression O O 0.9955646991729736
was O O 0.9999942779541016
determined O O 0.9999885559082031
by O O 0.9999605417251587

B E-protein E-protein 0.9650866985321045
in O O 0.9993621706962585
transcriptional O O 0.9235056042671204
regulation O O 0.9914105534553528
of O O 0.9999349117279053
this O O 0.9998672008514404
gene O O 0.9331414699554443
. O O 0.9999514818191528
Regulation O O 0.9995695948600769
of O O 0.9999754428863525
the O O 0.9999138116836548
interleukin-1 B-DNA B-DNA 0.49821147322654724
beta I-DNA I-DNA 0.42618921399116516
( I-DNA I-DNA 0.46172258257865906
IL-1 I-DNA I-DNA 0.8009507656097412
beta I-DNA I-DNA 0.5104802250862122
) I-DNA I-DNA 0.717377781867981
gene E-DNA E-DNA 0.9922947883605957
by O O 0.9995214939117432
mycobacterial B-protein O 0.6978849172592163
components E-protein O 0.5830747485160828
and O O 0.9960177540779114
lipopolysaccharide O O 0.8059582114219666
is O O 0.9993730187416077
mediated O O 0.9999181032180786
by O O 0.9999966621398926
two O O 0.9982386827468872
nuclear B-DNA B-DNA 0.7702090740203857
factor-IL6 I-DNA I-DNA 0.38062742352485657
motifs E-DNA E-DNA 0.5184972882270813

T B-cell_type B-cell_type 0.37883180379867554
cells E-cell_type E-cell_type 0.9180352687835693
by O O 0.9995864033699036
HTLV-I O O 0.7654483318328857
. O O 0.9997864365577698
Retinoic O O 0.890559732913971
acid O O 0.8530651926994324
downmodulates O O 0.9408696293830872
erythroid O O 0.7776832580566406
differentiation O O 0.9738860130310059
and O O 0.9992547631263733
GATA1 S-protein S-protein 0.6452934741973877
expression O O 0.9947928786277771
in O O 0.9999659061431885
purified B-cell_line B-cell_line 0.6608788967132568
adult-progenitor I-cell_line I-cell_line 0.3588571548461914
culture E-cell_line E-cell_line 0.8259344100952148
. O O 0.9998596906661987
All-trans O O 0.9609114527702332
retinoic O O 0.9475217461585999
acid O O 0.958424985408783
( O O 0.9993353486061096
RA O O 0.9835388660430908
) O O 0.9997968077659607
is O O 0.9999974966049194
an O O 0.9999955892562866
important O O 0.9975481629371643
morphogen O O 0.4199660122394562

in O O 0.9967775940895081
human B-cell_type B-cell_type 0.691993772983551
monocytes E-cell_type E-cell_type 0.9888317584991455
. O O 0.9996956586837769
The O O 0.9999911785125732
signal O O 0.8953017592430115
cascade O O 0.9102419018745422
transducing O O 0.9962823987007141
this O O 0.999731719493866
effect O O 0.9998146891593933
is O O 0.9999922513961792
not O O 0.9999324083328247
yet O O 0.9998494386672974
clear O O 0.998908281326294
. O O 0.9999980926513672
In O O 0.9999920129776001
this O O 0.9999929666519165
study O O 0.9999386072158813
, O O 0.9999953508377075
we O O 0.9999607801437378
examined O O 0.9999902248382568
whether O O 0.9999861717224121

inhibition O O 0.9800094962120056
of O O 0.9998698234558105
MAPK S-protein S-protein 0.9741199612617493
activity O O 0.9982317090034485
by O O 0.9999942779541016
Bcl-2 S-protein S-protein 0.9840810298919678
. O O 0.9998859167098999
Pancreatic O O 0.9175728559494019
islet O O 0.6517309546470642
expression O O 0.9868772029876709
studies O O 0.9994170665740967
and O O 0.9999504089355469

( O O 0.8766611218452454
CAT S-protein S-protein 0.8265640139579773
) O O 0.9106343388557434
and O O 0.9989230036735535
electrophoretic O O 0.8818222284317017
mobility O O 0.8960633277893066
shift O O 0.9638250470161438
assays O O 0.9936180114746094
, O O 0.9999876022338867
respectively O O 0.999985933303833
. O O 0.9999984502792358
The O O 0.9999898672103882
concentration O O 0.9936100840568542
of O O 0.9995570778846741
c-fos B-RNA S-DNA 0.5216323137283325
, I-RNA O 0.5499768257141113
c-jun I-RNA S-DNA 0.35185638070106506

the O O 0.9983497858047485
Ig B-DNA B-DNA 0.4884885549545288
kappa I-DNA I-DNA 0.7059676051139832
enhancer E-DNA E-DNA 0.9923632144927979
and O O 0.9977914094924927
the O O 0.9997778534889221
human B-DNA B-DNA 0.5285778045654297
immunodeficiency I-DNA I-DNA 0.5659067034721375
virus I-DNA I-DNA 0.776009202003479
( I-DNA I-DNA 0.5180801153182983
HIV I-DNA I-DNA 0.768879234790802
) I-DNA I-DNA 0.7570165991783142
long I-DNA I-DNA 0.9311034679412842
terminal I-DNA I-DNA 0.9602952003479004
repeat E-DNA E-DNA 0.9981470108032227
( O O 0.9898824095726013
LTR S-DNA S-DNA 0.9984898567199707
) O O 0.9741981625556946
in O O 0.9996854066848755
transfected B-cell_line O 0.5760713815689087
T I-cell_line B-cell_type 0.3143876791000366
cells E-cell_line E-cell_type 0.7021706700325012
. O O 0.9996552467346191
Effects O O 0.999946117401123
of O O 0.9999723434448242
the O O 0.9999370574951172

of O O 0.9941309094429016
GcR S-protein S-protein 0.978861927986145
in O O 0.999037504196167
intact B-cell_type B-cell_type 0.5614076852798462
cells E-cell_type E-cell_type 0.8853326439857483
, O O 0.9959063529968262
although O O 0.9999945163726807
it O O 0.9999788999557495
significantly O O 0.9998763799667358
inhibited O O 0.9994126558303833
[ O O 0.9868180751800537
3H O O 0.900942325592041
] O O 0.9774715304374695
dexamethasone O O 0.9371146559715271
binding O O 0.9951687455177307
in O O 0.9999607801437378
cytosolic O O 0.5406404733657837
preparations O O 0.5609554648399353
from O O 0.9998660087585449
rat O O 0.6874457597732544
tissues O O 0.8777125477790833
. O O 0.9999731779098511
The O O 0.9999978542327881
results O O 0.9999552965164185
suggested O O 0.9999916553497314

Apart O O 0.9986649751663208
from O O 0.9999910593032837
the O O 0.999834418296814
reduction O O 0.976068377494812
in O O 0.988128125667572
the O O 0.9878882765769958
patient O O 0.9897498488426208
' O O 0.9941369295120239
s O O 0.9921578168869019
level O O 0.9965973496437073
of O O 0.9970856308937073
consciousness O O 0.9622796177864075
, O O 0.9999819993972778
there O O 0.9999943971633911
were O O 0.9999936819076538
no O O 0.9999727010726929
signs O O 0.999736487865448
of O O 0.9999674558639526
motor O O 0.877388596534729
neurone O O 0.6129557490348816
damage O O 0.9175000190734863
or O O 0.9891439080238342
of O O 0.9995960593223572
any O O 0.9999575614929199
of O O 0.9999203681945801
the O O 0.999971866607666
other O O 0.9998878240585327
known O O 0.9997499585151672
predisposing O O 0.978386640548706
conditions O O 0.9726912379264832
for O O 0.9998757839202881
hyperkalaemia B-Disease B-Disease 0.9863682389259338
following O O 0.998104453086853
the O O 0.9999629259109497
administration O O 0.9985105395317078
of O O 0.9998165965080261
suxamethonium B-Chemical B-Chemical 0.926217794418335
. O O 0.9992753863334656

It O O 0.9984387755393982
could O O 0.9999892711639404
be O O 0.9999961853027344
inferred O O 0.9993078708648682
that O O 0.9999911785125732
gum B-Chemical B-Chemical 0.9325155019760132
Arabic E-Chemical I-Chemical 0.9529111385345459
treatment O O 0.9655337333679199
has O O 0.9999856948852539
induced O O 0.9998409748077393
a O O 0.9999464750289917
modest O O 0.9963237047195435
amelioration O O 0.8490983843803406
of O O 0.9919841885566711
some O O 0.9997393488883972
of O O 0.9999551773071289
the O O 0.9999107122421265
histological O O 0.8514726161956787
and O O 0.9513247013092041
biochemical O O 0.9015942811965942
indices O O 0.9886409044265747
of O O 0.9998775720596313
GM S-Chemical B-Chemical 0.8910531997680664
nephrotoxicity O B-Disease 0.9669263362884521
. O O 0.9993160963058472

the O O 0.9995241165161133
phenotypic O O 0.9671528339385986
analysis O O 0.9987561702728271
of O O 0.9999817609786987
NF-AT S-protein S-protein 0.988735020160675
-deficient O O 0.9902276992797852
mice O O 0.994817316532135
supports O O 0.9999884366989136
the O O 0.9999961853027344
idea O O 0.9997684359550476
that O O 0.9999983310699463
there O O 0.9999805688858032
are O O 0.9999922513961792
tissue- O O 0.8463802933692932
and O O 0.9407511353492737
gene- O O 0.9108545780181885
specific O O 0.9660869240760803
functions O O 0.9959405660629272
as O O 0.9999837875366211
well O O 0.9971727132797241
. O O 0.9999961853027344
In O O 0.9999924898147583
this O O 0.9999961853027344
study O O 0.9998515844345093
we O O 0.9999891519546509
have O O 0.9999946355819702
characterized O O 0.9998753070831299
the O O 0.9999622106552124
expression O O 0.9990224838256836
of O O 0.9999305009841919
NF-AT B-DNA B-DNA 0.46533361077308655
cDNAs E-DNA E-DNA 0.9471999406814575
in O O 0.9990266561508179
murine O B-cell_type 0.6833484172821045
mast B-cell_type I-cell_type 0.8327754735946655
cells E-cell_type E-cell_type 0.9403327703475952
. O O 0.9998165965080261
The O O 0.9999750852584839

Tat B-protein B-protein 0.26096564531326294
protein E-protein E-protein 0.9917429089546204
of O O 0.9965555667877197
HIV1 O O 0.347042977809906
in O O 0.9973583817481995
human B-cell_line B-cell_line 0.4794594347476959
promonocytic I-cell_line I-cell_line 0.3497745096683502
U937 I-cell_line I-cell_line 0.6681451797485352
cells E-cell_line E-cell_line 0.986527144908905
. O O 0.9998916387557983
Numerous O O 0.9999797344207764
studies O O 0.9998899698257446
have O O 0.9999982118606567
shown O O 0.9999926090240479
that O O 0.9999873638153076
, O O 0.997248113155365
upon O O 0.9986811280250549
HIV1 O O 0.8067677617073059
infection O O 0.9671446084976196
, O O 0.999812662601471
human B-cell_line B-cell_line 0.5330123901367188
promonocytic I-cell_line I-cell_line 0.41901895403862
U937 I-cell_line I-cell_line 0.5588869452476501

NK3.3 B-cell_line B-cell_line 0.6987501978874207
cell I-cell_line I-cell_line 0.7925464510917664
line E-cell_line E-cell_line 0.9979296922683716
. O O 0.9998273849487305
Gel O O 0.9038313627243042
mobility O O 0.9775891900062561
shift O O 0.9955588579177856
and O O 0.9998419284820557
immunoprecipitation O O 0.9268142580986023
analyses O O 0.9634906053543091
revealed O O 0.9999581575393677
that O O 0.9999960660934448
in O O 0.9997580647468567
addition O O 0.9998922348022461
to O O 0.9999638795852661
activating O O 0.9342066049575806
STAT3 S-protein S-protein 0.9609830975532532
( O O 0.9959564805030823
signal B-protein B-protein 0.502385675907135
transducer I-protein I-protein 0.533340334892273
and I-protein I-protein 0.8130684494972229
activator I-protein I-protein 0.510220468044281
of I-protein I-protein 0.8322967290878296
transcription-3 E-protein E-protein 0.9269766211509705
) O O 0.6349619626998901
and O O 0.9953025579452515
STAT5 S-protein S-protein 0.9771103858947754
, O O 0.9978061318397522
IL-2 S-protein S-protein 0.9728457927703857
induced O O 0.9979088306427002
tyrosine O O 0.8671761751174927
and O O 0.9962385892868042
serine O O 0.8622387647628784
phosphorylation O O 0.8999614119529724
of O O 0.996743381023407
STAT1 B-protein B-protein 0.491087943315506
alpha E-protein E-protein 0.9807568192481995
, O O 0.9885436296463013
which O O 0.9999608993530273
formed O O 0.999687910079956
IFN-gamma-activated B-protein B-protein 0.43666741251945496
sequence-binding I-protein I-protein 0.7640483975410461
complexes E-protein E-protein 0.99410480260849
by O O 0.9991124272346497
itself O O 0.9834581613540649
and O O 0.9995660185813904
with O O 0.9999247789382935
STAT3 S-protein S-protein 0.9490095973014832

the O O 0.9962015748023987

p65 I-protein S-protein 0.7772406339645386
) E-protein O 0.8524696826934814
to O O 0.9999141693115234
stimulate O O 0.9999125003814697
the O O 0.999868631362915
HIV B-DNA B-DNA 0.6449981927871704
enhancer E-DNA E-DNA 0.9831544160842896
in O O 0.9990780353546143
Jurkat O B-cell_line 0.5486204624176025
T-leukemia B-cell_line I-cell_line 0.8168528079986572
cells E-cell_line E-cell_line 0.9636353850364685
. O O 0.9999183416366577
Here O O 0.999987006187439
we O O 0.9999988079071045
examine O O 0.9999978542327881
the O O 0.999984622001648
biochemical O O 0.9529973864555359
basis O O 0.9931601285934448
for O O 0.9999808073043823
the O O 0.9999796152114868
transcriptional O O 0.9570721387863159
regulation O O 0.9980985522270203
of O O 0.9999736547470093
HIV O O 0.8197233080863953
by O O 0.9989861845970154

End O O 0.7827422618865967
- O O 0.9607705473899841
diastolic O O 0.45207998156547546
( O O 0.9753710031509399
ED O O 0.6130620241165161
) O O 0.9427052736282349
and O O 0.9998102784156799
end O O 0.981202244758606
- O O 0.9971998929977417
systolic O O 0.7967275381088257
( O O 0.9864912033081055
ES O O 0.6967595815658569
) O O 0.9868005514144897
LV O O 0.7251811027526855
diameters O O 0.8033665418624878
/ O O 0.999832272529602
BW O O 0.8972623348236084
significantly O O 0.9998382329940796
increased O O 0.9963647723197937
, O O 0.999724805355072
whereas O O 0.9999814033508301
LV O O 0.7137479186058044
FS O O 0.35359492897987366
was O O 0.999909520149231
decreased O O 0.9990898370742798
after O O 0.9999967813491821
9 O O 0.9998294115066528
weeks O O 0.9999843835830688
in O O 0.9999977350234985
the O O 0.9999500513076782
DOX B-Chemical B-Chemical 0.9144279360771179
group O O 0.9555004835128784
( O O 0.9999898672103882
p O O 0.9992414712905884
< O O 0.9998676776885986
0 O O 0.9998657703399658
. O O 0.9998495578765869
001 O O 0.9793602228164673
) O O 0.9996054768562317
. O O 0.9999970197677612

These O O 0.9996395111083984
results O O 0.9998877048492432
provide O O 0.9999992847442627
empirical O O 0.9959367513656616
support O O 0.9973185658454895
for O O 0.999995231628418
conducting O O 0.999958872795105
a O O 0.9999934434890747
further O O 0.9999383687973022
study O O 0.9999382495880127
of O O 0.9999370574951172
bupropion B-Chemical B-Chemical 0.9011823534965515
. O O 0.9995726943016052

macrophage-like O B-cell_line 0.38984352350234985
PMA-differentiated B-cell_line I-cell_line 0.32618722319602966
U937 I-cell_line I-cell_line 0.5092417001724243
cells E-cell_line E-cell_line 0.995934009552002
, O O 0.9882400035858154
as O O 0.9999877214431763
assessed O O 0.99920254945755
by O O 0.9999850988388062
trypan O O 0.7324307560920715
blue O O 0.7137830257415771
exclusion O O 0.869579017162323
cell O O 0.7652369737625122
counting O O 0.9608939290046692
, O O 0.9997878670692444
thymidine O O 0.5918882489204407

, O O 0.9938358664512634
a O O 0.9999793767929077
unique O O 0.9775713086128235
inhibitory O O 0.919379711151123
role O O 0.9766274690628052
of O O 0.9997280240058899
NFAT1 S-protein S-protein 0.8794230222702026
in O O 0.9995753169059753
IL-4 B-DNA B-DNA 0.7126112580299377
gene E-DNA E-DNA 0.812743067741394

variants O O 0.323521226644516
is O O 0.9999418258666992
not O O 0.9999780654907227
a O O 0.9999940395355225
characteristic O O 0.9994621872901917
of O O 0.9999927282333374
breast O O 0.9292340874671936
cancer O O 0.8679855465888977
. O O 0.999995231628418
The O O 0.9999963045120239
physiological O O 0.9774941802024841
significance O O 0.9992465972900391
and O O 0.999982476234436
possible O O 0.998956561088562
clinical O O 0.9939483404159546
relevance O O 0.9994327425956726
of O O 0.999984622001648
the O O 0.9999054670333862

recruitment O O 0.987826406955719
of O O 0.9998981952667236
cooperating O O 0.9433087706565857
nuclear B-protein B-protein 0.7499431371688843
transcription I-protein I-protein 0.618824303150177
factors E-protein E-protein 0.9949310421943665
even O O 0.9996224641799927
when O O 0.9999967813491821
it O O 0.9998818635940552
is O O 0.9999769926071167
expressed O O 0.9999538660049438
in O O 0.9999862909317017
the O O 0.9998562335968018

in O O 0.99801105260849
HIV-1-infected O O 0.6968013048171997
patients O O 0.9824129343032837
. O O 0.9999886751174927
NF-kappaB S-protein S-protein 0.9835197329521179
only O O 0.9986770749092102
partially O O 0.9949513673782349
mediates O O 0.9971639513969421
Epstein-Barr B-protein B-protein 0.5707590579986572
virus I-protein I-protein 0.5698802471160889
latent I-protein I-protein 0.7518630027770996
membrane I-protein I-protein 0.5774821639060974
protein I-protein I-protein 0.4444825053215027
1 E-protein E-protein 0.9552310705184937
activation O O 0.9394264221191406
of O O 0.9978117346763611
B O B-cell_type 0.9115659594535828
cells O E-cell_type 0.9909062385559082
. O O 0.9998239874839783
The O O 0.9999898672103882
latent B-protein O 0.5509746670722961

domain E-DNA E-protein 0.9607100486755371
) O O 0.9373884797096252
. O O 0.9999679327011108
Since O O 0.9998942613601685
anti-Ig O S-protein 0.8818536400794983
crosslinking O O 0.8710278868675232
leads O O 0.9997556805610657
to O O 0.9999701976776123
activation O O 0.9952839016914368
of O O 0.999911904335022
protein B-protein B-protein 0.45847511291503906
kinase I-protein I-protein 0.6533710956573486
C E-protein E-protein 0.9930579662322998
( O O 0.9913561344146729
PKC S-protein S-protein 0.9973688125610352
) O O 0.9937993884086609
and O O 0.9999110698699951
an O O 0.9999659061431885
increase O O 0.9978675842285156
in O O 0.9997960925102234
intracellular O O 0.9385671615600586
calcium O O 0.924904465675354
level O O 0.9996346235275269
, O O 0.999994158744812
Zp S-DNA S-DNA 0.7632613778114319
was O O 0.9993066787719727
tested O O 0.9999536275863647
for O O 0.9999912977218628
the O O 0.9999356269836426

homeodomain E-protein E-protein 0.7581592798233032
( O O 0.976243793964386
POU B-protein O 0.42293956875801086
[ I-protein O 0.6296773552894592
H I-protein O 0.798602819442749
] E-protein O 0.5397384762763977
) O O 0.7398808002471924
. O O 0.996695876121521
Here O O 0.9999077320098877
, O O 0.9999874830245972
we O O 0.9999570846557617
show O O 0.9999803304672241
that O O 0.9999898672103882
OCA-B S-protein S-protein 0.9048281311988831
alters O O 0.9975255131721497
the O O 0.9999624490737915
activity O O 0.9981221556663513
of O O 0.999945878982544
Oct-1 S-protein S-protein 0.9680573344230652
in O O 0.999755322933197
two O O 0.9998886585235596
ways O O 0.9998538494110107
. O O 0.9999978542327881

( O O 0.9928459525108337
8 O O 0.9996663331985474
of O O 0.9999561309814453
12 O O 0.9991986155509949
compared O O 0.9999803304672241
to O O 0.9999874830245972
only O O 0.9999542236328125
9 O O 0.999915599822998
of O O 0.9999791383743286
22 O O 0.9998148083686829
cases O O 0.9992258548736572
with O O 0.9999948740005493
prolactin O O 0.4252842366695404
between O O 0.9537219405174255
20 O O 0.9954450130462646
and O O 0.9998006224632263
35 O O 0.9997391104698181
ng O O 0.9988321661949158
. O O 0.9999947547912598
/ O O 0.9999934434890747
ml O O 0.9959272742271423
. O O 0.9997867941856384
) O O 0.9996353387832642
. O O 0.9999922513961792

in O O 0.9972319006919861
anti-CD3 B-cell_line B-cell_line 0.518592357635498
activated I-cell_line I-cell_line 0.414233535528183
Hut-78 I-cell_line I-cell_line 0.4032210409641266
T I-cell_line I-cell_line 0.8124076724052429
cells E-cell_line E-cell_line 0.9443967342376709
and O O 0.9969208240509033
human B-cell_type B-cell_type 0.7224608063697815
PBMCs E-cell_type E-cell_type 0.86981201171875
. O O 0.9997480511665344
Inhibition O O 0.9981069564819336
of O O 0.9998499155044556
RANTES S-protein S-protein 0.7477708458900452
expression O O 0.9981709718704224
did O O 0.9999927282333374
not O O 0.9999796152114868
appear O O 0.9999818801879883
to O O 0.9999815225601196
be O O 0.9999649524688721
secondary O O 0.9290930032730103

, O O 0.9892942905426025
glucocorticoid O O 0.9141998291015625
therapy O O 0.9950064420700073
may O O 0.9999978542327881
be O O 0.9999959468841553
unnecessary O O 0.9973945617675781
as O O 0.9999929666519165

transcription I-protein B-protein 0.44196322560310364
factor I-protein I-protein 0.8057026863098145
complex E-protein E-protein 0.9946735501289368
which O O 0.9995372295379639
includes O O 0.9999816417694092
GATA-1 S-protein S-protein 0.9754085540771484
, O O 0.9890451431274414
SCL/tal-1 B-protein S-protein 0.9718339443206787
, E-protein O 0.9919913411140442
E2A S-protein S-protein 0.9665138721466064
, O O 0.9901864528656006
Lmo2 S-protein S-protein 0.9418110251426697
and O O 0.9872764945030212
Ldb-1 S-protein S-protein 0.9689334034919739
. O O 0.9995562434196472
Point O O 0.9752197265625
mutations O O 0.9486413598060608
of O O 0.9999315738677979
the O O 0.9998528957366943
GATA B-DNA B-DNA 0.6733611822128296
site E-DNA E-DNA 0.9854801297187805
abolishes O O 0.9979518055915833
HS B-DNA B-DNA 0.4191851019859314
I E-DNA E-DNA 0.8658244013786316
function O O 0.9504648447036743
, O O 0.9998074173927307
whereas O O 0.9999922513961792

STAT-related O B-protein 0.6106390953063965
transcription B-protein I-protein 0.4214518964290619
factors E-protein E-protein 0.9964094758033752
are O O 0.9996442794799805
constitutively O O 0.9980321526527405
activated O O 0.9991162419319153
in O O 0.9998729228973389
peripheral B-cell_type B-cell_type 0.6700959801673889
blood I-cell_type I-cell_type 0.8863092064857483
cells E-cell_type E-cell_type 0.9857507944107056
from O O 0.9997739195823669
acute O O 0.6894122958183289
leukemia O O 0.5165470242500305
patients O O 0.9339783787727356
. O O 0.9999860525131226
A O O 0.9999022483825684
signal O O 0.920850396156311
transduction O O 0.8816960453987122
pathway O O 0.9871187210083008
activated O O 0.9997887015342712
by O O 0.9999920129776001
many O O 0.9928390383720398

pathways O O 0.9100270867347717
in O O 0.9999717473983765
NF-kappa B-protein B-protein 0.5198809504508972
B E-protein E-protein 0.9914165139198303
activation O O 0.9968888163566589
by O O 0.9999929666519165
several O O 0.997867226600647
inducers S-DNA O 0.7905160784721375
. O O 0.999816358089447
Double-stimulation O O 0.9758833050727844
was O O 0.9996726512908936
used O O 0.9999563694000244
to O O 0.9999831914901733
demonstrate O O 0.9999586343765259
that O O 0.9999690055847168
, O O 0.9986703395843506
in O O 0.9999350309371948
a O O 0.9997497200965881
T B-cell_line B-cell_line 0.4489803910255432
lymphocytic I-cell_line I-cell_line 0.8079553246498108
cell I-cell_line I-cell_line 0.956719696521759
line E-cell_line E-cell_line 0.9441788792610168
( O O 0.9852432012557983
CEM S-cell_line S-cell_line 0.9868984222412109
) O O 0.9222473502159119
, O O 0.9997852444648743
phorbol O O 0.6131883263587952
myristate O O 0.673578143119812
acetate O O 0.7816268801689148
( O O 0.9899100661277771

Pain O B-Disease 0.9884558916091919
was O O 0.9918310046195984
not O O 0.999530553817749
explained O O 0.9997202754020691
by O O 0.9999829530715942
other O O 0.9996342658996582
diseases O O 0.6335263252258301
causing O O 0.9982640147209167
foot O O 0.6900733709335327
pain O O 0.7494320869445801
, O O 0.9789001941680908
like O O 0.9987938404083252
reflex O B-Disease 0.5152407884597778
sympathetic O I-Disease 0.4869048595428467
dystrophy O I-Disease 0.9717985391616821
, O O 0.9584652781486511
polyneuropathy O B-Disease 0.9527485370635986
, O O 0.9853231906890869
Morton O O 0.5484263896942139
' O O 0.529635488986969
s O O 0.5813673138618469
neuralgia O O 0.6801707148551941
, O O 0.9529830813407898
gout O O 0.8315001130104065
, O O 0.8373270034790039
osteoporosis O O 0.8246821165084839
, O O 0.976269006729126
avascular O B-Disease 0.5194377899169922
necrosis O I-Disease 0.9470996856689453
, O O 0.9694700241088867
intermittent O O 0.7392776608467102
claudication O O 0.5820746421813965
, O O 0.9917623996734619
orthopaedic O B-Disease 0.654830276966095
foot O I-Disease 0.5926206111907959
deformities O I-Disease 0.9094986319541931
, O O 0.9742721319198608
stress O B-Disease 0.6557996869087219
fractures O I-Disease 0.9440171122550964
, O O 0.9688800573348999
and O O 0.9962918758392334
hyperparathyroidism O B-Disease 0.9858996272087097
. O O 0.9984756112098694

vectors O O 0.4332035481929779
lacking O O 0.9997468590736389
the O O 0.9999351501464844
immunodominant B-protein B-protein 0.5496681332588196
antigen E-protein E-protein 0.9351141452789307
( O O 0.9553737044334412
s O O 0.8438716530799866
) O O 0.8920459151268005
, O O 0.9994937181472778
and O O 0.9999136924743652
the O O 0.999903678894043
CTL S-cell_type O 0.2971659004688263
responses O O 0.8740913271903992
were O O 0.9998725652694702
measured O O 0.9994184970855713
. O O 0.9999911785125732
In O O 0.9990795850753784
C57BL/10 O B-cell_line 0.6338467597961426
( O I-cell_line 0.5022333860397339
B10 O I-cell_line 0.7651243805885315

transduction O O 0.8953112363815308
pathways O O 0.9912214279174805
distinct O O 0.9998828172683716
from O O 0.9999605417251587
those O O 0.999855637550354
in O O 0.9995067119598389
proliferating B-cell_type B-cell_type 0.49889910221099854
cells E-cell_type E-cell_type 0.7598020434379578
. O O 0.9996821880340576
Activation O O 0.9984513521194458
of O O 0.9998948574066162
the O O 0.9997238516807556
Jak S-protein S-protein 0.9854572415351868
-Stat S-protein O 0.5872104167938232
pathway O O 0.9643939137458801
correlates O O 0.9998652935028076
with O O 0.9999873638153076
proliferative O O 0.9425366520881653
signaling O O 0.9730942845344543
by O O 0.9999446868896484
the O O 0.9999083280563354
G-CSFR S-protein S-protein 0.5571011900901794
and O O 0.9645651578903198
requires O O 0.9998230338096619
the O O 0.9999711513519287
membrane-proximal B-protein B-DNA 0.7296329736709595
box I-protein I-DNA 0.43697381019592285
1 I-protein I-DNA 0.4735313057899475
PXP I-protein I-DNA 0.580580472946167
motif E-protein E-DNA 0.5091994404792786
, O O 0.9876701831817627
which O O 0.9998705387115479
is O O 0.9999439716339111
conserved O O 0.9994171857833862
in O O 0.9999662637710571
members O O 0.99782395362854
of O O 0.999922513961792
the O O 0.999862790107727
cytokine B-protein B-protein 0.23640599846839905
receptor I-protein I-protein 0.5655562877655029
superfamily E-protein E-protein 0.830959677696228
. O O 0.9964492321014404

T-cell-specific B-protein B-protein 0.2792671322822571
transcriptional I-protein I-protein 0.6225100755691528
regulator E-protein E-protein 0.8876073956489563
. O O 0.9980353713035583
These O O 0.9999978542327881
two O O 0.9991992115974426
related O O 0.9455463290214539
genes O O 0.666662335395813
share O O 0.9992109537124634
the O O 0.9999672174453735
evolutionarily O O 0.8425573706626892
conserved O O 0.7772326469421387
region O O 0.7067691087722778
encoding O O 0.989298939704895
the O O 0.9996896982192993

Lamivudine B-Chemical B-Chemical 0.9199150800704956
was O O 0.9974728226661682
well O O 0.991686999797821
tolerated O O 0.9927470088005066
and O O 0.9999656677246094
was O O 0.9999090433120728
continued O O 0.9996215105056763
in O O 0.9999443292617798
all O O 0.9997319579124451
patients O O 0.999758780002594
. O O 0.9999992847442627

D3 O O 0.36677905917167664
at O O 0.9943700432777405
doses O O 0.9967979788780212
that O O 0.9999810457229614
induce O O 0.9999642372131348
their O O 0.999921441078186
differentiation O O 0.9972420930862427
toward O O 0.9998650550842285
neutrophils S-cell_type S-cell_type 0.9898437261581421
or O O 0.9924334287643433
monocytes S-cell_type S-cell_type 0.987934947013855
, O O 0.9988715052604675
respectively O O 0.9999817609786987
. O O 0.999995231628418
Similarly O O 0.9992231130599976
, O O 0.9998490810394287
D3-induced O O 0.7349877953529358
monocyte O O 0.5109773874282837
differentiation O O 0.9924532771110535
of O O 0.9999682903289795
normal O B-cell_type 0.4864311218261719
myeloid B-cell_type I-cell_type 0.6524888873100281
progenitor I-cell_type I-cell_type 0.9326945543289185
cells E-cell_type E-cell_type 0.9624118804931641
was O O 0.9995042085647583
associated O O 0.9999827146530151
with O O 0.9999979734420776
increased O O 0.9963715076446533
capacity O O 0.9983792304992676
to O O 0.9999703168869019
generate O O 0.999688982963562
E1 O S-protein 0.3586013913154602
from O O 0.9896678924560547
E2 O O 0.2935760021209717
. O O 0.9983358979225159
When O O 0.9998747110366821

Corticosteroids O O 0.7450941205024719
different O O 0.8962835073471069
from O O 0.999115526676178
paramethasone B-Chemical B-Chemical 0.9237015843391418
also O O 0.9932188391685486
produced O O 0.9994066953659058
hypersensitivity B-Disease O 0.791312038898468
reactions O O 0.9710254073143005
in O O 0.9525438547134399
these O O 0.9930949807167053
patients O O 0.9990471005439758
; O O 0.9999935626983643
however O O 0.9999691247940063
, O O 0.9999938011169434
a O O 0.9999501705169678
few O O 0.9999735355377197
of O O 0.9999802112579346
them O O 0.9996140599250793
were O O 0.9999490976333618
tolerated O O 0.9967051148414612
. O O 0.9999991655349731

The O O 0.9996652603149414
time O O 0.9996504783630371
courses O O 0.9999113082885742
of O O 0.9999812841415405
urinary O O 0.9675612449645996
sodium B-Chemical B-Chemical 0.9153191447257996
excretion O O 0.8759499192237854
, O O 0.9999737739562988
plasma O O 0.9359461069107056
aldosterone B-Chemical B-Chemical 0.9335784912109375
concentration O O 0.9292123913764954
and O O 0.9998754262924194
proteinuria B-Disease O 0.907342255115509
were O O 0.9946698546409607
studied O O 0.9999328851699829
in O O 0.9999954700469971
male O O 0.9891760945320129
Sprague O O 0.9881979823112488
- O O 0.9988119602203369
Dawley O O 0.9038503766059875
rats O O 0.9931996464729309
treated O O 0.9999737739562988
with O O 0.999997615814209
a O O 0.9999071359634399
single O O 0.9994239807128906
dose O O 0.9998536109924316
of O O 0.999705970287323
either O O 0.9970048069953918
PAN B-Chemical B-Chemical 0.9083593487739563
or O O 0.9744910597801208
vehicle O O 0.844978928565979
. O O 0.9999237060546875

translocation O O 0.9471337199211121
of O O 0.9997279047966003
the O O 0.9999736547470093
IL-4/IL-13-inducible B-protein B-protein 0.3900494873523712
transcription I-protein I-protein 0.727206826210022
factor E-protein E-protein 0.9661679267883301
, O O 0.9866654276847839
Stat6 S-protein S-protein 0.9929673671722412
, O O 0.9975232481956482
suggesting O O 0.9999873638153076
a O O 0.9999865293502808
potential O O 0.9952929615974426
mechanism O O 0.9982080459594727
by O O 0.9999861717224121
which O O 0.9999916553497314
IFN-gamma S-protein S-protein 0.993578314781189
and O O 0.9958130717277527
IL-10 S-protein S-protein 0.9912029504776001
may O O 0.9998155236244202
mediate O O 0.999914288520813
their O O 0.9999819993972778
suppressive O O 0.9419028759002686
effects O O 0.9973300695419312
. O O 0.9999977350234985
These O O 0.9999970197677612
findings O O 0.9999377727508545
demonstrate O O 0.9999961853027344
that O O 0.9999953508377075
certain O O 0.9956660270690918
cytokines O S-protein 0.9962309002876282
, O O 0.9990981817245483

to O O 0.9962594509124756
the O O 0.9999016523361206
basic B-protein B-protein 0.8944225907325745
region/leucine I-protein I-protein 0.4151475727558136
zipper I-protein I-protein 0.7076231837272644
( I-protein I-protein 0.5221470594406128
bZIP I-protein I-protein 0.8110297322273254
) I-protein I-protein 0.6618730425834656
domain E-protein E-protein 0.9828134775161743
of O O 0.9900043606758118
HLF S-protein S-protein 0.9850949048995972
, O O 0.9987181425094604
functions O O 0.9998396635055542
as O O 0.9999958276748657
an O O 0.9999520778656006
anti-apoptotic B-protein B-protein 0.5924123525619507
transcription I-protein I-protein 0.6047601699829102
factor E-protein E-protein 0.9573675990104675
in O O 0.9965392351150513
leukemic O O 0.5132317543029785

Oct-1 S-protein S-protein 0.895146369934082
) O O 0.9847068190574646
found O O 0.9998977184295654
in O O 0.9999110698699951
nuclear O O 0.8748074173927307
and O O 0.9843471050262451
whole O O 0.9793128967285156
cell O O 0.9701300859451294
extracts O O 0.9922652244567871
of O O 0.9996519088745117
activated B-cell_type B-cell_type 0.5598436594009399
T I-cell_type I-cell_type 0.4548453390598297
cells E-cell_type E-cell_type 0.9147500991821289
. O O 0.9995930790901184
Strikingly O O 0.9999109506607056
, O O 0.999996542930603
the O O 0.9999868869781494
immunosuppressive O O 0.9378008246421814
effects O O 0.9994450211524963
of O O 0.9999768733978271
TPCK O O 0.5365408658981323
are O O 0.9998231530189514
blocked O O 0.9992465972900391
when O O 0.9999830722808838
T B-cell_type B-cell_type 0.7856251001358032
cells E-cell_type E-cell_type 0.9902926683425903
are O O 0.9996706247329712
pretreated O O 0.9998444318771362
for O O 0.9999955892562866
15 O O 0.9942261576652527
min O O 0.998539924621582
with O O 0.9999892711639404
5 O O 0.994198203086853
mM O O 0.9945898056030273
NAC O O 0.7988549470901489
. O O 0.9999144077301025
NAC O O 0.8734858632087708
not O O 0.9983612895011902
only O O 0.9999734163284302
blocks O O 0.9999152421951294
the O O 0.9999569654464722
effect O O 0.9999704360961914
of O O 0.9999746084213257
TPCK O O 0.511104941368103
but O O 0.9967203736305237

I-restricted O O 0.8434469699859619
peptide O O 0.9017648696899414
containing O O 0.9992103576660156
a O O 0.9997528195381165
cyclized O O 0.748523473739624
asparagine O O 0.5608614683151245
( O O 0.9691582322120667
succinimide O O 0.8452797532081604
) O O 0.9551205635070801
residue O O 0.9300495386123657
. O O 0.9999815225601196
This O O 0.9999887943267822
modification O O 0.9996877908706665
of O O 0.9999736547470093
the O O 0.9999330043792725
asparagine O B-protein 0.3867078423500061
side O I-protein 0.5984451770782471
chain O E-protein 0.987036406993866
is O O 0.9999353885650635
a O O 0.9999904632568359
common O O 0.9502598643302917
intermediate O O 0.8808329105377197
structure O O 0.8927672505378723
during O O 0.9999256134033203
deamidation O O 0.977128267288208
, O O 0.9996849298477173
isomerization O O 0.9606716632843018
, O O 0.9992744326591492
and O O 0.9997346997261047
bond O O 0.9378495812416077
rearrangements O O 0.9134977459907532
of O O 0.999457061290741
amide-containing O O 0.5420984625816345

Suxamethonium B-Chemical B-Chemical 0.9167768359184265
causes O O 0.997547447681427
prolonged O O 0.8409371376037598
apnea B-Disease O 0.6187416315078735
in O O 0.9649057388305664
patients O O 0.9995735287666321
in O O 0.999992847442627
whom O O 0.999971866607666
pseudocholinesterase O O 0.7334355115890503
enzyme O O 0.4632851183414459
gets O O 0.9958357810974121
deactivated O O 0.9377878308296204
by O O 0.999816358089447
organophosphorus B-Chemical O 0.8345195651054382
( I-Chemical O 0.5405120849609375
OP I-Chemical O 0.8822106719017029
) I-Chemical O 0.8400021195411682
poisons I-Chemical O 0.6780937314033508
. O O 0.9999603033065796

the O O 0.9961668848991394
interleukin-2 B-DNA B-DNA 0.5148423910140991
( I-DNA I-DNA 0.4293542802333832
IL-2 I-DNA I-DNA 0.6741061806678772
) I-DNA I-DNA 0.6717067360877991
promoter E-DNA E-DNA 0.9928624033927917
and O O 0.9906407594680786
is O O 0.9999289512634277
thought O O 0.9999895095825195
to O O 0.999981164932251
be O O 0.999981164932251
largely O O 0.9995576739311218
responsible O O 0.9999760389328003
for O O 0.9999871253967285
the O O 0.99992835521698
T O O 0.707850456237793
cell-specific O O 0.5915818214416504

lymphocytes E-cell_type E-cell_type 0.8209670186042786
during O O 0.9997041821479797
aging O O 0.9874795079231262
: O O 0.9998965263366699
evidence O O 0.9997125267982483
for O O 0.999985933303833
altered O O 0.9696062803268433
IkappaB-alpha S-protein S-protein 0.9798637628555298
phosphorylation O O 0.9912101030349731
and O O 0.9999009370803833
degradation O O 0.9923614263534546
. O O 0.9999825954437256
Nuclear B-protein B-protein 0.6214882731437683
Factor I-protein I-protein 0.7013425230979919
kappa I-protein I-protein 0.9229286909103394
B E-protein E-protein 0.9756878614425659
( O O 0.9774686694145203
NFkappaB S-protein S-protein 0.9824550747871399
) O O 0.9741811752319336
is O O 0.9999891519546509
a O O 0.9999912977218628
critical O O 0.9285678863525391
regulator O O 0.8689702749252319

The O O 0.9994242191314697
3 O O 0.9611955285072327
- O O 0.9972990155220032
week O O 0.9991071820259094
sulphasalazine B-Chemical B-Chemical 0.911191463470459
syndrome O O 0.36208993196487427
strikes O O 0.9960222840309143
again O O 0.9992965459823608
. O O 0.9999982118606567

did O O 0.9986478686332703
not O O 0.999972939491272
require O O 0.9999756813049316
protein O O 0.8773719668388367
synthesis O O 0.9721366763114929
, O O 0.9999655485153198
suggesting O O 0.999997615814209
that O O 0.9999972581863403
the O O 0.9998774528503418
PKC S-protein S-protein 0.9697401523590088
-dependent O O 0.9962038397789001
linkage O O 0.9980533123016357
between O O 0.9997548460960388
CD40 S-protein S-protein 0.8805903196334839
and O O 0.9856857061386108
fra-1 S-DNA S-DNA 0.7825079560279846
is O O 0.9991124272346497
direct O O 0.996772825717926
. O O 0.999911904335022
CD40 S-protein S-protein 0.9597722291946411
-mediated O O 0.9868888854980469
fra-1 S-DNA S-DNA 0.8584752678871155
induction O O 0.9797776937484741
did O O 0.9999712705612183
require O O 0.9999786615371704

TR O O 0.5671091675758362
( O O 0.9723889827728271
- O O 0.9855681657791138
) O O 0.9966513514518738
rats O O 0.9990710020065308
exhibited O O 0.9999212026596069
a O O 0.9999879598617554
significant O O 0.9996398687362671
up O O 0.9998854398727417
- O O 0.9998162388801575
regulation O O 0.9982239603996277
of O O 0.999906063079834
Pgp O O 0.4988766610622406
in O O 0.9991030693054199
brain O O 0.8411371111869812
capillary O O 0.8088065981864929
endothelial O O 0.7314140796661377
cells O O 0.75180983543396
compared O O 0.9999517202377319
with O O 0.9999982118606567
wild O O 0.9389866590499878
- O O 0.9957175850868225
type O O 0.9879204034805298
controls O O 0.9979416728019714
. O O 0.9999990463256836

The O O 0.9997904896736145
aim O O 0.9999511241912842
of O O 0.9999972581863403
the O O 0.9999966621398926
present O O 0.9987127780914307
study O O 0.9998261332511902
was O O 0.9999957084655762
to O O 0.9999934434890747
investigate O O 0.9999136924743652
changes O O 0.9958779811859131
in O O 0.9997798800468445
the O O 0.9995610117912292
plasma O O 0.9461075663566589
calcitonin B-Chemical B-Chemical 0.9279772639274597
gene I-Chemical O 0.9038214087486267
- I-Chemical O 0.6088595986366272
related I-Chemical O 0.9325165152549744
peptide E-Chemical O 0.8252679109573364
( O O 0.9202049970626831
CGRP S-Chemical O 0.6455956697463989
) O O 0.6953860521316528
concentration O O 0.9194251298904419
and O O 0.9998794794082642
platelet O O 0.6713138222694397
serotonin S-Chemical B-Chemical 0.8736163973808289
( O O 0.8976771235466003
5 B-Chemical B-Chemical 0.7711040377616882
- I-Chemical I-Chemical 0.9945833086967468
hydroxytriptamine E-Chemical I-Chemical 0.9387037754058838
, O O 0.7871198058128357
5 B-Chemical B-Chemical 0.6143879890441895
- I-Chemical I-Chemical 0.982043981552124
HT E-Chemical I-Chemical 0.951675534248352
) O O 0.7330493330955505
content O O 0.8436110615730286
during O O 0.999997615814209
the O O 0.9999687671661377
immediate O O 0.9596574902534485
headache O B-Disease 0.9034337997436523
and O O 0.975906491279602
the O O 0.9990804195404053
delayed O O 0.9674239754676819
genuine O O 0.7670689821243286
migraine O B-Disease 0.9307538270950317
attack O O 0.7427157163619995
provoked O O 0.9275412559509277
by O O 0.9995429515838623
nitroglycerin S-Chemical B-Chemical 0.9307172894477844
. O O 0.9996591806411743

A O O 0.9405404925346375
nonregenerative O O 0.5195234417915344
anemia B-Disease B-Disease 0.5012199282646179
was O O 0.9909358620643616
the O O 0.9999489784240723
most O O 0.9997281432151794
compromising O O 0.9930698275566101
of O O 0.9993228912353516
the O O 0.9999101161956787
cytopenias B-Disease O 0.45608067512512207
and O O 0.9971063733100891
occurred O O 0.9984028935432434
in O O 0.9999687671661377
approximately O O 0.9998470544815063
50 O O 0.9998655319213867
% O O 0.99997878074646
of O O 0.9999428987503052
dogs O O 0.966608464717865
receiving O O 0.999930739402771
400 O O 0.9932958483695984
- O O 0.9996060729026794
500 O O 0.999716579914093
mg O O 0.9994621872901917
/ O O 0.9999575614929199
kg O O 0.9989618062973022
cefonicid B-Chemical B-Chemical 0.9419469237327576
or O O 0.9511059522628784
540 O O 0.8558673858642578
- O O 0.9535568952560425
840 O O 0.9917681217193604
mg O O 0.9987232089042664
/ O O 0.9999386072158813
kg O O 0.9970830082893372
cefazedone B-Chemical B-Chemical 0.93083655834198
. O O 0.9996286630630493

part O O 0.9256565570831299
of O O 0.999921441078186
the O O 0.9999946355819702
anti-atherogenic O O 0.924265444278717
effect O O 0.9990752935409546
of O O 0.9999849796295166
aspirin O O 0.46310633420944214
may O O 0.9999617338180542
be O O 0.9999971389770508
due O O 0.9999969005584717
to O O 0.9999936819076538
the O O 0.9999408721923828
prevention O O 0.9993523955345154
of O O 0.9999845027923584
the O O 0.9997640252113342
adhesion O O 0.9842143058776855
of O O 0.9996652603149414
sensitized B-cell_type O 0.593226969242096
T I-cell_type B-cell_type 0.4114307463169098
cells E-cell_type E-cell_type 0.9148256182670593
to O O 0.9966920614242554
stressed O O 0.8970288038253784
EC S-cell_type S-cell_type 0.9250805974006653
; O O 0.9984021782875061
( O O 0.9994295239448547
2 O O 0.9986401200294495
) O O 0.9989219903945923
that O O 0.9999932050704956
part O O 0.9910597205162048

capacity O O 0.983655571937561
to O O 0.9999107122421265
produce O O 0.9989879727363586
virus O O 0.9076142907142639
progeny O O 0.9084694385528564
following O O 0.9999396800994873
transfection-cocultivation O O 0.9774940013885498
. O O 0.9999772310256958
Virus O O 0.8416406512260437
stocks O O 0.793286144733429
obtained O O 0.9979982972145081
from O O 0.9999082088470459

Depletion O O 0.9473939538002014
of O O 0.9984495639801025
dopamine S-Chemical B-Chemical 0.9322859048843384
in O O 0.9985350370407104
the O O 0.9997145533561707
striatum O O 0.5460962057113647
was O O 0.9988831877708435
also O O 0.9999693632125854
antagonized O O 0.9994932413101196
when O O 0.9999734163284302
LY274614 S-Chemical B-Chemical 0.9197349548339844
was O O 0.9900160431861877
given O O 0.999993085861206
after O O 0.9999977350234985
the O O 0.9999829530715942
injection O O 0.9881539940834045
of O O 0.9994962215423584
amphetamine S-Chemical B-Chemical 0.9368362426757812
; O O 0.9528088569641113
LY274614 S-Chemical B-Chemical 0.9284012913703918
protected O O 0.9883732199668884
when O O 0.9999769926071167
given O O 0.9999467134475708
up O O 0.9999760389328003
to O O 0.9998997449874878
4 O O 0.9995213747024536
hr O O 0.9966195821762085
after O O 0.9999523162841797
but O O 0.9998921155929565
not O O 0.9997653365135193
when O O 0.9999463558197021
given O O 0.9999524354934692
8 O O 0.9989117383956909
or O O 0.999951958656311
24 O O 0.9994009733200073
hr O O 0.9917855858802795
after O O 0.9999470710754395
amphetamine S-Chemical B-Chemical 0.9355435371398926
. O O 0.9993618130683899

THP B-Chemical B-Chemical 0.77019202709198
exhibited O O 0.99244225025177
an O O 0.9999260902404785
antipsychotic O O 0.6906296014785767
- O O 0.9294649362564087
like O O 0.9658669829368591
profile O O 0.9727890491485596
by O O 0.9999746084213257
potentiating O O 0.6312642693519592
haloperidol B-Chemical B-Chemical 0.9240548610687256
- O O 0.9349544048309326
induced O O 0.9987342953681946
catalepsy B-Disease B-Disease 0.9754976034164429
, O O 0.9922022819519043
reducing O O 0.996722400188446
amphetamine B-Chemical B-Chemical 0.9322397112846375
- O O 0.9064251780509949
induced O O 0.9987797141075134
hyperactivity B-Disease B-Disease 0.9833452105522156
and O O 0.9714739918708801
reducing O O 0.9952588677406311
apomorphine B-Chemical B-Chemical 0.9256635904312134
- O O 0.9624714851379395
induced O O 0.9986085295677185
climbing O O 0.8764037489891052
in O O 0.9672436118125916
mice O O 0.9912191033363342
. O O 0.999998927116394

demonstrated O O 0.9963403940200806
an O O 0.9999818801879883
association O O 0.997008740901947
between O O 0.9996082186698914
Elf-1 S-protein S-protein 0.9786840081214905
and O O 0.9942423701286316
Rb S-protein S-protein 0.9886570572853088
in O O 0.9989521503448486
resting B-cell_type B-cell_type 0.7261623740196228
normal I-cell_type I-cell_type 0.7302757501602173
human I-cell_type I-cell_type 0.8210629224777222
T I-cell_type I-cell_type 0.8993380665779114
cells E-cell_type E-cell_type 0.9523186087608337
. O O 0.9996224641799927
After O O 0.9999403953552246
T O O 0.8574463129043579
cell O O 0.7775998711585999
activation O O 0.9970201849937439
, O O 0.9999918937683105
the O O 0.9999802112579346

within O O 0.9964943528175354
the O O 0.9999456405639648
enhancer S-DNA S-DNA 0.8870599269866943
. O O 0.9997851252555847
Two O O 0.9998242259025574
of O O 0.999983549118042
these O O 0.9999232292175293
are O O 0.9998252987861633
potential O O 0.9927425384521484
binding O O 0.8592212796211243

Careful O O 0.9692773818969727
fluid O O 0.4344467520713806
administration O O 0.8687343001365662
and O O 0.9994003772735596
cautious O O 0.9118931293487549
use O O 0.9966931343078613
of O O 0.9999372959136963
titrated O O 0.6906704902648926
doses O O 0.9832187294960022
of O O 0.9995809197425842
ephedrine B-Chemical B-Chemical 0.9279942512512207
are O O 0.9976366758346558
advised O O 0.99997878074646
. O O 0.9999990463256836

3 E-DNA O 0.2443712204694748
) O O 0.6882339715957642
were O O 0.9996324777603149
chosen O O 0.999339759349823
, O O 0.9999693632125854
in O O 0.9999719858169556
which O O 0.9999841451644897
only O O 0.9932085871696472
site B-DNA B-DNA 0.874920129776001
2 E-DNA E-DNA 0.9106408953666687
is O O 0.9985805749893188
a O O 0.9999605417251587
noncanonical O B-DNA 0.48280298709869385
GATA B-DNA I-DNA 0.515142560005188
site E-DNA E-DNA 0.9787628054618835
. O O 0.9999039173126221
Direct O O 0.999406099319458
analysis O O 0.9998779296875
of O O 0.9999781847000122
sensorgrams O S-protein 0.620029091835022
, O O 0.9966840147972107
with O O 0.999936580657959
recombinant B-protein O 0.675216555595398
huGATA-3 E-protein S-protein 0.5696777701377869
, O O 0.9946901798248291
allowed O O 0.9999715089797974
the O O 0.9999880790710449
comparison O O 0.9990969896316528
of O O 0.9998748302459717
association O O 0.9448667168617249

life O O 0.9375907778739929
cycle O O 0.9874897599220276
of O O 0.9999322891235352
HCMV O O 0.8767582178115845
, O O 0.9989292025566101
which O O 0.9997287392616272
is O O 0.9999570846557617
endemic O O 0.9964324235916138
in O O 0.9999653100967407
the O O 0.9995958209037781
human O O 0.5998391509056091
population O O 0.6572051644325256
. O O 0.9998281002044678
Furthermore O O 0.9999955892562866
, O O 0.999996542930603
these O O 0.9999922513961792
data O O 0.9988383650779724
may O O 0.9999973773956299
provide O O 0.9999984502792358
new O O 0.9992577433586121
insights O O 0.9942687749862671

is O O 0.9908674955368042
regulated O O 0.9995205402374268
by O O 0.9999973773956299
a O O 0.9998067021369934
phosphotyrosine-containing B-protein B-protein 0.45550739765167236
protein E-protein E-protein 0.9651041626930237
. O O 0.9988276362419128
The O O 0.9999853372573853
proto-oncogene B-DNA B-DNA 0.2902669608592987
c-fos E-DNA E-DNA 0.7859058976173401
is O O 0.9990242719650269
an O O 0.9999692440032959
immediate-early B-DNA B-DNA 0.5058510899543762
gene E-DNA E-DNA 0.9522028565406799
, O O 0.9864845871925354
and O O 0.999913215637207
one O O 0.9995321035385132
of O O 0.9999872446060181
the O O 0.9999659061431885
first O O 0.8856344223022461
genes O O 0.6120453476905823
transcribed O O 0.9922451376914978

The O O 0.9993391633033752
renal O O 0.9521857500076294
function O O 0.9842047095298767
of O O 0.9997963309288025
74 O O 0.9915606379508972
children O O 0.9993543028831482
with O O 0.9999858140945435
malignant B-Disease O 0.6994582414627075
mesenchymal I-Disease O 0.42523637413978577
tumors I-Disease O 0.7867919206619263
in O O 0.9930233955383301
complete O O 0.9874585866928101
remission O O 0.7659918665885925
and O O 0.9996956586837769
who O O 0.9999576807022095
have O O 0.9999871253967285
received O O 0.9999327659606934
the O O 0.9999815225601196
same O O 0.9998224377632141
ifosfamide B-Chemical B-Chemical 0.9265611171722412
chemotherapy O O 0.49473756551742554
protocol O O 0.9709360599517822
( O O 0.9999938011169434
International O O 0.9981884360313416
Society O O 0.9907394647598267
of O O 0.999745786190033
Pediatric O O 0.8653551340103149
Oncology O O 0.8510910868644714
Malignant B-Disease O 0.95908123254776
Mesenchymal I-Disease O 0.637678861618042
Tumor I-Disease O 0.39366546273231506
Study O O 0.9683328866958618
84 O O 0.9807943105697632
[ O O 0.9999338388442993
SIOP O O 0.9383630156517029
MMT O O 0.9287911057472229
84 O O 0.9220961928367615
] O O 0.9993483424186707
) O O 0.9999550580978394
were O O 0.9999983310699463
studied O O 0.9999821186065674
1 O O 0.9998476505279541
year O O 0.9999654293060303
after O O 0.9999991655349731
the O O 0.9999949932098389
completion O O 0.9998751878738403
of O O 0.9999842643737793
treatment O O 0.9996733665466309
. O O 0.9999994039535522

the O O 0.9962015748023987

One O O 0.996535062789917
patient O O 0.9995566010475159
had O O 0.9999189376831055
complete O O 0.9845726490020752
response O O 0.9892352223396301
, O O 0.9999830722808838
seven O O 0.999154806137085
had O O 0.9995726943016052
stable O O 0.9246946573257446
disease O O 0.7621656656265259
, O O 0.9955496788024902
none O O 0.9988264441490173
had O O 0.99956876039505
partial O O 0.9799386262893677
response O O 0.9735855460166931
and O O 0.9998277425765991
five O O 0.9986943602561951
had O O 0.9997270703315735
progressive O O 0.807040810585022
disease O O 0.9195870161056519
. O O 0.9987928867340088

The O O 0.9995461106300354
effects O O 0.9997652173042297
of O O 0.9999873638153076
short O O 0.9931591153144836
- O O 0.997057318687439
term O O 0.9939688444137573
raloxifene S-Chemical B-Chemical 0.9356993436813354
therapy O O 0.993992269039154
on O O 0.9999713897705078
fibrinolysis O O 0.570850133895874
markers O O 0.8922669887542725
: O O 0.9999356269836426
TAFI O O 0.6051393747329712
, O O 0.9992890357971191
tPA O O 0.42730021476745605
, O O 0.9973670840263367
and O O 0.9998801946640015
PAI O O 0.8991402387619019
- O O 0.9939305782318115
1 O O 0.9927486777305603
. O O 0.999991774559021

27 O O 0.9269620776176453
informative O O 0.9558460116386414
female O O 0.9788349866867065
patients O O 0.9996089339256287
the O O 0.999998927116394
majority O O 0.9998998641967773
of O O 0.9999872446060181
the O O 0.9999252557754517
granulocytes S-cell_type S-cell_type 0.831895649433136
were O O 0.999483585357666
clonally O O 0.9113628268241882
derived O O 0.9964518547058105
. O O 0.9999971389770508
In O O 0.9999666213989258
5 O O 0.9954315423965454
patients O O 0.9998282194137573
the O O 0.9999891519546509
granulocytes S-cell_type O 0.7385045289993286
appeared O O 0.9974842071533203
polyclonal O O 0.6959595680236816
and O O 0.9841446876525879
in O O 0.9994986057281494
1 O O 0.9874869585037231
patient O O 0.9804912805557251
unilateral O O 0.8543916940689087

cloned O O 0.9152967929840088
the O O 0.9978614449501038
gene O O 0.973726749420166
for O O 0.9998071789741516
a O O 0.9998210072517395
new O O 0.9517151713371277
ets-related B-protein B-protein 0.5768643021583557
transcription I-protein I-protein 0.704075276851654
factor E-protein E-protein 0.9849517941474915
, O O 0.9877782464027405
ERP S-protein S-protein 0.8389952778816223
( O O 0.9508835077285767
ets-related B-protein B-protein 0.5279294848442078
protein E-protein E-protein 0.9382162094116211
) O O 0.7390168309211731
, O O 0.9985583424568176
from O O 0.9999696016311646
the O O 0.999839186668396
murine B-cell_line B-cell_line 0.3929917514324188
pre-B I-cell_line I-cell_line 0.663272500038147
cell I-cell_line I-cell_line 0.9147659540176392
line E-cell_line I-cell_line 0.7818131446838379
BASC B-cell_line I-cell_line 0.5954387784004211
6C2 E-cell_line E-cell_line 0.8852283358573914
and O O 0.995824933052063

, O O 0.973541259765625
inhibited O O 0.9946973323822021
nuclear O O 0.8536114692687988
NF-kappaB S-protein S-protein 0.88463294506073
activity O O 0.9979525804519653
, O O 0.9999768733978271
and O O 0.9999728202819824
that O O 0.9999847412109375
IL-4 S-protein S-protein 0.9847972989082336
and O O 0.993415117263794
IL-10 S-protein S-protein 0.9842219352722168
did O O 0.9997861981391907
not O O 0.999985933303833
affect O O 0.9999628067016602
NF- O O 0.6260668039321899
IL-6 S-protein S-protein 0.8470274806022644
activity O O 0.9971363544464111
. O O 0.9999959468841553
On O O 0.9999885559082031
the O O 0.9999881982803345
other O O 0.9999364614486694
hand O O 0.9996944665908813
, O O 0.9999830722808838
IL-10 S-protein S-protein 0.973543643951416
enhanced O O 0.9992786049842834
the O O 0.9999659061431885
degradation O O 0.9971023201942444
of O O 0.9998962879180908
IL-6 B-RNA B-RNA 0.9499486684799194
mRNA E-RNA E-RNA 0.9977328777313232
in O O 0.9996764659881592
a O O 0.9999599456787109
mRNA O O 0.3673234283924103
stability O O 0.88552325963974
assay O O 0.9930220246315002
. O O 0.999996542930603
These O O 0.9999943971633911
results O O 0.9999566078186035
suggest O O 0.9999974966049194
that O O 0.9999916553497314
IL-4 S-protein S-protein 0.9889560341835022
may O O 0.9999136924743652
inhibit O O 0.999969482421875
the O O 0.999919056892395
transcription O O 0.971825122833252
of O O 0.9993442893028259
the O O 0.9994091987609863
IL-6 B-DNA B-DNA 0.4754616618156433
gene E-DNA E-DNA 0.9747030138969421
by O O 0.9988447427749634

) I-DNA I-DNA 0.5193162560462952
binding I-DNA I-DNA 0.4279082119464874
site E-DNA E-DNA 0.9467105269432068
( O O 0.9954586029052734
located O O 0.9982276558876038
between O O 0.994949221611023
the O O 0.9991201758384705
LEF-1 B-DNA S-protein 0.6281399726867676
and I-DNA O 0.899477481842041
distal I-DNA O 0.6862304210662842
NF-kappaB I-DNA B-DNA 0.7161093950271606
transcription I-DNA I-DNA 0.553588330745697
factor I-DNA I-DNA 0.6418315172195435
binding I-DNA I-DNA 0.4632985293865204
sites E-DNA E-DNA 0.8093810677528381
) O O 0.990861177444458
that O O 0.9999822378158569
we O O 0.9999215602874756
identified O O 0.9999819993972778
in O O 0.9999949932098389
previous O O 0.9994612336158752
studies O O 0.999546229839325
of O O 0.9999880790710449
the O O 0.9999268054962158
HIV-1 B-DNA B-DNA 0.5581211447715759
LTR E-DNA E-DNA 0.9915510416030884
. O O 0.9997088313102722
These O O 0.9999942779541016
findings O O 0.9999685287475586
suggest O O 0.9999979734420776
that O O 0.999990701675415
LTR B-DNA S-DNA 0.9535880088806152
sequence E-DNA O 0.7424324154853821
changes O O 0.9968320727348328
can O O 0.9999897480010986
significantly O O 0.9998681545257568

Puromycin B-Chemical B-Chemical 0.9080287218093872
aminonucleoside E-Chemical I-Chemical 0.9166299700737
nephrosis O B-Disease 0.97995525598526
was O O 0.9807189702987671
induced O O 0.9997733235359192
by O O 0.9999964237213135
single O O 0.9921390414237976
intraperitoneal O O 0.916822612285614
injection O O 0.9413895010948181
of O O 0.9997157454490662
puromycin B-Chemical B-Chemical 0.9359298348426819
aminonucleoside E-Chemical I-Chemical 0.9444162249565125
( O O 0.9492141604423523
PAN S-Chemical B-Chemical 0.9360404014587402
, O O 0.9473239779472351
20 O O 0.9981112480163574
mg O O 0.9995761513710022
/ O O 0.9999752044677734
100g O O 0.9995112419128418
BW O O 0.9910356998443604
) O O 0.9999266862869263
. O O 0.9999988079071045

of O O 0.9957062602043152
potential O O 0.9436207413673401
Ets B-DNA B-DNA 0.48539888858795166
binding I-DNA I-DNA 0.7483721971511841
sites E-DNA E-DNA 0.9503507018089294
in O O 0.9990441203117371
the O O 0.9998223185539246
promoters S-DNA S-DNA 0.9834429621696472
and O O 0.9741199016571045
enhancers S-DNA S-DNA 0.9579916596412659
of O O 0.9985644221305847
many O O 0.995149552822113
inducible B-DNA B-DNA 0.6978507041931152
T-cell I-DNA I-DNA 0.2694758176803589
genes E-DNA E-DNA 0.9849892854690552
. O O 0.9997981190681458
In O O 0.9999758005142212
the O O 0.999977707862854
studies O O 0.9994837045669556
described O O 0.9999779462814331

of O O 0.9962437152862549
GLUT1 S-protein S-protein 0.7582840323448181
and O O 0.9871930480003357
GLUT4 S-protein S-protein 0.7671411633491516
expression O O 0.995938777923584
through O O 0.999982476234436
PPARgamma S-protein S-protein 0.9541584253311157
activation O O 0.992385983467102
. O O 0.9999892711639404
The O O 0.9999788999557495
nuclear B-protein B-protein 0.6095390915870667
receptor E-protein I-protein 0.42173150181770325
PPARgamma S-protein E-protein 0.7160221338272095
- O O 0.8820028901100159
bigger O O 0.8403472900390625
than O O 0.9903923273086548
fat O O 0.6275814175605774
. O O 0.9993788003921509
Work O O 0.997927188873291
reported O O 0.9999672174453735
over O O 0.9999946355819702
the O O 0.9999816417694092
past O O 0.9998509883880615
year O O 0.9986018538475037
has O O 0.9999943971633911
provided O O 0.9999879598617554
insights O O 0.9978216886520386
into O O 0.9999797344207764

The O O 0.9995330572128296
mechanisms O O 0.9998165965080261
of O O 0.9999579191207886
this O O 0.9998654127120972
ticlopidine B-Chemical B-Chemical 0.9291386008262634
- O O 0.9510928988456726
induced O O 0.9920974969863892
cholestasis B-Disease B-Disease 0.976904571056366
are O O 0.9879939556121826
unclear O O 0.9852792024612427
. O O 0.9999969005584717

RESULTS O O 0.9963163137435913
: O O 0.9996034502983093
Salbutamol B-Chemical B-Chemical 0.9082105755805969
significantly O O 0.9940190315246582
increased O O 0.9737663865089417
tremor B-Disease O 0.8394253253936768
severity O O 0.7632331252098083
in O O 0.9933550357818604
patients O O 0.9998574256896973
in O O 0.9999951124191284
a O O 0.9998748302459717
dose O O 0.9976377487182617
- O O 0.9997864365577698
dependent O O 0.9977884292602539
way O O 0.9998786449432373
. O O 0.999997615814209

Accordingly O O 0.9989650249481201
, O O 0.9999880790710449
the O O 0.9999808073043823
present O O 0.9990628361701965
, O O 0.9998739957809448
prospective O O 0.9896805882453918
double O O 0.9880697131156921
- O O 0.9978477954864502
blind O O 0.9695602059364319
study O O 0.9981060028076172
compares O O 0.9999843835830688
prilocaine S-Chemical B-Chemical 0.9121631383895874
with O O 0.9966769218444824
lidocaine S-Chemical B-Chemical 0.9234676957130432
and O O 0.9732717871665955
bupivacaine S-Chemical B-Chemical 0.9233722686767578
with O O 0.9992406368255615
respect O O 0.9991858601570129
to O O 0.9999845027923584
duration O O 0.9742709398269653
of O O 0.9963964819908142
action O O 0.91856849193573
and O O 0.9993614554405212
relative O O 0.9802089929580688
risk O O 0.9952874183654785
of O O 0.9999195337295532
TNSs O B-Disease 0.9588155150413513
. O O 0.9981077909469604

The O O 0.9997559189796448
purpose O O 0.999680757522583
of O O 0.9999958276748657
this O O 0.9999934434890747
report O O 0.999875545501709
is O O 0.9999977350234985
to O O 0.9999967813491821
describe O O 0.9999858140945435
two O O 0.9999407529830933
cases O O 0.9991913437843323
of O O 0.9999423027038574
a O O 0.9997350573539734
disulfiram B-Chemical B-Chemical 0.9158591628074646
- O O 0.7672537565231323
like O O 0.884335458278656
syndrome O O 0.6317331194877625
following O O 0.9997289776802063
occupational O O 0.8601140379905701
exposure O O 0.511828601360321
to O O 0.9961215853691101
hydrogen B-Chemical B-Chemical 0.9283567070960999
cyanamide I-Chemical I-Chemical 0.941196858882904
. O O 0.9993425011634827

FISH O O 0.22909238934516907
) O O 0.7095431685447693
results O O 0.9959171414375305
refined O O 0.9977243542671204
the O O 0.9999151229858398
previous O O 0.996867835521698
localization O O 0.9921600222587585
of O O 0.9997690320014954
15-LO S-protein S-DNA 0.5797708630561829
to O O 0.9719864130020142
human B-DNA B-DNA 0.4694770276546478
chromosome I-DNA I-DNA 0.6858696341514587
17p13.3 E-DNA E-DNA 0.9460979700088501
. O O 0.9988207221031189
Ex O O 0.9825789928436279
vivo O O 0.9726142287254333
activation O O 0.998079776763916
of O O 0.9999443292617798
tumor-draining B-cell_type B-protein 0.4821832776069641
lymph I-cell_type I-protein 0.4097416400909424

METHODS O O 0.9918999671936035
: O O 0.9999866485595703
The O O 0.9999716281890869
cardiovascular O O 0.7360641956329346
responses O O 0.8415788412094116
to O O 0.9989907145500183
standing O O 0.975664496421814
and O O 0.9972090125083923
head O O 0.9885330200195312
- O O 0.9995847344398499
up O O 0.9996809959411621
tilt O O 0.992770254611969
were O O 0.9999953508377075
studied O O 0.9999346733093262
repeatedly O O 0.999721109867096
in O O 0.9999871253967285
PD B-Disease O 0.942598819732666
patients O O 0.8490990400314331
receiving O O 0.9999158382415771
selegiline B-Chemical B-Chemical 0.9305305480957031
and O O 0.9919171929359436
as O O 0.9999711513519287
the O O 0.9999175071716309
drug O O 0.9978446960449219
was O O 0.9999649524688721
withdrawn O O 0.9998522996902466
. O O 0.9999991655349731

asthma O O 0.7570159435272217
. O O 0.9998247027397156
Synthetic O O 0.9142420887947083
glucocorticoids O O 0.9023846387863159
vary O O 0.9999301433563232
in O O 0.9999814033508301
their O O 0.999963641166687
binding O O 0.9620765447616577
affinity O O 0.9832556247711182
for O O 0.9999257326126099
the O O 0.9998544454574585
glucocorticoid O B-protein 0.5393268465995789
receptor O E-protein 0.9574998021125793
( O O 0.9629336595535278
GCR O S-protein 0.9209139347076416
) O O 0.9522407650947571
. O O 0.9995025396347046
METHODS O O 0.9641351103782654
: O O 0.9963786005973816

binding O O 0.880333662033081
of O O 0.9970279335975647
HMG-I B-protein B-protein 0.41518333554267883
( I-protein I-protein 0.6264619827270508
Y I-protein I-protein 0.8890321850776672
) E-protein E-protein 0.9514114260673523
to O O 0.9942877888679504
this O O 0.9997860789299011
oligonucleotide O O 0.6023440361022949
causes O O 0.996600329875946
bending/flexure O O 0.4661242961883545
of O O 0.9945031404495239
the O O 0.9997124075889587
DNA O O 0.7043135166168213
. O O 0.9994485974311829
HMG-I B-protein B-protein 0.5487061142921448
( I-protein I-protein 0.6052302718162537
Y I-protein I-protein 0.9495967030525208
) E-protein E-protein 0.960853636264801
also O O 0.99073326587677
binds O O 0.9997316002845764
to O O 0.9999699592590332
a O O 0.9999041557312012
second O O 0.9700647592544556
oligonucleotide O O 0.4103173017501831
containing O O 0.9860776662826538
a O O 0.9989091157913208
BP1 B-DNA B-DNA 0.4346701502799988

and/or O E-protein 0.6487035155296326
by O O 0.9982897639274597
causing O O 0.9996175765991211
degradation O O 0.9877205491065979
of O O 0.9999264478683472
newly O B-protein 0.8249399662017822
translated B-protein I-protein 0.7294324040412903
protein E-protein E-protein 0.9303207397460938
. O O 0.9985854625701904
The O O 0.9999967813491821
effect O O 0.999957799911499
of O O 0.9999868869781494
antioxidants O O 0.8251711130142212
on O O 0.9990389347076416
tumor B-protein B-protein 0.47434285283088684
necrosis I-protein I-protein 0.7325960993766785
factor E-protein E-protein 0.9174562692642212
appeared O O 0.9953135251998901
to O O 0.9999755620956421
be O O 0.9999450445175171
species O O 0.9832483530044556
specific O O 0.9985925555229187
, O O 0.999977707862854
with O O 0.9999923706054688
no O O 0.999887228012085
effect O O 0.9999375343322754
on O O 0.9999833106994629
LPS-induced O O 0.6712697148323059

infection O O 0.9023043513298035
are O O 0.9999274015426636
characterized O O 0.9998946189880371
by O O 0.9999912977218628
infiltration O O 0.9973968267440796
of O O 0.9999496936798096
CD4+ B-cell_type B-cell_type 0.8338969349861145
lymphocytes E-cell_type E-cell_type 0.9830060601234436
. O O 0.9997938275337219
We O O 0.9999886751174927
have O O 0.9999973773956299
investigated O O 0.9999884366989136
the O O 0.9999778270721436
antigenic O O 0.9257140755653381
specificity O O 0.9933232665061951
of O O 0.9999814033508301
47 O O 0.9024013876914978
HSV-specific B-cell_line B-cell_line 0.5030301213264465
CD4+ I-cell_line I-cell_line 0.7010032534599304
T-cell I-cell_line I-cell_line 0.8103426694869995
clones E-cell_line E-cell_line 0.9981667995452881
recovered O O 0.9987081289291382
from O O 0.9999924898147583
the O O 0.9997596144676208
HSV-2 O O 0.5580691695213318
buttock O O 0.6178390383720398
and O O 0.9954063892364502
thigh O O 0.8876713514328003
lesions O O 0.8101363778114319
of O O 0.9994800686836243
five O O 0.997433602809906
patients O O 0.9997473359107971
. O O 0.9999951124191284
Clones O O 0.7625313997268677
with O O 0.999496340751648

shown O O 0.9910408854484558

Stopping O O 0.9886067509651184
selegiline S-Chemical B-Chemical 0.913229763507843
also O O 0.9924989342689514
significantly O O 0.9997084736824036
reduced O O 0.9975208640098572
the O O 0.9981768131256104
supine O O 0.8766241073608398
systolic O O 0.5693349242210388
and O O 0.8865855932235718
diastolic O O 0.7818321585655212
blood O O 0.6296995282173157
pressures O O 0.5990787744522095
consistent O O 0.9969659447669983
with O O 0.9999961853027344
a O O 0.9999620914459229
previously O O 0.9979325532913208
undescribed O O 0.9967905879020691
supine O O 0.6745408773422241
pressor O O 0.546104371547699
action O O 0.9345502257347107
. O O 0.9999971389770508

A O O 0.8500245809555054

role O O 0.95672208070755
of O O 0.9998935461044312
retinoic O O 0.8172534108161926
acid O O 0.7009418606758118
( O O 0.9841070175170898
RA O O 0.8843586444854736
) O O 0.9827302694320679
in O O 0.9998108744621277
anti-CD40 S-protein S-protein 0.847678005695343
+ O O 0.9702657461166382
interleukin-4 S-protein S-protein 0.8725945949554443
( O O 0.9737783670425415

from O O 0.9994029998779297
the O O 0.9999545812606812
cotton O O 0.8376049995422363
top O O 0.8754939436912537
tamarin O O 0.3307385742664337
( O O 0.9984052777290344
Saguinus O O 0.9101483225822449
oedipus O O 0.8507265448570251
) O O 0.9902325868606567
, O O 0.9998511075973511
in O O 0.9999712705612183
combination O O 0.9918583035469055
with O O 0.9999316930770874
cytosol O O 0.7487146854400635
prepared O O 0.9745612144470215
from O O 0.9997784495353699
human O O 0.5729787945747375
or O O 0.9338158369064331
rat O O 0.8726984858512878
tissues O O 0.9517925977706909
. O O 0.9999701976776123
B95-8 O O 0.5939595103263855
cytosol O O 0.46509242057800293
inhibited O O 0.9887514710426331
specific O O 0.9869339466094971
binding O O 0.9814820289611816
of O O 0.999337375164032
[ O O 0.9548112750053406
3H O O 0.787395179271698
] O O 0.9168696403503418
dexamethasone O O 0.8656941056251526
( O O 0.9989970326423645
P O O 0.9880111813545227
< O O 0.9987527132034302
0.01 O O 0.9972524046897888
) O O 0.9998039603233337
when O O 0.9999935626983643
mixed O O 0.9953674077987671
with O O 0.9999655485153198
cytosol O O 0.6878445744514465
prepared O O 0.9538974165916443
from O O 0.999638557434082
either O O 0.9992890357971191
a O O 0.9992808699607849
human B-cell_line B-cell_line 0.4812197983264923
lymphoid I-cell_line I-cell_line 0.7903733849525452
cell I-cell_line I-cell_line 0.9558886289596558
line E-cell_line E-cell_line 0.9711187481880188
( O O 0.9932149648666382
HL S-cell_line S-cell_line 0.9895304441452026
) O O 0.8986807465553284
or O O 0.9994208812713623
rat O O 0.4874958395957947
thymus O O 0.43037018179893494
. O O 0.9922014474868774
The O O 0.9999241828918457

A O O 0.9874680042266846
nerve O O 0.6347200870513916
conduction O O 0.7484428882598877
study O O 0.9950001239776611
was O O 0.9999927282333374
consistent O O 0.999958872795105
with O O 0.9999973773956299
severe O O 0.9922634363174438
sensorimotor O O 0.6359283328056335
axonal O O 0.3974003195762634
polyneuropathy B-Disease O 0.5427113771438599
. O O 0.999755322933197

genes O E-DNA 0.8821449875831604

In O O 0.9994093179702759
the O O 0.9999876022338867
first O O 0.9958706498146057
series O O 0.9983277916908264
we O O 0.9999964237213135
found O O 0.9999948740005493
that O O 0.9999945163726807
the O O 0.9998840093612671
number O O 0.9798752069473267

On O O 0.9991766810417175
the O O 0.9999920129776001
contrary O O 0.9999359846115112
, O O 0.9999979734420776
the O O 0.9999490976333618
cataleptogenic O O 0.7711721062660217
effect O O 0.9400875568389893
of O O 0.9993952512741089
haloperidol B-Chemical B-Chemical 0.9323168992996216
was O O 0.9987561702728271
significantly O O 0.9998087286949158
reduced O O 0.9970903396606445
in O O 0.9998726844787598
rats O O 0.9898927807807922
treated O O 0.9998061060905457
with O O 0.9999755620956421
desipramine B-Chemical B-Chemical 0.9384548664093018
and O O 0.9095418453216553
6 B-Chemical B-Chemical 0.9707114696502686
- I-Chemical I-Chemical 0.9934125542640686
OHDA I-Chemical E-Chemical 0.9199622869491577
but O O 0.9922846555709839
not O O 0.9994472861289978
in O O 0.9999058246612549
rats O O 0.9894998669624329
treated O O 0.9998093247413635
with O O 0.9999854564666748
6 B-Chemical B-Chemical 0.9338551759719849
- I-Chemical I-Chemical 0.994657039642334
OHDA I-Chemical E-Chemical 0.9253876209259033
or O O 0.9831534028053284
in O O 0.9998799562454224
rats O O 0.9958246946334839
with O O 0.999968409538269
lesions O O 0.6347417831420898
of O O 0.9736180901527405
the O O 0.9948620200157166
locus O O 0.8076174855232239
coeruleus O O 0.28969335556030273
. O O 0.999854564666748

NF-IL6 S-protein S-protein 0.8272048830986023
. O O 0.9996986389160156
Neither O O 0.9997081160545349
IL-10 S-protein S-protein 0.9459536075592041
nor O O 0.9904701709747314
IL-4 S-protein S-protein 0.9533233642578125
inhibited O O 0.9989750385284424
LPS-induced O O 0.9204172492027283
NF-kappa B-protein B-protein 0.5320444703102112
B E-protein E-protein 0.9909522533416748
binding O O 0.9631392955780029
activity O O 0.9977259039878845
. O O 0.9999973773956299
In O O 0.9999774694442749
agreement O O 0.9996887445449829
with O O 0.999996542930603
this O O 0.9999792575836182
finding O O 0.9992886781692505
, O O 0.9999915361404419
Northern O O 0.9895988702774048
experiments O O 0.9996252059936523
where O O 0.9999845027923584
p65 O S-protein 0.4259411096572876
and O O 0.7606568336486816
p105 O B-RNA 0.32860085368156433
mRNA O E-RNA 0.967546284198761
levels O O 0.9977322816848755
were O O 0.9999959468841553
determined O O 0.99998939037323
, O O 0.9999935626983643
demonstrated O O 0.9999351501464844
that O O 0.9999898672103882
expression O O 0.9991804957389832
of O O 0.9999732971191406
these O O 0.9999171495437622
components O O 0.9936420321464539
of O O 0.9997535347938538
the O O 0.9997041821479797

A O O 0.9976639747619629
report O O 0.9999374151229858
of O O 0.9999897480010986
two O O 0.9999676942825317
cases O O 0.9989997744560242
. O O 0.9999991655349731

effector E-protein O 0.562667191028595
Bax S-protein S-protein 0.7666295766830444
, O O 0.9978333115577698
whereas O O 0.9999809265136719
treatment O O 0.9995506405830383
with O O 0.9999649524688721
PDBu O O 0.45864662528038025
did O O 0.9997596144676208
not O O 0.9999783039093018
significantly O O 0.9999299049377441
alter O O 0.9999223947525024
the O O 0.9998462200164795
levels O O 0.9993683695793152
of O O 0.9999667406082153
this O O 0.9996389150619507
protein O O 0.9209918975830078
. O O 0.999727189540863
However O O 0.9999675750732422
, O O 0.9999856948852539
treatment O O 0.9994795918464661
of O O 0.9999574422836304
HL-60 B-cell_line B-cell_line 0.6522915363311768
cells E-cell_line E-cell_line 0.9654019474983215
with O O 0.9997774958610535
PDBu O O 0.442304402589798
induced O O 0.9997866749763489
the O O 0.9999758005142212
rapid O O 0.9876375198364258
expression O O 0.9984889030456543
of O O 0.9999797344207764
the O O 0.9996850490570068
apoptosis B-protein O 0.8558976054191589

Five O O 0.995868980884552
cm O O 0.9736548662185669
H2O S-Chemical O 0.866855263710022
CPAP O O 0.7202507257461548
during O O 0.9963943362236023
nitroprusside S-Chemical B-Chemical 0.9238758683204651
did O O 0.9986646175384521
not O O 0.9999351501464844
further O O 0.9997684359550476
alter O O 0.9995741248130798
any O O 0.9999589920043945
of O O 0.9999254941940308
the O O 0.9999797344207764
above O O 0.9936489462852478
- O O 0.9995112419128418
mentioned O O 0.9996168613433838
variables O O 0.9903467297554016
. O O 0.9999970197677612

Post O O 0.9935637712478638
hoc O O 0.9540934562683105
analyses O O 0.9779426455497742
indicated O O 0.9999817609786987
that O O 0.9999204874038696
efficacy O O 0.8611371517181396
was O O 0.9997021555900574
similar O O 0.9998706579208374
with O O 0.9999911785125732
asenapine B-Chemical B-Chemical 0.9221485257148743
and O O 0.9661253094673157
haloperidol B-Chemical B-Chemical 0.9277163743972778
; O O 0.9975612163543701
greater O O 0.9990068078041077
contrasts O O 0.9843653440475464
were O O 0.9999451637268066
seen O O 0.9999833106994629
in O O 0.9999688863754272
AEs O O 0.5423398017883301
, O O 0.996694803237915
especially O O 0.9997110962867737
extrapyramidal B-Disease O 0.7760107517242432
symptoms I-Disease O 0.9531063437461853
. O O 0.9992297887802124

. O O 0.9978733062744141
Protein B-protein B-protein 0.7905218005180359
kinase I-protein I-protein 0.5980730652809143
C E-protein E-protein 0.9928065538406372
( O O 0.9939205646514893
PKC S-protein S-protein 0.9980095028877258
) O O 0.9917197227478027
does O O 0.9999828338623047
not O O 0.999980092048645
appear O O 0.999971866607666
to O O 0.999969482421875
play O O 0.9999889135360718
a O O 0.9999910593032837
role O O 0.9998924732208252
in O O 0.9999961853027344
the O O 0.9999847412109375
alpha-tcp O O 0.4292486011981964
effect O O 0.9556496739387512

The O O 0.9995231628417969
fact O O 0.9980165958404541
that O O 0.9999949932098389
5 O O 0.9989846348762512
of O O 0.9999741315841675
the O O 0.9999756813049316
6 O O 0.9973612427711487
patients O O 0.9987820982933044
who O O 0.9999858140945435
received O O 0.9999432563781738
concurrent O O 0.9456228613853455
calcium B-Chemical B-Chemical 0.9300768971443176
channel O O 0.6688535213470459
blockers O O 0.8995111584663391
died O O 0.9989302754402161
, O O 0.9999862909317017
should O O 0.9999864101409912
alert O O 0.9993312358856201
clinicians O O 0.9851799011230469
to O O 0.999957799911499
be O O 0.9999537467956543
more O O 0.9997861981391907
cautious O O 0.9975311160087585
when O O 0.9999918937683105
using O O 0.9998462200164795
these O O 0.999962329864502
two O O 0.9998408555984497
drugs O O 0.9988254904747009
simultaneously O O 0.999950647354126
. O O 0.9999991655349731

BACKGROUND O O 0.9807135462760925
: O O 0.9998800754547119
In O O 0.9999237060546875
vivo O O 0.9930903315544128
regulation O O 0.9994217157363892
of O O 0.9999721050262451
the O O 0.9999197721481323
glucocorticoid B-protein B-protein 0.3777313232421875
receptor E-protein E-protein 0.8771893382072449
( O O 0.827511727809906
GR S-protein S-protein 0.7534630298614502
) O O 0.8546661138534546

LTR E-DNA S-DNA 0.5786327123641968
. O O 0.9991944432258606
Sequence O O 0.9863627552986145
analyses O O 0.9988859295845032
of O O 0.9999614953994751
pCD41 S-DNA S-DNA 0.6626132130622864
indicate O O 0.9994414448738098
that O O 0.9999969005584717
there O O 0.9999850988388062
are O O 0.9999974966049194
two O O 0.9993509650230408
potential O O 0.9856436252593994
open B-DNA B-DNA 0.8254998922348022
reading I-DNA I-DNA 0.5926196575164795
frames E-DNA E-DNA 0.9631960391998291
( O O 0.9921649694442749
ORFs S-DNA S-DNA 0.9748849272727966
) O O 0.9854142665863037
, O O 0.9997432827949524
A S-DNA O 0.4085216522216797
and O O 0.8707442283630371

of O O 0.996752142906189
AIDS O O 0.9207244515419006
. O O 0.9999895095825195
To O O 0.9999878406524658
investigate O O 0.9999916553497314
the O O 0.9999815225601196
effects O O 0.9999486207962036
of O O 0.9999927282333374
human B-protein O 0.8913434743881226
immunodeficiency I-protein O 0.914644718170166
virus I-protein O 0.9576196074485779
type I-protein O 0.9568036794662476
1 I-protein O 0.9686278700828552
( I-protein O 0.998571515083313
HIV-1 I-protein O 0.9440305233001709

The O O 0.9985014200210571
angioedema B-Disease B-Disease 0.9792284965515137
resolved O O 0.912826418876648
after O O 0.9995782971382141
therapy O O 0.9991602897644043
with O O 0.9999988079071045
intravenous O O 0.6594599485397339
steroids B-Chemical B-Chemical 0.8919433951377869
and O O 0.9657757878303528
diphenhydramine B-Chemical B-Chemical 0.9279279708862305
hydrochloride O I-Chemical 0.9372605085372925
. O O 0.9995288848876953

and O O 0.9794086813926697
the O O 0.9995537400245667
Src B-protein B-protein 0.46817901730537415
family I-protein I-protein 0.7927403450012207
kinases E-protein E-protein 0.9587597250938416
Lck S-protein S-protein 0.9930182695388794
and O O 0.9958065748214722
Fyn S-protein S-protein 0.9732632040977478
. O O 0.9993399977684021
Ligation O O 0.9867092967033386
of O O 0.9980226755142212
CD3 S-protein S-protein 0.94769686460495
also O O 0.9982380867004395
induces O O 0.9999876022338867
the O O 0.9999563694000244
tyrosine O O 0.8025071620941162
phosphorylation O O 0.830463707447052
of O O 0.9892494678497314
HS1 S-protein S-protein 0.6355457305908203
, O O 0.9824687242507935
a O O 0.9979682564735413

This O O 0.999774158000946
study O O 0.9999765157699585
assessed O O 0.9999667406082153
the O O 0.9999339580535889
ability O O 0.9996119141578674
of O O 0.9998924732208252
IH636 B-Chemical B-Chemical 0.9088431596755981
grape I-Chemical I-Chemical 0.9530274868011475
seed I-Chemical I-Chemical 0.9735457897186279
proanthocyanidin I-Chemical I-Chemical 0.9644497036933899
extract E-Chemical I-Chemical 0.9683180451393127
( O O 0.9137789607048035
GSPE S-Chemical O 0.6832624673843384
) O O 0.9245865345001221
to O O 0.9998335838317871
prevent O O 0.9985407590866089
acetaminophen S-Chemical B-Chemical 0.933601438999176
( O O 0.9192068576812744
AAP S-Chemical B-Chemical 0.9274141788482666
) O O 0.6013656258583069
- O O 0.9934448003768921
induced O O 0.9974629878997803
nephrotoxicity O B-Disease 0.9829309582710266
, O O 0.9752998948097229
amiodarone S-Chemical B-Chemical 0.9386852979660034
( O O 0.9492252469062805
AMI S-Chemical B-Chemical 0.9346835017204285
) O O 0.7507136464118958
- O O 0.9967723488807678
induced O O 0.9986764788627625
lung O B-Disease 0.5796242356300354
toxicity O I-Disease 0.9257661700248718
, O O 0.9716334342956543
and O O 0.9994632601737976
doxorubicin S-Chemical B-Chemical 0.9381223917007446
( O O 0.8376941680908203
DOX S-Chemical B-Chemical 0.9276753067970276
) O O 0.6958345174789429
- O O 0.9978420734405518
induced O O 0.9988816380500793
cardiotoxicity O B-Disease 0.9847902655601501
in O O 0.973453938961029
mice O O 0.9937001466751099
. O O 0.9999988079071045

However O O 0.9989751577377319
, O O 0.9999896287918091
one O O 0.9999821186065674
drawback O O 0.9836196303367615
of O O 0.9996483325958252
such O O 0.999250590801239
studies O O 0.9965972304344177
in O O 0.999964714050293
genetically O O 0.8715755343437195
deficient O O 0.8943831920623779
rats O O 0.9646103978157043
is O O 0.9999935626983643
the O O 0.9999926090240479
fact O O 0.9997966885566711
that O O 0.9999951124191284
compensatory O O 0.8324547410011292
changes O O 0.8437197208404541
with O O 0.9996901750564575
upregulation O O 0.8942010998725891
of O O 0.9973243474960327
other O O 0.9990284442901611
transporters O O 0.9030666947364807
can O O 0.9997602105140686
occur O O 0.999525785446167
. O O 0.9999991655349731

The O O 0.9993849992752075
Calcineurin O O 0.5684460401535034
- O O 0.934920072555542
inhibitor O O 0.754433274269104
Induced O O 0.9557169675827026
Pain B-Disease B-Disease 0.8238557577133179
Syndrome O I-Disease 0.9763343334197998
( O O 0.9694032669067383
CIPS B-Disease O 0.9380457997322083
) O O 0.8430934548377991
is O O 0.9998204112052917
a O O 0.9999703168869019
rare O O 0.9731692671775818
but O O 0.9974421262741089
severe O O 0.9911375045776367
side O O 0.9679538011550903
effect O O 0.9978137016296387
of O O 0.999821126461029
cyclosporine B-Chemical B-Chemical 0.9192474484443665
or O O 0.9529637098312378
tacrolimus B-Chemical B-Chemical 0.9190111756324768
and O O 0.9720659255981445
is O O 0.9997187256813049
accurately O O 0.9991911053657532
diagnosed O O 0.9998795986175537
by O O 0.999995231628418
its O O 0.9999791383743286
typical O O 0.9958426356315613
presentation O O 0.9962249994277954
, O O 0.99997878074646
magnetic O O 0.9210881590843201
resonance O O 0.9004346132278442
imaging O O 0.8240103125572205
and O O 0.9992744326591492
bone O O 0.8974283337593079
scans O O 0.5679031610488892
. O O 0.9999681711196899

OBJECTIVE O O 0.9636845588684082
: O O 0.9998225569725037
To O O 0.9999785423278809
describe O O 0.9998811483383179
associations O O 0.9661974310874939
between O O 0.9991821646690369
the O O 0.9997518658638
use O O 0.9998681545257568
of O O 0.9998401403427124
benzodiazepines B-Chemical B-Chemical 0.9181121587753296
or O O 0.9898793697357178
related O O 0.9638518691062927
drugs O O 0.9484937787055969
( O O 0.9998606443405151
BZDs B-Chemical B-Chemical 0.8818458318710327
/ O O 0.9633010029792786
RDs O O 0.4636553227901459
) O O 0.9924774765968323
and O O 0.9997996687889099
health O O 0.8858996629714966
, O O 0.9962142109870911
functional O O 0.9692083597183228
abilities O O 0.9506160616874695
and O O 0.9995388984680176
cognitive O O 0.867988109588623
function O O 0.6060813069343567
in O O 0.9961323738098145
the O O 0.9983670115470886
elderly O O 0.9505334496498108
. O O 0.999991774559021

High O O 0.9794461727142334
incidence O O 0.9807590842247009
of O O 0.9994644522666931
primary O O 0.8293299674987793
pulmonary O O 0.5072602033615112
hypertension O O 0.8877081871032715
associated O O 0.9681613445281982
with O O 0.9998859167098999
appetite B-Chemical B-Chemical 0.9350240230560303
suppressants E-Chemical I-Chemical 0.9467571377754211
in O O 0.9976054430007935
Belgium O O 0.8652098774909973
. O O 0.999996542930603

COOH-terminal B-protein B-protein 0.3234294652938843
domain E-protein E-protein 0.9507752060890198
feeds O O 0.9854211211204529
barbed O O 0.8450121283531189
end O O 0.8920108079910278
growth O O 0.9590907692909241
of O O 0.9981542229652405
filaments O O 0.676395833492279
and O O 0.9972302317619324
lowers O O 0.9988129138946533
the O O 0.9997993111610413
critical O O 0.9762577414512634
concentration O O 0.9920178651809692
at O O 0.999991774559021
the O O 0.9999216794967651
bacterial O O 0.8753092288970947
surface O O 0.9288814663887024
. O O 0.9998825788497925
On O O 0.9999927282333374
the O O 0.9999817609786987
other O O 0.9999305009841919
hand O O 0.9997593760490417
, O O 0.9999971389770508
the O O 0.9999608993530273
NH B-protein B-protein 0.37292441725730896
( I-protein I-protein 0.48258015513420105
2 I-protein I-protein 0.5787608027458191
) I-protein I-protein 0.5756226778030396
-terminal I-protein I-protein 0.6713014841079712
domain E-protein E-protein 0.9669114947319031
of O O 0.9809466004371643
N-WASP S-protein S-protein 0.533702552318573

The O O 0.9993281364440918
dosing O O 0.9764926433563232
schedule O O 0.9979357719421387
, O O 0.9999946355819702
duration O O 0.9988399147987366
of O O 0.9998770952224731
lithium B-Chemical B-Chemical 0.9198407530784607
treatment O O 0.9930239915847778
, O O 0.999981164932251
and O O 0.9999754428863525
daily O O 0.9942289590835571
dose O O 0.9993253946304321
of O O 0.9992953538894653
lithium B-Chemical B-Chemical 0.9269366264343262
did O O 0.9984038472175598
not O O 0.9999760389328003
affect O O 0.999980092048645
maximum O O 0.9785312414169312
osmolality O O 0.8033536076545715
or O O 0.9820020198822021
creatinine B-Chemical B-Chemical 0.9159131646156311
clearance O O 0.9772118330001831
. O O 0.9999942779541016

corticosteroid B-protein B-protein 0.33924686908721924
receptors E-protein E-protein 0.9826080203056335
. O O 0.999699592590332
We O O 0.999976396560669
previously O O 0.9999839067459106
suggested O O 0.9999935626983643
that O O 0.9999983310699463
the O O 0.9999661445617676
measurement O O 0.9947882890701294
of O O 0.9998797178268433
corticosteroid B-protein B-protein 0.6723950505256653
receptors E-protein E-protein 0.890034019947052
in O O 0.9993096590042114
lymphocytes S-cell_type S-cell_type 0.7853000164031982
is O O 0.9996212720870972
an O O 0.9999945163726807
index O O 0.9954673051834106
of O O 0.9995220899581909
an O O 0.9998563528060913
analogous O O 0.7360588312149048
pattern O O 0.7343975901603699
in O O 0.9985217452049255
brain O O 0.7202133536338806
. O O 0.9984890222549438

a O O 0.9978524446487427
role O O 0.9997108578681946
in O O 0.9999910593032837
IL-2 S-protein S-protein 0.9827638864517212
production O O 0.9973092079162598
, O O 0.9999853372573853
indicating O O 0.9999954700469971
a O O 0.9999933242797852
critical O O 0.9970006346702576
involvement O O 0.9998626708984375
of O O 0.9999752044677734
Itk S-protein S-protein 0.9937993884086609
in O O 0.9999032020568848
the O O 0.999981164932251
initial O O 0.9959122538566589
stage O O 0.9996613264083862
of O O 0.9999781847000122
T O O 0.8881838917732239
cell O O 0.7663617730140686
activation O O 0.997745931148529
by O O 0.9999872446060181
mediating O O 0.9720371961593628
signals O O 0.98808753490448
from O O 0.999983549118042
the O O 0.9998795986175537
TCR/CD3 B-protein B-protein 0.37824302911758423
complex E-protein E-protein 0.9813443422317505
, O O 0.9884910583496094
CD2 S-protein S-protein 0.9834760427474976
, O O 0.9755123257637024
and O O 0.9949996471405029
CD28 S-protein S-protein 0.9905714988708496
. O O 0.9996627569198608
Expression O O 0.9987320303916931
of O O 0.9998507499694824
LAZ3/BCL6 S-protein S-protein 0.9325090646743774
in O O 0.9990895986557007
follicular O B-cell_type 0.4459753930568695
center O I-cell_type 0.6798950433731079
( O I-cell_type 0.532943069934845
FC O I-cell_type 0.735206663608551
) O I-cell_type 0.7438662648200989
B O I-cell_type 0.8120339512825012
cells O E-cell_type 0.8266448974609375
of O O 0.9931808710098267

This O O 0.9995940327644348
case O O 0.9970652461051941
illustrates O O 0.9999279975891113
that O O 0.9999798536300659
patients O O 0.9911057353019714
receiving O O 0.999957799911499
ritodrine S-Chemical B-Chemical 0.9323109984397888
for O O 0.9958415627479553
preterm O B-Disease 0.680439293384552
labor O I-Disease 0.9585756063461304
may O O 0.9695788621902466
risk O O 0.9984703660011292
interactions O O 0.9839215278625488
between O O 0.9998327493667603
the O O 0.999817430973053
residual O O 0.9102194309234619
betamimetic O O 0.4887555241584778
effects O O 0.9854665994644165
of O O 0.9997486472129822
ritodrine S-Chemical B-Chemical 0.9311944246292114
and O O 0.9929995536804199
the O O 0.9997745156288147
effects O O 0.9997245669364929
of O O 0.9999583959579468
anesthetics O O 0.7650498151779175
during O O 0.9988633394241333
cesarean O O 0.8295794725418091
section O O 0.9499068856239319
. O O 0.9999971389770508

. O O 0.9939748644828796
However O O 0.9999340772628784
, O O 0.9999911785125732
the O O 0.9999889135360718
response O O 0.9993851184844971
to O O 0.9999754428863525
HIV-1 B-protein B-protein 0.686276912689209
Tat E-protein E-protein 0.7473546862602234
by O O 0.9996893405914307
a O O 0.9996132254600525
LTR S-DNA S-DNA 0.9797021150588989
in O O 0.9986833930015564
which O O 0.9993622899055481

either O O 0.9996324777603149
the O O 0.9999535083770752
granulocytic B-cell_type B-cell_type 0.3955015540122986
or I-cell_type I-cell_type 0.7996594309806824
monocytic I-cell_type I-cell_type 0.3583071231842041
lineage E-cell_type E-cell_type 0.8087769746780396
are O O 0.9996059536933899
not O O 0.9998469352722168
fully O O 0.9975528120994568
understood O O 0.9998899698257446
. O O 0.9999972581863403
We O O 0.9999802112579346
have O O 0.9999948740005493
shown O O 0.999991774559021
that O O 0.9999966621398926
the O O 0.9997338652610779
c-Maf S-protein B-DNA 0.44424518942832947

dominant-acting B-protein I-protein 0.6816076636314392
repressor I-protein I-protein 0.5261944532394409
molecule E-protein E-protein 0.9604768753051758
that O O 0.9965983033180237
inhibits O O 0.999812662601471
signal O O 0.8756816983222961
transduction O O 0.9150503873825073
to O O 0.9993823766708374
the O O 0.9995145797729492
IL-2 B-DNA B-DNA 0.632504403591156
gene E-DNA E-DNA 0.9560277462005615
within O O 0.9984176158905029
viable O O 0.9028915166854858
anergic B-cell_type B-cell_type 0.6008068323135376
T I-cell_type I-cell_type 0.9115233421325684

under O O 0.9989994168281555
certain O O 0.999687671661377
circumstances O O 0.9998356103897095
. O O 0.9999980926513672
Octamer B-protein B-protein 0.43867263197898865
binding I-protein I-protein 0.802842378616333
factors E-protein E-protein 0.9922356009483337
and O O 0.9982202649116516
their O O 0.9999277591705322
coactivator S-protein O 0.46976807713508606
can O O 0.9983691573143005
activate O O 0.9999185800552368
the O O 0.999920129776001
murine B-DNA B-DNA 0.48857757449150085
PU.1 I-DNA I-DNA 0.3202042281627655
( I-DNA I-DNA 0.581108808517456
spi-1 I-DNA I-DNA 0.6573120355606079
) I-DNA I-DNA 0.5563317537307739
promoter E-DNA E-DNA 0.9945889711380005
. O O 0.9987019300460815
PU.1 S-protein S-protein 0.6318466067314148
( O O 0.898040771484375
spi-1 S-protein S-protein 0.2595253586769104

in O O 0.9981671571731567
heat B-protein B-protein 0.758659839630127
shock I-protein I-protein 0.7202706933021545
proteins E-protein E-protein 0.9254889488220215
, O O 0.9997766613960266
we O O 0.9999761581420898
obtained O O 0.9998459815979004
saturable O O 0.9481197595596313
binding O O 0.9389702677726746
of O O 0.9980243444442749
[ O O 0.9527599215507507
3H O O 0.6956114768981934
] O O 0.8855576515197754
aldosterone O O 0.8620012998580933
. O O 0.9998918771743774
The O O 0.9999600648880005

The O O 0.9995577931404114
results O O 0.9999035596847534
suggest O O 0.9999951124191284
that O O 0.9999573230743408
rigidity B-Disease B-Disease 0.9699532985687256
, O O 0.964002251625061
which O O 0.9994797110557556
is O O 0.9999457597732544
assumed O O 0.9999268054962158
to O O 0.999944806098938
be O O 0.9999330043792725
due O O 0.9999847412109375
to O O 0.9999804496765137
an O O 0.9999063014984131
action O O 0.9962576627731323
of O O 0.9980782270431519
morphine B-Chemical B-Chemical 0.9278395175933838
in O O 0.9983273148536682
the O O 0.9997507929801941
striatum O O 0.6451032757759094
, O O 0.9992938041687012
can O O 0.9999412298202515
be O O 0.999953031539917
antagonized O O 0.9971470236778259
by O O 0.9999895095825195
another O O 0.9999709129333496
process O O 0.999647855758667
leading O O 0.9999847412109375
to O O 0.9999697208404541
dopaminergic O O 0.4356171488761902
activation O O 0.6719129681587219
in O O 0.9995957016944885
the O O 0.9997435212135315
striatum O O 0.7618558406829834
. O O 0.9999668598175049

human B-cell_type B-cell_type 0.3562304377555847
monocytes E-cell_type E-cell_type 0.9862684011459351
, O O 0.9972776770591736
TNF-alpha S-protein S-protein 0.7674522399902344
increased O O 0.9993889331817627
to O O 0.9998302459716797
798+/-67 O O 0.9318034648895264
pg/mL O O 0.7012141346931458
( O O 0.999397873878479
p O O 0.9917522072792053
< O O 0.998630940914154
.001 O O 0.9946921467781067
versus O O 0.999859094619751
control O O 0.9885724782943726
) O O 0.9972322583198547
. O O 0.9999582767486572
IL-10 S-protein S-protein 0.9265646934509277
attenuated O O 0.9817866683006287
LPS-stimulated O O 0.7402865886688232
TNF-alpha S-protein S-protein 0.6805685758590698
production O O 0.9946427345275879
( O O 0.9998502731323242
297+/-54 O O 0.969414234161377

Low O O 0.9298751354217529
- O O 0.9894222617149353
dose O O 0.9972952008247375
haloperidol B-Chemical B-Chemical 0.9245980381965637
did O O 0.9987536668777466
not O O 0.9998779296875
differ O O 0.9999762773513794
from O O 0.9999850988388062
placebo O O 0.9702456593513489
on O O 0.9999381303787231
any O O 0.9999840259552002
measure O O 0.9998607635498047
of O O 0.9999089241027832
efficacy O O 0.5610747933387756
or O O 0.9921992421150208
side O O 0.921595573425293
effects O O 0.9408884048461914
. O O 0.9999936819076538

release O O 0.9213623404502869
, O O 0.9988104104995728
but O O 0.9998087286949158
not O O 0.9997193217277527
tyrosine B-protein B-protein 0.73221755027771
kinase E-protein E-protein 0.8982760906219482
activity O O 0.9608741402626038
, O O 0.999765932559967
correlates O O 0.9996077418327332
with O O 0.9999738931655884
IL-2 S-protein S-protein 0.8506020903587341
secretion O O 0.8846435546875
and O O 0.997249186038971
NF-AT S-protein S-protein 0.9767760038375854
induction O O 0.9974452257156372
in O O 0.9999392032623291
anti-CD3-activated B-cell_line B-cell_line 0.5367239117622375
peripheral I-cell_line I-cell_line 0.6643298268318176
human I-cell_line I-cell_line 0.824944257736206
T I-cell_line I-cell_line 0.869028627872467
lymphocytes E-cell_line E-cell_line 0.830545961856842
. O O 0.9997410178184509
The O O 0.999994158744812
cascade O O 0.952392578125
of O O 0.9984886646270752
events O O 0.990984320640564
within O O 0.9999687671661377
the O O 0.9999562501907349
first O O 0.9870641231536865
few O O 0.9993163347244263
minutes O O 0.9963293671607971
of O O 0.9999446868896484
T B-cell_type O 0.8608784675598145
cell E-cell_type O 0.7849435210227966
stimulation O O 0.9902689456939697
has O O 0.9999854564666748
been O O 0.9999499320983887
well O O 0.9987872242927551
characterized O O 0.9998145699501038
. O O 0.9999970197677612
Although O O 0.9999946355819702
many O O 0.9998094439506531
second O O 0.983744204044342
messengers O O 0.8774783611297607
have O O 0.9999319314956665
been O O 0.9999401569366455
shown O O 0.9999710321426392
to O O 0.9999843835830688
be O O 0.9999706745147705
necessary O O 0.9995883107185364
and O O 0.9999393224716187
sufficient O O 0.9995556473731995
for O O 0.9999041557312012
T B-cell_type O 0.7876436710357666
cell E-cell_type O 0.6546449065208435
activation O O 0.9965043067932129
in O O 0.9999866485595703
a O O 0.9983265995979309

We O O 0.999569833278656
studied O O 0.9999403953552246
the O O 0.9999254941940308
effects O O 0.9995610117912292
of O O 0.9999393224716187
terbutaline B-Chemical B-Chemical 0.9224334359169006
on O O 0.9978925585746765
microglial O O 0.6548881530761719
activation O O 0.6989262700080872
in O O 0.9996758699417114
different O O 0.999294638633728
brain O O 0.6842712163925171
regions O O 0.7144438028335571
and O O 0.9985937476158142
behavioral O O 0.8869177103042603
outcomes O O 0.7947851419448853
in O O 0.9996814727783203
developing O O 0.9577715992927551
rats O O 0.9620965123176575
. O O 0.9999966621398926

caused O O 0.9981372356414795
by O O 0.9999707937240601
bacille O O 0.9009093046188354
Calmette-Guerin O O 0.923881471157074
vaccine O O 0.9737988114356995
and O O 0.999748170375824
environmental O O 0.9535704851150513
mycobacteria O O 0.7951311469078064
in O O 0.9997751116752625
humans O O 0.9541401863098145
remains O O 0.9997813105583191
largely O O 0.999207079410553
unknown O O 0.999716579914093
. O O 0.9999986886978149
We O O 0.9999905824661255
describe O O 0.9999940395355225
18 O O 0.9953621029853821
patients O O 0.9998778104782104
from O O 0.9999990463256836
several O O 0.999825656414032
generations O O 0.999875545501709
of O O 0.9999892711639404
12 O O 0.9973698854446411
unrelated O O 0.8194364905357361
families O O 0.9545297622680664
who O O 0.9999486207962036
were O O 0.9999912977218628
heterozygous O O 0.7608351111412048
for O O 0.9995622038841248
1 O O 0.987415611743927
to O O 0.9984588623046875
5 O O 0.9957290291786194
overlapping B-DNA O 0.8907317519187927
IFNGR1 I-DNA B-DNA 0.37894895672798157
frameshift I-DNA I-DNA 0.3891237676143646
small I-DNA I-DNA 0.4903976619243622
deletions E-DNA E-DNA 0.8656712174415588
and O O 0.9989891648292542
a O O 0.999924898147583
wild-type B-DNA B-DNA 0.44265252351760864
IFNGR1 I-DNA I-DNA 0.3818891644477844
allele E-DNA E-DNA 0.9918444752693176
. O O 0.9997745156288147
There O O 0.9999929666519165
were O O 0.9999964237213135
12 O O 0.9958038926124573
independent O O 0.9701597094535828
mutation O O 0.9529993534088135
events O O 0.9758745431900024
at O O 0.9999980926513672
a O O 0.999954342842102
single B-DNA O 0.9832547307014465
mutation I-DNA B-DNA 0.7334977984428406
site E-DNA E-DNA 0.8891476392745972
, O O 0.9990403056144714

as O O 0.9950163960456848
IFN-alpha S-protein S-protein 0.9899988770484924
in O O 0.9996007084846497
normal O B-cell_type 0.5526251196861267
human O I-cell_type 0.5662867426872253
T B-cell_type I-cell_type 0.8748355507850647
cells E-cell_type E-cell_type 0.9846728444099426
and O O 0.9958576560020447
in O O 0.9992524981498718
NK B-cell_type B-cell_type 0.8955194354057312
cells E-cell_type E-cell_type 0.9686093330383301
. O O 0.9998321533203125
We O O 0.9999243021011353
showed O O 0.9999887943267822

with O O 0.9968327879905701
cellular O O 0.9430040717124939
membrane O O 0.8634462356567383
. O O 0.9998797178268433
The O O 0.9999991655349731
purpose O O 0.9989104270935059
of O O 0.9999910593032837
this O O 0.9999949932098389
review O O 0.9995693564414978
is O O 0.9999784231185913
to O O 0.9999862909317017
analyze O O 0.9999047517776489
and O O 0.9995080232620239
concilliate O O 0.9996304512023926
the O O 0.9999639987945557
reported O O 0.9778361320495605
data O O 0.990136444568634
on O O 0.999984860420227
the O O 0.9999608993530273
mechanism O O 0.9990928173065186
of O O 0.9999822378158569
action O O 0.9980037808418274
of O O 0.9999288320541382
estrogens O O 0.6893557906150818
. O O 0.9998524188995361
Reduced O O 0.9969587326049805
susceptibility O O 0.9950209856033325
to O O 0.9999536275863647
HIV-1 O O 0.8979503512382507
infection O O 0.981447696685791
of O O 0.9999202489852905
ethyl-methanesulfonate-treated B-cell_line B-cell_line 0.3911803960800171
CEM I-cell_line I-cell_line 0.665901780128479
subclones E-cell_line E-cell_line 0.9783797264099121
correlates O O 0.9993632435798645
with O O 0.9999957084655762
a O O 0.999953031539917
blockade O O 0.96321702003479

able O O 0.9747159481048584
to O O 0.999778687953949
protect O O 0.9998948574066162
the O O 0.9990124702453613
cells O O 0.9678868055343628
from O O 0.9999833106994629
apoptosis O O 0.9832333922386169
induced O O 0.9999440908432007
by O O 0.9999855756759644
IL-3 S-protein S-protein 0.9545074701309204
deprivation O O 0.9968323111534119
. O O 0.999998927116394
Surprisingly O O 0.9993370175361633
, O O 0.9999929666519165
different O O 0.9991052746772766
combinations O O 0.9986157417297363
of O O 0.9999215602874756
disabling O O 0.5929903984069824

CONCLUSIONS O O 0.99880051612854
: O O 0.9999959468841553
The O O 0.99998939037323
results O O 0.9998904466629028
indicated O O 0.9999955892562866
a O O 0.9999613761901855
favorable O O 0.9966288208961487
therapeutic O O 0.9917539358139038
profile O O 0.9977349042892456
for O O 0.9999864101409912
haloperidol S-Chemical B-Chemical 0.9315199255943298
in O O 0.9959814548492432
doses O O 0.9996562004089355
of O O 0.9999167919158936
2 O O 0.9962031245231628
- O O 0.9990434050559998
3 O O 0.9996250867843628
mg O O 0.9985867738723755
/ O O 0.9999774694442749
day O O 0.9999140501022339
, O O 0.9999953508377075
although O O 0.9999986886978149
a O O 0.9999784231185913
subgroup O O 0.9958420395851135
developed O O 0.9998899698257446
moderate O O 0.9416605830192566
to O O 0.9950866103172302
severe O O 0.981270968914032
extrapyramidal O O 0.6646270751953125
signs O O 0.897287130355835
. O O 0.9995738863945007

and O O 0.9505056738853455
PGE2 O O 0.4825429618358612
. O O 0.999042809009552
5 O O 0.947469174861908
. O O 0.9995299577713013
Finally O O 0.9999524354934692
, O O 0.9999936819076538
the O O 0.9999926090240479
addition O O 0.9998574256896973
of O O 0.9999675750732422
anti-CD28 B-protein B-protein 0.4467073678970337
mAb E-protein E-protein 0.9934647679328918
to O O 0.9968810081481934
anti-CD3 B-cell_type B-cell_type 0.4273267686367035
mAb-stimulated I-cell_type I-cell_type 0.26569414138793945
T I-cell_type I-cell_type 0.4933679401874542

primary B-cell_type B-cell_type 0.5743035078048706
T I-cell_type I-cell_type 0.8434890508651733
lymphocytes E-cell_type E-cell_type 0.9889117479324341
we O O 0.9919374585151672
show O O 0.9999972581863403
that O O 0.9999985694885254
CD28 S-protein S-protein 0.9739960432052612
ligation O O 0.9915822148323059
leads O O 0.9999661445617676
to O O 0.9999954700469971
the O O 0.9999662637710571
rapid O O 0.980686366558075
intracellular O O 0.9740061163902283
formation O O 0.9970301389694214
of O O 0.9999698400497437
reactive O O 0.8270047903060913
oxygen O O 0.6301613450050354
intermediates O O 0.5155187249183655
( O O 0.9982105493545532
ROIs O O 0.5264379382133484
) O O 0.9958627223968506
which O O 0.9999662637710571
are O O 0.9999899864196777
required O O 0.9999479055404663
for O O 0.9999699592590332
CD28 S-protein S-protein 0.9947861433029175
-mediated O O 0.9962109327316284
activation O O 0.9984999895095825
of O O 0.999971866607666
the O O 0.9997797608375549
NF-kappa B-protein B-protein 0.7334058284759521
B E-protein E-protein 0.9113659858703613
/ O O 0.9374005198478699
CD28-responsive B-protein B-protein 0.501759946346283
complex E-protein E-protein 0.9607083797454834
and O O 0.990670919418335
IL-2 S-protein S-protein 0.9766545295715332
expression O O 0.9980133771896362
. O O 0.9999946355819702
Delineation O O 0.9768165946006775

substrates E-protein O 0.7901679873466492
is O O 0.9997190833091736
often O O 0.9999709129333496
uncertain O O 0.999648928642273
. O O 0.9999980926513672
A O O 0.9993763566017151
mutant B-cell_line B-cell_line 0.46726199984550476
T I-cell_line I-cell_line 0.7204337120056152
cell I-cell_line I-cell_line 0.9120582938194275
line E-cell_line E-cell_line 0.9945797920227051
was O O 0.9991506338119507
isolated O O 0.9976977705955505
that O O 0.9999909400939941
lacked O O 0.9996951818466187
expression O O 0.9973757266998291
of O O 0.9998477697372437
SLP-76 S-protein S-protein 0.86309415102005
( O O 0.9240809082984924
SH2 B-protein B-protein 0.6298645734786987
domain-containing I-protein I-protein 0.6053468585014343
leukocyte I-protein I-protein 0.8742920756340027
protein E-protein E-protein 0.9513738751411438
of O O 0.9281644225120544

specific O O 0.9500293135643005
nuclear O B-protein 0.857495903968811
RA B-protein I-protein 0.540791392326355
receptors E-protein E-protein 0.9970406889915466
( O O 0.9924066662788391
RARs S-protein S-protein 0.9802037477493286
) O O 0.9926871061325073
. O O 0.9999585151672363
RARs S-protein S-protein 0.8624805212020874
are O O 0.9994009733200073
members O O 0.9943495392799377
of O O 0.999942421913147
the O O 0.9999368190765381
steroid/thyroid B-protein B-protein 0.44080349802970886
hormone I-protein I-protein 0.7768926620483398
receptor I-protein I-protein 0.5310125946998596
superfamily E-protein E-protein 0.9623880386352539
and O O 0.9924275279045105
exhibit O O 0.9984263181686401
a O O 0.9999337196350098
molecular O O 0.8937479853630066
structure O O 0.8351831436157227
that O O 0.9999071359634399
possess O O 0.9998248219490051
discrete O O 0.781659722328186
DNA-binding O O 0.5065264701843262
and O O 0.9637522101402283
RA B-protein O 0.7767856121063232
( I-protein O 0.9795196056365967
ligand I-protein O 0.7368258237838745

of O O 0.9926290512084961

cascade O O 0.7092182636260986
. O O 0.9995208978652954
In O O 0.9999831914901733
this O O 0.9998912811279297
system O O 0.9960528612136841
, O O 0.9999849796295166
late O O 0.9481720328330994
gene O O 0.7955441474914551
expression O O 0.9968976974487305
is O O 0.9999926090240479
sensitive O O 0.9985937476158142
to O O 0.9999674558639526
inhibitors O O 0.9732969403266907
of O O 0.9996893405914307
the O O 0.9994435906410217

Three O O 0.9983200430870056
yr O O 0.9837366938591003
after O O 0.999750554561615
transplantation O O 0.9759352207183838
she O O 0.9997422099113464
developed O O 0.9967977404594421
renal B-Disease O 0.8327999114990234
Fanconi I-Disease O 0.6069861650466919
syndrome I-Disease O 0.9664316177368164
with O O 0.9908053874969482
severe O O 0.9586102962493896
metabolic B-Disease O 0.691692054271698
acidosis I-Disease O 0.9104112982749939
, O O 0.9445216059684753
hypophosphatemia B-Disease B-Disease 0.9629831910133362
, O O 0.9316869974136353
glycosuria B-Disease B-Disease 0.9361770749092102
, O O 0.8946306705474854
and O O 0.9969280362129211
aminoaciduria B-Disease B-Chemical 0.5268521308898926
. O O 0.9976906776428223

Affinity O O 0.6011523008346558
profiles O O 0.965238630771637
of O O 0.9998977184295654
( O O 0.9995338916778564
+ O O 0.9999452829360962
/ O O 0.9999696016311646
- O O 0.9991039633750916
) O O 0.9991121888160706
- O O 0.9985721111297607
PG B-Chemical B-Chemical 0.9372461438179016
- I-Chemical I-Chemical 0.9828006029129028
9 E-Chemical I-Chemical 0.9557103514671326
for O O 0.5997231006622314
muscarinic O O 0.49143368005752563
receptor O O 0.7517576217651367
subtypes O O 0.7877942323684692
, O O 0.9999281167984009
determined O O 0.9999791383743286
by O O 0.9999908208847046
functional O O 0.990183413028717
studies O O 0.9982251524925232
( O O 0.9999914169311523
rabbit O O 0.8952933549880981
vas O O 0.9033803343772888
deferens O O 0.8144369125366211
for O O 0.9992387294769287
M1 O O 0.6449674963951111
, O O 0.9985073208808899
guinea O O 0.9605514407157898
pig O O 0.9832873344421387
atrium O O 0.8641718626022339
for O O 0.9996659755706787
M2 O O 0.6191271543502808
, O O 0.9986504912376404
guinea O O 0.9615270495414734
pig O O 0.976294219493866
ileum O O 0.9319796562194824
for O O 0.9998656511306763
M3 O O 0.5895565748214722
and O O 0.9965221881866455
immature O O 0.9375302195549011
guinea O O 0.8796076774597168
pig O O 0.9282870292663574
uterus O O 0.7846910357475281
for O O 0.9998311996459961
putative O O 0.8693146109580994
M4 O O 0.5032496452331543
) O O 0.9951130747795105
, O O 0.9999804496765137
have O O 0.9999942779541016
shown O O 0.9999934434890747
an O O 0.9999395608901978
M4 O O 0.7417625188827515
/ O O 0.9950409531593323
M1 O O 0.6763135194778442
selectivity O O 0.7930597066879272
ratio O O 0.9957772493362427
of O O 0.9998881816864014
10 O O 0.996466875076294
. O O 0.9999500513076782
2 O O 0.9828001260757446
that O O 0.9998979568481445
might O O 0.9999927282333374
be O O 0.9999904632568359
responsible O O 0.9998782873153687
for O O 0.9999727010726929
the O O 0.9998706579208374
antinociception O O 0.6019936203956604
and O O 0.9976867437362671
the O O 0.9999324083328247
anti O O 0.9303938746452332
- O O 0.9889732003211975
amnesic O O 0.5162675976753235
effect O O 0.8739091753959656
induced O O 0.9983406066894531
by O O 0.9999736547470093
( O O 0.9989416003227234
+ O O 0.9999463558197021
/ O O 0.9999654293060303
- O O 0.9991750121116638
) O O 0.9987074136734009
- O O 0.9991275668144226
PG B-Chemical B-Chemical 0.9244487881660461
- I-Chemical I-Chemical 0.9817480444908142
9 E-Chemical I-Chemical 0.9493297338485718
through O O 0.991375744342804
an O O 0.999946117401123
increase O O 0.9753794074058533
in O O 0.9943169951438904
acetylcholine S-Chemical B-Chemical 0.9258607029914856
extracellular O O 0.4068346619606018
levels O O 0.9479049444198608
. O O 0.9999939203262329

ER+ I-cell_line B-cell_line 0.5938594341278076
and I-cell_line I-cell_line 0.6819869875907898
ER- I-cell_line I-cell_line 0.3722882568836212
cells E-cell_line E-cell_line 0.5522406101226807
. O O 0.9996525049209595
These O O 0.9999957084655762
in O O 0.999596893787384
vitro O O 0.9934519529342651
results O O 0.9991100430488586
provide O O 0.9999977350234985
a O O 0.9999948740005493
preclinical O O 0.9599253535270691
rationale O O 0.9493033289909363
for O O 0.9999359846115112
in O O 0.9999076128005981
vivo O O 0.9893524646759033
testing O O 0.9995222091674805
of O O 0.9999878406524658
TAM O S-protein 0.47557950019836426
, O O 0.9661055207252502
interleukin-2 S-protein S-protein 0.9273852109909058
( O O 0.9810994267463684
IL-2 S-protein S-protein 0.9807552099227905
) O O 0.9683103561401367
, O O 0.9991807341575623
and O O 0.9996479749679565
breast O B-protein 0.7960494160652161
cancer O I-protein 0.7247037887573242
reactive O I-protein 0.8596213459968567
antibody-dependent O I-protein 0.8343679904937744
cellular O I-protein 0.8340497612953186
cytotoxicity O I-protein 0.6716206073760986
facilitating O I-protein 0.8985569477081299
antibody O E-protein 0.8330824375152588
in O O 0.9983629584312439
patients O O 0.9997691512107849
with O O 0.999983549118042
refractory O O 0.6306456923484802
or O O 0.921196699142456

in O O 0.999119222164154
robust O O 0.9300230741500854
tyrosine O O 0.8814985156059265
phosphorylation O O 0.9732752442359924
of O O 0.9996671676635742
CD28 S-protein S-protein 0.9190665483474731
itself O O 0.9138377904891968
, O O 0.9998798370361328
ligation O O 0.9912751913070679
with O O 0.9998204112052917
CHO-CD86 S-protein S-protein 0.8738346099853516
was O O 0.9994282126426697
unable O O 0.9999023675918579
to O O 0.9999864101409912
induce O O 0.9999604225158691
detectable O O 0.9771637916564941
CD28 S-protein S-protein 0.7824469208717346
tyrosyl O O 0.6374264359474182
phosphorylation O O 0.9604532122612
over O O 0.9999481439590454
a O O 0.9999431371688843
range O O 0.9987045526504517
of O O 0.9996638298034668
stimulation O O 0.9717214703559875
conditions O O 0.9984914064407349
. O O 0.9999983310699463
In O O 0.9991891980171204

of O O 0.9957054257392883
NF-kappa B-protein B-protein 0.6941657066345215
B E-protein E-protein 0.9813259840011597
[ O O 0.9892032742500305
published O O 0.976523220539093
erratum O O 0.8677554130554199
appears O O 0.999561607837677
in O O 0.9999898672103882
Science O O 0.9661328792572021
1993 O O 0.9982718229293823
Mar O O 0.9772195219993591
12 O O 0.9798262715339661
; O O 0.9999765157699585
259 O O 0.981094479560852
( O O 0.9997801184654236
5101 O O 0.9918666481971741
) O O 0.9995318651199341
: O O 0.999890923500061
1523 O O 0.9888323545455933
] O O 0.9998924732208252
Mice O O 0.7593881487846375
transgenic O O 0.7307235598564148

expression O O 0.98740154504776
by O O 0.9999837875366211
cytokines S-protein S-protein 0.987324595451355
or O O 0.9996857643127441
DEX O O 0.5047505497932434
may O O 0.9996101260185242
lead O O 0.9999868869781494
to O O 0.9999716281890869
cell O O 0.9735924601554871
survival O O 0.9965291619300842
or O O 0.9999229907989502

or I-DNA O 0.953532338142395
jun-D I-DNA B-DNA 0.3085632622241974
expression I-DNA I-DNA 0.5417100191116333
vectors E-DNA E-DNA 0.9845921397209167
, O O 0.9979285001754761
which O O 0.9999669790267944
augmented O O 0.992088794708252
GR S-protein S-protein 0.8017750978469849
-dependent O O 0.99437415599823
transcription O O 0.971470057964325
from O O 0.9999017715454102
either O O 0.9997641444206238
MMTV B-DNA B-DNA 0.5393695831298828
LTR E-DNA E-DNA 0.9780028462409973
or O O 0.995570957660675
GRE S-DNA S-DNA 0.9928446412086487
. O O 0.9996016621589661
Conversely O O 0.9964694976806641
, O O 0.9988741278648376
c-jun S-protein S-DNA 0.9218701124191284
and O O 0.9848054051399231
jun-B S-protein O 0.39630913734436035
transfection O O 0.6583788990974426
blunted O O 0.993470311164856
GR S-protein S-protein 0.3996551036834717

Lipopolysaccharide B-Chemical B-Chemical 0.9139310121536255
pretreatment O O 0.8365521430969238
did O O 0.999908447265625
not O O 0.9999699592590332
affect O O 0.9999860525131226
the O O 0.9997401833534241
basal O O 0.969613254070282
body O O 0.9686592817306519
temperature O O 0.9211034774780273
or O O 0.9999140501022339
methamphetamine B-Chemical B-Chemical 0.9181679487228394
- O O 0.9640356302261353
elicited O O 0.9908549785614014
hyperthermia B-Disease B-Disease 0.9862110018730164
three O O 0.9863125681877136
days O O 0.9999309778213501
later O O 0.9999936819076538
. O O 0.9999991655349731

1 O O 0.3383503556251526
and O O 0.7326713800430298
2 O O 0.5249581933021545
have O O 0.9980181455612183
a O O 0.9999098777770996
serine-rich B-protein B-DNA 0.6208117008209229
region E-protein E-DNA 0.6128819584846497
and O O 0.9969626069068909
an O O 0.9998929500579834
`` O B-DNA 0.7714650630950928
arginine B-protein I-DNA 0.383955180644989
element E-protein I-DNA 0.890652596950531
`` O E-DNA 0.9038705229759216
( O O 0.9859234094619751
RRLPIF S-protein S-DNA 0.9760246872901917
) O O 0.9753769040107727
at O O 0.9999792575836182

Warfarin B-Chemical B-Chemical 0.9174060821533203
- O O 0.9556873440742493
induced O O 0.9985395669937134
iliopsoas O B-Disease 0.8510915040969849
hemorrhage B-Disease I-Disease 0.8916952610015869
with O O 0.9805139899253845
subsequent O O 0.9893636703491211
femoral B-Disease O 0.7588008642196655
nerve I-Disease O 0.4927663505077362
palsy I-Disease O 0.9384778738021851
. O O 0.9986491799354553

Histological O O 0.6887288689613342
studies O O 0.9839110374450684
demonstrated O O 0.9999624490737915
that O O 0.9999840259552002
the O O 0.9994590878486633
rats O O 0.9875685572624207
developed O O 0.999721348285675
an O O 0.9999287128448486
infarct O O 0.6182245016098022
18 O O 0.9331041574478149
h O O 0.7998031377792358
after O O 0.9987401366233826
isoproterenol S-Chemical B-Chemical 0.9306804537773132
administration O O 0.9786954522132874
. O O 0.9999948740005493

binding O O 0.8781636953353882
of O O 0.9954795837402344
STAT5 S-protein S-protein 0.9783875942230225
to O O 0.9997513890266418
the O O 0.9999445676803589
high-affinity O B-DNA 0.6890364289283752
IFP53 O I-DNA 0.30900391936302185
GAS O I-DNA 0.577975332736969
site O E-DNA 0.975886344909668
. O O 0.9996059536933899
IFN-alpha S-protein S-protein 0.9600887298583984
enhanced O O 0.9965543746948242
tyrosine O O 0.9045041799545288
phosphorylation O O 0.9641425609588623
of O O 0.9987817406654358
STAT1 O S-protein 0.9024347066879272

. O O 0.9927403330802917
For O O 0.9999827146530151
this O O 0.9999788999557495
purpose O O 0.9994599223136902
, O O 0.9999954700469971
we O O 0.9999136924743652
transiently O O 0.8740363121032715
transfected O O 0.935360312461853
Jurkat B-cell_line B-cell_line 0.6679158806800842
T I-cell_line I-cell_line 0.8422622680664062
cells E-cell_line E-cell_line 0.9773634672164917
with O O 0.9999058246612549
the O O 0.999954104423523
reporter B-DNA B-DNA 0.5453481078147888
plasmid I-DNA I-DNA 0.6818282008171082
p I-DNA I-DNA 0.5232913494110107
[ I-DNA I-DNA 0.5931987762451172
( I-DNA I-DNA 0.7742086052894592
TRE I-DNA I-DNA 0.5761635899543762
) I-DNA I-DNA 0.47792676091194153

involved O O 0.9936741590499878
in O O 0.9998321533203125
cell O O 0.9789244532585144
transformation O O 0.996468186378479
, O O 0.9999737739562988
interferes O O 0.9991241097450256
with O O 0.9999877214431763
the O O 0.999954104423523
cellular O O 0.9496684074401855
response O O 0.9799304008483887
to O O 0.9995138645172119
type B-protein B-protein 0.7339232563972473
I I-protein I-protein 0.7869793176651001
interferons E-protein E-protein 0.9825992584228516
( O O 0.9907751679420471
IFN-alpha/beta S-protein S-protein 0.9783154726028442
) O O 0.9859311580657959
. O O 0.999981164932251
We O O 0.9999783039093018
investigated O O 0.9999743700027466
the O O 0.9999548196792603
function O O 0.9909266233444214

family E-protein E-protein 0.8895685076713562
. O O 0.9990248680114746
To O O 0.9999953508377075
analyze O O 0.9999790191650391
the O O 0.9999792575836182
effects O O 0.9999312162399292
of O O 0.9999879598617554
ectopic O O 0.9527142643928528
expression O O 0.9949029684066772
of O O 0.9998818635940552
spi-1 S-protein S-protein 0.8880432844161987
on O O 0.9993191957473755
the O O 0.9998040795326233
proliferation/differentiation O O 0.9172981381416321
of O O 0.9993818998336792
human B-cell_type B-cell_type 0.4596252739429474
myeloid I-cell_type I-cell_type 0.6756870150566101
leukemia I-cell_type I-cell_type 0.6981112360954285
cells E-cell_type E-cell_type 0.7288570404052734
, O O 0.9992519021034241
K562 B-cell_line B-cell_line 0.7334912419319153
cells E-cell_line E-cell_line 0.9945476651191711
were O O 0.9997022747993469
stably O O 0.9993896484375
transfected O O 0.9987169504165649
with O O 0.9999945163726807
a O O 0.9996623992919922
spi-1 B-DNA B-DNA 0.29002150893211365

On O O 0.9996211528778076
the O O 0.9999686479568481
13th O O 0.9984207153320312
day O O 0.9999651908874512
, O O 0.9999850988388062
antinociceptive O O 0.40999212861061096
effects O O 0.9475347995758057
were O O 0.999961256980896
assessed O O 0.9999856948852539
using O O 0.9999951124191284
a O O 0.9999312162399292
model O O 0.9991705417633057
of O O 0.9999618530273438
inflammatory O O 0.7240346074104309
nociception O O 0.8125706315040588
, O O 0.9909688830375671
pain B-Disease O 0.9001863598823547
- O O 0.9072234630584717
induced O O 0.9766953587532043
functional O O 0.9324126243591309
impairment O O 0.5972036719322205
model O O 0.8358263373374939
, O O 0.9995487332344055
and O O 0.9999850988388062
the O O 0.9999784231185913
charcoal B-Chemical O 0.42960771918296814
meal O O 0.9194632172584534
test O O 0.9968926310539246
was O O 0.9999914169311523
used O O 0.9999935626983643
to O O 0.9999970197677612
evaluate O O 0.9999794960021973
the O O 0.9998382329940796
intestinal O O 0.8748979568481445
transit O O 0.7347161173820496
. O O 0.9999778270721436

and O O 0.9674184322357178
cytokine S-protein S-protein 0.7095085978507996
responsiveness O O 0.9849749207496643
concerned O O 0.9999587535858154
both O O 0.9999828338623047
Y701 S-protein O 0.48805752396583557
and O O 0.9900432825088501
S727 B-protein O 0.5832614898681641
STAT1 E-protein S-protein 0.605922520160675
phosphorylation O O 0.8906441926956177
. O O 0.9998571872711182
Exogenous O O 0.9391322135925293
addition O O 0.9946202039718628
of O O 0.9998238682746887
transforming B-protein B-protein 0.7145662903785706
growth I-protein I-protein 0.4105833172798157
factor-beta E-protein E-protein 0.9084713459014893
, O O 0.9604899287223816
which O O 0.9998607635498047
exerts O O 0.9999098777770996
an O O 0.9998675584793091
inhibitory O O 0.8178334832191467

signals O O 0.8377009034156799
that O O 0.9999089241027832
control O O 0.9995287656784058
the O O 0.9998834133148193
development O O 0.9991384744644165
of O O 0.9999771118164062
the O O 0.9999316930770874
tissues O O 0.967498779296875
and O O 0.9983812570571899
that O O 0.9999222755432129
maintain O O 0.9996227025985718
the O O 0.9999192953109741
organized O O 0.9395942091941833
tissue O O 0.9139163494110107
microenvironment O O 0.9405142068862915
remain O O 0.9999436140060425
undefined O O 0.9980574250221252
. O O 0.9999982118606567
Studies O O 0.9999285936355591
over O O 0.9999933242797852
the O O 0.9999468326568604
past O O 0.9996898174285889
few O O 0.9996800422668457

) O O 0.782411515712738
treatment O O 0.9937114715576172
increased O O 0.9996942281723022
AP-1 S-protein S-protein 0.7923938035964966
and O O 0.9846359491348267
NF O B-protein 0.338925302028656
kappa O I-protein 0.43070995807647705
B O E-protein 0.9272196292877197
DNA O O 0.8043619394302368
binding O O 0.9884827733039856
by O O 0.999981164932251
up O O 0.9991613626480103
to O O 0.9997156262397766
200 O O 0.9940959215164185

year O O 0.9808589816093445
period O O 0.9999257326126099
in O O 0.9999867677688599
high O O 0.9649032354354858
risk O O 0.9894706010818481
women O O 0.9985814094543457
are O O 0.9999974966049194
needed O O 0.9999735355377197
but O O 0.9999809265136719
currently O O 0.9999332427978516

without O O 0.9967669248580933
the O O 0.9999679327011108
characteristic O O 0.9882091283798218
decline O O 0.9698099493980408
in O O 0.9988991022109985
barrier O O 0.918956995010376
function O O 0.9597356915473938
seen O O 0.9997928738594055
in O O 0.9999653100967407
polarized O O 0.5208007097244263
monolayers O O 0.6548161506652832
treated O O 0.9954458475112915
with O O 0.9999951124191284
the O O 0.9996899366378784
proinflammatory B-protein B-protein 0.6507329940795898
cytokine I-protein I-protein 0.786345899105072
gamma-IFN E-protein E-protein 0.7242140173912048
, O O 0.9960638880729675
facilitates O O 0.9996633529663086
antigen O O 0.8756535649299622
processing O O 0.9875605702400208
from O O 0.9999750852584839
the O O 0.9998626708984375
basolateral O O 0.7222766876220703
surface O O 0.8006190061569214
. O O 0.9999146461486816

, O O 0.9580179452896118
rapamycin-sensitive O O 0.8517501354217529
pathways O O 0.9897977113723755
in O O 0.9999803304672241
the O O 0.999954104423523
control O O 0.9933271408081055
of O O 0.9999126195907593
T-cell O O 0.6059869527816772
cycle O O 0.8358160853385925
progression O O 0.9928036332130432
. O O 0.9999964237213135
The O O 0.9999978542327881
present O O 0.9945927262306213
results O O 0.9997840523719788
thus O O 0.9999926090240479
show O O 0.9999954700469971
that O O 0.9999946355819702
p70 B-protein B-protein 0.8529506921768188
( I-protein I-protein 0.6989307403564453
s6k I-protein I-protein 0.8298521637916565
) E-protein E-protein 0.9897376894950867
is O O 0.9990637898445129
able O O 0.9999889135360718
to O O 0.9999943971633911
regulate O O 0.9997430443763733
E2F S-protein S-protein 0.960929274559021
transcriptional O O 0.9660218358039856
activity O O 0.9977263808250427
and O O 0.9999774694442749
provide O O 0.9999902248382568
direct O O 0.9980619549751282
evidence O O 0.9999597072601318
for O O 0.9999955892562866
the O O 0.9999827146530151
first O O 0.9987027645111084
time O O 0.9998792409896851
for O O 0.9999948740005493
a O O 0.9999728202819824
link O O 0.9978748559951782
between O O 0.9998327493667603
IL-2 S-protein B-protein 0.7896357178688049
receptors O E-protein 0.9696431756019592
, O O 0.9985167384147644
PI B-protein B-protein 0.6907310485839844
3-kinase E-protein E-protein 0.9856250882148743
, O O 0.9843652248382568
and O O 0.9979482293128967
p70 B-protein B-protein 0.8074218034744263
( I-protein I-protein 0.5701006054878235
s6k I-protein I-protein 0.683021605014801
) E-protein E-protein 0.9814372062683105
that O O 0.9989963173866272
regulates O O 0.9999427795410156
a O O 0.9999358654022217
crucial O O 0.972620964050293
G1 O O 0.37611332535743713
checkpoint O O 0.3480968773365021
in O O 0.9931846261024475
T B-cell_type B-cell_type 0.7170388698577881
lymphocytes E-cell_type E-cell_type 0.9935933947563171
. O O 0.9998067021369934
Oxidative O O 0.9576718807220459
stress O O 0.9828523993492126
triggers O O 0.9998101592063904
STAT3 S-protein S-protein 0.8852289915084839
tyrosine O O 0.8213289380073547
phosphorylation O O 0.9777366518974304
and O O 0.9997431635856628
nuclear O O 0.8900638818740845
translocation O O 0.9169605374336243
in O O 0.9996039271354675
human B-cell_type B-cell_type 0.7885070443153381
lymphocytes E-cell_type E-cell_type 0.9899916648864746
. O O 0.9997585415840149
Oxidizing O O 0.9164151549339294
agents O O 0.9499825239181519
are O O 0.9999868869781494
powerful O O 0.966925859451294
activators O O 0.8286781907081604
of O O 0.9979787468910217
factors O O 0.9340670704841614
responsible O O 0.9998264908790588
for O O 0.9999924898147583
the O O 0.9999639987945557
transcriptional O O 0.923751711845398
activation O O 0.9719803929328918

hypertension O O 0.8580621480941772
and O O 0.9996743202209473
low O O 0.9891098737716675
renin S-protein S-protein 0.6585816144943237
activity O O 0.9956081509590149
, O O 0.9999899864196777
which O O 0.9999896287918091
others O O 0.9999837875366211
have O O 0.9999897480010986
described O O 0.9999843835830688
in O O 0.9999818801879883
patients O O 0.999859094619751
with O O 0.9999791383743286
primary O O 0.7714138627052307
glucocorticoid O O 0.6494112610816956

the O O 0.9922502636909485
gene O O 0.919235348701477
, O O 0.9995952248573303
only O O 0.9999622106552124
a O O 0.9998910427093506
subset O O 0.9902532696723938
of O O 0.9998478889465332
myocytes O S-cell_type 0.9505833387374878
within O O 0.9993994235992432
each O O 0.9998855590820312
muscle O O 0.7845202088356018
were O O 0.9974415302276611
positive O O 0.9834985136985779
, O O 0.9998130202293396
indicating O O 0.9999221563339233
molecular O O 0.8924593925476074
heterogeneity O O 0.8668535947799683
within O O 0.9997240900993347
fetal O O 0.7386044859886169
muscle O O 0.7442070245742798
. O O 0.9998376369476318
Copyright O O 0.9452799558639526

Support O O 0.9933651089668274
of O O 0.9995074272155762
the O O 0.9998800754547119
arm O O 0.8233891725540161
decreased O O 0.9815282821655273
tremor B-Disease O 0.8621116876602173
severity O O 0.7699739933013916
, O O 0.9946678876876831
exhaustion O O 0.845228910446167
increased O O 0.8873382806777954
tremor B-Disease O 0.8705325126647949
severity O O 0.7478688955307007
significantly O O 0.9845107793807983
. O O 0.9999954700469971

unaffected O O 0.9821124076843262
by O O 0.9999593496322632
any O O 0.9999785423278809
of O O 0.9999732971191406
the O O 0.9999699592590332
molecules O O 0.9603873491287231
tested O O 0.9998701810836792
. O O 0.999997615814209
Both O O 0.9997842907905579
PPAR-alpha B-RNA S-protein 0.6124147176742554

Although O O 0.999845027923584
the O O 0.9999474287033081
intraocular O O 0.860706627368927
pressure O O 0.6202573180198669
elevation O O 0.78984534740448
caused O O 0.9994644522666931
by O O 0.9999394416809082
secondary O O 0.9828127026557922
acute O O 0.9404619336128235
angle O O 0.7723116874694824
- O O 0.9900252819061279
closure O O 0.9493125677108765
glaucoma B-Disease B-Disease 0.9119911789894104
decreased O O 0.8566208481788635
and O O 0.9966678023338318
ocular B-Disease O 0.7309024333953857
pain I-Disease O 0.4993418753147125
diminished O O 0.4732166826725006
, O O 0.9945206642150879
inexorable O O 0.8687214255332947
papilledema B-Disease O 0.8705195784568787
and O O 0.9708173871040344
exudative O O 0.9127587676048279
retinal B-Disease O 0.7942807078361511
detachment I-Disease O 0.820303738117218
continued O O 0.989236056804657
for O O 0.9999755620956421
3 O O 0.9996732473373413
weeks O O 0.9999662637710571
. O O 0.9999990463256836

beta I-RNA I-RNA 0.851427435874939
mRNA E-RNA E-RNA 0.9917075037956238
in O O 0.9995280504226685
response O O 0.9979650974273682
to O O 0.9999778270721436
LPS O O 0.9670519232749939
. O O 0.9999790191650391
Preincubation O O 0.9871194362640381
of O O 0.9993601441383362
cells O O 0.9561917185783386
with O O 0.9999583959579468
1 O O 0.8848289847373962
, O O 0.9871254563331604
25- O O 0.993257999420166
( O O 0.9992498755455017
OH O O 0.9760051369667053
) O O 0.9977693557739258
2D3 O O 0.9664533138275146
augmented O O 0.9983478784561157
IL-1 B-RNA B-RNA 0.5388708710670471
beta I-RNA I-RNA 0.5382660627365112
mRNA E-RNA E-RNA 0.879749059677124
levels O O 0.9938157796859741
only O O 0.9999536275863647
in O O 0.9991963505744934
U-937 S-cell_line S-cell_line 0.9783516526222229
and O O 0.9530397057533264
HL-60 S-cell_line B-cell_line 0.6620689034461975
cells O E-cell_line 0.9906636476516724
. O O 0.9995436072349548
From O O 0.9994959831237793

97 O O 0.8877344727516174
relatively O O 0.9870577454566956
young O O 0.9859161972999573
( O O 0.9992668032646179
18- O O 0.995144784450531
to O O 0.998599112033844
35-year-old O O 0.993656575679779
) O O 0.9986724853515625
healthy O O 0.9606015682220459
female O O 0.9737886786460876
volunteers O O 0.9922091960906982
. O O 0.9999978542327881
We O O 0.9999582767486572
found O O 0.9999873638153076

Intrarenal O O 0.5037383437156677
infusion O O 0.8700650930404663
of O O 0.9967124462127686
noradrenaline B-Chemical B-Chemical 0.931988000869751
caused O O 0.996976375579834
hypertension B-Disease B-Disease 0.9722512364387512
at O O 0.9772547483444214
doses O O 0.9943498969078064
which O O 0.9998949766159058
did O O 0.9999667406082153
not O O 0.9997350573539734
do O O 0.9999234676361084
so O O 0.999609649181366
when O O 0.9999393224716187
infused O O 0.8692611455917358
intravenously O O 0.9453848600387573
. O O 0.9999879598617554

FTOC O O 0.5338639616966248
infected O O 0.9683353900909424
with O O 0.9999523162841797
a O O 0.9997703433036804
control O O 0.9478134512901306
virus O O 0.9639173150062561
. O O 0.9999572038650513
Taken O O 0.9999778270721436
together O O 0.9999897480010986
, O O 0.9999970197677612
these O O 0.9999861717224121
results O O 0.9999600648880005
suggest O O 0.9999984502792358
that O O 0.9999921321868896
NF-kappa B-protein B-protein 0.750134289264679
B E-protein E-protein 0.9945026636123657
plays O O 0.9997764229774475
a O O 0.9999938011169434
crucial O O 0.9992120265960693
role O O 0.9998188614845276
in O O 0.9999784231185913
ensuring O O 0.9998272061347961

In O O 0.999697208404541
35 O O 0.9981303811073303
patients O O 0.9995484948158264
( O O 0.9999878406524658
ages O O 0.9999537467956543
20 O O 0.9999549388885498
to O O 0.9998621940612793
86 O O 0.999495267868042
yr O O 0.998897910118103
) O O 0.9992067217826843
receiving O O 0.9999076128005981
cimetidine B-Chemical B-Chemical 0.9312589168548584
therapeutically O O 0.9705302119255066
two O O 0.9998273253440857
serum O O 0.9857171773910522
samples O O 0.9942122101783752
and O O 0.9999915361404419
all O O 0.999863862991333
urine O O 0.7445497512817383
formed O O 0.9986733198165894
in O O 0.9999902248382568
the O O 0.9999728202819824
interim O O 0.9987955093383789
were O O 0.9999959468841553
collected O O 0.9999853372573853
for O O 0.9999971389770508
analysis O O 0.9935122132301331
of O O 0.9997538924217224
cimetidine B-Chemical B-Chemical 0.9328426718711853
by O O 0.9990553259849548
high O O 0.9819840788841248
- O O 0.9983031749725342
pressure O O 0.9666935801506042
liquid O O 0.76817387342453
chromatography O O 0.5165086388587952
and O O 0.9994871616363525
for O O 0.9999325275421143
creatinine B-Chemical B-Chemical 0.8800660371780396
. O O 0.9991733431816101

of O O 0.995495080947876
established O O 0.9218217134475708
Th2 O O 0.20081274211406708
responses O O 0.6726572513580322
, O O 0.9960903525352478
but O O 0.9995868802070618
only O O 0.9998233914375305
affecting O O 0.9987357258796692
newly O O 0.7608591318130493
recruited O O 0.8142691254615784
naive O B-cell_type 0.4094034433364868
Th B-cell_line I-cell_type 0.655156135559082
cells E-cell_line E-cell_type 0.90976881980896
. O O 0.9997076392173767
Cloning O O 0.9622606039047241
and O O 0.9976869821548462
expression O O 0.9992215633392334
of O O 0.9999722242355347
the O O 0.9997871518135071
Epstein-Barr B-protein B-protein 0.49359002709388733
virus-encoded I-protein I-protein 0.8309377431869507
dUTPase E-protein E-protein 0.5846234560012817
: O O 0.6527175903320312
patients O O 0.9795928001403809
with O O 0.999937891960144
acute O O 0.7420056462287903
, O O 0.9255712628364563

the O O 0.997826874256134
transcription B-DNA B-DNA 0.6913426518440247
start I-DNA I-DNA 0.4618566334247589
site E-DNA E-DNA 0.9830936193466187
( O O 0.9966517090797424
-7 O B-DNA 0.5754864811897278
to O I-DNA 0.6964855790138245
+13 O E-DNA 0.9638043642044067
) O O 0.9220939874649048
was O O 0.9999269247055054
capable O O 0.9999030828475952
of O O 0.9999563694000244
mediating O O 0.9845547080039978
transcription O O 0.8149187564849854
initiation O O 0.8645398616790771
and O O 0.9994494318962097
that O O 0.9999988079071045
an O O 0.999761164188385
IFN-gamma B-DNA B-DNA 0.566733181476593
responsive I-DNA I-DNA 0.684126079082489
element E-DNA E-DNA 0.9911762475967407
( O O 0.9908431768417358
GIRE S-DNA S-DNA 0.9978995323181152
) O O 0.9749476909637451
was O O 0.9998961687088013
present O O 0.999847412109375
within O O 0.9999617338180542
74 B-DNA B-DNA 0.7492420077323914
bp I-DNA I-DNA 0.43527814745903015
upstream E-DNA E-DNA 0.9078227281570435
of O O 0.9947618842124939
the O O 0.9998527765274048
transcription B-DNA B-DNA 0.5480829477310181
initiation I-DNA I-DNA 0.653122067451477
site E-DNA E-DNA 0.9781783223152161
. O O 0.9998780488967896
A O O 0.9996460676193237
17-bp B-DNA B-DNA 0.5962998867034912
sequence E-DNA E-DNA 0.9726362228393555
between O O 0.9970266222953796
positions O O 0.8641085028648376
-51 O O 0.5399048328399658
and O O 0.9194560050964355
-35 O O 0.5669348239898682
conferred O O 0.9772286415100098
IFN-gamma S-protein S-protein 0.658963680267334
responsiveness O O 0.8023672103881836
on O O 0.9996637105941772
a O O 0.9997078776359558
heterologous B-DNA B-DNA 0.6954783201217651
promoter E-DNA E-DNA 0.9878727197647095
. O O 0.9995032548904419
Double-stranded B-DNA O 0.8530128002166748
GIRE I-DNA B-DNA 0.2809179723262787
sequence E-DNA E-DNA 0.9651398062705994
, O O 0.9916316866874695
but O O 0.9996943473815918
not O O 0.9996742010116577
a O O 0.9990704655647278

may O O 0.9856941103935242

increased O O 0.98816978931427
expression O O 0.9989657402038574
of O O 0.9997369647026062
IL-2 B-RNA B-RNA 0.958825409412384
mRNA E-RNA E-RNA 0.9976251721382141
, O O 0.9966446161270142
resulting O O 0.9999890327453613
from O O 0.9999978542327881
enhanced O O 0.9902691841125488
IL-2 B-RNA B-RNA 0.5945733785629272
mRNA E-RNA E-RNA 0.9765245914459229
stability O O 0.9595692157745361
. O O 0.9999963045120239
In O O 0.9999896287918091
contrast O O 0.9998012185096741
to O O 0.9999924898147583
transcriptional O O 0.9583829641342163
activation O O 0.9956403970718384
in O O 0.9999566078186035
PBMC S-cell_type S-cell_type 0.9939017295837402
, O O 0.9995856881141663
EMSA O O 0.8806310892105103
revealed O O 0.9998873472213745
that O O 0.9999899864196777
CD28 S-protein S-protein 0.8994719982147217
coligation O O 0.9850214123725891
of O O 0.9996731281280518
CD2-activated B-cell_type B-cell_type 0.33706197142601013
LPMC E-cell_type E-cell_type 0.3735969364643097
does O O 0.9896747469902039
not O O 0.999818742275238

Nicoletti O O 0.8009206056594849
technique O O 0.971855640411377
demonstrating O O 0.9999730587005615
a O O 0.9999332427978516
subdiploid O O 0.7452720403671265
population O O 0.6148936748504639
by O O 0.9998117089271545
DNA O O 0.9439737796783447
staining O O 0.988965630531311
. O O 0.9999605417251587
RA O O 0.917972207069397
previously O O 0.9993728995323181
was O O 0.9999780654907227
found O O 0.9999434947967529
to O O 0.9999489784240723
inhibit O O 0.9990983009338379
granulocyte B-protein B-protein 0.6105033159255981
colony-stimulating I-protein I-protein 0.7593542337417603
factor E-protein E-protein 0.8791506290435791
-- O O 0.8793213367462158

on O O 0.9962136149406433
human B-cell_type B-cell_type 0.5453768968582153
neutrophils E-cell_type E-cell_type 0.9916422367095947
[ O O 0.9991291165351868
see O O 0.9996289014816284
comments O O 0.9965439438819885
] O O 0.9996562004089355
BACKGROUND O O 0.9978976249694824
: O O 0.9999942779541016
Recent O O 0.9997556805610657
studies O O 0.9999184608459473
have O O 0.9999982118606567
raised O O 0.9999610185623169
the O O 0.9998171925544739
hypothesis O O 0.9896844625473022
that O O 0.9999878406524658
glucocorticoids O O 0.8582510352134705
could O O 0.9999598264694214
diminish O O 0.999930739402771
the O O 0.9998726844787598
ability O O 0.9998446702957153
of O O 0.9999704360961914
endothelial B-cell_type B-cell_type 0.5703989267349243
cells E-cell_type E-cell_type 0.9843765497207642
to O O 0.9992595314979553
direct O O 0.9991264939308167
leukocyte O O 0.6654549837112427
traffic O O 0.9762791395187378
into O O 0.9999376535415649
inflamed O O 0.8772767782211304
tissues O O 0.9537038207054138
by O O 0.9999773502349854
inhibiting O O 0.9985815286636353
expression O O 0.9970815777778625
of O O 0.9998900890350342
the O O 0.9994750618934631
adhesion B-protein B-protein 0.5727752447128296
molecules E-protein E-protein 0.9506331086158752

with O O 0.9941409230232239
Tat S-protein S-protein 0.9628241062164307
to O O 0.9991505146026611
stimulate O O 0.9992800354957581
human O O 0.8201204538345337
immunodeficiency O O 0.8412925601005554
virus O O 0.8649312257766724
type O O 0.8504521250724792
1 O O 0.8937302827835083
transcription O O 0.9212517738342285
. O O 0.9997569918632507
NF-kappa B-protein B-protein 0.850651741027832
B E-protein E-protein 0.9898368716239929
is O O 0.9997288584709167
a O O 0.999981164932251
protein B-protein O 0.7858937382698059

for O O 0.9957618117332458
xanthine B-protein B-protein 0.8878191709518433
oxidase E-protein E-protein 0.9634122848510742
and O O 0.9968850016593933
H2O2 O O 0.42555028200149536
. O O 0.999561607837677
In O O 0.9999032020568848
comparison O O 0.9977272152900696
, O O 0.9998027682304382
platelet B-protein B-protein 0.6728963255882263
activating I-protein I-protein 0.5787571668624878
factor E-protein E-protein 0.9395946264266968
( O O 0.9264894723892212
PAF S-protein S-protein 0.9545810222625732
) O O 0.9447026252746582
contributed O O 0.999603807926178
to O O 0.9998204112052917

with O O 0.9946032166481018
Stat3 S-protein S-protein 0.9866525530815125
or O O 0.9978043437004089
block O O 0.9871056079864502
Stat3 S-protein S-protein 0.9789611101150513
activation O O 0.9985128045082092
. O O 0.9999983310699463
These O O 0.9999960660934448
data O O 0.999679446220398
demonstrate O O 0.999995231628418
that O O 0.9999923706054688
Stat3 S-protein S-protein 0.9933046698570251
but O O 0.9979959726333618
not O O 0.9989287257194519
Stat1 S-protein S-protein 0.9873724579811096
or O O 0.9966913461685181
Stat5 S-protein S-protein 0.9916604161262512
is O O 0.9990090131759644
directly O O 0.9987362027168274
recruited O O 0.9999462366104126
to O O 0.9999935626983643
the O O 0.9998669624328613
ligand-activated B-protein B-protein 0.6072667241096497
IL-10 I-protein I-protein 0.580169677734375
receptor E-protein E-protein 0.9371460676193237
by O O 0.9970640540122986
binding O O 0.9482762217521667
to O O 0.9986976385116577
specific O O 0.9515202045440674
but O O 0.9864669442176819
redundant O O 0.8568205237388611
receptor B-protein O 0.464784175157547
intracellular I-protein O 0.5290694832801819

the O O 0.9987209439277649
induction O O 0.9973172545433044
of O O 0.9999330043792725
endothelial B-protein B-protein 0.6065855026245117
cell I-protein I-protein 0.34491342306137085
adhesion I-protein I-protein 0.7674404978752136
molecules E-protein E-protein 0.9955822825431824
by O O 0.9998311996459961
TNF S-protein S-protein 0.983852744102478
. O O 0.9998722076416016
Because O O 0.9999985694885254
of O O 0.9999880790710449
their O O 0.9999939203262329
role O O 0.9997850060462952
in O O 0.9999011754989624
cell O O 0.9815752506256104
adhesion O O 0.9959896206855774
, O O 0.9999889135360718
PTPase S-protein S-protein 0.9610679745674133
may O O 0.9999239444732666
provide O O 0.9999983310699463
a O O 0.999994158744812
novel O O 0.97104811668396
target O O 0.9676494002342224
of O O 0.9996911287307739
drug O O 0.9839423298835754
development O O 0.9991125464439392
for O O 0.9999958276748657
treatment O O 0.9991804957389832
of O O 0.9999730587005615
inflammation O O 0.9174311757087708
, O O 0.9996261596679688
atherogenesis O O 0.903717041015625
, O O 0.999016284942627
and O O 0.9996378421783447

immunodeficiency O O 0.8425533771514893
virus O O 0.8876923322677612
type O O 0.8861253261566162
1 O O 0.9057461619377136
( O O 0.997222900390625
HIV-1 O O 0.9058593511581421
) O O 0.99457186460495
in O O 0.999743640422821
human B-cell_type B-cell_type 0.6122422814369202
cells E-cell_type E-cell_type 0.9820069670677185
. O O 0.9995152950286865
During O O 0.999970555305481
inflammatory O O 0.945396900177002
reactions O O 0.9363608956336975
, O O 0.999972939491272
many O O 0.9997808337211609
oxidative O O 0.8655776977539062
species O O 0.8280275464057922
are O O 0.9998076558113098
produced O O 0.9996793270111084
, O O 0.9999853372573853
one O O 0.9999617338180542
of O O 0.9999920129776001
which O O 0.9999712705612183
is O O 0.9999308586120605
hypochlorous O O 0.9029040336608887
acid O O 0.9133059978485107
( O O 0.9990215301513672
HOCl O O 0.9236733317375183
) O O 0.9977115392684937
, O O 0.9999388456344604
which O O 0.9999668598175049
is O O 0.9999810457229614
responsible O O 0.9999804496765137
for O O 0.9999929666519165
the O O 0.9999526739120483
microbicidal O O 0.9178990721702576
effects O O 0.9984334111213684
of O O 0.9999538660049438
activated O O 0.7509018778800964
human B-cell_type B-cell_type 0.47396570444107056
polymorphonuclear I-cell_type I-cell_type 0.3870510756969452
leukocytes E-cell_type E-cell_type 0.8708855509757996
. O O 0.9998769760131836
Treatment O O 0.9997406601905823
of O O 0.9999403953552246
a O O 0.999402642250061
T-lymphocytic B-cell_line B-cell_line 0.46868932247161865
cell I-cell_line I-cell_line 0.7063408493995667

Binding O O 0.9227596521377563
of O O 0.9978356957435608
nicotine B-Chemical B-Chemical 0.9198910593986511
to O O 0.9974005222320557
nicotinic O O 0.4619646966457367
acetylcholine B-Chemical B-Chemical 0.8634142875671387
receptors O O 0.5143958330154419
( O O 0.9987626075744629
nAChRs O O 0.47146478295326233
) O O 0.9926415085792542
elicits O O 0.9998277425765991
a O O 0.9999620914459229
series O O 0.9991413354873657
of O O 0.9999287128448486
dose O O 0.996927797794342
- O O 0.9995860457420349
dependent O O 0.9933340549468994
behaviors O O 0.8409842252731323
that O O 0.9996262788772583
go O O 0.9999475479125977
from O O 0.9999841451644897
altered O O 0.8939521908760071
exploration O O 0.7026151418685913
, O O 0.9984094500541687
sedation O O 0.5576977729797363
, O O 0.9878466725349426
and O O 0.9984594583511353
tremors B-Disease B-Disease 0.9631471633911133
, O O 0.9846283197402954
to O O 0.9996576309204102
seizures B-Disease B-Disease 0.957643449306488
and O O 0.9714624285697937
death B-Disease B-Disease 0.9738195538520813
. O O 0.9987075328826904

The O O 0.9988476037979126
sG145R O O 0.6116847395896912
mutation O O 0.9185497760772705
strongly O O 0.9977988600730896
reduced O O 0.9964711666107178
HBsAg S-Chemical B-Chemical 0.9231643676757812
levels O O 0.9907291531562805
and O O 0.9999319314956665
was O O 0.9999529123306274
able O O 0.9999918937683105
to O O 0.9999768733978271
fully O O 0.999790370464325
restore O O 0.9994534850120544
the O O 0.9997403025627136
impaired O O 0.916700005531311
replication O O 0.8816623091697693
of O O 0.999113142490387
LAM S-Chemical B-Chemical 0.9247150421142578
- O O 0.9461103677749634
resistant O O 0.9949694275856018
HBV O O 0.5830849409103394
mutants O O 0.7490720748901367
to O O 0.9993764758110046
the O O 0.9997145533561707
levels O O 0.9995670914649963
of O O 0.9999536275863647
wild O O 0.8839677572250366
- O O 0.981968343257904
type O O 0.9782503247261047
HBV O O 0.5191999673843384
, O O 0.9937995076179504
and O O 0.9994903802871704
PC O O 0.4848048985004425
or O O 0.9889265298843384
BCP O O 0.6561954021453857
mutations O O 0.7910787463188171
further O O 0.9978353381156921
enhanced O O 0.9955227375030518
viral O O 0.8590947389602661
replication O O 0.665864109992981
. O O 0.9999818801879883

We O O 0.9992677569389343
present O O 0.9999936819076538
a O O 0.9999827146530151
case O O 0.9989902377128601
of O O 0.9999692440032959
paramedic O O 0.6021374464035034
misjudgment O O 0.8828238248825073
in O O 0.9949734210968018
the O O 0.9998879432678223
execution O O 0.9935303330421448
of O O 0.999919056892395
a O O 0.9999692440032959
protocol O O 0.9777855277061462
for O O 0.9999566078186035
the O O 0.9998773336410522
treatment O O 0.9997137188911438
of O O 0.9999743700027466
allergic B-Disease B-Disease 0.5778955817222595
reaction I-Disease I-Disease 0.9761359691619873
in O O 0.9679225087165833
a O O 0.9980145692825317
case O O 0.9904122948646545
of O O 0.9997612833976746
pulmonary B-Disease O 0.6275543570518494
edema I-Disease O 0.9600400328636169
with O O 0.969871997833252
wheezing B-Disease O 0.9063368439674377
. O O 0.9986072182655334

lymphocytes E-cell_type E-cell_type 0.8961769342422485
from O O 0.9997890591621399
39 O O 0.9934543371200562
MS O O 0.9650313258171082
patients O O 0.9986000657081604
and O O 0.9999649524688721
14 O O 0.9966589212417603
age- O O 0.9768325090408325
and O O 0.9931354522705078
sex-matched O O 0.9777880311012268
controls O O 0.9953599572181702
with O O 0.9999961853027344
respect O O 0.9991536140441895
to O O 0.9999608993530273
dissociation O O 0.9226710796356201
constant O O 0.973809003829956
and O O 0.9985613226890564

Delirium B-Disease O 0.9222755432128906
during O O 0.993524432182312
clozapine B-Chemical B-Chemical 0.9123066663742065
treatment O O 0.980813205242157
: O O 0.9999327659606934
incidence O O 0.9792863726615906
and O O 0.99969482421875
associated O O 0.9717085957527161
risk O O 0.9670591950416565
factors O O 0.8793684840202332
. O O 0.9999902248382568

in O O 0.9967610239982605

Clinical O O 0.9733093976974487
examinations O O 0.989981472492218
and O O 0.9999110698699951
skin O O 0.5700021982192993
, O O 0.9812310338020325
oral O O 0.9496082067489624
and O O 0.9808411002159119
parenteral O O 0.8374519348144531
challenges O O 0.9201453328132629
with O O 0.9999525547027588
different O O 0.999187171459198
corticosteroids S-Chemical O 0.7953813076019287
and O O 0.9930790066719055
ELISA O O 0.5502004623413086
tests O O 0.9781030416488647
were O O 0.9999818801879883
performed O O 0.9999808073043823
. O O 0.9999992847442627

In O O 0.9985045194625854
vehicle O O 0.9620614051818848
- O O 0.9969735145568848
treated O O 0.9908785223960876
rats O O 0.992476761341095
, O O 0.9999665021896362
status O B-Disease 0.5789938569068909
epilepticus O I-Disease 0.9272395372390747
caused O O 0.9896379709243774
pronounced O O 0.988944411277771
neuronal O O 0.7587364315986633
damage O O 0.9731590747833252
in O O 0.944659948348999
the O O 0.9833884239196777
piriform O O 0.7964708209037781
cortex O O 0.8728243112564087
comprising O O 0.9997715353965759
both O O 0.999811589717865
pyramidal O O 0.5377453565597534
cells O O 0.437736451625824
and O O 0.9970705509185791
interneurons O O 0.5778451561927795
. O O 0.9998992681503296

a O O 0.9989941716194153
common O O 0.978226363658905
multi-point O O 0.8869395852088928
Scatchard O O 0.6239597201347351
analysis O O 0.9920703768730164
. O O 0.9999959468841553
The O O 0.9999873638153076
assay O O 0.9473593235015869
conditions-concentration O O 0.9775826930999756
of O O 0.9996793270111084
the O O 0.9997476935386658
ligand O O 0.5803318023681641
20 O O 0.7618114948272705
nmol/l O O 0.28301313519477844
, O O 0.9799434542655945
incubation O O 0.8781160116195679
time O O 0.9015899896621704
2 O O 0.973752498626709
h O O 0.8825376629829407
and O O 0.9988676309585571
the O O 0.9998160004615784
cell O O 0.9157668948173523
count O O 0.9776991605758667
2-6 O O 0.9851507544517517
mil O O 0.9909844398498535
. O O 0.9999653100967407
cells/tube O O 0.5791521668434143
in O O 0.9996877908706665
the O O 0.999931812286377
assay O O 0.8998467326164246
volume O O 0.9547484517097473
0.25 O O 0.9656224846839905
ml O O 0.9927391409873962

a O O 0.9903343319892883
target O O 0.9869323372840881
for O O 0.9998383522033691
the O O 0.9999350309371948
B-cell-specific B-protein B-protein 0.46242567896842957
transcription I-protein I-protein 0.7781914472579956
factor E-protein E-protein 0.9669581055641174
BSAP S-protein S-protein 0.6598089337348938
. O O 0.9998237490653992
The O O 0.9999697208404541
CD19 B-protein B-protein 0.8833513855934143
protein E-protein E-protein 0.9289089441299438
is O O 0.996582567691803
expressed O O 0.9998656511306763
on O O 0.9999017715454102
the O O 0.9998756647109985
surface O O 0.9949175119400024
of O O 0.999836802482605
all O O 0.9995249509811401
B-lymphoid B-cell_type B-cell_type 0.6524949073791504
cells E-cell_type E-cell_type 0.8496828079223633
with O O 0.9995182752609253
the O O 0.9999878406524658
exception O O 0.9999212026596069
of O O 0.9999730587005615
terminally B-cell_type B-cell_type 0.44472694396972656
differentiated I-cell_type I-cell_type 0.43378379940986633
plasma I-cell_type I-cell_type 0.6566281318664551
cells E-cell_type E-cell_type 0.831610918045044
and O O 0.9956012964248657
has O O 0.9999680519104004
been O O 0.9999425411224365
implicated O O 0.9997143149375916
as O O 0.9999549388885498

in O O 0.997553288936615
vivo O O 0.9949319958686829
. O O 0.9999721050262451
TNF S-protein S-protein 0.9890918731689453
is O O 0.9995813965797424
one O O 0.9999830722808838
of O O 0.9999887943267822
the O O 0.9999690055847168
cytokines S-protein S-protein 0.978919506072998
secreted O O 0.9989307522773743
by O O 0.9999661445617676
the O O 0.9994301199913025
cells O O 0.9732653498649597
of O O 0.9997419714927673
the O O 0.9998358488082886
immune O O 0.950710654258728
system O O 0.974239706993103
. O O 0.9999973773956299
Our O O 0.9985511898994446

other O O 0.994053304195404
activation-inducible B-protein B-protein 0.806931734085083
proteins E-protein E-protein 0.9779685139656067
. O O 0.9990965127944946
FGF-1 S-protein S-protein 0.9634606242179871
alone O O 0.9881582856178284
induces O O 0.9999606609344482
modest O O 0.9786852598190308
nuclear O O 0.9539563059806824
translocation O O 0.9774681329727173
of O O 0.9992668032646179
kappaB-binding B-protein B-protein 0.6500192284584045
proteins E-protein E-protein 0.9936683773994446
, O O 0.9948847889900208
and O O 0.9997547268867493

After O O 0.9997139573097229
her O O 0.9977184534072876
strength O O 0.9074261784553528
returned O O 0.998975396156311
, O O 0.9999598264694214
repetitive O O 0.7923440337181091
stimulation O O 0.4923148453235626
was O O 0.9992696642875671
normal O O 0.988739013671875
, O O 0.999966025352478
but O O 0.9999697208404541
single O O 0.9906373620033264
fiber O O 0.9282886981964111
EMG O O 0.6086952090263367
revealed O O 0.9997307658195496
increased O O 0.9787102937698364
jitter O O 0.8690098524093628
and O O 0.9422939419746399
blocking O O 0.593399167060852
. O O 0.99985671043396

subunit O E-protein 0.924540638923645
of O O 0.9981961846351624
NF-kappa B-protein B-protein 0.8083143830299377
B E-protein E-protein 0.9949700236320496
is O O 0.9997425675392151
inhibited O O 0.9997010827064514
by O O 0.9999940395355225
salicylate O O 0.9107713103294373
treatment O O 0.9982668161392212
and O O 0.9999808073043823
highlight O O 0.9998563528060913
the O O 0.9999758005142212
role O O 0.9998273253440857
of O O 0.9999557733535767
salicylate O O 0.7260071039199829
in O O 0.9987961053848267
the O O 0.99992835521698
control O O 0.9701209664344788

A O O 0.9974156618118286
total O O 0.9997746348381042
of O O 0.9998960494995117
sixty O O 0.9968273043632507
patients O O 0.999588668346405
were O O 0.9999953508377075
trated O O 0.9965245127677917
with O O 0.9999600648880005
bromperidol S-Chemical B-Chemical 0.9261491298675537
first O O 0.8372955322265625
in O O 0.9998062252998352
open O O 0.9356117844581604
conditions O O 0.7133597731590271
( O O 0.999503493309021
20 O O 0.9997636675834656
patients O O 0.9997252821922302
) O O 0.9999063014984131
, O O 0.9999909400939941
then O O 0.9999884366989136
on O O 0.999962329864502
a O O 0.9999262094497681
double O O 0.9853954911231995
blind O O 0.9548740983009338
basis O O 0.995257556438446
( O O 0.999991774559021
40 O O 0.9997950196266174
patients O O 0.9997987151145935
) O O 0.9999642372131348
with O O 0.9999954700469971
haloperidol S-Chemical B-Chemical 0.9295598268508911
as O O 0.9984182119369507
the O O 0.9999698400497437
reference O O 0.9803975820541382
substance O O 0.9413263201713562
. O O 0.9999953508377075

a O O 0.995311439037323
therapeutic O O 0.924655020236969

suggesting O O 0.9972102046012878
the O O 0.9999920129776001
presence O O 0.9998095631599426
of O O 0.9999916553497314
an O O 0.9998828172683716
inhibitor O O 0.9752064347267151
of O O 0.9994214773178101
NF-kappa B-protein B-protein 0.7339214086532593
B E-protein E-protein 0.9932559728622437
activity O O 0.9974483251571655
. O O 0.9999969005584717
Furthermore O O 0.999922513961792
, O O 0.9999868869781494
treatment O O 0.9997398257255554
of O O 0.9999780654907227
nuclear O O 0.8349950313568115
extracts O O 0.9337343573570251
from O O 0.9998900890350342
these O O 0.9989407658576965
cells O O 0.9621493816375732
that O O 0.9999468326568604
had O O 0.9999420642852783
restricted O O 0.9894495606422424
expression O O 0.9982692003250122
with O O 0.9999922513961792
lipopolysaccharide O O 0.6624786853790283
increased O O 0.9978299736976624
viral O O 0.9436026811599731
production O O 0.9915747046470642
and O O 0.9998167157173157
NF-kappa B-protein B-protein 0.5032449960708618
B E-protein E-protein 0.9918870329856873
activity O O 0.9982763528823853

It O O 0.9993656277656555
is O O 0.9999825954437256
concluded O O 0.9999954700469971
that O O 0.9999268054962158
flestolol S-Chemical B-Chemical 0.926378071308136
is O O 0.9921656847000122
a O O 0.9999834299087524
potent O O 0.9988499879837036
, O O 0.9995019435882568
well O O 0.997831404209137
- O O 0.9997605681419373
tolerated O O 0.9923416376113892
, O O 0.9997491240501404
ultra O O 0.9880714416503906
- O O 0.9991864562034607
short O O 0.9987645149230957
- O O 0.9995467066764832
acting O O 0.9843150973320007
beta O O 0.9580613374710083
- O O 0.9990140199661255
adrenergic O O 0.8512645959854126
blocking O O 0.8363119959831238
agent O O 0.9783695340156555
. O O 0.9999963045120239

cell-type O O 0.39465561509132385
specific O O 0.9554116725921631
induction O O 0.9981319308280945
by O O 0.9999946355819702
PMA O O 0.8081374168395996
treatment O O 0.9974269270896912
was O O 0.9999945163726807
further O O 0.9999808073043823
investigated O O 0.999991774559021
with O O 0.9999958276748657
respect O O 0.9998822212219238
to O O 0.9999943971633911
transcriptional O O 0.9560166001319885
control O O 0.9973932504653931
. O O 0.9999985694885254
A O O 0.9996263980865479
series O O 0.9969882369041443
of O O 0.9999374151229858

The O O 0.9995707869529724
results O O 0.9999040365219116
support O O 0.9999926090240479
the O O 0.9999821186065674
important O O 0.9991577863693237
potential O O 0.9997653365135193
of O O 0.9997722506523132
GNC92H2 S-Chemical B-Chemical 0.913358747959137
as O O 0.9989546537399292
a O O 0.9999958276748657
therapeutic O O 0.9801418781280518
tool O O 0.9986977577209473
against O O 0.9999922513961792
cocaine O B-Chemical 0.7330514192581177
overdose O B-Disease 0.6497188210487366
. O O 0.9989486336708069

large O O 0.921870768070221
prospective O O 0.9888314008712769
trial O O 0.9780902862548828
is O O 0.9998893737792969
needed O O 0.9999926090240479
to O O 0.9999964237213135
determine O O 0.9999945163726807
if O O 0.9999819993972778
one O O 0.9989637136459351
or O O 0.9998064637184143
more O O 0.9999446868896484
of O O 0.999983549118042
these O O 0.9999271631240845
biomarkers O O 0.34426426887512207
, O O 0.9951151609420776
is O O 0.999982476234436
predictive O O 0.9999386072158813
of O O 0.9999871253967285
breast O O 0.9604634642601013
cancer O O 0.9832385778427124
development O O 0.9996627569198608
. O O 0.9999995231628418
Inhibition O O 0.9925284385681152
of O O 0.9993615746498108
nuclear B-RNA B-protein 0.6158638000488281

Postural O O 0.5904099941253662
tremor O O 0.7148134708404541
showed O O 0.9928401708602905
no O O 0.9996309280395508
significant O O 0.9993442893028259
difference O O 0.9941767454147339
between O O 0.9999239444732666
the O O 0.9999444484710693
first O O 0.9993764758110046
and O O 0.9998493194580078
third O O 0.9996641874313354
session O O 0.9998644590377808
( O O 0.999995231628418
P O O 0.9994290471076965
= O O 0.9999781847000122
0 O O 0.9998816251754761
. O O 0.999942421913147
07 O O 0.9981868863105774
) O O 0.9994877576828003
. O O 0.9999966621398926

CONCLUSIONS O O 0.9981598258018494
: O O 0.9999951124191284
A O O 0.9999834299087524
comparison O O 0.999312162399292
of O O 0.9999767541885376
frequency O O 0.989325761795044
of O O 0.9996699094772339
adverse O O 0.9061148166656494
reactions O O 0.6103870868682861
to O O 0.9943694472312927
indocyanine B-Chemical B-Chemical 0.9395357966423035
green E-Chemical I-Chemical 0.9464288949966431
with O O 0.9953592419624329
the O O 0.9999747276306152
previously O O 0.9996165037155151
reported O O 0.9997699856758118
frequency O O 0.9891033172607422
of O O 0.9996724128723145
such O O 0.9940225481987
reactions O O 0.8932929635047913
to O O 0.9997838139533997
fluorescein B-Chemical B-Chemical 0.9253988265991211
sodium E-Chemical I-Chemical 0.9578564763069153
indicated O O 0.9989711046218872
that O O 0.9999948740005493
indocyanine B-Chemical B-Chemical 0.9353448748588562
green E-Chemical I-Chemical 0.9448745846748352
is O O 0.9709392189979553
a O O 0.9999676942825317
safe O O 0.9966791868209839
as O O 0.9999603033065796
fluorescein S-Chemical B-Chemical 0.9324817061424255
for O O 0.9645659327507019
use O O 0.9997536540031433
in O O 0.9999687671661377
angiography O O 0.5952296257019043
. O O 0.999828577041626

Maximum O O 0.8887665271759033
tolerated O O 0.9111698865890503
dose O O 0.9961534142494202
in O O 0.9999022483825684
good O O 0.9938942790031433
- O O 0.9985625147819519
risk O O 0.9934647679328918
patients O O 0.9989590644836426
was O O 0.9999964237213135
70 O O 0.9996989965438843
mg O O 0.999769389629364
/ O O 0.9999773502349854
m2 O O 0.9993603825569153
, O O 0.9999779462814331
and O O 0.99998939037323
in O O 0.9999611377716064
poor O O 0.9782558083534241
- O O 0.994475781917572
risk O O 0.9856168627738953
patients O O 0.9994850158691406
, O O 0.9999929666519165
60 O O 0.9987665414810181
mg O O 0.999678373336792
/ O O 0.9999867677688599
m2 O O 0.9992315769195557
. O O 0.9999908208847046

compared O O 0.9975112676620483
to O O 0.9999936819076538
the O O 0.9999722242355347
effects O O 0.9999550580978394
of O O 0.9999890327453613
LPS O O 0.9807040691375732
alone O O 0.999936580657959
. O O 0.9999963045120239
Not O O 0.9999681711196899
only O O 0.9999861717224121
was O O 0.9999762773513794
this O O 0.9999113082885742
effect O O 0.9996669292449951
observed O O 0.9998527765274048
at O O 0.9999971389770508
the O O 0.9999268054962158
mRNA O O 0.6104707717895508
level O O 0.9846169948577881
, O O 0.9999760389328003
but O O 0.9999237060546875
activator B-protein B-protein 0.7405138611793518
protein-1 E-protein E-protein 0.9127766489982605
( O O 0.9033303260803223
AP-1 S-protein S-protein 0.9569554328918457
) O O 0.9485333561897278

for O O 0.9983083009719849
the O O 0.9999901056289673
activation O O 0.994696855545044
of O O 0.9997842907905579
HSF2 S-protein S-protein 0.8359688520431519
and O O 0.9975911378860474
whether O O 0.9999910593032837
the O O 0.9999009370803833
HSF2 S-protein B-protein 0.3964560627937317
isoforms O E-protein 0.9094900488853455
play O O 0.9945521950721741
functionally O O 0.9820337891578674
distinct O O 0.9944222569465637
roles O O 0.9979110360145569
during O O 0.999997615814209
the O O 0.9999871253967285
hemin-mediated O O 0.830893337726593
erythroid O O 0.6290689706802368
differentiation O O 0.9813186526298523
, O O 0.999967098236084
we O O 0.9997343420982361
generated O O 0.9964351654052734
cell O O 0.9001983404159546

of O O 0.997363269329071
a O O 0.9994749426841736
size O O 0.8981212377548218
variant O O 0.5869591236114502
and O O 0.9995775818824768
the O O 0.9999537467956543
wild-type B-DNA B-DNA 0.4573962986469269
plasmid E-DNA E-DNA 0.9508500099182129
were O O 0.9990707039833069
cotransfected O O 0.9077087640762329
into O O 0.9990369081497192
T-cells S-cell_type S-cell_type 0.8946013450622559
. O O 0.9998230338096619
The O O 0.9999887943267822
virus O O 0.9674448370933533
with O O 0.9995114803314209
four O O 0.9914798736572266
Sp1 O B-DNA 0.44740551710128784
sites O E-DNA 0.9726799726486206
did O O 0.999333918094635
outgrow O O 0.9998965263366699
the O O 0.9999316930770874
three O O 0.9724738597869873

These O O 0.999810516834259
findings O O 0.9999125003814697
demonstrate O O 0.9999927282333374
a O O 0.9999468326568604
sexually O O 0.9314873218536377
- O O 0.9785715341567993
dimorphic O O 0.5225536823272705
interaction O O 0.84259033203125
between O O 0.9991317391395569
NMDA S-Chemical B-Chemical 0.9262300133705139
antagonists O O 0.483028769493103
and O O 0.9994572997093201
morphine S-Chemical B-Chemical 0.9338208436965942
in O O 0.9992651343345642
a O O 0.9999517202377319
persistent O O 0.8487353920936584
pain O B-Disease 0.867742657661438
model O O 0.594735324382782
that O O 0.9994291663169861
can O O 0.9999498128890991
be O O 0.9999589920043945
distinguished O O 0.9994838237762451
from O O 0.9999785423278809
those O O 0.9999479055404663
observed O O 0.9995018243789673
in O O 0.9999754428863525
acute O O 0.6077792048454285
pain O O 0.7181963920593262
models O O 0.7238321304321289
. O O 0.9999878406524658

The O O 0.999496579170227
effects O O 0.99983811378479
of O O 0.9999799728393555
intracoronary O O 0.8322569131851196
administration O O 0.8933485150337219
of O O 0.9987407326698303
methylergonovine B-Chemical B-Chemical 0.9309991598129272
were O O 0.9991229176521301
studied O O 0.9999463558197021
in O O 0.9999954700469971
21 O O 0.9987228512763977
patients O O 0.9998929500579834
with O O 0.9999774694442749
variant B-Disease O 0.7968264222145081
angina I-Disease O 0.491155743598938
and O O 0.9619975686073303
22 O O 0.9738004207611084
patients O O 0.9992565512657166
with O O 0.9999806880950928
atypical O O 0.7907881736755371
chest B-Disease O 0.6801850199699402
pain I-Disease O 0.8661404252052307
and O O 0.9926391839981079
in O O 0.9997164607048035
others O O 0.9999343156814575
without O O 0.999970555305481
angina B-Disease O 0.4972069263458252
pectoris I-Disease O 0.6396666169166565
( O O 0.990662157535553
control O O 0.9339721202850342
group O O 0.9351391792297363
) O O 0.998916745185852
. O O 0.9999948740005493

The O O 0.9989789724349976
surgery O O 0.9357365965843201
and O O 0.9991235136985779
anaesthesia O O 0.8497545719146729
were O O 0.9932858347892761
uneventful O O 0.9720109701156616
, O O 0.9999203681945801
but O O 0.9999505281448364
3 O O 0.9969778060913086
days O O 0.9999443292617798
after O O 0.9999830722808838
surgery O O 0.9921281337738037
, O O 0.999991774559021
the O O 0.9998784065246582
patient O O 0.9990583062171936
reported O O 0.9999871253967285
an O O 0.9999215602874756
area O O 0.9986012578010559
of O O 0.9999110698699951
hypoaesthesia O B-Disease 0.9582758545875549
over O O 0.9478107690811157
L3 O O 0.6836696267127991
- O O 0.8098981380462646
L4 O O 0.5748088359832764
dermatomes O O 0.6770617365837097
of O O 0.8239538073539734
the O O 0.9435415267944336
leg O O 0.8692142963409424
which O O 0.9984946250915527
had O O 0.999897837638855
been O O 0.9990819692611694
operated O O 0.9998676776885986
on O O 0.9994345307350159
( O O 0.9998857975006104
loss O O 0.8681089282035828
of O O 0.9438297748565674
pinprick O O 0.396494060754776
sensation O O 0.8011530041694641
) O O 0.9784467816352844
without O O 0.9998005032539368
reduction O O 0.8389632105827332
in O O 0.981981098651886
muscular O O 0.8003949522972107
strength O O 0.9178038835525513
. O O 0.999126136302948

Male O O 0.9218834042549133
rats O O 0.9931633472442627
were O O 0.9999912977218628
subcutaneously O O 0.9964224696159363
injected O O 0.9992436170578003
with O O 0.9998326301574707
morphine S-Chemical B-Chemical 0.9396843314170837
( O O 0.9919781684875488
10 O O 0.9996805191040039
mg O O 0.9996988773345947
/ O O 0.9999828338623047
kg O O 0.999702513217926
) O O 0.9999417066574097
twice O O 0.999997615814209
a O O 0.9999703168869019
day O O 0.9999696016311646
at O O 0.9999990463256836
12 O O 0.9997956156730652
hour O O 0.9997121691703796
intervals O O 0.9996429681777954
for O O 0.9999983310699463
10 O O 0.9997164607048035
days O O 0.9999583959579468
, O O 0.9999847412109375
and O O 0.9997199177742004
Rg1 S-Chemical B-Chemical 0.9181300401687622
( O O 0.9797606468200684
30 O O 0.9993150234222412
mg O O 0.9996482133865356
/ O O 0.999974250793457
kg O O 0.9992812275886536
) O O 0.9997736811637878
was O O 0.9999910593032837
intraperitoneally O O 0.8363099098205566
injected O O 0.9430376887321472
2 O O 0.9978871941566467
hours O O 0.9999723434448242
after O O 0.9999990463256836
the O O 0.9999949932098389
second O O 0.9995619654655457
injection O O 0.9807116389274597
of O O 0.9992177486419678
morphine S-Chemical B-Chemical 0.9422280192375183
once O O 0.9994020462036133
a O O 0.9999656677246094
day O O 0.9999818801879883
for O O 0.9999982118606567
10 O O 0.9996275901794434
days O O 0.9999842643737793
. O O 0.9999992847442627

Clinical O O 0.9659882187843323
tolerability O O 0.8555402159690857
of O O 0.9990083575248718
both O O 0.9998934268951416
agents O O 0.9837228655815125
has O O 0.9999767541885376
been O O 0.9999390840530396
good O O 0.9998511075973511
, O O 0.9999940395355225
with O O 0.9999920129776001
fewer O O 0.9998630285263062
than O O 0.9999450445175171
3 O O 0.9998799562454224
% O O 0.9999810457229614
of O O 0.9999548196792603
patients O O 0.9989922642707825
withdrawn O O 0.9990935325622559
from O O 0.9999673366546631
treatment O O 0.999349057674408
because O O 0.999998927116394
of O O 0.9999231100082397
clinical O O 0.9631544351577759
adverse O O 0.8810329437255859
experiences O O 0.9451221227645874
. O O 0.9999982118606567

cell-specific I-protein I-protein 0.5466631054878235
transacting I-protein I-protein 0.5154431462287903
factors E-protein E-protein 0.9919335246086121
. O O 0.9997813105583191
The O O 0.9999765157699585
mouse O B-DNA 0.6681002974510193
mammary O I-DNA 0.5956218838691711
tumor O I-DNA 0.46446388959884644
virus O I-DNA 0.5577135682106018
env B-DNA I-DNA 0.7383882999420166
gene E-DNA E-DNA 0.9945447444915771
contains O O 0.9992602467536926
a O O 0.9999090433120728
transcriptional B-DNA B-protein 0.6825928688049316
activator E-DNA E-protein 0.7309748530387878
( O O 0.937770426273346
META S-DNA S-protein 0.5284419059753418
) O O 0.9434862732887268
that O O 0.9994028806686401
can O O 0.9999030828475952
control O O 0.9948104619979858
transcription O O 0.9517669081687927
of O O 0.9979124665260315
the O O 0.9993245601654053
adjacent O B-DNA 0.5572296977043152
long B-DNA I-DNA 0.5068121552467346
terminal I-DNA I-DNA 0.7851078510284424
repeat I-DNA I-DNA 0.5291768908500671
region E-DNA E-DNA 0.9505537152290344
. O O 0.9998681545257568
Transcriptional O O 0.930608868598938
control O O 0.9792475700378418

TNF-alpha S-protein S-protein 0.7062613368034363
to O O 0.9990479350090027
delay O O 0.999482274055481
apoptosis O O 0.9731215238571167
at O O 0.9999972581863403
later O O 0.996538519859314
times O O 0.9994474053382874
( O O 0.9999881982803345
12-24 O O 0.9992601275444031
h O O 0.9977734684944153
) O O 0.9990617632865906
and O O 0.9999821186065674
limit O O 0.9995587468147278
its O O 0.9999426603317261
early O O 0.940955638885498
killing O O 0.8867102861404419
effect O O 0.9989872574806213
. O O 0.9999979734420776
Furthermore O O 0.99947589635849

In O O 0.9993649125099182
conclusion O O 0.9993820190429688
, O O 0.9999982118606567
ENaC O O 0.8544979691505432
mRNA O O 0.904335618019104
expression O O 0.9790282845497131
, O O 0.9999661445617676
especially O O 0.9999103546142578
alphaENaC O O 0.3737854063510895
, O O 0.9974300265312195
is O O 0.9999793767929077
increased O O 0.9991869330406189
in O O 0.9999624490737915
the O O 0.9999176263809204
very O O 0.9995675683021545
early O O 0.9982927441596985
phase O O 0.9999607801437378
of O O 0.9999313354492188
the O O 0.9999499320983887
experimental O O 0.9561238288879395
model O O 0.99720698595047
of O O 0.99954754114151
PAN S-Chemical B-Chemical 0.9122527241706848
- O O 0.9591469168663025
induced O O 0.9993916749954224
nephrotic O B-Disease 0.7607349753379822
syndrome O I-Disease 0.9904692769050598
in O O 0.9784123301506042
rats O O 0.978687584400177
, O O 0.9998238682746887
but O O 0.9999133348464966
appears O O 0.9996986389160156
to O O 0.9995143413543701
escape O O 0.9651474356651306
from O O 0.9996291399002075
the O O 0.9997383952140808
regulation O O 0.9948887228965759
by O O 0.9999809265136719
aldosterone S-Chemical B-Chemical 0.9065520167350769
after O O 0.9993382096290588
day O O 0.9992165565490723
3 O O 0.9986528158187866
. O O 0.9999971389770508

the O O 0.9981716871261597
variant B-DNA B-DNA 0.8768970966339111
allele E-DNA E-DNA 0.6318526268005371
can O O 0.9984084963798523
serve O O 0.9999861717224121
as O O 0.9999951124191284
a O O 0.999987006187439
primary O O 0.9434332847595215
tool O O 0.9876152276992798
for O O 0.9999115467071533

affinity O O 0.7167134284973145
chromatography O O 0.4778706431388855
in O O 0.9994499087333679
UT-7 B-protein B-protein 0.4780418276786804
Epo E-protein E-protein 0.6385179162025452
but O O 0.9029366970062256
not O O 0.9257040619850159
in O O 0.9912577867507935
UT-7 B-cell_line B-cell_line 0.7983309030532837
cells E-cell_line E-cell_line 0.9916369318962097
. O O 0.9998722076416016
The O O 0.9999972581863403
frequency O O 0.996729850769043
of O O 0.9999034404754639
the O O 0.9998176693916321
cells O O 0.9689740538597107
which O O 0.9998881816864014
expressed O O 0.998497724533081
beta- B-DNA B-DNA 0.38787803053855896
and I-DNA I-DNA 0.6129575371742249
gamma- I-DNA I-DNA 0.4512495994567871
globin I-DNA I-DNA 0.3106060028076172
genes E-DNA E-DNA 0.9784561395645142
in O O 0.9994555115699768
the O O 0.9999440908432007
two O O 0.9984058737754822
cell O O 0.933931291103363
populations O O 0.7787380218505859
was O O 0.9999926090240479
measured O O 0.9996083378791809

mechanism O O 0.9520642757415771
by O O 0.9999525547027588
which O O 0.999990701675415
NF-ATc S-protein S-protein 0.9899010062217712
enters O O 0.9993361830711365
the O O 0.9999750852584839
nucleus O O 0.9656850099563599
is O O 0.9999234676361084
unknown O O 0.999319314956665
, O O 0.9999822378158569
and O O 0.9999864101409912
although O O 0.9999916553497314
it O O 0.9998655319213867
appears O O 0.9999486207962036
to O O 0.9999693632125854
require O O 0.9999788999557495
calcineurin S-protein S-protein 0.9950835704803467
, O O 0.9991477727890015
NF-ATc S-protein S-protein 0.9944429993629456
has O O 0.9996860027313232
not O O 0.9999611377716064

kinase E-protein E-protein 0.8129324913024902
activity O O 0.9784945249557495
, O O 0.999906063079834
also O O 0.9998164772987366
inhibited O O 0.9896512031555176
erythroid O O 0.6518993973731995
differentiation O O 0.9513629674911499
of O O 0.9997981190681458
HEL B-cell_line B-cell_line 0.6683040857315063
cells E-cell_line E-cell_line 0.8889564275741577
. O O 0.9998401403427124
These O O 0.999997615814209
results O O 0.9999747276306152
suggest O O 0.9999979734420776
that O O 0.9999973773956299
( O O 0.9993336796760559
1 O O 0.9989733695983887
) O O 0.9994940757751465
the O O 0.9999656677246094
differentiation O O 0.9607900381088257
inhibitory O O 0.7949787378311157
activity O O 0.9981321692466736

that O O 0.9992756247520447
thymic O O 0.8526813387870789
atrophy O O 0.8329182863235474
induced O O 0.9997720122337341
by O O 0.999981164932251
2 O O 0.9750219583511353
, O O 0.9911207556724548
3 O O 0.989423930644989
, O O 0.9977454543113708
7 O O 0.990565836429596
, O O 0.9996721744537354
8-tetrachlorodibenzo-p-dioxin O O 0.978686511516571
( O O 0.999885082244873
TCDD O O 0.9375833868980408
) O O 0.9995436072349548
can O O 0.9999933242797852
be O O 0.9999871253967285
mediated O O 0.9992508292198181
, O O 0.999980092048645
at O O 0.9999949932098389

not O O 0.9555161595344543
of O O 0.999116837978363
Hlf S-protein S-protein 0.9218121767044067
, O O 0.9875460267066956
Dbp S-protein S-protein 0.9754210114479065
, O O 0.9915048480033875
or O O 0.9982494115829468
Tef S-protein S-protein 0.9568700790405273
, O O 0.9936425685882568
was O O 0.9999443292617798
found O O 0.9998928308486938
to O O 0.9999337196350098
be O O 0.9999048709869385
regulated O O 0.9990203380584717
by O O 0.9999748468399048
IL-3 S-protein S-protein 0.9917404651641846
in O O 0.999886155128479
mouse B-cell_line B-cell_line 0.5319182872772217
pro-B I-cell_line I-cell_line 0.5354126691818237
cell I-cell_line I-cell_line 0.8266844749450684
lines E-cell_line E-cell_line 0.9972993731498718
( O O 0.9988896250724792
Baf-3 S-cell_line S-cell_line 0.9944232106208801
and O O 0.9803544878959656
FL5.12 S-cell_line S-cell_line 0.9975456595420837
) O O 0.8298099637031555
. O O 0.9999803304672241
Northern O O 0.9933993816375732
blot O O 0.9819859266281128
analysis O O 0.9998644590377808
showed O O 0.9999972581863403
that O O 0.9999713897705078
Nfil3/E4bp4 S-protein S-protein 0.8035964965820312
is O O 0.9993150234222412
regulated O O 0.9994866847991943

growth O O 0.9515832662582397
and O O 0.9985193610191345
induced O O 0.989932656288147
functional O O 0.9847204685211182
and O O 0.9978245496749878
morphologic O O 0.9807707667350769
differentiation O O 0.9983102083206177
of O O 0.9999662637710571
HL-60 B-cell_line S-cell_line 0.9479377269744873
and I-cell_line O 0.9110802412033081
NB4 I-cell_line B-cell_line 0.6048850417137146
cells E-cell_line E-cell_line 0.9614118933677673
, O O 0.9974486231803894
whereas O O 0.9999986886978149
the O O 0.9999943971633911
combined O O 0.9856064915657043
treatment O O 0.9995230436325073
with O O 0.9999873638153076
differanisole O O 0.8423472046852112
A O O 0.635469913482666
and O O 0.9965106844902039
all-trans O O 0.9092649817466736
retinoic O O 0.7391338348388672

Neurotoxicity B-Disease O 0.8316701650619507
of O O 0.9442179799079895
halogenated B-Chemical O 0.3896155059337616
hydroxyquinolines I-Chemical O 0.6962601542472839
: O O 0.9985230565071106
clinical O O 0.9918786287307739
analysis O O 0.994434654712677
of O O 0.9999027252197266
cases O O 0.8951444625854492
reported O O 0.9998800754547119
outside O O 0.9999675750732422
Japan O O 0.9212384819984436
. O O 0.9999980926513672

was O O 0.9936426877975464

Procainamide S-Chemical B-Chemical 0.9222303032875061
- O O 0.8925413489341736
induced O O 0.9988207221031189
polymorphous O O 0.589979887008667
ventricular O B-Disease 0.4152562916278839
tachycardia O I-Disease 0.9431502223014832
. O O 0.9976623058319092

In O O 0.99980229139328
the O O 0.9999760389328003
absence O O 0.9965067505836487
of O O 0.9999184608459473
the O O 0.9999096393585205
carcinogen O O 0.39353010058403015
, O O 0.9962003827095032
5 B-Chemical B-Chemical 0.8125424385070801
- I-Chemical I-Chemical 0.9914129972457886
AzC I-Chemical I-Chemical 0.9477261900901794
given O O 0.9843010306358337
after O O 0.9999773502349854
a O O 0.9998935461044312
two O O 0.9995490908622742
thirds O O 0.9993021488189697
partial O O 0.9328792691230774
hepatectomy O O 0.8525223731994629
, O O 0.9944801330566406
when O O 0.9999712705612183
its O O 0.9996676445007324
incorporation O O 0.9563086032867432
should O O 0.9997588992118835
be O O 0.9999583959579468
maximum O O 0.9966976642608643
, O O 0.9999833106994629
failed O O 0.9973239898681641
to O O 0.9998947381973267
induce O O 0.9999594688415527
any O O 0.9999327659606934
gamma O O 0.5742899775505066
- O O 0.7187474370002747
GT O O 0.6769922375679016
positive O O 0.9521987438201904
foci O O 0.6117600202560425
. O O 0.9998998641967773

agonistic O O 0.8501657247543335
anti-CD28 B-protein B-protein 0.630186915397644
antibodies E-protein E-protein 0.994259238243103
in O O 0.9999021291732788
conjunction O O 0.9978740215301514
with O O 0.9999858140945435
phorbol O O 0.9183176755905151
12-myristate O O 0.9721135497093201
13-acetate O O 0.9807479381561279
( O O 0.9996811151504517
PMA O O 0.9716923236846924
) O O 0.9993240833282471
- O O 0.9998587369918823
or O O 0.9999500513076782
TcR S-protein S-protein 0.9485790729522705
-derived O O 0.9918456673622131
signals O O 0.9940999150276184
induces O O 0.9999961853027344
the O O 0.9999867677688599
enhanced O O 0.994515061378479
activation O O 0.9975070357322693
of O O 0.9999282360076904
the O O 0.9998044371604919
transcription B-protein B-protein 0.502587616443634
factor E-protein E-protein 0.7990108728408813
NF-kappa B-protein B-protein 0.5197243690490723
B E-protein E-protein 0.9169246554374695

4 O O 0.7982518672943115
kilobases O O 0.8471912145614624
5 O O 0.8956997394561768
' O O 0.9059413075447083
to O O 0.9975618124008179
the O O 0.9996680021286011
translation B-DNA B-DNA 0.7581390142440796
initiation I-DNA I-DNA 0.7160213589668274
codon E-DNA E-DNA 0.7245419025421143
, O O 0.9886744618415833
and O O 0.999940037727356
an O O 0.9999061822891235
RNA O O 0.4437585771083832
splice O O 0.3533298373222351
of O O 0.992185652256012
3863 O O 0.6434980630874634
bases O O 0.4610879421234131
occurs O O 0.9997285008430481
in O O 0.999985933303833
the O O 0.9999141693115234
5'-untranslated B-DNA B-DNA 0.4618796408176422
region E-DNA E-DNA 0.8329836130142212
to O O 0.9988349080085754
generate O O 0.9990744590759277
mature B-RNA O 0.6129153966903687
HeLa I-RNA B-RNA 0.293689489364624
cell I-RNA I-RNA 0.373210608959198
mRNA E-RNA E-RNA 0.9482486844062805
. O O 0.999858021736145
5 O O 0.9579936265945435
' O O 0.9753229022026062

and O O 0.9093616008758545
Sp1 S-protein S-protein 0.95917809009552
, O O 0.9979400038719177
is O O 0.9999762773513794
required O O 0.9999027252197266
for O O 0.9999871253967285
this O O 0.9998859167098999
expression O O 0.999736487865448
. O O 0.9999984502792358
The O O 0.9999946355819702
present O O 0.958011269569397

dodecyl O O 0.5461556315422058
sulfate O O 0.8101282119750977
polyacrylamide O O 0.8061168789863586
gel O O 0.903752863407135
electrophoresis O O 0.8553116321563721
( O O 0.9960445165634155
SDS-PAGE O O 0.37082210183143616
) O O 0.9621046781539917
and O O 0.9989281296730042
Western O O 0.8462067246437073
blot O O 0.530494749546051
. O O 0.9962206482887268
RESULTS O O 0.9828246831893921
: O O 0.9995606541633606
Phorbol-myristate-acetate O O 0.7317911386489868
and O O 0.9931125044822693
ionomycine O O 0.5401554107666016
strongly O O 0.9979422688484192
increase O O 0.9998980760574341
the O O 0.9998695850372314
percent-age O O 0.9812532067298889
of O O 0.9996917247772217
IL-2+ B-cell_line B-cell_line 0.5464798808097839
cells E-cell_line E-cell_line 0.5709415078163147
; O O 0.9989643096923828
an O O 0.9999957084655762
additional O O 0.9989815354347229
50 O O 0.9246671199798584
% O O 0.9946946501731873
HCSs O O 0.5732477903366089
significantly O O 0.998345136642456
suppresses O O 0.999727189540863
the O O 0.9998533725738525
percentage O O 0.9988105297088623
to O O 0.9999443292617798
, O O 0.9986490607261658
or O O 0.9996259212493896
below O O 0.9997972846031189
the O O 0.9999260902404785
level O O 0.9993940591812134
of O O 0.9999058246612549
unstimulated B-cell_type B-cell_type 0.4211175739765167
cells E-cell_type E-cell_type 0.819247305393219
. O O 0.9995377063751221
IFN-gamma O S-protein 0.9924375414848328
production O O 0.9973356127738953
is O O 0.9999847412109375

CPO S-protein B-DNA 0.43639877438545227
gene O E-DNA 0.979520857334137
between O O 0.9939945340156555
erythroid B-cell_type B-cell_type 0.5806887149810791
and I-cell_type I-cell_type 0.5423116087913513
nonerythroid I-cell_type I-cell_type 0.789628267288208
cells E-cell_type E-cell_type 0.9536171555519104
. O O 0.9998133778572083
Copyright O O 0.9955386519432068
1998 O O 0.9931631088256836
by O O 0.9999969005584717
The O O 0.9992530941963196
American O O 0.9601081609725952
Society O O 0.9480418562889099
of O O 0.9977506995201111
Hematology O B-protein 0.7225479483604431
Tumor B-protein I-protein 0.3792347311973572
suppressor I-protein I-protein 0.5757347345352173
proteins E-protein E-protein 0.9878461956977844
as O O 0.999708354473114
regulators O O 0.9546052813529968
of O O 0.9986028075218201
cell O O 0.8439821004867554

II O E-protein 0.6917730569839478
expression O O 0.9636511206626892
, O O 0.9998788833618164
being O O 0.9998021721839905
deficient O O 0.9990088939666748
in O O 0.9999220371246338
some O O 0.9995653033256531
B B-cell_line B-cell_line 0.580509603023529
cell I-cell_line I-cell_line 0.672077476978302
lines E-cell_line E-cell_line 0.9959849119186401
derived O O 0.9996730089187622
from O O 0.9999836683273315
patients O O 0.9994045495986938
with O O 0.999991774559021
class O O 0.6883783936500549
II-deficient O O 0.35512271523475647

model O O 0.5008998513221741
. O O 0.9992857575416565
Intracellular O O 0.8675732016563416
signals O O 0.9125315546989441
that O O 0.9999384880065918
mediate O O 0.994339644908905
differentiation O O 0.9965704679489136
of O O 0.9998482465744019
pluripotent B-cell_type B-cell_type 0.4621777832508087
hemopoietic I-cell_type I-cell_type 0.6794275641441345
progenitors E-cell_type E-cell_type 0.8124322295188904
to O O 0.976379930973053

from O O 0.9980487823486328
stat3 S-protein S-protein 0.8614606261253357
, O O 0.999762237071991
another O O 0.9999860525131226
cytoplasmic B-protein B-protein 0.4711192548274994
protein E-protein E-protein 0.9617840051651001
was O O 0.998224675655365
tyrosine O O 0.8866240382194519
phosphorylated O O 0.8639456629753113
and O O 0.9965952038764954
subsequently O O 0.9997407793998718
translocated O O 0.9969889521598816
to O O 0.9999158382415771
the O O 0.9992479681968689

to O O 0.9976454377174377
the O O 0.9999514818191528
release O O 0.9986490607261658
of O O 0.9999651908874512
inflammatory B-protein B-protein 0.6052742600440979
mediators E-protein E-protein 0.8715700507164001
by O O 0.9997920393943787
bronchial B-cell_type B-cell_type 0.5574198961257935
epithelial I-cell_type I-cell_type 0.8864669799804688
cells E-cell_type E-cell_type 0.9816290140151978
, O O 0.9994837045669556
we O O 0.9999526739120483
established O O 0.9999821186065674

70 I-protein O 0.7504714131355286
, I-protein O 0.8843538165092468
120 I-protein O 0.5609114766120911
, I-protein O 0.8917798399925232
and I-protein O 0.9733152389526367
130 I-protein O 0.8941484093666077
kDa E-protein O 0.6299884915351868
. O O 0.9955940842628479
There O O 0.999994158744812
was O O 0.9999977350234985
a O O 0.9999954700469971
good O O 0.9973286390304565
correlation O O 0.9974320530891418
between O O 0.9999014139175415
thrombin S-protein S-protein 0.9896233677864075
-induced O O 0.9981503486633301
tyrosine O O 0.8899704813957214
phosphorylation O O 0.9642514586448669
of O O 0.9995174407958984
the O O 0.9997603297233582
latter O O 0.9964011907577515
three O O 0.9978880286216736
proteins O O 0.9608350396156311

granulocytes S-cell_type E-cell_type 0.7606213092803955
. O O 0.9998985528945923
This O O 0.9997597336769104
1 O O 0.8509112596511841
, O O 0.9484543204307556
25 O O 0.9383352994918823
( O O 0.9952316880226135
OH O O 0.9389563798904419
) O O 0.9923456311225891
2D3-induced O O 0.987798810005188
G1 O O 0.771891713142395
arrest O O 0.9819086790084839
is O O 0.9999881982803345
enhanced O O 0.999942421913147
by O O 0.9999961853027344
all-trans O O 0.9481651782989502
RA O O 0.9230356812477112
. O O 0.9999749660491943
Also O O 0.9993473887443542
, O O 0.9999644756317139
1 O O 0.9667955040931702
, O O 0.9955956339836121
25 O O 0.9939007759094238
( O O 0.9996359348297119
OH O O 0.9791445136070251
) O O 0.9983378648757935
2D3 O O 0.9735494256019592
( O O 0.999687910079956
10 O O 0.9951683282852173
( O O 0.9991451501846313
-10 O O 0.9980396628379822
) O O 0.9989145994186401
to O O 0.9997631907463074
10 O O 0.9954107403755188

CLINICAL O O 0.9716166853904724
SIGNIFICANCE O O 0.9949872493743896
: O O 0.9999927282333374
This O O 0.9999738931655884
clinical O O 0.9902653098106384
case O O 0.9952930808067322
showing O O 0.9999974966049194
oral O O 0.9684136509895325
manifestations O O 0.9037800431251526
of O O 0.9991716146469116
meth B-Disease O 0.38313066959381104
mouth I-Disease O 0.8650297522544861
was O O 0.9924161434173584
presented O O 0.9999877214431763
to O O 0.9999958276748657
help O O 0.9999513626098633
dental O O 0.9542139172554016
practitioners O O 0.9422777891159058
recognize O O 0.9995399713516235
and O O 0.9996607303619385
manage O O 0.9997312426567078
patients O O 0.998779833316803
who O O 0.9999654293060303
may O O 0.9999756813049316
be O O 0.9999678134918213
abusing O O 0.9897376894950867
methamphetamines B-Chemical B-Chemical 0.9129720330238342
. O O 0.9994701743125916

of O O 0.9966300129890442
human B-cell_type B-cell_type 0.459033727645874
monocytes E-cell_type E-cell_type 0.9893966913223267
using O O 0.9992407560348511
polyclonal O B-protein 0.8636835217475891
anti-TF B-protein I-protein 0.30034732818603516
antibody E-protein E-protein 0.9908673763275146
showed O O 0.9997816681861877
that O O 0.9999973773956299
N-acetyl-cysteine O O 0.8273112773895264
treatment O O 0.9974839687347412
prevented O O 0.9999691247940063
the O O 0.9999878406524658
characteristic O O 0.9893269538879395
plasmalemmal O O 0.8512940406799316
localization O O 0.9938029050827026
of O O 0.9999240636825562
TF B-protein B-protein 0.47352200746536255
antigen E-protein E-protein 0.9771813154220581
that O O 0.9982457160949707
occurs O O 0.9999728202819824
in O O 0.9999774694442749
response O O 0.9965628981590271
to O O 0.9999403953552246
LPS O O 0.9646559953689575
. O O 0.9999924898147583
Western O O 0.9669930934906006

Randomized O O 0.9241527915000916
, O O 0.9977709054946899
double O O 0.9849268198013306
- O O 0.9977818131446838
blind O O 0.9459657669067383
trial O O 0.9860509037971497
of O O 0.9996260404586792
mazindol S-Chemical B-Chemical 0.9176998138427734
in O O 0.9963812828063965
Duchenne O B-Disease 0.49809882044792175
dystrophy O I-Disease 0.978717565536499
. O O 0.9988381266593933

) I-protein I-protein 0.4516863524913788
-kB E-protein E-protein 0.9740314483642578
, O O 0.9910030364990234
signal O O 0.9111330509185791
transduction O O 0.8608607053756714
pathways O O 0.979719340801239
, O O 0.9998655319213867
and O O 0.9999432563781738
potential O O 0.9921202659606934
interactions O O 0.9984769225120544
with O O 0.9999914169311523

( O O 0.8784348368644714
s O O 0.8802825212478638
) O O 0.8993090987205505
HIV-1 B-DNA B-DNA 0.6640754342079163
promoter E-DNA E-DNA 0.9173397421836853
transcription O O 0.826867401599884
in O O 0.9997642636299133
various O O 0.9891698956489563
non-irradiated B-cell_line B-cell_line 0.4460104703903198
transfected I-cell_line I-cell_line 0.5080646276473999
cell I-cell_line I-cell_line 0.7666319012641907
lines E-cell_line E-cell_line 0.9971317052841187
. O O 0.9999332427978516
Various O O 0.9994474053382874
cellular O O 0.9213252067565918
stress O O 0.8948003053665161
agents O O 0.9335051774978638
like O O 0.9998044371604919
ionizing O O 0.8919416069984436
radiation O O 0.9187435507774353
exposure O O 0.9943152070045471
could O O 0.9999922513961792

levels O O 0.9852095246315002
and O O 0.9999526739120483
increased O O 0.997219443321228
transcriptional O O 0.9479381442070007
activity O O 0.995292067527771
of O O 0.9999560117721558
AP-1/TPA B-DNA B-DNA 0.4190804958343506
responsive I-DNA I-DNA 0.49088481068611145
elements E-DNA E-DNA 0.9838414192199707
fused O O 0.996573805809021
to O O 0.9999377727508545
chloramphenicol B-DNA B-DNA 0.3890986144542694
acetyl-transferase I-DNA I-DNA 0.5185887813568115
vectors E-DNA E-DNA 0.9729436039924622
were O O 0.9994046688079834
observed O O 0.9997453093528748
in O O 0.9998562335968018
T B-cell_type B-cell_type 0.8426442742347717
cells E-cell_type E-cell_type 0.977935791015625
treated O O 0.999427318572998
with O O 0.9999970197677612
TPA O O 0.7716020941734314
alone O O 0.9980670809745789
or O O 0.9999730587005615
in O O 0.9996858835220337
combination O O 0.9418206214904785

in O O 0.9973485469818115
LPS O O 0.5383896231651306
signaling O O 0.9690771698951721
in O O 0.99980229139328
human B-cell_type B-cell_line 0.45721566677093506
dermal I-cell_type I-cell_line 0.4145829677581787
microvessel I-cell_type I-cell_line 0.4700266122817993
endothelial I-cell_type I-cell_line 0.6546453237533569
cells E-cell_type E-cell_line 0.6437203884124756
( O O 0.9655559062957764
HDMEC S-cell_type S-cell_line 0.9610316753387451
) O O 0.8263162970542908
and O O 0.9898149967193604
THP-1 B-cell_line B-cell_line 0.5882842540740967
monocytic I-cell_line I-cell_line 0.7819241285324097
cells E-cell_line E-cell_line 0.900314450263977
. O O 0.9998196959495544
LPS O O 0.9229177236557007
stimulation O O 0.9956051707267761
of O O 0.9998958110809326
HDMEC S-cell_type S-cell_line 0.6941863894462585
and O O 0.8869220614433289
THP-1 B-cell_line B-cell_line 0.4840322434902191
cells E-cell_line E-cell_line 0.9433298707008362
initiated O O 0.9997468590736389
an O O 0.9999897480010986
IL-1 B-protein B-protein 0.5407393574714661
receptor E-protein E-protein 0.904839038848877
-like O O 0.9378260374069214
NF-kappaB S-protein S-protein 0.9610640406608582
signaling O O 0.9379286766052246
cascade O O 0.9655485153198242
. O O 0.999971866607666
In O O 0.9999042749404907
transient O O 0.8006059527397156
cotransfection O O 0.7826958298683167
experiments O O 0.9449902176856995
, O O 0.9999771118164062
dominant O O 0.8685585260391235

Chronic O O 0.6294883489608765
hyperprolactinemia O B-Disease 0.7549348473548889
induced O O 0.9668848514556885
by O O 0.9998385906219482
the O O 0.9996019005775452
dopamine S-Chemical B-Chemical 0.9156339764595032
antagonist O O 0.5829451680183411
sulpiride S-Chemical B-Chemical 0.8846440315246582
caused O O 0.9994712471961975
a O O 0.9998968839645386
40 O O 0.9768897294998169
% O O 0.9983944296836853
reduction O O 0.9653341770172119
LH O O 0.7449446320533752
pulse O O 0.698222815990448
frequency O O 0.899690568447113
in O O 0.9998229146003723
ovariectomized O O 0.6505885720252991
rats O O 0.9213765263557434
, O O 0.9999176263809204
but O O 0.9999703168869019
only O O 0.9999785423278809
in O O 0.9999716281890869
the O O 0.9998794794082642
presence O O 0.9987921118736267
of O O 0.9999657869338989
chronic O O 0.7914527654647827
low O O 0.8232384324073792
levels O O 0.9309731721878052
of O O 0.9981622099876404
estradiol S-Chemical B-Chemical 0.9353167414665222
. O O 0.9992517828941345

World O O 0.9728139638900757
Health O O 0.9904102087020874
Organization O O 0.9990355968475342
Grade O O 0.9942666888237
3 O O 0.9742465019226074
- O O 0.9748964905738831
4 O O 0.9103626608848572
neutropenia B-Disease O 0.9399556517601013
and O O 0.7132660746574402
thrombocytopenia B-Disease B-Disease 0.8160452246665955
occurred O O 0.928618848323822
in O O 0.9997207522392273
39 O O 0.9977003931999207
. O O 0.9999890327453613
9 O O 0.9998966455459595
% O O 0.9999417066574097
and O O 0.9999085664749146
11 O O 0.9990168809890747
. O O 0.999984860420227
4 O O 0.9999136924743652
% O O 0.9999668598175049
of O O 0.999956488609314
patients O O 0.9996525049209595
, O O 0.9999929666519165
respectively O O 0.9999899864196777
. O O 0.999997615814209

higher O O 0.9828755855560303
levels O O 0.9992425441741943
of O O 0.999909520149231
5S O B-RNA 0.5893634557723999
rRNA O E-RNA 0.7110011577606201
and O O 0.977233350276947
tRNA O B-DNA 0.26468944549560547
gene O E-DNA 0.8550529479980469
transcription O O 0.8481356501579285
than O O 0.9981864094734192
chromatin S-DNA S-protein 0.35678669810295105
or O O 0.9692004323005676
extracts O O 0.950497031211853
from O O 0.9999692440032959
uninfected B-cell_type B-cell_type 0.5812237858772278
T I-cell_type I-cell_type 0.5045419335365295
lymphocytes E-cell_type E-cell_type 0.9072447419166565
. O O 0.9998396635055542
The O O 0.9999923706054688
viral B-protein B-protein 0.6249564290046692
protein I-protein I-protein 0.7186194658279419
Tax E-protein E-protein 0.7317041754722595
was O O 0.9989474415779114
likely O O 0.999963641166687
responsible O O 0.9999891519546509
for O O 0.9999942779541016
this O O 0.9999672174453735
higher O O 0.9972031116485596
level O O 0.9995114803314209
of O O 0.9999334812164307
class B-DNA B-DNA 0.7948655486106873
II I-DNA I-DNA 0.2397669404745102
gene E-DNA E-DNA 0.9296525120735168
transcription O O 0.8715029358863831
, O O 0.999578058719635
as O O 0.9999855756759644
purified B-protein O 0.7627130746841431
Tax E-protein S-protein 0.7055448293685913
was O O 0.9986659288406372
found O O 0.9999531507492065
to O O 0.9999735355377197
stimulate O O 0.9998530149459839
both O O 0.999472439289093
genes O O 0.7862086892127991
when O O 0.9999632835388184
added O O 0.9997150301933289
to O O 0.9999725818634033
the O O 0.9994251728057861
uninfected O O 0.7237651348114014
cell O O 0.638793408870697
extract O O 0.9339556097984314
or O O 0.9990363121032715
in O O 0.9975065588951111

shift O O 0.893963634967804
experiments O O 0.9981087446212769
further O O 0.9999932050704956
showed O O 0.9999970197677612
that O O 0.9999982118606567
the O O 0.9999326467514038
STAT1 B-protein B-protein 0.5529186129570007
alpha I-protein I-protein 0.727750301361084
protein E-protein E-protein 0.9818848967552185
bound O O 0.9988806843757629
to O O 0.999994158744812
the O O 0.9998730421066284
Fc B-DNA B-DNA 0.33806121349334717
gamma I-DNA I-DNA 0.33289358019828796
RIC I-DNA I-DNA 0.2868030071258545
GIRE E-DNA E-DNA 0.9133449792861938
in O O 0.9994370341300964
response O O 0.9980243444442749
to O O 0.9999858140945435
IFN-gamma S-protein S-protein 0.9727650284767151
treatment O O 0.9984246492385864
of O O 0.9999685287475586

that O O 0.9989137649536133
cortisol O O 0.7490056753158569
incubation O O 0.9903923273086548
induced O O 0.9999743700027466
a O O 0.9999345541000366
decrease O O 0.9941473007202148
in O O 0.999669075012207
IL-1ra B-RNA B-RNA 0.7988954782485962
mRNA E-RNA E-RNA 0.9906550049781799
expression O O 0.9916970729827881
and O O 0.9999679327011108
a O O 0.9999836683273315
significant O O 0.9977464079856873
inhibition O O 0.9953575730323792
of O O 0.9997757077217102
IL-1ra B-protein B-protein 0.4653199315071106
protein E-protein E-protein 0.891065776348114

virus O O 0.5581110119819641
( O O 0.9437376856803894
EBV O O 0.7244066596031189
) O O 0.8162376284599304
-induced O O 0.976093590259552
cytotoxic B-cell_type O 0.834257960319519
T-lymphocyte E-cell_type O 0.5817311406135559
( O O 0.9752150774002075
CTL O O 0.6163210272789001
) O O 0.9167251586914062
memory O O 0.8729146122932434
, O O 0.9980000853538513
by O O 0.9999885559082031
in O O 0.994855523109436
vitro O O 0.9911450743675232
stimulation O O 0.9982959628105164
with O O 0.9999954700469971
the O O 0.999862551689148
latently O O 0.7599661350250244
infected O O 0.8854598999023438
autologous O B-cell_line 0.5310915112495422
lymphoblastoid B-cell_line I-cell_line 0.47178149223327637
cell I-cell_line I-cell_line 0.84724360704422
line E-cell_line E-cell_line 0.9545971155166626
( O O 0.9891006350517273
LCL S-cell_line S-cell_line 0.9655369520187378
) O O 0.9144848585128784
, O O 0.9981873631477356
has O O 0.9999818801879883
important O O 0.9958927631378174
limitations O O 0.9979311227798462
. O O 0.9999986886978149
First O O 0.9959720969200134
, O O 0.9999536275863647
it O O 0.9999055862426758
gives O O 0.999975323677063
no O O 0.998238205909729

The O O 0.9996498823165894
most O O 0.9980722665786743
striking O O 0.9750880002975464
effect O O 0.9985364675521851
was O O 0.9999421834945679
sedation O O 0.8957851529121399
which O O 0.9994621872901917
increased O O 0.9950466156005859
with O O 0.9998522996902466
the O O 0.9995738863945007
dose O O 0.9990604519844055
, O O 0.9999840259552002
2 O O 0.9989469647407532
mg O O 0.995807409286499
producing O O 0.9983282685279846
deep O O 0.9416905045509338
sleep O O 0.680390477180481
although O O 0.9997991919517517
the O O 0.9999632835388184
subjects O O 0.9991859793663025
could O O 0.9999958276748657
still O O 0.9999567270278931
be O O 0.9999183416366577
aroused O O 0.9910593628883362
. O O 0.9999973773956299

by O O 0.997565746307373
lymphocytes S-cell_type S-cell_type 0.9603279829025269
in O O 0.9995749592781067
vitro O O 0.9900458455085754
and O O 0.9994844198226929
cortisol O O 0.9399564266204834
levels O O 0.9982788562774658
( O O 0.9999935626983643
571 O O 0.9950272440910339
+/- O O 0.9998323917388916
236 O O 0.9995280504226685
ng/mL O O 0.9900173544883728
) O O 0.9997757077217102
in O O 0.9999682903289795
plasma O O 0.4357721209526062
with O O 0.9972387552261353
the O O 0.9999368190765381
symptom O O 0.9507290720939636
score O O 0.9863533973693848
after O O 0.9999897480010986
active O O 0.9769187569618225
treatment O O 0.9993894100189209
were O O 0.9999966621398926

the O O 0.9968125224113464
fetal O O 0.8321698307991028
or O O 0.9828291535377502
the O O 0.9992668032646179
adult O B-DNA 0.9070583581924438
globin B-DNA I-DNA 0.526297390460968
gene E-DNA E-DNA 0.8355486989021301
program O O 0.8059649467468262
. O O 0.9999668598175049
To O O 0.9999886751174927
characterize O O 0.9999128580093384
the O O 0.9999477863311768
protein-DNA O O 0.7828591465950012
interactions O O 0.9628977179527283
important O O 0.9995092153549194
for O O 0.9999866485595703
the O O 0.999933123588562
developmental O O 0.983648419380188
control O O 0.9967537522315979
of O O 0.9999477863311768
the O O 0.9998764991760254
human B-DNA B-DNA 0.4661009609699249
beta-globin I-DNA I-DNA 0.5868657231330872
locus E-DNA E-DNA 0.9334140419960022
, O O 0.9984558820724487
we O O 0.9999603033065796
analyzed O O 0.9997656941413879

NF B-protein B-protein 0.5503749251365662
kappaB E-protein E-protein 0.982380747795105
activation O O 0.990435004234314
in O O 0.9997792840003967
astrocytes S-cell_type S-cell_type 0.9416513442993164
; O O 0.9971274733543396
instead O O 0.9999567270278931
PDTC O O 0.5538961887359619
itself O O 0.9230671525001526
induces O O 0.9999557733535767
NF B-protein B-protein 0.37253886461257935
kappaB E-protein E-protein 0.9614225625991821
activation O O 0.9889524579048157
in O O 0.9998672008514404
astrocytes S-cell_type S-cell_type 0.8897247910499573
, O O 0.9928963780403137
and O O 0.9998639822006226
this O O 0.9999605417251587
may O O 0.9999840259552002
be O O 0.9999935626983643
related O O 0.9999377727508545
to O O 0.9999758005142212
scavenging O O 0.9807999134063721
of O O 0.9995952248573303
endogenously O O 0.5306941866874695
produced O O 0.9301624894142151
NO O O 0.3460223972797394
by O O 0.9959831237792969
the O O 0.999843955039978
PDTC O B-protein 0.40161216259002686
iron O I-protein 0.6438391804695129
complex O E-protein 0.9909572601318359
. O O 0.999679446220398
In O O 0.999384880065918

Hyperkalemia O B-Disease 0.8827246427536011
has O O 0.9553121328353882
recently O O 0.9986383318901062
been O O 0.9999557733535767
recognized O O 0.999987006187439
as O O 0.9999958276748657
a O O 0.9999624490737915
complication O O 0.9750860929489136
of O O 0.999779999256134
nonsteroidal O O 0.8734732270240784
antiinflammatory O O 0.6649076342582703
agents O O 0.6658517718315125
( O O 0.9997826218605042
NSAID O O 0.7248438000679016
) O O 0.9822627305984497
such O O 0.9999309778213501
as O O 0.9999803304672241
indomethacin S-Chemical B-Chemical 0.9230016469955444
. O O 0.9988093376159668

The O O 0.999474823474884
data O O 0.9997544884681702
further O O 0.999994158744812
suggest O O 0.9999945163726807
that O O 0.9999873638153076
the O O 0.9998493194580078
consolidation O O 0.9884688258171082
of O O 0.9993348717689514
this O O 0.9999581575393677
memory O O 0.7882190942764282
is O O 0.9979760050773621
an O O 0.9999896287918091
important O O 0.9994007349014282
interim O O 0.9962245225906372
stage O O 0.9993007183074951
, O O 0.999990701675415
and O O 0.9999856948852539
may O O 0.9999935626983643
take O O 0.9999974966049194
up O O 0.999981164932251
to O O 0.9999618530273438
one O O 0.9999403953552246
day O O 0.9999179840087891
. O O 0.9999991655349731

Before O O 0.9982093572616577
nitroprusside S-Chemical B-Chemical 0.9194506406784058
infusion O O 0.6125015020370483
, O O 0.999125063419342
5 O O 0.9956640601158142
cm O O 0.9975001215934753
H2O S-Chemical B-Chemical 0.9212508201599121
CPAP O O 0.8337464332580566
significantly O O 0.9832358956336975
, O O 0.9998194575309753
P O O 0.801648736000061
less O O 0.9763239026069641
than O O 0.9994935989379883
. O O 0.9994083642959595
05 O O 0.9580867290496826
, O O 0.99991774559021
decreased O O 0.9980321526527405
arterial O O 0.9501734375953674
blood O O 0.9424301981925964
pressure O O 0.7488982081413269
, O O 0.9997227787971497
but O O 0.9999086856842041
did O O 0.9999582767486572
not O O 0.9999258518218994
significantly O O 0.999850869178772
alter O O 0.9995095729827881
heart O O 0.9273761510848999
rate O O 0.9267748594284058
, O O 0.9996825456619263
cardiac O O 0.7500371336936951
output O O 0.6669606566429138
, O O 0.9934992790222168
systemic O O 0.9431853890419006
vascular O O 0.7010148763656616
resistance O O 0.8684943318367004
, O O 0.9842548370361328
or O O 0.9993952512741089
QS O O 0.5950092077255249
/ O O 0.9884852170944214
QT O O 0.5575934648513794
. O O 0.9999368190765381

to O O 0.9965715408325195
be O O 0.9999159574508667
composed O O 0.9999561309814453
of O O 0.9999842643737793
the O O 0.9998879432678223
IL-4R B-protein B-protein 0.5499193072319031
alpha I-protein I-protein 0.5696154236793518
chain E-protein E-protein 0.9928111433982849
( O O 0.9973022937774658
IL-4R B-protein B-protein 0.4587039053440094
alpha E-protein E-protein 0.9538460969924927
) O O 0.7542807459831238
and O O 0.9990009665489197
either O O 0.9999620914459229
the O O 0.9997695088386536
IL-2R B-protein B-protein 0.6323989629745483
gamma I-protein I-protein 0.7809931635856628
chain E-protein E-protein 0.9926760792732239
or O O 0.9992235898971558
the O O 0.9999266862869263
IL-13R B-protein B-protein 0.5654080510139465
alpha I-protein I-protein 0.6043226718902588
chain E-protein E-protein 0.9952871799468994
. O O 0.9996047616004944
We O O 0.9999524354934692
have O O 0.9999901056289673
previously O O 0.9999614953994751
shown O O 0.9999904632568359
that O O 0.9999963045120239
the O O 0.9998382329940796
membrane-proximal B-protein O 0.48278212547302246
portion E-protein O 0.5089192390441895
in O O 0.9981666803359985
the O O 0.9999048709869385
cytoplasmic B-protein B-protein 0.44908958673477173
domain E-protein E-protein 0.9326141476631165
of O O 0.9876918196678162
the O O 0.9997156262397766
human B-protein B-protein 0.3740275800228119
IL-4R I-protein I-protein 0.5112593770027161
alpha E-protein E-protein 0.9331138730049133
( O O 0.9334462285041809
hIL-4R B-protein S-protein 0.6233320832252502

Basal O O 0.8280641436576843
CGRP B-Chemical B-Chemical 0.903924286365509
concentration O O 0.9781889319419861
was O O 0.9999704360961914
significantly O O 0.9998817443847656
higher O O 0.9984266757965088
and O O 0.9999469518661499
platelet O O 0.6056939363479614
5 B-Chemical B-Chemical 0.5897133350372314
- I-Chemical I-Chemical 0.9068189859390259
HT I-Chemical E-Chemical 0.9108074903488159
content O O 0.8345452547073364
tended O O 0.9999779462814331
to O O 0.9999839067459106
be O O 0.9999884366989136
lower O O 0.9996553659439087
in O O 0.9999727010726929
subjects O O 0.9994497895240784
who O O 0.9999830722808838
experienced O O 0.9998980760574341
a O O 0.9993171691894531
migraine B-Disease B-Disease 0.9752315282821655
attack O O 0.5237300395965576
. O O 0.9999722242355347

human O O 0.4196670949459076
thymus O O 0.3145051598548889
and O O 0.9406319856643677
is O O 0.9993889331817627
retained O O 0.9998881816864014
by O O 0.9999980926513672
the O O 0.9999822378158569
majority O O 0.9966490864753723
of O O 0.9999380111694336
mature O B-cell_type 0.7434678077697754
peripheral B-cell_type I-cell_type 0.8947426676750183
T I-cell_type I-cell_type 0.9667737483978271
lymphocytes E-cell_type E-cell_type 0.9923444390296936
. O O 0.9998158812522888
Here O O 0.999955415725708
we O O 0.9999903440475464
show O O 0.9999926090240479
that O O 0.9999932050704956
elevated O O 0.9240431785583496
cAMP O O 0.5029532313346863

shown O O 0.9976590871810913
by O O 0.999996542930603
their O O 0.999957799911499
localization O O 0.9855014681816101
outside O O 0.999697208404541
of O O 0.9999843835830688
the O O 0.9999828338623047
deletion O O 0.949236273765564
. O O 0.9999016523361206
The O O 0.9999467134475708
NR2 B-cell_line B-protein 0.43952426314353943
hybrid E-cell_line E-protein 0.4601023495197296
is O O 0.9974232912063599
a O O 0.9999839067459106
powerful O O 0.9657472372055054
tool O O 0.97762531042099
for O O 0.999927282333374
the O O 0.999972939491272
mapping O O 0.993370532989502
of O O 0.9998422861099243
new O O 0.9594014286994934
probes O O 0.6270920634269714
of O O 0.9990034699440002
this O O 0.9999364614486694
region O O 0.9592493772506714
, O O 0.9996291399002075
as O O 0.9999840259552002
well O O 0.9996597766876221
as O O 0.9999604225158691
for O O 0.999906063079834
obtaining O O 0.9985274076461792
new O O 0.9881809949874878
informative O O 0.906826913356781
probes O O 0.7199085354804993
specific O O 0.9983079433441162
for O O 0.9999847412109375
the O O 0.9999593496322632
deletion O O 0.9907671809196472
by O O 0.999964714050293
subtractive O O 0.9485686421394348
cloning O O 0.9098827838897705
of O O 0.9982019662857056
the O O 0.9999023675918579
region O O 0.9623993635177612
. O O 0.9999833106994629
Such O O 0.9997856020927429
markers O O 0.967847466468811
will O O 0.9999734163284302
be O O 0.9999953508377075
useful O O 0.9999388456344604
for O O 0.99998939037323
linkage O O 0.9958330988883972
analysis O O 0.9993138313293457
and O O 0.9999737739562988
screening O O 0.9982982277870178
of O O 0.9999176263809204
cDNA B-DNA B-DNA 0.46300777792930603
libraries E-DNA E-DNA 0.8921483755111694
. O O 0.9997286200523376
Positive O O 0.9766159057617188
and O O 0.9960947632789612
negative O O 0.9859080910682678
regulation O O 0.999315619468689
of O O 0.999977707862854
the O O 0.9999490976333618
composite B-DNA B-DNA 0.5113885998725891
octamer I-DNA I-DNA 0.4155454933643341
motif E-DNA E-DNA 0.8321459889411926
of O O 0.9980905652046204
the O O 0.9998020529747009
interleukin B-DNA B-DNA 0.6716290712356567
2 I-DNA I-DNA 0.5573153495788574
enhancer E-DNA E-DNA 0.9910926222801208
by O O 0.9989351630210876
AP-1 S-protein S-protein 0.9229112267494202
, O O 0.9746471643447876
Oct-2 S-protein S-protein 0.9717085361480713
, O O 0.9934533834457397
and O O 0.9994482398033142
retinoic B-protein B-protein 0.6528341770172119
acid I-protein I-protein 0.8012653589248657
receptor E-protein E-protein 0.9782766699790955
. O O 0.9992309808731079
The O O 0.9999955892562866
differentiating O O 0.9174759387969971
agent O O 0.9572262167930603
retinoic O O 0.9008973240852356
acid O O 0.8553922176361084
( O O 0.9959586262702942
RA O O 0.9604648947715759
) O O 0.9983641505241394
has O O 0.9999923706054688
been O O 0.9999669790267944
previously O O 0.9999388456344604
reported O O 0.9999451637268066
to O O 0.9999210834503174
interfere O O 0.9994807839393616
with O O 0.9998658895492554
12-O-tetradecanoyl-phorbol-13-acetate O O 0.6051969528198242
( O O 0.9494081735610962
TPA O O 0.41879162192344666
) O O 0.8066585659980774

TNF-alpha S-protein S-protein 0.7133975625038147
) O O 0.9777751564979553
. O O 0.9999861717224121
Furthermore O O 0.9999942779541016
, O O 0.999996542930603
the O O 0.999974250793457
phosphorylated B-protein O 0.7415559887886047
I I-protein B-protein 0.3404003381729126
kappa I-protein I-protein 0.7588879466056824
B I-protein I-protein 0.551060676574707
alpha E-protein E-protein 0.9863091707229614
from O O 0.9993528723716736
calyculin B-cell_line B-cell_line 0.40933865308761597
A-treated I-cell_line I-cell_line 0.44480806589126587
cells E-cell_line E-cell_line 0.6674100756645203
, O O 0.9907835721969604
but O O 0.9999170303344727
not O O 0.9996753931045532
that O O 0.9998539686203003
from O O 0.9976256489753723
TNF-alpha-stimulated B-cell_line B-cell_line 0.7369258403778076
cells E-cell_line E-cell_line 0.847645103931427
, O O 0.9971939325332642
is O O 0.9999942779541016
sensitive O O 0.9967488050460815
to O O 0.9999024868011475
PP-2A S-protein S-protein 0.7522842884063721
in O O 0.9990460276603699
vitro O O 0.9873598217964172
, O O 0.9997876286506653
suggesting O O 0.9999897480010986
the O O 0.9999895095825195
existence O O 0.9998987913131714
of O O 0.9999916553497314
fundamental O O 0.9769594073295593
differences O O 0.9969720840454102
in O O 0.9999871253967285
the O O 0.9998434782028198
phosphorylation O O 0.9551222920417786
of O O 0.9993160963058472
I B-protein B-protein 0.7571690082550049
kappa I-protein I-protein 0.8570312261581421
B I-protein I-protein 0.6252212524414062
alpha E-protein E-protein 0.9123015999794006

, O O 0.9539067149162292
has O O 0.999535322189331
been O O 0.9998407363891602
constructed O O 0.9994787573814392
. O O 0.9999980926513672
This O O 0.9999070167541504
protein O O 0.9582325220108032
reduces O O 0.9982652068138123
or O O 0.9988172650337219
abolishes O O 0.9997504353523254
in O O 0.9989087581634521
vitro O O 0.9923253059387207
the O O 0.9998563528060913
DNA O O 0.9408982992172241
binding O O 0.8681990504264832
activity O O 0.987862229347229
of O O 0.9997392296791077

death I-protein O 0.5894107222557068

study O O 0.9979388117790222
provides O O 0.9999955892562866
no O O 0.9999616146087646
evidence O O 0.9999867677688599
indicating O O 0.999998927116394
a O O 0.9999822378158569
regulatory O O 0.88715660572052
function O O 0.9878708720207214
of O O 0.999829888343811

Newborn O O 0.906684398651123
female O O 0.9681413769721985
Wistar O O 0.7430239319801331
rats O O 0.980652928352356
were O O 0.9999926090240479
fed O O 0.9995602965354919
a O O 0.9995954632759094
lithium B-Chemical B-Chemical 0.927118182182312
- O O 0.8851383924484253
containing O O 0.9982196688652039
diet O O 0.8443815112113953
( O O 0.9997082352638245
50 O O 0.9993066787719727
mmol O O 0.9991236329078674
/ O O 0.9999610185623169
kg O O 0.9987460374832153
) O O 0.9999066591262817
for O O 0.9999972581863403
8 O O 0.9998276233673096
weeks O O 0.9999690055847168
and O O 0.9999924898147583
then O O 0.9999831914901733
randomized O O 0.9956812858581543
to O O 0.9998346567153931
normal O O 0.9753926396369934
diet O O 0.9810473322868347
, O O 0.9999680519104004
HP O O 0.4489782750606537
diet O O 0.8723046779632568
( O O 0.999902606010437
40 O O 0.9992514252662659
vs O O 0.9996696710586548
. O O 0.9999672174453735
19 O O 0.9998260140419006
% O O 0.9998944997787476
) O O 0.9993632435798645
, O O 0.9999785423278809
NX O O 0.5744540095329285
or O O 0.9986262321472168
HP O O 0.8249015808105469
+ O O 0.9758815765380859
NX O O 0.5146535038948059
for O O 0.9998013377189636
another O O 0.9999867677688599
8 O O 0.99983811378479
weeks O O 0.9999597072601318
. O O 0.9999988079071045

The O O 0.9991931319236755
Receiver O O 0.9597474336624146
Operative O O 0.989626407623291
Characteristic O O 0.5477105975151062
Curve O O 0.7301106452941895
showed O O 0.9999301433563232
that O O 0.9999914169311523
OD O O 0.7251487374305725
> O O 0.9909047484397888
1 O O 0.992100179195404
. O O 0.9999765157699585
27 O O 0.9965355396270752
in O O 0.9999488592147827
the O O 0.9998955726623535
isolated O O 0.8198747038841248
- O O 0.9569100141525269
HIT B-Disease O 0.5854540467262268
group O O 0.7446520328521729
had O O 0.9995799660682678
a O O 0.9996590614318848
significantly O O 0.9991123080253601
higher O O 0.9994327425956726
chance O O 0.9998284578323364
of O O 0.9998939037322998
developing O O 0.9833616614341736
thrombosis B-Disease B-Disease 0.9779037237167358
by O O 0.9957634210586548
day O O 0.9989027976989746
30 O O 0.9978535771369934
. O O 0.9999970197677612

RESULTS O O 0.9984506368637085
: O O 0.9999836683273315
There O O 0.9999792575836182
were O O 0.9999938011169434
more O O 0.9998306035995483
incidents O O 0.9931964874267578
of O O 0.9997698664665222
bradycardia B-Disease B-Disease 0.9840888977050781
in O O 0.9695003032684326
subjects O O 0.9942260384559631
treated O O 0.9999611377716064
with O O 0.9999778270721436
clonidine B-Chemical B-Chemical 0.9360746741294861
compared O O 0.9981927275657654
with O O 0.9999898672103882
those O O 0.9998395442962646
not O O 0.9999308586120605
treated O O 0.999961256980896
with O O 0.9999810457229614
clonidine B-Chemical B-Chemical 0.9413131475448608
( O O 0.9846315383911133
17 O O 0.9983289837837219
. O O 0.999957799911499
5 O O 0.9999514818191528
% O O 0.9999053478240967
versus O O 0.9999748468399048
3 O O 0.9998501539230347
. O O 0.999976396560669
4 O O 0.9999308586120605
% O O 0.9999346733093262
; O O 0.999967098236084
p O O 0.998612642288208
= O O 0.9999315738677979
. O O 0.9997398257255554
02 O O 0.9958627223968506
) O O 0.9987916350364685
, O O 0.9999663829803467
but O O 0.9999641180038452
no O O 0.9997994303703308
other O O 0.9999102354049683
significant O O 0.9983419179916382
group O O 0.9937784075737
differences O O 0.9895679354667664
regarding O O 0.9999610185623169
electrocardiogram O O 0.5146114230155945
and O O 0.9930114150047302
other O O 0.9991550445556641
cardiovascular O O 0.815569281578064
outcomes O O 0.5473040342330933
. O O 0.999956488609314

The O O 0.9994242191314697
3 O O 0.9611955285072327
- O O 0.9972990155220032
week O O 0.9991071820259094
sulphasalazine S-Chemical B-Chemical 0.9111911654472351
syndrome O O 0.36208897829055786
strikes O O 0.9960222840309143
again O O 0.9992965459823608
. O O 0.9999982118606567

The O O 0.9992325305938721
areas O O 0.9997335076332092
where O O 0.9999616146087646
calcitonin S-Chemical B-Chemical 0.923485279083252
is O O 0.9950551986694336
most O O 0.9999147653579712
effective O O 0.999653697013855
in O O 0.9999783039093018
decreasing O O 0.9952929615974426
locomotor O O 0.8425150513648987
activity O O 0.5906083583831787
are O O 0.999763548374176
located O O 0.9999270439147949
in O O 0.9999892711639404
the O O 0.9996334314346313
hypothalamus O O 0.5734251141548157
and O O 0.9893723130226135
nucleus O O 0.775022566318512
accumbens O O 0.8741990923881531
, O O 0.9999562501907349
suggesting O O 0.9999959468841553
that O O 0.9999945163726807
these O O 0.9999741315841675
areas O O 0.999788224697113
are O O 0.9999990463256836
the O O 0.9999823570251465
major O O 0.9983256459236145
sites O O 0.9997017979621887
of O O 0.999975323677063
action O O 0.9865735769271851
of O O 0.9989062547683716
calcitonin S-Chemical B-Chemical 0.9180470108985901
in O O 0.9982481002807617
inhibiting O O 0.9960479140281677
amphetamine S-Chemical B-Chemical 0.9344552159309387
- O O 0.9296156167984009
induced O O 0.9970092177391052
locomotor O O 0.7033405900001526
activity O O 0.7853726148605347
. O O 0.9997981190681458

) O O 0.7211862206459045
was O O 0.9992338418960571
observed O O 0.9998569488525391
. O O 0.9999963045120239
Of O O 0.999996542930603
note O O 0.981130838394165
was O O 0.9999617338180542
the O O 0.9999828338623047
associated O O 0.9866988658905029
emergence O O 0.994802713394165
of O O 0.9999537467956543
second-site B-DNA O 0.8354945182800293
LTR E-DNA B-DNA 0.3954794406890869
revertants O E-DNA 0.6110326647758484
which O O 0.9993035793304443
involved O O 0.9999943971633911
an O O 0.9999866485595703
alteration O O 0.9969491362571716
of O O 0.9998279809951782
the O O 0.9999499320983887
TATA B-DNA B-DNA 0.47374486923217773
box E-DNA E-DNA 0.9522078037261963
. O O 0.9996355772018433
These O O 0.9999957084655762
results O O 0.9999499320983887
suggest O O 0.9999983310699463
that O O 0.9999983310699463
the O O 0.9999113082885742
human B-DNA O 0.5785467028617859
immunodeficiency I-DNA O 0.5413691401481628
virus I-DNA O 0.6154415607452393
type I-DNA O 0.7739743590354919

control O O 0.973969578742981
of O O 0.9993250370025635
GATA-1 S-protein S-protein 0.8829843401908875
transcription O O 0.9556844234466553
. O O 0.9999700784683228
To O O 0.9999969005584717
examine O O 0.9999957084655762
whether O O 0.9999923706054688
GATA-1 S-protein S-protein 0.9779320359230042
expression O O 0.9994702935218811
involves O O 0.9999977350234985
additional O O 0.9972285628318787
regulatory B-protein O 0.9054349064826965

their O O 0.9947861433029175
HIV B-RNA B-RNA 0.36356836557388306
genomic I-RNA I-RNA 0.5710695385932922
RNA E-RNA E-RNA 0.8856555819511414
. O O 0.9997599720954895
Measurement O O 0.9934192299842834
of O O 0.9998428821563721
the O O 0.9999361038208008
transcriptional O O 0.8451991081237793
activity O O 0.9856025576591492
of O O 0.9999392032623291
the O O 0.9997040629386902
HIV-1 B-DNA B-DNA 0.6716732978820801
promoter E-DNA E-DNA 0.9821605682373047
after O O 0.9986206293106079

Mice O O 0.7779074907302856
in O O 0.9995631575584412
which O O 0.9999934434890747
the O O 0.9996942281723022
CX3CR1 O O 0.5291422605514526
gene O O 0.44329744577407837
has O O 0.9997683167457581
been O O 0.999862790107727
deleted O O 0.9966300129890442
and O O 0.9999790191650391
replaced O O 0.9997580647468567
with O O 0.9999958276748657
a O O 0.999846339225769
cDNA O O 0.4013954997062683
encoding O O 0.8635231256484985
enhanced O O 0.9928792119026184
green O O 0.7965114712715149
fluorescent O O 0.8387914299964905
protein O O 0.7138962149620056
( O O 0.9981400966644287
eGFP O O 0.4382307231426239
) O O 0.9923343062400818
were O O 0.9999910593032837
treated O O 0.9999943971633911
with O O 0.9999943971633911
METH S-Chemical B-Chemical 0.8998915553092957
and O O 0.9937168955802917
examined O O 0.9994617104530334
for O O 0.99997878074646
striatal O O 0.7057029008865356
neurotoxicity O B-Disease 0.6447682976722717
. O O 0.9992814660072327

significantly O O 0.9885058403015137
different O O 0.9997439980506897
from O O 0.9999815225601196
those O O 0.9999330043792725
measured O O 0.999561607837677
with O O 0.9999892711639404
threshold O O 0.9981030225753784
of O O 0.9999595880508423
cathepsin B-protein B-protein 0.5853151679039001
G E-protein E-protein 0.8508061766624451
alone O O 0.9800262451171875
( O O 0.9999552965164185
p O O 0.998043417930603
> O O 0.9997555613517761
0.05 O O 0.9986028075218201
) O O 0.9998124241828918
, O O 0.9999935626983643
indicating O O 0.9999963045120239
that O O 0.9999984502792358
the O O 0.9999282360076904
phospholipase B-protein B-protein 0.4956907331943512
C E-protein E-protein 0.7310989499092102
/protein B-protein O 0.5521918535232544

, O O 0.9738038182258606
reversible O O 0.9959450364112854
, O O 0.9999576807022095
and O O 0.9999637603759766
according O O 0.999982476234436
to O O 0.9998791217803955
serum O O 0.9221621751785278
and O O 0.9871178269386292
urinary O O 0.9764965176582336
cortisol O O 0.9781048893928528
levels O O 0.9998699426651001
and O O 0.9999780654907227

Th2-type I-cell_line B-cell_type 0.2286902666091919
lymphocytes E-cell_line E-cell_type 0.83743816614151
. O O 0.9995269775390625
We O O 0.9999836683273315
have O O 0.9999909400939941
recently O O 0.9999587535858154
found O O 0.9999862909317017
a O O 0.9999768733978271
novel O O 0.9180639386177063
conserved B-DNA B-DNA 0.7547683119773865
motif E-DNA E-DNA 0.7756367325782776
in O O 0.9992967844009399
the O O 0.9998898506164551
promoters S-DNA S-DNA 0.9669256806373596
of O O 0.998111367225647
several O O 0.9948499798774719
T-cell-expressed B-protein B-protein 0.2697577476501465
cytokines E-protein E-protein 0.9633935689926147
[ O O 0.9918943047523499
human B-protein B-protein 0.3736647963523865
interleukin-2 I-protein I-protein 0.563939094543457
, I-protein I-protein 0.603068470954895
-4 I-protein I-protein 0.5214399099349976
, I-protein I-protein 0.6717338562011719
-5 I-protein I-protein 0.5692332983016968

assays O O 0.932441771030426
: O O 0.9996486902236938
nearly O O 0.9999606609344482
all O O 0.9999910593032837
of O O 0.9999898672103882
the O O 0.9999897480010986
activity O O 0.9954541921615601
was O O 0.999977707862854
due O O 0.999996542930603
to O O 0.9999500513076782
NFATp S-protein S-protein 0.9741515517234802
. O O 0.9999312162399292
This O O 0.9999812841415405
is O O 0.999991774559021
the O O 0.999997615814209
first O O 0.9995933175086975
study O O 0.9997668862342834
of O O 0.9999542236328125
expression O O 0.9962523579597473
of O O 0.9999583959579468
all O O 0.9997374415397644
family O O 0.7600411772727966
members O O 0.4509655237197876
at O O 0.9998425245285034
the O O 0.9999372959136963
protein O O 0.7443020343780518
level O O 0.9794871211051941
in O O 0.9998903274536133
normal B-cell_type B-cell_type 0.5162702798843384
human I-cell_type I-cell_type 0.5903918147087097
T I-cell_type I-cell_type 0.8533512949943542
cells E-cell_type E-cell_type 0.9800804853439331
. O O 0.9996236562728882
Of O O 0.9999974966049194
the O O 0.9999876022338867
GATA-binding B-protein B-protein 0.501604437828064
proteins E-protein E-protein 0.9945277571678162
, O O 0.9997023940086365
only O O 0.9999474287033081
GATA-4 S-protein S-protein 0.975663423538208
selectively O O 0.9942599534988403
regulates O O 0.9990021586418152

an O O 0.9982403516769409
in O O 0.995961606502533
vitro O O 0.9804035425186157
model O O 0.9883618950843811
of O O 0.9998859167098999
co-cultured B-cell_type B-cell_type 0.46932893991470337
blood I-cell_type I-cell_type 0.529614269733429
monocytes E-cell_type E-cell_type 0.5774738192558289
( O O 0.9626666903495789
BM S-cell_type S-cell_type 0.6239100098609924
) O O 0.7601921558380127
and O O 0.9810113906860352
BEAS-2B B-cell_line B-cell_line 0.5993677377700806
cells E-cell_line E-cell_line 0.9167047142982483
in O O 0.9999022483825684
a O O 0.9999698400497437
transwell O O 0.7829403877258301
system O O 0.5256224274635315
( O O 0.999509334564209
Costar O O 0.578460156917572
) O O 0.9496231079101562
. O O 0.9999077320098877
BM S-cell_type O 0.531186044216156
were O O 0.999666690826416
exposed O O 0.9990578293800354
to O O 0.9993311166763306

host O O 0.6228011250495911
and O O 0.9756691455841064
viral O O 0.9127863645553589
mechanisms O O 0.9790184497833252
that O O 0.9999858140945435
control O O 0.9916961789131165
transcription O O 0.935884952545166
. O O 0.9997909665107727
Low O O 0.9902163743972778
levels O O 0.9990060925483704
of O O 0.9999110698699951
viral O O 0.7617939710617065
transcription O O 0.47838303446769714
( O O 0.9825634360313416
basal O O 0.8491079807281494
transcription O O 0.7396274209022522
) O O 0.9603590965270996
occur O O 0.9998641014099121
before O O 0.9999942779541016
expression O O 0.9995817542076111
of O O 0.9999397993087769
the O O 0.9998733997344971
virally B-protein B-protein 0.4543593227863312
encoded I-protein I-protein 0.45372629165649414
Tax I-protein I-protein 0.4519818127155304
protein E-protein E-protein 0.9891351461410522
( O O 0.9322242736816406

This O O 0.9994345307350159
was O O 0.9999614953994751
a O O 0.999984860420227
case O O 0.9994149208068848
of O O 0.9999819993972778
acute O O 0.8182260394096375
palsy B-Disease O 0.6919357776641846
of O O 0.8237407207489014
the O O 0.9601278305053711
recurrent O O 0.9587599635124207
laryngeal O O 0.476514607667923
nerve O O 0.9032946825027466
and O O 0.887229323387146
superimposed O O 0.9673246145248413
severe O O 0.983646035194397
acute O O 0.8699091672897339
sensorimotor O O 0.7288991212844849
axonal O O 0.6133372187614441
polyneuropathy B-Disease O 0.6814028024673462
caused O O 0.9935630559921265
by O O 0.9999474287033081
high O O 0.990295946598053
- O O 0.9970316886901855
dose O O 0.9976195693016052
disulfiram B-Chemical B-Chemical 0.9186950325965881
intoxication O O 0.40374401211738586
. O O 0.9999780654907227

sequencing O O 0.8192287087440491

The O O 0.9993851184844971
first O O 0.9936532974243164
patient O O 0.9990317821502686
died O O 0.9993957281112671
without O O 0.9999715089797974
a O O 0.9998168349266052
diagnosis O O 0.9359822273254395
; O O 0.9999297857284546
the O O 0.9999743700027466
second O O 0.9981617331504822
patient O O 0.999664306640625
had O O 0.9999674558639526
a O O 0.9998733997344971
dramatic O O 0.9484560489654541
recovery O O 0.821849524974823
following O O 0.999942421913147
the O O 0.999968409538269
administration O O 0.9989175796508789
of O O 0.9999551773071289
vitamin B-Chemical B-Chemical 0.9518120288848877
B6 I-Chemical I-Chemical 0.9408246278762817
. O O 0.9990233182907104

Activation O O 0.9854388236999512
of O O 0.9997715353965759
STAT5 S-protein S-protein 0.9852205514907837
by O O 0.9997661709785461
IL-4 S-protein S-protein 0.9918391108512878
relies O O 0.9997443556785583
on O O 0.9999831914901733
Janus B-protein B-protein 0.43325674533843994
kinase E-protein E-protein 0.8889989852905273
function O O 0.9713691473007202
but O O 0.9996745586395264
not O O 0.9998586177825928
on O O 0.9995611310005188
receptor O O 0.8283675312995911
tyrosine O O 0.8033791780471802
phosphorylation O O 0.9579086303710938
, O O 0.999537467956543
and O O 0.9999456405639648
can O O 0.999975323677063
contribute O O 0.9999959468841553
to O O 0.9999924898147583
both O O 0.9996196031570435
cell O O 0.9765363335609436
proliferation O O 0.996336817741394
and O O 0.9998936653137207
gene O O 0.9610635638237
regulation O O 0.9980248212814331
. O O 0.9999978542327881
We O O 0.9999839067459106
have O O 0.9999970197677612
investigated O O 0.9997648596763611
mechanisms O O 0.9986000657081604
and O O 0.9999624490737915
consequences O O 0.9998531341552734
of O O 0.999976396560669
STAT5 S-protein S-protein 0.970984935760498
activation O O 0.9974709749221802
through O O 0.9999910593032837

In O O 0.9996269941329956
group O O 0.9851106405258179
C O O 0.9478525519371033
, O O 0.9999411106109619
AKBR O O 0.37763264775276184
showed O O 0.9997647404670715
a O O 0.9999692440032959
significant O O 0.9984184503555298
decrease O O 0.9322962760925293
at O O 0.9996823072433472
120 O O 0.998805046081543
min O O 0.9995290040969849
( O O 0.9999884366989136
- O O 0.9999380111694336
40 O O 0.9999159574508667
% O O 0.9999493360519409
) O O 0.9997053742408752
and O O 0.9999862909317017
at O O 0.9999924898147583
180 O O 0.9987156391143799
min O O 0.9994400143623352
( O O 0.9999916553497314
- O O 0.9999420642852783
49 O O 0.9999336004257202
% O O 0.9999690055847168
) O O 0.9997853636741638
after O O 0.9999978542327881
the O O 0.9999871253967285
start O O 0.9995146989822388
of O O 0.9999071359634399
hypotension B-Disease B-Disease 0.9609647393226624
and O O 0.9914829134941101
at O O 0.9999605417251587
60 O O 0.9994043111801147
min O O 0.9996154308319092
( O O 0.9999915361404419
- O O 0.999943733215332
32 O O 0.9999431371688843
% O O 0.9999734163284302
) O O 0.9997722506523132
after O O 0.9999803304672241
recovery O O 0.9715688228607178
of O O 0.9993163347244263
normotension O O 0.517253041267395
, O O 0.9963611960411072
and O O 0.9998267292976379
SGOT O O 0.8454978466033936
, O O 0.9845082759857178
SGPT O O 0.8399420380592346
, O O 0.9890521168708801
LDH O O 0.8397935628890991
and O O 0.9971837401390076
total O O 0.9140100479125977
bilirubin B-Chemical B-Chemical 0.9121972918510437
showed O O 0.999653697013855
significant O O 0.9958149790763855
increases O O 0.8258937001228333
after O O 0.9952822327613831
operation O O 0.9959000945091248
. O O 0.9999985694885254

Sp1 B-DNA B-DNA 0.6306419372558594
sites E-DNA E-DNA 0.9567010402679443
. O O 0.9998816251754761
No O O 0.9999167919158936
positive O O 0.9723981022834778
effect O O 0.9995914101600647
of O O 0.9999827146530151
the O O 0.999985933303833
duplicated O O 0.8111749887466431
CTG-motif S-DNA S-protein 0.30433180928230286
could O O 0.9988231062889099
be O O 0.9999772310256958
detected O O 0.9998032450675964
. O O 0.9999973773956299
In O O 0.999976634979248
order O O 0.999895453453064
to O O 0.9999945163726807
measure O O 0.999942421913147
small O O 0.9869744777679443
differences O O 0.9982585310935974
in O O 0.9999614953994751
virus O O 0.9701987504959106
production O O 0.9992477893829346
more O O 0.9999889135360718
accurately O O 0.9994989633560181
, O O 0.9999915361404419
equal O O 0.9980068802833557
amounts O O 0.9996941089630127

The O O 0.999482274055481
VAS O O 0.8313392400741577
scores O O 0.9926443099975586
for O O 0.9999849796295166
recall O O 0.9146899580955505
of O O 0.9856786131858826
pain B-Disease O 0.9321751594543457
in O O 0.9899342656135559
the O O 0.9992616772651672
recovery O O 0.9555388689041138
room O O 0.9970479607582092
were O O 0.9999957084655762
correlated O O 0.9999350309371948
with O O 0.9999957084655762
the O O 0.9999372959136963
VAS O O 0.7648977637290955
scores O O 0.9765268564224243
during O O 0.9999880790710449
induction O O 0.9693971872329712
( O O 0.9999064207077026
r O O 0.9993257522583008
= O O 0.9999291896820068
0 O O 0.999813973903656
. O O 0.9999305009841919
7045 O O 0.9524824023246765
; O O 0.9999111890792847
P O O 0.994612455368042
< O O 0.9997547268867493
0 O O 0.999664306640625
. O O 0.9998555183410645
0001 O O 0.9524437189102173
) O O 0.9992749094963074
. O O 0.9999966621398926

advances O O 0.9869856238365173
that O O 0.9999815225601196
have O O 0.9999884366989136
led O O 0.999984860420227
to O O 0.9999790191650391
a O O 0.9999850988388062
better O O 0.9998751878738403
understanding O O 0.999915599822998
of O O 0.9999837875366211
how O O 0.9999872446060181
cytokines S-protein S-protein 0.9924479722976685
elicit O O 0.9995272159576416
intracellular O O 0.9310179948806763
responses O O 0.9917706251144409
, O O 0.9999837875366211
as O O 0.9999878406524658
well O O 0.9997987151145935
as O O 0.999994158744812
their O O 0.9999836683273315
role O O 0.9994739890098572
in O O 0.999950647354126
normal O O 0.5429526567459106

and O O 0.9407603144645691
proliferating B-cell_type O 0.861348569393158
T I-cell_type B-cell_type 0.586695671081543
lymphocytes E-cell_type E-cell_type 0.9928810596466064
. O O 0.9996999502182007
Expression O O 0.9983968138694763
of O O 0.9994785189628601
c-jun B-DNA S-DNA 0.818557620048523
, I-DNA O 0.9130494594573975
jun I-DNA B-protein 0.21607595682144165
B I-DNA E-protein 0.6420150399208069
and I-DNA O 0.717549204826355

the O O 0.9989639520645142
duration O O 0.9997714161872864
of O O 0.9999936819076538
this O O 0.999970555305481
response O O 0.9988571405410767
by O O 0.9999957084655762
activating O O 0.9958539009094238
the O O 0.9999139308929443
transcription O O 0.9504000544548035
of O O 0.996951699256897
IRF-2 S-protein S-protein 0.9663919806480408
. O O 0.9995962977409363
Interferon B-protein B-protein 0.6465772986412048
alpha E-protein E-protein 0.983150064945221
selectively O O 0.9935061931610107
affects O O 0.9999598264694214
expression O O 0.9974598288536072
of O O 0.9999464750289917
the O O 0.9997970461845398
human B-protein O 0.4786740243434906
myeloid I-protein O 0.28290534019470215
cell I-protein O 0.48139122128486633
nuclear I-protein O 0.25991421937942505
differentiation I-protein O 0.6215727925300598

reactive O O 0.7872284054756165

Incidence O O 0.9945915341377258
of O O 0.9999390840530396
transient O O 0.8884302377700806
cyclophosphamide B-Chemical B-Chemical 0.9259885549545288
- O O 0.9439312219619751
related O O 0.9978274703025818
cardiac B-Disease B-Disease 0.5506470799446106
toxicity I-Disease I-Disease 0.9141965508460999
( O O 0.9590474963188171
10 O O 0.9986225366592407
% O O 0.9997597336769104
) O O 0.9995778203010559
is O O 0.9999908208847046
comparable O O 0.9999862909317017
to O O 0.999995231628418
previous O O 0.9998345375061035
recorded O O 0.9826229810714722
literature O O 0.5855780839920044
. O O 0.9999663829803467

In O O 0.9996545314788818
the O O 0.9999457597732544
remaining O O 0.9996551275253296
three O O 0.999594509601593
patients O O 0.9992758631706238
, O O 0.9999715089797974
procainamide B-Chemical B-Chemical 0.933659553527832
was O O 0.9949938654899597
administered O O 0.999871015548706
orally O O 0.9988129138946533
for O O 0.9999916553497314
treatment O O 0.9995538592338562
of O O 0.9999724626541138
chronic O O 0.764178991317749
premature B-Disease O 0.7859621047973633
ventricular I-Disease O 0.6558365821838379
contractions I-Disease O 0.9216902256011963
or O O 0.9750388264656067
atrial B-Disease B-Disease 0.6288228034973145
flutter I-Disease I-Disease 0.9747442603111267
. O O 0.9972142577171326

induced O O 0.9861802458763123
by O O 0.999901294708252
transfection O O 0.9943822622299194
of O O 0.9997828602790833
the O O 0.9998668432235718
cells O O 0.9722205996513367
with O O 0.999923825263977
the O O 0.9998866319656372
BRLF1/BZLF1 B-DNA B-DNA 0.36648479104042053
coding I-DNA I-DNA 0.40298885107040405
region E-DNA E-DNA 0.5948894023895264
of O O 0.9935270547866821
the O O 0.9997125267982483
P3HR-1 B-DNA B-DNA 0.28327295184135437
defective I-DNA I-DNA 0.6572198271751404
genome E-DNA E-DNA 0.9873991012573242
. O O 0.9997127652168274
We O O 0.9994025230407715
combined O O 0.9999369382858276

Sequential O O 0.9859557151794434
observations O O 0.9947541952133179
of O O 0.9998916387557983
exencephaly O O 0.5907410383224487
and O O 0.9277607798576355
subsequent O O 0.9876683354377747
morphological O O 0.9087970852851868
changes O O 0.9234486818313599
by O O 0.9999616146087646
mouse O O 0.897433876991272
exo O O 0.8563727736473083
utero O O 0.8828427195549011
development O O 0.9913977384567261
system O O 0.9978935122489929
: O O 0.9999909400939941
analysis O O 0.9989581108093262
of O O 0.9999634027481079
the O O 0.9999388456344604
mechanism O O 0.9981653094291687
of O O 0.999840497970581
transformation O O 0.8196467757225037
from O O 0.9994432330131531
exencephaly O O 0.823228120803833
to O O 0.9033511281013489
anencephaly O O 0.8018596768379211
. O O 0.9976845979690552

response O O 0.9728896617889404
to O O 0.9999122619628906
insulin-induced O O 0.9282552003860474
hypoglycemia O O 0.8449099063873291
, O O 0.9998323917388916
while O O 0.9999929666519165
cortisol O O 0.9377058744430542
production O O 0.9991037249565125
was O O 0.999990701675415
elevated O O 0.9995415210723877
in O O 0.999988317489624
three O O 0.9997484087944031
patients O O 0.999843955039978
. O O 0.9999986886978149
Circulating O O 0.8880852460861206
adrenal O O 0.8714900612831116
androgen O O 0.9281986355781555
levels O O 0.9996575117111206
were O O 0.9999914169311523
increased O O 0.9999374151229858
in O O 0.9999780654907227
all O O 0.9998557567596436
patients O O 0.9997603297233582
. O O 0.9999974966049194
Glucocorticoid B-protein B-protein 0.5226659774780273
receptors E-protein E-protein 0.9956837892532349
were O O 0.999790608882904
investigated O O 0.9999927282333374
in O O 0.999991774559021
a O O 0.999962329864502
whole O O 0.9483252167701721
cell O O 0.9496447443962097
dexamethasone O O 0.8473009467124939
binding O O 0.8611501455307007
assay O O 0.9901224970817566
in O O 0.9999446868896484
mononuclear B-cell_type B-cell_type 0.7584601640701294
leukocytes E-cell_type E-cell_type 0.9764003753662109

complex E-protein E-protein 0.9792161583900452
, O O 0.9983232617378235
whereas O O 0.9999886751174927
IL-7 S-protein S-protein 0.9943951368331909
acts O O 0.9973669648170471
as O O 0.9999951124191284
a O O 0.9999676942825317
cofactor O O 0.5776501893997192
by O O 0.9971953630447388
sustaining O O 0.9997288584709167
the O O 0.9999068975448608
expression O O 0.9992746710777283
of O O 0.9999567270278931
the O O 0.9997087121009827
p75 B-protein B-protein 0.5681785345077515
TNF I-protein I-protein 0.7129054665565491
receptor E-protein E-protein 0.9578742980957031
. O O 0.9980698227882385
The O O 0.9999966621398926
requirement O O 0.9992836117744446
for O O 0.9999232292175293
TNF S-protein S-protein 0.9903444647789001
is O O 0.999834418296814
further O O 0.9999375343322754
confirmed O O 0.9999667406082153
by O O 0.9999674558639526

All O O 0.9988861680030823
four O O 0.9977710247039795
recovered O O 0.9939064383506775
completely O O 0.9926303625106812
without O O 0.9999369382858276
neurological B-Disease O 0.8750106692314148
sequelae I-Disease O 0.7862432599067688
following O O 0.9978068470954895
the O O 0.9998998641967773
withdrawal O O 0.9771146178245544
of O O 0.9995207786560059
the O O 0.9999383687973022
offending O O 0.8322545289993286
agents O O 0.9660506248474121
. O O 0.9999960660934448

expressed O O 0.9863542914390564
exclusively O O 0.999521017074585
in O O 0.9997487664222717
lymphoid B-cell_type B-cell_type 0.6378729343414307
cells E-cell_type E-cell_type 0.9284499287605286
and O O 0.9957455992698669
can O O 0.9997779726982117
be O O 0.9999620914459229
detected O O 0.999843955039978
in O O 0.9999140501022339
early O O 0.6807291507720947
fetal O O 0.542853593826294
thymus O O 0.38305675983428955
and O O 0.9660230278968811
spleen O O 0.7101280093193054
. O O 0.9996235370635986
In O O 0.999775230884552
situ O O 0.9604049324989319
hybridizations O O 0.9497395753860474
of O O 0.9999372959136963
adult O O 0.8512662053108215
murine O O 0.7833724617958069
tissues O O 0.8502721190452576
demonstrate O O 0.9999792575836182
Spi-B B-RNA B-RNA 0.7882445454597473
mRNA E-RNA E-RNA 0.9975118637084961
in O O 0.9997071623802185
the O O 0.99994957447052
medulla O O 0.6631380319595337
of O O 0.9744850397109985

Clonidine B-Chemical B-Chemical 0.92396479845047
for O O 0.9974669218063354
attention B-Disease O 0.8816583752632141
- I-Disease O 0.9466692805290222
deficit I-Disease O 0.539879560470581
/ I-Disease O 0.9682775735855103
hyperactivity I-Disease B-Disease 0.861968994140625
disorder I-Disease I-Disease 0.9861652851104736
: O O 0.9282770156860352
II O O 0.4233952462673187
. O O 0.9998935461044312

The O O 0.9991965889930725
combined O O 0.9888272285461426
treatment O O 0.9996566772460938
resulted O O 0.9999902248382568
in O O 0.9999507665634155
more O O 0.9990367889404297
durable O O 0.9785876274108887
inhibition O O 0.9930351972579956
of O O 0.9999282360076904
HIV-1 O O 0.837410569190979
replication O O 0.9729318618774414
than O O 0.9999198913574219
was O O 0.999525785446167
seen O O 0.9999890327453613
with O O 0.9999969005584717
the O O 0.9998857975006104
NF-kappa B-protein B-protein 0.5270935297012329
B E-protein E-protein 0.9098243713378906
inhibitors O O 0.5782559514045715
alone O O 0.9959502220153809
or O O 0.9999740123748779
the O O 0.9999713897705078
anti- O O 0.8786574006080627
Tat B-protein B-protein 0.42612290382385254
sFv I-protein I-protein 0.4346565008163452
intrabodies E-protein E-protein 0.926509439945221
alone O O 0.9948832988739014
. O O 0.9999964237213135
Together O O 0.9999890327453613
, O O 0.9999948740005493
these O O 0.9999804496765137
results O O 0.9999175071716309
suggest O O 0.9999960660934448
that O O 0.999996542930603
in O O 0.9997908473014832
future O O 0.9951586127281189
clinical O O 0.9775197505950928
gene O O 0.8861711025238037
therapy O O 0.9968737363815308

In O O 0.9995750784873962
view O O 0.9999614953994751
of O O 0.9999938011169434
the O O 0.9999822378158569
potentially O O 0.9968037605285645
widespread O O 0.9930359721183777
use O O 0.9989584684371948
of O O 0.9999597072601318
these O O 0.9998878240585327
compounds O O 0.990328848361969
, O O 0.9999924898147583
there O O 0.9999970197677612
is O O 0.999992847442627
an O O 0.999972939491272
urgent O O 0.9952989220619202
need O O 0.9993281364440918
to O O 0.9999855756759644
develop O O 0.9999581575393677
safer O O 0.9938270449638367
alternatives O O 0.9990168809890747
. O O 0.999998927116394

The O O 0.9978762865066528
patient O O 0.9931212067604065
was O O 0.9999357461929321
treated O O 0.9999818801879883
with O O 0.9999849796295166
methylprednisolone S-Chemical B-Chemical 0.9264887571334839
and O O 0.9963239431381226
gradually O O 0.9940232634544373
improved O O 0.9969898462295532
. O O 0.9999915361404419

The O O 0.9993851184844971
first O O 0.9936532974243164
patient O O 0.9990317821502686
died O O 0.9993957281112671
without O O 0.9999715089797974
a O O 0.9998168349266052
diagnosis O O 0.9359822273254395
; O O 0.9999297857284546
the O O 0.9999743700027466
second O O 0.9981617331504822
patient O O 0.999664306640625
had O O 0.9999674558639526
a O O 0.9998733997344971
dramatic O O 0.9484560489654541
recovery O O 0.821849524974823
following O O 0.999942421913147
the O O 0.999968409538269
administration O O 0.9989175796508789
of O O 0.9999551773071289
vitamin B-Chemical B-Chemical 0.9518120288848877
B6 E-Chemical I-Chemical 0.9408246278762817
. O O 0.9990233182907104

OBJECTIVE O O 0.9002571702003479
: O O 0.9991047978401184
The O O 0.9999305009841919
globus O O 0.8595306873321533
pallidus O O 0.45810866355895996
plays O O 0.9994385838508606
a O O 0.9999747276306152
critical O O 0.9970124959945679
role O O 0.9994076490402222
in O O 0.999983549118042
movement O O 0.9787053465843201
regulation O O 0.9833312630653381
. O O 0.9999978542327881

Five O O 0.9936793446540833
patients O O 0.9976674914360046
died O O 0.9992440938949585
before O O 0.9999934434890747
the O O 0.9999879598617554
interview O O 0.9992325305938721
, O O 0.9999971389770508
all O O 0.9999889135360718
of O O 0.9999902248382568
them O O 0.9999712705612183
had O O 0.9998865127563477
taken O O 0.9998327493667603
appetite B-Chemical B-Chemical 0.934168815612793
suppressants E-Chemical I-Chemical 0.9412372708320618
. O O 0.9996166229248047

. O O 0.9969846606254578
The O O 0.9999663829803467
AP-1 B-DNA B-DNA 0.49456408619880676
mutant I-DNA I-DNA 0.41535502672195435
constructs E-DNA E-DNA 0.9750692844390869
also O O 0.9978693723678589
showed O O 0.9999901056289673
delayed O O 0.974798858165741
transcriptional O O 0.9190683364868164
activation O O 0.9886623024940491
in O O 0.999946117401123
PMA-treated B-cell_line B-cell_line 0.6243250370025635
fibroblasts E-cell_line E-cell_line 0.6653803586959839
. O O 0.9998064637184143
Western O O 0.9647107124328613
and O O 0.9927229285240173
supershift O O 0.9627267718315125
analyses O O 0.9899589419364929
indicated O O 0.999990701675415
that O O 0.9999967813491821
functional B-protein O 0.9074221849441528
Jun I-protein B-protein 0.8571138381958008
and I-protein I-protein 0.9341844320297241
Fos I-protein I-protein 0.5374257564544678
proteins E-protein E-protein 0.9847426414489746
were O O 0.9996719360351562
present O O 0.999969482421875
in O O 0.999977707862854
nuclear O O 0.9158934950828552
extracts O O 0.9716252088546753
of O O 0.9997807145118713
PMA-differentiated B-cell_line B-cell_line 0.6363138556480408
U937 I-cell_line I-cell_line 0.6337652206420898
cells E-cell_line E-cell_line 0.9946764707565308
. O O 0.9998894929885864
Promoter O O 0.8145436644554138
deletion O O 0.8285592198371887
constructs O O 0.590545117855072

A O O 0.9952822327613831
healthy O O 0.9803046584129333
17 O O 0.9975811243057251
- O O 0.9998470544815063
year O O 0.9999568462371826
- O O 0.9999053478240967
old O O 0.9993249177932739
male O O 0.9942071437835693
received O O 0.9999812841415405
standard O O 0.9925538897514343
intermittent O O 0.9112147092819214
doses O O 0.9911075234413147
of O O 0.999248206615448
pethidine S-Chemical B-Chemical 0.928927481174469
via O O 0.9980660080909729
a O O 0.999715268611908
patient O O 0.9979329109191895
- O O 0.9998513460159302
controlled O O 0.9930892586708069
analgesia O O 0.8358754515647888
( O O 0.9873338937759399
PCA O O 0.499199241399765
) O O 0.9802765846252441
pump O O 0.9818496108055115
for O O 0.9999823570251465
management O O 0.9946262240409851
of O O 0.9993876218795776
postoperative O O 0.8562692403793335
pain O O 0.6711414456367493
control O O 0.7642930746078491
. O O 0.9999825954437256

cells E-cell_line E-cell_type 0.6684248447418213
, O O 0.999269425868988
two O O 0.9998520612716675
other O O 0.9998360872268677
synthetic O O 0.8508776426315308
nonselective O O 0.8886114954948425
RAR O O 0.34590837359428406
ligands O O 0.671999990940094
are O O 0.9992344379425049
capable O O 0.9999092817306519
of O O 0.9999451637268066
inducing O O 0.9989745616912842
LAP S-protein O 0.4144538938999176
as O O 0.998333752155304
much O O 0.9998854398727417
as O O 0.9999412298202515
AM580 O O 0.3961070477962494
, O O 0.9894238114356995
whereas O O 0.9999759197235107
RAR O B-protein 0.2555524706840515
beta- O E-protein 0.6416055560112
or O O 0.8852075338363647
RAR O S-protein 0.5210842490196228
gamma-specific O O 0.4442884624004364
ligands O O 0.6645577549934387
are O O 0.9996765851974487
totally O O 0.9937959909439087
ineffective O O 0.9985235333442688
. O O 0.9999984502792358
These O O 0.9999959468841553
results O O 0.9999399185180664
show O O 0.9999977350234985
that O O 0.9999958276748657
AM580 O O 0.6808988451957703
is O O 0.9997586607933044
more O O 0.9996980428695679
powerful O O 0.9910208582878113
than O O 0.9998680353164673
ATRA O O 0.6622297167778015
in O O 0.9990342855453491
modulating O O 0.9053274989128113

No O O 0.9991797804832458
significant O O 0.9993395209312439
changes O O 0.9867125749588013
in O O 0.9941334128379822
diastolic O O 0.9434028267860413
blood O O 0.9249576926231384
pressure O O 0.6405898332595825
, O O 0.9996824264526367
pulse O O 0.7901121973991394
rate O O 0.9675233364105225
and O O 0.9998425245285034
basal O O 0.9207108020782471
tear O O 0.6559737920761108
secretion O O 0.8080363273620605
were O O 0.9998816251754761
noted O O 0.9999942779541016
. O O 0.999998927116394

IL-10 S-protein S-protein 0.6568127870559692

Compared O O 0.9997114539146423
with O O 0.9999940395355225
MDMA S-Chemical O 0.7581013441085815
- O O 0.9690514206886292
free O O 0.9953418970108032
polydrug O O 0.9283173680305481
controls O O 0.9638562798500061
, O O 0.9999889135360718
MDMA S-Chemical O 0.7843381762504578
polydrug O O 0.46525028347969055
users O O 0.9675853848457336
showed O O 0.9999794960021973
impairments O O 0.7707322835922241
in O O 0.9963812232017517
set O O 0.9900197982788086
shifting O O 0.9226221442222595
and O O 0.9985342025756836
memory O O 0.9122331738471985
updating O O 0.9083476662635803
, O O 0.9997746348381042
and O O 0.9999504089355469
also O O 0.9999531507492065
in O O 0.9999575614929199
social O O 0.968789279460907
and O O 0.9850563406944275
emotional O O 0.9219422936439514
judgement O O 0.9614330530166626
processes O O 0.9983325600624084
. O O 0.9999992847442627

necrosis I-protein I-protein 0.4986129701137543
factor-alpha E-protein E-protein 0.9770076274871826
( O O 0.9763585329055786
TNF S-protein S-protein 0.993550181388855
) O O 0.9876894950866699
can O O 0.9999300241470337
occur O O 0.9999876022338867
independently O O 0.9999686479568481
of O O 0.9999867677688599
protein B-protein B-protein 0.6341263055801392
kinase I-protein I-protein 0.6345473527908325
C E-protein E-protein 0.9935057163238525
and O O 0.9953522682189941
activation O O 0.9853470325469971
of O O 0.9996730089187622
a O O 0.9997078776359558
protein B-protein B-protein 0.7063095569610596
tyrosine I-protein I-protein 0.638753354549408
kinase E-protein E-protein 0.9781112670898438
( O O 0.98919278383255
PTK S-protein S-protein 0.9826570153236389
) O O 0.9906407594680786
has O O 0.9999431371688843
recently O O 0.9998962879180908
been O O 0.9999394416809082
implicated O O 0.9998935461044312
in O O 0.9999693632125854
the O O 0.9999269247055054
upregulation O O 0.9940949082374573
of O O 0.9999260902404785
vascular B-protein O 0.5166733860969543
cell I-protein O 0.3225187063217163

Here O O 0.9988804459571838
we O O 0.9999926090240479
show O O 0.9999902248382568
that O O 0.9999914169311523
Delta S-protein S-protein 0.9477283358573914
still O O 0.9978480339050293
utilizes O O 0.9999743700027466
the O O 0.9999808073043823
same O O 0.9998754262924194
pathways O O 0.9983476400375366
as O O 0.999995231628418
wild-type O B-protein 0.6609385013580322
ZAP-70 S-protein E-protein 0.8425747752189636
to O O 0.9880713224411011
mediate O O 0.9950921535491943
NF-AT S-protein S-protein 0.9750291705131531
induction O O 0.9982424974441528
. O O 0.9999955892562866
This O O 0.9999499320983887
is O O 0.9998685121536255
manifested O O 0.9998433589935303
by O O 0.999988317489624
the O O 0.9999517202377319
ability O O 0.9999091625213623
of O O 0.9999722242355347
Delta S-protein S-protein 0.9837280511856079
to O O 0.998970627784729
restore O O 0.9996123909950256
induction O O 0.9963569045066833
of O O 0.9998844861984253
calcium O O 0.6926460862159729
fluxes O O 0.6163216829299927
and O O 0.9925435781478882
mitogen-activated B-protein B-protein 0.6018416285514832
protein I-protein I-protein 0.41127514839172363
kinase E-protein E-protein 0.9475671052932739
activation O O 0.9736194610595703
and O O 0.9994491934776306
by O O 0.9999874830245972
the O O 0.9999438524246216
ability O O 0.998365581035614

Simvastatinezetimibe S-Chemical B-Chemical 0.9313985109329224
and O O 0.9637601375579834
escitalopram S-Chemical B-Chemical 0.937073290348053
( O O 0.9770737290382385
which O O 0.9997062087059021
she O O 0.9945977926254272
was O O 0.9998805522918701
taking O O 0.9999533891677856
for O O 0.9998447895050049
depression O B-Disease 0.9655731320381165
) O O 0.9356926083564758
were O O 0.9998137354850769
discontinued O O 0.9887303709983826
, O O 0.9999344348907471
and O O 0.9999696016311646
other O O 0.9999206066131592
potential O O 0.9988698363304138
causes O O 0.9986687898635864
of O O 0.9998408555984497
hepatotoxicity O B-Disease 0.9812960028648376
were O O 0.9902763366699219
excluded O O 0.999460756778717
. O O 0.9999991655349731

BACKGROUND O O 0.9928881525993347
: O O 0.9999858140945435
Current O O 0.9947130084037781
animal O O 0.8990500569343567
models O O 0.968762218952179
of O O 0.9995885491371155
obsessive B-Disease B-Disease 0.6712266206741333
- I-Disease I-Disease 0.7820831537246704
compulsive I-Disease I-Disease 0.5162416100502014
disorder I-Disease I-Disease 0.9559077620506287
( O O 0.9753748774528503
OCD B-Disease B-Disease 0.9761601686477661
) O O 0.8136275410652161
typically O O 0.9983616471290588
involve O O 0.9999873638153076
acute O O 0.8664164543151855
, O O 0.9847260117530823
drug O O 0.8686617016792297
- O O 0.9600585699081421
induced O O 0.9950404763221741
symptom O O 0.5046855807304382
provocation O O 0.799480676651001
or O O 0.9830465912818909
a O O 0.9992891550064087
genetic O O 0.7989809513092041
association O O 0.5088388323783875
with O O 0.9969185590744019
stereotypies O O 0.8802096247673035
or O O 0.9666247367858887
anxiety B-Disease B-Disease 0.946099579334259
. O O 0.9986020922660828

of O O 0.9983174800872803
the O O 0.999984860420227
proximal B-DNA B-DNA 0.6786367297172546
CD19 I-DNA I-DNA 0.28511491417884827
promoter E-DNA E-DNA 0.9930859804153442
reveal O O 0.9982917904853821
important O O 0.9945729374885559
roles O O 0.9949656128883362
for O O 0.9999837875366211
an O O 0.999783456325531
SP1/Egr-1 B-DNA B-DNA 0.38139107823371887
binding I-DNA I-DNA 0.8573183417320251
site E-DNA E-DNA 0.9790840148925781
and O O 0.9987531900405884
a O O 0.9998984336853027
novel O B-DNA 0.6923110485076904
site O E-DNA 0.8315700888633728
termed O O 0.9986078143119812
the O O 0.9999668598175049
PyG B-DNA B-DNA 0.6510705351829529
box E-DNA E-DNA 0.978289008140564
. O O 0.9993622899055481
CD19 S-protein S-protein 0.6789451241493225
expression O O 0.982528030872345
begins O O 0.9998476505279541
at O O 0.9999974966049194
the O O 0.9999861717224121
pro-B O O 0.6817011833190918
cell O O 0.7103121876716614
stage O O 0.9782124161720276
of O O 0.9997897744178772
B O O 0.7690181732177734
cell O O 0.6089209318161011
development O O 0.9912444949150085
. O O 0.9999966621398926

postulated O O 0.9415521025657654
that O O 0.9999508857727051
this O O 0.9999291896820068
NF-kappaB-regulated B-DNA B-DNA 0.7398430705070496
promoter E-DNA E-DNA 0.9933885335922241
might O O 0.9992075562477112
play O O 0.99997878074646
a O O 0.9999909400939941
role O O 0.9998451471328735
in O O 0.9999901056289673
the O O 0.9999505281448364
activation O O 0.9967576861381531
of O O 0.9998725652694702
the O O 0.9998000264167786
accessory O B-cell_type 0.5466324090957642
cells O E-cell_type 0.891241729259491
as O O 0.9993840456008911
well O O 0.9997791647911072
as O O 0.9999960660934448
the O O 0.999976634979248
rate O O 0.9996354579925537
of O O 0.9999381303787231
replication O O 0.992344319820404
of O O 0.9999228715896606
HIV-1 O O 0.5019842982292175
in O O 0.9962804913520813
monocyte-derived B-cell_type B-cell_type 0.4277150630950928
macrophages E-cell_type E-cell_type 0.9153509140014648
. O O 0.9997684359550476
Transcription B-protein B-protein 0.6790490746498108
factors E-protein E-protein 0.9918642044067383
Sp1 S-protein S-protein 0.962551474571228
and O O 0.9967969059944153
AP-2 S-protein S-protein 0.9814231991767883
mediate O O 0.9967748522758484
induction O O 0.999195396900177
of O O 0.9999655485153198
acid B-protein B-protein 0.7060169577598572
sphingomyelinase E-protein E-protein 0.9517213702201843
during O O 0.9994170665740967

Damage O O 0.6170371174812317
to O O 0.9859073162078857
the O O 0.9889945387840271
capillary O O 0.5297043323516846
was O O 0.9978772401809692
accompanied O O 0.9999344348907471
by O O 0.9999880790710449
marked O O 0.9848669171333313
damage O O 0.6804120540618896
to O O 0.9945188164710999
neuroglial O O 0.48289185762405396
cells O O 0.7307705283164978
, O O 0.9991030693054199
mainly O O 0.9998956918716431
to O O 0.9999672174453735
perivascular O O 0.843026876449585
processes O O 0.9531896114349365
of O O 0.9991781115531921
astrocytes O O 0.2986287474632263
. O O 0.9999247789382935

Rats O O 0.9107669591903687
treated O O 0.9989801049232483
for O O 0.9999741315841675
11 O O 0.9972949624061584
days O O 0.9999091625213623
with O O 0.9999924898147583
morphine B-Chemical B-Chemical 0.9392783045768738
and O O 0.9956607222557068
withdrawn O O 0.9856973886489868
for O O 0.9997194409370422
36 O O 0.9980785846710205
- O O 0.9989370703697205
40 O O 0.9982947707176208
h O O 0.9969147443771362
showed O O 0.9999616146087646
differences O O 0.9827585816383362
in O O 0.9997127652168274
the O O 0.9996602535247803
development O O 0.9963957667350769
of O O 0.999267041683197
tolerance O O 0.5068811774253845
: O O 0.9991528987884521
about O O 0.9999440908432007
half O O 0.9999711513519287
of O O 0.9999836683273315
the O O 0.9999268054962158
animals O O 0.9880148768424988
showed O O 0.9999881982803345
a O O 0.99988853931427
rigidity B-Disease O 0.9047897458076477
after O O 0.9971542358398438
the O O 0.9999321699142456
test O O 0.9983779191970825
dose O O 0.9999594688415527
of O O 0.9996840953826904
morphine B-Chemical B-Chemical 0.9377308487892151
that O O 0.987998366355896
was O O 0.9998793601989746
not O O 0.9999591112136841
significantly O O 0.9998823404312134
less O O 0.9997732043266296
than O O 0.9999598264694214
in O O 0.9997977614402771
the O O 0.9997144341468811
controls O O 0.9987200498580933
and O O 0.9999909400939941
were O O 0.9999901056289673
akinetic B-Disease O 0.6451064348220825
( O O 0.9740493893623352
A O O 0.9548478126525879
group O O 0.996912956237793
) O O 0.999924898147583
. O O 0.9999969005584717

a O O 0.9981306195259094
unique O O 0.9220981597900391
DNA-protein B-protein B-protein 0.3897961974143982
complex E-protein E-protein 0.9902661442756653
was O O 0.9995371103286743
detected O O 0.9999768733978271
when O O 0.9999957084655762
the O O 0.9997747540473938
promoter O B-DNA 0.513677716255188
central O I-DNA 0.881607174873352
21 B-DNA I-DNA 0.7957967519760132
bp I-DNA I-DNA 0.5278320908546448
repeat E-DNA E-DNA 0.9931685924530029
was O O 0.9985314607620239
reacted O O 0.9998863935470581
with O O 0.9999861717224121
nuclear O O 0.9387110471725464
extracts O O 0.9635027050971985
derived O O 0.9998558759689331
from O O 0.999924898147583
either O O 0.9993799924850464
the O O 0.9976842403411865
U-373 B-cell_line S-DNA 0.3284512162208557

METHODS O O 0.9862146973609924
: O O 0.9999240636825562
Patients O O 0.9983641505241394
receiving O O 0.9999865293502808
an O O 0.9999741315841675
OLTX O O 0.6796228885650635
only O O 0.999600350856781
from O O 0.9999940395355225
June O O 0.995349109172821
1985 O O 0.9998605251312256
through O O 0.9999970197677612
December O O 0.999923586845398
of O O 0.9999921321868896
1994 O O 0.9999005794525146
who O O 0.9999914169311523
survived O O 0.9998446702957153
6 O O 0.9992744326591492
months O O 0.9999319314956665
postoperatively O O 0.9990966320037842
were O O 0.9999948740005493
studied O O 0.9998894929885864
( O O 0.999991774559021
n O O 0.9982935786247253
= O O 0.9998763799667358
834 O O 0.9630380272865295
) O O 0.999817430973053
. O O 0.9999970197677612

series O O 0.5005554556846619
with O O 0.9993996620178223
4C O B-DNA 0.29805704951286316
DNA O I-DNA 0.4467707574367523
content O E-DNA 0.7096604108810425
( O O 0.9675910472869873
100B O O 0.5292192101478577
and O O 0.9595642685890198
200B O O 0.4519771933555603
) O O 0.9211949706077576
also O O 0.9996824264526367
differed O O 0.9999309778213501
from O O 0.9999773502349854
the O O 0.9999531507492065
A B-cell_line O 0.6501802206039429
series I-cell_line O 0.8124249577522278
4C I-cell_line B-cell_line 0.3489591181278229
cells E-cell_line E-cell_line 0.6196505427360535
by O O 0.9998636245727539
the O O 0.9999945163726807
absence O O 0.9996534585952759
of O O 0.9999630451202393
DNA O O 0.8960595726966858
binding O O 0.9806667566299438
by O O 0.9999284744262695
the O O 0.9999507665634155
full-length O B-protein 0.7424164414405823
Sp1 S-protein I-protein 0.7688830494880676
transcription B-protein I-protein 0.4488336145877838
factor E-protein E-protein 0.9665189981460571
. O O 0.9973957538604736
However O O 0.9990365505218506

necrosis I-protein I-protein 0.5162579417228699
factor-alpha E-protein E-protein 0.977581799030304
( O O 0.9807639122009277
TNF-alpha S-protein S-protein 0.9889445304870605
) O O 0.9718652367591858
induces O O 0.9999442100524902
NF B-protein B-protein 0.35165834426879883
kappaB E-protein E-protein 0.956155002117157
activation O O 0.9850694537162781
that O O 0.9998874664306641
is O O 0.999962568283081
inhibited O O 0.999602735042572
by O O 0.9999908208847046
PDTC O O 0.8115087151527405
. O O 0.9999641180038452
Contrary O O 0.9999421834945679
to O O 0.9999854564666748
the O O 0.9999817609786987
results O O 0.9993576407432556
in O O 0.9998757839202881
Jurkat B-cell_line B-cell_line 0.807551920413971
cells E-cell_line E-cell_line 0.9837279319763184
, O O 0.9997549653053284
PDTC O O 0.6841687560081482
did O O 0.999840497970581
not O O 0.9999858140945435
inhibit O O 0.999797523021698
tumor B-protein B-protein 0.5420798659324646
necrosis I-protein I-protein 0.738746702671051
factor-alpha E-protein E-protein 0.979070782661438
-induced O O 0.9629645943641663

Severe O O 0.9865790009498596
side O O 0.9450179934501648
effects O O 0.9688878655433655
in O O 0.9998862743377686
terms O O 0.9996546506881714
of O O 0.9998917579650879
mental O O 0.929985523223877
confusion O O 0.488781213760376
and O O 0.9863860607147217
progressive O O 0.7563806176185608
hyperbilirubinemia O B-Disease 0.9078364968299866
, O O 0.9237868189811707
however O O 0.9992074370384216
, O O 0.9999730587005615
point O O 0.9997631907463074
to O O 0.9999908208847046
an O O 0.9998922348022461
enhancement O O 0.9870426654815674
not O O 0.9998551607131958
only O O 0.9999830722808838
of O O 0.9998615980148315
antineoplastic O O 0.5357882380485535
effects O O 0.7856997847557068
but O O 0.9995595812797546
also O O 0.9999736547470093
of O O 0.9997493624687195
toxicity O B-Disease 0.965777575969696
in O O 0.9775672554969788
normal O O 0.8796589374542236
tissues O O 0.8227776885032654
. O O 0.9999896287918091

by O O 0.9922661185264587

PU.1 S-protein S-protein 0.9198346734046936
binding O O 0.9689468741416931
decrease O O 0.9962677359580994
M-CSF B-protein B-DNA 0.54612135887146
receptor E-protein I-DNA 0.7212986350059509
promoter O E-DNA 0.9580841064453125
activity O O 0.9865708947181702
significantly O O 0.9999496936798096
in O O 0.999579131603241
macrophage B-cell_line B-cell_line 0.4306553900241852
cell I-cell_line I-cell_line 0.635310709476471
lines E-cell_line E-cell_line 0.9945751428604126
only O O 0.9990812540054321
. O O 0.9999967813491821
Furthermore O O 0.9999709129333496
, O O 0.9999586343765259
PU.1 S-protein S-protein 0.8766793608665466
transactivates O O 0.9973445534706116
the O O 0.9999316930770874
M-CSF B-DNA B-DNA 0.4582097828388214
receptor I-DNA I-DNA 0.4387899935245514
promoter E-DNA E-DNA 0.9532654285430908
in O O 0.9979771971702576

and O O 0.963017463684082
7.7 O O 0.9852173924446106
micromol/L O O 0.9416216611862183
, O O 0.9986934065818787
and O O 0.9996064305305481
0.7 O O 0.9336123466491699
and O O 0.9968532919883728
1.6 O O 0.9923432469367981
micromol/ O O 0.9544391632080078
( O O 0.9986482262611389
mg O O 0.9954485297203064
protein. O O 0.9974341988563538
min O O 0.9958491325378418
) O O 0.9996747970581055
, O O 0.9999881982803345
respectively O O 0.9999856948852539
. O O 0.9999979734420776
The O O 0.9999967813491821
absence O O 0.9996127486228943
of O O 0.9999709129333496
ultraviolet O O 0.811042308807373
absorbance O O 0.856800377368927
maxima O O 0.5202535390853882
shifts O O 0.9896367192268372
in O O 0.999977707862854
the O O 0.9999192953109741
presence O O 0.983339786529541

B-beta E-protein E-protein 0.7990275025367737
. O O 0.9969244599342346
PNU156804 O S-protein 0.5210875272750854
action O O 0.9903806447982788
is O O 0.9999682903289795
restricted O O 0.999808132648468
to O O 0.999990701675415
some O O 0.9998831748962402
signaling O O 0.8902527093887329
pathways O O 0.9834180474281311
; O O 0.999957799911499
it O O 0.9999778270721436
does O O 0.9999889135360718
not O O 0.999964714050293
affect O O 0.9999785423278809
NF-kappa B-protein B-protein 0.6600176692008972
B E-protein E-protein 0.9952065348625183
activation O O 0.9966302514076233
by O O 0.9999920129776001
PMA O O 0.9069243669509888
in O O 0.9993459582328796
T B-cell_type B-cell_type 0.9223202466964722
cells E-cell_type E-cell_type 0.9906187653541565
but O O 0.9985474944114685
blocks O O 0.9987322688102722
that O O 0.9998509883880615
induced O O 0.953013002872467

Lymphocyte B-protein O 0.6622354984283447
glucocorticoid I-protein O 0.6635841131210327
receptor E-protein O 0.7170257568359375
binding O O 0.634377121925354
parameters O O 0.71293044090271
were O O 0.9999170303344727
studied O O 0.9999897480010986
in O O 0.9999929666519165
15 O O 0.9983658194541931
severely O O 0.9859117269515991
depressed O O 0.9048482179641724
patients O O 0.9990856647491455
during O O 0.9999932050704956
depression O O 0.8867762684822083
and O O 0.999909520149231
after O O 0.9999476671218872
clinical O O 0.9940874576568604
recovery O O 0.9987672567367554
, O O 0.9999923706054688

in O O 0.9990864992141724
our O O 0.9999817609786987
understanding O O 0.9995573163032532
of O O 0.9999942779541016
mechanisms O O 0.9987123012542725
of O O 0.9999676942825317
MHC B-protein B-protein 0.3893519639968872
class I-protein I-protein 0.8025957345962524
II E-protein E-protein 0.9284672737121582
signaling O O 0.9527218341827393
and O O 0.9983128309249878
analyse O O 0.9995384216308594
their O O 0.9999912977218628
role O O 0.999810516834259
in O O 0.9999774694442749
human O O 0.7597169876098633
B-cell S-cell_type O 0.3900804817676544
activation O O 0.9835453629493713
. O O 0.9999866485595703
Effects O O 0.9999576807022095
of O O 0.9999756813049316
glucocorticoids O O 0.9085128307342529
in O O 0.9998680353164673
rheumatoid O O 0.9036621451377869
arthritis O O 0.9528525471687317
. O O 0.9999943971633911
Diminished O O 0.962542712688446
glucocorticoid B-protein B-protein 0.4578194320201874
receptors E-protein E-protein 0.9940952062606812
do O O 0.9998658895492554
not O O 0.9999774694442749
result O O 0.9997621178627014

tests O O 0.993992269039154
in O O 0.9999865293502808
MS O O 0.5022364854812622
have O O 0.9994532465934753
revealed O O 0.999970555305481
dysregulation O O 0.9912970066070557
of O O 0.9998462200164795
the O O 0.999811589717865
hypothalamic-pituitary-adrenal O O 0.7513534426689148
system O O 0.9123102426528931
in O O 0.9999630451202393
a O O 0.9999110698699951
substantial O O 0.996396005153656
proportion O O 0.9995506405830383
of O O 0.9999778270721436
patients O O 0.9996065497398376
. O O 0.9999978542327881
We O O 0.9998971223831177
characterized O O 0.9971979856491089
glucocorticoid B-protein B-protein 0.4995345175266266
receptor E-protein E-protein 0.9707968235015869
( O O 0.9390375018119812
GR S-protein S-protein 0.9345031976699829
) O O 0.9493180513381958
binding O O 0.9435579180717468
in O O 0.9996768236160278
peripheral B-cell_type B-cell_type 0.8252111673355103
blood I-cell_type I-cell_type 0.966543436050415

and O O 0.9271194934844971
promonocytic B-cell_line B-cell_line 0.3957211375236511
THP-1 I-cell_line I-cell_line 0.7069844603538513
cells E-cell_line E-cell_line 0.9690964221954346
. O O 0.9998015761375427
Nuclear B-protein B-protein 0.7411066889762878
factor-kappaB E-protein E-protein 0.9733480215072632
was O O 0.9967306852340698
found O O 0.9999345541000366
to O O 0.9999384880065918
be O O 0.9998897314071655
activated O O 0.9764869809150696
in O O 0.9994692206382751
ventilated B-cell_type B-cell_type 0.3334658741950989
macrophages E-cell_type E-cell_type 0.7598551511764526
. O O 0.9997619986534119
Synergistic O O 0.9474856853485107
proinflammatory O O 0.9314940571784973
effects O O 0.9993674159049988
of O O 0.9999775886535645
mechanical O O 0.9371572732925415
stress O O 0.9399024844169617
and O O 0.9994062185287476
molecules O O 0.9103546142578125
such O O 0.9993372559547424

Thirty O O 0.997488260269165
- O O 0.9997302889823914
five O O 0.9998735189437866
patients O O 0.9991648197174072
with O O 0.9999575614929199
primary O O 0.7623149752616882
pulmonary O O 0.5294907689094543
hypertension O O 0.8475576043128967
and O O 0.9812240600585938
85 O O 0.9902554154396057
matched O O 0.9995336532592773
controls O O 0.9940827488899231
were O O 0.9999951124191284
recruited O O 0.9998372793197632
over O O 0.9999985694885254
32 O O 0.999880313873291
months O O 0.9999654293060303
( O O 0.9999940395355225
1992 O O 0.9998688697814941
- O O 0.999005138874054
1994 O O 0.9972965121269226
) O O 0.9999784231185913
in O O 0.9999964237213135
Belgium O O 0.9723221063613892
. O O 0.9999990463256836

and O O 0.9805594682693481
the O O 0.9998754262924194
various O O 0.9968430995941162
chains O O 0.9850363731384277
of O O 0.9999208450317383
its O O 0.9997755885124207
receptor O O 0.6664345264434814
are O O 0.9975554347038269
transcriptionally O O 0.9758577346801758
induced O O 0.9978563189506531
. O O 0.9999951124191284
In O O 0.9999034404754639
turn O O 0.9886015057563782
, O O 0.9996985197067261
secreted O O 0.8924001455307007
IL-2 S-protein S-protein 0.9711271524429321
serves O O 0.990929901599884
to O O 0.9999285936355591
stimulate O O 0.9999158382415771
the O O 0.9998340606689453

subdomains O E-protein 0.6478029489517212
of O O 0.9726455807685852
the O O 0.9993155002593994
POU B-DNA B-protein 0.34125858545303345
domain E-DNA E-protein 0.8337690830230713
, O O 0.989777147769928
requiring O O 0.9999295473098755
both O O 0.9999665021896362
an O O 0.9998962879180908
A O O 0.5665417313575745
at O O 0.9953857064247131
the O O 0.9998263716697693
fifth B-DNA O 0.986284613609314
position E-DNA O 0.993668258190155
of O O 0.9999096393585205
the O O 0.9999752044677734
octamer B-DNA B-DNA 0.4711061120033264
element E-DNA E-DNA 0.9591501355171204
and O O 0.993511974811554
contact O O 0.994766354560852
with O O 0.9999755620956421
the O O 0.9997108578681946
POU B-DNA B-DNA 0.5116004943847656
domain E-DNA E-DNA 0.4715408980846405
. O O 0.9983515739440918

cell O O 0.5025565028190613
repertoire O O 0.5172922611236572
, O O 0.9986281394958496
with O O 0.999997615814209
an O O 0.9999852180480957
emphasis O O 0.997057318687439
placed O O 0.9999873638153076
on O O 0.9999896287918091
current O O 0.9701293706893921
literature O O 0.9858150482177734
within O O 0.9999837875366211
this O O 0.9999860525131226
field O O 0.9897516965866089
. O O 0.9999877214431763
CD28 S-protein S-protein 0.9304354786872864
costimulation O O 0.9608460664749146
augments O O 0.9994661211967468
IL-2 S-protein S-protein 0.7930051684379578
secretion O O 0.8856677412986755
of O O 0.9955909252166748
activated O B-cell_type 0.6584301590919495
lamina O I-cell_type 0.5601577162742615
propria O I-cell_type 0.7748022675514221
T O I-cell_type 0.8707109689712524
cells O E-cell_type 0.8503275513648987
by O O 0.9995290040969849
increasing O O 0.9993458390235901

They O O 0.9992782473564148
were O O 0.9999845027923584
given O O 0.9999916553497314
a O O 0.9999881982803345
ten O O 0.9958212375640869
day O O 0.9994514584541321
pretreatment O O 0.9985424280166626
with O O 0.9999892711639404
either O O 0.9801135659217834
L B-Chemical B-Chemical 0.945097804069519
- I-Chemical I-Chemical 0.9909839630126953
alpha I-Chemical I-Chemical 0.9611213207244873
- I-Chemical I-Chemical 0.9923143982887268
GFC E-Chemical I-Chemical 0.9543697834014893
or O O 0.9858875870704651
placebo O O 0.692809522151947
, O O 0.9935325384140015
p O O 0.9904842376708984
. O O 0.9999656677246094
o O O 0.9992165565490723
. O O 0.9995342493057251
, O O 0.9998157620429993
and O O 0.9999524354934692
on O O 0.9999583959579468
the O O 0.9999674558639526
eleventh O O 0.9739125967025757
day O O 0.9988775849342346
either O O 0.9999502897262573
scopolamine S-Chemical B-Chemical 0.9242019057273865
or O O 0.9853364825248718
placebo O O 0.7649648189544678
, O O 0.9981293082237244
i O O 0.9992730021476746
. O O 0.9997921586036682
m O O 0.9651476740837097
. O O 0.9997829794883728

. O O 0.9958082437515259
These O O 0.9999978542327881
studies O O 0.9999206066131592
indicate O O 0.9999979734420776
that O O 0.9999953508377075
heterologous B-DNA B-DNA 0.6729885935783386
enhancer I-DNA I-DNA 0.6034769415855408
elements E-DNA E-DNA 0.9945148229598999
are O O 0.9995438456535339
capable O O 0.9999113082885742
of O O 0.9999794960021973
restoring O O 0.995759904384613
Tat S-protein S-protein 0.9109840393066406
responsiveness O O 0.9887519478797913
to O O 0.9999758005142212
the O O 0.9997848868370056
HIV B-DNA B-DNA 0.7276760935783386
LTR E-DNA E-DNA 0.9938700199127197
in O O 0.9991169571876526
the O O 0.9999873638153076
context O O 0.9999045133590698
of O O 0.9999922513961792
directing O O 0.9378653168678284
reporter B-DNA O 0.7264708876609802
gene E-DNA O 0.7444747090339661
expression O O 0.9755800366401672
as O O 0.9999669790267944
well O O 0.9996548891067505
as O O 0.9999839067459106
in O O 0.999804675579071
the O O 0.9997029900550842

related O O 0.9921601414680481
to O O 0.9999444484710693
a O O 0.9997095465660095
PMA-induced B-protein O 0.4772959351539612
AP-1 E-protein S-protein 0.40970906615257263
and O O 0.9771437644958496
a O O 0.9990978240966797
PMA/A23187-induced B-protein B-protein 0.5851414203643799
NF-AT E-protein E-protein 0.7138559818267822
. O O 0.9989376664161682
We O O 0.9999762773513794
examined O O 0.9999862909317017
whether O O 0.9999954700469971
signal O B-protein 0.7627196311950684
transducing O I-protein 0.4877251982688904
components O E-protein 0.8777987360954285
in O O 0.9971966743469238
T B-cell_type B-cell_type 0.8110510110855103
cells E-cell_type E-cell_type 0.9823179244995117
can O O 0.9995129108428955
activate O O 0.9993595480918884
transcription O O 0.9400741457939148
of O O 0.9981122016906738
the O O 0.9995156526565552
GM-CSF B-DNA B-DNA 0.45455464720726013
gene E-DNA E-DNA 0.9806375503540039
. O O 0.9995132684707642
Cotransfection O O 0.965368390083313
of O O 0.9983524084091187
NF-kappa B-DNA B-protein 0.8638872504234314
B I-DNA E-protein 0.9396651387214661
( I-DNA O 0.9398340582847595
p50/p65 I-DNA S-protein 0.5326333045959473

increase O O 0.9889817833900452
was O O 0.9999264478683472
demonstrated O O 0.9999686479568481
by O O 0.999996542930603
the O O 0.9999886751174927
proliferative O O 0.9783673882484436
advantage O O 0.9969545602798462
provided O O 0.9999871253967285
by O O 0.9999880790710449
EC S-cell_type S-cell_type 0.8805936574935913
to O O 0.9974284768104553
PBL S-cell_type S-protein 0.43562063574790955
suboptimally O O 0.9343551397323608
stimulated O O 0.9984728693962097
with O O 0.999974250793457
mAb B-protein B-protein 0.6098031401634216
OKT3 E-protein E-protein 0.9584906101226807
. O O 0.9995790123939514
We O O 0.9999895095825195
now O O 0.9999985694885254
report O O 0.9999973773956299
that O O 0.9999947547912598
EC S-cell_type S-cell_type 0.6498297452926636
costimulation O O 0.9722344279289246
causes O O 0.9999358654022217
increased O O 0.9965301156044006
levels O O 0.9991970658302307
of O O 0.9995635151863098
IL-2 B-RNA B-RNA 0.9504714012145996
mRNA E-RNA E-RNA 0.999010443687439
as O O 0.9999363422393799
a O O 0.9999982118606567
result O O 0.9999815225601196
of O O 0.999997615814209
increased O O 0.9956028461456299
IL-2 S-protein S-protein 0.9576544761657715
transcription O O 0.9566736221313477
in O O 0.9997403025627136
PBL S-cell_type S-cell_type 0.7782182693481445

Capecitabine S-Chemical B-Chemical 0.9290471076965332
has O O 0.9983199238777161
a O O 0.9999485015869141
well O O 0.9913851022720337
- O O 0.999812662601471
established O O 0.9985207915306091
safety O O 0.971184253692627
profile O O 0.9884005784988403
and O O 0.9999438524246216
can O O 0.9999247789382935
be O O 0.9999825954437256
given O O 0.9999895095825195
safely O O 0.9999521970748901
to O O 0.9999375343322754
patients O O 0.9996534585952759
with O O 0.999988317489624
advanced O O 0.9208696484565735
age O O 0.7172959446907043
, O O 0.9939145445823669
hepatic O B-Disease 0.6752733588218689
and O I-Disease 0.5567894577980042
renal O I-Disease 0.7177209854125977
dysfunctions O I-Disease 0.9924012422561646
. O O 0.9986635446548462

individuals O O 0.9090125560760498
in O O 0.9999502897262573
response O O 0.998734176158905
to O O 0.9999964237213135
the O O 0.9999842643737793
different O O 0.9974959492683411
stimuli O O 0.935982346534729
, O O 0.9999160766601562
whereas O O 0.9999984502792358
the O O 0.9999873638153076
levels O O 0.9995697140693665
of O O 0.9999310970306396
IL-2 S-protein S-protein 0.9909879565238953
produced O O 0.9992733597755432
by O O 0.999948263168335
stimulated O O 0.7636244893074036
T B-cell_type B-cell_type 0.46398240327835083
cells E-cell_type E-cell_type 0.9141879677772522
from O O 0.9998534917831421
other O O 0.9997345805168152
elderly O O 0.9377403855323792
individuals O O 0.9953639507293701
were O O 0.9999961853027344
equivalent O O 0.9989720582962036
to O O 0.9997430443763733

breast O O 0.8494962453842163
cancer O O 0.5274292826652527
. O O 0.9999738931655884
Specific O O 0.9930846691131592
glucocorticoid O O 0.5148390531539917
binding O O 0.5154023766517639
at O O 0.9987635612487793
different O O 0.998616099357605
levels O O 0.999523401260376
of O O 0.9998910427093506
human O O 0.7543010711669922
motor O O 0.6280686259269714
activity O O 0.6300283670425415
. O O 0.9999489784240723

of O O 0.9923151135444641
Stat3alpha S-protein S-protein 0.9861224293708801
is O O 0.9996247291564941
involved O O 0.9999879598617554
in O O 0.9999887943267822
transcriptional O O 0.9485304355621338
activation O O 0.9937388896942139
, O O 0.9999542236328125

the O O 0.9979180693626404
GM-CSF S-protein B-DNA 0.6639149785041809
promoter O E-DNA 0.9341801404953003
activity O O 0.9758895635604858
, O O 0.9999784231185913
the O O 0.9999885559082031
present O O 0.9966328740119934
findings O O 0.9997847676277161
suggested O O 0.9999936819076538
the O O 0.9999889135360718
importance O O 0.9999126195907593
of O O 0.9999867677688599
the O O 0.9999687671661377
relative O O 0.9865359663963318
ratio O O 0.9987478256225586
of O O 0.9999819993972778
different O O 0.9982738494873047
PEBP2 B-protein B-protein 0.21826687455177307
isoforms E-protein E-protein 0.9229488968849182
in O O 0.9993870258331299
regulating O O 0.9960170388221741
the O O 0.9997742772102356
levels O O 0.9997190833091736
of O O 0.9999737739562988
the O O 0.9998145699501038
promoter O O 0.5801138281822205
activity O O 0.990610659122467
. O O 0.999984622001648
IFN-gamma S-protein S-protein 0.9460595846176147
priming O O 0.9667747616767883
of O O 0.9991313815116882
monocytes S-cell_type S-cell_type 0.982071578502655
enhances O O 0.9994673132896423
LPS-induced O O 0.9379233121871948
TNF S-protein S-protein 0.9492819309234619
production O O 0.9980046153068542
by O O 0.9999927282333374
augmenting O O 0.9994206428527832
both O O 0.9998155236244202
transcription O O 0.8685704469680786
and O O 0.9774126410484314

QTLs O O 0.36360886693000793
for O O 0.9964848756790161
susceptibility O O 0.7562790513038635
to O O 0.996548593044281
pilocarpine B-Chemical B-Chemical 0.9293201565742493
- O O 0.9413595199584961
induced O O 0.9945366382598877
seizures B-Disease B-Disease 0.9840651154518127
, O O 0.9928340911865234
a O O 0.9991683959960938
model O O 0.9965901374816895
of O O 0.9998871088027954
temporal B-Disease B-Disease 0.7665225267410278
lobe I-Disease I-Disease 0.7867273688316345
epilepsy I-Disease I-Disease 0.9232586622238159
, O O 0.9783746600151062
have O O 0.9998069405555725
not O O 0.9997735619544983
been O O 0.9999270439147949
reported O O 0.999671459197998
, O O 0.9998736381530762
and O O 0.9998108744621277
CSS O O 0.47572919726371765
have O O 0.998216450214386
not O O 0.999852180480957
previously O O 0.9999600648880005
been O O 0.9999362230300903
used O O 0.9999725818634033
to O O 0.9999904632568359
localize O O 0.9922831654548645
seizure B-Disease O 0.7746769785881042
susceptibility O O 0.5667102336883545
genes O O 0.7323054075241089
. O O 0.999923586845398

It O O 0.9985835552215576
has O O 0.9999780654907227
been O O 0.9999401569366455
consistently O O 0.999553382396698
shown O O 0.9999812841415405
that O O 0.9999905824661255
ecstasy B-Chemical B-Chemical 0.9311037659645081
users O O 0.7693049907684326
display O O 0.9961981177330017
impairments B-Disease O 0.6875084638595581
in I-Disease O 0.9934086799621582
learning I-Disease O 0.8329693675041199
and I-Disease O 0.9597718119621277
memory I-Disease O 0.49436134099960327
performance O O 0.7915574312210083
. O O 0.9999852180480957

Preactivation O O 0.9728323817253113
of O O 0.9994179010391235
T B-cell_type B-cell_type 0.8735301494598389
cells E-cell_type E-cell_type 0.991064190864563
resulting O O 0.9994257688522339
in O O 0.9999814033508301
NF-kappa B-protein B-protein 0.4886326491832733
B E-protein E-protein 0.9814792275428772
nuclear O O 0.9179793000221252
translocation O O 0.9033437371253967
protected O O 0.9778851866722107
cells O O 0.7227951884269714
from O O 0.9999921321868896
SN50-induced O O 0.8108690977096558
apoptosis O O 0.9649804830551147
. O O 0.9999947547912598
Our O O 0.9999969005584717
findings O O 0.9998918771743774
demonstrate O O 0.9999978542327881
an O O 0.9999847412109375
essential O O 0.9946216344833374
role O O 0.9995847344398499
of O O 0.9999257326126099
NF-kappa B-protein B-protein 0.9022465944290161
B E-protein E-protein 0.9949102997779846
in O O 0.9996329545974731
survival O O 0.8341977000236511

, O O 0.987092912197113
particularly O O 0.999923586845398
in O O 0.9999605417251587
relationship O O 0.985049307346344
to O O 0.9998292922973633
nephrotoxicity O O 0.8358793258666992
and O O 0.9978134632110596
fibrogenesis O O 0.8485551476478577
? O O 0.9999659061431885
How O O 0.9999655485153198
important O O 0.9997134804725647
are O O 0.9999984502792358
the O O 0.999967098236084
anti-inflammatory O O 0.8299921751022339
( O O 0.9826847910881042
non O O 0.972307026386261
T O O 0.8207680583000183
) O O 0.9594376683235168
effects O O 0.9997245669364929
of O O 0.9999828338623047
CyA O O 0.722263514995575
, O O 0.9980068802833557
and O O 0.9999580383300781
which O O 0.9999611377716064
cells O O 0.9704956412315369
do O O 0.9999784231185913
they O O 0.9999477863311768
operate O O 0.9999428987503052
in O O 0.9999041557312012
? O O 0.9994245767593384
Are O O 0.9999701976776123
there O O 0.9999830722808838
effects O O 0.999893307685852
of O O 0.9999514818191528
CyA O O 0.7456345558166504
and O O 0.99955815076828
FK O O 0.6177669763565063
506 O O 0.9238767623901367
all O O 0.9979660511016846
attributable O O 0.9997406601905823

of O O 0.996556282043457
RCC O O 0.42812567949295044
patient O O 0.6973876357078552
and O O 0.9889113903045654
determined O O 0.9991990923881531
whether O O 0.9999822378158569
supernatant O O 0.8308770656585693
fluid O O 0.893677830696106
from O O 0.9998635053634644
RCC O O 0.5198041200637817
explants O O 0.5865581631660461
( O O 0.9981213212013245
RCC-S O O 0.5175879001617432
) O O 0.9945873022079468
induced O O 0.999954104423523
the O O 0.9999691247940063
same O O 0.9998158812522888
phenotype O O 0.9343293309211731
of O O 0.9983491897583008
NF-kappaB S-protein S-protein 0.9770763516426086
suppression O O 0.9879544973373413
in O O 0.9998891353607178
normal B-cell_type B-cell_type 0.5345844626426697
T I-cell_type I-cell_type 0.725479006767273
cells E-cell_type E-cell_type 0.9679813981056213
that O O 0.9966739416122437
is O O 0.9999632835388184
observed O O 0.999339759349823
in O O 0.9998337030410767
patient O B-cell_type 0.4894362688064575
T B-cell_type I-cell_type 0.8100674152374268

We O O 0.9996222257614136
studied O O 0.9998999834060669
the O O 0.9999688863754272
role O O 0.9994623064994812
of O O 0.999961256980896
xanthine S-Chemical O 0.873814046382904
oxidase O O 0.8870447874069214
( O O 0.9785187244415283
XO O O 0.7013512253761292
) O O 0.9695945382118225
, O O 0.9998959302902222
which O O 0.999908447265625
is O O 0.999950647354126
implicated O O 0.9996047616004944
in O O 0.9999532699584961
the O O 0.9997966885566711
production O O 0.9951776266098022
of O O 0.9999157190322876
reactive O O 0.9310592412948608
oxygen O B-Chemical 0.9086872339248657
species O O 0.6045660376548767
, O O 0.9993946552276611
in O O 0.999980092048645
dexamethasone S-Chemical B-Chemical 0.9265796542167664
- O O 0.736049473285675
induced O O 0.9916649460792542
hypertension O B-Disease 0.9822331666946411
( O O 0.9414377808570862
dex S-Chemical B-Chemical 0.8936339616775513
- O O 0.5453341007232666
HT O O 0.5418490767478943
) O O 0.9069430232048035
. O O 0.9999864101409912

in O O 0.9979134202003479
transcriptional B-protein B-protein 0.8159973621368408
regulatory I-protein I-protein 0.5615316033363342
proteins E-protein E-protein 0.9829535484313965
. O O 0.9997735619544983
In O O 0.9999897480010986
the O O 0.9999933242797852
current O O 0.9982693195343018
studies O O 0.9995044469833374
, O O 0.999982476234436
IL-2 S-protein S-protein 0.9879036545753479
production O O 0.998710036277771
by O O 0.9998767375946045
T B-cell_type B-cell_type 0.9304563403129578
cells E-cell_type E-cell_type 0.9931960105895996
from O O 0.9991834759712219
elderly O O 0.5424237847328186
( O O 0.8451550006866455

The O O 0.9983831644058228
patient O O 0.9945223331451416
has O O 0.999944806098938
been O O 0.9992234706878662
followed O O 0.9999852180480957
for O O 0.9999866485595703
six O O 0.9998782873153687
years O O 0.9999520778656006
and O O 0.9999867677688599
has O O 0.9999426603317261
required O O 0.9999583959579468
pharmacologic O O 0.9256320595741272
doses O O 0.9878115057945251
of O O 0.9993959665298462
pyridoxine S-Chemical B-Chemical 0.9300368428230286
to O O 0.9981290698051453
control O O 0.9994423985481262
her O O 0.9849415421485901
behavior O O 0.8080862760543823
. O O 0.9999860525131226

. O O 0.9955405592918396
A O O 0.9993680119514465
characteristic O O 0.998824417591095
of O O 0.9999676942825317
HTLV-I-transformed B-cell_type B-cell_line 0.40294885635375977
T I-cell_type I-cell_line 0.43473219871520996
cells E-cell_type E-cell_line 0.537608802318573
is O O 0.9998844861984253
the O O 0.9999984502792358
constitutive O O 0.9742772579193115
nuclear O O 0.9569605588912964
expression O O 0.9916786551475525
of O O 0.9997926354408264
NF-kappaB/Rel B-protein B-protein 0.519467830657959
family E-protein E-protein 0.9591401219367981
of O O 0.9759153127670288
transcription O B-protein 0.6157923340797424
factors O E-protein 0.9950789213180542
, O O 0.9966561794281006
which O O 0.9999794960021973
appears O O 0.9999758005142212
to O O 0.9999903440475464
be O O 0.9999880790710449
essential O O 0.9998500347137451
for O O 0.9999810457229614
the O O 0.9999390840530396
growth O O 0.9948793649673462
of O O 0.9998816251754761
these O O 0.9998674392700195
transformed B-cell_type B-cell_line 0.542029082775116
cells E-cell_type E-cell_line 0.8068482279777527
. O O 0.9998162388801575
Although O O 0.9998660087585449

prolactin B-protein O 0.378775030374527

The O O 0.9997928738594055
aim O O 0.999941349029541
of O O 0.9999973773956299
this O O 0.9999953508377075
study O O 0.9999231100082397
was O O 0.9999979734420776
to O O 0.9999961853027344
examine O O 0.9999903440475464
the O O 0.9998859167098999
role O O 0.9996181726455688
of O O 0.999982476234436
metabotropic O O 0.6128460764884949
glutamate B-Chemical B-Chemical 0.7230599522590637
receptor O O 0.428912878036499
5 O O 0.3524948060512543
( O O 0.99483722448349
mGluR5 O O 0.5885850191116333
) O O 0.9938714504241943
in O O 0.9999896287918091
the O O 0.9999356269836426
toxic O O 0.5686190724372864
action O O 0.6667742729187012
of O O 0.9949045181274414
methamphetamine B-Chemical B-Chemical 0.9211728572845459
on O O 0.9960099458694458
dopaminergic O O 0.4947056472301483
neurones O O 0.6970669031143188
in O O 0.9982342720031738
rats O O 0.9945743680000305
. O O 0.9999978542327881

MAIN O O 0.9865956902503967
OUTCOME O O 0.9982652068138123
MEASURE O O 0.999977707862854
: O O 0.9999897480010986
Odds O O 0.9733380675315857
ratios O O 0.990964412689209
( O O 0.9999463558197021
ORs O O 0.8275545239448547
) O O 0.9977474808692932
measuring O O 0.9998683929443359
the O O 0.9998151659965515
association O O 0.9283579587936401
between O O 0.9960540533065796
antibacterial O O 0.450796514749527
use O O 0.8977081775665283
and O O 0.9996683597564697
selected O O 0.9766961932182312
birth O B-Disease 0.7273625731468201
defects O I-Disease 0.9898079037666321
adjusted O O 0.9541561603546143
for O O 0.9997742772102356
potential O O 0.9855459332466125
confounders O O 0.9730420112609863
. O O 0.999996542930603

that O O 0.9889334440231323
control O O 0.9983317255973816
the O O 0.9999070167541504
population O O 0.9799372553825378
of O O 0.9997888207435608
type B-cell_type B-cell_type 0.681673526763916
2 I-cell_type I-cell_type 0.7882809638977051
T I-cell_type I-cell_type 0.459378719329834
cells E-cell_type E-cell_type 0.8277636170387268
and O O 0.9960591793060303
disease O O 0.9054166078567505
susceptibility O O 0.9843512773513794
, O O 0.9999839067459106
we O O 0.999974250793457
have O O 0.9999902248382568
created O O 0.9988657236099243
lines O O 0.9847164154052734
of O O 0.9998857975006104
transgenic O O 0.7440741062164307
mice O O 0.9468443393707275
in O O 0.9999723434448242
which O O 0.9999849796295166
expression O O 0.9919936656951904
of O O 0.9993259906768799
a O O 0.962542712688446

It O O 0.9992570281028748
was O O 0.9999614953994751
found O O 0.9999779462814331
that O O 0.9999927282333374
the O O 0.9998194575309753
transformation O O 0.968633234500885
of O O 0.9990611672401428
exencephalic B-Disease O 0.6199690103530884
tissue O O 0.5850938558578491
was O O 0.9998664855957031
not O O 0.9999432563781738
simply O O 0.9999085664749146
size O O 0.9989713430404663
- O O 0.9997450709342957
dependent O O 0.9979922771453857
, O O 0.9999719858169556
and O O 0.9999539852142334
all O O 0.9998599290847778
cases O O 0.993013322353363
of O O 0.9997172951698303
anencephaly B-Disease B-Chemical 0.835460364818573
at O O 0.9894614815711975
E18 O O 0.7365697026252747
. O O 0.9998584985733032
5 O O 0.9923651814460754
resulted O O 0.9995088577270508
from O O 0.9999649524688721
embryos O O 0.921836793422699
with O O 0.9999274015426636
a O O 0.999927282333374
large O O 0.9983313679695129
amount O O 0.9998030066490173
of O O 0.9999697208404541
exencephalic B-Disease O 0.6764712333679199
tissue O O 0.5624247789382935
at O O 0.9999206066131592
E13 O O 0.8862521648406982
. O O 0.9999628067016602
5 O O 0.9907622933387756
. O O 0.9999363422393799

ability O O 0.9917119741439819
of O O 0.9998935461044312
CIITA S-protein S-protein 0.9338078498840332
to O O 0.999523401260376
facilitate O O 0.999902606010437

Massive O O 0.9611838459968567
urinary O O 0.9514107704162598
protein O O 0.8310354351997375
excretion O O 0.8847349286079407
has O O 0.999932050704956
been O O 0.9999438524246216
observed O O 0.999937891960144
after O O 0.9999849796295166
conversion O O 0.9950902462005615
from O O 0.9999651908874512
calcineurin O O 0.5353403091430664
inhibitors O O 0.5802265405654907
to O O 0.9994163513183594
mammalian O O 0.5051645040512085
target O O 0.8576558828353882
of O O 0.9964021444320679
rapamycin S-Chemical B-Chemical 0.9329084157943726
( O O 0.8571227192878723
mToR O O 0.3504957854747772
) O O 0.8855686783790588
inhibitors O O 0.5834696888923645
, O O 0.9998931884765625
especially O O 0.9997636675834656
sirolimus S-Chemical B-Chemical 0.9145562648773193
, O O 0.9970062375068665
in O O 0.9999873638153076
renal O O 0.8659400343894958
transplant O O 0.6267792582511902
recipients O O 0.9245330095291138
with O O 0.999946117401123
chronic O B-Disease 0.788414478302002
allograft O I-Disease 0.3388679027557373
nephropathy O I-Disease 0.7899335622787476
. O O 0.9990959167480469

All O O 0.9994391798973083
six O O 0.9996651411056519
patients O O 0.9993651509284973
had O O 0.999970555305481
supersaturated O O 0.8836653828620911
bile O O 0.6287508010864258
( O O 0.9986382126808167
mean O O 0.9963919520378113
( O O 0.9995748400688171
SEM O O 0.6861530542373657
) O O 0.9882636070251465
cholesterol B-Chemical B-Chemical 0.9354225993156433
saturation O O 0.7699031829833984
index O O 0.9059168696403503
of O O 0.9953666925430298
1 O O 0.9973499774932861
. O O 0.9999035596847534
19 O O 0.9981439113616943
( O O 0.9999738931655884
0 O O 0.9999183416366577
. O O 0.9993736147880554
08 O O 0.9977536797523499
) O O 0.9986693859100342
( O O 0.9999626874923706
range O O 0.998138427734375
1 O O 0.9997009038925171
. O O 0.9999017715454102
01 O O 0.9996957778930664
- O O 0.9995477795600891
1 O O 0.9995983242988586
. O O 0.9996778964996338
53 O O 0.9934533834457397
) O O 0.9959660768508911
) O O 0.9994974136352539
and O O 0.9999850988388062
all O O 0.9999673366546631
had O O 0.9998527765274048
abnormally O O 0.9748807549476624
rapid O O 0.9824805855751038
cholesterol B-Chemical B-Chemical 0.912931501865387
microcrystal O O 0.49471190571784973
nucleation O O 0.6384721398353577
times O O 0.9929748773574829
( O O 0.9999960660934448
< O O 0.9999076128005981
4 O O 0.999850869178772
days O O 0.9999483823776245
( O O 0.9999874830245972
range O O 0.9995324611663818
1 O O 0.9997259974479675
- O O 0.9952646493911743
4 O O 0.9862574934959412
) O O 0.9949855804443359
) O O 0.9997921586036682
, O O 0.9999927282333374
whilst O O 0.9999579191207886
in O O 0.9999679327011108
four O O 0.9995875954627991
, O O 0.9999827146530151
the O O 0.999961256980896
bile O O 0.9938807487487793
contained O O 0.9999755620956421
cholesterol B-Chemical B-Chemical 0.9102743864059448
microcrystals O O 0.7324303984642029
immediately O O 0.9995959401130676
after O O 0.9999922513961792
sampling O O 0.9974004030227661
. O O 0.9999980926513672

binds O O 0.8144820332527161
stronger O O 0.9653291702270508
than O O 0.9983114004135132
NF-kB S-protein S-protein 0.9097976088523865
to O O 0.9954798221588135
TCEd S-DNA B-DNA 0.605506420135498
DNA O E-DNA 0.988796591758728
. O O 0.999860405921936
The O O 0.9999945163726807
conversion O O 0.9975383281707764
of O O 0.9998916387557983
the O O 0.9998431205749512
TCEd S-DNA S-DNA 0.5380452275276184
to O O 0.9409463405609131
a O O 0.9844101667404175
'perfect B-DNA B-DNA 0.6614267826080322
' I-DNA I-DNA 0.4827197790145874
NF-kB I-DNA I-DNA 0.4365348815917969
binding I-DNA I-DNA 0.8723119497299194
site E-DNA E-DNA 0.9840481281280518
leads O O 0.9989107847213745
to O O 0.9999935626983643
a O O 0.9999706745147705
tighter O O 0.9871464967727661
binding O O 0.9817627668380737
of O O 0.9993242025375366
NF-kB S-protein S-protein 0.9345865845680237
to O O 0.997270405292511
TCEd B-DNA B-DNA 0.3594394028186798
DNA E-DNA E-DNA 0.9830625057220459
and O O 0.9935582280158997
, O O 0.9997498393058777
as O O 0.9999936819076538
a O O 0.9999797344207764
functional O O 0.9443208575248718
consequence O O 0.9709842801094055
, O O 0.9999585151672363
to O O 0.9999814033508301
the O O 0.9998968839645386
activity O O 0.9983958601951599
of O O 0.9999597072601318
the O O 0.9998818635940552
'converted B-DNA B-DNA 0.647781491279602
' I-DNA I-DNA 0.5033097863197327
TCEd I-DNA I-DNA 0.5614198446273804
motifs E-DNA E-DNA 0.9592211842536926
in O O 0.9995057582855225
HeLa B-cell_line B-cell_line 0.875804603099823
cells E-cell_line E-cell_line 0.9918065071105957
. O O 0.9998695850372314
Thus O O 0.993070662021637

: O O 0.8922021985054016
Platelets S-cell_type S-cell_type 0.5598011016845703
were O O 0.9997195601463318
collected O O 0.9999905824661255
from O O 0.9999958276748657
112 O O 0.993192732334137
drug-free O O 0.9586824178695679
patients O O 0.9990850687026978
with O O 0.9999845027923584
bipolar O O 0.9179126024246216
disorder O O 0.5835211277008057
( O O 0.9992890357971191
52 O O 0.9816332459449768
euthymic O O 0.9226007461547852
, O O 0.9977715015411377
29 O O 0.9975907802581787
depressed O O 0.9392656683921814
, O O 0.9978125095367432
and O O 0.999854564666748
31 O O 0.9976054430007935
manic O O 0.7947829365730286

outside O O 0.9906489253044128
the O O 0.9998776912689209
pituitary O O 0.6550452709197998
, O O 0.982396125793457
since O O 0.9999313354492188
it O O 0.9999494552612305
is O O 0.9999604225158691
present O O 0.9999629259109497
in O O 0.9999879598617554
diverse O O 0.7468405961990356
cell O O 0.7145177125930786
types O O 0.5265019536018372
, O O 0.9995704293251038
including O O 0.9999775886535645
differentiated O O 0.7555511593818665
HL-60 B-cell_type B-cell_line 0.43407267332077026
promyelocytic I-cell_type I-cell_line 0.7884194850921631
leukemia I-cell_type I-cell_line 0.9016355276107788
cells E-cell_type E-cell_line 0.9280246496200562

Behavioral O O 0.7530617117881775
effects O O 0.9346254467964172
of O O 0.9992490410804749
urotensin B-Chemical B-Chemical 0.935540497303009
- I-Chemical I-Chemical 0.974563479423523
II E-Chemical E-Chemical 0.9266146421432495
centrally O O 0.9478965997695923
administered O O 0.9988389611244202
in O O 0.9999834299087524
mice O O 0.9984377026557922
. O O 0.999998927116394

. O O 0.9971503615379333
Preliminary O O 0.996895432472229
experiments O O 0.9994476437568665
yielded O O 0.9999940395355225
a O O 0.999940037727356
Km O O 0.6465282440185547
value O O 0.8602012991905212
of O O 0.9980387091636658
about O O 0.9998728036880493
0.8 O O 0.9959867596626282
microM O O 0.9911050200462341
for O O 0.9998375177383423
dUTP O O 0.6358219981193542
. O O 0.9993258714675903
MAbs O S-protein 0.8885037302970886
against O O 0.9971230626106262
the O O 0.9998121857643127
dUTPase S-protein S-protein 0.7013418078422546
reacted O O 0.9978965520858765
with O O 0.9999847412109375
a O O 0.9999110698699951
protein O O 0.9058999419212341
of O O 0.9892705678939819
approximately O O 0.9945777654647827
31 O O 0.9448220133781433
kDa O O 0.3988852798938751
in O O 0.997849702835083
12-O-tetradecanoyl-phorbol-13-acetate B-cell_line O 0.5038727521896362

transcription B-protein B-protein 0.4053345024585724
factor E-protein E-protein 0.9671170711517334
interacting O O 0.9686723947525024
with O O 0.999755322933197
functional B-DNA B-DNA 0.9000113606452942
motifs E-DNA E-DNA 0.6866744160652161
in O O 0.9987126588821411
the O O 0.999923586845398
CD3-epsilon B-DNA S-protein 0.32518357038497925
and I-DNA O 0.8619695901870728
T I-DNA B-protein 0.6795024871826172
cell I-DNA I-protein 0.5133110880851746
receptor I-DNA E-protein 0.5130062103271484

amounts O O 0.990672767162323
of O O 0.9997981190681458
activity O O 0.9971043467521667
were O O 0.9999935626983643
obtained O O 0.9999810457229614
from O O 0.9999914169311523
the O O 0.9997902512550354
-557 B-DNA B-DNA 0.5441714525222778
and I-DNA I-DNA 0.5934735536575317
-417 I-DNA I-DNA 0.4259374439716339
zeta-luciferase I-DNA I-DNA 0.6065232753753662
constructs E-DNA E-DNA 0.9948521256446838
and O O 0.9991804957389832
the O O 0.9998925924301147
alpha-luciferase B-DNA B-DNA 0.515367865562439
constructs E-DNA E-DNA 0.9661957621574402

center O I-protein 0.46875202655792236
( B-DNA I-protein 0.9389883279800415
XIC I-DNA I-protein 0.42737865447998047
) I-DNA I-protein 0.5283379554748535
/XIST E-DNA E-protein 0.6162983775138855
in O O 0.9925170540809631
differentiated B-cell_type B-cell_type 0.41853123903274536
cells E-cell_type E-cell_type 0.765447199344635
. O O 0.9996935129165649
Autosome/ O O 0.8449670672416687
Xi S-DNA O 0.4801850914955139
translocations O O 0.3930968940258026
were O O 0.9997411370277405
detected O O 0.999936580657959
by O O 0.9999881982803345
fluorescence O O 0.9420404434204102
in O O 0.9996063113212585
situ O O 0.8536596894264221
hybridization O O 0.9394434094429016
( O O 0.9980302453041077
FISH O O 0.6823774576187134
) O O 0.9898964166641235

We O O 0.9967130422592163
also O O 0.9999809265136719
found O O 0.999994158744812
that O O 0.9999936819076538
the O O 0.9999039173126221
active O O 0.884770393371582
CN S-protein B-DNA 0.3465774655342102

However O O 0.998737633228302
, O O 0.9999169111251831
at O O 0.9999829530715942
the O O 0.999983549118042
end O O 0.9998635053634644
of O O 0.9999922513961792
3 O O 0.9998704195022583
weeks O O 0.9999724626541138
, O O 0.9999871253967285
amphotericin B-Chemical B-Chemical 0.946600079536438
B I-Chemical E-Chemical 0.9181638956069946
levels O O 0.9884140491485596
in O O 0.999955415725708
the O O 0.9993495345115662
kidneys O O 0.8225685358047485
and O O 0.9975079298019409
liver O O 0.766433596611023
were O O 0.999169111251831
significantly O O 0.999921441078186
higher O O 0.9994575381278992
in O O 0.9999439716339111
salt O O 0.5200337171554565
- O O 0.9878365397453308
depleted O O 0.9760787487030029
and O O 0.9991994500160217
normal O O 0.9770694375038147
- O O 0.9980916380882263
salt O O 0.9133995175361633
rats O O 0.995566189289093
than O O 0.9999936819076538
those O O 0.9999761581420898
in O O 0.9999711513519287
salt O O 0.4978677034378052
- O O 0.9971956014633179
loaded O O 0.997599184513092
rats O O 0.9981485605239868
, O O 0.9999727010726929
with O O 0.9999545812606812
plasma O O 0.7427315711975098
/ O O 0.9769783616065979
kidney O O 0.9123630523681641
ratios O O 0.9733266830444336
of O O 0.998404324054718
21 O O 0.9957444071769714
, O O 0.9986199140548706
14 O O 0.9877579212188721
, O O 0.9988318085670471
and O O 0.9996966123580933
8 O O 0.9943172335624695
in O O 0.9998804330825806
salt O O 0.6944890022277832
- O O 0.9972482323646545
depleted O O 0.9975384473800659
, O O 0.9999674558639526
normal O O 0.9900059103965759
- O O 0.9994300007820129
salt O O 0.9033393859863281
, O O 0.9997962117195129
and O O 0.9998925924301147
salt O O 0.5255253911018372
- O O 0.9976119995117188
loaded O O 0.9986532926559448
rats O O 0.9985671043395996
, O O 0.9999861717224121
respectively O O 0.9999874830245972
. O O 0.9999973773956299

significantly O O 0.9899280667304993
negative O O 0.994648277759552
for O O 0.9998676776885986
estrogen B-protein B-protein 0.34730738401412964
receptor E-protein E-protein 0.9803095459938049
and O O 0.9779532551765442
progesterone B-protein B-protein 0.5931203365325928
receptor E-protein E-protein 0.9713186621665955
, O O 0.9923487901687622
and O O 0.9992415904998779
positive O O 0.9679298996925354
for O O 0.9970088601112366
p53 S-protein S-protein 0.9406315088272095
and O O 0.9853708744049072
HER-2/neu S-protein S-protein 0.7572195529937744
more O O 0.9901131391525269
often O O 0.9992953538894653
than O O 0.9999850988388062
the O O 0.9999527931213379
noncomedo O O 0.4531136453151703
variant O O 0.5989608764648438
. O O 0.999484658241272
All O O 0.9999343156814575
seven O O 0.9990096092224121
IDCs O O 0.2789452075958252
associated O O 0.9989166259765625
with O O 0.999984622001648

Before O O 0.9939847588539124
and O O 0.9996881484985352
0 O O 0.9998329877853394
. O O 0.9999175071716309
5 O O 0.9995248317718506
, O O 0.9999474287033081
1 O O 0.9993745684623718
, O O 0.9999067783355713
2 O O 0.9996767044067383
, O O 0.9998648166656494
3 O O 0.9992958307266235
, O O 0.9999332427978516
and O O 0.9999547004699707
6 O O 0.9997873902320862
h O O 0.9979263544082642
after O O 0.9997511506080627
injection O O 0.9782854318618774
the O O 0.9995660185813904
subjects O O 0.9997345805168152
were O O 0.9999967813491821
given O O 0.9999773502349854
attention O O 0.9922918677330017
and O O 0.9995521903038025
mnemonic O O 0.7155646085739136
tests O O 0.9712887406349182
. O O 0.9999983310699463

regulation O O 0.9906454086303711
of O O 0.999936580657959
the O O 0.9998915195465088
immune O O 0.9420281648635864
response O O 0.9871072173118591
by O O 0.9999679327011108
preventing O O 0.9984201192855835
apoptosis O O 0.9824461936950684
of O O 0.9997184872627258
monoblastoid B-cell_type B-cell_type 0.7493487000465393
cells E-cell_type E-cell_type 0.950951099395752
; O O 0.9984281063079834
this O O 0.9999855756759644
effect O O 0.9999761581420898
might O O 0.9999980926513672
have O O 0.9999966621398926
important O O 0.9984717965126038
consequences O O 0.999750554561615
in O O 0.999997615814209
the O O 0.9999834299087524
clinical O O 0.9879317879676819
use O O 0.9996190071105957
of O O 0.9999743700027466

Phenobarbitone B-Chemical B-Chemical 0.9276435375213623
- O O 0.9152518510818481
induced O O 0.9979397654533386
enlargement B-Disease O 0.5192426443099976
of I-Disease O 0.8509505987167358
the I-Disease O 0.8637815713882446
liver I-Disease O 0.4660120904445648
in O O 0.9932896494865417
the O O 0.9963243007659912
rat O O 0.9475810527801514
: O O 0.9998311996459961
its O O 0.9998873472213745
relationship O O 0.9961060881614685
to O O 0.9999591112136841
carbon B-Chemical B-Chemical 0.9383278489112854
tetrachloride I-Chemical I-Chemical 0.934775710105896
- O O 0.8971414566040039
induced O O 0.9992228746414185
cirrhosis B-Disease B-Disease 0.9735479354858398
. O O 0.9988844990730286

CONCLUSIONS O O 0.9984971284866333
: O O 0.9999954700469971
Results O O 0.9998997449874878
of O O 0.9999949932098389
these O O 0.9999959468841553
studies O O 0.9998766183853149
suggest O O 0.9999973773956299
that O O 0.999993085861206
B1 O O 0.5784409642219543
and O O 0.9945905208587646
B2 O O 0.8296010494232178
receptors O O 0.9230119585990906
are O O 0.9999932050704956
engaged O O 0.9997826218605042
in O O 0.9999474287033081
transmission O O 0.9852446913719177
of O O 0.9997660517692566
nociceptive O O 0.5479273200035095
stimuli O O 0.6111533045768738
in O O 0.9988422989845276
both O O 0.9993298053741455
diabetic O B-Disease 0.9063575863838196
and O I-Disease 0.5698638558387756
toxic O I-Disease 0.5659690499305725
neuropathy O I-Disease 0.9397846460342407
. O O 0.9990578293800354

We O O 0.9994843006134033
describe O O 0.9999730587005615
the O O 0.9999572038650513
effect O O 0.9997815489768982
of O O 0.9998651742935181
phenylephrine S-Chemical B-Chemical 0.9211671948432922
and O O 0.9721025228500366
ephedrine S-Chemical B-Chemical 0.9258777499198914
on O O 0.9981493949890137
frontal O O 0.9419035315513611
lobe O O 0.6726998090744019
oxygenation O O 0.7535325288772583
( O O 0.9958492517471313
S O O 0.9765909910202026
( O O 0.9982486963272095
c O O 0.9960981607437134
) O O 0.9994250535964966
O O O 0.9952699542045593
( O O 0.9998019337654114
2 O O 0.9979962110519409
) O O 0.997853696346283
) O O 0.9998546838760376
following O O 0.9999809265136719
anesthesia O O 0.7269186973571777
- O O 0.9463139772415161
induced O O 0.985798180103302
hypotension O B-Disease 0.9835172891616821
. O O 0.9986793398857117

of O O 0.9982835054397583
these O O 0.9999725818634033
functional O O 0.9506864547729492
responses O O 0.9907957911491394
is O O 0.9999765157699585
greatly O O 0.9998652935028076
augmented O O 0.9998052716255188
when O O 0.9999656677246094
T B-cell_type B-cell_type 0.8307593464851379
cells E-cell_type E-cell_type 0.987896203994751
are O O 0.9994416832923889
activated O O 0.9927446842193604

. O O 0.9964020252227783

. O O 0.9937963485717773
CONCLUSIONS O O 0.9999282360076904
: O O 0.9999955892562866
Our O O 0.999985933303833
results O O 0.9999361038208008
demonstrated O O 0.9999953508377075
that O O 0.9999947547912598
HIV-1 O O 0.9306688904762268
infection O O 0.9633984565734863

Biological O O 0.946614146232605
features O O 0.9895408749580383
of O O 0.9997703433036804
hepatitis B-Disease B-Disease 0.9509150981903076
disappeared O O 0.693378746509552
in O O 0.9982472658157349
all O O 0.9999126195907593
cases O O 0.9984716773033142
after O O 0.9999935626983643
cessation O O 0.9966583251953125
of O O 0.9999252557754517
the O O 0.9996176958084106
incriminated O O 0.701175332069397
drug O O 0.8048877120018005
, O O 0.9991545677185059
while O O 0.9999878406524658
biliary O O 0.791410505771637
, O O 0.9833283424377441
viral O O 0.7406314015388489
and O O 0.9704521894454956
immunological O O 0.9276285171508789
searches O O 0.959520161151886
were O O 0.999958872795105
negative O O 0.9946392178535461
. O O 0.9999991655349731

uptake O O 0.7583612203598022
procedure O O 0.904137372970581
was O O 0.9999105930328369
employed O O 0.9999539852142334
, O O 0.999994158744812
incorporating O O 0.9998403787612915
multiple O B-protein 0.8952003121376038
microbiological B-protein I-protein 0.7064797282218933
antigens E-protein E-protein 0.9406723976135254
. O O 0.9995204210281372
Five O O 0.998993456363678
patients O O 0.999613344669342
were O O 0.9999920129776001
found O O 0.9999825954437256
with O O 0.9999868869781494
repeated O O 0.9708389639854431
maximal O O 0.949769139289856
responses O O 0.9926568865776062
to O O 0.9999712705612183
adenovirus B-protein B-protein 0.5485407114028931
antigen E-protein E-protein 0.9260314702987671
; O O 0.9970235228538513
in O O 0.9999431371688843
one O O 0.9996931552886963
of O O 0.9999507665634155

Biphasic O O 0.7759113907814026
control O O 0.9873896837234497
of O O 0.9997844099998474
NF-kappa B-protein B-protein 0.7023019194602966
B E-protein E-protein 0.9970518350601196
activation O O 0.9966955184936523
induced O O 0.9999158382415771
by O O 0.9999862909317017
the O O 0.9999505281448364
triggering O O 0.9903414249420166
of O O 0.9995391368865967
HLA-DR B-protein B-protein 0.2945491671562195
antigens E-protein E-protein 0.9871289730072021
expressed O O 0.9987064599990845
on O O 0.9993602633476257
B B-cell_type B-cell_type 0.9013586640357971
cells E-cell_type E-cell_type 0.9882539510726929
. O O 0.9997833371162415
The O O 0.9999979734420776
regulation O O 0.9996631145477295
of O O 0.9999595880508423
NF-kappa B-protein B-protein 0.7676225900650024
B E-protein E-protein 0.986791729927063
activation O O 0.992198646068573

negative O O 0.870737612247467
regulation O O 0.9951372742652893
by O O 0.9999970197677612
the O O 0.9999890327453613
various O O 0.980018675327301
NF-kappaB B-protein B-protein 0.6827722191810608
subunits E-protein E-protein 0.9828163981437683
. O O 0.9997496008872986
We O O 0.9999854564666748
further O O 0.9999723434448242
demonstrate O O 0.9999938011169434
that O O 0.9999942779541016
p105 S-protein S-protein 0.9749564528465271
undergoes O O 0.9992675185203552
degradation O O 0.9940643906593323
in O O 0.9999631643295288
lipopolysaccharide-stimulated B-cell_line B-cell_line 0.4476333260536194
human I-cell_line I-cell_line 0.6030694246292114
monocytic I-cell_line I-cell_line 0.8095114231109619
cells E-cell_line E-cell_line 0.7062014937400818
. O O 0.999784529209137
However O O 0.9991506338119507

inhibit O O 0.9876075387001038
HSV-1-mediated O O 0.9276618957519531
induction O O 0.9972394704818726
of O O 0.9999822378158569
HIV-1 O O 0.7912623286247253
provirus O O 0.8912954330444336
. O O 0.9999738931655884
Surprisingly O O 0.9997640252113342
, O O 0.999996542930603
the O O 0.9999595880508423
NF-kappa B-protein B-protein 0.6074303984642029
B E-protein E-protein 0.9556658267974854
and O O 0.9741109609603882
HLP-1 O O 0.5317625999450684
binding O O 0.5567305088043213
activities O O 0.8617316484451294
were O O 0.9999624490737915
substantially O O 0.9995476603507996
inhibited O O 0.999275267124176
in O O 0.9999133348464966
acyclovir-treated B-cell_line O 0.3859015107154846
cells E-cell_line O 0.5803675651550293
. O O 0.9997090697288513

kB O E-protein 0.7796218395233154
. O O 0.9915080070495605
This O O 0.999943733215332
was O O 0.9998723268508911
detectable O O 0.9992408752441406
by O O 0.9999842643737793
24 O O 0.971855103969574
h O O 0.9046212434768677
and O O 0.997707724571228
persisted O O 0.9990459084510803
until O O 0.9999810457229614
72 O O 0.9944039583206177
h O O 0.990738570690155
. O O 0.9999896287918091
The O O 0.9999903440475464
DNA B-protein B-protein 0.8178905844688416
binding I-protein I-protein 0.5434492826461792
protein I-protein E-protein 0.9538859724998474
NF-kB E-protein S-protein 0.7656035423278809
is O O 0.9999544620513916
a O O 0.9999915361404419
central O O 0.9349327087402344
mediator O O 0.6870125532150269
in O O 0.9994200468063354
cytokine S-protein S-protein 0.8313947916030884
activation O O 0.9946921467781067
of O O 0.9999161958694458
HIV O O 0.7900332808494568
transcription O O 0.9075435400009155
. O O 0.999697208404541
NF-kB S-protein S-protein 0.9655352830886841
levels O O 0.9978530406951904
were O O 0.9999897480010986
higher O O 0.9998608827590942
in O O 0.9999278783798218
unstimulated B-cell_line B-cell_line 0.5875141620635986
U1 I-cell_line I-cell_line 0.3345232605934143
cells E-cell_line E-cell_line 0.9253844022750854
as O O 0.9998432397842407
compared O O 0.9998917579650879
to O O 0.9999841451644897
the O O 0.9999289512634277
parent B-cell_line B-cell_line 0.6759882569313049
cell I-cell_line I-cell_line 0.5218186378479004
line E-cell_line E-cell_line 0.8776314854621887

Because O O 0.9992092251777649
sirolimus S-Chemical B-Chemical 0.9197226166725159
does O O 0.9966506361961365
not O O 0.9998185038566589
share O O 0.999881386756897
the O O 0.9999030828475952
vasomotor O O 0.6472517251968384
renal O O 0.7073768377304077
adverse O O 0.583859920501709
effects O O 0.8861265182495117
exhibited O O 0.9993178844451904
by O O 0.9999877214431763
calcineurin O B-Chemical 0.9084084630012512
inhibitors O E-Chemical 0.9032213687896729
, O O 0.9890069961547852
it O O 0.9998807907104492
has O O 0.9999861717224121
been O O 0.9998977184295654
designated O O 0.9999927282333374
a O O 0.9999310970306396
' O O 0.9951722025871277
non O O 0.9755807518959045
- O O 0.9945218563079834
nephrotoxic O O 0.5767502784729004
drug O O 0.5724514126777649
' O O 0.9831492304801941
. O O 0.999996542930603

irradiation O O 0.9388068318367004
. O O 0.999976634979248
To O O 0.9999927282333374
find O O 0.9999741315841675
out O O 0.999992847442627
if O O 0.9999828338623047
the O O 0.999967098236084
induction O O 0.9942417144775391
by O O 0.9997209906578064

alpha I-DNA E-protein 0.6821486353874207

kilobases O O 0.3579416871070862
. O O 0.998859167098999
A O O 0.9997186064720154
transcription O B-DNA 0.7454352974891663
start O I-DNA 0.5926089286804199
site O E-DNA 0.9623891115188599
is O O 0.9988046884536743
located O O 0.99991774559021
approximately O O 0.9998512268066406

These O O 0.9992331266403198
episodes O O 0.9621891975402832
are O O 0.9998946189880371
asymptomatic O O 0.6924758553504944
and O O 0.9961417317390442
reversible O O 0.9906270503997803
when O O 0.9999696016311646
therapy O O 0.9823538064956665
is O O 0.9999417066574097
discontinued O O 0.9993334412574768
. O O 0.9999991655349731

in O O 0.9984627962112427
2 O O 0.9482204914093018
bipotent O B-cell_type 0.7641391754150391
human B-cell_type I-cell_type 0.49105891585350037
myeloid I-cell_type I-cell_type 0.5813965201377869
progenitor I-cell_type I-cell_type 0.7855531573295593
cells E-cell_type E-cell_type 0.8634490370750427
. O O 0.9998277425765991
Elevated O O 0.9714162945747375
levels O O 0.9979761242866516
of O O 0.9998841285705566
c-Maf B-protein B-protein 0.6563628911972046
protein E-protein E-protein 0.8904514312744141

differentiation O O 0.9431595206260681
. O O 0.9997065663337708
Thymocytes S-cell_type S-cell_type 0.9410727024078369
, O O 0.992128849029541
activated B-cell_type B-cell_type 0.6720170378684998
peripheral I-cell_type I-cell_type 0.3312629759311676
T I-cell_type I-cell_type 0.6061318516731262
lymphocytes E-cell_type E-cell_type 0.723791241645813
, O O 0.9599030613899231
or O O 0.999411940574646
an O O 0.9980900883674622
activated B-cell_line B-cell_line 0.6397261023521423
T-cell I-cell_line I-cell_line 0.41346198320388794
clone E-cell_line E-cell_line 0.9882396459579468
were O O 0.9996154308319092
used O O 0.999884843826294

an O O 0.9976913928985596
important O O 0.9994093179702759
role O O 0.9999434947967529
in O O 0.9999963045120239
the O O 0.9999864101409912
establishment O O 0.9990266561508179
and O O 0.9999501705169678
maintenance O O 0.9992663264274597
of O O 0.9999856948852539
the O O 0.9998847246170044
mature B-cell_type O 0.7178419828414917
T I-cell_type O 0.5330070853233337
cell I-cell_type O 0.3901796042919159
phenotype E-cell_type O 0.39206069707870483
. O O 0.9963870048522949
[ O O 0.9984095692634583
Regulatory O O 0.9740886688232422
effect O O 0.9991124272346497
of O O 0.999972939491272
insulin S-protein S-protein 0.6532724499702454
on O O 0.9924774765968323
glucocorticoid B-protein B-protein 0.4693866968154907
receptor E-protein E-protein 0.983253002166748
in O O 0.9988818764686584
human B-cell_type B-cell_type 0.8498467803001404
peripheral I-cell_type I-cell_type 0.8931340575218201
leukocytes E-cell_type E-cell_type 0.9886391162872314
] O O 0.9967828989028931
The O O 0.9999184608459473
regulatory O O 0.6151508688926697

induction O O 0.8853153586387634
systems O O 0.8024581670761108
of O O 0.9999029636383057
human B-cell_type B-cell_type 0.4645962715148926
leukemic I-cell_type I-cell_type 0.7174441814422607
cells E-cell_type E-cell_type 0.9401693344116211
including O O 0.9969207048416138
HL-60 B-cell_line S-cell_line 0.9855191707611084
, I-cell_line O 0.9542049765586853
U937 I-cell_line S-cell_line 0.9927241206169128
, I-cell_line O 0.9780902862548828
HEL/S I-cell_line S-cell_line 0.9906401634216309
, I-cell_line O 0.9510204195976257
KU812F I-cell_line S-cell_line 0.9933342933654785
, I-cell_line O 0.959160566329956
K562 I-cell_line S-cell_line 0.983660876750946
, I-cell_line O 0.8828282952308655
and I-cell_line O 0.9912703037261963
HEL I-cell_line B-cell_line 0.6342902183532715
cells E-cell_line E-cell_line 0.9558010697364807
. O O 0.9999110698699951
Native B-protein B-protein 0.855830729007721
human I-protein I-protein 0.7375256419181824
erythrocyte I-protein I-protein 0.6601717472076416
NDP I-protein I-protein 0.4190760850906372
kinase I-protein I-protein 0.5628478527069092
protein E-protein E-protein 0.9811029434204102
inhibited O O 0.9987118244171143
the O O 0.9999654293060303
induction O O 0.9911696910858154

human B-cell_line B-cell_line 0.42540836334228516
T-cell I-cell_line I-cell_line 0.3772388696670532
leukemia I-cell_line I-cell_line 0.3898080289363861
virus I-cell_line I-cell_line 0.4614993929862976
type I-cell_line I-cell_line 0.6760594248771667
1 I-cell_line I-cell_line 0.5075139403343201
( I-cell_line I-cell_line 0.47986409068107605
HTLV-1 I-cell_line I-cell_line 0.9002225995063782
) I-cell_line I-cell_line 0.9367311000823975
-infected I-cell_line I-cell_line 0.9511435031890869
T I-cell_line I-cell_line 0.9733009934425354
cells E-cell_line E-cell_line 0.9731993079185486
. O O 0.9998362064361572
When O O 0.999998927116394
the O O 0.9999197721481323
HTLV-1 B-DNA B-DNA 0.343458890914917
tax I-DNA I-DNA 0.48057034611701965
gene E-DNA E-DNA 0.9863969683647156
was O O 0.9984027743339539
expressed O O 0.9977626800537109
or O O 0.9993498921394348
phorbol O O 0.7298088669776917
myristake O O 0.7992846965789795
acetate-A23187 O O 0.28936317563056946
stimulation O O 0.9567272067070007
was O O 0.9999171495437622
used O O 0.9999496936798096
, O O 0.9999855756759644
ICSAT S-protein S-protein 0.7445900440216064
expression O O 0.996701180934906
was O O 0.9999839067459106
induced O O 0.9998331069946289
in O O 0.9998329877853394
Jurkat B-cell_line B-cell_line 0.8712990283966064
cells E-cell_line E-cell_line 0.9877497553825378

In O O 0.9998315572738647
the O O 0.9999877214431763
pre O O 0.9985036849975586
- O O 0.9997374415397644
treatment O O 0.9978699684143066
evaluation O O 0.9996833801269531
, O O 0.9999974966049194
signs O O 0.9989904761314392
of O O 0.9999583959579468
cardiovascular B-Disease B-Disease 0.6221709251403809
disease I-Disease I-Disease 0.9819064140319824
were O O 0.9871195554733276
found O O 0.9999476671218872
in O O 0.999985933303833
33 O O 0.9961659908294678
patients O O 0.9998364448547363
( O O 0.9999924898147583
43 O O 0.999921441078186
% O O 0.9999454021453857
) O O 0.9998140931129456
. O O 0.9999969005584717

With O O 0.9997667670249939
mild O O 0.939899206161499
toxicity O B-Disease 0.8728346824645996
, O O 0.993127703666687
a O O 0.9997664093971252
reduction O O 0.9715184569358826
to O O 0.9932599663734436
30 O O 0.9930013418197632
or O O 0.9999184608459473
40 O O 0.9997290968894958
mg O O 0.999488353729248
/ O O 0.9999762773513794
kg O O 0.9994454979896545
per O O 0.9999394416809082
dose O O 0.9998760223388672
should O O 0.9999949932098389
result O O 0.9999847412109375
in O O 0.9999850988388062
a O O 0.9999371767044067
reversal O O 0.9939817786216736
of O O 0.9980418682098389
the O O 0.999470055103302
abnormal O O 0.8298296928405762
results O O 0.9176478385925293
to O O 0.9982377290725708
normal O O 0.985602080821991
within O O 0.999971866607666
four O O 0.9999679327011108
weeks O O 0.9999786615371704
. O O 0.999998927116394

isolated O O 0.9512567520141602
from O O 0.9999595880508423
Stephania O O 0.964518129825592
cepharantha O O 0.9685580730438232
Hayata O O 0.8158838748931885
and O O 0.9993434548377991
has O O 0.9999245405197144
been O O 0.9999314546585083
shown O O 0.9999727010726929
to O O 0.9999864101409912
have O O 0.9999229907989502
antiinflammatory O O 0.8921206593513489
, O O 0.9842467308044434
antiallergic O O 0.9496703147888184
, O O 0.9975115060806274
and O O 0.9993388056755066
immunomodulatory O O 0.9437466263771057
activities O O 0.9949913620948792
in O O 0.9999836683273315
vivo O O 0.9866151213645935
. O O 0.9999741315841675
As O O 0.999958872795105
several O O 0.9987221360206604
inflammatory B-protein B-protein 0.7316816449165344
cytokines E-protein E-protein 0.9529302716255188
and O O 0.9984513521194458

hypoactivity O O 0.9261985421180725
of O O 0.9995703101158142
the O O 0.999983549118042
stress O O 0.959850013256073
system O O 0.9947405457496643
might O O 0.999997615814209
influence O O 0.9999921321868896
the O O 0.9999723434448242
susceptibility O O 0.9991195797920227
of O O 0.999991774559021
an O O 0.9997743964195251
individual O O 0.9921257495880127
to O O 0.9999719858169556
certain O O 0.9978244304656982
autoimmune O O 0.922959566116333
, O O 0.9910173416137695
allergic O O 0.9534644484519958
, O O 0.9958361387252808
infectious O O 0.9757314324378967
, O O 0.9983188509941101
or O O 0.9996528625488281
neoplastic O O 0.9555808901786804
diseases O O 0.9221023917198181
. O O 0.9999961853027344
Activation O O 0.9966593980789185
of O O 0.9998863935470581
human B-cell_type B-cell_type 0.5091294050216675
monocytic I-cell_type I-cell_type 0.7349039912223816
cells E-cell_type E-cell_type 0.958417534828186
by O O 0.9997655749320984
Treponema B-protein O 0.7568026781082153
pallidum I-protein O 0.7297122478485107
and I-protein O 0.9991950392723083
Borrelia I-protein O 0.9322535991668701
burgdorferi I-protein O 0.9213014245033264
lipoproteins E-protein O 0.6163465976715088
and O O 0.99946528673172
synthetic O O 0.8482838869094849
lipopeptides O O 0.6392008066177368
proceeds O O 0.9983130693435669
via O O 0.9996262788772583

and O O 0.9477782249450684

Its O O 0.9987589120864868
activity O O 0.9909732341766357
is O O 0.9999772310256958
believed O O 0.999992847442627
to O O 0.9999880790710449
be O O 0.9999622106552124
due O O 0.9999618530273438
modulation O O 0.9963494539260864
of O O 0.9997925162315369
the O O 0.9998164772987366
tumour B-Disease O 0.6632734537124634
milieu O O 0.6174619197845459
, O O 0.9989446997642517
including O O 0.9999897480010986
downregulation O O 0.9401003122329712
of O O 0.9974315762519836
angiogenesis O O 0.8367317318916321
and O O 0.9862340688705444
inflammatory O B-protein 0.8204598426818848
cytokines O E-protein 0.6372132897377014
. O O 0.999875545501709

Octreotide S-Chemical B-Chemical 0.9221648573875427
- O O 0.9466660022735596
induced O O 0.9981257319450378
hypoxemia O B-Disease 0.9820559620857239
and O O 0.9427975416183472
pulmonary O B-Disease 0.5008576512336731
hypertension O I-Disease 0.9006139039993286
in O O 0.9731524586677551
premature O O 0.7533371448516846
neonates O O 0.5844599604606628
. O O 0.9998873472213745

of O O 0.9958244562149048
HL-60 B-cell_line B-cell_line 0.7608647346496582
cells E-cell_line E-cell_line 0.9826661348342896
treated O O 0.9997802376747131
with O O 0.9999978542327881
the O O 0.9999161958694458
phorbol O O 0.8828161358833313
ester O O 0.9138588905334473
12 O O 0.9449911713600159
, O O 0.9998927116394043
13-phorbol O O 0.9843885898590088
dibutyric O O 0.9923621416091919
acid O O 0.9904282093048096
( O O 0.9999687671661377
PDBu O O 0.8996887803077698
) O O 0.9993435740470886
or O O 0.999984860420227
DMSO O O 0.9613372683525085
. O O 0.9999890327453613
After O O 0.9999744892120361
DMSO O O 0.8088197112083435
treatment O O 0.9977699518203735
, O O 0.9999840259552002
HL-60 B-cell_line B-cell_line 0.6914340853691101
cells E-cell_line E-cell_line 0.985714852809906
eventually O O 0.9997555613517761
died O O 0.9999645948410034
via O O 0.9997395873069763
apoptosis O O 0.9831383228302002
, O O 0.9999711513519287
whereas O O 0.999995231628418
the O O 0.9999721050262451
viability O O 0.9986940026283264
of O O 0.9999604225158691
PDBu-treated B-cell_line B-cell_line 0.5294037461280823
cells E-cell_line E-cell_line 0.7843064665794373
was O O 0.9997795224189758
not O O 0.9999738931655884
affected O O 0.9999121427536011
during O O 0.999996542930603
the O O 0.9999933242797852
same O O 0.999968409538269
interval O O 0.9933182001113892
. O O 0.9999972581863403
The O O 0.9999626874923706

ubiquitous B-protein B-protein 0.6517829895019531
transcription I-protein I-protein 0.41839414834976196
factor E-protein E-protein 0.9142787456512451
and O O 0.924400806427002
pleiotropic B-protein O 0.6414490938186646
regulator E-protein O 0.6783797740936279
of O O 0.9724703431129456
numerous O O 0.9882644414901733
genes O O 0.609345555305481
involved O O 0.9998605251312256
in O O 0.9999833106994629
the O O 0.9999115467071533
immune O O 0.9627557396888733
and O O 0.994936466217041
inflammatory O O 0.9762662649154663
responses O O 0.9976246953010559
. O O 0.999998927116394
This O O 0.9998806715011597
transcription B-protein B-protein 0.6297805309295654
factor E-protein E-protein 0.9367669820785522
is O O 0.99276202917099

NO S-Chemical B-Chemical 0.9303584694862366
- O O 0.9756405353546143
induced O O 0.994661271572113
migraine O B-Disease 0.965852677822113
attack O O 0.7959860563278198
: O O 0.9964761137962341
strong O O 0.9904600381851196
increase O O 0.8395640254020691
in O O 0.9550296664237976
plasma O O 0.9087550640106201
calcitonin B-Chemical B-Chemical 0.9276309013366699
gene I-Chemical O 0.906086802482605
- I-Chemical O 0.5800555348396301
related I-Chemical O 0.877505898475647
peptide E-Chemical O 0.8616207838058472
( O O 0.9221682548522949
CGRP S-Chemical O 0.678450345993042
) O O 0.7137015461921692
concentration O O 0.9055673480033875
and O O 0.9996139407157898
negative O O 0.8889039754867554
correlation O O 0.8206735849380493
with O O 0.9998148083686829
platelet O O 0.6308742165565491
serotonin S-Chemical B-Chemical 0.8962295055389404
release O O 0.958061933517456
. O O 0.9999839067459106

microorganisms O O 0.2714952230453491
. O O 0.9998719692230225
Potential O O 0.9877012372016907
cis-acting B-DNA B-DNA 0.5389043092727661
elements E-DNA E-DNA 0.9955129027366638
were O O 0.9992257356643677
identified O O 0.9999698400497437
in O O 0.9999864101409912
the O O 0.99993896484375
promoter B-DNA B-DNA 0.633407711982727
region E-DNA E-DNA 0.9440224170684814
of O O 0.9963192939758301
the O O 0.9999099969863892
NGAL B-DNA B-DNA 0.6962211728096008
gene E-DNA E-DNA 0.9842372536659241
by O O 0.9994788765907288
computer O O 0.9539651870727539
analysis O O 0.9927430152893066
and O O 0.9999487400054932
include O O 0.9999735355377197
binding B-DNA B-DNA 0.7352914810180664
sites E-DNA E-DNA 0.8656324148178101
for O O 0.9985806941986084
CTF/CBP S-protein S-protein 0.29110267758369446

plasma B-protein O 0.5540744066238403
interleukin-1 E-protein S-protein 0.5890414714813232
( O O 0.9884279370307922
IL-1 S-protein S-protein 0.9856842756271362
) O O 0.9840585589408875
and O O 0.9998936653137207
their O O 0.999972939491272
possible O O 0.9939647316932678
relationship O O 0.9975141286849976
with O O 0.9999825954437256
the O O 0.9999252557754517
changes O O 0.9951057434082031
in O O 0.9997467398643494
glucocorticoid B-protein B-protein 0.47516804933547974
receptor E-protein E-protein 0.9829724431037903
( O O 0.9595873355865479
GR S-protein S-protein 0.9731451869010925
) O O 0.9782881736755371
, O O 0.9996733665466309
plasma B-protein O 0.6499482989311218
IL-1 E-protein S-protein 0.6412147283554077
and O O 0.9869855046272278
GR S-protein S-protein 0.9656157493591309
in O O 0.9994004964828491
peripheral B-cell_type B-cell_type 0.6160287857055664
blood I-cell_type I-cell_type 0.8824214339256287
leukocytes E-cell_type E-cell_type 0.9855071306228638
in O O 0.9992578625679016
aged O O 0.9346596598625183
long-distance O O 0.7847006320953369
runner O O 0.7504041194915771
were O O 0.9993853569030762
measured O O 0.9995872378349304
simultaneously O O 0.9999532699584961
. O O 0.9999986886978149
The O O 0.9999638795852661

chimeric O O 0.5011543035507202
animals O O 0.4392997920513153
, O O 0.9979786276817322
based O O 0.9999593496322632
on O O 0.9999939203262329
analysis O O 0.9985294342041016
of O O 0.9999676942825317
glucose B-protein B-protein 0.48102006316185
phosphate I-protein I-protein 0.41818058490753174
isomerase-1 I-protein I-protein 0.9233641028404236
( I-protein I-protein 0.8844061493873596
GPI-1 I-protein I-protein 0.7396559715270996
) I-protein I-protein 0.5801997184753418
isozymes E-protein E-protein 0.8599821925163269
and O O 0.9865759015083313
hemoglobins O S-protein 0.6371103525161743
that O O 0.9962044358253479
distinguish O O 0.9994282126426697
ES B-cell_type O 0.35583192110061646
cell-derived I-cell_type O 0.5137903094291687

These O O 0.999828577041626
data O O 0.9999312162399292
indicate O O 0.9999986886978149
that O O 0.9999927282333374
nitroprusside S-Chemical B-Chemical 0.9302151799201965
infusion O O 0.8866868019104004
rates O O 0.9938856959342957
that O O 0.9999964237213135
decrease O O 0.9965400695800781
mean O O 0.9984984397888184
arterial O O 0.9687682390213013
blood O O 0.9419341087341309
pressure O O 0.5824587345123291
by O O 0.9999163150787354
40 O O 0.9998347759246826
- O O 0.9999024868011475
50 O O 0.9998477697372437
per O O 0.9999632835388184
cent O O 0.9999692440032959
do O O 0.9999972581863403
not O O 0.9999338388442993
change O O 0.998489499092102
cardiac O O 0.5302422046661377
output O O 0.7419025897979736
or O O 0.9924437403678894
QS O O 0.6075626611709595
/ O O 0.9972290396690369
QT O O 0.8778462409973145
. O O 0.9999939203262329

200 O O 0.9264757633209229
to O O 0.9954197406768799
580 O O 0.9931158423423767
kb O O 0.9871891140937805
. O O 0.9999905824661255
Influence O O 0.9973226189613342
of O O 0.9995273351669312
age O O 0.9993420243263245
on O O 0.9999833106994629
the O O 0.9997870326042175
production O O 0.9936931133270264
of O O 0.9998698234558105
Fos S-protein S-protein 0.7180528044700623
and O O 0.965065598487854
Jun S-protein S-protein 0.5848806500434875
by O O 0.9990020394325256
influenza B-cell_type B-cell_type 0.43501976132392883
virus-exposed I-cell_type I-cell_type 0.41234660148620605
T I-cell_type I-cell_type 0.6008468270301819
cells E-cell_type E-cell_type 0.8057244420051575
. O O 0.9998002648353577
This O O 0.9999971389770508
study O O 0.9999361038208008

both O O 0.9961764812469482
in O O 0.9997132420539856
transfected B-cell_line B-cell_line 0.5993160605430603
cells E-cell_line E-cell_line 0.847443699836731
and O O 0.9987691044807434
in O O 0.9997188448905945
HTLV-I-infected B-cell_line B-cell_line 0.5923041105270386
leukemic I-cell_line I-cell_line 0.6944859623908997
T-cell I-cell_line I-cell_line 0.8496128916740417
lines E-cell_line E-cell_line 0.9978049397468567
. O O 0.999904990196228
Furthermore O O 0.9999932050704956
, O O 0.9999973773956299
the O O 0.9999911785125732
physical O O 0.9869728684425354
interaction O O 0.9992629885673523
of O O 0.9999490976333618
Tax S-protein S-protein 0.996034562587738
with O O 0.9996612071990967
p100 S-protein S-protein 0.955731987953186
leads O O 0.9993401169776917
to O O 0.9999922513961792
the O O 0.9999797344207764
inhibition O O 0.9943422079086304
of O O 0.9998512268066406

activation O I-protein 0.6249005198478699
Ag O E-protein 0.9596418142318726
found O O 0.998323380947113
on O O 0.9999207258224487
certain O O 0.9959803819656372
bone B-cell_type B-cell_type 0.7369478940963745
marrow-derived I-cell_type I-cell_type 0.43182724714279175
cells E-cell_type E-cell_type 0.5787774324417114
. O O 0.9998592138290405
Recently O O 0.9998433589935303
, O O 0.9999334812164307
CD40 S-protein S-protein 0.9672105312347412
also O O 0.9985461235046387
has O O 0.9999836683273315
been O O 0.9999436140060425
shown O O 0.9999632835388184

the O O 0.9980893731117249
transgenic O O 0.8610134124755859
mice O O 0.9677063822746277
had O O 0.9999337196350098
normal O O 0.9862159490585327
numbers O O 0.9981545805931091
of O O 0.9999113082885742
circulating B-cell_type B-cell_type 0.558671236038208
neutrophils E-cell_type E-cell_type 0.9556707143783569
, O O 0.9997572302818298
their O O 0.9999668598175049
bone O O 0.9418008327484131
marrow O O 0.9616918563842773
contained O O 0.9993560910224915
increased O O 0.9949336647987366
numbers O O 0.994417667388916
of O O 0.9998922348022461
immature B-cell_type B-cell_type 0.4471546709537506
neutrophilic I-cell_type I-cell_type 0.6839654445648193
cells E-cell_type E-cell_type 0.9138174057006836
, O O 0.9961114525794983
which O O 0.9999343156814575
exhibited O O 0.9987257122993469
abnormal O O 0.915510356426239
characteristics O O 0.9036940932273865
. O O 0.9999927282333374
In O O 0.9999785423278809
addition O O 0.999769389629364
, O O 0.9999827146530151
PEBP2betaMYH11 S-protein O 0.5394760966300964
inhibited O O 0.9965448975563049

The O O 0.9997528195381165
results O O 0.9999630451202393
of O O 0.9999940395355225
this O O 0.9999940395355225
case O O 0.998362123966217
report O O 0.9999802112579346
support O O 0.9999918937683105
the O O 0.9999922513961792
idea O O 0.9977877140045166
that O O 0.9999899864196777
in O O 0.9998631477355957
contrast O O 0.9989902377128601
with O O 0.9999889135360718
carbamazepine S-Chemical B-Chemical 0.9227827191352844
oxcarbazepine S-Chemical B-Chemical 0.751303493976593
does O O 0.99913090467453
not O O 0.9999699592590332
induce O O 0.9999806880950928
the O O 0.999848484992981
hepatic O O 0.6525670289993286
microsomal O O 0.5095268487930298
enzyme O O 0.4860939085483551
systems O O 0.9767727255821228
regulating O O 0.9999314546585083
the O O 0.9997968077659607
inactivation O O 0.9148072600364685
of O O 0.9991387128829956
antipsychotic O O 0.6557738184928894
drugs O O 0.685013473033905
. O O 0.9999679327011108

with O O 0.9964215755462646
GD O O 0.8007325530052185
, O O 0.9997813105583191
maintained O O 0.9964991807937622
euthyroid O O 0.8205478191375732
on O O 0.9993693232536316
ATD O O 0.6051875948905945
, O O 0.9989263415336609
were O O 0.9999805688858032
lower O O 0.9997560381889343
than O O 0.9999676942825317
those O O 0.999969482421875
before O O 0.9999186992645264
surgery O O 0.9985243678092957
or O O 0.9999821186065674
RAI O O 0.7502843141555786
therapy O O 0.9981912970542908
. O O 0.999998927116394
The O O 0.9999958276748657
reactivity O O 0.9943417310714722
of O O 0.9998934268951416
T B-cell_line B-cell_line 0.4186823070049286
cell I-cell_line I-cell_line 0.35443004965782166
lines E-cell_line E-cell_line 0.9941202998161316
in O O 0.9997400641441345

, O O 0.9515672922134399
and O O 0.9981583952903748
gradually O O 0.9994924068450928
returns O O 0.9991773962974548
to O O 0.9996623992919922
basal O O 0.8991753458976746
level O O 0.9972406625747681
by O O 0.9999909400939941
24 O O 0.9959229230880737
h O O 0.9955072402954102
. O O 0.9999690055847168
rBPI21 S-protein S-protein 0.6738798022270203
, O O 0.9984449744224548
a O O 0.9999288320541382
recombinant B-protein O 0.656419575214386

3 E-protein E-protein 0.6412066221237183
and O O 0.9297550320625305
interleukin-4 B-protein B-protein 0.5694894194602966
Stat E-protein E-protein 0.9355980753898621
. O O 0.9988523721694946
Germ B-RNA O 0.7755818367004395
line I-RNA O 0.673324465751648
C I-RNA O 0.3720090985298157
transcripts E-RNA O 0.28952890634536743
can O O 0.9995856881141663
be O O 0.9999817609786987
induced O O 0.9999423027038574
by O O 0.9999891519546509
IL-4 S-protein S-protein 0.9735471606254578
in O O 0.9997392296791077
the O O 0.9998856782913208
human B-cell_line B-cell_line 0.5665891170501709
B I-cell_line I-cell_line 0.4884811043739319
cell I-cell_line I-cell_line 0.8475289940834045
line E-cell_line E-cell_line 0.9644742012023926
, O O 0.9944581985473633
BL-2 S-cell_line S-cell_line 0.9959343671798706
. O O 0.9979807734489441
Utilizing O O 0.9997907280921936
a O O 0.9997480511665344
IFN-gamma B-DNA B-DNA 0.6235936284065247
activation I-DNA I-DNA 0.3703986704349518
site-like I-DNA I-DNA 0.39816439151763916
DNA I-DNA E-DNA 0.7296960949897766

findings O O 0.9940071105957031
suggest O O 0.999997615814209
the O O 0.9999899864196777
presence O O 0.9988651275634766
in O O 0.9999806880950928
vaginal O O 0.834435760974884
fluid O O 0.8761714100837708
of O O 0.9976286292076111
agent O O 0.7784862518310547
( O O 0.9963531494140625
s O O 0.9617487192153931

In O O 0.994425892829895
promoter B-DNA B-DNA 0.8851075768470764
regions E-DNA E-DNA 0.9540457129478455
, O O 0.9995684027671814
the O O 0.9999386072158813
actively B-DNA B-DNA 0.8438493609428406
transcribed I-DNA I-DNA 0.8391133546829224
genes E-DNA E-DNA 0.8453575372695923
demonstrated O O 0.9986916184425354
extensive O O 0.9812171459197998
and O O 0.9966597557067871
consistent O O 0.975506067276001
footprints O O 0.9274848699569702
over O O 0.9999274015426636
the O O 0.9998295307159424
canonical O B-DNA 0.7551564574241638
elements O E-DNA 0.959663450717926
, O O 0.9972147345542908
such O O 0.9999693632125854
as O O 0.999961256980896
CACCC B-DNA B-DNA 0.8289697766304016
and I-DNA I-DNA 0.8640011548995972
CCAAT I-DNA I-DNA 0.3280637264251709
motifs E-DNA E-DNA 0.9718979597091675
. O O 0.99989914894104
The O O 0.9999914169311523
adult B-cell_type B-cell_line 0.8359336256980896
globin I-cell_type I-cell_line 0.27918797731399536
expressing I-cell_type I-cell_line 0.2971244752407074
cells E-cell_type E-cell_line 0.5371854901313782
displayed O O 0.9990116357803345
more O O 0.9987125396728516
extensive O O 0.95304274559021
footprints O O 0.9677887558937073

to O O 0.9897034764289856
lymphocytes S-cell_type S-cell_type 0.9768037796020508
postnatally O O 0.9844216108322144
. O O 0.9999854564666748
Expression O O 0.9955019354820251
studies O O 0.9998586177825928
on O O 0.9999616146087646
TCF-1 B-protein B-protein 0.7947772145271301
protein E-protein E-protein 0.958938479423523
have O O 0.9997448325157166
been O O 0.9999673366546631
hampered O O 0.9999599456787109
by O O 0.9999971389770508
the O O 0.9999711513519287
difficulty O O 0.9991627931594849
to O O 0.9999648332595825
raise O O 0.9988161325454712

to O O 0.9893532991409302
accumulate O O 0.9995304346084595
as O O 0.9997360110282898
transformed B-cell_type B-cell_line 0.49096250534057617
lymphoblasts E-cell_type E-cell_line 0.7845439314842224
. O O 0.9998470544815063
To O O 0.999993085861206
determine O O 0.9999880790710449
the O O 0.9999485015869141
structural O O 0.9535347819328308

their O O 0.9973291158676147
mechanisms O O 0.9995493292808533
of O O 0.9999457597732544
action O O 0.9986191987991333
are O O 0.9999957084655762
still O O 0.9999642372131348
unknown O O 0.999822199344635
. O O 0.999998927116394
Although O O 0.9999966621398926
all O O 0.9999343156814575
nm23 B-protein B-protein 0.6104946732521057
proteins E-protein E-protein 0.9814513325691223
contain O O 0.9994490742683411
nucleoside B-protein B-protein 0.7685696482658386
diphosphate I-protein I-protein 0.4140728712081909
( I-protein I-protein 0.9041056036949158
NDP I-protein I-protein 0.6130803823471069
) I-protein I-protein 0.49129992723464966
kinase E-protein E-protein 0.9464614391326904
activity O O 0.9949787259101868
, O O 0.9999949932098389
it O O 0.999983549118042
has O O 0.9999943971633911
not O O 0.99992835521698
been O O 0.9999465942382812
established O O 0.9999163150787354
that O O 0.9999836683273315

Three O O 0.9985818862915039
to O O 0.999487042427063
6 O O 0.9997424483299255
months O O 0.9999185800552368
after O O 0.999996542930603
RAI O O 0.9735325574874878
, O O 0.9999597072601318
T O O 0.7635303735733032
cell O O 0.5880033373832703
responses O O 0.9879903197288513
to O O 0.9999754428863525
TSHR S-protein O 0.44541680812835693
peptides O O 0.8123987913131714
were O O 0.9999934434890747
less O O 0.9999868869781494
than O O 0.9999897480010986
those O O 0.9999957084655762
6-8 O O 0.9871320724487305

or O O 0.963935136795044
IL-10 S-protein S-protein 0.8844483494758606
secretion O O 0.929804801940918
were O O 0.999966025352478
blocked O O 0.9996898174285889
completely O O 0.9999507665634155
by O O 0.9999947547912598
propranolol O O 0.9124616980552673
, O O 0.9998798370361328
a O O 0.9999481439590454
beta-adrenoreceptor O O 0.7350347638130188
antagonist O O 0.4599646031856537
, O O 0.9988943934440613
indicating O O 0.9999878406524658
that O O 0.9999909400939941
they O O 0.9998432397842407
were O O 0.9999744892120361
mediated O O 0.9995517134666443
by O O 0.999991774559021
the O O 0.9998468160629272
beta-adrenergic B-protein B-protein 0.47714337706565857
receptor E-protein E-protein 0.8969613909721375
. O O 0.9975253939628601
These O O 0.9999474287033081

model O O 0.6055633425712585
using O O 0.9986936450004578
MPL O O 0.41135314106941223
concentrations O O 0.7729560732841492
in O O 0.9997711777687073
plasma S-cell_type O 0.6828020811080933
as O O 0.9985973238945007
an O O 0.9999605417251587
input O O 0.9802446365356445
function O O 0.998855471611023
. O O 0.9999990463256836
A O O 0.99993896484375
nonlinear O O 0.7202407121658325
relationship O O 0.9469831585884094
was O O 0.9999247789382935
found O O 0.9999765157699585
between O O 0.9989101886749268
suppression O O 0.9827053546905518
of O O 0.9995177984237671

both O O 0.9965291619300842
transcriptionally O O 0.9309617877006531
and O O 0.9846745729446411
posttranscriptionally O O 0.914350688457489
for O O 0.9940325617790222
IL-1beta S-protein S-protein 0.9882866740226746
. O O 0.9995926022529602
Characterization O O 0.9976492524147034
and O O 0.9997040629386902
purification O O 0.9910486936569214
of O O 0.9999128580093384
a O O 0.9999167919158936
protein B-protein B-protein 0.5069695115089417
kinase I-protein I-protein 0.6745111346244812
C I-protein I-protein 0.7753898501396179
substrate E-protein E-protein 0.9230534434318542
in O O 0.9987143278121948
human B-cell_type B-cell_type 0.6305080056190491
B I-cell_type I-cell_type 0.8173279762268066
cells E-cell_type E-cell_type 0.9598090052604675
. O O 0.9993828535079956
Identification O O 0.9987788796424866
as O O 0.9999879598617554
lymphocyte-specific B-protein B-protein 0.5782815217971802
protein I-protein I-protein 0.5861861705780029
1 E-protein E-protein 0.9640234112739563
( O O 0.846107006072998

to O O 0.9780224561691284

binds O O 0.8934696912765503
lipopolysaccharide O O 0.46362820267677307
and O O 0.9951186180114746
other O O 0.9981143474578857
microbial O B-protein 0.7225599884986877
products O E-protein 0.9631955623626709
. O O 0.99956876039505
To O O 0.9999722242355347
begin O O 0.9998713731765747
to O O 0.9999103546142578
elucidate O O 0.9993401169776917
the O O 0.9999511241912842
mechanisms O O 0.9978964328765869
that O O 0.9999836683273315
regulate O O 0.9998990297317505
the O O 0.9998142123222351
transcription O O 0.9180099964141846
of O O 0.9969274401664734
cytokine B-DNA B-DNA 0.5627573132514954
genes E-DNA E-DNA 0.9841277003288269
, O O 0.9994895458221436
we O O 0.999976396560669
wanted O O 0.9999780654907227
to O O 0.9999899864196777
determine O O 0.9999953508377075
which O O 0.9999222755432129
transcription B-protein B-protein 0.47147655487060547
factors E-protein E-protein 0.9871799349784851
are O O 0.9992616772651672
activated O O 0.9992775321006775
by O O 0.9999939203262329
PGN O O 0.4419756531715393
in O O 0.9988106489181519
mouse B-cell_line B-cell_line 0.46987542510032654
RAW264.7 E-cell_line E-cell_line 0.6995116472244263
and O O 0.9076184034347534

Tax S-protein S-protein 0.9623035788536072
function O O 0.9991738200187683
. O O 0.9999984502792358
An O O 0.9999442100524902
allosteric O O 0.8408651947975159
drug O O 0.7840767502784729
, O O 0.9987162351608276
o O O 0.982550323009491
, O O 0.9990596175193787
o'-bismyristoyl O O 0.9905804991722107
thiamine O O 0.9853549003601074
disulfide O O 0.9827715754508972
, O O 0.9999641180038452
suppresses O O 0.9995750784873962
HIV-1 O O 0.8623982071876526
replication O O 0.9817827343940735
through O O 0.9999562501907349
prevention O O 0.9988909363746643
of O O 0.9999780654907227
nuclear O O 0.9128344655036926
translocation O O 0.9340342283248901
of O O 0.998532772064209
both O O 0.9993021488189697
HIV-1 B-protein B-protein 0.3235589563846588
Tat E-protein E-protein 0.9202317595481873
and O O 0.9908382296562195
NF-kappa B-protein B-protein 0.849270761013031
B E-protein E-protein 0.9875447750091553
. O O 0.9996743202209473
The O O 0.9999964237213135
efficacy O O 0.9937346577644348
of O O 0.9997521042823792
o O O 0.6415840983390808
, O O 0.916118323802948
o'-bismyristoyl O O 0.9270808696746826
thiamine O O 0.9284030199050903
disulfide O O 0.9710838794708252
( O O 0.9995936751365662
BMT O O 0.7928897738456726

Dexamethasone S-Chemical B-Chemical 0.9213513135910034
( O O 0.9933791160583496
10 O O 0.9984169006347656
microg O O 0.9858672022819519
/ O O 0.9998782873153687
kg O O 0.9993908405303955
per O O 0.9999157190322876
day O O 0.9998801946640015
, O O 0.9999912977218628
s O O 0.9993264675140381
. O O 0.9998303651809692
c O O 0.9963514804840088
. O O 0.9995937943458557
) O O 0.9977030158042908
or O O 0.9999663829803467
saline O O 0.5381852388381958
was O O 0.9995556473731995
started O O 0.9998788833618164
after O O 0.9999970197677612
4 O O 0.9992653727531433
days O O 0.9999452829360962
in O O 0.9999488592147827
Ato S-Chemical B-Chemical 0.9105844497680664
- O O 0.7774658799171448
treated O O 0.9969184398651123
and O O 0.99993896484375
non O O 0.9421355128288269
- O O 0.9938234090805054
treated O O 0.9967166781425476
rats O O 0.9882636070251465
and O O 0.9999418258666992
continued O O 0.9992662072181702
for O O 0.9999793767929077
11 O O 0.9993398785591125
- O O 0.9997313618659973
13 O O 0.9997506737709045
days O O 0.9999892711639404
. O O 0.9999990463256836

human B-DNA B-DNA 0.42340803146362305
beta-globin I-DNA I-DNA 0.5295857191085815
gene I-DNA I-DNA 0.8457122445106506
locus E-DNA E-DNA 0.959055483341217
assumes O O 0.9995328187942505
a O O 0.9999780654907227
transcriptionally-active O O 0.7993994951248169
conformation O O 0.8844969272613525
in O O 0.9995865225791931
erythroid B-cell_type B-cell_type 0.7934190034866333
cells E-cell_type E-cell_type 0.9846514463424683
. O O 0.9998699426651001
One O O 0.9997826218605042
feature O O 0.9987664222717285
of O O 0.9999818801879883
this O O 0.9999650716781616
chromatin O S-protein 0.4633997082710266
reorganization O O 0.8435847759246826
is O O 0.9999357461929321
the O O 0.9999946355819702
formation O O 0.9994238615036011
of O O 0.999964714050293
DNase B-DNA B-DNA 0.30004826188087463
1 I-DNA I-DNA 0.6965168714523315
hypersensitive I-DNA I-DNA 0.37665796279907227
sites E-DNA E-DNA 0.7790153622627258
in O O 0.9991569519042969

to O O 0.9912850260734558
Ala O S-protein 0.6479876637458801
, O O 0.9960203766822815
Ala618 O S-protein 0.605324387550354
to O O 0.88457190990448
Ser O S-protein 0.45899829268455505
, O O 0.9411314725875854
and O O 0.9938042163848877
Ile761 O S-protein 0.4105477035045624
to O O 0.8646658062934875
Leu O S-DNA 0.46513837575912476
) O O 0.7409512996673584
, O O 0.9994888305664062
all O O 0.9999858140945435
of O O 0.9999833106994629
which O O 0.9999333620071411
are O O 0.9999479055404663
present O O 0.999743640422821
in O O 0.9999312162399292
owl B-protein O 0.894938051700592
monkey I-protein O 0.6491920948028564
and I-protein O 0.9804051518440247
cotton-top I-protein B-protein 0.858736515045166
tamarin I-protein I-protein 0.55873042345047
receptors E-protein E-protein 0.958380401134491
. O O 0.9998712539672852
The O O 0.9999761581420898
DNA-binding B-protein B-protein 0.5288416743278503
domain E-protein E-protein 0.9122232794761658
( O O 0.9825664758682251
amino B-protein B-protein 0.3975922167301178

The O O 0.9996625185012817
morphological O O 0.9771896004676819
analysis O O 0.9978471994400024
of O O 0.999980092048645
the O O 0.9999505281448364
kidneys O O 0.7603843212127686
included O O 0.9998196959495544
a O O 0.9999719858169556
semi O O 0.9841257333755493
- O O 0.9983059167861938
quantitative O O 0.9809445142745972
scoring O O 0.9830921292304993
system O O 0.9938416481018066
analysing O O 0.9999880790710449
the O O 0.9999508857727051
degree O O 0.9997283816337585
of O O 0.9999582767486572
striped O O 0.6747838258743286
fibrosis B-Disease B-Disease 0.6115880012512207
, O O 0.9792777895927429
subcapsular O O 0.4867144823074341
fibrosis B-Disease O 0.8690962195396423
and O O 0.9888702630996704
the O O 0.9991446733474731
number O O 0.9995755553245544
of O O 0.9999710321426392
basophilic O O 0.5948598384857178
tubules O O 0.5254970192909241
, O O 0.9996867179870605
plus O O 0.9999895095825195
an O O 0.9999884366989136
additional O O 0.9996954202651978
stereological O O 0.9790822267532349
analysis O O 0.9926122426986694
of O O 0.9999215602874756
the O O 0.9999532699584961
total O O 0.9912070631980896
grade O O 0.9902210235595703
of O O 0.9995644688606262
fibrosis B-Disease B-Disease 0.970003068447113
in O O 0.9749341011047363
the O O 0.9940938353538513
cortex O O 0.8735101819038391
stained O O 0.9976061582565308
with O O 0.9999918937683105
Sirius O O 0.4625379741191864
Red O O 0.758914589881897
. O O 0.999235987663269

min O O 0.6278173327445984
, O O 0.9885669946670532
and O O 0.9995589852333069
then O O 0.9992820620536804
declined O O 0.9993127584457397
. O O 0.9999943971633911
This O O 0.9999210834503174
activation O O 0.996559202671051
is O O 0.9999760389328003
inhibited O O 0.9997501969337463
by O O 0.999995231628418
known O O 0.9950146079063416
inhibitors O O 0.9870275259017944
of O O 0.9998880624771118
NF-kappa B-protein B-protein 0.767247200012207
B E-protein E-protein 0.9838399291038513
or O O 0.9966519474983215
by O O 0.99988853931427
simultaneous O O 0.9801422357559204
treatment O O 0.9971900582313538
of O O 0.9999250173568726
the O O 0.9996317625045776
cells O O 0.970177173614502
with O O 0.9999628067016602
surfactant O O 0.7949684262275696
lipids O O 0.5487704277038574
. O O 0.9998772144317627
Moreover O O 0.9989734888076782
, O O 0.9998804330825806

cells E-cell_line E-cell_type 0.6724439859390259
, O O 0.9980272650718689
IL-2 S-protein S-protein 0.9545254111289978
induced O O 0.9992699027061462
comparable O O 0.9911623001098633
formation O O 0.9923789501190186
of O O 0.9998156428337097
c-fos B-protein B-DNA 0.40977656841278076
promoter I-protein I-DNA 0.7050424814224243
sis-inducible I-protein I-DNA 0.31721824407577515
element I-protein E-DNA 0.8733276128768921
IFN-gamma-activated I-protein B-protein 0.5324293375015259
sequence-binding I-protein I-protein 0.46901148557662964
complexes E-protein E-protein 0.980747640132904
containing O O 0.9966452717781067
STAT3 S-protein S-protein 0.9751706123352051
alone O O 0.9940457344055176
with O O 0.9999040365219116
complexes O O 0.6413023471832275
containing O O 0.9944677352905273
STAT3 S-protein S-protein 0.9637461304664612
and O O 0.9855153560638428
STAT1 B-protein B-protein 0.4395439624786377
alpha E-protein E-protein 0.9736435413360596
, O O 0.9888984560966492
while O O 0.999983549118042
in O O 0.9996111989021301
preactivated B-cell_line B-cell_type 0.46572256088256836
primary I-cell_line I-cell_type 0.4112035036087036
NK I-cell_line I-cell_type 0.7773942351341248
cells E-cell_line E-cell_type 0.7210025787353516
, O O 0.9987443685531616
it O O 0.9999399185180664
preferentially O O 0.9925087094306946
induced O O 0.9965355396270752
complexes O O 0.8580854535102844
containing O O 0.9985948204994202
STAT3 S-protein S-protein 0.9236438274383545
and O O 0.9815007448196411
STAT1 B-protein B-protein 0.4411104917526245
alpha E-protein E-protein 0.9205459952354431

5 B-DNA I-DNA 0.6613966226577759
' I-DNA I-DNA 0.6989185214042664
palindromic I-DNA I-DNA 0.5592278242111206
octamer I-DNA I-DNA 0.30134961009025574
sequence E-DNA E-DNA 0.9790425896644592
. O O 0.9997358918190002
Expression O O 0.9989411234855652
of O O 0.9999463558197021
the O O 0.9999067783355713
gene O O 0.8132026195526123
encoding O O 0.9426484704017639
human B-protein B-protein 0.5605179071426392
inosine- I-protein I-protein 0.4689543843269348
5'-monophosphate I-protein I-protein 0.5402479767799377
dehydrogenase I-protein E-protein 0.9812164902687073
( I-protein O 0.9806717038154602
IMPDH I-protein S-protein 0.8484951257705688

The O O 0.9995976090431213
selective O O 0.9904114603996277
5 O O 0.6851096153259277
- O O 0.5809165239334106
HT6 O O 0.8424332141876221
receptor O O 0.6777244806289673
antagonist O O 0.6455119848251343
Ro4368554 B-Chemical B-Chemical 0.9207215905189514
restores O O 0.9848323464393616
memory O O 0.7581599354743958
performance O O 0.782530665397644
in O O 0.9988918900489807
cholinergic O O 0.4851374626159668
and O O 0.9324570894241333
serotonergic O O 0.5211866497993469
models O O 0.9609440565109253
of O O 0.9988483190536499
memory B-Disease O 0.6214671730995178
deficiency I-Disease O 0.9554596543312073
in O O 0.9356998205184937
the O O 0.9819996356964111
rat O O 0.9345079660415649
. O O 0.9999363422393799

We O O 0.9994027614593506
report O O 0.9999960660934448
a O O 0.9999604225158691
patient O O 0.9927263259887695
in O O 0.9999527931213379
whom O O 0.9998738765716553
hypersensitivity O B-Disease 0.9587555527687073
to O O 0.9002516865730286
carbamazepine S-Chemical B-Chemical 0.9320738911628723
presented O O 0.9987201690673828
with O O 0.9999538660049438
generalized O O 0.9021192789077759
erythroderma O B-Disease 0.8623635768890381
, O O 0.9877118468284607
a O O 0.9990443587303162
severe O O 0.9847918748855591
leukemoid O B-Disease 0.7290371656417847
reaction O I-Disease 0.9816126227378845
, O O 0.9128657579421997
eosinophilia O B-Disease 0.9678565263748169
, O O 0.957876443862915
hyponatremia O B-Disease 0.9832590818405151
, O O 0.9408565163612366
and O O 0.9956157207489014
renal O B-Disease 0.5644708871841431
failure O I-Disease 0.9732449054718018
. O O 0.9970269799232483

a O O 0.9955276846885681
QR S-protein S-protein 0.9698446393013
-specific O O 0.9876576662063599
inhibitor O O 0.9736964106559753
. O O 0.9999786615371704
Since O O 0.9999223947525024
human B-cell_type B-cell_type 0.48446279764175415
T I-cell_type I-cell_type 0.6793611645698547
cells E-cell_type E-cell_type 0.9312683939933777
and O O 0.9897148013114929
T B-cell_type B-cell_line 0.38314929604530334
cell I-cell_type I-cell_line 0.4084985554218292
lines E-cell_type E-cell_line 0.9926213026046753
do O O 0.9998959302902222
not O O 0.999976634979248
metabolize O O 0.9941364526748657
arachidonic O O 0.8980617523193359
acid O O 0.9370381236076355
, O O 0.9998314380645752

We O O 0.9954580068588257
have O O 0.999993085861206
examined O O 0.9999740123748779
the O O 0.9999778270721436
requirements O O 0.9997468590736389
of O O 0.9999856948852539
the O O 0.9999790191650391
individual O O 0.9269862174987793
E-boxes S-DNA O 0.34000715613365173
in O O 0.9987331032752991
MLV O O 0.5485734939575195
transcriptional O O 0.8246846199035645
regulation O O 0.9856217503547668
. O O 0.9999847412109375
In O O 0.9995978474617004
lymphoid B-cell_line B-cell_line 0.5779246687889099
cell I-cell_line I-cell_line 0.7360171675682068
lines E-cell_line E-cell_line 0.9872393012046814
only O O 0.9983875751495361
, O O 0.999996542930603
the O O 0.9999643564224243
E B-protein B-protein 0.3428867757320404
( I-protein I-protein 0.3838004171848297
gre I-protein I-protein 0.6343274116516113
) I-protein I-protein 0.5360619425773621
-binding I-protein I-protein 0.8622543811798096
protein I-protein I-protein 0.7237754464149475
complexes E-protein E-protein 0.9957960844039917
included O O 0.9993372559547424
ALF1 S-protein S-protein 0.9225699305534363
or O O 0.992583155632019
HEB S-protein S-protein 0.7765640616416931
and O O 0.930777907371521
E2A B-protein B-protein 0.6091561913490295
basic I-protein I-protein 0.6542016863822937
helix-loop-helix I-protein I-protein 0.8576161861419678
proteins E-protein E-protein 0.9963617920875549
. O O 0.9998113512992859
Ectopic O O 0.7903529405593872
ALF1 S-protein S-protein 0.6879501342773438
and O O 0.9522203207015991
E2A B-protein B-protein 0.4280779957771301
proteins E-protein E-protein 0.9882955551147461
required O O 0.9991796612739563

with O O 0.9992007613182068
a O O 0.9999375343322754
poor O O 0.9910857081413269
prognosis O O 0.9984277486801147
. O O 0.9999992847442627
The O O 0.9999712705612183
translocation B-DNA B-DNA 0.74675452709198
t I-DNA I-DNA 0.3872019052505493
( I-DNA I-DNA 0.8813496232032776
10 I-DNA I-DNA 0.7125141024589539
; I-DNA I-DNA 0.48546791076660156
11 I-DNA I-DNA 0.856372058391571
) I-DNA I-DNA 0.6784495115280151
( I-DNA I-DNA 0.8144910931587219
p13 I-DNA I-DNA 0.9298111200332642
; I-DNA I-DNA 0.9923871755599976
q14 I-DNA I-DNA 0.968166172504425
) E-DNA I-DNA 0.6632053852081299

with O O 0.9989755153656006
an O O 0.9999816417694092
increased O O 0.995394766330719
kappa O B-protein 0.7821421027183533
B O E-protein 0.9326439499855042
binding O O 0.8923221230506897
activity O O 0.9946850538253784
. O O 0.9999943971633911
Human O B-cell_type 0.6044201254844666
peripheral O I-cell_type 0.4558877944946289
blood O I-cell_type 0.844066858291626
monocytes S-cell_type E-cell_type 0.9652444124221802
responded O O 0.9996182918548584
to O O 0.9999884366989136
stimulation O O 0.993120551109314
of O O 0.9997162222862244
platelet-activating B-protein B-protein 0.47690439224243164
factor E-protein E-protein 0.8760915398597717
( O O 0.8324827551841736
PAF S-protein S-protein 0.45172280073165894

Antinociceptive O O 0.5228295922279358
effect O O 0.9824070930480957
of O O 0.9995357990264893
morphine B-Chemical B-Chemical 0.9339429140090942
was O O 0.9986347556114197
reduced O O 0.9980941414833069
in O O 0.9999606609344482
chronically O O 0.8712356686592102
treated O O 0.9152629971504211
rats O O 0.985031008720398
( O O 0.9999794960021973
39 O O 0.9998262524604797
+ O O 0.999964714050293
/ O O 0.9999947547912598
- O O 0.9999606609344482
10 O O 0.9999204874038696
vs O O 0.9998359680175781
. O O 0.9999750852584839
18 O O 0.9999291896820068
+ O O 0.9999765157699585
/ O O 0.9999960660934448
- O O 0.9999583959579468
5 O O 0.9998956918716431
au O O 0.9994509816169739
) O O 0.9999116659164429
while O O 0.999998927116394
the O O 0.9999657869338989
combination O O 0.9797415733337402
- O O 0.9986497759819031
induced O O 0.9868115782737732
antinociception O O 0.8959122896194458
was O O 0.99410480260849
remained O O 0.9998069405555725
similar O O 0.9998986721038818
as O O 0.9999978542327881
an O O 0.9999668598175049
acute O O 0.7762354612350464
treatment O O 0.9855153560638428
( O O 0.9999905824661255
298 O O 0.9996501207351685
+ O O 0.9999743700027466
/ O O 0.9999977350234985
- O O 0.9999626874923706
7 O O 0.9999148845672607
vs O O 0.9996751546859741
. O O 0.9999667406082153
280 O O 0.9997000694274902
+ O O 0.9999898672103882
/ O O 0.9999979734420776
- O O 0.9999613761901855
17 O O 0.9998693466186523
au O O 0.9994547963142395
) O O 0.9998871088027954
. O O 0.9999982118606567

some O O 0.995721697807312
commonly O O 0.919378399848938
known O O 0.9924601912498474
lymphokines S-protein O 0.34720712900161743
. O O 0.9993687272071838
The O O 0.9999932050704956
interaction O O 0.9959586262702942
between O O 0.9988866448402405
lymphoid B-cell_type B-cell_type 0.5568757653236389
and I-cell_type I-cell_type 0.7106348872184753
prostatic I-cell_type I-cell_type 0.46300265192985535
cells E-cell_type E-cell_type 0.9556711316108704
in O O 0.9989567995071411
growth O O 0.9603779911994934
and O O 0.9978258013725281
development O O 0.9986196756362915
is O O 0.9999878406524658
described O O 0.9999724626541138
. O O 0.9999898672103882
Platelet-activating B-protein B-protein 0.39342209696769714
factor E-protein E-protein 0.7710960507392883

TPA S-protein S-protein 0.6835200786590576
-induced O O 0.993049144744873
HL-60 O O 0.332369327545166
differentiation O O 0.9662318825721741
but O O 0.9995611310005188
unchanged O O 0.9980820417404175
during O O 0.9999369382858276
granulocyte O O 0.6892770528793335
differentiation O O 0.9943934679031372
. O O 0.9999977350234985
From O O 0.9999932050704956
these O O 0.9999830722808838
data O O 0.9992247819900513
, O O 0.999997615814209
we O O 0.9999943971633911
conclude O O 0.9999990463256836
that O O 0.9999986886978149
the O O 0.9999730587005615
induction O O 0.9984849095344543
of O O 0.9999003410339355
PO-B S-protein S-protein 0.6830881834030151
DNA O O 0.7346320748329163
binding O O 0.9779965281486511
is O O 0.9999897480010986
a O O 0.9999969005584717
general O O 0.9450231790542603
marker O O 0.9090493321418762

on O O 0.9970952272415161
chromosome B-DNA B-DNA 0.5057902336120605
3 I-DNA I-DNA 0.8736932873725891
band I-DNA I-DNA 0.4957388937473297
q26 E-DNA E-DNA 0.7917189002037048
, O O 0.990638256072998
encodes O O 0.9981483221054077
a O O 0.999761164188385
zinc-finger B-protein B-protein 0.37315452098846436
DNA-binding I-protein I-protein 0.5612728595733643
transcription I-protein I-protein 0.6334330439567566
activator E-protein E-protein 0.9471205472946167
not O O 0.9860302805900574
detected O O 0.9992343187332153
in O O 0.9996384382247925
normal B-cell_type B-cell_type 0.48938894271850586
hematopoietic I-cell_type I-cell_type 0.7464612722396851
cells E-cell_type E-cell_type 0.9342796206474304
but O O 0.9967093467712402
expressed O O 0.999782145023346
in O O 0.9998449087142944
several O O 0.997519314289093
normal O O 0.8166080713272095
tissues O O 0.9187107086181641

synthesis O O 0.6966836452484131
, O O 0.9980624318122864
and O O 0.9999039173126221
in O O 0.9993553757667542
macrophages S-cell_type S-cell_type 0.9617046117782593
, O O 0.9969518184661865
which O O 0.9998676776885986
are O O 0.9999661445617676
involved O O 0.9999537467956543
in O O 0.9999730587005615
iron O O 0.8132714629173279
storage O O 0.9689326286315918
, O O 0.9999566078186035
transcriptional O O 0.9387680888175964
regulation O O 0.9765526652336121
seemed O O 0.9999806880950928
to O O 0.999984622001648
be O O 0.9999926090240479
a O O 0.9999909400939941
relevant O O 0.9881470799446106
mechanism O O 0.9986635446548462
. O O 0.999998927116394

free O O 0.9027469158172607

pathway O O 0.9648544788360596
and O O 0.9999181032180786
suggest O O 0.9999945163726807
that O O 0.9999949932098389
NF-kappa B-protein B-protein 0.7696254253387451
B E-protein E-protein 0.9743321537971497
sensitive O O 0.9423806667327881
to O O 0.9986944794654846
NAC O O 0.2926956117153168
may O O 0.9988194108009338
play O O 0.9999926090240479
a O O 0.9999964237213135
role O O 0.9995357990264893
in O O 0.9999850988388062

, O O 0.9940066337585449
the O O 0.9999451637268066
GR S-protein S-protein 0.9753564596176147
in O O 0.9991711378097534
MNL S-cell_type S-cell_type 0.7178060412406921
did O O 0.999284565448761
not O O 0.9999889135360718
demonstrate O O 0.9999381303787231
circadian O O 0.9272181987762451
variation O O 0.9830650091171265
, O O 0.9999529123306274
in O O 0.9999828338623047
contrast O O 0.9998711347579956
to O O 0.9999862909317017
concentrations O O 0.9974316954612732
of O O 0.9999611377716064
plasma O O 0.8529724478721619
cortisol O O 0.8196759819984436
. O O 0.9994850158691406
Synergism O O 0.8775042295455933
between O O 0.9992176294326782
two O O 0.9980646967887878
distinct O O 0.9857585430145264
elements O O 0.7644365429878235
of O O 0.9998860359191895
the O O 0.9997803568840027
HTLV-I B-DNA B-DNA 0.5089784264564514
enhancer E-DNA E-DNA 0.9907907247543335
during O O 0.9987207055091858
activation O O 0.9982430934906006
by O O 0.9999959468841553
the O O 0.9998410940170288
trans-activator S-protein O 0.38191497325897217
of O O 0.9114046096801758
HTLV-I O O 0.5223288536071777
. O O 0.9993243217468262
We O O 0.9999762773513794
have O O 0.9999960660934448
conducted O O 0.9999293088912964
functional O O 0.988234281539917
studies O O 0.9992641806602478

Severe O O 0.9249054193496704
toxicity B-Disease B-Disease 0.9456602931022644
was O O 0.9688414335250854
correlated O O 0.9990853071212769
with O O 0.9999879598617554
the O O 0.9999133348464966
higher O O 0.9967089891433716
cumulative O O 0.9561609029769897
dose O O 0.9902618527412415
of O O 0.9996700286865234
60 O O 0.9899628758430481
g O O 0.9989915490150452
/ O O 0.99988853931427
m2 O O 0.999014139175415
of O O 0.9990471005439758
ifosfamide B-Chemical B-Chemical 0.9360917210578918
, O O 0.9952076077461243
a O O 0.9998737573623657
younger O O 0.996414303779602
age O O 0.9992552399635315
( O O 0.9999945163726807
less O O 0.9995478987693787
than O O 0.9999037981033325
2 O O 0.999653697013855
1 O O 0.9999274015426636
/ O O 0.9999880790710449
2 O O 0.9999663829803467
years O O 0.9999772310256958
old O O 0.9995177984237671
) O O 0.999907374382019
, O O 0.9999650716781616
and O O 0.9999645948410034
a O O 0.9998632669448853
predominance O O 0.9872334003448486
of O O 0.9996893405914307
vesicoprostatic O O 0.5815667510032654
tumor B-Disease O 0.5280776023864746
involvement O O 0.7107179760932922
. O O 0.9999194145202637

Both O O 0.9997352957725525
anti O O 0.9490276575088501
- O O 0.9775674343109131
arrhythmic O O 0.672394335269928
efficacy O O 0.8807153701782227
and O O 0.999167799949646
bioavailability O O 0.5207998156547546
were O O 0.9995993971824646
compared O O 0.9999866485595703
to O O 0.9999864101409912
oral O O 0.8722443580627441
drug O O 0.901178777217865
. O O 0.9999200105667114

4 I-DNA I-protein 0.5559871196746826
and I-DNA I-protein 0.5225223898887634
5 E-DNA E-protein 0.8126457333564758
. O O 0.9932675361633301
This O O 0.9996716976165771
exon O S-DNA 0.6723730564117432
was O O 0.9904276132583618
inserted O O 0.9997972846031189
between B-DNA O 0.9995392560958862
glutamine-rich I-DNA O 0.5802617073059082
regions I-DNA O 0.3682191073894501
2 I-DNA O 0.3398745656013489
and I-DNA O 0.929660975933075
3 E-DNA O 0.5788747072219849
, O O 0.988304615020752
carboxy B-protein O 0.5561888217926025
terminal E-protein O 0.5727092623710632
of O O 0.9259262084960938
a O O 0.997492790222168
tentative O O 0.8717048168182373
leucine-zipper B-protein O 0.33529385924339294
structure E-protein O 0.6524865627288818
. O O 0.9992547631263733
In O O 0.9999744892120361
addition O O 0.9994866847991943
, O O 0.9999896287918091
a O O 0.9999510049819946
new O O 0.9798454642295837
combination O O 0.9021221399307251
isoform O O 0.7392755746841431
containing O O 0.9904648065567017
Oct2a B-protein S-protein 0.8366498947143555
's I-protein O 0.930162250995636
amino I-protein B-protein 0.5651906132698059
terminal I-protein I-protein 0.7561548352241516
insert E-protein E-protein 0.7191411256790161
( O O 0.9580157399177551
exon B-DNA B-DNA 0.3941446542739868
7a E-DNA E-DNA 0.7342055439949036
) O O 0.9186552166938782
and O O 0.998180627822876

. O O 0.9926770925521851
Since O O 0.9999972581863403
a O O 0.999984860420227
mutation O O 0.9972403049468994
of O O 0.9999487400054932
CBP S-protein S-protein 0.8891339302062988
abolishing O O 0.994795024394989
HAT O S-protein 0.7760977745056152
activity O O 0.9957647323608398
is O O 0.9999912977218628
almost O O 0.9998565912246704
as O O 0.999944806098938
active O O 0.9983687996864319
as O O 0.9999878406524658
wild-type B-protein B-protein 0.6368962526321411
CBP E-protein E-protein 0.7588878273963928
in O O 0.9988191723823547
T B-cell_type B-cell_type 0.8903195858001709
cells E-cell_type E-cell_type 0.9914291501045227
, O O 0.9994944334030151
functions O O 0.9997909665107727
of O O 0.9999433755874634
CBP/p300 S-protein S-protein 0.5266523361206055
other O O 0.9954162836074829
than O O 0.9998947381973267
histone O O 0.3367270529270172
acetylation O O 0.7900778651237488
appear O O 0.9993127584457397
to O O 0.999990701675415
control O O 0.9999771118164062
the O O 0.9998370409011841
NF-AT S-protein S-protein 0.9726903438568115
-dependent O O 0.9919889569282532
transcription O O 0.9558334946632385
in O O 0.9997290968894958
T B-cell_type B-cell_type 0.913642406463623

, O O 0.9503923654556274

eicosanoids O O 0.30611976981163025

, O O 0.9644759893417358
and O O 0.9992426633834839
we O O 0.9999771118164062
showed O O 0.9999924898147583
that O O 0.9999980926513672
the O O 0.99991774559021
neomycin B-DNA B-DNA 0.2784283459186554
resistance I-DNA I-DNA 0.5296446681022644
gene E-DNA E-DNA 0.9838778972625732
( O O 0.9936337471008301
which O O 0.99972003698349
is O O 0.9999784231185913
the O O 0.9999704360961914
positive O O 0.9084926843643188
selection O O 0.8145299553871155
marker O O 0.6223098635673523
in O O 0.9993461966514587
ES B-cell_type B-cell_line 0.4435787796974182
cells E-cell_type E-cell_line 0.5188220739364624
) O O 0.9922952651977539
was O O 0.9999760389328003
expressed O O 0.9997944235801697

We O O 0.993689775466919
also O O 0.9999624490737915
demonstrated O O 0.9999761581420898
that O O 0.9999972581863403
the O O 0.9999631643295288
CMV B-protein B-protein 0.5993238687515259
immediate I-protein I-protein 0.7334589958190918
early I-protein I-protein 0.48847195506095886
1 I-protein I-protein 0.45636066794395447
gene I-protein I-protein 0.6383225917816162
product E-protein E-protein 0.8486182689666748
increased O O 0.9960125684738159
expression O O 0.9991294741630554
of O O 0.9999727010726929
the O O 0.9996793270111084
IL-6 B-DNA B-DNA 0.5834200978279114
promoter E-DNA E-DNA 0.9928702712059021
. O O 0.9996732473373413
This O O 0.9999876022338867
effect O O 0.9999833106994629
of O O 0.9999932050704956
the O O 0.9999500513076782
CMV B-protein B-protein 0.47538307309150696
immediate I-protein I-protein 0.5023106336593628
early I-protein I-protein 0.51031094789505
1 I-protein I-protein 0.3973289728164673
gene I-protein I-protein 0.7052174210548401
product E-protein E-protein 0.9243010878562927
was O O 0.9997909665107727
dependent O O 0.9999836683273315
upon O O 0.9999922513961792
the O O 0.999983549118042
presence O O 0.9997815489768982
of O O 0.9999877214431763
specific O O 0.9542236924171448
transcription B-DNA B-DNA 0.3647180497646332
factor I-DNA I-DNA 0.7381371855735779
binding I-DNA I-DNA 0.44438934326171875
sites E-DNA E-DNA 0.7903652787208557
in O O 0.9996931552886963
the O O 0.9998462200164795
IL-6 B-DNA B-DNA 0.6618392467498779
promoter E-DNA E-DNA 0.9836729168891907
. O O 0.9995496869087219

of O O 0.9952725768089294
the O O 0.9999288320541382
3'-region S-DNA S-DNA 0.6388194561004639
revealed O O 0.9876701831817627
no O O 0.9998354911804199
alterations O O 0.9955169558525085
. O O 0.9999814033508301
Western O O 0.947996199131012
blot O O 0.6514236927032471
with O O 0.9992722868919373
an O O 0.9997026324272156
N-terminal O B-protein 0.4920533299446106
antibody O E-protein 0.9897435307502747
showed O O 0.9997789263725281
normal O O 0.9801586866378784
levels O O 0.9986931681632996
of O O 0.9998444318771362
immunoreactive B-protein B-protein 0.642192006111145
GR E-protein E-protein 0.8840805292129517
, O O 0.9883813261985779
but O O 0.9995867609977722

, O O 0.9865255355834961
reexpression O O 0.9959462285041809
of O O 0.9998345375061035
human B-DNA B-DNA 0.5060610771179199
MHC I-DNA I-DNA 0.369813472032547
class I-DNA I-DNA 0.5585178136825562
II I-DNA I-DNA 0.40200409293174744
genes E-DNA E-DNA 0.9850353002548218
in O O 0.9997164607048035
RJ B-cell_line O 0.3656401038169861
2.2.5 I-cell_line O 0.6213590502738953
x I-cell_line O 0.7619126439094543
mouse I-cell_line O 0.7611889243125916
spleen I-cell_line O 0.8120664954185486

we O O 0.9932363629341125
have O O 0.9999963045120239
investigated O O 0.9996423721313477
IL-12 S-protein S-protein 0.9605733156204224
expression O O 0.9931013584136963
in O O 0.9998733997344971
B B-cell_type B-cell_type 0.9179218411445618
cells E-cell_type E-cell_type 0.9892123937606812
during O O 0.9997851252555847
in O O 0.9994205236434937
vitro O O 0.9919643402099609
transformation O O 0.9931715726852417

They O O 0.9976143836975098
are O O 0.99988853931427
almost O O 0.9997872710227966
always O O 0.9998906850814819
benign O O 0.9647288918495178
, O O 0.9997848868370056
but O O 0.9999349117279053
can O O 0.9997566342353821
be O O 0.999862551689148
mistaken O O 0.9989694356918335
for O O 0.9999938011169434
a O O 0.9999700784683228
serious O O 0.9966963529586792
adverse O O 0.6351406574249268
event O O 0.555620014667511
by O O 0.9980029463768005
the O O 0.9994196891784668
patient O O 0.997710108757019
. O O 0.9999988079071045

the O O 0.9986571073532104
activity O O 0.9984410405158997
of O O 0.9999629259109497
nuclear B-protein B-protein 0.6006594300270081
proteins E-protein E-protein 0.9804316163063049
that O O 0.9988483190536499
bind O O 0.9997418522834778
to O O 0.9999465942382812
the O O 0.9997641444206238
IL-2 O B-DNA 0.5222899317741394
promoter O E-DNA 0.9956501126289368
. O O 0.9993805885314941
Nuclear O O 0.9585462212562561
extracts O O 0.9837555885314941
from O O 0.9998548030853271
primary B-cell_type B-cell_type 0.5336355566978455
human I-cell_type I-cell_type 0.5848057270050049
T I-cell_type I-cell_type 0.8135253190994263
lymphocytes E-cell_type E-cell_type 0.944064199924469
were O O 0.9995293617248535
analyzed O O 0.9999462366104126
by O O 0.9999958276748657
electrophoretic O O 0.8871878981590271
DNA O O 0.8888098001480103
mobility O O 0.9823351502418518
shift O O 0.99033522605896
assays O O 0.9989691972732544
. O O 0.9999988079071045
Both O O 0.9999145269393921
Dex O O 0.6456698775291443
and O O 0.9862483143806458
CsA O O 0.8099650740623474
inhibited O O 0.9995980858802795
the O O 0.9999696016311646
binding O O 0.9934237003326416
of O O 0.9996817111968994
transcription O B-protein 0.47179704904556274
factors O E-protein 0.994049072265625
AP-1 S-protein S-protein 0.9725020527839661
and O O 0.9930552840232849
NF-AT S-protein S-protein 0.9978627562522888
, O O 0.9926820397377014
but O O 0.9993529915809631
not O O 0.9993789196014404
of O O 0.9989235997200012
NF-kB S-protein S-protein 0.9771206378936768
and O O 0.9822916984558105
OCT-1/OAF S-protein S-protein 0.9717288017272949
, O O 0.9908203482627869

HL60 I-cell_line B-cell_line 0.6476917862892151
cells E-cell_line E-cell_line 0.9947602152824402
with O O 0.9997662901878357
3-methylcholanthrene O O 0.7539082169532776
, O O 0.9976939558982849
a O O 0.9998310804367065
ligand O O 0.9675026535987854
of O O 0.9968428611755371
AhR S-protein S-protein 0.6841839551925659
, O O 0.9901102185249329
induced O O 0.9998447895050049
the O O 0.999858021736145
expression O O 0.9984942674636841
of O O 0.9999464750289917
the O O 0.9992520213127136
P450IA1 S-protein B-DNA 0.4855208098888397
gene O E-DNA 0.9728781580924988
. O O 0.9996601343154907
These O O 0.9999974966049194
results O O 0.9999507665634155
indicated O O 0.9999973773956299
that O O 0.9999936819076538
expression O O 0.9979063272476196
of O O 0.9998421669006348
AhR B-RNA S-protein 0.3080461323261261

within O O 0.9984297156333923
the O O 0.9999898672103882
first O O 0.9965112805366516
hours O O 0.9996839761734009
of O O 0.9999834299087524
IFN-gamma S-protein S-protein 0.9919837117195129
-HCMV O O 0.9440549612045288
coincubation O O 0.994813084602356
and O O 0.9999364614486694
results O O 0.9990569949150085
in O O 0.9999932050704956
the O O 0.99997878074646
absence O O 0.9996427297592163
of O O 0.9999845027923584
HLA-DR S-protein S-protein 0.5780496001243591
synthesis O O 0.8894174098968506
. O O 0.9999449253082275
This O O 0.9999752044677734
defect O O 0.9940329194068909
leads O O 0.9999890327453613
to O O 0.9999949932098389
the O O 0.999990701675415
absence O O 0.9998366832733154
of O O 0.9999662637710571
presentation O O 0.9918873906135559
of O O 0.9997051358222961

inflammatory O O 0.8406870365142822
effects O O 0.997153639793396
of O O 0.9999713897705078
gamma-IFN S-protein S-protein 0.9207419157028198
signaling O O 0.9722434878349304
could O O 0.999993085861206
play O O 0.9999866485595703
a O O 0.9999951124191284
role O O 0.9998419284820557
in O O 0.999985933303833
foam O O 0.8776982426643372
cell O O 0.78128582239151
formation O O 0.9907218217849731
and O O 0.9998987913131714
xanthomatosis O O 0.976341724395752
. O O 0.999991774559021
Redox O O 0.5439071655273438
signals O O 0.9813336730003357
and O O 0.9982459545135498
NF-kappaB S-protein S-protein 0.9898994565010071
activation O O 0.9959319233894348

the O O 0.998144268989563
apoptosis O O 0.9570341110229492
and O O 0.9994376301765442
cell O O 0.9408515691757202
cycle O O 0.9464151859283447
arrest O O 0.9919820427894592
that O O 0.9999682903289795
occur O O 0.999884843826294
upon O O 0.9990500807762146
v-Abl S-protein B-protein 0.6748194098472595
kinase O E-protein 0.9373205304145813
inactivation O O 0.9843263030052185
. O O 0.9999687671661377
IL-7 S-protein S-protein 0.9770316481590271
also O O 0.9991611242294312
delayed O O 0.9999620914459229
the O O 0.9999752044677734
decreases O O 0.9978190660476685
in O O 0.9999382495880127
the O O 0.9995341300964355

. O O 0.9921162724494934
Upon O O 0.9966984391212463
cotransfection O O 0.9567201137542725
into O O 0.9996892213821411
non-T B-cell_type B-cell_type 0.7063616514205933
cells E-cell_type E-cell_type 0.9392671585083008
, O O 0.9981945157051086
TCF-1 S-protein S-protein 0.9481834173202515
could O O 0.9997058510780334
transactivate O O 0.9975920915603638
through O O 0.9999691247940063
its O O 0.9998650550842285
cognate O O 0.9102445244789124
motif O O 0.4018866717815399
. O O 0.9998887777328491
These O O 0.9999951124191284
results O O 0.9993483424186707
identify O O 0.9997068047523499

In O O 0.9996101260185242
contrast O O 0.9996802806854248
with O O 0.9999983310699463
the O O 0.9999195337295532
literature O O 0.9925538897514343
, O O 0.9999890327453613
serum O O 0.9389345049858093
levels O O 0.9860971570014954
of O O 0.9995929598808289
angiogenesis O O 0.6445707678794861
factors O O 0.7159078121185303
did O O 0.9998018145561218
not O O 0.9999209642410278
change O O 0.9992759823799133
significantly O O 0.9994163513183594
by O O 0.9999953508377075
pegylated B-Chemical B-Chemical 0.8470709323883057
interferon E-Chemical I-Chemical 0.955878734588623
and O O 0.5914058685302734
ribavirin S-Chemical B-Chemical 0.9001556634902954
therapy O O 0.992304265499115
. O O 0.9999986886978149

recovered O O 0.8541219830513
protein O O 0.6365615725517273
was O O 0.9993489384651184
identified O O 0.999990701675415
as O O 0.9999902248382568
genuine O O 0.9166920781135559
huGATA-3 S-protein S-protein 0.813783586025238
by O O 0.9990943670272827
SDS-PAGE O S-protein 0.5554869174957275
, O O 0.9912262558937073
Western O O 0.9690577983856201
blotting O O 0.9664254784584045
, O O 0.9990756511688232
and O O 0.9998093247413635
bandshift O O 0.8728209733963013
assays O O 0.9889608025550842
. O O 0.9999963045120239
Copyright O O 0.9752039909362793
1997 O O 0.9809237718582153
Academic O O 0.9950225353240967
Press O O 0.9899258613586426
. O O 0.9999940395355225
Stable O O 0.9674602746963501
transfection O O 0.9950699806213379
of O O 0.9998983144760132
U937 B-cell_line B-cell_line 0.8769156336784363
cells E-cell_line E-cell_line 0.995630145072937
with O O 0.9997891783714294

Withdrawal O B-Disease 0.5713253617286682
- O I-Disease 0.6281636357307434
emergent O I-Disease 0.5619402527809143
rabbit O I-Disease 0.758212149143219
syndrome O I-Disease 0.9949280023574829
during O O 0.9902192950248718
dose O O 0.9769119620323181
reduction O O 0.8555275201797485
of O O 0.9975057244300842
risperidone S-Chemical B-Chemical 0.9281163811683655
. O O 0.9996354579925537

SAR O O 0.5088933110237122
studies O O 0.9856742024421692
led O O 0.999977707862854
to O O 0.9999582767486572
compound O O 0.9711187481880188
14 O O 0.8840169310569763
with O O 0.9997636675834656
excellent O O 0.9798598885536194
potency O O 0.8931767344474792
( O O 0.9997056126594543
K O O 0.7138757109642029
( O O 0.9950506091117859
i O O 0.9980608820915222
) O O 0.9993649125099182
= O O 0.9999866485595703
0 O O 0.9998278617858887
. O O 0.9999618530273438
4 O O 0.9997908473014832
nM O O 0.9891794919967651
) O O 0.9985008239746094
, O O 0.9999768733978271
selectivity O O 0.7765851616859436
( O O 0.999485969543457
A O O 0.8178367018699646
( O O 0.9987428784370422
1 O O 0.9990442395210266
) O O 0.998150110244751
/ O O 0.9999805688858032
A O O 0.8735910058021545
( O O 0.9993487000465393
2A O O 0.9869464039802551
) O O 0.9989511966705322
> O O 0.9999017715454102
100 O O 0.995205819606781
) O O 0.9996721744537354
, O O 0.9999840259552002
and O O 0.9999551773071289
efficacy O O 0.6904935240745544
( O O 0.9987745881080627
MED O O 0.5167419910430908
10 O O 0.9309700727462769
mg O O 0.996832549571991
/ O O 0.999957799911499
kg O O 0.9995923638343811
p O O 0.9961548447608948
. O O 0.9999591112136841
o O O 0.999845027923584
. O O 0.9998401403427124
) O O 0.9996479749679565
in O O 0.999992847442627
the O O 0.9999593496322632
rat O O 0.9641783237457275
haloperidol B-Chemical B-Chemical 0.927967369556427
- O O 0.9482481479644775
induced O O 0.9938362240791321
catalepsy B-Disease O 0.8500920534133911
model O O 0.5909125208854675
for O O 0.9988265633583069
Parkinson B-Disease O 0.7426396012306213
' I-Disease O 0.7129716277122498
s I-Disease O 0.5726276636123657
disease I-Disease O 0.974117636680603
. O O 0.9980758428573608

proteins E-protein E-protein 0.9308853149414062
were O O 0.9994072914123535
Oct-1 S-protein S-protein 0.9856378436088562
and O O 0.9928970336914062
Oct-2 S-protein S-protein 0.9890549182891846
. O O 0.999887228012085
The O O 0.9999932050704956
affinity O O 0.9960592985153198
of O O 0.9998925924301147
the O O 0.9999481439590454
BAT B-protein B-protein 0.6279162168502808
box I-protein I-protein 0.8390045166015625
binding I-protein I-protein 0.971855878829956
proteins E-protein E-protein 0.9865567088127136
for O O 0.9985804557800293
the O O 0.999876856803894
BAT B-DNA B-DNA 0.3702574074268341

the O O 0.9970384836196899
CD40 S-protein S-protein 0.92636638879776
-TRAF2 S-protein S-protein 0.7460115551948547
interaction O O 0.9952371120452881
. O O 0.9999924898147583
Copyright O O 0.965974748134613
1999 O O 0.9634859561920166
Academic O O 0.991441547870636
Press O O 0.9521161317825317
. O O 0.9999809265136719
A O O 0.999890923500061
direct O O 0.9917927384376526
interaction O O 0.9982560276985168
between O O 0.9999431371688843
the O O 0.9998645782470703
adaptor B-protein B-protein 0.3499816656112671
protein E-protein E-protein 0.8607437610626221
Cbl-b S-protein S-protein 0.5394837260246277
and O O 0.9970093369483948
the O O 0.9993384480476379
kinase S-protein B-protein 0.4280570447444916
zap-70 S-protein E-protein 0.8401803970336914
induces O O 0.9992582201957703
a O O 0.9999798536300659
positive O O 0.9573962092399597
signal O O 0.9844895601272583
in O O 0.9998154044151306
T B-cell_type B-cell_type 0.8793969750404358
cells E-cell_type E-cell_type 0.9914010167121887
. O O 0.9997901320457458
Engagement O O 0.999408483505249
of O O 0.9999545812606812

T B-DNA I-DNA 0.4896509349346161
cell-specific I-DNA I-DNA 0.46728479862213135
enhancer E-DNA E-DNA 0.9635729789733887
in O O 0.999213695526123
the O O 0.999883770942688
interleukin-3 B-DNA B-DNA 0.4632885754108429
locus E-DNA E-DNA 0.9730339050292969
is O O 0.9988991022109985
activated O O 0.9988341927528381
cooperatively O O 0.9998838901519775
by O O 0.9999434947967529

METHODS O O 0.9750534296035767
: O O 0.9998515844345093
We O O 0.9999600648880005
analyzed O O 0.9999828338623047
the O O 0.9999862909317017
clinical O O 0.9873111248016357
and O O 0.9981942772865295
laboratory O O 0.9945764541625977
information O O 0.9995779395103455
available O O 0.9999926090240479
for O O 0.9999980926513672
all O O 0.9999805688858032
119 O O 0.9976866245269775
patients O O 0.9996383190155029
transplanted O O 0.9998413324356079
at O O 0.9999953508377075
the O O 0.9999406337738037
Washington O O 0.9304454922676086
Hospital O O 0.9699289202690125
Center O O 0.9977450966835022
between O O 0.9999979734420776
1999 O O 0.9997922778129578
- O O 0.9998409748077393
2003 O O 0.9997171759605408
for O O 0.9999969005584717
whom O O 0.9999839067459106
sirolimus S-Chemical B-Chemical 0.9279806017875671
was O O 0.9991405010223389
a O O 0.9999768733978271
component O O 0.9997014403343201
of O O 0.9999567270278931
their O O 0.9999469518661499
immunosuppressant O O 0.7013759613037109
regimen O O 0.6788718104362488
. O O 0.9999831914901733

Oct I-DNA B-DNA 0.2165539264678955
sites E-DNA E-DNA 0.9469272494316101
is O O 0.9997604489326477
not O O 0.9999827146530151
sensitive O O 0.9997261166572571
to O O 0.9999932050704956
phorbol O O 0.9113677740097046
ester O O 0.908852756023407
treatment O O 0.9991206526756287
, O O 0.9999905824661255
and O O 0.9999905824661255
that O O 0.9999922513961792
mutations O O 0.9809085130691528

The O O 0.9996656179428101
protective O O 0.9417012929916382
action O O 0.957425594329834
of O O 0.9985451698303223
subcutaneously O O 0.7904747128486633
( O O 0.9883624911308289
SC O O 0.5559061765670776
) O O 0.9387828707695007
administered O O 0.9887136220932007
antidotes O O 0.5477997064590454
or O O 0.9993957281112671
their O O 0.999755322933197
combinations O O 0.9779856204986572
in O O 0.9998986721038818
DFP S-Chemical B-Chemical 0.9268390536308289
( O O 0.9655648469924927
2 O O 0.9963065385818481
. O O 0.9997850060462952
0 O O 0.9997274279594421
mg O O 0.9994617104530334
/ O O 0.9999531507492065
kg O O 0.9989966750144958
BW O O 0.9417409300804138
) O O 0.9950356483459473
intoxication O O 0.5776912569999695
was O O 0.9997738003730774
studied O O 0.9999561309814453
in O O 0.9999973773956299
9 O O 0.9986929297447205
- O O 0.9987358450889587
10 O O 0.9996676445007324
- O O 0.9998908042907715
weeks O O 0.9999876022338867
- O O 0.999955415725708
old O O 0.9994615912437439
Han O O 0.80801922082901
- O O 0.9787361025810242
Wistar O O 0.775122344493866
male O O 0.9334542751312256
rats O O 0.9954727292060852
. O O 0.9999984502792358

RESULTS O O 0.9982683658599854
: O O 0.9999898672103882
The O O 0.9999871253967285
main O O 0.997271716594696
pathologic O O 0.6924697756767273
diagnoses O O 0.9426078796386719
( O O 0.9999502897262573
some O O 0.9999527931213379
overlap O O 0.6851168274879456
) O O 0.9522596001625061
were O O 0.9998874664306641
acute O O 0.6544666290283203
rejection O O 0.4229344129562378
( O O 0.9968823194503784
AR O O 0.6903195381164551
; O O 0.9937201738357544
n O O 0.9968516230583191
= O O 0.9998879432678223
4 O O 0.9984362721443176
) O O 0.999116837978363
, O O 0.9999822378158569
chronic O O 0.7075947523117065
rejection O O 0.7880382537841797
( O O 0.9920877814292908
CR O O 0.6823657155036926
; O O 0.9875360131263733
n O O 0.9955255389213562
= O O 0.9998428821563721
5 O O 0.9989521503448486
) O O 0.999056875705719
, O O 0.99997878074646
AR O O 0.414640873670578
+ O O 0.987823486328125
CR O O 0.5925315022468567
( O O 0.999110996723175
n O O 0.9976561069488525
= O O 0.9999148845672607
4 O O 0.9989379048347473
) O O 0.999313235282898
, O O 0.999992847442627
recurrent O O 0.9379451274871826
IgA O O 0.47531095147132874
nephropathy O B-Disease 0.537512481212616
( O O 0.9872339963912964
n O O 0.992228090763092
= O O 0.9997285008430481
5 O O 0.9989047050476074
) O O 0.9988032579421997
, O O 0.9999716281890869
normal O O 0.9313217997550964
findings O O 0.9318885207176208
( O O 0.9999526739120483
n O O 0.9987874627113342
= O O 0.9999388456344604
2 O O 0.9994093179702759
) O O 0.9988271594047546
, O O 0.9999810457229614
minimal O O 0.9416236877441406
- O O 0.9878116250038147
type O O 0.9549822211265564
chronic O O 0.8333166837692261
FK506 S-Chemical B-Chemical 0.9068431854248047
nephropathy O B-Disease 0.9853083491325378
( O O 0.9872922897338867
n O O 0.9771373867988586
= O O 0.99891197681427
9 O O 0.9979806542396545
) O O 0.9981219172477722
, O O 0.9999039173126221
and O O 0.9999260902404785
mild O O 0.9804661870002747
- O O 0.9952214360237122
type O O 0.9426710605621338
FK506 S-Chemical B-Chemical 0.9197474122047424
nephropathy O B-Disease 0.9874782562255859
( O O 0.993324339389801
n O O 0.9877651333808899
= O O 0.9995566010475159
11 O O 0.9984837174415588
) O O 0.999506950378418
. O O 0.9999963045120239

gene E-DNA E-DNA 0.6602354645729065

runt O O 0.41297128796577454
polypeptides O O 0.5438076853752136
in O O 0.9988266825675964
differentiating B-cell_type B-cell_type 0.561596155166626
myeloid I-cell_type I-cell_type 0.7408049702644348
cells E-cell_type E-cell_type 0.9334558248519897
and O O 0.9955652356147766
in O O 0.9983032941818237
B B-cell_type B-cell_type 0.8958691358566284
lymphocytes E-cell_type E-cell_type 0.9887893199920654
. O O 0.9993257522583008
Within O O 0.9999861717224121
the O O 0.9999533891677856

At O O 0.9995525479316711
least O O 0.9998230338096619
one O O 0.9999741315841675
episode O O 0.9924276471138
of O O 0.9996479749679565
grade O O 0.9869458079338074
3 O O 0.9297930002212524
or O O 0.9983548521995544
4 O O 0.9916312098503113
granulocytopenia O B-Disease 0.9665431976318359
was O O 0.9877457022666931
seen O O 0.9999271631240845
in O O 0.9999910593032837
59 O O 0.9996696710586548
% O O 0.9999823570251465
of O O 0.9999631643295288
patients O O 0.9998117089271545
. O O 0.9999992847442627

to O O 0.9780224561691284

. O O 0.9948785305023193
The O O 0.9999955892562866
discrepancy O O 0.9943447113037109
in O O 0.9999181032180786
the O O 0.9999797344207764
degree O O 0.9996029734611511
of O O 0.9999713897705078
inhibition O O 0.9753691554069519
by O O 0.9999703168869019
membrane O O 0.6373735070228577
extracts O O 0.7058833837509155
and O O 0.9892004728317261
NK B-cell_type B-cell_type 0.767311692237854
cells E-cell_type E-cell_type 0.9636103510856628
with O O 0.9996080994606018
mutant B-protein B-protein 0.7748230695724487
TNFRI E-protein E-protein 0.7014841437339783
suggests O O 0.9993808269500732
that O O 0.9999967813491821
additional O O 0.9967935681343079
pathways O O 0.9983434677124023
are O O 0.9999881982803345
utilized O O 0.9996875524520874
by O O 0.9999746084213257
NK B-cell_type B-cell_type 0.7684931755065918
cells E-cell_type E-cell_type 0.9448243379592896
to O O 0.9991233944892883
activate O O 0.9984738230705261
EC S-cell_type B-protein 0.5201306939125061
Ras S-protein E-protein 0.9488804340362549
-dependent O O 0.9744052290916443
, O O 0.9995051622390747
Ca2+-stimulated O O 0.6968359351158142
activation O O 0.8929821252822876
of O O 0.9929885268211365
nuclear B-protein B-protein 0.5186548233032227
factor I-protein I-protein 0.5919183492660522
of I-protein I-protein 0.9445028901100159
activated I-protein I-protein 0.9794259667396545
T I-protein I-protein 0.9695265293121338
cells E-protein E-protein 0.8742564916610718
by O O 0.9959577918052673

malignancies O O 0.8409724831581116

complex E-protein E-protein 0.9734137654304504
is O O 0.999485969543457
derived O O 0.999946117401123
by O O 0.9999985694885254
a O O 0.9999698400497437
calcium-dependent O O 0.8272457122802734
, O O 0.9608942866325378
cyclosporin-sensitive O O 0.8605616688728333
, O O 0.9939416646957397
posttranslational O O 0.9641122817993164
modification O O 0.9914475679397583
of O O 0.9997314810752869
NF-ATp S-protein S-protein 0.9904921650886536
, O O 0.9978430271148682
and O O 0.9998984336853027
that O O 0.9999732971191406
Fos S-protein S-protein 0.9267289042472839
and O O 0.9345995783805847
Jun S-protein B-protein 0.7369479537010193
proteins O E-protein 0.9613444209098816
stabilize O O 0.999569833278656
its O O 0.9999591112136841
interaction O O 0.9988250136375427
with O O 0.9999905824661255
DNA O O 0.7619644999504089

latency O O 0.7062425017356873
, O O 0.9985130429267883
and O O 0.99996018409729
to O O 0.9999634027481079
stimulate O O 0.9995502829551697
replication O O 0.9960038065910339
at O O 0.9999980926513672
the O O 0.9999674558639526
EBV B-DNA O 0.6093816757202148
lytic I-DNA O 0.4808056652545929
origin E-DNA O 0.5996167063713074
. O O 0.9998458623886108
Additional O O 0.9990934133529663
work O O 0.9985546469688416
, O O 0.9999756813049316
employing O O 0.9975579977035522
sequential O O 0.9624415636062622
and O O 0.9931279420852661
internal O O 0.9802370667457581
deletions O O 0.9828768372535706
of O O 0.9998360872268677
ZEBRA S-protein S-protein 0.7096269726753235
's O O 0.9558252096176147
N-terminal B-protein B-protein 0.4992462396621704
activation I-protein I-protein 0.8625271916389465
domain E-protein E-protein 0.9870229959487915
, O O 0.9968963861465454
indicates O O 0.9999948740005493
that O O 0.9999971389770508
its O O 0.9999747276306152
separate O O 0.9831227660179138
activities O O 0.9983673691749573
are O O 0.9999911785125732
not O O 0.9999297857284546

involves O O 0.9985254406929016
cooperation O O 0.9999326467514038
between O O 0.9999778270721436
the O O 0.9999247789382935
HSV-1-activated B-protein B-protein 0.3557167053222656
cellular I-protein I-protein 0.6662543416023254
factor E-protein E-protein 0.8369519710540771
, O O 0.8990938663482666
NF-kappa B-protein B-protein 0.7701843976974487
B E-protein E-protein 0.9176252484321594
, O O 0.939308762550354
and O O 0.9917513728141785

the O O 0.9989191293716431
earliest O O 0.997978150844574
crucial O O 0.9989364743232727
steps O O 0.9997274279594421
in O O 0.9999961853027344
the O O 0.9999725818634033
lysis O O 0.9273689985275269
of O O 0.9991973042488098
normal B-cell_line O 0.5005054473876953
and I-cell_line O 0.7527895569801331
dex-resistant I-cell_line B-cell_line 0.46859878301620483
CEM I-cell_line I-cell_line 0.5389661192893982
cells E-cell_line E-cell_line 0.7919174432754517
, O O 0.9927096366882324
or O O 0.9999194145202637
might O O 0.999370276927948
serve O O 0.9999822378158569
as O O 0.9999868869781494
a O O 0.9999558925628662
marker O O 0.9816837906837463
for O O 0.9998443126678467
the O O 0.9999630451202393
process O O 0.9998102784156799
. O O 0.9999982118606567
However O O 0.9998966455459595
, O O 0.999982476234436
the O O 0.999942421913147

that O O 0.9940788745880127
Sp3 S-protein S-protein 0.9133760333061218
participates O O 0.9964748024940491
in O O 0.9999618530273438
activation O O 0.9975767731666565
of O O 0.9999295473098755
the O O 0.9996769428253174
CD11c B-DNA B-DNA 0.6572383046150208
and I-DNA I-DNA 0.6104743480682373
CD11b I-DNA I-DNA 0.5626705884933472
promoters E-DNA E-DNA 0.9935692548751831
in O O 0.9991099238395691
vivo O O 0.9831489324569702
. O O 0.9999808073043823
The O O 0.9999778270721436
winged-helix B-protein B-protein 0.5226961970329285
transcription I-protein I-protein 0.542177677154541
factor E-protein E-protein 0.94621741771698
Trident S-protein S-protein 0.6018727421760559
is O O 0.997445821762085
expressed O O 0.999826967716217
in O O 0.9998544454574585
actively O O 0.7611134648323059
dividing B-cell_type O 0.8901734948158264
lymphocytes E-cell_type S-cell_type 0.7974039912223816
. O O 0.999854564666748
We O O 0.9999032020568848
recently O O 0.9999442100524902
identified O O 0.9999818801879883
the O O 0.9999407529830933
winged-helix B-protein B-protein 0.44025370478630066
transcription I-protein I-protein 0.6883127689361572
factor E-protein E-protein 0.944981575012207
Trident S-protein S-protein 0.4694216549396515
and O O 0.9918105006217957
described O O 0.9999072551727295
its O O 0.9999406337738037
expression O O 0.9788805842399597
pattern O O 0.9919169545173645
in O O 0.9998981952667236

Recovery O O 0.9661789536476135
of O O 0.9993000030517578
tacrolimus S-Chemical B-Chemical 0.924178957939148
- O O 0.9362285733222961
associated O O 0.9974836707115173
brachial O B-Disease 0.6852187514305115
neuritis O I-Disease 0.8692138195037842
after O O 0.983733594417572
conversion O O 0.9496315121650696
to O O 0.9994053840637207
everolimus S-Chemical B-Chemical 0.9266619086265564
in O O 0.9984591007232666
a O O 0.9999686479568481
pediatric O O 0.8170101046562195
renal O O 0.7756900191307068
transplant O O 0.6451624631881714
recipient O O 0.9221738576889038
- O O 0.9973998069763184
- O O 0.9998549222946167
case O O 0.9963303208351135
report O O 0.9993467926979065
and O O 0.9999896287918091
review O O 0.9971824884414673
of O O 0.9998952150344849
the O O 0.9999186992645264
literature O O 0.9458613395690918
. O O 0.9999902248382568

controls O O 0.8697596192359924
; O O 0.9995195865631104
P O O 0.9334861636161804
less O O 0.9981243014335632
than O O 0.9999219179153442
0.01 O O 0.9942113757133484
) O O 0.9994283318519592
. O O 0.9999847412109375
[ O O 0.9975807666778564
3H O O 0.9760333299636841
] O O 0.9970038533210754
Thymidine O O 0.8797760009765625
incorporation O O 0.9993624091148376
was O O 0.9999881982803345
decreased O O 0.9998039603233337
dose-dependently O O 0.9998992681503296
by O O 0.9999856948852539
dexamethasone O O 0.9090651869773865
in O O 0.9993426203727722
controls O O 0.9780012369155884
and O O 0.9993545413017273
patients O O 0.9973680377006531
; O O 0.9999898672103882
the O O 0.9999904632568359
effect O O 0.9998903274536133
was O O 0.9999926090240479
significantly O O 0.9995438456535339
blunted O O 0.9935364127159119
( O O 0.9998151659965515
P O O 0.9837570190429688
less O O 0.9991360306739807
than O O 0.9999183416366577
0.05 O O 0.9960842132568359
) O O 0.9995061159133911
in O O 0.9999911785125732
group O O 0.9403932690620422
1 O O 0.972703754901886
patients O O 0.998803973197937
, O O 0.9999946355819702
which O O 0.9999946355819702
suggests O O 0.9999964237213135
that O O 0.9999935626983643
activation O O 0.9962540864944458
of O O 0.999789297580719
glucocorticoid B-protein B-protein 0.8135286569595337
receptor E-protein E-protein 0.9864048957824707
is O O 0.9990098476409912
impaired O O 0.9991698265075684
as O O 0.9999984502792358
a O O 0.9999954700469971
result O O 0.9999558925628662
of O O 0.9999890327453613

paternal B-DNA B-DNA 0.8046063184738159
X I-DNA I-DNA 0.3072572648525238
chromosome E-DNA E-DNA 0.9727556705474854
carries O O 0.9990693926811218
the O O 0.9999750852584839
de O O 0.8936458230018616
novo O O 0.8792460560798645
alpha-galactosidase B-protein O 0.7872360348701477
A E-protein O 0.5092322826385498
mutation O O 0.7755378484725952
and O O 0.9998512268066406
that O O 0.999996542930603
uneven O O 0.8868039846420288
X O O 0.3644266426563263
inactivation O O 0.9364258646965027
is O O 0.9999656677246094
the O O 0.999995231628418
underlying O O 0.9569894671440125
mechanism O O 0.9950174689292908
for O O 0.9999717473983765
disease O O 0.9466698169708252
expression O O 0.9962339997291565
in O O 0.9999940395355225
this O O 0.9999186992645264
novel O O 0.8875331282615662
female O O 0.9174772500991821
MZ O O 0.6337169408798218
twin O O 0.8390802145004272
pair O O 0.721337080001831
. O O 0.9999353885650635
This O O 0.999992847442627
is O O 0.9999939203262329
the O O 0.9999970197677612
first O O 0.9993844032287598
documented O O 0.9923201203346252
case O O 0.9957877993583679
of O O 0.9999227523803711

The O O 0.9994788765907288
most O O 0.9980419874191284
common O O 0.9960151314735413
primary O O 0.8274608850479126
tumor O B-Disease 0.9350137710571289
site O O 0.678522527217865
was O O 0.9984920024871826
the O O 0.9998550415039062
head O O 0.9780835509300232
and O O 0.9986546039581299
neck O O 0.9870595932006836
. O O 0.9999969005584717

Transient O O 0.6758884191513062
hypotension O B-Disease 0.6571837067604065
( O O 0.9787020683288574
SAP O O 0.5481756925582886
< O O 0.9225767850875854
90mmHg O O 0.5259813070297241
) O O 0.9547934532165527
occurred O O 0.9995649456977844
in O O 0.9999740123748779
1 O O 0.9994679093360901
patient O O 0.9994533658027649
( O O 0.9999880790710449
0 O O 0.9999344348907471
. O O 0.9999011754989624
7 O O 0.9999327659606934
% O O 0.9998642206192017
) O O 0.9993988275527954
. O O 0.9999933242797852

site E-protein E-DNA 0.8453787565231323
( O O 0.9957150816917419
Y518 O S-DNA 0.9177266359329224
and O O 0.9821358323097229
Y519 O S-DNA 0.9625012874603271
) O O 0.9790493249893188
, O O 0.999970555305481
both O O 0.9999165534973145
Src B-protein B-protein 0.3837267756462097
homology I-protein I-protein 0.3574575185775757
2 I-protein I-protein 0.3050782382488251
domains E-protein E-protein 0.6839037537574768
and O O 0.9983720183372498
it O O 0.9991783499717712
was O O 0.9999557733535767
blocked O O 0.9999046325683594
by O O 0.9999970197677612
the O O 0.9998480081558228
inhibitory B-protein B-protein 0.6699985265731812
N17-mutated I-protein I-protein 0.36516550183296204
dominant-negative I-protein I-protein 0.4836251735687256
Ras I-protein E-protein 0.5480772852897644

Possible O O 0.985929548740387
effects O O 0.9995155334472656
of O O 0.999977707862854
ACE O O 0.5948493480682373
inhibition O O 0.5135416388511658
were O O 0.9995966553688049
tested O O 0.9999566078186035
. O O 0.9999990463256836

in O O 0.9967610239982605

experimentally O O 0.6541533470153809
derived O O 0.8660977482795715
B-lymphoblastoid B-cell_line B-cell_line 0.3909875750541687
cell I-cell_line I-cell_line 0.7214182019233704
line E-cell_line E-cell_line 0.9878458380699158
, O O 0.9991648197174072
clone B-cell_line B-cell_line 0.4523155987262726
13 E-cell_line E-cell_line 0.9932265877723694
, O O 0.9757693409919739
expresses O O 0.9995735287666321
high O O 0.9748978614807129
levels O O 0.9983312487602234
of O O 0.9999560117721558
HLADQ S-protein O 0.34982699155807495
in O O 0.9993333220481873
the O O 0.999951958656311
absence O O 0.9995129108428955
of O O 0.9999712705612183
HLA-DR S-DNA S-protein 0.5752090811729431
and O O 0.9406117796897888
HLA-DP S-DNA O 0.33277276158332825
, O O 0.9966069459915161
despite O O 0.9999942779541016
its O O 0.9999872446060181
mapping O O 0.9726005792617798
by O O 0.9993058443069458

The O O 0.9994686245918274
amount O O 0.9998699426651001
of O O 0.9999597072601318
daily O O 0.9404645562171936
urinary O O 0.9576733112335205
protein O O 0.9079814553260803
decreased O O 0.9997102618217468
from O O 0.9999885559082031
15 O O 0.9996305704116821
. O O 0.9999887943267822
6 O O 0.9998443126678467
to O O 0.9997789263725281
2 O O 0.9997963309288025
. O O 0.9999909400939941
8 O O 0.9994888305664062
g O O 0.9949349761009216
. O O 0.9999250173568726

incubation O O 0.9626950621604919
with O O 0.9999195337295532
MDHM O O 0.4329746663570404
while O O 0.9998495578765869
positive O O 0.9552879333496094
c-fos S-DNA S-DNA 0.9684590101242065
expression O O 0.9859268665313721
remained O O 0.9999397993087769
unaffected O O 0.9994056224822998
. O O 0.999998927116394

erythropoietic O O 0.7456672191619873
differentiation O O 0.9936500191688538
in O O 0.9999489784240723
liquid O O 0.5853625535964966
culture O O 0.5702536106109619
caused O O 0.9998342990875244
a O O 0.9999818801879883
virtually O O 0.9878437519073486
complete O O 0.9938446283340454
inhibition O O 0.9937582015991211
of O O 0.9997099041938782
GATA1 B-RNA B-RNA 0.9350484609603882
mRNA E-RNA E-RNA 0.9908105134963989

. O O 0.9964020252227783

cosmid S-DNA S-DNA 0.304275780916214
containing O O 0.9849299788475037
the O O 0.9995433688163757
human B-DNA B-DNA 0.49168792366981506
CIITA I-DNA I-DNA 0.7347819209098816
gene E-DNA E-DNA 0.9886953234672546
, O O 0.9843234419822693
but O O 0.9999120235443115
lacking O O 0.9999319314956665
the O O 0.9999574422836304
1.8 B-DNA B-DNA 0.5622360110282898
kb I-DNA I-DNA 0.3948514461517334
promoter E-DNA E-DNA 0.9627202749252319
described O O 0.9992142915725708
above O O 0.998976469039917
. O O 0.9999964237213135
Taken O O 0.999984622001648
together O O 0.9999940395355225
, O O 0.9999980926513672
these O O 0.9999884366989136
data O O 0.9993910789489746
suggest O O 0.9999979734420776
the O O 0.999993085861206
existence O O 0.9999006986618042
of O O 0.9999938011169434
an O O 0.9998663663864136
intragenic O B-DNA 0.5013970136642456
promoter O E-DNA 0.9252527356147766
driving O O 0.9931954145431519
an O O 0.9998524188995361
IFN-gamma S-protein S-protein 0.8548703789710999
-inducible O O 0.9745844602584839
expression O O 0.9978188276290894
of O O 0.9998745918273926
CIITA S-protein S-protein 0.4625997841358185

This O O 0.9997578263282776
study O O 0.999961256980896
was O O 0.9999985694885254
conducted O O 0.9999985694885254
to O O 0.9999986886978149
examine O O 0.9999921321868896
whether O O 0.9999949932098389
prolonged O O 0.9302412867546082
pretreatment O O 0.8991793990135193
with O O 0.9998905658721924
isoproterenol B-Chemical B-Chemical 0.9364764094352722
could O O 0.9991568326950073
abolish O O 0.9585373401641846
bromocriptine B-Chemical B-Chemical 0.936917245388031
- O O 0.9278640151023865
induced O O 0.9979838132858276
tachycardia B-Disease B-Disease 0.964748740196228
in O O 0.8549967408180237
conscious O O 0.8736386299133301
rats O O 0.9709571003913879
. O O 0.9999978542327881

Acute B-Disease O 0.7649481296539307
psychosis I-Disease B-Disease 0.7516350150108337
due O O 0.9971861243247986
to O O 0.9998986721038818
treatment O O 0.9988144636154175
with O O 0.9999765157699585
phenytoin B-Chemical B-Chemical 0.928679347038269
in O O 0.9980487823486328
a O O 0.9998194575309753
nonepileptic O B-Disease 0.94234299659729
patient O O 0.6278663873672485
. O O 0.9999778270721436

protein O O 0.4932015538215637
synthesis O O 0.9653251767158508
. O O 0.9999723434448242
Inhibition O O 0.9976596832275391
of O O 0.9999208450317383
cytokine S-protein S-protein 0.9848299026489258
production O O 0.997996985912323
by O O 0.9999837875366211
PBMC S-cell_type S-cell_type 0.978559136390686
was O O 0.9994552731513977
observed O O 0.9999728202819824
also O O 0.9999922513961792
when O O 0.999997615814209
other O O 0.9996824264526367
inducers O O 0.8103010654449463
were O O 0.9998863935470581
used O O 0.9995232820510864
( O O 0.9998923540115356
staphylococci O O 0.922046959400177
, O O 0.9979727864265442
silica O O 0.9089019894599915
, O O 0.9993590712547302
zymosan O O 0.7972725629806519
) O O 0.9956181049346924
. O O 0.9999959468841553
Much O O 0.9999446868896484
higher O O 0.9985299110412598
concentrations O O 0.9988709092140198
of O O 0.9998663663864136

assay O O 0.7019465565681458
reproducibility O O 0.9626398086547852
to O O 0.9998646974563599
be O O 0.9996065497398376
controlled O O 0.9986888766288757
more O O 0.999950647354126
reliably O O 0.9990662932395935
. O O 0.9999973773956299
Thus O O 0.9809517860412598
enabled O O 0.9994680285453796
to O O 0.9997848868370056
perform O O 0.9998648166656494

activation O O 0.9710550904273987
of O O 0.9995498061180115
the O O 0.9998952150344849
NFAT B-protein B-DNA 0.5028548836708069
element E-protein E-DNA 0.9904214143753052
. O O 0.999189555644989
CIF S-protein S-protein 0.9378572702407837
failed O O 0.9975565671920776
to O O 0.9999607801437378
inhibit O O 0.9999704360961914
several O O 0.9993904829025269
other O O 0.9987214207649231
enhancer B-DNA B-DNA 0.6035951972007751
elements E-DNA E-DNA 0.9818312525749207
. O O 0.9998613595962524
The O O 0.9999858140945435
NFAT-controlled B-DNA B-DNA 0.45002272725105286
luciferase I-DNA I-DNA 0.5811538100242615
gene I-DNA E-DNA 0.8654961585998535
system E-DNA O 0.6214121580123901
distinguishes O O 0.9995354413986206
CIF S-protein S-protein 0.81632399559021
from O O 0.9996570348739624
other O O 0.999171257019043

In O O 0.9997705817222595
several O O 0.9996932744979858
models O O 0.9987165927886963
of O O 0.9998242259025574
hypertension O B-Disease 0.9675298929214478
, O O 0.9872653484344482
elevation O O 0.9699200987815857
of O O 0.9982588887214661
intracellular O O 0.9207112789154053
sodium S-Chemical B-Chemical 0.9297358989715576
level O O 0.9906768798828125
was O O 0.9999748468399048
documented O O 0.9999650716781616
in O O 0.9999842643737793
cardiac O O 0.8412021398544312
tissue O O 0.6037297248840332
. O O 0.9999521970748901

CONCLUSION O O 0.9984111785888672
: O O 0.9999924898147583
These O O 0.9999953508377075
data O O 0.9998923540115356
indicate O O 0.9999979734420776
that O O 0.9999911785125732
VNB S-Chemical B-Chemical 0.9056500196456909
is O O 0.9971216320991516
an O O 0.9999905824661255
active O O 0.9827166795730591
agent O O 0.9886208176612854
in O O 0.9999735355377197
metastatic O O 0.8392629623413086
esophageal O O 0.7591109275817871
squamous O O 0.7626901268959045
cell O O 0.6265990734100342
carcinoma O O 0.922118604183197
. O O 0.9986487030982971

a O O 0.9979269504547119
variety O O 0.9963274598121643
of O O 0.9999366998672485
stimuli O O 0.7338854074478149
, O O 0.9980884194374084
including O O 0.9999308586120605
TNF-alpha S-protein S-protein 0.993693470954895
, O O 0.9976338148117065
leads O O 0.9999092817306519
to O O 0.9999899864196777
the O O 0.9999523162841797
translocation O O 0.9916907548904419
of O O 0.9998518228530884
the O O 0.9996210336685181
active O O 0.8959187269210815
p65-50 B-protein B-protein 0.5081274509429932
heterodimer E-protein E-protein 0.9428564310073853
to O O 0.9954261183738708
the O O 0.999768078327179
nucleus O O 0.9294816255569458
, O O 0.9987977743148804
albeit O O 0.9992855191230774
at O O 0.9999959468841553
a O O 0.9999663829803467
lower O O 0.9977512955665588
level O O 0.9997498393058777
in O O 0.9998970031738281
T B-cell_type B-cell_type 0.9103395938873291
cells E-cell_type E-cell_type 0.993126392364502
from O O 0.9996869564056396
the O O 0.999829888343811
elderly O O 0.9886026382446289
. O O 0.9999927282333374
We O O 0.9999938011169434
demonstrate O O 0.9999959468841553
here O O 0.99998939037323
that O O 0.9999977350234985
pretreatment O O 0.9938096404075623
with O O 0.9999686479568481
PAO O O 0.5140720009803772
results O O 0.9991599321365356
in O O 0.9999933242797852
the O O 0.9999804496765137
inhibition O O 0.9890762567520142
of O O 0.9996743202209473
NFkappaB S-protein S-protein 0.9759716391563416
induction O O 0.9976469874382019

CSS O O 0.6717422604560852
mapping O O 0.9709330201148987
suggests O O 0.999987006187439
seizure O O 0.8270619511604309
susceptibility O O 0.6371094584465027
loci O O 0.5799864530563354
on O O 0.993812084197998
mouse O O 0.8923874497413635
Chromosomes O O 0.8024938106536865
10 O O 0.9740425944328308
and O O 0.9987003803253174
18 O O 0.9712730050086975
. O O 0.9999891519546509

RESULTS O O 0.9983710646629333
: O O 0.9999794960021973
Sixty O O 0.9994738698005676
percent O O 0.9999696016311646
in O O 0.9999885559082031
Group O O 0.929033637046814
A O O 0.9222126603126526
developed O O 0.9997492432594299
postoperative B-Disease O 0.7658458352088928
emetic I-Disease O 0.45558980107307434
symptoms I-Disease O 0.8280004858970642
, O O 0.9917144179344177
headache B-Disease B-Disease 0.9771164059638977
, O O 0.9318570494651794
or O O 0.9964579939842224
both O O 0.9994403719902039
; O O 0.9998121857643127
1 O O 0.9990467429161072
patient O O 0.9964854717254639
in O O 0.9999781847000122
Group O O 0.8635538816452026
B O O 0.5620642900466919
developed O O 0.995762050151825
symptoms O O 0.7596187591552734
. O O 0.9999864101409912

ZEBRA O S-protein 0.9017488360404968
, O O 0.99959796667099
the O O 0.9999641180038452
product O O 0.9936844706535339
of O O 0.9997462630271912
BZLF1 S-DNA S-protein 0.9320803880691528
, O O 0.9971588850021362
is O O 0.9999798536300659
sufficient O O 0.9998856782913208
to O O 0.99996018409729
disrupt O O 0.9996826648712158
latency O O 0.9536388516426086
in O O 0.9995495676994324
B B-cell_type B-cell_type 0.9070174694061279
lymphocytes E-cell_type E-cell_type 0.9917598366737366
and O O 0.9907941222190857
epithelial B-cell_type B-cell_type 0.7538243532180786
cells E-cell_type E-cell_type 0.9756385087966919
by O O 0.9998051524162292
stimulating O O 0.9940806031227112
expression O O 0.9961845278739929
of O O 0.9999055862426758
lytic B-DNA B-DNA 0.5170257687568665
cycle I-DNA I-DNA 0.36601123213768005
genes E-DNA E-DNA 0.9608567357063293
, O O 0.9977553486824036
including O O 0.9999583959579468
BRLF1 S-DNA S-DNA 0.8841605186462402

PPAR S-protein O 0.22815664112567902
) O O 0.565524697303772
ligands O O 0.7223915457725525
, O O 0.9969186782836914
15d-PGJ O O 0.3300616145133972
( O O 0.8594531416893005
2 O O 0.7987326979637146
) O O 0.6012610793113708
and O O 0.9957789182662964
troglitazone O O 0.5706494450569153
( O O 0.9887776970863342
PPARgamma S-protein O 0.4404684007167816
) O O 0.9768528938293457
, O O 0.9998985528945923
Wy14 O O 0.6074177026748657
, O O 0.996711015701294
643 O O 0.8819472789764404
( O O 0.9982337951660156
PPARalpha S-protein O 0.3363640606403351
) O O 0.9545507431030273

in O O 0.9962273836135864
T-cell B-protein B-cell_line 0.42860648036003113
hybridomas E-protein E-cell_line 0.8790217041969299
, O O 0.9997410178184509
the O O 0.9999873638153076
reports O O 0.9995653033256531
on O O 0.9998090863227844
nur77 O O 0.29771688580513
knock-out O O 0.5180766582489014
mice O O 0.5004591941833496
and O O 0.991529107093811
nur77 O O 0.2580440640449524
dominant O O 0.6215546727180481
negative O O 0.5550439953804016
transgenic O O 0.5695855617523193
mice O O 0.9360259175300598
suggest O O 0.9999942779541016
that O O 0.9999973773956299
there O O 0.9999920129776001
is O O 0.9999966621398926
a O O 0.9999799728393555
functional O O 0.9468355774879456

with O O 0.9931439161300659
Jak3 S-protein S-protein 0.987818717956543
. O O 0.9997498393058777
In O O 0.9999947547912598
these O O 0.9999791383743286
experiments O O 0.9976770281791687
, O O 0.999982476234436
SOCS-3 S-protein S-protein 0.7927781343460083
associated O O 0.9981576800346375
with O O 0.9998959302902222
Jak1 S-protein S-protein 0.9913665652275085
and O O 0.9989840388298035
inhibited O O 0.9937865734100342
Jak1 S-protein S-protein 0.8113258481025696
phosphorylation O O 0.9562833309173584
, O O 0.9998878240585327
and O O 0.9999868869781494
this O O 0.9999655485153198
inhibition O O 0.9920485615730286
was O O 0.9999810457229614
markedly O O 0.9990161657333374

NFAT B-protein B-protein 0.7339614629745483
complex E-protein E-protein 0.9946902990341187
in O O 0.9997475743293762
both O O 0.9995583891868591
cell O O 0.9225822687149048
types O O 0.7866301536560059
. O O 0.9999936819076538
An O O 0.9997105002403259
NFAT S-protein B-DNA 0.584148645401001
oligonucleotide O E-DNA 0.6066199541091919
carrying O O 0.7017814517021179
mutations O O 0.4704170227050781
in O O 0.9998315572738647
the O O 0.9994671940803528
5 B-DNA B-DNA 0.5298899412155151
' I-DNA I-DNA 0.7333807349205017
purine-rich I-DNA I-DNA 0.859119176864624
part E-DNA E-DNA 0.6061356663703918
of O O 0.8947966694831848
the O O 0.9888820052146912
NFAT B-DNA B-DNA 0.5656244158744812
sequence E-DNA E-DNA 0.9280208945274353
failed O O 0.9977548718452454
to O O 0.9999762773513794
form O O 0.9999293088912964
a O O 0.9999496936798096
complex O O 0.7514577507972717
and O O 0.9129326939582825

-induced O O 0.924342930316925

higher O O 0.9591777324676514
than O O 0.9994444251060486
that O O 0.9999310970306396
of O O 0.9999121427536011
an O O 0.9998008608818054
LTR S-DNA S-DNA 0.9852063059806824
from O O 0.9996044039726257
a O O 0.999893307685852
non-acutely O O 0.886363685131073
pathogenic O O 0.8531114459037781
strain O O 0.8799870014190674
. O O 0.9999825954437256
These O O 0.9999830722808838
LTRs S-DNA S-DNA 0.9183699488639832
differ O O 0.9988080263137817
by O O 0.9999936819076538
five O O 0.9921773076057434
point O O 0.9835125803947449
mutations O O 0.9412698149681091
and O O 0.9999889135360718
a O O 0.9999610185623169
22-bp B-DNA O 0.4433128237724304
duplication E-DNA O 0.37531551718711853
in O O 0.9916600584983826
SIVsmmPBj14 O S-DNA 0.6824253797531128
, O O 0.9811841249465942
which O O 0.9999083280563354
includes O O 0.9999884366989136
a O O 0.9997667670249939
nuclear B-DNA B-DNA 0.6881202459335327
factor I-DNA I-DNA 0.40760475397109985
kappa I-DNA I-DNA 0.47512611746788025
B I-DNA I-DNA 0.626762330532074
( I-DNA I-DNA 0.5915520191192627
NF I-DNA I-DNA 0.7322783470153809
kappa I-DNA I-DNA 0.8739819526672363
B I-DNA I-DNA 0.6668503284454346
) I-DNA I-DNA 0.7889471054077148
site E-DNA E-DNA 0.9875257015228271
. O O 0.9998418092727661
Transcriptional O O 0.9340354800224304
differences O O 0.9933567643165588

to O O 0.9964924454689026
the O O 0.9997699856758118
cell B-protein B-protein 0.8357344269752502
cycle I-protein I-protein 0.5476202964782715
regulator E-protein E-protein 0.8153328895568848
E2F S-protein S-protein 0.8394465446472168
. O O 0.9996148347854614
Cell O O 0.9199829697608948
cycle O O 0.9425978660583496
progression O O 0.9965798258781433
initiated O O 0.9999616146087646
by O O 0.9999570846557617
interleukin-2 S-protein S-protein 0.9225633144378662
( O O 0.9411860704421997
IL-2 S-protein S-protein 0.9813118577003479
) O O 0.9732891917228699

All O O 0.9991276860237122
had O O 0.9997846484184265
myofibre O B-Disease 0.4067080318927765
necrosis B-Disease I-Disease 0.8742474317550659
but O O 0.9757802486419678
only O O 0.999648928642273
3 O O 0.9068976044654846
had O O 0.9992782473564148
an O O 0.999930739402771
inflammatory O O 0.47028815746307373
infiltrate O O 0.7086800336837769
. O O 0.9998076558113098

gamma E-protein I-protein 0.9057613015174866
and O I-protein 0.9049872159957886
type B-protein I-protein 0.4866512417793274
II I-protein I-protein 0.6696434617042542
TGase E-protein E-protein 0.9514871835708618
) O O 0.9574655890464783
. O O 0.9999750852584839
These O O 0.9999954700469971
data O O 0.9997041821479797
demonstrate O O 0.9999957084655762
that O O 0.9999959468841553
PML-RAR B-protein B-protein 0.2621116638183594
alpha E-protein E-protein 0.9420357346534729
and O O 0.9766462445259094
PLZF-RAR B-protein B-protein 0.39727598428726196
alpha E-protein E-protein 0.9701131582260132
have O O 0.9987049102783203
similar O O 0.9966613054275513
( O O 0.9988143444061279
inhibitory O O 0.9436153173446655

for O O 0.9967279434204102
viral B-DNA B-DNA 0.8077600002288818
promoter E-DNA E-DNA 0.9073944687843323
switching O O 0.9802649021148682
during O O 0.9999814033508301
the O O 0.9999942779541016
initial O O 0.9975374937057495
stages O O 0.9998984336853027
of O O 0.9999852180480957
infection O O 0.9810896515846252
in O O 0.9999830722808838
which O O 0.999962568283081
Wp O S-DNA 0.7980992197990417
activity O O 0.9937292337417603

PB B-cell_type B-cell_type 0.3056502044200897
precursors E-cell_type E-cell_type 0.9218673706054688
or O O 0.9890282154083252
monocytes S-cell_type S-cell_type 0.974724292755127
and O O 0.9959011673927307
in O O 0.9983226656913757
activated B-cell_type B-cell_type 0.5306042432785034
B I-cell_type I-cell_type 0.5388356447219849
cells E-cell_type E-cell_type 0.9299797415733337
. O O 0.9997081160545349
These O O 0.9999920129776001
RelB+ B-cell_type B-cell_type 0.2623569369316101
APC E-cell_type E-cell_type 0.4717273712158203
were O O 0.9984111785888672
potent O O 0.9917741417884827
stimulators O O 0.9761715531349182
of O O 0.9999127388000488
the O O 0.9999325275421143
MLR S-protein S-protein 0.5199232697486877
. O O 0.9974307417869568
The O O 0.9999946355819702
data O O 0.9997904896736145
indicate O O 0.999997615814209
that O O 0.9999867677688599

effect O O 0.9894095659255981
in O O 0.9999653100967407
P19 B-cell_line B-cell_line 0.8532134890556335
cells E-cell_line E-cell_line 0.9862409830093384
. O O 0.9999096393585205
Transcriptional O O 0.9650954008102417
activation O O 0.9964015483856201
by O O 0.9999731779098511
CBF B-protein B-protein 0.5280505418777466
beta E-protein E-protein 0.9796016216278076
required O O 0.9931929707527161
binding O O 0.9859381318092346
to O O 0.9998441934585571
the O O 0.9997333884239197

. O O 0.9944214224815369
An O O 0.9999871253967285
alternative O O 0.9824636578559875
possibility O O 0.9985859394073486
is O O 0.9999983310699463
that O O 0.9999991655349731
in O O 0.9999535083770752
the O O 0.999954342842102
absence O O 0.9991039633750916
of O O 0.999914288520813
gamma B-protein B-protein 0.31558293104171753
( I-protein I-protein 0.8328099250793457
c I-protein I-protein 0.9432203769683838
) E-protein E-protein 0.954099178314209
, O O 0.9859480857849121

tumor O O 0.5980238914489746
growth O O 0.9524911046028137
through O O 0.9999556541442871
specific O O 0.9894258975982666
T-cell O O 0.70624178647995
tolerance O O 0.9025943279266357
induction O O 0.9979344606399536
. O O 0.9999960660934448
Vaccination O O 0.9959607720375061
with O O 0.9999455213546753
synthetic O O 0.8287219405174255
peptides O O 0.7402947545051575
representing O O 0.9992652535438538
cytotoxic O B-protein 0.5965472459793091
T O I-protein 0.5741530656814575
lymphocyte O I-protein 0.37294691801071167
( O I-protein 0.6776564717292786
CTL O I-protein 0.27654099464416504
) O I-protein 0.28381624817848206
epitopes O E-protein 0.885783851146698
can O O 0.999708354473114
lead O O 0.9999784231185913
to O O 0.9999912977218628
a O O 0.9999165534973145
protective O O 0.918246328830719

Native O O 0.9252991080284119
kidney O O 0.75584477186203
specimens O O 0.7455217242240906
included O O 0.9997568726539612
a O O 0.9998036026954651
wide O O 0.990395724773407
range O O 0.9989821314811707
of O O 0.9998376369476318
glomerulopathies O O 0.835155725479126
as O O 0.991620659828186
well O O 0.9991366267204285
as O O 0.9999916553497314
cases O O 0.9673215746879578
of O O 0.999022364616394
thrombotic O B-Disease 0.6867061257362366
microangiopathy O I-Disease 0.9120898246765137
, O O 0.9658673405647278
malignant O O 0.49329233169555664
hypertension O O 0.5878745317459106
, O O 0.9854245781898499
acute O O 0.7014042139053345
interstitial O O 0.4550918936729431
nephritis O O 0.7285256385803223
, O O 0.9730271100997925
and O O 0.9987358450889587
acute O O 0.7765873670578003
tubular O O 0.560934841632843
necrosis O O 0.8623219728469849
. O O 0.9982407093048096

Optimising O O 0.9942857623100281
stroke B-Disease O 0.5343064665794373
prevention O O 0.7316694259643555
in O O 0.9993089437484741
non O O 0.955315887928009
- O O 0.989608108997345
valvular O O 0.8048418760299683
atrial B-Disease B-Disease 0.5454103946685791
fibrillation I-Disease I-Disease 0.9795754551887512
. O O 0.9979312419891357

Between O O 0.999758780002594
July O O 0.9991006851196289
2001 O O 0.9998801946640015
and O O 0.9999983310699463
April O O 0.9999209642410278
2004 O O 0.999964714050293
, O O 0.999995231628418
24 O O 0.9992226362228394
patients O O 0.999745786190033
with O O 0.9999685287475586
relapsed O O 0.5540655255317688
/ O O 0.9621905088424683
refractory O O 0.8349449038505554
indolent O O 0.7594969868659973
lymphomas B-Disease O 0.5916063189506531
received O O 0.9974160194396973
thalidomide B-Chemical B-Chemical 0.9376682639122009
200 O O 0.5852208137512207
mg O O 0.9214296340942383
daily O O 0.9982306361198425
with O O 0.9999939203262329
escalation O O 0.513033390045166
by O O 0.9988453388214111
100 O O 0.9989271759986877
mg O O 0.9994744658470154
daily O O 0.999923825263977
every O O 0.999998927116394
1 O O 0.9999350309371948
- O O 0.9997575879096985
2 O O 0.9995799660682678
weeks O O 0.999966025352478
as O O 0.9999960660934448
tolerated O O 0.9986342787742615
, O O 0.9999942779541016
up O O 0.9999548196792603
to O O 0.9999388456344604
a O O 0.9999759197235107
maximum O O 0.9998310804367065
of O O 0.9999699592590332
800 O O 0.9937644004821777
mg O O 0.9982529282569885
daily O O 0.9995484948158264
. O O 0.9999991655349731

NFkappaB O O 0.4393221139907837
activity O O 0.962306559085846
was O O 0.9999264478683472
decreased O O 0.9996587038040161
in O O 0.999967098236084
the O O 0.9997004270553589
frontal O O 0.9797634482383728
cortex O O 0.9706717133522034
of O O 0.9991994500160217
cocaine B-Chemical B-Chemical 0.9146817922592163
treated O O 0.9496961236000061
rats O O 0.9855602383613586
, O O 0.9999405145645142
as O O 0.999964714050293
well O O 0.9996638298034668
as O O 0.9999860525131226
GSH B-Chemical B-Chemical 0.9113085269927979
concentration O O 0.916799008846283
and O O 0.999713122844696
glutathione B-Chemical B-Chemical 0.9272174835205078
peroxidase O O 0.7758926749229431
activity O O 0.7529873251914978
in O O 0.9995027780532837
the O O 0.9997904896736145
hippocampus O O 0.6604442596435547
, O O 0.9990717172622681
whereas O O 0.9999935626983643
nNOS O O 0.4833419919013977
activity O O 0.9093322157859802
in O O 0.9995980858802795
the O O 0.9997089505195618
hippocampus O O 0.6106519103050232
was O O 0.9990874528884888
increased O O 0.9996084570884705
. O O 0.9999977350234985

and O O 0.9477782249450684

Preparations O O 0.9900813698768616
containing O O 0.999691367149353
lindane S-Chemical B-Chemical 0.911789059638977
continue O O 0.9956777691841125
to O O 0.999935507774353
be O O 0.9999247789382935
sold O O 0.9999113082885742
over O O 0.9999834299087524
the O O 0.9997289776802063
counter O O 0.9982434511184692
and O O 0.9999855756759644
may O O 0.9999887943267822
represent O O 0.999995231628418
a O O 0.999921441078186
hazard O O 0.5720987319946289
to O O 0.9884662628173828
poorly O O 0.9098162055015564
informed O O 0.8304283618927002
patients O O 0.9973215460777283
. O O 0.999998927116394

Phase O O 0.9866739511489868
II O O 0.9630249738693237
study O O 0.9998087286949158
of O O 0.9999573230743408
the O O 0.9998798370361328
amsacrine B-Chemical B-Chemical 0.9239401817321777
analogue O O 0.6252890825271606
CI B-Chemical B-Chemical 0.8728128671646118
- I-Chemical I-Chemical 0.9836292862892151
921 I-Chemical I-Chemical 0.9347755908966064
( O O 0.9794765114784241
NSC B-Chemical B-Chemical 0.8794150352478027
343499 I-Chemical I-Chemical 0.9561246037483215
) O O 0.7572641968727112
in O O 0.999954342842102
non B-Disease O 0.9275881052017212
- I-Disease O 0.9762595891952515
small I-Disease O 0.9360499382019043
cell I-Disease O 0.8525933623313904
lung I-Disease O 0.674920380115509
cancer I-Disease O 0.8530135154724121
. O O 0.9990791082382202

correlations O O 0.8140011429786682
were O O 0.9999501705169678
observed O O 0.9999663829803467
for O O 0.999997615814209
these O O 0.9999861717224121
variables O O 0.9980515241622925
with O O 0.9999963045120239
blood O O 0.8981572985649109
pressure O O 0.9690104126930237
or O O 0.9997463822364807
serum B-protein B-protein 0.7119675278663635
lipoproteins E-protein E-protein 0.9742360711097717
. O O 0.9997618794441223
We O O 0.999990701675415
conclude O O 0.9999980926513672
the O O 0.9999910593032837
FECa2+ O S-protein 0.5054286122322083
and O O 0.9607641100883484
the O O 0.9966397285461426
Vmax O O 0.3316088318824768
of O O 0.8889811038970947
the O O 0.9946736693382263
SERCA S-protein S-DNA 0.6592174768447876
are O O 0.9983329176902771
reliable O O 0.9943053126335144
indicators O O 0.9977978467941284
of O O 0.9999858140945435
Ca2+ O O 0.7760741710662842
load O O 0.6969818472862244
in O O 0.9982985854148865
platelets S-cell_type S-cell_type 0.9892774820327759
from O O 0.999680757522583
women O O 0.9977279305458069
. O O 0.9999958276748657
However O O 0.9998067021369934
, O O 0.9999736547470093
in O O 0.999839186668396
women O O 0.9975945353507996
, O O 0.9999775886535645
unlike O O 0.9997827410697937

Akathisia B-Disease B-Disease 0.7323288917541504
appeared O O 0.9580140709877014
to O O 0.9991233944892883
be O O 0.9999793767929077
a O O 0.9999054670333862
common O O 0.992922306060791
side O O 0.9887416958808899
effect O O 0.9990122318267822
of O O 0.9997466206550598
fluoxetine B-Chemical B-Chemical 0.9271031022071838
and O O 0.9957990050315857
generally O O 0.9963909983634949
responded O O 0.9999750852584839
well O O 0.9998406171798706
to O O 0.9999799728393555
treatment O O 0.9993614554405212
with O O 0.9999963045120239
the O O 0.9997567534446716
beta O O 0.9134728312492371
- O O 0.9783333539962769
adrenergic O O 0.8449423313140869
antagonist O O 0.9562232494354248
propranolol B-Chemical B-Chemical 0.9373179078102112
, O O 0.9820475578308105
dose O O 0.9858512282371521
reduction O O 0.9295141696929932
, O O 0.99892657995224
or O O 0.9998654127120972
both O O 0.999901533126831
. O O 0.9999829530715942

IFN-gamma S-protein S-protein 0.5328809022903442
pre-treatment O O 0.9415267705917358
affected O O 0.9996215105056763
the O O 0.999811589717865
magnitude O O 0.9500741958618164
rather O O 0.999887228012085
than O O 0.9999849796295166
the O O 0.9999316930770874
sensitivity O O 0.9982866644859314
of O O 0.9999783039093018
the O O 0.9999489784240723
LPS O O 0.6481093168258667
response O O 0.9045745134353638
. O O 0.9999817609786987

Details O O 0.9899605512619019
of O O 0.9998586177825928
spinal O O 0.9267626404762268
puncture O O 0.6063576340675354
, O O 0.9906657934188843
extension O O 0.9626140594482422
and O O 0.9968854784965515
regression O O 0.8269609212875366
of O O 0.989029049873352
spinal O O 0.8685630559921265
block O O 0.7305699586868286
, O O 0.9772278666496277
and O O 0.9996687173843384
the O O 0.9999418258666992
times O O 0.999841570854187
to O O 0.9999855756759644
reach O O 0.999931812286377
discharge O O 0.9179880619049072
criteria O O 0.9964145421981812
were O O 0.999996542930603
noted O O 0.9999943971633911
. O O 0.9999983310699463

secretion O O 0.9132119417190552
of O O 0.9991869330406189
bioactive O B-protein 0.7908031344413757
macrophage B-protein I-protein 0.4597010314464569
colony-stimulating I-protein I-protein 0.7181441783905029
factor I-protein I-protein 0.7513042688369751
protein E-protein E-protein 0.970377504825592
by O O 0.998210072517395
monocytes S-cell_type S-cell_type 0.9895961880683899
and O O 0.9964099526405334
involves O O 0.9999494552612305
activation O O 0.9982430934906006
of O O 0.9999145269393921
the O O 0.999806821346283
transcription B-protein B-protein 0.4934849739074707
factor E-protein E-protein 0.8394714593887329
NF-kappa B-protein B-protein 0.460246741771698
B E-protein E-protein 0.994674563407898
. O O 0.9997537732124329
Human B-cell_type B-cell_type 0.6144970655441284
peripheral I-cell_type I-cell_type 0.5010309219360352
blood I-cell_type I-cell_type 0.8694738149642944
monocytes E-cell_type E-cell_type 0.9800242781639099
( O O 0.9901536107063293
Mo S-cell_type S-cell_type 0.944047749042511
) O O 0.9645123481750488
constitutively O O 0.9993448853492737
display O O 0.9999818801879883
the O O 0.9999876022338867
beta-chain O O 0.4382092356681824
of O O 0.8526277542114258
the O O 0.9851041436195374
receptor O O 0.7968845963478088
for O O 0.9866572022438049
IL-2 S-protein S-protein 0.9820594191551208
, O O 0.9986099004745483
whereas O O 0.9999876022338867
expression O O 0.9975982308387756
of O O 0.9998190999031067
the O O 0.9990882873535156
IL-2R B-protein B-protein 0.3736612796783447
alpha-chain E-protein E-protein 0.7403103113174438
is O O 0.9950404763221741
not O O 0.9998144507408142
constitutive O O 0.9844332933425903
but O O 0.9983079433441162
inducible O O 0.9880468845367432

in O O 0.9991884827613831
a O O 0.9999208450317383
variety O O 0.9942896366119385
of O O 0.9999479055404663
zinc O B-protein 0.45553502440452576
finger O I-protein 0.7147756814956665
proteins O E-protein 0.995466947555542
and O O 0.9988303780555725
a O O 0.9999003410339355
group O O 0.9946235418319702
of O O 0.9998648166656494
poxvirus B-protein B-protein 0.3905473053455353
proteins E-protein E-protein 0.9831094145774841
and O O 0.9963074922561646
which O O 0.9999278783798218
mediates O O 0.9975359439849854
protein-protein O O 0.6367315649986267
interactions O O 0.9364374876022339
. O O 0.999993085861206

activity O O 0.9816869497299194
after O O 0.9998856782913208
stimulation O O 0.9976855516433716
. O O 0.9999978542327881
Increased O O 0.9972055554389954
turnover O O 0.9921191930770874
has O O 0.9999829530715942
been O O 0.999944806098938
implicated O O 0.9999550580978394
in O O 0.9999840259552002
the O O 0.99994957447052
regulation O O 0.9994611144065857
of O O 0.9999717473983765
constitutive O O 0.924223780632019
NF-kappa B-protein B-protein 0.6157324910163879
B E-protein E-protein 0.9939572811126709
activity O O 0.9961119294166565
in O O 0.9999524354934692
mature B-cell_type B-cell_type 0.5602479577064514
B I-cell_type I-cell_type 0.5841529369354248
cells E-cell_type E-cell_type 0.9533417820930481
. O O 0.9994257688522339
We O O 0.9999896287918091
therefore O O 0.9999979734420776
compared O O 0.9999961853027344
the O O 0.9999921321868896
turnover O O 0.9934676289558411
of O O 0.9999091625213623
I B-protein B-protein 0.5969531536102295
kappa I-protein I-protein 0.8380928635597229
B I-protein I-protein 0.6953892707824707
alpha E-protein E-protein 0.9490872025489807
and O O 0.9816185832023621
I B-protein B-protein 0.751846194267273
kappa I-protein I-protein 0.9390187859535217
B I-protein I-protein 0.676563024520874
beta E-protein E-protein 0.9606689214706421
in O O 0.9982348680496216
mature B-cell_type B-cell_type 0.51127028465271
B I-cell_type I-cell_type 0.6369772553443909
cells E-cell_type E-cell_type 0.9505566358566284
and O O 0.9954367280006409
HeLa B-cell_line B-cell_line 0.8860324621200562
cells E-cell_line E-cell_line 0.9904944896697998

that O O 0.9986007809638977
association O O 0.9991806149482727
of O O 0.9999281167984009
X S-protein O 0.33158227801322937
with O O 0.9919483661651611
charged O O 0.9192942976951599
phospholipid O O 0.6630850434303284
surfaces O O 0.6252109408378601
enhances O O 0.9998778104782104
the O O 0.9999784231185913
proteolytic O O 0.886025607585907
activation O O 0.9845867156982422
of O O 0.999830961227417
this O O 0.9998993873596191
zymogen S-protein O 0.4195486605167389
by O O 0.9977217316627502
increasing O O 0.9990870952606201
recognition O O 0.9980584979057312
and O O 0.9998719692230225
susceptibility O O 0.9973406195640564
of O O 0.9999333620071411

a O O 0.9970422387123108
combination O O 0.9989519119262695
of O O 0.9999916553497314
these O O 0.9999842643737793
cellular O O 0.9058276414871216
activation O O 0.8811124563217163
signals O O 0.9664280414581299
, O O 0.9998786449432373
which O O 0.9999644756317139
are O O 0.9999778270721436
sufficient O O 0.9998893737792969
to O O 0.9999723434448242
lead O O 0.9999821186065674
to O O 0.9999812841415405
G1 O O 0.7199894785881042
cell O O 0.8162239193916321
cycle O O 0.9582690596580505
progression O O 0.9981470108032227
. O O 0.999997615814209
In O O 0.9999704360961914
the O O 0.9999738931655884
presence O O 0.9993590712547302
of O O 0.9999492168426514
1 O O 0.8585042953491211

rejection O O 0.971822202205658

The O O 0.9994869232177734
similarity O O 0.9538297057151794
between O O 0.9992087483406067
the O O 0.9998642206192017
histologic O O 0.5182164311408997
appearances O O 0.9386686682701111
of O O 0.9997294545173645
busulfan B-Chemical B-Chemical 0.8699474930763245
cystitis B-Disease B-Disease 0.6977744102478027
and O O 0.993852972984314
both O O 0.9987768530845642
radiation O O 0.5086372494697571
and O O 0.9889752864837646
cyclophosphamide B-Chemical B-Chemical 0.9290390014648438
- O O 0.9511293768882751
induced O O 0.994247555732727
cystitis B-Disease B-Disease 0.9829368591308594
is O O 0.9838842749595642
discussed O O 0.9997525811195374
and O O 0.9999903440475464
the O O 0.9999067783355713
world O O 0.9982903599739075
literature O O 0.9940266609191895
reviewed O O 0.9999740123748779
. O O 0.9999985694885254

to O O 0.9819653630256653
CD8+ B-cell_type B-cell_type 0.8827840089797974
T I-cell_type I-cell_type 0.9471237659454346
cells E-cell_type E-cell_type 0.9464988112449646
, O O 0.9919438362121582
double-negative B-cell_type B-cell_type 0.624978244304657
thymocytes E-cell_type E-cell_type 0.9459134936332703
, O O 0.9947378039360046
gammadelta-type B-cell_type B-cell_type 0.6603962182998657
T I-cell_type I-cell_type 0.7852445840835571
cells E-cell_type E-cell_type 0.856583833694458
, O O 0.9722685813903809
and O O 0.993527352809906
NK B-cell_type B-cell_type 0.8854037523269653
cells E-cell_type E-cell_type 0.9602516889572144
. O O 0.9997071623802185
In O O 0.9999427795410156
humans O O 0.9330745339393616
, O O 0.9999023675918579
there O O 0.9999971389770508
are O O 0.9999977350234985
two O O 0.999728262424469
highly O O 0.926067590713501

establish O O 0.9974128603935242
persistent O O 0.9724456667900085
infections O O 0.8982265591621399
which O O 0.9999125003814697
may O O 0.999982476234436
reactivate O O 0.9993140697479248
and O O 0.9996166229248047
cause O O 0.9998980760574341
disease O O 0.9740163683891296
in O O 0.9999494552612305
immunocompromised O O 0.7190713286399841
hosts O O 0.612921953201294
. O O 0.9998418092727661
Lymphocytes S-cell_type S-cell_type 0.9369391202926636
have O O 0.9994862079620361
been O O 0.9999126195907593
postulated O O 0.9932346940040588
to O O 0.9999107122421265
serve O O 0.9999537467956543
as O O 0.9999605417251587
a O O 0.999954342842102
site O O 0.9747549891471863
of O O 0.998994767665863
adenoviral O O 0.7240279316902161
persistence O O 0.8579760193824768
based O O 0.9993973970413208
upon O O 0.9998471736907959

CONCLUSION O O 0.9987605810165405
: O O 0.9999961853027344
In O O 0.9999972581863403
this O O 0.999997615814209
preliminary O O 0.996185839176178
report O O 0.9998385906219482
, O O 0.9999858140945435
divalproex B-Chemical B-Chemical 0.9229058623313904
sodium E-Chemical I-Chemical 0.9489830732345581
was O O 0.9981160163879395
a O O 0.999995231628418
superior O O 0.9966849684715271
alternative O O 0.9993222951889038
to O O 0.9999796152114868
lithium S-Chemical B-Chemical 0.9145635366439819
in O O 0.9960903525352478
bipolar O O 0.8517583012580872
patients O O 0.6611667275428772
experiencing O O 0.9997759461402893
cognitive O B-Disease 0.669940173625946
deficits O I-Disease 0.9893125891685486
, O O 0.9496007561683655
loss O O 0.6132494211196899
of O O 0.5435307621955872
creativity O O 0.9251139760017395
, O O 0.8662194013595581
and O O 0.9859740138053894
functional O O 0.8717712163925171
impairments O O 0.8744213581085205
. O O 0.9993422627449036

results O O 0.990988552570343
with O O 0.9999970197677612
21 O O 0.9879436492919922
different O O 0.9987502098083496
EMCV B-DNA B-DNA 0.501388430595398
IRES I-DNA I-DNA 0.2273010015487671
fragments E-DNA E-DNA 0.932587742805481
and O O 0.9976351261138916
cytoplasmic O O 0.6017074584960938
HeLa O O 0.6192002296447754
extract O O 0.3343442380428314
or O O 0.9375976920127869
rabbit O O 0.6158960461616516
reticulocyte O O 0.4257199466228485
lysate O O 0.3627391457557678
as O O 0.9992214441299438
the O O 0.999993085861206
source O O 0.998698353767395

. O O 0.9953059554100037
An O O 0.9999887943267822
unknown O O 0.9868149757385254
event O O 0.9960610270500183
might O O 0.9999961853027344
be O O 0.9999946355819702
involved O O 0.9999783039093018
in O O 0.9999872446060181
GC-resistance O O 0.8275777697563171
of O O 0.998986542224884
CRF O S-protein 0.8537828922271729
. O O 0.9999440908432007
Alteration O O 0.9988659620285034
of O O 0.9999288320541382
a O O 0.9998985528945923
single O O 0.8993707299232483
serine O O 0.5734503865242004
in O O 0.9985187649726868
the O O 0.9999580383300781
basic B-protein B-protein 0.8102791905403137
domain E-protein E-protein 0.9051793217658997
of O O 0.9934588074684143
the O O 0.9997597336769104
Epstein-Barr B-protein B-protein 0.5070345401763916
virus I-protein I-protein 0.7917455434799194
ZEBRA I-protein I-protein 0.8766496777534485
protein E-protein E-protein 0.9591284990310669
separates O O 0.9669271111488342

Thirteen O O 0.9903910160064697
biopsies O O 0.7057815790176392
were O O 0.9994257688522339
performed O O 0.9999610185623169
from O O 0.9999960660934448
stable O O 0.9326303601264954
functioning O O 0.975753664970398
renal O O 0.9632653594017029
allografts O O 0.9565016031265259
with O O 0.999985933303833
informed O O 0.9933701753616333
consent O O 0.9938734769821167
( O O 0.999967098236084
nonepisode O O 0.7045522928237915
biopsy O O 0.6396452188491821
) O O 0.9982621073722839
and O O 0.9999833106994629
the O O 0.9999873638153076
other O O 0.9999608993530273
13 O O 0.9937087297439575
were O O 0.9999666213989258
from O O 0.9999938011169434
dysfunctional O O 0.8465988039970398
renal O O 0.7708529233932495
allografts O O 0.5545235276222229
with O O 0.9998842477798462
a O O 0.9999831914901733
clinical O O 0.9920642971992493
indication O O 0.9994188547134399
for O O 0.999984860420227
biopsy O O 0.5421014428138733
( O O 0.9957262277603149
episode O O 0.7754067182540894
biopsy O O 0.47015252709388733
) O O 0.9961734414100647
. O O 0.9999948740005493

Subjects O O 0.9959915280342102
were O O 0.9999903440475464
able O O 0.9999773502349854
to O O 0.9999457597732544
reliably O O 0.9997314810752869
discriminate O O 0.9960451722145081
pain O B-Disease 0.9610523581504822
magnitude O O 0.8102428317070007
and O O 0.9855419397354126
duration O O 0.9822642207145691
across O O 0.9998902082443237
capsaicin S-Chemical B-Chemical 0.928305983543396
doses O O 0.9017367362976074
( O O 0.9999823570251465
both O O 0.9999964237213135
p O O 0.9948617815971375
< O O 0.9995927214622498
0 O O 0.9997655749320984
. O O 0.9997840523719788
001 O O 0.971874475479126
) O O 0.9995865225791931
, O O 0.9999966621398926
regardless O O 0.9999855756759644
of O O 0.9999706745147705
whether O O 0.9999978542327881
first O O 0.9992215633392334
- O O 0.9998283386230469
time O O 0.9996616840362549
ratings O O 0.9997934699058533
were O O 0.999998927116394
requested O O 0.9999940395355225
immediately O O 0.9999772310256958
, O O 0.9999936819076538
after O O 0.9999922513961792
one O O 0.9999879598617554
hour O O 0.9998860359191895
or O O 0.9999958276748657
after O O 0.9999798536300659
one O O 0.9999674558639526
day O O 0.9999532699584961
. O O 0.9999992847442627

in O O 0.9981350898742676
which O O 0.9999833106994629
nuclear O O 0.9670957922935486
export O O 0.9929456114768982
of O O 0.9998019337654114
the O O 0.9999535083770752
shuttling O B-protein 0.7199718356132507
transcription B-protein I-protein 0.5650507211685181
factor I-protein E-protein 0.9300251007080078
NFAT E-protein S-protein 0.6982183456420898
( O O 0.9920329451560974
nuclear B-protein B-protein 0.5881362557411194
factor I-protein I-protein 0.5866366028785706
of I-protein I-protein 0.9235346913337708

and O O 0.9699540734291077
six O O 0.9875714778900146

The O O 0.9996956586837769
first O O 0.9970965385437012
series O O 0.9993746876716614
of O O 0.9999735355377197
experiments O O 0.9980416297912598
examined O O 0.9999856948852539
the O O 0.9999470710754395
influence O O 0.9856842756271362
of O O 0.9960118532180786
age O O 0.9797620177268982
and O O 0.9994683861732483
growth O O 0.8063091039657593
status O O 0.8920450806617737
on O O 0.999593198299408
artery B-Disease O 0.5873364806175232
calcification I-Disease O 0.9399476647377014
in O O 0.9872329235076904
Warfarin B-Chemical B-Chemical 0.9144797921180725
- O O 0.9369105696678162
treated O O 0.9973510503768921
rats O O 0.9876178503036499
. O O 0.9999983310699463

in O O 0.9970574378967285
human B-cell_type B-cell_type 0.6355758905410767
B I-cell_type I-cell_type 0.8415676951408386
lymphocytes E-cell_type E-cell_type 0.9848926067352295
. O O 0.9998477697372437
2 O O 0.9637545347213745
, O O 0.9895694851875305
3 O O 0.9885627031326294
, O O 0.997266411781311
7 O O 0.9902315735816956
, O O 0.9995251893997192
8-tetrachlorodibenzo-p-dioxin O O 0.9409371614456177
( O O 0.9995094537734985
TCDD O O 0.8661572337150574
) O O 0.9990585446357727
inhibits O O 0.9999771118164062
murine O O 0.5025202035903931

cells E-cell_line E-cell_type 0.6165165901184082

an O O 0.9982916712760925
induced O O 0.9883984923362732
DNA-binding O O 0.7465080618858337
activity O O 0.9731371998786926
in O O 0.9999475479125977
these O O 0.9994839429855347
cells O O 0.9676697254180908
in O O 0.9999629259109497
response O O 0.9987540245056152
to O O 0.9999840259552002
LPS O O 0.9723567366600037
. O O 0.9999926090240479
Characterization O O 0.998865008354187
of O O 0.9999598264694214
the O O 0.9999436140060425
DNA-binding B-protein B-protein 0.610515832901001
protein E-protein E-protein 0.9746904373168945
by O O 0.999390721321106
UV O O 0.44296568632125854
cross-linking O O 0.6252899765968323
, O O 0.9858555197715759

shown O O 0.992002010345459
to O O 0.9999401569366455
be O O 0.9999262094497681
involved O O 0.9999269247055054
in O O 0.9999901056289673
the O O 0.9999755620956421
expression O O 0.9981247782707214
of O O 0.9999731779098511
the O O 0.9997795224189758
IL-9 B-DNA B-DNA 0.5975639224052429
gene E-DNA E-DNA 0.9686747193336487
. O O 0.9995689988136292
A O O 0.9997004270553589
proximal B-DNA B-DNA 0.6142573952674866
region E-DNA E-DNA 0.7200807929039001
between O O 0.9931949377059937
-46 B-DNA O 0.39019775390625
and I-DNA O 0.8122492432594299

Pathologically O O 0.977392852306366
, O O 0.9999288320541382
granular O O 0.84330815076828
cytoplasmic O O 0.7631959915161133
changes O O 0.8697609901428223
were O O 0.9999173879623413
found O O 0.9999898672103882
in O O 0.9999780654907227
cardiac O O 0.8392659425735474
myocytes O O 0.5937035083770752
, O O 0.9991231560707092
indicating O O 0.9999569654464722
enlarged O O 0.7832925915718079
, O O 0.9666028618812561
damaged O O 0.631001353263855
mitochondria O O 0.4817589819431305
. O O 0.9991962313652039

accompanied O O 0.9955937266349792
by O O 0.9999890327453613
increase O O 0.9979991316795349
of O O 0.9998533725738525
DEVD-cleavable O O 0.3967801034450531
caspases S-protein O 0.5272189378738403
activity O O 0.9921590089797974
and O O 0.9999184608459473
degradation O O 0.9900984168052673
of O O 0.9998773336410522
caspase B-protein B-protein 0.48382091522216797
substrate I-protein I-protein 0.3218228220939636
poly I-protein I-protein 0.6169479489326477
( I-protein I-protein 0.6985647678375244
ADP-ribose I-protein I-protein 0.6521150469779968
) I-protein I-protein 0.633567214012146
polymerase E-protein E-protein 0.9797315001487732
( O O 0.9909817576408386
PARP S-protein S-protein 0.8392239212989807
) O O 0.9846227765083313
. O O 0.9999693632125854
A O O 0.9985839128494263
specific O O 0.979617178440094

in O O 0.9967003464698792
growth O O 0.9517147541046143
and O O 0.9964358806610107
differentiation O O 0.9940127730369568
of O O 0.9998264908790588
cells O O 0.8421457409858704
along O O 0.9992356300354004
erythroid B-cell_type B-cell_type 0.6086238622665405
and/or I-cell_type I-cell_type 0.583974301815033
megakaryocytic I-cell_type I-cell_type 0.6880635619163513
lineages E-cell_type E-cell_type 0.7219015955924988
, O O 0.999444305896759
because O O 0.9999995231628418
a O O 0.9999927282333374
significant O O 0.9976534247398376
level O O 0.9998955726623535
of O O 0.9999300241470337
the O O 0.9997401833534241
AML1 S-protein S-protein 0.366390585899353

now O O 0.9982680082321167
show O O 0.9999536275863647
that O O 0.9999973773956299
CD15 O S-protein 0.7976933717727661
( O O 0.9945659637451172
Lewis O O 0.9536759257316589
X O O 0.7201217412948608
) O O 0.9880563020706177
, O O 0.9999902248382568
a O O 0.9999849796295166
monocyte B-protein O 0.6783795952796936
counter-receptor E-protein O 0.6177598834037781
for O O 0.980767011642456
endothelial B-protein O 0.7571248412132263
selectins E-protein O 0.5844518542289734
may O O 0.9997847676277161
participate O O 0.9999927282333374
in O O 0.9999920129776001
this O O 0.999977707862854
response O O 0.998808741569519
. O O 0.9999973773956299
We O O 0.9980722665786743

MAPk B-protein B-protein 0.4664645195007324
kinase E-protein E-protein 0.9849897623062134
( O O 0.9758718609809875
MKK S-protein S-protein 0.997847318649292
) O O 0.9689303040504456
that O O 0.9999141693115234
activates O O 0.9984240531921387
p38 B-protein B-protein 0.7300177216529846
MAPk E-protein E-protein 0.9759541749954224
in O O 0.999835729598999
response O O 0.9975365400314331
to O O 0.999970555305481
LPS O O 0.9456347823143005
, O O 0.9996786117553711
the O O 0.9999339580535889

, O O 0.9696407914161682
IL2 S-protein S-protein 0.9112301468849182
does O O 0.9998956918716431
not O O 0.9999735355377197
reverse O O 0.999079704284668
CsA O O 0.7055608034133911
inhibition O O 0.9743175506591797
, O O 0.9999490976333618
suggesting O O 0.9999920129776001
that O O 0.999992847442627
at O O 0.9999326467514038
least O O 0.9992021918296814
one O O 0.9999600648880005
other O O 0.9997497200965881
NFAT-sensitive B-DNA B-DNA 0.5264185070991516
gene E-DNA E-DNA 0.9699240326881409
may O O 0.9984709620475769
be O O 0.9999845027923584
involved O O 0.9999456405639648
. O O 0.9999991655349731
The O O 0.9999752044677734
human B-DNA B-DNA 0.40937355160713196
G0/G1 I-DNA I-DNA 0.5740658640861511
switch I-DNA I-DNA 0.6812256574630737
gene E-DNA E-DNA 0.9799705743789673
, O O 0.9910218119621277
G0S2 S-DNA S-DNA 0.9979454874992371
, O O 0.9899929165840149
has O O 0.9999808073043823
potential O O 0.9964565634727478
NFAT-binding B-DNA B-DNA 0.389870285987854

unlike O O 0.995512068271637

CREB/ATF S-protein S-protein 0.9368283152580261
, O O 0.9895408749580383
and O O 0.9965225458145142
NF-kappa B-protein B-protein 0.762990415096283
B/Rel/NFAT I-protein I-protein 0.4670040011405945
transcription I-protein I-protein 0.5132562518119812
factors E-protein E-protein 0.9951003193855286
; O O 0.9985895752906799
the O O 0.9999258518218994
Stat B-protein B-protein 0.5291335582733154
proteins E-protein E-protein 0.9888615012168884
; O O 0.9967373013496399
and O O 0.9997245669364929
HMG B-protein B-protein 0.6534662246704102
box I-protein I-protein 0.6110833883285522
transcription I-protein I-protein 0.9487457871437073
factors E-protein E-protein 0.9950677156448364
such O O 0.9986698627471924
as O O 0.9999452829360962
LEF1 S-protein S-protein 0.9683568477630615
, O O 0.9882972836494446
TCF1 S-protein S-protein 0.983180820941925
, O O 0.9745338559150696
and O O 0.9903455376625061
Sox4 S-protein S-protein 0.9487870931625366
. O O 0.9995675683021545
In O O 0.9999885559082031
this O O 0.999988317489624
review O O 0.9996223449707031
, O O 0.999976396560669

cytokines S-protein S-protein 0.6971673369407654
or O O 0.9993005990982056
growth B-protein B-protein 0.6355523467063904
factors E-protein E-protein 0.9825007319450378
. O O 0.9998377561569214
Recent O O 0.9998699426651001
studies O O 0.9999591112136841
suggest O O 0.9999973773956299
that O O 0.9999964237213135
one O O 0.9986109733581543
or O O 0.9995425939559937
more O O 0.9996770620346069
cytoplasmic B-protein B-protein 0.49999749660491943
serine I-protein I-protein 0.7286823391914368
kinases E-protein E-protein 0.9888743162155151
also O O 0.9987371563911438
phosphorylate O O 0.8371865749359131
STAT3 S-protein S-protein 0.8995905518531799
and O O 0.9900842905044556

by O O 0.9972892999649048
acting O O 0.9983454942703247
as O O 0.9999198913574219
cofactors O O 0.8699448108673096
for O O 0.9965516328811646
GATA3 S-protein S-protein 0.9230269193649292
. O O 0.9998843669891357
Previously O O 0.9998192191123962
, O O 0.9999804496765137
we O O 0.9996787309646606
have O O 0.9999880790710449
shown O O 0.9999822378158569
that O O 0.9999916553497314
TAL1 S-protein S-protein 0.6941425204277039
and O O 0.9963417649269104
the O O 0.9994587302207947
LIM-only B-DNA B-DNA 0.3090052902698517
protein I-DNA I-DNA 0.4690497815608978
gene E-DNA E-DNA 0.9725704789161682
( O O 0.9861875772476196
LMO S-DNA S-DNA 0.9646394848823547
) O O 0.979399561882019
are O O 0.9998809099197388
regularly O O 0.9990522265434265
coactivated O O 0.998543381690979
in O O 0.9999512434005737
T-cell O O 0.5254086852073669
acute O O 0.5841295719146729
lymphoblastic O O 0.5956811904907227
leukemia O O 0.5406287908554077
( O O 0.9815394282341003
T-ALL O O 0.823716938495636
) O O 0.9942843317985535
. O O 0.9999912977218628
This O O 0.9999898672103882
observation O O 0.999723494052887
is O O 0.9999978542327881
likely O O 0.9999750852584839
to O O 0.9999957084655762
relate O O 0.9999899864196777
to O O 0.9999914169311523
the O O 0.999961256980896
findings O O 0.9997420907020569
that O O 0.9999954700469971

latency O O 0.8549607992172241
. O O 0.9999477863311768
Here O O 0.9999798536300659
we O O 0.9999923706054688
show O O 0.9999850988388062
that O O 0.9999966621398926
, O O 0.9994543194770813
unexpectedly O O 0.9991626739501953
, O O 0.9999864101409912
expression O O 0.9967921376228333
of O O 0.999909520149231
another O O 0.9996987581253052
viral B-protein B-protein 0.47015953063964844
immediate-early I-protein I-protein 0.7427632212638855
protein E-protein E-protein 0.9836581349372864
, O O 0.9913086891174316
BRLF1 S-protein S-protein 0.9702163338661194
, O O 0.9977777600288391
can O O 0.9999538660049438
disrupt O O 0.9996650218963623
viral O O 0.9374015927314758
latency O O 0.9833914041519165
in O O 0.9999889135360718
an O O 0.9999722242355347
epithelial O O 0.785455048084259
cell-specific O O 0.789704442024231
fashion O O 0.958276629447937
. O O 0.9999828338623047
Therefore O O 0.9999803304672241
, O O 0.9999947547912598
the O O 0.999988317489624
mechanisms O O 0.9996689558029175
leading O O 0.9999899864196777
to O O 0.9999853372573853
disruption O O 0.9952237010002136
of O O 0.9997281432151794

B E-protein E-protein 0.9302579760551453
. O O 0.9923679232597351
By O O 0.9999314546585083
contrast O O 0.9989559650421143
, O O 0.999984860420227
treatment O O 0.9993094205856323
of O O 0.9999001026153564
cells O O 0.942646324634552
with O O 0.9999239444732666
pyrrolidine O O 0.8780782222747803
dithiocarbamate O O 0.8835293054580688

with O O 0.9963990449905396
anti-CD28 B-protein B-protein 0.25113630294799805
mAb E-protein E-protein 0.9838903546333313
or O O 0.9937248826026917
CHO B-cell_line B-cell_line 0.38737332820892334
cells E-cell_line E-cell_line 0.8312486410140991
expressing O O 0.999176561832428
the O O 0.9999483823776245
CD28 B-protein B-protein 0.6127089262008667
ligands E-protein E-protein 0.9073668122291565
CD80 S-protein S-protein 0.790071427822113
or O O 0.9969403743743896
CD86 S-protein S-protein 0.9366914629936218
did O O 0.9997672438621521
not O O 0.999987006187439
lead O O 0.9999872446060181
to O O 0.9999910593032837
tyrosine O O 0.9132190942764282
phosphorylation O O 0.958824098110199
of O O 0.9991101622581482
HS1 S-protein S-protein 0.6192033290863037
in O O 0.9995275735855103
Jurkat B-cell_line B-cell_line 0.7471608519554138
T I-cell_line I-cell_line 0.8933821320533752
cells E-cell_line E-cell_line 0.981991708278656

Antagonism O O 0.8281242251396179
between O O 0.9122873544692993
interleukin O O 0.6067798137664795
3 O O 0.9045015573501587
and O O 0.9445599913597107
erythropoietin O O 0.5083000659942627
in O O 0.9923958778381348
mice O O 0.9960427284240723
with O O 0.9999839067459106
azidothymidine S-Chemical B-Chemical 0.9357542395591736
- O O 0.969774067401886
induced O O 0.9973015189170837
anemia O B-Disease 0.975166916847229
and O O 0.9599462151527405
in O O 0.9984464049339294
bone O O 0.9068530201911926
marrow O O 0.830146849155426
endothelial O O 0.6165885329246521
cells O O 0.5238840579986572
. O O 0.9999771118164062

activated O O 0.9154525995254517
via O O 0.9990662932395935
the O O 0.9998993873596191
selective O O 0.9461674690246582
phosphorylation O O 0.9227744936943054
, O O 0.9976890087127686
ubiquination O O 0.8620285987854004
and O O 0.9896849393844604
degradation O O 0.9867336750030518
of O O 0.9996329545974731
its O O 0.9997017979621887
inhibitor B-protein B-protein 0.8747931122779846
protein I-protein I-protein 0.41826173663139343
I-kB E-protein E-protein 0.8409575819969177
thereby O O 0.998612642288208
allowing O O 0.9999066591262817
translocation O O 0.9900897741317749
of O O 0.9997428059577942
NF-kappa B-protein B-protein 0.8644849061965942
B E-protein E-protein 0.991364598274231
into O O 0.9993687272071838
the O O 0.999863862991333
nucleus O O 0.9524649977684021
where O O 0.9997329115867615
it O O 0.9995197057723999
upregulates O O 0.9998056292533875
the O O 0.9997596144676208
transcription O O 0.9504191875457764
of O O 0.9975770115852356
a O O 0.999495267868042
variety O O 0.9875980019569397
of O O 0.9994640946388245
adhesion B-protein B-protein 0.4671649932861328
molecules E-protein E-protein 0.9899347424507141
( O O 0.9883127808570862
e.g O S-protein 0.7153284549713135
. O O 0.9964884519577026
ICAM-1 S-protein S-protein 0.8602755665779114

is O O 0.9988622665405273
an O O 0.9999806880950928
activin O O 0.8384724259376526
A-inducible O O 0.7234079837799072
antagonist O O 0.4956880509853363
of O O 0.9996744394302368
activin O O 0.6556527614593506
A-induced O O 0.8815790414810181
growth O O 0.9235789179801941
arrest O O 0.9436826109886169
and O O 0.9997082352638245
apoptosis O O 0.9474209547042847
in O O 0.9999371767044067
HS-72 B-cell_line B-cell_line 0.7577894330024719
cells E-cell_line E-cell_line 0.9725382328033447
. O O 0.9998676776885986
Interestingly O O 0.9998792409896851
, O O 0.9999938011169434
although O O 0.9999731779098511
mRNA O O 0.6948803663253784
expression O O 0.9934473633766174
of O O 0.9997909665107727
Smad6 S-protein S-protein 0.9532666206359863
was O O 0.9993693232536316
induced O O 0.9999326467514038
by O O 0.999980092048645
activin O B-protein 0.6792474985122681
A O E-protein 0.8829237222671509
in O O 0.998715877532959
HS-72 B-cell_line B-cell_line 0.7776384949684143
cells E-cell_line E-cell_line 0.9807511568069458
, O O 0.9996129870414734
Smad6 S-protein S-protein 0.6104920506477356
showed O O 0.9995700716972351
no O O 0.9995492100715637

BACKGROUND O O 0.9822875261306763
AND O O 0.9998834133148193
OBJECTIVE O O 0.9957334399223328
: O O 0.9999399185180664
Despite O O 0.9998550415039062
advantages O O 0.9978571534156799
of O O 0.9996991157531738
induction O O 0.8214728236198425
and O O 0.9980568289756775
maintenance O O 0.9319705367088318
of O O 0.9913519620895386
anaesthesia O O 0.8782501220703125
with O O 0.9906888008117676
sevoflurane B-Chemical B-Chemical 0.9253402352333069
, O O 0.9987038373947144
postoperative B-Disease O 0.7700912356376648
nausea I-Disease O 0.737050473690033
and I-Disease O 0.9217581152915955
vomiting I-Disease O 0.8684557676315308
occurs O O 0.8840574622154236
frequently O O 0.9867501854896545
. O O 0.9999983310699463

Twenty O O 0.9837092161178589
- O O 0.9988873600959778
two O O 0.9996649026870728
patients O O 0.9993683695793152
in O O 0.9999929666519165
the O O 0.9998619556427002
affected O O 0.966330885887146
group O O 0.995016872882843
had O O 0.9999549388885498
abnormal O O 0.8234031200408936
audiograms O O 0.5297968983650208
with O O 0.9976033568382263
deficits O O 0.6353759765625
mostly O O 0.9713286757469177
in O O 0.9953075051307678
the O O 0.9953346848487854
high O O 0.9730802774429321
frequency O O 0.9651678800582886
range O O 0.9953870177268982
of O O 0.9997543692588806
4 O O 0.9566348791122437
, O O 0.9981546998023987
000 O O 0.9974462985992432
to O O 0.9994020462036133
8 O O 0.9928551316261292
, O O 0.9998065829277039
000 O O 0.9953697323799133
Hz O O 0.9107460975646973
and O O 0.9998032450675964
in O O 0.999937891960144
the O O 0.99972003698349
hearing O O 0.9119957685470581
threshold O O 0.9810193181037903
levels O O 0.9996591806411743
of O O 0.9999547004699707
30 O O 0.9973458647727966
to O O 0.9996752738952637
100 O O 0.9995991587638855
decibels O O 0.999207079410553
. O O 0.9999986886978149

Assay O O 0.85365229845047
for O O 0.9991418123245239
mitochondrial O O 0.925269603729248
respiratory O O 0.8405886292457581
function O O 0.554141104221344
and O O 0.9985678195953369
histopathological O O 0.958561897277832
examination O O 0.9827122688293457
of O O 0.9998189806938171
heart O O 0.8170009851455688
tissues O O 0.6158666610717773
were O O 0.9993898868560791
performed O O 0.9999833106994629
. O O 0.9999990463256836

, O O 0.9523138403892517
but O O 0.998696506023407
not O O 0.9998182654380798
to O O 0.9998664855957031
that O O 0.9999008178710938
in O O 0.9996178150177002
the O O 0.9998657703399658
promoter B-DNA B-DNA 0.6902320384979248
region E-DNA E-DNA 0.9322081208229065
of O O 0.9970034956932068
the O O 0.99974125623703
COX-2 B-DNA B-DNA 0.5074626803398132
gene E-DNA E-DNA 0.9764812588691711
, O O 0.9961976408958435
whereas O O 0.9999895095825195
IFN-gamma-activated B-protein O 0.5418198108673096
STAT1 E-protein S-protein 0.5777850151062012
and O O 0.987231433391571
STAT5 S-protein S-protein 0.9418373107910156
could O O 0.9998924732208252
bind O O 0.9988477230072021
to O O 0.9989509582519531

and O O 0.9672315716743469
cloning O O 0.9755294322967529
of O O 0.999713122844696
this O O 0.9998922348022461
protein O O 0.8400790095329285
, O O 0.9931614398956299
termed O O 0.9997685551643372
early O B-protein 0.7659965753555298
B-cell B-protein I-protein 0.44520270824432373
factor E-protein E-protein 0.6984351277351379

The O O 0.9995498061180115
present O O 0.9987275004386902
study O O 0.999800980091095
was O O 0.9999966621398926
carried O O 0.9999971389770508
out O O 0.9999990463256836
to O O 0.9999953508377075
test O O 0.9999704360961914
the O O 0.999916672706604
effects O O 0.9998449087142944
of O O 0.999893069267273
L B-Chemical B-Chemical 0.9333436489105225
- I-Chemical I-Chemical 0.9884267449378967
alpha I-Chemical I-Chemical 0.9561333060264587
- I-Chemical I-Chemical 0.9887897968292236
glycerylphosphorylcholine I-Chemical I-Chemical 0.9411432147026062
( O O 0.8712786436080933
L B-Chemical B-Chemical 0.9481659531593323
- I-Chemical I-Chemical 0.9897333979606628
alpha I-Chemical I-Chemical 0.9439657330513
- I-Chemical I-Chemical 0.9905970692634583
GFC I-Chemical I-Chemical 0.9437392950057983
) O O 0.9178364872932434
on O O 0.9999334812164307
memory B-Disease O 0.5259784460067749
impairment I-Disease O 0.9719631671905518
induced O O 0.6257413029670715
by O O 0.9877641797065735
scopolamine B-Chemical B-Chemical 0.9343464374542236
in O O 0.9983848333358765
man O O 0.9839707016944885
. O O 0.9999867677688599

IL-5 S-protein S-protein 0.8859617114067078
) O O 0.9631166458129883
, O O 0.9992189407348633
which O O 0.999792754650116
is O O 0.9998120665550232
produced O O 0.9997383952140808
by O O 0.9998847246170044
CD4 B-cell_type B-cell_type 0.43970105051994324
( I-cell_type I-cell_type 0.4774686098098755
+ I-cell_type I-cell_type 0.507896900177002
) I-cell_type I-cell_type 0.49690788984298706
T I-cell_type I-cell_type 0.736343502998352
helper I-cell_type I-cell_type 0.8533006906509399
2 I-cell_type I-cell_type 0.7529353499412537
( I-cell_type I-cell_type 0.878754198551178
Th2 I-cell_type I-cell_type 0.857353925704956
) I-cell_type I-cell_type 0.8759327530860901
cells E-cell_type E-cell_type 0.8544297218322754
, O O 0.985288679599762
but O O 0.9996709823608398
not O O 0.9990164041519165
by O O 0.9996065497398376
Th1 B-cell_type B-cell_type 0.7599533200263977
cells E-cell_type E-cell_type 0.9113650918006897
, O O 0.9959902167320251
plays O O 0.9999834299087524
a O O 0.9999943971633911
key O O 0.9980016350746155
role O O 0.9998770952224731
in O O 0.9999953508377075
the O O 0.9999866485595703
development O O 0.9995136260986328
of O O 0.9999721050262451

irreversible O O 0.9490335583686829
, O O 0.9994465708732605
however O O 0.9999747276306152
, O O 0.9999819993972778
upon O O 0.9998931884765625
simultaneous O O 0.9971461892127991
treatment O O 0.9998319149017334
with O O 0.9999945163726807
dexamethasone O O 0.8945057392120361
and O O 0.9983565211296082
transforming B-protein B-protein 0.9361019730567932
growth I-protein I-protein 0.7676423788070679
factor-beta I-protein I-protein 0.3259880244731903
1 E-protein E-protein 0.9763926267623901
( O O 0.9878694415092468
TGF-beta B-protein B-protein 0.4678134322166443
1 E-protein E-protein 0.9272264838218689
) O O 0.8598054647445679
, O O 0.9995193481445312
which O O 0.9999533891677856
did O O 0.999961256980896
not O O 0.9999096393585205

, O O 0.9290496110916138
i.e O O 0.9361009001731873
. O O 0.9997456669807434
adult B-cell_type B-cell_type 0.6640821099281311
CD34+ I-cell_type I-cell_type 0.32617607712745667
bone I-cell_type I-cell_type 0.4971969723701477
marrow I-cell_type I-cell_type 0.5435127019882202
cells E-cell_type E-cell_type 0.5687944293022156
, O O 0.9923466444015503
was O O 0.9999223947525024

in O O 0.9987194538116455
the O O 0.999957799911499
transformation O O 0.995087206363678
of O O 0.9998531341552734
T B-cell_type B-cell_type 0.9057324528694153
cells E-cell_type E-cell_type 0.9925175905227661
by O O 0.9996404647827148
HTLV-I O O 0.7827575206756592
. O O 0.999804675579071
However O O 0.9999222755432129
, O O 0.9999908208847046
the O O 0.9999496936798096
HTLV-I B-DNA B-DNA 0.34360769391059875
genes E-DNA E-DNA 0.979282557964325
including O O 0.9983543157577515
Tax S-protein S-protein 0.9945369362831116
are O O 0.9997268319129944
not O O 0.9999452829360962

level O O 0.9862198829650879
by O O 0.9998974800109863
functional O O 0.9868344664573669
analysis O O 0.9986830353736877
of O O 0.9999681711196899
deletion B-DNA B-protein 0.7429969310760498
mutants E-DNA E-protein 0.6555555462837219
or O O 0.9979664087295532
synthetic B-DNA O 0.8114532232284546
GRE I-DNA O 0.2616457939147949
oligonucleotides E-DNA O 0.4008409082889557
driving O O 0.9781422019004822
chloramphenicol B-protein B-protein 0.6089043617248535
acetyl-transferase E-protein E-protein 0.9128172397613525
expression O O 0.9958927631378174
. O O 0.9999897480010986
Synergism O O 0.8423916697502136
required O O 0.9996527433395386
an O O 0.9999790191650391
intact O O 0.9456378817558289
GR B-protein B-protein 0.7509763836860657
DNA-binding I-protein I-protein 0.5263190865516663
domain E-protein E-protein 0.9051921963691711
, O O 0.9972600936889648
whereas O O 0.9999874830245972
amino- B-protein B-protein 0.45787379145622253
or I-protein I-protein 0.5904347896575928
carboxyl-terminal I-protein I-protein 0.78130704164505
domains E-protein E-protein 0.9790028929710388
were O O 0.9994744658470154
dispensable O O 0.9901200532913208
. O O 0.9999825954437256
The O O 0.9999955892562866
effect O O 0.9994496703147888

with O O 0.9954361319541931
Syk S-protein S-protein 0.988797128200531
and O O 0.9934450387954712
Lyn S-protein S-protein 0.8990199565887451
and O O 0.9292643666267395
associates O O 0.9451959133148193
with O O 0.9997017979621887
signaling B-protein B-protein 0.8822097778320312
molecules E-protein E-protein 0.8763111233711243
including O O 0.9805701375007629
Syk S-protein S-protein 0.9937916398048401
and O O 0.9981539845466614
a O O 0.99928879737854
putative B-protein O 0.7371169328689575
chicken I-protein O 0.4530642628669739

. O O 0.995186984539032
Treatment O O 0.9995050430297852
with O O 0.9999849796295166
soluble O O 0.8910351991653442
, O O 0.9954016208648682
bivalent O O 0.9238704442977905
mAb B-protein B-protein 0.3800830841064453
J393 E-protein E-protein 0.7872297763824463
killed O O 0.9964330196380615
25-50 O O 0.9714058041572571
% O O 0.997675359249115
of O O 0.9999216794967651
the O O 0.9999020099639893
cell B-cell_line O 0.9165769219398499
population E-cell_line O 0.7362110614776611
, O O 0.9999287128448486
while O O 0.9999961853027344
concomitant O O 0.9633210897445679
engagement O O 0.9959153532981873
of O O 0.9999544620513916
either O O 0.999981164932251
the O O 0.9997063279151917
CD3.TcR B-protein B-protein 0.39206352829933167
complex E-protein E-protein 0.9742137789726257
or O O 0.9975861310958862
the O O 0.9999037981033325
integrins S-protein O 0.7276226282119751
CD18 S-protein S-protein 0.5744476914405823
and O O 0.9732053875923157
CD29 S-protein S-protein 0.942494809627533
significantly O O 0.9974666833877563
potentiated O O 0.9998235106468201
this O O 0.9999860525131226

Improvements O O 0.9639288187026978
were O O 0.9995762705802917
seen O O 0.9999860525131226
in O O 0.999907374382019
the O O 0.99974125623703
number O O 0.9996562004089355
of O O 0.9999550580978394
tender O O 0.6349804401397705
joints O O 0.7845588326454163
, O O 0.9974253177642822
the O O 0.9999386072158813
severity O O 0.9763216376304626
of O O 0.9985842704772949
swelling O O 0.9364208579063416
and O O 0.8958921432495117
tenderness O B-Disease 0.9413154721260071
, O O 0.9866887927055359
the O O 0.999883770942688
time O O 0.9999443292617798
of O O 0.9999755620956421
walk O O 0.9792611002922058
50 O O 0.9958445429801941
feet O O 0.9945300221443176
, O O 0.9999741315841675
the O O 0.9999483823776245
duration O O 0.993939995765686
of O O 0.9995654225349426
morning O O 0.8593509793281555
stiffness O O 0.5864512920379639
and O O 0.9891648888587952
the O O 0.9989601373672485
circumference O O 0.715885579586029
of O O 0.9597898125648499
the O O 0.9880444407463074
left O O 0.8935684561729431
knee O O 0.6605750918388367
. O O 0.9999837875366211

and O O 0.9529322981834412
dissociation O O 0.9429214000701904
profiles O O 0.9596201777458191
of O O 0.9999910593032837
the O O 0.9999860525131226
three O O 0.9928921461105347
DNA B-DNA B-DNA 0.6443880200386047
regions E-DNA E-DNA 0.8736725449562073
and O O 0.9992362260818481
their O O 0.9999655485153198
ranking O O 0.9944475889205933
according O O 0.9999567270278931
to O O 0.9999523162841797
their O O 0.9998623132705688
relative O O 0.9684924483299255
affinities O O 0.986629843711853
. O O 0.9999982118606567
This O O 0.9999853372573853
result O O 0.999891996383667
, O O 0.9999954700469971
confirmed O O 0.9999850988388062
by O O 0.9999932050704956
competitions O O 0.9950249791145325
with O O 0.9999812841415405
each O O 0.9998231530189514
GATA B-DNA B-DNA 0.6516204476356506
site E-DNA E-DNA 0.9836524724960327
, O O 0.9986281394958496
demonstrated O O 0.9999839067459106
the O O 0.9999834299087524
higher O O 0.96771240234375
relative O O 0.945000410079956

lipopolysaccharide O O 0.5104246139526367
( O O 0.987773597240448
LPS O O 0.9508098363876343
) O O 0.9970859885215759
. O O 0.9999902248382568
In O O 0.9999921321868896
this O O 0.9999972581863403
study O O 0.9999043941497803
we O O 0.9999918937683105
have O O 0.9999980926513672
investigated O O 0.999992847442627
the O O 0.999983549118042
effect O O 0.9999582767486572
of O O 0.9999876022338867
FCM O O 0.5142354965209961
on O O 0.9996755123138428
the O O 0.9998248219490051

concentrations O O 0.9785512685775757
of O O 0.9999151229858398
reactive O O 0.9223787784576416
metabolites O O 0.7752397656440735
of O O 0.9996337890625
oxygen O O 0.7763913869857788
and O O 0.9940845370292664
nitrogen O O 0.8824254274368286
play O O 0.999833345413208
an O O 0.9999899864196777
important O O 0.9990854263305664
role O O 0.9993628859519958
in O O 0.9999785423278809

Postmortem O O 0.893409252166748
cytoarchitectural O O 0.8225597739219666
features O O 0.9626189470291138
identifying O O 0.9996691942214966
A1 O O 0.44800272583961487
were O O 0.9995256662368774
correlated O O 0.9999064207077026
with O O 0.9999966621398926
the O O 0.9999382495880127
electrophysiologic O O 0.8712179064750671
data O O 0.9685679078102112
. O O 0.9999982118606567

METHODS O O 0.9918121099472046
: O O 0.9999898672103882
A O O 0.9999861717224121
Phase O O 0.9964762330055237
II O O 0.9598200917243958
study O O 0.9997826218605042
of O O 0.9999586343765259
the O O 0.9999452829360962
combination O O 0.9949748516082764
of O O 0.9996029734611511
cisplatin B-Chemical B-Chemical 0.9325798749923706
plus O O 0.6997671127319336
amifostine B-Chemical B-Chemical 0.9337525367736816
was O O 0.9987069368362427
conducted O O 0.9999920129776001
in O O 0.9999933242797852
patients O O 0.9999610185623169
with O O 0.9999724626541138
progressive O O 0.8988368511199951
metastatic O O 0.7995392084121704
breast B-Disease O 0.6807903051376343
carcinoma I-Disease O 0.9445914626121521
who O O 0.9574472308158875
had O O 0.999556839466095
received O O 0.9995255470275879
one O O 0.9992244243621826
, O O 0.9998579025268555
but O O 0.9999265670776367
not O O 0.9999022483825684
more O O 0.9994286894798279
than O O 0.9999569654464722
one O O 0.9997811913490295
, O O 0.9997116923332214
chemotherapy O O 0.7518777847290039
regimen O O 0.940240204334259
for O O 0.9999066591262817
metastatic O O 0.6602085828781128
disease O O 0.9527308940887451
. O O 0.9990872144699097

T I-cell_type B-cell_type 0.38633981347084045
cells E-cell_type E-cell_type 0.8668053150177002
stimulated O O 0.9982792139053345
with O O 0.9999659061431885
CD3/CD28 S-protein S-protein 0.7838290333747864
. O O 0.9998325109481812
In O O 0.9999939203262329
this O O 0.9999934434890747
report O O 0.9998617172241211
, O O 0.9999932050704956
we O O 0.9999898672103882
demonstrate O O 0.9999949932098389
that O O 0.9999988079071045
the O O 0.9999086856842041
T O O 0.5936083197593689
cell O O 0.532362163066864
tropic O O 0.4697573781013489
strain O O 0.46837031841278076
of O O 0.9989144802093506
HIV O O 0.8277081847190857
, O O 0.9975888729095459
LAI O O 0.5468403697013855
, O O 0.995736837387085
does O O 0.9999607801437378
not O O 0.9999430179595947
replicate O O 0.9996640682220459
in O O 0.999674916267395
naive B-cell_type B-cell_type 0.5824080109596252
CD4 I-cell_type I-cell_type 0.7395928502082825
T I-cell_type I-cell_type 0.8495411276817322
cells E-cell_type E-cell_type 0.729857861995697
stimulated O O 0.998572826385498
by O O 0.9999974966049194
cross-linking O O 0.8760772347450256
CD3 S-protein S-protein 0.42812708020210266

One O O 0.9949935078620911
patient O O 0.9991381168365479
had O O 0.99989914894104
thrombotic B-Disease B-Disease 0.5649625658988953
thrombocytopenic I-Disease I-Disease 0.6052977442741394
purpura I-Disease I-Disease 0.9444208145141602
, O O 0.9775552749633789
three O O 0.9994452595710754
the O O 0.9998496770858765
hemolytic B-Disease O 0.6613096594810486
- I-Disease O 0.7990607023239136
uremic I-Disease O 0.5407193899154663
syndrome I-Disease O 0.9472976922988892
, O O 0.987466037273407
and O O 0.9999064207077026
one O O 0.9999796152114868
an O O 0.9999713897705078
apparent O O 0.9919398427009583
forme O O 0.988312304019928
fruste O O 0.8659183382987976
of O O 0.9565151333808899
one O O 0.9943899512290955
of O O 0.9998812675476074
these O O 0.9991422891616821
disorders O O 0.5475531220436096
. O O 0.9998836517333984

A O O 0.9991005659103394
lesser O O 0.9940160512924194
degree O O 0.9985803365707397
of O O 0.9999063014984131
orthostatic B-Disease O 0.5484651923179626
hypotension I-Disease O 0.5540637373924255
occurred O O 0.9869058728218079
with O O 0.9999678134918213
standing O O 0.9847678542137146
. O O 0.9999651908874512

Current O O 0.9785522818565369
protein O O 0.9610012769699097
- O O 0.9988594055175781
based O O 0.9995574355125427
technology O O 0.9989389777183533
offers O O 0.9999973773956299
a O O 0.999995231628418
new O O 0.9992015957832336
therapeutic O O 0.9922681450843811
venue O O 0.9962400197982788
by O O 0.9999970197677612
which O O 0.9999969005584717
antibodies O O 0.7241019010543823
bind O O 0.9994599223136902
the O O 0.9998273849487305
drug O O 0.9828823804855347
in O O 0.9997490048408508
the O O 0.9993288516998291
blood O O 0.9245878458023071
stream O O 0.9622644782066345
, O O 0.9999698400497437
inactivating O O 0.9983768463134766
its O O 0.9994601607322693
toxic O O 0.5306699275970459
effects O O 0.7915494441986084
. O O 0.999985933303833

In O O 0.999401330947876
addition O O 0.9998475313186646
, O O 0.9999936819076538
we O O 0.9999092817306519
performed O O 0.9999405145645142
a O O 0.9999837875366211
high O O 0.9925843477249146
- O O 0.9985357522964478
resolution O O 0.9907454252243042
3D O O 0.8798929452896118
gradient O O 0.9117798209190369
echo O O 0.9569205641746521
, O O 0.9999226331710815
T1 O O 0.7616546154022217
- O O 0.981437087059021
weighted O O 0.9848330616950989
sequences O O 0.992966890335083
at O O 0.9999986886978149
a O O 0.9999485015869141
1 O O 0.9720591306686401
- O O 0.9987486600875854
mm O O 0.9987130165100098
slice O O 0.7701108455657959
thickness O O 0.84939044713974
. O O 0.9999970197677612

line E-cell_line E-cell_line 0.9837782382965088
. O O 0.9998893737792969
The O O 0.9999984502792358
expression O O 0.9991982579231262
of O O 0.9999662637710571
major B-protein B-protein 0.6839898228645325
histocompatibility I-protein I-protein 0.520205020904541
complex I-protein I-protein 0.8918140530586243
( I-protein I-protein 0.7864589691162109
MHC I-protein I-protein 0.5064849257469177
) I-protein I-protein 0.6706259846687317
class I-protein I-protein 0.8349502086639404
II I-protein I-protein 0.5630936026573181
antigens E-protein E-protein 0.9964848756790161
is O O 0.9997594952583313
constitutive O O 0.9987494945526123
in O O 0.9999384880065918
professional B-cell_type B-cell_type 0.4837147891521454
antigen I-cell_type I-cell_type 0.7308598756790161
presenting I-cell_type I-cell_type 0.9235246181488037
cells E-cell_type E-cell_type 0.9523839354515076
( O O 0.976203203201294
APCs S-cell_type S-cell_type 0.8397056460380554
) O O 0.9886921644210815
but O O 0.9998762607574463
can O O 0.999813973903656

These O O 0.9997938275337219
results O O 0.9999370574951172
suggest O O 0.9999983310699463
that O O 0.9999961853027344
a O O 0.9998815059661865
diet O O 0.8709216117858887
comprised O O 0.9996685981750488
of O O 0.9999021291732788
alternating O O 0.8625263571739197
deprivation O O 0.7204076647758484
and O O 0.9967566132545471
access O O 0.994364857673645
to O O 0.9999158382415771
a O O 0.9998205304145813
sugar O O 0.8504303693771362
solution O O 0.958818793296814
and O O 0.9999814033508301
chow O O 0.7153635025024414
produces O O 0.9995495676994324
bingeing O O 0.6227003335952759
on O O 0.9906626343727112
sugar O O 0.5807740092277527
that O O 0.9972125887870789
leads O O 0.999866247177124
to O O 0.9999523162841797
a O O 0.9999121427536011
long O O 0.9930511713027954
lasting O O 0.9634692668914795
state O O 0.9925734996795654
of O O 0.9995325803756714
increased O O 0.9501568675041199
sensitivity O O 0.5728259086608887
to O O 0.9954816102981567
amphetamine S-Chemical B-Chemical 0.9307767748832703
, O O 0.9940576553344727
possibly O O 0.9999215602874756
due O O 0.9999971389770508
to O O 0.9999747276306152
a O O 0.9998218417167664
lasting O O 0.989834725856781
alteration O O 0.9785956740379333
in O O 0.9994584918022156
the O O 0.9992603659629822
dopamine S-Chemical B-Chemical 0.9187090992927551
system O O 0.8593379855155945
. O O 0.9999926090240479

of O O 0.9982373714447021
the O O 0.9998906850814819
adult O O 0.8465858101844788
T-cell O O 0.6294947266578674
leukemia O O 0.5840259194374084
( O O 0.9801637530326843
ATL O O 0.8470451831817627
) O O 0.9941092729568481
as O O 0.9999479055404663
well O O 0.9996809959411621
as O O 0.9999958276748657
degenerative O O 0.8466764688491821
neurologic O O 0.8348314762115479
syndrome O O 0.758826732635498
termed O O 0.999869704246521
tropical O O 0.819725513458252
spastic O O 0.731748104095459
paraparesis O O 0.5951641201972961
( O O 0.995808482170105
TSP O O 0.8433815836906433
) O O 0.9982064962387085
. O O 0.9999909400939941
HTLV-I O O 0.6024787425994873
encodes O O 0.9979593753814697
a O O 0.999947190284729
potent O O 0.9741039276123047
transactivator S-protein B-protein 0.4121650755405426
protein O E-protein 0.9618675112724304
termed O O 0.9888850450515747
Tax S-protein S-protein 0.9913797378540039
that O O 0.9992960691452026
appears O O 0.9998489618301392
to O O 0.9999582767486572
play O O 0.9999785423278809
an O O 0.9999855756759644
important O O 0.9993023872375488
role O O 0.9996597766876221
in O O 0.9999898672103882
the O O 0.9999414682388306

types O O 0.7663549184799194
. O O 0.9998500347137451
The O O 0.9999728202819824
cDNA S-DNA S-DNA 0.790233314037323
encoding O O 0.7486955523490906
hTAFII105 S-protein S-DNA 0.5867115259170532
reveals O O 0.999292254447937
a O O 0.9999622106552124
highly O O 0.9269137978553772
conserved O O 0.904977560043335
C-terminal B-protein B-protein 0.46318382024765015
domain E-protein E-protein 0.9431697130203247
shared O O 0.9949313998222351
by O O 0.9999501705169678
hTAFII130 S-protein S-protein 0.7395009994506836
and O O 0.9626280069351196
oTAFII110 S-protein S-protein 0.7883532047271729
, O O 0.9951704144477844
while O O 0.9999808073043823
the O O 0.9999443292617798
N-terminal B-protein B-protein 0.6237685680389404
coactivator I-protein I-protein 0.6727141737937927
domain E-protein E-protein 0.9889475107192993
has O O 0.9989205598831177
diverged O O 0.9997552037239075
significantly O O 0.9999642372131348
. O O 0.9999951124191284
All O O 0.9948262572288513
cells O O 0.9094817638397217
tested O O 0.9996557235717773
express O O 0.9853633642196655
TAFII105 B-RNA B-RNA 0.9192639589309692
mRNA E-RNA E-RNA 0.9890648126602173

gene I-DNA E-DNA 0.6602354645729065

role O O 0.9727766513824463
in O O 0.999981164932251
the O O 0.9999905824661255
development O O 0.9997629523277283
of O O 0.9999935626983643
the O O 0.9999265670776367
mature O O 0.6188594698905945
T-cell O O 0.25483623147010803
phenotype O O 0.38053807616233826
by O O 0.9934079647064209
functioning O O 0.9992140531539917
as O O 0.9999604225158691
'master O O 0.7351016998291016
regulators O O 0.8191781640052795
of O O 0.9929077625274658
T-cell O O 0.5957237482070923
differentiation' O O 0.6795189380645752
. O O 0.9998650550842285
A O O 0.9999215602874756
study O O 0.9998372793197632
on O O 0.9999847412109375
the O O 0.9998944997787476
circadian O O 0.8123154640197754
rhythm O O 0.7580409049987793
of O O 0.9935528039932251
glucocorticoid B-protein B-protein 0.6767822504043579
receptor E-protein E-protein 0.9847860932350159
. O O 0.9994558691978455
Circadian O O 0.8482547402381897
rhythm O O 0.7488695383071899
in O O 0.9991475343704224
glucocorticoid B-protein B-protein 0.4651219844818115
receptor E-protein E-protein 0.9674724340438843
( O O 0.974692702293396
GR S-protein S-protein 0.9546828269958496
) O O 0.9773396849632263
was O O 0.9999212026596069
studied O O 0.9999710321426392
in O O 0.9999649524688721
the O O 0.9998806715011597

Health O O 0.961112380027771
status O O 0.9726657867431641
and O O 0.9999345541000366
MHb O O 0.8136020302772522
levels O O 0.997755229473114
were O O 0.9999959468841553
monitored O O 0.9999668598175049
following O O 0.9999961853027344
exposure O O 0.9963061809539795
. O O 0.9999973773956299

and O O 0.8367411494255066
cells O O 0.6891199946403503
of O O 0.9958204030990601
the O O 0.9999312162399292
hematopoietic B-cell_type B-cell_type 0.5236544609069824
lineage E-cell_type E-cell_type 0.8425003290176392
is O O 0.9989473223686218
directed O O 0.9999569654464722
by O O 0.9999966621398926
an O O 0.9998668432235718
alternative B-DNA B-DNA 0.853628396987915
promoter E-DNA E-DNA 0.8614354729652405
which O O 0.9876903295516968
is O O 0.9999576807022095
located O O 0.9997298121452332
approximately O O 0.9996122717857361
6 B-DNA O 0.9615316390991211
kilobases I-DNA O 0.7392406463623047
( I-DNA O 0.9894782900810242
kb I-DNA O 0.781164288520813
) I-DNA O 0.8697460889816284
upstream E-DNA O 0.8306255340576172
of O O 0.9994910955429077
the O O 0.9998958110809326
pituitary-specific B-DNA B-DNA 0.4993359446525574
start I-DNA I-DNA 0.6615609526634216
site E-DNA E-DNA 0.9652700424194336
. O O 0.9997192025184631
In O O 0.999981164932251
order O O 0.9999102354049683
to O O 0.9999939203262329
delineate O O 0.9999531507492065
the O O 0.9999146461486816
tissue-specific O O 0.8484290242195129
mechanisms O O 0.962208092212677
governing O O 0.9993096590042114

Patients O O 0.9968269467353821
who O O 0.9999678134918213
develop O O 0.9995777010917664
ESRD O B-Disease 0.7197955846786499
have O O 0.9873747825622559
a O O 0.9996877908706665
higher O O 0.9967184662818909
preoperative O O 0.9493598341941833
and O O 0.9959979057312012
1 O O 0.9986989498138428
- O O 0.999659538269043
year O O 0.9996036887168884
serum O O 0.9673790335655212
creatinine S-Chemical B-Chemical 0.9215200543403625
and O O 0.9962008595466614
are O O 0.9999321699142456
more O O 0.9997360110282898
likely O O 0.9999376535415649
to O O 0.9999833106994629
have O O 0.9999574422836304
hepatorenal O O 0.4594632089138031
syndrome O O 0.970127284526825
. O O 0.9991182684898376

Stat6 S-protein S-protein 0.8221055269241333
. O O 0.9998767375946045
Both O O 0.999976396560669
cytokines S-protein S-protein 0.9782000184059143
are O O 0.999868631362915
able O O 0.9999696016311646
to O O 0.999982476234436
stimulate O O 0.9991284012794495
cell O O 0.9806004166603088
proliferation O O 0.9982115030288696
, O O 0.999935507774353
differentiation O O 0.9961806535720825
, O O 0.9994342923164368
and O O 0.9997908473014832
survival O O 0.9980941414833069
. O O 0.9999969005584717
We O O 0.9999722242355347
investigated O O 0.999983549118042
the O O 0.9999738931655884
transactivation O O 0.9292141199111938
potential O O 0.9885494112968445
of O O 0.999914288520813
Stat6 S-protein S-protein 0.992020308971405
and O O 0.997238278388977
found O O 0.9999582767486572
that O O 0.9999816417694092
it O O 0.9997835755348206
is O O 0.9999699592590332
not O O 0.9996590614318848
restricted O O 0.9975053668022156

CD3-epsilon B-DNA S-protein 0.42429643869400024

Experiments O O 0.9981630444526672
with O O 0.9999926090240479
systemic O O 0.9794021844863892
administration O O 0.9797869920730591
of O O 0.9995942711830139
the O O 0.9998202919960022
Pgp O O 0.603855550289154
substrate O O 0.6506397724151611
phenobarbital S-Chemical B-Chemical 0.906743049621582
and O O 0.9783560633659363
the O O 0.9998875856399536
selective O O 0.973071277141571
Pgp O O 0.7680704593658447
inhibitor O O 0.8611699938774109
tariquidar S-Chemical B-Chemical 0.9117249250411987
in O O 0.9926405549049377
TR O O 0.3103652596473694
( O O 0.7733746767044067
- O O 0.804634153842926
) O O 0.9178942441940308
rats O O 0.9917342662811279
substantiated O O 0.9998456239700317
that O O 0.9999881982803345
Pgp O O 0.6434566378593445
is O O 0.9907035827636719
functional O O 0.994434654712677
and O O 0.9998263716697693
compensates O O 0.9999498128890991
for O O 0.9999794960021973
the O O 0.9999827146530151
lack O O 0.9966089725494385
of O O 0.9998239874839783
MRP2 O O 0.4232740104198456
in O O 0.9985191226005554
the O O 0.9998795986175537
BBB O O 0.6820704340934753
. O O 0.9994970560073853

Furthermore O O 0.9994567036628723
, O O 0.9999958276748657
the O O 0.9999713897705078
PA O O 0.9562659859657288
-and O O 0.9996379613876343
the O O 0.9999406337738037
anti-CD3 S-protein S-protein 0.9548834562301636
-induced O O 0.9956823587417603
increases O O 0.9930586814880371
in O O 0.9996546506881714
AP-1 B-DNA B-DNA 0.684502124786377
enhancer E-DNA E-DNA 0.9549912810325623
activity O O 0.964094340801239
were O O 0.9999842643737793
blocked O O 0.9998359680175781
by O O 0.9999969005584717
the O O 0.9999526739120483
presence O O 0.9929487705230713

degradation O O 0.9430602788925171
rate O O 0.999657392501831
of O O 0.999761164188385
ER B-RNA B-RNA 0.9675617218017578
mRNA E-RNA E-RNA 0.9980415105819702
in O O 0.999119222164154
monocytes S-cell_type S-cell_type 0.9790105819702148
. O O 0.999890923500061
3. O O 0.9939953684806824
Danazol O O 0.8581770658493042
decreased O O 0.9992679953575134

Liver B-Disease O 0.8222892880439758
enlargement I-Disease O 0.49227407574653625
and O O 0.998019814491272
muscle B-Disease O 0.655479907989502
wastage I-Disease O 0.9259747266769409
occurred O O 0.9745470881462097
in O O 0.9997561573982239
Wistar O O 0.8225210309028625
rats O O 0.9937585592269897
following O O 0.9999977350234985
the O O 0.9999926090240479
subcutaneous O O 0.9530943036079407
administration O O 0.9933423399925232
of O O 0.9995299577713013
prednisolone B-Chemical B-Chemical 0.9202451705932617
. O O 0.9992891550064087

site O O 0.6186177134513855
of O O 0.9981155395507812
one O O 0.9953359961509705
or O O 0.9997312426567078
more O O 0.9996985197067261
genes O O 0.5555858612060547
, O O 0.9976813793182373
loss O O 0.9667374491691589
or O O 0.9983006119728088
inactivation O O 0.9933711290359497
of O O 0.9997656941413879
which O O 0.9999163150787354
plays O O 0.9998248219490051
a O O 0.9999890327453613
role O O 0.9997243285179138
in O O 0.9999881982803345
the O O 0.9999605417251587
regulation O O 0.9993775486946106
of O O 0.9999595880508423
normal B-cell_type B-cell_type 0.47495555877685547
hematopoietic I-cell_type I-cell_type 0.7145809531211853
progenitors E-cell_type E-cell_type 0.9831720590591431
. O O 0.999580442905426
We O O 0.9999798536300659
have O O 0.9999927282333374
recently O O 0.9999641180038452
performed O O 0.9999858140945435
a O O 0.9999909400939941
detailed O O 0.9887169599533081
molecular O O 0.9855591058731079
analysis O O 0.9992678761482239
of O O 0.9999821186065674
20q B-DNA B-DNA 0.2755591571331024
deletions E-DNA E-DNA 0.818010151386261
in O O 0.9993104934692383
peripheral B-cell_type B-cell_type 0.9020515084266663

women O O 0.9798054099082947
, O O 0.9999079704284668
women O O 0.999749481678009
with O O 0.9999880790710449
threatened O O 0.9753831028938293
pre-term O O 0.8931575417518616
delivery O O 0.9759756326675415
, O O 0.9999078512191772
and O O 0.99994957447052
men O O 0.9966300129890442
showed O O 0.9999943971633911
equivalent O O 0.9871066212654114
levels O O 0.999833345413208
: O O 0.9999862909317017
3 O O 0.9973847270011902
+/- O O 0.9998441934585571
1 O O 0.998813271522522
, O O 0.9998747110366821
3 O O 0.9990732669830322
+/- O O 0.9997665286064148
2 O O 0.9972200393676758
and O O 0.9998119473457336

after O O 0.9983159303665161
RNA O O 0.670434832572937
extraction O O 0.9977129697799683
using O O 0.9999325275421143
RNAzol O O 0.3729577660560608
and O O 0.9752064347267151
analysed O O 0.996040940284729
after O O 0.9999228715896606
reverse B-protein B-protein 0.8494147062301636
transcriptase E-protein E-protein 0.8491986989974976
, O O 0.9990399479866028
by O O 0.9999667406082153
polymerase O O 0.8549723029136658
chain O O 0.8668642640113831
reaction O O 0.994424045085907
using O O 0.9999881982803345
a O O 0.999923586845398
semiquantitative O O 0.8606577515602112
competitive O O 0.8842146396636963
hybridization O O 0.9181193113327026
assay O O 0.9976028800010681
. O O 0.9999982118606567
All O O 0.9998353719711304
asthmatic O O 0.8242278099060059
patients O O 0.9936830997467041
showed O O 0.9999977350234985
an O O 0.9999879598617554
improvement O O 0.9993108510971069
in O O 0.999908447265625
their O O 0.9997921586036682
FEV1 O S-protein 0.6132944822311401
values O O 0.693230926990509
after O O 0.9999808073043823
corticosteroid O O 0.8981794714927673
treatment O O 0.9963853359222412
( O O 0.9999926090240479
per O O 0.9996798038482666
cent O O 0.9996045231819153
of O O 0.9999469518661499
predicted O O 0.9714744687080383
value O O 0.9832010865211487
68.28 O O 0.995468258857727
+/- O O 0.9999357461929321
4.93 O O 0.9996672868728638
versus O O 0.9999873638153076
95.57 O O 0.9965850114822388
+/- O O 0.9999600648880005
6.41 O O 0.9998297691345215
, O O 0.9999746084213257
P O O 0.9993591904640198
< O O 0.9999340772628784
0.02 O O 0.9996077418327332
) O O 0.9998561143875122
, O O 0.9999895095825195

studied O O 0.9882538318634033
, O O 0.9998849630355835
as O O 0.9999442100524902
well O O 0.9997528195381165
as O O 0.9999938011169434
the O O 0.9999734163284302
involvement O O 0.9999632835388184
of O O 0.9999920129776001
several O O 0.9954700469970703
oncogenes S-DNA S-DNA 0.9081882834434509
in O O 0.9995092153549194
glucocorticoid-induced O O 0.7485777735710144
cell O O 0.7073338627815247
lysis O O 0.932378888130188
. O O 0.9999932050704956
In O O 0.9999849796295166
addition O O 0.9999322891235352
, O O 0.9999973773956299
the O O 0.999984622001648
clinical O O 0.9906193017959595
importance O O 0.9997707009315491
of O O 0.9999932050704956
glucocorticoid-induced O O 0.8839085698127747
apoptosis O O 0.9702098369598389
in O O 0.9999693632125854
the O O 0.9999213218688965
treatment O O 0.9990339279174805
of O O 0.9999841451644897
lymphoid O O 0.4879360795021057
neoplasms O O 0.35015830397605896
has O O 0.9993160963058472
recently O O 0.9999551773071289
received O O 0.9999775886535645
increased O O 0.997641921043396

ZEBRA S-protein S-protein 0.9348748922348022
's O O 0.9964854717254639
ability O O 0.9997175335884094
to O O 0.9999803304672241
induce O O 0.999954104423523
early B-protein O 0.9252949953079224
antigen E-protein O 0.7481222748756409
and O O 0.9906443357467651
to O O 0.9998644590377808
stimulate O O 0.9976568222045898
origin O O 0.666701078414917
replication O O 0.9859219193458557
to O O 0.9998983144760132
levels O O 0.999562680721283
that O O 0.9999866485595703
were O O 0.9999774694442749
equal O O 0.9994508624076843
to O O 0.9998266100883484
or O O 0.998615026473999
greater O O 0.9997326731681824
than O O 0.9999544620513916
those O O 0.9999572038650513
of O O 0.9999433755874634
wild O O 0.6775439381599426
type O O 0.4623657166957855
. O O 0.9991901516914368
These O O 0.9999963045120239
studies O O 0.999936580657959
suggest O O 0.9999969005584717
that O O 0.9999904632568359

Polymyxin O B-protein 0.48143234848976135
B O E-protein 0.9590551257133484
abrogated O O 0.9969720840454102
only O O 0.9999406337738037
the O O 0.9999717473983765
response O O 0.9979621171951294
to O O 0.9999375343322754
LPS O O 0.9491668939590454
. O O 0.9999246597290039
By O O 0.9998615980148315
using O O 0.9979833364486694
70Z/3-derived B-cell_line B-cell_line 0.5593560338020325
pre-B-cell I-cell_line I-cell_line 0.6920376420021057
lines E-cell_line E-cell_line 0.9975422620773315
either O O 0.9994639754295349
lacking O O 0.9989734888076782
or O O 0.9989925026893616
expressing O O 0.9920543432235718

BACKGROUND O O 0.9784377813339233
: O O 0.9998252987861633
Glioblastoma B-Disease O 0.8675505518913269
is O O 0.9895463585853577
a O O 0.9995380640029907
malignant B-Disease O 0.529961347579956
tumor I-Disease B-Disease 0.6663193106651306
that O O 0.9405633211135864
occurs O O 0.99700528383255
in O O 0.9998390674591064
the O O 0.999605119228363
cerebrum O O 0.4870673418045044
during O O 0.999043881893158
adulthood O O 0.8622333407402039
. O O 0.9999909400939941

These O O 0.9997350573539734
results O O 0.9999077320098877
suggest O O 0.9999978542327881
that O O 0.999990701675415
antithrombosis O O 0.7871767282485962
of O O 0.8943266868591309
TET S-Chemical B-Chemical 0.9246177077293396
and O O 0.9679096937179565
FAN S-Chemical B-Chemical 0.9165797233581543
in O O 0.997885525226593
mice O O 0.9983106851577759
may O O 0.9999964237213135
be O O 0.9999943971633911
mainly O O 0.9998396635055542
related O O 0.9999761581420898
to O O 0.9999904632568359
the O O 0.9998639822006226
antiplatelet O O 0.831146240234375
aggregation O O 0.919264018535614
activities O O 0.9988677501678467
. O O 0.9999992847442627

Recurrent O O 0.9701352119445801
acute O O 0.8110515475273132
interstitial B-Disease O 0.5468616485595703
nephritis I-Disease O 0.5667588710784912
induced O O 0.9282618761062622
by O O 0.9994097948074341
azithromycin B-Chemical B-Chemical 0.9273819923400879
. O O 0.9992246627807617

multifactorial O O 0.8401891589164734
process O O 0.9648880958557129
affecting O O 0.9999661445617676
several O O 0.9979438185691833
transcription B-protein B-protein 0.5004215240478516
factors E-protein E-protein 0.9905739426612854
that O O 0.9995903372764587
control O O 0.9998539686203003
the O O 0.9998216032981873
cell-specific O O 0.9320927262306213
and O O 0.9826379418373108
developmental O O 0.9839942455291748
activity O O 0.9987229704856873
of O O 0.9999779462814331
the O O 0.9996697902679443
enhancer S-DNA S-DNA 0.94941645860672
. O O 0.9997945427894592
Activation O O 0.9975437521934509
of O O 0.9998793601989746
the O O 0.9998846054077148
NF-kappaB S-protein S-protein 0.9671294093132019
transcription B-protein B-protein 0.7134782671928406
factor E-protein E-protein 0.9003815054893494
in O O 0.9979656934738159
a O O 0.9996429681777954
T-lymphocytic B-cell_line B-cell_line 0.6782019734382629
cell I-cell_line I-cell_line 0.8652583360671997
line E-cell_line E-cell_line 0.9911706447601318
by O O 0.999830961227417
hypochlorous O O 0.9057079553604126
acid O O 0.9416307806968689
. O O 0.9999022483825684
Reactive O O 0.9332848787307739
oxygen O O 0.8435077667236328
species O O 0.8654251098632812
( O O 0.9992161989212036
ROS O O 0.8833801746368408

Clonidine S-Chemical B-Chemical 0.9239649176597595
for O O 0.9974669218063354
attention O O 0.8816583752632141
- O O 0.9466695189476013
deficit O O 0.5398813486099243
/ O O 0.9682778120040894
hyperactivity O B-Disease 0.8619691729545593
disorder O I-Disease 0.9861652851104736
: O O 0.9282765984535217
II O O 0.4233948588371277
. O O 0.9998935461044312

Of O O 0.9998408555984497
20 O O 0.9994308352470398
patients O O 0.9994764924049377
evaluable O O 0.9999356269836426
for O O 0.9998724460601807
toxicity O B-Disease 0.9802621603012085
, O O 0.9912328124046326
four O O 0.9989590644836426
had O O 0.9998101592063904
stage O O 0.9703734517097473
III O O 0.4119985103607178
and O O 0.9979274272918701
16 O O 0.9813352823257446
had O O 0.9994485974311829
stage O O 0.9529733657836914
IV O O 0.5183187127113342
disease O O 0.8833090662956238
. O O 0.999703586101532

NF-kappaB-like B-DNA B-DNA 0.33368220925331116
site E-DNA E-DNA 0.9456047415733337
at O O 0.9997304081916809
-20 O B-DNA 0.5628734827041626
to O I-DNA 0.5969491600990295
-10 O E-DNA 0.8703919053077698
had O O 0.9970942735671997
no O O 0.9999412298202515
effect O O 0.9998243451118469
. O O 0.9999947547912598
Nuclear O O 0.9571472406387329
extracts O O 0.9899755120277405
from O O 0.9998658895492554
LPS O O 0.5581479668617249
-and O O 0.9634448289871216
zymosan-treated B-cell_type B-cell_line 0.43637800216674805
cells E-cell_type E-cell_line 0.71632981300354

. O O 0.9955184459686279
Electrophoretic O O 0.9587786197662354
mobility-shift O O 0.9576252698898315
assays O O 0.9987481832504272
of O O 0.999981164932251
HUVEC S-cell_line B-protein 0.23619888722896576
nuclear B-protein I-protein 0.698904812335968
proteins E-protein E-protein 0.9944109320640564
revealed O O 0.9996829032897949
a O O 0.9999910593032837
decrease O O 0.9958964586257935
in O O 0.9997879862785339
TNF-alpha-stimulated B-protein B-protein 0.5815052390098572
nuclear I-protein I-protein 0.6064676642417908
factor-kappa I-protein I-protein 0.4457128047943115
B E-protein E-protein 0.9620627760887146
( O O 0.9777511358261108
NF-kappa B-protein B-protein 0.5647451281547546
B E-protein E-protein 0.9794020652770996
) O O 0.9459285736083984
activation O O 0.9945701956748962
after O O 0.999993085861206
pretreatment O O 0.9984586238861084
of O O 0.9999315738677979
HUVEC S-cell_line S-cell_line 0.7098459005355835
with O O 0.994586706161499
TCP O O 0.40064769983291626
succinate O O 0.7742463946342468
but O O 0.9972943663597107
not O O 0.9998691082000732
with O O 0.9998424053192139
TCP O O 0.4762134850025177
, O O 0.9987492561340332
TCP O O 0.6215927004814148
acetate O O 0.5636342763900757
, O O 0.9908137917518616

, O O 0.9954439401626587
the O O 0.9999874830245972
inducible O O 0.9742257595062256
degradation O O 0.9897581338882446
of O O 0.9999071359634399
p105 S-protein S-protein 0.8904153108596802
is O O 0.9989196062088013
not O O 0.9999500513076782
coupled O O 0.9999688863754272
with O O 0.999995231628418
the O O 0.9999676942825317
generation O O 0.9947255253791809
of O O 0.9994595646858215
p50 S-protein S-protein 0.8636124730110168
. O O 0.9789436459541321
Together O O 0.9999548196792603
, O O 0.9999456405639648

OBJECTIVE O O 0.8661623001098633
: O O 0.9983261227607727
to O O 0.9999434947967529
analyze O O 0.9999520778656006
aspects O O 0.9999430179595947
of O O 0.9999759197235107
TEE O O 0.4913640320301056
safety O O 0.5820406675338745
associated O O 0.9929684996604919
to O O 0.9999262094497681
the O O 0.9996906518936157
use O O 0.9997045397758484
of O O 0.9998360872268677
Midazolan B-Chemical B-Chemical 0.9224981665611267
( O O 0.9098944664001465
MZ B-Chemical B-Chemical 0.9163654446601868
) O O 0.7310733795166016
and O O 0.9992080330848694
Flumazenil B-Chemical B-Chemical 0.9297581315040588
( O O 0.9367127418518066
FL B-Chemical B-Chemical 0.9056147336959839
) O O 0.9215729832649231
and O O 0.9998999834060669
the O O 0.9999703168869019
influence O O 0.9940284490585327
of O O 0.9998432397842407
the O O 0.9999678134918213
clinical O O 0.9524723887443542
variables O O 0.9869006276130676
on O O 0.9999849796295166
the O O 0.9999300241470337
event O O 0.9828646183013916
rate O O 0.9997344613075256
. O O 0.999998927116394

significant O O 0.9844233393669128
correlations O O 0.9914290308952332
were O O 0.9999798536300659
observed O O 0.9999619722366333
for O O 0.9999750852584839
FECa2+ O S-protein 0.6928153038024902
in O O 0.9995540976524353
the O O 0.9999144077301025
dense O O 0.7966345548629761
tubules O O 0.7288655638694763
with O O 0.9998966455459595
: O O 0.9996975660324097
1 O O 0.9989066123962402
) O O 0.9994168281555176
the O O 0.9999849796295166
maximal O O 0.9440010786056519
reaction O O 0.9531258940696716
velocity O O 0.9448213577270508
( O O 0.9998078942298889
Vmax O O 0.564395546913147
) O O 0.9929931163787842
of O O 0.999889612197876
the O O 0.9999520778656006
SERCA S-protein O 0.421816885471344
( O O 0.9422249794006348
r O O 0.9758544564247131
= O O 0.9984416365623474
0.592 O O 0.9782935380935669
, O O 0.9997403025627136

compared O O 0.997053861618042
for O O 0.9999912977218628
their O O 0.9999655485153198
ability O O 0.9997350573539734
to O O 0.9999736547470093
retard O O 0.9998751878738403
the O O 0.9999202489852905
migration O O 0.9955089092254639
of O O 0.9999181032180786
radiolabeled O O 0.5185851454734802
double O O 0.6506912708282471
stranded O O 0.6430139541625977
oligomers O O 0.47484710812568665
representative O O 0.81005859375
of O O 0.996760904788971
the O O 0.9998249411582947
VDREs S-DNA S-DNA 0.7703949809074402
of O O 0.9894060492515564
the O O 0.999342143535614
human B-DNA B-protein 0.35444799065589905
osteocalcin I-DNA E-protein 0.528878927230835
and I-DNA O 0.7241510152816772

The O O 0.9989497065544128
hypotensive O B-Disease 0.9658346176147461
drug O O 0.806634247303009
was O O 0.986169695854187
discontinued O O 0.9986390471458435
at O O 0.9999985694885254
the O O 0.9999922513961792
completion O O 0.9998537302017212
of O O 0.9999953508377075
the O O 0.999982476234436
operative O O 0.9869768023490906
procedure O O 0.9978592991828918
. O O 0.9999994039535522

very O O 0.9376814365386963

DNA O B-DNA 0.6347845792770386
fragment O E-DNA 0.8467381000518799
, O O 0.9974895715713501
there O O 0.9999845027923584
were O O 0.9999912977218628
two O O 0.9985023736953735
novel O O 0.941209614276886
9-bp O B-DNA 0.46066051721572876
motifs O E-DNA 0.97065269947052
( O O 0.9946922659873962
-90/-82 O B-DNA 0.5699551105499268
and O I-DNA 0.7865015864372253
-40/-32 O E-DNA 0.8378489017486572
) O O 0.8912842869758606
with O O 0.9998950958251953
high O O 0.9061256647109985
homology O O 0.8335539102554321
to O O 0.999799907207489
the O O 0.999756395816803
nuclear B-DNA B-DNA 0.6910274624824524
factor-IL6 I-DNA I-DNA 0.3650710880756378
( I-DNA I-DNA 0.5717322826385498
NF-IL6 I-DNA I-DNA 0.6502655744552612
) I-DNA I-DNA 0.7353698015213013
binding I-DNA I-DNA 0.8161948919296265
site E-DNA E-DNA 0.9721631407737732
. O O 0.9995111227035522
Site-directed O O 0.9236173033714294
mutagenesis O O 0.9434929490089417

growth O O 0.9685099124908447
. O O 0.9999821186065674
This O O 0.999988317489624
finding O O 0.9998538494110107
indicates O O 0.9999974966049194
that O O 0.9999964237213135
L. O O 0.9246286153793335
pneumophila O O 0.9122454524040222
RpoS S-protein S-protein 0.6574599742889404
is O O 0.9997095465660095
not O O 0.9999376535415649
required O O 0.9999638795852661
for O O 0.9999938011169434
a O O 0.9999368190765381
stationary-phase-dependent O O 0.889400064945221
resistance O O 0.9786708950996399
to O O 0.9998600482940674
stress O O 0.9818835258483887
. O O 0.9999953508377075
Although O O 0.9999967813491821
the O O 0.9999728202819824
mutant O O 0.8692370653152466
strain O O 0.9248300194740295
was O O 0.9999538660049438
able O O 0.9999823570251465
to O O 0.9999575614929199
kill O O 0.9906954765319824
HL-60- B-cell_type B-cell_line 0.5064643025398254
and I-cell_type I-cell_line 0.4288797676563263
THP-1-derived I-cell_type I-cell_line 0.7410089373588562
macrophages E-cell_type E-cell_line 0.8773062229156494
, O O 0.9997372031211853
it O O 0.999983549118042
could O O 0.999996542930603
not O O 0.9999853372573853
replicate O O 0.9999195337295532
within O O 0.9999788999557495
a O O 0.9999669790267944
protozoan O O 0.6099640727043152
host O O 0.5542362332344055
, O O 0.9994785189628601
Acanthamoeba O O 0.9546806812286377
castellanii O O 0.9609798192977905

in O O 0.9980742931365967
the O O 0.9999332427978516
activation O O 0.9567669034004211
pathways O O 0.9928816556930542
of O O 0.999964714050293
neutrophils S-cell_type S-cell_type 0.986143946647644
. O O 0.9999077320098877
The O O 0.9999371767044067
p65 B-protein B-protein 0.6428420543670654
subunit E-protein E-protein 0.9638770222663879
of O O 0.9937545657157898
NF-kappa B-protein B-protein 0.8619553446769714
B E-protein E-protein 0.9903202652931213
regulates O O 0.994729220867157
I B-protein B-protein 0.6890177726745605
kappa I-protein I-protein 0.9238475561141968
B E-protein E-protein 0.9789639711380005
by O O 0.9992941617965698
two O O 0.9975374937057495
distinct O O 0.9920456409454346
mechanisms O O 0.9944421648979187
. O O 0.9999946355819702
Transcription O B-protein 0.6646983027458191
factor O E-protein 0.8162856698036194
NF-kappa B-protein B-protein 0.49413496255874634
B E-protein E-protein 0.9909424185752869
( O O 0.9844458699226379
p50/p65 S-protein S-protein 0.9611588716506958
) O O 0.6683569550514221
is O O 0.9996850490570068
generally O O 0.999799907207489
localized O O 0.998907208442688
to O O 0.9999895095825195
the O O 0.9998691082000732
cytoplasm O O 0.6637638807296753
by O O 0.9993892908096313
its O O 0.9999158382415771
inhibitor O O 0.9291710257530212
I B-protein B-protein 0.7460048198699951
kappa I-protein I-protein 0.9452863335609436
B E-protein E-protein 0.9348809123039246
. O O 0.9942387342453003
Overproduced O O 0.9793838858604431
I B-protein B-protein 0.7871043086051941
kappa I-protein I-protein 0.9589473009109497
B E-protein E-protein 0.8828389048576355
, O O 0.9559080004692078
free O O 0.9925276041030884
from O O 0.9993934631347656
NF-kappa B-protein B-protein 0.7029792666435242
B E-protein E-protein 0.895164430141449
, O O 0.9698746800422668

exhibited O O 0.9953363537788391
a O O 0.9999668598175049
greater O O 0.9989665746688843
than O O 0.9997346997261047
threefold O O 0.9812852144241333
increase O O 0.9971469044685364
in O O 0.9997797608375549
steady O O 0.947062075138092
state O O 0.9607875347137451
levels O O 0.997740626335144
of O O 0.9999147653579712
IFN-gamma-induced B-RNA B-RNA 0.8040350079536438
mRNA E-RNA E-RNA 0.9939654469490051
for O O 0.9990788698196411
the O O 0.9999804496765137
high B-protein O 0.9531632661819458
affinity I-protein O 0.8398494124412537
Fc I-protein B-protein 0.45099687576293945
gammaRI I-protein I-protein 0.48185139894485474
receptor E-protein E-protein 0.9726862907409668
. O O 0.9989045858383179
By O O 0.9998924732208252
electrophoretic O O 0.8700836896896362
mobility O O 0.9338772296905518
shift O O 0.9919271469116211
assays O O 0.9981293082237244
, O O 0.999992847442627
this O O 0.9999858140945435

The O O 0.9988284707069397
expression O O 0.9936664700508118
and O O 0.9993769526481628
binding O O 0.966972827911377
activity O O 0.9947848916053772
of O O 0.9999552965164185
the O O 0.9996516704559326
Nfil3 B-protein B-protein 0.5428555011749268
protein E-protein E-protein 0.9752674698829651
( O O 0.9815248250961304
also O O 0.9946528673171997
called O O 0.9985610842704773
E4bp4 S-protein S-protein 0.9838821887969971
) O O 0.9803295135498047
, O O 0.9997377991676331
but O O 0.9998488426208496

factor I-protein I-protein 0.28221315145492554
1 I-protein I-protein 0.8963153958320618
( I-protein I-protein 0.8278693556785583
ATF-1 I-protein I-protein 0.6015403866767883
) I-protein I-protein 0.47852635383605957
family E-protein E-protein 0.9534536004066467
of O O 0.9871211647987366
transcription B-protein B-protein 0.5915428996086121
factors E-protein E-protein 0.9952965378761292
bind O O 0.9941524863243103
three O O 0.9969426989555359
21-bp B-DNA B-DNA 0.548429012298584

assay O O 0.850607693195343

The O O 0.9996452331542969
rate O O 0.9998723268508911
- O O 0.9999145269393921
limiting O O 0.9925923347473145
constituent O O 0.9897951483726501
of O O 0.9993701577186584
collecting O O 0.9757444858551025
duct O O 0.9506633877754211
sodium S-Chemical B-Chemical 0.9272878170013428
transport O O 0.9104242324829102
is O O 0.9999961853027344
the O O 0.9999901056289673
epithelial O O 0.7324444055557251
sodium S-Chemical B-Chemical 0.8695526123046875
channel O O 0.8013314008712769
( O O 0.9998592138290405
ENaC O O 0.8454787135124207
) O O 0.9995490908622742
. O O 0.9999974966049194

Systemic O O 0.7556843757629395
cocaine B-Chemical B-Chemical 0.9155201315879822
( O O 0.9951367974281311
10 O O 0.9992455244064331
mg O O 0.9994750618934631
/ O O 0.9999781847000122
kg O O 0.9989939332008362
) O O 0.9996517896652222
significantly O O 0.9999560117721558
increased O O 0.9966604709625244
the O O 0.9989120960235596
locomotor O O 0.8922972679138184
activity O O 0.8575482964515686
of O O 0.997174859046936
rats O O 0.960289716720581
. O O 0.9999878406524658

might O O 0.9941429495811462
belong O O 0.9999765157699585
to O O 0.999993085861206
the O O 0.9999395608901978
immediate/early B-DNA B-DNA 0.44413843750953674
gene I-DNA I-DNA 0.44273078441619873
family E-DNA E-DNA 0.6205607056617737
, O O 0.9568493366241455
which O O 0.9998832941055298
controls O O 0.9998980760574341
the O O 0.9999237060546875
signal O O 0.7636426091194153
transduction O O 0.6036688089370728
cascade O O 0.563779354095459
downstream O O 0.8261324167251587
of O O 0.9987150430679321
the O O 0.9999071359634399
TCR S-protein S-protein 0.6779877543449402
. O O 0.9964751601219177
As O O 0.9999693632125854
the O O 0.9998928308486938
expression O O 0.9748857021331787
level O O 0.9980188608169556
of O O 0.9999288320541382
the O O 0.9998695850372314
RP1 B-DNA B-DNA 0.37692227959632874
gene E-DNA E-DNA 0.9668589234352112
in O O 0.9961497783660889
activated B-cell_type B-cell_type 0.504991888999939
T I-cell_type I-cell_type 0.5253734588623047
cells E-cell_type E-cell_type 0.9229514598846436
and O O 0.9967175126075745
a O O 0.9997981190681458
spectrum O O 0.9891757369041443
of O O 0.9993821382522583
tumor-derived B-cell_line B-protein 0.3490021526813507

A O O 0.9988738894462585
few O O 0.9999831914901733
minutes O O 0.9999382495880127
after O O 0.9999959468841553
administration O O 0.9990467429161072
of O O 0.9999567270278931
the O O 0.9998584985733032
drugs O O 0.9845789670944214
, O O 0.9999223947525024
they O O 0.9999295473098755
presented O O 0.9998183846473694
urticaria B-Disease B-Disease 0.9172386527061462
( O O 0.9110069274902344
patients O O 0.9938374161720276
1 O O 0.9984867572784424
and O O 0.9994644522666931
2 O O 0.9891616106033325
) O O 0.9989650249481201
and O O 0.9999293088912964
conjunctivitis B-Disease B-Disease 0.9664427638053894
( O O 0.9688623547554016
patient O O 0.9027348160743713
1 O O 0.9641584157943726
) O O 0.9974104762077332
. O O 0.9999960660934448

Whatever O O 0.9990295171737671
was O O 0.9999626874923706
the O O 0.9999791383743286
dose O O 0.9996157884597778
, O O 0.9999961853027344
the O O 0.9999822378158569
central O O 0.9850660562515259
administration O O 0.9971574544906616
of O O 0.9998824596405029
U B-Chemical B-Chemical 0.9313284754753113
- I-Chemical I-Chemical 0.9840003848075867
II E-Chemical I-Chemical 0.9364975094795227
had O O 0.9970013499259949
no O O 0.999923825263977
effect O O 0.9989227652549744
on O O 0.9999817609786987
body O O 0.9881107807159424
temperature O O 0.8598585724830627
, O O 0.9998036026954651
nociception O O 0.8357231616973877
, O O 0.9834364652633667
apomorphine S-Chemical B-Chemical 0.9246087074279785
- O O 0.9458360075950623
induced O O 0.9982981085777283
penile O O 0.5931888222694397
erection O O 0.9262924194335938
and O O 0.9338089227676392
climbing O O 0.573674201965332
behavior O O 0.7549065947532654
, O O 0.9928030371665955
and O O 0.9998792409896851
stress O O 0.518056333065033
- O O 0.9694622159004211
induced O O 0.995422899723053
plasma O O 0.673461377620697
corticosterone S-Chemical B-Chemical 0.9393004775047302
level O O 0.9912676215171814
. O O 0.9999939203262329

This O O 0.999485969543457
view O O 0.9992412328720093
supports O O 0.9999866485595703
the O O 0.9999790191650391
contention O O 0.999863862991333
that O O 0.9999969005584717
the O O 0.9995195865631104
liver O O 0.8610793352127075
and O O 0.9821392893791199
muscle O O 0.7523308396339417
are O O 0.9992769360542297
independent O O 0.9865584969520569
sites O O 0.998487114906311
of O O 0.9999662637710571
prednisolone B-Chemical B-Chemical 0.881964921951294
action O O 0.867189347743988
. O O 0.9999936819076538

[ O O 0.9740385413169861
Nat O O 0.39047929644584656
. O O 0.9980927109718323
Neurosci O O 0.6783427596092224
. O O 0.9976701140403748
9 O O 0.9708648324012756
( O O 0.9998767375946045
2006 O O 0.9939162135124207
) O O 0.9985874891281128
, O O 0.9999475479125977
917 O O 0.8798497319221497
] O O 0.9978644251823425
recently O O 0.9999384880065918
identified O O 0.9999849796295166
the O O 0.9999788999557495
microglial O O 0.628762423992157
- O O 0.9742845892906189
specific O O 0.9944239258766174
fractalkine O B-Chemical 0.9267672896385193
receptor O O 0.43069174885749817
( O O 0.9892003536224365
CX3CR1 O O 0.536690354347229
) O O 0.9963310360908508
as O O 0.9999969005584717
an O O 0.9999946355819702
important O O 0.9993298053741455
mediator O O 0.9978612065315247
of O O 0.9998968839645386
MPTP S-Chemical B-Chemical 0.9006218314170837
- O O 0.9738425612449646
induced O O 0.9975898265838623
neurodegeneration O O 0.773983895778656
of O O 0.8674189448356628
DA S-Chemical O 0.7918450236320496
neurons O O 0.4508983790874481
. O O 0.9998936653137207

IL-13 S-protein S-protein 0.7740508317947388

protein I-protein E-protein 0.7384864687919617

of O O 0.997214138507843
RU O O 0.3950202465057373
486 O O 0.2832048535346985
with O O 0.9870784282684326
dexamethasone O O 0.88104647397995
. O O 0.9995942711830139
Thus O O 0.9990941286087036
, O O 0.9999675750732422
the O O 0.9999761581420898
glucocorticoid-induced O O 0.8170583248138428
membrane O O 0.6530197858810425
perturbation O O 0.8697017431259155
, O O 0.9998788833618164
the O O 0.9999949932098389
possibility O O 0.9997953772544861
to O O 0.999990701675415
inhibit O O 0.9999455213546753
it O O 0.9982200264930725
by O O 0.9999887943267822
RU O O 0.7528426647186279
486 O O 0.5677840113639832
, O O 0.9917518496513367
and O O 0.9999099969863892
the O O 0.9999864101409912
inactivity O O 0.9952056407928467
of O O 0.9999254941940308
the O O 0.9998267292976379

When O O 0.9993401169776917
drugs O O 0.9848217368125916
disappear O O 0.9926655888557434
from O O 0.9999743700027466
the O O 0.9994081258773804
patient O O 0.9982923865318298
: O O 0.9999908208847046
elimination O O 0.9607847929000854
of O O 0.9994207620620728
intravenous O O 0.6507228016853333
medication O O 0.6694576740264893
by O O 0.9982030391693115
hemodiafiltration O O 0.5332438945770264
. O O 0.9997734427452087

, I-protein I-protein 0.8781245350837708
000 I-protein I-protein 0.6812889575958252
protein E-protein E-protein 0.9622595310211182
. O O 0.9989632368087769
Cloning O O 0.9589413404464722
of O O 0.9986059069633484
the O O 0.9997615218162537
cDNA S-DNA S-DNA 0.8987604975700378
encoding O O 0.8297877311706543
human B-protein B-protein 0.4557889699935913
SR-BP E-protein E-protein 0.8165234923362732
shows O O 0.998127281665802
an O O 0.9999908208847046
open B-DNA B-DNA 0.793370246887207
reading I-DNA I-DNA 0.532280445098877
frame E-DNA E-DNA 0.9434223771095276
for O O 0.9991937279701233
a O O 0.9998917579650879
223-amino B-protein B-protein 0.4944613575935364
acid I-protein I-protein 0.8709610104560852
protein E-protein E-protein 0.9822577834129333
, O O 0.9909268617630005
which O O 0.999932050704956
is O O 0.9999741315841675
homologous O O 0.9633736610412598
to O O 0.9994814991950989
the O O 0.9995181560516357
recently O O 0.9327583909034729
cloned O O 0.9124844074249268
sigma B-protein O 0.6155710220336914

for O O 0.9987896084785461
the O O 0.9999896287918091
stress-induced O O 0.9775308966636658
susceptibility O O 0.9968819618225098
of O O 0.9999774694442749
the O O 0.99993896484375
organism O O 0.9721516370773315
to O O 0.9999622106552124
certain O O 0.9986673593521118
infections O O 0.9652280807495117
. O O 0.9999969005584717
Through O O 0.9999740123748779
the O O 0.9999915361404419
same O O 0.999962568283081
or O O 0.9999262094497681
a O O 0.9999420642852783
reciprocal O O 0.932456374168396
mechanism O O 0.9870894551277161
, O O 0.9999790191650391
states O O 0.9993404746055603
associated O O 0.9999666213989258
with O O 0.9999898672103882
chronic O O 0.962905764579773
hyperactivity O O 0.9012009501457214
or O O 0.9996050000190735

effect O O 0.9963860511779785
of O O 0.9999567270278931
dexamethasone O O 0.9091706871986389
, O O 0.9998056292533875
of O O 0.9999879598617554
further O O 0.9905862212181091
glucocorticoids O O 0.9189565181732178
, O O 0.9997171759605408
and O O 0.9999709129333496
of O O 0.9999847412109375
the O O 0.9999613761901855
glucocorticoid O B-protein 0.5058199763298035
receptor O E-protein 0.8891947269439697
antagonist O O 0.7806836366653442
RU O O 0.6948654055595398
486 O O 0.5176011323928833
, O O 0.9957691431045532
on O O 0.9999303817749023
structural O O 0.9472718238830566
order O O 0.9769787192344666
of O O 0.9998840093612671
human O O 0.5366191864013672
erythrocyte O O 0.31833216547966003
ghost O O 0.42518696188926697
membranes O O 0.2602700889110565
was O O 0.9990617632865906
investigated O O 0.9999896287918091
by O O 0.9999961853027344
determining O O 0.9999573230743408
the O O 0.9998973608016968

to O O 0.9916431903839111
Mono B-cell_line B-cell_line 0.8080487847328186
Mac I-cell_line I-cell_line 0.9215467572212219
6 I-cell_line I-cell_line 0.6261774897575378
cells E-cell_line E-cell_line 0.9971362352371216
, O O 0.999047577381134
primary B-cell_type B-cell_type 0.6780521869659424
blood I-cell_type I-cell_type 0.8937001824378967
monocytes E-cell_type E-cell_type 0.992183268070221
, O O 0.996976375579834
when O O 0.9999330043792725
precultured O O 0.9665229320526123
with O O 0.9999226331710815
a O O 0.999920129776001
low O O 0.9787431359291077
dose O O 0.9946693778038025

Thirty O O 0.9947838187217712
milliliters O O 0.9977555871009827
of O O 0.9998027682304382
blood O O 0.7742262482643127
was O O 0.9977412223815918
obtained O O 0.9999724626541138
for O O 0.9999881982803345
isolation O O 0.9899397492408752
of O O 0.9997658133506775
peripheral O B-cell_type 0.5754752159118652
blood O I-cell_type 0.6436159014701843
mononuclear O I-cell_type 0.826948344707489
cells O E-cell_type 0.8989786505699158
after O O 0.9997667670249939
each O O 0.9999933242797852
treatment O O 0.999686598777771
period O O 0.999997615814209
. O O 0.9999995231628418

IRAK S-protein S-protein 0.8070078492164612
, O O 0.9954482913017273
which O O 0.9998524188995361
is O O 0.9999667406082153
consistent O O 0.9998352527618408
with O O 0.9999959468841553
the O O 0.9999769926071167
inability O O 0.9990838766098022
of O O 0.9999856948852539
these O O 0.9999696016311646
mutants O O 0.7992882132530212
to O O 0.9987500905990601
transmit O O 0.9984900951385498
LPS O O 0.8051502704620361
cellular O O 0.9263982176780701
signaling O O 0.9868897199630737
. O O 0.9999895095825195
Moreover O O 0.9998990297317505
, O O 0.9999896287918091
both O O 0.9999384880065918
deletion O O 0.8856374025344849
mutants O O 0.6473578214645386
could O O 0.9999653100967407
still O O 0.9999600648880005
form O O 0.9990792274475098
complexes O O 0.971684992313385

important O O 0.9830990433692932
for O O 0.999690055847168
basal O O 0.8337689638137817
and O O 0.9881276488304138
Tax-mediated O O 0.9404897689819336
transcription O O 0.9777863621711731
. O O 0.9999489784240723
Using O O 0.998868465423584
mitogen O B-cell_type 0.2643263339996338
stimulated O I-cell_type 0.4152703881263733
and O I-cell_type 0.4685653746128082
quiescent O I-cell_type 0.31695252656936646
peripheral B-cell_type I-cell_type 0.4909421503543854
blood I-cell_type I-cell_type 0.5111023783683777
mononuclear I-cell_type I-cell_type 0.567216157913208
cells E-cell_type E-cell_type 0.5639978647232056
( O O 0.9678969383239746
PBMC S-cell_type S-cell_type 0.920580267906189
) O O 0.9679712057113647
and O O 0.9970652461051941
Jurkat B-cell_line B-cell_line 0.7692211866378784
cells E-cell_line E-cell_line 0.9849587678909302
, O O 0.9985210299491882
we O O 0.9999663829803467
compared O O 0.9999262094497681

. O O 0.997721254825592
External O O 0.9807004928588867
stimuli O O 0.9643766283988953
, O O 0.9999481439590454
including O O 0.9999814033508301
those O O 0.999953031539917
that O O 0.9999349117279053
activate O O 0.978171169757843
T B-cell_type B-cell_type 0.7051883935928345
cells E-cell_type E-cell_type 0.9851670861244202
, O O 0.9975091218948364
result O O 0.9999864101409912
in O O 0.9999921321868896
nuclear O O 0.914463996887207
translocation O O 0.9389857649803162

In O O 0.9997499585151672
the O O 0.9999935626983643
current O O 0.9988396763801575
study O O 0.9999222755432129
, O O 0.9999974966049194
the O O 0.9999483823776245
frequency O O 0.9979897737503052
of O O 0.9999300241470337
thrombotic B-Disease B-Disease 0.5524691939353943
microangiopathy I-Disease I-Disease 0.8778752684593201
was O O 0.9955014586448669
similar O O 0.9999688863754272
to O O 0.9999921321868896
the O O 0.9999672174453735
percentage O O 0.9996594190597534
reported O O 0.9999889135360718
in O O 0.999981164932251
the O O 0.999866247177124
literature O O 0.9777184128761292
( O O 0.9999562501907349
20 O O 0.9999338388442993
% O O 0.9999502897262573
) O O 0.9998695850372314
. O O 0.999997615814209

, O O 0.8642558455467224
and O O 0.9612976312637329
p65 S-protein S-protein 0.9701405167579651
or O O 0.9834622144699097
c-Jun S-protein S-protein 0.9371659755706787
and O O 0.9830766916275024
p65 S-protein S-protein 0.9566442966461182
required O O 0.9980977177619934
the O O 0.9999487400054932
transactivation B-protein B-protein 0.5578909516334534
domains E-protein E-protein 0.9698012471199036
of O O 0.9934597015380859
c-Jun S-protein S-protein 0.9864518642425537
and O O 0.9831629991531372
p65 S-protein S-protein 0.9553217887878418
. O O 0.9965007305145264
These O O 0.9999879598617554
data O O 0.9995858073234558
indicated O O 0.999991774559021
that O O 0.9999699592590332
c-Fos S-protein S-protein 0.991398811340332
/c-Jun S-protein S-protein 0.9823752045631409
, O O 0.997103750705719
c-Rel S-protein S-protein 0.9905725121498108
/p65 S-protein S-protein 0.879553496837616
, O O 0.9939811825752258
and O O 0.99950110912323
Sp1 S-protein S-protein 0.9647630453109741
regulate O O 0.9962659478187561
TF B-DNA S-protein 0.4764893352985382

subunit E-protein E-protein 0.9250056743621826
of O O 0.9986509680747986
nuclear O B-protein 0.6708483695983887
factor-kappa B-protein I-protein 0.7880412340164185
B E-protein E-protein 0.9793913960456848
revealed O O 0.9987006187438965
that O O 0.9999936819076538
iNO O O 0.42978954315185547
inhibited O O 0.9973996877670288
the O O 0.999896764755249
activation O O 0.9967271089553833
of O O 0.9998823404312134
nuclear B-protein B-protein 0.48835110664367676
factor-kappa I-protein I-protein 0.8361200094223022
B E-protein E-protein 0.9802882671356201
. O O 0.997697651386261
These O O 0.9999977350234985
studies O O 0.999893069267273
indicate O O 0.9999972581863403
that O O 0.999995231628418
iNO O O 0.43248093128204346
attenuates O O 0.992253839969635
iNOS S-protein S-protein 0.6750905513763428
expression O O 0.9701730608940125
in O O 0.9997792840003967
macrophages S-cell_type S-cell_type 0.9698858857154846
and O O 0.9929307699203491
inhibits O O 0.9991567134857178
monocyte O O 0.4412701427936554
adhesion O O 0.9123637676239014
to O O 0.9988235831260681
endothelial B-cell_type B-cell_type 0.7729869484901428
cells E-cell_type E-cell_type 0.9675783514976501
, O O 0.9967871904373169
and O O 0.9999703168869019
suggest O O 0.9999959468841553
that O O 0.9999977350234985
endogenously O O 0.7451924085617065
derived O O 0.9384921789169312
iNO O O 0.31925684213638306
may O O 0.9996762275695801
be O O 0.9999986886978149
an O O 0.9999943971633911
important O O 0.9977547526359558
autoregulatory O O 0.9139233231544495
inhibitor O O 0.8176354169845581
of O O 0.9995007514953613
vascular O O 0.9084097146987915
inflammation O O 0.9710161089897156
Detection O O 0.9982866644859314
of O O 0.9999600648880005
oestrogen B-protein B-protein 0.37787318229675293
receptor I-protein E-protein 0.7146679162979126
variants E-protein O 0.6455397605895996

of O O 0.9964159727096558
the O O 0.999933123588562
thymus O O 0.5619675517082214
. O O 0.9991391897201538
However O O 0.9998843669891357
, O O 0.9999921321868896
the O O 0.9999693632125854
profound O O 0.9610726237297058
T O O 0.7222631573677063
cell O O 0.5829365849494934
deficit O O 0.9307867884635925
of O O 0.9997231364250183
nude O O 0.763201117515564
mice O O 0.9672378301620483
indicates O O 0.999977707862854
that O O 0.9999977350234985
the O O 0.999744713306427
thymus O O 0.5595337748527527
is O O 0.9971150159835815
by O O 0.9999576807022095
far O O 0.9994207620620728
the O O 0.9999321699142456
most O O 0.9975277781486511
potent O O 0.9803633093833923

TF S-protein S-protein 0.6589997410774231
, O O 0.9955899715423584
namely O O 0.9994295239448547
the O O 0.9999213218688965
zymogen B-protein B-protein 0.34803134202957153
plasma I-protein I-protein 0.7270406484603882
factors I-protein E-protein 0.9768179655075073
VII E-protein S-protein 0.7804932594299316
and O O 0.9993594288825989
the O O 0.9998095631599426
serine B-protein B-protein 0.5897989869117737
protease I-protein I-protein 0.4465997815132141
factor I-protein E-protein 0.7862100601196289
VIIa E-protein S-protein 0.6580764055252075
, O O 0.9893686175346375
with O O 0.9999054670333862
the O O 0.9998489618301392
soluble B-protein O 0.8566283583641052
surface I-protein O 0.784505307674408

of O O 0.9973701238632202
normal O B-cell_type 0.5858790278434753
cells O E-cell_type 0.9622784852981567
mimicking O O 0.9948605895042419
clonal O O 0.9259915351867676
cell O O 0.763753354549408
growth O O 0.9916585087776184
: O O 0.9999663829803467
We O O 0.9999035596847534
analyzed O O 0.9994664788246155
XCI O O 0.48988229036331177
patterns O O 0.9101415276527405
at O O 0.999993085861206
the O O 0.999977707862854
human B-DNA B-DNA 0.6738882660865784
androgen I-DNA I-DNA 0.331482470035553
receptor I-DNA I-DNA 0.7278250455856323
( I-DNA I-DNA 0.5677236318588257
HUMARA I-DNA I-DNA 0.5626827478408813
) I-DNA I-DNA 0.6729039549827576
locus E-DNA E-DNA 0.946508526802063
in O O 0.9990425705909729
146 O O 0.7024557590484619
healthy O O 0.820316731929779

The O O 0.9991130232810974
EF O O 0.4151632785797119
was O O 0.9992613196372986
40 O O 0.9999278783798218
% O O 0.9999899864196777
, O O 0.999985933303833
in O O 0.999984622001648
the O O 0.9998643398284912
group O O 0.9992927312850952
with O O 0.9999942779541016
MP B-Disease O 0.6169508695602417
and O O 0.9748461842536926
44 O O 0.9984316229820251
% O O 0.9999687671661377
in O O 0.9999771118164062
the O O 0.9998112320899963
group O O 0.9982469081878662
with O O 0.999993085861206
severe O O 0.9825291633605957
MR B-Disease O 0.925581693649292
and O O 0.8425217866897583
it O O 0.9845402836799622
can O O 0.9997413754463196
be O O 0.999994158744812
a O O 0.9999463558197021
factor O O 0.9816833734512329
associated O O 0.9998356103897095
with O O 0.9999904632568359
clinical O O 0.9742020964622498
events O O 0.9100750684738159
in O O 0.9998589754104614
the O O 0.9999102354049683
last O O 0.999232292175293
group O O 0.9997053742408752
. O O 0.999998927116394

INTERVENTION O O 0.9919915795326233
: O O 0.9999669790267944
Each O O 0.9999792575836182
patient O O 0.9996745586395264
received O O 0.9999673366546631
either O O 0.9996193647384644
intravenous O O 0.9251539707183838
docetaxel S-Chemical B-Chemical 0.9289745688438416
30 O O 0.8151755332946777
mg O O 0.986354410648346
/ O O 0.9999812841415405
m2 O O 0.999868631362915
/ O O 0.999992847442627
week O O 0.9999697208404541
for O O 0.9999963045120239
3 O O 0.9999082088470459
consecutive O O 0.9999606609344482
weeks O O 0.9998261332511902
, O O 0.9999948740005493
followed O O 0.9999971389770508
by O O 0.9999784231185913
1 O O 0.9997665286064148
week O O 0.9997455477714539
off O O 0.9995131492614746
, O O 0.9999502897262573
or O O 0.9999856948852539
the O O 0.9999434947967529
combination O O 0.9984939098358154
of O O 0.9999642372131348
continuous O O 0.9485914707183838
oral O O 0.6035370826721191
thalidomide S-Chemical B-Chemical 0.9170743227005005
200 O O 0.6193557381629944
mg O O 0.84187251329422
every O O 0.999915361404419
evening O O 0.9993114471435547
plus O O 0.9999905824661255
the O O 0.9999723434448242
same O O 0.9998600482940674
docetaxel S-Chemical B-Chemical 0.8919849991798401
regimen O O 0.4629844129085541
. O O 0.9999825954437256

for O O 0.9986163377761841
significant O O 0.9979016780853271
GR B-RNA B-RNA 0.7286657094955444
mRNA E-RNA E-RNA 0.9900410771369934
induction O O 0.9953355193138123
. O O 0.9999984502792358
Increased O O 0.9994563460350037
levels O O 0.9996140599250793
of O O 0.9997507929801941
GR B-RNA B-RNA 0.9792612195014954
mRNA E-RNA E-RNA 0.9991716146469116
were O O 0.9997939467430115
noticed O O 0.9999817609786987
as O O 0.9999943971633911
early O O 0.9975086450576782
as O O 0.9999961853027344
3 O O 0.9997349381446838
h O O 0.9970729351043701
after O O 0.9999856948852539
treatment O O 0.9999547004699707
. O O 0.9999991655349731
A O O 0.9989625215530396

line E-cell_line E-cell_line 0.9754220247268677
, O O 0.9988033771514893
PC12 S-cell_line S-cell_line 0.9571791291236877
, O O 0.9859768152236938
PMA O O 0.4366142153739929
activated O O 0.8893529176712036
NF-kappa B-protein B-protein 0.5935878753662109
B E-protein E-protein 0.9519556164741516
, O O 0.9884046316146851
whereas O O 0.999923586845398
NGF S-protein S-protein 0.9252594113349915
did O O 0.9966597557067871

Serum O O 0.8994446992874146
samples O O 0.9429359436035156
were O O 0.9999611377716064
PCR O O 0.44309303164482117
amplified O O 0.9951104521751404
with O O 0.9999873638153076
HBV O O 0.7847731113433838
reverse O O 0.9295379519462585
transcriptase O O 0.5144869089126587
( O O 0.9960681200027466
RT O O 0.8785350918769836
) O O 0.9903203845024109
primers O O 0.9755891561508179
, O O 0.99997878074646
followed O O 0.9999990463256836
by O O 0.9999959468841553
direct O O 0.9977501034736633
sequencing O O 0.9978963136672974
across O O 0.9999896287918091
the O O 0.9996894598007202
tyrosine B-Chemical B-Chemical 0.9130639433860779
- O O 0.6630846858024597
methionine B-Chemical B-Chemical 0.8008151650428772
- O O 0.5600036978721619
aspartate B-Chemical B-Chemical 0.7889456748962402
- O O 0.5618623495101929
aspartate B-Chemical B-Chemical 0.7483670115470886
( O O 0.8907776474952698
YMDD O O 0.39062729477882385
) O O 0.8166630268096924
motif O O 0.4155965745449066
of O O 0.9982879757881165
the O O 0.9999488592147827
major O O 0.7936455607414246
catalytic O O 0.5656090378761292
region O O 0.4090830385684967
in O O 0.9992809891700745
the O O 0.99982750415802
C O O 0.5126277208328247
domain O O 0.5865353345870972
of O O 0.9812379479408264
the O O 0.9994590878486633
HBV O O 0.7540658712387085
RT O O 0.5708938241004944
enzyme O O 0.47060152888298035
. O O 0.9998620748519897

Fifteen O O 0.9961199760437012
polydrug O O 0.43604394793510437
ecstasy S-Chemical B-Chemical 0.8289398550987244
users O O 0.6955081820487976
and O O 0.9990164041519165
15 O O 0.9921179413795471
polydrug O O 0.6090785264968872
non O O 0.8764153718948364
- O O 0.978600800037384
ecstasy S-Chemical B-Chemical 0.905390202999115
user O O 0.8264703750610352
controls O O 0.9696868658065796
completed O O 0.9999644756317139
a O O 0.9999830722808838
general O O 0.9857535362243652
drug O O 0.9672183394432068
use O O 0.9971035122871399
questionnaire O O 0.9949830770492554
, O O 0.9999966621398926
the O O 0.9999903440475464
Brixton O O 0.9448410868644714
Spatial O O 0.9517324566841125
Anticipation O O 0.9714934825897217
task O O 0.9915444850921631
( O O 0.9999864101409912
set O O 0.9984431862831116
shifting O O 0.9938374161720276
) O O 0.9997484087944031
, O O 0.9999856948852539
Backward O O 0.9592544436454773
Digit O O 0.9010388851165771
Span O O 0.9570830464363098
procedure O O 0.9945918917655945
( O O 0.9999790191650391
memory O O 0.9539293050765991
updating O O 0.9719233512878418
) O O 0.9996366500854492
, O O 0.9999876022338867
Inhibition O O 0.734143078327179
of O O 0.985544741153717
Return O O 0.5782783627510071
( O O 0.9877853393554688
inhibition O O 0.8352586627006531
) O O 0.9917166829109192
, O O 0.9999730587005615
an O O 0.9999675750732422
emotional O O 0.9196414351463318
intelligence O O 0.9509384036064148
scale O O 0.977384090423584
, O O 0.9999916553497314
the O O 0.999990701675415
Tromso O O 0.8419841527938843
Social O O 0.8467177748680115
Intelligence O O 0.9389703273773193
Scale O O 0.9753201603889465
and O O 0.9999022483825684
the O O 0.9999867677688599
Dysexecutive O O 0.8856748938560486
Questionnaire O O 0.8955556750297546
( O O 0.9978439807891846
DEX O O 0.6774603724479675
) O O 0.998259961605072
. O O 0.9999960660934448

patient O O 0.7904083132743835
, O O 0.9950904846191406
remain O O 0.9974320530891418
obscure O O 0.9882087707519531
. O O 0.9999269247055054
Mineralocorticoids O O 0.5351623892784119
and O O 0.9237411618232727
mineralocorticoid B-protein B-protein 0.46391627192497253
receptors E-protein E-protein 0.9898635745048523
in O O 0.9994650483131409
mononuclear B-cell_type B-cell_type 0.7434716820716858
leukocytes E-cell_type E-cell_type 0.9945812821388245
in O O 0.9997517466545105
patients O O 0.999963641166687
with O O 0.9999914169311523
pregnancy-induced O O 0.974663257598877
hypertension O O 0.9365342259407043
. O O 0.9999959468841553
To O O 0.9999923706054688
examine O O 0.9999935626983643
the O O 0.9999773502349854
role O O 0.9997873902320862
of O O 0.999963641166687
mineralocorticoids O O 0.46404826641082764
in O O 0.9992197751998901
the O O 0.9997360110282898
pathophysiology O O 0.944023609161377
of O O 0.9991483688354492
pregnancy-induced O O 0.7785213589668274

find O O 0.997804582118988
that O O 0.9999992847442627
a O O 0.9999326467514038
short O B-DNA 0.781728208065033
enhancer O I-DNA 0.4369315207004547
element O E-DNA 0.992609441280365
containing O O 0.9990531802177429
the O O 0.9998257756233215
NF-kappa B-DNA B-DNA 0.788468599319458
B I-DNA I-DNA 0.5406002402305603
binding I-DNA I-DNA 0.8840506672859192
site E-DNA E-DNA 0.9787312746047974
from O O 0.9995450377464294
the O O 0.9998082518577576
interleukin-2 B-DNA B-DNA 0.5171380043029785
receptor I-DNA I-DNA 0.6864117383956909
alpha-chain I-DNA I-DNA 0.8249104619026184
gene E-DNA E-DNA 0.9855086207389832
( O O 0.9918318390846252
IL-2R B-protein B-protein 0.27919453382492065
alpha E-protein E-protein 0.7824186682701111
) O O 0.6722322702407837
is O O 0.9990158081054688
preferentially O O 0.9924411773681641
activated O O 0.9907348155975342
in O O 0.9997455477714539
T B-cell_type B-cell_type 0.8697192072868347
cells E-cell_type E-cell_type 0.9867122173309326
. O O 0.9997430443763733
The O O 0.9999804496765137
IL-2R B-protein B-DNA 0.3237454891204834
alpha E-protein I-DNA 0.4759274125099182
enhancer O E-DNA 0.9626606702804565
binds O O 0.9850388765335083
NF-kappa B-protein B-protein 0.6671322584152222
B E-protein E-protein 0.9290432333946228
poorly O O 0.9210853576660156
and O O 0.9978360533714294
is O O 0.9999537467956543
only O O 0.9999381303787231
weakly O O 0.9912075400352478
activated O O 0.996353030204773
by O O 0.9999921321868896
the O O 0.9996167421340942
NF-kappa B-DNA B-protein 0.702887237071991

form O O 0.49865180253982544
of O O 0.9987898468971252
peripheral O O 0.8652547001838684
resistance O O 0.9625816345214844
to O O 0.9996988773345947
glucocorticoids O O 0.844494104385376
was O O 0.9996805191040039
suspected O O 0.9999046325683594
. O O 0.9999980926513672
We O O 0.9999301433563232
, O O 0.9999785423278809
therefore O O 0.9999781847000122
, O O 0.999983549118042
examined O O 0.9995120763778687
glucocorticoid B-protein B-protein 0.5640349984169006
receptor E-protein E-protein 0.9288367629051208
characteristics O O 0.8931220769882202
on O O 0.9999115467071533
mononuclear B-cell_type B-cell_type 0.7269721031188965
leukocytes E-cell_type E-cell_type 0.988232433795929

spleen O O 0.3659745156764984
and O O 0.9428519010543823
peripheral B-cell_type B-cell_type 0.6476032137870789
blood I-cell_type I-cell_type 0.6841487884521484
lymphocytes E-cell_type E-cell_type 0.9800406694412231
express O O 0.9983296990394592
progesterone B-protein B-protein 0.6227583289146423
receptors E-protein E-protein 0.9680166840553284
whose O O 0.9988886713981628
concentration O O 0.9977577328681946
is O O 0.9999833106994629
increased O O 0.9998356103897095
greatly O O 0.999976634979248
during O O 0.9999933242797852
the O O 0.9999203681945801

A O O 0.9880302548408508
placebo O O 0.9620729088783264
had O O 0.999448835849762
no O O 0.9998821020126343
effect O O 0.9983577132225037
, O O 0.9999897480010986
but O O 0.9998483657836914
niacinamide B-Chemical B-Chemical 0.9302241802215576
was O O 0.9990449547767639
as O O 0.9999909400939941
effective O O 0.9998329877853394
as O O 0.9999866485595703
pyridoxine B-Chemical B-Chemical 0.9237812161445618
. O O 0.9996325969696045

